<SEC-DOCUMENT>0001000694-24-000007.txt : 20240228
<SEC-HEADER>0001000694-24-000007.hdr.sgml : 20240228
<ACCEPTANCE-DATETIME>20240228073055
ACCESSION NUMBER:		0001000694-24-000007
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		128
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240228
DATE AS OF CHANGE:		20240228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVAVAX INC
		CENTRAL INDEX KEY:			0001000694
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				222816046
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26770
		FILM NUMBER:		24690178

	BUSINESS ADDRESS:	
		STREET 1:		700 QUINCE ORCHARD ROAD
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
		BUSINESS PHONE:		240-268-2000

	MAIL ADDRESS:	
		STREET 1:		700 QUINCE ORCHARD ROAD
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>nvax-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nvax="http://www.novavax.com/20231231" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nvax-20231231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-32">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-33">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-34">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-35">0001000694</ix:nonNumeric><ix:nonNumeric contextRef="c-6" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-45">185</ix:nonNumeric><ix:nonNumeric contextRef="c-61" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="f-398">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="c-219" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="f-745">P1Y8M</ix:nonNumeric><ix:nonNumeric contextRef="c-19" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-749">http://www.novavax.com/20231231#LeaseRightOfUseAsset</ix:nonNumeric><ix:nonNumeric contextRef="c-20" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-750">http://www.novavax.com/20231231#LeaseRightOfUseAsset</ix:nonNumeric><ix:nonNumeric contextRef="c-19" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-753">http://www.novavax.com/20231231#LeaseRightOfUseAsset</ix:nonNumeric><ix:nonNumeric contextRef="c-20" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-754">http://www.novavax.com/20231231#LeaseRightOfUseAsset</ix:nonNumeric><ix:nonNumeric contextRef="c-20" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-759">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-19" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-760">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-20" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-767">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-19" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-768">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonFraction unitRef="usdPerShare" contextRef="c-224" decimals="INF" name="nvax:ConvertibleDebtConversionRate" scale="0" id="f-900">0.08</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="INF" name="nvax:ConvertibleDebtConversionRate" scale="0" id="f-901">0.02</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="c-230" decimals="INF" name="nvax:ConvertibleDebtConversionRate" scale="0" id="f-902">.0073411</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="INF" name="nvax:ConvertibleDebtConversionRate" scale="0" id="f-903">.0089928</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-235" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-904">.05</ix:nonFraction><ix:nonNumeric contextRef="c-254" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-931">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nvax-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nvax:FilipDubovskyMDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nvax:FilipDubovskyMDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">nvax:FilipDubovskyMDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:RoyaltiesAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:RoyaltiesAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:RoyaltiesAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CanadaAdvancePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:EuropeanCommissionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:EuropeanCommissionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:EuropeanCommissionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:EuropeanCommissionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:GovernmentOfAustraliaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:GovernmentOfAustraliaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:GovernmentOfCanadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:GovernmentOfCanadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:GovernmentOfIsraelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:USGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:USGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:USGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:USGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:SKBioscienceCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="reporting_unit"><xbrli:measure>nvax:reporting_unit</xbrli:measure></xbrli:unit><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>nvax:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nvax:RevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:AmendedAndRestatedUKSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nvax:RevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:AmendedAndRestatedUKSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementCOVAXFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementSIIPLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="dose"><xbrli:measure>nvax:dose</xbrli:measure></xbrli:unit><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementCOVAXFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementSIIPLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementSIIPLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementCOVAXFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-16</xbrli:startDate><xbrli:endDate>2024-02-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nvax:RestOfTheWorldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nvax:RestOfTheWorldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">nvax:WholesaleDistributorFeesDiscountsAndChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">nvax:ProductReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">nvax:WholesaleDistributorFeesDiscountsAndChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">nvax:ProductReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">nvax:WholesaleDistributorFeesDiscountsAndChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">nvax:ProductReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:AustralianAPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:AustralianAPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:EuropeanCommissionsECMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:EuropeanCommissionsECMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:EuropeanCommissionsECMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:EuropeanCommissionsECMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CanadaAdvancePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CanadaAdvancePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CanadaAdvancePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">nvax:AmendedAndRestatedUKSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">nvax:AmendedAndRestatedUKSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:JointCommitteeOnVaccinationAndImmunizationJCVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">nvax:AmendedAndRestatedUKSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">nvax:AmendedAndRestatedUKSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USDepartmentOfDefenseDoDContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USDepartmentOfDefenseDoDContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USDepartmentOfDefenseDoDContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CoalitionForEpidemicPreparednessInnovationsAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CoalitionForEpidemicPreparednessInnovationsAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CoalitionForEpidemicPreparednessInnovationsAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:OtherGrantRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:OtherGrantRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:OtherGrantRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentPartnershipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CEPIGrantFundingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CEPIGrantFundingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:SalesBasedRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:MatrixMAdjuvantSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:MilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:SalesBasedRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:MilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:MatrixMAdjuvantSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:SalesBasedRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:MilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:TakedaArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:TakedaArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:TakedaArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SecuritiesSubscriptionArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SecuritiesSubscriptionArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SecuritiesSubscriptionArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SecuritiesSubscriptionArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SecuritiesSubscriptionArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="installment"><xbrli:measure>nvax:installment</xbrli:measure></xbrli:unit><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nvax:LeaseImpairmentChargeAxis">nvax:CMOAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:CMOAndCMDAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:CMOAndCMDAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:A700QuinceOrchardRoadAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:A700QuinceOrchardRoadAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:A700QuinceOrchardRoadAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:A700QuinceOrchardRoadAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:A700QuinceOrchardRoadAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:FacilityLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:FacilityLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nvax:LeaseImpairmentChargeAxis">nvax:ROUFacilityLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>nvax:day</xbrli:measure></xbrli:unit><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-31</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:CallOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:CallOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:August2023SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:August2023SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:June2021SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:June2021AndAugust2023SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:June2021AndAugust2023SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:August2023SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:June2021SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:UnderwriterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:UnderwriterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandTwentyThreeStockInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandTwentyThreeStockInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandTwentyThreeStockInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFiveStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandTwentyThreeStockInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFiveStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFiveStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandTwentyThreeStockInducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandTwentyThreeStockInducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandTwentyThreeStockInducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CollectiveBargainingArrangementAxis">nvax:FirstThreePercentOfParticipantsDeferralMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CollectiveBargainingArrangementAxis">nvax:NextTwoPercentOfParticipantsDeferralMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nvax:ComputerSoftwareAndHardwareMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nvax:ComputerSoftwareAndHardwareMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CZ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CZ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">nvax:SubjectToExpirationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">nvax:NoExpirationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-12</xbrli:startDate><xbrli:endDate>2022-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="defendant"><xbrli:measure>nvax:defendant</xbrli:measure></xbrli:unit><xbrli:unit id="payment"><xbrli:measure>nvax:payment</xbrli:measure></xbrli:unit><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-31</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i65591fd2146e456aac589be2afadc864_1"></div><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.123%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December&#160;31</ix:nonNumeric>, 2023</ix:nonNumeric> </span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.123%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;to &#160;&#160;&#160;&#160;&#160;.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File No.&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">000-26770</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">NOVAVAX,&#160;INC</ix:nonNumeric>.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of Registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:28.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.932%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">22-2816046</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(State of incorporation)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(I.R.S. Employer Identification No.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">700 Quince Orchard Road,</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Gaithersburg,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">Maryland</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">20878</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">(240)</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">268-2000</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:38.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.837%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.578%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, Par Value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">NVAX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(g)&#160;of the Act: Not Applicable</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d)&#160;of the Act. Yes &#9744; <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric> &#9746;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the Registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part&#160;III of this Form&#160;10-K or any amendment to this Form&#160;10-K. &#9746;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. (Check one):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:23.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.344%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-24">&#9744;</ix:nonNumeric></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-25">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant had elected not to use the extended transition period for complying with any new or revised financial accounting standards provide pursuant to Section&#160;13(a)&#160;of the Exchange Act. &#9744;</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;&#160;&#160; <ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-26">&#9746;</ix:nonNumeric> </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Exchange Act, indicate by check mark whether the financial</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-27">&#9744;</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b). &#9744;</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes <ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-28">&#9744;</ix:nonNumeric> No &#9746;</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant (based on the last reported sale price of Registrants common stock on June&#160;30, 2023 on the Nasdaq Global Select Market) was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="f-29">699,000,000</ix:nonFraction>.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;23, 2024, there were <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">139,953,143</ix:nonFraction> shares of the Registrant&#8217;s common stock outstanding.</span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-31" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Documents incorporated by reference: Portions of the Registrant&#8217;s Definitive Proxy Statement to be filed no later than 120 days after the fiscal year ended December&#160;31, 2023 in connection with the Registrant&#8217;s 2024 Annual Meeting of Stockholders are incorporated by reference into Part&#160;III of this Annual Report on Form&#160;10-K to the extent indicated herein.</span></div></ix:nonNumeric><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i65591fd2146e456aac589be2afadc864_7"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOVAVAX, INC.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:76.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.192%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_13">Item 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_13">BUSINESS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_13">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_64">Item 1A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_64">RISK FACTORS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_64">27</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_67">Item 1B.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_67">UNRESOLVED STAFF COMMENTS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_67">64</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_3848290698844">Item 1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_3848290698844">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_3848290698844">.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_3848290698844">CYBERSECURITY</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_3848290698844">64</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_70">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_70">PROPERTIES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_70">64</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_73">Item 3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_73">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_73">64</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_76">Item 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_76">MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_76">67</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_82">Item 5.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_82">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_82">68</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_85">Item 6.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_85">RESERVED</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_85">69</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_88">Item 7.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_88">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_88">69</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_112">Item 7A.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_112">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_112">84</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_115">Item 8.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_115">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_115">85</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_118">Item 9.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_118">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_118">85</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_121">Item 9A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_121">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_121">85</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_124">Item 9B.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_124">OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_124">86</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_127">Item 9C.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_127">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_127">86</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_133">Item 10.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_133">DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_133">86</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_136">Item 11.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_136">EXECUTIVE COMPENSATION</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_136">87</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_139">Item 12.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_139">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_139">87</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_142">Item 13.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_142">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_142">87</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_145">Item 14.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_145">PRINCIPAL ACCOUNTING FEES AND SERVICES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_145">87</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_151">Item 15.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_151">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_151">88</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_154">Item 16.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_154">FORM 10-K SUMMARY</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_154">97</a></span></div></td></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN DEFINITIONS</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All references in this Annual Report on Form 10-K to &#8220;Novavax,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Novavax, Inc. including its wholly-owned subsidiaries (unless the context otherwise indicates). All references in this Annual Report on Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to "NVX-CoV2373,&#8221; or &#8220;prototype vaccine&#8221; refer to our Nuvaxovid&#8482; prototype COVID-19 vaccine, and all references to &#8220;NVX-CoV2601,&#8221; or &#8220;updated vaccine&#8221; refer to our Nuvaxovid&#8482; updated COVID-19 vaccine. We refer to our prototype vaccine and updated vaccine, collectively, as our &#8220;COVID-19 Vaccine&#8221;. Local regulatory authorities have also specified nomenclature for the prototype and updated vaccines for labeling within their territories (e.g., &#8220;Novavax COVID-19 Vaccine, Adjuvanted&#8221; and &#8220;Novavax COVID-19, Adjuvanted (2023-2024 Formula),&#8221; respectively, for the U.S.). The Company&#8217;s partner, Serum Institute of India Pvt. Ltd., markets NVX-CoV2373 as &#8220;Covovax&#8482;.&#8221; </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE REGARDING TRADEMARKS</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novavax&#8482;, Nuvaxovid&#8482;, Matrix-M&#8482;, Matrix&#8482;, Prepare&#8482;, Resolve&#8482;, and ResVax&#8482; are trademarks of Novavax. Any other trademarks referred to in this Annual Report on Form 10-K are the property of their owners. All rights reserved. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply an endorsement or sponsorship of us by such companies, or any relationship with any of these companies.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING INFORMATION</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties. As a result of many factors, such as those set forth under &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K, our actual results may differ materially from those anticipated in these forward-looking statements. Please also see the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF RISKS ASSOCIATED WITH OUR BUSINESS </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous risks which are discussed more fully under the heading &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K. These risks include, but are not limited to, the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a history of losses and our future profitability is uncertain.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will continue to require significant funding to maintain our current level of operations and fund the further development of our vaccine candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because our vaccine product development efforts depend on new and rapidly evolving technologies, we cannot be certain that our efforts will be successful.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The regulatory and commercial success of our COVID-19 Vaccine remains uncertain. While we have received full marketing authorization provisional registration, conditional marketing authorization (&#8220;CMA&#8221;), or emergency use authorization (&#8220;EUA&#8221;) for our prototype COVID-19 Vaccine and our updated COVID-19 vaccine in a number of jurisdictions, we may be unable to obtain full regulatory approvals in the United States (&#8220;U.S.&#8221;) or other jurisdictions for our updated vaccine or new versions in the future, or produce a successful vaccine in a timely manner, if at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The emergence and transmissibility of variants of the SARS-CoV-2 virus, and the demand for bivalent vaccines, may affect market acceptance or sales of our COVID-19 Vaccine, and our strategy to develop new versions of our COVID-19 Vaccine to protect against certain variants may not be successful.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are a biotechnology company and face significant risk in developing, manufacturing, and commercializing our products and product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because we depend on third parties to conduct some of our laboratory testing and clinical trials, and a significant amount of our vaccine manufacturing and distribution, we may encounter delays in or lose some control over our efforts to develop and supply products and product candidates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are highly dependent on the commercial success of our COVID-19 Vaccine, and even though we have received provisional registration, CMA, or EUA or full marketing authorization in certain jurisdictions for our COVID-19 </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaccine, and even if we have products licensed in additional markets, our vaccine products may not be initially or ever profitable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The risks associated with COVID-19 and related governmental public health policies continue to evolve, which may have unpredictable effects on the prospects for commercial success of our COVID-19 commercial program.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Many of our competitors have significantly greater resources and experience, which may negatively impact our commercial opportunities and those of our current and future licensees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There is significant competition in the development of a vaccine against COVID-19 and a combined vaccine against COVID-19 and influenza, and we may never see returns on the significant resources we are devoting to our vaccine candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not succeed in obtaining full U.S. Food and Drug Administration (&#8220;U.S. FDA&#8221;) licensure or foreign regulatory approvals necessary to sell our vaccine candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidates might fail to meet their primary endpoints in clinical trials, meaning that we will not have the clinical data required to support full regulatory approvals.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The regulatory pathway for our COVID-19 Vaccine is continually evolving, and such evolution may result in unexpected or unforeseen challenges.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have conducted, are conducting, and plan to conduct in the future, a number of clinical trials for our COVID-19 Vaccine at sites outside the U.S. and the U.S. FDA may not accept data from trials conducted in such locations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The later discovery of previously unknown problems with a product, manufacturer, or facility may result in restrictions, including withdrawal of a vaccine that had previously received regulatory approval in certain jurisdictions from the market.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success depends on our ability to maintain the proprietary nature of our technology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business may be adversely affected if we do not successfully execute our business development initiatives.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Given our current cash position and cash flow forecast, and significant uncertainties related to 2024 revenue, substantial doubt exists regarding our ability to continue as a going concern through one year from the date that the financial statements included in this Annual Report were issued.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Servicing our 5.00% convertible senior unsecured notes due 2027 (the &#8220;Notes&#8221;) requires a significant amount of cash, and we may not have sufficient cash flow resources to pay our debt.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because our stock price has been and will likely continue to be highly volatile, the market price of our common stock may be lower or more volatile than expected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Litigation could have a material adverse impact on our results of operation and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We or the third parties upon whom we depend may be adversely affected by natural or man-made disasters or public health emergencies, such as the COVID-19 pandemic.</span></div><div id="i65591fd2146e456aac589be2afadc864_10"></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i65591fd2146e456aac589be2afadc864_13"></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;&#160;&#160;BUSINESS</span></div><div id="i65591fd2146e456aac589be2afadc864_16"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novavax, Inc., together with our wholly owned subsidiaries, is a biotechnology company that promotes improved global health through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Our proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticle vaccines designed to address urgent global health needs. </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our vaccine candidates are nanostructures of conformationally correct recombinant proteins that mimic those found on pathogens. This technology enables the immune system to recognize target proteins and develop protective immune responses. We believe that our vaccine technology may lead to the induction of a differentiated immune response that may be more efficacious than naturally occurring immunity or other vaccine approaches. Our vaccine candidates also incorporate our proprietary saponin-based Matrix-M&#8482; adjuvant to enhance the immune response, stimulate higher levels of functional antibodies, and induce a cellular immune response.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed an updated COVID-19 vaccine for the 2023-2024 vaccination season. In October 2023, the U.S. FDA granted EUA for our updated vaccine for active immunization to prevent COVID-19. The updated vaccine is authorized as (1) a single dose in individuals 12 years and older who have been vaccinated with any COVID-19 vaccine at least 2 months after receipt of the last previous dose of COVID-19 vaccine, and (2) a series of 2 doses administered 3 weeks apart to individuals 12 years and older who were not previously vaccinated with any COVID-19 vaccine. Our updated vaccine is available within the U.S. at many major pharmacy retailers. Outside the U.S. for our updated vaccine, in January 2024, we were granted marketing authorization by the United Kingdom&#8217;s (&#8220;UK&#8221;) Medicines and Healthcare Products Regulatory Agency (&#8220;MHRA&#8221;), in December 2023, we were granted expanded authorization by Health Canada, and in October 2023, we were granted approval by the European Commission (&#8220;EC&#8221;). We are committed to supplying of our key target markets through advance purchase agreements (&#8220;APAs&#8221;) covering such markets. We continue to work closely with regulatory authorities in many jurisdictions for authorization of our updated vaccine. We previously developed a prototype COVID-19 vaccine, which has received full marketing authorization (&#8220;MA&#8221;), marketing approval, interim authorization, provisional approval, CMA, from multiple regulatory authorities in over 40 countries globally. We continue to progress our regulatory authorizations for our prototype vaccine in select territories, as we believe these may facilitate authorization of our vaccine candidates for updated strains in the future.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we are developing a COVID-19 Influenza Combination (&#8220;CIC&#8221;) vaccine candidate. Our other areas of focus include providing Matrix-M&#8482; adjuvant for collaborations, including in R21/Matrix-M&#8482; adjuvant malaria vaccine, which in December 2023 received prequalification from the World Health Organization (&#8220;WHO&#8221;) and previously received authorization in several countries, as well as other preclinical vaccine research with our Matrix-M&#8482; adjuvant, including through a partnership with the Bill &amp; Melinda Gates Medical Research Institute.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in 1987 under the laws of the State of Delaware. Our principal executive offices are located at 700 Quince Orchard Road, Gaithersburg, Maryland, 20878, and our telephone number is (240) 268-2000. Our common stock is listed on the Nasdaq Global Select Market under the symbol &#8220;NVAX.&#8221;</span></div><div id="i65591fd2146e456aac589be2afadc864_19"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Technology Overview</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our recombinant nanoparticle vaccine technology, together with our proprietary Matrix-M&#8482; adjuvant, is well suited for the development and commercialization of vaccine candidates targeting a broad scope of respiratory and other endemic and emerging infectious diseases at scale.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recombinant Nanoparticle Vaccine Technology</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a target of interest has been identified, the genetic sequence encoding the antigen is selected for developing the vaccine construct. The genetic sequence may be optimized to enhance protein stability or confer resistance to degradation. This genetic construct is inserted into the baculovirus </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Spodoptera frugiperda </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;Sf-/BV&#8221;) insect cell-expression system, which enables efficient, large-scale expression of the optimized protein. The Sf-/BV system produces protein-based antigens that are properly folded and modified&#8212;which can be critical for functional, protective immunity. Protein antigens are purified and organized around a polysorbate-based nanoparticle core in a configuration that resembles their native presentation. This results in a highly immunogenic nanoparticle that is ready to be formulated with Matrix-M&#8482; adjuvant.</span></div><div style="margin-bottom:12pt;text-indent:21pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Matrix-M&#8482; Adjuvant</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our proprietary Matrix-M&#8482; adjuvant has been a key differentiator within our platform. This adjuvant has enabled potent, well-tolerated, and durable efficacy by stimulating the entry of antigen presenting cells (&#8220;APCs&#8221;) into the injection site and enhancing antigen presentation in local lymph nodes. This in turn activates APCs, T-cell and B-cell populations, and plasma cells, which promotes the production of high-affinity antibodies. This potent mechanism of action enables a lower dose of antigen to achieve the desired immune response, thereby contributing to increased vaccine supply and manufacturing capacity. These immune-boosting and dose-sparing capabilities contribute to the adjuvant&#8217;s highly unique profile.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate commercial opportunities for the use of our Matrix-M&#8482; adjuvant alongside vaccine antigens produced by other manufacturers. Matrix-M&#8482; adjuvant is being evaluated in combination with several partner-led malaria vaccine candidates, including the R21/Matrix-M&#8482; adjuvant malaria vaccine created by the Jenner Institute, University of Oxford. The R21/Matrix-M&#8482; adjuvant vaccine has been licensed to Serum Institute of India Pvt. Ltd. (&#8220;SIIPL&#8221;) for commercialization and in December 2023 received prequalification by the WHO, along with authorizations received earlier in the year in Burkino Faso, Ghana, and Nigeria. Additionally, in May 2023, we entered into a 3-year agreement with the Bill &amp; Melinda Gates Medical Research Institute to provide our Matrix-M&#8482; adjuvant for use in preclinical vaccine research. In June 2023, we signed a material transfer agreement with SK bioscience Co., Ltd. (&#8220;SK&#8221;) for use of our Matrix-M&#8482; adjuvant in preclinical vaccine experiments for shingles, influenza, and pan-sarbecovirus vaccine. Our adjuvant technology is also being used by commercial partners as a key component in veterinary vaccines against equine influenza and Strangles, as well as the manufacture of black-widow anti-venom.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div id="i65591fd2146e456aac589be2afadc864_22"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Vaccine Regulatory and Licensure</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received full authorizations in select territories for our prototype vaccine developed for the 2022-2023 COVID-19 vaccination season and continue to receive authorizations for our updated vaccine developed for the 2023-2024 COVID-19 vaccination season in accordance with the updated strain protocol guidance. We continue to progress our regulatory authorizations for our prototype vaccine in select territories, as we believe these may facilitate authorization of our vaccine candidates for updated strains in the future. Additionally, we progress our regulatory authorizations for our updated vaccine and plan to continue to do so for subsequent future variant strains for each annual respiratory season.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the U.S. market, our updated vaccine received EUA in October 2023 from the U.S. FDA to prevent COVID-19 in individuals aged 12 and older. Our updated vaccine is marketed in the U.S. under the name Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula). The formulation for our updated vaccine aligns with global harmonized guidance from the U.S. FDA, the European Medicines Agency (&#8220;EMA&#8221;), and WHO recommendations for the 2023-2024 vaccination season. In September 2023, the U.S. Centers for Disease Control and Prevention (&#8220;CDC&#8221;) Advisory Committee on Immunization Practices (&#8220;ACIP&#8221;) voted in favor of a recommendation for the use of 2023-2024 monovalent XBB containing COVID-19 vaccines authorized under EUA or approved by Biologics License Application (&#8220;BLA&#8221;) in individuals 6 months and older, which was adopted by the CDC Director. The U.S. FDA&#8217;s grant of EUA and CDC&#8217;s September 2023 recommendation makes our updated vaccine the only protein-based non-mRNA COVID-19 vaccine available in the U.S. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the U.S. market, we continue to progress regulatory authorizations for our updated vaccine globally. We highlight as follows our fourth quarter 2023 and subsequent authorizations received through the date of filing this Annual Report on Form 10-K.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, we were granted marketing authorization by the UK MHRA for our updated vaccine, marketed under the name Nuvaxovid&#8482; XBB.1.5 Vaccine, in individuals aged 12 and older.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, we were granted expanded authorization by Health Canada and EUA by the Taiwan Food and Drug Administration for our updated vaccine, marketed under the name Nuvaxovid&#8482; XBB.1.5 Vaccine, in individuals aged 12 and older.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, our updated vaccine received EUA in South Korea where SK bioscience has exclusive commercial rights to our updated vaccine. Additionally, in November 2023, we were granted emergency use license (&#8220;EUL&#8221;) by the WHO for our updated vaccine, marketed under the name Nuvaxovid&#8482; XBB.1.5 Vaccine, in individuals aged 12 and older. The EUL assists WHO member states in assessing vaccines with the aim of expediting availability and enables the WHO&#8217;s 194 member states to expedite regulatory approvals to import and administer the vaccine.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, we were granted approval by the EC for our updated vaccine in individuals aged 12 and older, which followed the positive opinion for approval from the Committee for Medicinal Products for Human Use of the EMA. We expect to deliver doses to European countries pursuant to existing APAs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have previously received authorizations for our prototype COVID-19 vaccine in over 40 countries globally including from major regulatory agencies such as the U.S. FDA, WHO, EMA, and MHRA. To date, we have received full MA, approval, interim authorization, provisional approval, CMA, and EUA for the adult population, aged 18 and older, the adolescent population, aged 12 to 17 years, and the pediatric population, aged 7 to 11 years in select territories. The regulatory authorizations for our prototype vaccine include primary series and both homologous and heterologous booster indications within specific countries. For the territories in which our vaccine has received regulatory authorizations, our prototype vaccine </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is marketed under the names (i) Nuvaxovid&#8482; (SARS-CoV-2 rS Recombinant, adjuvanted), (ii) Covovax&#8482; (manufacturing and commercialization by SIIPL), or (iii) Novavax COVID-19 Vaccine, Adjuvanted. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, our prototype vaccine received full marketing authorization in the UK from the MHRA in individuals aged 12 and older, full approval in Singapore from Singapore&#8217;s Health Sciences Authority in individuals aged 12 and older, full registration in Australia from Australia&#8217;s Therapeutic Goods Administration as a booster in individuals aged 12 and older, and authorization in the EU from EMA for use as a booster in adolescents aged 12 through 17 years. We believe these authorizations for our prototype vaccine may facilitate authorizations of our vaccine candidates for our COVID-19 vaccine strain updates in the future.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are working to continue to expand our label for heterologous boosting in adults and adolescents, to expand our label for primary and re-vaccination in younger children, and to achieve supportive policy recommendations enabling broad market access. We continue to work closely with governments, regulatory authorities, and non-governmental organizations in our commitment to facilitate global access to our COVID-19 vaccine.</span></div><div id="i65591fd2146e456aac589be2afadc864_25"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APAs</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into APAs (also referred to as &#8220;supply agreements&#8221; throughout this Annual Report on Form 10-K) with the EC and various countries globally. The APAs typically contain terms that include upfront payments intended to assist us in funding investments related to building out and operating our manufacturing and distribution network, among other expenses, in support of our global supply commitment. Such upfront payments generally become non-refundable upon our achievement of certain development milestones. We currently have approximately $2 billion in committed APAs anticipated for future delivery.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had an APA with the EC, acting on behalf of various European Union member states to supply a minimum of 20 million and up to 100 million initial doses of prototype vaccine, with the option for the EC to purchase an additional 100 million doses up to a maximum aggregate of 200 million doses in one or more tranches through 2023. In 2022, we were notified by the EC that it was cancelling approximately 7&#160;million doses of its prior commitment originally scheduled for delivery in the first and second quarters of 2022, in accordance with the APA, and reducing the order to approximately 63&#160;million doses. In January 2023, we finalized a revised delivery schedule for the remaining 20&#160;million committed doses under the APA that were originally scheduled for delivery during the first and second quarters of 2022. The APA expired in August 2023 and required that any open and outstanding orders from European Union member states be satisfied by February 2024. Since August 2023, any additional doses have been managed by amending outstanding orders with deliveries made by February 2024. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an APA with the Commonwealth of Australia for the purchase of doses of COVID-19 Vaccine (the &#8220;Australia APA&#8221;). In April 2023, we amended the Australia APA to reduce the number of doses to be delivered with a commensurate increase in the per-dose price, such that the total contract value of the Australia APA is maintained with doses to be delivered through 2024. In May 2023, we extended a credit for certain doses delivered in 2022 to Australia that qualified for replacement under the Australia APA. This credit is the result of a single lot sold to the Australian government that upon pre-planned 6-month stability testing was found to have fallen below the defined specifications and the lot therefore was removed from the market. The credit will be applied against the future sale of doses to Australia. In July 2023, we amended the Australia APA to provide for replacement doses and to extend the delivery schedule through 2025. As of February 2024, we had not yet received Therapeutic Goods Administration (&#8220;TGA&#8221;) authorization or delivered doses as contemplated in the July 2023 amendment and are in active discussions with the Australian government on both the TGA authorization and delivery of the doses previously scheduled for the fourth quarter of 2023. In February 2024, we received notice from the Australian government purporting to cancel its order for such prototype vaccine doses. We believe the cancellation was not proper under the amended Australia APA. However, if such a cancellation were determined to be allowable, $6.0 million of the deferred revenue would become a credit towards future deliveries of doses and approximately $48 million of the contract value related to future deliverables would no longer be available.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an APA with His Majesty the King in Right of Canada as represented by the Minister of Public Works and Government Services, as successor in interest to Her Majesty the Queen in Right of Canada, as represented by the Minister of Public Works and Government Services (the &#8220;Canadian government&#8221;), for the purchase of doses of COVID-19 Vaccine (the &#8220;Canada APA&#8221;). In April 2023, we amended the Canada APA, pursuant to which the Canadian government forfeited certain doses originally scheduled for delivery in 2022 for a payment of $100.4&#160;million, which we received in the second quarter of 2023. In June 2023, we entered into an additional amendment (the &#8220;June 2023 Amendment&#8221;) to the Canada APA. Pursuant to the June 2023 Amendment, (i) the Canadian government forfeited certain doses of COVID-19 Vaccine previously scheduled </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for delivery and agreed to pay a total amount of $349.6&#160;million to us in two equal installments, which total amount equaled the remaining balance owed by the Canadian government with respect to such forfeited vaccine doses, (ii) the amount of doses of COVID-19 Vaccine due for delivery was reduced, (iii) the delivery schedule for the remaining doses of COVID-19 Vaccine to be delivered was revised, and (iv) the parties agreed Novavax would use the Biologics Manufacturing Centre (&#8220;BMC&#8221;) Inc. to produce bulk antigen for doses in 2024 and 2025. The June 2023 Amendment maintained the total contract value of the original Canada APA. The first Installment of $174.8&#160;million was payable upon execution of the June 2023 Amendment and received by Novavax in July 2023, and the second installment of $174.8&#160;million was contingent and payable upon the delivery of vaccine doses in the second half of 2023 and received by Novavax in January 2024. The Canadian government may terminate the Canada APA, as amended, if we fail to receive regulatory approval for our COVID-19 Vaccine using bulk antigen produced at BMC on or before December 31, 2024. Our 2024 plans do not currently anticipate the submission for regulatory approval of our COVID-19 Vaccine using bulk antigen produced at BMC, and we plan to work with the Canadian government on an amendment that addresses possible alternatives, which may not be achievable. As of December 31, 2023, $102.8&#160;million was classified as short-term Deferred revenue and $485.3&#160;million was classified as long-term Deferred revenue with respect to the Canadian APA on our consolidated balance sheet. If the Canadian government terminates the Canada APA, $28.0&#160;million of the deferred revenue would become refundable and approximately $224&#160;million of the contract value related to future deliverables would no longer be available (see Note 3 to our consolidated financial statements). In the event that the contract is terminated, we would consider competing in the Canadian commercial market. Pursuant to the June 2023 Amendment, Novavax and the Canadian government will endeavor to expand the previously agreed in-country commitment to Canada and to further partner to provide health, economic, and future pandemic preparedness benefits to Canada, which value may be provided through a number of activities, including without limitation, capital investments, the performance of activities or services, or the provision of technology or intellectual property licenses. Further, the parties will endeavor to enter into a memorandum of understanding (the &#8220;MOU&#8221;) to illustrate our ability to deliver such benefits over a 15-year period with an aggregate value of not less than 100% of the amount remaining to be paid under the June 2023 Amendment and ultimately received by us. As of December&#160;31, 2023, discussions regarding the MOU were ongoing. We agreed to hold $20.0&#160;million of the second installment payment received in January 2024 in escrow for the benefit of the Canadian government, which amount is the sole recourse available to the Canadian government in the event of non-performance under the MOU. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we entered into an Amended and Restated SARS-CoV-2 Vaccine Supply Agreement (as amended on September 26, 2022, the &#8220;Amended and Restated UK Supply Agreement&#8221;) with The Secretary of State for Business, Energy and Industrial Strategy (as assigned to the UK Health Security Agency), acting on behalf of the government of the United Kingdom of Great Britain and Northern Ireland (the &#8220;Authority&#8221;), which amended and restated in its entirety the SARS-CoV-2 Vaccine Supply Agreement, dated October 22, 2020, between the parties (the &#8220;Original UK Supply Agreement&#8221;). Under the Original UK Supply Agreement, the Authority agreed to purchase 60&#160;million doses of prototype vaccine and made an upfront payment to us. Under the terms of the Amended and Restated UK Supply Agreement, the Authority agreed to purchase a minimum of 1&#160;million doses and up to an additional 15&#160;million doses (the &#8220;Conditional Doses&#8221;) of prototype vaccine, with the number of Conditional Doses contingent on, and subject to reduction based on, our timely achievement of supportive recommendations from the Joint Committee on Vaccination and Immunisation (the &#8220;JCVI&#8221;) that is approved by the UK Secretary of State for Health, with respect to use of the vaccine for (a) the general adult population as part of a SARS-CoV-2 vaccine booster campaign in the United Kingdom or (b) the general adolescent population as part of a SARS-CoV-2 vaccine booster campaign in the United Kingdom or as a primary series SARS-CoV-2 vaccination, excluding where that recommendation relates only to one or more population groups comprising less than one million members in the United Kingdom. If the Authority did not purchase the Conditional Doses or if the number of such Conditional Doses was reduced below 15&#160;million doses of prototype vaccine, we would have to repay up to $225&#160;million related to the upfront payment previously received from the Authority under the Original UK Supply Agreement. Under the Amended and Restated UK Supply Agreement, the Authority also has the option to purchase up to an additional 44&#160;million doses, in one or more tranches, through 2024.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November 30, 2022, the JCVI had not made a supportive recommendation with respect to prototype vaccine, thereby triggering, under the terms of the Amended and Restated UK Supply Agreement, (i) a reduction of the number of Conditional Doses from 15&#160;million doses to 7.5&#160;million doses, which reduced number of Conditional Doses were contingent on, and subject to further reduction based on, our timely achievement by November 30, 2023 of a supportive recommendation from JCVI that is approved by the UK Secretary of State for Health as described in the paragraph above, and (ii) an obligation for us to repay $112.5&#160;million related to the upfront payment previously received from the Authority under the Original UK Supply Agreement. In April 2023, we repaid the $112.5&#160;million related to the November 30, 2022 triggering event. As of November 30, 2023, the JCVI had not made a supportive recommendation with respect to the prototype vaccine, thereby triggering a reduction in the number of Conditional Doses from 7.5 million doses to zero. As of February 2024, the Company is in </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discussions with the Authority regarding the treatment of the remaining upfront payment previously received of $112.5&#160;million, which is reflected in Other current liabilities. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2021, we entered into an APA with Gavi, the Vaccine Alliance (&#8220;Gavi&#8221; and &#8220;the Gavi APA&#8221;). Under the terms of the Gavi APA and a separate purchase agreement between Gavi and SIIPL, 1.1&#160;billion doses of the prototype vaccine were to be made available to countries participating in the COVAX Facility, which was established to allocate and distribute vaccines equitably to participating countries and economies. We expected to manufacture and distribute 350&#160;million doses of the prototype vaccine to countries participating in the COVAX Facility. Under a separate purchase agreement with Gavi, SIIPL was expected to manufacture and deliver the balance of the 1.1&#160;billion doses of prototype vaccine to low- and middle-income countries participating in the COVAX Facility. We expected to deliver doses with antigen and adjuvant manufactured at facilities directly funded under our funding agreement with the Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;), with initial doses supplied by SIIPL and Serum Life Sciences Limited (&#8220;SLS&#8221;) under a supply agreement. We expected to supply significant doses that Gavi would allocate to low-, middle- and high-income countries, subject to certain limitations, utilizing a tiered pricing schedule and Gavi could prioritize such doses to low- and middle- income countries, at lower prices. Additionally, we could provide additional doses of prototype vaccine, to the extent available from CEPI-funded manufacturing facilities, in the event that SIIPL could not materially deliver expected vaccine doses to the COVAX Facility. Under the agreement, we received an upfront payment of $350.0&#160;million from Gavi in 2021 and an additional payment of $350.0&#160;million in 2022 related to our achieving an emergency use license for our prototype vaccine by the WHO (the &#8220;Advance Payment Amount&#8221;).</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 18, 2022, we delivered written notice to Gavi to terminate the Gavi APA on the basis of Gavi&#8217;s failure to procure the purchase of 350&#160;million doses of our prototype vaccine from us as required by the Gavi APA. As of November 18, 2022, we had only received orders under the Gavi APA for approximately 2&#160;million doses. On December 2, 2022, Gavi issued a written notice purporting to terminate the Gavi APA based on Gavi&#8217;s contention that we had repudiated the agreement and, therefore, materially breached the Gavi APA. Gavi also contended that, based on its purported termination of the Gavi APA, it was entitled to a refund of the Advance Payment Amount less any amounts that have been credited against the purchase price for binding orders placed by a buyer participating in the COVAX Facility. The remaining Gavi Advance Payment Amount, which was $696.4&#160;million as of December&#160;31, 2023 has been classified within Other current liabilities in the Company&#8217;s consolidated balance sheet. On January 24, 2023, Gavi filed a demand for arbitration with the International Court of Arbitration based on the claims described above. We filed our Answer and Counterclaims on March 2, 2023. On April 5, 2023, Gavi filed its Reply to our Counterclaims. On February 16, 2024, we and Gavi entered into a Termination and Settlement Agreement (the &#8220; Gavi Settlement Agreement&#8221;) terminating the Gavi APA, settling the arbitration proceedings and releasing both parties of all claims arising from, under or otherwise in connection with the Gavi APA. Pursuant to the Settlement Agreement, we are responsible for payment to Gavi of (i) an initial settlement payment of $75 million, which we paid on February 20, 2024, and (ii) deferred payments, in equal annual amounts of $80 million payable each calendar year through a deferred payment term ending December 31, 2028. The deferred payments are due in variable quarterly installments beginning in the first quarter of 2024 and total $400 million during the deferred payment term. Such deferred payments may be reduced through Gavi&#8217;s use of an annual vaccine credit equivalent to the unpaid balance of such deferred payments each year, which may be applied to qualifying sales of any of our vaccines for supply to certain low-income and lower-middle income countries. We have the right to price the vaccines offered to such low-income and lower-middle income countries at our discretion, and, when utilized by Gavi, we will credit the actual price per vaccine paid against the applicable credit. We intend to price vaccines offered via the tender process, consistent with our shared goal with Gavi to provide equitable access to those countries. Also in the Settlement Agreement, we grant Gavi an additional credit of up to $225 million, which may be applied against any additional qualifying sales, exceeding the $80 million deferred payment amount in any calendar year, of our vaccines in such countries during such deferred payment term. In addition, we and Gavi entered into a security agreement pursuant to which we granted Gavi a security interest in accounts receivable from SIIPL under the SIIPL R21 Agreement (see Note 4 to our consolidated financial statements for more details on SIIPL R21 Agreement), which will continue for the deferred payment term of the Gavi Settlement Agreement.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i65591fd2146e456aac589be2afadc864_28"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Product Pipeline</span></div><div style="margin-bottom:12pt;text-align:justify"><img src="nvax-20231231_g1.jpg" alt="Pipeline (2024.02.16).jpg" style="height:147px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1)&#160;&#160;&#160;&#160;Authorized in select geographies under trade names Novavax COVID-19 Vaccine, Adjuvanted; Covovax&#8482;; and Nuvaxovid&#8482;, and authorized in the U.S. under trade name, Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula); Ongoing post-authorization Phase 3 strain change trial.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2)&#160;&#160;&#160;&#160;Authorized in Ghana, Nigeria, and Burkina Faso; Commercialized by Serum Institute of India; Granted prequalification by the WHO.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pipeline Overview</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our clinical pipeline encompasses vaccine candidates for infectious diseases, with our COVID-19 prototype vaccine (NVX-CoV2373) and our COVID-19 updated vaccine (NVX-CoV2601), as our lead products. Our prototype and updated vaccine has received authorizations for both adult and adolescent populations globally. Our updated vaccine has received authorization from the U.S. FDA, the EC, the WHO, and several other countries globally. We advanced our updated vaccine to a post-authorization Phase 3 safety and immunogenicity trial. Beyond our COVID-19 vaccine, our clinical pipeline includes a CIC vaccine candidate, in addition to our Matrix-M&#8482; adjuvant being used for collaboration in R21/Matrix-M&#8482; adjuvant malaria vaccine.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing a CIC vaccine candidate, which combines our COVID-19 vaccine and our updated seasonal nanoparticle influenza vaccine candidate in a single formulation. We continue to progress a Phase 2 trial of our CIC vaccine candidate. We have selected the CIC dose formulation for advanced development, and contingent upon U.S. FDA concurrence, we are prepared to move directly into a Phase 3 trial in the second half of 2024 to support accelerated approval, with a potential launch in the U.S. in the fall of 2026.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our CIC vaccine candidate, we believe our partner-led R21/Matrix&#8482; adjuvant malaria vaccine presents significant potential. Based on preliminary results from an ongoing Phase 3 trial in infants and toddlers in Africa, showing 72-79% efficacy, the R21/Matrix&#8482; adjuvant malaria vaccine has been authorized in Ghana, Nigeria, and Burkina Faso, and in December 2023, was granted prequalification by the WHO.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div id="i65591fd2146e456aac589be2afadc864_31"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Coronavirus Vaccine Clinical Development</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain focused on expanding our COVID-19 vaccine label within the booster, adolescent, and pediatric indications. We continue to evaluate vaccine safety, immunogenicity, and effectiveness through ongoing clinical trials and collaborative evidence-generating real-world studies. We expect to leverage these clinical insights to advance additional regulatory approvals of our COVID-19 vaccine globally, amidst the evolving COVID-19 landscape.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Phase 3 Strain-Change and Re-vaccination Studies</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Study 311 Part 2: In August 2023, we announced topline results demonstrating immunologic superiority of our bivalent prototype and Omicron BA.5 vaccine compared to our prototype vaccine (NVX-CoV2373) for Omicron BA.5 specific responses. This study is ongoing with the last patient visit expected to occur in the first quarter of 2024. This study design was developed in consultation with regulatory agencies to support our U.S. BLA and regulatory filings in other territories for our strain-change request for our updated vaccine (NVX-CoV2601), and to demonstrate that our protein-based vaccine can be successfully adapted to new variant strains.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Study 313: In September 2023, we fully enrolled 332 adults aged 18 and older in Part 1 of the study to evaluate the immunogenicity and safety of our updated vaccine (NVX-CoV2601) in previously mRNA vaccinated individuals. Preliminary topline results indicate that the study achieved its co-primary endpoints and successfully demonstrated immunological </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">superiority of NVX-CoV2601 compared to our prototype vaccine for Omicron XBB.1.5 specific immune responses. In November 2023, we fully enrolled 338 adults aged 18 and older in Part 2 of the study which will evaluate the immunogenicity of our updated vaccine (NVX-CoV2601) in previously unvaccinated individuals. Part 2 topline results are expected in the second quarter of 2024. Data from Study 313 are intended to support BLA supplements and similar regulatory submissions in other territories for future variant strain formulations.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Study 314: In September 2023, we fully enrolled 401 adolescents aged 12 to 17 years who were previously vaccinated with mRNA vaccines to evaluate the immunogenicity of boosting with our updated vaccine (NVX-CoV2601) and with a bivalent format vaccine containing our updated vaccine (NVX-CoV2373 + NVX-CoV2601). These data are intended to support adolescent heterologous booster label expansion in some territories with topline results expected in the second quarter of 2024.</span></div><div style="text-align:justify;text-indent:32.39pt"><span><br/></span></div><div style="text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Phase 2b/3 Pediatric Hummingbird&#8482; Study</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:32.39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, we announced topline results from our Phase 2b/3 Hummingbird&#8482; trial that met its primary endpoints in children aged 6 through 11 years demonstrating both tolerability and immunologic responses. We remain on track to submit data for this cohort to the U.S. FDA in the first half of 2024. This ongoing trial is evaluating the safety, effectiveness (immunogenicity), and efficacy of two doses of our prototype vaccine (NVX-CoV2373), followed by a booster 6 months after the primary vaccination series. The trial includes three age de-escalation cohorts of 1,200 children each. The next cohort aged 2 through 5 years is fully enrolled, with topline results expected in the first quarter of 2024. The last cohort aged 6 to 23 months is fully enrolled and topline results are expected in the second quarter of 2024.</span></div><div style="text-align:justify;text-indent:32.39pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Vaccine Funding</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained critical funding from the U.S. government to support the development of COVID-19 Vaccine for the U.S. population, including $1.8&#160;billion from a partnership formerly known as Operation Warp Speed. In July 2020, we entered into a Project Agreement (the &#8220;Project Agreement&#8221;) with Advanced Technology International, Inc. (&#8220;ATI&#8221;), the Consortium Management Firm acting on behalf of the Medical CBRN Defense Consortium in connection with the partnership. The partnership was among components of the U.S. Department of Health and Human Services and the U.S. Department of Defense working to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics. The Project Agreement relates to the Base Agreement we entered into with ATI in June 2020 (the &#8220;Base Agreement,&#8221; together with the Project Agreement, the &#8220;USG Agreement&#8221;). The original USG Agreement required us to conduct certain clinical, regulatory, and other activities, including a pivotal Phase 3 clinical trial to determine the safety and efficacy of prototype vaccine, and to manufacture and deliver to the U.S. government 100&#160;million doses of the vaccine candidate. Funding under the USG Agreement is payable to us for various development, clinical trial, manufacturing, regulatory, and other activities. The USG Agreement contains terms and conditions that are customary for U.S. government agreements of this nature, including provisions giving the U.S. government the right to terminate the Base Agreement or the Project Agreement based on a reasonable determination that the funded project will not produce beneficial results commensurate with the expenditure of resources and that termination would be in the U.S. government&#8217;s interest. If the Project Agreement was terminated prior to completion, we were entitled to be paid for work performed and costs or obligations incurred prior to termination and consistent with the terms of the USG Agreement. As of December 31, 2023, we have recognized the full $1.8&#160;billion-funding under the USG Agreement in grant revenue. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:28.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our funding agreement with CEPI, under which CEPI agreed to fund up to $399.5&#160;million to us to support the development of prototype vaccine, provided up to $257.0&#160;million in CEPI Grant Funding and up to $142.5&#160;million in CEPI Forgivable Loan Funding, which are loans in the form of one or more forgivable no-interest term loans to fund certain manufacturing activities and are not subject to restrictive or financial covenants. Payments received under the CEPI Forgivable Loan Funding are only repayable if project vaccine, as defined under the CEPI funding agreement, manufactured by the contract manufacturing organization (&#8220;CMO&#8221;) network funded by CEPI is sold to one or more third parties (which could include sales credited under the Gavi Settlement Agreement), and such sales cover our costs of manufacturing such vaccine, not including manufacturing costs funded by CEPI.&#160;The timing and amount of any loan repayments is currently uncertain.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary and status of our historical COVID-19 funding developments follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.753%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:57.819%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Funding Partner</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Details</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CEPI</span></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$399.5 million</span></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Funding of up to $399.5 million to support the development of prototype vaccine</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">To supply prototype vaccine through the COVAX Facility </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Government through USG Agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$1.8 billion</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">Allotted $1.8 billion to support the development of prototype vaccine</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13.8pt">Full $1.8 billion recognized in revenue as of December 31, 2023 </span></div></td></tr></table></div><div id="i65591fd2146e456aac589be2afadc864_1650"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19-Influenza Combination Vaccine</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phase 2 Clinical Trial of COVID-19-Influenza Combination Vaccine</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we shared that we previously evaluated 11 discrete CIC formulations in our Phase 2 dose-confirming trial, in which we then selected the CIC dose formulation and remain on track to initiate the Phase 3 trial. We also observed a favorable reactogenicity profile with our combination vaccine that was clinically indistinguishable from the licensed influenza vaccine comparators. This preliminary data suggests that our technology can increase the antigen load while maintaining acceptable tolerability. Pending regulatory concurrence from the U.S. FDA, we expect to initiate a pivotal Phase 3 trial for our CIC vaccine candidate in the second half of 2024, with potential accelerated approval and launch in the fall of 2026.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, we announced preliminary topline data from our Phase 2 trial for CIC, stand-alone influenza, and high-dose COVID-19 vaccine candidates. All three vaccine candidates contain our Matrix-M&#8482; adjuvant, showed preliminary robust immune responses, reassuring safety profiles, and reactogenicity that was comparable to the licensed influenza vaccine comparator arms. The Phase 2 dose-confirming randomized, observer-blinded trial evaluated the safety and effectiveness (immunogenicity) of different formulations of the CIC and influenza vaccine candidates, and higher doses of Novavax's COVID-19 vaccine in 1,575 adults aged 50 through 80 years. The CIC vaccine candidate achieved both anti-SARS-CoV-2 immunoglobulin G (IgG) and neutralizing levels comparable to our prototype vaccine. In addition, several of the combination formulations achieved responses to both SARS-CoV-2 and to the four homologous influenza strains that were comparable to the reference comparators, supporting their prioritization for advanced development. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">High-dose COVID-19 Vaccine Study</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Study 205: In October 2023, we completed enrollment in a Phase 2 trial to evaluate our high-dose COVID-19 vaccine for annual vaccination in 994 adults ages 50 years and older. The trial will compare immunogenicity levels of 5 micrograms of our prototype vaccine (NVX-CoV2373) against 5 micrograms, 35 micrograms, and 50 micrograms of our updated vaccine (NVX-CoV2601) that are matched with different levels of adjuvant. Data from this trial is intended to potentially support further development of a higher-dose formulation for older adults, similar to that of influenza vaccines. Topline results are expected in the first quarter of 2024.</span></div><div id="i65591fd2146e456aac589be2afadc864_40"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Malaria</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Malaria is a life-threatening disease caused by a parasite that infects mosquitos and is subsequently transmitted to humans. According to the 2023 WHO World Malaria Report, in 2022, there were an estimated 249 million malaria cases and 608,000 malaria-related deaths worldwide. We believe malaria has the potential to be preventable through our partner-led R21/Matrix-M&#8482; adjuvant malaria vaccine, which in 2023 received authorization in several countries and prequalification by the WHO.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">R21/Matrix-M&#8482; Adjuvant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Malaria Vaccine</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R21/Matrix-M&#8482; adjuvant malaria vaccine, formulated with our Matrix-M&#8482; adjuvant is developed by our partner, the Jenner Institute, University of Oxford, and manufactured by SIIPL. We have an agreement with SIIPL related to its manufacture of R21/Matrix-M&#8482; adjuvant malaria vaccine under which SIIPL purchases our Matrix-M&#8482; adjuvant for use in development activities at cost and for commercial purposes at a tiered commercial supply price, and pays a royalty in the single- </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to low-double digit range based on vaccine sales for a period of 15 years after the first commercial sale of the vaccine in each country.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 3 Clinical Trial of R21/Matrix-M&#8482; Adjuvant Malaria Vaccine</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R21/Matrix-M&#8482; adjuvant malaria vaccine is being evaluated in an ongoing Phase 3 trial conducted by our partner, the Jenner Institute, University of Oxford. In February 2024, peer-reviewed results from the Phase 3 efficacy trial were published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Lancet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reporting R21/Matrix-M&#8482; adjuvant malaria vaccine has a well-tolerated safety profile and offers high-level efficacy against clinical malaria in African children at sites of both seasonal and perennial transmission. This Phase 3 trial enrolled 4,800 children aged 5 to 36 months across five sites in four African countries with differing malaria transmission intensities and seasonality. The trial demonstrated efficacy of 75% when administered prior to the high transmission season during the 12 months following a three-dose series and efficacy of 68% when administered in an age-based schedule in regions where malaria is present perennially during the 12 months following the first three doses. This R21/Matrix-M&#8482; adjuvant malaria vaccine is a low-cost vaccine and has the potential to make a substantial contribution to reducing the burden of malaria disease and deaths in sub-Saharan Africa.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">R21/Matrix-M&#8482; Adjuvant Malaria Vaccine Regulatory and Licensure</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the WHO announced it prequalified the R21/Matrix-M&#8482; adjuvant malaria vaccine to prevent malaria disease in children caused by the P. falciparum parasite in endemic areas. Prequalification status enables United Nations agencies to procure the vaccine for eligible countries and will enable rollout of the vaccine in mid-2024. The WHO recommended that the R21/Matrix-M&#8482; adjuvant malaria vaccine be administered in a four-dose schedule beginning at five months of age.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, R21/Matrix-M&#8482; adjuvant malaria vaccine received authorization in Burkina Faso and in April 2023, received authorizations in Ghana and Nigeria.</span></div><div><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i65591fd2146e456aac589be2afadc864_43"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License and Collaboration</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitment to partnering globally in efforts to further develop our COVID-19 Vaccine is demonstrated through our partnership with SIIPL to supply COVID-19 vaccines to India and low- and middle-income countries. </span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"><tr><td style="width:1.0%"/><td style="width:36.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.118%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.619%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Licensee</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Marketed Under</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Territories</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Serum Institute of India Private Limited</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Covovax&#8482;</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">India</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">COVAX Facility</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The Philippines</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Indonesia</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">South Africa</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Bangladesh</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Takeda Pharmaceutical Company Limited</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Nuvaxovid&#8482;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Japan</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">South Korea</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">SK bioscience Co., Ltd.</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Nuvaxovid&#8482;</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">South Korea</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;SK bioscience also has non-exclusive licenses in Thailand and Vietnam.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our license and collaboration agreements follows:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIIPL</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We previously granted SIIPL exclusive and non-exclusive licenses for the development, co-formulation, filling and finishing, registration, and commercialization of our prototype vaccine, our proprietary COVID-19 variant antigen candidate(s), and our CIC vaccine candidate. SIIPL agreed to purchase our Matrix-M&#8482; adjuvant, and we granted SIIPL a non-exclusive license to manufacture the antigen drug substance component of our COVID-19 Vaccine in SIIPL&#8217;s licensed territory solely for use in the manufacture of COVID-19 Vaccine. Novavax and SIIPL equally split the revenue from SIIPL&#8217;s sale of COVID-19 Vaccine in its licensed territory, net of agreed costs. We also have a supply agreement with SIIPL and SLS under which SIIPL and SLS supply us with prototype vaccine, our proprietary COVID-19 variant antigen candidate(s), and our CIC vaccine candidate for commercialization and sale in certain territories, as well as a contract development manufacture agreement with SLS, under which SLS manufactures and supplies finished vaccine product to us using antigen drug substance and Matrix-M&#8482; adjuvant supplied by us. In March 2020, we entered into an agreement with SIIPL that granted SIIPL a non-exclusive license for the use of Matrix-M&#8482; adjuvant supplied by us to develop, manufacture, and commercialize R21/Matrix-M&#8482; adjuvant, a malaria vaccine created by the Jenner Institute, University of Oxford (&#8220;R21/Matrix-M&#8482;&#8221;). R21/Matrix-M&#8482; adjuvant vaccine has been licensed to SIIPL for commercialization and in December 2023 received prequalification by the WHO. Under the agreement, SIIPL purchases our Matrix-M&#8482; adjuvant for use in development activities at cost and for commercial purposes at a tiered commercial supply price, and pays a royalty in the single-to low- double-digit range based on vaccine sales for a period of 15 years after the first commercial sale of the vaccine in each country. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Takeda</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration and license agreement with Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;) under which we granted Takeda an exclusive license to develop, manufacture, and commercialize the Company&#8217;s COVID-19 Vaccine in Japan. Under the agreement, Takeda purchases Matrix-M&#8482; adjuvant from us to manufacture doses of COVID-19 Vaccine, and we are entitled to receive milestone and sales-based royalty payments from Takeda based on the achievement of certain development and commercial milestones, as well as a portion of net profits from the sale of COVID-19 Vaccine. In September 2021, Takeda finalized an agreement with the Government of Japan&#8217;s Ministry of Health, Labour and Welfare ("MHLW") for the purchase of 150&#160;million doses of its prototype vaccine. In February 2023, MHLW canceled the remainder of doses under its agreement with Takeda. As a result, it is uncertain whether we will receive future sales-based royalty payments from Takeda under the terms and conditions of their current collaboration and licensing agreement.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SK bioscience</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration and license agreement with SK bioscience to manufacture and commercialize our prototype vaccine for sale to the governments of South Korea, Thailand, and Vietnam. SK bioscience pays a royalty in the low to middle double-digit range. </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i65591fd2146e456aac589be2afadc864_46"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Supply</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to discovering, developing, and commercializing innovative vaccines to prevent serious infectious diseases and are exploring a number of combination vaccine candidates, including a CIC vaccine, directly and by leveraging our strategic global partnerships. In 2021 and 2020, we established a global supply chain and worldwide partnerships to support the commercialization of our prototype vaccine. In 2023 and 2022, we modified and continued to assess our manufacturing needs and our global manufacturing footprint consistent with our contractual obligations to supply, and anticipated demand for COVID-19 Vaccine.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our key manufacturing and supply arrangements follows:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Adjuvant</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture our proprietary saponin-based Matrix-M&#8482; adjuvant at our Novavax AB facility in Uppsala, Sweden. We also have contract manufacturing arrangements with AGC Biologics and the Polypeptide Group to provide contract development and manufacturing services, supplying us with large-scale production of Matrix-M&#8482; adjuvant.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antigen Component of COVID-19 Vaccine</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture the antigen component of our COVID-19 Vaccine at our Novavax CZ facility in the Czech Republic. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a supply agreement with SIIPL and SLS, an affiliate of SIIPL, for the manufacture of the antigen component of COVID-19 Vaccine and the co-formulation, fill, and finishing of the finished vaccine product. In May and August 2022, we expanded our license and supply arrangements with SIIPL to include our proprietary COVID-19 variant antigen candidate(s), and our CIC vaccine candidate, so that SIIPL can manufacture and commercialize a vaccine targeting COVID-19 variants, including the Omicron subvariants, and CIC vaccine, and supply such vaccines to us.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finished COVID-19 Vaccine</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the supply agreement with SIIPL and SLS for the co-formulation, fill, and finishing of the finished vaccine product, we have a contract development manufacture agreement with SLS, pursuant to which SLS will manufacture and supply finished vaccine product to us using antigen drug substance and Matrix-M&#8482; adjuvant supplied by us. Currently, we depend primarily on this supply agreement for co-formulation, filling and finishing (other than in Europe) and our service agreement with PCI Pharma Services (&#8220;PCI&#8221;) for finishing in Europe.</span></div><div id="i65591fd2146e456aac589be2afadc864_49"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition in COVID-19 and Combination Vaccines</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vaccine market is intensely competitive, characterized by rapid technological progress. Our technology is based upon utilizing the baculovirus expression system in insect cells to make recombinant vaccines. Our Matrix-M&#8482; adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response. We believe this baculovirus expression system with our nanoparticle configuration formulated with our Matrix-M&#8482; adjuvant offers many advantages compared to other technologies, such as enabling dose-sparing effects and refrigerator temperature storage that is well suited for developing COVID-19 and combination vaccines, as well as vaccines against a number of other infectious diseases.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of vaccine manufacturers, research institutions, and other organizations have developed a vaccine for SARS-CoV-2, the virus that causes COVID-19. A variety of different vaccine technologies are being studied, including nucleic acid (RNA/DNA), viral vectors, live attenuated or inactivated, and protein-based vaccines. Novavax is the first protein-based COVID-19 vaccine that received EUA by the U.S. FDA and a CMA by EMA in the European Union. As of February 2024, Novavax is one of three manufacturers that have a COVID-19 vaccine that has received authorization by the U.S. FDA for the 2023-2024 vaccination season, with the other manufacturers being Pfizer and Moderna. As of February 2024, the U.S. FDA has granted Pfizer and Moderna BLA approval for their updated vaccines in individuals 12 years and older and EUA for their updated vaccines in individuals 6 months to 11 years, while Novavax received EUA by the U.S. FDA for our updated vaccine in individuals 12 years and older. Based on our COVID-19 vaccine and its high efficacy against both the original and variant strains and its well-tolerated profile demonstrated in clinical trials, including two pivotal Phase 3 trials in the UK and U.S., we believe our vaccine candidate will continue to play an important role in addressing this global public health crisis.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we believe that our platform is well suited for combination vaccines, for example influenza and COVID-19. Following our Phase 2 trial results, we have selected a CIC dose formulation and pending regulatory concurrence are on track to initiate a pivotal Phase 3 trial in the second half of 2024, with potential accelerated approval and launch in the fall of 2026. Other manufacturers, including Moderna and Pfizer, are in Phase 3 clinical trials with COVID-19-influenza combination candidates and have publicly disclosed an expected launch date as early as 2025.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, competition among pharmaceutical products is based in part on product efficacy, safety, reliability, availability, price, and patent position. An important factor is the relative timing of the market introduction of our products and our competitors&#8217; products. Accordingly, the speed with which we can develop products, complete the clinical trials and approval processes, and supply commercial quantities of the products to the market is an important competitive factor. Our competitive position also may depend upon our ability to show differentiation with a product that is more efficacious and/or less expensive and quicker to manufacture. Other factors affecting our competitive position include our ability to attract and retain qualified personnel, obtain patent protection or otherwise develop proprietary products or processes, and secure sufficient capital resources for the lengthy period between technological conception and commercial sale.</span></div><div id="i65591fd2146e456aac589be2afadc864_52"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents and Proprietary Rights</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally seek patent protection for our technology and product candidates in the U.S. and abroad. The patent position of biotechnology and pharmaceutical firms generally is highly uncertain and involves complex legal and factual questions. Our success will depend, in part, on whether we can:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">obtain patents to protect our own technologies and product candidates;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">obtain licenses to use the technologies of third-parties, which may be protected by patents;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">protect our trade secrets and know-how; and</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">operate without infringing the intellectual property and proprietary rights of others.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Rights; Licenses</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have intellectual property (patents, licenses, know-how) related to our vaccines, manufacturing processes, and other technologies. Currently, we have or have rights to over 630 U.S. and foreign patents and patent applications relating to vaccines and vaccine-related technologies.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents related to our Virus-Like Particle (&#8220;VLP&#8221;) program include U.S. Patent No. 7,763,450, which covers, in part, the use of influenza gene sequences for high-yield production of consistent influenza VLP vaccines to protect against current and future seasonal and pandemic strains of influenza viruses. Corresponding European patent, European Patent No. 1644037 also covers this technology. U.S. Patent Nos. 8,080,255, 8,551,756, 8,506,967 and 8,592,197 are directed to methods of producing VLPs and inducing substantial immunity to an influenza virus infection by administering VLPs comprising HA and NA proteins, and our M1 protein derived from the avian influenza strain, A/Indonesia/5/05. Certain claims also encompass similar methods and compositions where the M1 protein is from a different strain of influenza virus than the influenza HA protein and the influenza NA protein. Related patent protection in Europe is provided by European Patent No. 2343084, which covers, in part, vaccine compositions containing VLPs that contain M1, HA, and NA proteins. Our VLP patent portfolio contains many other patents, including U.S. Patent Nos. 8,951,537, 8,992,939, 9,144,607, 9,050,290, 9,180,180, 9,381,239, 9,464,276, 9,474,799, and other patents in multiple ex-U.S. jurisdictions.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition to our focus on vaccine programs, we also pursue patent protection for our Matrix Adjuvant program. Issued U.S. Patent Nos. 7,838,019, 9,205,147, 9,901,634, 8,821,881, and 10,729,764 provide examples of patents related to our Matrix Adjuvant program.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pursue patents related to our COVID-19 vaccine program, including to NVX-CoV2373, our COVID-19 vaccine candidate. Issued U.S. Patent Nos. 10,953,089, 11,253,586, 11,541,112 provide examples of patents related to our COVID-19 program.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have four pending PCT applications directed to our COVID program (PCT/US2022/020974, PCT/US2022/080700, PCT/US2022/082331 and PCT/US2022/027465) and two pending PCT applications directed to our malaria program (PCT/US2022/078665 and PCT/US2022/080334).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to prepare, file, and prosecute patent applications to provide broad and strong protection of our proprietary rights related to our vaccine products and our adjuvant program.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Federal Technology Transfer Act of 1986 and related statutory guidance encourages the dissemination of science and technology innovation. While our expired contract with the U.S. Department of Health and Human Services (&#8220;DHHS&#8221;), Biomedical Advanced Research and Development Authority provided us with the right to retain ownership in our inventions that may have arisen during performance of that contract, with respect to certain other collaborative research efforts with the U.S. government, certain developments and results that may have commercial potential are to be freely published, not treated as confidential, and we may be required to negotiate a license to developments and results in order to commercialize products. There can be no assurance that we will be able to successfully obtain any such license at a reasonable cost, or that such development and results will not be made available to our competitors on an exclusive or non-exclusive basis.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trade Secrets</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely significantly on trade secret protection and confidentiality agreements to protect our interests. It is our policy to require employees, consultants, contractors, manufacturers, collaborators, and other advisors to execute confidentiality agreements upon the commencement of employment, consulting, or collaborative relationships with us. We also require confidentiality agreements from any entity that is to receive confidential information from us. With respect to employees, consultants, and contractors, the agreements generally provide that all inventions made by the individual while rendering services to us shall be assigned to us as our property.</span></div><div id="i65591fd2146e456aac589be2afadc864_58"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;23, 2024, we have 1,543 full-time employees, of whom approximately 9% hold M.D. or Ph.D. degrees and approximately 20% hold other advanced degrees. Of our total workforce, approximately 68% of employees are engaged primarily in research, development, and manufacturing activities and approximately 32% of employees are engaged primarily in executive, business development, commercial, finance and accounting, legal, and administrative functions. Except for certain employees located in Europe, who are covered by collective agreements with trade unions pursuant to local law, none of our employees are represented by a labor union or works council and none of our employees have entered into a collective bargaining agreement with us.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To nurture, grow, and treat our employees fairly is an integral part of our culture. We are proud to have won a Silver Stevie Award in 2023 for Great Employer in the Pharmaceutical category. We believe this award reflects our investment in an exceptional work culture.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation and Benefits; Health and Wellness</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total rewards package is designed to attract, engage, motivate, and retain top talent. We strive to provide compensation, benefits, and services that help meet the varying needs of our employees. Our generous total rewards package for employees in the U.S. includes competitive market pay and comprehensive benefits, including insurance to protect and maintain health; income protection through our short- and long-term disability programs and life insurance; adoption assistance and paid parental leave programs; and services to assist in balancing work and personal life, such as backup child, adult, and elder care, and financial well-being programs, including monthly financial wellness seminars, one-on-one financial planning sessions, and debt and credit management support.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our wellness initiatives include a monthly newsletter, which highlights organizations and partners, tools, and resources intended to help our employees lead healthier and happier lives. We offer several digital apps that allow our employees to connect to an online licensed therapist or to access activities that are designed to reduce stress and anxiety and increase mindfulness and emotional well-being. We have a robust employee assistance program for employees to access support for a variety of life events.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we offer the majority of employees the benefit of equity ownership in the Company through equity grants or participation in our employee stock purchase plan. We believe that equity compensation has been, and will continue to be, a critical component of our compensation package because it develops a culture of ownership among our employees and aligns their interests with the interests of our stockholders.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recruitment, Development, and Training</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The attraction, development, and retention of employees is a critical factor for our success. We utilize a variety of recruitment vehicles to source top talent, including strategic partnerships with search firms, leveraging social media channels, and a robust employee referral program. In 2023, we launched the Leading@Novavax competency model to define great leadership. At Novavax, everyone is a leader and this model and associated tools, resources, and programs develops leadership skills at all levels of the organization.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To support the growth and advancement of our employees, we offer tuition and continuing education reimbursement, and an array of training and professional development opportunities, including on-the-spot coaching with executive coaches and access to the LinkedIn Learning library of over 16,000 on-demand video tutorials that address skills, knowledge, and behaviors related to business, leadership, technology, and innovation. In the last 12 months, videos were viewed and completed over 40,000 times by our employees. In addition, approximately 135 employees have participated in spot coaching. We provide an Executive Development Program for employees identified as having high potential and for employees who have been identified as potential successors to leadership positions through our talent review and succession planning process. Our Executive Development Program includes executive coaching engagements and leadership development programs designed to strengthen our leadership bench and accelerate and prepare our top talent for future growth. The Executive Development Program includes a diverse and global group of 34 employees. Professional development learning series are available to all employees and focus on self-awareness, collaboration, hybrid working, leadership, and business acumen.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Internal Communications</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We employ a variety of tools to facilitate open and direct communication, including global forums with executives, employee surveys, and engagement through forums and committees. Our executive leadership team recognizes the importance of increased employee engagement to the success of each individual&#8217;s career and to our success as a whole.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Diversity, Equity and Inclusion</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our culture of diversity, equity and inclusion (&#8220;DEI&#8221;) helps us to create, develop and leverage the strengths of our workforce to meet our growth objectives. Our multi-year DEI roadmap includes three pillars: </span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Embed DEI into our hiring decisions and processes.</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Enable our employees, who we refer to as our SuperNovas, to live our values and thrive in a culture of inclusion.</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Equip our leaders and SuperNovas with the understanding, capability, education, tools and resources on DEI.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acknowledge global DEI-related observances and we invest in training to build an inclusive culture and develop our leaders to access different perspectives when generating ideas and decision making. In 2023, we also made progress in increasing representation for women and minorities at the Executive level. We commenced and completed the reviews of three people processes, namely, Talent Acquisition, Promotion and Performance Management. We also have intentionally incorporated DEI principles into our Novavax Leadership Model. We believe our multi-year DEI strategy and roadmap will enable us to continuously improve and excel.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Empowering our Employees</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, Novavax sought to motivate and empower employees through a variety of programs: </span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Made charitable donations in employees&#8217; name to other mission-driven organizations in the U.S., Sweden and Czech Republic through employee match and direct giving.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Furthered personal and professional development by providing tuition and education reimbursement and providing access to professional coaching and Executive Development programming for high-potential employees.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental, Social, and Governance</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the DEI and human capital initiatives described above, a range of other initiatives related to environmental, social and governance (&#8220;ESG&#8221;) are underway. These include environmental sustainability, innovating for vaccine access and improving global health, empowering our employees and governing responsibly. We believe that our multi-stakeholder approach through these focus areas is critical to our long-term success and enhances value for our shareholders. Examples of initiatives supportive of these focus areas include the following:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Environmental Sustainability</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Resource management and greenhouse gas reduction strategy, which includes tracking emissions.</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">An approach to Procurement that incorporates sustainability metrics into vendor evaluation and selection rubrics.</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Lease of approximately 170,000 square foot property in Gaithersburg, Maryland at 700 Quince Orchard Road, certified LEED Silver and designed with energy efficiency and sustainability measures in place.</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Conserving water (e.g., by replacing single-serve water bottles with refillable options) and monitoring energy use across multi-use leased and owned facilities.</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Award of WELL certifications at multiple leased facilities.</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Sustainable saponin sourcing from our partner Desert King, the key supplier of the Quillaja saponaria (Soapbark), a tree native to central Chile. Saponin is used to produce our Matrix-M&#8482; adjuvant.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Innovating for Vaccine Access and Improving Global Health</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.8pt">R21/Matrix-M&#8482; malaria vaccine, developed by the University of Oxford and its Jenner Institute and the Serum Institute of India, and formulated with our Matrix-M adjuvant is now approved in three countries and prequalified by the WHO.</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Advocacy efforts to build a bureau of third-party organizations who are registered with the CDC to provide public commentary on behalf of Novavax, including the National Health Council, Vaccinate Your Families and the National Black Nurses Association.</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Efforts focused on clinical trial diversity (economic, race, age).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Affordability</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Focused on seeking to foster an environment with no barriers to use of our vaccines due to either physical availability or pricing of the product.</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">100% returns for certain vaccinators offered with Novavax assuming all financial risk related to returns.</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In the U.S., participated in the Vaccines for Children (VFC) Program, which serves as a critical safety net for children under 19 who are Medicaid-eligible, uninsured, underinsured or American Indian/Alaskan Native.</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In the U.S., participated in the 317 Program, which serves uninsured and underinsured adults and supports Federal Qualified Health Centers that potentially vaccinate uninsured and underinsured patients.</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In the U.S., participated in the &#8220;Bridge Access Program For COVID Vaccines and Treatments&#8221; to provide access to COVID-19 vaccine option for adults without other sources of coverage.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Governing Responsibly</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Policy remains in place to comply with all government and regulatory agency requirements and industry standards with good laboratory practices (&#8220;GLP&#8221;), current good manufacturing practices (&#8220;cGMP&#8221;) and good distribution practices (&#8220;GDP&#8221;).</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Practice responsible animal welfare practices including searching for non-animal alternatives whenever possible, abiding by the 3R-principle (Reduce, Refine, Replace), working with accredited animal facilities with regional independent animal experimentation ethical review boards approving all experiments.</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">&#8220;The NovaCode,&#8221; a robust handbook of written standards and business ethics policies remains in place.</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Maintain a global hotline for reporting compliance concerns with established internal investigating protocols.</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Maintain a Strategic Compliance Governance Committee to help our partners comply with U.S. regulations.</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Chief Compliance Officer elevated to report to the CEO with a dotted line to the Audit Committee.</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Hold company-wide business ethics training, guidance, and raw materials review.</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Keep an anti-bribery and anti-corruption policy in place to ensure a transparent and ethical business model.</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Standard operating procedures guide decision-making.</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Abide by robust cybersecurity standards, meeting elevated government contracting requirements.</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Chief Safety Officer continues to build out a robust epidemiology benefit / risk group to better understand the safety profiles of different vaccines.</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Ongoing employee training for updated Safety Policy.</span></div><div id="i65591fd2146e456aac589be2afadc864_55"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulations</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development, production, and marketing of biological products, which include the vaccine candidates being developed by Novavax or our collaborators, are subject to regulation for safety, efficacy, and quality by numerous governmental authorities in the U.S. and other countries. We focus on the U.S. regulatory process and the standards imposed by the U.S. FDA, the International Council for Harmonisation (&#8220;ICH&#8221;), and other agencies because we believe meeting U.S. and ICH standards generally allows us to also satisfy regulatory agencies&#8217; standards in other countries where we intend to do business. However, we are mindful that expectations in some venues, notably in the European Union and the United Kingdom (in relation to Great Britain), differ to some degree and we take proactive steps to address such differences by maintaining regular filings and correspondence and attending regular meetings with many other non-U.S. regulatory agencies. In the U.S., the development, manufacturing, and marketing of human pharmaceuticals and vaccines are subject to extensive regulation under the Federal Food, Drug, and Cosmetic Act, and biological products are subject to regulation under provisions of that act and the Public Health Service Act. The U.S. FDA not only assesses the safety and efficacy of these products, but it also regulates, among other things, the testing, manufacture, labeling, storage, record-keeping, advertising, and promotion of such products. The process of obtaining U.S. FDA licensure for a new vaccine is costly and time-consuming.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaccine clinical development in most countries follows the same general regulatory pathway as drugs and other biologics. Before applying for U.S. FDA licensure to market any new vaccine candidate, we expect to first submit an investigational new drug application (&#8220;IND&#8221;) that explains to the U.S. FDA, among other things, the results of preclinical toxicology testing conducted in laboratory animals, the method of manufacture, quality control tests for release, the stability of the investigational product, and our proposed plans for human testing. At this stage, the U.S. FDA decides whether it is reasonably safe to move forward with testing the vaccine candidate in humans. We must then conduct Phase 1 clinical trials and larger-scale Phase 2 and 3 clinical trials that demonstrate the safety, immunogenicity, and efficacy of our vaccine candidate to the satisfaction of the U.S. FDA. Following successful completion of all three phases of clinical development, a BLA can be submitted to the U.S. FDA requesting licensure of the vaccine for marketing based on the vaccine&#8217;s safety and efficacy. Similar pathways exist in Europe and other geographies.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. FDA will only approve a BLA if the vaccine is demonstrated to be safe, pure, and potent. During the U.S. FDA&#8217;s review of a BLA, the proposed manufacturing facility undergoes a pre-approval inspection during which the U.S. FDA examines in detail the production of the vaccine, the manufacturing facility, and the quality documentation related to the vaccine. Vaccine licensure also requires the provision of adequate product labeling to allow health care providers to understand the vaccine&#8217;s proper use, including its potential benefits and risks, to communicate with patients and parents, and to safely deliver the vaccine to the public. Until a vaccine is given to the general population, all potential adverse events cannot be anticipated. Thus, the U.S. FDA typically requires Phase 4 post-marketing clinical trials for vaccines after licensure to continue gathering safety, and sometimes effectiveness/efficacy data in the indicated and additional populations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Commissioner of the U.S. FDA may, following the issuance of an appropriate declaration by the Secretary of the DHHS, issue an EUA that would permit the use of an unapproved medical product or unapproved use of an approved medical product to diagnose, treat, or prevent serious or life-threatening diseases or conditions when there are no adequate, approved, and available alternatives. When issuing an EUA, the U.S. FDA imposes conditions of authorization, with which the EUA holder must comply. Such conditions include, but may not be limited to, compliance with labeling, distribution of materials designed to ensure proper use, reporting obligations, and restrictions on advertising and promotion. The EUA is only effective for the duration of the declaration issued by the Secretary of the DHHS that EUAs are appropriate. The U.S. FDA may also revise or revoke the EUA sooner if the criteria for issuance are no longer met or other circumstances make a revision or revocation appropriate to protect the public health or safety. For example, an EUA may be revoked when the U.S. FDA determines that the underlying public health threat no longer exists or warrants such authorization, or for reasons such as significant adverse inspectional findings, reports of adverse events linked to or suspected of being caused by the EUA product, or newly emerging data that may demonstrate the product may not be effective. An EUA is separate from and not dependent on the issuance of a public health emergency (&#8220;PHE&#8221;) by the Secretary of the DHHS. Therefore, although the COVID-19 PHE expired on May 11, 2023, that expiration will not terminate EUAs issued by the U.S. FDA.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to ensure continuing safety, the U.S. FDA and most other non-U.S. based regulatory agencies continue to oversee the production of vaccines even after the vaccine and manufacturing processes are approved. For example, monitoring of the vaccine and of production activities, including periodic facility inspections, must continue as long as the manufacturer holds a license for the product. Manufacturers may also be required to submit the results of their own tests for potency, safety, and purity for each vaccine lot, if requested by the relevant regulatory agency. They may also be required to submit samples of each vaccine lot to the agency for testing.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to obtaining U.S. FDA licensure for each product, each domestic manufacturing establishment must be registered with the U.S. FDA, is subject to U.S. FDA inspection, and must comply with current Good Manufacturing Practices (&#8220;GMP&#8221;) regulations. To supply products for use either in the U.S. or outside the U.S., including clinical trials, U.S. and foreign manufacturing establishments, including third-party facilities, must comply with GMP regulations and are subject to periodic inspection by the U.S. FDA or by corresponding regulatory agencies in their home country.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EU and the UK similarly provide a faster means to achieve approval by offering CMA to fulfil unmet medical needs. CMAs are granted with the proviso of obtaining additional comprehensive data to confirm the benefit/risk so that the MA will eventually become unconditional. The benefit to public health of the immediate availability on the market of the medicinal product concerned should outweigh the risk inherent in the fact that additional data are still required.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. FDA has several programs designed to expedite the development and approval of drugs and biological products intended to treat serious or life-threatening diseases or conditions, including fast track designation, breakthrough therapy designation, priority review designation, and accelerated approval. First, the U.S. FDA may designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition and demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have more frequent interactions with the U.S. FDA and the U.S. FDA may initiate review of sections of a Fast Track product&#8217;s application before the application is complete. The U.S. FDA granted Fast Track Designation for our prototype vaccine in November 2020 and for our recombinant quadrivalent seasonal influenza vaccine candidate, in January 2020.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Second, a product may be designated as a Breakthrough Therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. The U.S. FDA may hold meetings with the sponsor throughout the development process, provide timely advice to </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the product sponsor regarding development and approval, involve more senior staff in the review process, assign a cross-disciplinary project lead for the review team, and take other steps to design the clinical trials in an efficient manner.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third, the U.S. FDA may designate a product for priority review if it is a product that treats a serious disease or life-threatening condition and, if approved, would provide a significant improvement in safety or effectiveness over available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and, for a drug product (including a vaccine), to shorten the U.S. FDA&#8217;s goal for taking action on a marketing application from ten months to six months.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fourth, a product may be eligible for accelerated approval, if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (&#8220;IMM&#8221;) that is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the U.S. FDA may require that a sponsor of a drug or biologic receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials to confirm efficacy using a clinically meaningful endpoint, thereby confirming efficacy observed pre-approval using a surrogate endpoint. In June 2019, we announced that the U.S. FDA acknowledged that the accelerated approval pathway is available for our recombinant quadrivalent seasonal influenza vaccine candidate.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulatory approvals that must be obtained in the U.S., an investigational product is also subject to regulatory approval in other countries in which it is intended to be marketed. No such product can be marketed in a country until the regulatory authorities of that country have approved an appropriate marketing application. U.S.FDA licensure does not guarantee approval by other regulatory authorities. In addition, in many countries, the government is involved in the pricing of the product. In such cases, the pricing review period often begins after market approval is granted.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act, and other present and potential federal, state, or local regulations, including national and local regulations that govern our facilities in Sweden, the Czech Republic and Switzerland. These and other laws govern our use, handling, and disposal of various biological and chemical substances used in, and waste generated by, our operations. Our research and development involves the controlled use of hazardous materials, chemicals, and viruses. Although we believe that our safety procedures for handling and disposing of such materials comply with the standards prescribed by state and federal regulations, the risk of accidental contamination or injury from these materials cannot be completely eliminated. In the event of such an accident, we could be held liable for any damages that result and any such liability could exceed our resources. Additionally, for formulations containing controlled substances, we are subject to Drug Enforcement Act regulations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both domestic and foreign markets, sales of any products for which we receive regulatory approval for commercial sale will depend in part on the availability of reimbursement from third-party payers. Third-party payers include government authorities or programs, private health insurers (including managed care plans), and other organizations. These third-party payers are increasingly challenging the price and examining the cost-effectiveness of medical products and services. In addition, significant uncertainty exists as to the reimbursement status of newly approved healthcare products. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost-effectiveness of our products. There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the indications for which the product is approved by the U.S. FDA or similar regulatory authorities outside the United States. Our product candidates may not be considered cost-effective at certain prices. Adequate third-party reimbursement may not be available in certain markets to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. Third-party payors may also control access to, or manage utilization of, our products with various utilization management techniques. Decreases in third-party reimbursement for our product candidates or a decision by a third-party payer to not cover our product candidates could reduce physician utilization of our products and have a material adverse effect on our sales, results of operations, and financial condition.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the U.S., if we obtain appropriate approval in the future to market any of our product candidates, those products could potentially be covered by various government health benefit programs, as well as purchased by government agencies. The participation in such programs or the sale of products to such agencies is subject to regulation. In exchange for </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">coverage, we may be obligated to provide rebates or offer discounts under government health programs or to government and private purchasers.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. and state governments continue to propose and pass legislation designed to reform delivery of, or payment for, health care, including initiatives to reduce the cost of healthcare. In March 2010, the U.S. Congress enacted the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act (&#8220;ACA&#8221;), which includes changes to the coverage and reimbursement of drug products under government health care programs. Since its enactment, there have been several executive, judicial and Congressional challenges to certain aspects of the ACA, and additional challenges and amendments to the ACA may reduce the profitability of drug products. Adoption of price controls and cost-containment measures and adoption of more restrictive policies in jurisdictions with existing controls and measures could further limit our net revenue and results.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted that impact drug pricing. For example, through the process created by the Budget Control Act of 2011, there are automatic reductions of Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2030. Under the American Rescue Plan Act of 2021 (&#8220;ARPA&#8221;), Medicaid and Children&#8217;s Health Insurance Program (&#8220;CHIP&#8221;) programs must cover without cost-sharing COVID-19 vaccines for most Medicaid and CHIP enrollees through September 30, 2024. After such date, under the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;), Medicaid and CHIP programs will be required to cover without cost-sharing only U.S. FDA-approved COVID-19 vaccines for adults as recommended by the ACIP.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been considerable public and government scrutiny in the U.S. of pharmaceutical pricing and proposals to address the perceived high cost of pharmaceuticals. There have also been several recent state legislative efforts to address drug costs, which generally have focused on increasing transparency around drug costs or limiting drug prices or price increases. Adoption of new legislation at the federal or state level could affect demand for, or pricing of, our product candidates if approved for sale. It is also possible that additional governmental action will be taken in response to the COVID-19 pandemic. We cannot predict the ultimate content, timing, or effect of any federal and state reform efforts. There is no assurance that federal or state health care reform will not adversely affect our future business and financial results.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, in many countries outside the U.S., pharmaceutical pricing is subject to regulatory control, particularly in countries where healthcare is provided mainly through government funding or government backed insurers. In such countries governmental organizations will generally determine firstly if a medicinal product might be reimbursed and secondly the maximum price payable.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the U.S., we may be subject to various federal and state laws pertaining to health care &#8220;fraud and abuse,&#8221; including anti-kickback laws and false claims laws, for activities related to future sales of any of our product candidates that may in the future receive regulatory and marketing approval. Anti-kickback laws generally prohibit a pharmaceutical manufacturer from soliciting, offering, receiving, or paying any remuneration to generate business, including the purchase, prescription, or use of a particular drug. Although the specific provisions of these laws vary, their scope is generally broad and there may not be regulations, guidance, or court decisions that apply the laws to particular industry practices. There is therefore a possibility that our practices might be challenged under such anti-kickback laws. False claims laws, including the federal False Claims Act (&#8220;FCA&#8221;), prohibit anyone from knowingly and willingly presenting, or causing to be presented, any claims for payment for reimbursed drugs or services to third party payers (including Medicare and Medicaid) that are false or fraudulent. Our activities relating to the sale and marketing of our products may be subject to scrutiny under these laws. Violations of fraud and abuse laws may be punishable by criminal or civil sanctions, including fines and civil monetary penalties, and exclusion from federal health care programs (including Medicare and Medicaid). In the U.S., federal and state authorities are paying increased attention to enforcement of these laws within the pharmaceutical industry and private individuals have been active in alleging violations of the laws and bringing suits on behalf of the government under the FCA. If we were subject to allegations concerning, or were convicted of violating, these laws, our business could be harmed.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 20, 2020, the DHHS published a Final Rule entitled &#8220;Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection,&#8221; commonly referred to as the &#8220;Rebate Rule,&#8221; which amends the federal Anti-Kickback Statute discount safe harbor by eliminating protection for price concessions, including rebates, that are offered by pharmaceutical manufacturers to plan sponsors, or pharmacy benefit managers under contract with them, under the Medicare Part D program and Medicare Advantage Plans, unless the price reduction is one required by law. The IRA will delay implementation of this Rebate Rule until 2032. This new rule could result in a change in incentives for health plans and pharmacy benefit managers in negotiating rebates and discounts with </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufactures for preferred formulary placement. At this time, we cannot predict how these developments may impact our business and operations if our products are commercialized in the U.S.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the European Union and the United Kingdom, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order, or use of medicinal products is prohibited. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of EU Member States and the United Kingdom, such as the UK Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to the U.S. Foreign Corrupt Practices Act (&#8220;FCPA&#8221;), which prohibits any U.S. individual or business from paying, offering, authorizing payment of, or offering anything of value, directly or indirectly, to any foreign official, political party, or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the U.S. to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. Various laws, regulations, and executive orders also restrict the use and dissemination outside the U.S. or the sharing with certain non-U.S. nationals of information classified for national security purposes, as well as certain products and technical data relating to those products. As we expand our presence outside the U.S., it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside the United States, which could limit our growth potential and increase our development costs. We cannot guarantee that we, our employees, our consultants, or our third-party contractors are or will be in compliance with all federal, state, and foreign regulations regarding bribery and corruption. Moreover, our strategic collaborators and third-party contractors located outside the U.S. may have inadequate compliance programs or may fail to respect the laws and guidance of the territories in which they operate. The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The Securities and Exchange Commission (&#8220;SEC&#8221;) also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could also have an adverse effect on our business, financial condition, and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), created additional federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors; knowingly and willfully embezzling or stealing from a healthcare benefit program; willfully obstructing a criminal investigation of a healthcare offense; and knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false, fictitious, or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items, or services. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), and their implementing regulations, impose requirements regarding the privacy and security of individually identifiable health information, including mandatory contractual terms, for covered entities, or certain healthcare providers, health plans, and healthcare clearinghouses, and their business associates that provide services to the covered entity that involve individually identifiable health information and their subcontractors that use, disclose, or otherwise process individually identifiable health information. HITECH also increased the civil and criminal penalties that may be imposed against covered entities and business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA. While pharmaceutical and biotechnology companies are typically not directly regulated by HIPAA, our business may be indirectly impacted by HIPAA in our interactions with providers, payors, and others that have HIPAA compliance obligations. We are also subject to state and foreign laws governing the privacy and security of health or personal information such as the European Union General Data Protection Regulation (&#8220;GDPR&#8221;) and the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;).</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There also are U.S. federal transparency requirements under the Physician Payments Sunshine Act that require manufacturers of U.S. FDA-approved drugs, devices, biologics and medical supplies covered by Medicare or Medicaid to report, on an annual basis, to CMS information related to payments and other transfers of value to physicians, teaching hospitals, and certain advanced non-physician health care practitioners and physician ownership and investment interests. Some </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. states have transparency laws requiring the reporting of information that differs from the scope of information reported under the federal law, which permits these additional state requirements.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the European Union and the United Kingdom, payments made to physicians must be publicly disclosed. Moreover, agreements with physicians must in some countries be the subject of prior notification and approval by the physician&#8217;s employer, their competent professional organization, or the regulatory authorities of the individual country. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the European Union Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines, or imprisonment.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws and regulations have been enacted by the federal government and various states to regulate the sales and marketing practices of pharmaceutical manufacturers with marketed products. The laws and regulations generally limit financial interactions between manufacturers and health care providers and/or require disclosure to the government and public of such interactions. Many of these laws and regulations contain ambiguous requirements or require administrative guidance for implementation. Given the lack of clarity in laws and their implementation, any future activities (if we obtain approval and/or reimbursement from federal healthcare programs for our product candidates) could be subject to challenge.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the significant global impact of the COVID-19 pandemic, it is possible that one or more government entities may take actions, including the U.S. government under the Defense Production Act of 1950, as amended, which could directly or indirectly have the effect of diminishing some of our rights or opportunities with respect to our COVID-19 Vaccine and the economic value of a COVID-19 vaccine to us could be limited. In addition, during a global health crisis, such as the COVID-19 pandemic, where the spread of a disease needs to be controlled, closed or heavily regulated national borders will create challenges and potential delays in our development and production activities and may necessitate that we pursue strategies to develop and produce our vaccine candidates within self-contained national or international borders, at potentially much greater expense and with longer timeframes for public distribution.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and commercialization of our products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing, or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability, and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. In the United States, the Public Readiness and Emergency Preparedness Act (the &#8220;PREP Act&#8221;), when applicable, provides immunity for manufacturers from all claims under state or federal law for &#8220;loss&#8221; arising out of the administration or use of a &#8220;covered countermeasure.&#8221; However, injured persons may still bring a suit for &#8220;willful misconduct&#8221; against the manufacturer under some circumstances. &#8220;Covered countermeasures&#8221; include security countermeasures and &#8220;qualified pandemic or epidemic products,&#8221; including products intended to diagnose or treat pandemic or epidemic disease, such as pandemic vaccines, as well as treatments intended to address conditions caused by such products. For these immunities to apply, the Secretary of DHHS must invoke the PREP Act by issuing a declaration that a public health emergency or &#8220;credible risk&#8221; of a future public health emergency exists. On March 17, 2020, the Secretary of DHHS issued a declaration under the PREP Act and has issued subsequent amendments thereto since then to provide liability immunity for activities related to certain countermeasures against the ongoing COVID-19 pandemic. The current declaration will end on December 31, 2024, unless it is renewed. While we believe our products would be covered under the current PREP Act declaration, this cannot be assured.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, there can be no assurance that the Secretary of the DHHS will make other declarations in the future that cover any of our other product candidates or that the U.S. Congress will not act in the future to reduce coverage under the PREP Act or to repeal it altogether. If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></div><div id="i65591fd2146e456aac589be2afadc864_61"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Availability of Information</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our website address is www.novavax.com. We make available, free of charge and through our website, our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and our other filings with the SEC, and any amendments to any such reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after filed with or furnished to the SEC. The SEC maintains an Internet site </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that contains reports, proxy, and information statements, and other information regarding issuers that file electronically with the SEC at www.sec.gov.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use our website (www.novavax.com) as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation Fair Disclosure promulgated by the SEC. These disclosures are included on our website (www.novavax.com) in the &#8220;Investors&#8221; or &#8220;News&#8221; sections. Accordingly, investors should monitor these portions of our website (www.novavax.com), in addition to following our press releases, SEC filings, and public conference calls and webcasts.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also available on our website is information relating to corporate governance at Novavax and our Board of Directors, including our Code of Conduct. We intend to disclose on our website any future amendments to and waivers from this code that apply to our Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer and Controller, and persons performing similar functions, as promptly as practicable, as may be required under applicable SEC and Nasdaq rules.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We webcast our earnings calls and certain events we participate in or host with members of the investment community on the investor relations section of our website. Additionally, we provide notifications of news or announcements regarding press and earnings releases as part of the investor relations section of our website. The contents of our website are not part of this Annual Report on Form 10-K, or any other report we file with, or furnish to, the SEC.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i65591fd2146e456aac589be2afadc864_64"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="padding-left:45pt;text-indent:-45pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should carefully consider the following risk factors in evaluating our business. A number of risks could cause our actual results to differ materially from those that are indicated by forward-looking statements. Some risks relate principally to our business and the industry in which we operate. Others relate principally to the securities market and ownership of our common stock. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties of which we are unaware, or that we currently deem immaterial, also may become important factors that affect us. Any of the following risks could result in material adverse impacts on our business, financial condition, or results of operations. You also should consider the other information included in this Annual Report on Form 10-K as well as our other filings with the SEC.</span></div><div style="padding-left:5.5pt;padding-right:5.45pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous risks. The following is a summary of the principal risk factors described in this section:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a history of losses and our future profitability is uncertain.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will continue to require significant funding to maintain our current level of operations and fund the further development of our vaccine candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because our vaccine product development efforts depend on new and rapidly evolving technologies, our efforts may not succeed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The regulatory and commercial success of our COVID-19 Vaccine remains uncertain. While we have received full MA, provisional registration, CMA, or EUA for our prototype COVID-19 Vaccine and our updated COVID-19 vaccine in a number of jurisdictions, we may be unable to obtain full regulatory approvals in the U.S. or other jurisdictions for our updated vaccine or new versions in the future or produce a successful vaccine in a timely manner, if at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The emergence and transmissibility of variants of the SARS-CoV-2 virus, may affect market acceptance or sales of our COVID-19 Vaccine, and our strategy to develop new versions of our COVID-19 Vaccine to protect against certain variants may not be successful.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are a biotechnology company and face significant risk in developing, manufacturing, and commercializing our products and product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because we depend on third parties to conduct some of our laboratory testing and clinical trials, and a significant amount of our vaccine manufacturing and distribution, we may encounter delays in or lose some control over our efforts to develop and supply products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are highly dependent on the commercial success of our COVID-19 Vaccine, and even though we have received provisional registration, CMA, EUA or full marketing authorization in certain jurisdictions for our COVID-19 Vaccine, and even if we have products licensed in additional markets, our vaccine products may not be initially or ever profitable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The risks associated with COVID-19 and related governmental public health policies continue to evolve, which may have unpredictable effects on the prospects for commercial success of our COVID-19 Vaccine.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Many of our competitors have significantly greater resources and experience, which may negatively impact our commercial opportunities and those of our current and future licensees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There is significant competition in the development of a vaccine against COVID-19 and a combined vaccine against COVID-19 and influenza, and we may never see returns on the significant resources we are devoting to our vaccine candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not succeed in obtaining full U.S. FDA licensure or foreign regulatory approvals necessary to sell our vaccine candidates.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidates might fail to meet their primary endpoints in clinical trials, meaning that we will not have the clinical data required to support full regulatory approvals.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The regulatory pathway for our COVID-19 Vaccine is continually evolving, and such evolution may result in unexpected or unforeseen challenges.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have conducted, are conducting, and plan to conduct in the future, a number of clinical trials for our COVID-19 Vaccine at sites outside the U.S. and the U.S. FDA may not accept data from trials conducted in such locations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The later discovery of previously unknown problems with a product, manufacturer, or facility may result in restrictions, including withdrawal of a vaccine that had previously received regulatory approval in certain jurisdictions from the market.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success depends on our ability to maintain the proprietary nature of our technology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business may be adversely affected if we do not successfully execute our business development initiatives.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Given our current cash position and cash flow forecast, and significant uncertainties related to 2024 revenue, substantial doubt exists regarding our ability to continue as a going concern through one year from the date that the financial statements included in this Annual Report were issued.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Servicing our 5.00% convertible senior unsecured notes due 2027 requires a significant amount of cash, and we may not have sufficient cash flow resources to pay our debt.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because our stock price has been and will likely continue to be highly volatile, the market price of our common stock may be lower or more volatile than expected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Litigation or regulatory investigations could have a material adverse impact on our results of operation and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We or the third parties upon whom we depend may be adversely affected by natural or man-made disasters or public health emergencies, such as the COVID-19 pandemic.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Condition and Capital Requirements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a history of losses and our future profitability is uncertain.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expenses have exceeded our revenue since our formation in 1987, and our accumulated deficit at December&#160;31, 2023 was $4.8 billion. Our revenue and expenses fluctuate significantly from period to period.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For most of our history our expenses have exceeded our revenue, which may occur during most periods in the foreseeable future. Our net losses for the last three fiscal years were $0.5 billion in 2023, $0.7 billion in 2022, and $1.7 billion in 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, our losses have resulted predominantly from research and development expenses for our vaccine candidates, manufacturing-related expenses, expenses associated with efforts to obtain regulatory approvals, costs related to protection of our intellectual property, and other general and administrative operating expenses, a significant portion of which have been noncash. Our expenses have exceeded our revenue since inception, and we believe our expenses will fluctuate over time, and may substantially increase in some years, as a result of continuing efforts to develop, test, manufacture, and make regulatory filings for our vaccine candidates, and commercialize our COVID-19 Vaccine and any other product candidates that receive requisite regulatory approvals.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of fiscal year 2023, our investment in the development and manufacture of our COVID-19 Vaccine has been substantial, and we expect such levels of investment to continue for the rest of 2024 and beyond, although the precise magnitude of our total investment will depend on the duration of the impact of COVID-19, the competitive landscape, the timing and results of our applications for regulatory approvals, the availability of funding, and whether and what booster shot protocols are recommended by governments, regulatory authorities, and healthcare providers. If we are unable to timely </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialize a vaccine against COVID-19 in sufficient jurisdictions, we likely would never recoup our investments. We expect to continue to incur significant operating expenses and anticipate significant losses over time as we seek to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">conduct additional clinical trials and continue to seek regulatory approvals for our COVID-19 Vaccine and other potential vaccine candidates;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">conduct preclinical studies for other potential vaccine candidates;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">expand our global manufacturing and distribution capacity, and further commercialize our COVID-19 Vaccine; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">maintain, expand and protect our intellectual property portfolio.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, we expect our cumulative operating losses to increase until such time, if ever, that product sales, licensing fees, royalties, milestones, contract research and other sources generate sufficient revenue to fully fund our operations. We may never achieve profitability and may not sustain profitability, if achieved.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will continue to require significant funding to maintain our current level of operations and fund the further development of our vaccine candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently generate sufficient revenue from product sales, licensing fees, royalties, milestones, contract research or other sources to fully fund our operations. We, therefore, will use our cash resources, and expect to require additional funds, to maintain our operations, continue our research and development programs, advance preclinical studies and clinical trials, seek regulatory approvals and manufacture and market our COVID-19 Vaccine and any other product candidates that are approved for commercialization.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have financed our operations primarily through the sale of equity and debt securities, government funding and grant agreements, and supply agreements (also sometimes referred to as advance purchase agreements) for our COVID-19 Vaccine. Although we have entered into supply agreements for our COVID-19 Vaccine that include prepayments from the purchasers, until we can generate sufficient product revenue from such agreements to fully fund our operations, which we may never do, we expect to finance our cash needs through a combination of additional public or private equity or debt financings, as well as existing cash, potential collaborations, strategic alliances and marketing, distribution or licensing arrangements, funding from governmental and non-governmental funding entities, and potentially other sources. While we may continue to apply for contracts or grants from academic institutions, non-profit organizations and governmental entities, we may not be successful. Adequate additional funding may not be available to us on favorable terms, or at all. Furthermore, negative interpretations of clinical trial data or setbacks, or perceived setbacks, with respect to manufacturing ability and/or capacity or regulatory filing timelines for our COVID-19 Vaccine or our other vaccine candidates, as well as the competitive landscape posed by other COVID-19 vaccines, may impair our ability to raise additional financing on favorable terms, or at all. Additionally, under certain supply agreements, if we do not timely achieve requisite regulatory milestones for our COVID-19 Vaccine in the relevant jurisdictions, obtain supportive recommendations from governmental advisory committees, and/or achieve product volume or delivery timing obligations, purchasers may seek to terminate such agreements, reduce their purchase commitments, require us to refund all or some prepayments we have received, or renegotiate such agreements. If we cannot raise the additional funds required for our anticipated operations, we may be required to delay significantly, reduce the scope of or eliminate one or more of our research or development programs, downsize our organization, or seek alternative measures to avoid insolvency, including arrangements with collaborative partners or others that may require us to relinquish rights to certain of our technologies or vaccine candidates. If we raise additional funds through future offerings of shares of our common stock or other securities, such offerings would cause dilution of current stockholders&#8217; percentage ownership in the Company, which could be substantial. Future offerings also could have a material and adverse effect on the price of our common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Economic and political uncertainty may adversely affect our access to capital, cost of capital and ability to execute our business plan as scheduled.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, worldwide economic conditions remain uncertain, particularly due to the impact of increased interest rates, and inflation. In addition, our operations and performance may be affected by political or civil unrest or military action, including the ongoing conflicts between Russia and Ukraine and Israel and Hamas as well as hostilities elsewhere in the </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Middle East. Access to capital markets is critical to our ability to operate. Traditionally, biotechnology companies have funded their research and development expenditures by raising capital in the equity markets. Declines and uncertainties in these markets in the past have severely restricted raising new capital and have affected companies&#8217; ability to continue to expand or fund existing development, manufacturing, regulatory and commercialization efforts. We require significant capital for our current and expected operations. The general economic and capital market conditions, both in the U.S. and worldwide, have been volatile in the past and at times have adversely affected our access to capital and increased the cost of capital. The capital and credit markets may not be available to support future capital raising activity on favorable terms. If economic conditions decline, our future cost of equity or debt capital and access to the capital markets could be adversely affected. In addition, if we are unable to access the capital markets on favorable terms, our ability to execute our business plan as contemplated would be compromised. Moreover, we rely and intend to rely on third parties, including clinical research organizations, contract manufacturing organizations and other important vendors and consultants. Global economic conditions may result in a disruption or delay in the performance of our third-party contractors and suppliers. If such third parties are unable to adequately satisfy their contractual commitments to us in a timely manner, our business could be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our existing funding and supply agreements or our advance purchase agreements do not assure success of our vaccine candidates or vaccines or that we will be able to fully fund our vaccine candidates or vaccines or our company operations, and if we are unable to satisfy the performance obligations under such agreements the agreements may be terminated, the purchase commitments may be reduced or we may be required to refund advance payments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our funding agreements with the U.S. government (&#8220;USG&#8221;) and CEPI each reimburse a portion of the expenses associated with the development and commercialization of our COVID-19 Vaccine. To the extent funding commitments in such agreements are conditioned on our meeting certain milestones or conditions, we may not ultimately receive the full amount of committed funds and may require additional funding to support our COVID-19 Vaccine development and commercialization activities, and we may be unable to timely obtain additional funding. For example, in July 2021, in connection with funding from the USG partnership formerly known as Operation Warp Speed, the USG instructed us to prioritize alignment with the FDA on our analytic methods before conducting additional U.S. manufacturing, and the USG indicated that it would not fund additional U.S. manufacturing until such alignment was reached, which did not occur until June 2022. In February 2023, in connection with the execution of Modification 17 to the USG Agreement, the U.S. government indicated to us that the award may not be extended past its current period of performance. The USG Agreement also includes provisions giving the USG termination rights based on a determination that the funded project will not produce beneficial results commensurate with the expenditure of resources and that termination would be in the USG&#8217;s interest. Such a determination would result in the loss of funding under that agreement and could result in other actions by the USG. The CEPI funding agreement, meanwhile, provides CEPI certain &#8220;march-in&#8221; rights in the event of certain breaches of that agreement. Additionally, we have entered into, and plan to continue entering into, supply agreements (also sometimes referred to as advance purchase agreements) for our COVID-19 Vaccine that include prepayments from the purchasers to help fund our development and manufacture of the vaccine. Under certain supply agreements, if we do not timely achieve requisite regulatory milestones for our COVID-19 Vaccine in the relevant jurisdictions, obtain supportive recommendations from governmental advisory committees, and/or achieve product volume or delivery timing obligations, purchasers may seek to terminate such agreements, reduce their purchase commitments, require us to refund all or some prepayments we have received, or renegotiate such agreements, each of which could have a material and adverse effect on our financial condition. The timing to fulfill performance obligations related to supply agreements will depend on timing of product manufacturing, receipt of marketing authorizations for additional indications, delivery of doses based on customer demand, and the ability of the customer to request variant vaccine in place of prototype vaccine under certain of our supply agreements. The supply agreements typically contain terms that include upfront payments intended to assist us in funding investments related to building out and operating our manufacturing and distribution network, among other expenses, in support of our global supply commitment, and are applied to billings upon delivery of COVID-19 Vaccine. Such upfront payments generally become non-refundable upon our achievement of certain development, regulatory and commercial milestones. We may not achieve such milestones, which could have a material and adverse effect on our financial condition. For example, in September 2022, following a delay in obtaining regulatory approval in the United Kingdom, we entered into the Amended and Restated UK Supply Agreement, which amended and restated in its entirety the Original UK Supply Agreement, which reduced the volume of vaccine doses that the Authority is committed to purchase as compared to the Original UK Supply Agreement. Under the terms of the Amended and Restated UK Supply Agreement, the Authority agreed to purchase a minimum of 1&#8239;million doses and up to an additional 15&#8239;million doses (the &#8220;Conditional Doses&#8221;) of our prototype vaccine, with the number of Conditional Doses contingent on, and subject to reduction based on, our timely achievement of supportive recommendations from the JCVI that is approved by the UK Secretary of State for Health. If the Authority did not purchase the Conditional Doses or the number of such Conditional Doses was reduced below 15&#8239;million doses of our prototype </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vaccine, we would have to repay up to $225.0&#160;million related to the upfront payment previously received from the Authority under the Original UK Supply Agreement. Under the Amended and Restated UK Supply Agreement, the Authority also has the option to purchase up to an additional 44&#8239;million doses, in one or more tranches, through 2024. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November 30, 2022, the JCVI had not made a supportive recommendation with respect to our prototype vaccine, thereby triggering, under the terms of the Amended and Restated UK Supply Agreement, (i) a reduction of the number of Conditional Doses from 15&#8239;million doses to 7.5&#8239;million doses, which reduced number of Conditional Doses are contingent on, and subject to further reduction based on, our timely achievement by November 30, 2023 of a supportive recommendation from JCVI that is approved by the UK Secretary of State for Health as described in the paragraph above, and (ii) an obligation for us to repay $112.5&#160;million related to the upfront payment previously received from the Authority under the Original UK Supply Agreement. In April 2023, we repaid the $112.5&#160;million related to the November 30, 2022 triggering event. As of November 30, 2023, the JCVI had not made a supportive recommendation with respect to the prototype vaccine, thereby triggering a reduction in the number of Conditional Doses from 7.5&#8239;million doses to zero. As of February 2024, the Company is in discussions with the Authority regarding the treatment of the remaining upfront amount previously received of $112.5&#160;million, which is reflected in Other current liabilities on our consolidated balance sheet. </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, we amended the Australia APA to provide for replacement doses and to extend the delivery schedule through 2025. As of February 2024, we had not yet received TGA authorization or delivered doses as contemplated in the July 2023 amendment and are in active discussions with the Australian government on both the TGA authorization and delivery of the doses previously scheduled for the fourth quarter of 2023. In February 2024, we received notice from the Australian government purporting to cancel its order for such prototype vaccine doses. We believe the cancellation was not proper under the amended Australia APA. However, if such a cancellation were determined to be allowable,  $6.0 million of the deferred revenue would become a credit towards future deliveries of doses and approximately $48 million of the contract value related to future deliverables would no longer be available.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we amended the Canada APA, pursuant to which the Canadian government forfeited certain doses originally scheduled for delivery in 2022 for a payment of $100.4 million, which we received in the second quarter of 2023. In June 2023, we entered into an additional amendment (the &#8220;June 2023 Amendment&#8221;) to the Canada APA. Pursuant to the June 2023 Amendment, (i) the Canadian government forfeited certain doses of COVID-19 Vaccine previously scheduled for delivery and agreed to pay a total amount of $349.6 million to us in two equal installments, which total amount equaled the remaining balance owed by the Canadian government with respect to such forfeited vaccine doses, (ii) the amount of doses of COVID-19 Vaccine due for delivery was reduced, (iii) the delivery schedule for the remaining doses of COVID-19 Vaccine to be delivered was revised, and (iv) the parties agreed Novavax would use the Biologics Manufacturing Centre (&#8220;BMC&#8221;) Inc. to produce bulk antigen for doses in 2024 and 2025. The June 2023 Amendment maintained the total contract value of the original Canada APA. The first installment of $174.8&#160;million was payable upon execution of the June 2023 Amendment and received by Novavax in July 2023, and the second installment of $174.8&#160;million was contingent and payable upon the delivery of vaccine doses in the second half of 2023 and received by Novavax in January 2024. The Canadian government may terminate the Canada APA, as amended, if we fail to receive regulatory approval for our COVID-19 Vaccine using bulk antigen produced at BMC on or before December 31, 2024. Our 2024 plans do not currently anticipate the submission for regulatory approval of our COVID-19 Vaccine using bulk antigen produced at BMC, and we plan to work with the Canadian government on an amendment that addresses possible alternatives, which may not be achievable. As of December 31, 2023, $102.8&#160;million was classified as short-term Deferred revenue and $485.3&#160;million was classified as long-term Deferred revenue with respect to the Canadian APA on our consolidated balance sheet. If the Canadian government terminates the Canada APA, $28.0&#160;million of the deferred revenue would become refundable and approximately $224&#160;million of the contract value related to future deliverables would no longer be available (see Note 3 to our consolidated financial statements). As a result, our existing funding and supply agreements or our advance purchase agreements do not assure success of our vaccine candidates and may be insufficient to fully fund the development and commercialization of our vaccine candidates, our vaccines or our company operations and if we are unable to satisfy the performance obligations under such agreements the agreements may be terminated, the purchase commitments may be reduced or we may be required to refund advance payments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Product Development and Commercialization</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because our vaccine product development efforts depend on new and rapidly evolving technologies, our efforts may not succeed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our vaccine development efforts depend on new, rapidly evolving technologies and on the marketability and profitability of our products. Our development efforts and, if those are successful, commercialization of our COVID-19 Vaccine and our other vaccines could fail for a variety of reasons, including if:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our recombinant nanoparticle vaccine technologies, any or all of the products based on such technologies or our proprietary manufacturing process prove ineffective or unsafe; </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">new strains of COVID-19 evolve, with respect to which our COVID-19 Vaccine proves less effective;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we or our third-party manufacturer facilities fail to reproducibly scale-up and maintain manufacturing with sufficiently high yields at reasonable cost and on projected timelines, or such manufacturing fails to generate product that consistently satisfies purity, potency, quality, stability, and shelf-life standards necessary for obtaining regulatory approvals or achieving commercial viability;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the products are uneconomical to market or manufacture;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">some or all of the products that we or our third-party partners have manufactured may be determined to be unsalable based on criteria imposed by regulators as they complete regulatory approvals;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our in-house or third-party manufacturing facilities fail regulatory inspections;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">proprietary rights of third-parties prevent us or our collaborators from exploiting technologies, and manufacturing or marketing products; or</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">third-party competitors achieve and maintain greater market share due to earlier approvals or superior marketing capabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory and commercial success of our COVID-19 Vaccine remains uncertain. While we have received provisional registration, conditional marketing authorization or emergency use authorization for our COVID-19 Vaccine in a number of jurisdictions, we may be unable to obtain full regulatory approvals in the U.S. or other jurisdictions for our updated vaccine or new versions in the future or produce a successful vaccine in a timely manner, if at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the outbreak of COVID-19, we began pursuing, and continue to pursue, the development and manufacture of our COVID-19 Vaccine. Even though we have reported positive data from Phase 1, 2 and 3 clinical trials, and we and our partners have received either </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provisional registration, conditional marketing authorization, emergency use authorization, or full approval from the World Health Organization and in several jurisdictions, suc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h results may not be sufficient to support regulatory submissions, authorizations and approvals, accelerated or otherwise, in any other relevant jurisdictions on our projected timelines, if at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, even though our COVID-19 Vaccine has received regulatory authorizations in certain jurisdictions and may receive further regulatory approval in others, successful commercialization depends on our ability to effectively scale up and maintain manufacturing capabilities at our own locations and those of our manufacturing partners and contractors. In May 2020, we acquired Novavax CZ (formerly Praha Vaccines, a.s.) including its vaccine manufacturing facility in Bohumil, Czech Republic and approximately 150 of its employees but we have yet to receive regulatory approval at this site. We also are actively entering into agreements with third parties to manufacture the antigen component of COVID-19 Vaccine and our proprietary Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#8482; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adjuvant, as well as to distribute our COVID-19 Vaccine. Because of contractual restraints and the limited number of third-party manufacturers with the relevant expertise, required regulatory approvals and facilities to manufacture our COVID-19 Vaccine and its components at commercial scale, replacement of a manufacturer may be expensive and time-consuming and may cause interruptions in production. Manufacturing of our COVID-19 Vaccine and its components involves a complicated process that will require significant investments of time and financial resources to implement, and our efforts to establish and maintain manufacturing capabilities may not meet expectations as to timing, scale-up, reproducibility, yields, purity, cost, potency or quality. Shortages of raw materials and supplies also negatively </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impact our manufacturing efforts. We may not be able to timely and effectively produce or receive regulatory approvals for our COVID-19 Vaccine in adequate quantities to address global demand.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited experience with the commercial launch of vaccine products. In addition to scaling up our manufacturing capabilities, we need to develop global distribution channels and form partnerships with third parties worldwide, as well as hire, train and integrate additional management, administrative and sales and marketing personnel. Rapid and significant growth may strain our administrative and operational infrastructure, imposing significant additional responsibilities on our organization, and our efforts to establish and maintain these capabilities may not meet expectations as to timing, scale-up, reproducibility, yields, purity, cost, potency or quality. If we fail to successfully manage our growth and the increased complexity of our operations, our business, financial position, results of operations and prospects may be materially and adversely affected.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The emergence and transmissibility of variants of the SARS-CoV-2 virus, and the demand for bivalent vaccines, may affect market acceptance or sales of our COVID-19 Vaccine, and our strategy to develop new versions of our COVID-19 Vaccine to protect against certain variants may not be successful.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our prototype vaccine was a monovalent vaccine developed based upon the genetic sequence of the SARS-CoV-2 virus that was first discovered in December 2019. Our updated vaccine is a monovalent vaccine developed based upon the XBB.1.5 strain for the fall 2023 COVID-19 Vaccine season. As the SARS-CoV-2 virus continues to evolve, new strains of the virus, or those that are already in circulation, may prove more transmissible or cause more severe forms of COVID-19 disease than the predominant strains to date. For example, Alpha, Beta, Delta and Omicron (including subvariants such as XBB.1.5 and JN.1)</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">variants have been observed to be more transmissible, or contagious, than previous variants.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our COVID-19 Vaccine may not be as effective in protecting against these or other future variant strains. Additionally, we expect the demand for bivalent vaccines to continue to increase, which may negatively impact the demand, particularly in the U.S., for our COVID-19 Vaccine and would likely require significant expenditures by the Company to successfully market a bivalent formulation, particularly in the U.S. Our COVID-19 Vaccine may fail to achieve market acceptance or significant sales, despite gaining regulatory approval, provisional registration, conditional marketing authorization or emergency use authorization in a number of jurisdictions, including emergency use authorization the U.S., as demand for variant-specific or bivalent vaccines increases. We have several variant-specific vaccine candidates in development, including for Omicron subvariants and may develop others in the future. However, if these efforts are unsuccessful, these candidates do not receive regulatory approvals expeditiously, we are slower to develop variant-specific or bivalent vaccines than competitors, these vaccine candidates prove less effective than competitors&#8217; vaccines, or we are unable to successfully manufacture, distribute or market such vaccine candidates once approved, these shortcomings may lead to reputational harm, loss of market share, and adverse financial results.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2024 revenue depends on our ability to successfully develop, manufacture, distribute, or market an updated monovalent or bivalent formulation of a vaccine candidate for COVID-19 in a single dose vial or pre-filled syringe for the fall 2024 COVID vaccine season, which is inherently uncertain and subject to a number of risks, including regulatory approval. We experienced delays in early 2023 in manufacturing our BA.5 clinical trial materials, which delayed regulatory approval from the U.S. FDA for our vaccine candidate for the fall 2023 COVID vaccine season. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, counterparties to certain of our existing supply agreements may request variant-specific vaccines in place of our COVID-19 Vaccine and, depending on when we are able to offer such variant-specific vaccines, if at all, such counterparties may seek to delay, reduce or otherwise renegotiate their purchase commitments, which may adversely impact our ability to realize the full financial benefit of such supply agreements. In addition, we may expend significant resources adapting our COVID-19 Vaccine or conducting clinical trials to protect against variants of the SARS-CoV-2 virus, but a market for this adapted vaccine may not develop and demand may not align with our projections or cost expenditures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a biotechnology company and face significant risk in developing, manufacturing and commercializing our products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We focus our research and development activities on vaccines, an area in which we believe we have particular strengths and a technology that appears promising. The outcome of any research and development program is highly uncertain. Only a small fraction of biopharmaceutical development programs ultimately result in commercial products or even product candidates and a number of events could delay our development efforts and negatively impact our ability to make regulatory submissions or obtain regulatory approval for, and to manufacture, market and sell, our COVID-19 Vaccine </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or any other vaccine on our projected timelines, if at all. Vaccine candidates that initially appear promising often fail to yield successful products, and we may not ultimately be able to demonstrate the safety, potency, purity, stability and efficacy necessary to obtain or maintain regulatory authorization to market our product candidates. In many cases, preclinical studies or clinical trials will show that a product candidate is not efficacious or that it raises safety concerns or has other side effects that outweigh its intended benefit. Success in preclinical or early clinical trials may not translate into success in large-scale clinical trials. Further, success in clinical trials often leads to increased investment, accelerating cumulative losses. Even if clinical trial results appear positive, regulatory approval may not be obtained if the U.S. FDA, or a foreign equivalent, does not agree with our interpretation of the results, and we may face challenges when scaling-up the production process to commercial levels. Even after a product is approved and launched, general usage or post-marketing clinical trials may identify safety or other previously unknown problems with the product, or manufacturing issues may emerge, either of which may result in regulatory approvals being suspended, limited to narrow the scope of the approval, or revoked, which may otherwise prevent successful commercialization. Intense competition in the vaccine industry could also limit the successful commercialization of any products for which we receive commercial approval.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will require approval from the U.S. FDA of any name we intend to use for our products regardless of whether we have secured a trademark registration from the USPTO. The U.S. FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. The U.S. FDA may object to any product name we submit if it believes the name inappropriately implies medical claims. If the U.S. FDA objects to any of our proposed product names, we may be required to adopt an alternative name for our proposed products. If we adopt an alternative name, we would lose the benefit of any existing trademark applications for such developmental candidate and may be required to expend significant additional resources in an effort to identify a suitable product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the U.S. FDA. We may be unable to build a successful brand identity for a new trademark in a timely manner or at all, which would limit our ability to commercialize our products, if approved.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we depend on third parties to conduct some of our laboratory testing and clinical trials, and a significant amount of our vaccine manufacturing and distribution, we may encounter delays in or lose some control over our efforts to develop and supply products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on third-party organizations to conduct some of our laboratory testing and clinical trials and a significant amount of our vaccine manufacturing activities and distribution. If we are unable to obtain any necessary services on acceptable terms, we may not complete our product development or commercialization efforts in a timely manner. We may lose control over these activities or become too dependent upon these parties. These third parties may not complete testing, manufacturing or distribution activities on schedule, or in satisfaction of regulatory or commercial requirements. In particular, we currently depend significantly on SIIPL and SLS for co-formulation, filling, and finishing our COVID-19 Vaccine (except in Europe, where we rely on PCI Pharma Services (&#8220;PCI&#8221;)). If SLS or PCI is unable to provide sufficient co-formulation, fill, and finish services to us, fails to meet regulatory requirements, or otherwise defaults on its obligations to us, we may not be able to obtain alternative co-formulation, fill, and finish services from other providers on acceptable terms in a timely manner or at all, which could prevent or delay delivery of customer orders, or otherwise negatively affect our business. Certain of our facilities are also contracted for defined time frames and through association with USG and CEPI, and we may not be able to access those facilities for sufficient periods of time to provide adequate supply. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for confirming that each of our clinical trials is conducted in accordance with its general investigational plan and protocol. Moreover, the U.S. FDA and foreign regulatory agencies require us to comply with regulations and standards, commonly referred to as good clinical practices, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, safety and welfare of clinical trial participants are adequately protected. The U.S. FDA and foreign regulatory agencies also require us to comply with good manufacturing practices. Our reliance on third parties does not relieve us of these responsibilities and requirements. These third parties may not successfully carry out their contractual duties or regulatory obligations. Furthermore, if a third-party manufacturer is producing materials or products for themselves or other companies, that manufacturer is exposed to regulatory risks for the production of such materials and products. As a result, failure to meet the regulatory requirements for the production of those materials and products may generally affect the regulatory status of the third-party manufacturer&#8217;s facility, which could impact its ability to produce our materials and products. Any of our third-party service providers may need to be replaced, the quality or accuracy of the data they obtain may be compromised, the services provided to us may be delayed, or the product they manufacture may be contaminated and unusable due to the failure to adhere to our clinical and manufacturing protocols, regulatory requirements or for other reasons. In any such event, our </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preclinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval of, or successfully commercially manufacture on a timely basis, our vaccine candidates.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may have product liability exposure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The administration of drugs or vaccines to humans, whether in clinical trials or after marketing approval, can result in product liability claims. We maintain product liability insurance coverage for our current clinical programs, including our NVX-CoV2373 and NVX-CoV2601 trials, and for commercialization of our updated vaccine. However, we may not be able to obtain additional insurance coverage or maintain insurance coverage on commercially reasonable terms, at a reasonable cost or in sufficient amounts to protect us against losses due to liability. Furthermore, such insurance coverage and our resources may not be sufficient to satisfy all liabilities that result from product liability claims. A successful claim may prevent us from obtaining adequate product liability insurance in the future on commercially desirable terms, if at all. Even if a claim is not successful, defending such a claim would be time- consuming and expensive, may damage our reputation in the marketplace and would likely divert management&#8217;s attention.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are developing our COVID-19 Vaccine in response to the outbreak of COVID-19, a global pandemic, we have received either provisional registration, conditional marketing authorization, emergency use authorization, or full approval </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from the World Health Organization and various jurisdictions,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and we have a widely used vaccine as an investigational vaccine or a product authorized for temporary or emergency use prior to our receipt of marketing approval in other jurisdictions as well. Unexpected safety issues in these circumstances could lead to product liability claims and our existing insurance may not be adequate for such claims.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">decreased demand for our products;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">withdrawal of regulatory authorizations and approvals;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">voluntary or mandatory recalls of our products;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">necessity for additional nonclinical or clinical studies, changes in labeling, or changes to manufacturing processes, specifications and/or facilities;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">impairment of our business reputation and negative media attention;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">withdrawal of clinical trial participants;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">costs of related litigation;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">substantial monetary awards to participants or other claimants;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">loss of revenue; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">inability to commercialize our vaccine candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the PREP Act, when applicable, provides immunity for manufacturers from all claims under state or federal law for &#8220;loss&#8221; arising out of the administration or use of a &#8220;covered countermeasure.&#8221; However, injured persons may still bring a suit for &#8220;willful misconduct&#8221; against the manufacturer under some circumstances. &#8220;Covered countermeasures&#8221; include security countermeasures and &#8220;qualified pandemic or epidemic products&#8221;, including products intended to diagnose or treat pandemic or epidemic disease, such as pandemic vaccines, as well as treatments intended to address conditions caused by such products. For these immunities to apply, the Secretary of DHHS must invoke the PREP Act by issuing a declaration that a public health emergency or &#8220;credible risk&#8221; of a future public health emergency exists. Such a PREP Act declaration is </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">separate from other declarations such as a PHE or EUA declaration and, among other things, defines the scope and duration of the PREP Act immunities. On March 17, 2020, the Secretary of DHHS issued a declaration under the PREP Act and has issued subsequent amendments thereto to provide liability immunity for activities related to certain countermeasures against the evolving effects of COVID-19. The current declaration will end on December 31, 2024, unless it is renewed. While we believe our products are covered under the current PREP Act declaration, this cannot be assured. Also, the Secretary of the DHHS may not make other declarations in the future that cover any of our other product candidates, and the U.S. Congress may reduce coverage under the PREP Act or repeal it altogether. Product liability lawsuits may result in substantial liabilities and may require us to limit commercialization of our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to effectively manufacture our COVID-19 Vaccine in sufficient quantities, at sufficient yields or are unable to obtain regulatory approvals for a manufacturing facility for our COVID-19 Vaccine, we may experience delays or an adverse impact on product development, clinical trials, regulatory approvals and commercial distribution.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuing to pursue the manufacture, distribution and clinical testing of our COVID-19 Vaccine for commercialization. Completion of our clinical trials and commercialization of our COVID-19 Vaccine and our other vaccine candidates requires access to, or development of, facilities to effectively manufacture our COVID-19 Vaccine and our other vaccine candidates at sufficient yields and at commercial-scale. We have limited experience manufacturing any of our vaccine candidates in the volumes necessary to support commercial sales. While we have increased our global manufacturing capacity for our COVID-19 Vaccine, our efforts to establish and maintain manufacturing capabilities may not meet expectations as to timing, scale-up, reproducibility, yields, purity, cost, potency or quality. We are highly dependent on third-party organizations to conduct a significant amount of our vaccine manufacturing activities. We do not have sufficient internal manufacturing infrastructure to support global commercialization of our COVID-19 Vaccine and we have entered into third-party agreements for the components, as well as for commercial fill-finish manufacturing, for our COVID-19 Vaccine. The antigen component of our COVID-19 Vaccine is currently being manufactured at SIIPL in India, and the Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> adjuvant component of our COVID-19 Vaccine is currently being manufactured at Novavax AB as well as our partnered manufacturing site at AGC Biologics in Europe. Challenges in manufacturing either the antigen component or the adjuvant, or issues in later manufacturing stages, could compromise production of our COVID-19 Vaccine. </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we currently depend substantially on SIIPL and SLS for co-formulation, filling, and finishing our COVID-19 Vaccine (other than in Europe) and PCI for finishing in Europe, and any delays or disruptions in these suppliers&#8217; operations could prevent or delay the delivery of customer orders.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, to ensure adequate inventory supply and manage our operations, we forecast anticipated manufacturing requirements and customer demand to predict inventory needs and place orders with our third-party manufacturers based on such predictions. Our ability to accurately forecast demand for our COVID-19 Vaccine could be negatively affected by many factors, including challenges in managing our commercial strategy, unanticipated changes in general market conditions or regulatory matters, and market demand for variant-specific COVID-19 vaccines, among others. If we underestimate our third-party manufacturing requirements, we may not be able to timely meet obligations under our customer supply agreements. Conversely, if we overestimate our third-party manufacturing requirements, we may end up with inventory levels in excess of customer demand that result in a portion of our inventory becoming obsolete or expiring, as well as inventory write-downs or write-offs, or we may need to cancel previously forecasted batches of product from our third-party manufacturers, which may result in material cancellation fees. In September 2022, for example, we entered into a Confidential Settlement Agreement and Release with FUJIFILM under which we are responsible for up to $185 million to FUJIFILM in connection with the termination of manufacturing activity. In December 2022, we agreed to approximately $95 million in fees owed to AGC Biologics in connection with the cancellation of batches in 2022. If we are unable to accurately forecast demand for our COVID-19 Vaccine and the required services from third-party manufacturers, our results of operations could be materially harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing our COVID-19 Vaccine and our other vaccine candidates involves a complicated process with which we have limited experience. If we and our third-party manufacturers are unable to manufacture our COVID-19 Vaccine and our other vaccine candidates in clinical quantities or, if and when necessary, in commercial quantities and at sufficient yields and at required specifications, then clinical trials and commercialization will be delayed, and we will need to identify and reach supply arrangements with additional third parties. Third-party manufacturers also must receive U.S. FDA or equivalent foreign regulatory body approval before they can produce clinical material or commercial product which could cause delays and alter our production schedule. Our COVID-19 vaccines are in competition with other products for access to these third-party facilities and may be subject to delays in manufacture if third parties prioritize other products. We may not be able to enter into any necessary additional third-party manufacturing arrangements on acceptable terms, or on a timely basis. In </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addition, we have to enter into technical transfer agreements and share our know-how with the third-party manufacturers, which can be time-consuming and may result in delays.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of contractual restraints and the limited number of third-party manufacturers with the expertise, required regulatory approvals and facilities to manufacture bulk vaccines at commercial-scale, replacement of a manufacturer may be expensive and time-consuming and may cause interruptions in the production of our vaccine and negatively impact our ability to timely meet obligations under our customer supply agreements. We and our third-party manufacturers may also encounter production challenges related to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">costs, scale up, and yields;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">shortages of raw materials and supplies;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">shipment delays or other supply chain disruptions</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">quality control and assurance;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">contamination, lot consistency, potency, and purity;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">shortages of qualified personnel and other capacity constraints;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">compliance with strictly enforced and evolving federal, state and foreign regulations that vary in each country where products might be sold including nationalization or other territory restrictions placed on our owned and third-party manufacturing sites; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">capital funding.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delays or interruptions could have a material adverse effect on our business, financial condition, results of operations and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We must identify vaccines for development with our technologies and establish successful third-party relationships.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The near and long-term viability of our vaccine candidates depend in part on our ability to successfully establish new strategic collaborations with pharmaceutical and biotechnology companies, non-profit organizations and government agencies. Establishing strategic collaborations and obtaining government funding is difficult and time-consuming. Potential collaborators may reject collaborations based upon their assessment of our financial, regulatory or intellectual property position or based on their internal pipelines; government agencies may reject contract or grant applications based on their assessment of public need, the public interest, our products&#8217; ability to address these areas, or other reasons beyond our expectations or control. Collaborators also may seek to modify or terminate relationships.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Past success in establishing strategic collaborations with pharmaceutical and biotechnology companies, non-profit organizations and government agencies in the past is no guarantee of future success in entering into new relationships or in performing under existing relationships. If we fail to establish a sufficient number of collaborations or government relationships on acceptable terms, or fail to perform under collaborations or relationships to the satisfaction of counter-parties, we may not be able to commercialize our vaccine candidates or generate sufficient revenue to fund further research and development efforts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaborations we have established or may establish may not result in the successful development or commercialization of any vaccine candidates for several reasons, including the fact that:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we may not have the ability to control the activities of our partners and cannot provide assurance that they will fulfill their obligations to us, including with respect to the license, development and commercialization of vaccine candidates, in a timely manner or at all;</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">such partners may not devote sufficient resources to our vaccine candidates or properly maintain or defend our intellectual property rights;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our partners could independently develop, or develop with third parties, products that compete directly or indirectly with our vaccine candidates if such partners believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">any failure on the part of our partners to perform or satisfy their obligations to us could lead to delays in the development or commercialization of our vaccine candidates and affect our ability to realize product revenue; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">disagreements, including disputes over the ownership of technology developed with such collaborators, could result in litigation, which would be time consuming and expensive, and may delay or terminate research and development efforts, regulatory approvals and commercialization activities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our collaborators fail to maintain our existing agreements or in the event we fail to establish agreements as necessary, we could be required to undertake research, development, manufacturing and commercialization activities solely at our own expense. These activities would significantly increase our capital requirements and, given our lack of sales, marketing and distribution capabilities, significantly delay the commercialization of our vaccine candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on the commercial success of our COVID-19 Vaccine, and even though we have received provisional registration, conditional marketing authorization or emergency use authorization in certain jurisdictions for our COVID-19 Vaccine, and even if we have products licensed in additional markets, our vaccine products may not be initially or ever profitable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the commercial success of our COVID-19 Vaccine, which is currently our only commercial product and source of product revenues. Whether we make a profit from the sale of our vaccine products is dependent on a number of variables, including the costs we incur manufacturing, testing and releasing, packaging and shipping such vaccine product. Additionally, the CEPI funding agreement necessitates that we allocate a certain number of doses of our COVID-19 Vaccine to certain middle and lower income countries which may impact negatively our ability to generate profit. We cannot predict when, if at all, our approved vaccine products will be profitable to the Company, and, ultimately, we may never generate sufficient revenues from our products to reach or maintain profitability or sustain our anticipated levels of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we successfully commercialize any of our vaccine candidates, either alone or in collaboration, we face uncertainty with respect to pricing, third-party reimbursement and healthcare reform, all of which could be subject to change and could adversely affect any commercial success of our vaccine candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to collect revenue from the commercial sale of our vaccines may depend on our ability, and that of any current or potential future collaboration partners or customers, to obtain and if obtained, maintain adequate levels of approval, coverage and reimbursement for such products from third-party payers such as:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">government health administration authorities such as the Advisory Committee for Immunization Practices of the Centers for Disease Control and Prevention;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">private health insurers;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">managed care organizations;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">pharmacy benefit management companies; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">other healthcare related organizations.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payers are increasingly challenging the prices charged for medical products and may deny coverage or offer inadequate levels of reimbursement if they determine that a product has not received appropriate clearances from the U.S. FDA, or foreign equivalent, or other government regulators; is not used in accordance with cost-effective treatment methods as determined by the third-party payer; or is experimental, unnecessary or inappropriate. Prices could also be driven down by managed care organizations that control or significantly influence utilization of healthcare products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both the U.S. and some foreign jurisdictions, there have been a number of legislative and regulatory proposals and initiatives to change the health care system in ways that could affect our ability to sell vaccines and could adversely affect the prices that we receive for our vaccine candidates, if approved. Some of these proposed and implemented reforms could result in reduced drug pricing or reimbursement rates for medical products, and while we have no current vaccines available for commercial sale other than subject to provisional registration, conditional marketing authorization or emergency use authorization in certain foreign jurisdictions, the impact of such reform could nevertheless adversely affect our business strategy, operations and financial results. Our exposure to price-related regulation could depend on whether our products are reimbursed by Medicare under Part B or Part D. Medicare Part B vaccine coverage includes vaccines to prevent influenza, pneumococcal disease, hepatitis B for beneficiaries who are at medium or high risk, and COVID-19. Vaccines for such conditions do not have any cost-sharing requirements. Meanwhile, Medicare Part D vaccine coverage includes all other commercially available vaccines that are determined to be reasonable and necessary to prevent illness. Part D vaccine coverage historically included cost-sharing requirements, but, effective January 1, 2023, the IRA provides access to CDC and ACIP-recommended vaccines covered under Medicare Part D without cost-sharing.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the beginning of the COVID-19 pandemic, the U.S. federal government has been the predominant purchaser of COVID-19 vaccines, making it possible for population-wide access to vaccinations. This population-wide access may change as the pandemic moves past the crisis phase and the market transitions to a third&#8208;party reimbursement model. This transition to a more traditional third&#8208;party reimbursement model is not tied to the ending of the PHE and in part reflects the fact that the U.S. federal government has not received additional funds from Congress to continue to purchase more vaccines. As federal funding declines for COVID-19 vaccines, the USG will most likely transition to standard commercial purchasing through different health care system channels, including commercial insurers and pharmacy benefit managers, and consequently shift the cost of COVID-19 vaccines to insurers and patients (in the form of premiums and out-of-network costs). With respect to the government health care programs and commercial insurance, there may no longer be blanket coverage of COVID-19 vaccines without, in certain instances, accompanying conditions of reimbursement, such as the institution of prior authorization protocols. Medicare (including traditional Medicare and Medicare Advantage) will continue to pay for vaccinations in full; effective January 1, 2023, all Medicare Part D plans are required to cover all adult vaccines recommended by the ACIP, with no cost-sharing, even if the beneficiary is in the deductible phase of the benefit. Provisions in the ARPA and IRA require Medicaid (specifically, with respect to enrollees who receive coverage under traditional Medicaid and all Medicaid medically needy enrollees in specified states) and CHIP programs to cover all ACIP&#8208;recommended vaccines, including COVID&#8208;19 vaccines/boosters with no cost sharing even when the emergency declarations expire and there is no longer any supply of federally purchased vaccines. Under the ACA, people enrolled in non&#8208;grandfathered plans (i.e., the vast majority of people with private insurance) will continue to pay nothing for ACIP&#8208;recommended COVID&#8208;19 vaccines and associated appointments, so long as the enrollee receives this care from an in&#8208;network provider. Even if consumers are guaranteed free access or protected against some costs, they could face access challenges to our product if sufficient amounts of our product are not available compared to that of our competitors or not procured by pharmacies or other providers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the pharmaceutical industry has also been the subject of significant publicity in recent years regarding the pricing of pharmaceutical products, including publicity and pressure resulting from prices charged by pharmaceutical companies for new products as well as price increases by pharmaceutical companies on older products that some people have deemed excessive. As a result, pharmaceutical product prices have been the focus of increased scrutiny by the United States government, including certain state attorneys general, members of Congress, presidential candidates and the United States Department of Justice. If reforms in the health care industry make reimbursement for our potential products less likely, the market for our potential products will be reduced, and we could lose potential sources of revenue. The existence or threat of cost control measures could cause our corporate collaborators to be less willing or able to pursue research and development programs related to our vaccine candidates. Further, it is also possible that additional governmental action is taken in response to the COVID-19 pandemic. We cannot predict the ultimate content, timing or effect of any healthcare reform legislation or the impact of potential legislation on us.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited marketing capabilities, and if we are unable to enter into collaborations with marketing partners or develop our own sales and marketing capability, we may not be successful in commercializing any approved products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have initiated commercialization of our COVID-19 Vaccine, we currently have limited dedicated sales, marketing or distribution capabilities. As a result, we depend on collaborations with third parties that have established distribution systems and sales forces, including our collaboration with SIIPL, among others. To the extent that we enter into co-promotion or other licensing arrangements, our revenue will depend upon the efforts of third parties, over which we may have little or no control. If we are unable to reach and maintain agreements with one or more pharmaceutical companies or collaborators, we may be required to market our products directly. Developing a marketing and sales force is expensive and time-consuming and could delay a product launch. We may not be able to attract and retain qualified sales personnel or otherwise develop this capability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our vaccine candidates may never achieve market acceptance even if we obtain full regulatory approvals.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we receive full regulatory approvals for the commercial sale of our vaccine candidates, the commercial success of these vaccine candidates will depend on, among other things, their acceptance by physicians, patients and third-party payers, such as health insurance companies and other members of the medical community, as a vaccine and cost-effective alternative to competing products. If our vaccine candidates fail to gain market acceptance, we may be unable to earn sufficient revenue to continue our business. Market acceptance of, and demand for, any product that we may develop and commercialize will depend on many factors, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to provide acceptable evidence of safety and efficacy (including against emerging COVID-19 variants);</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the prevalence and severity of adverse side effects;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">whether our vaccines are differentiated from other vaccines;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">availability, relative cost and relative efficacy of alternative and competing treatments;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the effectiveness of our marketing and distribution strategy;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">publicity concerning our products or competing products and treatments; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to obtain sufficient third party insurance coverage or reimbursement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our vaccine candidates do not become widely accepted by physicians, patients, third-party payers and other members of the medical community as well as the relevant public health authorities responsible for scheduling immunizations, our business, financial condition and results of operations could be materially and adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to secure sufficient supplies of a key component of our adjuvant technology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because an important component of our adjuvant technology is extracted from a species of soap-bark tree (Quillaja saponaria) grown in Chile, we need long term access to quillaja extract with a consistent and sufficiently high quality. We need a secure supply of raw material, as well as back-up suppliers, or our adjuvant products may be delayed and we may not be able to meet our obligations under our various collaboration and supply agreements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current or future regional relationships may hinder our ability to engage in larger transactions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into regional collaborations to develop, manufacture and distribute our vaccine candidates in certain parts of the world, and we anticipate entering into additional regional collaborations. Our relationships with SIIPL, Takeda, and SK bioscience are examples of these regional relationships. These relationships often involve the licensing of our technology to our partner or entering into a distribution agreement, frequently on an exclusive basis. Generally, exclusive agreements are restricted to certain territories. Because we have entered into exclusive license and distribution agreements, </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">larger companies may not be interested, or able, to enter into collaborations with us on a worldwide-scale. Also, these regional relationships may make us an unattractive target for an acquisition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates are sensitive to shipping and storage conditions, which could subject our vaccine candidates to risk of loss or damage.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our vaccine candidates are sensitive to storage and handling conditions. Loss in vaccine candidates could occur if the product or product intermediates are not stored or handled properly. It is possible that our vaccine candidates could be lost due to expiration prior to use. If we do not effectively maintain our supply logistics, then we may experience an unusual number of returned or out of date products. Failure to effectively maintain our supply logistics, by us or third parties, could lead to additional manufacturing costs and delays in our ability to supply required quantities for clinical trials or otherwise.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our vaccine candidates could become subject to a product recall which could harm our reputation, business, and financial results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. FDA and similar foreign governmental authorities have the authority to require the recall of certain vaccine candidates. Manufacturers may, under their own initiative, recall a product if any material deficiency in a product is found. A government-mandated or voluntary recall by us or our strategic collaborators could occur as a result of manufacturing errors, design or labeling defects or other deficiencies and issues. For example, we have extended a credit of $64.7 million under the Australia APA for a single lot of NVX-CoV2373 doses sold to the Australian government that upon pre-planned 6-month stability testing was found to have fallen below the defined specifications, and the lot was therefore removed from the market. Recalls of any of our vaccine candidates would divert managerial and financial resources and have an adverse effect on our financial condition and results of operations. Additionally, a recall announcement could harm our reputation with customers and negatively affect our sales.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Industry and Competition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Many of our competitors have significantly greater resources and experience, which may negatively impact our commercial opportunities and those of our current and future licensees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are subject to intense competition and rapid and significant technological change. We have many potential competitors, including major pharmaceutical companies, specialized biotechnology firms, academic institutions, government agencies and private and public research institutions. Many of our competitors have significantly greater financial and technical resources, experience and expertise in:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">research and development;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">preclinical testing;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">designing and implementing clinical trials;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">regulatory processes and approvals;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">production and manufacturing; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">sales and marketing of approved products. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal competitive factors in our industry include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the quality and breadth of an organization&#8217;s technology;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">management of the organization and the execution of the organization&#8217;s strategy;</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the skill and experience of an organization&#8217;s employees and its ability to recruit and retain skilled and experienced employees;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">an organization&#8217;s intellectual property portfolio;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the range of capabilities, from target identification and validation to drug discovery and development to manufacturing and marketing; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the availability of substantial capital resources to fund discovery, development and commercialization activities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large and established companies, such as Merck &amp; Co., Inc., GlaxoSmithKline plc, CSL Ltd., Sanofi Pasteur, SA, Pfizer Inc., Johnson &amp; Johnson, AstraZeneca, and Moderna, among others, compete in the vaccine market. In particular, these companies have greater experience and expertise in securing government contracts and grants to support their research and development efforts, conducting testing and clinical trials, obtaining regulatory approvals to market products, manufacturing such products on a broad scale and marketing approved products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regardless of the disease, smaller or early-stage companies and research institutions also may prove to be significant competitors, particularly through collaborative arrangements with large and established pharmaceutical companies. As these companies develop their technologies, they may develop proprietary positions, which may prevent or limit our product development and commercialization efforts. We will also face competition from these parties in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and participant registration for clinical trials and in acquiring and in-licensing technologies and products complementary to our programs or potentially advantageous to our business. If any of our competitors succeed in obtaining approval from the U.S. FDA or other regulatory authorities for their products sooner than we do or for products that are more effective or less costly than ours, our commercial opportunity could be significantly reduced.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to effectively compete, we will have to make substantial investments in development, testing, manufacturing and sales and marketing or partner with one or more established companies. We may not be successful in gaining significant market share for any vaccine. Our technologies and vaccines also may be rendered obsolete or non-competitive as a result of products introduced by our competitors to the marketplace more rapidly and at a lower cost.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There is significant competition in the development of a vaccine against COVID-19 and a combined vaccine against COVID-19 and influenza, and we may never see returns on the significant resources we are devoting to our vaccine candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our COVID-19 Vaccine has moved rapidly through the regulatory review and authorization processes in the U.S. and other jurisdictions. The speed at which COVID-19 vaccines and therapeutics are being created and tested is atypical, and evolving or changing plans or priorities within the U.S. FDA or other regulatory authorities, including changes based on new knowledge of COVID-19 and how the disease, and new variants of the virus, affect the human body, may significantly affect our ability to establish a competitive market share for our COVID-19 Vaccine. A large number of vaccine manufacturers, academic institutions and other organizations have developed COVID-19 vaccines or are developing COVID-19 vaccine candidates. In particular, Moderna, and Pfizer/BioNTech have received full regulatory approvals for their COVID-19 vaccines and, along with Johnson &amp; Johnson have received emergency use authorizations for their COVID-19 vaccines in the U.S. and other countries. All of these companies have obtained the relevant Emergency Use Licenses (&#8220;EULs&#8221;) from the World Health Organization for their respective vaccines to be supplied to the countries or international coalition partners, including the relevant United Nations agencies, which rely upon the World Health Organization&#8217;s EULs to support the local immunization programs. Despite funding provided to us to date, many of our competitors pursuing vaccine candidates have significantly greater product candidate development, manufacturing and marketing resources than we do. Larger pharmaceutical and biotechnology companies have extensive experience in clinical testing and obtaining regulatory approval for their products and may have the resources to heavily invest to accelerate discovery and development of their vaccine candidates. The success of our COVID-19 Vaccine will depend, in part, on its relative safety, efficacy (including against emerging variant strains), side effect profile, convenience, and cost. COVID-19 vaccines approved prior to our vaccine have developed broad market acceptance that we are challenged to overcome. The U.S. FDA has also approved Gilead&#8217;s Veklury (remdesivir) for treatment of COVID-19 in both adult and pediatric populations, as well as Eli Lilly&#8217;s Olumiant (baricitinib) and Genentech&#8217;s Actemra (tocilizumab) for treatment of COVID-19 in certain hospitalized adults. Furthermore, if any </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">competitors are successful in producing a more efficacious vaccine or other treatment for COVID-19 (including against emerging variant strains), or if any competitors are able to manufacture and distribute any such vaccines or treatments with greater efficiency there may be a diversion of potential governmental and other funding away from us and toward such other parties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are allocating significant financial and personnel resources to the development and commercialization of our COVID-19 Vaccine, which may cause delays in or otherwise negatively impact our other development programs. Our business could be negatively impacted by our allocation of significant resources to combating a global health threat that is unpredictable or against which our vaccine may ultimately prove unsuccessful or unprofitable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many seasonal influenza vaccines are currently approved and marketed. Competition in the sale of these seasonal influenza vaccines is intense. Therefore, newly developed and approved products must be differentiated from existing vaccines in order to have commercial success. In order to show differentiation in the seasonal influenza market, a product may need to be more efficacious, particularly in older adults, be less expensive or quicker to manufacture, or contain other differentiating characteristics, such as being combined with another vaccine. Many competitors are working on new products and new generations of current products, intended to be more efficacious than those currently marketed. Our CIC vaccine candidate may not prove to be more efficacious than current or future seasonal influenza products or future COVID-19 influenza combination products under development by our competitors. Further, our in-house or third-party manufacturing arrangements may not provide enough savings of time or money to provide the required differentiation for commercial success.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulatory and Compliance Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not succeed in obtaining full U.S. FDA licensure or foreign regulatory approvals necessary to sell our vaccine candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development, manufacture and marketing of our pharmaceutical and biological products are subject to government regulation by the U.S. FDA and regulatory authorities in other jurisdictions, including the EMA, the Czech Republic&#8217;s State Institute for Drug Control (SUKL) with respect to our manufacturing facility in the Czech Republic and the Swedish Medical Products Agency (L&#228;kemedelsverket, LV) with respect to our adjuvant product being developed in Sweden, as well as other country authorities into which active pharmaceutical ingredients and excipients are imported and/or manufactured by us or our sub-contracted manufacturers. In the U.S. and most foreign countries, we must complete rigorous preclinical testing and extensive clinical trials that demonstrate the safety and efficacy of a product in order to apply for regulatory approval to market the product. Additionally, we must demonstrate that our manufacturing facilities, processes and controls are adequate with respect to such product to assure safety, purity and potency and comply with applicable good manufacturing practice requirements. None of our vaccine candidates has yet gained full regulatory approval in the U.S., although our COVID-19 Vaccine has received provisional registration, conditional marketing authorization, emergency use authorization, or full approval in the various jurisdictions. We also have vaccine candidates in clinical trials and preclinical laboratory or animal studies. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products might fail to meet their primary endpoints in clinical trials, meaning that we will not have the clinical data required to support regulatory approvals.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The steps generally required by the U.S. FDA before our proposed investigational products may be marketed in the U.S. include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">performance of preclinical (animal and laboratory) tests;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">submission to the U.S. FDA of an IND, which must become effective before clinical trials may commence;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">performance of adequate and well controlled clinical trials to establish the safety and efficacy of the investigational product in the intended target population;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">performance of a consistent and reproducible manufacturing process at commercial scale capable of passing U.S. FDA inspection;</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">submission to the U.S. FDA of a BLA or a NDA; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">U.S.FDA approval of the BLA or NDA before any commercial sale or shipment of the product.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials that we undertake in other countries will be subject to similar or equivalent processes and requirements, In Europe, as well as an authorization for the trial itself, it is necessary to obtain the consent of a local ethics committee for each trial site and to provide for publication specific information about the trial and its outcome. If endpoints are not met, this information will be made publicly available and could be damaging to the reputation of the Company.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These processes are expensive and can take many years to complete, and we may not be able to demonstrate the safety, purity, potency and efficacy of our vaccine candidates to the satisfaction of regulatory authorities. The start of clinical trials can be delayed or take longer than anticipated for many and varied reasons, many of which are out of our control. Safety concerns may emerge that could lengthen the ongoing clinical trials or require additional clinical trials to be conducted. Promising results in early clinical trials may not be replicated in subsequent clinical trials. For example, the first batch of top line results from our Phase 2 CIC clinical trial evaluating safety and immunogenicity of different formulations of CIC may not be consistent with top line results from subsequent batches in such trial. Regulatory authorities may also require additional testing, and we may be required to demonstrate that our proposed products represent an improved form of treatment over existing therapies, which we may be unable to do without conducting further clinical trials. Moreover, if a regulatory authority grants regulatory approval of a product, the approval may be limited to specific indications or limited with respect to its distribution. Expanded or additional indications for approved products may not be approved, which could limit our revenue. Foreign regulatory authorities may apply similar limitations or may refuse to grant any approval. Consequently, even if we believe that preclinical and clinical data are sufficient to support regulatory approval for our vaccine candidates, the U.S. FDA and foreign regulatory authorities ultimately may not grant approval for commercial sale in their applicable jurisdiction, or may impose regulatory requirements that make further pursuit of approval uneconomical in one or more jurisdictions. If our vaccine candidates are not approved, our ability to generate revenue will be limited, and our business will be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may fail to obtain regulatory approval for our products on a timely basis or comply with our continuing regulatory obligations after approval is obtained.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delays in obtaining regulatory approval can be extremely costly in terms of lost sales opportunities, loss of any potential marketing advantage of being early to market and increased clinical trial costs. For example, certain of our APAs and supply agreements may be terminated by the counterparty if we do not timely achieve requisite regulatory approval for our COVID-19 Vaccine in the relevant jurisdictions under such agreements. The speed with which we begin and complete the preclinical studies necessary to begin clinical trials, the clinical trials themselves and our applications for marketing approval will depend on several factors, including the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to scale-up and maintain manufacturing capability that reproducibly generates consistent yields of product with required purity,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potency and quality; that such scale-up occurs on a timely basis; and that we have access to sufficient quantities of materials for use in necessary preclinical studies and clinical trials;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">regulatory authority review and approval of proposed clinical trial protocols;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">approval of clinical trials protocols and informed consent forms by institutional review boards responsible for overseeing the ethical conduct of the trial;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the rate of participant enrollment and retention, which is a function of many factors, including the size of the participant population, the proximity of participants to clinical sites, the eligibility criteria for the clinical trial and the nature of the protocol;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">unfavorable test results or side effects experienced by clinical trial participants;</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">analysis of data obtained from preclinical and clinical activities, which are susceptible to varying interpretations and which interpretations could delay, limit, result in the suspension or termination of, or prevent further conduct of clinical studies or regulatory approval;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the availability of skilled and experienced staff to conduct and monitor clinical trials and to prepare the appropriate regulatory applications; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in the policies of regulatory authorities for drug or vaccine approval during the period of product development.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have somewhat limited experience in conducting and managing the preclinical studies and clinical trials necessary to obtain regulatory marketing approvals. We may not be permitted to continue or commence additional clinical trials. We also face the risk that the results of our clinical trials may be inconsistent with the results obtained in preclinical studies or clinical trials of similar products or that the results obtained in later phases of clinical trials may be inconsistent with those obtained in earlier phases. A number of companies in the biotechnology and product development industry have suffered significant setbacks in advanced clinical trials, even after experiencing promising results in early animal and human testing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory agencies may require us or our collaborators to delay, restrict or discontinue clinical trials on various grounds, including a finding that the participants are being exposed to an unacceptable health risk. In addition, we or our collaborators may be unable to submit applications to regulatory agencies within the time frame we currently expect. Once submitted, applications must be approved by various regulatory agencies before we or our collaborators can commercialize the product described in the application. All statutes and regulations governing the conduct of clinical trials are subject to change in the future, which could affect the cost of such clinical trials. Any unanticipated costs or delays in our clinical trials or regulatory submissions could delay our ability to generate revenue and harm our financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If we are unable to effectively pursue the manufacture, clinical testing, regulatory authorization, and export of our COVID-19 Vaccine, or COVID-19 vaccines against future strain changes, we may encounter delays or challenges in commercially distributing these vaccines as well as&#8239;gaining market acceptance for them.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect that regulatory authorities will continue to monitor and assess SARS-CoV-2 evolution and recommend that manufacturers make corresponding updates to the composition of their COVID-19 vaccines at least annually.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inherent to this evolving approach to manufacturing new strains of COVID-19 vaccines, including our development of our COVID-19 Vaccine, we may encounter regulatory authorization, manufacturing, and distribution challenges, including export challenges. In doing so, we expect to seek alignment and acceptance by regulatory authorities that would allow us to use manufacturing and analytical testing methods employed in earlier COVID-19 vaccine production and commercialization efforts, that support an accurate characterization profile (including purity, potency, stability and like standards) of the relevant COVID-19 vaccine. Our inability to overcome product development challenges and gaining regulatory authority alignment may adversely affect our ability to obtain licensure of our COVID-19 vaccine or future COVID-19 vaccines at all, or in a timely manner.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Regarding future COVID-19 vaccine development, we may fail to receive authorization by regulatory authorities if we are unable to generate sufficient batch analysis data to demonstrate batch-to-batch consistency at commercial scale, if the data generated from our incremental research and development program do not support continued effectiveness of the vaccine to protect individuals against the then-relevant variant of SARS-CoV-2 because the vaccine does not induce an adequate level of neutralization titers against such variant, or if the product otherwise exhibits an unacceptable safety profile, rendering the benefit/risk balance unfavorable. Moreover, the new vaccine lots may not be accepted for distribution if required batch-release testing undertaken by officially designated laboratories does not show that such vaccine is of acceptable quality.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We were unable to accomplish the timely validation of the single-dose vial or pre-filled syringe presentation we had intended to use with the our COVID-19 Vaccine in the U.S. As a result, the five dose vial presentation for the fall 2023 vaccination season may have adversely impacted market acceptance, rate of product returns, or required higher price concessions in the U.S and may adversely impact us in the future if a single-dose or pre-filled syringe presentation is not authorized.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain regulatory approval in foreign jurisdictions would prevent us from marketing our products internationally.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to have our vaccine candidates marketed outside the U.S. In furtherance of this objective, we have entered into supply agreements with various foreign governments and international distribution agreements with commercial entities. In order to market our products in various countries globally , we must obtain separate regulatory approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing and data review. The time required to obtain foreign regulatory approval may differ from that required to obtain U.S. FDA approval. The foreign regulatory approval process may include all of the risks associated with obtaining U.S. FDA approval. Additionally, regulatory authorities outside the U.S. might not accept data from trials conducted in other countries. Although our COVID-19 Vaccine has received provisional registration, conditional marketing authorization or emergency use authorization in a number of jurisdictions, we may not obtain regulatory approvals in other relevant jurisdictions on a timely basis, if at all. Approval by one regulatory agency does not ensure approval by regulatory agencies in other jurisdictions. However, a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in other jurisdictions, including approval by the U.S. FDA. The failure to obtain regulatory approval in foreign jurisdictions could harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory pathway for our COVID-19 Vaccine is continually evolving and may result in unexpected or unforeseen challenges.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory pathway for our COVID-19 Vaccine is evolving and failure by us to comply with any laws, rules and standards, some of which may not exist yet or are subject to interpretation and may be subject to change, could result in a variety of adverse consequences, including penalties, fines and delays in vaccine licensure. Efforts to comply with evolving laws, regulations and standards have resulted in, and are likely to continue to result in, increased general and administrative expenses and a diversion of management time and attention to regulatory compliance activities. For example, the rules, regulations and standards governing the USG Agreement are uncertain and may evolve as the program progresses. Such rules or standards may adversely affect our plans to develop our COVID-19 Vaccine and failure by us to comply with any laws, rules or standards, some of which may not exist yet or may change, could result in a range of adverse consequences, such as penalties, fines or failure to receive funding.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The speed at which multiple stakeholders are moving to create, test and approve vaccines for COVID-19 is highly unusual and may increase the risks associated with traditional vaccine development, which typically takes between eight and ten years. Given this accelerated timeline, we and regulators, such as the U.S. FDA, the EMA, and the UK&#8217;s Medicines and Healthcare Products Regulatory Agency (&#8220;MHRA&#8221;) may make decisions more rapidly than is typical. Evolving or changing plans or priorities at the U.S. FDA or other regulatory bodies to whom we wish to apply for authorization, including based on new knowledge of COVID-19 and how the disease affects the human body, and new variants of the virus, may significantly affect the regulatory pathway for our COVID-19 Vaccine. Results from clinical testing may raise new questions and require us to redesign proposed clinical trials, including revising proposed endpoints or adding new clinical trial sites or cohorts of subjects. In addition, the U.S. FDA&#8217;s or other regulatory authorities&#8217; analysis of clinical data may differ from our interpretation, or regulators&#8217; requirements and expectations for vaccine authorization or approval may change over time, with the result that the U.S. FDA or other regulators may require that we conduct additional clinical trials or non-clinical studies. The evolving regulatory pathway may impede the development, commercialization and/or licensure of our COVID-19 Vaccine.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because the path to licensure of any vaccine against COVID-19 is unclear, we may have a widely used vaccine in circulation in certain countries as an investigational vaccine or a product authorized for temporary or emergency use prior to our receipt of full marketing approval. Unexpected safety issues in these circumstances could lead to significant reputational damage for Novavax and our technology platform going forward and other issues, including delays in our other programs, the need for re-design of our clinical trials and the need for significant additional financial resources. For example, although we currently operate under an emergency use authorization provided by the U.S. FDA for our updated COVID-19 Vaccine, the U.S. FDA may revoke such authorization if it determines that the underlying health emergency no longer exists or warrants such authorization, and we cannot predict how long such authorization will remain in place. Such revocation could adversely impact our business in a variety of ways.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have conducted, continue to conduct and plan to conduct in the future, a number of clinical trials for our COVID-19 Vaccine at sites outside the U.S. and the U.S. FDA may not accept data from trials conducted in such locations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have and are currently conducting several clinical trials of our COVID-19 Vaccine at sites outside the U.S., including a Phase 3 pediatric study (2019nCoV-503) in the Dominican Republic, Guatemala, Honduras, the Philippines, and Mexico. Although the U.S. FDA may accept data from clinical trials conducted outside the U.S., acceptance of these data is subject to conditions imposed by the U.S. FDA. For example, the clinical trial must be well designed and conducted and be performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the U.S. FDA deems clinically meaningful. Other regulatory authorities impose equivalent requirements for their countries. In addition, while these clinical trials are subject to the applicable local laws, where the data is to be used to support our BLA, U.S. FDA acceptance of the data will depend on its determination that the trials also complied with all applicable U.S. laws and regulations. If the U.S. FDA does not accept the data from any trial that we conduct outside the U.S., it could result in delay pending completion of our trials conducted in the U.S. or result in the need for additional trials, which would be costly and time-consuming and could delay or permanently halt our development and commercialization of our COVID-19 Vaccine.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The later discovery of previously unknown problems with a product, manufacturer or facility may result in restrictions, including withdrawal of a vaccine that had previously received regulatory approval in certain jurisdictions from the market.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after a product gains regulatory approval, the product and the manufacturer of the product will be subject to continuing regulatory review, including adverse event reporting requirements and prohibitions against promoting products for unapproved uses. Failure to comply with any post-approval requirements can, among other things, result in warning letters, product seizures, recalls, substantial fines, injunctions, suspensions or revocations of marketing authorizations or licenses, operating restrictions and criminal prosecutions. Any such enforcement actions, any unanticipated changes in existing regulatory requirements or the adoption of new requirements, or any safety issues that arise with any approved products, could adversely affect our ability to market products and generate revenue and thus adversely affect our ability to continue our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may be restricted or prohibited from marketing or manufacturing a product, even after obtaining product approval, if previously unknown problems with the product or its manufacture are subsequently discovered. We cannot provide assurance that newly discovered or developed safety issues will not arise following regulatory approval. With the use of any vaccine by a wide patient population, serious adverse events may occur from time to time that did not arise in the clinical trials of the product or that initially appeared to be unrelated to the vaccine itself and only with the collection of subsequent information were found to be causally related to the product. Any such safety issues could cause us to suspend or cease marketing of our approved products, possibly subject us to substantial liabilities, and adversely affect our ability to generate revenue and our financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to produce a successful vaccine may be curtailed by one or more government actions or interventions, which may be more likely during a global health crisis such as COVID-19.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the significant global impact of the COVID-19 pandemic, it is possible that one or more government entities may take actions, including under the USG under the Defense Production Act of 1950, as amended, that directly or indirectly have the effect of diminishing some of our rights or opportunities with respect to our COVID-19 Vaccine, and the economic value of a COVID-19 vaccine to us could be limited. In addition, during a global health crisis, such as the COVID-19 pandemic, where the spread of a disease needs to be controlled, closed or heavily regulated national borders create challenges and delays in our development, production and distribution activities and may necessitate that we pursue strategies to develop, produce and distribute our vaccine candidates within self-contained national or international borders or with additional safety measures or checks in place, at potentially much greater expense and with longer timeframes for public distribution.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inadequate funding for the U.S. FDA, the SEC and other regulatory authorities could hinder their ability to hire and retain key leadership and other personnel, or otherwise perform their normal functions on which the operation of our business may rely, which could negatively impact our ability to develop or commercialize new products or services, access capital markets, or otherwise operate our business.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the U.S. FDA and other regulatory authorities to review and approve new product applications is affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. For example, average review times at the U.S. FDA have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the U.S. FDA and other agencies may also slow the time necessary for new drugs to be reviewed and approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the USG has shut down several times and certain regulatory agencies, such as the U.S. FDA and the SEC, have had to furlough employees and stop or slow the pace of critical activities. Equally, the move of the EMA to the Netherlands from London caused a significant loss of experienced staff and the UK&#8217;s MHRA&#8217;s loss of funding from the E.U. has caused a loss of funding and consequently of staff. If a prolonged government shutdown or slowdown of the relevant regulatory authority occurs, it could significantly impact the ability of that Authority to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fast Track Designation by the U.S. FDA, the issue of conditional marketing authorizations by the EMA or MHRA, or other regulatory acceleration options may not actually lead to a faster development or regulatory review or approval process and does not assure approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address an unmet medical need for this condition, the drug sponsor may apply for U.S. FDA Fast Track Designation or similar fast track processes with other regulatory agencies. In the EU and the UK, rolling review procedure was relied upon for conditional marketing authorizations to be granted. However, Fast Track Designation or conditional authorizations do not ensure that the drug sponsor will receive marketing approval or that approval will be granted within any particular timeframe. The U.S. FDA granted Fast Track Designation for our prototype vaccine in November 2020, and for our recombinant quadrivalent seasonal influenza vaccine candidate, in January 2020. We may also seek Fast Track Designation for more of our other vaccine candidates. If we do seek Fast Track Designation for our other vaccine candidates, we may not receive it, and even if we receive Fast Track Designation, we may not experience a faster development process, review or approval compared to conventional U.S. FDA procedures. In addition, the U.S. FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast Track Designation alone does not guarantee qualification for the U.S. FDA&#8217;s priority review procedures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining a Fast Track Designation does not change the standards for product approval, but may expedite the development or approval process. Even though the U.S. FDA has granted such designation for our prototype vaccine, it may not actually result in faster clinical development or regulatory review or approval. Furthermore, such a designation does not increase the likelihood that our COVID-19 Vaccine will receive marketing approval in the U.S.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we are subject to environmental, health and safety laws, we may be unable to conduct our business in the most advantageous manner.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various laws and regulations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals, emissions and wastewater discharges, and the use and disposal of hazardous or potentially hazardous substances used in connection with our research, including infectious disease agents. We also cannot accurately predict the extent of regulations that might result from any future legislative or administrative action. Any of these laws or regulations could cause us to incur additional expense or restrict our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our facilities in Maryland are subject to various local, state and federal laws and regulations relating to safe working conditions, laboratory practices, the experimental use of animals and the use and disposal of hazardous or potentially hazardous substances, including chemicals, microorganisms and various hazardous compounds used in connection with our research and development activities. In the U.S., these laws include the Occupational Safety and Health Act, the Toxic Test Substances Control Act and the Resource Conservation and Recovery Act. Similar national and local regulations govern our facilities in Sweden, the Czech Republic, and Switzerland. We cannot eliminate the risk of accidental contamination or </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discharge or injury from these materials. Federal, state and local laws and regulations govern the use, manufacture, storage, handling and disposal of these materials. We could be subject to civil damages in the event of an improper or unauthorized release of, or exposure of individuals to, these hazardous materials. In addition, claimants may sue us for injury or contamination that results from our use or the use by third parties of these materials, and our liability may exceed our total assets. Compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development or production efforts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have general liability insurance, these policies contain exclusions from insurance against claims arising from pollution from chemicals or pollution from conditions arising from our operations. Our collaborators are working with these types of hazardous materials in connection with our collaborations. In the event of a lawsuit or investigation, we could be held responsible for any injury we or our collaborators cause to persons or property by exposure to, or release of, any hazardous materials. However, we believe that we are currently in compliance with all material applicable environmental and occupational health and safety regulations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">For our product candidates, we will be subject to additional healthcare laws and our failure to comply with those laws could have a material adverse effect on our results of operations and financial conditions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the U.S. (and within foreign countries), if we obtain full approval for any of our product candidates and begin commercializing them, our operations may be directly, or indirectly through our arrangements with third-party payors and customers, subject to additional healthcare regulation and enforcement by the federal and state governments (or the regulatory bodies or governments of foreign countries), which may constrain the business or financial arrangements and relationships through which we sell, market and distribute our products. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials. The applicable U.S. federal and state healthcare laws and regulations (which may be comparable to foreign laws existing in foreign countries) that may affect our ability to operate include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the Federal Food, Drug and Cosmetic Act, which among other things, strictly regulates drug product marketing and promotion and prohibits manufacturers from marketing such products for unapproved uses;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving or providing remuneration, directly or indirectly, to induce the referral for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as Medicare and Medicaid;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">federal false claims laws, including the FCA, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, information or claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims; the FCA also permits a private individual acting as whistleblower to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.53pt">the federal Physician Payment Sunshine Act and its implementing regulations, which require manufacturers of drugs, devices, biologicals, and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the DHHS information related </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; effective January 1, 2022, these reporting obligations extend to include transfers of value made to certain non-physician providers such as physician assistants and nurse practitioners; similar reporting requirements have also been enacted on the state level in the U.S., and an increasing number of countries worldwide either have adopted or are considering similar laws requiring disclosure of interactions with health care professionals;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the federal law known as HIPAA, which, in addition to privacy protections applicable to healthcare providers and other entities, prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">state law equivalents of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers, and state gift ban and transparency laws, many of which state laws differ from each other in significant ways and often are not preempted by federal laws, thus complicating compliance efforts; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">state laws restricting interactions with healthcare providers and other members of the healthcare community or requiring pharmaceutical manufacturers to implement certain compliance standards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to, on a corporate or individual basis, penalties, including civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, the exclusion from participation in federal and state healthcare programs and even imprisonment, any of which could materially adversely affect our ability to operate our business and our financial results. In addition, the cost of implementing sufficient systems, controls, and processes to ensure compliance with all of the aforementioned laws could be significant. Any action for violation of these laws, even if successfully defended, could cause us to incur significant legal expenses and divert management&#8217;s attention from the operation of the company&#8217;s business. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, that person or entity may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect business in an adverse way.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights those actions, our business may be impaired. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are also subject to anti-bribery and anti-corruption laws, including the FCPA, the UK Bribery Act, and other similar worldwide anti-bribery laws, as well as various trade laws and regulations (including economic sanctions, export laws, and customs laws), and our failure to comply with those laws could have a material adverse effect on our results of operations and financial conditions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FCPA and similar worldwide anti-bribery and anti-corruption laws prohibit companies and their intermediaries from corruptly providing any payments or other benefits to foreign government officials for the purpose of obtaining or </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">retaining business. The U.S. Departments of Justice, Securities &amp; Exchange Commission, Commerce, State and Treasury and other federal agencies and authorities have a broad range of civil and criminal penalties they may seek to impose against corporations and individuals for violations of the FCPA, economic sanctions laws, export control laws, and other federal statutes and regulations, including those established by the Office of Foreign Assets Control, or OFAC. In addition, the UK Bribery Act of 2010, or the Bribery Act, prohibits both domestic and international bribery, as well as bribery across both private and public sectors. An organization that fails to prevent bribery by anyone associated with the organization can be charged under the Bribery Act unless the organization can establish the defense of having implemented adequate procedures to prevent bribery.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, U.S. and similar worldwide trade laws, including economic sanctions, export laws, and customs laws, regulate our ability to conduct business with certain jurisdictions and counterparties, and regulate the ways in which we may export and import products around the world. In connection with these laws, various government agencies may require us to obtain export licenses, and may impose modifications to business practices, including requiring the cessation of business activities in or with countries, entities, and individuals targeted with sanctions. The breadth and dynamic nature of these laws and regulations may increase compliance costs, and may subject us to fines.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novavax has received a number of regulatory approvals in ex-U.S. jurisdictions and has commenced commercial operations in these international locations, including partnering with third-parties in certain higher-risk jurisdictions. Further, a portion of our business with respect to our manufacturing is conducted outside of the U.S. in higher-risk jurisdictions. We expect our international activities to increase in the future. Though we maintain policies, internal controls and other measures reasonably designed to promote compliance with applicable anti-corruption and trade laws and regulations, our employees or agents may nevertheless engage in improper conduct for which we might be held responsible. Any violations of these anti-corruption or trade laws, or even allegations of such violations, can lead to an investigation and/or enforcement action, which could disrupt our operations, involve significant management distraction, and lead to significant costs and expenses, including legal fees. If we, or our employees or agents acting on our behalf, are found to have engaged in practices that violate these laws and regulations, we could be subject to criminal and civil enforcement action, suffer severe fines and penalties, profit disgorgement, injunctions on future conduct, securities litigation, bans on transacting government business, delisting from securities exchanges and other consequences that may have a material adverse effect on our business, financial condition and results of operations. In addition, our reputation, our revenue or our stock price could be adversely affected if we become the subject of any negative publicity related to actual or potential violations of anti-corruption or trade laws and regulations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Intellectual Property</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends on our ability to maintain the proprietary nature of our technology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success in large part depends on our ability to maintain the proprietary nature of our technology and other trade secrets. To do so, we must prosecute and maintain existing patents, obtain new patents and pursue trade secret and other intellectual property protection. We also must operate without infringing the proprietary rights of third-parties or allowing third-parties to infringe our rights. We currently have or have rights to over 630 U.S. and foreign patents and patent applications covering our technologies. However, patent issues relating to pharmaceuticals and biologics involve complex legal, scientific and factual questions. To date, no consistent policy has emerged regarding the breadth of biotechnology patent claims that are granted by the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) or enforced by the federal courts. Therefore, we do not know whether any particular patent applications will result in the issuance of patents, or that any patents issued to us will provide us with any competitive advantage. We also cannot be sure that we will develop additional proprietary products that are patentable. Furthermore, there is a risk that others will independently develop or duplicate similar technology or products or circumvent the patents issued to us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our patent filings include claims covering various features of our vaccine candidates, including composition, methods of manufacture and use, our patents do not provide us with complete protection against the development of competing products. Some of our know-how and technology is not patentable. To protect our proprietary rights in unpatentable intellectual property and trade secrets, we require employees, consultants, advisors and collaborators to enter into confidentiality agreements. These agreements may not provide meaningful protection for our trade secrets, know-how or other proprietary information, and such risk has been enhanced by the departure of employees in connection with our global restructuring and cost reduction plan.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain trademark registrations for proposed product names/brands, in the U.S. or abroad, may adversely impact our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademark registration to protect the trademarks for our proposed products will require approval from the USPTO in the U.S. and in trademark offices throughout the world in our key markets. The USPTO or a trademark office in a key international jurisdiction may refuse registration of any of our trademarks on a variety of potential grounds. If registration is not granted to one of our trademarks in the U.S. or in another key international jurisdiction, we may be required to adopt an alternative name for that proposed product. If we adopt an alternative name, we would lose the benefit of any existing trademark applications for such developmental candidate and may be required to expend significant additional resources in an effort to identify a suitable product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the U.S. FDA and other regulatory authorities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may claim we infringe their intellectual property rights.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research, development and commercialization activities, including any vaccine candidates resulting from these activities, may be found to infringe patents or trademarks owned by third-parties and to which we do not hold licenses or other rights. There may be rights we are not aware of, including applications that have been filed, but not published that, when issued, could be asserted against us. These third-parties could bring claims against us, and that may cause us to incur substantial expenses and, if successful against us, could cause us to pay substantial damages. Further, if a patent or trademark infringement suit were brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or biologic drug candidate that is the subject of the suit.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of patent or trademark infringement claims, or in order to avoid potential claims, we may choose or be required to seek a license from the third party. These licenses may not be available on acceptable terms, or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be non- exclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent or trademark infringement claims, we are unable to enter into licenses on acceptable terms. All of the issues described above could also impact our collaborators, which would also impact the success of the collaboration and therefore us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been substantial litigation and other proceedings regarding patent, trademark, and other intellectual property rights in the pharmaceutical and biotechnology industries.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in litigation to defend or enforce our intellectual property or the intellectual property of our collaborators or licensors, which could be expensive and time-consuming.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our patents or the patents of our collaborators or licensors. As a result, we may be required to file patent infringement suits to prevent unauthorized uses. This can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover its technology. An adverse determination of any litigation or defense proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at the risk of not issuing. Competitors may infringe our trademarks or the trademarks of collaborators or licensors. As a result, we may be required to file suit to counter infringement for unauthorized use of an identical or confusingly similar trademark. This can be expensive and time-consuming.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are successful, litigation may result in substantial costs and distraction to our management. Even with a broad portfolio, we may not be able, alone or with our collaborators and licensors, to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the U.S.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If investors perceive these results to be negative, the market price for our common stock could be significantly harmed.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The scope, validity, and ownership of our patent claims may be challenged in various venues and, if we do not prevail, our ability to exclude competitors may be harmed, potentially reducing our ability to succeed commercially.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to a variety of challenges from third parties that relate to the scope of the claims or to their validity. Such challenges can be mounted in post-grant review, ex parte re-examination, and inter partes review proceedings before the USPTO, or similar adversarial proceedings in other jurisdictions. If we are unsuccessful in any such challenge, the scope of our claims could be narrowed or could be invalidated. Any such outcome could impair our ability to exclude competitors from the market in those countries, potentially impacting our commercial success.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patents may be subject to various challenges related to ownership and inventorship, including interference or derivation proceedings. Third parties may assert that they are inventors on our patents or that they are owners of the patents. While we perform inventorship analyses to insure that the correct inventors are listed on our patents, we cannot be certain that a court of competent jurisdiction would arrive at the same conclusions we do. If we are unsuccessful in defending against ownership or inventorship challenges, a court may require us to list additional inventors, may invalidate the patent, or may transfer ownership of the patent to a third party. Any of these outcomes may harm our ability to exclude competitors and potentially impact our commercial success. Further, if ownership is transferred to a third party we may be required to seek a license to those rights to preserve our exclusive ability to practice the invention. Such a license may not be available on commercially reasonable terms, or at all. If we are unable to obtain a license, we may be required to expend time, effort, and other resources to design around the patent. Any such license may be non-exclusive and if a competitor is able to obtain a license from the third party, our ability to exclude that competitor from the market may be negatively impacted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are ultimately successful, defending any such challenges may cause us to incur substantial expenses and may require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The scope, validity, and ownership of our trademark rights/registrations may be challenged in various venues in the U.S. and abroad and, if we do not prevail, our ability to exclude competitors from using and registering confusingly similar trademarks may be harmed, potentially reducing our ability to succeed commercially.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to a variety of challenges from third parties that relate to the validity of our trademark registrations in the U.S. and internationally. Such challenges can be mounted in trademark cancellation and opposition proceedings before the USPTO, or similar adversarial proceedings in other jurisdictions. If we are unsuccessful in any such challenge, our trademark registrations could be narrowed or could be refused or canceled. Any such outcome could impair our ability to exclude competitors from using a confusingly similar mark, potentially impacting our commercial success.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trademark registrations may be subject to various challenges related to likelihood of confusion, use of a trademark in commerce, or other grounds in the U.S. and internationally. Third parties may assert that our trademarks infringe on their prior rights or that we are not using a trademark in a particular jurisdiction in connection with the goods/services identified in the trademark registration. While we perform trademark clearance searches and analysis to determine that we are not infringing upon the trademark rights of others, we cannot be certain that a court of competent jurisdiction would arrive at the same conclusions we do. If we are unsuccessful in defending against such challenges, a court may cancel our trademark registration and/or issue an injunction requiring that we cease use of the trademark. We may also not be able to rely on common law rights that we may have in any trademark. Any of these outcomes may potentially impact our commercial success. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are ultimately successful, defending any such challenges may cause us to incur substantial expenses and may require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to license intellectual property from third parties and, if our right to use the intellectual property we license is affected, our ability to develop and commercialize our vaccine candidates may be harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in the past, and we expect in the future to license intellectual property from third parties and that these licenses will be material to our business. We will not own the patents or patent applications that underlie these licenses, and </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we may not control either the prosecution or the enforcement of the patents. Under such circumstances, we may be forced to rely upon our licensors to properly prosecute and file those patent applications and prevent infringement of those patents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While many of the licenses under which we have rights provide us with rights in specified fields, the scope of our rights under these and other licenses may be subject to dispute by our licensors or third parties. In addition, our rights to use these technologies and practice the inventions claimed in the licensed patents and patent applications are subject to our licensors abiding by the terms of those licenses and not terminating them. Any of our licenses may be terminated by the licensor if we are in breach of a term or condition of the license agreement, or in certain other circumstances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, any disputes regarding obligations in licenses may require us to take expensive and time-consuming legal action to resolve, and, even if we are successful, may delay our ability to commercialize products and generate revenue. Further, if we are unable to resolve license issues that arise we may lose rights to practice intellectual property that is required to make, use, or sell products. Any such loss could compromise our development and commercialization efforts for current or future product candidates and/or may require additional effort and expense to design around.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our vaccine candidates and potential vaccine candidates will require several components that may each be the subject of a license agreement. The cumulative license fees and royalties for these components may make the commercialization of these vaccine candidates uneconomical.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If patent laws or the interpretation of patent laws change, our competitors may be able to develop and commercialize our discoveries.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Important legal issues remain to be resolved as to the extent and scope of available patent protection for biopharmaceutical products and processes in the U.S. and other important markets outside the U.S., such as Europe and Japan. In addition, foreign markets may not provide the same level of patent protection as provided under the U.S. patent system. Litigation or administrative proceedings may be necessary to determine the validity and scope of certain of our and others&#8217; proprietary rights. Any such litigation or proceeding may result in a significant commitment of resources in the future and could force us to do one or more of the following: cease selling or using any of our products that incorporate the challenged intellectual property, which would adversely affect our revenue; obtain a license from the holder of the intellectual property right alleged to have been infringed, which license may not be available on reasonable terms, if at all; and redesign our products to avoid infringing the intellectual property rights of third parties, which may be time-consuming or impossible to do. In addition, changes in, or different interpretations of, patent laws in the U.S. and other countries may result in patent laws that allow others to use our discoveries or develop and commercialize our products. We cannot provide assurance that the patents we obtain or the unpatented technology we hold will afford us significant commercial protection. In Europe, a new unitary patent system, which took effect on June 1, 2023, may significantly impact European patents, including those granted before the introduction of the new system. Under the new system, applicants can, upon grant of a patent, opt for that patent to become a Unitary Patent which will be subject to the jurisdiction of a new Unitary Patent Court (&#8220;UPC&#8221;). Patents granted before the implementation of the new system can be opted out of UPC jurisdiction, remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC may be challenged in a single UPC-based revocation proceeding that, if successful, could invalidate the patent in all countries who are signatories to the UPC. Further, because the UPC is a new court system and there is no precedent for the court&#8217;s laws, there is increased uncertainty regarding the outcome of any patent litigation. We are unable to predict what impact the new patent regime may have on our ability to exclude competitors in the European market. In addition to changes in patents laws, geopolitical dynamics, including Russia&#8217;s incursion into Ukraine, may also impact our ability to obtain and enforce patents in particular jurisdictions. If we are unable to obtain and enforce patents as needed in particular markets, our ability to exclude competitors in those markets may be reduced.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extension and/or patent term adjustment in the U.S. under the Hatch-Waxman Act and similar extensions in foreign countries, our ability to exclude competitors may be harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the patent term is 20 years from the earliest U.S. non-provisional filing date. Extensions of patent term may be available under certain circumstances. Depending upon the timing, duration and conditions of U.S. FDA marketing approval of our product candidates, we may be able to extend the term of one patent that covers a marketed product under the Drug Price Competition and Patent Term Restoration Act of 1984, (the &#8220;Hatch-Waxman Amendments&#8221;) and similar legislation in the European Union and the United Kingdom.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Hatch-Waxman Amendments permit patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the U.S. FDA regulatory review process. We may not receive any extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent term covering our products may also be extended for time spent during the prosecution of the patent application in the USPTO. This extension is referred to as Patent Term Adjustment (&#8220;PTA&#8221;). The laws and regulations governing how the USPTO calculates the PTA is subject to change and changes in the law can reduce or increase any such PTA. Further, the PTA granted by the USPTO may be challenged by a third party. If we do not prevail under such a challenge, the PTA may be reduced or eliminated, shortening the patent term, which may negatively impact our ability to exclude competitors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Employee Matters, Managing Growth and Information Technology</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be adversely affected if we do not successfully execute our business development initiatives.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate growing through both internal development projects, as well as external opportunities, which include the acquisition, partnering and in-licensing of products, technologies and companies or the entry into strategic alliances and collaborations. The availability of high quality opportunities is limited, and we may fail to identify candidates that we and our stockholders consider suitable or complete transactions on terms that prove advantageous. In order to pursue such opportunities, we may require significant additional financing, which may not be available to us on favorable terms, if at all. Even if we are able to successfully identify and complete acquisitions, like our business combinations with Novavax CZ (formerly Praha Vaccines) and Novavax AB, strategic transactions involve many risks, including, among others, those related to diversion of management&#8217;s attention from other business concerns, unanticipated expenses and liabilities, and increased complexity of our operations, which could prevent us from effectively exploiting acquired facilities, successfully integrating the acquired business and personnel, or fully realizing expected synergies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To effectively manage our current and future potential growth, we will need to continue to enhance our operational, financial and management processes and to effectively expand, train and manage our employee base. Supporting our growth initiatives will require significant expenditures and management resources, including investments in research and development, manufacturing in-house and through third-party manufacturers and other areas of our business. If we do not successfully manage our growth and do not successfully execute our growth initiatives, then our business and financial results may be adversely impacted, and we may incur asset impairment or restructuring charges.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Given our current cash position and cash flow forecast, and significant uncertainties related to 2024 revenue substantial doubt exists regarding our ability to continue as a going concern through one year from the date that the financial statements included in this Annual Report were issued.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date the financial statements are issued. At December 31, 2023, we had $0.6 billion in cash and cash equivalents and restricted cash. During 2023, we incurred a net loss of $545.1 million and had net cash flows used in operating activities of $714.0&#160;million.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our current cash flow forecast for the one-year going concern look forward period estimates that we have sufficient capital available to fund operations, this forecast is subject to significant uncertainty, including as it relates to the following:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">2024 Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Our 2024 revenue depends on our ability to successfully develop, manufacture, distribute, or market an updated monovalent or bivalent formulation of a vaccine candidate for COVID-19 in a single dose vial or pre-filled syringe product presentation for the fall 2024 COVID-19 vaccine season, which is inherently uncertain and subject to a number of risks, including regulatory authorizations and our ability to introduce a single-dose vial or pre-filled syringe product presentation for the U.S. commercial and certain other markets. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that, given the significance of these uncertainties, substantial doubt exists regarding our ability to continue as a going concern through one year from the date that these financial statements are issued.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to fund Company operations is dependent upon revenue related to vaccine sales for our products and product candidates, if such product candidates receive marketing approval and are successfully commercialized; the resolution of certain matters; and management&#8217;s plans, which may include raising additional capital through a combination of equity and debt financing, collaborations, strategic alliances, and marketing, distribution, or licensing arrangements. New financings may not be available to us on commercially acceptable terms, or at all. Also, any collaborations, strategic alliances, and marketing, distribution, or licensing arrangements may require us to give up some or all of our rights to a product or technology, which in some cases may be at less than the full potential value of such rights. In addition, the regulatory and commercial success of our COVID-19 Vaccine and our other vaccine candidates, including CIC vaccine candidate, or future COVID-19 variant strain-containing monovalent or bivalent formulations, remains uncertain. If we are unable to obtain additional capital, we will assess our capital resources and may be required to delay, reduce the scope of, or eliminate some or all of our operations, or downsize our organization, any of which may have a material adverse effect on our business, financial condition, results of operations, and ability to operate as a going concern.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our announced global restructuring and cost reduction plans may not result in anticipated reductions in combined research and development and selling, general, and administrative expenses and may disrupt our business.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, we announced a global restructuring and cost reduction plan. This plan includes a more focused investment in our COVID-19 commercial program, reduction to our pipeline spending, the continued rationalization of our manufacturing network, a reduction to our global workforce, as well as the consolidation of facilities and infrastructure. The planned workforce reduction includes an approximately 25% reduction in our global workforce, comprised of an approximately 20% reduction in full-time Novavax employees and the remainder comprised of contractors and consultants. We expect the full annual impact of the cost savings to be realized in 2024. During 2023, we recorded a charge of $4.5&#160;million related to one-time employee severance and benefit costs and $10.1&#160;million costs related to the consolidation of facilities and infrastructure, the majority of which were incurred in the second quarter of 2023.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in January 2024 we announced an additional 12% reduction of our global workforce, comprised of an additional 9% reduction in the Company&#8217;s full-time employees and the remainder comprised of contractors and consultants. The Company expects the full annual impact of the cost savings to be realized in 2025 and approximately 85% of the annual impact, excluding one-time charges, to be realized in 2024 due to timing of implementing the measures and the applicable laws, regulations and other factors in the jurisdictions in which it operates. The Company is expected to record an additional charge of approximately $4 million to $7 million related to one-time employee severance and benefit costs, the majority of which is expected to be incurred in the first quarter of 2024. Upon completion, the resulting Company workforce is expected to be approximately 30% lower as compared to the end of the first quarter of 2023.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not realize, in full or in part, the anticipated benefits, savings and improvements in our cost structure from these efforts due to unforeseen difficulties, delays or unexpected costs. If we are unable to realize the potential development progress and cost savings from the global restructuring and cost reduction plan, including the reduction to our global workforce, our business strategy, operating results and financial condition would be adversely affected. Our workforce reductions could yield unanticipated consequences, such as attrition beyond planned workforce reductions or disruptions in our day-to-day operations. Our global restructuring and cost reduction plan, including the reduction to our global workforce, could also harm our ability to attract and retain qualified management and development personnel who are critical to our business. If we are unable to realize the expected benefits from the restructuring and cost reduction plan, we may decide to undertake additional workforce reductions.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Security breaches and other disruptions to our information technology systems or those of the vendors on whom we rely could compromise our information and expose us to liability, reputational damage, or other costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we and many of our current and future strategic partners, vendors, contractors, and consultants collect and store sensitive data, including intellectual property, our proprietary business information and data about our clinical participants, suppliers and business partners, including personally identifiable information. The secure maintenance of this information is critical to our operations and business strategy. Some of this information represents an attractive target of criminal attack by malicious third parties with a wide range of motives and expertise, including nation-states, organized criminal groups, &#8220;hacktivists,&#8221; patient groups, disgruntled current or former employees and others. Our ongoing operating activities also depend on functioning information technology systems. We are </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">required to expend significant resources in an effort to protect against security incidents, and may be required or choose to spend additional resources or modify our business activities, particularly where required by applicable data privacy and security laws or regulations or industry standards. Cyber attacks are of ever-increasing levels of sophistication and frequency and, despite our security measures, our information technology systems and infrastructure and those of our vendors and partners are not immune to such attacks or breaches. Our profile as a recipient of funding under the USG Agreement and our development of our COVID-19 Vaccine may result in greater risk of cyber attack. Any such attack could result in a material compromise of our networks, and the information stored there could be accessed, publicly disclosed, lost, or rendered permanently or temporarily inaccessible. Furthermore, we may not promptly discover a system intrusion. Like other companies in our industry, we have and third parties with connections to our systems or with data relevant to our business have experienced attacks on our data and systems, including malware and computer viruses. Additionally, we partner with sites that store our clinical trial data, and their systems are also subject to the risk of cyberattacks, disruptions, or other security incidents. Attacks could have a material impact on our business, operations or financial results. Any access, disclosure or other loss of information, whether stored by us or our partners, or other cyberattack causing disruption to our business, including ransomware, could result in reputational, business, and competitive harms, significant costs related to remediation and strengthening our cyber defenses, legal claims or proceedings, government investigations, liability including under laws that protect the privacy of personal information, and increased insurance premiums, any of which could have a material adverse effect on our business, operations or financial results. We also may need to pay a ransom if a &#8220;ransomware&#8221; infection prevents access or use of our systems and we may face reputational and other harms in addition to the cost of the ransom if an attacker steals certain critical data in the course of such an attack.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with global privacy and data security requirements could result in additional costs and liabilities or inhibit our ability to collect and process data globally, and our failure to comply with data protection laws and regulations could lead to government enforcement actions, fines, and other harms which would cause our business and reputation to suffer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolving state, federal and foreign laws, regulations and industry standards regarding privacy and security apply to our collection, use, retention, protection, disclosure, transfer and other processing of personal data. Privacy and data protection laws may be interpreted and applied differently from country to country and may create inconsistent or conflicting requirements, which increases the costs incurred by us in complying with such laws, which may be substantial. For example, the GDPR, which became effective in May 2018, imposes a broad array of requirements for processing personal data, including elevated disclosure requirements regarding collection and use of such data, requirements that companies allow individuals to exercise data protection rights such as their right to obtain copies or demand deletion of personal data held by those companies, limitations on retention of information, and public disclosure of significant data breaches, among other things. The GDPR provides for substantial penalties for non-compliance of up to the greater of &#8364;20 million or 4% of global annual revenue for the preceding financial year. </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1, 2021 the</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GDPR</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has been retained</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in UK, as it forms part of the law of England and Wales, Scotland and Northern Ireland by virtue of section 3 of the European Union (Withdrawal) Act 2018, as amended by the Data Protection, Privacy and Electronic Communications (Amendments etc.) (EU Exit) Regulations 2019 (SI 2019/419) (&#8220;UK GDPR&#8221;), alongside the UK&#8217;s Data Protection Act 2018. The UK GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of global turnover. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our efforts to comply with GDPR, the UK GDPR and other privacy and data protection laws impose significant costs and challenges that are likely to increase over time, and we may be exposed to substantial penalties or litigation related to violations of existing or future data privacy laws and regulations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, transferring personal information across international borders is complex and subject to legal and regulatory requirements as well as active litigation and enforcement in a number of jurisdictions around the world, each of which could have an adverse impact on our ability to process and transfer personal data as part of our business operations. For example, the GDPR and UK GDPR impose strict restrictions surrounding the transfer of personal data to countries outside the EEA and the UK The mechanisms that we and many other companies rely upon for European data transfers (for example, Standard Contractual Clauses and the EU - US Data Privacy Framework) are the subject of legal challenge, regulatory interpretation and judicial decisions by the Court of Justice of the European Union. The suitability of Standard Contractual Clauses for data transfer in some scenarios has recently been the subject of legal challenge, and while the United States and the European Union reached agreement on the EU - US Data Privacy Framework, there are legal challenges to that data transfer mechanism as well. We continue to closely monitor for developments related to valid transfer mechanisms available for transferring personal data outside the European Economic Area (including the EU - US Data Privacy Framework) and other countries that have similar trans-border data flow requirements and adjust our practices accordingly. If we are unable to implement a valid compliance mechanism for cross-border personal information transfers, we may face increased exposure to regulatory actions, substantial fines and injunctions against processing or transferring personal </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information from Europe to the U.S. An inability to import personal information from Europe to the U.S. may significantly and negatively impact our business operations, including by limiting our ability to conduct clinical trials in Europe&#894; limiting our ability to collaborate with contract research organizations, service providers, contractors and other companies subject to the GDPR; or requiring us to increase our data processing capabilities in Europe at significant expense. Several other countries have also established specific legal requirements for cross-border transfers of personal information and certain countries have also established specific legal requirements for data localization (such as where personal data must remain stored in the country). If other countries implement more restrictive regulations for cross-border data transfers or do not permit data to leave the country of origin, such developments could adversely impact our business and our enterprise customers&#8217; business, our financial condition and our results of operations in those jurisdictions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Privacy laws and regulations are also expanding in the U.S. For example, the CCPA requires disclosures to California consumers, imposes rules for collecting or using information about minors and affords consumers abilities, such as the right to know whether their data is sold or disclosed and to whom, the right to request that a company delete their personal information, the right to opt-out of the sale of personal information and the right to non-discrimination in terms of price or service when a consumer exercises a privacy right. Like the GDPR, the CCPA establishes potentially significant penalties for violation. The CCPA also provides a private right of action along with statutory damages for certain data breaches. The California Privacy Rights Act (&#8220;CPRA&#8221;), became operational in 2023 and expands on the CCPA, creating new consumer rights and protections, including the right to correct personal information, the right to opt out of the use of personal information in automated decision making, the right to opt out of &#8220;sharing&#8221; consumer&#8217;s personal information for cross-context behavioral advertising, and the right to restrict use and disclosure of sensitive personal information. Virginia, Connecticut and Utah have also passed comprehensive privacy laws that became effective in 2023, and similar laws have been passed or are being considered in several other states, as well as at the federal and local levels. We will need to evaluate and update our privacy program to seek to comply with the CPRA, VCDPA, CPA and other federal and state privacy and data security laws, and we expect to incur additional expense in our effort to comply.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such legislation may add additional complexity, variation in requirements, restrictions and potential legal risk, and may require additional investment of resources in compliance programs, impact strategies, reduce the availability of previously useful data and result in increased compliance costs and/or changes in business practices and policies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborations and contracts of our wholly owned subsidiaries Novavax AB and Novavax CZ, with regional partners, such as SIIPL, Takeda and SK bioscience, as well as with international providers, expose us to additional risks associated with doing business outside the U.S.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Swedish-based Novavax AB and Czech Republic-based Novavax CZ are wholly owned subsidiaries of Novavax, Inc. We also have entered into a supply and license agreement with SIIPL, collaboration and license agreements with each of Takeda and SK bioscience and other agreements and arrangements with foreign governments and companies in other countries. We plan to continue to enter into collaborations or partnerships with companies, non-profit organizations and local governments in various parts of the world. Risks of conducting business outside the U.S. include negative consequences of:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the costs associated with seeking to comply with multiple regulatory requirements that govern our ability to develop, manufacture and sell products in local markets;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">failure to comply with anti-bribery laws such as the U.S. Foreign Corrupt Practices Act and similar anti-bribery laws in other jurisdictions;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">new or changes in interpretations of existing trade measures, including tariffs, embargoes, sanctions, import restrictions, and export licensing requirements;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">difficulties in and costs of staffing, managing and operating our international operations;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in environmental, health and safety laws;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">fluctuations in foreign currency exchange rates;</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">new or changes in interpretations of existing tax laws;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">political instability and actual or anticipated military or potential conflicts (including, without limitation, the ongoing conflict between Russia and Ukraine, and a wider European or global conflict);</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">economic instability, inflation, recession and interest rate fluctuations;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">minimal or diminished protection of intellectual property in many jurisdictions; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">possible nationalization and expropriation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These risks, individually or in the aggregate, could have a material adverse effect on our business, financial conditions, results of operations and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to attract or retain key management or other personnel, our business, operating results and financial condition could be materially adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on our senior executive officers, as well as key scientific and other personnel. The loss of these individuals or our failure to implement an appropriate succession plan could harm our business and significantly delay or prevent the achievement of research, development or business objectives. Turnover in key executive positions resulting in lack of management continuity and long-term history with our Company could result in operational and administrative inefficiencies and added costs. These risks have increased since our global restructuring and cost reduction plan and related workforce reduction implemented in May 2023 and January 2024, which increased the risk that we will lose technical know-how or other trade secrets as experienced personnel depart.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to attract qualified individuals for key positions on terms acceptable to us. Competition for qualified employees is intense among pharmaceutical and biotechnology companies, and the loss of qualified employees, or an inability to attract, retain and motivate additional highly skilled employees could hinder our ability to complete clinical trials successfully and otherwise develop marketable products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely from time to time on outside advisors who assist us in formulating our research and development and clinical strategy. We may not be able to attract and retain these individuals on acceptable terms, which could delay our development efforts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Convertible Senior Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Servicing our 5.00% convertible senior unsecured notes due 2027 requires a significant amount of cash, and we may not have sufficient cash flow to pay our debt.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we issued $175.3 million aggregate principal amount of Notes. Our ability to make scheduled payments of the principal of, to pay interest on, or to refinance our indebtedness, including the Notes, depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. We do not expect our business to be able to generate cash flow from operations sufficient to service our debt and make necessary capital expenditures and may therefore be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness, which matures in 2027, unless earlier converted, redeemed, or repurchased, will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations, and limit our flexibility in planning for and reacting to changes in our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not have the ability to raise the funds necessary to repurchase the Notes as required upon a fundamental change, and our future debt may contain limitations on our ability to repurchase the Notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the Notes will have the right to require us to repurchase their Notes for cash upon the occurrence of a fundamental change at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">repurchased, plus accrued and unpaid interest, if any. A fundamental change may also constitute an event of default or prepayment under, and result in the acceleration of the maturity of, our then-existing indebtedness. We cannot assure that we will have sufficient financial resources, or will be able to arrange financing, to pay the fundamental change repurchase price in cash with respect to any Notes surrendered by holders for repurchase upon a fundamental change. In addition, restrictions in our then existing credit facilities or other indebtedness, if any, may not allow us to repurchase the Notes upon a fundamental change. Our failure to repurchase the Notes upon a fundamental change when required would result in an event of default pursuant to the indenture governing the Notes which could, in turn, constitute a default under the terms of our other indebtedness, if any. If the repayment of the related indebtedness were to be accelerated after any applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness and repurchase the Notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because our stock price has been and will likely continue to be highly volatile, the market price of our common stock may be lower or more volatile than expected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price has been highly volatile. From January 1, 2023 through December 31, 2023, the closing sale price of our common stock has been as low as $4.80 per share and as high as $12.48 per share. The stock market in general and the market for biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. For example, the trading prices of biopharmaceutical companies in particular have been highly volatile as a result of the COVID-19 pandemic, inflation and increased interest rates. These broad market fluctuations may cause the market price of our common stock to be lower or more volatile than expected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, given the global focus on the COVID-19 pandemic and our investment in developing a COVID-19 vaccine, information in the public arena on this topic, whether or not accurate, has had and will likely continue to have an outsized impact (positive or negative) on our stock price. Information related to our development, manufacturing, regulatory and commercialization efforts with respect to our COVID-19 Vaccine, or information regarding such efforts by competitors with respect to their COVID-19 vaccines and vaccine candidates, may meaningfully impact our stock price. As a result of this volatility, you may not be able to sell your common stock at or above your initial purchase price. The market price of our common stock may be influenced by many other factors, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">future announcements about us or our collaborators or competitors, including the results of testing, technological innovations or new commercial products;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">clinical trial results;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays in making regulatory submissions; </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">depletion of our cash reserves;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">sale of equity securities or issuance of additional debt;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">announcement by us of significant strategic partnerships, collaborations, joint ventures, capital commitments or acquisitions;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in government regulations;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">impact of competitor successes and in particular development success of vaccine candidates that compete with our own vaccine candidates;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">developments in our relationships with our collaboration and funding partners;</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">announcements relating to health care reform and reimbursement levels for new vaccines and other matters affecting our business and results, regardless of accuracy;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">sales of substantial amounts of our stock by us or existing stockholders (including stock by insiders or 5% stockholders);</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">development, spread or new announcements related to pandemic diseases;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">litigation;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">public concern as to the safety of our products;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">significant set-backs or concerns with the industry or the market as a whole;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">regulatory inquiries, reviews and potential action, including from the U.S. FDA or the SEC;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">demand for bivalent vaccines;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">recommendations by securities analysts or changes in earnings estimates; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the other factors described in this Risk Factors section.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class-action litigation often has been instituted against that company. Such litigation, if instituted against us, could cause us to incur substantial costs to defend such claims and divert management&#8217;s attention and resources, which could seriously harm our business, financial condition, and results of operations, and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital by issuing securities or through collaboration and licensing arrangements may cause dilution to existing stockholders or require us to relinquish rights to our technologies or vaccine candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to partner with a third-party to advance the development of one or more of our vaccine candidates, we will need to raise money through additional debt or equity financings. To the extent that we raise additional capital by issuing equity securities, our stockholders will experience immediate dilution, which may be significant. There is also a risk that such equity issuances may cause an ownership change under the Internal Revenue Code of 1986, as amended, and similar state provisions, thus limiting our ability to use our net operating loss carryforwards and credits. To the extent that we raise additional capital through licensing arrangements or arrangements with collaborative partners, we may be required to relinquish, on terms that may not be favorable to us, rights to some of our technologies or vaccine candidates that we would otherwise seek to develop or commercialize ourselves. In addition, economic conditions may also negatively affect the desire or ability of potential collaborators to enter into transactions with us. They may also have to delay or cancel research and development projects or reduce their overall budgets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions of our Second Amended and Restated Certificate of Incorporation and Amended and Restated By-Laws and Delaware law could delay or prevent the acquisition of the Company, even if such acquisition would be beneficial to stockholders, and could impede changes in our Board.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our organizational documents could hamper a third party&#8217;s attempt to acquire, or discourage a third-party from attempting to acquire control of, the Company. Stockholders who wish to participate in these transactions may not have the opportunity to do so. Our organizational documents also could limit the price investors are willing to pay in the future for our securities and make it more difficult to change the composition of our Board in any one year. For example, our organizational documents provide for a staggered board with three classes of directors serving staggered three-year terms and advance notice requirements for stockholders to nominate directors and make proposals.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a Delaware corporation, we are also afforded the protections of Section 203 of the Delaware General Corporation Law, which will prevent us from engaging in a business combination with a person who acquires at least 15% of our common stock for a period of three years from the date such person acquired such common stock, unless advance board or stockholder approval was obtained.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay or prevention of a change of control transaction or changes in our Board or management could deter potential acquirers or prevent the completion of a transaction in which our stockholders could receive a substantial premium over the then current market price for their shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never paid dividends on our capital stock, and we do not anticipate paying any such dividends in the foreseeable future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never paid cash dividends on our common stock. We currently anticipate that we will retain all of our earnings for use in the development of our business and do not anticipate paying any cash dividends in the foreseeable future. As a result, capital appreciation, if any, of our common stock would be the only source of gain for stockholders until dividends are paid, if at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation or regulatory investigations could have a material adverse impact on our results of operation and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to intellectual property litigation, from time to time, we may be subject to other litigation or regulatory investigations. Regardless of the merits of any claims that may be brought against us, litigation or regulatory investigations could result in a diversion of management&#8217;s attention and resources and we may be required to incur significant expenses defending against these claims. If we are unable to prevail in litigation or regulatory investigations, we could incur substantial liabilities. Where we can make a reasonable estimate of the liability relating to pending litigation and determine that it is probable, we record a related liability. As additional information becomes available, we assess the potential liability and revise estimates as appropriate. However, because of uncertainties relating to litigation, the amount of our estimates could be wrong.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We or the third parties upon whom we depend may be adversely affected by natural or man-made disasters or public health emergencies, such as the COVID-19 pandemic.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations, and those of our clinical research organizations, contract manufacturing organizations, vendors of materials needed in manufacturing, collaboration partners, distributors and other third parties upon whom we depend, could be subject to fires, extreme weather conditions, earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, war, political unrest, sabotage or terrorism and other natural or man-made disasters, as well as public health emergencies, such as the COVID-19 pandemic. The occurrence of any of these business disruptions could prevent us from using all or a significant portion of our facilities and it may be difficult or impossible for us to continue certain activities for a substantial period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event and we may incur substantial expenses and delays as a result. Our ability to manufacture our product candidates and obtain necessary clinical supplies for our product candidates could be disrupted if the operations of our contract manufacturing organizations or suppliers are affected by a natural or man-made disaster, or a public health emergency.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a target for public scrutiny, and our business may be impacted by unfavorable publicity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given that COVID-19 represented an unprecedented urgent public health crisis and that we have received significant funding from the U.S. and foreign governments and other sources to support the development and commercialization of our COVID-19 Vaccine, we have observed and are likely to continue to face significant public attention and scrutiny over the complex decisions we have made and will be making regarding the development, testing, manufacturing, allocation and pricing of our COVID-19 Vaccine. If we are unable to successfully manage these risks, we could face significant reputational harm, which could negatively affect our stock price. The intense public interest, including speculation by the media, in the development of our COVID-19 Vaccine has caused significant volatility in our stock price, which we expect to continue as </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">data and other information from our ongoing clinical trials become publicly available. If concerns should arise about the actual or anticipated efficacy or safety of any of our product candidates, such concerns could adversely affect the market&#8217;s perception of these candidates, which could lead to a decline in investors&#8217; expectations and a decline in the price of our common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The increasing use of social media platforms presents new risks and challenges to our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Social media is increasingly being used to communicate about pharmaceutical companies&#8217; research, product candidates, and the diseases such product candidates are being developed to prevent. Social media practices in the pharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us. For example, subjects may use social media channels to comment on their experience in an ongoing blinded clinical trial or to report an alleged adverse event. When such events occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our investigational product candidates. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social media or networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions, or incur reputational or other harm to our business.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="i65591fd2146e456aac589be2afadc864_67"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. UNRESOLVED STAFF COMMENTS</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i65591fd2146e456aac589be2afadc864_3848290698844"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1C. CYBERSECURITY</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risk Management and Strategy</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has adopted a cybersecurity risk management program that includes processes designed to identify, assess, manage, and monitor risks from cybersecurity threats. We have integrated cybersecurity risk management into our broader risk management framework to promote a company-wide culture of cybersecurity awareness and risk management. Those processes include conducting an assessment of internal and external threats to the security, confidentiality, integrity and availability of Company data and systems along with other material risks to Company operations, at least annually or whenever there are material changes to the Company&#8217;s systems or operations and responding to risks identified. The Company uses NIST cybersecurity and risk management frameworks to assess its cybersecurity controls, risks, and overall program effectiveness. As part of our risk management process, the Company also engages outside providers to conduct periodic internal and external penetration testing and security assessments. As part of our third-party risk management program, we conduct assessments of vendor cybersecurity risks, including risks associated with our cloud vendors and other third parties.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this report, we have not experienced a cybersecurity incident that resulted in a material effect on our business strategy, results of operations, or financial condition. Despite our continuing efforts, we cannot guarantee that our cybersecurity safeguards will prevent breaches or breakdowns of our or our third-party service providers&#8217; information technology systems, particularly in the face of continually evolving cybersecurity threats and increasingly sophisticated threat actors. For example, in 2020, several domestic and foreign security agencies announced that government actors or government-affiliated actors were specifically targeting organizations, like us, engaging in COVID-19 vaccine development and research. For more information, see Item 1A Risk Factors, &#8220;Security breaches and other disruptions to our information technology systems or those of the vendors on whom we rely could compromise our information and expose us to liability, reputational damage, or other costs.&#8221;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Governance</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cybersecurity risk management program is led by the Company&#8217;s Chief Information Officer (&#8220;CIO&#8221;) who has over 20 years of experience in information systems, cybersecurity, and data protection. The CIO reports to the Company&#8217;s Audit Committee at least annually, as well as to the Board of Directors, the Company&#8217;s Chief Executive Officer, and other members of our senior management as appropriate. These reports may feature an overall assessment of the Company&#8217;s compliance with the Company&#8217;s cybersecurity policies and include topics such as risk assessment, risk management and control decisions, service provider arrangements, test results, security incidents and responses, and recommendations for changes and updates to policies and procedures. Our program is evaluated by internal and external experts with the results of those reviews reported to senior management and the Board.</span></div><div id="i65591fd2146e456aac589be2afadc864_70"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. PROPERTIES</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we leased approximately 170,000 square feet of office space in Gaithersburg, Maryland that serves as our corporate headquarters (&#8220;700QO&#8221;), and intend to use for manufacturing and research and development. The term of the 700QO lease agreement is approximately 15 years, and we have the option to extend the Lease Agreement for two successive five-year terms.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we also lease and own approximately 192,000 square feet of office and other space in the U.S., apart from our corporate headquarters and approximately 260,000 in various foreign locations. We use this space for our services and support, commercial, research and development, manufacturing, and administrative personnel. Although we believe that our facilities are suitable and adequate for our present needs, the Company&#8217;s management continues to review and assess real property requirements that may be necessary to address our current business plan.</span></div><div id="i65591fd2146e456aac589be2afadc864_73"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. LEGAL PROCEEDINGS</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 12, 2021, Sothinathan Sinnathurai filed a purported securities class action in the U.S. District Court for the District of Maryland (the &#8220;Maryland Court&#8221;) against the Company and certain members of senior management, captioned </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sothinathan Sinnathurai v. Novavax, Inc., et al., No. 8:21-cv-02910-TDC (the &#8220;Sinnathurai Action&#8221;). On January 26, 2022, the Maryland Court entered an order designating David Truong, Nuggehalli Balmukund Nandkumar, and Jeffrey Gabbert as co-lead plaintiffs in the Sinnathurai Action. The co-lead plaintiffs filed a consolidated amended complaint on March 11, 2022, alleging that the defendants made certain purportedly false and misleading statements concerning the Company&#8217;s ability to manufacture prototype vaccine on a commercial scale and to secure the prototype vaccine&#8217;s regulatory approval. The amended complaint defines the purported class as those stockholders who purchased the Company&#8217;s securities between February 24, 2021 and October 19, 2021. On April 25, 2022, the defendants filed a motion to dismiss the consolidated amended complaint. On December 12, 2022, the Maryland Court issued a ruling granting in part and denying in part defendants&#8217; motion to dismiss. The Maryland Court dismissed all claims against two individual defendants and claims based on certain public statements challenged in the consolidated amended complaint. The Maryland Court denied the motion to dismiss as to the remaining claims and defendants, and directed the Company and other remaining defendants to answer within fourteen days. On December 27, 2022, the Company filed its answer and affirmative defenses. On March 16, 2023, the plaintiffs filed a motion for class certification and to appoint class representatives and counsel. Due to the Maryland Court&#8217;s ruling on the dismissal motion, the motion sought to certify a class of stockholders who purchased the Company&#8217;s securities between May 11, 2021, and October 19, 2021. The Company filed its opposition to the plaintiffs&#8217; motion on September 22, 2023. On December 4, 2023, the parties agreed to a binding settlement in principle (the &#8220;Proposed Settlement&#8221;) to fully resolve the surviving claims in the Sinnathurai Action. Under the Proposed Settlement&#8217;s terms, the Company agreed to pay $47 million into a settlement fund, which will be funded by the Company&#8217;s directors and officers&#8217; liability insurance and paid to members of a putative settlement class. On January 12, 2024, after the parties negotiated and executed a written agreement governing the Proposed Settlement, plaintiffs filed an unopposed motion for the Proposed Settlement&#8217;s preliminary approval. On January 23, 2024, the Maryland Court granted the motion for preliminary approval and, as requested by the parties, preliminarily certified, for the purposes of settlement only, the settlement class. The court also scheduled a settlement hearing to consider final approval of the settlement for May 23, 2024.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the Sinnathurai Action was filed, eight derivative lawsuits were filed: (i) Robert E. Meyer v. Stanley C. Erck, et al., No. 8:21-cv-02996-TDC (the &#8220;Meyer Action&#8221;), (ii) Shui Shing Yung v. Stanley C. Erck, et al., No. 8:21-cv-03248-TDC (the &#8220;Yung Action&#8221;), (iii) William Kirst, et al. v. Stanley C. Erck, et al., No. C-15-CV-21-000618 (the &#8220;Kirst Action&#8221;), (iv) Amy Snyder v. Stanley C. Erck, et al., No. 8:22-cv-01415-TDC (the &#8220;Snyder Action&#8221;), (v) Charles R. Blackburn, et al. v. Stanley C. Erck, et al., No. 1:22-cv-01417-TDC (the &#8220;Blackburn Action&#8221;), (vi) Diego J. Mesa v. Stanley C. Erck, et al., No. 2022-0770-NAC (the &#8220;Mesa Action&#8221;), (vii) Sean Acosta v. Stanley C. Erck, et al., No. 2022-1133-NAC (the &#8220;Acosta Action&#8221;), and (viii) Jared Needelman v. Stanley C. Erck, et al., No. C-15-CV-23-001550 (the &#8220;Needelman Action&#8221;). The Meyer, Yung, Snyder, and Blackburn Actions were filed in the Maryland Court. The Kirst and Needelman Actions were filed in the Circuit Court for Montgomery County, Maryland. The Mesa and Acosta Actions were filed in the Delaware Court of Chancery (the &#8220;Delaware Court&#8221;). The derivative lawsuits name members of the Company&#8217;s board of directors and certain members of senior management as defendants. The Company is deemed a nominal defendant. The plaintiffs assert derivative claims arising out of substantially the same alleged facts and circumstances as the Sinnathurai Action. Collectively, the derivative complaints assert claims for breach of fiduciary duty, insider selling, unjust enrichment, violation of federal securities law, abuse of control, waste, and mismanagement. Plaintiffs seek declaratory and injunctive relief, as well as an award of monetary damages and attorneys&#8217; fees.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 7, 2022, the Maryland Court entered an order consolidating the Meyer and Yung Actions (the &#8220;First Consolidated Derivative Action&#8221;). The plaintiffs in the First Consolidated Derivative Action filed their consolidated derivative complaint on April 25, 2022. On May 10, 2022, the Maryland Court entered an order granting the parties&#8217; request to stay all proceedings and deadlines pending the earlier of dismissal or the filing of an answer in the Sinnathurai Action. On June 10, 2022, the Snyder and Blackburn Actions were filed. On October 5, 2022, the Maryland Court entered an order granting a request by the plaintiffs in the First Consolidated Derivative Action and the Snyder and Blackburn Actions to consolidate all three actions and appoint co-lead plaintiffs and co-lead and liaison counsel (the &#8220;Second Consolidated Derivative Action&#8221;). The co-lead plaintiffs in the Second Consolidated Derivative Action filed a consolidated amended complaint on November 21, 2022. On February 10, 2023, defendants filed a motion to dismiss the Second Consolidated Derivative Action. The plaintiffs filed their opposition to the motion to dismiss on April 11, 2023. Defendants filed their reply brief in further support of their motion to dismiss on May 11, 2023. On August 21, 2023, the court entered an order granting in part and denying in part the motion to dismiss; the court allowed claims for alleged insider selling under Brophy v. Cities Service Co., et al., 70 A.2d 5 (Del. Ch. 1949) and unjust enrichment claims to proceed, but dismissed the remaining claims in the second consolidated amended complaint. On September 5, 2023, the Company filed an Answer to the consolidated amended complaint. On September 6, 2023, the court entered an order granting the individual defendants an extension of time to file their answer until November 6, 2023. On October 6, 2023, the Board of Directors of the Company formed a Special Litigation Committee (&#8220;SLC&#8221;) with full and exclusive power and authority of the Board to, among other things, investigate, review, and analyze the </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">facts and circumstances surrounding the claims asserted in the pending derivative actions, including the claims that remain following the court&#8217;s order on the motion to dismiss in the Second Consolidated Derivative Action. On November 7, 2023, the court entered an order granting the parties&#8217; request to stay the Second Consolidated Derivative Action for up to six months from the date of entry of the order. This includes staying the deadline for the individual defendants to respond to the consolidated amended complaint.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Kirst Action was filed on December 28, 2021, and the defendants immediately removed the case to the Maryland Court. On July 21, 2022, the Maryland Court issued a memorandum opinion and order remanding the Kirst Action to state court. The plaintiffs filed an amended complaint on December 30, 2022. On January 23, 2023, defendants filed a motion to stay the Kirst action. On February 22, 2023, the parties in the Kirst Action filed, for the Court&#8217;s approval, a stipulation staying the Kirst Action pending the resolution of defendants&#8217; motion to dismiss in the Second Consolidated Derivative Action. On March 22, 2023, the Court entered the parties&#8217; stipulated stay of the Kirst Action pending resolution of the motion to dismiss in the Second Consolidated Derivative Action.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2022, the Mesa Action was filed. On October 3, 2022, the Delaware Court entered an order granting the parties&#8217; request to stay all proceedings and deadlines in the Mesa Action pending the earlier of dismissal of the Sinnathurai Action or the filing of an answer to the operative complaint in the Sinnathurai Action. On January 18, 2023, defendants filed a motion to stay the Mesa Action pending a final judgment in the Second Consolidated Derivative Action. The plaintiff filed his opposition on February 8, 2023. Defendants filed their reply on February 22, 2023. On February 28, 2023, the court granted the defendants&#8217; motion to stay. On August 31, 2023, the plaintiff filed a motion to lift the stay. On October 6, 2023, the Company filed an opposition to plaintiff&#8217;s motion to lift the stay. Plaintiff filed his reply on October 17, 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 27, 2023, the parties filed a letter informing the Court that the Second Consolidated Derivative Action had been stayed for a period of six months and asked the Court to stay further proceedings in the Mesa Action until expiration of that stay.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2022, the Acosta Action was filed. On February 6, 2023, defendants accepted service of the complaint and summons in the Acosta Action. On March 9, 2023, the court entered an order granting the parties&#8217; request to stay the Acosta Action pending the entry of a final, non-appealable judgment in the Second Consolidated Derivative Action. On October 13, 2023, the parties filed, and the Delaware Court entered, a stipulated order providing that (i) if the Delaware Court declines to lift the stay in the Mesa Action, the Acosta Action will also remain stayed, and (ii) if the Delaware Court lifts the stay in the Mesa Action, the stay in the Acosta Action will also be lifted.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2023, the Needelman Action was filed. On July 12, 2023, the parties filed a stipulation and proposed order to stay the Needelman Action pending the Maryland Court&#8217;s decision on the motion to dismiss in the Second Consolidated Derivative Action. The court entered that order on July 17, 2023. The parties continue to discuss next steps in the litigation following the Maryland Court&#8217;s ruling on the motion to dismiss the Second Consolidated Derivative Action. The court entered that order on July 17, 2023.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2023, the court entered an order consolidating the Kirst and Needelman Actions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2023, the parties filed a stipulation (i) extending the plaintiffs&#8217; deadline to file a consolidated complaint until January 29, 2024, and (ii) otherwise staying all other proceedings in the case (including the defendants&#8217; deadline to respond to the consolidated complaint) until February 12, 2024. The stipulation entered by the court instructs the parties to discuss whether the stay should be further extended in light of the then-current status of the SLC&#8217;s investigation. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 18, 2022, the Company delivered written notice to Gavi to terminate the Gavi APA based on Gavi&#8217;s failure to procure the purchase of 350&#160;million doses of prototype vaccine from the Company as required by the Gavi APA. As of November 18, 2022, the Company had only received orders under the Gavi APA for approximately 2&#160;million doses. On December 2, 2022, Gavi issued a written notice purporting to terminate the Gavi APA based on Gavi&#8217;s contention that the Company repudiated the agreement and, therefore, materially breached the Gavi APA. Gavi also contended that, based on its purported termination of the Gavi APA, it was entitled to a refund of the Advance Payment Amount less any amounts that have been credited against the purchase price for binding orders placed by a buyer participating in the COVAX Facility. Since December 31, 2022, the remaining Gavi Advance Payment Amount, which is $696.4&#160;million as of December 31, 2023, pending resolution of the dispute with Gavi related to a return of the remaining Advance Payment Amount, has been classified within Other current liabilities in the Company&#8217;s consolidated balance sheet. On January 24, 2023, Gavi filed a demand for arbitration with the International Court of Arbitration based on the claims described above. The Company filed its Answer and Counterclaims on March 2, 2023. On April 5, 2023, Gavi filed its Reply to the Company&#8217;s Counterclaims. On February 16, 2024, the Company and Gavi entered into a Termination and Settlement Agreement (the &#8220;Settlement Agreement&#8221;) terminating the Gavi APA, which related to the supply of the Company&#8217;s vaccine against SARS-COV-2 for the prevention of COVID-19, </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">settling the arbitration proceedings initiated by Gavi against the Company relating to the APA and releasing both parties of all claims arising from, under or otherwise in connection with the APA. Pursuant to the Settlement Agreement, the Company is responsible for payment to Gavi of (i) an initial settlement payment of $75 million, which the Company paid on February 20, 2024, and (ii) deferred payments, in equal annual amounts of $80 million payable each calendar year through a deferred payment term ending December 31, 2028. The deferred payments are due in variable quarterly installments beginning in the first quarter of 2024 and total $400 million during the deferred payment term. Such deferred payments may be reduced through Gavi&#8217;s use of an annual vaccine credit equivalent to the unpaid balance of such deferred payments each year, which may be applied to qualifying sales of any of the Company&#8217;s vaccines funded by Gavi for supply to certain low-income and lower-middle income countries. The Company has the right to price the vaccines offered to such low-income and lower-middle income countries in its discretion, and, when utilized by Gavi, the Company will credit the actual price per vaccine paid against the applicable credit. The Company intends to price vaccines offered via the tender process, consistent with its shared goal with Gavi to provide equitable access to those countries. On February 22, 2024, the claims and counterclaims were dismissed with prejudice.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, the Company, FUJIFILM Diosynth Biotechnologies UK Limited (&#8220;FDBK&#8221;), FUJIFILM Diosynth Biotechnologies Texas, LLC (&#8220;FDBT&#8221;), and FUJIFILM Diosynth Biotechnologies USA, Inc. (&#8220;FDBU&#8221; and together with FDBK and FDBT, &#8220;Fujifilm&#8221;) entered into a Confidential Settlement Agreement and Release (the &#8220;Fujifilm Settlement Agreement&#8221;) regarding amounts due to Fujifilm in connection with the termination of manufacturing activity at FDBT under the Commercial Supply Agreement (the &#8220;CSA&#8221;) dated August 20, 2021 and Master Services Agreement dated June 30, 2020 and associated statements of work (the &#8220;MSA&#8221;) by and between the Company and Fujifilm. The MSA and CSA established the general terms and conditions applicable to Fujifilm&#8217;s manufacturing and supply activities related to the Company&#8217;s prototype vaccine under the associated statements of work. Pursuant to the Fujifilm Settlement Agreement, the Company agreed to pay up to $185.0&#160;million (the &#8220;Settlement Payment&#8221;) to Fujifilm in connection with cancellation of manufacturing activity at FDBT. Under the Fujifilm Settlement Agreement, the final two quarterly installments due to Fujifilm were subject to Fujifilm&#8217;s obligation to use commercially reasonable efforts to mitigate losses associated with the vacant manufacturing capacity caused by the termination of manufacturing activities at FDBT under the CSA. Any replacement revenue achieved by Fujifilm&#8217;s mitigation efforts between July 1, 2023 and December 31, 2023 would offset the final two settlement payments owed by the Company. On October 2, 2023, the Company sent a notice of breach under the Fujifilm Settlement Agreement to Fujifilm setting forth the Company&#8217;s position that Fujifilm had not used commercially reasonable efforts to mitigate losses. The Company withheld two installments of $34.3&#160;million due to Fujifilm on September&#160;30, 2023 and December&#160;31, 2023, pending resolution of the issues identified in the notice of breach. On October 30, 2023, FDBT filed a demand for arbitration with Judicial Arbitration and Mediation Services (&#8220;JAMS&#8221;) seeking payment of the third quarter installment of the Settlement Payment. An arbitration hearing has been scheduled for May 2024.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also involved in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently difficult to predict, management does not expect the resolution of these legal proceedings to have a material adverse effect on our financial position, results of operations, or cash flows.</span></div><div id="i65591fd2146e456aac589be2afadc864_76"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="i65591fd2146e456aac589be2afadc864_79"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i65591fd2146e456aac589be2afadc864_82"></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock trades on the Nasdaq Global Select Market under the symbol &#8220;NVAX.&#8221; Our common stock was held by approximately 177 stockholders of record as of February&#160;23, 2024, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">one of which is Cede &amp; Co., a nominee for Depository Trust Company (&#8220;DTC&#8221;). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the shares of common stock held by brokerage firms, banks, and other financial institutions as nominees for beneficial owners are deposited into participant accounts at DTC, and are therefore considered to be held of record by Cede &amp; Co. as one stockholder. We do not anticipate declaring or paying any cash dividends in the foreseeable future.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance under our Equity Compensation Plans</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding our equity compensation plans, including both stockholder approved plans and non-stockholder approved plans, is included in Part III, Item 12 of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graph below matches Novavax, Inc.'s cumulative 5-Year total shareholder return on common stock with the cumulative total returns of the Nasdaq Composite Index and the Russell 2000 Growth Biotechnology Index. The graph tracks the performance of a $100 investment in our common stock and in each index (with the reinvestment of all dividends) from December 31, 2018 to December&#160;31, 2023.</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">COMPARISON OF 5 YEAR CUMULATIVE RETURN*</span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among Novavax Inc., the NASDAQ Composite index, </span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the Russell 2000 Growth Biotechnology Index</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><img src="nvax-20231231_g2.jpg" alt="1529" style="height:400px;margin-bottom:5pt;vertical-align:text-bottom;width:750px"/></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*$100 invested on 12/31/18 in stock or index, including reinvestment of dividends. </span></div><div style="padding-left:72pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fiscal year ending December 31.</span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Value of $100 invested on December 31, 2018 in stock or index, including reinvestment of dividends, for fiscal years ended:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:31.248%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.978%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.978%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.978%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.978%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.802%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2018</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novavax, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303.02&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">388.78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.93&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.04&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NASDAQ Composite</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.03&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russell 2000 Growth Biotechnology</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">157.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This graph is not &#8220;soliciting material,&#8221; is not deemed &#8220;filed&#8221; with the SEC, and is not to be incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.</span></div><div id="i65591fd2146e456aac589be2afadc864_85"></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;&#160;&#160;RESERVED</span></div><div id="i65591fd2146e456aac589be2afadc864_88"></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any statements in the discussion below and elsewhere in this Annual Report on Form 10-K about expectations, beliefs, plans, objectives, assumptions, or future events or performance of Novavax, Inc. (&#8220;Novavax,&#8221; together with its wholly owned subsidiaries, the &#8220;Company,&#8221; &#8220;we,&#8221; or &#8220;us&#8221;) are not historical facts and are forward-looking statements. Such forward-looking statements include, without limitation, statements about our capabilities, goals, expectations regarding future revenue and expense levels, and capital raising activities; our operating plans and prospects, including our ability to continue as a going concern through one year from the date of Novavax&#8217; audited financial statements for the year ended December 31, 2023; our global restructuring and cost reduction plan (&#8220;Restructuring Plan&#8221;), which includes a more focused investment in our COVID-19 commercial program (which currently includes Nuvaxovid&#8482; prototype COVID-19 vaccine ("NVX-CoV2373&#8221; or &#8220;prototype vaccine&#8221;) and Nuvaxovid&#8482; updated COVID-19 vaccine (&#8220;NVX-CoV2601&#8221; or &#8220;updated vaccine&#8221;) collectively referred to as our (&#8220;COVID-19 Vaccine&#8221;)), potential market sizes and demand for our product candidates; the efficacy, safety, and intended utilization of our product candidates; the development of our clinical-stage product candidates and our recombinant vaccine and adjuvant technologies; the development of our preclinical product candidates; our expectations related to enrollment in our clinical trials; the conduct, timing, and potential results from clinical trials and other preclinical studies; plans for and potential timing of regulatory filings; our expectation of manufacturing capacity, timing, production, distribution, and delivery for our COVID-19 Vaccine by us and our partners; our estimate of the number of individuals who may potentially be reached by our COVID-19 Vaccine; our expectations with respect to the anticipated ongoing development and commercialization or licensure of the COVID-19 Vaccine, ongoing development of COVID-19 variant strain-containing monovalent or bivalent formulation, efforts to expand our COVID-19 Vaccine label worldwide as a booster, and to various age groups and geographic locations; the expected timing, content, and outcomes of regulatory actions; funding from the U.S. government partnership formerly known as Operation Warp Speed under the USG Agreement, the U.S. Department of Defense (&#8220;DoD&#8221;), and CEPI; funding under our APAs and supply agreements and amendments to, termination of, discussion regarding, or legal disputes relating to any such agreement; our available cash resources and usage and the availability of financing generally; plans regarding partnering activities and business development initiatives; and other matters referenced herein. Generally, forward-looking statements can be identified through the use of words or phrases such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;possible,&#8221; &#8220;can,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;ongoing,&#8221; &#8220;consider,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;seek,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;expect,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;aim,&#8221; or &#8220;assume,&#8221; the negative of these terms, or other comparable terminology, although not all forward-looking statements contain these words.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs and expectations about the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Forward-looking statements involve estimates, assumptions, risks, and uncertainties that could cause actual results or outcomes to differ materially from those expressed or implied in any forward-looking statements, and, therefore, you should not place considerable reliance on any such forward-looking statements. Such risks and uncertainties include, without limitation, our ability to successfully manufacture, distribute, or market our updated COVID-19 vaccine in a single dose vial or pre-filled syringe product presentation for the 2024-2025 vaccination season; challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements, including those related to process qualification, assay validation, and stability testing, necessary to satisfy applicable regulatory authorities; challenges or delays in conducting clinical trials; challenges or delays in obtaining regulatory authorization for our product candidates, including our updated COVID-19 vaccine in time for the 2024-2025 vaccination season or for future COVID-19 variant strain changes; manufacturing, distribution or export delays or challenges; our substantial dependence on Serum Institute of India Pvt. Ltd. and Serum Life Sciences Limited for co-formulation and filling and PCI Pharma Services for finishing our COVID-19 vaccines and the impact of any delays or disruptions in their operations on the delivery of customer orders; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, constraints on the ability of Novavax to pursue planned regulatory pathways, alone or with partners, in multiple jurisdictions simultaneously, leading to staggering of regulatory filings, and potential regulatory actions; challenges in implementing our global restructuring and cost reduction plan; our ability to timely deliver doses; challenges in obtaining commercial adoption and market acceptance of our updated COVID-19 vaccine or any COVID-19 variant strain-containing formulation; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities, including requirements to deliver doses that may require Novavax to refund portions of upfront and other payments previously received or result in reduced future payments pursuant to such agreements; challenges related to the seasonality of vaccinations against COVID-19; and other risks and uncertainties identified in Part I, Item 1A &#8220;Risk Factors&#8221; of this Annual Report on Form 10-K, which may be detailed and modified or updated in other documents filed with the SEC from time to time, and are available at www.sec.gov and at www.novavax.com. You are encouraged to read these filings as they are made.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee future results, events, level of activity, performance, or achievement. Any or all of our forward-looking statements in this Annual Report on Form 10-K may turn out to be inaccurate or materially different from actual results. Further, any forward-looking statement speaks only as of the date when it is made, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information in this Annual Report on Form 10-K, includes a financial measure that was not prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;), which we refer to as adjusted cost of sales. We are presenting this non-GAAP financial measure to assist an understanding of our business and its performance. Adjusted cost of sales includes an estimate of standard manufacturing costs that were previously expensed to research and development prior to regulatory approvals for our COVID-19 Vaccine that would otherwise have been capitalized to inventory. Any non-GAAP financial measures presented are not, and should not be viewed as, substitutes for financial measures required by GAAP, have no standardized meaning prescribed by GAAP, and may not be comparable to the calculation of similar measures of other companies.</span></div><div id="i65591fd2146e456aac589be2afadc864_91"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company that promotes improved global health through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Our proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticle vaccines designed to address urgent global health needs.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our vaccine candidates are nanostructures of conformationally correct recombinant proteins that mimic those found on pathogens. This technology enables the immune system to recognize target proteins and develop protective immune responses. We believe that our vaccine technology may lead to the induction of a differentiated immune response that may be more efficacious than naturally occurring immunity or some other vaccine approaches. Our vaccine candidates also incorporate our proprietary saponin-based Matrix-M&#8482; adjuvant to enhance the immune response, stimulate higher levels of functional antibodies, and induce a cellular immune response.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed an updated COVID-19 vaccine for the 2023-2024 vaccination season. In October 2023, the U.S. FDA granted emergency use authorization (&#8220;EUA&#8221;) for our updated vaccine for active immunization to prevent COVID-19. The updated vaccine is authorized as (1) a single dose in individuals 12 years and older who have been vaccinated with any COVID-19 vaccine at least 2 months after receipt of the last previous dose of COVID-19 vaccine, and (2) a series of 2 doses administered 3 weeks apart to individuals 12 years and older who were not previously vaccinated with any COVID-19 vaccine. Our updated vaccine is available within the U.S. at many major pharmacy retailers. Outside the U.S. for our updated vaccine, in January 2024, we were granted marketing authorization by the United Kingdom&#8217;s (&#8220;UK&#8221;) Medicines and Healthcare products </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory Agency (&#8220;MHRA&#8221;), in December 2023, we were granted expanded authorization by Health Canada, and in October 2023, we were granted approval by the European Commission (&#8220;EC&#8221;). We are committed to meeting the full supply of our key target markets through advance purchase agreements (&#8220;APAs&#8221;) covering such markets. We continue to work closely with regulatory authorities globally for authorization of our updated vaccine. We previously developed a prototype COVID-19 vaccine, which has received full marketing authorization (&#8220;MA&#8221;), marketing approval, interim authorization, provisional approval, conditional marketing authorization (&#8220;CMA&#8221;), from multiple regulatory authorities in over 40 countries globally. We continue to progress our regulatory authorizations for our prototype vaccine in select territories, as we believe these may facilitate authorization of our vaccine candidates for updated strains in the future.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we are developing a CIC vaccine candidate. In addition to COVID-19, our other areas of focus include providing Matrix-M&#8482; adjuvant for collaborations, including in R21/Matrix-M&#8482; adjuvant malaria vaccine, which recently received authorization in several countries, as well as other preclinical vaccine research with our Matrix-M&#8482; adjuvant, including through a partnership with the Bill &amp; Melinda Gates Medical Research Institute.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to focus the organization to align our investments and activities with our top priority of delivering our updated vaccine for the 2023-2024 vaccination season. To maximize our opportunities and mitigate the significant risks and uncertainties of the COVID-19 market, we have progressed our cost restructuring measures to reduce spend, extend our cash runway, and operate efficiently to seek to best position the Company to deliver longer-term growth. We discuss these cost restructuring strategies in greater detail in Note 2 to our consolidated financial statements in this Annual Report.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div id="i65591fd2146e456aac589be2afadc864_94"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Highlights </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fourth Quarter 2023 and Recent Highlights</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">U.S. Market: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Demonstrated ability to update COVID-19 vaccine and deliver the only protein-based non-mRNA option to market.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Gained commercial experience in the U.S. after receiving EUA with future efforts to focus on a recalibration of U.S. field teams to focus on the retail segment</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Progressed efforts to position Novavax for a stronger performance in 2024-2025 COVID-19 vaccination season with focus on a single-dose product presentation for delivery at the start of the season and planned BLA approval to enable marketing and promotion for Nuvaxovid&#8482; during season</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Progressed efforts to streamline manufacturing and to advance strain selection at risk while advocating for more timely identification of strains by regulatory authorities</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">Continued advancement of discussions for 2024-2025 COVID-19 vaccination season with major retailers who have driven 90% of the pharmacy business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Global Markets:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Delivered on 2023 APA obligations in Europe, Canada, Australia, New Zealand, Singapore and Taiwan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">For 2024, made strategic decision to prioritize and focus commercial effort in Europe on select key countries including Italy, Spain, France and the UK. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">Spring 2024 U.K. private market launch expected for Novavax&#8217;s COVID-19 vaccine as enabled by the recent Green Book addition by the UK Health Security Agency </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Novavax has made significant progress on its commitment to improve its financial position while maintaining the capabilities that support long-term value creation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Reduced full year 2023 operating expenses by $1.1 billion, or 41%, as compared to 2022</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Reduced workforce by a total of 30% compared to first quarter of 2023</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Delivered fourth quarter 2023 doses under the Canada APA agreement and received $175 million contingent payment in January 2024</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Settled arbitration with Gavi, removing financial uncertainty and enabling focus on shared public health mission</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Novavax remains focused on leveraging its technology platform, including its proprietary Matrix-M&#8482; adjuvant, to drive long-term growth and protect global public health.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Expect to initiate a pivotal Phase 3 trial for CIC vaccine candidate in the second half of 2024, with potential for accelerated approval and anticipated launch in 2026</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">R21/Matrix-M&#8482; adjuvant malaria vaccine received prequalification by the WHO based on Phase 3 efficacy trial results, which were recently published in The Lancet, enabling global rollout of the vaccine in eligible United Nation countries</span></div><div style="text-align:justify"><span><br/></span></div><div id="i65591fd2146e456aac589be2afadc864_97"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financing Transactions</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, we entered into an At Market Issuance Sales Agreement (the "August 2023 Sales Agreement"), which allows us to issue and sell up to $500 million in gross proceeds of shares of our common stock, and terminated our then-existing At Market Issuance Sales agreement entered in June 2021 (the &#8220;June 2021 Sales Agreement&#8221;). During the year ended December&#160;31, 2023, we sold 38.3 million shares of our common stock under our August 2023 Sales Agreement and 7.9 million shares of our common stock under our June 2021 Sales Agreement, resulting in net proceeds of approximately $321 million, of which $6.9&#160;million was included in Prepaid expenses and other current assets as of December 31, 2023 and received in cash in January 2024. As of December&#160;31, 2023, the remaining balance available under the August 2023 Sales Agreement was approximately $242 million.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, we sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.2 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of our common stock resulting in net proceeds of approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$179 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under our June 2021 Sales Agreement. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, pursuant to the Securities Subscription Agreement with SK, we agreed to sell and issue to SK 6.5 million shares of our common stock at a price of $13.00 per share (the &#8220;Shares&#8221;) in a Private Placement for aggregate gross proceeds to us of approximately $84.5 million. We recognized the Shares at the settlement date fair value of $46.5 million (see Note 4 to our consolidated financial statements for additional discussion of the Securities Subscription Agreement with SK). The closing of the Private Placement occurred on August 10, 2023.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we completed a public offering of 7,475,000 shares of our common stock, including 975,000 shares of common stock that were issued upon the exercise in full of the option to purchase additional shares granted to the underwriters, at a price of $10.00 per share resulting in net proceeds, net of offering costs of $4.9 million, of approximately $70 million. We completed this public offering concurrent with the issuance of the 2027 Notes (see Note 10 to our consolidated financial statements).</span></div><div id="i65591fd2146e456aac589be2afadc864_100"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of our consolidated financial statements requires us to make estimates, assumptions, and judgments that affect the reported amounts of assets, liabilities, and equity and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. These estimates, particularly estimates relating to accounting for product sales revenue, pre-launch inventory, inventory realizability, and research and development expenses have a material impact on our consolidated financial statements and are discussed in detail throughout our analysis of the results of operations discussed below. We base our estimates on historical experience and various other assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets, liabilities, and equity that are not readily apparent from other sources. Actual results and outcomes could differ from these estimates and assumptions.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For an in-depth discussion of each of our significant accounting policies, including our critical accounting policies and further information regarding estimates and assumptions involved in their application, see Note 2 to the accompanying consolidated financial statements included in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report on Form 10-K.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition, Product Sales - Advance Purchase Agreements </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales include sales associated with COVID-19 Vaccine supply agreements, sometimes referred to as advance purchase agreements (&#8220;APAs&#8221;), with various international governments. We recognize revenue from product sales related to these APA&#8217;s based on the transaction price per dose calculated in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Revenue from Contracts with Customers,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at the point in time when control of the product transfers to the customer and customer acceptance has occurred, unless such acceptance provisions are deemed perfunctory. The APAs typically contain terms that include upfront payments which are reflected in Deferred revenue. We constrain the transaction price for APA&#8217;s until it is probable that a significant reversal in revenue recognized will not occur. Specifically, if an APA includes a provision whereby the customer may request a discount, return, or refund, or includes a term that may have the effect of decreasing the price per dose of previously delivered shipments, revenue is constrained based on an estimate of the impact of the transaction price until it is probable that a significant reversal in revenue recognized will not occur. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition, Product Sales - U.S. Commercial </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2023, we commenced sales of COVID-19 Vaccine to the U.S. commercial market. Product sales in the U.S. are primarily made through large pharmaceutical wholesale distributors at the wholesale acquisition cost (&#8220;WAC&#8221;). We recognize revenue upon title transfer (which is typically at time of delivery), provided all other revenue recognition criteria have been met. The transaction price includes estimates of variable consideration for which reserves are established that primarily result from invoice discounts for prompt payment, wholesale distributor fees, chargebacks, and product returns (collectively, &#8220;gross-to-net deductions&#8221;). These estimates are based on the amounts earned or to be claimed for related sales and are classified as either reductions of gross accounts receivable or a current liability based on the nature of the estimate, the expected settlement method, and net position by individual customer. Where appropriate, these estimates are based on factors such as industry data and forecasted customer buying and payment patterns, our experience, current contractual and statutory requirements, specific known market events, and trends. Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. If actual results vary from estimates, we will adjust the estimates, which would affect product sales in the period such variances become known. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross-to-net deductions include the following</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Wholesale distributor fees, discounts, and chargebacks: We have arrangements under which our indirect customers such as retailers and healthcare providers receive discounts to the WAC. The chargeback represents the difference between the WAC and this negotiated discounted price. For distribution and related services, we pay service fees to our wholesale distributors. In addition, we typically offer wholesale distributor customers invoice discounts on product sales for prompt payments. We estimate chargebacks, discounts, and fees we will owe and deduct these amounts from gross product sales at the time the revenue is recognized based on the contractual terms and our expectations regarding future customer behaviors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Product returns: We offer U.S. customers the right to return COVID-19 Vaccine. These return rights include the right of wholesale distributors to return unsold and expired doses and the right of indirect customers to return any partial or unused vials upon expiry. Estimated returns for COVID-19 Vaccine are determined considering levels of inventory in the distribution channel, projected market demand, utilization data, returns claims received, and product shelf life. Our estimates of product returns are subject to significant uncertainty. Actual customer product returns could vary significantly from our estimates, resulting in changes to the estimates in subsequent periods. The estimated amount for product returns is deducted from gross product sales in the period the related product sales are recognized.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Other: Fees payable to retailers, healthcare providers, and buying groups, including certain patient assistance programs, are deducted from gross product sales in the period the related product sales are recognized.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, we recognized gross-to-net deductions against U.S. commercial product sales of $84.7 million for product returns and $47.0 million for wholesale distributor fees, discounts and chargebacks. As of December 31, 2023, $82.5&#160;million related to product returns and $20.6&#160;million related to wholesale distributor fees, discounts, </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and chargebacks were included in Other current liabilities and $2.6&#160;million was included in Accounts receivable on our consolidated balance sheet. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pre-Launch Inventory</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize raw materials and production costs as inventory when we determine that commercialization of a product is probable and have a present right to the economic benefit associated with the product. Our estimate of when commercialization is probable is based primarily on our experience with obtaining regulatory approval of comparable products. We began to capitalize inventory in 2022. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory Realizability</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically analyze our inventories for excess amounts or obsolescence and write down obsolete or otherwise unmarketable inventory to its estimated net realizable value. We estimate excess or obsolete inventory and losses on firm purchase commitments of inventory quarterly based on multiple factors, including assumptions about expected future demand and market conditions, current sales orders, and product expiry dates. Our assumptions about expected future demand are inherently uncertain and if we were to change any of these judgments or estimates, it could cause a material increase or decrease in the amount of inventory write down that we report in a particular period. We began to capitalize inventory in 2022. Subsequently, for the year ended, December&#160;31, 2022 we recorded inventory write-downs of $447.6&#160;million and losses on firm purchase commitments of inventory of $155.9&#160;million to the extent the cost cannot be recovered based on estimates about future demand. For the year ended December&#160;31, 2023, we recorded inventory write-downs of $72.4&#160;million and losses on firm purchase commitments of inventory of $73.5&#160;million. In addition, for the year ended December&#160;31, 2023, we recorded recoveries on firm purchase commitments of $40.2&#160;million related primarily to negotiated reductions to previously recognized firm purchase commitments.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Research and Development Expenses</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate our prepaid and accrued expenses related to our research and development activities using a process that involves reviewing contracts and purchase orders, communicating with our project managers and service providers to identify services that have been performed on our behalf, and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or for which we have been invoiced in advance of the service. This estimation process includes a review of:</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with contract research organizations (&#8220;CROs&#8221;) that conduct our clinical trials and third party consultants; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of developing and manufacturing vaccine components under third-party CMOs and contract development and manufacturing organizations (&#8220;CDMOs&#8221;) agreements, including expenses incurred for the procurement of raw materials, laboratory supplies and equipment.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base our expenses on our estimates of the services provided and efforts expended pursuant to contracts, statements of work and related change orders with the service provider, and discussion with internal personnel and external service providers as to the progress of the services and the agreed-upon fee to be paid for such services. The financial terms of these agreements are based on negotiated terms, vary from contract to contract, and may result in an uneven level of activity over time. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Additionally, invoicing from third-party service providers may not coincide with actual work performed and can result in a prepaid or an accrual position at the end of the period. The estimation process requires us to make significant judgments and estimates in determining the services incurred as of the balance sheet date, which may result in either a prepaid or an accrual balance. As actual costs become known, we adjust our estimates. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed may vary from the related estimates and could result in us reporting amounts that are too high or too low in a particular period. Our prepaid and accrued expenses are dependent, in part, upon the receipt of timely and accurate reporting from CROs, CMOs, CDMOs, and third-party service providers. Due to the nature of the estimation process, there may be a difference between estimated costs and actual costs incurred. Historically, we have not experienced any material differences in prior periods.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Note 2&#8213;Summary of Significant Accounting Policies&#8221; included in our Notes to Consolidated Financial Statements (under the caption &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</span></div><div id="i65591fd2146e456aac589be2afadc864_103"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations for Fiscal Years 2023 and 2022</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a discussion of our historical consolidated financial condition and results of operations, and should be read in conjunction with the consolidated financial statements and notes thereto set forth in this Annual Report on Form 10-K. Additional information concerning factors that could cause actual results to differ materially from those in our forward-looking statements is described under Part&#160;I,&#160;Item 1A, &#8220;Risk Factors&#8221; of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our discussion of the year ended December&#160;31, 2022, compared to the year ended December&#160;31, 2021, please read Item 7.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management's Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;located in Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue (in thousands):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,023,572)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18,997)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983,705&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,981,872&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(998,167)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the year ended December&#160;31, 2023 was $983.7 million as compared to $2.0 billion for the year ended December 31, 2022, a decrease of $1.0 billion. Revenue for the years ended December&#160;31, 2023 and 2022 was primarily comprised of revenue from product sales of COVID-19 Vaccine and services performed under our U.S. government agreement with Advanced Technology International (&#8220;USG Agreement&#8221;), the Consortium Management Firm acting on behalf of the Medical CBRN Defense Consortium in connection with the partnership formerly known as Operation Warp Speed. The decrease in revenue is primarily due to a decreased quantity of dose sales of COVID-19 Vaccine.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product sales</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales for 2023 were $531.4 million as compared to $1.6 billion for 2022, a decrease of $1.0 billion. The decrease in product sales is primarily due to a decreased quantity of dose sales of COVID-19 Vaccine during the year ended December&#160;31, 2023 as compared to 2022. Product sales for 2023 related to revenue from commercial sales of COVID-19 Vaccine, which commenced in 2022. The geographic distribution of product sales in 2023 was as follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Product Sales (in thousands)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">North America</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164,521)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(555,181)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rest of the world</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536,939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303,870)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales revenue</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531,389&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554,961&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,023,572)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Grants</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognized grant revenue as follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grant Revenue (in thousands)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">USG Agreement </span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.S. DoD</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,925)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,323&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,921&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,402&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant revenue for 2023 was $427.3 million compared to $382.9 million for 2022, an increase of $44.4 million. Grant revenue comprised revenue for services performed under our USG Agreement. The increase was primarily due to increased support activities under the USG Agreement during 2023. As of December 31, 2023, the Company has recognized the full contract funding under the USG Agreement in revenue. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties and Other</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties and other includes royalty milestone payments, sales-based royalties, and Matrix-M&#8482; adjuvant sales. Royalties and other revenue for 2023 was $25.0 million as compared to $44.0 million for 2022, a decrease of $19.0 million. The decrease was primarily due to decreased revenue related to milestone payments, partially offset by an increase in Matrix-M&#8482; adjuvant sales. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Expenses:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses (in thousands):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343,768&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(558,871)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(497,776)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,745)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,550,216&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626,608&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,076,392)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales was $343.8&#160;million, or 65% of product sales, for the year ended December&#160;31, 2023, including expense of $145.9&#160;million related to excess, obsolete, or expired inventory and losses on certain firm purchase commitments, $6.1&#160;million ROU asset impairment charges for CMO manufacturing capacity of excess quantities, $64.0&#160;million related to unutilized manufacturing capacity, and a credit of $40.2&#160;million related to negotiated reductions to certain previously recognized firm purchase commitments. Cost of sales was $902.6&#160;million, or 58% of product sales, for 2022, including expense of $603.5&#160;million related to excess, obsolete, or expired inventory and losses on firm purchase commitments. Prior to receiving approval, we expensed manufacturing costs as research and development expenses. After receiving approval, we capitalize the costs of production for a particular supply chain when we determine that we have a present right to the economic benefit associated with the product. While we tracked the quantities of our manufactured vaccine product and components, we did not track pre-approval manufacturing costs and therefore the manufacturing cost of our pre-launch inventory produced prior to approval is not reasonably determinable. If inventory sold during 2023 was valued at expected standard cost, including expenses related to excess and obsolete inventory, adjusted cost of sales for the year would have been $382.8&#160;million, an adjustment of $39.0&#160;million as compared to cost of sales recognized. If inventory sold during 2022 was valued at expected standard cost, adjusted cost of sales for the year would have been approximately $1.1&#160;billion, an adjustment of $164.8&#160;million. The cost of sales as a percentage of product sales may fluctuate in the future as a result of changes to our customer mix or standard costs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses decreased to $737.5 million for 2023 as compared to $1.2 billion for 2022, a decrease of $497.8 million. The decrease was primarily due to a reduction in overall expenditures relating to development </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities on coronavirus vaccines, including our COVID-19 Vaccine and CIC, as summarized in the table below (in thousands): </span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Research and Development Expenses (in thousands):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coronavirus vaccines</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other vaccine development programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total direct external research and development expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,689&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857,863&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facility expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737,502&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235,278&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for coronavirus vaccines for the year ended December&#160;31, 2023 and 2022 decreased to $413.4&#160;million from $848.0&#160;million primarily as a result of a reduction in manufacturing and support costs due, in part, to a reduction in our global manufacturing footprint consistent with our contractual obligations to supply, and anticipated demand for, COVID-19 Vaccine, including under manufacturing supply agreements with CMOs and CDMOs, and a reduction in clinical study costs and the commercialization of internal manufacturing capabilities. The decrease was also due to a benefit of $57.7&#160;million during the year ended December&#160;31, 2023 resulting from our settlement agreement and Private Placement with SK (see Note 4 to our consolidated financial statements). The decrease was partially offset by a benefit of $35.2&#160;million and $201.4&#160;million for the years ended December&#160;31, 2023 and 2022, respectively, related to previously accelerated manufacturing costs for leases that we determined were embedded in manufacturing supply agreements with CMOs and CDMOs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not provide forward-looking estimates of costs and time to complete our research programs due to the many uncertainties associated with vaccine development. As we obtain data from preclinical studies and clinical trials, we may elect to discontinue or delay clinical trials in order to focus our resources on more promising vaccine candidates. Completion of clinical trials may take several years or more, but the length of time can vary substantially depending upon the phase, size of clinical trial, primary and secondary endpoints, and the intended use of the vaccine candidate. The cost of clinical trials may vary significantly over the life of a project as a result of a variety of factors, including:</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of participants who participate in the clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of sites included in the clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if clinical trial locations are domestic, international, or both;</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time to enroll participants;</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the duration of treatment and follow-up;</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the safety and efficacy profile of the vaccine candidate; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of, and the ability to secure, regulatory approvals.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these uncertainties, we are unable to determine the duration and completion costs of our research and development projects or when, and to what extent, we will generate future cash flows from our research projects.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2024, we expect research and development expenses to decrease as compared to 2023 as we continue to assess our manufacturing needs and modify our global manufacturing footprint consistent with our contractual obligations to supply, and anticipated demand for, COVID-19 Vaccine and as additional manufacturing activities that were previously recognized as research and development expenses begin to meet the criteria for capitalization as inventory.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Selling, General, and Administrative Expenses</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Selling, general, and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">decreased to $468.9&#160;million for 2023 from $488.7&#160;million for 2022, a decrease of $19.7&#160;million. The decrease in selling, general, and administrative expenses is primarily due to cost containment measures to reduce our operating spend including a decrease in professional fees and advertising and promotion costs in support of our COVID-19 commercial program, partially offset by restructuring expenses. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Expense, Net:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other income (expense) (in thousands):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,416)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,880)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income (expense), net</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,480&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,911)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32,391&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total net other income of $23.5&#160;million for 2023 compared to total net other expense of $8.9&#160;million for 2022, an increase of $32.4&#160;million. During 2023, other income, net increased primarily due to the favorable impact in 2023 as compared to 2022 of exchange rates on foreign currency denominated balances, including an intercompany loan with Novavax CZ, and an increase in investment income due to higher interest rates. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Tax Expense:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2023 and 2022, we recognized $2.0&#160;million and $4.3 million of income tax expense, respectively, related to federal, state, and foreign income taxes.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss (in thousands, except per share information):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(545,062)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(657,939)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,768&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss for 2023 was $545.1&#160;million, or $5.41 per share, as compared to $657.9&#160;million, or $8.42 per share, for 2022, a decrease of $112.9&#160;million, or $3.01 per share. The decrease in net loss was primarily due to the decline in cost of sales and research and development expenses associated with our COVID-19 Vaccine, partially offset by a decrease in revenue from product sales. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in weighted average shares outstanding for 2023 is primarily a result of sales of our common stock.</span></div><div id="i65591fd2146e456aac589be2afadc864_106"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity Matters and Capital Resources</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our future capital requirements depend on numerous factors including, but not limited to, revenue from our product sales and royalties under licensing arrangements with our strategic partners; repayments under our grant agreements; our projected activities related to the development and commercial support of our COVID-19 Vaccine and our CIC vaccine candidate, including significant commitments under various CRO, CMO, and CDMO agreements; the progress of preclinical studies and clinical trials; the time and costs involved in obtaining regulatory approvals; the costs of filing, prosecuting, defending, and enforcing patent claims and other intellectual property rights; and other manufacturing, sales, and distribution costs. We plan to continue developing other vaccines and product candidates, such as our potential combination vaccines candidates, which are in various stages of development.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into supply agreements, sometimes referred to as APAs, with the EC and various countries globally. We also have license agreements. As of December&#160;31, 2023, the aggregate amount of the transaction price allocated to performance obligations that were unsatisfied (or partially unsatisfied), excluding amounts related to sales-based royalties under the licensing agreements, was approximately $2&#160;billion, of which $863.5&#160;million is included in Deferred revenue on our </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated balance sheet. Failure to timely meet regulatory milestones, or achieve product volume or delivery timing obligations under our APAs may require us to refund portions of upfront or other payments or result in reduced future payments, which could adversely impact our ability to realize revenue from our unsatisfied performance obligations. The timing to fulfill performance obligations related to supply agreements will depend on timing of product manufacturing, receipt of marketing authorizations for additional indications, delivery of doses based on customer demand, and the ability of the customer to request variant vaccine in place of the prototype vaccine under certain of our APAs. The supply agreements typically contain terms that include upfront payments intended to assist us in funding investments related to building out and operating our manufacturing and distribution network, among other expenses, in support of our global supply commitment, and are applied to billings upon delivery of COVID-19 Vaccine. Such upfront payments generally become non-refundable upon our achievement of certain development, regulatory, and commercial milestones.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 3, 2023, our updated vaccine received EUA from the U.S. FDA for active immunization to prevent COVID-19 in individuals aged 12 and older. Immediately upon authorization, our updated vaccine has also been included in the recommendations issued by the CDC in September 2023. Doses became available within the U.S. at many major pharmacy retailers, following the Center for Biologics Evaluation and Research release of vaccine batches. We have established reserves for gross-to-net deductions for amounts that we expect to return to our customers. As of December 31, 2023, gross-to-net reserve balances are $84.6&#160;million related to product returns and $21.1&#160;million related to wholesale distributor fees, discounts, and chargebacks, of which $103.1&#160;million is included in Accrued expenses and $2.6&#160;million is included in Accounts receivable on our consolidated balance sheet. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Fujifilm Settlement Agreement (see Note 4 to our consolidated financial statements), we agreed to pay up to $185.0 million (the &#8220;Settlement Payment&#8221;) to Fujifilm in connection with the cancellation of manufacturing activity at FDBT under the Fujifilm CSA, of which (i) $47.8 million, constituting the initial reservation fee under the CSA, was credited against the Settlement Payment on September 30, 2022 and (ii) the remaining balance was to be paid in four equal quarterly installments of $34.3 million each, which began on March 31, 2023. Under the Fujifilm Settlement Agreement, the final two quarterly installments due to Fujifilm were subject to Fujifilm&#8217;s obligation to use commercially reasonable efforts to mitigate losses associated with the vacant manufacturing capacity caused by the termination of manufacturing activities at FDBT under the CSA. Any replacement revenue achieved by Fujifilm&#8217;s mitigation efforts between July 1, 2023 and December 31, 2023 would offset the final two settlement payments owed by the Company. On October 2, 2023, we sent a notice of breach under the Fujifilm Settlement Agreement to Fujifilm setting forth the Company&#8217;s position that Fujifilm had not used commercially reasonable efforts to mitigate losses. We withheld two installments of $34.3 million due to Fujifilm on September&#160;30, 2023 and December&#160;31, 2023, pending resolution of the issues identified in the notice of breach. We paid the first two installments totaling $68.6 million during the twelve months ended December&#160;31, 2023, and the remaining balance of $68.6 million is reflected in Accrued expenses on our consolidated balance sheet. On October 30, 2023, FDBT filed a demand for arbitration with Judicial Arbitration and Mediation Services (&#8220;JAMS&#8221;) seeking payment of the third quarter installment of the Settlement Payment. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, we entered into a Settlement Agreement and General Release (the &#8220;Settlement Agreement&#8221;) with SK regarding the mutual release by the parties of all claims arising from or in relation to certain statements of work (&#8220;SOWs&#8221;) under the Development and Supply Agreement entered into in August 2020 and the Collaboration and License Agreement, entered into in February 2021 as amended in December 2021 and July 2022 in connection with the cessation of all drug substance and drug product manufacturing activity at SK for supply to us. Pursuant to the Settlement Agreement, we agreed to pay $149.8&#160;million, of which (i) $130.4&#160;million was paid in August 2023 and (ii) the remaining balance was paid in November 2023. Under the Settlement Agreement, we also agreed with SK to a wind down plan with respect to the remaining products, materials and equipment under the SOWs (see Note 4 to our consolidated financial statements).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, we entered into a Securities Subscription Agreement (the &#8220;Subscription Agreement&#8221;) with SK, pursuant to which we agreed to sell and issue to SK, in a private placement (the &#8220;Private Placement&#8221;), 6.5&#160;million shares of our common stock, par value $0.01 per share at a price of $13.00 per share for aggregate gross proceeds to us of approximately $84.5&#160;million. The closing of the Private Placement occurred on August 10, 2023 (see Note 4 to our consolidated financial statements).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an APA with the Commonwealth of Australia for the purchase of doses of COVID-19 Vaccine (the &#8220;Australia APA&#8221;). In April 2023, we amended the Australia APA to reduce the number of doses to be delivered with a commensurate increase in the per-dose price, such that the total contract value of the Australia APA is maintained with doses to be delivered through 2024. In May 2023, we extended a credit for certain doses delivered in 2022 to Australia that qualified for replacement under the Australia APA. This credit is the result of a single lot sold to the Australian government that upon pre-</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">planned 6-month stability testing was found to have fallen below the defined specifications and the lot therefore was removed from the market. The credit will be applied against the future sale of doses to Australia. In July 2023, we amended the Australia APA to provide for replacement doses and to extend the delivery schedule through 2025. As of February 2024, we had not yet received TGA authorization or delivered doses as contemplated in the July 2023 amendment and are in active discussions with the Australian government on both the TGA authorization and delivery of the doses previously scheduled for the fourth quarter of 2023. In February 2024, we received notice from the Australian government purporting to cancel its order for such prototype vaccine doses. We believe the cancellation was not proper under the amended Australia APA. However, if such a cancellation were determined to be allowable, $6.0 million of the deferred revenue would become a credit towards future deliveries of doses and approximately $48 million of the contract value related to future deliverables would no longer be available.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we amended the Canada APA, pursuant to which the Canadian government forfeited certain doses originally scheduled for delivery in 2022 for a payment of $100.4&#160;million, which we received in the second quarter of 2023. In June 2023, we entered into an additional amendment (the &#8220;June 2023 Amendment&#8221;) to the Canada APA. Pursuant to the June 2023 Amendment, (i) the Canadian government forfeited certain doses of COVID-19 Vaccine previously scheduled for delivery and agreed to pay a total amount of $349.6&#160;million to us in two equal installments, which total amount equaled the remaining balance owed by the Canadian government with respect to such forfeited vaccine doses, (ii) the amount of doses of COVID-19 Vaccine due for delivery was reduced, (iii) the delivery schedule for the remaining doses of COVID-19 Vaccine to be delivered was revised, and (iv) the parties agreed Novavax would use the Biologics Manufacturing Centre (&#8220;BMC&#8221;) Inc. to produce bulk antigen for doses in 2024 and 2025. The June 2023 Amendment maintained the total contract value of the original Canada APA. The first Installment of $174.8&#160;million was payable upon execution of the June 2023 Amendment and received by Novavax in July 2023, and the second installment of $174.8&#160;million was contingent and payable upon the delivery of vaccine doses in the second half of 2023 and received by Novavax in January 2024. The Canadian government may terminate the Canada APA, as amended, if we fail to receive regulatory approval for our COVID-19 Vaccine using bulk antigen produced at BMC on or before December 31, 2024. Our 2024 plans do not currently anticipate the submission for regulatory approval of our COVID-19 Vaccine using bulk antigen produced at BMC, and we plan to work with the Canadian government on an amendment that addresses possible alternatives, which may not be achievable. As of December 31, 2023, $102.8&#160;million was classified as short-term Deferred revenue and $485.3&#160;million was classified as long-term Deferred revenue with respect to the Canadian APA on our consolidated balance sheet. If the Canadian government terminates the Canada APA, $28.0&#160;million of the deferred revenue would become refundable and approximately $224&#160;million of the contract value related to future deliverables would no longer be available (see Note 3 to our consolidated financial statements). In the event that the contract is terminated, we would consider competing in the Canadian commercial market. Pursuant to the June 2023 Amendment, we and the Canadian government will endeavor to expand our previously agreed in-country commitment to Canada and to partner to provide health, economic, and future pandemic preparedness benefits to Canada, which value may be provided through a number of activities, including without limitation, capital investments, the performance of activities or services, or the provision of technology or intellectual property licenses. Further, the parties will endeavor to enter into a memorandum of understanding (the &#8220;MOU&#8221;) to illustrate our ability to deliver such benefits over a 15-year period with an aggregate value of not less than 100% of the amount remaining to be paid under the June 2023 Amendment and ultimately received by us. As of December&#160;31, 2023, discussions regarding the MOU were ongoing. We agreed to hold $20.0 million of the second installment payment received in January 2024 in escrow for the benefit of the Canadian government, which amount is the sole recourse available to the Canadian government in the event of non-performance under the MOU. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we entered into an Amended and Restated SARS-CoV-2 Vaccine Supply Agreement (the &#8220;Amended and Restated UK Supply Agreement&#8221;) with the Authority. Under the terms of the Amended and Restated UK Supply Agreement, the Authority agreed to purchase a minimum of 1&#160;million doses and up to an additional 15&#160;million doses (the &#8220;Conditional Doses&#8221;) of our prototype vaccine, with the number of Conditional Doses contingent on, and subject to reduction based on, our timely achievement of supportive recommendations from the JCVI that is approved by the UK Secretary of State for Health. If the Authority did not purchase the Conditional Doses or the number of such Conditional Doses was reduced below 15&#160;million doses of our prototype vaccine, we would have to repay up to $225.0&#160;million related to the upfront payment previously received from the Authority under the Original UK Supply Agreement. Under the Amended and Restated UK Supply Agreement, the Authority also has the option to purchase up to an additional 44&#160;million doses, in one or more tranches, through 2024.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November 30, 2022, the JCVI had not made a supportive recommendation with respect to our prototype vaccine, thereby triggering, under the terms of the Amended and Restated UK Supply Agreement, (i) a reduction of the number of Conditional Doses from 15&#160;million doses to 7.5&#160;million doses, which reduced number of Conditional Doses are contingent on, and subject to further reduction based on, our timely achievement by November 30, 2023 of a supportive recommendation from JCVI that is approved by the UK Secretary of State for Health as described in the paragraph above, and (ii) an obligation for us </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to repay $112.5&#160;million related to the upfront payment previously received from the Authority under the Original UK Supply Agreement. In April 2023, we repaid the $112.5&#160;million related to the November 30, 2022 triggering event. As of November 30, 2023, the JCVI had not made a supportive recommendation with respect to the prototype vaccine, thereby triggering a reduction in the number of Conditional Doses from 7.5&#160;million doses to zero. As of February 2024, the Company is in discussions with the Authority regarding the treatment of the remaining upfront amount previously received of $112.5&#160;million, which is reflected in Other current liabilities on our consolidated balance sheet. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:28.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Gavi APA, we received an upfront payment of $350.0&#160;million from Gavi in 2021 and an additional payment of $350.0&#160;million in 2022 related to our achieving EUL for our prototype vaccine by the WHO (the &#8220;Advance Payment Amount&#8221;). On November 18, 2022, we delivered written notice to Gavi to terminate the Gavi APA on the basis of Gavi&#8217;s failure to procure the purchase of 350&#160;million doses of our prototype vaccine from us as required by the Gavi APA. As of November 18, 2022, we had only received orders under the Gavi APA for approximately 2&#160;million doses. On December 2, 2022, Gavi issued a written notice purporting to terminate the Gavi APA based on Gavi&#8217;s contention that the Company repudiated the agreement and, therefore, materially breached the Gavi APA. Gavi also contended that, based on its purported termination of the Gavi APA, it was entitled to a refund of the Advance Payment Amount less any amounts that have been credited against the purchase price for binding orders placed by a buyer participating in the COVAX Facility. As of December&#160;31, 2023, the remaining Gavi Advance Payment Amount of $696.4&#160;million, pending resolution of the dispute with Gavi related to a return of the remaining Advance Payment Amount, was reclassified from Deferred revenue to Other current liabilities on our consolidated balance sheet. On January 24, 2023, Gavi filed a demand for arbitration with the International Court of Arbitration based on the claims described above. We filed our Answer and Counterclaims on March 2, 2023. On April 5, 2023, Gavi filed its Reply to our Counterclaims. On February 16, 2024, we and Gavi entered into a Termination and Settlement Agreement (the &#8220;Gavi Settlement Agreement&#8221;) terminating the Gavi APA, settling the arbitration proceedings, and releasing both parties of all claims arising from, under or otherwise in connection with the Gavi APA. Pursuant to the Gavi Settlement Agreement, we are responsible for payment to Gavi of (i) an initial settlement payment of $75 million, which we paid on February 20, 2024, and (ii) deferred payments, in equal annual amounts of $80 million payable each calendar year through a deferred payment term ending December 31, 2028. The deferred payments are due in variable quarterly installments beginning in the first quarter of 2024 and total $400 million during the deferred payment term. Such deferred payments may be reduced through Gavi&#8217;s use of an annual vaccine credit equivalent to the unpaid balance of such deferred payments each year, which may be applied to qualifying sales of any of our vaccines funded by Gavi for supply to certain low-income and lower-middle income countries. We have the right to price the vaccines offered to such low-income and lower-middle income countries at our discretion, and, when utilized by Gavi, we will credit the actual price per vaccine paid against the applicable credit. We intend to price vaccines offered via the tender process, consistent with our shared goal with Gavi to provide equitable access to those countries. Also in the Gavi Settlement Agreement, we grant Gavi an additional credit of up to $225 million, which may be applied against any additional qualifying sales, exceeding the $80 million deferred payment amount in any calendar year, of our vaccines in such countries during such deferred payment term. In addition, we and Gavi entered into a security agreement pursuant to which we granted Gavi a security interest in accounts receivable from SIIPL under the SIIPL R21 Agreement (see Note 4 to our consolidated financial statements for more details on SIIPL R21 Agreement), which will continue for the deferred payment term of the Gavi Settlement Agreement. On February 22, 2024, the claims and counterclaims were dismissed with prejudice.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:28.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our funding agreements currently include funding from CEPI in the form of one or more forgivable no interest term loans (&#8220;CEPI Forgivable Loan Funding&#8221;). Payments received under the CEPI Forgivable Loan Funding are only repayable if project vaccine, as defined under the CEPI funding agreement, manufactured by the CMO network funded by CEPI is sold to one or more third parties (which could include sales credited under the Gavi Settlement Agreement), and such sales cover our costs of manufacturing such vaccine, not including manufacturing costs funded by CEPI.&#160;The timing and amount of any loan repayments is currently uncertain.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to assess our manufacturing needs and modify our global manufacturing footprint consistent with our contractual obligations to supply, and anticipated demand for, COVID-19 Vaccine, and in doing so recognize that significant costs may be incurred. For the 2023-2024 vaccination season, we depend exclusively on SIIPL and SLS for co-formulation and filling (other than in Europe), and PCI Pharma Services for finishing COVID-19 Vaccine in Europe. For the 2024-2025 vaccination season, we are seeking to expand our supply chain network and introduce new single-dose vial or pre-filled syringe product presentations in certain markets. Any delays or disruptions in these suppliers&#8217; operations could prevent or delay the delivery of customer orders. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had $583.8&#160;million in cash and cash equivalents and restricted cash as compared to $1.3&#160;billion as of December&#160;31, 2022. </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We funded our operations in 2023 primarily with cash and cash equivalents, upfront payments under APAs, revenue from product sales, royalties under licensing arrangements with our strategic partners, and proceeds from the sale of common stock, together with revenue under the USG Agreement that support our COVID-19 Vaccine development activities. In May 2023, we announced our plan to restructure our global footprint to reduce our planned expenditures and in January 2024, we announced further reductions in our global workforce. We anticipate our future operations to be funded primarily by revenue from product sales, our cash and cash equivalents, and other potential funding sources including equity financings, which may include at the market offerings under our August 2023 Sales Agreement, debt financings, collaborations, strategic alliances, asset sales, and marketing, distribution or licensing arrangements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes cash flows for 2023 and 2022:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(713,967)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(415,937)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(298,030)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(58,806)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(92,985)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">324,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(320,522)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect on exchange rate on cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net increase in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(765,035)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(179,414)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(585,621)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and restricted cash at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,348,845&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,528,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(179,414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and restricted cash at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">583,810&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,348,845&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(765,035)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $714.0&#160;million for 2023, as compared to cash used in operating activities of $415.9 million in 2022. The increase in cash used in operating activities is primarily due to the timing of payments to vendors and cash receipts from customers, primarily APAs. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $58.8&#160;million for 2023, as compared to $93.0&#160;million in 2022. The decrease in cash used in investing activities is primarily due to lower expenditures on equipment and leasehold improvements. Capital expenditures for the years ended December&#160;31, 2023 and 2022 were $53.8&#160;million and $89.1&#160;million, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $4.5&#160;million for 2023, as compared to $325.0&#160;million in 2022. The decrease in cash provided by financing activities is primarily due to the repayment of our 3.75% Convertible notes of $325.0&#160;million in 2023 as compared to gross proceeds of $175.3 million through the issuance of our 2027 Notes in 2022, partially offset by an increase in net proceeds from the sales of our common stock under our June 2021 and August 2023 Sales Agreements and the Private Placement with SK in 2023. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Going Concern</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements in Part II, Item 8, &#8220;Financial Statements and Supplementary Data,&#8221; of this Annual Report on Form 10-K have been prepared assuming that we will continue as a going concern within one year after the date that the financial statements are issued and contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainty described below. At December&#160;31, 2023, we had $568.5 million in cash and cash equivalents and had a working capital deficiency. During 2023, we incurred a net loss of $545.1 million and had net cash flows used in operating activities of $714.0&#160;million.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC Topic 205-40,&#8239;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements - Going Concern,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> we evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. While our current cash flow forecast for the one-year going concern look forward period estimates that we have sufficient capital available to fund operations, this forecast is subject to significant uncertainty, including as it relates to revenue for the next twelve months and our ability to execute on certain cost-reduction initiatives. Our revenue projections depend on our ability to successfully develop, manufacture, distribute, or market our COVID-19 Vaccine for the 2024-2025 vaccination season, which is inherently uncertain and subject to a number of risks, including our ability to obtain regulatory authorizations, introduce a single-dose vial or pre-filled syringe product presentation for the U.S. commercial and certain other markets, the incidence of COVID-19 during </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the 2024-2025 vaccination season, our ability to timely deliver doses and commercial adoption and market acceptance of our updated vaccine. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, failure to meet regulatory milestones or achieve product volume or delivery timing obligations under our advance purchase agreements may require us to refund portions of upfront and other payments or result in reduced future payments which could adversely affect our ability to continue as a going concern. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that, given our history of recurring losses, negative working capital and accumulated deficit, conditions or events exist that raise substantial doubt about our ability to continue as a going concern through one year from the date that these financial statements are issued. Our plans to alleviate the conditions that exist include restructuring and cost reduction measures and successful execution of its commercial plans. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, we announced our Restructuring Plan, which includes a more focused investment in our COVID-19 Vaccine, reduction to our pipeline spending, the continued rationalization of our manufacturing network, a reduction to our global workforce, as well as the consolidation of facilities, and infrastructure. In our May 2023 announcement, the workforce reduction plan included an approximately 25% reduction in the Company&#8217;s global workforce, comprised of an approximately 20% reduction in full-time Company employees and the remainder comprised of contractors and consultants. We incurred one time restructuring expenses of $14.6&#160;million during the twelve months ended December&#160;31, 2023. See Note 17 to our consolidated financial statements for more details on restructuring. We expect the full annual impact of the cost savings to be realized in 2024 due to timing of implementing the measures, and the applicable laws, regulations, and other factors in the jurisdictions in which we operate. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we announced that we anticipated further reducing our research and development and selling, general and administrative expenses and our supply network costs. We intend to prioritize improvements to our long-term supply chain efficiency. In January 2024, as part of reducing combined research and development and selling. general and administrative expenses, we announced an approximately 12% reduction of our global workforce, comprised of an approximately 9% reduction in our full-time employees and the remainder comprised of contractors and consultants. We expect the full annual impact of the cost savings to be realized in 2025 and approximately 85% of the annual impact, excluding one-time charges, to be realized in 2024 due to the timing of implementing the measures and the applicable laws, regulations and other factors in the jurisdictions in which it operates. We expect to record a charge of approximately $4 million to $7 million related to one-time employee severance and benefit costs, the majority of which is expected to be incurred in the first quarter of 2024. Upon completion, our resulting workforce is expected to be approximately 30% lower as compared to the end of the first quarter of 2023.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our plans may include raising additional capital through a combination of equity financings, which may include at the market offerings under our August 2023 Sales Agreement, debt financings, collaborations, strategic alliances, asset sales and marketing, distribution, or licensing arrangements. New financings may not be available to us on commercially acceptable terms, or at all. Also, any collaborations, strategic alliances, asset sales and marketing, distribution, or licensing arrangements may require us to give up some or all of our rights to a product or technology, which in some cases may be at less than the full potential value of such rights. If we are unable to obtain additional capital, we will assess our capital resources and may be required to delay, reduce the scope of, or eliminate some or all of our operations, or further downsize our organization, any of which may have a material adverse effect on our business, financial condition, results of operations, and ability to operate as a going concern.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the uncertainties associated with our plans, there is substantial doubt about our ability to continue as a going concern for at least one year from the date that these financial statements are issued.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="i65591fd2146e456aac589be2afadc864_109"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contractual obligations as of December&#160;31, 2023 (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.046%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.118%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual&#160;Obligations:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Less&#160;than&#160;<br/>One&#160;Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1&#160;&#8211;&#160;3<br/>Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3&#160;&#8211;&#160;5<br/>Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">More&#160;than<br/>5&#160;Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,883&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,097&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,030&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual obligations recognized as of December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,082&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,353&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,808&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,625&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,296&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total contractual obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383,078&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,349&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,808&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,625&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,296&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;In 2022, we issued $175.3 million of 5.00% convertible senior unsecured notes due in 2027. See &#8220;Note 10&#8212;Long-term Debt&#8221; included in our Notes to Consolidated Financial Statements for additional information related to our convertible notes.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)&#160;&#160;&#160;&#160;Purchase commitments primarily represent our non-cancelable fixed payment obligations under certain CMO, CDMO, and laboratory supply agreements that we are not contractually able to terminate for convenience. Certain agreements provide for termination rights subject to termination fees. Under such agreements, we are contractually obligated to make payments to vendors, mainly to reimburse them for their estimated unrecoverable expenses incurred. As of December&#160;31, 2023, these agreements are active ongoing arrangements and we expect to receive value from these arrangements in the future. The amount of such obligations is dependent on the timing of termination and the terms of the relevant agreement, and cannot be reasonably estimated. Our current obligations under non-cancelable purchase agreements are reflected on our consolidated balance sheets.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above obligations, we enter into a variety of agreements and financial commitments in the normal course of business. The terms generally allow us the option to cancel, reschedule, or adjust our requirements based on our business needs, prior to the delivery of goods or performance of services. It is not possible to predict the maximum potential amount of future payments under these agreements due to the conditional nature of our obligations and the unique facts and circumstances involved in each particular agreement.</span></div><div id="i65591fd2146e456aac589be2afadc864_112"></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to certain risks that may affect our results of operations, cash flows, and fair values of assets and liabilities, including volatility in foreign currency exchange rates and interest rate movements.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we are headquartered in the U.S. our results of operations, including our foreign subsidiaries&#8217; operations, are subject to foreign currency exchange rate fluctuations, primarily the U.S. dollar against the Euro, Pound Sterling, Swedish Krona, and Czech Koruna. This exchange exposure may have a material effect on our cash and cash equivalents, cash flows, and results of operations, particularly in cases of revenue generated under APAs that include provisions that impact our and our counterparty&#8217;s currency exchange exposure. To date, we have not entered into any foreign currency hedging contracts, although we may do so in the future.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face foreign currency exchange exposure that arises from translating the results of our global operations to the U.S. dollar at exchange rates that have fluctuated from the beginning of the period. While the financial results of our global activities are reported in U.S. dollars, the functional currency for our foreign subsidiaries is generally their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. A 10% decline in the foreign exchange rates (primarily against the U.S. dollar) relating to our foreign subsidiaries would result in a decline of stockholders&#8217; equity (deficit) of approximately $52 million as of December&#160;31, 2023.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market and Interest Rate Risk</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of our investment activities is preservation of capital, with the secondary objective of maximizing income.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to interest rate risk is primarily confined to our investment portfolio. We do not believe that a change in the market rates of interest would have any significant impact on the realizable value of our investment portfolio. Changes in interest rates may affect the investment income we earn on our marketable securities when they mature and the proceeds are reinvested into new marketable securities and, therefore, could impact our cash flows and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and dividend income is recorded when earned and included in investment income. Premiums and discounts, if any, on marketable securities are amortized or accreted to maturity and included in investment income. The specific identification method is used in computing realized gains and losses on the sale of our securities.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our convertible senior unsecured notes have a fixed interest rate and we have no additional material debt. As such, we do not believe that we are exposed to any material interest rate risk as a result of our borrowing activities.</span></div><div id="i65591fd2146e456aac589be2afadc864_115"></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is set forth on pages&#160;F-1 to F-45.</span></div><div id="i65591fd2146e456aac589be2afadc864_118"></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.&#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i65591fd2146e456aac589be2afadc864_121"></div><div style="margin-bottom:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term &#8220;disclosure controls and procedures&#8221; (defined in SEC Rule&#160;13a-15(e)) refers to the controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files under the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) is recorded, processed, summarized, and reported, within time periods specified in the rules&#160;and forms of the Securities and Exchange Commission. &#8220;Disclosure controls and procedures&#8221; include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management, with the participation of the chief executive officer and the chief financial officer, has evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures as of the end of the period covered by this Annual Report on Form 10-K (the &#8220;Evaluation Date&#8221;). Based on that evaluation, the Company&#8217;s chief executive officer and chief financial officer have concluded that, as of the Evaluation Date, such controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control over Financial Reporting</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rules&#160;13a-15(f)&#160;and 15d-15(f)&#160;promulgated under the Exchange Act, as a process designed by, or under the supervision of, the Company&#8217;s principal executive officer and principal financial officer and effected by the Company&#8217;s board of directors, management, and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Such internal control includes those policies and procedures that:</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company;</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">provide reasonable assurance regarding prevention or timely detection of an unauthorized acquisition, use, or disposition of the Company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2023. In making this assessment, our management used the criteria set forth in the 2013 Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on its assessment, our management has determined that, as of December&#160;31, 2023, our internal controls over financial reporting are effective based on those criteria.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ernst&#160;&amp; Young LLP has issued a report on our internal control over financial reporting. This report is included in the Reports of Independent Registered Public Accounting Firm in Item 15(a)(1).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our chief executive officer and chief financial officer, has evaluated any changes in our internal control over financial reporting that occurred during the year ended December&#160;31, 2023 and has concluded that there was no change that occurred during the year ended December&#160;31, 2023 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i65591fd2146e456aac589be2afadc864_124"></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adoption of 10b5-1 <ix:nonNumeric contextRef="c-4" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-36"><ix:nonNumeric contextRef="c-4" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-37"><ix:nonNumeric contextRef="c-4" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-38">Trading Plans</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> by our Officers and Directors</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During our fiscal quarter ended December 31, 2023, one of our officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) entered into a contract, instruction or written plan for the purchase or sale of our securities that is intended to satisfy the conditions specified in Rule 10b5-1(c) under the Exchange Act for an affirmative defense against liability for trading in securities on the basis of material nonpublic information. We refer to this contract, instruction, and written plan as a &#8220;Rule 10b5-1 trading plan.&#8221; We describe the material terms of this Rule 10b5-1 trading plan below.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Filip Dubovsky, MD, President, Research &amp; Development</span></div><ix:nonNumeric contextRef="c-5" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-39" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On <ix:nonNumeric contextRef="c-6" name="ecd:TrdArrAdoptionDate" id="f-40">December 12, 2023</ix:nonNumeric>, <ix:nonNumeric contextRef="c-6" name="ecd:TrdArrIndName" id="f-41">Filip Dubovsky, MD</ix:nonNumeric>, our <ix:nonNumeric contextRef="c-6" name="ecd:TrdArrIndTitle" id="f-42">President, Research &amp; Development</ix:nonNumeric>, <ix:nonNumeric contextRef="c-6" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-43">entered into a Rule 10b5-1 trading plan</ix:nonNumeric> that is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides that Dr. Dubovsky, acting through a broker, may sell up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" id="f-44">13,365</ix:nonFraction> shares of our common stock, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur from March 15, 2024 to June 14, 2024. The plan is scheduled to terminate on June 14, 2024, subject to earlier termination upon the sale of all shares subject to the plan or the expiration of all sale orders under the plan, upon termination by Dr. Dubovsky or the broker, or as otherwise provided in the plan.</span></div></ix:nonNumeric><div id="i65591fd2146e456aac589be2afadc864_127"></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C.&#160;&#160;&#160;&#160;DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i65591fd2146e456aac589be2afadc864_130"></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i65591fd2146e456aac589be2afadc864_133"></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10.&#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from our definitive Proxy Statement for our 2024 Annual Meeting of Stockholders scheduled to be held in June&#160;2024 (the &#8220;2024 Proxy Statement&#8221;). We expect to file the 2024 Proxy Statement within 120 days after the close of the fiscal year ended December&#160;31, 2023.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="i65591fd2146e456aac589be2afadc864_136"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11.&#160;&#160;&#160;&#160;EXECUTIVE COMPENSATION</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate herein by reference the information required by this item concerning executive compensation to be contained in the 2024 Proxy Statement.</span></div><div id="i65591fd2146e456aac589be2afadc864_139"></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12.&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate herein by reference the information required by this item concerning security ownership of certain beneficial owners and management and related stockholder matters to be contained in the 2024 Proxy Statement.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides our equity compensation plan information as of December&#160;31, 2023. Under these plans, our common stock may be issued upon the exercise or vesting of equity awards and purchases under our Employee Stock Purchase Plan (&#8220;ESPP&#8221;). See also the information regarding our equity awards and ESPP in Note 12 to the consolidated financial statements included herewith.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.258%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Plan Category</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Securities<br/>to be Issued<br/>Upon Exercise of<br/>Outstanding Options,<br/>Warrants and Rights<br/>(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average<br/>Exercise Price of<br/>Outstanding<br/>Options, Warrants<br/>and Rights<br/>(b)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Securities<br/>Remaining Available for<br/>Future Issuance Under<br/>Equity Compensation<br/>Plans (Excluding<br/>Securities Reflected in<br/>Column (a))<br/>(c)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity compensation plans approved by security holders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,560,187</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$39.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,412,669</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity compensation plans not approved by security holders (Inducement Plan)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786,790</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10.67</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,210</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,346,977</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$36.80</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,625,879</span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes our 2015 Stock Incentive Plan, 2005 Stock Incentive Plan, and ESPP. The weighted-average exercise price in column (b)&#160;excludes restricted stock units, which are not subject to an exercise price.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes our 2023 Inducement Plan only</span></div><div id="i65591fd2146e456aac589be2afadc864_142"></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13.&#160;&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We incorporate herein by reference the information required by this item concerning certain relationships and related transactions and director independence to be contained in the 2024 Proxy Statement.</span></div><div id="i65591fd2146e456aac589be2afadc864_145"></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14.&#160;&#160;&#160;&#160;PRINCIPAL ACCOUNTING FEES AND SERVICES</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate herein by reference the information required by this item concerning principal accountant fees and services to be contained in the 2024 Proxy Statement.</span></div><div id="i65591fd2146e456aac589be2afadc864_148"></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><div id="i65591fd2146e456aac589be2afadc864_151"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15.&#160;&#160;&#160;&#160;EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-top:10pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">The following documents are filed as part of the Annual Report on Form 10-K:</span></div><div style="margin-top:10pt;padding-left:81pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Index to Financial Statements</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"/><td style="width:92.018%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.782%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_163">Reports of Independent Registered Public Accounting Firm (PCAOB ID:42)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">F- 2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_166">Consolidated Statements of Operations and Statements of Comprehensive Loss for the years ended December&#160;31, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_166">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_166">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_166">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_166">, and 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_166">1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">F- 6</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_169">Consolidated Balance Sheets as of December&#160;31, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_169">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_169"> and 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_169">2</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">F- 7</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_172">Consolidated Statements of Stockholders&#8217; Equity (Deficit) for the years ended December&#160;31, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_172">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_172">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_172">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_172">, and 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_172">1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">F- 8</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_175">Consolidated Statements of Cash Flows for the years ended December&#160;31, 2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_172">02</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_172">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_172">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_172">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_172">, and 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_172">1</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">F- 9</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_178">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">F- 10</span></div></td></tr></table></div><div style="margin-top:10pt;padding-left:81pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Financial Statement Schedules</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial statement schedules are omitted because they are not applicable, not required under the instructions or all the information required is set forth in the financial statements or notes thereto.</span></div><div style="margin-top:10pt;padding-left:81pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Exhibits</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibits marked with a single asterisk (*) are filed herewith.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Exhibits marked with a double plus sign (&#8224;&#8224;) refer to management contracts, compensatory plans, or arrangements.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Confidential treatment has been granted for portions of exhibits marked with a double asterisk (**).</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Confidential information contained in exhibits marked with a caret (&#x5E;) has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other exhibits listed have previously been filed with the SEC and are incorporated herein by reference.</span></div><div><span><br/></span></div><div style="padding-left:9pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Description</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex3-1.htm">Second Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to Exhibit&#160;3.1 to the Company&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended June&#160;30, 2015, filed on August&#160;10, 2015 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420419024901/tv521192_ex3-1.htm">Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to Exhibit&#160;3.1 to the Company&#8217;s Current Report on Form&#160;8-K filed on May&#160;9, 2019 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">3.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069423000011/nvax-20230330.htm">Amended and Restated By-Laws of the Company (Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069423000011/nvax-20230330.htm">April </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069423000011/nvax-20230330.htm">4, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069423000011/nvax-20230330.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069423000011/nvax-20230330.htm"> (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">3.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465920075307/tm2023024d1_ex3-1.htm">Certificate of Designation of Series A Convertible Preferred Stock of the Registrant (Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed June 19, 2020 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000110465919077299/tv535518_ex4-1.htm">Specimen stock certificate for shares of common stock of the Company, par value $.01 per share (Incorporated by reference to Exhibit 4.1 to the Company&#8217;s Registration Statement on Form S-3, filed on December 31, 2019 (File No. 333-235761))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922128864/tm2232888d2_ex4-1.htm">Indenture (including form of Notes) with respect to the Company's 5.00% Convertible Senior Notes due 2027, dated as of December 20, 2022, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (Incorporated by reference to Exhibit&#160;4.1 to the Company&#8217;s Current Report on Form&#160;8-K, filed on December 21, 2022 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">4.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000110465920075307/tm2023024d1_ex4-1.htm">Form of Series A Convertible Preferred Stock Certificate of the Company (Incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed June 19, 2020 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="padding-left:9pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">4.4*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex44.htm">Description of the Company's Securities</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.1&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420413014545/v335539_ex10-2.htm">The Company's Amended and Restated 2005 Stock Incentive Plan (Incorporated by reference to Exhibit&#160;10.2 to the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2012, filed on March&#160;12, 2013 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.2&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420414026440/v376628_def14a.htm">Amendment to Amended and Restated 2005 Stock Incentive Plan (Incorporated by reference to Appendix 1 of the Company&#8217;s Definitive Proxy Statement filed on April&#160;30, 2014 in connection with the Annual Meeting held on June&#160;12, 2014 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.3&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420415012379/v401319_ex10-4.htm">Form&#160;of Non-Statutory Stock Option Award Agreement granted under the Company's Amended and Restated 2005 Stock Incentive Plan (Incorporated by reference to Exhibit&#160;10.4 to the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2014, filed on February&#160;27, 2015 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.4&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420415012379/v401319_ex10-5.htm">Form&#160;of Incentive Stock Option Award Agreement granted under the Company's Amended and Restated 2005 Stock Incentive Plan (Incorporated by reference to Exhibit&#160;10.5 to the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2014, filed on February&#160;27, 2015 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.5&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465922054754/tm223592d3_def14a.htm">Amended and Restated Novavax, Inc. 2013 Employee Stock Purchase Plan (Incorporated by reference to Appendix D of the Company&#8217;s Definitive Proxy Statement filed on May 2, 2022 in connection with the Annual Meeting held on June 16, 2022 (File No. 000-26770)) </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.6&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000026/nvax-20230428.htm">Amended and Restated Novavax, Inc. 2015 Stock Incentive Plan (Incorporated by reference to </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000026/nvax-20230428.htm">Appendix </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000026/nvax-20230428.htm">B</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000026/nvax-20230428.htm"> of the Company&#8217;s Definitive Proxy Statement filed on</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000026/nvax-20230428.htm"> April 28,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000026/nvax-20230428.htm"> 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000026/nvax-20230428.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000026/nvax-20230428.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000026/nvax-20230428.htm">in connection with the Annual Meeting held on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000026/nvax-20230428.htm">July 11</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000026/nvax-20230428.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000026/nvax-20230428.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000026/nvax-20230428.htm"> (File No. 000-26770)) </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.7&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex10-3.htm">Form&#160;of Non-Statutory Stock Option Award Agreement granted under the Amended and Restated Novavax, Inc. 2015 Stock Incentive Plan (Incorporated by reference to Exhibit&#160;10.3 to the Company&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended June&#160;30, 2015, filed on August&#160;10, 2015 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.8&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-20230630xex109.htm">Form of Non-Statutory Stock Option Award Agreement (Non-Employee Director) granted under the Company&#8217;s Amended and Restated 2015 Stock Incentive Plan (Incorporated by reference to Exhibit 10.9 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, filed on August 8, 2023 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.9&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-20230630xex1010.htm">Form of Global Non-Statutory Stock Option Award Agreement granted under the Company&#8217;s Amended and Restated 2015 Stock Incentive Plan (Incorporated by reference to Exhibit 10.10 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, filed on August 8, 2023 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.10&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex10-4.htm">Form&#160;of Incentive Stock Option Award Agreement granted under the Amended and Restated Novavax, Inc. 2015 Stock Incentive Plan (Incorporated by reference to Exhibit&#160;10.4 to the Company&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended June&#160;30, 2015, filed on August&#160;10, 2015 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.11&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420417011334/v459518_ex10-9.htm">Form&#160;of Incentive Stock Option Award Agreement granted under the Amended and Restated Novavax, Inc. 2015 Stock Incentive Plan (Incorporated by reference to Exhibit&#160;10.9 to the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2016, filed on February&#160;27, 2017 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.12&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420416134953/v453291_ex10-1.htm">Form&#160;of Incentive Stock Option Agreement granted under the Amended and Restated Novavax, Inc. 2015 Stock Incentive Plan (Performance- and Time-Based Vesting) (Incorporated by reference to Exhibit&#160;10.1 to the Company&#8217;s Current Report on Form&#160;8-K, filed on November&#160;16, 2016 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.13&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420415047742/v416489_ex10-5.htm">Form&#160;of Restricted Stock Award Agreement granted under the Amended and Restated Novavax, Inc. 2015 Stock Incentive Plan (Incorporated by reference to Exhibit&#160;10.5 to the Company&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended June&#160;30, 2015, filed on August&#160;10, 2015 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.14&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420419014640/tv512700_ex10-12.htm">Form&#160;of Restricted Stock Unit Agreement granted under the Amended and Restated Novavax, Inc. 2015 Stock Incentive Plan (Incorporated by reference to Exhibit&#160;10.12 to the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019, filed on March&#160;18, 2019 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.15&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-20230630xex1011.htm">Form of Restricted Stock Unit Award Agreement (Non-Employee Director) granted under the Company&#8217;s Amended and Restated 2015 Stock Incentive Plan (Incorporated by reference to Exhibit 10.11 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, filed on August 8, 2023 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="padding-left:9pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.16&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-20230630xex1012.htm">Form of Global Restricted Stock Unit Award Agreement granted under the Company&#8217;s Amended and Restated 2015 Stock Incentive Plan (Incorporated by reference to Exhibit 10.12 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, filed on August 8, 2023 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.17&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465919061157/tm1919566d1_ex10-1.htm">Form&#160;of Stock Appreciation Right Award Agreement granted under the Amended and Restated Novavax, Inc. 2015 Stock Incentive Plan (Incorporated by reference to Exhibit&#160;10.1 to the Company&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended September&#160;30, 2019, filed on November&#160;7, 2019&#160;(File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.18&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420416084770/v431853_ex10-10.htm">Form&#160;of Director Deferred Fee Agreement (Incorporated by reference to Exhibit&#160;10.10 to the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2015, filed on February&#160;29, 2016 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.19&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465923002102/tm232657d1_ex10-1.htm">Novavax, Inc. 2023 Inducement Plan (Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed on January 9, 2023 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.20&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465923002102/tm232657d1_ex10-2.htm">Form of Non-Statutory Stock Option Agreement under the Novavax, Inc. 2023 Inducement Plan (Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed on January 9, 2023 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">10.21&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465923002102/tm232657d1_ex10-3.htm">Form of Restricted Stock Unit Award Agreement under the Novavax, Inc. 2023 Inducement Plan (Incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K, filed on January 9, 2023 (File No. 000-26770))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">10.22&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000005/nvax-20221231xex1018.htm">Employment Agreement between the Company and John C. Jacobs, dated as of January 5, 2023 (Incorporated by reference to Exhibit 10.18 to the Company&#8217;s Annual Report on Form 10-K, filed on February 28, 2023 (File No. 000-26770))</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.23&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420411044872/v231158_ex10-2.htm">Employment Agreement between the Company and Stanley C. Erck, dated as of June&#160;22, 2011 (Incorporated by reference to Exhibit&#160;10.2 to the Company&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended June&#160;30, 2011, filed on August&#160;9, 2011 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.24&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000005/nvax-20221231xex1020.htm">Consulting and Advisory Agreement between the Company and Stanley C. Erck, dated as of January 5, 2023 (Incorporated by reference to Exhibit 10.20 to the Company&#8217;s Annual Report on Form 10-K, filed on February 28, 2023 (File No. 000-26770))</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.25&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420410036677/v189965_ex10-1.htm">Employment Agreement between the Company and Gregory M. Glenn dated July&#160;1, 2010 (Incorporated by reference to Exhibit&#160;10.1 to the Company&#8217;s Current Report on Form&#160;8-K, filed on July&#160;6, 2010 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.26&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000040/nvax-20230331xex104.htm">Consulting and Advisory Agreement between the Company and Dr. Gregory M. Glenn, dated as of March 20, 2023</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000040/nvax-20230331xex104.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000040/nvax-20230331xex104.htm">&#160;(Incorporated by reference to Exhibit&#160;10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000040/nvax-20230331xex104.htm">4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000040/nvax-20230331xex104.htm"> to the Company&#8217;s </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000040/nvax-20230331xex104.htm">Q</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000040/nvax-20230331xex104.htm">ua</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000040/nvax-20230331xex104.htm">rterly</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000040/nvax-20230331xex104.htm"> Report on Form&#160;10-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000040/nvax-20230331xex104.htm">Q</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000040/nvax-20230331xex104.htm"> filed on Ma</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000040/nvax-20230331xex104.htm">y</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000040/nvax-20230331xex104.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000040/nvax-20230331xex104.htm">9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000040/nvax-20230331xex104.htm">, 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000040/nvax-20230331xex104.htm">23</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000040/nvax-20230331xex104.htm"> (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.27&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420416099046/v435593_ex10-2.htm">Employment Agreement between the Company and John A. Herrmann dated April&#160;1, 2012 (Incorporated by reference to Exhibit&#160;10.2 to the Company's Quarterly Report on Form&#160;10-Q for the quarter ended March&#160;31, 2016, filed on May&#160;5, 2016 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28&#8224;&#8224;*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20231231xex1028.htm">Consulting and Advisory Agreement between the Company and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20231231xex1028.htm">John A. Herrmann</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20231231xex1028.htm">, dated as of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20231231xex1028.htm">November 17</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20231231xex1028.htm">, 2023</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.29&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420416099046/v435593_ex10-3.htm">Employment Agreement between the Company and John J. Trizzino dated March&#160;3, 2014 (Incorporated by reference to Exhibit&#160;10.3 to the Company&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended March&#160;31, 2016, filed on May&#160;5, 2016 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.30&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000020/nvax-20210930xex101.htm">Employment Agreement between the Company and James P. Kelly dated July 12, 2021 (Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed on November 5, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.31&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000020/nvax-20210930xex102.htm">Offer letter to James P. Kelly dated J</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000020/nvax-20210930xex102.htm">u</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000020/nvax-20210930xex102.htm">l</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000020/nvax-20210930xex102.htm">y</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000020/nvax-20210930xex102.htm"> 12, 2021 (Incorporated by reference to Exhibit 10.2 to the Company&#8217;s</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000020/nvax-20210930xex102.htm"> </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000020/nvax-20210930xex102.htm">Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed on November 5, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.32&#8224;&#8224;*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1032.htm">Offer letter to </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1032.htm">Mark Casey</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1032.htm"> dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1032.htm">N</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1032.htm">o</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1032.htm">vember </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1032.htm">10</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1032.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1032.htm">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.33&#8224;&#8224;*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1033.htm">Employment Agreement between the Company and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1033.htm">Mark Casey</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1033.htm"> dated</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1033.htm"> November</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1033.htm"> 10</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1033.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1033.htm">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="padding-left:9pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.34&#8224;&#8224;*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1034.htm">Offer Letter to Elaine O&#8217;Hara dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1034.htm">February 4, 2023</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.35&#8224;&#8224;*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1035.htm">Employment Agreement between the Company and</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1035.htm"> Elaine O</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1035.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1035.htm">Hara</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1035.htm"> dated</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1035.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1035.htm">February 4,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1035.htm"> 2023</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.36&#8224;&#8224;*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1036.htm">Offer Letter to </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1036.htm">Filip Dubovsky, M.D. </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1036.htm"> dat</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1036.htm">ed </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1036.htm">May 26, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1036.htm">2020</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.37&#8224;&#8224;*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1037.htm">Employment Agreement between the Company and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1037.htm">Filip Dubovsky, M.D.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1037.htm"> dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1037.htm">May 26, 2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="nvax-20231231xex1037.htm">020</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.38&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069421000016/nvax-20210630xex102.htm">Form of Amendment to Employment Agreement, dated June 17, 2021, between the Company and each of Stanley C. Erck, Gregory M. Glenn, John J. Trizzino</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069421000016/nvax-20210630xex102.htm">, Filip Dubovsky,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069421000016/nvax-20210630xex102.htm"> and John A. Herrmann, III (Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, filed on August 5, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.39&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000016/nvax-20210630xex104.htm">Company Amended and Restated Change in Control Severance Benefit Plan (Incorporated by reference to Exhibit 10.4 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, filed on August 5, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.40&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420410013614/v176992_ex10-19.htm">Form&#160;of Indemnification Agreement entered into between the Company and its directors and officers&#160;(Incorporated by reference to Exhibit&#160;10.19 to the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2009, filed on March&#160;16, 2010 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.41</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420412014910/v304706_ex10-25.htm">Lease Agreement for space at 22 Firstfield Road between ARE-20/22/1300 Firstfield Quince Orchard, LLC and the Company, dated as of November&#160;18, 2011 (Incorporated by reference to Exhibit&#160;10.25 to the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2011, filed on March&#160;14, 2012 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.42</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420415051329/v418551_ex10-1.htm">Deed of Lease for space at 21 Firstfield Road between Firstfield Holdco, LLC and the Company, dated as of February&#160;4, 2015 (Incorporated by reference to Exhibit&#160;10.1 to the Company's Current Report on Form&#160;8-K, filed on August&#160;21, 2015 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.43</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420415051329/v418551_ex10-2.htm">First Amendment to Deed of Lease for space at 21 Firstfield Road between Firstfield Holdco, LLC and the Company, dated as of August&#160;17, 2015 (Incorporated by reference to Exhibit&#160;10.2 to the Company&#8217;s Current Report on Form&#160;8-K, filed on August&#160;21, 2015 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.44</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420417025227/v465353_ex10-2.htm">Second Amendment to Deed of Lease for space at 21 Firstfield Road between BMR-Firstfield LLC (formerly Firstfield Holdco, LLC) and the Company, dated as of March&#160;31, 2017 (Incorporated by reference to Exhibit&#160;10.2 to the Company&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended March&#160;31, 2017, filed on May&#160;8, 2017 (File No.&#160;000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.45</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069421000004/exhibit1027.htm">Deed of Lease for space at 700 Quince Orchard Road between ARE-MARYLAND NO. 51, LLC and the Company, dated October 22, 2020 (Incorporated by reference to Exhibit 10.27 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed on March 1, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.46</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1033.htm">Amendment to Deed of Lease for space at 700 Quince Orchard Road between ARE-MARYLAND NO. 51, LLC and the Company, dated June 22, 2021 (Incorporated by reference to Exhibit 10.33 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on March 1, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.47&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000020/nvax-20210930xex104.htm">Amended and Restated Supply and License Agreement, dated July 1, 2021, between the Company and Serum Institute of India Private Limited (Incorporated by reference to Exhibit 10.4 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed on November 5, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.48&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1037.htm">Supply Agreement between the Company, Serum Institute of India Private Limited and Serum Life Sciences Limited, executed as of October 26, 2021 (Incorporated by reference to Exhibit 10.37 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on March 1, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.49&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000016/nvax-20220630xex103.htm">Contract Development Manufacture Agreement, dated October 21, 2021, between the Company and Serum Life Sciences Limited (Incorporated by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed on August </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000016/nvax-20220630xex103.htm">9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000016/nvax-20220630xex103.htm">, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="padding-left:9pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.50&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000016/nvax-20220630xex104.htm">Amendment No. 1 to the Contract Development Manufacture Agreement, executed as of April 29, 2022, between the Company and Serum Life Sciences Limited (Incorporated by reference to Exhibit 10.4 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed on August </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000016/nvax-20220630xex104.htm">9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000016/nvax-20220630xex104.htm">, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.51&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000016/nvax-20220630xex105.htm">Statement of Work No. 1 to the Contract Development Manufacture Agreement, effective as of April 29, 2022, between the Company and Serum Life Sciences Limited (Incorporated by reference to Exhibit 10.5 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed on August </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000016/nvax-20220630xex105.htm">9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000016/nvax-20220630xex105.htm">, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.52&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000008/nvax-20210331xex101.htm">Collaboration and Exclusive License Agreement between the Company and SK bioscience Company Limited, dated as of February 12, 2021 (Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, filed on May 10, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.53&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1039.htm">Fir</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1039.htm">st </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1039.htm">Amendment to Collaboration and Exclusive License Agreement between the Company and SK bioscience Company Limited, dated as of December 23, 2021 (Incorporated by reference to Exhibit 10.39 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on March 1, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.54&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1040.htm">Statement of Work No. 1 to Collaboration and Exclusive License Agreement between the Company and SK bioscience Company Limited, dated as of December 23, 2021 (Incorporated by reference to Exhibit 10.40 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on March 1, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.55&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000009/nvax-20220331xex102.htm">Change Order No. 1 to Statement of Work No. 1 to Collaboration and Exclusive License Agreement between the Company and SK bioscience Company Limited, dated as of March 31, 2022 (Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, filed on May 9, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.56&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000008/nvax-20210331xex102.htm">Collaboration and Exclusive License Agreement between the Company and Takeda Pharmaceutical Company Limited, dated as of February 24, 2021 (Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, filed on May 10, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.57**</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420415063483/v422902_ex10-2.htm">Global Access Commitments Agreement between Bill &amp; Melinda Gates Foundation and the Company, dated as of September 25, 2015 (Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, filed on November 9, 2015 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.58&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000114420419038206/tv526077_ex10-3.htm">Asset Purchase Agreement between Company and Paragon Bioservices, Inc., dated June 26, 2019 (Incorporated by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, filed on August 7, 2019 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.59&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex101.htm">Amended and Restated SARS-CoV-2 Vaccine Supply Agreement, dated as of July 1, 2022, between the Company and The Secretary of State for Business, Energy and Industrial Strategy, acting on behalf of the government of the United Kingdom of Great Britain and Northern Ireland (Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed on November 9, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.60&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex102.htm">Letter of Amendment to the Amended and Restated SARS-CoV-2 Vaccine Supply Agreement, dated as of September 26, 2022, between the Company and The Secretary of State for Business, Energy and Industrial Strategy, acting on behalf of the government of the United Kingdom of Great Britain and Northern Ireland (Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed on November 9, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.61&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069421000004/exhibit1036.htm">Advanced Purchase Agreement, effective as of December 31, 2020, between the Company and the Commonwealth of Australia as represented by the Department of Health (Incorporated by reference to Exhibit 10.36 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed on March 1, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.62&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1047.htm">Amendment to Advanced Purchase Agreement between the Company, and the Commonwealth of Australia as represented by the Department of Health, dated as of December 23, 2021 (Incorporated by reference to Exhibit 10.47 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on March 1, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="padding-left:9pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.63&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex106.htm">Amendment No. 2 to Advanced Purchase Agreement, dated as of April 6, 2022, between the Company and the Commonwealth of Australia as Represented by the Department of Health</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex106.htm"> (Incorporated by reference to Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex106.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex106.htm"> to the Company&#8217;s Quarterly Report on Form 10-Q</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex106.htm"> filed on August, 8 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex106.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex106.htm"> (File No. 000-26770))</a></span></div><div style="text-align:justify"><span><br/></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.64&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex107.htm">Amendment No. 3 to Advanced Purchase Agreement, dated as of April 5, 2023, between the Company and the Commonwealth of Australia as Represented by the Department of Health</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex107.htm"> (Incorporated by reference to Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex107.htm">7</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex107.htm"> to </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex107.htm">the Company&#8217;s Quarterly Report on Form 10-Q filed on August, 8 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex107.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex107.htm"> (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.65&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex108.htm">Amendment No. 4 to Advanced Purchase Agreement, dated as of July 5, 2023, between the Company and the Commonwealth of Australia as Represented by the Department of Health</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex108.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex108.htm">(Incorporated by reference to Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex108.htm">8</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex108.htm"> to the Company&#8217;s Quarterly Report on Form 10-Q</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex108.htm"> filed on August, 8 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex108.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex108.htm"> (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.66&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069421000004/exhibit1037.htm">Advanced Purchase Agreement, effective as of January 19, 2021, between the Company and Her Majesty the Queen in Right of Canada, as represented by the Minister of Public Works and Government Services (Incorporated by reference to Exhibit 10.37 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed on March 1, 2021 (File No. 000-26770)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.67&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex102.htm">Amendment No. 1 to Advanced Purchase Agreement, effective as of January 26, 2022, between the Company and His Majesty the King in Right of Canada, as represented by the Minister of Public Works and Government Services, as successor in interest to Her Majesty the Queen in Right of Canada, as represented by the Minister of Public Works and Government Services</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex102.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex102.htm">(Incorporated by reference to Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex102.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex102.htm"> to the Company&#8217;s Quarterly Report on Form 10-Q filed on August, 8 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex102.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex102.htm"> (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.68&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex103.htm">Amendment No. 2 to Advanced Purchase Agreement, effective as of October 18, 2022, between the Company and His Majesty the King in Right of Canada, as represented by the Minister of Public Works and Government Services, as successor in interest to Her Majesty the Queen in Right of Canada, as represented by the Minister of Public Works and Government Services</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex103.htm">(Incorporated by reference to Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex103.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex103.htm"> to the Company&#8217;s Quarterly Report on Form 10-Q filed on August, 8 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex103.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex103.htm"> (File No. 000-26770)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex103.htm">)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.69&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex104.htm">Amendment No. 3 to Advanced Purchase Agreement, effective as of April 25, 2023, between the Company and His Majesty the King in Right of Canada, as represented by the Minister of Public Works and Government Services, as successor in interest to Her Majesty the Queen in Right of Canada, as represented by the Minister of Public Works and Government Services</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex104.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex104.htm">(Incorporated by reference to Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex104.htm">4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex104.htm"> to the Company&#8217;s Quarterly Report on Form 10-Q filed on August, 8 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex104.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex104.htm"> (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.70&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex105.htm">Amendment No. 4 to Advanced Purchase Agreement, effective as of June 30, 2023, between the Company and His Majesty the King in Right of Canada, as represented by the Minister of Public Works and Government Services, as successor in interest to Her Majesty the Queen in Right of Canada, as represented by the Minister of Public Works and Government Services</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex105.htm"> (Incorporated by reference to Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex105.htm">5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex105.htm"> to the Company&#8217;s Quarterly Report on Form 10-Q filed on August, 8 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex105.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex105.htm"> (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.71&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000020/nvax-20210930xex108.htm">Advance Purchase Agreement, dated August 16, 2021, between the Company, Novavax CZ and the European Commission (Incorporated by reference to Exhibit 10.8 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed on November 5, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.72&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000155837020013462/nvax-20200930xex10d1.htm">Base Agreement between the Company and Advanced Technology International, dated June 25, 2020 (Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.73&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000009/nvax-20220331xex101.htm">Modification No. 01 to Base Agreement between the Company and Advanced Technology International, dated as of March 23, 2022 (Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, filed on May 9, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.74&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex103.htm">Modification No. 02 to Base Agreement between the Company and Advanced Technology International, dated as of August 2, 2022 (Incorporated by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed on November 9, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.75&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000005/nvax-20221231xex1056.htm">Modification No. 03 to Base Agreement between the Company and Advanced Technology International, dated as of November 30, 2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000005/nvax-20221231xex1056.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000005/nvax-20221231xex1056.htm">(Incorporated by reference to Exhibit 10.56 to the Company&#8217;s Annual Report on Form 10-K, filed on February 28, 2023 (File No. 000-26770))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.76&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000155837020013462/nvax-20200930xex10d2.htm">Undefinitized Project Agreement No. 1 between the Company and Advanced Technology International, dated July 6, 2020 (Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 (File No. 000-26770))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.77&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000155837020013462/nvax-20200930xex10d3.htm">Modification No. 01 to Undefinitized Project Agreement No. 1 between the Company and Advanced Technology International, dated July 9, 2020 (Incorporated by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="padding-left:9pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.78&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069421000004/exhibit1041.htm">Modification No. 02 to Undefinitized Project Agreement No. 01, entered into September 10, 2020, between the Company and Advanced Technology International (Incorporated by reference to Exhibit 10.41 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed on March 1, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.79&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069421000004/exhibit1042.htm">Modification No. 03 to Undefinitized Project Agreement No. 01, entered into September 18, 2020, between the Company and Advanced Technology International (Incorporated by reference to Exhibit 10.42 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed on March 1, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.80&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069421000004/exhibit1043.htm">Modification No. 04 to Undefinitized Project Agreement No. 01, entered into December 23, 2020, between the Company and Advanced Technology International (Incorporated by reference to Exhibit 10.43 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed on March 1, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.81&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069421000004/exhibit1044.htm">Modification No. 05 to Undefinitized Project Agreement No. 01, dated January 12, 2021, between the Company and Advanced Technology International (Incorporated by reference to Exhibit 10.44 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed on March 1, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.82&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069421000004/exhibit1045.htm">Modification No. 06 to Undefinitized Project Agreement No. 01, entered into January 19, 2021, between the Company and Advanced Technology International (Incorporated by reference to Exhibit 10.45 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed on March 1, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.83&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000016/nvax-20210630xex106.htm">Modification No. 07 to Undefinitized Project Agreement No. 01, dated April 23, 2021, between the Company and Advanced Technology International (Incorporated by reference to Exhibit 10.6 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, filed on August 5, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.84&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000016/nvax-20210630xex107.htm">Modification No. 08 to Undefinitized Project Agreement No. 01, dated June 4, 2021, between the Company and Advanced Technology International (Incorporated by reference to Exhibit 10.7 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, filed on August 5, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.85&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000020/nvax-20210930xex105.htm">Modification No. 09 to Undefinitized Project Agreement No. 01, dated July 16, 2021, between the Company and Advanced Technology International (Incorporated by reference to Exhibit 10.5 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed on November 5, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.86&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000020/nvax-20210930xex106.htm">Modification No. 10 to Undefinitized Project Agreement No. 01, dated August 6, 2021, between the Company and Advanced Technology International (Incorporated by reference to Exhibit 10.6 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed on November 5, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.87&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001000694/000100069421000020/nvax-20210930xex107.htm">Modification No. 11 to Undefinitized Project Agreement No. 01, dated August 26, 2021, between the Company and Advanced Technology International (Incorporated by reference to Exhibit 10.7 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed on November 5, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.88&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1064.htm">Modification No. 12 to Undefinitized Project Agreement No. 01, dated December 20, 2021, between the Company and Advanced Technology International (Incorporated by reference to Exhibit 10.64 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on March 1, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.89&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex1065.htm">Modification No. 13 to Undefinitized Project Agreement No. 01, dated February 1, 2022, between the Company and Advanced Technology International (Incorporated by reference to Exhibit 10.65 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on March 1, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.90&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex104.htm">Modification No. 14 to Undefinitized Project Agreement No. 01, dated July 1, 2022, between the Company and Advanced Technology International (Incorporated by reference to Exhibit 10.4 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed on November 9, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="padding-left:9pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.91&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex105.htm">Modification No. 15 to Undefinitized Project Agreement No. 01, dated August 9, 2022, between the Company and Advanced Technology International (Incorporated by reference to Exhibit 10.5 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed on November 9, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.92&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex106.htm">Modification No. 16 to Undefinitized Project Agreement No. 01, dated September 9, 2022, between the Company and Advanced Technology International (Incorporated by reference to Exhibit 10.6 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed on November 9, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.93&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000040/nvax-20230331xex101.htm">Modification No. 17 to Undefinitized Project Agreement No. 1, dated February 6, 2023, between the Company and Advanced Technology International</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000040/nvax-20230331xex101.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000040/nvax-20230331xex101.htm">(Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000040/nvax-20230331xex101.htm"> filed on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000040/nvax-20230331xex101.htm">May</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000040/nvax-20230331xex101.htm">, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000040/nvax-20230331xex101.htm">9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000040/nvax-20230331xex101.htm"> 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000040/nvax-20230331xex101.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000040/nvax-20230331xex101.htm"> (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10.94&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex101.htm">Modification No. 18 to Undefinitized Project Agreement No. 1, dated May 25, 2023, between the Company and Advanced Technology International</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex101.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex101.htm">(Incorporated by reference to Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex101.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex101.htm"> to the Company&#8217;s Quarterly Report on Form 10-Q</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex101.htm"> filed on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex101.htm">August</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex101.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex101.htm"> 8</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex101.htm"> 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex101.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000047/nvax-2023x06x30xex101.htm"> (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">10.95&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465920075307/tm2023024d1_ex10-1.htm">Series A Convertible Preferred Subscription Agreement, dated June 15, 2020, between the Company and RA Capital Healthcare Fund, L.P. (Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed June 19, 2020 (File No. 000-26770))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">10.96&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465920092782/nvax-20200630xex10d1.htm">Restated Funding Agreement, entered into on May 11, 2020, between the Company and the Coalition for Epidemic Preparedness Innovations (Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">10.97&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069421000004/exhibit1056.htm">Amendment Number 1 to the iPDP and Budget of the Outbreak Response Funding Agreement (Step 2), entered into on November 2, 2020, between the Company and the Coalition for Epidemic Preparedness Innovations (Incorporated by reference to Exhibit 10.56 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed on March 1, 2021 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">10.98&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000024/nvax-20220930xex108.htm">Settlement Agreement, dated September 30, 2022, between the Company and FUJIFILM Diosynth Biotechnologies UK Limited, FUJIFILM Diosynth Biotechnologies Texas, LLC, and FUJIFILM Diosynth Biotechnologies USA, Inc. (Incorporated by reference to Exhibit 10.8 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed on November 9, 2022 (File No. 000-26770))</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">10.99&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000055/nvax-20230930xex101.htm">Settlement Agreement and General Release, dated August 8, 2023, between the Company and SK bioscience Co., Ltd.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000055/nvax-20230930xex101.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000055/nvax-20230930xex101.htm">(Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000055/nvax-20230930xex101.htm">Septembe</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000055/nvax-20230930xex101.htm">r</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000055/nvax-20230930xex101.htm"> 30, 2023, filed on</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000055/nvax-20230930xex101.htm"> November</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000055/nvax-20230930xex101.htm">, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000055/nvax-20230930xex101.htm">9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000055/nvax-20230930xex101.htm"> 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000055/nvax-20230930xex101.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069423000055/nvax-20230930xex101.htm"> (File No. 000-26770))</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">10.100&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000110465923088596/tm2323012d4_ex10-1.htm">Securities Subscription Agreement, dated as of August 8, 2023, between the Company and SK bioscience Co., Ltd. (Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on August 8, 2023 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">10.101&#x5E;*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20231231xex10101.htm">Termination and Settlement Agreement, dated as of February 16, 2024, between the Company and Gavi Alliance</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">14</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1000694/000100069422000004/nvax-20211231xex14.htm">Code of Conduct (Incorporated by reference to Exhibit 14 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on March 1, 2022 (File No. 000-26770))</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">21*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20231231xex21.htm">Subsidiaries of the Company</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">23.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20231231xex231.htm">Consent of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">31.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20231231xex311.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(e) of the Securities Exchange Act</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">31.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20231231xex312.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(e) of the Securities Exchange Act</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">32.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20231231xex321.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">32.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20231231xex322.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">97*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nvax-20231231xex97.htm">Novavax, Inc. Amended and Restated Recoupment Policy</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="padding-left:9pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">101</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following financial information from our Annual Report on Form 10-K for the year ended December 31, 2023, formatted in Extensible Business Reporting Language (XBRL): (i) the Consolidated Balance Sheets as of December 31, 2023 and 2022, (ii) the Consolidated Statements of Operations for the three years in the period ended December 31, 2023, (iii) the Consolidated Statements of Comprehensive Loss for the three years in the period ended December 31, 2023, (iv) the Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit) for the three years in the period ended December 31, 2023, (v) the Consolidated Statements of Cash Flows for the three years in the period ended December 31, 2023, and (vi) the Notes to Consolidated Financial Statements.</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr></table></div><div><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="i65591fd2146e456aac589be2afadc864_154"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div style="margin-top:10pt;padding-left:81pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="i65591fd2146e456aac589be2afadc864_157"></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:47.948%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.585%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.167%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOVAVAX,&#160;INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ John C. Jacobs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">John C. Jacobs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: February&#160;28, 2024 </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:</span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.747%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.898%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ John C. Jacobs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer and Director (Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">John C. Jacobs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ James P. Kelly</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Executive Vice President, Chief Financial Officer, and Treasurer (Principal Financial and Accounting Officer)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2024</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">James P. Kelly</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ James F. Young</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chairman of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">James F. Young</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Gregg H. Alton</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gregg H. Alton</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Richard H. Douglas</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Richard H. Douglas</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Rachel K. King</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rachel K. King</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Margaret G. McGlynn</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Margaret G. McGlynn</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ David M. Mott</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">David M. Mott</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Richard J. Rodgers</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Richard J. Rodgers</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><div id="i65591fd2146e456aac589be2afadc864_160"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ended December&#160;31, 2023, 2022, and 2021</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contents</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:91.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.672%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_163">Reports of Independent Registered Public Accounting Firm </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(PCAOB ID:<ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-46">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F- <a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_163">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_166">Consolidated Statements of Operations and Statements of Comprehensive Loss for the years ended December&#160;31, 2023, 2022, and 2021</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F- <a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_166">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_169">Consolidated Balance Sheets as of December&#160;31, 2023 and 2022</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F- <a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_169">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_172">Consolidated Statements of Changes in Stockholders&#8217; </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_172">Equity (</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_172">Deficit</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_172">)</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_172"> for the years ended December&#160;31, 2023, 2022, and 2021</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F- <a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_172">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_175">Consolidated Statements of Cash Flows for the years ended December&#160;31, 2023, 2022, and 2021</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F- <a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_175">9</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_178">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F- <a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i65591fd2146e456aac589be2afadc864_178">10</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 1</span></div></div></div><div id="i65591fd2146e456aac589be2afadc864_163"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Stockholders of</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novavax,&#160;Inc.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Novavax,&#160;Inc. (the Company) as of December&#160;31, 2023 and 2022, the related consolidated statements of operations, comprehensive loss, changes in stockholders&#8217; equity (deficit), and cash flows for each of the three years in the period ended December&#160;31, 2023, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2023, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December&#160;31, 2023, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February&#160;28, 2024 expressed an unqualified opinion thereon.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company&#8217;s Ability to Continue as a Going Concern</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses, has negative working capital, and an accumulated deficit and has stated that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management&#8217;s evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules&#160;and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matters do not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing a separate opinion on the critical audit matter or on the account or disclosures to which they relate. </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.694%"><tr><td style="width:1.0%"/><td style="width:12.717%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.804%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Inventory Excess and Obsolescence Reserve<br/></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company had $41.7&#160;million of inventory. As disclosed in Note 2, inventories are stated at the lower of cost or net realizable value. The Company assesses its inventory levels each reporting period and writes down inventory that is either expected to be at risk of expiration prior to sale, or for which there are inventory quantities in excess of expected requirements. For the year ended December&#160;31, 2023, inventory write-downs were $72.4&#160;million and losses on firm purchase commitments were $73.5&#160;million. In addition, for the year ended December 31, 2023, the Company recorded recoveries on firm purchase commitments of $40.2 million related primarily to negotiated reductions to previously recognized firm purchase commitments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing management's estimates for excess and obsolete inventory involved subjective auditor judgment because the estimates rely on a number of factors that are affected by market and economic conditions outside the Company's control. In particular, the obsolete and excess inventory calculations are sensitive to significant assumptions, including the expected demand for the Company&#8217;s products, assumptions about the vaccine&#8217;s life cycle, the effect on demand of competitive products and the Company's purchase commitments.</span></div><div style="text-align:justify"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design, and tested the operating effectiveness of internal controls over the Company's excess and obsolete inventory reserve process including management&#8217;s review of the significant assumptions described above and controls over the completeness and accuracy of the information used to develop the estimate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our substantive audit procedures included, among others, evaluating methodologies, assumptions and data utilized in the analysis for inventory expected to be at risk for expiration or excess. We evaluated and compared forecasted demand to historical trends, compared actual inventory levels to forecasted demand requirements and evaluated the sensitivity of sales forecast assumptions on the amount of inventory reserves recorded.</span></div></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.694%"><tr><td style="width:1.0%"/><td style="width:12.717%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.804%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Product Return Reserve Estimate- U.S. Commercial Sales</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company recorded a liability for product returns related to US commercial sales of $82.5&#160;million. As disclosed in Note 2, the Company offers U.S. commercial customers the right to return its product. These return rights include the right of wholesale distributors to return unsold and expired doses and indirect customers the right to return any partial or unused vials upon expiry. The Company estimates variable consideration resulting from these product returns based on quantitative and qualitative data from various internal and external sources.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing management&#8217;s estimate of product returns was complex and judgmental given the Company&#8217;s limited history of US commercial sales, and management considers the level of inventory in the distribution channel, projected market demand, utilization data, returns claims received, and product shelf life.  </span></div><div style="text-align:justify"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design, and tested the operating effectiveness of internal controls over the product return reserve estimation process for U.S. commercial sales, including management&#8217;s review of the level of inventory in the distribution channel, as well as inputs and assumptions used to develop the estimate of the product returns reserve.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our substantive audit procedures included, among others, testing the level of product in the channel held by a sample of wholesale distributors at December&#160;31, 2023. For indirect customers, we obtained and reviewed the Company&#8217;s estimated channel mix, and compared relevant inputs to underlying actual sales data. In addition, we assessed management&#8217;s estimate of projected market demand for the product through the expiration dates, by analyzing available internal and third party utilization data for the product for the current vaccination season, and we also assessed management&#8217;s estimate of total U.S. commercial market size for the season by analyzing available third party data. We also evaluated the sensitivities of changes in projected demand on the product return reserve estimate recorded. </span></div><div style="text-align:justify"><span><br/></span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:109%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-47">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:109%">We have served as the Company&#8217;s auditor since 2014.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:109%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-48">Tysons, Virginia</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:109%">February 28, 2024</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:144pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:109%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Stockholders of</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novavax,&#160;Inc.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Novavax, Inc.&#8217;s internal control over financial reporting as of December&#160;31, 2023, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Novavax,&#160;Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2023, based on the COSO criteria.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December&#160;31, 2023 and 2022, the related consolidated statements of operations, comprehensive loss, changes in stockholders&#8217; equity (deficit), and cash flows for each of the three years in the period ended December&#160;31, 2023, and the related notes and our report dated February&#160;28, 2024 expressed an unqualified opinion that included an explanatory paragraph regarding the Company&#8217;s ability to continue as a going concern.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Report on Internal Control over Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in Item 9A. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules&#160;and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-49">Ernst&#160;&amp; Young LLP</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-50">Tysons, Virginia</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;28, 2024</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 5</span></div></div></div><div id="i65591fd2146e456aac589be2afadc864_166"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOVAVAX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share information)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-51">531,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-52">1,554,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-54">427,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-55">382,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-56">948,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-57">24,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-58">43,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-59">197,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-60">983,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-61">1,981,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-62">1,146,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-63">343,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-64">902,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:fixed-zero" scale="3" id="f-65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-66">737,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-67">1,235,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-68">2,534,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-69">468,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-70">488,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-71">298,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-72">1,550,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-73">2,626,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-74">2,832,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-75">566,511</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-76">644,736</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-77">1,686,576</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-78">14,416</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-79">19,880</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-80">21,127</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-81">37,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-82">10,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-83">6,833</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income tax expense</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-84">543,031</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-85">653,647</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-86">1,714,536</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-87">2,031</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-88">4,292</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-89">29,215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-90">545,062</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-91">657,939</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-92">1,743,751</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-93"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-94">5.41</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-95"><ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-96">8.42</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-18" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-97"><ix:nonFraction unitRef="usdPerShare" contextRef="c-18" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-98">23.44</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-99"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-100">100,768</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-101"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-102">78,183</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-103"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-104">74,400</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:30pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-105">545,062</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-106">657,939</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-107">1,743,751</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gains (losses) on marketable securities available-for-sale, net of reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="f-108">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="f-109">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-110">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-111">9,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-112">5,024</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-113">8,368</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-114">9,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-115">5,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-116">8,377</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-117">535,963</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-118">662,963</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-119">1,752,128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 6</span></div></div></div><div id="i65591fd2146e456aac589be2afadc864_169"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOVAVAX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share information)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-120">568,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-121">1,336,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-122">10,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-123">10,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="3" id="f-124">297,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="3" id="f-125">82,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-126">41,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-127">36,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-128">226,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-129">237,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-130">1,143,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-131">1,703,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-132">305,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-133">294,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="nvax:LeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-134">185,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="nvax:LeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-135">106,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-136">127,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-137">126,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-138">35,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-139">28,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-140">1,797,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-141">2,258,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-142">132,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-143">216,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-144">394,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-145">591,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-146">241,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-147">370,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-148">5,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-149">27,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:ConvertibleNotesPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-150">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:ConvertibleNotesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-151">324,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-152">861,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-153">930,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-154">1,635,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-155">2,459,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-156">622,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-157">179,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-158">168,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-159">166,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-160">55,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-161">31,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-162">33,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-163">55,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-164">2,514,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-165">2,892,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 16)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-19" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-166"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-20" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-167"></ix:nonFraction></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-19" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-168"><ix:nonFraction unitRef="usdPerShare" contextRef="c-20" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-169">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-170"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-171">2,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December&#160;31, 2023 and 2022; no shares issued and outstanding at December&#160;31, 2023 and 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-172">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-173">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; deficit:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-19" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-174"><ix:nonFraction unitRef="usdPerShare" contextRef="c-20" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-175">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-176"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-177">600,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December&#160;31, 2023 and 2022; and <ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-178">140,506,093</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-179">139,505,770</ix:nonFraction> shares outstanding at December&#160;31, 2023 and <ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-180">86,806,554</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-181">86,039,923</ix:nonFraction> shares outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="f-182">1,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-183">868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-184">4,192,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-185">3,737,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-186">4,820,951</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-187">4,275,889</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, <ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-188">1,000,323</ix:nonFraction> shares, cost basis at December&#160;31, 2023 and <ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-189">766,631</ix:nonFraction> shares, cost basis at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="3" id="f-190">92,267</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="3" id="f-191">90,659</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-192">2,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-193">6,377</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; deficit</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-194">716,927</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-195">634,078</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; deficit</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-196">1,797,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-197">2,258,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 7</span></div></div></div><div id="i65591fd2146e456aac589be2afadc864_172"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOVAVAX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share information)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:28.182%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.298%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; Equity (Deficit)</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-198">71,350,365</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-199">714</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-200">2,535,476</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-201">1,874,199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-202">41,806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-203">7,024</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-204">627,209</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-205">183,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-206">183,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Stock issued under incentive programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="INF" name="nvax:ShareBasedCompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="0" id="f-207">2,503,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" scale="3" id="f-208">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="3" id="f-209">68,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="nvax:CompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="3" id="f-210">43,295</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="3" id="f-211">24,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-212">7,292</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-213">2,578,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-214">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-215">564,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-216">564,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-217">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-218">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-219">8,368</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-220">8,368</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-221">1,743,751</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-222">1,743,751</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-223">76,433,151</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-224">764</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-225">3,351,967</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-226">3,617,950</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-227">85,101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-228">1,353</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-229">351,673</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-230">131,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-231">131,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Stock issued under incentive programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="nvax:ShareBasedCompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="0" id="f-232">701,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" scale="3" id="f-233">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="3" id="f-234">4,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="nvax:CompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="3" id="f-235">5,558</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="nvax:CompensationStockIssuedUnderIncentiveProgram" scale="3" id="f-236">639</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-237">7,216</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-238">9,672,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-239">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-240">249,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-241">249,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-242">5,024</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-243">5,024</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-244">657,939</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-245">657,939</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-246">86,806,554</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-247">868</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-248">3,737,979</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-249">4,275,889</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-250">90,659</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-251">6,377</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-252">634,078</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-253">85,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-254">85,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Stock issued under incentive programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-49" decimals="INF" name="nvax:ShareBasedCompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="0" id="f-255">902,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" scale="3" id="f-256">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="3" id="f-257">1,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" sign="-" name="nvax:CompensationStockIssuedUnderIncentiveProgram" format="ixt:num-dot-decimal" scale="3" id="f-258">1,608</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="nvax:CompensationStockIssuedUnderIncentiveProgram" scale="3" id="f-259">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-260">6,171</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-49" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-261">52,796,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-262">528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-263">366,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-264">367,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-265">9,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-266">9,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-267">545,062</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-268">545,062</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-53" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-269">140,506,093</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-270">1,405</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-271">4,192,164</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-272">4,820,951</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-273">92,267</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-274">2,722</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-275">716,927</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 8</span></div></div></div><div id="i65591fd2146e456aac589be2afadc864_175"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOVAVAX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-276">545,062</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-277">657,939</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-278">1,743,751</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation of net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-279">41,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-280">29,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-281">12,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets expensed, net of credits received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="nvax:OperatingAndFinanceLeaseWriteOff" format="ixt:num-dot-decimal" scale="3" id="f-282">6,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="nvax:OperatingAndFinanceLeaseWriteOff" format="ixt:num-dot-decimal" scale="3" id="f-283">18,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="nvax:OperatingAndFinanceLeaseWriteOff" format="ixt:num-dot-decimal" scale="3" id="f-284">144,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-285">85,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-286">130,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-287">183,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for excess and obsolete inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="nvax:ProvisionForExcessAndObsoleteInventory" format="ixt:num-dot-decimal" scale="3" id="f-288">72,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="nvax:ProvisionForExcessAndObsoleteInventory" format="ixt:num-dot-decimal" scale="3" id="f-289">447,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="nvax:ProvisionForExcessAndObsoleteInventory" format="ixt:fixed-zero" scale="3" id="f-290">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of long-lived assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="f-291">10,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="f-292">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="f-293">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-294">7,042</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-295">21,903</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-296">7,641</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-297">74,457</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-298">477,801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-299">8,872</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, prepaid expenses, and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-300">274,442</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-301">249,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-302">183,393</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable, accrued expenses, and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-303">378,805</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-304">913,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-305">600,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="f-306">350,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="f-307">1,045,914</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="f-308">1,325,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-309">713,967</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-310">415,937</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-311">322,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForCapitalImprovements" format="ixt:num-dot-decimal" scale="3" id="f-312">53,771</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:PaymentsForCapitalImprovements" format="ixt:num-dot-decimal" scale="3" id="f-313">89,056</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:PaymentsForCapitalImprovements" format="ixt:num-dot-decimal" scale="3" id="f-314">54,501</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForSoftware" format="ixt:num-dot-decimal" scale="3" id="f-315">5,035</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:PaymentsForSoftware" format="ixt:num-dot-decimal" scale="3" id="f-316">3,929</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:PaymentsForSoftware" format="ixt:num-dot-decimal" scale="3" id="f-317">2,985</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:fixed-zero" scale="3" id="f-318">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:fixed-zero" scale="3" id="f-319">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-320">2,167</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:fixed-zero" scale="3" id="f-321">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:fixed-zero" scale="3" id="f-322">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-323">159,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-324">58,806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-325">92,985</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-326">100,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds from sales of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-327">360,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-328">249,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-329">564,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of 2027 Convertible notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:fixed-zero" scale="3" id="f-330">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="f-331">175,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:fixed-zero" scale="3" id="f-332">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments of costs related to issuance of 2027 Convertible notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-333">3,591</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-334">5,258</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-335">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds from the exercise of stock-based awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="nvax:NetProceedsFromTheExerciseOfStockBasedAwards" scale="3" id="f-336">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="nvax:NetProceedsFromTheExerciseOfStockBasedAwards" scale="3" id="f-337">639</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="nvax:NetProceedsFromTheExerciseOfStockBasedAwards" format="ixt:num-dot-decimal" scale="3" id="f-338">24,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of 2023 Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="f-339">325,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:fixed-zero" scale="3" id="f-340">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:fixed-zero" scale="3" id="f-341">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="f-342">27,345</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="f-343">93,595</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="f-344">127,907</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-345">4,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-346">324,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-347">461,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate on cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-348">3,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-349">4,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-350">5,292</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents, and restricted cash</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-351">765,035</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-352">179,414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-353">879,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-354">1,348,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-355">1,528,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-356">648,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-357">583,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-358">1,348,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-359">1,528,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of common stock under the Sales Agreement not settled at year-end</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="nvax:ProceedsFromIssuanceOrSaleOfEquityNotSettled" format="ixt:num-dot-decimal" scale="3" id="f-360">6,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="nvax:ProceedsFromIssuanceOrSaleOfEquityNotSettled" format="ixt:fixed-zero" scale="3" id="f-361">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="nvax:ProceedsFromIssuanceOrSaleOfEquityNotSettled" format="ixt:fixed-zero" scale="3" id="f-362">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures included in accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-363">7,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-364">17,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-365">10,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets from new lease agreements</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="nvax:NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-366">103,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="nvax:NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-367">91,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="nvax:NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-368">179,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash interest payments, net of amounts capitalized</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-369">17,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-370">18,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-371">19,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="f-372">190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="f-373">17,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="f-374">12,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;padding-left:103.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 9</span></div></div></div><div id="i65591fd2146e456aac589be2afadc864_178"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOVAVAX,&#160;INC.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div id="i65591fd2146e456aac589be2afadc864_181"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-375" continuedAt="f-375-1" escape="true">Organization &amp; Business</ix:nonNumeric></span></div><ix:continuation id="f-375-1"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novavax, Inc. (&#8220;Novavax,&#8221; and together with its wholly owned subsidiaries, the &#8220;Company&#8221;) is a biotechnology company that promotes improved health by discovering, developing, and commercializing innovative vaccines to prevent serious infectious diseases. Novavax offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and patented Matrix-M&#8482; adjuvant to enhance the immune response. Novavax currently has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid&#8482; prototype COVID-19 vaccine ("NVX-CoV2373,&#8221; or &#8220;prototype vaccine&#8221;) and Nuvaxovid&#8482; updated COVID-19 vaccine (&#8220;NVX-CoV2601,&#8221; or &#8220;updated vaccine&#8221;) (collectively, &#8220;COVID-19 Vaccine&#8221;). Local regulatory authorities have also specified nomenclature for the prototype and updated vaccines within their territories (e.g., &#8220;Novavax COVID-19 Vaccine, Adjuvanted&#8221; and &#8220;Novavax COVID-19, Adjuvanted (2023-2024 Formula)&#8221;, respectively, for the U.S.). The Company&#8217;s partner, Serum Institute of India Pvt. Ltd. (&#8220;SIIPL&#8221;), markets NVX-CoV2373 as &#8220;Covovax&#8482;.&#8221; </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2022, the Company received approval, interim authorization, provisional approval, conditional marketing authorization, and emergency use authorization (&#8220;EUA&#8221;) from multiple regulatory authorities globally for its prototype vaccine for both adult and adolescent populations as a primary series and for both homologous and heterologous booster indications in select territories. In October 2023, the U.S. Food and Drug Administration (&#8220;U.S. FDA&#8221;) amended the EUA for its prototype vaccine to include its updated vaccine. The amended EUA authorizes use of the Company&#8217;s updated vaccine in individuals 12 years and older. In October 2023, the European Commission (&#8220;EC&#8221;) granted approval for the Company&#8217;s updated vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 and older. Currently, the Company significantly depends on its supply agreement with SIIPL and its subsidiary, Serum Life Sciences Limited (&#8220;SLS&#8221;), for co-formulation, filling and finishing (other than in Europe) and on its service agreement with PCI Pharma Services for finishing in Europe. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novavax is advancing development of other vaccine candidates, including its COVID19-Influenza Combination (&#8220;CIC&#8221;) vaccine candidate and additional vaccine candidates. The Company&#8217;s COVID-19 Vaccine and its other vaccine candidates incorporate the Company&#8217;s proprietary Matrix-M&#8482; adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.</span></div></ix:continuation><div id="i65591fd2146e456aac589be2afadc864_184"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="f-376" continuedAt="f-376-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-376-1" continuedAt="f-376-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-377" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Novavax,&#160;Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="nvax:LiquidityAndGoingConcernPolicyTextBlock" id="f-378" continuedAt="f-378-1" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Going Concern</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern within one year after the date that the financial statements are issued and contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainty described below. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-379">568.5</ix:nonFraction> million in cash and cash equivalents and had a working capital deficiency. In January 2024, pursuant to the June 2023 Amendment to the advance purchase agreement between the Company and the Canadian government (the &#8220;Canada APA&#8221;), the Company received the second installment of $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="nvax:InstallmentChargesOfTheCompany" format="ixt:num-dot-decimal" scale="6" id="f-380">174.8</ix:nonFraction>&#160;million from the Canadian government that was contingent and payable upon the Company&#8217;s delivery of vaccine doses (see Note 3). During the year ended December&#160;31, 2023, the Company incurred a net loss of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-381">545.1</ix:nonFraction> million and had net cash flows used in operating activities of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-382">714.0</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 205-40</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Presentation of Financial Statements - Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that these consolidated financial </span></div></ix:nonNumeric></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-376-2" continuedAt="f-376-3"><ix:continuation id="f-378-1"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements are issued. While the Company&#8217;s current cash flow forecast for the one-year going concern look forward period estimates that there will be sufficient capital available to fund operations, this forecast is subject to significant uncertainty, including as it relates to revenue for the next 12 months and the Company&#8217;s ability to execute on certain cost-reduction initiatives. The Company&#8217;s revenue projections depend on its ability to successfully develop, manufacture, distribute and market its updated vaccine for the 2024-2025 vaccination season, which is inherently uncertain and subject to a number of risks, including the Company&#8217;s ability to obtain regulatory authorizations, introduce a single-dose vial or pre-filled syringe  product presentation for the U.S. commercial and certain other markets, the incidence of COVID-19 during the 2024-2025 vaccination season, the Company&#8217;s ability to timely deliver doses and achieve commercial adoption and market acceptance of its updated vaccine. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to meet regulatory milestones or achieve product volume or delivery timing obligations under the Company&#8217;s advance purchase agreements (&#8220;APAs&#8221;) may require the Company to refund portions of upfront and other payments or result in reduced future payments which would adversely affect the Company&#8217;s ability to continue as a going concern. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that, given the history of recurring losses, negative working capital and accumulated deficit, conditions or events exist that raise substantial doubt about the Company&#8217;s ability to continue as a going concern through one year from the date that these financial statements are issued. Management&#8217;s plans to alleviate the conditions that exist include restructuring and cost reduction measures and successful execution of its commercial plans. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, the Company announced a global restructuring and cost reduction plan (the &#8220;Restructuring Plan&#8221;), which includes a more focused investment in its COVID-19 Vaccine, reduction to its pipeline spending, the continued rationalization of its manufacturing network, a reduction to the Company&#8217;s global workforce, as well as the consolidation of facilities, and infrastructure. In January 2024, as part of reducing combined research and development and selling, general and administrative expenses, the Company announced further reductions in its global workforce (the &#8220;2024 Cost Reduction Plan&#8221;) (see Note 18). The Company intends to prioritize improvements to its long-term supply chain efficiency. The Company expects the full annual impact of the Restructuring Plan to be realized in 2024 and the full annual impact of the 2024 Cost Reduction Plan to be realized in 2025 and approximately <ix:nonFraction unitRef="number" contextRef="c-19" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" scale="-2" id="f-383">85</ix:nonFraction>% of the annual impact, excluding one-time charges, to be realized in 2024. During the year ended December&#160;31, 2023, the Company recorded a charge of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="f-384">4.5</ix:nonFraction>&#160;million related to one-time employee severance and benefit costs and recorded an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="f-385">10.1</ix:nonFraction>&#160;million related to the consolidation of facilities and infrastructure (see Note 17) and expects to record an additional charge of approximately $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="f-386">4</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="f-387">7</ix:nonFraction>&#160;million related to one-time employee severance and benefit costs, the majority of which is expected to be incurred in the first quarter of 2024. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Management&#8217;s plans may also include raising additional capital through a combination of equity and debt financing, collaborations, strategic alliances, asset sales, and marketing, distribution, or licensing arrangements. New financings may not be available to the Company on commercially acceptable terms, or at all. Also, any collaborations, strategic alliances, asset sales and marketing, distribution, or licensing arrangements may require the Company to give up some or all of its rights to a product or technology, which in some cases may be at less than the full potential value of such rights. If the Company is unable to obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate some or all of its operations, or further downsize its organization, any of which may have a material adverse effect on its business, financial condition, results of operations, and ability to operate as a going concern.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Due to the uncertainties associated with management&#8217;s plans, there is substantial doubt about the Company&#8217;s ability to continue as a going concern for at least one year from the date that these financial statements are issued.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-388" continuedAt="f-388-1" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-388-1">The preparation of the consolidated financial statements in conformity with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="f-389" continuedAt="f-389-1" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company analyzes its revenue arrangements to determine the appropriate accounting under U.S. GAAP. Currently, the Company&#8217;s revenue arrangements represent customer contracts within the scope of ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 606&#8221;), or are contributions subject to the guidance in ASC Topic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities &#8211; Revenue Recognition </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 958-605&#8221;). The Company recognizes revenue from arrangements within the </span></div></ix:nonNumeric></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-389-1" continuedAt="f-389-2"><ix:continuation id="f-376-3" continuedAt="f-376-4"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">scope of ASC 606 following the five-step model: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) it satisfies a performance obligation. The Company only recognizes revenue under the five-step model when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to its customer. The Company recognizes contribution revenue within the scope of ASC 958-605 when the funder-imposed conditions have been substantially met. Contributions are recorded as deferred revenue until the period in which research and development activities are performed that satisfy the funder-imposed conditions.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Sales - Advance Purchase Agreements </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales include sales associated with COVID-19 Vaccine supply agreements, sometimes referred to as APAs, with various international governments. The Company recognizes revenue from product sales related to these APA&#8217;s based on the transaction price per dose calculated in accordance with ASC 606 at the point in time when control of the product transfers to the customer and customer acceptance has occurred, unless such acceptance provisions are deemed perfunctory. The APAs typically contain terms that include upfront payments which are reflected in Deferred revenue. The Company constrains the transaction price for APA&#8217;s until it is probable that a significant reversal in revenue recognized will not occur. Specifically, if an APA includes a provision whereby the customer may request a discount, return, or refund, or includes a term that may have the effect of decreasing the price per dose of previously delivered shipments, revenue is constrained based on an estimate of the impact of the transaction price until it is probable that a significant reversal in revenue recognized will not occur. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Sales - U.S. Commercial </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2023, the Company commenced sales of COVID-19 Vaccine to the U.S. commercial market. Product sales in the U.S. are primarily made through large pharmaceutical wholesale distributors at the wholesale acquisition cost (&#8220;WAC&#8221;). The Company recognizes revenue upon title transfer (which is typically at time of delivery), provided all other revenue recognition criteria have been met. The transaction price includes estimates of variable consideration for which reserves are established that primarily result from invoice discounts for prompt payment, wholesale distributor fees, chargebacks, and product returns (collectively, &#8220;gross-to-net deductions&#8221;). These estimates are based on the amounts earned or to be claimed for related sales and are classified as either reductions of gross accounts receivable or a current liability based on the nature of the estimate, the expected settlement method, and net position by individual customer. Where appropriate, these estimates are based on factors such as industry data and forecasted customer buying and payment patterns, the Company&#8217;s experience, current contractual and statutory requirements, specific known market events, and trends. Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. If actual results vary from estimates, the Company will adjust the estimates, which would affect product sales in the period such variances become known. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross-to-net deductions include the following:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Wholesale distributor fees, discounts, and chargebacks: The Company has arrangements under which indirect customers such as retailers, healthcare providers, and others receive discounts to the WAC. The chargeback represents the difference between the WAC and this negotiated discounted price. For distribution and related services, the Company incurs service fees to its wholesale distributors. In addition, the Company typically offers wholesale distributor customers invoice discounts on product sales for prompt payments. The Company estimates chargebacks, discounts, and fees it will owe and deducts these amounts from gross product sales at the time the revenue is recognized based on the contractual terms and the Company&#8217;s expectations regarding future customer behaviors. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product returns: The Company offers U.S. customers the right to return COVID-19 Vaccine. These return rights include the right of wholesale distributors to return unsold and expired doses and the right of indirect customers to return any partial or unused vials upon expiry. Estimated returns for COVID-19 Vaccine are determined considering levels of inventory in the distribution channel, projected market demand, utilization data, returns claims received, and product shelf life. The estimated amount for product returns is deducted from gross product sales in the period the related product sales are recognized.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Other: Fees payable to retailers, healthcare providers, and buying groups, including certain patient assistance programs, are deducted from gross product sales in the period the related product sales are recognized.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-389-2" continuedAt="f-389-3"><ix:continuation id="f-376-4" continuedAt="f-376-5"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Grants</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant revenue includes both revenue from government contracts and grants from organizations such as the Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;). The Company performs research and development under government funding, grant, license, and clinical development agreements. The revenue primarily consists of funding under U.S. government contracts and other arrangements to advance the clinical development and manufacturing of COVID-19 Vaccine.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under U.S. government contracts, the Company is entitled to receive funding on a cost-reimbursable or cost-reimbursable-plus-fixed-fee basis, to support certain activities related to the development, manufacture, and delivery of COVID-19 Vaccine to the U.S. government. The Company analyzed these contracts and determined that they are within the scope of ASC 606. The obligations under each of the contracts are not distinct in the context of the contract as they are highly interdependent or interrelated and, as such, they are accounted for as a single performance obligation. The transaction price under these arrangements is the consideration the Company is expecting to receive and consists of the funded contract amount and the unfunded variable amount to the extent that it is probable that a significant reversal of revenue will not occur. The Company recognizes revenue for these contracts over time as the Company transfers control over the goods and services and satisfies the performance obligation. The Company measures progress toward satisfaction of the performance obligation using an Estimate-at-Completion (&#8220;EAC&#8221;) process, which is a cost-based input method that reviews and monitors the progress towards the completion of the Company&#8217;s performance obligation. Under this process, management considers the costs that have been incurred to-date, as well as projections to completion using various inputs and assumptions, including, but not limited to, progress towards completion, labor costs and level of effort, material and subcontractor costs, indirect administrative costs, and other identified risks. Estimating the total allowable cost at completion of the performance obligation under a contract is subjective and requires the Company to make assumptions about future activity and cost drivers. Changes in these estimates can occur for a variety of reasons and, if significant, may impact the timing of revenue and fee recognition on the Company&#8217;s contracts. Allowable contract costs include direct costs incurred on the contract and indirect costs that are applied in the form of rates to the direct costs. Progress billings under the contracts are initially based on provisional indirect billing rates, agreed upon between the Company and the U.S. government. These indirect rates are subject to review on an annual basis. The Company records the impact of changes in the indirect billing rates in the period when such changes are identified. These changes reflect the difference between actual indirect costs incurred compared to the estimated amounts used to determine the provisional indirect billing rates agreed upon with the U.S. government. The Company recognizes revenue on the U.S. government contracts based on reimbursable allowable contract costs incurred in the period up to the transaction price. For cost-reimbursable-plus-fixed-fee contracts, the Company recognizes the fixed-fee based on the proportion of reimbursable contract costs incurred to total estimated allowable contract costs expected to be incurred on completion of the underlying performance obligation as determined under the EAC process. The Company recognizes changes in estimates related to the EAC process in the period when such changes are made on a cumulative catch-up basis. The Company includes the transaction price comprising both funded and unfunded portions of customer contracts in this estimate.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:28.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s other funding agreements currently include funding from CEPI in the form of a grant (&#8220;CEPI Grant Funding&#8221;) and one or more forgivable no interest term loans (&#8220;CEPI Forgivable Loan Funding&#8221;). Under the Company&#8217;s grant funding arrangements, including the CEPI arrangement, the Company is primarily entitled to reimbursement for costs that support development related activities of COVID-19 Vaccine. The Company analyzed these other funding arrangements and determined that they are not within the scope of ASC 606 as they do not provide a direct economic benefit to the grantor. Payments received under the grant funding arrangements are considered conditional contributions under the scope of ASC 958-605 and are recorded as deferred revenue until the period in which such research and development activities are actually performed in a manner that satisfies the funder-imposed conditions. Payments received under the CEPI Forgivable Loan Funding are only repayable if project vaccine, as defined under the CEPI funding agreement, manufactured by the contract manufacturing organization (&#8220;CMO&#8221;) network funded by CEPI is sold to one or more third parties (which could include sales credited under the Gavi Settlement Agreement), and such sales cover the Company&#8217;s costs of manufacturing such vaccine, not including manufacturing costs funded by CEPI. As the financial risk remains with CEPI, the Company determined that the use of the funds from the CEPI agreement is outside the scope of ASC Topic 470, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The research and development risk was considered substantive, such that it was not probable that the development would be successful at the inception of the contract. Therefore, the Company concluded that ASC Topic 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 730&#8221;) was considered applicable and most appropriate. Given the financial risk associated with the research and development activities lies with CEPI because repayment of any funds provided by CEPI depends solely on the results of the research and development activities having future economic benefit, the Company has accounted for the obligation under the CEPI Forgivable Loan Funding as a contract to perform research and development for others. The Company has determined that payments received under these agreements should be recorded as revenue under ASC 958-605 rather than a reduction to research and development expenses. This is consistent with the Company&#8217;s policy of presenting such amounts as revenue. In reaching this determination, the Company </span></div></ix:continuation></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-376-5" continuedAt="f-376-6"><ix:continuation id="f-389-3"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">considered a number of factors, including whether it is principal under the arrangement, and whether the arrangement is significant to, and part of, the Company&#8217;s core operations. The Company will record revenue as it performs the contractual research and development services.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments received in advance related to arrangements where revenue is recognized under ASC 958-605 that are related to future performance are deferred and recognized as revenue when the research and development activities are performed. Such cash payments are restricted as to their use and are reflected in Restricted cash until expenditures contemplated in the funding agreements are incurred.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Royalties and Other</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has various arrangements that include a right for a customer to use the Company's intellectual property as a functional license, where the Company&#8217;s performance obligation is satisfied at the point in time at which the license is granted. These licensing arrangements include sales-based royalties, certain development and commercial milestone payments, and the sale of proprietary Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> adjuvant. Because development milestone payments are contingent on the achievement of milestones, such as regulatory approvals, that are not within the Company or licensee's control, the payments are not considered probable of being achieved and are excluded from the transaction price until the milestone is achieved, at which point the Company recognizes revenue. For arrangements that include sales-based royalties related to a previously granted license, including milestone payments based upon the achievement of a certain level of product sales, the license is deemed to be the sole or predominant item to which the royalties relate and the Company recognizes revenue when the related sales occur.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the transaction price to each performance obligation based on a relative standalone selling price basis. It develops assumptions that require judgment to determine the standalone selling price for each performance obligation in consideration of applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:CostOfSalesPolicyTextBlock" id="f-390" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales includes cost of raw materials, production, and manufacturing overhead costs associated with the Company&#8217;s product sales during the period. Cost of sales also includes adjustments for excess, obsolete, or expired inventory; idle capacity; and losses on firm purchase commitments to the extent the cost cannot be recovered based on estimates about future demand. Cost of sales does not include certain expenses related to raw materials, production, and manufacturing overhead costs that were expensed prior to regulatory authorization as described under the caption &#8220;Inventory.&#8221;</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-391" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include salaries; stock-based compensation; laboratory supplies; consultants and subcontractors, including external contract research organizations (&#8220;CROs&#8221;), CMOs, and contract development and manufacturing organizations (&#8220;CDMOs&#8221;); and other expenses associated with the Company&#8217;s process development, manufacturing, clinical, regulatory, and quality assurance activities for its clinical development programs. In addition, related indirect costs such as fringe benefits and overhead expenses are also included in research and development expenses. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates its research and development expense related to services performed under its contracts with external service providers based on an estimate of the level of service performed in the period. Research and development activities are expensed as incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="nvax:AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" id="f-392" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development Expenses</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues research and development expenses, including clinical trial-related expenses, as the services are performed, which may include estimates of those expenses incurred, but not invoiced. The Company uses information provided by third-party service providers and CRO, CMO, and CDMO invoices and internal estimates to determine the progress of work performed on the Company&#8217;s behalf. Assumptions based on clinical trial protocols, contracts, and participant enrollment data are also used to estimate these accruals.</span></div></ix:nonNumeric></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-376-6" continuedAt="f-376-7"><ix:nonNumeric contextRef="c-1" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="f-393" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed as incurred. The Company had advertising costs of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="f-394">91.5</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="f-395">84.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="f-396">8.9</ix:nonFraction>&#160;million during the years ended December&#160;31, 2023, 2022 and 2021, respectively.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="f-397" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation related to grants of stock options, stock appreciation rights (&#8220;SARs&#8221;), and restricted stock awards (&#8220;RSUs&#8221;), and purchases under the Company&#8217;s Employee Stock Purchase Plan (&#8220;ESPP&#8221;), at fair value. The Company recognizes compensation expense related to such awards on a straight-line basis over the requisite service period (generally the vesting period) of the equity awards, based on the award's fair value at the grant date. The requisite service period is typically <span style="-sec-ix-hidden:f-398">one</span> to <ix:nonNumeric contextRef="c-62" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="f-399">four years</ix:nonNumeric>. Forfeitures for all awards are recognized as incurred. The Company generally settles stock-based awards with newly issued shares.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options and SARs is measured on the date of grant using the Black-Scholes option pricing model. The expected term of stock options and SARs is based on the Company&#8217;s historical option exercise experience and post-vesting forfeiture experience using the historical expected term from the vesting date, and the expected term for purchases under the ESPP is based on the purchase periods included in the offering. The expected volatility is determined using historical volatilities based on stock prices over a look-back period corresponding to the expected term. The risk-free interest rate is determined using the yield available for zero-coupon U.S. government issues with a remaining term equal to the expected term. The Company has never paid a dividend and the Company does not intend to pay dividends in the foreseeable future, and as such, the expected dividend yield is zero.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-400" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of highly liquid investments with maturities of three months or less from the date of purchase. Cash equivalents are recorded at cost, which approximates fair value due to their short-term nature.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-401" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), for financial and non-financial assets and liabilities. ASC 820 discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The statement utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Unobservable inputs that reflect the reporting entity&#8217;s own assumptions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="f-402" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s current and non-current restricted cash includes payments received under grant agreements and cash collateral accounts under letters of credit that serve as security deposits for certain facility leases. Payments received under grant agreements become unrestricted as the Company incurs expenses for services performed under these agreements. As of December&#160;31, 2023 and 2022, restricted cash balances (both current and non-current) consisted primarily of payments under the CEPI funding agreements and letter of credits.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="f-403" continuedAt="f-403-1" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes amounts due from customers as accounts receivable when its right to payment is unconditional. Gross-to-net deductions are classified as reductions of gross accounts receivable if settlement is expected to occur through a reduction in the amount paid to Novavax by its customer. Account receivables are recorded net of any </span></div></ix:nonNumeric></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-376-7" continuedAt="f-376-8"><ix:continuation id="f-403-1"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allowance for credit losses. The Company&#8217;s estimate for the allowance for credit losses, which has not been significant to date, is determined based on the credit risk of its customers based on historical loss experience, economic conditions, the aging of receivables, and customer-specific risks.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-404" continuedAt="f-404-1" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments expose the Company to concentration of credit risk and consist primarily of cash and cash equivalents. The Company&#8217;s investment policy limits investments to certain types of instruments, including asset-backed securities, high-grade corporate debt securities, and money market funds; places restrictions on maturities and concentrations in certain industries; and requires the Company to maintain a certain level of liquidity. At times, the Company maintains cash balances in financial institutions that may exceed federally insured limits. The Company has not experienced any losses relating to such accounts and believes it is not exposed to a significant credit risk on its cash and cash equivalents.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="f-405" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's accounts receivable arise from revenue arrangements with customers in different countries. The Company's revenue is primarily due to product sales, grants made by government-sponsored and private organizations, and royalties from its collaboration and license partners. The following customers accounted for more than 10% of total revenue or accounts receivable for the periods presented:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Revenue<br/>&#160;for Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Accounts Receivable as of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European Commission</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-63" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-406">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-64" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-407">40</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-65" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-408">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-66" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-409">10</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government of Australia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-67" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-410">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-68" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-411">21</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government of Canada</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-69" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-412">10</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-70" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-413">59</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government of Israel</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-71" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-414">21</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-72" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-415">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-73" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-416">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-74" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-417">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-75" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-418">46</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CEPI</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-76" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-419">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SK bioscience, Co., Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-77" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-420">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Amounts represent less than 10%</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Including the USG Agreement (as defined in Note 3) and the U.S. Department of Defense.</span></div></ix:nonNumeric><ix:continuation id="f-404-1"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently depends significantly on one supplier for co-formulation, filling, and finishing of COVID-19 Vaccine. The loss of this supplier could prevent or delay the Company&#8217;s delivery of customer orders.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-421" continuedAt="f-421-1" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is recorded at the lower of cost or net realizable value under the First In, First Out methodology, taking into consideration the expiration of the inventory item. The Company determines the cost of raw materials using moving average costs and the cost of semi-finished and finished goods using a standard cost method adjusted on a periodic basis to reflect the deviation in the actual cost from the standard cost estimate. Standard costs consist primarily of the cost of manufacturing goods, including direct materials, direct labor, and the services and products of third-party suppliers. Manufacturing overhead costs are applied to semi-finished and finished goods based on expected production levels. The Company utilizes third-party CMOs, CDMOs, and other suppliers and service organizations to support the procurement and processing of raw materials, management of inventory, packaging, and the delivery process. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess, obsolete, or expired inventory through cost of sales. At each reporting period, the Company assesses whether there are excess firm, non-cancelable, purchase commitment liabilities, resulting from supply agreements with third-party CMOs and CDMOs. The determination of net realizable value of inventory and firm purchase commitment liabilities requires judgment, including consideration of many factors, such as estimates of future product demand, current and future market conditions, potential product obsolescence, expiration and utilization of raw materials under firm purchase commitments, and contractual minimums.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to initial regulatory authorization for its product candidates, the Company expenses costs relating to raw materials, production, and manufacturing overhead costs as research and development expenses in the consolidated statements of operations, in the period incurred. Subsequent to initial regulatory authorization for a product candidate, the Company </span></div></ix:nonNumeric></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-376-8" continuedAt="f-376-9"><ix:continuation id="f-421-1"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capitalizes the costs of production for a particular supply chain as inventory when the Company determines that it has a present right to the economic benefit associated with the product.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-422" continuedAt="f-422-1" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-422-1">Property and equipment are stated at cost, net of accumulated depreciation. and are depreciated using the straight-line method over the estimated useful lives of the assets. Repairs and maintenance costs are expensed as incurred.</ix:continuation> <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-423" continuedAt="f-423-1" escape="true">The estimated useful lives of property and equipment are described below:</ix:nonNumeric></span></div><ix:continuation id="f-423-1" continuedAt="f-423-2"><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.316%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-78" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-424">25</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-79" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-425">5</ix:nonNumeric> - <ix:nonNumeric contextRef="c-80" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-426">7</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-81" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-427">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or remaining term of the lease</span></div></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-428" continuedAt="f-428-1" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Accounting</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into manufacturing supply agreements with CMOs and CDMOs to manufacture its vaccine candidates. Certain of these manufacturing supply agreements include the use of identified manufacturing facilities and equipment that are controlled by the Company and for which the Company obtains substantially all the output and may qualify as an embedded lease. The Company treats manufacturing supply agreements that contain an embedded lease as lease arrangements in their entirety. The evaluation of leases that are embedded in the Company&#8217;s CMO and CDMO agreements is complex and requires judgment in determining whether the contract, either explicitly or implicitly, is for the use of an identified asset and the Company has the right to direct the use of, and obtain substantially all of the benefit from, the identified asset which generally is the use of a portion of the manufacturing facility of the CMO or CDMO, the term of the lease, and the fixed lease payments under the contract. Depending on the contract, the lease commencement date, defined as the date on which the lessor makes the underlying asset available for use by the lessee and on which the Company is required to accrue lease expenses, may be different than the inception date of the contract. The Company determines the non-cancellable lease term of its embedded leases based on the impact of certain expected milestones on its option to terminate the lease where it is reasonably certain to not exercise that option. The Company evaluates changes to the terms and conditions of a lease contract to determine if they result in a new lease or a modification of an existing lease. For lease modifications, the Company remeasures and reallocates the remaining consideration in the contract and reassesses the lease classification at the effective date of the modification. Leases are classified as either operating or finance leases based on the economic substance of the agreement. The Company also enters into non-cancelable lease agreements for facilities and certain equipment.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For leases that have a lease term of more than 12 months at the lease commencement date, the Company recognizes lease liabilities, which represent the Company&#8217;s obligation to make lease payments arising from the lease, and corresponding right-of-use (&#8220;ROU&#8221;) assets, which represent the right to use an underlying asset for the lease term, based on the present value of the fixed future payments over the lease term. The Company calculates the present value of future payments using the discount rate implicit in the lease, if available, or the Company&#8217;s incremental borrowing rate. For all leases that have a lease term of 12 months or less at the commencement date (referred to as &#8220;short-term&#8221; leases), the Company has elected to apply the practical expedient in ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 842&#8221;), to not recognize a lease liability or ROU asset but, instead, recognize lease payments as an expense on a straight-line basis over the lease term and variable lease payments that do not depend on an index or rate as an expense in the period in which the variable lease costs are incurred based on performance or usage in accordance with contractual agreements. In determining the lease period, the Company evaluates facts and circumstances that could affect the period over which it is reasonably certain to use the underlying asset while taking into consideration the non-cancelable period over which it has the right to use the underlying asset and any option period to extend or terminate the lease if it is reasonably certain to exercise the option. The Company re-evaluates short-term leases that are modified and if they no longer meet the requirements to be treated as a short-term lease, recognizes and measures the lease liability and ROU asset as if the date of the modification is the lease commencement date. For short-term leases that are modified and continue to meet the requirements to be treated as a short-term lease, the Company remeasures the fixed lease payments under the modified lease and recognize lease payments as an expense on a straight-line basis over the modified lease term.</span></div></ix:nonNumeric></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-376-9" continuedAt="f-376-10"><ix:continuation id="f-428-1"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For operating leases, the Company recognizes lease expense related to fixed payments on a straight-line basis from the lease commencement date through the end of the lease term and lease expense related to variable payments as incurred based on performance or usage in accordance with the contractual agreements. For finance leases, the Company recognizes the amortization of the ROU asset over the shorter of the lease term or useful life of the underlying asset. The Company expenses ROU assets acquired for research and development activities under ASC 730 if they do not have an alternative future use, in research and development projects or otherwise.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses significant assumptions and judgment in evaluating its lease contracts and other agreements under ASC 842, including the determination of whether an agreement is or contains a lease; whether a change in the terms and conditions of a lease contract represent a new or modified lease; whether a lease represents an operating or finance lease; the discount rate used to determine the present value of lease obligations; the term of a lease embedded in its manufacturing supply agreements; and the Company&#8217;s incremental borrowing rate, which is determined using estimates such as the estimated value of the underlying leased asset and financial profile of comparable companies.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-429" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, including property and equipment, internal-use software, and ROU assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable based on the criteria for accounting for the impairment or disposal of long-lived assets under ASC Topic 360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If such events or changes in circumstances occur, the Company assesses the recoverability of the long-lived assets (or asset group) by comparing their projected future undiscounted net cash flows over their remaining lives against their respective carrying amounts. If the cash flows are not expected to be sufficient to recover the carrying amount of the assets (or asset group), they are written down to their estimated fair values.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" id="f-430" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes restructuring charges when such costs are incurred. The Company&#8217;s restructuring charges consist of employee severance and other termination benefits related to the reduction of its workforce, the consolidation of facilities and infrastructure and other costs. Termination benefits are expensed on the date the Company notifies the employee, unless the employee must provide future service, in which case the benefits are expensed ratably over the future service period. Ongoing benefits are expensed when restructuring activities are probable and the benefit estimable. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 17 for additional information on the severance and employee benefit costs for terminated employees and impairment of long-lived assets in connection with the Company&#8217;s Restructuring Plan and Note 18 for information on the expected severance and employee benefit costs as a result of the Company&#8217;s workforce reduction announced on January 31, 2024.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="f-431" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Goodwill is subject to impairment tests annually or more frequently should indicators of impairment arise. The Company has determined that, because its only business is the development and commercialization of innovative vaccines, it operates as a single operating segment and has <ix:nonFraction unitRef="reporting_unit" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="f-432">one</ix:nonFraction> reporting unit. The one-step impairment test, which requires a comparison of the fair value of a reporting unit to its carrying value, including goodwill, is required to be applied to all reporting units including reporting units with zero or negative carrying value. A reporting unit with a zero or negative carrying value likely will not have an impairment. If the carrying value of the reporting unit exceeds its fair value, step two of the impairment analysis is performed. In step two of the analysis, an impairment loss is recorded equal to the excess of the carrying value of the reporting unit&#8217;s goodwill over its implied fair value, should such a circumstance arise. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and 2022, the Company had a negative carrying value and did <ix:nonFraction unitRef="usd" contextRef="c-17" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-433"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-434">not</ix:nonFraction></ix:nonFraction> have any impairment of goodwill.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-435" continuedAt="f-435-1" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes in accordance with ASC Topic 740,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the liability method, deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect of changes in tax rates on deferred tax assets and </span></div></ix:nonNumeric></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-376-10" continuedAt="f-376-11"><ix:continuation id="f-435-1"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liabilities is recognized in income in the period such changes are enacted. A valuation allowance is established when necessary to reduce net deferred tax assets to the amount expected to be realized.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Global Intangible Low-Taxed Income (&#8220;GILTI&#8221;) provisions under the Tax Cuts and Jobs Act of 2017 impose U.S. tax on certain foreign income in excess of a deemed return on tangible assets of foreign corporations. The Company has elected to treat any potential GILTI inclusions as period costs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax benefits associated with uncertain tax positions are recognized in the period in which one of the following conditions is satisfied: (1) the more-likely-than-not recognition threshold is satisfied; (2) the position is ultimately settled through negotiation or litigation; or (3) the statute of limitations for the taxing authority to examine and challenge the position has expired. Tax benefits associated with an uncertain tax position are reversed in the period in which the more-likely-than-not recognition threshold is no longer satisfied.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically generated significant federal, state, and foreign tax net operating losses, which may be subject to limitation in future periods. Management has fully reserved the related deferred tax assets with a valuation allowance in the current reporting period as it is more likely than not that the related benefit will not be realized. The Company is currently subject to examination in all open tax years.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-436" continuedAt="f-436-1" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-436-1">Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted net loss per share is computed using the treasury stock method by dividing net loss by the weighted-average number of common shares outstanding after giving consideration to the dilutive effect of certain securities outstanding during the period.</ix:continuation> As of December&#160;31, 2023, the Company's 2027 Notes (see Note 10) would have been convertible into approximately <ix:nonFraction unitRef="shares" contextRef="c-82" decimals="-6" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="6" id="f-437">14</ix:nonFraction>&#160;million shares of the Company's common stock assuming the common stock price is equal to or greater than $<ix:nonFraction unitRef="usdPerShare" contextRef="c-83" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-438">12.50</ix:nonFraction>. These shares, after giving effect to the add back of interest expense and unamortized discounts and debt issuance costs on the Notes and any shares due to the Company upon settlement of its capped call transactions, are excluded from the computation, as their effect is antidilutive under the if-converted method. In addition, all stock options, SARs, and unvested RSUs are excluded from the computation as their effect is antidilutive. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-439" continuedAt="f-439-1" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-439-1">The accompanying consolidated financial statements are presented in U.S. dollars. The functional currency of the Company&#8217;s international subsidiaries is generally the local currency. The financial statements of international subsidiaries are translated to U.S. dollars using the exchange rate in effect at the consolidated balance sheet date for assets and liabilities, historical rates for equity accounts, and average exchange rates for the consolidated statement of operations. Cash flows from operations are translated at the average exchange rate in effect for the period, while cash flows from investing and financing activities are translated at the exchange rate in effect at the date of the underlying transaction. Translation gains and losses are recognized as a component of accumulated other comprehensive income (loss) in the accompanying consolidated balance sheets.</ix:continuation> The foreign currency translation adjustment balance included in accumulated other comprehensive income (loss) was $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-440">2.7</ix:nonFraction> million of income and $<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-441">6.4</ix:nonFraction> million losses at December&#160;31, 2023 and 2022, respectively. The aggregate foreign currency transaction gains and losses resulting from the conversion of the transaction currency to functional currency were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-442">7.9</ix:nonFraction>&#160;million of gains, $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" sign="-" name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-443">2.5</ix:nonFraction>&#160;million of losses, and $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" sign="-" name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-444">5.3</ix:nonFraction>&#160;million of losses for the years ended December&#160;31, 2023, 2022, and 2021, respectively, which are reflected in Other income (expense).</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-445" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages its business as <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-446">one</ix:nonFraction> operating segment, the development and commercialization of innovative vaccines. The Company does not operate separate lines of business with respect to its vaccine or vaccine candidates. Accordingly, the Company does not have separately reportable segments as defined by ASC Topic 280, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-447" escape="true"><ix:continuation id="f-376-11"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Not Yet Adopted</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-06, Disclosure Improvements (&#8220;ASU 2023-06&#8221;), to clarify or improve disclosure and presentation requirements of a variety of topics and align the requirements in the FASB ASC with the SEC's regulations. The Company is currently evaluating ASU 2023-06 to determine its impact on the Company's consolidated financial statements and disclosures.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (&#8220;ASU 2023-09&#8221;). The standard enhances transparency in income tax disclosures by requiring, on an annual basis, certain disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation and income taxes paid. The ASU also requires disaggregated disclosure related to pre-tax income (or loss) and income tax expense (or benefit) and eliminates certain disclosures related to the balance of an entity&#8217;s unrecognized tax benefit and the cumulative amount of certain temporary differences. The ASU is effective for the Company beginning on January 1, 2025. The Company is currently evaluating ASU 2023-09 to determine its impact on the Company's disclosures.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline">Adopted</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;), with amendments in 2018, 2019, 2020, and 2022. The ASU sets forth a &#8220;current expected credit loss&#8221; model that requires companies to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. ASU 2016-13 applies to financial instruments that are not measured at fair value, including receivables that result from revenue transactions. The Company adopted ASU 2020-06 on January 1, 2023, using a modified retrospective approach, and it did not have a material impact on the Company&#8217;s consolidated financial statements.</span></div></ix:continuation></ix:nonNumeric><div id="i65591fd2146e456aac589be2afadc864_187"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-448" continuedAt="f-448-1" escape="true">Revenue</ix:nonNumeric></span></div><ix:continuation id="f-448-1" continuedAt="f-448-2"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's accounts receivable, net, included $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:BilledContractReceivables" format="ixt:num-dot-decimal" scale="6" id="f-449">286.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:BilledContractReceivables" format="ixt:num-dot-decimal" scale="6" id="f-450">53.8</ix:nonFraction> million related to amounts that were billed to customers and $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:UnbilledContractsReceivable" format="ixt:num-dot-decimal" scale="6" id="f-451">10.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:UnbilledContractsReceivable" format="ixt:num-dot-decimal" scale="6" id="f-452">28.6</ix:nonFraction> million related to amounts which had not yet been billed to customers as of December&#160;31, 2023 and 2022, respectively. <ix:nonNumeric contextRef="c-1" name="nvax:ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" id="f-453" continuedAt="f-453-1" escape="true">During the years ended December&#160;31, 2023 and 2022, changes in the Company's accounts receivables, deferred revenue, and allowance for doubtful accounts balances were as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-453-1" continuedAt="f-453-2"><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.747%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.010%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance, Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deductions </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance, End of Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2023</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AccountsReceivableGross" format="ixt:num-dot-decimal" scale="3" id="f-454">96,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="nvax:AccountsReceivableBeforeAllowanceForCreditLossAdditions" format="ixt:num-dot-decimal" scale="3" id="f-455">1,472,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="nvax:AccountsReceivableBeforeAllowanceForCreditLossDeductions" format="ixt:num-dot-decimal" scale="3" id="f-456">1,264,062</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AccountsReceivableGross" format="ixt:num-dot-decimal" scale="3" id="f-457">304,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:AccountsReceivableGross" format="ixt:num-dot-decimal" scale="3" id="f-458">454,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="nvax:AccountsReceivableBeforeAllowanceForCreditLossAdditions" format="ixt:num-dot-decimal" scale="3" id="f-459">1,768,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="nvax:AccountsReceivableBeforeAllowanceForCreditLossDeductions" format="ixt:num-dot-decimal" scale="3" id="f-460">2,127,240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AccountsReceivableGross" format="ixt:num-dot-decimal" scale="3" id="f-461">96,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allowance for doubtful accounts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-462">13,835</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="nvax:AccountsReceivableAllowanceForCreditLossDeductions" format="ixt:num-dot-decimal" scale="3" id="f-463">6,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-464">7,676</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:fixed-zero" scale="3" id="f-465">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="nvax:AccountsReceivableAllowanceForCreditLossAdditions" format="ixt:num-dot-decimal" scale="3" id="f-466">13,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="nvax:AccountsReceivableAllowanceForCreditLossDeductions" format="ixt:fixed-zero" scale="3" id="f-467">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-468">13,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-469">549,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="nvax:ContractWithCustomerLiabilityAdditions" format="ixt:num-dot-decimal" scale="3" id="f-470">581,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="nvax:ContractWithCustomerLiabilityDeductions" format="ixt:num-dot-decimal" scale="3" id="f-471">267,599</ix:nonFraction>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-472">863,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-473">1,595,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="nvax:ContractWithCustomerLiabilityAdditions" format="ixt:num-dot-decimal" scale="3" id="f-474">46,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="nvax:ContractWithCustomerLiabilityDeductions" format="ixt:num-dot-decimal" scale="3" id="f-475">1,092,829</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-476">549,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Bad debt expense was $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="nvax:AccountsReceivableAllowanceForCreditLossAdditions" format="ixt:num-dot-decimal" scale="6" id="f-477">13.8</ix:nonFraction>&#160;million in the year ended 2022. There was no bad debt expense in the year ended December 31, 2023 or 2021. There was a $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="nvax:AccountsReceivableAllowanceForCreditLossDeductions" format="ixt:num-dot-decimal" scale="6" id="f-478">6.2</ix:nonFraction>&#160;million reversal of a bad debt expense during the year ended December&#160;31, 2023 due to the collection of a previously recognized allowance for doubtful accounts. To estimate the allowance for doubtful accounts, the Company evaluates the credit risk related to its customers based on historical loss experience, economic conditions, the aging of receivables, and customer-specific risks.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Deductions from Deferred revenue generally related to the recognition of revenue once performance obligations on a contract with a customer are met. Amount is comprised of $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-479">241.3</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-8" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="9" id="f-480">0.4</ix:nonFraction>&#160;billion, and $<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-8" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="9" id="f-481">1.4</ix:nonFraction>&#160;billion current Deferred </span></div></ix:continuation></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-448-2" continuedAt="f-448-3"><ix:continuation id="f-453-2"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue and $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-482">622.2</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-483">179.4</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-484">172.5</ix:nonFraction>&#160;million non-current Deferred revenue as of December&#160;31, 2023, 2022, and 2021 respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;In 2023, deductions from Deferred revenue included $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-485">151.1</ix:nonFraction>&#160;million that was realized in Revenue and $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="nvax:CollaborationAgreementUpfrontPaymentAmount" format="ixt:num-dot-decimal" scale="6" id="f-486">112.5</ix:nonFraction>&#160;million related to the Amended and Restated UK Supply Agreement (as described below), that was reclassified to Other current liabilities, as described below. In 2022, deduction from Deferred revenue included $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-487">273.8</ix:nonFraction>&#160;million that was realized in Revenue and $<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="nvax:CollaborationAgreementUpfrontPaymentAmount" format="ixt:num-dot-decimal" scale="6" id="f-488">819.0</ix:nonFraction>&#160;million, including $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="nvax:CollaborationAgreementUpfrontPaymentAmount" format="ixt:num-dot-decimal" scale="6" id="f-489">697.4</ix:nonFraction>&#160;million related to the Advance Payment Amount (as described below) related to the Gavi arbitration and $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="nvax:CollaborationAgreementUpfrontPaymentAmount" format="ixt:num-dot-decimal" scale="6" id="f-490">112.5</ix:nonFraction>&#160;million related to the Amended and Restated UK Supply Agreement, that was reclassified to Other current liabilities, as described below.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the aggregate amount of the transaction price allocated to performance obligations that were unsatisfied (or partially unsatisfied), excluding amounts related to sales-based royalties, the Gavi APA, and the reduction in doses related to the Amended and Restated SARS-CoV-2 Vaccine Supply Agreement, dated as of July 1, 2022 (as amended on September 26, 2022, the &#8220;Amended and Restated UK Supply Agreement&#8221;) between the Company and The Secretary of State for Business, Energy and Industrial Strategy (as assigned to the UK Health Security Agency), acting on behalf of the government of the United Kingdom of Great Britain and Northern Ireland (the &#8220;Authority&#8221;), which amended and restated the Original UK Supply Agreement, was approximately $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-9" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="9" id="f-491">2</ix:nonFraction>&#160;billion of which $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-492">863.5</ix:nonFraction>&#160;million was included in Deferred revenue. Failure to meet regulatory milestones, obtain timely supportive recommendations from governmental advisory committees, or achieve product volume or delivery timing obligations under the Company&#8217;s APAs may require the Company to refund portions of upfront payments or result in reduced future payments, which could adversely impact the Company&#8217;s ability to realize revenue from its unsatisfied performance obligations. The timing to fulfill performance obligations related to APAs will depend on timing of product manufacturing, receipt of marketing authorizations for additional indications, delivery of doses based on customer demand, and the ability of the customer to request variant vaccine in place of the prototype vaccine under certain of the Company&#8217;s APAs. The remaining unfilled performance obligations not related to APAs are expected to be fulfilled in less than <ix:nonNumeric contextRef="c-89" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durwordsen" id="f-493">one year</ix:nonNumeric>.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Gavi APA and a separate purchase agreement between Gavi and SIIPL, <ix:nonFraction unitRef="dose" contextRef="c-90" decimals="-8" name="nvax:NumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="9" id="f-494">1.1</ix:nonFraction>&#160;billion doses of the prototype vaccine were to be made available to countries participating in the COVAX Facility. The Company expected to manufacture and distribute <ix:nonFraction unitRef="dose" contextRef="c-91" decimals="-6" name="nvax:NumberOfDosesToBeDistributed" scale="6" id="f-495">350</ix:nonFraction>&#160;million doses of the prototype vaccine to countries participating under the COVAX Facility. Under a separate purchase agreement with Gavi, SIIPL was expected to manufacture and deliver the balance of the <ix:nonFraction unitRef="dose" contextRef="c-90" decimals="-8" name="nvax:NumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="9" id="f-496">1.1</ix:nonFraction>&#160;billion doses of prototype vaccine for low- and middle-income countries participating in the COVAX Facility. The Company expected to deliver doses with antigen and adjuvant manufactured at facilities directly funded under the Company's funding agreement with CEPI, with initial doses supplied by SIIPL and SLS under a supply agreement. The Company expected to supply significant doses that Gavi would allocate to low-, middle- and high-income countries, subject to certain limitations, utilizing a tiered pricing schedule and Gavi could prioritize such doses to low- and middle- income countries, at lower prices. Additionally, the Company could provide additional doses of prototype vaccine, to the extent available from CEPI-funded manufacturing facilities, in the event that SIIPL could not materially deliver expected vaccine doses to the COVAX Facility. Under the agreement, the Company received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-497">350.0</ix:nonFraction>&#160;million from Gavi in 2021 and an additional payment of $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="nvax:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="f-498">350.0</ix:nonFraction>&#160;million in 2022 related to the Company&#8217;s achieving an emergency use license for the Company&#8217;s prototype vaccine by the World Health Organization (&#8220;WHO&#8221;) (the &#8220;Advance Payment Amount&#8221;). </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 18, 2022, the Company delivered written notice to Gavi to terminate the Gavi APA on the basis of Gavi&#8217;s failure to procure the purchase of <ix:nonFraction unitRef="dose" contextRef="c-91" decimals="-6" name="nvax:NumberOfDosesToBeDistributed" scale="6" id="f-499">350</ix:nonFraction>&#160;million doses of the Company&#8217;s prototype vaccine from the Company as required by the Gavi APA. As of November 18, 2022, the Company had only received orders under the Gavi APA for approximately 2&#160;million doses. On December 2, 2022, Gavi issued a written notice purporting to terminate the Gavi APA based on Gavi&#8217;s contention that the Company repudiated the agreement and, therefore, materially breached the Gavi APA. Gavi also contended that, based on its purported termination of the Gavi APA, it was entitled to a refund of the Advance Payment Amount less any amounts that have been credited against the purchase price for binding orders placed by a buyer participating in the COVAX Facility. As of December&#160;31, 2023 and 2022, the remaining Gavi Advance Payment was $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="nvax:CollaborationAgreementUpfrontPaymentAmount" format="ixt:num-dot-decimal" scale="6" id="f-500">696.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="nvax:CollaborationAgreementUpfrontPaymentAmount" format="ixt:num-dot-decimal" scale="6" id="f-501">697.4</ix:nonFraction>&#160;million, respectively, pending resolution of the dispute with Gavi related to the return of the remaining Advance Payment Amount, and was classified within Other current liabilities in the Company&#8217;s consolidated balance sheet. On January 24, 2023, Gavi filed a demand for arbitration with the International Court of Arbitration based on the claims described above. The Company filed its Answer and Counterclaims on March 2, 2023. On April 5, 2023, Gavi filed its Reply to the Company&#8217;s Counterclaims. On February 16, 2024, the Company and Gavi entered into a Termination and Settlement Agreement (the &#8220;Gavi Settlement Agreement&#8221;) terminating the Gavi APA, settling the arbitration proceedings and releasing both parties of all claims arising from, under or otherwise in connection with the Gavi APA. Pursuant to the Gavi Settlement Agreement, the Company is responsible for payment to Gavi of (i) an initial settlement payment of $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="f-502">75</ix:nonFraction>&#160;million, which the Company paid on February 20, </span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-448-3" continuedAt="f-448-4"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024, and (ii) deferred payments, in equal annual amounts of $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-6" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="f-503">80</ix:nonFraction>&#160;million payable each calendar year through a deferred payment term ending December 31, 2028. The deferred payments are due in variable quarterly installments beginning in the first quarter of 2024 and total $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-6" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="f-504">400</ix:nonFraction>&#160;million during the deferred payment term. Such deferred payments may be reduced through Gavi&#8217;s use of an annual vaccine credit equivalent to the unpaid balance of such deferred payments each year, which may be applied to qualifying sales of any of the Company&#8217;s vaccines for supply to certain low-income and lower-middle income countries. The Company has the right to price the vaccines offered to such low-income and lower-middle income countries in its discretion, and, when utilized by Gavi, the Company will credit the actual price per vaccine paid against the applicable credit. The Company intends to price vaccines offered via the tender process, consistent with its shared goal with Gavi to provide equitable access to those countries. Also, pursuant to the Gavi Settlement Agreement, the Company granted Gavi an additional credit of up to $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-6" name="us-gaap:GrantsReceivable" format="ixt:num-dot-decimal" scale="6" id="f-505">225</ix:nonFraction>&#160;million that may be applied against qualifying sales of any of the Company&#8217;s vaccines for supply to such low-income and lower-middle income countries that exceed the $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-6" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="f-506">80</ix:nonFraction>&#160;million deferred payment amount in any calendar year during the deferred payment term. In addition, the Company and Gavi entered into a security agreement pursuant to which Novavax granted Gavi a security interest in accounts receivable from SIIPL under the SIIPL R21 Agreement (see Note 4), which will continue for the deferred payment term of the Gavi Settlement Agreement. On February 22, 2024, the claims and counterclaims were dismissed with prejudice.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="f-507" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue by the Company&#8217;s customer&#8217;s geographic location was as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt 0 7pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">North America</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-508">29,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-509">194,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-510">268,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-511">823,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rest of the world</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-512">233,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-513">536,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-514">531,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-515">1,554,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2023, the Company commenced sales of COVID-19 Vaccine to the U.S. commercial market, in addition to continuing sales to various international governments. Product sales in the U.S. are primarily made through large pharmaceutical wholesale distributors at the WAC. Product sales in the U.S. are recorded net of gross-to-net deductions, as described in Note 2.</span></div><ix:nonNumeric contextRef="c-1" name="nvax:ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock" id="f-516" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, changes in the Company&#8217;s gross-to-net deductions balances were as follows (in thousands):</span></div><div style="padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.497%"><tr><td style="width:1.0%"/><td style="width:51.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.247%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.827%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Wholesale Distributor Fees, Discounts, and Chargebacks</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Returns</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-517">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-518">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-519">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts charged against product sales</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="nvax:AmountsChargedAgainstProductSales" format="ixt:num-dot-decimal" scale="3" id="f-520">47,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="nvax:AmountsChargedAgainstProductSales" format="ixt:num-dot-decimal" scale="3" id="f-521">84,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="nvax:AmountsChargedAgainstProductSales" format="ixt:num-dot-decimal" scale="3" id="f-522">131,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-523">25,956</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="f-524">72</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-525">26,028</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-526">21,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-527">84,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-528">105,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-529">103.1</ix:nonFraction>&#160;million of gross-to-net deductions were included in Accrued expenses and $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-530">2.6</ix:nonFraction>&#160;million were included in Accounts receivable on the consolidated balance sheet. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has an APA with the Commonwealth of Australia for the purchase of doses of COVID-19 Vaccine (the &#8220;Australia APA&#8221;). In May 2023, the Company extended a credit for certain doses delivered and recognized within product revenue in 2022 that qualified for replacement under the Australia APA. This credit is the result of a single lot sold to the Australian government that upon pre-planned 6-month stability testing was found to have fallen below the defined specifications and the lot therefore was removed from the market. The credit will be applied against the future sale of doses to Australia and, during the year ended December&#160;31, 2023, the Company recorded a reduction of $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-531">64.7</ix:nonFraction>&#160;million in product sales, with a corresponding increase to Deferred revenue, non-current. In July 2023, the Company amended the Australia APA to provide for replacement doses and to extend the delivery schedule through 2025. As of February 2024, the Company had not yet received Therapeutic Goods Administration (&#8220;TGA&#8221;) authorization or delivered doses as contemplated in the July 2023 </span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-448-4" continuedAt="f-448-5"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">amendment and is in active discussions with the Australian government on both the TGA authorization and delivery of the doses previously scheduled for the fourth quarter of 2023. In February 2024, the Company received notice from the Australian government purporting to cancel its order for such prototype vaccine doses. The Company believes the cancellation was not proper under the amended Australia APA. However, if such a cancellation were determined to be allowable, $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-532">6.0</ix:nonFraction> million of the deferred revenue would become a credit towards future deliveries of doses and approximately $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-6" name="nvax:AmountsChargedAgainstProductSales" format="ixt:num-dot-decimal" scale="6" id="f-533">48</ix:nonFraction> million of the contract value related to future deliverables would no longer be available.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an APA with the European Commission (&#8220;EC&#8221;) acting on behalf of various European Union member states to supply a minimum of <ix:nonFraction unitRef="dose" contextRef="c-116" decimals="-6" name="nvax:NumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="f-534">20</ix:nonFraction>&#160;million and up to <ix:nonFraction unitRef="dose" contextRef="c-117" decimals="-6" name="nvax:NumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="f-535">100</ix:nonFraction>&#160;million initial doses of prototype vaccine, with the option for the EC to purchase an additional <ix:nonFraction unitRef="dose" contextRef="c-118" decimals="-6" name="nvax:NumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="f-536">100</ix:nonFraction>&#160;million doses up to a maximum aggregate of <ix:nonFraction unitRef="dose" contextRef="c-118" decimals="-6" name="nvax:NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption" format="ixt:num-dot-decimal" scale="6" id="f-537">200</ix:nonFraction>&#160;million doses in one or more tranches, through 2023. Under the terms of the APA, the Company agreed to manufacture the vaccine in facilities located in the European Union and ensure continued efficacy of the vaccine against variants of the SARS-CoV-2 virus. Pursuant to the terms of the APA, the Company is prohibited from supplying prototype vaccine to any third party if such delivery would impede or limit the fulfillment of the Company&#8217;s obligations to the EC under the APA, except with respect to the Company&#8217;s obligations under the Gavi APA. In 2022, the Company was notified by the EC that it was cancelling approximately <ix:nonFraction unitRef="dose" contextRef="c-118" decimals="-6" name="nvax:PurchaseAgreementNumberOfDosesCancelled" format="ixt:num-dot-decimal" scale="6" id="f-538">7</ix:nonFraction>&#160;million doses of its prior commitment originally scheduled for delivery in the first and second quarters of 2022, in accordance with the APA, and reducing the order to approximately <ix:nonFraction unitRef="dose" contextRef="c-118" decimals="-6" name="nvax:PurchaseAgreementNumberOfVaccineDoses" format="ixt:num-dot-decimal" scale="6" id="f-539">63</ix:nonFraction>&#160;million doses. In January 2023, the Company finalized a revised delivery schedule for the remaining <ix:nonFraction unitRef="dose" contextRef="c-119" decimals="-6" name="nvax:NumberOfDosesOfVaccineCandidate" format="ixt:num-dot-decimal" scale="6" id="f-540">20</ix:nonFraction>&#160;million committed doses under the APA that were originally scheduled for delivery during the first and second quarters of 2022. The APA expired in August 2023 and required that any open and outstanding orders from European Union member states be satisfied by February 2024. Since August 2023, any additional doses have been managed by amending outstanding orders with deliveries made by February 2024.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an APA with His Majesty the King in Right of Canada as represented by the Minister of Public Works and Government Services, as successor in interest to Her Majesty the Queen in Right of Canada, as represented by the Minister of Public Works and Government Services (the &#8220;Canadian government&#8221;), for the purchase of doses of COVID-19 Vaccine (the &#8220;Canada APA&#8221;). In April 2023, the Company amended the &#8220;Canada APA&#8221;, pursuant to which the Canadian government forfeited certain doses originally scheduled for delivery in 2022 for a payment of $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" name="nvax:CollaborationAgreementUpfrontPaymentAmount" format="ixt:num-dot-decimal" scale="6" id="f-541">100.4</ix:nonFraction>&#160;million, which the Company received in the second quarter of 2023. In June 2023, the Company entered into an additional amendment (the &#8220;June 2023 Amendment&#8221;) to the Canada APA. Pursuant to the June 2023 Amendment, (i) the Canadian government forfeited certain doses of COVID-19 Vaccine previously scheduled for delivery and agreed to pay a total amount of $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-542">349.6</ix:nonFraction>&#160;million to the Company in two equal installments, which total amount equaled the remaining balance owed by the Canadian government with respect to such forfeited vaccine doses, (ii) the amount of doses of COVID-19 Vaccine due for delivery was reduced, (iii) the delivery schedule for the remaining doses of COVID-19 Vaccine to be delivered was revised, and (iv) the parties agreed Novavax would use the Biologics Manufacturing Centre (&#8220;BMC&#8221;) Inc. to produce bulk antigen for doses in 2024 and 2025. The June 2023 Amendment maintained the total contract value of the original Canada APA. The first Installment of $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="nvax:InstallmentChargesOfTheCompany" format="ixt:num-dot-decimal" scale="6" id="f-543">174.8</ix:nonFraction>&#160;million was payable upon execution of the June 2023 Amendment and received by Novavax in July 2023, and the second installment of $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="nvax:InstallmentChargesOfTheCompany" format="ixt:num-dot-decimal" scale="6" id="f-544">174.8</ix:nonFraction>&#160;million was contingent and payable upon the delivery of vaccine doses in the second half of 2023 and received by Novavax in January 2024. The Canadian government may terminate the Canada APA, as amended, if the Company fails to receive regulatory approval for its COVID-19 Vaccine using bulk antigen produced at BMC on or before December 31, 2024. The Company&#8217;s 2024 plans do not currently anticipate the submission for regulatory approval of its COVID-19 Vaccine using bulk antigen produced at BMC, and it plans to work with the Canadian government on an amendment that addresses possible alternatives, which may not be achievable. As of December 31, 2023, $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-545">102.8</ix:nonFraction>&#160;million <span id="i6df5a9d3262e4de6b703aaf6230c4c93_96276"></span>was classified as short-term Deferred revenue and $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-546">485.3</ix:nonFraction>&#160;million was classified as long-term Deferred revenue with respect to the Canadian APA in the Company&#8217;s consolidated balance sheet. If the Canadian government terminates the Canada APA, $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-547">28.0</ix:nonFraction>&#160;million of the deferred revenue would become refundable and approximately $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-6" name="us-gaap:CustomerRefundLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-548">224</ix:nonFraction>&#160;million of the contract value related to future deliverables would no longer be available. Pursuant to the June 2023 Amendment, Novavax and the Canadian government will endeavor to expand the previously agreed in-country commitment to Canada and to further partner to provide health, economic, and future pandemic preparedness benefits to Canada, which value may be provided through a number of activities, including without limitation, capital investments, the performance of activities or services, or the provision of technology or intellectual property licenses. Further, the parties will endeavor to enter into a memorandum of understanding (the &#8220;MOU&#8221;) to illustrate the Company&#8217;s ability to deliver such benefits over a <ix:nonNumeric contextRef="c-58" name="nvax:ContractWithCustomerObligationToDeliverTerms" format="ixt-sec:durwordsen" id="f-549">15-year</ix:nonNumeric> period with an aggregate value of not less than <ix:nonFraction unitRef="number" contextRef="c-120" decimals="2" name="nvax:PercentOfRemainingAmountToBePaid" scale="-2" id="f-550">100</ix:nonFraction>% of the amount remaining to be paid under the June 2023 Amendment and ultimately received by the Company. As of December&#160;31, 2023, discussions regarding the MOU were ongoing. The Company agreed to hold, when received, $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="nvax:EscrowDepositsRelatedToSalesHold" format="ixt:num-dot-decimal" scale="6" id="f-551">20.0</ix:nonFraction>&#160;million of the second installment payment in escrow for the benefit of the Canadian government, which amount is the sole recourse available to the Canadian government in the event of non-performance under the MOU. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, the Company entered into an Amended and Restated SARS-CoV-2 Vaccine Supply Agreement (as amended on September 26, 2022, the &#8220;Amended and Restated UK Supply Agreement&#8221;) with The Secretary of State for </span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-448-5" continuedAt="f-448-6"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business, Energy and Industrial Strategy (as assigned to the UK Health Security Agency), acting on behalf of the government of the United Kingdom of Great Britain and Northern Ireland (the &#8220;Authority&#8221;), which amended and restated in its entirety the SARS-CoV-2 Vaccine Supply Agreement, dated October 22, 2020, between the parties (the &#8220;Original UK Supply Agreement&#8221;). Under the Original UK Supply Agreement, the Authority agreed to purchase <ix:nonFraction unitRef="dose" contextRef="c-123" decimals="-6" name="nvax:PurchaseAgreementNumberOfVaccineDoses" format="ixt:num-dot-decimal" scale="6" id="f-552">60</ix:nonFraction>&#160;million doses of prototype vaccine and made an upfront payment to the Company. Under the terms of the Amended and Restated UK Supply Agreement, the Authority agreed to purchase a minimum of <ix:nonFraction unitRef="dose" contextRef="c-124" decimals="-6" name="nvax:NumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="f-553">1</ix:nonFraction>&#160;million doses and up to an additional <ix:nonFraction unitRef="dose" contextRef="c-125" decimals="-6" name="nvax:NumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="f-554">15</ix:nonFraction>&#160;million doses (the &#8220;Conditional Doses&#8221;) of prototype vaccine, with the number of Conditional Doses contingent on, and subject to reduction based on, the Company&#8217;s timely achievement of supportive recommendations from the Joint Committee on Vaccination and Immunisation (the &#8220;JCVI&#8221;) that is approved by the UK Secretary of State for Health, with respect to use of the vaccine for (a) the general adult population as part of a SARS-CoV-2 vaccine booster campaign in the United Kingdom or (b) the general adolescent population as part of a SARS-CoV-2 vaccine booster campaign in the United Kingdom or as a primary series SARS-CoV-2 vaccination, excluding where that recommendation relates only to one or more population groups comprising less than one million members in the United Kingdom. If the Authority did not purchase the Conditional Doses or the number of such Conditional Doses was reduced below <ix:nonFraction unitRef="dose" contextRef="c-125" decimals="-6" name="nvax:NumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="f-555">15</ix:nonFraction>&#160;million doses of prototype vaccine, the Company would have to repay up to $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="nvax:CollaborationAgreementUpfrontPaymentAmount" format="ixt:num-dot-decimal" scale="6" id="f-556">225.0</ix:nonFraction>&#160;million related to the upfront payment previously received from the Authority under the Original UK Supply Agreement. Under the Amended and Restated UK Supply Agreement, the Authority also has the option to purchase up to an additional <ix:nonFraction unitRef="dose" contextRef="c-126" decimals="-6" name="nvax:NumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="f-557">44</ix:nonFraction>&#160;million doses, in one or more tranches, through 2024.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November 30, 2022, the JCVI had not made a supportive recommendation with respect to prototype vaccine, thereby triggering, under the terms of the Amended and Restated UK Supply Agreement, (i) a reduction of the number of Conditional Doses from <ix:nonFraction unitRef="dose" contextRef="c-125" decimals="-6" name="nvax:NumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="f-558">15</ix:nonFraction>&#160;million doses to <ix:nonFraction unitRef="dose" contextRef="c-127" decimals="-5" name="nvax:NumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="f-559">7.5</ix:nonFraction>&#160;million doses, which reduced number of Conditional Doses are contingent on, and subject to further reduction based on, the Company&#8217;s timely achievement by November 30, 2023 of a supportive recommendation from JCVI that is approved by the UK Secretary of State for Health as described in the paragraph above, and (ii) an obligation for the Company to repay $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="nvax:CollaborationAgreementUpfrontPaymentAmount" format="ixt:num-dot-decimal" scale="6" id="f-560">112.5</ix:nonFraction>&#160;million related to the upfront payment previously received from the Authority under the Original UK Supply Agreement. In April 2023, the Company repaid the $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="nvax:CollaborationAgreementUpfrontPaymentAmount" format="ixt:num-dot-decimal" scale="6" id="f-561">112.5</ix:nonFraction>&#160;million related to the November 30, 2022 triggering event. As of November 30, 2023, the JCVI had not made a supportive recommendation with respect to the prototype vaccine, thereby triggering a reduction in the number of Conditional Doses from <ix:nonFraction unitRef="dose" contextRef="c-127" decimals="-5" name="nvax:NumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="f-562">7.5</ix:nonFraction>&#160;million doses to <ix:nonFraction unitRef="dose" contextRef="c-128" decimals="INF" name="nvax:NumberOfDosesToBeDistributed" format="ixt:fixed-zero" scale="0" id="f-563">zero</ix:nonFraction>. As of February 2024, the Company is in discussions with the Authority regarding the treatment of the remaining upfront payment previously received of $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="nvax:CollaborationAgreementUpfrontPaymentAmount" format="ixt:num-dot-decimal" scale="6" id="f-564">112.5</ix:nonFraction>&#160;million, which is reflected in Other current liabilities. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grants</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" id="f-565" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized grant revenue as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt 0 7pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">USG Agreement</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-566">427,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-567">380,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-568">788,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.S. DoD</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-569">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-570">1,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-571">21,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CEPI</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-572">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-573">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-574">135,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other grant revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-575">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-576">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-577">2,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-578">427,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-579">382,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-580">948,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Government</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. government agreement consists of a Project Agreement (the &#8220;Project Agreement&#8221;) and a Base Agreement with Advanced Technology International, the Consortium Management Firm acting on behalf of the Medical CBRN Defense Consortium in connection with the partnership formerly known as Operation Warp Speed (the Base Agreement together with the Project Agreement the &#8220;USG Agreement&#8221;). </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The original USG Agreement required the Company to conduct certain clinical, regulatory, and other activities, including a pivotal Phase 3 clinical trial to determine the safety and efficacy of prototype vaccine, and to manufacture and deliver to the U.S. government <ix:nonFraction unitRef="dose" contextRef="c-141" decimals="-6" name="nvax:NumberOfDosesOfVaccineCandidate" format="ixt:num-dot-decimal" scale="6" id="f-581">100</ix:nonFraction>&#160;million doses of the vaccine candidate. Funding under the USG Agreement is payable to the Company for various development, clinical trial, manufacturing, regulatory, and other activities. The USG Agreement contains terms and conditions that are customary for U.S. government agreements of this nature, including provisions giving the U.S. government the right to terminate the Base Agreement or the Project Agreement based on a reasonable determination that the funded project will not produce beneficial results commensurate with the expenditure of resources and that termination would </span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-448-6" continuedAt="f-448-7"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be in the U.S. government&#8217;s interest. If the Project Agreement is terminated prior to completion, the Company is entitled to be paid for work performed and costs or obligations incurred prior to termination and consistent with the terms of the USG Agreement. As of December 31, 2023, the Company has recognized the full $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-8" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="9" id="f-582">1.8</ix:nonFraction>&#160;billion funding under the USG Agreement in revenue. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coalition for Epidemic Preparedness Innovations</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:28.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company entered into a restated funding agreement which was amended in November 2020 with CEPI, under which CEPI agreed to provide funding of up to $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="nvax:ResearchAndDevelopmentArrangementContractToPerformForOthersFunding" format="ixt:num-dot-decimal" scale="6" id="f-583">399.5</ix:nonFraction>&#160;million to the Company to support the development of prototype vaccine. The agreement provided up to $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="nvax:ResearchAndDevelopmentArrangementContractToPerformForOthersGrant" format="ixt:num-dot-decimal" scale="6" id="f-584">257.0</ix:nonFraction>&#160;million in CEPI Grant Funding and up to $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="nvax:ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans" format="ixt:num-dot-decimal" scale="6" id="f-585">142.5</ix:nonFraction>&#160;million in CEPI Forgivable Loan Funding, which are loans in the form of one or more forgivable no-interest term loans to fund certain manufacturing activities and are not subject to restrictive or financial covenants. As of December&#160;31, 2023 and 2022, the Company had recognized total revenue related to CEPI of $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="nvax:RevenueFromContractWithCustomerCommitment" format="ixt:num-dot-decimal" scale="6" id="f-586"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="nvax:RevenueFromContractWithCustomerCommitment" format="ixt:num-dot-decimal" scale="6" id="f-587">358.6</ix:nonFraction></ix:nonFraction>&#160;million, with the unused amounts primarily related to CEPI Forgivable Loan Funding. Payments received under the CEPI Forgivable Loan Funding are only repayable if project vaccine, as defined under the CEPI funding agreement, manufactured by the CMO network funded by CEPI is sold to one or more third parties (which could include sales credited under the Gavi Settlement Agreement), and such sales cover the Company&#8217;s costs of manufacturing such vaccine, not including manufacturing costs funded by CEPI.&#160;The timing and amount of any loan repayments is currently uncertain.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties and Other</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties and other includes royalty milestone payments, sales-based royalties, and Matrix-M&#8482; adjuvant sales. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-588">8.5</ix:nonFraction>&#160;million in revenue related to license fees, and $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-589">16.5</ix:nonFraction>&#160;million in revenue related to a Matrix-M&#8482; adjuvant sales. During the year ended December&#160;31, 2023, the Company did <ix:nonFraction unitRef="usd" contextRef="c-148" decimals="INF" name="us-gaap:Revenues" format="ixt-sec:numwordsen" scale="0" id="f-590">no</ix:nonFraction>t recognize revenue related to milestone payments.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-591">9.0</ix:nonFraction>&#160;million in revenue related to sales-based royalties, $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-592">20.0</ix:nonFraction>&#160;million related to milestone payments, and $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-593">15.0</ix:nonFraction>&#160;million in revenue related to a Matrix-M&#8482; adjuvant sales.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-448-7">During the year ended December&#160;31, 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-594">178.6</ix:nonFraction>&#160;million in revenue related to sales-based royalties and $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-595">20.0</ix:nonFraction>&#160;million related to milestone payments.</ix:continuation> </span></div><div id="i65591fd2146e456aac589be2afadc864_190"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-596" continuedAt="f-596-1" escape="true">Collaboration, License, and Supply Agreements </ix:nonNumeric></span></div><ix:continuation id="f-596-1" continuedAt="f-596-2"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SIIPL</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously granted SIIPL exclusive and non-exclusive licenses for the development, co-formulation, filling and finishing, registration, and commercialization of its prototype vaccine, its proprietary COVID-19 variant antigen candidate(s), and its CIC vaccine candidate. SIIPL agreed to purchase the Company's Matrix-M&#8482; adjuvant and the Company granted SIIPL a non-exclusive license to manufacture the antigen drug substance component of the Company&#8217;s COVID-19 Vaccine in SIIPL&#8217;s licensed territory solely for use in the manufacture of COVID-19 Vaccine. The Company and SIIPL equally split the revenue from SIIPL&#8217;s sale of COVID-19 Vaccine in its licensed territory, net of agreed costs. The Company also has a supply agreement with SIIPL and SLS under which SIIPL and SLS supply the Company with prototype vaccine, its proprietary COVID-19 variant antigen candidate(s), and its CIC vaccine candidate for commercialization and sale in certain territories, as well as a contract development manufacture agreement with SLS, under which SLS manufactures and supplies finished vaccine product to the Company using antigen drug substance and Matrix-M&#8482; adjuvant supplied by the Company. In March 2020, the Company entered into an agreement with SIIPL that granted SIIPL a non-exclusive license for the use of Matrix-M&#8482; adjuvant supplied by the Company to develop, manufacture, and commercialize R21/Matrix-M&#8482; adjuvant (&#8220;SIIPL R21 Agreement&#8221;), a malaria vaccine created by the Jenner Institute, University of Oxford (&#8220;R21/Matrix-M&#8482;&#8221;). In December 2023 received prequalification by the WHO. Under the SIIPL R21 Agreement, SIIPL purchases the Company's Matrix-M&#8482; adjuvant for use in development activities at cost and for commercial purposes at a tiered commercial supply price, and pays a royalty in the single-to low- double-digit range based on vaccine sales for a period of <ix:nonNumeric contextRef="c-1" name="nvax:RoyaltyPeriod" format="ixt-sec:duryear" id="f-597">15</ix:nonNumeric> years after the first commercial sale of the vaccine in each country. </span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-596-2" continuedAt="f-596-3"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a collaboration and license agreement with Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;) under which the Company granted Takeda an exclusive license to develop, manufacture, and commercialize the Company&#8217;s COVID-19 Vaccine in Japan. Under the agreement, Takeda purchases Matrix-M&#8482; adjuvant from the Company to manufacture doses of COVID-19 Vaccine, and the Company is entitled to receive milestone and sales-based royalty payments from Takeda based on the achievement of certain development and commercial milestones, as well as a portion of net profits from the sale of COVID-19 Vaccine. In September 2021, Takeda finalized an agreement with the Government of Japan&#8217;s Ministry of Health, Labour and Welfare ("MHLW") for the purchase of <ix:nonFraction unitRef="dose" contextRef="c-154" decimals="-6" name="nvax:NumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="f-598">150</ix:nonFraction>&#160;million doses of its prototype vaccine. In February 2023, MHLW canceled the remainder of doses under its agreement with Takeda. As a result, it is uncertain whether the Company will receive future sales-based royalty payments from Takeda under the terms and conditions of their current collaboration and licensing agreement. For the year ended December&#160;31, 2023, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-599">6.0</ix:nonFraction>&#160;million of revenue as consideration for changes to certain terms of the license agreement which is included in Royalties and other revenue on the consolidated statements of operations. For the year ended December 31, 2022, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="f-600">20.0</ix:nonFraction>&#160;million, upon the sale of prototype vaccine in Japan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which is included in Royalties and other revenue on the consolidated statements of operations. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bill &amp; Melinda Gates Medical Research Institute</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, the Company entered into a 3-year agreement with the Bill &amp; Melinda Gates Medical Research Institute to provide the Company&#8217;s Matrix-M&#8482; adjuvant for use in preclinical vaccine research. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SK bioscience, Co., Ltd.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company entered into a Collaboration and License Agreement (&#8220;CLA&#8221;) with SK bioscience, Co., Ltd. (&#8220;SK&#8221;) to manufacture and commercialize its prototype vaccine for sale to the government of South Korea. The CLA was amended in December 2021 and July 2022 to include the sale of its prototype vaccine to Thailand and Vietnam and to supply the Company with the antigen component of prototype vaccine for use in the final drug product globally, including product to be distributed by the COVAX Facility. Under the CLA, as amended, SK agreed to pay the Company a royalty on the sale of its prototype vaccine in the low to middle double-digit range. The CLA was in addition to the Company's existing manufacturing arrangement with SK under a Development and Supply Agreement (&#8220;DSA&#8221;) entered into in August 2020. In July 2022, the Company signed an additional agreement with SK for the technology transfer of the Company&#8217;s proprietary COVID-19 variant antigen materials so that SK can manufacture the drug substance targeting COVID-19 variants, including the Omicron subvariants. The companies also signed an agreement to manufacture and supply its prototype vaccine in a prefilled syringe.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, the Company entered into a material transfer agreement with SK for the use by SK of the Company&#8217;s Matrix-M&#8482; adjuvant in preclinical vaccine experiments for shingles, influenza, and pan-sarbecovirus vaccine.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company and SK entered into a Settlement Agreement and General Release (the &#8220;Settlement Agreement&#8221;) regarding mutual release by the parties of all claims arising from or in relation to statements of work (&#8220;SOWs&#8221;) canceled by the Company under the DSA and the CLA (collectively the &#8220;Business Agreements&#8221;), and other SOWs under the Business Agreements (collectively, the &#8220;Subject SOWs&#8221;), in each case, in connection with the cessation of all drug substance and drug product manufacturing activity at SK for supply to the Company. Subject SOWs canceled by the Company under the Settlement Agreement included (i) Statement of Work No. 1 dated as of December 23, 2021 as amended to date under the CLA; (ii) Statement of Work No. 5 dated as of July 18, 2022 under the DSA; and (iii) Statement of Work No. 6 dated as of July 18, 2022, and as amended as of December 28, 2022 under the DSA. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Settlement Agreement, the Company is responsible for payment of $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="nvax:SettlementPayment" format="ixt:num-dot-decimal" scale="6" id="f-601">149.8</ix:nonFraction>&#160;million to SK in connection with the cancellation of manufacturing activity for the SOWs under the Business Agreements, of which (i) $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="nvax:SettlementAgreementInitialReservationFee" format="ixt:num-dot-decimal" scale="6" id="f-602">130.4</ix:nonFraction>&#160;million was paid in August 2023 and (ii) the remaining balance was paid in November 2023. Under the Settlement Agreement, the Company and SK agreed to a wind down plan with respect to the remaining products, materials and equipment under the SOWs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Settlement Agreement, the Company and SK agreed to remove certain restrictions under the CLA that have been triggered by the launch of SK&#8217;s competing vaccine SKYCovione&#8482; in the Republic of Korea. In addition, the Company agreed to extend the term of an exclusive license to SK under the CLA for the exploitation of antigen and vaccine products </span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-596-3"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">utilizing Company&#8217;s proprietary coronavirus vaccine antigens and Matrix-M adjuvant in certain territories. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-603">4.0</ix:nonFraction>&#160;million to Deferred revenue related to the extended licenses granted to SK under the Settlement Agreement. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company also entered into a Securities Subscription Agreement (the &#8220;Subscription Agreement&#8221;) with SK, pursuant to which the Company agreed to sell and issue to SK, in a private placement (the &#8220;Private Placement&#8221;), <ix:nonFraction unitRef="shares" contextRef="c-158" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="6" id="f-604">6.5</ix:nonFraction>&#160;million shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-159" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-605">0.01</ix:nonFraction> per share (the &#8220;Shares&#8221;) at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-159" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-606">13.00</ix:nonFraction> per share for aggregate gross proceeds to the Company of approximately $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-607">84.5</ix:nonFraction>&#160;million. The closing of the Private Placement occurred on August 10, 2023. The fair value of the Company&#8217;s common stock on the date of closing, based on the quoted market price, was $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="nvax:CommonStockQuotedMarketPrice" format="ixt:num-dot-decimal" scale="6" id="f-608">46.5</ix:nonFraction>&#160;million, which results in a premium paid by SK of approximately $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="nvax:CommonStockPremiumPaid" format="ixt:num-dot-decimal" scale="6" id="f-609">38</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Settlement Agreement and the Subscription Agreement were negotiated concurrently between the parties, and therefore were combined for accounting purposes and analyzed as a single arrangement. As a result, the Company recorded the $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="nvax:CommonStockQuotedMarketPrice" format="ixt:num-dot-decimal" scale="6" id="f-610">46.5</ix:nonFraction>&#160;million fair value of common stock issued to SK, based on the quoted market price on the date of close, as an equity transaction. The remaining elements of the arrangement were deemed to relate to the settlement of the Company&#8217;s outstanding liabilities due to SK. These elements consist primarily of the cash payable to SK of $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="nvax:SettlementPayment" format="ixt:num-dot-decimal" scale="6" id="f-611">149.8</ix:nonFraction>&#160;million, offset by the premium paid on the common stock purchase by SK of $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="nvax:CommonStockPremiumPaid" format="ixt:num-dot-decimal" scale="6" id="f-612">38.0</ix:nonFraction>&#160;million, which resulted in a net gain upon derecognition of the liabilities due to SK of $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="nvax:SettlementAgreementBenefit" format="ixt:num-dot-decimal" scale="6" id="f-613">79.2</ix:nonFraction>&#160;million in connection with the settlement. As a result, during the year ended December&#160;31, 2023, the Company recorded this net gain of $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="nvax:SettlementAgreementBenefit" format="ixt:num-dot-decimal" scale="6" id="f-614">79.2</ix:nonFraction>&#160;million between research and development expense, for $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="nvax:SettlementAgreementBenefit" format="ixt:num-dot-decimal" scale="6" id="f-615">57.7</ix:nonFraction>&#160;million, and cost of sales, for $<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="nvax:SettlementAgreementBenefit" format="ixt:num-dot-decimal" scale="6" id="f-616">21.5</ix:nonFraction>&#160;million, proportionally based on the where the underlying costs were originally recorded.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Supply Agreements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, the Company, FUJIFILM Diosynth Biotechnologies UK Limited (&#8220;FDBK&#8221;), FUJIFILM Diosynth Biotechnologies Texas, LLC (&#8220;FDBT&#8221;), and FUJIFILM Diosynth Biotechnologies USA, Inc. (&#8220;FDBU&#8221; and together with FDBK and FDBT, &#8220;Fujifilm&#8221;) entered into a Confidential Settlement Agreement and Release (the &#8220;Fujifilm Settlement Agreement&#8221;) regarding amounts due to Fujifilm in connection with the termination of manufacturing activity at FDBT under the Commercial Supply Agreement (the &#8220;Fujifilm CSA&#8221;) dated August 20, 2021 and Master Services Agreement dated June 30, 2020 and associated statements of work (the &#8220;Fujifilm MSA&#8221;) by and between the Company and Fujifilm. The Fujifilm MSA and Fujifilm CSA established the general terms and conditions applicable to Fujifilm&#8217;s manufacturing and supply activities related to prototype vaccine under the associated statements of work.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Fujifilm Settlement Agreement, the Company agreed to pay up to $<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="nvax:SettlementPayment" format="ixt:num-dot-decimal" scale="6" id="f-617">185.0</ix:nonFraction>&#160;million (the &#8220;Settlement Payment&#8221;) to Fujifilm in connection with cancellation of manufacturing activity at FDBT under the CSA, of which (i) $<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="nvax:SettlementAgreementInitialReservationFee" format="ixt:num-dot-decimal" scale="6" id="f-618">47.8</ix:nonFraction>&#160;million, constituting the initial reservation fee under the CSA, was credited against the Settlement Payment on September&#160;30, 2022 and (ii) the remaining balance was to be paid in <ix:nonFraction unitRef="installment" contextRef="c-163" decimals="INF" name="nvax:NumberOfQuarterlyInstallmentPayments" format="ixt-sec:numwordsen" scale="0" id="f-619">four</ix:nonFraction> equal quarterly installments of $<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="nvax:SettlementAgreementQuarterlyInstallmentAmount" format="ixt:num-dot-decimal" scale="6" id="f-620">34.3</ix:nonFraction>&#160;million each, which began on March 31, 2023. Under the Fujifilm Settlement Agreement, the final <ix:nonFraction unitRef="installment" contextRef="c-164" decimals="INF" name="nvax:NumberOfQuarterlyInstallmentPayments" format="ixt-sec:numwordsen" scale="0" id="f-621">two</ix:nonFraction> quarterly installments due to Fujifilm were subject to Fujifilm&#8217;s obligation to use commercially reasonable efforts to mitigate losses associated with the vacant manufacturing capacity caused by the termination of manufacturing activities at FDBT under the CSA. Any replacement revenue achieved by Fujifilm&#8217;s mitigation efforts between July 1, 2023 and December 31, 2023 would offset the final <ix:nonFraction unitRef="installment" contextRef="c-164" decimals="INF" name="nvax:NumberOfQuarterlyInstallmentPayments" format="ixt-sec:numwordsen" scale="0" id="f-622">two</ix:nonFraction> settlement payments owed by the Company. On October 2, 2023, the Company sent a notice of breach under the Fujifilm Settlement Agreement to Fujifilm setting forth the Company&#8217;s position that Fujifilm had not used commercially reasonable efforts to mitigate losses. The Company withheld <ix:nonFraction unitRef="installment" contextRef="c-164" decimals="INF" name="nvax:NumberOfQuarterlyInstallmentPayments" format="ixt-sec:numwordsen" scale="0" id="f-623">two</ix:nonFraction> installments of $<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="nvax:SettlementAgreementQuarterlyInstallmentAmount" format="ixt:num-dot-decimal" scale="6" id="f-624">34.3</ix:nonFraction>&#160;million due to Fujifilm on September&#160;30, 2023 and December&#160;31, 2023, pending resolution of the issues identified in the notice of breach. On October 30, 2023, FDBT filed a demand for arbitration with Judicial Arbitration and Mediation Services (&#8220;JAMS&#8221;) seeking payment of the third quarter installment of the Settlement Payment. As of December&#160;31, 2023, the remaining payment of $<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="nvax:SettlementPayment" format="ixt:num-dot-decimal" scale="6" id="f-625">68.6</ix:nonFraction>&#160;million was reflected in Accrued expenses.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to assess its manufacturing needs and intends to modify its global manufacturing footprint consistent with its contractual obligations to supply, and anticipated demand for, its COVID-19 Vaccine, and in doing so, recognizes that significant costs may be incurred.</span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 27</span></div></div></div><div id="i65591fd2146e456aac589be2afadc864_196"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="f-626" continuedAt="f-626-1" escape="true">Cash, Cash Equivalents, and Restricted Cash</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="f-627" continuedAt="f-627-1" escape="true"><ix:continuation id="f-626-1" continuedAt="f-626-2"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the consolidated balance sheets that sum to the total of the same such amounts shown in the statement of cash flows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-628">568,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-629">1,336,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-630">1,515,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-631">10,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-632">10,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-633">11,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash non-current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-634">4,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-635">1,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-636">1,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-637">583,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-638">1,348,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-639">1,528,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-627-1"><ix:continuation id="f-626-2">(1)&#160;&#160;&#160;&#160;Classified as Other non-current assets as of December&#160;31, 2023 and 2022</ix:continuation></ix:continuation>.</span></div><div id="i65591fd2146e456aac589be2afadc864_199"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-640" continuedAt="f-640-1" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="f-640-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" id="f-641" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the estimated fair value of the Company&#8217;s financial assets and liabilities (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.581%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-642">171,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-643">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-644">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-645">398,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-646">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-647">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-backed securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-648">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-649">200,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-650">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-651">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-652">296,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-653">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-654">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-655">45,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-656">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-657">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-658">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-659">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-660">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-661">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-662">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-663">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-664">104,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-665">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-666">171,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-667">245,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-668">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-669">398,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-670">400,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-671">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-196" decimals="INF" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" id="f-672"><ix:nonFraction unitRef="number" contextRef="c-197" decimals="INF" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" id="f-673">3.75</ix:nonFraction></ix:nonFraction>% Convertible notes due 2023</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-674">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-675">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-676">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-677">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-678">322,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-679">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-204" decimals="2" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" id="f-680"><ix:nonFraction unitRef="number" contextRef="c-83" decimals="2" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" id="f-681">5.00</ix:nonFraction></ix:nonFraction>% Convertible notes due 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-682">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-683">100,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-684">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-685">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-686">172,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-687">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total convertible notes payable</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-688">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-689">100,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-690">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-691">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-692">494,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-693">&#8212;</ix:nonFraction></span></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">All investments are classified as Cash and cash equivalents as of December&#160;31, 2023 and 2022, on the consolidated balance sheets.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed-income investments categorized as Level 2 are valued at the custodian bank by a third-party pricing vendor&#8217;s valuation models that use verifiable observable market data, such as interest rates and yield curves observable at commonly quoted intervals and credit spreads, bids provided by brokers or dealers, or quoted prices of securities with similar characteristics.&#160;Pricing of the Company&#8217;s convertible notes has been estimated using observable inputs, including the price of the Company&#8217;s common stock, implied volatility, interest rates, and credit spreads.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2023 and 2022, the Company did not have any transfers between Levels.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount in the Company&#8217;s consolidated balance sheets for accounts payable and accrued expenses approximates its fair value due to its short-term nature.</span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 28</span></div></div></div><div id="i65591fd2146e456aac589be2afadc864_202"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;7&#160;&#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryDisclosureTextBlock" id="f-694" continuedAt="f-694-1" escape="true">Inventory</ix:nonNumeric></span></div><ix:continuation id="f-694-1" continuedAt="f-694-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-695" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="f-696">6,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="f-697">13,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Semi-finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="f-698">7,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="f-699">21,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="f-700">27,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="f-701">1,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-702">41,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-703">36,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory write-downs as a result of excess, obsolescence, expiry, or other reasons, and losses on firm purchase commitments are recorded as a component of Cost of sales in the consolidated statements of operations. For the year ended December&#160;31, 2023, inventory write-downs were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-704">72.4</ix:nonFraction>&#160;million and losses on firm purchase commitments were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:InventoryFirmPurchaseCommitmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-705">73.5</ix:nonFraction>&#160;million. In addition, for the year ended December&#160;31, 2023, the Company recorded recoveries on firm purchase commitments of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="nvax:InventoryFirmPurchaseCommitmentRecoveries" format="ixt:num-dot-decimal" scale="6" id="f-706">40.2</ix:nonFraction>&#160;million related primarily to negotiated reductions to previously recognized firm purchase commitments. Also, during the year ended December&#160;31, 2023, the Company recorded an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-707">6.1</ix:nonFraction>&#160;million in Cost of sales related to an embedded lease agreement with a CMO for production capacity in excess of production needs. For the year ended December 31, 2022, inventory write-downs and losses on firm purchase commitments were $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-708">447.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:InventoryFirmPurchaseCommitmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-709">155.9</ix:nonFraction>&#160;million respectively. There were <ix:nonFraction unitRef="usd" contextRef="c-18" decimals="INF" name="us-gaap:InventoryFirmPurchaseCommitmentLoss" format="ixt:fixed-zero" scale="0" id="f-710"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="INF" name="us-gaap:InventoryWriteDown" format="ixt:fixed-zero" scale="0" id="f-711">no</ix:nonFraction></ix:nonFraction> inventory write-downs or losses on firm purchase commitments during 2021. Inventory reserves for write-downs are relieved when the inventory is disposed of through scrap or sale. <ix:nonNumeric contextRef="c-1" name="nvax:ScheduleOfInventoryReserveTableTextBlock" id="f-712" continuedAt="f-712-1" escape="true">Activity in the reserve for excess and obsolete inventory was as follows (in thousands): </ix:nonNumeric></span></div><ix:continuation id="f-712-1"><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.306%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.908%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="3" id="f-713">368,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:InventoryValuationReserves" format="ixt:fixed-zero" scale="3" id="f-714">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to Cost of sales, including impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="nvax:InventoryReserveChargedToCostsOfSales" format="ixt:num-dot-decimal" scale="3" id="f-715">72,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="nvax:InventoryReserveChargedToCostsOfSales" format="ixt:num-dot-decimal" scale="3" id="f-716">447,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other additions </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="nvax:InventoryReserveOtherAdditions" format="ixt:num-dot-decimal" scale="3" id="f-717">65,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="nvax:InventoryReserveOtherAdditions" format="ixt:fixed-zero" scale="3" id="f-718">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deductions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="nvax:InventoryReserveDeductions" format="ixt:num-dot-decimal" scale="3" id="f-719">239,814</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="nvax:InventoryReserveDeductions" format="ixt:num-dot-decimal" scale="3" id="f-720">79,214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31,</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="3" id="f-721">266,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="3" id="f-722">368,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-694-2">Other additions include receipts of inventory previously recorded as losses on firm purchase commitments.</ix:continuation> </span></div><div id="i65591fd2146e456aac589be2afadc864_205"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillDisclosureTextBlock" id="f-723" continuedAt="f-723-1" escape="true">Goodwill</ix:nonNumeric></span></div><ix:continuation id="f-723-1"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="reporting_unit" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="f-724"><ix:nonFraction unitRef="reporting_unit" contextRef="c-17" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="f-725">one</ix:nonFraction></ix:nonFraction> reporting unit, which has a negative carrying amount as of December&#160;31, 2023 and 2022, <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfGoodwillTextBlock" id="f-726" continuedAt="f-726-1" escape="true">The change in the carrying amounts of goodwill was as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-726-1"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-727">126,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-728">131,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-729">1,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-730">5,148</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-731">127,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-732">126,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div id="i65591fd2146e456aac589be2afadc864_211"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeFinanceLeasesTextBlock" id="f-734" continuedAt="f-734-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-733" continuedAt="f-733-1" escape="true">Leases </ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="f-734-1" continuedAt="f-734-2"><ix:continuation id="f-733-1" continuedAt="f-733-2"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has embedded leases related to multiple manufacturing supply agreements with CMOs and CMOS to manufacture COVID-19 Vaccine, as well as operating and finance leases for its research and development and manufacturing facilities, corporate headquarters and offices. During the year ended December&#160;31, 2023, the Company continued to align its global manufacturing footprint as a result of its ongoing assessment of manufacturing needs consistent with its contractual obligations related to the supply, and anticipated demand for, its COVID-19 Vaccine.</span></div></ix:continuation></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-734-2" continuedAt="f-734-3"><ix:continuation id="f-733-2" continuedAt="f-733-3"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2023 and 2022, the Company modified certain of its CMO and CDMO agreements that had previously been determined to represent embedded leases and, in accordance with its policy, the Company remeasured and reallocated the remaining consideration under the contracts and reassessed the lease classification as of the effective dates of the respective modifications. During the year ended December&#160;31, 2023 and 2022, as a result of new or modified leases, the Company recognized ROU assets, net of credits on modifications, and a corresponding lease liability of $<ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="nvax:RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-735">6.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" name="nvax:RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-736">18.6</ix:nonFraction>&#160;million, respectively, for its long-term finance and operating leases embedded in CMO and CDMO manufacturing supply agreements. Also, during the year ended December&#160;31, 2023, the Company recorded an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-737">6.1</ix:nonFraction>&#160;million in Cost of sales related to an embedded lease agreement with a CMO for production capacity in excess of production needs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the Company entered into a lease agreement for the premises located at 700 Quince Orchard Road, Gaithersburg, Maryland ("700QO"). The lease is for approximately <ix:nonFraction unitRef="sqft" contextRef="c-214" decimals="INF" name="nvax:FacilityNumberOfSquareFeet" format="ixt:num-dot-decimal" scale="0" id="f-738">170,000</ix:nonFraction> square feet of space that the Company is using for manufacturing, research and development, and offices. The term of the lease expires in 2035 with options to extend the lease. The lease provides for an annual base rent of $<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-739">5.8</ix:nonFraction>&#160;million that is subject to future rent increases and obligates the Company to pay building operating costs. During the year ended December 31, 2022, the Company obtained the right to direct the use of, and obtain substantially all of the benefit from, certain floors located at the premises and recognized an ROU asset and related lease obligation of $<ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-740"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-741">73.2</ix:nonFraction></ix:nonFraction>&#160;million as lease commencement for accounting purposes occurred in 2022. During the year ended December&#160;31, 2023, the Company obtained the right to direct the use of, and obtain substantially all of the benefit from, the remaining floors located at the premises and recognized a ROU asset and related lease obligation of $<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-742"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-743">96.5</ix:nonFraction></ix:nonFraction>&#160;million as the lease commencement dates for accounting purposes had occurred for such remaining floors. The lease obligation was reduced by $<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-744">73.4</ix:nonFraction>&#160;million for prepaid rent and prior costs incurred on behalf of the landlord during 2023.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, facility leases, including the 700QO lease, have expirations that range from approximately <span style="-sec-ix-hidden:f-745">two</span> to <ix:nonNumeric contextRef="c-220" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="f-746">thirteen years</ix:nonNumeric>, some of which include options to extend the lease term. The facility leases contain provisions for future rent increases and obligate the Company to pay building operating costs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, the Company recorded an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-747">5.9</ix:nonFraction>&#160;million related to ROU facility leases used for research and development, manufacturing and offices space that are impacted by the Restructuring Plan (see Note 17). </span></div></ix:continuation></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-734-3" continuedAt="f-734-4"><ix:continuation id="f-733-3" continuedAt="f-733-4"><ix:nonNumeric contextRef="c-1" name="nvax:ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock" id="f-748" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases as of December&#160;31, 2023 and 2022 was as follows (in thousands, except weighted-average remaining lease term and discount rate):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.577%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease Assets and Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets, operating, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-749"><span style="-sec-ix-hidden:f-750">Right of use asset, net</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-751">24,985</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-752">36,384</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets, finance, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-753"><span style="-sec-ix-hidden:f-754">Right of use asset, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-755">160,233</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-756">69,857</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current ROU assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="nvax:LeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-757">185,218</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="nvax:LeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-758">106,241</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-759"><span style="-sec-ix-hidden:f-760">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-761">22,977</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-762">16,867</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-763">5,142</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-764">27,196</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="nvax:LeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-765">28,119</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="nvax:LeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-766">44,063</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-767"><span style="-sec-ix-hidden:f-768">Other non-current liabilities</span></span> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-769">28,577</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-770">50,085</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion of finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-771">55,923</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-772">31,238</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="nvax:LeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-773">84,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="nvax:LeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-774">81,323</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-19" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-775">3.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-20" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-776">4.6</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-19" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-777">11.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-20" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-778">8.3</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-19" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-779">6.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-20" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-780">6.4</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-19" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-781">8.9</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-20" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-782">5.4</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-783" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense for the operating and short-term leases for the years ended December&#160;31, 2023, 2022, and 2021 was as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-784">6,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-785">6,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-786">37,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease expense (benefit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="nvax:ShortTermLeaseCostBenefit" format="ixt:num-dot-decimal" scale="3" id="f-787">48,009</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="nvax:ShortTermLeaseCostBenefit" format="ixt:num-dot-decimal" scale="3" id="f-788">94,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="nvax:ShortTermLeaseCostBenefit" format="ixt:num-dot-decimal" scale="3" id="f-789">468,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-790">10,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-791">6,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-792">116,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease expense:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets expensed</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="f-793">12,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="f-794">7,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="f-795">112,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-796">2,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-797">1,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-798">7,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total finance lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-799">15,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-800">9,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-801">119,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;During the year ended December&#160;31, 2023, the Company recognized a short-term lease benefit of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="nvax:ShortTermLeaseCostBenefit" format="ixt:num-dot-decimal" scale="6" id="f-802">48.0</ix:nonFraction>&#160;million due to gains on the settlement of manufacturing supply agreements with CMOs and CDMOs that included embedded leases.</span></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-734-4"><ix:continuation id="f-733-4"><ix:nonNumeric contextRef="c-1" name="nvax:ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock" id="f-803" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases for the year ended December&#160;31, 2023, 2022, and 2021 was as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows used in operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-804">101,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-805">190,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-806">203,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows used in finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" format="ixt:num-dot-decimal" scale="3" id="f-807">2,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" format="ixt:num-dot-decimal" scale="3" id="f-808">1,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" format="ixt:num-dot-decimal" scale="3" id="f-809">7,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows used in finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="f-810">27,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="f-811">93,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="f-812">127,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for operating lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-813">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-814">30,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-815">66,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-816">103,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-817">73,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-818">112,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-819" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, maturities of lease liabilities were as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-820">34,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-821">17,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-822">13,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-823">14,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="f-824">14,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-825">67,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-826">160,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-827">48,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-828">112,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div id="i65591fd2146e456aac589be2afadc864_214"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-829" continuedAt="f-829-1" escape="true">Long-Term Debt</ix:nonNumeric></span></div><ix:continuation id="f-829-1" continuedAt="f-829-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtTableTextBlock" id="f-830" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s long-term debt consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-196" decimals="INF" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" id="f-831"><ix:nonFraction unitRef="number" contextRef="c-197" decimals="INF" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" id="f-832">3.75</ix:nonFraction></ix:nonFraction>% Convertible notes due 2023</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="nvax:DebtInstrumentFaceAmountCurrent" format="ixt:fixed-zero" scale="3" id="f-833">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="nvax:DebtInstrumentFaceAmountCurrent" format="ixt:num-dot-decimal" scale="3" id="f-834">325,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:UnamortizedDebtIssuanceExpense" format="ixt:fixed-zero" scale="3" id="f-835">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="3" id="f-836">119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current convertible notes payable</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:ConvertibleNotesPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-837">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:ConvertibleNotesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-838">324,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-204" decimals="2" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" id="f-839"><ix:nonFraction unitRef="number" contextRef="c-83" decimals="2" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" id="f-840">5.00</ix:nonFraction></ix:nonFraction>% Convertible notes due 2027</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-841">175,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-842">175,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-843">7,234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-844">8,784</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current convertible notes payable</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-845">168,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-846">166,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="nvax:InterestExpenseRelatedToConvertibleNotesTableTextBlock" id="f-847" escape="true"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense incurred in connection with the convertible notes payable consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coupon interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-848">9,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-849">12,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-850">12,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-851">1,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-852">1,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-853">1,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense on convertible notes payable</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-854">11,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-855">14,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-856">13,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-829-2" continuedAt="f-829-3"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2027 Convertible Notes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company issued $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-857">175.3</ix:nonFraction> million aggregate principal amount of convertible senior unsecured notes that will mature on December 15, 2027 (the &#8220;2027 Notes&#8221;), unless earlier converted, redeemed, or repurchased. The 2027 Notes were issued in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended, and pursuant to an indenture dated December 20, 2022 (the &#8220;2027 Indenture&#8221;) between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee. Concurrently with the issuance of the 2027 Notes, the Company completed a public offering of shares of its common stock (see Note 11). The Company received $<ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfUnsecuredDebt" format="ixt:num-dot-decimal" scale="6" id="f-858">166.4</ix:nonFraction> million in net proceeds from the issuance of the 2027 Notes after deducting the initial purchasers&#8217; fees and the Company&#8217;s offering expenses. The 2027 Notes bear cash interest at a rate of <ix:nonFraction unitRef="number" contextRef="c-204" decimals="2" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" id="f-859"><ix:nonFraction unitRef="number" contextRef="c-83" decimals="2" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" id="f-860">5.00</ix:nonFraction></ix:nonFraction>% per year, payable semiannually in arrears on June 15 and December 15 of each year, beginning on June 15, 2023.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2027 Notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding September 15, 2027, only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2023 (and only during such calendar quarter), if the last reported sale price of the Company&#8217;s common stock for at least <ix:nonFraction unitRef="day" contextRef="c-225" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="f-861">20</ix:nonFraction> trading days (whether or not consecutive) during a period of <ix:nonFraction unitRef="day" contextRef="c-225" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="f-862">30</ix:nonFraction> consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to <ix:nonFraction unitRef="number" contextRef="c-225" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="f-863">130</ix:nonFraction>% of the conversion price for the 2027 Notes on each applicable trading day; (2) during the <ix:nonFraction unitRef="day" contextRef="c-226" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" format="ixt-sec:numwordsen" scale="0" id="f-864">five</ix:nonFraction> business day period after any <ix:nonFraction unitRef="day" contextRef="c-226" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="f-865">ten</ix:nonFraction> consecutive trading day period (the &#8220;measurement period&#8221;) in which the trading price (as defined in the 2027 Indenture) per $1,000 principal amount of the 2027 Notes for each trading day of the measurement period was less than <ix:nonFraction unitRef="number" contextRef="c-226" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="f-866">98</ix:nonFraction>% of the product of the last reported sale price of the Company&#8217;s common stock and the conversion rate for the 2027 Notes on each such trading day; (3) if the Company calls such 2027 Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the 2027 Notes called (or deemed called) for redemption; and (4) upon the occurrence of specified corporate events as set forth in the 2027 Indenture. On or after September 15, 2027, until the close of business on the business day immediately preceding the maturity date (December 15, 2027), holders of the 2027 Notes may convert all or any portion of their 2027 Notes at any time, regardless of the foregoing conditions. Upon conversion, the Company may satisfy its conversion obligation by paying or delivering, as the case may be, cash, shares of the Company&#8217;s common stock, or a combination of cash and shares of the Company&#8217;s common stock, at the Company&#8217;s election, in the manner and subject to the terms and conditions provided in the 2027 Indenture.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conversion rate for the 2027 Notes will initially be 80.0000 shares of the Company&#8217;s common stock per $1,000 principal amount of 2027 Notes, which is equivalent to an initial conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-83" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-867">12.50</ix:nonFraction> per share of common stock. The initial conversion price of the 2027 Notes represents a conversion premium of <ix:nonFraction unitRef="number" contextRef="c-83" decimals="2" name="nvax:ConversionPremiumPercentage" scale="-2" id="f-868">25</ix:nonFraction>% of the public offering price in the Company&#8217;s concurrent common stock offering that closed on December 20, 2022 (see Note 11). The conversion rate for the 2027 Notes is subject to adjustment under certain circumstances in accordance with the terms of the 2027 Indenture. In addition, following certain corporate events that occur prior to the maturity date of the 2027 Notes or if the Company delivers a notice of redemption in respect of the 2027 Notes, the Company will, under certain circumstances, increase the conversion rate of the 2027 Notes for a holder who elects to convert its 2027 Notes (or any portion thereof) in connection with such a corporate event or convert its 2027 Notes called (or deemed called) for redemption during the related redemption period (as defined in the 2027 Indenture), as the case may be.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not redeem the 2027 Notes prior to December 22, 2025. The Company may redeem for cash all or any portion of the 2027 Notes, at its option, on or after December 22, 2025, if the last reported sale price of the common stock has been at least <ix:nonFraction unitRef="number" contextRef="c-225" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="f-869">130</ix:nonFraction>% of the conversion price for the 2027 Notes then in effect for at least <ix:nonFraction unitRef="day" contextRef="c-225" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="f-870">20</ix:nonFraction> trading days (whether or not consecutive) during any <ix:nonFraction unitRef="day" contextRef="c-225" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="f-871">30</ix:nonFraction> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="c-225" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="f-872">100</ix:nonFraction>% of the principal amount of the 2027 Notes to be redeemed, plus accrued and unpaid interest, to, but excluding, the redemption date. If the Company redeems less than all the outstanding 2027 Notes, at least $<ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-873">50</ix:nonFraction>&#160;million aggregate principal amount of 2027 Notes must be outstanding and not subject to redemption as of the date of the relevant notice of redemption. No sinking fund is provided for the 2027 Notes.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company undergoes a Fundamental Change (as defined in the 2027 Indenture), holders may require, subject to certain conditions and exceptions as set forth in the 2027 Indenture, the Company to repurchase for cash all or any portion of their 2027 Notes at a Fundamental Change repurchase price equal to <ix:nonFraction unitRef="number" contextRef="c-224" decimals="INF" name="nvax:DebtInstrumentRepurchaseOfPrincipalAmountPercentage" scale="-2" id="f-874">100</ix:nonFraction>% of the principal amount of the 2027 Notes to be repurchased, plus accrued and unpaid interest, to, but excluding, the Fundamental Change repurchase date. If a holder of the 2027 Notes converted upon a Make-Whole Fundamental Change (as described in the 2027 Indenture), they may be eligible to </span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-829-3" continuedAt="f-829-4"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">receive a make-whole premium through an increase to the conversion rate up to a maximum of 20.0000 shares per $1,000 principal amount of 2027 Notes (subject to other adjustments as described in the 2027 Indenture).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accounting for the issuance of the 2027 Notes, the Company determined that the scope exceptions provided under ASC Topic 815-40,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(&#8220;ASC 815-40&#8221;) apply to all but one of the conversion features embedded in the 2027 Notes. This remaining conversion feature, which is associated with a Fundamental Change of the Company, was determined to have a de minimis value as of December&#160;31, 2023, and 2022.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial purchasers&#8217; fees and the Company&#8217;s issuance costs related to the 2027 Notes totaled $<ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-5" name="us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-875">8.8</ix:nonFraction> million, which were recorded as a reduction to the 2027 Notes on the consolidated balance sheet. The $<ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-5" name="us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-876">8.8</ix:nonFraction> million of debt issuance costs is being amortized and recognized as additional interest expense over the <ix:nonNumeric contextRef="c-224" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-877">five-year</ix:nonNumeric> contractual term of the 2027 Notes using an effective interest rate of <ix:nonFraction unitRef="number" contextRef="c-83" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-878">6.2</ix:nonFraction>%.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2023 Convertible Notes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company issued $<ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-879"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-6" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-880">325</ix:nonFraction></ix:nonFraction> million&#160;aggregate principal amount of convertible senior unsecured notes that matured on&#160;February&#160;1, 2023&#160;(the &#8220;2023 Notes&#8221;).&#160;The 2023 Notes were senior unsecured debt obligations and were issued at par. On January 31, 2023, the Company funded the outstanding principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-881"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-6" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-882">325</ix:nonFraction></ix:nonFraction> million on the 2023 Notes, due February 1, 2023 and the indenture governing the 2023 Notes was subsequently satisfied and discharged in accordance with its terms. The Company&#8217;s related &#8220;capped call transactions&#8221; expired by their terms on January 27, 2023. The Company repaid the outstanding principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-883"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-6" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-884">325</ix:nonFraction></ix:nonFraction> million together with accrued but unpaid interest on the maturity date. The repayment was funded by the issuance of the 2027 Notes and the concurrent common stock offering, as well as cash on hand.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Notes were issued pursuant to an indenture dated January&#160;29, 2016 (the &#8220;2023 Indenture&#8221;) between the Company and the trustee.&#160;The Company received $<ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfUnsecuredDebt" format="ixt:num-dot-decimal" scale="6" id="f-885">315.0</ix:nonFraction> million in net proceeds from the offering after deducting underwriting fees and offering expenses. The 2023 Notes bore cash interest at a rate of <ix:nonFraction unitRef="number" contextRef="c-196" decimals="INF" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" id="f-886"><ix:nonFraction unitRef="number" contextRef="c-197" decimals="INF" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" id="f-887">3.75</ix:nonFraction></ix:nonFraction>%, payable on&#160;February&#160;1&#160;and&#160;August&#160;1&#160;of each year. The 2023 Notes were not redeemable prior to maturity and were convertible into shares of&#160;the Company&#8217;s&#160;common stock. As a result of the Company&#8217;s one-for-twenty reverse stock split in 2019 and pursuant to Section&#160;14.04(a)&#160;of the 2023 Indenture, the 2023 Notes were initially convertible into approximately <ix:nonFraction unitRef="shares" contextRef="c-230" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="f-888">2,385,800</ix:nonFraction> shares of the Company&#8217;s common stock based on the initial conversion rate of 7.3411 shares of the Company&#8217;s common stock per&#160;$1,000&#160;principal amount of the 2023 Notes. This represents an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="c-231" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-889">136.20</ix:nonFraction>&#160;per share of the Company&#8217;s common stock,&#160;representing an approximate <ix:nonFraction unitRef="number" contextRef="c-231" decimals="3" name="nvax:ConversionPremiumPercentage" scale="-2" id="f-890">22.5</ix:nonFraction>% conversion premium based on the last reported sale price of the Company&#8217;s common stock of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-232" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-891">111.20</ix:nonFraction> per share on January&#160;25, 2016. In addition, the holders of the 2023 Notes may have required the Company to repurchase the 2023 Notes at par value plus accrued and unpaid interest following the occurrence of a Fundamental Change (as described in the 2023 Indenture). If a holder of the 2023 Notes converted upon a Make-Whole Adjustment Event (as described in the 2023 Indenture), they may have been eligible to receive a make-whole premium through an increase to the conversion rate up to a maximum of 8.9928 shares per $1,000 principal amount of 2023 Notes (subject to other adjustments as described in the 2023 Indenture).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Notes are accounted for in accordance with ASC 470-20,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt with Conversion and Other Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(&#8220;ASC 470-20&#8221;) and ASC 815-40.&#160;Under ASC 815-40, to qualify for equity classification (or non-bifurcation, if embedded) the instrument (or embedded feature) must be both (1)&#160;indexed to the issuer&#8217;s stock and (2) meet the requirements of the equity classification guidance. Based upon the Company&#8217;s analysis, it was determined the 2023 Notes did contain embedded features indexed to its own stock, but did not meet the requirements for bifurcation, and therefore do not need to be separately accounted for as an equity component. Since the embedded conversion feature met the equity scope exception from derivative accounting, and also since the embedded conversion option did not need to be separately accounted for as an equity component under ASC 470-20,&#160;the proceeds received from the issuance of the convertible debt were recorded as a liability on the consolidated balance sheets.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the 2023 Notes,&#160;the Company&#160;also paid $<ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-5" name="nvax:PaymentForCappedCallTransactions" format="ixt:num-dot-decimal" scale="6" id="f-892">38.5</ix:nonFraction> million, including expenses, to enter into privately negotiated capped call transactions with certain financial institutions (the &#8220;capped call transactions&#8221;). The capped call transactions expired by their terms on January 27, 2023. The capped call transactions were generally expected to reduce the potential dilution upon conversion of the 2023 Notes in the event that the market price per share of the Company&#8217;s common stock, as measured under the terms of the capped call transactions, was greater than the strike price of the capped call transactions, which initially corresponded to the conversion price of the 2023 Notes, and was subject to anti-dilution adjustments generally similar to those applicable to the conversion rate of the 2023 Notes. The cap price of the capped call transactions was initially $<ix:nonFraction unitRef="usdPerShare" contextRef="c-234" decimals="2" name="nvax:DebtCapPrice" scale="0" id="f-893">194.60</ix:nonFraction> per share, which represented a premium of approximately <ix:nonFraction unitRef="number" contextRef="c-234" decimals="2" name="nvax:ConversionPremiumPercentage" scale="-2" id="f-894">75</ix:nonFraction>% based on the last reported sale </span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-829-4"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">price of the Company&#8217;s common stock of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-232" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-895">111.20</ix:nonFraction> per share on January&#160;25, 2016, and was subject to certain adjustments under the terms of the capped call transactions. If, however, the market price per share of the Company&#8217;s common stock, as measured under the terms of the capped call transactions, exceeded the cap price, there would nevertheless have been dilution upon conversion of the 2023 Notes to the extent that such market price exceeded the cap price. The Company evaluated the capped call transactions under ASC Topic 815-10,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8211; Overall</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and determined that they should be accounted for as a separate transaction and that the capped call transactions would be classified as an equity instrument.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred approximately $<ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-5" name="us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-896">10</ix:nonFraction> million of debt issuance costs in 2016 relating to the issuance of the 2023 Notes, which were recorded as a reduction to the 2023 Notes on the consolidated balance sheet. The $<ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-5" name="us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-897">10.0</ix:nonFraction> million of debt issuance costs was amortized and recognized as additional interest expense over the <ix:nonNumeric contextRef="c-235" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-898">seven-year</ix:nonNumeric> contractual term of the 2023 Notes on a straight-line basis, which approximated the effective interest rate method. The Company also incurred $<ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-5" name="us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-899">0.9</ix:nonFraction> million of expenses related to the capped call transactions, which were recorded as a reduction to additional paid-in-capital.</span></div></ix:continuation><div id="i65591fd2146e456aac589be2afadc864_223"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-905" continuedAt="f-905-1" escape="true">Stockholders&#8217; Deficit</ix:nonNumeric></span></div><ix:continuation id="f-905-1"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company entered into an At Market Issuance Sales Agreement (the "August 2023 Sales Agreement"), which allows it to issue and sell up to $<ix:nonFraction unitRef="usd" contextRef="c-238" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="f-906">500</ix:nonFraction> million in gross proceeds of shares of its common stock, and terminated its then-existing At Market Issuance Sales agreement entered in June 2021 (the &#8220;June 2021 Sales Agreement&#8221;). During the year ended December&#160;31, 2023, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-239" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="f-907">38.3</ix:nonFraction> million shares of its common stock under its August 2023 Sales Agreement and <ix:nonFraction unitRef="shares" contextRef="c-240" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="f-908">7.9</ix:nonFraction> million shares of its common stock under its June 2021 Sales Agreement, resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-909">321</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-910">6.9</ix:nonFraction>&#160;million was included in Prepaid expenses and other current assets as of December 31, 2023 and received in cash in January 2024. As of December&#160;31, 2023, the remaining balance available under the August 2023 Sales Agreement was approximately $<ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-6" name="nvax:SaleOfStockAmountOfRemainingUnissuedShares" format="ixt:num-dot-decimal" scale="6" id="f-911">242</ix:nonFraction> million.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, the Company sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-244" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="f-912">2.2</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of its common stock resulting in net proceeds of approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-6" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-913">179</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under its June 2021 Sales Agreement. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, pursuant to the Securities Subscription Agreement with SK, the Company agreed to sell and issue to SK <ix:nonFraction unitRef="shares" contextRef="c-158" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="6" id="f-914">6.5</ix:nonFraction> million shares of the Company&#8217;s common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-159" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-915">13.00</ix:nonFraction> per share (the &#8220;Shares&#8221;) in a Private Placement for aggregate gross proceeds to the Company of approximately $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-916">84.5</ix:nonFraction> million. The Company recognized the Shares at the settlement date fair value of $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="6" id="f-917">46.5</ix:nonFraction> million (see Note 4 for additional discussion of the Securities Subscription Agreement with SK). The closing of the Private Placement occurred on August 10, 2023.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company completed a public offering of <ix:nonFraction unitRef="shares" contextRef="c-245" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-918">7,475,000</ix:nonFraction> shares of its common stock, including <ix:nonFraction unitRef="shares" contextRef="c-246" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-919">975,000</ix:nonFraction> shares of common stock that were issued upon the exercise in full of the option to purchase additional shares granted to the underwriters, at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-247" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="f-920">10.00</ix:nonFraction> per share resulting in net proceeds, net of offering costs of $<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-921">4.9</ix:nonFraction> million, of approximately $<ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-922">70</ix:nonFraction> million. The Company completed this public offering concurrent with the issuance of the 2027 Notes (see Note 10).</span></div></ix:continuation><div id="i65591fd2146e456aac589be2afadc864_226"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-923" continuedAt="f-923-1" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-923-1" continuedAt="f-923-2"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Plans</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company established the 2023 Inducement Plan (the &#8220;2023 Inducement Plan&#8221;), which provides for the granting of share-based awards to individuals who were not previously employees, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with the Company. The Company reserved <ix:nonFraction unitRef="shares" contextRef="c-248" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-924">1.0</ix:nonFraction>&#160;million shares of common stock for grants under the 2023 Inducement Plan. As of December&#160;31, 2023, there were <ix:nonFraction unitRef="shares" contextRef="c-249" decimals="-5" name="nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance" format="ixt:num-dot-decimal" scale="6" id="f-925">0.2</ix:nonFraction>&#160;million shares available for issuance under the 2023 Inducement Plan.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2015 Stock Incentive Plan, as amended (&#8220;2015 Plan&#8221;), was approved at the Company&#8217;s annual meeting of stockholders in June&#160;2015. Under the 2015 Plan, equity awards may be granted to officers, directors, employees, and consultants of and advisors to the Company and any present or future subsidiary.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2015 Plan authorizes the issuance of up to <ix:nonFraction unitRef="shares" contextRef="c-250" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-926">21.0</ix:nonFraction> million shares of common stock under equity awards granted under the 2015 Plan, which includes an increase of <ix:nonFraction unitRef="shares" contextRef="c-251" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-927">6.2</ix:nonFraction> million shares approved for issuance under the 2015 Plan at the Company&#8217;s 2023 annual meeting of stockholders. All such shares authorized for issuance under the 2015 Plan have been reserved.&#160;The 2015 Plan will expire on March&#160;30, 2033. As of December&#160;31, 2023, there were <ix:nonFraction unitRef="shares" contextRef="c-250" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-928">6.9</ix:nonFraction> million shares available for issuance under the 2015 Plan.</span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-923-2" continuedAt="f-923-3"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended and Restated 2005 Stock Incentive Plan (&#8220;2005 Plan&#8221;) expired in February&#160;2015 and no new awards may be made under such plan, although awards will continue to be outstanding in accordance with their terms.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2015 Plan permits and the 2005 Plan permitted the grant of stock options (including incentive stock options), restricted stock, SARs, and RSUs. In addition, under the 2015 Plan, unrestricted stock, stock units, and performance awards may be granted. Stock options and SARs generally have a maximum term of <ix:nonNumeric contextRef="c-252" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-929">ten years</ix:nonNumeric> and may be or were granted with an exercise price that is no less than <ix:nonFraction unitRef="number" contextRef="c-253" decimals="2" name="nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" scale="-2" id="f-930">100</ix:nonFraction>% of the fair market value of the Company&#8217;s common stock at the time of grant. Grants of stock options are generally subject to vesting over periods ranging from <span style="-sec-ix-hidden:f-931">one</span> to <ix:nonNumeric contextRef="c-255" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-932">four years</ix:nonNumeric>.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-933" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the consolidated statements of operations as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.746%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-934">3,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-935">1,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-936">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-937">41,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-938">66,565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-939">86,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-940">40,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-941">62,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-942">96,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-943">85,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-944">130,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-945">183,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023 and 2022, total stock-based compensation capitalized in inventory was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="6" id="f-946">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="6" id="f-947">1.7</ix:nonFraction> million, respectively. No stock-based compensation was capitalized in inventory during the year ended December 31, 2021. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there was approximately $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="f-948">81.4</ix:nonFraction> million of total unrecognized compensation expense related to unvested stock options, SARs, RSUs, and the ESPP. This unrecognized non-cash compensation expense is expected to be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-949">1.0</ix:nonNumeric> year and will be allocated between cost of sales, research and development, and general and administrative expenses accordingly. This estimate does not include the impact of other possible stock-based awards that may be made during future periods.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value represents the total intrinsic value (the difference between the Company&#8217;s closing stock price on the last trading day of the period and the exercise price, multiplied by the number of in-the-money stock options and SARs) that would have been received by the holders had all stock option and SARs holders exercised their stock options and SARs on December&#160;31, 2023. This amount is subject to change based on changes to the closing price of the Company&#8217;s common stock. The aggregate intrinsic value of stock options and SARs exercises and vesting of RSUs for the years ending December&#160;31, 2023, 2022, and 2021 was approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-950">5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-951">21</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-952">454</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Stock Appreciation Rights</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-953" escape="true"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock options and SARs activity under the 2023 Inducement Plan, 2015 Plan and the 2005 Plan for the year ended December&#160;31, 2023:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.212%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.460%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.460%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.460%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.522%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.460%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.522%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.460%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.522%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023 Inducement Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2015 Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2005 Plan</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options &amp; SARs</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock<br/>Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-265" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:fixed-zero" scale="0" id="f-954">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-265" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-955">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-266" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-956">4,053,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-266" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-957">46.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-267" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-958">63,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-267" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-959">112.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-268" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-960">422,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-268" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-961">10.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-251" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-962">1,021,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-251" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-963">7.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-269" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="f-964">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-269" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-965">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-268" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-966">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-268" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-967">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-251" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-968">9,483</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-251" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-969">6.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-269" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-970">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-269" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-971">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-268" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:fixed-zero" scale="0" id="f-972">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-268" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-973">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-251" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-974">278,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-251" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-975">41.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-269" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-976">5,450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-269" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-977">39.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-249" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-978">422,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-249" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-979">10.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-250" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-980">4,787,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-250" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-981">38.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-270" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-982">58,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-270" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-983">119.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares exercisable at December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-249" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:fixed-zero" scale="0" id="f-984">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-249" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-985">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-250" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-986">3,436,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-250" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-987">41.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-270" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-988">58,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-270" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-989">119.79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-923-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-990" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted under the 2023 Inducement Plan and the 2015 Plan was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:53.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average Black-Scholes fair value of stock<br/>options and SARs granted</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-271" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-991">7.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-272" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-992">55.32</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-273" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-993">158.02</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-271" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-994">3.5</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-271" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-995">4.8</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-272" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-996">1.4</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-272" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-997">4.3</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-273" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-998">0.5</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-273" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-999">1.3</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-271" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1000">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-272" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1001">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-273" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1002">&#8212;</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-271" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-1003">120.4</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-271" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-1004">140.3</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-272" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-1005">120.5</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-272" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-1006">140.1</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-273" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-1007">124.7</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-273" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-1008">142.0</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-274" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1009">3.9</ix:nonNumeric>-<ix:nonNumeric contextRef="c-275" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1010">6.4</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-276" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1011">4.0</ix:nonNumeric>-<ix:nonNumeric contextRef="c-277" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1012">6.3</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-278" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1013">4.1</ix:nonNumeric>-<ix:nonNumeric contextRef="c-279" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1014">6.1</ix:nonNumeric></span></div></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total aggregate intrinsic value and weighted-average remaining contractual term of stock options and SARs outstanding under the 2023 Inducement Plan, 2015 Plan and 2005 Plan as of December&#160;31, 2023 was less than $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-1015">0.1</ix:nonFraction> million and <ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1016">6.9</ix:nonNumeric> years, respectively. The total aggregate intrinsic value and weighted-average remaining contractual term of stock options and SARs exercisable under the 2023 Inducement Plan, 2015 Plan and 2005 Plan as of December&#160;31, 2023 was less than $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="6" id="f-1017">0.1</ix:nonFraction> million and <ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1018">5.9</ix:nonNumeric> years, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="c-1" name="nvax:ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" id="f-1019" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of RSU activity for the year ended December&#160;31, 2023:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.481%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.533%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023 Inducement Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2015 Plan</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per Share<br/>Weighted-<br/>Average<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per Share<br/>Weighted-<br/>Average<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-280" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="f-1020">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-280" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-1021">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-281" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-1022">2,034,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-281" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1023">61.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-282" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1024">363,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-282" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1025">10.66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-283" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1026">3,314,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-283" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1027">7.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-282" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="0" id="f-1028">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-282" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-1029">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-283" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1030">696,553</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-283" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1031">73.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-282" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="f-1032">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-282" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-1033">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-283" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1034">937,603</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-283" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1035">27.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-284" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-1036">363,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-284" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1037">10.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-285" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-1038">3,714,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-285" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1039">19.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP was approved at the Company&#8217;s annual meeting of stockholders in June&#160;2013. The ESPP currently authorizes an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-286" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-1040">1.2</ix:nonFraction> million shares of common stock to be purchased, and the aggregate amount of shares will continue to increase <ix:nonFraction unitRef="number" contextRef="c-287" decimals="INF" name="nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" scale="-2" id="f-1041">5</ix:nonFraction>% on each anniversary of its adoption up to a maximum of <ix:nonFraction unitRef="shares" contextRef="c-287" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-1042">1.65</ix:nonFraction> million shares. The ESPP allows employees to purchase shares of common stock of the Company at each purchase date through payroll deductions of up to a maximum of <ix:nonFraction unitRef="number" contextRef="c-286" decimals="2" name="nvax:MaximumContributionOfEmployeesAsPayrollDeductions" scale="-2" id="f-1043">15</ix:nonFraction>% of their compensation, at <ix:nonFraction unitRef="number" contextRef="c-286" decimals="2" name="nvax:PercentageOfMarketPriceForStockPurchase" scale="-2" id="f-1044">85</ix:nonFraction>% of the lesser of the market price of the shares at the time of purchase or the market price on the beginning date of an option period (or, if later, the date during the option period when the employee was first eligible to participate). At December&#160;31, 2023, there were <ix:nonFraction unitRef="shares" contextRef="c-287" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-1045">0.5</ix:nonFraction> million shares available for issuance under the ESPP.</span></div></ix:continuation><div id="i65591fd2146e456aac589be2afadc864_229"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="f-1046" continuedAt="f-1046-1" escape="true">Employee Benefits</ix:nonNumeric></span></div><ix:continuation id="f-1046-1" continuedAt="f-1046-2"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a defined contribution 401(k)&#160;retirement plan, pursuant to which employees may elect to contribute up to <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="f-1047">100</ix:nonFraction>% of their compensation on a tax deferred basis up to the maximum amount permitted by the Internal Revenue Code of 1986, as amended. The Company matches <ix:nonFraction unitRef="number" contextRef="c-288" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="f-1048">100</ix:nonFraction>% of the first <ix:nonFraction unitRef="number" contextRef="c-288" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="f-1049">3</ix:nonFraction>% of the participants&#8217; deferral, and <ix:nonFraction unitRef="number" contextRef="c-289" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="f-1050">50</ix:nonFraction>% on the next <ix:nonFraction unitRef="number" contextRef="c-289" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="f-1051">2</ix:nonFraction>% of the participants&#8217; deferral, up to a potential <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="f-1052">4</ix:nonFraction>% Company match. The Company&#8217;s matching contributions to the 401(k)&#160;plan vest immediately. Under its 401(k)&#160;plan, the Company has recorded expense of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="f-1053">7.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="f-1054">6.0</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="f-1055">3.4</ix:nonFraction> million in 2023, 2022, and 2021, respectively.</span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-1046-2"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s foreign subsidiaries have pension plans under local tax and labor laws and are obligated to make contributions to the plan. Contributions and other expenses related to this plan were $<ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="f-1056">3.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="f-1057">2.4</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="f-1058">1.7</ix:nonFraction> million in 2023, 2022, and 2021, respectively.</span></div></ix:continuation><div id="i65591fd2146e456aac589be2afadc864_232"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="f-1059" continuedAt="f-1059-1" escape="true">Other Financial Information </ix:nonNumeric></span></div><ix:continuation id="f-1059-1" continuedAt="f-1059-2"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="f-1060" escape="true"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following as of (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:Supplies" format="ixt:num-dot-decimal" scale="3" id="f-1061">70,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:Supplies" format="ixt:num-dot-decimal" scale="3" id="f-1062">160,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1063">155,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1064">76,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1065">226,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1066">237,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span></div><ix:continuation id="f-423-2"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is comprised of the following as of (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and buildings</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1067">102,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1068">101,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1069">148,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1070">134,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1071">48,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1072">18,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1073">5,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1074">4,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1075">76,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1076">81,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1077">380,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1078">341,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1079">74,968</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1080">47,292</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-1081">305,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-1082">294,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, approximately $<ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-1083">155</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-1084">170</ix:nonFraction> million, respectively, of net assets used in operations were located in the Czech Republic. Depreciation expense was approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1085">41</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1086">29</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1087">13</ix:nonFraction> million for the years ended December&#160;31, 2023, 2022, and 2021, respectively.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="f-1088" escape="true"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following as of (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee benefits and compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1089">55,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1090">52,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross-to-net deductions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="nvax:AccruedGrossToNetDeductionsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1091">20,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="nvax:AccruedGrossToNetDeductionsCurrent" format="ixt:fixed-zero" scale="3" id="f-1092">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. product sales returns accrual </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="nvax:U.S.ProductSalesReturnsAccrual" format="ixt:num-dot-decimal" scale="3" id="f-1093">82,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="nvax:U.S.ProductSalesReturnsAccrual" format="ixt:fixed-zero" scale="3" id="f-1094">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="nvax:ResearchAndDevelopmentAccrualsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1095">131,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="nvax:ResearchAndDevelopmentAccrualsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1096">468,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1097">104,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1098">70,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1099">394,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1100">591,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-1059-2"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="f-1101" escape="true"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consist of the following as of (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refunds due to APA customers </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:CustomerRefundLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1102">142,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:CustomerRefundLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1103">210,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liability related to Gavi (see Note 3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="nvax:OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements" format="ixt:num-dot-decimal" scale="3" id="f-1104">696,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="nvax:OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements" format="ixt:num-dot-decimal" scale="3" id="f-1105">697,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1106">22,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1107">22,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1108">861,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1109">930,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i65591fd2146e456aac589be2afadc864_235"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 15 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-1110" continuedAt="f-1110-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="f-1110-1" continuedAt="f-1110-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" id="f-1111" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s loss before income tax expense by jurisdiction is as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-1112">628,984</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-1113">712,183</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-1114">1,633,016</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-1115">85,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-1116">58,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-1117">81,520</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1118">543,031</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1119">653,647</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1120">1,714,536</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-1121" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the current and deferred income tax expense (benefit) are as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1122">1,300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1123">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1124">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-1125">157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-1126">503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1127">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1128">1,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1129">2,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1130">29,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current income tax expense (benefit)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-1131">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1132">4,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1133">29,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred: </span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1134">2,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1135">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1136">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total income tax expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1137">2,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1138">4,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1139">29,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-1110-2" continuedAt="f-1110-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-1140" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense to the amount computed by applying the U.S. federal statutory tax rate to the Company&#8217;s effective tax rate is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Statutory federal tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1141">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1142">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-18" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1143">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1144">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1145">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-18" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1146">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development and other tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" format="ixt:fixed-zero" scale="-2" id="f-1147">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-1148">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-18" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-1149">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-deductible expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" format="ixt:fixed-zero" scale="-2" id="f-1150">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-17" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-1151">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-18" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-1152">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" sign="-" name="nvax:EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent" scale="-2" id="f-1153">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-17" decimals="2" sign="-" name="nvax:EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent" scale="-2" id="f-1154">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-18" decimals="2" name="nvax:EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent" scale="-2" id="f-1155">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxation of foreign operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" sign="-" name="nvax:EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations" scale="-2" id="f-1156">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-17" decimals="2" sign="-" name="nvax:EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations" scale="-2" id="f-1157">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-18" decimals="2" name="nvax:EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations" format="ixt:fixed-zero" scale="-2" id="f-1158">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancellation of Indebtedness</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" sign="-" name="nvax:EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent" scale="-2" id="f-1159">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="2" name="nvax:EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent" format="ixt:fixed-zero" scale="-2" id="f-1160">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-18" decimals="2" sign="-" name="nvax:EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent" scale="-2" id="f-1161">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-US tax credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1162">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" format="ixt:fixed-zero" scale="-2" id="f-1163">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-18" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" format="ixt:fixed-zero" scale="-2" id="f-1164">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="-2" id="f-1165">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1166">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-18" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1167">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" format="ixt:fixed-zero" scale="-2" id="f-1168">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-17" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="f-1169">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-18" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" format="ixt:fixed-zero" scale="-2" id="f-1170">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1171">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-17" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1172">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-18" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1173">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="f-1174">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-17" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1175">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-18" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1176">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company has available federal and state net operating losses of $<ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-8" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="9" id="f-1177">2.4</ix:nonFraction>&#160;billion, $<ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1178">877.6</ix:nonFraction>&#160;million, respectively, that may be applied against future taxable income in the respective jurisdiction. The federal net operating losses of $<ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-8" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="9" id="f-1179">2.4</ix:nonFraction>&#160;billion can be carried forward indefinitely, with all but $<ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1180">11.3</ix:nonFraction>&#160;million, which expires in 2037, limited to 80% of annual taxable income. State net operating losses of $<ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1181">457.4</ix:nonFraction>&#160;million have various expiration dates between 2028 and 2042. The remaining state net operating losses of $<ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1182">420.2</ix:nonFraction>&#160;million can be carried forward indefinitely. The Company also has research tax credits of $<ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-1183">51.9</ix:nonFraction>&#160;million that will begin to expire in 2024 through 2043 and a foreign tax credit carryforward of $<ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-1184">18.7</ix:nonFraction>&#160;million that will expire in 2030.&#160;Utilization of the federal and state net operating loss carryforwards and research tax credits may be subject to an annual limitation due to potential ownership changes of the Company. As of December&#160;31, 2023, the Company does not expect such limitation, if any, to impact the use of its net operating losses and research tax credits.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the U.S. federal jurisdiction and in various states, as well as in multiple foreign jurisdictions including Sweden and the Czech Republic. The Company has U.S. federal and state net operating losses and credit carryforwards that are subject to examination from 2003 through 2023. The returns in Sweden are subject to examination from 2016 through 2023 and the returns for the Czech Republic are subject to examination from 2019 through 2023.</span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-1110-3" continuedAt="f-1110-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-1185" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company&#8217;s deferred tax assets and liabilities as of December 31 were as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" format="ixt:num-dot-decimal" scale="3" id="f-1186">550,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" format="ixt:num-dot-decimal" scale="3" id="f-1187">479,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign net operating loss carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" format="ixt:fixed-zero" scale="3" id="f-1188">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" format="ixt:num-dot-decimal" scale="3" id="f-1189">5,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-1190">51,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-1191">45,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="nvax:DeferredTaxAssetLeasingLiability" format="ixt:num-dot-decimal" scale="3" id="f-1192">25,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="nvax:DeferredTaxAssetLeasingLiability" format="ixt:num-dot-decimal" scale="3" id="f-1193">27,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="f-1194">266,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="f-1195">195,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" format="ixt:num-dot-decimal" scale="3" id="f-1196">79,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" format="ixt:num-dot-decimal" scale="3" id="f-1197">213,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowance for sales returns</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="f-1198">20,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" format="ixt:fixed-zero" scale="3" id="f-1199">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1200">30,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1201">27,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-1202">132,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-1203">49,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign tax credit carryforward</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign" format="ixt:num-dot-decimal" scale="3" id="f-1204">18,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign" format="ixt:fixed-zero" scale="3" id="f-1205">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-1206">10,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-1207">13,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1208">1,186,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1209">1,056,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1210">1,128,941</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1211">1,020,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1212">57,852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1213">36,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-1214">41,456</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-1215">23,330</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1216">17,160</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1217">11,587</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1218">1,279</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1219">1,055</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="f-1220">704</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1221">59,895</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1222">36,676</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1223">2,043</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-1224">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the positive and negative evidence bearing upon the realization of its deferred tax assets, including its history of significant losses in every year since inception and, in accordance with U.S GAAP, has fully reserved the net deferred tax asset. The Company concluded that realization of its net deferred tax assets is not more-likely-than-not to be realized as of December&#160;31, 2023 and 2022. The valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="f-1225">108.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="f-1226">4.8</ix:nonFraction> million for the years ended December&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net deferred tax liability of $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1227">2.0</ix:nonFraction>&#160;million at December&#160;31, 2023 is included within other non-current liabilities on the accompanying consolidated balance sheet.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the effect of an income tax position when it is more likely than not, based on the technical merits, that the income tax position will be sustained upon examination. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-1228" continuedAt="f-1228-1" escape="true">A reconciliation of the beginning and ending amounts of unrecognized tax benefits in the year ended December&#160;31, 2023, 2022, and 2021 is as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-1228-1"><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized tax benefits balance at January 1</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1229">5,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1230">11,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1231">8,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions for tax positions of current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="f-1232">271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1233">1,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1234">4,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-1235">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="f-1236">807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-1237">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reductions for tax positions of prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1238">1,228</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1239">8,027</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1240">1,770</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Settlements of tax positions of prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="3" id="f-1241">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="3" id="f-1242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="3" id="f-1243">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized tax benefits balance at December 31,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1244">4,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-1245">5,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1246">11,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-1110-4"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense. As of December&#160;31, 2023 and 2022, the Company had no accruals for interest or penalties. The total amount of unrecognized tax benefits that, if recognized, could affect the effective tax rate was $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="f-1247">4.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="f-1248">5.2</ix:nonFraction> million as of December&#160;31, 2023 and 2022, respectively. However, the Company maintains a full valuation allowance as of December&#160;31, 2023 and 2022 and the recognition of any unrecognized tax benefits would be offset with a change in the valuation allowance and therefore there would be no income statement impact. As of December&#160;31, 2023, the Company does not expect a significant change in the recorded unrecognized tax benefits liability balance during the next twelve months. The unrecognized tax benefits are presented in the financial statements as a reduction to the deferred tax assets for all periods.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021 the Organization for Economic Cooperation and Development (&#8220;OECD&#8221;) developed guidance on Base Erosion and Profit Shifting (&#8220;BEPS&#8221;) Pillar Two Model Rules (&#8220;Pillar Two&#8221;), which addresses corporate tax planning strategies used by some large multinational corporations to shift profits from higher-tax jurisdictions to lower-tax jurisdictions or zero-tax locations. This guidance imposes a 15% minimum tax on the earnings of large multinational corporations. Pillar Two is expected to be effective in 2024 for the jurisdictions in which the Company operates. The Company is currently evaluating the application of Pillar Two and does not expect these rules to have a significant impact on its effective tax rate or its consolidated financial statements.</span></div></ix:continuation><div id="i65591fd2146e456aac589be2afadc864_241"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 16 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-1249" continuedAt="f-1249-1" escape="true">Commitment and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-1249-1" continuedAt="f-1249-2"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stockholder Litigation</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 12, 2021, Sothinathan Sinnathurai filed a purported securities class action in the U.S. District Court for the District of Maryland (the &#8220;Maryland Court&#8221;) against the Company and certain members of senior management, captioned Sothinathan Sinnathurai v. Novavax, Inc., et al., No. 8:21-cv-02910-TDC (the &#8220;Sinnathurai Action&#8221;). On January 26, 2022, the Maryland Court entered an order designating David Truong, Nuggehalli Balmukund Nandkumar, and Jeffrey Gabbert as co-lead plaintiffs in the Sinnathurai Action. The co-lead plaintiffs filed a consolidated amended complaint on March 11, 2022, alleging that the defendants made certain purportedly false and misleading statements concerning the Company&#8217;s ability to manufacture prototype vaccine on a commercial scale and to secure the prototype vaccine&#8217;s regulatory approval. The amended complaint defines the purported class as those stockholders who purchased the Company&#8217;s securities between February 24, 2021 and October 19, 2021. On April 25, 2022, the defendants filed a motion to dismiss the consolidated amended complaint. On December 12, 2022, the Maryland Court issued a ruling granting in part and denying in part defendants&#8217; motion to dismiss. The Maryland Court dismissed all claims against <ix:nonFraction unitRef="defendant" contextRef="c-312" decimals="INF" name="us-gaap:LossContingencyNumberOfDefendants" format="ixt-sec:numwordsen" scale="0" id="f-1250">two</ix:nonFraction> individual defendants and claims based on certain public statements challenged in the consolidated amended complaint. The Maryland Court denied the motion to dismiss as to the remaining claims and defendants, and directed the Company and other remaining defendants to answer within <ix:nonNumeric contextRef="c-312" name="nvax:LossContingencyPeriodToAnswer" format="ixt-sec:durwordsen" id="f-1251">fourteen days</ix:nonNumeric>. On December 27, 2022, the Company filed its answer and affirmative defenses. On March 16, 2023, the plaintiffs filed a motion for class certification and to appoint class representatives and counsel. Due to the Maryland Court&#8217;s ruling on the dismissal motion, the motion sought to certify a class of stockholders who purchased the Company&#8217;s securities between May 11, 2021, and October 19, 2021. The Company filed its opposition to the plaintiffs&#8217; motion on September 22, 2023. On December 4, 2023, the parties agreed to a binding settlement in principle (the &#8220;Proposed Settlement&#8221;) to fully resolve the surviving claims in the Sinnathurai Action. Under the Proposed Settlement&#8217;s terms, the Company agreed to pay $47 million into a settlement fund, which will be funded by the Company&#8217;s directors and officers&#8217; liability insurance and paid to members of a putative settlement class. On January 12, 2024, after the parties negotiated and executed a written agreement governing the Proposed Settlement, plaintiffs filed an unopposed motion for the Proposed Settlement&#8217;s preliminary approval. On January 23, 2024, the Maryland Court granted the motion for preliminary approval and, as requested by the parties, preliminarily certified, for the purposes of settlement only, the settlement class. The court also scheduled a settlement hearing to consider final approval of the settlement for May 23, 2024.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">After the Sinnathurai Action was filed, eight derivative lawsuits were filed: (i) Robert E. Meyer v. Stanley C. Erck, et al., No. 8:21-cv-02996-TDC (the &#8220;Meyer Action&#8221;), (ii) Shui Shing Yung v. Stanley C. Erck, et al., No. 8:21-cv-03248-TDC (the &#8220;Yung Action&#8221;), (iii) William Kirst, et al. v. Stanley C. Erck, et al., No. C-15-CV-21-000618 (the &#8220;Kirst Action&#8221;), (iv) Amy Snyder v. Stanley C. Erck, et al., No. 8:22-cv-01415-TDC (the &#8220;Snyder Action&#8221;), (v) Charles R. Blackburn, et al. v. Stanley C. Erck, et al., No. 1:22-cv-01417-TDC (the &#8220;Blackburn Action&#8221;), (vi) Diego J. Mesa v. Stanley C. Erck, et al., No. 2022-0770-NAC (the &#8220;Mesa Action&#8221;), (vii) Sean Acosta v. Stanley C. Erck, et al., No. 2022-1133-NAC (the &#8220;Acosta Action&#8221;), and (viii) Jared Needelman v. Stanley C. Erck, et al., No. C-15-CV-23-001550 (the &#8220;Needelman Action&#8221;). The Meyer, Yung, Snyder, and Blackburn Actions were filed in the Maryland Court. The Kirst and Needelman Actions were filed in the Circuit Court for Montgomery County, Maryland. The Mesa and Acosta Actions were filed in the Delaware Court of Chancery (the &#8220;Delaware Court&#8221;). The derivative lawsuits name members of the Company&#8217;s board of directors and certain members of senior management as defendants. The Company is deemed a nominal defendant. The plaintiffs assert derivative claims arising out of </span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-1249-2" continuedAt="f-1249-3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">substantially the same alleged facts and circumstances as the Sinnathurai Action. Collectively, the derivative complaints assert claims for breach of fiduciary duty, insider selling, unjust enrichment, violation of federal securities law, abuse of control, waste, and mismanagement. Plaintiffs seek declaratory and injunctive relief, as well as an award of monetary damages and attorneys&#8217; fees.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 7, 2022, the Maryland Court entered an order consolidating the Meyer and Yung Actions (the &#8220;First Consolidated Derivative Action&#8221;). The plaintiffs in the First Consolidated Derivative Action filed their consolidated derivative complaint on April 25, 2022. On May 10, 2022, the Maryland Court entered an order granting the parties&#8217; request to stay all proceedings and deadlines pending the earlier of dismissal or the filing of an answer in the Sinnathurai Action. On June 10, 2022, the Snyder and Blackburn Actions were filed. On October 5, 2022, the Maryland Court entered an order granting a request by the plaintiffs in the First Consolidated Derivative Action and the Snyder and Blackburn Actions to consolidate all three actions and appoint co-lead plaintiffs and co-lead and liaison counsel (the &#8220;Second Consolidated Derivative Action&#8221;). The co-lead plaintiffs in the Second Consolidated Derivative Action filed a consolidated amended complaint on November 21, 2022. On February 10, 2023, defendants filed a motion to dismiss the Second Consolidated Derivative Action. The plaintiffs filed their opposition to the motion to dismiss on April 11, 2023. Defendants filed their reply brief in further support of their motion to dismiss on May 11, 2023. On August 21, 2023, the court entered an order granting in part and denying in part the motion to dismiss; the court allowed claims for alleged insider selling under Brophy v. Cities Service Co., et al., 70 A.2d 5 (Del. Ch. 1949) and unjust enrichment claims to proceed, but dismissed the remaining claims in the second consolidated amended complaint. On September 5, 2023, the Company filed an Answer to the consolidated amended complaint. On September 6, 2023, the court entered an order granting the individual defendants an extension of time to file their answer until November 6, 2023. On October 6, 2023, the Board of Directors of the Company formed a Special Litigation Committee (&#8220;SLC&#8221;) with full and exclusive power and authority of the Board to, among other things, investigate, review, and analyze the facts and circumstances surrounding the claims asserted in the pending derivative actions, including the claims that remain following the court&#8217;s order on the motion to dismiss in the Second Consolidated Derivative Action. On November 7, 2023, the court entered an order granting the parties&#8217; request to stay the Second Consolidated Derivative Action for up to six months from the date of entry of the order. This includes staying the deadline for the individual defendants to respond to the consolidated amended complaint.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Kirst Action was filed on December 28, 2021, and the defendants immediately removed the case to the Maryland Court. On July 21, 2022, the Maryland Court issued a memorandum opinion and order remanding the Kirst Action to state court. The plaintiffs filed an amended complaint on December 30, 2022. On January 23, 2023, defendants filed a motion to stay the Kirst action. On February 22, 2023, the parties in the Kirst Action filed for the Court&#8217;s approval of a stipulation staying the Kirst Action pending the resolution of defendants&#8217; motion to dismiss in the Second Consolidated Derivative Action. On March 22, 2023, the Court entered the parties&#8217; stipulated stay of the Kirst Action pending resolution of the motion to dismiss in the Second Consolidated Derivative Action.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2022, the Mesa Action was filed. On October 3, 2022, the Delaware Court entered an order granting the parties&#8217; request to stay all proceedings and deadlines in the Mesa Action pending the earlier of dismissal of the Sinnathurai Action or the filing of an answer to the operative complaint in the Sinnathurai Action. On January 18, 2023, defendants filed a motion to stay the Mesa Action pending a final judgment in the Second Consolidated Derivative Action. The plaintiff filed his opposition on February 8, 2023. Defendants filed their reply on February 22, 2023. On February 28, 2023, the court granted the defendants&#8217; motion to stay. On August 31, 2023, the plaintiff filed a motion to lift the stay. On October 6, 2023, the Company filed an opposition to plaintiff&#8217;s motion to lift the stay. Plaintiff filed his reply on October 17, 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 27, 2023, the parties filed a letter informing the Court that the Second Consolidated Derivative Action had been stayed for a period of six months and asked the Court to stay further proceedings in the Mesa Action until expiration of that stay.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2022, the Acosta Action was filed. On February 6, 2023, defendants accepted service of the complaint and summons in the Acosta Action. On March 9, 2023, the court entered an order granting the parties&#8217; request to stay the Acosta Action pending the entry of a final, non-appealable judgment in the Second Consolidated Derivative Action. On October 13, 2023, the parties filed, and the Delaware Court entered, a stipulated order providing that (i) if the Delaware Court declines to lift the stay in the Mesa Action, the Acosta Action will also remain stayed, and (ii) if the Delaware Court lifts the stay in the Mesa Action, the stay in the Acosta Action will also be lifted.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2023, the Needelman Action was filed. On July 12, 2023, the parties filed a stipulation and proposed order to stay the Needelman Action pending the Maryland Court&#8217;s decision on the motion to dismiss in the Second Consolidated Derivative Action. The court entered that order on July 17, 2023. The parties continue to discuss next steps in the litigation following the Maryland Court&#8217;s ruling on the motion to dismiss the Second Consolidated Derivative Action. The court entered that order on July 17, 2023.</span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-1249-3" continuedAt="f-1249-4"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2023, the court entered an order consolidating the Kirst and Needelman Actions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2023, the parties filed a stipulation (i) extending the plaintiffs&#8217; deadline to file a consolidated complaint until January 29, 2024, and (ii) otherwise staying all other proceedings in the case (including the defendants&#8217; deadline to respond to the consolidated complaint) until February 12, 2024. The stipulation entered by the court instructs the parties to discuss whether the stay should be further extended in light of the then-current status of the SLC&#8217;s investigation. The financial impact of the derivative claims is not estimable.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 18, 2022, the Company delivered written notice to Gavi to terminate the Gavi APA based on Gavi&#8217;s failure to procure the purchase of <ix:nonFraction unitRef="dose" contextRef="c-91" decimals="-6" name="nvax:NumberOfDosesToBeDistributed" format="ixt:num-dot-decimal" scale="6" id="f-1252">350</ix:nonFraction>&#160;million doses of prototype vaccine from the Company as required by the Gavi APA. As of November 18, 2022, the Company had only received orders under the Gavi APA for approximately <ix:nonFraction unitRef="dose" contextRef="c-91" decimals="-6" name="nvax:PurchaseAgreementNumberOfVaccineDoses" format="ixt:num-dot-decimal" scale="6" id="f-1253">2</ix:nonFraction>&#160;million doses. On December 2, 2022, Gavi issued a written notice purporting to terminate the Gavi APA based on Gavi&#8217;s contention that the Company repudiated the agreement and, therefore, materially breached the Gavi APA. Gavi also contended that, based on its purported termination of the Gavi APA, it was entitled to a refund of the Advance Payment Amount less any amounts that have been credited against the purchase price for binding orders placed by a buyer participating in the COVAX Facility. Since December 31, 2022, the remaining Gavi Advance Payment Amount, which is $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="nvax:CollaborationAgreementRemainingPaymentAmount" format="ixt:num-dot-decimal" scale="6" id="f-1254">696.4</ix:nonFraction>&#160;million as of December 31, 2023, pending resolution of the dispute with Gavi related to a return of the remaining Advance Payment Amount, has been classified within Other current liabilities in the Company&#8217;s consolidated balance sheet. On January 24, 2023, Gavi filed a demand for arbitration with the International Court of Arbitration based on the claims described above. The Company filed its Answer and Counterclaims on March 2, 2023. On April 5, 2023, Gavi filed its Reply to the Company&#8217;s Counterclaims. On February 16, 2024, the Company and Gavi entered into a Termination and Settlement Agreement (the &#8220;Gavi Settlement Agreement&#8221;) terminating the Gavi APA, settling the arbitration proceedings and releasing both parties of all claims arising from, under or otherwise in connection with the Gavi APA. Pursuant to the Gavi Settlement Agreement, the Company is responsible for payment to Gavi of (i) an initial settlement payment of $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="f-1255">75</ix:nonFraction>&#160;million, which the Company paid on February 20, 2024, and (ii) deferred payments, in equal annual amounts of $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-6" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="f-1256">80</ix:nonFraction>&#160;million payable each calendar year through a deferred payment term ending December 31, 2028. The deferred payments are due in variable quarterly installments beginning in the first quarter of 2024 and total $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-6" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="f-1257">400</ix:nonFraction>&#160;million during the deferred payment term. Such deferred payments may be reduced through Gavi&#8217;s use of an annual vaccine credit equivalent to the unpaid balance of such deferred payments each year, which may be applied to qualifying sales of any of the Company&#8217;s vaccines funded by Gavi for supply to certain low-income and lower-middle income countries. The Company has the right to price the vaccines offered to such low-income and lower-middle income countries at its discretion, and, when utilized by Gavi, the Company will credit the actual price per vaccine paid against the applicable credit. The Company intends to price vaccines offered via the tender process, consistent with its shared goal with Gavi to provide equitable access to those countries. On February 22, 2024, the claims and counterclaims were dismissed with prejudice.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 30, 2022, the Company and Fujifilm entered into the Fujifilm Settlement Agreement regarding amounts due to Fujifilm in connection with the termination of manufacturing activity at FDBT under the CSA dated August 20, 2021 and the MSA by and between the Company and Fujifilm. The MSA and CSA established the general terms and conditions applicable to Fujifilm&#8217;s manufacturing and supply activities related to the Company&#8217;s prototype vaccine under the associated statements of work. Pursuant to the Fujifilm Settlement Agreement, the Company agreed to pay up to $<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="nvax:SettlementPayment" format="ixt:num-dot-decimal" scale="6" id="f-1258">185.0</ix:nonFraction>&#160;million (the &#8220;Settlement Payment&#8221;) to Fujifilm in connection with cancellation of manufacturing activity at FDBT. Under the Fujifilm Settlement Agreement, the final <ix:nonFraction unitRef="installment" contextRef="c-164" decimals="INF" name="nvax:NumberOfQuarterlyInstallmentPayments" format="ixt-sec:numwordsen" scale="0" id="f-1259">two</ix:nonFraction> quarterly installments due to Fujifilm were subject to Fujifilm&#8217;s obligation to use commercially reasonable efforts to mitigate losses associated with the vacant manufacturing capacity caused by the termination of manufacturing activities at FDBT under the CSA. Any replacement revenue achieved by Fujifilm&#8217;s mitigation efforts between July 1, 2023 and December 31, 2023 would offset the final <ix:nonFraction unitRef="payment" contextRef="c-163" decimals="INF" name="nvax:NumberOfSettlementPayments" format="ixt-sec:numwordsen" scale="0" id="f-1260">two</ix:nonFraction> settlement payments owed by the Company. On October 2, 2023, the Company sent a notice of breach under the Fujifilm Settlement Agreement to Fujifilm setting forth the Company&#8217;s position that Fujifilm had not used commercially reasonable efforts to mitigate losses. The Company withheld <ix:nonFraction unitRef="payment" contextRef="c-163" decimals="INF" name="nvax:NumberOfSettlementPayments" format="ixt-sec:numwordsen" scale="0" id="f-1261">two</ix:nonFraction> installments of $<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="nvax:SettlementAgreementQuarterlyInstallmentAmount" format="ixt:num-dot-decimal" scale="6" id="f-1262">34.3</ix:nonFraction>&#160;million due to Fujifilm on September&#160;30, 2023 and December&#160;31, 2023, pending resolution of the issues identified in the notice of breach. On October 30, 2023, FDBT filed a demand for arbitration with Judicial Arbitration and Mediation Services (&#8220;JAMS&#8221;) seeking payment of the third quarter installment of the Settlement Payment. An arbitration hearing has been scheduled for May 2024. As of December&#160;31, 2023, the remaining payment of $<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="nvax:SettlementPayment" format="ixt:num-dot-decimal" scale="6" id="f-1263">68.6</ix:nonFraction>&#160;million was reflected in Accrued expenses. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also involved in various other legal proceedings arising in the normal course of business. Although the outcomes of these other legal proceedings are inherently difficult to predict, the Company does not expect the resolution of these other legal proceedings to have a material adverse effect on its financial position, results of operations, or cash flows.</span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Table </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65591fd2146e456aac589be2afadc864_7">Contents</a></span></div></div><ix:continuation id="f-1249-4"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into agreements in the normal course of business with CMOs and CDMOs supplying the Company with production capabilities, and with vendors for preclinical studies, clinical trials, and other goods or services. A number of these arrangements are within the scope of lease accounting (see Note 9). Certain agreements provide for termination rights subject to termination fees. Under such agreements, the Company is contractually obligated to make payments to vendors, mainly to reimburse them for their estimated unrecoverable expenses. The exact amount of such obligations are dependent on the timing of termination and the terms of the relevant agreement, and cannot be reasonably estimated. As of December&#160;31, 2023, most of these agreements were active ongoing arrangements and the Company expects to receive value from these arrangements in the future. The Company recognizes fees related to obligations for terminated contracts where such fees are reasonably estimable. The Company did not accrue obligations that were not reasonably estimable. As of December&#160;31, 2023, the Company had <ix:nonFraction unitRef="usd" contextRef="c-19" decimals="INF" name="us-gaap:PurchaseObligation" format="ixt-sec:numwordsen" id="f-1264">no</ix:nonFraction> non-cancelable purchase commitments with a remaining term of more than one year.</span></div></ix:continuation><div id="i65591fd2146e456aac589be2afadc864_1605"></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; </span><ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-1265" continuedAt="f-1265-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring </span></ix:nonNumeric></div><ix:continuation id="f-1265-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="f-1266" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the restructuring charge recorded by the Company comprised (in thousands): </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"/><td style="width:80.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.982%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severance and employee benefit costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="3" id="f-1267">4,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="f-1268">10,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Restructuring charge </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-1269">14,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Restructuring charges of $<ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-1270">0.5</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-1271">2.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-1272">11.5</ix:nonFraction>&#160;million are included in Cost of sales, Research and development and Selling, general, and administrative expenses, respectively, in the Consolidated Statements of Operations for the period ended December&#160;31, 2023. These charges reflect substantially all expected restructuring charges under the Restructuring Plan.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Severance and employee benefit costs</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employees affected by the reduction in force under the Restructuring Plan are entitled to receive severance payments and certain termination benefits. The Company recorded a severance and termination benefit cost in full for employees who were notified of their termination during the year ended December&#160;31, 2023 and had no requirements for future service. The Company fully paid $<ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="f-1273">4.5</ix:nonFraction>&#160;million for severance and employee benefit costs during the year ended December&#160;31, 2023 and no remaining liability for the severance and employee benefit costs is included in the Company&#8217;s consolidated balance sheet as of December&#160;31, 2023. There were <ix:nonFraction unitRef="usd" contextRef="c-315" decimals="INF" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="0" id="f-1274"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="INF" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="0" id="f-1275">no</ix:nonFraction></ix:nonFraction> severance and employee benefit costs during the year ended December 31, 2022 and 2021.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of long-lived assets</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Restructuring Plan, the Company evaluated its long-lived assets for impairment including certain leased laboratory and office spaces located in Gaithersburg, Maryland. The evaluation is subject to judgment and actual results may vary from the estimates, resulting in potential future adjustments to amounts recorded. During the year ended December&#160;31, 2023, the Company recorded an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="f-1276">10.1</ix:nonFraction>&#160;million related to the impairment of long-lived assets, including $<ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-1277">5.9</ix:nonFraction>&#160;million related to ROU assets for facility leases. There were no impairment charges recorded during the year ended December 31, 2022 and 2021.</span></div></ix:continuation><div><span><br/></span></div><div id="i65591fd2146e456aac589be2afadc864_244"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 18 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-1278" continuedAt="f-1278-1" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="f-1278-1" continuedAt="f-1278-2"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2024, the Company announced that the Board of Directors of the Company approved an approximately <ix:nonFraction unitRef="number" contextRef="c-317" decimals="2" name="nvax:RestructuringAndRelatedCostNumberOfPositionsEliminatedGlobalPercent" scale="-2" id="f-1279">12</ix:nonFraction>% reduction of its global workforce, comprised of an approximately <ix:nonFraction unitRef="number" contextRef="c-317" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="f-1280">9</ix:nonFraction>% reduction in the Company&#8217;s full-time employees and the remainder comprised of contractors and consultants. </span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1278-2">On February 16, 2024, the Company and Gavi entered into the Gavi Settlement Agreement terminating the Gavi APA, settling the arbitration proceedings and releasing both parties of all claims arising from, under or otherwise in connection with the Gavi APA. The terms of the Gavi Settlement Agreement are outlined in Note 3 and Note 16.</ix:continuation> </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 45</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>2
<FILENAME>nvax-20231231xex44.htm
<DESCRIPTION>EX-4.4
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i4d8a60661297443b9442a727923f867a_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 4.4</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">REGISTERED PURSUANT TO SECTION 12 OF THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SECURITIES EXCHANGE ACT OF 1934</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As of December 31, 2023, Novavax, Inc. (the &#8220;Company&#8221;) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Description of Common Stock</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The following description of the Company&#8217;s Common Stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the Company&#8217;s Second Amended and Restated Certificate of Incorporation, as amended, (the &#8220;Certificate of Incorporation&#8221;), Certificate of Designation of Series A Convertible Preferred Stock (the &#8220;Certificate of Designation&#8221;) and Amended and Restated By-Laws (the &#8220;By-Laws&#8221;), each of which is incorporated by reference as an exhibit to this Annual Report on Form 10-K. The Company encourages you to read the Certificate of Incorporation, the Certificate of Designation, the By-Laws, and the applicable provisions of the Delaware General Corporation Law for additional information. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Authorized Capital Shares</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Certificate of Incorporation authorizes the issuance of 600,000,000 shares of common stock, $0.01 par value per share (&#8220;Common Stock&#8221;), and 2,000,000 shares of preferred stock, $0.01 par value per share (&#8220;Preferred Stock&#8221;), of which 438,885 shares of Preferred Stock have been designated as Series A Convertible Preferred Stock, par value $0.01 per share, pursuant to the Certificate of Designation (&#8220;Series A Convertible Preferred Stock&#8221;). The outstanding shares of Common Stock are fully paid and nonassessable. As of December 31, 2023, there are no shares of Preferred Stock outstanding.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Preferred Stock </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Authorized but Unissued Preferred Stock </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Board of Directors (the &#8220;Board&#8221;), without further stockholder approval, has the power to issue Preferred Stock in one or more series and determine certain terms relative to any Preferred Stock to be issued, such as the power to establish different series and to set voting rights, the dividend rights and dates, conversion rights, redemption privileges and liquidation preferences. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Each share of Series A Convertible Preferred Stock is convertible into ten shares of Common Stock, subject to mandatory conversion upon the earlier of (1) the tenth anniversary of the issuance date or (2) immediately prior to the effectiveness of certain change of control transactions. </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Holders of Series A Convertible Preferred Stock are not entitled to vote on matters submitted to the holders of Common Stock and do not have the right to cumulative dividends. In the event that the Company declares a dividend upon Common Stock, a holder of the Series A Convertible Preferred Stock is entitled to receive the amount of dividends per share of Series A Convertible Preferred Stock that such holder would have been entitled to receive if it had converted such Series A Convertible Preferred Stock into Common Stock immediately prior to such declaration of a dividend. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event of a liquidation, dissolution or winding up of the Company that does not constitute a change of control transaction triggering mandatory conversion of the Series A Convertible Preferred Stock, any holder of Series A Convertible Preferred Stock will be entitled to receive, in preference to the holders of Common Stock and any junior Preferred Stock, an amount per share equal to the greater of (1) the sum of the purchase price plus an amount equal to any declared and unpaid dividends on the Series A Convertible Preferred Stock, or (2) the amount that such shares of Series A Convertible Preferred Stock </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">would have been entitled to receive if they had converted into Common Stock immediately prior to such liquidation, dissolution or winding up.</font></div><div style="text-indent:36pt"><font><br></font></div><div><font><br></font></div><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 4.4</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As of December 31, 2023, there are no shares of the Series A Convertible Preferred Stock outstanding.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Common Stock </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Dividend Rights</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to the rights of holders of outstanding shares of Preferred Stock, if any, the holders of Common Stock are entitled to receive dividends, if any, as may be declared from time to time by the Board in its discretion out of funds legally available for the payment of dividends. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Voting Rights</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The holders of Common Stock are entitled to one vote per share on all matters voted on by the stockholders, including the election of directors, and do not have cumulative voting rights. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Classified Board</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The members of the Board are divided into three classes, designated as Class I, Class II, and Class III, each serving staggered three-year terms, with no one class having more than one more director than any other class. The By-Laws provide for directors in director elections to be elected by a plurality of the votes entitled to vote.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Liquidation Rights</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to any preferential rights of outstanding shares of Preferred Stock, holders of Common Stock will share ratably in all assets legally available for distribution to the Company&#8217;s stockholders in the event of dissolution.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Other Rights and Preferences</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Common Stock has no redemption provisions or preemptive, conversion or exchange rights. No shares of any class of the Company&#8217;s capital stock are subject to any sinking fund provisions, restrictions on the alienability of securities to be registered, calls, assessments by, or liabilities of the Company. Holders of Common Stock may act by written consent.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Certain Provisions of the Certificate of Incorporation, By-laws, and Delaware Law </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Certain provisions of the Certificate of Incorporation and By-Laws may be deemed to have an anti-takeover effect and may prevent, delay, or defer a tender offer or takeover attempt, including&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Classified Board, Removal of Directors, and Charter Amendments relating to the Board </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Certificate of Incorporation and the By-Laws provide for the division of members of the Board into three classes, with no one class having more than one more director than any other class, serving staggered three-year terms. The Certificate of Incorporation provides that any amendments to the charter relating to the number, classes, election, term, removal, vacancies, and related provisions with respect to the Board may only be made by the affirmative vote of the holders of at least 75% of the shares of capital stock issued and outstanding and entitled to vote. These provisions may have the effect of making it more difficult for a third party to acquire control of the Company, or of discouraging a third party from attempting to acquire control of the Company. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Authorized but Unissued Shares </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The authorized but unissued shares of Common Stock and Preferred Stock are available for future issuance without stockholder approval, subject to any limitations imposed by the Nasdaq Stock Market. These additional shares may be utilized for a variety of corporate purposes. In particular, the Board could issue shares of Preferred Stock that could, depending on the terms of the series, impede the completion of a takeover effort. The Board may determine that the issuance of such shares of Preferred Stock is in the best interest of the Company and its stockholders. Such issuance could discourage a potential acquiror from making an unsolicited acquisition attempt through which such acquiror may be able to change the composition of the Board, including a tender offer or other transaction a majority of the Company&#8217;s stockholders might believe to be in their best interest or in which stockholders might receive a substantial premium for their stock over the then-current market price. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Advance Notice Requirements for Stockholder Proposals and Director Nominations </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The By-Laws provide that a stockholder seeking to bring business before an annual meeting of stockholders, or to nominate candidates for election as directors, must provide timely notice of such stockholder&#8217;s intention in writing. To be timely, a stockholder nominating individuals for election to the Board or proposing business must provide advanced notice to the Company not less than 60 days nor more than 90 days prior to the anniversary date of the prior year&#8217;s annual meeting of stockholders or, in the case of any special meeting, not less than 60 days nor more than 90 days prior to the special meeting, unless, in the case of annual meeting, such meeting occurs more than 30 days before or after such anniversary date, or, in the case of a special meeting, such meeting occurs less than 100 days after notice or public disclosure of the date of the special meeting is given or made, in which cases notice will be timely if received not later than the close of business on the tenth day after the day on which notice or public announcement of the date of such meeting was made. </font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Limits on Ability of Stockholders to Act by Written Consent </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Certificate of Incorporation provides that the stockholders may not act by written consent. In addition, the Certificate of Incorporation requires that special meetings of stockholders be called only by the Board, the Company&#8217;s chief executive officer, or the Company&#8217;s president if there is no chief executive officer. Further, business transacted at any special meeting of stockholders is limited to matters relating to the purpose or purposes stated in the notice of meeting. This limit on the ability of the Company&#8217;s stockholders to act by written consent or to call a special meeting may lengthen the amount of time required to take stockholder proposed actions. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Section 203 of the General Corporation Law of the State of Delaware </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company is subject to Section 203 of the Delaware General Corporation Law. This statute regulating corporate takeovers prohibits a Delaware corporation from engaging in any business combination with an interested stockholder for three years following the date that the stockholder became an interested stockholder, unless&#58; </font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder&#59; </font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;upon completion of the transaction that resulted in the interested stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (1) shares owned by persons who are directors and also officers, and (2) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer&#59; or </font></div><div style="padding-left:54pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2&#47;3% of the outstanding voting stock that is not owned by the interested stockholder.</font></div><div style="padding-left:54pt;text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Generally, a business combination includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. An interested stockholder is any person who, together with such person&#8217;s affiliates and associates (1) owns 15% or more of a corporation&#8217;s voting securities or (2) is an affiliate or associate of a corporation and was the owner of 15% or more of the corporation&#8217;s voting securities at any time within the three year period immediately preceding a business governed by Section 203. The existence of this provision may have an anti-takeover effect with respect to transactions the Board does not approve.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Listing</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company&#8217;s Common Stock is traded on The Nasdaq Global Select Market under the trading symbol &#8220;NVAX.&#8221;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.28
<SEQUENCE>3
<FILENAME>nvax-20231231xex1028.htm
<DESCRIPTION>EX-10.28
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ib5cbff86f46b47b981a8320fdf76068c_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.28</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CONSULTING AND ADVISORY AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This CONSULTING AND ADVISORY AGREEMENT (this &#34;Agreement&#34;) is entered into effect as of November 17, 2023, by and between Novavax, Inc., a Delaware corporation having its principal office at 700 Quince Orchard Road Gaithersburg MD 20878 (&#34;Novavax&#34; or the &#34;Company&#34;), and John A. Herrmann III, an individual (&#34;Executive&#34;).</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#202020;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, Executive is retiring from his employment with the Company as its Executive Vice President, Chief Legal Officer and Corporate Secretary (&#34;Retirement&#34;) effective as of December 8, 2023 (the &#34;Effective Date&#34;)&#59;</font></div><div style="text-align:justify"><font style="color:#202020;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#202020;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;WHEREAS, Executive has agreed to act as an advisor to the Company immediately following his Retirement&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#202020;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;WHEREAS, the Company and Executive desire to enter into this Agreement setting forth the terms of Executive's consulting and advisory relationship with the Company and certain other matters relating to his transition to an advisor role.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#202020;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements herein contained, the parties hereto agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:9pt;padding-right:5.7pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.5pt">Consulting Services. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive agrees to serve as a Senior Advisor for legal matters </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and to advise the Company's Chief Executive Officer (&#8220;CEO&#8221;) and Chief Legal Officer (&#8220;CLO&#8221;) and such other individuals, if any, as determined by Company's CEO from time to time regarding certain transition-related matters, including with respect to any matters including the Board of Directors (&#8220;BOD&#8221;), as well as to provide certain other consulting and advisory services relating to the Company's business as reasonably requested by the CEO and CLO from time to time (collectively, the &#34;Services&#34;). Executive agrees to devote an amount of time that is reasonably required to perform the Services. Nothing in this agreement will be construed to prevent or preclude Executive from working part-time or full-time for any other third party, provided Executive does not violate the terms of Section 6, herein below. The term of this Agreement will commence on the Effective Date and end on December 10, 2024, unless earlier terminated as provided herein (the &#34;Consulting Period&#34;). The Consulting Period may be extended by mutual written agreement of the parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="padding-left:31.5pt;padding-right:5.7pt;text-align:justify"><font><br></font></div><div style="padding-left:9pt;padding-right:5.7pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.5pt">Independent Contractor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Executive's relationship with the Company will be that of an independent contractor and not that of an employee. The CEO (and CLO as required) and Executive will jointly determine the method, details, and means of performing the Services. Executive will have no authority to enter into contracts that bind the Company or create obligations on the part of the Company without the prior written authorization of the Company. Executive acknowledges and agrees that he will not be eligible for any benefits available to employees of the Company other than as described in this Agreement. Services to be performed by Executive will be as agreed between Executive and the CEO and CLO, and Executive will be required to report only to the CEO or such other individuals, if any, as determined by the CEO from time to time, concerning the Services performed under this Agreement. The nature and frequency of these reports will be left to the discretion of the CEO. Executive will have full responsibility for applicable withholding taxes for all compensation paid to Executive under this Agreement and will have full responsibility for compliance with all applicable labor and employment requirements with respect to Executive's self-employment. Executive agrees to indemnify, defend, and hold the Company harmless from any liability for, or assessment of, any claims or penalties with respect to such withholding taxes, labor or employment requirements, including any liability for, or assessment of, withholding taxes imposed on the Company by the relevant taxing authorities with respect to any compensation paid to Executive in his capacity as a non-employee of the Company.</font></div><div style="padding-left:31.5pt;padding-right:5.7pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.28</font></div></div><div style="padding-left:9pt;padding-right:5.7pt;text-align:justify;text-indent:22.5pt"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.5pt">Compensation and Other Benefits.</font></div><div style="padding-left:10.55pt;padding-right:5.7pt;text-align:justify;text-indent:71.85pt"><font><br></font></div><div style="padding-left:9pt;padding-right:5.7pt;text-align:justify;text-indent:58.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.2pt">Consulting Fee. </font><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As compensation for the Services provided hereunder, during the Consulting Period, the Company will pay to Executive a consulting fee (the &#34;Consulting Fee&#34;) of $44,167.00 per month for the Consulting Period. The Consulting Fee will be paid to Executive on the first business day of each month during the Consulting Period, in arrears, and will be pro-rated for partial service.</font></div><div style="padding-left:67.5pt;padding-right:5.7pt;text-align:justify"><font><br></font></div><div style="padding-left:9pt;padding-right:5.7pt;text-align:justify;text-indent:58.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.52pt">Incentive payment. </font><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to the recommendation of the CEO and approval of the Compensation Committee of the BOD, the Executive will be eligible to receive a one-time payment in respect of the 2023 bonus the Executive would have been awarded if his employment had continued through the end of 2023, pro-rated to reflect the portion of the year during which the Executive served as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CLO and Corporate Secretary</font><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The p</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ayment will be calculated using a method consistent with that used for other Executives and will be made on the date the Company pays bonuses to its Executive team, but in any event no later than April 30, 2024.</font></div><div style="padding-left:10.55pt;padding-right:5.7pt;text-align:justify;text-indent:71.85pt"><font><br></font></div><div style="padding-left:9pt;padding-right:5.7pt;text-align:justify;text-indent:58.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.2pt">Equity Awards. </font><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Regarding stock options previously granted (and not yet exercised) to Executive by the Company as of the Effective Date (the &#34;Stock Options&#34;) and all outstanding and unvested restricted stock unit awards previously granted to Executive by the Company as of the Effective Date (the &#34;RSUs&#34;, and together with the Stock Options the &#34;Equity Awards&#34;). The Equity Awards will remain outstanding and each of the Equity Awards that is unvested as of the Effective Date will continue to vest for so long as Executive continues to provide the Services during the Consulting Period, in each case, in accordance with the terms of the applicable equity plan and the equity award agreement between Executive and the Company and subject to the provisions of this Agreement. Executive's &#34;Service&#34; (as defined in the applicable equity award agreements) solely for purposes of the Equity Awards shall be deemed to terminate, upon the end of the Consulting Period. For the avoidance of doubt, Executive's &#34;Service&#34; shall only be deemed to terminate prior to the end of the Consulting Period for purposes of the Equity Awards if this Agreement is terminated by the Company for &#34;Cause&#34; or Executive terminates this Agreement without &#34;Good Reason&#34;, as such terms are defined in Section 4 below. With respect to any Stock Options that remain outstanding and unexercised as of the last day of the Consulting Period, such Stock Options shall remain exercisable by Executive for a period of ninety (90) days thereafter.</font></div><div style="padding-left:67.5pt;padding-right:5.7pt;text-align:justify"><font><br></font></div><div style="padding-left:9pt;padding-right:5.7pt;text-align:justify;text-indent:58.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.52pt">Reimbursable Expenses. </font><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive shall be entitled to reimbursement for reasonable expenses incurred by him in connection with the performance of the Services in accordance with the applicable policies and procedures of the Company as in effect from time to time.</font></div><div style="padding-left:10.55pt;padding-right:5.7pt;text-align:justify;text-indent:71.85pt"><font><br></font></div><div style="padding-left:36pt;padding-right:5.7pt;text-align:justify;text-indent:-18pt"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">Termination.</font></div><div style="padding-left:72pt;padding-right:5.7pt;text-align:justify"><font><br></font></div><div style="padding-left:9pt;padding-right:5.7pt;text-align:justify;text-indent:40.5pt"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.2pt">&#160;&#160;&#160;&#160;The Company may terminate this Agreement at any time for Cause (as defined below) upon giving thirty (30) days' advance written notice of such termination to Executive. This Agreement may be terminated at any time without Cause (as defined below) by mutual written agreement of the parties and Executive may terminate this Agreement at any time, with or without Good Reason (as defined below) upon giving thirty (30) days' advance written notice of such termination to the Company. Except as set forth in Section 5 below, in the event of a termination of this Agreement, the Company's only obligation will be to pay Executive any earned but unpaid Consulting Fee as of the termination date.</font></div><div style="padding-left:49.5pt;padding-right:5.7pt;text-align:justify"><font><br></font></div><div style="padding-left:9pt;padding-right:5.7pt;text-align:justify;text-indent:40.5pt"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.52pt">&#160;&#160;&#160;&#160;For purposes of this Agreement, &#34;Cause&#34; and &#34;Good Reason&#34; shall be defined as follows&#58;</font></div><div style="padding-left:49.5pt;padding-right:5.7pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.28</font></div></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#34;Cause&#34; shall be limited to Executive's willful refusal or failure to perform his material obligations hereunder (other than due to illness, death, or disability) that is not cured within thirty (30) days of Executive's receipt of written notice from the Company containing reasonable specificity of such refusal or failure and a statement of corrective actions.</font></div><div style="padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#34;Good Reason&#34; shall be limited to the Company's material breach of this Agreement that is not cured within thirty (30) days of the Company's receipt of written notice from</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive identifying such breach with reasonable specificity.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:4.5pt;padding-right:5.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.5pt">Effect of Termination. </font><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If this Agreement is terminated by the Company without Cause or by Executive with Good Reason, in each case prior to the expiration of the Consulting Period (but not, for the avoidance of doubt, during any extension of the Consulting Period, if applicable), the Company will pay Executive, in a 1ump sum payment, the amount of unpaid Consulting Fees, if any, that would otherwise be payable from the date of termination through December 31, 2024. For the avoidance of doubt, Executive&#8217;s &#8220;Service&#8221; for purposes of Section 3(c) of this Agreement and the Equity Awards shall be deemed to continue through December 10, 2024.</font></div><div style="padding-left:27pt;padding-right:5.7pt;text-align:justify"><font><br></font></div><div style="padding-left:4.5pt;padding-right:5.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.5pt">Restrictive Covenants</font><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="padding-left:10.55pt;padding-right:5.7pt;text-align:justify;text-indent:71.85pt"><font><br></font></div><div style="padding-left:4.5pt;padding-right:5.7pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:4.7pt">&#160;&#160;&#160;&#160;Continuing Obligations. </font><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive acknowledges and agrees that he remains bound by certain obligations under the Employment Agreement between the Company and Executive dated April 1, 2012, as amended (the &#34;Employment Agreement&#34;), which survive the termination of his employment by the terms thereof, which including without limitation his obligations under Sections 9-12 of the Employment Agreement (such obligations, together with any other covenant or obligations with respect to confidentiality, assignment of intellectual property, non-solicitation or noncompetition, the &#34;Continuing Obligations&#34;). The Company agrees to limit the extent of the Executives Non-Competition obligations to cover businesses and entities that compete directly with the Company.</font></div><div style="padding-left:54pt;padding-right:5.7pt;text-align:justify"><font><br></font></div><div style="padding-left:4.5pt;padding-right:5.7pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:4.02pt">&#160;&#160;&#160;&#160;Confidentiality. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive hereby reaffirms and agrees to comply with the policies and procedures of the Company and its affiliates for protecting confidential information (as described in Section 10 of the Employment Agreement) and will never disclose to any person (except as required by applicable law or for the proper performance of his duties and responsibilities to the Company and its affiliates), or use for his own benefit or gain, any confidential information obtained by Executive incident to his employment or other association with the Company or any of its affiliates. Executive understands that this restriction will continue to apply after the termination of this Agreement, regardless of the reason for such termination. For the avoidance of doubt, (i) nothing contained in this Agreement limits, restricts or in any other way affects </font><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Executive&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">communicating with any governmental agency or entity, or communicating with any official or staff person of a governmental agency or entity, concerning matters relevant to such governmental agency or entity and (ii) Executive will not be held criminally or civilly liable under any federal or state trade secret law for disclosing a trade secret(y) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, solely for the purpose of reporting or investigating a suspected violation of law, or (z) in a complaint or other document filed under seal in a lawsuit or other proceeding&#59; provided, however, that notwithstanding this immunity from liability, Executive may be held liable if he unlawfully accesses trade secrets by unauthorized mean</font><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s.</font></div><div style="padding-left:54pt;padding-right:5.7pt;text-align:justify"><font><br></font></div><div style="padding-left:4.5pt;padding-right:5.7pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:4.7pt">      Non-Compete and Non-Solicit. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limiting the generality of subsection (a) above, Executive acknowledges and agrees that he continues </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be bound by each of his undertakings under Sections 11 and 12 of the Employment Agreement, with the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.28</font></div></div><div style="padding-left:4.5pt;padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">post- employment portion of the Non-Competition Period, as defined in the Employment Agreement, commencing on the Effective Dat</font><font style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font></div><div style="padding-left:10.55pt;padding-right:5.7pt;text-align:justify;text-indent:71.85pt"><font><br></font></div><div style="padding-left:4.5pt;padding-right:5.7pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:4.02pt">              Remedies&#59; Enforceability. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If Executive commits a breach, or threatens to commit a breach, of any of the provisions of this Section 6, the Company shall have the right and remedy to have the provisions of this Agreement specifically enforced by any court having equity jurisdiction, it being acknowledged and agreed that any such breach or threatened breach will cause irreparable injury to the Company and that money damages may not provide an adequate </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">remedy to the Company. Executive therefore agrees that the Company, in addition to any other remedies available to it, shall be entitled to preliminary and permanent injunctive relief against any breach or threatened breach by Executive of any of the provisions of this Section 6, without having to post bond. If any of the covenants contained in this Section 6, or any part thereof, is hereafter construed to be invalid or unenforceable, the same shall not affect the remainder of the covenant or covenants, which shall be given full effect without regard to the invalid portions. If any of the covenants contained in this Section 6, or any part thereof, is held to be unenforceable because of the duration or scope of such provision or the area covered thereby, the parties agree that the court making such determination shall have the power to reduce the duration and&#47;or area of such provision and, in its reduced form, such provision shall then be enforceable. In the event that the courts of any one or more of such states shall hold any such covenant wholly unenforceable by reason of the breadth of such scope or otherwise, it is the intention of the parties hereto that such determination not bar or in any way affect the Company&#8217;s right to the relief provided above in the courts of any other states within the  geographical scope of such other covenants, as to breaches of such covenants in such other respective jurisdictions, the above covenants as they relate to each state being, for this purpose, severable into diverse and independent covenants.</font></div><div style="padding-right:5.7pt;text-align:justify;text-indent:67.5pt"><font><br></font></div><div style="padding-left:4.5pt;padding-right:5.7pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:4.7pt">&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securities Trading&#59; Conflicts of Interest. </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive further agrees that he will not buy, sell, or otherwise trade any securities of Novavax based on any material confidential information (as described in Section 10 of the Employment Agreement) learned as a consultant of Novavax, or tip others to do so. If Executive is ever unsure about Executive&#8217;s compliance with this Section 6(e), Executive shall contact the Company&#8217;s Executive Vice President, CLO and Corporate Secretary. Executive further agrees that during the Consulting Period (and any extension of the Consulting Period, if applicable) he will continue to comply with all Company policies and processes related to insider trading and stock clearance and with the Company's Conflicts of interest and Outside Activities Policy.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:4.5pt;padding-right:5.7pt;text-align:justify;text-indent:49.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">&#160;&#160;&#160;&#160;Section 409A of the Code. </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement is intended to comply with, or be exempt from, the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the &#34;Code&#34;), and shall be construed consistent with such intent. Notwithstanding the foregoing, in no event shall the Company have any liability relating to the failure or alleged failure of any payment or benefit under this Agreement to comply with, or be exempt from, the requirements of Section 409A of the Code. Executive's right to payment or reimbursement for expenses under this Agreement will be subject to the following additional rules&#58; (i) the amount of expenses eligible for payment or reimbursement during any calendar year shall not affect the expenses eligible for payment or reimbursement in any other calendar year, (ii) payment or reimbursement shall be made promptly, and in all events not later than December 31 of the calendar year following the calendar year in which the expense or payment was incurred, and (iii) the right to payment or reimbursement is not subject to liquidation or exchange for any other benefit.</font></div><div style="padding-left:18pt;padding-right:5.7pt;text-align:justify"><font><br></font></div><div style="padding-left:4.5pt;padding-right:5.7pt;text-align:justify;text-indent:45pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:13.5pt">Miscellaneous.</font></div><div style="padding-left:10.55pt;padding-right:5.7pt;text-align:justify;text-indent:71.85pt"><font><br></font></div><div style="padding-left:4.5pt;padding-right:5.7pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:4.7pt">&#160;&#160;&#160;&#160;No Severance. </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive acknowledges and agrees that except as expressly provided in this Agreement, he is not eligible for any severance benefits in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.28</font></div></div><div style="padding-left:4.5pt;padding-right:5.7pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">connection with or following his Retirement, including but not limited to under the Company's Amended and Restated Change in Control Severance Benefit Plan.</font></div><div style="padding-left:54pt;padding-right:5.7pt;text-align:justify"><font><br></font></div><div style="padding-left:4.5pt;padding-right:5.7pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:4.02pt">Entire Agreement. </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement constitutes the sole agreement of the parties and supersedes all oral negotiations and prior writings with respect to the subject matter hereof&#59; it being understood that the Continuing Obligations and the plans and agreements </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">governing the Equity Awards will remain outstanding and will survive in accordance with their terms.</font></div><div style="padding-left:10.55pt;padding-right:5.7pt;text-align:justify;text-indent:71.85pt"><font><br></font></div><div style="padding-left:4.5pt;padding-right:5.7pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:4.7pt">Amendments and Waivers. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any term of this Agreement may be amended or waived only with the written consent of the parties.</font></div><div style="padding-left:10.55pt;padding-right:5.7pt;text-align:justify;text-indent:71.85pt"><font><br></font></div><div style="padding-left:4.5pt;padding-right:5.7pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:4.02pt">Choice of Law. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The validity, interpretation, construction, and performance of this Agreement will be governed by the laws of the State of Maryland, without giving effect to the principles of conflict of laws.</font></div><div style="padding-left:10.55pt;padding-right:5.7pt;text-align:justify;text-indent:71.85pt"><font><br></font></div><div style="padding-left:4.5pt;padding-right:5.7pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:4.7pt">Severability. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If one or more provisions of this Agreement are held to be unenforceable under applicable law, such portion will be deemed to be modified or altered to the extent necessary to conform thereto or, if that is not possible, to be omitted from this Agreement. The invalidity of any such portion will not affect the force, effect, and validity of the remaining portion hereof.</font></div><div style="padding-left:10.55pt;padding-right:5.7pt;text-align:justify;text-indent:71.85pt"><font><br></font></div><div style="padding-left:4.5pt;padding-right:5.7pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:6.03pt">Counterparts. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement may be executed in counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument.</font></div><div style="padding-left:10.55pt;padding-right:5.7pt;text-align:justify;text-indent:71.85pt"><font><br></font></div><div style="padding-left:4.5pt;padding-right:5.7pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:4.02pt">Successors. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement is personal to Executive and, without the prior written consent of the Company, will not be assignable by Executive otherwise than by will or the laws of descent and distribution. This Agreement will inure to the benefit of and be enforceable by Executive's legal representatives. This Agreement will inure to the benefit of and be binding upon the Company and its successors and assigns. As used in this Agreement, &#34;the Company&#34; will mean both the Company as defined above and any such successor assign to or of the Company. The Company shall require that any successor or assign agree to perform this Agreement in the same manner as the Company.</font></div><div style="padding-left:10.55pt;padding-right:5.7pt;text-align:justify;text-indent:71.85pt"><font><br></font></div><div style="padding-left:4.5pt;padding-right:5.7pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:4.02pt">No Publicity. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Neither the Company nor Executive shall directly or indirectly cause or permit any use of the other party's name or trademarks, without the other party's prior written consent, save and except as such disclosure is required by law or any securities exchange or governmental body to which either party is subject or submits, wherever situated, including (without limitation) the Securities and Exchange Commission, The NASDAQ OMX Group, or the Food and Drug Administration whether or not the requirement has the force of law.</font></div><div style="padding-left:10.55pt;padding-right:5.7pt;text-align:justify;text-indent:71.85pt"><font><br></font></div><div style="padding-left:4.5pt;padding-right:5.7pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:6.69pt">Sunshine Act. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each of the Company and Executive acknowledge that certain state or federal laws now or in the future may require Novavax to disclose information regarding compensation, funding, gifts, payments, or other remuneration (&#34;Remuneration&#34;) provided to physicians and other members of the health care community. Novavax may report information about Remuneration provided under this Agreement as required by applicable law. Once reported, such information will be publicly accessible.</font></div><div style="padding-left:10.55pt;padding-right:5.7pt;text-align:justify;text-indent:71.85pt"><font><br></font></div><div style="padding-left:4.5pt;padding-right:5.7pt;text-align:justify;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">Advice of Counsel. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EACH PARTY ACKNOWLEDGES THAT, IN EXECUTING THIS AGREEMENT, SUCH PARTY HAS HAD THE OPPORTUNITY TO SEEK THE ADVICE OF INDEPENDENT LEGAL COUNSEL AND HAS READ AND UNDERSTOOD ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT. THIS AGREEMENT </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.28</font></div></div><div style="padding-left:4.5pt;padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SHALL NOT BE CONSTRUED AGAINST ANY PARTY BY REASON OF THE DRAFTING OR PREPARATION HEREOF.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:157.25pt"><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Remainder of page intentionally left blank.&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.28</font></div></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:12.25pt;padding-right:8.35pt;text-indent:35.6pt"><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">This Agreement has been executed as a sealed instrument by the Company, by its duly authorized representative, and by Executive.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:264.05pt"><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOVAVAX, INC.</font></div><div style="margin-top:11pt"><font><br></font></div><div style="padding-left:264.05pt"><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">   &#47;s&#47; Ian Watkins                  </font></div><div style="padding-left:264.05pt"><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Ian Watkins</font></div><div style="padding-left:294.3pt;padding-right:8.35pt;text-indent:-30.25pt"><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">Title&#58; Executive Vice President &#38; Chief Human Resources Officer</font></div><div style="margin-top:13.75pt;padding-left:261.05pt"><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; November 17, 2023</font></div><div style="margin-top:13.75pt;padding-left:261.05pt"><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">JOHN A. HERRMANN III</font></div><div style="margin-top:13.75pt;padding-left:261.05pt"><font><br></font></div><div style="padding-left:261.35pt"><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">     &#47;s&#47; John A. Herrmann III             </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:264.3pt"><font><br></font></div><div style="padding-left:252pt"><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">     Address&#58;&#91; *** &#93;</font></div><div style="margin-top:2.8pt;padding-left:264.3pt;padding-right:33.95pt"><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:152%"> Date&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:152%">17-Nov-23 &#124; 11&#58;59 PST</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.32
<SEQUENCE>4
<FILENAME>nvax-20231231xex1032.htm
<DESCRIPTION>EX-10.32
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i50c3bd65bcfe4358ad4d50196058111b_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.7pt;padding-left:8.15pt;text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.32</font></div><div style="margin-top:4.7pt;padding-left:8.15pt"><img alt="image.jpg" src="image.jpg" style="height:151px;margin-bottom:5pt;vertical-align:text-bottom;width:294px"></div><div style="margin-top:4.7pt;padding-left:8.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Mark Casey</font></div><div style="margin-top:0.5pt;padding-left:7.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive Vice President Chief Legal Officer &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;November 17, 2023</font></div><div style="margin-top:0.5pt;padding-left:7.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-top:0.5pt;padding-left:7.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="padding-left:7.15pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dear Mark.</font></div><div style="margin-top:3.3pt"><font><br></font></div><div style="padding-left:6.8pt;padding-right:39.75pt;text-align:justify;text-indent:0.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:131%">I am pleased to offer you the full-time position of (title) at Novavax. Inc In this position you will report John </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:131%">C </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:131%">Jacobs. President &#38; Chief Executive Officer Your first day of employment is expected to be on or about December 11, 2023</font></div><div style="margin-top:11.8pt;padding-left:6.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This offer is contingent upon the following&#58;</font></div><div style="margin-top:11.8pt;padding-left:39.8pt;padding-right:40.2pt;text-align:justify;text-indent:-16.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.7pt">Successful and satisfactory completion of our standard background check All information provided by you in your employment application. interviews. and any other verbal or written correspondence will be verified by a third-party background checking company or by Novavax. Any discrepancies found may delay your start date or could potentially cause withdrawal of this offer. Candidates cannot begin employment until the background check is completed, including verification of current employment.</font></div><div style="margin-top:1.85pt;padding-left:39.35pt;padding-right:40.95pt;text-align:justify;text-indent:-16.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:111%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:111%;padding-left:12.25pt">Your assurance that there </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:111%">are </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:111%">no contractual or other obligations owed by you to previous employers or other parties that would in any way limit your ability to perform your job at the Company. If there are any obligations that might limit your ability to perform, such matters must be disclosed and resolved prior to commencement of employment.</font></div><div style="margin-top:1.05pt;padding-left:38.9pt;padding-right:54.65pt;text-align:justify;text-indent:-16.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:114%;padding-left:12.25pt">&#160;&#160;&#160;&#160;Compliance with the Novavax COVID-19 Vaccination Policy for US Employees. which may include providing proof of vaccination at the time you begin working or requesting an accommodation or exemption. A copy of the policy is attached for your review. If you need an accommodation or believe you are exempt due </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:114%">to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:114%">applicable state law, please email our Benefits Team at </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:114%;text-decoration:underline">NovavaxBenefits&#64;novavax.com.</font></div><div style="margin-top:1.55pt;padding-left:40.65pt;padding-right:40.75pt;text-align:justify;text-indent:-16.35pt"><font style="color:#1f2a36;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.68pt">Execution of the Employment Agreement and the Company's Non-Disclosure. Invention Assignment. Non-Solicitation and Non-Compete Agreement. a copy of which is enclosed for your review Successful verification of your employment eligibility in the United States. In order to verify this information, please be prepared to produce acceptable documents. BY FEDERAL LAW, IT IS REQUIRED THAT YOU PRESENT THIS DOCUMENTATION WITHIN THREE DAYS OF YOUR START AT WORK.</font></div><div style="margin-top:6.9pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:7.35pt;padding-right:23.45pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:102%">The specific terms of this offer are outlined in the enclosed Employment Agreement, and include the following&#58;</font></div><div style="margin-top:8.75pt"><font><br></font></div><div style="padding-left:6.85pt;padding-right:26.5pt;text-indent:-0.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:130%;text-decoration:underline">SALARY</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#58; Your initial annualized base salary will be $550,000 per year, payable semi-monthly, less applicable payroll taxes. and authorized deductions.</font></div><div style="margin-top:2.25pt"><font><br></font></div><div style="padding-left:6.25pt;padding-right:40.1pt;text-align:justify;text-indent:0.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:135%;text-decoration:underline">BONUS PROGRAM&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:135%"> You will be eligible to participate in the Company's annual incentive bonus program beginning in 2023, under which award payments. if any, will be based on performance criteria and milestones to be determined by the Company. and you will be paid (by March 31) in the following year in which the compensation is earned. Your bonus at 100% of target will be 50% of your actual salary earned for the performance year and will be prorated your first year of employment based on your hire date.</font></div><div style="margin-top:1.8pt"><font><br></font></div><div style="padding-left:5.75pt;padding-right:40.55pt;text-align:justify;text-indent:0.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:137%;text-decoration:underline">ONE TIME SIGNING BONUS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:137%">&#58; You are eligible to receive a one-time signing bonus of $94,000. which will be paid within the first 30 days of commencement of your employment with the company. The signing bonus will be paid on a regularly scheduled pay date (subject to applicable withholdings and deductions). You agree that in the event (i) you resign from the company before you have completed twelve (12) full months of service, or (ii) the Company terminates your employment for any reason other than a reduction in force before you have completed twelve (12) full months of service. you will then. within seven (7) days of such resignation or termination. refund the Company the gross amount of the signing bonus paid hereunder, however, the repayment will be reduced by 25% for each 3 month period of service completed</font></div><div style="padding-left:5.75pt;padding-right:40.55pt;text-align:justify;text-indent:0.3pt"><font><br></font></div><div style="padding-left:5.75pt;padding-right:40.55pt;text-align:justify;text-indent:0.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:137%;text-decoration:underline">COMMUTING ALLOWANCE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:137%">&#58; The Company will provide a monthly commuting allowance of $6000 for the cost of housing and other related commuting expenses incurred by you to commute between your home in &#91;***&#93;. and the Company's Gaithersburg offices (the &#34;Allowance'). In addition, the Company will pay an additional sum to reimburse you for the personal income taxes associated with the Allowance such that the economic benefit is the same as if such Allowance were provided on a non-taxable basis. It is expected that when you are not on company business travel, you will be in the Gaithersburg, MD office a majority of your time.</font></div><div style="margin-top:3.6pt;padding-right:36pt"><font><br></font></div><div style="padding-left:6.25pt;padding-right:39.85pt;text-align:justify;text-indent:0.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:135%;text-decoration:underline">EMPLOYEE EQUITY PLAN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:135%">&#58; As an employee, you will participate in the Employee Equity Plan C Plan') established from time to time by the Board of Directors. The objective of the Plan is to allow employees and other stakeholders to build an equity stake in the Company and thereby participate directly in the Company's long-term success. Following hiring grants. equity is generally granted to all employees annually in the first calendar quarter following the end of the calendar year First year grants are typically pro-rated for actual time employed.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.95pt;padding-left:22.9pt;padding-right:40.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:135%;text-decoration:underline">STOCK OPTIONS&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:135%"> Upon approval by the Board of Directors or your employment start date (whichever is later) you will receive an initial stock option grant of 144,694 shares of Company common stock, at an exercise price equal to fair market value on the date the options are granted. These stock options are subject to plan limits within the 2015 Stock Option Plan and will vest 25% after the first year from the date of grant and monthly thereafter for the following 36 months. The options will be non-qualified stock options to the extent permitted by law and our plan.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:22.6pt;padding-right:40.8pt;text-align:justify;text-indent:0.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:137%;text-decoration:underline">RESTRICTED STOCK UNITS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:137%">&#58; Subject to approval by the Company's Board of Directors and plan limits within the 2015 Stock Option Plan. you will be granted 125.698 restricted stock units('RSUs'). You will be restricted from any activity (selling or transferring) in such RSUs until vested&#59; RSUs will vest in three years. one-third per year on the anniversary of the date of grant. You will be responsible for all taxes owed on such Stock as of the date of vesting, and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:137%">Novavax </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:137%">will be entitled to sell sufficient stock to address any tax withholdings as further specified in an RSU Agreement between you and the Company.</font></div><div style="padding-left:22.6pt;padding-right:40.8pt;text-align:justify;text-indent:0.45pt"><font><br></font></div><div style="padding-left:22.6pt;padding-right:40.8pt;text-align:justify;text-indent:0.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:137%">Your employment and compensation with </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:137%">Novavax </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:137%">are &#183;at will' At will employment is defined as an employee&#47;employer relationship which may be ended by either the employee or employer at any time, without cause. except as otherwise provided by law or defined in the terms of the Employment Agreement.</font></div><div style="padding-left:22.6pt;padding-right:40.8pt;text-align:justify;text-indent:0.45pt"><font><br></font></div><div style="padding-left:22.6pt;padding-right:40.8pt;text-align:justify;text-indent:0.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:137%">Mark, if you agree with and accept the terms of this offer letter and the Employment Agreement. please sign below and return this letter and the Employment Agreement to my office. We are confident your employment with Novavax will prove mutually beneficial and we look forward to you joining the Novavax team.</font></div><div style="margin-top:6.55pt;padding-left:5.4pt;padding-right:25.6pt;text-align:justify;text-indent:0.35pt"><font><br></font></div><div style="margin-top:6.55pt;padding-left:5.4pt;padding-right:25.6pt;text-align:justify;text-indent:0.35pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Sincerely,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accepted by&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Ian Watkins                   </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Mark Casey</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_____</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">             </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Ian Watkins &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Mark Casey</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Executive Vice President&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Chief Human Resources Officer</font></div><div style="margin-top:6.55pt;padding-left:5.4pt;padding-right:25.6pt;text-align:justify;text-indent:0.35pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33
<SEQUENCE>5
<FILENAME>nvax-20231231xex1033.htm
<DESCRIPTION>EX-10.33
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="iacf98d69acef48ea93cd705c955fdfe7_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:80%">d</font></div></div><div style="margin-top:9.35pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.33</font></div><div style="padding-left:10.42pt;padding-right:10.42pt;text-align:center"><font style="color:#262826;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EMPLOYMENT AGREEMENT</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This</font><font style="color:#262826;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Employment Agreement (&#34;Agreement&#34;) is dated as of </font><font style="color:#262826;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">November 17, 2023, </font><font style="color:#262826;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">between Novavax, Inc., (''Novavax&#34; or the &#34;Company&#34;) a Delaware corporation having its principal office at 700Quince Orchard Road, Gaithersburg, MD20878, and Mark</font><font style="color:#262826;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#262826;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Casey, an individual residing at &#91;***&#93; (&#34;Executive&#34;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;In</font><font style="color:#262826;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> consideration of the mutual promises and covenants set forth herein and other good and valuable consideration the sufficiency of which is hereby acknowledged, Company and Executive agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">&#160;&#160;&#160;&#160;Employment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company will employ Executive as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Executive Vice President </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#38; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Chief Legal Officer </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">upon the terms and conditions hereinafter set forth, effective as of December 11, 2023. As used throughout this Agreement, &#34;Company&#34; shall mean and include any and all of its present and future subsidiaries and any and all subsidiaries of a subsidiary. Executive warrants and represents that he is free to enter into and perform this Agreement. Executive has disclosed to the Company all employment, confidentiality, non-competition, or other agreements which purport to restrict or otherwise prohibit his ability to provide services to or accept employment with the Company.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">&#160;&#160;&#160;&#160;Duties. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">During the Term (as hereinafter defined), Executive shall devote his full business time to the performance of services as Executive Vice President, Chief Legal Officer of Novavax, performing such services, assuming such duties and responsibilities as prescribed by the Company's President and CEO (&#34;CEO) and the Company's Board of Directors. During the Term, Executive's services shall be completely exclusive to the Company</font><font style="color:#5b5d5b;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and he shall devote his entire business time, attention and energies to the business of the Company and the duties which the Company shall assign to him from time to time. Executive agrees to perform his services faithfully and to the best of his ability and to carry out the policies and directives of the Company. Executive may seek prior written permission from the CEO to serve as a director of any company whose products do not compete with those of the Company or to serve as a director, trustee, officer</font><font style="color:#444946;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or consultant to a charitable or non-profit entity&#59; provided in any case that such service does not adversely affect Executive's ability to perform his obligations hereunder and comply with the Company's Conflict of Interest Policy. Executive agrees not to take action that is in bad faith and prejudicial to the interests of the Company during his employment hereunder. Notwithstanding the location where Executive shall be based, as set forth in this Agreement, he also may be required from time to time to perform duties hereunder for reasonably short periods of time outside of said area.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">&#160;&#160;&#160;&#160;Term. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The term of this Agreement shall be the period of time beginning on the Executive's first date of employment as Executive Vice President &#38; Chief Legal Officer and shall continue for so long as Executive shall be an at-will employee of the Company hereunder.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Compensation.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:5.8pt">&#160;&#160;&#160;&#160;Base Compensation. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For all Executive's services and covenants under this Agreement, the Company shall pay Executive an annual salary, which is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$550,000 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as of the effective date of this Agreement, as established or ratified by the Board of Directors or an authorized committee thereof(in accordance with established management processes), and payable in accordance with the Company's payroll policy as constituted from time to time. The Company may withhold from any amounts payable under this Agreement all required federal, state, city or other taxes and all other deductions as may be required pursuant to any law or government regulation or ruling.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:5.18pt">&#160;&#160;&#160;&#160;Bonus Program. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company agrees to pay the Executive a performance</font><font style="color:#2b2d2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and incentive bonus in respect of Executive's employment with the Company each year in an amount determined by the CEO and Board of Directors (or any committee of the Board of Directors authorized to make that determination)to be appropriate based upon Executive's, and the Company's</font><font style="color:#484b48;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#2b2d2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">achievement of certain specified goals, with a target bonus of 50%, or any other percentage determined by the Board of Directors, of Executive's base earnings during the year to which the bonus relates. The bonus shall be paid out partly in cash and partly in shares of stock options or restricted stock, at the discretion of the Board of Directors and shall be prorated for the first year of employment based on hire date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:80%">d</font></div></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#2b2d2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">&#160;&#160;&#160;&#160;Reimbursable Expenses. </font><font style="color:#2b2d2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive shall be entitled to reimbursement for reasonable expenses incurred by him in connection with the performance of his duties hereunder in accordance with such procedures and policies for executive officers as the Company has heretofore or may hereafter establish. The amount of expenses eligible for reimbursement during any calendar year shall not affect the expenses eligible for reimbursement in another calendar year, and the reimbursement of an eligible expense shall be made as soon as practicable after Executive submits the request for reimbursement but not later than December 31 following the calendar year in which the expense was incurred. In addition, Executive shall receive a monthly commuting allowance of up to </font><font style="color:#2b2d2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$6,000 </font><font style="color:#2b2d2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">to cover the costs of housing and other related commuting expenses incurred by Executive to commute from his personal residence in Rhode Island to the Company&#8217;s offices in Gaithersburg, Maryland. &#34;). In addition, the Company will pay an additional sum to reimburse you for the personal income taxes associated with the Allowance such that the economic benefit is the same as if such Allowance were provided on a non-taxable basis. It is expected that when you are not on company business travel, you will be in the Gaithersburg, MD office a majority of your time. The Company shall also reimburse Executive for all reasonable legal fees actually incurred by Executive in the negotiation and review of this Agreement, in an amount not to exceed </font><font style="color:#2b2d2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$10,000.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font><font style="color:#2b2d2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">&#160;&#160;&#160;&#160;Benefits.</font></div><div style="margin-top:1.15pt"><font><br></font></div><div style="margin-top:0.4pt;padding-left:11pt;padding-right:7.45pt;text-align:justify;text-indent:66.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%">(a)</font><font style="color:#2b2d2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%;padding-left:18.4pt">Executive shall be entitled to four weeks of paid vacation time per year starting from the date of commencement of employment, calculated and administered in accordance with Company policies for executive officers in effect from timelotem. The Executive shall be entitled to all other benefits associated with normal full-time employment in accordance with Company policies.</font></div><div style="margin-top:0.4pt;padding-left:77.4pt;padding-right:7.45pt;text-align:justify"><font><br></font></div><div style="margin-top:0.4pt;padding-left:11pt;padding-right:7.45pt;text-align:justify;text-indent:66.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%">(b)</font><font style="color:#2b2d2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%;padding-left:17.78pt">Subject to approval by the Board of Directors (or any committee of the Board of Directors authorized to make that determination)</font><font style="color:#484b48;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%">, </font><font style="color:#2b2d2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%">Executive shall be entitled to participate in the Company Amended and Restated Change in Control Severance Benefit Plan adopted on August I 0, 2005, amended restated on July 26, 2006andas further amended on December 31, 2008, June 15, 2011 and June 17, 2021 (the &#34;Change in Control Severance Benefit Plan&#34;).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-top:0.4pt;padding-right:7.45pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%">7.</font><font style="color:#2b2d2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:111%;padding-left:27.75pt">Termination of Employment</font></div><div style="margin-top:9.5pt;padding-left:4.5pt;padding-right:10.2pt;text-align:right;text-indent:36pt"><font style="color:#2b2d2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%">(a)</font><font style="color:#2b2d2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%;padding-left:19.3pt">Notwithstanding any other prov1s1on of this Agreement, Executive's employment may be terminated, without such action constituting a breach of this Agreement&#58;</font></div><div style="margin-top:10.6pt;padding-left:141.1pt;text-indent:-32.9pt"><font style="color:#2b2d2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#2b2d2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.53pt">By the Company, for &#34;Cause,&#34; as defined in Section 7(b) below&#59;</font></div><div style="margin-top:7.3pt;padding-left:12.25pt;padding-right:41.95pt;text-indent:98.2pt"><font style="color:#2b2f2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:106%">(ii)</font><font style="color:#2b2d2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:106%;padding-left:20.13pt">By the Company, without Cause&#59;</font></div><div style="padding-left:108pt;padding-right:41.95pt;text-align:right"><font><br></font></div><div style="padding-right:41.95pt;text-align:justify;text-indent:108pt"><font style="color:#2b2f2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#2b2d2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">By the Company, upon 30 days' notice to Executive, if he should be pre</font><font style="color:#484b48;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">v</font><font style="color:#2b2d2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ented by illness, accident, or other disability (mental or physical) from discharging his duties hereunder for one or more periods totaling three consecutive months during any twelve-month period&#59; </font></div><div style="padding-left:12.25pt;padding-right:41.95pt;text-align:justify"><font><br></font></div><div style="padding-left:12.25pt;padding-right:41.95pt;text-indent:95.75pt"><font style="color:#2b2f2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#2b2f2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">By the Executive with &#34;Good Reason&#34;, as defined in Section 7(c) below, within 30 days of the occurrence or commencement of such Good Reason</font></div><div style="padding-left:12.25pt;padding-right:41.95pt;text-align:justify"><font><br></font></div><div style="padding-left:4.5pt;padding-right:41.95pt;text-indent:103.5pt"><font style="color:#2b2f2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)</font><font style="color:#2b2f2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">By the Executive without Good Reason upon 30 days prior written notice&#59;</font></div><div style="padding-left:10.9pt"><font><br></font></div><div style="padding-left:10.9pt"><font style="color:#2b2f2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or</font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#2b2f2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#2b2f2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">By the event of Executive's death during the Term.</font></div><div><font><br></font></div><div style="padding-right:41.85pt;text-align:justify;text-indent:72.85pt"><font style="color:#2b2f2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(b)</font><font style="color:#2b2f2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:23.18pt">&#34;Cause&#34; shall mean (i) Executive's failure or refusal to perform in all material respects the services required of his hereby,(ii) if, in connection with any prior </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:80%">d</font></div></div><div style="padding-right:41.85pt;text-align:justify"><font style="color:#2b2f2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">agreement between Executive and a third-party, Executive is precluded from providing services to the Company and fulfilling his duties, as set forth in Section 2 of this Agreement, for a period of more than 3 consecutive months&#59; (iii) Executive's failure or refusal to cany out any proper and material direction by the CEO or the Board of Directors with respect to the services to be rendered by him hereunder or the manner of rendering such services,(iv) Executive's misconduct in the performance of bis duties hereunder, (v) Executive's commission of an act of fraud, embezzlement or theft or a felony involving moral turpitude, (vi)Executive's use or disclosure of confidential information (as defined in Section 10 of this Agreement), other than for the benefit of the Company in the course of rendering services to the Company, or (vii) Executive's engagement in any activity prohibited by Section 11 or 12 of this Agreement. For purposes of this Section 7, the Company shall be required to provide Executive a specific written warning with regard to any occurrence of subsections (b)(i),(iii)and (iv)above, which warning shall include a statement of corrective actions and a 30-day period for the Executive to respond to and implement such actions, prior to any termination of employment by the Company pursuant to Section 7(a)(i) above.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-right:42.45pt;text-align:justify;text-indent:72.85pt"><font style="color:#2b2f2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">(c)</font><font style="color:#2b2f2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%;padding-left:23.8pt">&#34;Good Reason&#34; shall mean(a)the Company's material reduction or diminution of Executive's responsibilities and authority, other than for Cause, without his consent or (b) the relocation of Executive's primary place of employment without his consent.</font></div><div style="margin-top:11pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#2b2f2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#2b2f2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">&#160;&#160;&#160;&#160;</font><font style="color:#2b2f2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Separation Pay.</font></div><div style="padding-right:36pt;text-align:justify"><font><br></font></div><div style="padding-right:36pt;text-align:justify;text-indent:72.7pt"><font style="color:#2b2f2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#2b2f2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Subject to the Executive's execution and delivery to the Company of the Company's standing fonn of Separation and Release Agreement, the Company shall pay Executive with the Separation Payas defined herein, upon the occurrence of the applicable Separation Event, as defined below. The Separation Pay shall be payable after the date the Separation and Release Agreement becomes effective and, in no event, later than two and one-half months following the year in which the Separation Event occurs. Separation Pay shall be payable in accordance with the Company's payroll policy </font><font style="color:#2b2f2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">as </font><font style="color:#2b2f2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">constituted from time to time and shall be subject to withholding of all applicable federal, state, and local taxes and any other deductions required by applicable law. In the event of Executive's death, the Company's obligation to pay further compensation hereunder shall cease forthwith, except that Executive's legal representative shall be entitled to receive his fixed compensation for the period up to the last day of the month in which such death shall have occurred.</font></div><div style="padding-left:72pt;padding-right:36pt;text-align:justify"><font><br></font></div><div style="padding-right:43.7pt;text-align:justify;text-indent:77.35pt"><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#2b2f2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.68pt">Section 8(a) above shall not apply should the Executive receive severance benefits. under the Company's Change in Control Severance Benefit Plan.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-right:43.7pt;text-align:justify;text-indent:77.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#2b2f2a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.3pt">&#34;Separation Pay&#34; shall mean (i) a lump sum amount equal to twelve (12) months of Executive's then effective base salary and (ii) an amount equal to one hundred percent of The monthly COBRA premiums, including the two percent (2%) administrative fee, as in effect as of the date of termination for the Company's group medical, dental, vision and hospitalization insurance benefits in which the Executive is enrolled as of the date of termination for the Executive and his eligible dependents for 12 months, subject to the Executive&#8217;s timely and proper election of coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&#34;COBRA&#34;).</font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#34;Separation Event</font><font style="color:#0c110e;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#34; </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall mean&#58;</font></div><div style="padding-left:76.5pt;padding-right:43.7pt;text-align:justify"><font><br></font></div><div style="padding-left:10.9pt;padding-right:28.2pt;text-indent:98.65pt"><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:97%">(vii)</font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:97%;padding-left:15.53pt">the Company's termination of Executive's employment by the Company without Cause, during the Tern&#59; or</font></div><div style="margin-top:4.6pt;text-indent:108pt"><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.03pt">the termination of Executive's employment by </font><font style="color:#1d1f1c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive for Good Reason.</font></div><div style="margin-top:4.6pt;text-indent:36pt"><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">All Business to be Property of the Company&#59; Assignment of intellectual Property</font></div><div style="margin-top:4.6pt;padding-left:36pt"><font><br></font></div><div style="margin-top:2.9pt;padding-right:5.7pt;text-align:justify;text-indent:72pt"><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:27.46pt">Executive agrees that any and all presently existing business of the Company and all business developed by him or any other employee of the Company including without limitation </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:80%">d</font></div></div><div style="margin-top:2.9pt;padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">all contracts, fees</font><font style="color:#494b48;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">commissions, compensation</font><font style="color:#494b48;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">records</font><font style="color:#494b48;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">customer or client lists, agreements and any other incident of any business developed, earned, or carried on by Executive for the Company is and shall be the exclusive property of the Company</font><font style="color:#494b48;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">and (where applicable) shall be payable directly to the Company.</font></div><div style="margin-top:2.9pt;padding-left:72pt;padding-right:5.7pt;text-align:justify"><font><br></font></div><div style="margin-top:2.9pt;padding-right:5.7pt;text-align:justify;text-indent:72pt"><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">b)</font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:26.84pt">Executive hereby acknowledges that any plan, method, data, know-how, research, information, procedure, development, invention, improvement, modification, discovery, design, process, software and work of authorship, documentation, formula, </font><font style="color:#1d1f1c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">technique, </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">trade secret or intellectual property right whatsoever or any interest therein whether patentable or non-patentable, patents and applications therefor, trademarks and applications therefor or copyrights and applications therefor (herein sometimes collectively referred to as &#34;Intellectual Property&#34;) made, conceived, created, invested</font><font style="color:#494b48;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">developed, reduced to practice and&#47;or acquired by Executive solely or jointly with others during the Term is the sole and exclusi</font><font style="color:#494b48;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">v</font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">e property of the Company, as work for hire</font><font style="color:#494b48;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">and that </font><font style="color:#1d1f1c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">he </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">has no personal right in any such </font><font style="color:#1d1f1c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Intellectual </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Property. Executive hereby grants </font><font style="color:#1d1f1c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">to </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">the Company (without any separate remuneration or compensation other than that received </font><font style="color:#1d1f1c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">by </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">him from time to time in the course of his employment) his entire right, title and interest throughout the world in and to, all Intellectual Property</font><font style="color:#494b48;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">which is </font><font style="color:#1d1f1c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">made, </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">conceived, created, invested, developed, reduced to practice and&#47;or acquired by him solely or jointly with others </font><font style="color:#1d1f1c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">during </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">the Tenn.</font></div><div style="margin-top:2.9pt;padding-right:5.7pt;text-align:justify;text-indent:72pt"><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">c)</font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:27.46pt">Executive shall cooperate fully with the Company, both during and after his employment with or engagement by the Company, with respect to the procurement, maintenance and enforcement of copyrights</font><font style="color:#494b48;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">patents and other intellectual property rights (both in the United States and foreign countries) relating to Intellectual Property. Without </font><font style="color:#1d1f1c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">limiting </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">the foregoing, Executive agrees that to </font><font style="color:#1d1f1c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">the </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">extent copyrightable, any such original works of authorship shall be deemed to be &#34;works for hire&#34; and that the Company shall be deemed the author thereof under the U.S. Copyright Act, as amended, provided that in the event and to the extent such works are determined not to constitute &#34;works for hire&#34; as a matter of law, Executive hereby irrevocably assigns and transfers to the Company all right, title and interest in such works, including but not limited to copyrights thereof. Executive shall sign all papers, including, without limitation, copyright applications</font><font style="color:#494b48;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">patent applications. declarations. oaths, formal assignments. Assignments of priority rights and </font><font style="color:#1d1f1c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">powers</font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> of attorney, which the Company may deem </font><font style="color:#1d1f1c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">necessary </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">or desirable in order to protect its rights and interests in any Intellectual Property (at the Company's expense) and agrees that these obligations are binding upon his assigns</font><font style="color:#494b48;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">executors, administrators</font><font style="color:#494b48;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">and other legal representatives. To that end</font><font style="color:#494b48;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Executive shall provide current contact information </font><font style="color:#1d1f1c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">to </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">the Company including, but not limited to, home address, telephone number and email address, and shall update </font><font style="color:#1d1f1c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">his </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">contact information whenever necessary.</font></div><div style="margin-top:2.9pt;padding-left:72pt;padding-right:5.7pt;text-align:justify"><font><br></font></div><div style="margin-top:2.9pt;padding-right:7.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">10.</font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:22.25pt">Confidentiality.</font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> Executive acknowledges his obligation of confidentiality with respect to all proprietary, confidential, and non-public information of the Company, including all Intellectual Property. By way of illustration, but not limitation, confidential and proprietary information shall be deemed to include any plan, method, data</font><font style="color:#494b48;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">know-how, research, information, procedure</font><font style="color:#494b48;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, </font><font style="color:#1d1f1c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">development, </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">invention, improvement, modification, discovery, process, work of authorship, documentation, formula, technique, product, idea, concept ,design, drawing, specification, technique, trade secret or </font><font style="color:#2d2f2b;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">intellectual property right whatsoever or any interest therein whether patentable or non-patentable, patents and applications therefor, trademarks and applications therefor or copyrights and applications therefor, personnel data, records, marketing techniques and materials, marketing and development plans, customer names and other information related to customers, including prospective customers and contacts at customers, price lists, pricing policies and supplier lists of the Company, in each case coming into Executive's possession, or which Executive learns, or to which Executive bas access, or which Executive may discover or develop (whether or not related to the business of the Company at the time this Agreement is signed or any information Executive originates, discovers or develops, in whole or in part) as a result of Executive's employment by (either full-time or part-time), or retention as a consultant of, the Company. Executive shall not, either during the Term or for an unlimited period </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:80%">d</font></div></div><div style="margin-top:2.9pt;padding-right:7.9pt;text-align:justify"><font style="color:#2d2f2b;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">of time thereafter, use for any purpose other than the furtherance of the Company's business, or disclose to any person other than a person with a need to know such confidential, proprietary or non-public information for the furtherance of the Company's business who is obligated to maintain the confidentiality of such information, any information concerning any Intellectual Property, or other confidential, proprietary or non-public information of the Company, whether Executive bas such information in his memory or such information is embodied in writing, electronic or other tangible form.</font></div><div style="margin-top:2.9pt;padding-right:7.9pt;text-align:justify;text-indent:36pt"><font style="color:#2d2f2b;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">All originals and copies of any of the foregoing, however and whenever produced, shall be the sole property of the Company. All files, letters, memoranda, reports, records, data, sketches, drawings, program listings, or other written, photographic, or other tangible or electronic material containing confidential or proprietary information or Intellectual Property, whether created by Executive or others, which shall come into Executive's custody or possession, shall be and are the exclusive property of the Company to be used by Executive only in the performance of his duties for the Company. All electronic material containing confidential or proprietary information or Intellectual Property will be stored on a computer supplied to Executive by the Company and, under no circumstances, will it be transferred to a personal computer. Executive will promptly deliver to the Company and&#47;or a person or entity identified by the Company all such materials or copies of such materials and all tangible property of the Company in Executive's custody or possession, upon the earlier of (i) a request by the Company or (ii) termination of employment or engagement by the Company. After such delivery, Executive will not retain any such materials or copies or any such tangible property or any summaries or memoranda regarding same.</font></div><div style="margin-top:2.9pt;padding-left:36pt;padding-right:7.9pt;text-align:justify"><font><br></font></div><div style="margin-top:2.9pt;padding-right:7.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">11.</font><font style="color:#2d2f2b;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:22.25pt">Non-Competition Covenant. </font><font style="color:#2d2f2b;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As the Executive has been granted options to purchase stock in the Company and as such bas a financial interest in the success of the Company's business and as Executive recognizes that the Company would be substantially injured by Executive competing with the Company, Executive agrees and warrants that, during his employment with the Company and for a period of one (1) year after the termination of Executive's employment, Executive will not, on his own behalf or on behalf of any other person or entity, in any capacity (whether as an employee, independent contractor or other capacity), render services that are the same or substantially similar in function or purpose to the services Executive performed for the Company during the Look Back Period to any Competing Organization in connection with any Competing Product or Service provided by such Competing Organization within the Restricted Area Notwithstanding the foregoing provisions of this paragraph, Executive may directly or indirectly own, solely as a passive investment, securities of an entity which are publicly traded on a national securities exchange or regional securities exchange if Executive(i) is not a controlling person or a member of a group which controls such entity, and (ii) does not directly or indirectly own one percent (1%) or more of any class of securities of such entity.</font></div><div style="margin-top:0.25pt;text-align:justify"><font><br></font></div><div style="padding-left:7.05pt;padding-right:11.25pt;text-align:justify;text-indent:32.8pt"><font style="color:#2d2f2b;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%">The term &#34;Competing Organization&#34; as used herein shall mean any partnership, association organization, entity, or individual, including the Executive, engaged in, or actively planning to engage in, research, development, production, distribution, marketing, providing, or selling of any Competitive Product or Service.</font></div><div style="margin-top:10.3pt;padding-left:6.95pt;padding-right:12.65pt;text-align:justify;text-indent:31.95pt"><font style="color:#2d2f2b;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The term &#34;Competitive Product or Service&#34; as used herein shall mean any product, process, or service that is substantially similar to any product, process, or service of the Company with respect to</font><img alt="image_01a.jpg" src="image_01a.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:764px"><font style="color:#2d2f2b;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">which the </font><font style="color:#424441;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">had material duties or responsibilities or acquired Confidential Information at any time during the Look Back Period.</font></div><div style="padding-right:9pt;text-align:justify"><font><br></font></div><div style="padding-right:9pt;text-align:justify"><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The term &#34;Look Back Period&#34; shall mean the one (1) year preceding the last date of Executive's employment with the Company.</font></div><div style="padding-right:9pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:80%">d</font></div></div><div style="padding-right:9pt;text-align:justify"><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The term &#34;Restricted Area&#34; means any geographic area in which the Company offers, or Executive knows the Company is actively planning to offer, any product, process, or service during the Executive's employment with the Company or, with respect to the portion of the applicable restricted period that follows the last date of Executive's employment.</font></div><div style="padding-right:9pt;text-align:justify"><font><br></font></div><div style="padding-right:4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.</font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Non-Solicitation Agreement </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">During the Tenn of this Agreement and for a period of one (1)year after his last date of employment with the Company, Executive agrees and covenants that he will not on his own behalf or on behalf of any other person or entity, solicit for employment or hire, or assist in the solicitation or hiring, of any other employee or contractor who works for the Company for purposes of performing </font><font style="color:#424441;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">services </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">for a Competing Organization. This prohibition includes, but is not limited to&#58;</font></div><div style="padding-right:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(a)</font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:24.36pt">Providing to any such prospective employer, recruiter or search firm the identities of any of the Company's employees or contractors&#59;</font></div><div style="padding-left:72pt;padding-right:4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(b)</font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.77pt">Providing to any such prospective employer, recruiter, or search firm any information regarding the Company's employees' or contractors' compensation, skill sets, or other information regarding the Company's employees' employment or contractors' engagement&#59; or</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-right:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(c)</font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.36pt">Assisting any of the Company's employees or contractors in obtaining employment or a consultancy relationship with the Employee's new employer by way of recommendation, dissemination of resumes or otherwise.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-right:4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.</font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Notices. </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All notices and other communications hereunder </font><font style="color:#424441;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">be in writing and shall be deemed to have been given on actual receipt after having been delivered by hand, mailed by first class mail, postage prepaid, or sent by Federal Express or similar overnight delivery services, as follows&#58; (a) if to Executive, at the address shown at the head of this Agreement, or to </font><font style="color:#424441;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">such </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">other person(s) or address(es) as Executive shall have furnished to the Company in writing and, if to the Company, to the Company's Executive Vice President &#38; Chief Human Resources Officer,700 Quince Orchard Road, Gaithersburg. MD 20878 or to such other person(s) or address(es) as the Company shall have furnished to Executive in writing.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-right:4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.</font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%;padding-left:22.25pt">Assignability. </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">In the event of a change of control (as defined in the Company's Change in Control Severance Benefit Plan), the terms of this Agreement shall inure to the benefit of, and be assumed by, the acquiring person(as defined in the Company's Change in Control Severance Benefit Plan). This Agreement </font><font style="color:#424441;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">shall </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">not be assignable by Executive, but </font><font style="color:#424441;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">it shall </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">be binding upon, and to the extent provided in Section 8 shall inure to the benefit of, his heirs, executors, administrators and legal representatives.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-right:4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.</font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Entire Agreement. </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement, along with the Offer Letter to Executive from the Company dated November 17, 2023, contain the </font><font style="color:#424441;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">entire </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">agreement between the Company and Executive with respect to the subject matter hereof and there have been no oral or other prior agreements of any kind whatsoever as a condition precedent or inducement to the signing of this Agreement or otherwise concerning this Agreement or the subject matter hereof. Notwithstanding the foregoing, Executive acknowledges that he is required as a condition to continued employment to comply at all times </font><font style="color:#424441;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">with </font><font style="color:#2d2f2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the Company's policies affecting employees, including the Company's published Code of Conduct, as in effect from time to time.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-right:4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.</font><img alt="image_1a.jpg" src="image_1a.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:808px"><font style="color:#313431;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Equitable Relief. </font><font style="color:#313431;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive recognizes and agrees that the Company's remedy at Law for any breach of the provisions of Sections 9, 10, 11 or 12hereofwould be inadequate, and he agrees that for breach of such provisions, the Company shall, in addition to such other remedies as may be available to it at law or in equity or as provided in this Agreement, be entitled to injunctive relief and to enforce its rights by an action for specific performance. Should Executive engage in any activities prohibited by this Agreement, he agrees to pay over to the Company all compensation, remuneration or monies or property of any sort received in connection with such activities&#59; such payment shall not impair any rights or remedies of the Company or obligations or liabilities of Executive which such parties may have under this Agreement or applicable law.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:80%">d</font></div></div><div style="padding-right:4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.</font><font style="color:#313431;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Amendments. </font><font style="color:#313431;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement may not be amended, nor shall any change, waiver, modification, consent or discharge be effected except by written instrument executed by the Company and Executive.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-right:4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.</font><font style="color:#313431;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%;padding-left:22.25pt">Severability. </font><font style="color:#313431;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">If any part of any term or provision of this Agreement shall be held or deemed to be invalid, inoperative or unenforceable to any extent by a court of competent jurisdiction, such circumstances shall in no way affect any other term or provision of this Agreement, the application of such term or provision in any other circumstances, or the validity or enforceability of this Agreement. Executive agrees that the restrictions set for this Sections 11 and 12 above (including but not limited to, the geographical scope and time period of restrictions) are fair and reasonable and are reasonably required for the protection of the interests of the Company and its affiliates. In the event that any provision of Section 11 or 12 relating to time period and&#47;or areas of restriction shall be declared by a court of competent jurisdiction to exceed the maximum time period or areas such court deems reasonable and enforceable, said time period and&#47;or areas of restriction shall be deemed to become and thereafter be the maximum time period and&#47;or areas which such court deems </font><font style="color:#4f504f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">r</font><font style="color:#313431;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">easonable and enforceable.</font></div><div style="padding-left:36pt;padding-right:4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.</font><font style="color:#313431;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%;padding-left:22.25pt">Paragraph Headings, </font><font style="color:#313431;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">The paragraph headings used in this Agreement are included solely for convenience and shall not affect, or be used in connection with, the interpretation hereof.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-right:4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.</font><font style="color:#313431;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%;padding-left:22.25pt">Governing Law. </font><font style="color:#313431;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">This Agreement shall be governed by and construed and enforced in accordance with the law of the State of Maryland, without regard to the principles of conflict of laws thereof.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-right:4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.</font><font style="color:#313431;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Resolution of Disputes. </font><font style="color:#313431;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">With the exception of proceedings for equitable relief brought pursuant to Section 16 of this Agreement, any disputes arising under or in connection with this&#59; Agreement including. without limitation. any assertion by any party hereto that the other party has&#58; breached any provision of this Agreement, shall be resolved by arbitration, to be conducted in Baltimore, Maryland, in accordance with the rules and procedures of the American Arbitration Association. The parties shall bear equally the cost of such arbitration</font><font style="color:#6b6e69;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#313431;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">excluding attorneys' fees and disbursements which shall be borne solely by the party incurring the same&#59; provided, however, that if the arbitrator rules in favor of Executive on at least one material component of the dispute, Company shall be solely responsibl</font><font style="color:#4f504f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">e </font><font style="color:#313431;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">for the payment of all costs, fees and expenses (including without limitation Executive's reasonable attorneys' fees and disbursements) of such arbitration. The Company shall reimburse Executive for any such fees and expenses incurred by Executive in any calendar year within a reasonable time following Executive's submission of a request for such reimbursement, which in no case shall be later than the end of the calendar year following the calendar year in which such expenses were incurred Executive shall submit any such reimbursement request no later than the June 30th next following the calendar year in which the fees and expenses are incurred. In the event the arbitrator rules against Executive, Executive shall repay the Company the amount of such reimbursed expenses no later than 180 days following the date as of which such arbitrator's decision becomes final. The provisions of this Section 21 shall survive the termination for any reason of the Term (whether such termination is by the Company, by Executive or upon the expiration of the Term)</font><img alt="image_2a.jpg" src="image_2a.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:800px"><font style="color:#313431;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="padding-left:36pt;padding-right:4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22.</font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Indemnification&#59; </font><font style="color:#282a26;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Insurance. </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Executive shall be </font><font style="color:#282a26;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">entitled </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">to </font><font style="color:#282a26;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">liability </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and expense indemnification and reimbursement to the fullest extent permitted by </font><font style="color:#282a26;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Company's current Amended and Restated By-laws and Second Amended and Restated Certificate of Incorporation, whether or not the </font><font style="color:#4f504f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">same </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">are </font><font style="color:#4f504f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">subsequently </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">amended During the Term, the Company will use commercially </font><font style="color:#282a26;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">reasonable </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">efforts to </font><font style="color:#282a26;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">maintain </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">in effect directors' and officers' </font><font style="color:#282a26;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">liability </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">insurance </font><font style="color:#282a26;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">no </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">less favorable to Executive than that </font><font style="color:#282a26;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">in </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">effect as of the date </font><font style="color:#282a26;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">of </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">this Agreement.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-right:4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23.</font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Survival </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sections 8 through 23 shall survive termination of this Agreement for the period and to the extent specified therein.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-right:4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24.</font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Protected Conduct. </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nothing in this Agreement prohibits Executive from opposing or reporting to the </font><font style="color:#282a26;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">r</font><font style="color:#4f504f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">elevant </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">law-enforcement agency (such as </font><font style="color:#282a26;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Securities and Exchange Commission, Equal Employment Commission, or Department of Labor) an event that Executive in good faith believes is </font><font style="color:#282a26;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">violation </font><font style="color:#282a26;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">of law</font><font style="color:#626260;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">requires notice to or approval from the Company </font><font style="color:#282a26;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">before </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">doing so, or prohibits Executive from cooperating in an investigation conducted </font><font style="color:#282a26;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">by </font><font style="color:#4f504f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">such </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a government agency.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:80%">d</font></div></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-right:4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25.</font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">All </font><font style="color:#282a26;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Duties and </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">At-Will Status </font><font style="color:#282a26;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Preserved </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement creates obligations that supplement, </font><font style="color:#282a26;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">but </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">do </font><font style="color:#282a26;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">not replace </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or </font><font style="color:#282a26;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">diminish the </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">obligations Executive would otherwise have to the Company. Nothing in this </font><font style="color:#4f504f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Agreement </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">modifies any at-will employment relationship between the Parties.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:18pt;padding-right:4.5pt;text-align:justify"><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN </font><font style="color:#282a26;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WITNESS </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREOF, </font><font style="color:#282a26;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">parties have executed or caused </font><font style="color:#282a26;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">to be </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">executed under </font><font style="color:#4f504f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">sea</font><font style="color:#282a26;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">l </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">this Agreement as of the date first above written.</font></div><div style="padding-left:15.85pt;padding-right:11.5pt;text-align:justify"><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:15.85pt;padding-right:11.5pt"><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#96;&#96;&#96;&#96;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOVAVAX</font></div><div style="padding-left:15.85pt;padding-right:11.5pt"><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:243.05pt"><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline"> </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">   &#47;s&#47; Ian Watkins     </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font></div><div style="padding-left:243.05pt"><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Ian </font><font style="color:#282a26;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Watkins</font></div><div style="padding-left:243.7pt;padding-right:11.35pt"><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Executive </font><font style="color:#282a26;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Vice President &#38; Chief </font><font style="color:#3a3b38;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Human Resources </font><font style="color:#282a26;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Officer</font></div><div style="padding-left:243.7pt;padding-right:11.35pt"><font><br></font></div><div style="padding-left:243.7pt;padding-right:11.35pt"><font><br></font></div><div style="padding-left:243.7pt;padding-right:11.35pt"><font style="color:#282a26;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTIVE</font></div><div style="padding-left:243.7pt;padding-right:11.35pt"><font><br></font></div><div style="padding-left:243.7pt;padding-right:11.35pt"><font style="color:#282a26;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">  &#47;s&#47; Mark Casey  </font></div><div style="padding-left:243.7pt;padding-right:11.35pt"><font style="color:#282a26;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Mark Casey</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.34
<SEQUENCE>6
<FILENAME>nvax-20231231xex1034.htm
<DESCRIPTION>EX-10.34
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i2a8c010afff44c17b5f065a0c961de6e_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.34</font></div><div><img alt="image1a.jpg" src="image1a.jpg" style="height:158px;margin-bottom:5pt;vertical-align:text-bottom;width:295px"></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Elaine J O'Hara</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91; *** &#93;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;February 4, 2023</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91; *** &#93;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dear Elaine, </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">I am pleased to offer you the full-time position of Executive Vice President &#38; Chief Strategy Officer at Novavax, Inc In this position you will report John </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">C </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Jacobs, President &#38; Chief Executive Officer. Your first day of employment is expected to be on or about March 1,2023</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This offer is contingent upon the following&#58;</font></div><div style="margin-top:0.1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.15pt">Successful and satisfactory completion of our standard background check All information provided by you in your employment application, interviews. and any other verbal or written correspondence will be verified by a third-party background checking company or by Novavax. Any discrepancies found may delay your start date or could potentially cause withdrawal of this offer. Candidates cannot begin employment until the background check is completed, including verification of current employment.</font></div><div style="margin-top:0.1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.15pt">Your disclosure of all contractual or other obligations owed by you to previous employers or other parties that would in any way limit your ability to perform your job at the Company. If there are any obligations that might limit your ability to perform, such matters must be disclosed and addressed by the Company prior to commencement of employment.</font></div><div style="margin-top:0.1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.15pt">Compliance with the Novavax COVID-19 Vaccination Policy for US Employees. which may include providing proof of vaccination at the time you begin working or requesting an accommodation or exemption. A copy of the policy is attached for your review If you need an accommodation or believe you are exempt due to applicable state law, please email our Benefits Team at </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">NovavaxBenetits&#64;novavax.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.15pt">Execution of the Employment Agreement, a copy of which is enclosed for your review.</font></div><div style="margin-top:0.1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.15pt">Successful verification of your employment eligibility in the United States. To verify this information, please be prepared to produce acceptable documents. BY FEDERAL LAW, IT IS REQUIRED THAT YOU PRESENT THIS DOCUMENTATION WITHIN THREE DAYS OF YOUR START AT WORK.</font></div><div style="padding-left:20.15pt;text-indent:-0.5pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The specific of this offer are outlined in the enclosed Employment Agreement and include the following</font><font style="color:#4f4d4f;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#211f1f;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">SALARY&#58;</font><font style="color:#211f1f;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Your initial annualized base salary will be $520,000 per year, payable semi-monthly, less applicable payroll taxes and authorized deductions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#211f1f;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">BONUS PROGRAM</font><font style="color:#211f1f;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You will be eligible to participate in the Company's annual incentive bonus program, under which award payments, if any, will be based on performance criteria and milestones to be determined by the Company. You will be paid in the following year in which the compensation is earned. Your bonus at 100% of target will be 50% of your earnings for the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">performance year. The bonus shall be paid out partly in cash and partly in shares of stock options or restricted stock, at the discretion of the Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#211f1f;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">COMMUTING ALLOWANCE&#58;</font><font style="color:#211f1f;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">During the term of your employment, the Company will provide a monthly commuting allowance of up to $5,000 for the cost of housing and other related commuting expenses incurred by you to commute between your home in &#91; * * * &#93; and the Company's Gaithersburg offices (the &#34;Allowance&#34;) In addition, the Company will pay an additional sum to reimburse you for the personal income taxes associated with the Allowance, such that the economic benefit is the same as if such Allowance were provided on a non-taxable basis.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#4f4d4f;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">INI</font><font style="color:#211f1f;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">T</font><font style="color:#4f4d4f;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">I</font><font style="color:#211f1f;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">AL E</font><font style="color:#3b3a3a;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">OU</font><font style="color:#211f1f;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">lT</font><font style="color:#3b3a3a;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Y G</font><font style="color:#211f1f;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">R</font><font style="color:#3b3a3a;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">AN</font><font style="color:#211f1f;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">T&#58;</font><font style="color:#211f1f;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As soon as reasonably practicable following your start date and subject to the approval of the Board of Directors or the Compensation Committee. as a material inducement to commence employment with the Company and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">accordance </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">with </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nasdaq Listing Rule 5635(c)(4), you will receive an initial stock option grant of 67,900 shares ('Inducement Stock Options&#34;) and an initial grant of 58,800 restricted stock units ('Inducement Restricted Stock Units&#34;)  The Inducement Restricted Stock Units will vest as to one-third (1&#47;3) of the shares underlying the Inducement Restricted Stock Units on each of the first three (3) anniversaries of the date of grant. in each case subject to your continued employment with the Company through the applicable vesting date. The Inducement Stock Options will vest as to one-quarter (1&#47;4) of the shares underlying the Inducement Stock Options on the first anniversary of the date of grant and as to the remaining shares in equal monthly installments for thirty-six (36) months thereafter, in each case subject to your continued employment with the Company through the applicable vesting date. Each of the Inducement Restricted Stock Units and Inducement Stock Options will be granted under and subject to the terms of the Company's inducement equity plan and an agreement in substantially the form of a restricted stock unit agreement or the form of a stock option award agreement, as applicable, previously approved by the Board of Directors or the Compensation Committee.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#1f1d1d;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">ANNUAL EQUITY GRANTS&#58;</font><font style="color:#1f1d1d;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Beginning in 2024, you will be eligible to receive an additional annual equity award based upon performance and subject to the approval of the Board of Directors or the Compensation Committee.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Your employment and compensation with Novavax are &#34;at will&#34;. At will employment is defined as an employee&#47;employer relationship which may be ended by either the employee or employer at any time. without cause, except as otherwise provided by law or defined in the terms of the Employment Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Elaine, if you agree with and accept the terms of this offer letter and the Employment Agreement, please sign below and return this letter and the Employment Agreement to my office. We are confident your employment with Novavax will prove mutually beneficial. and we look forward to you joining the Novavax team.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:237.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sincerely,</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:2.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;       </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> &#47;s&#47; Jill Hoyt                              </font></div><div style="padding-left:237.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Jill Hoyt</font></div><div style="margin-top:0.35pt;padding-left:237.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive Vice President</font></div><div style="margin-top:0.3pt;padding-left:237.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chief Human Resources Officer</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ACCEPTED BY&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> &#47;s&#47; Elaine J. O&#8217;Hara     </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Elaine J. O&#8217;Hara</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.35
<SEQUENCE>7
<FILENAME>nvax-20231231xex1035.htm
<DESCRIPTION>EX-10.35
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i94b6e80d6e7848838eff509b9b79cde1_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:4.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.35</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:2.37pt;padding-right:2.37pt;text-align:center"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EMPLOYMENT AGREEMENT</font></div><div style="padding-left:10.8pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Employment Agreement (&#34;Agreement&#34;) is dated as of </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">February 4, 2023, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">between </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Novavax, Inc., </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(&#34;Novavax&#34; or the &#34;Company&#34;) a Delaware corporation having its principal office at 21 Firstfield Road, Gaithersburg, MD 20878, and </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Elaine O'Hara, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">an individual residing at &#91; * * * &#93; (&#34;Executive&#34;).</font></div><div style="padding-left:10.85pt;padding-right:5.95pt;text-align:justify"><font><br></font></div><div style="padding-left:10.85pt;padding-right:5.95pt;text-align:justify"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;In consideration of the mutual promises and covenants set forth herein and other good and valuable consideration, the sufficiency of which is hereby acknowledged, Company and Executive agree as follows&#58;</font></div><div style="padding-left:10.85pt;padding-right:5.95pt;text-align:justify"><font><br></font></div><div style="padding-left:10.4pt;padding-right:5.35pt;text-align:justify;text-indent:48.1pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:5.25pt">&#160;&#160;&#160;&#160;Employment. </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company will employ Executive as </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Executive Vice President &#38; Chief Strategy Officer </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">upon the terms and conditions hereinafter set forth, effective as of March 1, 2023. As used throughout this Agreement, </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#34;Company&#34; </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall mean and include any and all of its present and future subsidiaries and any and all subsidiaries of a subsidiary. Executive warrants and represents that she is free to enter into and perform this Agreement. Executive has disclosed to the Company all employment, confidentiality, non-competition or other agreements which purport to restrict or otherwise prohibit her ability to provide services to or accept employment with the Company.</font></div><div style="padding-left:58.5pt;padding-right:5.35pt"><font><br></font></div><div style="padding-left:9.35pt;padding-right:5.05pt;text-align:justify;text-indent:49.1pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:5.3pt">&#96;Duties. </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">During the Term (as hereinafter defined), Executive shall devote her full business time to the performance of services as Executive Vice President &#38; Chief Strategy Officer of Novavax, performing such services, assuming such duties and responsibilities as prescribed by the Company's President and CEO (&#34;CEO) and the Company's Board of Directors. During the Term, Executive's services shall be completely exclusive to the Company and she shall devote her entire business time, attention and energies to the business of the Company and the duties which the Company shall assign to her from time to time. Executive agrees to perform her services faithfully and to the best of her ability and to carry out the policies and directives of the Company. Notwithstanding the foregoing, it shall not be a violation of this Agreement for the Executive to serve as a director of any company whose products do not compete with those of the Company and to serve as a director, trustee, officer, or consultant to a charitable or non-profit entity&#59; provided that such service does not adversely affect Executive's ability to perform her obligations hereunder and comply with the Company's Conflict of Interest Policy. Executive agrees not to take any action that is in bad faith and prejudicial to the interests of the Company during her employment hereunder. Notwithstanding the location where Executive shall be based, as set forth in this Agreement, she also may be required from time to time to perform duties hereunder for reasonably short periods of time outside of said area</font></div><div style="padding-left:58.45pt;padding-right:5.05pt;text-align:right"><font><br></font></div><div style="padding-left:9.35pt;padding-right:5.05pt;text-align:justify;text-indent:49.15pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:5.25pt">Term. </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The term of this Agreement shall be the period of time beginning on the Executive's first date of employment as Executive Vice President &#38; Chief Strategy Officer and shall continue for so long as Executive shall be an at-will employee of the Company hereunder</font></div><div style="margin-top:11.85pt;padding-left:8.65pt;text-align:justify;text-indent:-36.35pt"><font><br></font></div><div style="padding-left:9.35pt;padding-right:5.05pt;text-align:justify;text-indent:49.15pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:5.25pt">Compensation.</font></div><div style="padding-left:8.65pt;text-align:justify"><font><br></font></div><div style="padding-left:9.15pt;padding-right:5.15pt;text-align:justify;text-indent:67.35pt"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:18.68pt">Base Compensation. </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For all Executive's services and covenants under this Agreement, the Company shall pay Executive an annual salary, which is </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$520,000 </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as of the effective date of this Agreement, as established or ratified by the Board of Directors or an authorized committee thereof (in accordance with established management processes), and payable in accordance with the Company's payroll policy as constituted from time to time. The Company may withhold from any amounts payable under this Agreement all required federal, state, city or other taxes and all other deductions as may be required pursuant to any law or government regulation or ruling.</font></div><div style="padding-left:76.5pt;padding-right:5.15pt;text-align:justify"><font><br></font></div><div style="padding-left:9.4pt;padding-right:6.55pt;text-align:justify;text-indent:80.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:5.18pt">Bonus Program. </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company agrees to pay the Executive a performance and incentive bonus in respect of Executive's employment with the Company each year in an amount </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">determined by the CEO and Board of Directors (or any committee of the Board of Directors authorized to make that determination) to be appropriate based upon Executive's, and the Company's, achievement of certain specified goals, with a target bonus of 50%, or any other percentage </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:9.4pt;padding-right:6.55pt;text-align:justify"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">determined by the Board of Directors, of Executive's base earnings during the year to which the bonus relates. The bonus shall be paid out partly in cash and partly in shares of stock options or restricted stock, at the discretion of the Board of Directors.</font></div><div style="padding-left:90pt;padding-right:6.55pt;text-align:justify"><font><br></font></div><div style="padding-left:8.65pt;padding-right:6.65pt;text-align:justify;text-indent:49.85pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%;padding-left:5.25pt">Reimbursable Expenses. </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive shall be entitled to reimbursement for reasonable expenses incurred by her in connection with the performance of her duties hereunder in accordance with such procedures and policies for executive officers as the Company has heretofore or may hereafter establish. The amount of expenses eligible for reimbursement during any calendar year shall not affect the expenses eligible for reimbursement in any other calendar year, and the reimbursement of an eligible expense shall be made as soon as practicable after Executive submits the request for reimbursement, but not later than December 31 following the calendar year in which the expense was incurred. In addition, Executive shall receive a monthly commuting allowance of up to $5,000 to cover the costs of housing and other related commuting expenses incurred by Executive to commute from her personal residence in Pennsylvania to the Company's offices in Gaithersburg, Maryland.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:81.2pt;text-align:justify;text-indent:-22.7pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%;padding-left:14.45pt">Benefits.</font></div><div style="padding-left:8.2pt;padding-right:6.8pt;text-align:justify;text-indent:81.8pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.8pt">Executive shall be entitled to four weeks of paid vacation time per year starting from the date of commencement of employment, calculated and administered in accordance with Company policies for executive officers in effect from time to time. The Executive shall be entitled to all other benefits associated with normal full-time employment in accordance with Company policies.</font></div><div style="padding-left:7.95pt;padding-right:6.65pt;text-align:justify;text-indent:77.55pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.68pt">Subject to approval by the Board of Directors (or any committee of the Board of Directors authorized to make that determination), Executive shall be entitled to participate in the Company's Amended and Restated Change in Control Severance Benefit Plan adopted on August 10, 2005, as amended and restated on July 26, 2006 and as further amended on December 31, 2008, June 15, 2011 and June 17, 2021 (the &#34;Change in Control Severance Benefit Plan&#34;).</font></div><div style="padding-left:80.35pt;text-align:right"><font><br></font></div><div style="padding-left:80.35pt;text-align:justify;text-indent:-21.85pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%;padding-left:13.6pt">Termination of Employment.</font></div><div style="padding-left:7.8pt;text-align:justify;text-indent:77.7pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.3pt">Notwithstanding any other provision of this Agreement, Executive's employment may be terminated, without such action constituting a breach of this Agreement&#58;</font></div><div style="padding-left:85.7pt;padding-right:7.9pt;text-align:justify"><font><br></font></div><div style="padding-left:9pt;text-align:justify;text-indent:108pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.63pt">By the Company, for &#34;Cause,&#34; as defined in Section 7(b) below&#59;</font></div><div style="padding-left:152.65pt;text-align:justify"><font><br></font></div><div style="padding-left:152.4pt;text-align:justify;text-indent:-35.4pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.98pt">By the Company, without Cause&#59;</font></div><div style="padding-left:152.4pt;text-align:justify"><font><br></font></div><div style="padding-left:7pt;padding-right:6.9pt;text-align:justify;text-indent:110pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.53pt">By the Company, upon 30 days' notice to Executive, if she should be prevented by illness, accident or other disability (mental or physical) from discharging her duties hereunder for one or more periods totaling three consecutive months during any twelve-month period&#59;</font></div><div style="padding-left:117pt;padding-right:6.9pt;text-align:justify"><font><br></font></div><div style="padding-left:6.85pt;padding-right:7.3pt;text-align:justify;text-indent:110.15pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.13pt">By the Executive with &#34;Good Reason&#34;, as defined in Section 7(c) below, within 30 days of the occurrence or commencement of such Good Reason&#59;</font></div><div style="padding-left:153pt;padding-right:7.3pt;text-align:justify"><font><br></font></div><div style="padding-left:9pt;text-align:justify;text-indent:108pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.18pt">By the Executive without Good Reason upon 30 days prior written notice&#59;</font></div><div style="padding-left:6.55pt;text-align:justify"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or</font></div><div style="padding-left:151.7pt;text-align:justify;text-indent:-31.5pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.63pt">By the event of Executive's death during the Term.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:8.75pt;padding-right:6.35pt;text-align:justify;text-indent:81.25pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.18pt">&#34;Cause&#34; shall mean (i) Executive's failure or refusal to perform in all material respects the services required of her hereby, (ii) if, in connection with any prior agreement between Executive and a third-party, Executive is precluded from providing services to the Company and fulfilling her duties, as set forth in Section 2 of this Agreement, for a period of more than 3 consecutive months&#59; (iii) Executive's failure or refusal to carry out any proper and material direction by the CEO or the Board of Directors with respect to the services to be rendered by her hereunder or the manner of rendering such services, (iv) Executive's misconduct in the performance of her duties hereunder, (v) Executive's commission of an act of fraud, embezzlement or theft or a felony involving moral turpitude, (vi) Executive's use or disclosure of confidential information (as defined in Section 10 of this Agreement), other than for the benefit of the Company in the course of rendering services to the Company, or (vii) Executive's engagement in any activity prohibited by Section 11 or 12 of this Agreement. For purposes of this Section 7, the Company shall be required to provide Executive a specific written warning with regard to any occurrence of subsections (b)(i), (iii) and (iv) above, which </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:8.75pt;padding-right:6.35pt;text-align:justify"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">warning shall include a statement of corrective actions and a 30-day period for the Executive to respond to and implement such actions, prior to any termination of employment by the Company pursuant to Section 7(a)(i) above.</font></div><div style="padding-left:90pt;padding-right:6.35pt"><font><br></font></div><div style="padding-left:8.75pt;padding-right:6.35pt;text-align:justify;text-indent:81.25pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.8pt">&#34;Good Reason&#34; shall mean (a) the Company's material reduction or diminution of Executive's responsibilities and authority, other than for Cause, without her consent or (b) the relocation of Executive's primary place of employment without her consent.</font></div><div style="padding-left:90pt;padding-right:6.35pt;text-align:justify"><font><br></font></div><div style="padding-left:81.15pt;text-align:justify;text-indent:-27.15pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%;padding-left:18.9pt">Separation Pay</font><font style="color:#545454;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">.</font></div><div style="padding-left:90pt;padding-right:6.3pt;text-align:justify"><font><br></font></div><div style="padding-left:7.9pt;padding-right:7.2pt;text-align:justify;text-indent:82.1pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.8pt">&#160;&#160;&#160;&#160;Subject to the Executive's execution and delivery to the Company of the Company's standard form of Separation and Release Agreement, the Company shall pay Executive with the Separation Pay as defined herein, upon the occurrence of the applicable Separation Event, as defined below. The Separation Pay shall be payable after the date the Separation and Release Agreement becomes effective and, in no event, later than two and one-half months following the year in which the Separation Event occurs. Separation Pay shall be payable in accordance with the Company's payroll policy as constituted from time to time, and shall be subject to withholding of all applicable federal, state and local taxes and any other deductions required by applicable law. In the event of Executive's death, the Company's obligation to pay further compensation hereunder shall cease forthwith, except that Executive's legal representative shall be entitled to receive her fixed compensation for the period up to the last day of the month in which such death shall have occurred.</font></div><div style="padding-left:90pt;padding-right:7.2pt;text-align:justify"><font><br></font></div><div style="padding-left:7.05pt;padding-right:6.7pt;text-align:justify;text-indent:82.95pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.18pt">Section 8(a) above shall not apply should Executive receive severance benefits under the Company's Change in Control Severance Benefit Plan.</font></div><div style="margin-top:11.85pt;padding-left:8.65pt;text-align:justify;text-indent:-36.35pt"><font><br></font></div><div style="padding-left:7.05pt;padding-right:6.7pt;text-align:justify;text-indent:82.95pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.8pt">&#34;Separation Pay&#34; shall mean (i) a lump sum amount equal to twelve (12) months of Executive's then effective base salary and (ii) an amount equal to one hundred percent of the monthly COBRA premiums, including the two percent (2%) administrative fee, as in effect as of the date of termination for the Company's group medical, dental, vision and hospitalization insurance benefits in which the Executive is enrolled as of the date of termination for the Executive and her eligible dependents for 12 months, subject to the Executive's timely and proper election of coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&#34;COBRA&#34;).</font></div><div style="padding-left:90pt;padding-right:6.7pt;text-align:justify"><font><br></font></div><div style="padding-left:115.8pt;text-align:justify;text-indent:-30.3pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.48pt">&#34;Separation Event&#34; shall mean&#58;</font></div><div style="padding-left:115.8pt;text-align:justify"><font><br></font></div><div style="padding-left:6.6pt;padding-right:7.75pt;text-align:justify;text-indent:110.4pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.63pt">the Company's termination of Executive's employment by the Company without Cause, during the Term&#59; or</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:9.4pt;text-align:justify;text-indent:107.6pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:13.58pt">the termination of Executive's employment by the Executive for Good Reason.</font></div><div style="padding-left:9.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:18.35pt">All Business to be Property of the Company&#59; Assignment of intellectual Property.</font></div><div style="padding-left:81.35pt;text-align:right"><font><br></font></div><div style="padding-left:9.15pt;padding-right:6.75pt;text-align:justify;text-indent:76.35pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.3pt">Executive agrees that any and all presently existing business of the Company and all business developed by her or any other employee of the Company including without limitation all contracts, fees, commissions, compensation, records, customer or client lists, agreements and any other incident of any business developed, earned or carried on by Executive for the Company is and shall be the exclusive property of the Company, and (where applicable) shall be payable directly to the Company.</font></div><div style="padding-left:85.5pt;padding-right:6.75pt;text-align:justify"><font><br></font></div><div style="padding-left:8.45pt;padding-right:6.5pt;text-align:justify;text-indent:77.05pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.68pt">Executive hereby acknowledges that any plan, method, data, know-how, research, information, procedure, development, invention, improvement, modification, discovery, design, process, software and work of authorship, documentation, formula, technique, trade secret or intellectual property right whatsoever or any interest therein whether patentable or non-patentable, patents and applications therefor, trademarks and applications therefor or copyrights and applications therefor (herein sometimes collectively referred to as &#34;Intellectual Property&#34;) made, conceived, created, invested, developed, reduced to practice and&#47;or acquired by Executive solely or jointly with others during the Term is the sole and exclusive property of the Company, as work for hire, and that </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:8.45pt;padding-right:6.5pt;text-align:justify"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">she has no personal right in any such Intellectual Property. Executive hereby grants to the Company (without any separate remuneration or compensation other than that received by her from time to time in the course of her employment) her entire right, title and interest throughout the world in and to, all Intellectual Property, which is made, conceived, created, invested, developed, reduced to practice and&#47;or acquired by her solely or jointly with others during the Term.</font></div><div style="padding-left:85.5pt;padding-right:6.5pt;text-align:justify"><font><br></font></div><div style="padding-left:7.55pt;padding-right:6.55pt;text-align:justify;text-indent:77.95pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.3pt">Executive shall cooperate fully with the Company, both during and after her employment with or engagement by the Company, with respect to the procurement, maintenance and enforcement of copyrights, patents and other intellectual property rights (both in the United States and foreign countries) relating to Intellectual Property. Without limiting the foregoing, Executive agrees that to the extent copyrightable, any such original works of authorship shall be deemed to be &#34;works for hire&#34; and that the Company shall be deemed the author thereof under the U.S. Copyright Act, as amended, provided that in the event and to the extent such works are determined not to constitute &#34;works for hire&#34; as a matter of law, Executive hereby irrevocably assigns and transfers to the Company all right, title and interest in such works, including but not limited to copyrights thereof. Executive shall sign all papers, including, without limitation, copyright applications, patent applications, declarations, oaths, formal assignments, assignments of priority rights and powers of attorney, which the Company may deem necessary or desirable in order to protect its rights and interests in any Intellectual Property (at the Company's expense) and agrees that these obligations are binding upon her assigns, executors, administrators and other legal representatives. To that end, Executive shall provide current contact information to the Company including, but not limited to, home address, telephone number and email address, and shall update her contact information whenever necessary.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:4.5pt;padding-right:6.55pt;text-align:justify;text-indent:58.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:31.25pt">&#160;&#160;&#160;&#160;Confidentiality. </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive acknowledges her obligation of confidentiality with respect to all proprietary, confidential and non-public information of the Company, including all Intellectual Property. By way of illustration, but not limitation, confidential and proprietary information shall be deemed to include any plan, method, data, know-how, research, information, procedure, development, invention, improvement, modification, discovery, process, work of authorship, documentation, formula, technique, product, idea, concept, design, drawing, specification, technique, trade secret or intellectual property right whatsoever or any interest therein whether patentable or non-patentable, patents and applications therefor, trademarks and applications therefor or copyrights and applications therefor, personnel data, records, marketing techniques and materials, marketing and development plans, customer names and other information related to customers, including prospective customers and contacts at customers, price lists, pricing policies and supplier lists of the Company, in each case coming into Executive's possession, or which Executive learns, or to which Executive has access, or which Executive may discover or develop (whether or not related to the business of the Company at the time this Agreement is signed or any information Executive originates, discovers or develops, in whole or in part) as a result of Executive's employment by (either full-time or part-time), or retention as a consultant of, the Company. Executive shall not, either during the Term or for an unlimited period of time thereafter, use for any purpose other than the furtherance of the Company's business, or disclose to any person other than a person with a need to know such confidential, proprietary or non-public information for the furtherance of the Company's business who is obligated to maintain the confidentiality of such information, any information concerning any Intellectual Property, or other confidential, proprietary or non-public information of the Company, whether Executive has such information in her memory or such information is embodied in writing, electronic or other tangible form.</font></div><div style="padding-left:63pt;padding-right:6.55pt;text-align:right"><font><br></font></div><div style="padding-left:8.65pt;padding-right:6.5pt;text-align:justify"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All originals and copies of any of the foregoing, however and whenever produced, shall be the sole property of the Company. All files, letters, memoranda, reports, records, data, sketches, drawings, program listings, or other written, photographic, or other tangible or electronic material containing confidential or proprietary information or Intellectual Property, whether created by Executive or others, which shall come into Executive's custody or possession, shall be and are the exclusive property of the Company to be used by Executive only in the performance of her duties for the Company. All electronic material containing confidential or proprietary information or Intellectual Property will be stored on a computer supplied to Executive by the Company and, under no circumstances, will it be transferred to a personal computer. Executive will promptly deliver to the Company and&#47;or a person or entity identified by the Company all such materials or copies of such materials and all tangible property of the Company in Executive's custody or possession, upon the earlier of (i) a request by the Company or (ii) termination of employment or engagement by the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:8.65pt;padding-right:6.5pt;text-align:justify"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Company. After such delivery, Executive will not retain any such materials or copies or any such tangible property or any summaries or memoranda regarding same.</font></div><div style="padding-left:8.65pt;padding-right:6.5pt;text-align:justify"><font><br></font></div><div style="padding-left:7.75pt;padding-right:6.8pt;text-align:justify;text-indent:55.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%;padding-left:31.25pt">&#160;&#160;&#160;&#160;Non-Competition Covenant. </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As the Executive has been granted options to purchase stock in the Company and as such has a financial interest in the success of the Company's business and as Executive recognizes that the Company would be substantially injured by Executive competing with the Company, Executive agrees and warrants that, during her employment with the Company and for a period of one (1) year after the termination of Executive's employment, Executive will not, on her own behalf or on behalf of any other person or entity, in any capacity (whether as an employee, independent contractor or other capacity), render services that are the same or substantially similar in function or purpose to the services Executive performed for the Company during the Look Back Period to any Competing Organization in connection with any Competing Product or Service provided by such Competing Organization within the Restricted Area. Notwithstanding the foregoing provisions of this paragraph, Executive may directly or indirectly own, solely as a passive investment, securities of an entity which are publicly traded on a national securities exchange or regional securities exchange if Executive (i) is not a controlling person or a member of a group which controls such entity, and (ii) does not directly or indirectly own one percent (1%) or more of any class of securities of such entity.</font></div><div style="padding-left:44.35pt;padding-right:6.8pt;text-align:justify"><font><br></font></div><div style="padding-left:7.25pt;padding-right:7.2pt;text-align:justify"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The term &#34;Competing Organization&#34; as used herein shall mean any partnership, association organization, entity, or individual, including the Executive, engaged in, or actively planning to engage in, research, development, production, distribution, marketing, providing, or selling of any Competitive Product or Service.</font></div><div style="padding-left:7.1pt;padding-right:7.05pt;text-align:justify"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The term &#34;Competitive Product or Service&#34; as used herein shall mean any product, process, or service that is substantially similar to any product, process, or service of the Company with respect to which the Executive had material duties or responsibilities or acquired Confidential Information at any time during the Look Back Period.</font></div><div style="padding-left:7.1pt;padding-right:7.05pt;text-align:justify"><font><br></font></div><div style="padding-left:8.9pt;padding-right:7.65pt;text-align:justify"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The term &#34;Look Back Period&#34; shall mean the one (1) year preceding the last date of Executive's employment with the Company.</font></div><div style="padding-left:8.9pt;padding-right:7.65pt;text-align:justify"><font><br></font></div><div style="padding-left:8.65pt;padding-right:6.5pt;text-align:justify"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The term &#34;Restricted Area&#34; means any geographic area within the United States in which the Company offers, or Executive knows the Company is actively planning to offer, any product, process, or service during the Executive's employment with the Company or, with respect to the portion of the applicable restricted period that follows the last date of Executive's employment.</font></div><div style="padding-left:8.65pt;padding-right:6.5pt;text-align:justify"><font><br></font></div><div style="padding-left:9pt;padding-right:6.9pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%;padding-left:17.75pt">Non-Solicitation Agreement. </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">During the Term of this Agreement and for a period of one (1) year after her last date of employment with the Company, Executive agrees and covenants that she will not on her own behalf or on behalf of any other person or entity, solicit for employment or hire, or assist in the solicitation or hiring, of any other employee or contractor who works for the Company for purposes of performing services for a Competing Organization. This prohibition includes, but is not limited to&#58;</font></div><div style="padding-left:40.5pt;padding-right:6.9pt;text-align:right"><font><br></font></div><div style="padding-left:8.2pt;padding-right:7.05pt;text-align:justify;text-indent:72.8pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.8pt">Providing to any such prospective employer, recruiter or search firm the identities of any of the Company's employees or contractors&#59;</font></div><div style="padding-left:81pt;padding-right:7.05pt;text-align:justify"><font><br></font></div><div style="padding-left:8.3pt;padding-right:6.75pt;text-align:justify;text-indent:72.7pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.18pt">Providing to any such prospective employer, recruiter, or search firm any information regarding the Company's employees' or contractors' compensation, skill sets, or other information regarding the Company's employees' employment or contractors' engagement&#59; or</font></div><div style="padding-left:81pt;padding-right:6.75pt;text-align:justify"><font><br></font></div><div style="padding-left:7.75pt;padding-right:6.45pt;text-align:justify;text-indent:73.25pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.8pt">Assisting any of the Company's employees or contractors in obtaining employment or a consultancy relationship with the Employee's new employer by way of recommendation, dissemination of resumes or otherwise.</font></div><div style="padding-left:81pt;padding-right:6.45pt;text-align:justify"><font><br></font></div><div style="padding-left:7.35pt;padding-right:6.7pt;text-align:justify;text-indent:33.15pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%;padding-left:17.75pt">Notices. </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All notices and other communications hereunder shall be in writing and shall be deemed to have been given on actual receipt after having been delivered by hand, mailed by first class mail, postage prepaid, or sent by Federal Express or similar overnight delivery services, as follows&#58; (a) if to Executive, at the address shown at the head of this Agreement, or to such other person(s) or address(es) as Executive shall have furnished to the Company in writing and, if to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:7.35pt;padding-right:6.7pt;text-align:justify"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Company, to the Company's Executive Vice President, Chief Legal Officer and Corporate Secretary, 21 Firstfield Road, Gaithersburg, MD 20878 or to such other person(s) or address(es) as the Company shall have furnished to Executive in writing.</font></div><div style="padding-left:40.5pt;padding-right:6.7pt;text-align:right"><font><br></font></div><div style="padding-left:7.1pt;padding-right:7pt;text-align:justify;text-indent:33.4pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%;padding-left:17.75pt">Assignability. </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event of a change of control (as defined in the Company's Change in Control Severance Benefit Plan), the terms of this Agreement shall inure to the benefit of, and be assumed by, the acquiring person (as defined in the Company's Change in Control Severance Benefit Plan). This Agreement shall not be assignable by Executive, but it shall be binding upon, and to the extent provided in Section 8 shall inure to the benefit of, her heirs, executors, administrators and legal representatives.</font></div><div style="padding-left:40.5pt;padding-right:7pt;text-align:right"><font><br></font></div><div style="padding-left:6.25pt;padding-right:7.05pt;text-align:justify;text-indent:34.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15.</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:17.75pt">Entire Agreement. </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement, along with the Offer Letter to Executive from the Company dated February 4, 2023, contain the entire agreement between the Company and Executive with respect to the subject matter hereof and there have been no oral or other prior agreements of any kind whatsoever as a condition precedent or inducement to the signing of this Agreement or otherwise concerning this Agreement or the subject matter hereof. Notwithstanding the foregoing, Executive acknowledges that she is required as a condition to continued employment to comply at all times with the Company's policies affecting employees, including the Company's published Code of Conduct, as in effect from  time to time.</font></div><div style="margin-top:11.85pt;padding-left:8.65pt;text-align:justify;text-indent:-36.35pt"><font><br></font></div><div style="padding-left:10.4pt;padding-right:7.15pt;text-align:justify;text-indent:31.49pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16.</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:16.36pt">Equitable Relief. </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Executive recognizes and agrees that the Company's remedy at law for any breach of the provisions of Sections 9, 10, 11 or 12 hereof would be inadequate, and she agrees that for breach of such provisions, the Company shall, in addition to such other remedies as may be available to it at law or in equity or as provided in this Agreement, be entitled to injunctive relief and to enforce its rights by an action for specific performance. Should Executive engage in any activities prohibited by this Agreement, she agrees to pay over to the Company all compensation, remuneration or monies or property of any sort received in connection with such activities&#59; such payment shall not impair any rights or remedies of the Company or obligations or liabilities of Executive which such parties may have under this Agreement or applicable law.</font></div><div style="padding-left:10.4pt;padding-right:7.15pt;text-align:justify"><font><br></font></div><div style="padding-left:10.4pt;padding-right:7.15pt;text-align:justify;text-indent:31.49pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">17.</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:16.99pt">Amendments. </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">This Agreement may not be amended, nor shall any change, waiver, modification, consent or discharge be effected except by written instrument executed by the Company and Executive.</font></div><div style="padding-left:10.4pt;padding-right:7pt;text-align:justify;text-indent:31.49pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">18.</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:16.99pt">Severability. </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">If any part of any term or provision of this Agreement shall be held or deemed to be invalid, inoperative or unenforceable to any extent by a court of competent jurisdiction, such circumstances shall in no way affect any other term or provision of this Agreement, the application of such term or provision in any other circumstances, or the validity or enforceability of this Agreement. Executive agrees that the restrictions set forth in Sections 11 and 12 above (including, but not limited to, the geographical scope and time period of restrictions) are fair and reasonable and are reasonably required for the protection of the interests of the Company and its affiliates. In the event that any provision of Section 11 or 12 relating to time period and&#47;or areas of restriction shall be declared by a court of competent jurisdiction to exceed the maximum time period or areas such court deems reasonable and enforceable, said time period and&#47;or areas of restriction shall be deemed to become and thereafter be the maximum time period and&#47;or areas which such court deems reasonable and enforceable.</font></div><div style="margin-top:11.35pt;padding-left:10.4pt;padding-right:7.6pt;text-align:justify;text-indent:31.49pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">19.</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:16.99pt">Paragraph Headings. </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">The paragraph headings used in this Agreement are included solely for convenience and shall not affect, or be used in connection with, the interpretation hereof.</font></div><div style="margin-top:11.75pt;padding-left:10.4pt;padding-right:7.35pt;text-align:justify;text-indent:31.49pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:123%">20.</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:123%;padding-left:16.36pt">Governing Law. </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:123%">This Agreement shall be governed by and construed and enforced in accordance with the law of the State of Maryland, without regard to the principles of conflict of laws thereof.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:10.4pt;padding-right:7.35pt;text-align:justify;text-indent:31.49pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21.</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:16.36pt">Resolution of Disputes. </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">With the exception of proceedings for equitable relief brought pursuant to Section 16 of this Agreement, any disputes arising under or in connection with this Agreement including, without limitation, any assertion by any party hereto that the other party has breached any provision of this Agreement, shall be resolved by arbitration, to be conducted in Baltimore, Maryland, in accordance with the rules and procedures of the American Arbitration Association. The parties shall bear equally the cost of such arbitration, excluding attorneys' fees and disbursements which shall be borne solely by the party incurring the same&#59; provided, however, that if the arbitrator rules in favor of Executive on at least one material component of the dispute, Company shall be solely responsible for the payment of all costs, fees and expenses (including without limitation Executive's reasonable attorneys' fees and disbursements) of such arbitration. The Company shall reimburse Executive for any such fees and expenses incurred by Executive in any calendar year within a reasonable time following Executive's submission of a request for such reimbursement, which in no case shall be later than the end of the calendar year following the calendar year in which such expenses were incurred. Executive shall submit any such reimbursement request no later than the June 30</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:6.82pt;font-weight:400;line-height:120%;position:relative;top:-3.67pt;vertical-align:baseline">th</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> next following the calendar year in which the fees and expenses are incurred. In the event the arbitrator rules against Executive, Executive shall repay the Company the amount of such reimbursed expenses no later than 180 days following the date as of which such arbitrator's decision becomes final. The provisions of this Section 21 shall survive the termination for any reason of the Term (whether such termination is by the Company, by Executive or upon the expiration of the Term).</font></div><div style="margin-top:11.85pt;padding-right:7.35pt;text-align:justify;text-indent:49.49pt"><font><br></font></div><div style="padding-left:10.4pt;padding-right:7.35pt;text-align:justify;text-indent:31.49pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">22.</font><font style="color:#202020;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:16.36pt">Indemnification&#59; Insurance. </font><font style="color:#202020;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">The Executive shall be entitled to liability and expense indemnification and reimbursement to the fullest extent permitted by the Company's current Amended and Restated By-laws and Second Amended and Restated Certificate of lncorporation, whether or not the same are subsequently amended. During the Term, the Company will use commercially reasonable efforts to maintain in effect directors' and officers' liability insurance no less favorable to Executive than that in effect as of the date of this Agreement.</font></div><div style="padding-left:10.1pt;text-align:justify"><font><br></font></div><div style="padding-left:10.1pt;text-align:justify;text-indent:39.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">23.</font><font style="color:#202020;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:9.38pt">Survival. </font><font style="color:#202020;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Sections 8 through 23 shall survive termination of this Agreement for the period and to the extent specified therein</font></div><div style="text-align:justify;text-indent:57.4pt"><font><br></font></div><div style="margin-top:11.85pt;padding-left:10.1pt;text-align:justify;text-indent:39.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24.</font><font style="color:#202020;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%;padding-left:8.75pt">Protected Conduct. </font><font style="color:#202020;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Nothing in this Agreement prohibits Executive from opposing or reporting to the relevant law-enforcement agency (such as the Securities and Exchange Commission, Equal Employment Commission, or Department of Labor) an event that Executive in good faith believes is a violation of law, requires notice to or approval from the Company before doing so, or prohibits Executive from cooperating in an investigation conducted by such a government agency.</font></div><div style="text-indent:57.4pt"><font><br></font></div><div style="padding-left:10.1pt;text-align:justify;text-indent:39.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25.</font><font style="color:#202020;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:8.75pt">All Duties and At-Will Status Preserved, </font><font style="color:#202020;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">This Agreement creates obligations that supplement, but do not replace or diminish the obligations Executive would otherwise have to the Company. Nothing in this Agreement modifies any at-will employment relationship between the Parties.</font></div><div style="margin-top:12.6pt;padding-left:8.25pt;text-indent:36.45pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#202020;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties have executed or caused to be executed under seal this Agreement as of the date first above written.</font></div><div><font><br></font></div><div style="padding-right:7.05pt;text-indent:-17.95pt"><font><br></font></div><div style="margin-top:11.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;NOVAVAX, INC.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">  &#47;s&#47; John A. Herrmann III        </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name&#58; John A. Herrmann III</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; Executive Vice President &#38; Chief Legal</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;EXECUTIVE&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">   &#47;s&#47; Elaine J. O&#8217;Hara               </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Elaine J. O&#8217;Hara</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.36
<SEQUENCE>8
<FILENAME>nvax-20231231xex1036.htm
<DESCRIPTION>EX-10.36
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i4d96f7efc0d24aaba96dafbe92eccc9a_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:378pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Exhibit 10.36</font></div><div><img alt="image_02a.jpg" src="image_02a.jpg" style="height:54px;margin-bottom:5pt;vertical-align:text-bottom;width:252px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">20 Firstfield Road</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gaithersburg, MD 20878</font></div><div style="margin-top:0.05pt;padding-left:324pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">T 240-268-2000</font></div><div style="padding-left:324pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">F 240-268-2100</font></div><div style="padding-left:369pt"><font><br></font></div><div style="padding-left:369pt;padding-right:27pt"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">www.novavax.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </font></div><div style="padding-left:355.5pt;padding-right:36.65pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nasdaq&#58; NVAX</font></div><div style="margin-top:4.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">May 26, 2020</font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This Offer Letter Supersedes previous Offer Letter, dated May 18, 2020</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Filip Dubovsky, MD, MPH, FAAP</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:90%">&#91; * * * &#93;</font></div><div style="padding-right:360.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:232%">&#91; * * * &#93;</font></div><div style="padding-right:360.35pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:232%">Dear Filip</font></div><div style="padding-right:23.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">I am pleased to offer you the full time position of Senior Vice President &#38; Chief Medical Officer at Novavax, Inc. In this position you will report to Greg Glenn, M.D., President, Research &#38; Development. Your first day of employment is expected to be no later than June 26, 2020.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This offer is contingent upon the following&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.15pt">Successful and satisfactory completion of our standard background check. All information provided by you in your employment application, interviews, and any other verbal or written correspondence will be verified by a third party background checking company or by Novavax. Any discrepancies found may delay your start date or could potentially cause withdrawal of this offer. Candidates cannot begin employment until the background check is completed, including verification of current employment.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.15pt">Your assurance that there are no contractual or other obligations owed by you to previous employers or other parties that would in any way limit your ability to perform your job at the Company. If there are any obligations that might limit your ability to perform, such matters must be disclosed and resolved prior to commencement of employment.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.15pt">Successful verification of your employment eligibility in the United States. In order to verify this information, please be prepared to produce acceptable documents. BY FEDERAL LAW, IT IS REQUIRED THAT YOU PRESENT THIS DOCUMENTATION WITHIN THREE DAYS OF YOUR START AT WORK.</font></div><div style="margin-top:0.05pt;padding-left:41pt"><font><br></font></div><div style="margin-top:0.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The specific terms of this offer are outlined in the enclosed Employment Agreement, and include the following&#58;</font></div><div style="padding-left:41pt;padding-right:23.8pt;text-align:justify"><font><br></font></div><div style="padding-right:23.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">SALARY</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Your initial annualized base salary will be $450,000 per year, payable semi-monthly, less applicable payroll taxes and authorized deductions.</font></div><div style="margin-top:2.35pt"><font><br></font></div><div style="padding-right:23.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">BONUS PROGRAM</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You will be eligible to participate in the Company&#8217;s annual incentive bonus program, under which award payments, if any, will be based on performance criteria and milestones to be mutually determined by the Company, and you will be paid in the following year in which the compensation is earned. Your bonus at 100% of target will be 40% of your earnings for the performance year. For the 2020 performance year, you will receive a full year bonus of at least 100% of target, subject to review and approval by the Board of Directors for 2020 payments to the senior executives. Beyond 2020, your annual incentive bonus will be calculated and paid in the same manner as other senior executives.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.95pt"><font><br></font></div><div style="padding-left:41pt;padding-right:23.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">ONE TIME SIGNING BONUS&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">You are eligible to receive a one-time signing bonus of $68,000. All signing bonus amounts will be paid on a regularly scheduled pay date (subject to applicable withholding and deductions). You agree that in the event that (i) you resign from the company before you have completed twelve (12) full months of service or (ii) the Company terminates your employment for any reason other than a reduction in force before you have completed twelve (12) full months of service, you will then, within seven (7) days of such resignation or termination, refund to the Company the gross amount of the signing bonus paid hereunder.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:41pt;padding-right:23.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">EMPLOYEE EQUITY PLAN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As an employee, you will participate in the Employee Equity Plan (&#8221;Plan&#8221;) established from time to time by the Board of Directors. The objective of the Plan is to allow employees and other stakeholders to build an equity stake in the Company and thereby participate directly in the Company&#8217;s long-term success. Following hiring grants, equity is generally granted to all employees annually at the end of the calendar year.</font></div><div style="margin-top:12.6pt;padding-left:59pt;padding-right:23.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">STOCK OPTIONS&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Upon approval by the Board of Directors or your employment start date (whichever is later) you will receive an initial stock option grant of 30,000 shares of Company common stock, at an exercise price equal to fair market value on the date the options are granted. These stock options are subject to plan limits within the 2015 Stock Option Plan and will vest 50% after the first year from the date of grant and 50% after the second year. The options will be non-qualified stock options to the extent permitted by law and our plan.</font></div><div><font><br></font></div><div style="padding-left:59pt;padding-right:23.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">INITIAL RSU GRANT</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to approval by the Company&#8217;s Board of Directors and plan limits within the 2015 Stock Option Plan, you will be granted Restricted Stock Units (&#8220;RSUs&#8221;) valued at $650,000. You will be restricted from any activity (selling or transferring) in such RSUs until vested&#59; RSUs will vest in three years, one-third per year on the anniversary of the date of grant. You will be responsible for all taxes owed on such Stock as of the date of vesting, and Novavax will be entitled to sell sufficient Stock to address any tax withholding as further specified in an RSU Agreement between you and the Company.</font></div><div style="margin-top:12.05pt;padding-left:59pt;padding-right:23.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">INITIAL ANNUAL GRANT&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to approval by the Company&#8217;s Board of Directors and plan limits within the 2015 Stock Option Plan, you will receive an annual equity grant, along with other senior executives, which will not be subject to pro-ration, if granted during 2020.</font></div><div style="margin-top:11.95pt;padding-right:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Your employment and compensation with Novavax are &#8220;at will&#8221;. At will employment is defined as an employee&#47;employer relationship which may be ended by either the employee or employer at any time, without cause, except as otherwise provided by law or defined in the terms of the Employment Agreement.</font></div><div style="padding-right:5.8pt;text-align:justify"><font><br></font></div><div style="padding-right:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Filip, if you agree with and accept the terms of this offer letter and the Employment Agreement, please sign below and return this letter and the Employment Agreement to my office. We are confident your employment with Novavax will prove mutually beneficial, and we look forward to you joining the Novavax team.</font></div><div style="padding-left:40.5pt;text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Sincerely,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accepted by&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jill Hoyt                   </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Filip Dubovsky             </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Jill Hoyt&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Filip Dubovsky</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Senior Vice President</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Human Resources</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.37
<SEQUENCE>9
<FILENAME>nvax-20231231xex1037.htm
<DESCRIPTION>EX-10.37
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ifadd88a8234143b3b272d35f49bfe093_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4pt;padding-left:7.9pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.37</font></div><div style="margin-top:11.95pt;padding-left:43.47pt;padding-right:43.47pt;text-align:center;text-indent:-35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EMPLOYMENT AGREEMENT</font></div><div style="margin-top:11.95pt;padding-left:14.95pt;padding-right:6.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Employment Agreement (this &#8220;Agreement&#8221;) is dated as of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">May 26, 2020</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, between </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Novavax, Inc.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, (&#8220;Novavax&#8221; or the &#8220;Company&#8221;) a Delaware corporation having its principal office at 21 Firstfield Road, Gaithersburg, MD 20878, and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Filip Dubovsky, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">an individual having a current mailing address of &#91; * * * &#93; (&#8220;Executive&#8221;).</font></div><div style="margin-top:0.05pt;padding-left:14.95pt;padding-right:6.8pt;text-align:justify"><font><br></font></div><div style="margin-top:0.05pt;padding-left:14.95pt;padding-right:6.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, Executive will commence employment with the Company on or about June 26, 2020, now therefore the Company and Executive hereby agree as follows&#58;</font></div><div style="margin-top:11.95pt;padding-left:14.95pt;padding-right:6.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:11.89pt">Employment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company hereby employs Executive and Executive hereby accepts employment as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Senior Vice President &#38; Chief Medical Officer </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">upon the terms and conditions hereinafter set forth, effective the date of employment. As used throughout this Agreement, &#8220;Company&#8221; shall mean and include any and all of its present and future subsidiaries and any and all subsidiaries of a subsidiary. Executive warrants and represents that he is free to enter into and perform this Agreement and is not subject to any employment, confidentiality, non-competition or other agreement which prohibits, restricts, or would be breached by either his acceptance or his performance of this Agreement.</font></div><div style="margin-top:12pt;padding-left:14.95pt;padding-right:6.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:11.89pt">Duties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. During the Term (as hereinafter defined), Executive shall devote his full business time to the performance of services as Senior Vice President &#38; Chief Medical Officer of Novavax, performing such services, assuming such duties and responsibilities as prescribed by the Company&#8217;s President, Research and Development, the Company&#8217;s President and CEO (&#8220;CEO&#8221;) and the Company&#8217;s &#8220;Board of Directors.&#8221; During the Term, Executive&#8217;s services shall be completely exclusive to the Company and he shall devote his entire business time, attention and energies to the business of the Company and the duties which the Company shall assign to him from time to time. Executive agrees to perform his services faithfully and to the best of his ability and to carry out the policies and directives of the Company. Notwithstanding the foregoing, it shall not be a violation of this Agreement for the Executive to serve as a director of any company whose products do not compete with those of the Company and to serve as a director, trustee, officer, or consultant to a charitable or non-profit entity&#59; provided that such service does not adversely affect Executive&#8217;s ability to perform his obligations hereunder. Executive agrees not to take any action that is in bad faith and prejudicial to the interests of the Company during his employment hereunder. Notwithstanding the location where Executive shall be based, as set forth in this Agreement, he also may be required from time to time to perform duties hereunder for reasonably short periods of time outside of said area.</font></div><div style="margin-top:12pt;padding-left:14.95pt;padding-right:6.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:11.89pt">Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The term of this Agreement shall be the period of time beginning on the Executive&#8217;s first date of employment as Senior Vice President &#38; Chief Medical Officer and shall continue for so long as Executive shall be an at-will employee of the Company hereunder.</font></div><div style="margin-top:11.95pt;padding-left:14.95pt;padding-right:6.8pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.39pt">Compensation</font></div><div style="margin-top:12pt;padding-left:13.5pt;padding-right:6.8pt;text-align:justify;text-indent:58.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.57pt">Base Compensation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. For all Executive&#8217;s services and covenants under this Agreement, the Company shall pay Executive an annual salary, which is </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$450,000 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as of the date of this Agreement, as established or ratified by the Board of Directors or an authorized committee thereof (in accordance with established management processes), and payable in accordance with the Company&#8217;s payroll policy as constituted from time to time. The Company may withhold from any amounts payable under this Agreement all required federal, state, city or other taxes and all other deductions as may be required pursuant to any law or government regulation or ruling.</font></div><div style="margin-top:12pt;padding-left:13.5pt;padding-right:6.8pt;text-align:justify;text-indent:58.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.57pt">Bonus Program</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company agrees to pay the Executive a performance and incentive bonus in respect of Executive&#8217;s employment with the Company </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:13.5pt;padding-right:6.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">each year in an amount determined by the CEO and Board of Directors (or any committee of the Board of Directors authorized to make that determination) to be appropriate based upon Executive&#8217;s, and the Company&#8217;s, achievement of certain specified goals, with a target bonus of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">40%</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, or any other percentage determined by the Board of Directors, of Executive&#8217;s base salary during the year to which the bonus relates. Such bonus shall be payable no later than two and one-half months following the year for which the bonus applies. The bonus shall be paid out partly in cash and partly in shares of stock options or restricted stock, at the discretion of the Board of Directors.</font></div><div style="margin-top:12pt;padding-left:14.95pt;padding-right:6.8pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.39pt">Reimbursable Expenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Executive shall be entitled to reimbursement for reasonable expenses incurred by him in connection with the performance of his duties hereunder in accordance with such procedures and policies for executive officers as the Company has heretofore or may hereafter establish. The amount of expenses eligible for reimbursement during any calendar year shall not affect the expenses eligible for reimbursement in any other calendar year, and the reimbursement of an eligible expense shall be made as soon as practicable after Executive submits the request for reimbursement, but not later than December 31 following the calendar year in which the expense was incurred.</font></div><div style="margin-top:11.95pt;padding-left:14.95pt;padding-right:6.8pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.39pt">Benefits</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;padding-left:13.5pt;padding-right:6.8pt;text-align:justify;text-indent:58.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">Executive shall be entitled to four weeks of paid vacation time per year starting from the date of commencement of employment, calculated and administered in accordance with Company policies for executive officers in effect from time to time. The Executive shall be entitled to all other benefits associated with normal full time employment in accordance with Company policies.</font></div><div style="margin-top:12pt;padding-left:13.5pt;padding-right:6.8pt;text-align:justify;text-indent:58.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">Subject to approval by the Board of Directors (or any committee of the Board of Directors authorized to make that determination), Executive shall be entitled to participate in the Company&#8217;s Change of Control Severance Benefit Plan adopted on August 10, 2005, as amended and restated on July 26, 2006 and as further amended on December 31, 2008 and June 15, 2011 (the &#8220;Change of Control Severance Benefit Plan&#8221;).</font></div><div style="margin-top:11.95pt;padding-left:14.95pt;padding-right:6.8pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.39pt">Termination of Employment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;padding-left:13.5pt;padding-right:6.8pt;text-align:justify;text-indent:58.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">Notwithstanding any other provision of this Agreement, Executive&#8217;s employment may be terminated, without such action constituting a breach of this Agreement&#58;</font></div><div style="margin-top:12pt;padding-left:86.95pt;padding-right:6.8pt;text-align:justify;text-indent:21.74pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.55pt">By the Company, for &#8220;Cause,&#8221; as defined in Section 7(b) below&#59;</font></div><div style="margin-top:12pt;padding-left:86.95pt;padding-right:6.8pt;text-align:justify;text-indent:19.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.55pt">By the Company, without Cause</font></div><div style="margin-top:12pt;padding-left:13.5pt;padding-right:6.8pt;text-align:justify;text-indent:93.36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.5pt">By the Company, upon 30 days&#8217; notice to Executive, if he should be prevented by illness, accident or other disability (mental or physical) from discharging his duties hereunder for one or more periods totaling three consecutive months during any twelve- month period.</font></div><div style="margin-top:12pt;padding-left:13.5pt;padding-right:6.8pt;text-align:justify;text-indent:92.74pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.5pt">By the Executive with &#8220;Good Reason&#8221;, as defined in Section 7(c) below, within 30 days of the occurrence or commencement of such Good Reason&#59;</font></div><div style="margin-top:12pt;padding-left:13.5pt;padding-right:6.8pt;text-align:justify;text-indent:95.18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.5pt">By the Executive without Good Reason upon 30 days prior written notice&#59; or</font></div><div style="margin-top:12pt;padding-left:13.5pt;padding-right:6.8pt;text-align:justify;text-indent:92.74pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.5pt">By the event of Executive&#8217;s death during the Term.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:13.5pt;padding-right:6.8pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.07pt">&#8220;Cause&#8221; shall mean (i) Executive&#8217;s failure or refusal to perform in all material respects the services required of him hereby, (ii) Executive&#8217;s failure or refusal to carry out any proper and material direction by the CEO or the Board of Directors with respect to the services to be rendered by him hereunder or the manner of rendering such services, (iii) Executive&#8217;s misconduct in the performance of his duties hereunder, (iv) Executive&#8217;s commission of an act of fraud, embezzlement or theft or a felony involving moral turpitude, (v) Executive&#8217;s use or disclosure of confidential information (as defined in Section 10 of this Agreement), other than for the benefit of the Company in the course of rendering services to the Company, or (vi) Executive&#8217;s engagement in any activity prohibited by Section 11 or 12 of this Agreement. For purposes of this Section 7, the Company shall be required to provide Executive a specific written warning with regard to any occurrence of subsections (b)(i), (ii) and (iii) above, which warning shall include a statement of corrective actions and a 30 day period for the Executive to respond to and implement such actions, prior to any termination of employment by the Company pursuant to Section 7(a)(i) above.</font></div><div style="margin-top:12pt;padding-right:6.8pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.68pt">&#8220;Good Reason&#8221; shall mean (a) the Company&#8217;s material reduction or diminution of Executive&#8217;s responsibilities and authority, other than for Cause, without his consent or (b) the relocation of Executive&#8217;s primary place of employment without his consent.</font></div><div style="margin-top:11.95pt;padding-left:14.95pt;padding-right:6.8pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.39pt">Separation Pay</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;padding-right:6.8pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.07pt">Subject to Executive&#8217;s execution and delivery to the Company of the Company&#8217;s standard form of Separation and Release Agreement, the Company shall pay Executive an amount equal to the Separation Pay upon the occurrence of the applicable Separation Event but in no case later than two and one-half months following the year in which the Separation Event occurs. Separation Pay shall be payable in accordance with the Company&#8217;s payroll policy as constituted from time to time and shall be subject to withholding of all applicable federal, state and local taxes and any other deductions required by applicable law. In the event of Executive&#8217;s death, the Company&#8217;s obligation to pay further compensation hereunder shall cease forthwith, except that Executive&#8217;s legal representative shall be entitled to receive his fixed compensation for the period up to the last day of the month in which such death shall have occurred.</font></div><div style="margin-top:12pt;padding-right:6.8pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.07pt">Section 8(a) above shall not apply should Executive receive severance benefits under the Company&#8217;s Change in Control Severance Benefit Plan.</font></div><div style="margin-top:12pt;padding-right:6.8pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.68pt">&#8220;Separation Pay&#8221; shall mean a lump sum amount equal to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">twelve (12) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">months of Executive&#8217;s then effective salary.</font></div><div style="margin-top:12pt;padding-right:6.8pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.07pt">&#8220;Separation Event&#8221; shall mean&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;padding-right:6.8pt;text-align:justify;text-indent:57.74pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.5pt">the Company&#8217;s termination of Executive&#8217;s employment by the Company without Cause, during the Term&#59; or</font></div><div style="margin-top:12pt;padding-left:36pt;padding-right:6.8pt;text-align:justify;text-indent:55.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.5pt">the termination of Executive&#8217;s employment by the Executive for Good Reason,</font></div><div style="margin-top:11.95pt;padding-right:6.8pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:31.34pt">All Business to be Property of the Company&#59; Assignment of Intellectual Property</font></div><div style="margin-top:12pt;padding-right:6.8pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.07pt">Executive agrees that any and all presently existing business of the Company and all business developed by him or any other employee of the Company including without limitation all contracts, fees, commissions, compensation, records, customer or client lists, agreements and any other incident of any business developed, earned or carried on by Executive for the Company is and shall be the exclusive property of the Company, and (where applicable) shall be payable directly to the Company</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-right:6.8pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.07pt">Executive hereby acknowledges that any plan, method, data, know-how, research, information, procedure, development, invention, improvement, modification, discovery, design, process, software and work of authorship, documentation, formula, technique, trade secret or intellectual property right whatsoever or any interest therein whether patentable or non-patentable, patents and applications therefor, trademarks and applications therefor or copyrights and applications therefor (herein sometimes collectively referred to as &#8220;Intellectual Property&#8221;) made, conceived, created, invested, developed, reduced to practice and&#47;or acquired by Executive solely or jointly with others during the Term is the sole and exclusive property of the Company, as work for hire, and that he has no personal right in any such Intellectual Property. Executive hereby grants to the Company (without any separate remuneration or compensation other than that received by him from time to time in the course of him employment) his entire right, title and interest throughout the world in and to, all Intellectual Property, which is made, conceived, created, invested, developed, reduced to practice and&#47;or acquired by him solely or jointly with others during the Term</font></div><div style="margin-top:12pt;padding-right:6.8pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.68pt">Executive shall cooperate fully with the Company, both during and after his employment with or engagement by the Company, with respect to the procurement, maintenance and enforcement of copyrights, patents and other intellectual property rights (both in the United States and foreign countries) relating to Intellectual Property. Without limiting the foregoing, Executive agrees that to the extent copyrightable, any such original works of authorship shall be deemed to be &#34;works for hire&#34; and that the Company shall be deemed the author thereof under the U.S. Copyright Act, as amended, provided that in the event and to the extent such works are determined not to constitute &#34;works for hire&#34; as a matter of law, Executive hereby irrevocably assigns and transfers to the Company all right, title and interest in such works, including but not limited to copyrights thereof. Executive shall sign all papers, including, without limitation, copyright applications, patent applications, declarations, oaths, formal assignments, assignments of priority rights and powers of attorney, which the Company may deem necessary or desirable in order to protect its rights and interests in any Intellectual Property (at the Company&#8217;s expense) and agrees that these obligations are binding upon his assigns, executors, administrators and other legal representatives. To that end, Executive shall provide current contact information to the Company including, but not limited to, home address, telephone number and email address, and shall update his contact information whenever necessary.</font></div><div style="margin-top:12pt;padding-right:6.8pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.23pt">Confidentiality</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Executive acknowledges his obligation of confidentiality with respect to all proprietary, confidential and non-public information of the Company, including all Intellectual Property. By way of illustration, but not limitation, confidential and proprietary information shall be deemed to include any plan, method, data, know-how, research, information, procedure, development, invention, improvement, modification, discovery, process, work of authorship, documentation, formula, technique, product, idea, concept, design, drawing, specification, technique, trade secret or intellectual property right whatsoever or any interest therein whether patentable or non-patentable, patents and applications therefor, trademarks and applications therefor or copyrights and applications therefor, personnel data, records, marketing techniques and materials, marketing and development plans, customer names and other information related to customers, including prospective customers and contacts at customers, price lists, pricing policies and supplier lists of the Company, in each case coming into Executive&#8217;s possession, or which Executive learns, or to which Executive has access, or which Executive may discover or develop (whether or not related to the business of the Company at the time this Agreement is signed or any information Executive originates, discovers or develops, in whole or in part) as a result of Executive&#8217;s employment by (either full-time or part- time), or retention as a consultant of, the Company. Executive shall not, either during the Term or for a period of ten (10) years thereafter, use for any purpose other than the furtherance of the Company&#8217;s business, or disclose to any person other than a person with a need to know such confidential, proprietary or non-public information for the furtherance of the Company&#8217;s business who is obligated to maintain the confidentiality of such information, any information concerning any Intellectual Property, or other confidential, proprietary or non-public information of the Company, whether Executive has such information in his memory or such information is embodied in writing, electronic or other tangible form.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.95pt;padding-right:6.8pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All originals and copies of any of the foregoing, however and whenever produced, shall be the sole property of the Company. All files, letters, memoranda, reports, records, data, sketches, drawings, program listings, or other written, photographic, or other tangible or electronic material containing confidential or proprietary information or Intellectual Property, whether created by Executive or others, which shall come into Executive&#8217;s custody or possession, shall be and are the exclusive property of the Company to be used by Executive only in the performance of his duties for the Company. All electronic material containing confidential or proprietary information or Intellectual Property will be stored on a computer supplied to Executive by the Company and, under no circumstances, will it be transferred to a personal computer. Executive will promptly deliver to the Company and&#47;or a person or entity identified by the Company all such materials or copies of such materials and all tangible property of the Company in Executive&#8217;s custody or possession, upon the earlier of (i) a request by the Company or (ii) termination of employment or engagement by the Company. After such delivery, Executive will not retain any such materials or copies or any such tangible property or any summaries or memoranda regarding same.</font></div><div style="margin-top:12pt;padding-right:6.8pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.23pt">Non-Competition Covenant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. As the Executive has been granted options to purchase stock in the Company and as such has a financial interest in the success of the Company&#8217;s business and as Executive recognizes that the Company would be substantially injured by Executive competing with the Company, Executive agrees and warrants that within the United States, he will not, unless acting with the Company&#8217;s express prior written consent, directly or indirectly, while an employee of the Company and during the Non-Competition Period, as defined below, engage in the development, production, marketing or sale of products that compete (or, upon commercialization, would compete) with products or candidate products that, as of the date of Executive&#8217;s termination or any date during the following six (6) months, are in clinical development, awaiting regulatory licensure or being actively marketed or sold by the Company&#59; provided, however, that Executive may own, and exercise rights with respect to, less than one percent of the equity of a publicly traded company. The &#8220;Non-Competition Period&#8221; shall be a period of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">twelve (12) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">months following termination of employment.</font></div><div style="margin-top:11.95pt;padding-right:6.8pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive and the Company are of the belief that the period of time and the area herein specified are reasonable in view of the nature of the business in which the Company is engaged and proposes to engage, the state of its business development and Executive&#8217;s knowledge of this business&#59; however, if such period or such area should be adjudged unreasonable in any judicial proceeding, then the period of time shall be reduced by such number of months or such area shall be reduced by elimination of such portion of such area, or both, as are deemed unreasonable, so that this covenant may be enforced in such area and during such period of time as is adjudged to be reasonable.</font></div><div style="margin-top:12pt;padding-right:6.8pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.23pt">Non-Solicitation Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Executive agrees and covenants that he will not, unless acting with the Company&#8217;s express written consent, directly or indirectly, during the Term of this Agreement or during the Non-Competition Period (as defined in Section 11 above) solicit, entice or attempt to entice away or interfere in any manner with the Company&#8217;s relationships or proposed relationships with any customer, officer, employee, consultant, proposed customer, vendor, supplier, proposed vendor or supplier or person or entity or person providing or proposed to provide research and&#47;or development services to, on behalf of or with the Company.</font></div><div style="margin-top:12pt;padding-right:6.8pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.23pt">Notices</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. All notices and other communications hereunder shall be in writing and shall be deemed to have been given on actual receipt after having been delivered by hand, mailed by first class mail, postage prepaid, or sent by Federal Express or similar overnight delivery services, as follows&#58; (a) if to Executive, at the address shown at the head of this Agreement, or to such other person(s) or address(es) as Executive shall have furnished to the Company in writing and, if to the Company, to John A. Herrmann, III, Esq., Senior Vice President, General Counsel and Corporate Secretary, 21 Firstfield Road, Gaithersburg, MD 20878 or to such other person(s) or address(es) as the Company shall have furnished to Executive in writing.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:14.95pt;padding-right:6.8pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.28pt">Assignability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In the event of a change of control (as defined in the Company&#8217;s Change of Control Severance Benefit Plan), the terms of this Agreement shall inure to the benefit of, and be assumed by, the acquiring person (as defined in the Company&#8217;s Change of Control Severance Benefit Plan). This Agreement shall not be assignable by Executive, but it shall be binding upon, and to the extent provided in Section 8 shall inure to the benefit of, his heirs, executors, administrators and legal representatives.</font></div><div style="margin-top:12pt;padding-left:14.95pt;padding-right:6.8pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.28pt">Entire Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Agreement along with (a) the Offer Letter to Executive from the Company dated May 26, 2020, and (b) with the Non-Disclosure, Proprietary Information and Invention Assignment Agreement contain the entire agreement between the Company and Executive with respect to the subject matter hereof and there have been no oral or other prior agreements of any kind whatsoever as a condition precedent or inducement to the signing of this Agreement or otherwise concerning this Agreement or the subject matter hereof. Notwithstanding the foregoing, Executive acknowledges that he is required as a condition to continued employment, to comply at all times, with the Company&#8217;s policies affecting employees, including the Company&#8217;s published Code of Business Ethics, as in effect from time to time.</font></div><div style="margin-top:12pt;padding-left:14.95pt;padding-right:6.8pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.28pt">Equitable Relief</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Executive recognizes and agrees that the Company&#8217;s remedy at law for any breach of the provisions of Sections 9, 10, 11 or 12 hereof would be inadequate, and he agrees that for breach of such provisions, the Company shall, in addition to such other remedies as may be available to it at law or in equity or as provided in this Agreement, be entitled to injunctive relief and to enforce its rights by an action for specific performance. Should Executive engage in any activities prohibited by this Agreement, he agrees to pay over to the Company all compensation, remuneration or monies or property of any sort received in connection with such activities&#59; such payment shall not impair any rights or remedies of the Company or obligations or liabilities of Executive which such parties may have under this Agreement or applicable law.</font></div><div style="margin-top:12pt;padding-left:14.95pt;padding-right:6.8pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.28pt">Amendments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Agreement may not be amended, nor shall any change, waiver, modification, consent or discharge be effected except by written instrument executed by the Company and Executive.</font></div><div style="margin-top:12pt;padding-left:14.95pt;padding-right:6.8pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.28pt">Severability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If any part of any term or provision of this Agreement shall be held or deemed to be invalid, inoperative or unenforceable to any extent by a court of competent jurisdiction, such circumstances shall in no way affect any other term or provision of this Agreement, the application of such term or provision in any other circumstances, or the validity or enforceability of this Agreement. Executive agrees that the restrictions set forth in Sections 10 and 11 above (including, but not limited to, the geographical scope and time period of restrictions) are fair and reasonable and are reasonably required for the protection of the interests of the Company and its affiliates. In the event that any provision of Section 11 or 12 relating to time period and&#47;or areas of restriction shall be declared by a court of competent jurisdiction to exceed the maximum time period or areas such court deems reasonable and enforceable, said time period and&#47;or areas of restriction shall be deemed to become and thereafter be the maximum time period and&#47;or areas which such court deems reasonable and enforceable.</font></div><div style="margin-top:12pt;padding-left:14.95pt;padding-right:6.8pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.28pt">Paragraph Headings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The paragraph headings used in this Agreement are included solely for convenience and shall not affect, or be used in connection with, the interpretation hereof.</font></div><div style="margin-top:12pt;padding-left:14.95pt;padding-right:6.8pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.28pt">Governing Law</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Agreement shall be governed by and construed and enforced in accordance with the law of the State of Maryland, without regard to the principles of conflict of laws thereof.</font></div><div style="margin-top:12pt;padding-left:14.95pt;padding-right:6.8pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.28pt">Resolution of Disputes</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. With the exception of proceedings for equitable relief brought pursuant to Section 16 of this Agreement, any disputes arising under or in connection with this Agreement including, without limitation, any assertion by any party </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:14.95pt;padding-right:6.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">hereto that the other party has breached any provision of this Agreement, shall be resolved by arbitration, to be conducted in Baltimore, Maryland, in accordance with the rules and procedures of the American Arbitration Association. The parties shall bear equally the cost of such arbitration, excluding attorneys&#8217; fees and disbursements which shall be borne solely by the party incurring the same&#59; provided, however, that if the arbitrator rules in favor of Executive on at least one material component of the dispute, Company shall be solely responsible for the payment of all costs, fees and expenses (including without limitation Executive&#8217;s reasonable attorneys&#8217; fees and disbursements) of such arbitration. The Company shall reimburse Executive for any such fees and expenses incurred by Executive in any calendar year within a reasonable time following Executive&#8217;s submission of a request for such reimbursement, which in no case shall be later than the end of the calendar year following the calendar year in which such expenses were incurred. Executive shall submit any such reimbursement request no later than the June 30</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">th </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">next following the calendar year in which the fees and expenses are incurred. In the event the arbitrator rules against Executive, Executive shall repay the Company the amount of such reimbursed expenses no later than 180 days following the date as of which such arbitrator&#8217;s decision becomes final. The provisions of this Section 21 shall survive the termination for any reason of the Term (whether such termination is by the Company, by Executive or upon the expiration of the Term).</font></div><div style="margin-top:12pt;padding-left:14.95pt;padding-right:6.8pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.28pt">Indemnification&#59; Insurance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Executive shall be entitled to liability and expense indemnification and reimbursement to the fullest extent permitted by the Company&#8217;s current Amended and Restated By-laws and Second Amended and Restated Certificate of Incorporation, whether or not the same are subsequently amended. During the Term, the Company will use commercially reasonable efforts to maintain in effect directors&#8217; and officers&#8217; liability insurance no less favorable to Executive than that in effect as of the date of this Agreement.</font></div><div style="margin-top:12pt;padding-left:14.95pt;padding-right:6.8pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:10.28pt">Survival</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Sections 8 through 23 shall survive termination of this Agreement for the period and to the extent specified therein.</font></div><div style="margin-top:11.95pt;padding-left:15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties have executed or caused to be executed under seal this Agreement as of the date first above written.</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;NOVAVAX, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#58; &#47;s&#47; John A. Herrmann III          </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name&#58; John A. Herrmann III</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; Sr Vice President &#38; General Counsel </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;EXECUTIVE&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">   &#47;s&#47; Filip Dubovsky                         </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Filip Dubovsky</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.101
<SEQUENCE>10
<FILENAME>nvax-20231231xex10101.htm
<DESCRIPTION>EX-10.101
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="iaf19c3e881804f65aa8d22eef60092aa_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Exhibit 10.101</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TERMINATION AND SETTLEMENT AGREEMENT</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This TERMINATION AND SETTLEMENT AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is entered into as a deed as of 16 February 2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), by and between Gavi Alliance, an independent non-profit foundation within the meaning of Articles 80 to 89 of the Swiss Civil Code with a registered office at Chemin du Pommier 40, 1218 Le Grand-Saconnex, Geneva, Switzerland (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gavi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and Novavax, Inc., an entity organized and doing business under the laws of Delaware, which maintains its headquarters at 700 Quince Orchard Road, Gaithersburg, MD 20878, U.S.A. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Novavax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Each of Gavi and Novavax are sometimes referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and together as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.&#8221; </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Parties entered into an Advance Purchase Agreement dated May 5, 2021 relating to the supply of Novavax&#8217;s vaccine against SARS-CoV-2 for the prevention of COVID-19 that incorporates NVX-CoV2373 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">APA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Novavax purported to terminate the APA for Gavi&#8217;s alleged material breach in a letter dated November 16, 2022, and Gavi responded on November 22, 2022 disputing Novavax&#8217;s allegation of material breach and itself alleging a material breach by Novavax for which Gavi purported to terminate the APA (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">November Letters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Gavi provided formal notice on December 2, 2022 under Clause 14.1 of the APA that, in view of the November Letters, a dispute under the APA had arisen, and after additional negotiation between the Parties, Gavi initiated arbitration proceedings against Novavax on January 24, 2023 (ICC Arbitration Case No.  27537&#47;PAR, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Parties have agreed&#58; (a) to settle the Arbitration and any and all other disputes or claims arising out of or in connection with the APA, as further contemplated in this Agreement&#59; (b) to terminate the APA, notwithstanding any allegation, term, or statement set forth in the November Letters, the Arbitration, or otherwise&#59; and (c) to provide an opportunity for a continued business relationship between the Parties to advance their shared mission to distribute life-saving vaccines&#59; in each case ((a) &#8211; (c)), in accordance with the terms set forth herein&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Novavax desires to grant, and Gavi desires to receive, a security interest in the Secured Accounts Receivable (as defined below) to secure Novavax&#8217;s obligations under this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOW THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Capitalized terms that are used in this Agreement have the meaning set forth in this Section 1 (Defined Terms)&#58; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.8pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 10(a) (Release by Novavax).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Additional Vaccine Credit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 4(k) (Additional Vaccine Credit).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.8pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means with respect to a Person, any Person that directly, or indirectly through one or more intermediaries, Controls, is Controlled by or is under common Control with such first Person.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Agreed Discrepancy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 4(l) (Disputed Qualifying Sales).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.8pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in the Preamble.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:25.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Alleged Discrepancy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 4(l) (Disputed Qualifying Sales).</font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">APA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in the Preamble.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in the Preamble.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:25.63pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">AMC92</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the countries set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit A (AMC92 Countries)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, as may be amended &#91;***&#93; by notice from Gavi to Novavax, which notice may&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i) remove from Exhibit A any country that is not designated by the World Bank in published data as a low-income country or a lower-middle income country&#59; or</font></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii) add to Exhibit A any country that is designated by the World Bank in published data as a low-income country or a lower-middle income country, </font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">whereupon the term &#8220;AMC92&#8221; shall mean the countries set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit A (AMC92 Countries)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, as so amended.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:25.63pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any day other than a Saturday or Sunday or a day which is a public holiday in Geneva, Switzerland or Maryland, USA.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Calendar Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the respective periods of three consecutive calendar months ending on March 31, June 30, September 30, and December 31.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:25.63pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Calendar Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the 12-month period from January 1 to December 31, inclusive.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.13pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Collateral</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in the Security Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any and all (i) information or material, including any documents, notes, analyses, studies, financial summaries, samples, drawings, diagrams, designs, flowcharts, databases, models and plans, that at any time on or after or prior to the First Payment Date has been or is provided or communicated by or on behalf of one Party (such Party in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) or any of its Representatives to the other Party (such Party in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) or any of its Representatives in connection with this Agreement, the Arbitration or the APA, including any discussions or negotiations with respect thereto and any data, ideas, concepts or techniques contained therein and (ii) modifications thereof or derivations therefrom, including documents, memoranda, notes, studies and analyses prepared by the Receiving Party or its Representatives that contain, incorporate or are derived from the Disclosing Party&#8217;s Confidential Information, in each case, to the extent containing any information or material described in sub-section (i) above.  Confidential Information may be disclosed either orally, visually, electronically, in writing, by delivery of materials containing Confidential Information or in any other form now known or hereafter invented. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Confirmatory Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 8 (Security Interest).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; and, with correlative meanings, the terms &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Controlled by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">under common Control with</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; mean&#58; (i) the power to direct the management or policies of a Person, whether through ownership of voting securities or by contract relating to voting rights or corporate governance, resolution, regulation or otherwise&#59; or (ii) to own more than 50 per cent of the outstanding voting securities or other ownership interest of such Person. </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">COVAX Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the AMC92 and all countries and economies set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit B (Self-Financing Participants)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:25.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Deferred Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 4(h) (Deferred Payments).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:24.4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Deferred Payment Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the period commencing on the Effective Date and expiring on December 31, 2028. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:25.63pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 1(n) (&#8220;Confidential Information&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(u)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Disputed Qualifying Sales Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 4(l) (Disputed Qualifying Sales).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Disputed Qualifying Sales Response</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 4(l) (Disputed Qualifying Sales).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(w)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.74pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Dollar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">$</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means United States dollar.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in the Preamble.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(y)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 6 (Events of Default).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(z)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.8pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Excess Qualifying Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 4(j) (Excess Qualifying Sales).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(aa)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18.92pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Expert</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means a person having appropriate qualifications, practical experience in accounting or finance, and English-language skills to resolve a dispute arising between the Parties under Section 4(l) (Disputed Qualifying Sales), to be agreed by the Parties within &#91;***&#93; of receipt of a notice by one to the other requiring such agreement, or failing such agreement to be appointed on the application of either Party by the ICC International Centre for ADR in accordance with the ICC Rules for the Appointment of Experts and Neutrals.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ab)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">First Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the date on which Gavi receives the Initial Settlement Payment in full. For the avoidance of doubt, although Section 4(b) (Initial Settlement Payment) stipulates a deadline by which Novavax is obliged to pay the Initial Settlement Payment, the First Payment Date may be a date after the expiry of such deadline, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> Gavi has not exercised its right to terminate this Agreement in accordance with Section 12 (Termination) (in which case, the First Payment Date will never occur). </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ac)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18.92pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Gavi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in the Preamble.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ad)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Gavi Releasees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 10(a) (Release by Novavax).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ae)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18.92pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Gavi Releasors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 10(b) (Release by Gavi).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(af)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">ICC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 17(f) (Dispute Resolution).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ag)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">ICC Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 17(f) (Dispute Resolution).</font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ah)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Initial Settlement Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 4(b) (Initial Settlement Payment).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ai)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Intellectual Property Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means trade marks, service marks, rights in trade names, business names, logos and get-up and any goodwill attaching to the same, patents, rights in inventions, design rights, copyrights (including copyrights in software), database rights, rights in domain names and URLs, rights in Know-how, and all other similar rights in any part of the world including, where such rights are obtained or enhanced by registration, any registration of such rights and applications and rights to apply for such registrations. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(aj)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Know-how</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means industrial and commercial information and techniques, in each case, in any form, and that is not in the public domain, and including instruction, operational and training manuals, reports, drawings, tables of operating conditions, market forecasts, and lists and particulars of customers and suppliers.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ak)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 10(a) (Release by Novavax).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(al)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Novavax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in the Preamble.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(am)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:15.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Novavax AB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means Novavax AB, a private limited liability company organized and existing under the laws of Sweden having its principal place of business at Kungsgatan, 109 Uppsala, SE-753 18 Sweden.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(an)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Novavax Intercompany Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the Novavax Intercompany License Agreement and the Novavax Intercompany Services Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ao)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Novavax Intercompany License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ap)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Novavax Intercompany Services Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(aq)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Novavax Releasees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 10(b) (Release by Gavi).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ar)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Novavax Releasors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 10(a) (Release by Novavax).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(as)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:19.52pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">November Letters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in the Preamble.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(at)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">PAHO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the Pan American Health Organization, the specialized international health agency for the Americas.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(au)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in the Preamble.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(av)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in the Preamble.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(aw)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:15.86pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including a government or political subdivision, department or agency of a government. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ax)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Qualifying Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means all sales of Vaccine by Novavax or a Third Party Acquiror or their Affiliates during the Deferred Payment Term under purchase orders placed by </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">UNICEF or PAHO on behalf of any AMC92 country, to the extent such sale is funded by Gavi (or would have been funded by Gavi, in the absence of the Yearly Vaccine Credit and Additional Vaccine Credit).  A Qualifying Sale shall be deemed to have occurred on the date on which &#91;***&#93; in accordance with the terms of the procurement agreement applicable to the sale of such Vaccine. For the purposes of calculating the value of Qualifying Sales under this Agreement, the per-dose Vaccine price in any AMC92 country will be the actual contract price of the sale agreed between, on the one hand, Novavax (or its Third Party Acquiror, or their Affiliates, as applicable) and, on the other hand, the purchaser thereof. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ay)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Qualifying Sales Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means a report setting out the number and value of Qualifying Sales made in the previous Calendar Quarter, together with the purchase order numbers pursuant to which such Qualifying Sales were made, in the form set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 1(yy) (Documentation for Qualifying Sales Notice)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(az)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18.92pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 1(n) (Confidential Information).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ba)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Rejection Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 4(m) (Restoration of Credit). </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(bb)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Remaining Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, as of a reference date, the Settlement Amount </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> any cash payments (including the Initial Settlement Payment and Deferred Payments) received by Gavi in accordance with this Agreement and Qualifying Sales that have been applied to reduce any Deferred Payment in accordance with this Agreement (and that are not the subject of an unresolved Disputed Qualifying Sales Notice), in each case as of such date. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(bc)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, with respect to any Person, such Person&#8217;s attorneys, accountants and other experts and advisers that are not Affiliates.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(bd)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Restored Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 4(m) (Restoration of Credit).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(be)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18.3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Secured Accounts Receivable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 8 (Security Interest).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(bf)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:19.52pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Security</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means a mortgage, charge, pledge, lien or other security interest securing any obligation of any person or any other agreement or arrangement having a similar effect.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(bg)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Security Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 8 (Security Interest).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(bh)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Security Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in the Security Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(bi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.13pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Serum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the Serum Institute of India Pvt. Ltd.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(bj)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.13pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Serum License and Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the License and Supply Agreement dated as of March 10, 2020, by and between Novavax AB and Serum, including any amendments, supplements or extensions to such agreement, including the assignment and transfer by Novavax AB of all of its rights and liabilities thereunder and delegation of its obligations thereunder, in each case, to Novavax.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(bk)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Settlement Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 4(a) (Settlement Amount).</font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(bl)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.13pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Settlement Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means this Agreement, the Security Agreement, and the Confirmatory Assignment. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(bm)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.63pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Solvency-Related Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the occurrence of any of the following&#58; (a) any Party (i) shall institute any proceeding or voluntary case seeking to adjudicate it a bankrupt or insolvent, or seeking dissolution, liquidation, winding up, reorganization, arrangement, adjustment, protection, suspension of payments, moratorium of any indebtedness, relief or composition of it or its debts under any law relating to bankruptcy, insolvency, reorganization or relief of debtors, or seeking the entry of an order for relief or the appointment of a receiver, trustee, custodian or other similar official for any such Party or for any substantial part of its property, including, for the avoidance of doubt, the filing of any voluntary or involuntary case under the US Bankruptcy Code with respect to a Party, (ii) shall make a general assignment for the benefit of creditors, or (iii) shall take any action to authorize or effect any of the actions set forth above in this subsection (a)&#59; or (b) any proceeding shall be instituted against any Party seeking to adjudicate it a bankrupt or insolvent, or seeking dissolution, liquidation, winding up, reorganization, arrangement, adjustment, protection, suspension of payments, moratorium of any indebtedness, relief of debtors, or seeking the entry of an order for relief or the appointment of a receiver, trustee, custodian or other similar official for any such Party or for any substantial part of its property, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> any such proceeding is not a frivolous or vexatious proceeding and is not discharged, dismissed or stayed within &#91;***&#93; of commencement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(bn)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Third Party Acquiror</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means a Third Party that acquires&#58; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i) Novavax&#59; or </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii) substantially all of the assets of Novavax or its Affiliates relating to vaccine products that were owned or controlled by Novavax or its Affiliates immediately prior to the date of such acquisition. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">For the purposes of this definition, &#8220;owned or controlled&#8221; by a company means that company is the seller of a particular vaccine product and books the sale of such product.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(bo)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any Person other than a Party or its Affiliates.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(bp)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Transfer Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 9 (Transfer of Serum License and Supply Agreement).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(bq)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">UNICEF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the United Nations Children&#8217;s Fund.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(br)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:19.52pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">US Bankruptcy Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means title 11 of the United States Code, 11 U.S.C. 101 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">et seq.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(bs)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18.9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Vaccine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any vaccine product that is owned or controlled by&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:25.63pt">Novavax&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.58pt">any Affiliate of Novavax&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:19.53pt">(subject to the proviso below) a Third Party Acquiror&#59; or </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.13pt">(subject to the proviso below) any Affiliate of a Third Party Acquiror,</font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">in each case ((i) to (iv)), including any product&#58; (A) incorporating NVX-CoV2373 or any updated or improved version thereof or any other vaccine product against a variant of SARS-CoV2&#59; or (B) co-packaged or sold either as a single fixed dose&#47;unit or as separate doses&#47;units in a single package for co-administration either simultaneously or sequentially, in either case, with NVX-CoV2373 or any update or improved version thereof or any other vaccine product against a variant of SARS-CoV2, such as a COVID-19&#47;flu combination vaccine.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Notwithstanding the foregoing, a vaccine product that is owned or controlled by a Third Party Acquiror or any Affiliate of a Third Party Acquiror will be deemed a Vaccine hereunder only if&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i) it was owned or controlled by Novavax or its Affiliates immediately prior to the date of such acquisition&#59; or </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii) it&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;a. is owned or controlled by (a) Novavax&#59; or (b) Novavax&#8217;s Affiliates (including Affiliates that become Affiliates of Novavax as a result of such acquisition)&#59; or (c) a Third Party Acquiror&#59; or (d) a Third Party Acquiror&#8217;s Affiliates, in each case ((a) to (d)) on or after the date of such acquisition&#59; and </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;b. incorporates or makes use of the proprietary adjuvant technology belonging to Novavax or its Affiliates immediately before such acquisition, as such technology existed as of the date of such acquisition.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">For the purposes of this definition, &#8220;owned or controlled&#8221; by a company means that company is the seller of a particular vaccine product and books the sale of such product.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(bt)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.13pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Voidable Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 17(g) (No Avoidance of Settlement Amount).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(bu)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Yearly Vaccine Credit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 4(d) (Yearly Vaccine Credit).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Secretary&#8217;s Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. On or prior to the Effective Date, Gavi shall have received a certificate, signed on behalf of Novavax by its corporate secretary, and on behalf of Novavax AB by its Managing Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">in the form set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 2 (Form of Secretary&#8217;s Certificate)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, which will be delivered with the attachments referenced therein. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Termination of the APA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Parties hereby acknowledge and agree that, on the First Payment Date, and notwithstanding their respective positions in the Arbitration, the APA will be terminated in its entirety.  With effect on and after the First Payment Date&#58; (i) neither Party will have any further rights or obligations under the APA&#59; and (ii) no provisions of the APA survive termination of the APA.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Settlement Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Novavax hereby agrees to pay Gavi an aggregate amount of $475,000,000 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Settlement Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) in immediately available funds in full and final settlement of the Arbitration and any and all other disputes or claims arising out of or in connection with the APA, which amounts shall be payable in installments as follows&#58; (i) the Initial Settlement Payment as set forth in Section 4(b) (Initial Settlement </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Payment)&#59; and (ii) the Deferred Payments as set forth in Section 4(h) (Deferred Payments), subject to reduction for Qualifying Sales made during the Deferred Payment Term in accordance with this Section 4 (Payments). </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Initial Settlement Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  By no later than &#91;***&#93; after the Effective Date, Novavax will pay Gavi a non-refundable payment in immediately available funds of $75,000,000 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Initial Settlement Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) by wire transfer in accordance with the following wire instructions&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%"> </font></div><div style="padding-left:108pt"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#93;</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Payment Details.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Save where otherwise expressly set forth in this Agreement, all payments due from Novavax to Gavi in accordance with this Agreement shall be made by wire transfer, in immediately available funds, in accordance with the wire instructions set forth in Section 4(b) (Initial Settlement Payment), or such other wire instructions as may be notified in writing by Gavi to Novavax no less than &#91;***&#93; prior to the date on which such Deferred Payment falls due. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Yearly Vaccine Credit.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As of the date hereof, Novavax agrees to grant to Gavi five credits of $80,000,000, one for each of the five Calendar Years of the Deferred Payment Term (each such Calendar Year credit, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Yearly Vaccine Credit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) (for a total of $400,000,000 in Yearly Vaccine Credits) to be applied against any Qualifying Sales during the applicable Calendar Year. Each Yearly Vaccine Credit, and Gavi&#8217;s right to apply such credit against any Qualifying Sales, will expire upon the expiration of the applicable Calendar Year for such Yearly Vaccine Credit, regardless of the amount of Yearly Vaccine Credit then remaining.  For clarity, Novavax shall release (or shall cause any applicable selling Third Party Acquiror or their Affiliates to release) Gavi (or, at Gavi&#8217;s direction, UNICEF or PAHO) irrevocably from any obligation they may otherwise have to pay in cash for Qualifying Sales of Vaccine, up to the value of the Yearly Vaccine Credit remaining in the applicable Calendar Year after reductions have been applied in accordance with Section 4(f) (Reduction of Yearly Vaccine Credit), plus any remaining Additional Vaccine Credit as provided in Section 4(k) (Additional Vaccine Credit).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Amendment of Procurement Terms. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Novavax agrees that, upon the request of UNICEF or PAHO (as applicable), it shall agree (or, if applicable, shall cause any relevant Third Party Acquiror or Affiliate to agree) to such amendments or additions to the terms of any existing or future agreement (but excluding any agreed purchase order under any such agreement) to which UNICEF or PAHO is a counterparty for the procurement of Vaccine as may be necessary or reasonable to enable UNICEF or PAHO to obtain full benefit from the Yearly Vaccine Credit (including by extending UNICEF or PAHO&#8217;s deadline to pay Novavax (or applicable Third Party Acquiror or Affiliate) for Vaccine such that UNICEF or PAHO is not required to pay Novavax (or applicable Third Party Acquiror or Affiliate) prior to the time when Novavax would recognize a Qualifying Sale and Gavi would be entitled to the corresponding Yearly Vaccine Credit or Additional Vaccine Credit (as applicable) in accordance with this Agreement). </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.02pt">Reduction of Yearly Vaccine Credit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to Section 4(m) (Restoration of Credit), the total amount of the Yearly Vaccine Credit for an applicable Calendar Year will be reduced on a Dollar-for-Dollar basis for such Calendar Year upon the occurrence, and in the amount, of each of&#58; (i) Novavax&#8217;s cash payment of each Deferred Payment in accordance with Section 4(h) (Deferred Payments)&#59; and (ii) Qualifying Sales evidenced by Gavi&#8217;s receipt of a Qualifying Sales Notice. The Yearly Vaccine Credit in any given Calendar Year shall not be reduced to an amount less than zero. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">No Purchase Obligation&#59; No Sale Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Neither Gavi, nor any Person entitled to benefit from the Yearly Vaccine Credit and Additional Vaccine Credit, is under any </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">obligation, at any time, to purchase any doses of Vaccines or to fund any purchase of Vaccines pursuant to this Agreement. Notwithstanding any provision to the contrary set forth in this Agreement, Gavi acknowledges and agrees that Novavax has the sole right to set the price per dose for Vaccines it offers to supply to UNICEF or PAHO.  Nothing in this Agreement obliges Novavax, at any time, to sell doses to UNICEF or PAHO at any price below the price offered by Novavax in a tender offer to UNICEF or PAHO, as applicable.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Deferred Payments.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prior to the expiration of the Deferred Payment Term, Novavax will pay Gavi an amount equal to $400,000,000 in immediately available funds, divided into equal annual amounts of $80,000,000 each Calendar Year of the Deferred Payment Term, payable in quarterly installments for each Calendar Quarter during the Deferred Payment Term in the amounts set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 4(h) (Deferred Payment Schedule)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (each such payment, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Deferred Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  No later than &#91;***&#93; after the end of each Calendar Quarter, Novavax will&#58; (i) provide Gavi with a complete and accurate Qualifying Sales Notice for all Qualifying Sales in such Calendar Quarter&#59; and (ii) subject to Section 4(i) (Deferred Payment Reductions), pay the Deferred Payment for such Calendar Quarter to Gavi in such amount as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 4(h) (Deferred Payment Schedule)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.63pt">Deferred Payment Reductions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding Section 4(h) (Deferred Payments), the Deferred Payment amount that Novavax is obligated to pay Gavi with respect to a Calendar Quarter (as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 4(h) (Deferred Payment Schedule)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) will be reduced, subject to Section 4(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Disputed Qualifying Sales) and Section 4(m) (Restoration of Credit), on a Dollar-for-Dollar basis by&#58; (i) the value of the Qualifying Sales made in such Calendar Quarter as evidenced by a Qualifying Sales Notice&#59; and (ii) any Excess Qualifying Sales that are applied to reduce the amount of such Deferred Payment pursuant to Section 4(j) (Excess Qualifying Sales)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that no Deferred Payment will be less than zero.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.63pt">Excess Qualifying Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If the amount of all Qualifying Sales in a Calendar Quarter, as evidenced by a Qualifying Sales Notice, exceeds the Deferred Payment amount for such Calendar Quarter (the amount of such excess, if any, being the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Excess Qualifying Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), then Novavax may carry forward such Excess Qualifying Sales and apply them on a Dollar-for-Dollar basis against any Deferred Payment due in the same Calendar Year as such Calendar Quarter. For the avoidance of doubt, any such Excess Qualifying Sales may not be applied against Deferred Payments in any Calendar Year other than the Calendar Year in which such Qualifying Sales occurred. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Additional Vaccine Credit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  As of the date hereof, Novavax agrees to grant to Gavi a credit of $225,000,000 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Additional Vaccine Credit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to be applied against any Qualifying Sales in any Calendar Year after the Yearly Vaccine Credit for such Calendar Year has been fully applied against Qualifying Sales in such Calendar Year. The total amount of the Additional Vaccine Credit will be reduced on a Dollar-for-Dollar basis by the amount of any Qualifying Sales it is applied against, evidenced by Gavi&#8217;s receipt of a Qualifying Sales Notice. The Additional Vaccine Credit will expire upon the expiration of the Deferred Payment Term, regardless of the amount of the Additional Vaccine Credit then remaining, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that if Novavax (or its Affiliate) agrees to deliver Vaccines to UNICEF or PAHO, or under any agreement with UNICEF or PAHO, in the last Calendar Year of the Deferred Payment Term, but such Vaccines are actually delivered after the expiration of the Deferred Payment Term, then the Additional Vaccine Credit may be credited against Qualifying Sales for such Vaccines.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.63pt">Disputed Qualifying Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:25.63pt">No later than &#91;***&#93; after Gavi&#8217;s receipt of a Qualifying Sales Notice in respect of a Calendar Quarter where the value of any Qualifying Sales specified therein has been applied against the Yearly Vaccine Credit in accordance with Section 4(f) </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(Reduction of Yearly Vaccine Credit) or Additional Vaccine Credit in accordance with Section 4(k) (Additional Vaccine Credit), or in reduction of a Deferred Payment in accordance with Section 4(i) (Deferred Payment Reductions), if Gavi reasonably believes, acting in good faith, that the true value of the Qualifying Sales in that Calendar Quarter is less than the value of the Qualifying Sales specified in the corresponding Qualifying Sales Notice (such alleged difference in value, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Alleged Discrepancy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), then Gavi may provide written notice to Novavax of the Alleged Discrepancy, such notice specifying in &#91;***&#93; detail Gavi&#8217;s basis for asserting there is an Alleged Discrepancy (such notice a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Disputed Qualifying Sales Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;). </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.58pt">Novavax shall have a period of &#91;***&#93; after receipt of the Disputed Qualifying Sales Notice to provide Gavi with a &#91;***&#93; response (such response a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Disputed Qualifying Sales Response</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;)&#58; (a) confirming that Novavax agrees that the true value of the Qualifying Sales in the Calendar Quarter do not match the value of the Qualifying Sales specified in the corresponding Qualifying Sales Notice (the amount of any agreed discrepancy being an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Agreed Discrepancy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;)&#59; or (b) if Novavax, reasonably believes, acting in good faith, that there is not an Alleged Discrepancy or that the actual discrepancy is less than the Alleged Discrepancy asserted by Gavi in its Disputed Qualifying Sales Notice, providing Gavi with Novavax&#8217;s basis for that belief in reasonable detail. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:19.53pt">If Novavax does not provide Gavi with a Disputed Qualifying Sales Response within &#91;***&#93; after receipt of a Disputed Qualifying Sales Notice, then the Disputed Qualifying Sales Notice shall be final and binding on the Parties for all purposes, and the full amount of the Alleged Discrepancy specified in the Disputed Qualifying Sales Notice shall be treated from that date as an Agreed Discrepancy for the purposes of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.13pt">If Novavax provides Gavi with a Disputed Qualifying Sales Response within &#91;***&#93; after receipt of a Disputed Qualifying Sales Notice where Novavax disputes the existence of some or all of the Alleged Discrepancy, then the Parties shall negotiate in good faith, for a period of &#91;***&#93; after Gavi&#8217;s receipt of such Disputed Qualifying Sales Response, regarding the amount (if any) of such discrepancy. If the Parties reach agreement as to the amount (if any) of such discrepancy within such &#91;***&#93; period, then the amount agreed shall be treated from the date of such agreement as an Agreed Discrepancy for the purposes of this Agreement. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.18pt">If the Parties are unable to reach agreement within &#91;***&#93; after Gavi&#8217;s receipt of such Disputed Qualifying Sales Response, then either Party may by written notice to the other require that the dispute be referred to an Expert and the procedure set out in Schedule 4(l) (Expert Determination Procedure) shall apply. The discrepancy (if any) determined by the Expert in accordance with Schedule 4(l) (Expert Determination Procedure) shall be treated as an Agreed Discrepancy from the date of the Expert&#8217;s determination for the purposes of this Agreement. Notwithstanding any provision to the contrary set forth in this Agreement, a Party&#8217;s dispute as to the adequacy of the information contained within a purported Disputed Qualifying Sales Notice or purported Disputed Qualifying Sales Response will not prevent or delay the other Party from referring a dispute to an Expert in accordance with this Section 4(l)(v).  </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.13pt">In the event that there is an Agreed Discrepancy, there shall immediately be a corresponding restoration to the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Yearly Vaccine Credit for the Calendar Year in which Novavax recorded such Qualifying Sale or the Additional Vaccine Credit, as applicable, in accordance with Section 4(m) (Restoration of Credit).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:20.13pt">Restoration of Credit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If either&#58; (i) Novavax and a Vaccine customer agree, or it is finally determined through the applicable dispute resolution procedure for such Vaccine customer, that Vaccine delivered in a Qualifying Sale and applied against the Yearly Vaccine Credit in accordance with Section 4(f) (Reduction of Yearly Vaccine Credit) or Additional Vaccine Credit in accordance with Section 4(k) (Additional Vaccine Credit) was properly rejected by such customer and as a result such customer requested and was entitled to a refund by Novavax (rather than Novavax providing replacement Vaccine) (the date of such agreement or final determination, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Rejection Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; or (ii) there is an Agreed Discrepancy pursuant to Section 4(l) (Disputed Qualifying Sales), then, the Yearly Vaccine Credit for the Calendar Year in which Novavax recorded such Qualifying Sale for such rejected Vaccine or Agreed Discrepancy, or the Additional Vaccine Credit, as applicable, will be restored in the amount of such rejected Qualifying Sale or Agreed Discrepancy (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Restored Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). If such Restored Amount was used to reduce one or more Deferred Payments in accordance with Section 4(i) (Deferred Payment Reductions) and there were no other Qualifying Sales in such Calendar Year that could be used to reduce the amount of the cash Deferred Payment in accordance with Section 4(j) (Excess Qualifying Sales) (including because the Calendar Year in which the Qualifying Sale was made has ended), then Novavax will pay Gavi such Restored Amount in cash within &#91;***&#93; after the Rejection Date or date of an Agreed Discrepancy (as applicable) that gave rise to the Restored Amount. For clarity, if a Vaccine customer receives replacement Vaccine for rejected Vaccine at no charge, then the Yearly Vaccine Credit or Additional Vaccine Credit used to purchase such rejected Vaccine will not be restored.    </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Vaccine Purchases</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Gavi will&#58; (i) if requested to do so by written notice (provided &#91;***&#93;) from Novavax, inform UNICEF and PAHO annually in writing of the existence of the Yearly Vaccine Credit and Additional Vaccine Credit&#59; (ii) provide a copy of each such written notice to Novavax&#59; and (iii) not &#91;***&#93; influence UNICEF or any AMC92 country, or their employees, officials, or other representatives to (A) dissuade them from purchasing Vaccines or (B) alter the decision to purchase or procure Vaccines from Novavax, or the timing of Qualifying Sales, in each case (A) and (B), in a manner intended to reduce the amount of reductions to cash Deferred Payments pursuant to Section 4(i) (Deferred Payment Reductions). For the avoidance of doubt, Gavi will not be taken to &#91;***&#93; influence any of the foregoing Person(s) by reason of its sharing, in the ordinary course of its activities, data with such Person(s) regarding the characteristics of Vaccine(s) or other vaccine product(s), (including, data concerning vaccine presentations, pricing, indicative wastage rates, manufacturers, cold chain volume or handling). </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Examples.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For example, and without limitation, the below chart sets forth example scenarios of how Qualifying Sales are applied against Deferred Payments owed to Gavi and the outstanding balance of the Yearly Vaccine Credit and Additional Vaccine Credit, with each example assuming that&#58; (i) no Qualifying Sales are subject to Section 4(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Disputed Qualifying Sales) or Section 4(m) (Restoration of Credit)&#59; and (ii) save whether otherwise indicated, Qualifying Sales are spread evenly over each Calendar Quarter of the Deferred Payment Term&#58; </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:22.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.331%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:109%">Qualifying Sales</font></td><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:109%">Deferred Payments made in cash by Novavax to Gavi</font></td><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.25pt;text-align:center;text-indent:-4.5pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:109%">Total Yearly Vaccine Credits applied during Deferred Payment Term</font></td><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.25pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:109%">Additional Vaccine Credit applied during Deferred Payment Term</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">$0 each Calendar Year during Deferred Payment Term</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">$80M each Calendar Year, with total of $400M paid in cash by end of Deferred Payment Term</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:-27pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">$0M</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:-36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">$0M</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">$40M each Calendar Year during Deferred Payment Term</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">$40M each Calendar Year, with total of $200M paid in cash by end of Deferred Payment Term</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 14.5pt;text-align:center;text-indent:-27pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">$200M</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:-36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">$0M</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">$80M each Calendar Year during Deferred Payment Term</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">$0</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:-27pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">$400M</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:-36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">$0M</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">$100M each Calendar Year during Deferred Payment Term</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:-36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">$0</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:-27pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">$400M</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:-36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">$100M</font></td></tr></table></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:22.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.331%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">$200M in one Calendar Year, and 0$ during all other Calendar Years</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:-36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">$320M</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">$80M (in one Calendar Year)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">$120M (in one Calendar Year)</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">$100M in the final Calendar Quarter of 2024 and $0 subsequently</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$5M, $10M, $25M in respect of the first, second and third Calendar Quarters of 2024, respectively&#59; $0 in respect of the fourth Calendar Quarter of 2024</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">$80M in each of the Calendar Years 2025, 2026, 2027 and 2028, with a total of $320M paid in cash for these four Calendar Years</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 5.5pt 2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">$40M in 2024&#59; $0 in each subsequent Calendar Year</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:-36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">$60M (in 2024)</font></td></tr></table></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding any provisions to the contrary contained in the APA or in any other written agreement or other arrangement between the Parties, but without prejudice to the Parties&#8217; rights and remedies in respect of any breach of any Settlement Document or upon the occurrence of any Event of Default, the Parties expressly acknowledge and agree that, as of the First Payment Date, save for the amounts owed by Novavax under this Agreement and the Security Agreement&#59; (i) no other amounts are owed by Novavax or Gavi under the APA or any other written agreement or other arrangement between the Parties&#59; (ii) Novavax is not obligated to pay, and Gavi is not entitled to receive, any further amounts under the APA or any other written agreement or other arrangement between the Parties&#59; (iii) Gavi is not obligated to pay, and Novavax is not entitled to receive, any amounts under the APA, this Agreement or any other written agreement or other arrangement between the Parties&#59; and (iv) the Parties expressly waive any right to receive any other or additional payment under the APA or any other written agreement or other arrangement between the Parties.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Prepayment of Entire Remaining Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Novavax may pay the entire amount of the Remaining Payments in cash at any time in its sole discretion, and upon the date of Gavi&#8217;s receipt of such payment in full together with any other amounts accrued or outstanding under this Agreement&#59; (a) all unpaid Deferred Payments will be paid in full and (b) all Yearly Vaccine Credits unapplied as of such date will expire.  The Security Agreement, and therefore also the Security Interest, will be terminated and of no further force and effect upon the date of Gavi&#8217;s receipt of such pre-payment in full of the Remaining Payments (together with any other amounts accrued or outstanding under this </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Agreement) in accordance with this Section 4(q) (Prepayment of Entire Remaining Payments). For the avoidance of doubt, Novavax&#8217;s pre-payment of the Remaining Payments as contemplated by this Section 4(q) (Prepayment of Entire Remaining Payments) will have no effect on the Additional Vaccine Credit, which may continue to be applied to Qualifying Sales during the Deferred Payment Term and, for the purposes of Section 4(k) (Additional Vaccine Credit), the requirement that the Yearly Vaccine Credit for a Calendar Year be fully applied before Qualifying Sales may be applied against the Additional Vaccine Credit shall be disregarded. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Interest. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.8pt">If Novavax fails to pay when due any Deferred Payment or Restored Amount payable under this Agreement (including where such amounts become due by virtue of acceleration in accordance with Section 7 (Acceleration)), Novavax shall pay interest on such overdue sum from the date when such payment became due until the date of actual payment (whether before or after any judgment or award) at a rate per annum of &#91;***&#93;. Such interest shall accrue &#91;***&#93; and shall be compounded &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.18pt">For the purposes of this Section 5 (Interest)&#58;   </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:25.63pt">where a Restored Amount arises from an Agreed Discrepancy that was caused by Novavax&#8217;s negligence, fraud or willful misconduct, the payment shall be treated as overdue from the date on which the reduction to the relevant Deferred Payment occurred in accordance with Section 4(i) (Deferred Payment Reductions)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.58pt">where a Restored Amount arises for any other reason, the payment of the Restored Amount shall be treated as overdue from the date that is &#91;***&#93; after the Rejection Date or date of the Agreed Discrepancy (as applicable) that gave rise to the Restored Amount, in accordance with Section 4(m) (Restoration of Credit). </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Events of Default. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Each of the following shall be an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; under this Agreement, unless explicitly waived by Gavi (and, for the avoidance of doubt, references to &#8220;Novavax&#8221; and &#8220;Novavax AB&#8221; in this Section 6 shall also include their respective successors and assigns)&#58; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.8pt">Novavax does not pay, within &#91;***&#93; of the due date thereof, any Deferred Payment or Restored Amount payable to Gavi pursuant to this Agreement,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%"> provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that such &#91;***&#93; period shall be tolled with respect to the amount (if any) of a Deferred Payment that is the subject of a non-frivolous, non-vexatious dispute, during the pendency of any dispute resolution procedure initiated by Novavax for resolution of such dispute in accordance with Section 17(f) (Dispute Resolution)&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.18pt">Novavax breaches the covenant set forth in Section 13(e)(i), provided that&#58; (i) the breach is not capable of remedy&#59; or (ii) Novavax fails to remedy the breach within &#91;***&#93; of Gavi giving notice to Novavax of the breach&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.8pt">Novavax breaches the covenant set forth in Section 13(e)(vi), provided that&#58; (i) the breach is not capable of remedy&#59; or (ii) Novavax fails to remedy the breach within &#91;***&#93; of the earlier of&#58; (x) Gavi giving notice to Novavax of the breach&#59; and (y) Novavax becoming aware of the breach&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.18pt">Novavax or Novavax AB materially breaches an express provision of any of the Settlement Documents (other than a breach referred to in Sections 6(a), 6(b) or 6(c), </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">which shall give rise to an Event of Default in the circumstances set out in Sections 6(a), 6(b) or 6(c), respectively), which has or can reasonably be expected to have a material adverse effect on&#58; (a) the validity, effectiveness, ranking or enforceability of the Security Interest&#59; or (b) the Secured Accounts Receivable&#59; or (c) the ability of Novavax to comply with its payment obligations under the Settlement Documents, provided that&#58; (i) the material breach and corresponding effect on the Security Interest or Secured Accounts Receivable or payment obligations are not capable of remedy&#59; or (ii) Novavax or Novavax AB (as applicable) fails to remedy the material breach and corresponding effect on the Security Interest or Secured Accounts Receivable or payment obligations within &#91;thirty (30) days&#93; of Gavi giving notice to Novavax of the breach&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.8pt">Novavax&#58; (i) rescinds, or purports to rescind, or repudiates, or purports to repudiate, any of the Settlement Documents, or the Security Interest created or expressed to be created thereunder, or directly or indirectly itself or through any Affiliate (including Novavax AB)&#59; (ii) contests the validity or enforceability of any of the Settlement Documents, or the Security Interest created or expressed to be created thereunder&#59; (iii) a proceeding is commenced by Novavax or any of its Affiliates (including Novavax AB) seeking to establish the invalidity or unenforceability of any of the Settlement Documents, or the Security Interest created or expressed to be created thereunder&#59; or (iv) Novavax or one of its Affiliates (including Novavax AB) denies in writing that it has any liability or obligation purported to be created under any of the Settlement Documents&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:25.02pt">any of the Settlement Documents, the Security Interest or any of Novavax&#8217;s obligations created or expressed to be created thereunder, ceases to be legal, valid, binding, effective, or enforceable&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.18pt">one or more of the following occurs&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:25.63pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.58pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that, in the case of (i) only&#58; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(A) &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(B) &#91;***&#93;&#59; and </font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(C) &#91;***.&#93; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.18pt">&#91;***&#93; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:25.63pt">a representation made by Novavax pursuant to Section 13(c)(ii), 13(c)(viii), 13(c)(ix), or 13(c)(xiv) of this Agreement is or proves to have been incorrect in any material respect when made or deemed to be made&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:25.63pt">&#91;***&#93;&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.18pt">a Solvency-Related Event occurs in respect of Novavax during the Deferred Payment Term or at any time prior to &#91;***&#93; after receipt of the final Deferred Payment constituting the Settlement Amount or, if such final Deferred Payment is subject to an Alleged </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Discrepancy that becomes an Agreed Discrepancy, receipt of any Restored Amount in respect of such Agreed Discrepancy.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Acceleration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.8pt">Upon the occurrence of an Event of Default resulting from a Solvency-Related Event, the Remaining Payments, together with accrued interest pursuant to Section 5 (Interest), and all other amounts accrued or outstanding under this Agreement will be immediately due and payable. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.18pt">On and at any time after the occurrence of an Event of Default other than with respect to a Solvency-Related Event, Gavi may, by notice in writing to Novavax, declare that the Remaining Payments, together with accrued interest pursuant to Section 5 (Interest), and all other amounts accrued or outstanding under this Agreement be immediately due and payable, whereupon they shall become immediately due and payable.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.8pt">If any amounts become immediately due and payable pursuant this Section 7 (Acceleration), Gavi may exercise any or all of its right, remedies, powers or discretions under this Agreement or the Security Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Security Interest. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Concurrently with the execution of this Agreement, Gavi and Novavax will enter into a Security Agreement in the form set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit C (Form of Security Agreement)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Security Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) pursuant to which Novavax will grant Gavi a security interest in all its receivables from Serum (or its Affiliates) pursuant to the Serum License and Supply Agreement (which accounts receivable have been assigned by Novavax AB to Novavax) for the duration of the term of the Serum License and Supply Agreement in and to all accounts receivable due to Novavax, including the purchase price of Matrix-M adjuvant (or its bulk components) supplied thereunder and royalties paid with respect to the sale of Serum&#8217;s R21 malaria vaccine (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Secured Accounts Receivable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to secure Novavax&#8217;s obligations under this Agreement. The form of agreement between Novavax and Novavax AB providing for a confirmatory assignment of the Secured Accounts Receivable from Novavax AB to Novavax is set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit D (Form of Confirmatory Assignment of Accounts Receivable)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Confirmatory Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), which Confirmatory Assignment has been executed by Novavax AB and Novavax prior to the Effective Date.  For the avoidance of doubt, Gavi&#8217;s rights, powers, and remedies provided in this Agreement are in addition to, and not exclusive of, any rights, powers, or remedies set forth in the other Settlement Documents, and no exercise of any right, power, or remedy by Gavi hereunder shall be deemed a waiver of any right, power, or remedy under the other Settlement Documents. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Transfer of Serum License and Supply Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> A form of agreement between Novavax and Novavax AB providing for the present assignment and transfer to Novavax of Novavax AB&#8217;s obligations and rights (save for its rights in the Secured Accounts Receivable, which have been assigned by Novavax AB to Novavax as described in Section 8 (Security Interest)), and Novavax&#8217;s assumption of Novavax AB&#8217;s obligations under the Serum License and Supply Agreement, is set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit E (Form of Transfer Agreement)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Transfer Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), which agreement has been executed by Novavax AB and Novavax, Inc. prior to the Effective Date.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Mutual Release of Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Release by Novavax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to Section 10(c) (Actions or Liabilities under the Settlement Agreement), but notwithstanding any provision to the contrary set forth in the APA, from and after the First Payment Date&#58; Novavax, on behalf of itself and each of its Affiliates and each of their respective successors and assigns (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Novavax Releasors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), do hereby now and forever release, remise, hold harmless and forever </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">discharge Gavi, its Affiliates, its sublicensees and each of its, its Affiliates&#8217;, and its sublicensees&#8217; respective sublicensees, officers, directors, employees, consultants, contractors and agents, and its and any and all of the foregoing Persons&#8217; respective successors and assigns (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gavi Releasees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) of and from any and all claims, potential claims, counterclaims, actions, causes of action, choses in action, or suits (whether in contract or tort or otherwise), litigation (whether at law or in equity, whether civil or criminal), controversies, assessments, arbitration, examinations, audits, investigations, hearings, charges, complaints, demands, or proceedings to, from, by or before any governmental authority, in each case in any jurisdiction (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), losses, liabilities, damages, judgments, rights, debts, dues, set-offs, sums of money, accounts, reckonings, obligations, costs, expenses, liens, bonds, bills, specialties, covenants, contracts, controversies, agreements, promises, variances, trespasses, of every kind and nature whatsoever, whether secured, proprietary, by way of tracing, priority or otherwise, whether by way of indemnity, contribution subrogation or otherwise, whether now known or unknown, foreseen or unforeseen, matured or unmatured, suspected or unsuspected, in law, admiralty or equity (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), whether known or unknown, suspected or unsuspected and that arose at any time on or prior to the First Payment Date, or that thereafter could arise based on any act, fact, transaction, matter, or cause that occurred on or prior to the First Payment Date arising from, under or otherwise in connection with the APA, in each case, other than for a violation of applicable law by Gavi unless such violation is caused by the action or omission of a Novavax Releasor.  The Novavax Releasors agree that they will&#58; (i) forbear from exercising any rights or remedies against any Gavi Releasee in respect of any or all Actions and Liabilities in connection with the APA&#59; and (ii) not commence any lawsuit or bring any legal or equitable action against any Gavi Releasee in respect of any Action or Liability in connection with the APA, in each case, except to the extent relating to a violation of applicable law by Gavi unless such violation is caused by the action or omission of a Novavax Releasor.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Release by Gavi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to Section 10(c) (Actions or Liabilities under the Settlement Agreement), but notwithstanding any provision to the contrary set forth in the APA, from and after the First Payment Date&#58; Gavi, on behalf of itself and each of its Affiliates and each of their respective successors and assigns (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gavi Releasors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), do hereby now and forever release, remise, hold harmless and forever discharge Novavax, its Affiliates, its sublicensees and each of its, its Affiliates&#8217;, and its sublicensees&#8217; respective sublicensees, officers, directors, employees, consultants, contractors and agents, and its and any and all of the foregoing Persons&#8217; respective successors and assigns (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Novavax Releasees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) of and from any and all Actions and Liabilities, whether known or unknown, suspected or unsuspected and that arose at any time on or prior to the First Payment Date, or that thereafter could arise based on any act, fact, transaction, matter, or cause that occurred on or prior to the First Payment Date arising from, under or otherwise in connection with the APA, in each case, other than for obligations arising under this Agreement or a violation of applicable law by Novavax unless such violation is caused by the action or omission of a Gavi Releasor.  The Gavi Releasors agree that they will&#58; (i) forbear from exercising any rights or remedies against any Novavax Releasee in respect of any or all Actions and Liabilities in connection with the APA&#59; and (ii) not commence any lawsuit or bring any legal or equitable action against any Novavax Releasee in respect of any Action or Liability in connection with the APA, in each case, except to the extent relating to a violation of applicable law by Novavax unless such violation is caused by the action or omission of a Gavi Releasor. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Actions or Liabilities under the Settlement Documents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Sections 10(a) (Release by Novavax) and 10(b) (Release by Gavi) shall not apply to any Actions or Liabilities arising from, under or otherwise in connection with the terms of any of the Settlement Documents, including any breach thereof by any Party.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Third Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as expressly provided by this Section 10(d) (Third Party Beneficiaries), no Third Party shall have any rights under the Contracts (Rights of </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Third Parties) Act of 1999 to enforce the terms of this Agreement. Notwithstanding the foregoing, each Gavi Releasee and each Novavax Releasee will be an express beneficiary of the rights and releases granted under this Section 10 (Mutual Release of Claims) subject to, and in accordance with, the Contracts (Rights of Third Parties) Act of 1999, and will be entitled to rely on the same as a defense to any Actions or Liabilities asserted against such Gavi Releasee or Novavax Releasee, as applicable, in contravention of the provisions of this Section 10 (Mutual Release of Claims), without regard to the fact that such Gavi Releasee or Novavax Releasee, as applicable, may not be a Party to this Agreement. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:22.25pt">Dismissal of Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.  Within &#91;***&#93; after the First Payment Date, the Parties will instruct their respective counsel to prepare, execute, and submit a joint motion to dismiss with prejudice all claims and counterclaims and terminate the Arbitration, with each Party bearing its own fees and costs, including any cost the ICC already invoiced.  The Parties will promptly proceed with any additional procedures needed to dismiss the Arbitration with prejudice, or any procedural equivalent available under the ICC Rules.  The Parties will jointly request that the ICC allocate any additional arbitration costs equally between the Parties and reimburse all unused portions of the advances paid by each Party with respect to the Arbitration, in accordance with the ICC Rules.  If the ICC declines to dismiss the Arbitration (or any claim therein) based on the joint motions to dismiss, the Parties and their counsel will cooperate to prepare, execute, and submit revised submissions, mutually acceptable to the Parties and the ICC, that most closely approximate a joint motion to dismiss with prejudice. For clarity, the Parties shall not be required to take any action under this Section 11 (Dismissal of Arbitration) if Novavax fails to pay Gavi the Initial Settlement Payment.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Termination.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding any provision of this Agreement to the contrary, if the First Payment Date has not occurred within &#91;***&#93; of the Effective Date, Gavi shall be entitled to terminate this Agreement with immediate effect by giving notice in writing to Novavax. For the avoidance of doubt, and without prejudice to any accrued rights and remedies under this Agreement, in the event of termination in accordance with this Section 12, the First Payment Date will have not occurred and accordingly (but without limitation), the Parties shall remain entitled to pursue all Actions arising under or in connection with the APA in the Arbitration or otherwise. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Representations, Warranties, and Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Mutual Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each of the Parties hereby represents and warrants to the other Party as of the Effective Date that&#58; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:25.63pt">it is an entity duly organized, validly existing and in good standing under applicable law of the jurisdiction of its organization, and has all requisite power and authority, corporate or otherwise, to execute, deliver, and perform the Settlement Documents&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.58pt">the obligations expressed to be incurred or assumed in the Settlement Documents are legal, valid, binding and enforceable in accordance with its terms, subject to the effects of bankruptcy, insolvency or other applicable law of general application affecting the enforcement of creditor rights, judicial principles affecting the availability of specific performance, and general principles of equity (whether enforceability is considered a proceeding at law or equity)&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:19.53pt">the execution, delivery and performance of the Settlement Documents by such Party have been duly authorized by all necessary corporate action and do not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it is bound, nor violate any applicable law or any </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">order, writ, judgment, injunction, decree, determination or award of any court or governmental body, or administrative or other agency presently in effect applicable to such Party&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.13pt">it is not aware of any government authorization, consent, approval, license, exemption of or filing or registration with any court or governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any applicable law, currently in effect, necessary for, or in connection with, the transactions contemplated by the Settlement Documents or any other agreement or instrument executed in connection herewith, or for the performance by it of its obligations under the Settlement Documents and such other agreements&#59; and </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.02pt">neither Party is under any obligation, contractual or otherwise, to any Person, that conflicts with or is inconsistent in any material respect with the terms of the Settlement Documents, or that would impede the diligent and complete fulfillment of its obligations thereunder. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Additional Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party represents and warrants to the other Party and the Gavi Releasees or Novavax Releasees, as applicable, as of the Effective Date and the First Payment Date that&#58; (i) it has all requisite legal capacity to grant the rights and releases set forth in Section 10 (Mutual Release of Claims) of this Agreement on behalf of itself and its respective Gavi Releasors or Novavax Releasors, as applicable&#59; and (ii) neither it nor any of the other Gavi Releasors or Novavax Releasors, as applicable, have assigned, transferred or granted to any Person that is not a Gavi Releasor or Novavax Releasor, as applicable, any Action or Liability intended to be covered or released pursuant to Section 10 (Mutual Release of Claims) of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:23.8pt">Novavax Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.  Novavax hereby represents and warrants that&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:24.69pt">&#91;***&#93;&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.58pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:19.53pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.13pt">the Confirmatory Assignment is in full force and effect and Novavax has not received from Novavax AB or delivered to Novavax AB any written notice of any breach of the Confirmatory Assignment (nor has Novavax been notified in writing or notified Novavax AB in writing that such a breach is alleged)&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.18pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.13pt">the Confirmatory Assignment constitutes the legal and valid obligation of Novavax, and to the knowledge of Novavax, Novavax AB, enforceable in accordance with its terms, subject to the effects of insolvency and other similar laws relating to or affecting creditors&#8217; rights generally and general equitable principles (whether considered in a proceeding in equity or law)&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.08pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.03pt">&#91;***&#93;&#59;</font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.13pt">Novavax is the legal and beneficial owner of all rights, title, and interests in and to the Secured Accounts Receivable, which is free from any claims, third party rights or competing interests&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.18pt">to the knowledge of Novavax, there are no restrictions on transfer or any other agreements that would limit or restrict&#58; (i) the grant of the Security Interest in favour of Gavi&#59; (ii) the perfection of the Security Interest&#59; (iii) the exercise of remedies in respect of such perfected Security Interest&#59; or (iv) the sale or transfer of the Collateral, in each case as contemplated by the Security Agreement&#59;  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(xi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.13pt">no Event of Default is continuing or might reasonably be expected to result from the entry into, the performance of, or any transaction contemplated by, any Settlement Document&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(xii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.08pt">to Novavax&#8217;s knowledge, the factual information provided by Novavax in connection with the Serum License and Supply Agreement and each of the Novavax Intercompany Agreements, and the rights enjoyed by Novavax AB and Novavax pursuant to the Serum License and Supply Agreement and Novavax Intercompany Agreements, are true and accurate in all material respects as at the date it was provided or as at the date (if any) at which it is stated&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(xiii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.03pt">to Novavax&#8217;s knowledge, nothing has occurred or been omitted from the information provided in respect of the agreements and rights referred to in Section 13(c)(xii), and no information has been given or withheld, that results in such information being untrue or misleading in any material respect&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(xiv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.63pt">to Novavax&#8217;s knowledge, the financial statements, and other financial information included in Novavax&#8217;s most recently filed annual and quarterly reports filed on SEC forms 10K and 10Q, respectively, fairly present in all material respects the financial condition and results of operations of Novavax as of, and for, the periods presented in such reports&#59; and </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(xv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.68pt">the Security Interest created or expressed to be created pursuant to the Security Agreement has or will have first ranking priority and it is not subject to any prior ranking or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">pari passu</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> ranking Security. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:23.18pt">Repetition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. The representations and warranties set out in Section 13(c) (Novavax Representations) are deemed to be made by Novavax by reference to the facts and circumstances then existing on&#58; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:25.63pt">the Effective Date&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:21.36pt">the First Payment Date. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:23.8pt">Novavax Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:24.69pt">Novavax will not, itself or through an Affiliate (including Novavax AB)&#58; </font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.68pt">&#91;***&#93; </font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9pt">&#91;***&#93; </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.58pt">Novavax will &#91;***&#93; obtain, comply with and do all that is necessary, and will ensure that Novavax AB &#91;***&#93; obtains, complies with and does all that is necessary, to maintain in full force and effect and supply certified copies to Gavi of any authorization required under any applicable law or regulation to&#58;</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:10.37pt">enable Novavax or Novavax AB to perform its or their obligations under the Settlement Documents&#59; and</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.75pt">ensure the legality, validity, enforceability, or admissibility in evidence of any Settlement Document and the Security Interest. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:19.53pt">Novavax will comply in all respects, and will cause Novavax AB to comply in all respects, with all laws to which it or they may be subject, if failure so to comply would materially impair its or their ability to perform its obligations under the Settlement Documents.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.13pt">Novavax will, and will procure that Novavax AB will, &#91;***&#93; perform all such acts or execute all such documents (including assignments, transfers, mortgages, charges, notices and instructions) as Gavi may reasonably specify&#58; </font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:10.37pt">to execute, document, or perfect, as necessary (and to the extent this has not already occurred), the assignment of the Secured Account Receivable to Novavax&#59;</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.75pt">to perfect the Security Interest created or intended to be created under or evidenced by the Security Agreement or for the exercise of any rights, powers and remedies of Gavi provided by or pursuant to the Settlement Documents or by law&#59; or</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:10.37pt">to facilitate the realisation of the assets which are, or are intended to be, the subject of Security Interest created or intended to be created under or evidenced by the Security Agreement.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.18pt">Novavax will take all such action as is available to it (including making all filings and registrations) as may be necessary for the purpose of the creation, perfection, protection or maintenance of any Security Interest conferred or intended to be conferred on Gavi by or pursuant to the Security Agreement, and Novavax shall not take or permit any action that could prejudice or negatively impact such Security Interest, including creating or permitting to be created or suffer to exist any Security of any kind in the Secured Accounts Receivable or Novavax&#8217;s rights, title, and interests under the Confirmatory Assignment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">unless</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> such Security is junior to Gavi&#8217;s Security Interest and Gavi has given its prior written consent to the creation of such Security, such consent not to be unreasonably withheld, conditioned or delayed (it being agreed that it would be unreasonable for Gavi to withhold its consent if a Third Party offers to enter into a reasonable and customary intercreditor agreement or other agreement subordinating its rights to the Security Interest that is in form and substance reasonably satisfactory to Gavi).</font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.13pt">Novavax will ensure that, if and to the extent there is a change of Control with respect to Novavax&#58;</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:10.37pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.75pt">&#91;***</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.08pt">Novavax will ensure that, if and to the extent there is a change of Control with respect to Novavax&#58;</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:10.37pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.75pt">&#91;***&#93;</font></div><div style="margin-bottom:8pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:14.03pt">Neither Novavax nor Novavax AB shall enter, nor purport to enter, into a transaction or transactions for the sale, transfer, set-off, or disposal by any means of any asset or assets that has or would have a material adverse effect on&#58; (a) the validity, effectiveness, ranking or enforceability of the Security Interest&#59; or (b) the Secured Accounts Receivable.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.13pt">Novavax shall notify Gavi&#58; (A) of any Event of Default (and, to the extent applicable, steps, if any, being taken to remedy it) promptly upon becoming aware of its occurrence (and in no event more than &#91;***&#93; after becoming so aware)&#59; (B) of any amendment, supplement, renewal, or replacement to the terms of the Serum License and Supply Agreement or Confirmatory Assignment promptly after entering into such amendment, supplement, renewal, or replacement (and in no event more than &#91;***&#93; after so doing)&#59; and (C) promptly of the receipt of any written notice of any&#58; (i) actual or threatened breach of the Serum License and Supply Agreement or Confirmatory Assignment (by any party thereto)&#59; or (ii) any actual or threatened set-off in writing by Serum of any amounts owed under the Serum License and Supply Agreement (in each case ((i) and (ii)), in no event more than &#91;***&#93; after receipt of such written notice). </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.18pt">Novavax will take any and all actions reasonably necessary to defend the Security Interest and the first priority thereof against any other Security (except any Security more junior than Gavi&#8217;s Security Interest that has been granted in compliance with this Agreement), in each case against all claims and demands of all Persons at any time.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(xi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.13pt">Within &#91;***&#93; after the date thereof, Novavax will provide notice to Gavi of&#58; (A) any change in any of the information described in Section 3.2 of the Security Agreement&#59; or (B) any action taken which would cause any financing statement filed in connection with the Security Agreement to become seriously misleading.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(xii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:15.36pt">Novavax will not, itself or through an Affiliate (including Novavax AB) directly or indirectly amend (or cause to be amended) the Confirmatory Assignment in any manner that has, or will have, an adverse effect on the Security Interest or the Secured Accounts Receivable, without Gavi&#8217;s prior written consent.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(xiii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.03pt">Novavax will keep and maintain (and will cause Novavax AB to keep and maintain) satisfactory and complete records of the Secured Accounts Receivable. </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Novavax shall notify Gavi of any material claim made or asserted against the Secured Accounts Receivable by any Person and of any change in the composition of the Secured Accounts Receivable &#91;***&#93; which is reasonably likely to adversely affect the value of the Secured Accounts Receivable or Gavi&#8217;s Security Interest thereon.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(xiv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.63pt">At any time following the occurrence of an Event of Default, Novavax will continue to collect all amounts due or to become due under the Secured Accounts Receivable and diligently exercise its material rights under and with respect to the Secured Accounts Receivable, and in connection with such collections and exercise, at Gavi&#8217;s request, Novavax will take (and will cause Novavax AB to take) such action as Gavi may deem necessary or advisable. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(xv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.68pt">At any time following the occurrence of an Event of Default, any payment of the Secured Accounts Receivable received by Novavax will be promptly (and in any event within one Business Day) deposited by Novavax (in the exact form received, duly indorsed by Novavax to Gavi or in blank, if required), in a Cash Collateral Account (as defined in the Security Agreement), and until so deposited, all amounts and Proceeds (as defined in the Security Agreement), including checks and other Instruments (as defined in the Security Agreement) received by Novavax in respect of the Secured Accounts Receivable or any Supporting Obligation (as defined in the Security Agreement) will be held in trust for the benefit of Gavi and will not be commingled with any other property of Novavax.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(xvi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.63pt">Novavax shall provide (or cause Novavax AB to provide) information related to payments made on the Secured Accounts Receivables under the Serum License and Supply Agreement as may be reasonably requested by Gavi from time to time.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Confidential Treatment prior to First Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. From the Effective Date until the First Payment Date&#58; (i) the existence or terms of this Agreement&#59; (ii) the content of the Parties&#8217; discussions and negotiations regarding this Agreement&#59; and (iii) any documents or correspondence exchanged between the Parties in connection with their discussions or negotiations regarding this Agreement&#59; in each case ((i) through (iii)), will be considered &#8220;Confidential Information&#8221; of both Parties, as such term is defined in the APA, and will be subject to the provisions regarding confidentiality and non-disclosure set forth in Clause 16.1 of the APA, with each Party being deemed both the Disclosing Party and Receiving Party with respect thereto. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Confidential Treatment from First Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  From and after the First Payment Date&#58; (i) the existence or terms of this Agreement and the APA&#59; (ii) the content of the Parties&#8217; discussions and negotiations regarding this Agreement&#59; and (iii) any documents or correspondence exchanged between the Parties in connection with their discussions or negotiations regarding this Agreement&#59; in each case ((i) through (iii)), will be considered Confidential Information of both Parties and will be subject to the provisions regarding confidentiality and non-disclosure set forth in Sections 14(b) to (f) (Confidentiality), with each Party being deemed both the Disclosing Party and Receiving Party with respect thereto.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Disclosure&#59; Permitted Use.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> From and after the First Payment Date, the Receiving Party will treat as strictly confidential and not disclose or use any Confidential Information of </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the Disclosing Party, unless the Disclosing Party has given prior written approval to the disclosure or use, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that a Receiving Party may disclose Confidential Information to the extent&#58; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:25.63pt">it is already, or becomes, publicly available other than as a result of a breach of an obligation of confidentiality&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.58pt">the information is (at the time of its original disclosure to the Receiving Party) already in the lawful possession of the Receiving Party or is independently developed by the Receiving Party, and is not subject to an independent obligation of confidentiality or restriction on use&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:19.53pt">necessary for the performance of either Party&#8217;s obligations under this Agreement&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.13pt">that Gavi discloses to&#58;</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:10.37pt">&#91;***&#93; </font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.75pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:10.37pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.75pt">&#91;***&#93;&#59; </font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:10.37pt">&#91;***&#93;&#59; or</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:11.59pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.18pt">that Novavax discloses to its Affiliates and Serum, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> in each case such disclosure is&#58; (a) necessary for the performance of Novavax&#8217;s obligations or exercise of its rights under this Agreement&#59; and (b) the relevant recipient of such Confidential Information is subject to confidentiality obligations broadly equivalent to those set out in this Section 14 (Confidentiality)&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.13pt">is required by&#58; (a) applicable law or regulation (including the rules of any stock exchange)&#59; (b) a valid order of a court of competent jurisdiction&#59; or (c) for the purpose of any judicial, investigatory or regulatory proceedings&#59; in each case ((a) through (c)), arising out of or in connection with this Agreement or any other agreement entered into under or pursuant to this Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.08pt">the disclosure is required to fulfil reporting obligations to financial institutions providing funding relating to this Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.03pt">the disclosure is made to a tax authority in connection with the tax affairs of a Party&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.13pt">that disclosure is made in the financial statements of either Party to the extent required to meet any accounting or disclosure requirements applicable to that Party (including any applicable listing rules)&#59; or</font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.18pt">the disclosure is to the professional advisers or experts of a Party (including a Party&#8217;s insurers, financial advisors or any auditor) and those advisers are subject to confidentiality obligations broadly equivalent to those set out in this Section 14 (Confidentiality).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Press Release. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unless otherwise agreed by the Parties, the Parties will issue the joint press release set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit F (Joint Press Release)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#91;***&#93; after the First Payment Date. Except as set forth in this Section 14(d) (Press Release), neither Party will issue any public announcement, press release or other public disclosure regarding this Agreement or its subject matter without the other Party&#8217;s prior written consent, such consent not to be unreasonably withheld, delayed or conditioned, except for any such disclosure that is, in the opinion of the Disclosing Party&#8217;s counsel, required by applicable law or the rules of a stock exchange on which the securities of the disclosing Party are listed (or to which an application for listing has been submitted).  In the event a Party is, in the opinion of its counsel, required by applicable law or the rules of a securities exchange on which its securities are listed (or to which an application for listing has been submitted) to make such a public disclosure, such Party will submit the proposed disclosure in writing to the other Party with sufficient opportunity (to the extent practicable) for the other Party to review and comment on such required disclosure and request confidential treatment thereof or a protective order therefor.   Neither Party will be required to seek the permission of the other Party to repeat any information, nor express an opinion publicly (orally or in writing) in relation to such information, that has already been publicly disclosed by such Party or by the other Party, in accordance with this Section 14(d), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that such information remains accurate as of such time.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">News Agencies. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding any provision to the contrary set forth in this Agreement, either Party may provide an advance copy of a public disclosure authorized under Section 14(d) (Press Release) or otherwise agreed by the Parties to any news agency no more than &#91;***&#93; prior to the agreed disclosure date, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58; (i) each such news agency agrees to binding terms to keep such disclosure strictly confidential until a Party issues such disclosure in accordance with this Agreement&#59; and (ii) each Party informs the other Party in writing of the identity of any such news agency to which it intends to provide an advance copy at least &#91;***&#93; prior to any such disclosure taking place.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.02pt">Regulatory disclosure by Novavax.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Notwithstanding any provision to the contrary set forth in this Agreement (including Sections 14(c)(vi) and 14(d) (Press Release)), Novavax shall make the first disclosure in connection with its entry into this Agreement that it is required to make by applicable law or the rules of a securities exchange on which its securities are listed no earlier than the First Payment Date. Novavax shall provide to Gavi a copy of such first disclosure no less than &#91;***&#93; prior to the date on which it makes such disclosure. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:22.25pt">No termination for breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. No Party shall be entitled to terminate this Agreement on the grounds of a breach by another Party of Section 4(n) (Vaccine Purchases) or Section 14 (Confidentiality).</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Limitation of liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. With the exception of losses that cannot be excluded or limited at law, neither Party shall be liable to the other or to any Third Party, whether in contract (including under any indemnity), in tort (including negligence), under any statute or otherwise under or in connection with this Agreement for or in respect of any&#58; (i) loss of profit, sales, business, contracts or use of information&#59; or (ii) indirect or consequential loss of whatever nature. However, nothing in this Section 16 (Limitation of liability) shall limit Novavax&#8217;s payment obligations under this Agreement. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">No Admission of Liability.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Except for the obligations expressly set forth in this Agreement, nothing in this Agreement will be construed to be an admission of liability by either Party to the other Party or to any Third Party.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  No rights or obligations in respect of either Party&#8217;s Intellectual Property Rights are granted, or are implied to be granted, to the other Party by this Agreement.  In particular, as between the Parties, Novavax will be the sole owner of all Intellectual Property Rights generated during the development, manufacture and supply of Vaccine or otherwise related to Vaccine, and nothing in this Agreement will affect Novavax&#8217;s ownership of such rights.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If any provision of this Agreement is declared illegal, invalid or unenforceable by a court of last resort or by any court or other governmental body from the decision of which an appeal is not taken within the time provided by law, then and in such event, this Agreement will be deemed to have been terminated only as to the portion thereof that relates to the provision declared illegal, invalid or unenforceable by that decision and only in the relevant jurisdiction, but this Agreement, in all other respects and all other jurisdictions, will remain in force&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that if the provision declared illegal, invalid or unenforceable is essential to the Agreement as a whole, then the Parties will negotiate in good faith to amend the terms hereof as nearly as practical to carry out the original intent of the Parties, and, failing such amendment, either Party may submit the matter for resolution pursuant to Section 17(f) (Dispute Resolution) of this Agreement.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Assurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Parties agree to reasonably cooperate with each other in connection with any actions required to be taken as part of their respective obligations under this Agreement, and will&#58; (i) furnish to each other such further information&#59; (ii) execute and deliver to each other such other documents&#59; and (iii) do such other acts and things (including working collaboratively to correct any clerical, typographical, or other similar errors in this Agreement)&#59; in each case ((i) through (iii)), all as the other Party may reasonably request for the purpose of carrying out the intent of this Agreement. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Governing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement and all amendments, modifications, alterations, or supplements hereto, and the rights of the Parties hereunder, will be construed under and governed by the laws of &#91;***&#93;, exclusive of its conflicts of laws principles.  This Agreement has been prepared in the English language and the English language will control its interpretation.  All consents, notices, reports, and other written documents to be delivered or provided by a Party under this Agreement will be in the English language, and in the event of any conflict between the provisions of any document and the English language translation thereof, the terms of the English language translation will control.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.02pt">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  &#91;***&#93;  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">No Avoidance of Settlement Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If payment of the Settlement Amount or any portion thereof (including the Initial Settlement Payment, a Deferred Payment, or a Restored Amount) should for any reason be declared to be void or voidable under any applicable law relating to creditors&#8217; rights or otherwise, including provisions of the US Bankruptcy Code relating to fraudulent transfers, preferences or other voidable or recoverable payments of money or transfers of property (whether under the US Bankruptcy Code or any equivalent law of any other jurisdiction) (any of the foregoing, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Voidable Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and if Gavi is required to repay or restore, in whole or in part, any such Voidable Transfer, or elects to do so upon the reasonable advice of its counsel, then the liability of Novavax for the amount thereof that Gavi is required or elects to repay or restore for such Voidable Transfer shall automatically be revived, reinstated and restored and shall exist as though such Voidable Transfer had never been made, and Gavi shall have a claim for such reinstated amounts plus the Remaining Payments under this Agreement, together with&#58; (a) interest on any portion of the Remaining Payments that has accrued in accordance with Section 5 (Interest)&#59; and (b) interest on such reinstated </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">amounts, calculated in accordance with Section 5 (Interest) (as though, for the purposes of applying Section 5 (Interest), such reinstated amount were a Deferred Payment that became due and payable by Novavax on the date on which Gavi was required or elected to repay or restore such amount). Nothing herein shall be used as evidence that, or deemed to be an acknowledgement that, all or any portion of the Settlement Amount constitutes or may constitute a Voidable Transfer. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any notice required to be given under this Agreement will be in writing and will be mailed by internationally recognized express delivery service, or sent by email and confirmed by mailing, as follows (or to such other address as the Party to whom notice is to be given has provided to the other Party by way of written notice sent in accordance with this Section 17(h) (Notices))&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If to Gavi&#58; </font></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Global Health Campus<br>Chemin du Pommier 40<br>1218 Grand-Saconnex<br>Geneva<br>Switzerland <br>Attention&#58; the Chief Executive Officer<br>Email&#58; &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">With a copy to (which will not constitute notice for purposes of this Agreement)&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Linklaters LLP<br>One Silk Street<br>London, EC2Y 8HQ<br>United Kingdom<br>Attention&#58; Matthew Weiniger KC<br>Email&#58; &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and</font></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If to Novavax&#58; </font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Novavax, Inc.</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">700 Quince Orchard Road</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Gaithersburg, MD, USA 20878</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58; Mark Casey, EVP, Chief Legal Officer</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Email&#58; &#91;***&#93;</font></div><div style="padding-left:108pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">With a copy to (which will not constitute notice for purposes of this Agreement)&#58;</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Ropes &#38; Gray LLP <br>Prudential Tower, 800 Boylston Street <br>Boston, MA  02199-3600 <br>Attention&#58;  Matthew Rizzolo <br>Email&#58;  &#91;***&#93;</font></div><div><font><br></font></div><div style="padding-left:108pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.63pt">Deemed receipt of notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. A notice sent in accordance with Section 17(h) (Notices) shall be effective upon receipt and shall be deemed to have been received&#58; at the time of delivery, if delivered by express delivery service alone&#59; or at the time of sending by e-mail, if sent by e-mail and express delivery service, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58; (a) receipt shall not </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">occur if the sender receives an automated message that the e-mail has not been delivered to the recipient&#59; and (b) a notice that is deemed by this Section 17(i) (Deemed receipt of notices) to be received after 5.00 p.m. on any day, or on a Saturday, Sunday or public holiday in the place of receipt, shall be deemed to be received at 9.00 a.m. on the next day that is not a Saturday, Sunday or public holiday in the place of receipt. For the purposes of this Section 17(i) (Deemed receipt of notices), all references to time are to local time in the place of receipt, and for the purposes of notices by e-mail, the place of receipt is the place in which the Party to whom the notice is sent has its postal address for the purpose of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.63pt">Assignment, transfer and novation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i) Subject to sub-paragraph (ii), neither Party may assign and transfer the benefit and burdens of the whole or any part of this Agreement without the other Party&#8217;s prior written consent. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii) A Party may assign the benefit of this Agreement to&#58; (a) a Third Party successor or purchaser of all or substantially all of the assets or businesses to which this Agreement relates whether pursuant to a sale of assets, merger, or other transaction, in which case the assigning Party will provide prior written notice of such assignment to the other Party and need not obtain the other Party&#8217;s consent&#59; or (a) an Affiliate of such Party, in which case the assigning Party will provide prior written notice of such assignment to the other Party and need not obtain the other Party&#8217;s consent&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, in each case ((a) and (b))&#58; (x) the assignee executes and delivers to the other Party a deed (in form and substance satisfactory to that other Party, acting reasonably) in which it agrees to assume all of the assigning Party&#8217;s obligations under this Agreement&#59; and (y) the assigning Party remains fully liable for the performance of its obligations hereunder. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any other assignment of this Agreement by a Party, (save as set out in sub-paragraph (ii)), or transfer or novation of this Agreement by a Party, requires the prior written consent of the other Party. Any purported assignment, transfer, or novation in violation of this Section 17(j) (Assignment, transfer and novation) will be null and void.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement will inure to the benefit of the permitted assigns of the Parties.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Entire Agreement&#59; Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement, together with all exhibits attached hereto, constitutes the entire agreement between the Parties with respect to the subject matter hereof, and supersedes any previous written or oral agreement between the Parties in relation to the matters dealt with in this Agreement. To the maximum extent permitted by law, all terms, conditions and warranties, other than those expressly set out in this Agreement, are excluded. Subject to Section 1(i) (AMC92) and Section 17(h) (Notices), this Agreement will not be modified, or amended, except by an agreement in writing executed by the Parties.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.63pt">No Strict Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement has been prepared jointly by the Parties and will not be strictly construed against either Party.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:20.13pt">Interpretation.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Except where the context expressly requires otherwise&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:25.63pt">the use of any gender herein will be deemed to encompass references to either or both genders, and the use of the singular will be deemed to include the plural (and vice versa)&#59; </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.58pt">the words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; will be deemed to be followed by the phrase &#8220;without limitation&#8221; and will not be interpreted to limit the provision to which it relates&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:19.53pt">the word &#8220;will&#8221; will be construed to have the same meaning and effect as the word &#8220;shall&#8221;&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.13pt">any definition of or reference to any agreement, instrument or other document herein will be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein)&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.18pt">any reference herein to any Person will be construed to include the Person&#8217;s successors and assigns&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.13pt">the words &#8220;herein,&#8221; &#8220;hereof,&#8221; and &#8220;hereunder,&#8221; and words of similar import, will be construed to refer to this Agreement in its entirety, as the context requires, and not to any particular provision hereof&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.08pt">all references herein to Sections, Schedules or Exhibits will be construed to refer to sections, schedules or exhibits of this Agreement, and references to this Agreement include all Schedules and Exhibits hereto&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.03pt">the word &#8220;notice&#8221; means notice in writing (whether or not specifically stated) and will include notices, consents, approvals and other written communications contemplated under this Agreement&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.13pt">provisions that require that a Party, the Parties, or any committee hereunder &#8220;agree,&#8221; &#8220;consent,&#8221; or &#8220;approve&#8221; or the like will require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding e-mail and instant messaging)&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.18pt">references to any specific law, rule, or regulation, or article, section, or other division thereof, will be deemed to include the then-current amendments thereto or any replacement or successor law, rule, or regulation thereof&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(xi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.13pt">the term &#8220;or&#8221; will be interpreted in the inclusive sense commonly associated with the term &#8220;and&#47;or&#8221; unless preceded by the word &#8220;either&#8221; or other language indicating the subjects of the conjunction are, or are intended to be, mutually exclusive&#59; and </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(xii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:15.36pt">unless otherwise specified, &#8220;day&#8221; means a calendar day.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Remedies and waivers. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A waiver of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">any right or remedy under this Agreement or by law shall only be effective if given in writing. No failure to exercise, nor any delay in exercising, on the part of any Party, any right or remedy under this Agreement shall operate as a waiver, nor shall any single or partial exercise of any right or remedy prevent any further or other exercise or the exercise of any other right or remedy. The rights and remedies provided in this Agreement are cumulative and, save as expressly provided in this agreement, are not exclusive of any rights or remedies provided by law.</font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement may be executed in counterparts, all of which taken together will be regarded as one and the same instrument.  Each Party may execute this Agreement in Adobe&#8482; Portable Document Format (PDF) sent by electronic mail.  PDF signatures of authorized signatories of the Parties will be deemed to be original signatures, will be valid and binding upon the Parties, and, upon delivery, will constitute due execution of this Agreement.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#91;SIGNATURE PAGE FOLLOWS&#93;</font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30</font></div><div><font><br></font></div></div></div><div id="iaf19c3e881804f65aa8d22eef60092aa_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Parties have caused their duly authorized representatives to execute this Agreement as a deed, which is delivered as of the Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gavi</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:6.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Novavax</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;          &#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">***&#93;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:6.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Mark J. Casey</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;     &#91;***&#93;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:6.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;    Mark J. Casey</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;      &#91;***&#93;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;       EVP, CLO &#38; Corporate Secretary</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:100%">&#91;Signature Page to Termination and Settlement Agreement&#93;</font></div><div style="text-align:center"><font><br></font></div></div></div><div id="iaf19c3e881804f65aa8d22eef60092aa_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1(yy)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Documentation for Qualifying Sales Notice</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Schedule setting forth the documentation for qualifying sales notice has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted exhibits to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.575%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.580%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="6" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:16pt"><td colspan="9" style="border-bottom:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#002060;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="background-color:#002060;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="background-color:#002060;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="9" style="border-left:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="9" style="border-left:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="9" style="border-left:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="9" style="border-left:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="9" style="border-left:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#b4c6e7;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="background-color:#b4c6e7;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="background-color:#b4c6e7;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="9" style="border-left:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:16pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="6" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:16pt"><td colspan="9" style="border-bottom:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#002060;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="background-color:#002060;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="background-color:#002060;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="background-color:#002060;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="background-color:#002060;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="background-color:#002060;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="background-color:#002060;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">******</font></td><td colspan="6" style="background-color:#002060;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UNICEF&#47;PAHO</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***</font></div></td><td colspan="9" style="border-left:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-left:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-left:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-left:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-left:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-left:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-left:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-left:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-left:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-left:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-left:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-left:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#b4c6e7;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="background-color:#b4c6e7;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="background-color:#b4c6e7;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="background-color:#b4c6e7;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="background-color:#b4c6e7;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="background-color:#b4c6e7;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="6" style="background-color:#b4c6e7;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#b4c6e7;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-left:0.5pt solid #000000;padding:0 1pt"></td></tr><tr style="height:16pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:16pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="39" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="iaf19c3e881804f65aa8d22eef60092aa_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 2</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Form of Secretary&#8217;s Certificate</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 4(h)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Deferred Payment Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Schedule setting forth the deferred payment schedule has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted exhibits to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#b8cce4;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#b8cce4;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">***</font></td><td colspan="3" style="background-color:#b8cce4;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">***</font></td></tr><tr><td colspan="9" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">***</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td></tr><tr><td colspan="9" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">***</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td></tr><tr><td colspan="9" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">***</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td></tr><tr><td colspan="9" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">***</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td></tr><tr><td colspan="9" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">***</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***</font></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 4(l)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Expert Determination Procedure</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Schedule setting forth the expert determination procedure has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted exhibits to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMC92 Countries</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Exhibit setting forth the AMC92 countries has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted exhibits to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="margin-bottom:5.25pt;margin-top:5pt;padding-left:51pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.5pt">&#91;***&#93;</font></div><div style="margin-bottom:5.25pt;margin-top:5pt;padding-left:51pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.5pt">&#91;***&#93; </font></div><div style="margin-bottom:5.25pt;margin-top:5pt;padding-left:51pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.5pt">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5.25pt;padding-left:51pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit B</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Self-Financing Participants</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Exhibit setting forth the self-financing participants has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted exhibits to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="margin-bottom:5.25pt;margin-top:5pt;padding-left:51pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.5pt">&#91;***&#93;</font></div><div style="margin-bottom:5.25pt;margin-top:5pt;padding-left:51pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.5pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit C</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Form of Security Agreement </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Exhibit setting forth the form of security agreement has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted exhibits to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit D</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Form of Confirmatory Assignment of Accounts Receivable </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Exhibit setting forth the form of confirmatory assignment of accounts receivable has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted exhibits to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit E</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Transfer Agreement</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Exhibit setting forth the transfer agreement has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted exhibits to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="iaf19c3e881804f65aa8d22eef60092aa_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit F</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Joint Press Release</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Pursuant to Regulation S-K, Item 601(a)(5), this Exhibit setting forth the joint press release has not been filed. The Registrant agrees to furnish supplementally a copy of any omitted exhibits to the Securities and Exchange Commission upon request&#59; provided, however, that the Registrant may request confidential treatment of omitted items.&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>11
<FILENAME>nvax-20231231xex21.htm
<DESCRIPTION>EX-21
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i74ad57087b804036b57872110a15f751_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Exhibit 21</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">LIST OF SUBSIDIARIES </font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The following is a list of subsidiaries of the Company as of December 31, 2023</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Name of Subsidiary            &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Jurisdiction of Incorporation or Organization</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">14 Firstfield Holdings, LLC&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Delaware</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Novavax NL B.V.                    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Netherlands</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Novavax DE GmbH&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Germany</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Novavax AB                         &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Sweden</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Novavax CZ (formerly Praha Vaccines a.s.)         &#160;&#160;&#160;&#160;The Czech Republic</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Novavax UK Limited &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;United Kingdom</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Novavax CH GmbH                    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Switzerland</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Novavax FR SAS&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;France</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Novavax ES S.L.U.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Spain</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Novavax IT S.r.L&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Italy</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>12
<FILENAME>nvax-20231231xex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i17821bac7b954a72a32104bc007e2976_1"></div><div style="min-height:72pt;width:100%"><div><img alt="image_0b.jpg" src="image_0b.jpg" style="height:70px;margin-bottom:5pt;vertical-align:text-bottom;width:56px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">                                                                                                                                                             Exhibit 23.1</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:11.926%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Consent of Independent Registered Public Accounting Firm</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">Registration Statement (Form S-8 No. 333-273791) pertaining to the Novavax, Inc. stock incentive plan and the 2013 employee stock purchase plan, </font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">Registration Statement (Form S-3 No. 333-270137) pertaining to Novavax, Inc. common stock, preferred stock, debt securities, warrants and units, </font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">Registration Statement (Form S-8 No. 333-269309) pertaining to the Novavax, Inc. 2023 inducement plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">Registration Statement (Form S-8 No. 333-266681) pertaining to the Novavax, Inc. stock incentive plan and 2013 employee stock purchase plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">Registration Statement (Form S-8 No. 333-258517) pertaining to the Novavax, Inc. stock incentive plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">Registration Statement (Form S-8 No. 333-243758) pertaining to the Novavax, Inc. stock incentive plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">Registration Statement (Form S-8 No. 333-233133) pertaining to the Novavax, Inc. stock incentive plan and 2013 employee stock purchase plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">Registration Statement (Form S-8 No. 333-226498) pertaining to the Novavax, Inc. stock incentive plan and 2013 employee stock purchase plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(9)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">Registration Statement (Form S-8 No. 333-219829) pertaining to the Novavax, Inc. stock incentive plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(10)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.52pt">Registration Statement (Form S-8 No. 333-213069) pertaining to the Novavax, Inc. stock incentive plan and 2013 employee stock purchase plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(11)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.52pt">Registration Statement (Form S-8 No. 333-206354) pertaining to the Novavax, Inc. stock incentive plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(12)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.52pt">Registration Statement (Form S-8 No. 333-198121) pertaining to the Novavax, Inc. stock incentive plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(13)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.52pt">Registration Statement (Form S-8 No. 333-190600) pertaining to the Novavax, Inc. stock incentive plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(14)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.52pt">Registration Statement (Form S-8 No. 333-190599) pertaining to the Novavax, Inc. 2013 employee stock purchase plan, </font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(15)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.52pt">Registration Statement (Form S-8 No. 333-183113) pertaining to the Novavax, Inc. stock incentive plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(16)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.52pt">Registration Statement (Form S-8 No. 333-145298) pertaining to the Novavax, Inc. stock incentive plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(17)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.52pt">Registration Statement (Form S-8 No. 333-130990) pertaining to the Novavax, Inc. stock incentive plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(18)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.52pt">Registration Statement (Form S-8 No. 333-110401) pertaining to the Novavax, Inc. stock incentive plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(19)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.52pt">Registration Statement (Form S-8 No. 333-97931) pertaining to the Novavax, Inc. stock incentive plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(20)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.52pt">Registration Statement (Form S-8 No. 333-46000) pertaining to the Novavax, Inc. stock incentive plan, </font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(21)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.52pt">Registration Statement (Form S-8 No. 333-77611) pertaining to the Novavax, Inc. stock incentive plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(22)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.52pt">Registration Statement (Form S-8 No. 333-03384) pertaining to the Novavax, Inc. stock incentive plan,</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(23)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.52pt">Registration Statement (Form S-8 No. 33-80279) pertaining to the Novavax, Inc. stock incentive plan, and</font></div><div style="padding-left:49.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(24)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.52pt">Registration Statement (Form S-8 No. 33-80277) pertaining to the Novavax, Inc. stock incentive plan</font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142573595_2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="image_0b.jpg" src="image_0b.jpg" style="height:70px;margin-bottom:5pt;vertical-align:text-bottom;width:56px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">                                                                                                                                                             Exhibit 23.1</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:11.926%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of our reports dated February 28, 2024, with respect to the consolidated financial statements of Novavax, Inc., and the effectiveness of internal control over financial reporting of Novavax, Inc., included in this Annual Report (Form 10-K) of Novavax, Inc. for the year ended December 31, 2023.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tysons, Virginia</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">February 28, 2024</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142573595_2</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>13
<FILENAME>nvax-20231231xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i992302cf07124c47978a74d42aa41694_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 31.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I, John C. Jacobs, certify that&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt">I have reviewed this Annual Report on Form 10-K of Novavax, Inc.&#59; </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.69pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.69pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.01pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.69pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.01pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:39.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; February&#160;28, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; John C. Jacobs</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">John C. Jacobs</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>14
<FILENAME>nvax-20231231xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i573330756e20459397cf3dbf93af35b9_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 31.2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I, James P. Kelly, certify that&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.01pt">I have reviewed this Annual Report on Form 10-K of Novavax, Inc.&#59; </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.01pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.01pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.01pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.69pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.01pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.69pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.01pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.01pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.69pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.01pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:39.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; February&#160;28, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; James P. Kelly</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">James P. Kelly</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive Vice President, Chief </font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Financial Officer and Treasurer</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>15
<FILENAME>nvax-20231231xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i884a2e3aa2394abc9a103ecfb48b3e93_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 32.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TO 18 UNITED STATES CODE &#167;1350<br>(SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In connection with the Annual Report of Novavax, Inc. (the &#8220;Company&#8221;) on Form 10-K for the fiscal period ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, John C. Jacobs, President and Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that&#58; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the dates and periods covered by this Report. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:39.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; February&#160;28, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; John C. Jacobs</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">John C. Jacobs</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates it by reference.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>16
<FILENAME>nvax-20231231xex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i68410dfa194b42e0af2aea3f26a59ec5_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 32.2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 UNITED STATES CODE &#167;1350<br>(SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In connection with the Annual Report of Novavax, Inc. (the &#8220;Company&#8221;) on Form 10-K for the fiscal period ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, James P. Kelly, Executive Vice President and Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the dates and periods covered by this Report. </font></div><div style="text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:39.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; February&#160;28, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; James P. Kelly</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">James P. Kelly</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive Vice President, Chief </font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Financial Officer and Treasurer</font></div></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates it by reference.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97
<SEQUENCE>17
<FILENAME>nvax-20231231xex97.htm
<DESCRIPTION>EX-97
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i96f24ff1f1584f899ddea6db087088dc_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 97</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Novavax, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Second Amended and Restated Recoupment Policy</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt;text-decoration:underline">Introduction</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Second Amended and Restated Recoupment Policy (as amended from time to time, the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Policy</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) has been prepared in accordance with Section 10D of the Securities Exchange Act of 1934, as amended, and the regulations thereunder, and approved by the Board of Directors (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Board</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of Novavax, Inc. (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) providing for the Company&#8217;s recoupment of certain incentive-based compensation paid to Covered Executives (as defined below) in the event that the Company is required to prepare an accounting restatement due to its material noncompliance with any financial reporting requirement under the securities laws.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt;text-decoration:underline">Administration</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Administration and enforcement of this Policy is delegated to the Compensation Committee of the Board (as constituted from time to time, and including any successor committee, the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Committee</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The Committee shall make all determinations under this Policy in its sole discretion. Determinations of the Committee under this Policy need not be uniform with respect to any or all Covered Executives and will be final and binding.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt;text-decoration:underline">Effective Date</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Policy shall be effective as of June 16, 2023 (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and shall apply only to Covered Compensation (as defined below) that is awarded or granted to, achieved or received by, Covered Executives on or after the Effective Date, except as otherwise agreed to by any Covered Executive.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt;text-decoration:underline">Covered Executives</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Policy covers each current or former officer of the Company subject to Section 16 of the Securities Exchange Act of 1934, as amended (each, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Covered Executive</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt;text-decoration:underline">Covered Compensation</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Policy applies to any cash-based and equity-based incentive compensation, bonuses, and awards granted, paid, earned or that become vested wholly or in part upon the attainment of any financial reporting measure (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Covered Compensation</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to Covered Executives.  This Policy shall apply to any Covered Compensation received by an employee who served as a Covered Executive at any time during the performance period for that Covered Compensation.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt;text-decoration:underline">Financial Restatements&#59; Recoupment</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event that the Company is required to prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (such an accounting restatement, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Restatement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Committee shall review the Covered Compensation received by a Covered Executive during the three-year period preceding the Required Financial Restatement Date as well as any transition period that results from a change in the Company&#8217;s fiscal year within or immediately following those three completed fiscal years. Regardless of whether the Company filed the restated financial statements, the Committee shall, to the full extent permitted by governing law, seek </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 97</font></div></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">recoupment of any Covered Compensation, whether in the form of cash or equity, awarded or paid to a Covered Executive (computed without regard to any taxes paid), if and to the extent&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.68pt">the amount of the Covered Compensation was calculated based upon the achievement of certain financial results that were subsequently the subject of a Restatement&#59; and</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">the amount of the Covered Compensation that would have been awarded to the Covered Executive had the financial results been properly reported would have been lower than the amount actually awarded.  </font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the achievement of a certain financial result was considered in determining the Covered Compensation awarded or paid, but the Covered Compensation is not awarded or paid on a formulaic basis, the Committee shall determine the amount, if any, by which the payment or award should be reduced or recouped.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Policy, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Required Financial Restatement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; is the earlier to occur of&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.68pt">the date the Board, a committee of the Board, or any officer or officers authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare a Restatement&#59; or </font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">the date a court, regulator, or other legally authorized body directs the Company to prepare a Restatement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the avoidance of doubt, a Covered Executive will be deemed to have received Covered Compensation in the Company&#8217;s fiscal period during which the financial reporting measure specified in the award is attained, even if the Covered Executive remains subject to additional payment conditions with respect to such award.  </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt;text-decoration:underline">Method of Recoupment</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Committee will determine, in its sole discretion, the method for recouping erroneously awarded Covered Compensation, which may include, without limitation&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.68pt">requiring reimbursement of cash incentive compensation previously paid&#59;</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">cancelling or rescinding some or all outstanding vested or unvested equity (and&#47;or equity-based) awards&#59; </font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.68pt">adjusting or withholding from unpaid compensation or other set-off to the extent permitted by applicable law&#59; and&#47;or</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">reducing or eliminating future salary increases, cash-based or equity-based incentive compensation, bonuses, awards or severance.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt;text-decoration:underline">Impracticability Exceptions</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Committee shall not seek recoupment of any erroneously awarded Covered Compensation to the extent it determines that&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.68pt">the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount of erroneously-awarded Covered Compensation to be recovered after reasonable attempt to recover such Covered Compensation&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 97</font></div></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">recovery would violate home country law, per an opinion form counsel in the relevant jurisdiction, where that law was adopted prior to November 28, 2022&#59; and&#47;or </font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.68pt">recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to Company employees, to fail to meet the requirements of Sections 401(a)(13) and 411(a) of the Internal Revenue Code of 1986, as amended, and the regulations thereunder.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt;text-decoration:underline">No Indemnification</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the avoidance of doubt, the Company shall not indemnify any Covered Executive against the loss of any erroneously awarded Covered Compensation or any Covered Compensation that is recouped pursuant to the terms of this Policy, or any claims relating to the Company&#8217;s enforcement of its rights under this Policy.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:3pt;text-decoration:underline">Severability</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If any provision of this Policy or the application of any such provision to any Covered Executive shall be adjudicated to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Policy, and the invalid, illegal or unenforceable provisions shall be deemed amended to the minimum extent necessary to render any such provision or application enforceable.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:3pt;text-decoration:underline">Amendments</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Committee may amend, modify or terminate this Policy in whole or in part at any time and may adopt such rules and procedures that it deems necessary or appropriate to implement this Policy or to comply with applicable laws and regulations.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:3pt;text-decoration:underline">No Impairment of Other Remedies</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The remedies under this Policy are in addition to, and not in lieu of, any legal and equitable claims the Company may have, the Company&#8217;s ability to enforce, without duplication, the recoupment provisions set forth in any separate Company policy or in any Company plan, program or agreement (each, a &#8220;Separate Recoupment Policy&#8221; and collectively, the &#8220;Separate Recoupment Policies&#8221;), or any actions that may be imposed by law enforcement agencies, regulators or other authorities.  Notwithstanding the foregoing, in the event that there is a conflict between the application of this Policy to a Covered Executive in the event of a Restatement and any additional recoupment provisions set forth in a Separate Recoupment Policy to which a Covered Executive is subject, the provisions of this Policy shall control.  The Company may also adopt additional Separate Recoupment Policies in the future or amend existing requirements as required by law or regulation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>18
<FILENAME>nvax-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:02f62cea-2ee5-4f46-a427-e5f89894c0b1,g:b653a9b6-e98d-435f-a6cb-06522e8cacbf-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nvax="http://www.novavax.com/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.novavax.com/20231231">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvax-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvax-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvax-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvax-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.novavax.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.novavax.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0000003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>0000004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000005 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000006 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical" roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical">
        <link:definition>0000008 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationBusiness" roleURI="http://www.novavax.com/role/OrganizationBusiness">
        <link:definition>0000010 - Disclosure - Organization &amp; Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000011 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.novavax.com/role/Revenue">
        <link:definition>0000012 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandSupplyAgreements" roleURI="http://www.novavax.com/role/CollaborationLicenseandSupplyAgreements">
        <link:definition>0000013 - Disclosure - Collaboration, License, and Supply Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandRestrictedCash" roleURI="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCash">
        <link:definition>0000014 - Disclosure - Cash, Cash Equivalents, and Restricted Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.novavax.com/role/FairValueMeasurements">
        <link:definition>0000015 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.novavax.com/role/Inventory">
        <link:definition>0000016 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Goodwill" roleURI="http://www.novavax.com/role/Goodwill">
        <link:definition>0000017 - Disclosure - Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.novavax.com/role/Leases">
        <link:definition>0000018 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://www.novavax.com/role/LongTermDebt">
        <link:definition>0000019 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeficit" roleURI="http://www.novavax.com/role/StockholdersDeficit">
        <link:definition>0000020 - Disclosure - Stockholders&#8217; Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.novavax.com/role/StockBasedCompensation">
        <link:definition>0000021 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefits" roleURI="http://www.novavax.com/role/EmployeeBenefits">
        <link:definition>0000022 - Disclosure - Employee Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformation" roleURI="http://www.novavax.com/role/OtherFinancialInformation">
        <link:definition>0000023 - Disclosure - Other Financial Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.novavax.com/role/IncomeTaxes">
        <link:definition>0000024 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingencies" roleURI="http://www.novavax.com/role/CommitmentandContingencies">
        <link:definition>0000025 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuring" roleURI="http://www.novavax.com/role/Restructuring">
        <link:definition>0000026 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.novavax.com/role/SubsequentEvents">
        <link:definition>0000027 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.novavax.com/role/RevenueTables">
        <link:definition>9954473 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandRestrictedCashTables" roleURI="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashTables">
        <link:definition>9954474 - Disclosure - Cash, Cash Equivalents, and Restricted Cash (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.novavax.com/role/FairValueMeasurementsTables">
        <link:definition>9954475 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.novavax.com/role/InventoryTables">
        <link:definition>9954476 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillTables" roleURI="http://www.novavax.com/role/GoodwillTables">
        <link:definition>9954477 - Disclosure - Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.novavax.com/role/LeasesTables">
        <link:definition>9954478 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtTables" roleURI="http://www.novavax.com/role/LongTermDebtTables">
        <link:definition>9954479 - Disclosure - Long-Term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.novavax.com/role/StockBasedCompensationTables">
        <link:definition>9954480 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationTables" roleURI="http://www.novavax.com/role/OtherFinancialInformationTables">
        <link:definition>9954481 - Disclosure - Other Financial Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.novavax.com/role/IncomeTaxesTables">
        <link:definition>9954482 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringTables" roleURI="http://www.novavax.com/role/RestructuringTables">
        <link:definition>9954483 - Disclosure - Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>9954484 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails">
        <link:definition>9954485 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails" roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails">
        <link:definition>9954486 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueAdditionalInformationDetails" roleURI="http://www.novavax.com/role/RevenueAdditionalInformationDetails">
        <link:definition>9954487 - Disclosure - Revenue - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueAdditionalInformationDetails_1" roleURI="http://www.novavax.com/role/RevenueAdditionalInformationDetails_1">
        <link:definition>9954487 - Disclosure - Revenue - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails" roleURI="http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails">
        <link:definition>9954488 - Disclosure - Revenue - Schedule of Accounts Receivable, Unbilled Services, and Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueScheduleofProductRevenueDetails" roleURI="http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails">
        <link:definition>9954489 - Disclosure - Revenue - Schedule of Product Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails" roleURI="http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails">
        <link:definition>9954490 - Disclosure - Revenue - Schedule of Revenue Gross to Net Deductions Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueScheduleofGrantRevenueDetails" roleURI="http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails">
        <link:definition>9954491 - Disclosure - Revenue - Schedule of Grant Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandSupplyAgreementsDetails" roleURI="http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails">
        <link:definition>9954492 - Disclosure - Collaboration, License, and Supply Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>9954493 - Disclosure - Cash, Cash Equivalents, and Restricted Cash - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.novavax.com/role/FairValueMeasurementsDetails">
        <link:definition>9954494 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryScheduleofInventoryDetails" roleURI="http://www.novavax.com/role/InventoryScheduleofInventoryDetails">
        <link:definition>9954495 - Disclosure - Inventory - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryAdditionalInformationDetails" roleURI="http://www.novavax.com/role/InventoryAdditionalInformationDetails">
        <link:definition>9954496 - Disclosure - Inventory - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryScheduleofInventoryReservesDetails" roleURI="http://www.novavax.com/role/InventoryScheduleofInventoryReservesDetails">
        <link:definition>9954497 - Disclosure - Inventory - Schedule of Inventory Reserves (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillDetails" roleURI="http://www.novavax.com/role/GoodwillDetails">
        <link:definition>9954498 - Disclosure - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetails" roleURI="http://www.novavax.com/role/LeasesAdditionalInformationDetails">
        <link:definition>9954499 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails" roleURI="http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails">
        <link:definition>9954500 - Disclosure - Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofOperatingLeaseExpensesDetails" roleURI="http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails">
        <link:definition>9954501 - Disclosure - Leases - Schedule of Operating Lease Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofSupplementalCashFlowInformationofLeasesDetails" roleURI="http://www.novavax.com/role/LeasesScheduleofSupplementalCashFlowInformationofLeasesDetails">
        <link:definition>9954502 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information of Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofLeaseLiabilitiesDetails" roleURI="http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails">
        <link:definition>9954503 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofLeaseLiabilitiesDetails_1" roleURI="http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1">
        <link:definition>9954503 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtScheduleofNotesPayableDetails" roleURI="http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails">
        <link:definition>9954504 - Disclosure - Long-Term Debt - Schedule of Notes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtScheduleofInterestExpenseDetails" roleURI="http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails">
        <link:definition>9954505 - Disclosure - Long-Term Debt - Schedule of Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtAdditionalInformationDetails" roleURI="http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails">
        <link:definition>9954506 - Disclosure - Long-Term Debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeficitDetails" roleURI="http://www.novavax.com/role/StockholdersDeficitDetails">
        <link:definition>9954507 - Disclosure - Stockholders&#8217; Deficit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>9954508 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails">
        <link:definition>9954509 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails" roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails">
        <link:definition>9954510 - Disclosure - Stock-Based Compensation - Schedule of Option and Appreciation Rights Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails" roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails">
        <link:definition>9954511 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used in Estimation of Fair Value of Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails" roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails">
        <link:definition>9954512 - Disclosure - Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitsDetails" roleURI="http://www.novavax.com/role/EmployeeBenefitsDetails">
        <link:definition>9954513 - Disclosure - Employee Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://www.novavax.com/role/OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>9954514 - Disclosure - Other Financial Information - Schedule of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails" roleURI="http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails">
        <link:definition>9954515 - Disclosure - Other Financial Information - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationAdditionalInformationDetails" roleURI="http://www.novavax.com/role/OtherFinancialInformationAdditionalInformationDetails">
        <link:definition>9954516 - Disclosure - Other Financial Information - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationScheduleofAccruedExpensesDetails" roleURI="http://www.novavax.com/role/OtherFinancialInformationScheduleofAccruedExpensesDetails">
        <link:definition>9954517 - Disclosure - Other Financial Information - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationScheduleofOtherCurrentLiabilitiesDetails" roleURI="http://www.novavax.com/role/OtherFinancialInformationScheduleofOtherCurrentLiabilitiesDetails">
        <link:definition>9954518 - Disclosure - Other Financial Information - Schedule of Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails" roleURI="http://www.novavax.com/role/IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails">
        <link:definition>9954519 - Disclosure - Income Taxes - Schedule of Company's Income (Loss) from Operations Before Income Tax Provision (Benefit) by Jurisdiction (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails" roleURI="http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails">
        <link:definition>9954520 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>9954521 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofTaxRateDifferencesDetails" roleURI="http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails">
        <link:definition>9954522 - Disclosure - Income Taxes - Schedule of Tax Rate Differences (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>9954523 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollforwardDetails" roleURI="http://www.novavax.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollforwardDetails">
        <link:definition>9954524 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesDetails" roleURI="http://www.novavax.com/role/CommitmentandContingenciesDetails">
        <link:definition>9954525 - Disclosure - Commitment and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringScheduleofImpairmentChargesDetails" roleURI="http://www.novavax.com/role/RestructuringScheduleofImpairmentChargesDetails">
        <link:definition>9954526 - Disclosure - Restructuring - Schedule of Impairment Charges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringNarrativeDetails" roleURI="http://www.novavax.com/role/RestructuringNarrativeDetails">
        <link:definition>9954527 - Disclosure - Restructuring - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.novavax.com/role/SubsequentEventsDetails">
        <link:definition>9954528 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="nvax_August2023SalesAgreementMember" abstract="true" name="August2023SalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_ShortTermLeaseCostBenefit" abstract="false" name="ShortTermLeaseCostBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_GovernmentOfAustraliaMember" abstract="true" name="GovernmentOfAustraliaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_WeightedAverageDiscountRateAbstract" abstract="true" name="WeightedAverageDiscountRateAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember" abstract="true" name="WholesaleDistributorFeesDiscountsAndChargebacksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_UnderwriterMember" abstract="true" name="UnderwriterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_AccruedGrossToNetDeductionsCurrent" abstract="false" name="AccruedGrossToNetDeductionsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage" abstract="false" name="DebtInstrumentRepurchaseOfPrincipalAmountPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="nvax_CollaborativeArrangementAbstract" abstract="true" name="CollaborativeArrangementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_MilestonePaymentsMember" abstract="true" name="MilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_MatrixMAdjuvantSalesMember" abstract="true" name="MatrixMAdjuvantSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_NumberOfQuarterlyInstallmentPayments" abstract="false" name="NumberOfQuarterlyInstallmentPayments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nvax_SecuritiesSubscriptionArrangementMember" abstract="true" name="SecuritiesSubscriptionArrangementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward" abstract="true" name="AccountsReceivableBeforeAllowanceForCreditLossRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_ProductReturnsMember" abstract="true" name="ProductReturnsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_ComputerSoftwareAndHardwareMemberMember" abstract="true" name="ComputerSoftwareAndHardwareMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements" abstract="false" name="OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_FacilityNumberOfSquareFeet" abstract="false" name="FacilityNumberOfSquareFeet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:areaItemType"/>
  <xs:element id="nvax_USGovernmentAgreementMember" abstract="true" name="USGovernmentAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_NumberOfSettlementPayments" abstract="false" name="NumberOfSettlementPayments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nvax_PercentageOfMarketPriceForStockPurchase" abstract="false" name="PercentageOfMarketPriceForStockPurchase" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="nvax_InventoryReserveRollForward" abstract="true" name="InventoryReserveRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nvax_InventoryReserveOtherAdditions" abstract="false" name="InventoryReserveOtherAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_SubjectToExpirationMember" abstract="true" name="SubjectToExpirationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_FacilityLeaseAgreementMember" abstract="true" name="FacilityLeaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_NumberOfDosesOfVaccineCandidate" abstract="false" name="NumberOfDosesOfVaccineCandidate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" abstract="false" name="NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_FirstThreePercentOfParticipantsDeferralMemberMember" abstract="true" name="FirstThreePercentOfParticipantsDeferralMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_AccountsReceivableAllowanceForCreditLossDeductions" abstract="false" name="AccountsReceivableAllowanceForCreditLossDeductions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_PurchaseAgreementNumberOfVaccineDoses" abstract="false" name="PurchaseAgreementNumberOfVaccineDoses" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember" abstract="true" name="CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_LossContingencyPeriodToAnswer" abstract="false" name="LossContingencyPeriodToAnswer" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nvax_RevenueMember" abstract="true" name="RevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_CollaborationAgreementUpfrontPaymentAmount" abstract="false" name="CollaborationAgreementUpfrontPaymentAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember" abstract="true" name="CoalitionForEpidemicPreparednessInnovationsAwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_CMOAndCMDAgreementsMember" abstract="true" name="CMOAndCMDAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_TwoThousandFifteenStockIncentivePlanMember" abstract="true" name="TwoThousandFifteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_TwoThousandTwentyThreeStockInducementPlanMember" abstract="true" name="TwoThousandTwentyThreeStockInducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_SettlementPayment" abstract="false" name="SettlementPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_SettlementAgreementInitialReservationFee" abstract="false" name="SettlementAgreementInitialReservationFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_FivePointZeroConvertibleNotesDue2027Member" abstract="true" name="FivePointZeroConvertibleNotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_ContractWithCustomerObligationToDeliverTerms" abstract="false" name="ContractWithCustomerObligationToDeliverTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nvax_NoExpirationMember" abstract="true" name="NoExpirationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_TwoThousandFiveStockIncentivePlanMember" abstract="true" name="TwoThousandFiveStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_ContractWithCustomerLiabilityAdditions" abstract="false" name="ContractWithCustomerLiabilityAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations" abstract="false" name="EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount" abstract="false" name="RevenueRemainingPerformanceObligationVariableConsiderationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_EuropeanCommissionsECMember" abstract="true" name="EuropeanCommissionsECMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_PercentOfRemainingAmountToBePaid" abstract="false" name="PercentOfRemainingAmountToBePaid" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nvax_InventoryReserveChargedToCostsOfSales" abstract="false" name="InventoryReserveChargedToCostsOfSales" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_AmountsChargedAgainstProductSales" abstract="false" name="AmountsChargedAgainstProductSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember" abstract="true" name="JointCommitteeOnVaccinationAndImmunizationJCVIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nvax_RevenueFromContractWithCustomerCommitment" abstract="false" name="RevenueFromContractWithCustomerCommitment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_RestructuringAndRelatedCostNumberOfPositionsEliminatedGlobalPercent" abstract="false" name="RestructuringAndRelatedCostNumberOfPositionsEliminatedGlobalPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" abstract="false" name="ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nvax_CanadaAdvancePurchaseAgreementMember" abstract="true" name="CanadaAdvancePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract" abstract="true" name="CashFlowOperatingAndFinancingActivitiesLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_LiquidityAndGoingConcernPolicyTextBlock" abstract="false" name="LiquidityAndGoingConcernPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nvax_ConversionPremiumPercentage" abstract="false" name="ConversionPremiumPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="nvax_SettlementAgreementBenefit" abstract="false" name="SettlementAgreementBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_DebtCapPrice" abstract="false" name="DebtCapPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="nvax_June2021AndAugust2023SalesAgreementMember" abstract="true" name="June2021AndAugust2023SalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_ConvertibleNotesPayableNoncurrentAbstract" abstract="true" name="ConvertibleNotesPayableNoncurrentAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_LeaseRightOfUseAsset" abstract="false" name="LeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled" abstract="false" name="ProceedsFromIssuanceOrSaleOfEquityNotSettled" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_PurchaseAgreementNumberOfDosesCancelled" abstract="false" name="PurchaseAgreementNumberOfDosesCancelled" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock" abstract="false" name="ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nvax_CollaborationAgreementRemainingPaymentAmount" abstract="false" name="CollaborationAgreementRemainingPaymentAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_DeferredRevenueIncreaseDecreaseAbstract" abstract="true" name="DeferredRevenueIncreaseDecreaseAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" abstract="false" name="ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember" abstract="true" name="GaviAdvancePurchaseAgreementCOVAXFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_CEPIGrantFundingMember" abstract="true" name="CEPIGrantFundingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_InventoryFirmPurchaseCommitmentRecoveries" abstract="false" name="InventoryFirmPurchaseCommitmentRecoveries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_CommonStockPremiumPaid" abstract="false" name="CommonStockPremiumPaid" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_ContractWithCustomerLiabilityRollForward" abstract="true" name="ContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_NumberOfDosesToBeDistributed" abstract="false" name="NumberOfDosesToBeDistributed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nvax_FilipDubovskyMDMember" abstract="true" name="FilipDubovskyMDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_SKBioscienceCoLtdMember" abstract="true" name="SKBioscienceCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_June2021SalesAgreementMember" abstract="true" name="June2021SalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_SaleOfStockAmountOfRemainingUnissuedShares" abstract="false" name="SaleOfStockAmountOfRemainingUnissuedShares" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_AmendedAndRestatedUKSupplyAgreementMember" abstract="true" name="AmendedAndRestatedUKSupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_AustralianAPAMember" abstract="true" name="AustralianAPAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_RoyaltyPeriod" abstract="false" name="RoyaltyPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability" abstract="false" name="RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="nvax_EuropeanCommissionMember" abstract="true" name="EuropeanCommissionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_GaviAdvancePurchaseAgreementSIIPLMember" abstract="true" name="GaviAdvancePurchaseAgreementSIIPLMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_DebtInstrumentFaceAmountCurrent" abstract="false" name="DebtInstrumentFaceAmountCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_LeaseLiabilityCurrent" abstract="false" name="LeaseLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_RoyaltiesAndOtherMember" abstract="true" name="RoyaltiesAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_U.S.ProductSalesReturnsAccrual" abstract="false" name="U.S.ProductSalesReturnsAccrual" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_OperatingAndFinanceLeaseWriteOff" abstract="false" name="OperatingAndFinanceLeaseWriteOff" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock" abstract="false" name="ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member" abstract="true" name="ThreePointSeventyFiveConvertibleNotesDue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_EscrowDepositsRelatedToSalesHold" abstract="false" name="EscrowDepositsRelatedToSalesHold" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_InventoryReserveDeductions" abstract="false" name="InventoryReserveDeductions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_GrantsUSGovernmentContractAndJointVentureAbstract" abstract="true" name="GrantsUSGovernmentContractAndJointVentureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nvax_PaymentForCappedCallTransactions" abstract="false" name="PaymentForCappedCallTransactions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_CommonStockQuotedMarketPrice" abstract="false" name="CommonStockQuotedMarketPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nvax_ConvertibleDebtConversionRate" abstract="false" name="ConvertibleDebtConversionRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="nvax_ContractWithCustomerLiabilityDeductions" abstract="false" name="ContractWithCustomerLiabilityDeductions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_DeferredTaxAssetLeasingLiability" abstract="false" name="DeferredTaxAssetLeasingLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_ProvisionForExcessAndObsoleteInventory" abstract="false" name="ProvisionForExcessAndObsoleteInventory" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_GovernmentOfIsraelMember" abstract="true" name="GovernmentOfIsraelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_CoalitionForEpidemicPreparednessInnovationsMember" abstract="true" name="CoalitionForEpidemicPreparednessInnovationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_SalesBasedRoyaltiesMember" abstract="true" name="SalesBasedRoyaltiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_ROUFacilityLeasesMember" abstract="true" name="ROUFacilityLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="nvax_LeaseImpairmentChargeAxis" abstract="true" name="LeaseImpairmentChargeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption" abstract="false" name="NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nvax_USGovernmentMember" abstract="true" name="USGovernmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram" abstract="false" name="ShareBasedCompensationStockIssuedUnderIncentiveProgram" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock" abstract="false" name="ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" abstract="false" name="AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nvax_GovernmentOfCanadaMember" abstract="true" name="GovernmentOfCanadaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_MaximumContributionOfEmployeesAsPayrollDeductions" abstract="false" name="MaximumContributionOfEmployeesAsPayrollDeductions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="nvax_USGovernmentPartnershipMember" abstract="true" name="USGovernmentPartnershipMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_CompensationStockIssuedUnderIncentiveProgram" abstract="false" name="CompensationStockIssuedUnderIncentiveProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock" abstract="false" name="InterestExpenseRelatedToConvertibleNotesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nvax_SettlementAgreementQuarterlyInstallmentAmount" abstract="false" name="SettlementAgreementQuarterlyInstallmentAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_ResearchAndDevelopmentAccrualsCurrent" abstract="false" name="ResearchAndDevelopmentAccrualsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions" abstract="false" name="AccountsReceivableBeforeAllowanceForCreditLossAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_CMOAgreementMember" abstract="true" name="CMOAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_TakedaArrangementMember" abstract="true" name="TakedaArrangementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_NextTwoPercentOfParticipantsDeferralMemberMember" abstract="true" name="NextTwoPercentOfParticipantsDeferralMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_LeaseImpairmentChargeDomain" abstract="true" name="LeaseImpairmentChargeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nvax_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_ConvertibleNotesPayableCurrentAbstract" abstract="true" name="ConvertibleNotesPayableCurrentAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_SettlementAgreementMember" abstract="true" name="SettlementAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_ScheduleOfInventoryReserveTableTextBlock" abstract="false" name="ScheduleOfInventoryReserveTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="nvax_USDepartmentOfDefenseDoDContractMember" abstract="true" name="USDepartmentOfDefenseDoDContractMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_LeaseLiabilityNoncurrent" abstract="false" name="LeaseLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_A700QuinceOrchardRoadAgreementMember" abstract="true" name="A700QuinceOrchardRoadAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_WeightedAverageRemainingLeaseTermAbstract" abstract="true" name="WeightedAverageRemainingLeaseTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions" abstract="false" name="AccountsReceivableBeforeAllowanceForCreditLossDeductions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_OtherGrantRevenueMember" abstract="true" name="OtherGrantRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_RestOfTheWorldMember" abstract="true" name="RestOfTheWorldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_InstallmentChargesOfTheCompany" abstract="false" name="InstallmentChargesOfTheCompany" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nvax_NetProceedsFromTheExerciseOfStockBasedAwards" abstract="false" name="NetProceedsFromTheExerciseOfStockBasedAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember" abstract="true" name="FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nvax_AccountsReceivableAllowanceForCreditLossAdditions" abstract="false" name="AccountsReceivableAllowanceForCreditLossAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>19
<FILENAME>nvax-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:02f62cea-2ee5-4f46-a427-e5f89894c0b1,g:b653a9b6-e98d-435f-a6cb-06522e8cacbf-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="nvax-20231231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9a420e43-ef4d-445a-bf09-358bbadae930" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_b4dcd504-4936-46ba-b881-c4fc7b15f281" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_9a420e43-ef4d-445a-bf09-358bbadae930" xlink:to="loc_us-gaap_CostOfRevenue_b4dcd504-4936-46ba-b881-c4fc7b15f281" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9ffc734d-8d09-4303-ba3a-8c4b849eee10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_9a420e43-ef4d-445a-bf09-358bbadae930" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9ffc734d-8d09-4303-ba3a-8c4b849eee10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4115a018-66d1-4297-9d65-1c7fb463e2da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_9a420e43-ef4d-445a-bf09-358bbadae930" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4115a018-66d1-4297-9d65-1c7fb463e2da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_902e2f61-17a0-4688-b524-c7424803ab73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_cb513233-5fe3-4288-99fe-6d60a3a791a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_902e2f61-17a0-4688-b524-c7424803ab73" xlink:to="loc_us-gaap_Revenues_cb513233-5fe3-4288-99fe-6d60a3a791a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_7f2fc07c-2b60-4b7a-88ee-e512120d30f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_902e2f61-17a0-4688-b524-c7424803ab73" xlink:to="loc_us-gaap_CostsAndExpenses_7f2fc07c-2b60-4b7a-88ee-e512120d30f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_96607345-834b-4ae9-9d6e-281208b50f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_08ed711c-4412-487f-a627-72eeeb80f706" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_96607345-834b-4ae9-9d6e-281208b50f3b" xlink:to="loc_us-gaap_InterestExpense_08ed711c-4412-487f-a627-72eeeb80f706" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5ef05213-8346-42d2-8519-e9072c24fc24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_96607345-834b-4ae9-9d6e-281208b50f3b" xlink:to="loc_us-gaap_OperatingIncomeLoss_5ef05213-8346-42d2-8519-e9072c24fc24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a5a8ae96-2016-4ec3-b2c3-268d298ca246" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_96607345-834b-4ae9-9d6e-281208b50f3b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a5a8ae96-2016-4ec3-b2c3-268d298ca246" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_36372254-c7a6-4adf-beaf-5de64a62b3be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_079df7ea-9601-4bed-9e04-e431e7ba1d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_36372254-c7a6-4adf-beaf-5de64a62b3be" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_079df7ea-9601-4bed-9e04-e431e7ba1d2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_128946e0-5fbf-4a8b-a6ef-b6cacc4e7631" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_36372254-c7a6-4adf-beaf-5de64a62b3be" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_128946e0-5fbf-4a8b-a6ef-b6cacc4e7631" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="nvax-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e32d6648-8c8e-4cf6-aa5d-c130ce011806" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2c11c183-5afd-4ad6-8352-1a09881f6b63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e32d6648-8c8e-4cf6-aa5d-c130ce011806" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2c11c183-5afd-4ad6-8352-1a09881f6b63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_27abdaa9-8f01-427a-986c-551d3599ecbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e32d6648-8c8e-4cf6-aa5d-c130ce011806" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_27abdaa9-8f01-427a-986c-551d3599ecbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f0be25be-9e0b-4571-b94d-f049beff9b68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_12b3fa34-c027-4b30-807c-e8b83e150614" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f0be25be-9e0b-4571-b94d-f049beff9b68" xlink:to="loc_us-gaap_NetIncomeLoss_12b3fa34-c027-4b30-807c-e8b83e150614" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_89a7d3df-5d86-4736-96f6-5cab38c4dea9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f0be25be-9e0b-4571-b94d-f049beff9b68" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_89a7d3df-5d86-4736-96f6-5cab38c4dea9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="nvax-20231231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_221ce64d-5f01-4165-ad28-189557a386e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_4c2f8852-fd4a-4260-8584-2cfbefddc259" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_221ce64d-5f01-4165-ad28-189557a386e1" xlink:to="loc_us-gaap_PreferredStockValue_4c2f8852-fd4a-4260-8584-2cfbefddc259" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7e03ad86-73d2-4c71-8e9d-5af4c9408ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_221ce64d-5f01-4165-ad28-189557a386e1" xlink:to="loc_us-gaap_CommonStockValue_7e03ad86-73d2-4c71-8e9d-5af4c9408ab6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_a7dae290-570a-49f9-b58d-5ea721917433" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_221ce64d-5f01-4165-ad28-189557a386e1" xlink:to="loc_us-gaap_AdditionalPaidInCapital_a7dae290-570a-49f9-b58d-5ea721917433" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4513b565-dd88-478c-9b0c-66cd51686eed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_221ce64d-5f01-4165-ad28-189557a386e1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4513b565-dd88-478c-9b0c-66cd51686eed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_85ddddb4-4619-4f5e-aca6-32963aa47898" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_221ce64d-5f01-4165-ad28-189557a386e1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_85ddddb4-4619-4f5e-aca6-32963aa47898" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_ace62788-b5ac-4a3a-8296-b7ed63abde03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_221ce64d-5f01-4165-ad28-189557a386e1" xlink:to="loc_us-gaap_TreasuryStockCommonValue_ace62788-b5ac-4a3a-8296-b7ed63abde03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4af19368-4dff-426b-a7ab-2321f7515a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c6295057-b018-4fa6-b011-f3f4915c81fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4af19368-4dff-426b-a7ab-2321f7515a2c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c6295057-b018-4fa6-b011-f3f4915c81fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_142274bd-0f4a-4756-8943-2644b29112ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4af19368-4dff-426b-a7ab-2321f7515a2c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_142274bd-0f4a-4756-8943-2644b29112ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_80cede4c-31e8-4a4a-a5a6-24507d31abf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4af19368-4dff-426b-a7ab-2321f7515a2c" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_80cede4c-31e8-4a4a-a5a6-24507d31abf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_00470731-ba03-4d6e-bbae-da5181e48cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4af19368-4dff-426b-a7ab-2321f7515a2c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_00470731-ba03-4d6e-bbae-da5181e48cf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f8a5586c-d77e-459e-897c-ecab4df1c962" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4af19368-4dff-426b-a7ab-2321f7515a2c" xlink:to="loc_us-gaap_LiabilitiesCurrent_f8a5586c-d77e-459e-897c-ecab4df1c962" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_707a1a37-5952-43dd-a1ff-a96cc6ff3410" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_498deebc-e15a-4c65-85bc-4c3d2857f477" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_707a1a37-5952-43dd-a1ff-a96cc6ff3410" xlink:to="loc_us-gaap_Liabilities_498deebc-e15a-4c65-85bc-4c3d2857f477" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_1fb6e127-451a-45c6-aac0-bce99ac659f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_707a1a37-5952-43dd-a1ff-a96cc6ff3410" xlink:to="loc_us-gaap_CommitmentsAndContingencies_1fb6e127-451a-45c6-aac0-bce99ac659f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_de60ac09-7641-44c8-b5fb-609924a9c940" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_707a1a37-5952-43dd-a1ff-a96cc6ff3410" xlink:to="loc_us-gaap_StockholdersEquity_de60ac09-7641-44c8-b5fb-609924a9c940" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4d9c7623-1ffe-4691-b64c-c41c11d97208" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_720e5edb-3949-4d31-80f8-e3e741f9a049" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4d9c7623-1ffe-4691-b64c-c41c11d97208" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_720e5edb-3949-4d31-80f8-e3e741f9a049" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_f6857f08-b5cb-45db-b620-cb392bb25e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4d9c7623-1ffe-4691-b64c-c41c11d97208" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_f6857f08-b5cb-45db-b620-cb392bb25e3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0800d5f0-652b-466e-8020-130056dc77fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4d9c7623-1ffe-4691-b64c-c41c11d97208" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0800d5f0-652b-466e-8020-130056dc77fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_6bdb6b78-e143-496e-a825-efedba9a8a27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4d9c7623-1ffe-4691-b64c-c41c11d97208" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_6bdb6b78-e143-496e-a825-efedba9a8a27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4932e233-da5c-4f85-ba3b-65340bb2ac7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4d9c7623-1ffe-4691-b64c-c41c11d97208" xlink:to="loc_us-gaap_AccountsPayableCurrent_4932e233-da5c-4f85-ba3b-65340bb2ac7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7b6ef8f9-feae-4545-b045-de8f85b06348" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4d9c7623-1ffe-4691-b64c-c41c11d97208" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7b6ef8f9-feae-4545-b045-de8f85b06348" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8ee3e619-7e9e-48de-b0e4-2d72fc2ccaee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f74bc510-c13a-46d6-b28b-f639c50fa06b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8ee3e619-7e9e-48de-b0e4-2d72fc2ccaee" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f74bc510-c13a-46d6-b28b-f639c50fa06b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_17463c56-a71c-4c6b-a149-3a7602642bda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8ee3e619-7e9e-48de-b0e4-2d72fc2ccaee" xlink:to="loc_us-gaap_InventoryNet_17463c56-a71c-4c6b-a149-3a7602642bda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_55bd6cd2-1c29-4079-8bd2-14c4960a02bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8ee3e619-7e9e-48de-b0e4-2d72fc2ccaee" xlink:to="loc_us-gaap_AccountsReceivableNet_55bd6cd2-1c29-4079-8bd2-14c4960a02bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7d2d6b8e-5522-472d-b94c-159ade154f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8ee3e619-7e9e-48de-b0e4-2d72fc2ccaee" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7d2d6b8e-5522-472d-b94c-159ade154f6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_50264647-48b5-4e47-8278-30a7fc56818b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8ee3e619-7e9e-48de-b0e4-2d72fc2ccaee" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_50264647-48b5-4e47-8278-30a7fc56818b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_13bb1348-ef87-43e5-a8fb-518059e72607" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f7065573-a00f-441a-bb5c-14ad2f3c1c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_13bb1348-ef87-43e5-a8fb-518059e72607" xlink:to="loc_us-gaap_AssetsCurrent_f7065573-a00f-441a-bb5c-14ad2f3c1c8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7d54ef66-bb48-4237-80ad-843e5e2cc0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_13bb1348-ef87-43e5-a8fb-518059e72607" xlink:to="loc_us-gaap_Goodwill_7d54ef66-bb48-4237-80ad-843e5e2cc0f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_974a788f-87aa-4826-8eff-b4fdbbbb085b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_13bb1348-ef87-43e5-a8fb-518059e72607" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_974a788f-87aa-4826-8eff-b4fdbbbb085b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c6f91075-23fc-47d1-bb81-76c466cbfd71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_13bb1348-ef87-43e5-a8fb-518059e72607" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c6f91075-23fc-47d1-bb81-76c466cbfd71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseRightOfUseAsset_05ad2a15-54c9-461e-98b5-4814863c79d7" xlink:href="nvax-20231231.xsd#nvax_LeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_13bb1348-ef87-43e5-a8fb-518059e72607" xlink:to="loc_nvax_LeaseRightOfUseAsset_05ad2a15-54c9-461e-98b5-4814863c79d7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="nvax-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c819eeeb-6ff0-4846-a7c3-418241fbeb31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_64d77416-a755-403f-98fa-5253679a086e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c819eeeb-6ff0-4846-a7c3-418241fbeb31" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_64d77416-a755-403f-98fa-5253679a086e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_a83b4a44-d85e-4ded-9e7a-6e6c9233a43e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c819eeeb-6ff0-4846-a7c3-418241fbeb31" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_a83b4a44-d85e-4ded-9e7a-6e6c9233a43e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_c0e7051c-a226-402e-aa0a-da13936158ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c819eeeb-6ff0-4846-a7c3-418241fbeb31" xlink:to="loc_us-gaap_DepreciationAndAmortization_c0e7051c-a226-402e-aa0a-da13936158ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_951f09dc-3045-46af-b4e7-038dcff3a1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c819eeeb-6ff0-4846-a7c3-418241fbeb31" xlink:to="loc_us-gaap_ShareBasedCompensation_951f09dc-3045-46af-b4e7-038dcff3a1fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ProvisionForExcessAndObsoleteInventory_f9a2c19d-3bad-49d0-9c8f-1f65ad3742d1" xlink:href="nvax-20231231.xsd#nvax_ProvisionForExcessAndObsoleteInventory"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c819eeeb-6ff0-4846-a7c3-418241fbeb31" xlink:to="loc_nvax_ProvisionForExcessAndObsoleteInventory_f9a2c19d-3bad-49d0-9c8f-1f65ad3742d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_11f4583e-7e34-43a6-a41e-04cd38c5008e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c819eeeb-6ff0-4846-a7c3-418241fbeb31" xlink:to="loc_us-gaap_NetIncomeLoss_11f4583e-7e34-43a6-a41e-04cd38c5008e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b67668de-eb99-4ec7-9302-bad6a10011ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c819eeeb-6ff0-4846-a7c3-418241fbeb31" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b67668de-eb99-4ec7-9302-bad6a10011ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_OperatingAndFinanceLeaseWriteOff_c933f1a8-3b4a-447f-97cf-64f8f6dca3bd" xlink:href="nvax-20231231.xsd#nvax_OperatingAndFinanceLeaseWriteOff"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c819eeeb-6ff0-4846-a7c3-418241fbeb31" xlink:to="loc_nvax_OperatingAndFinanceLeaseWriteOff_c933f1a8-3b4a-447f-97cf-64f8f6dca3bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_9ed54d0c-f722-409b-96d7-662255e87779" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c819eeeb-6ff0-4846-a7c3-418241fbeb31" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_9ed54d0c-f722-409b-96d7-662255e87779" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_b0449af4-1a47-4050-b8be-dfde9dfc95fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c819eeeb-6ff0-4846-a7c3-418241fbeb31" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_b0449af4-1a47-4050-b8be-dfde9dfc95fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_e1bf3283-a5bb-4e9f-9af3-38c0d6b223f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c819eeeb-6ff0-4846-a7c3-418241fbeb31" xlink:to="loc_us-gaap_AssetImpairmentCharges_e1bf3283-a5bb-4e9f-9af3-38c0d6b223f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c4e31869-8654-46ac-a7c3-41b0255f0a57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_5626646c-27e7-4ae5-bb3a-91a6c2f0c3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c4e31869-8654-46ac-a7c3-41b0255f0a57" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_5626646c-27e7-4ae5-bb3a-91a6c2f0c3a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5fe82f93-a571-40e9-a347-38eb7bf07a75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c4e31869-8654-46ac-a7c3-41b0255f0a57" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5fe82f93-a571-40e9-a347-38eb7bf07a75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_141548d0-7311-4d7a-96b1-30294b657601" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c4e31869-8654-46ac-a7c3-41b0255f0a57" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_141548d0-7311-4d7a-96b1-30294b657601" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_f7744e24-ecd4-44a9-a00a-d01dc2958ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c4e31869-8654-46ac-a7c3-41b0255f0a57" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_f7744e24-ecd4-44a9-a00a-d01dc2958ec1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NetProceedsFromTheExerciseOfStockBasedAwards_7a30d62e-c620-4844-b618-7193618b4d9b" xlink:href="nvax-20231231.xsd#nvax_NetProceedsFromTheExerciseOfStockBasedAwards"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c4e31869-8654-46ac-a7c3-41b0255f0a57" xlink:to="loc_nvax_NetProceedsFromTheExerciseOfStockBasedAwards_7a30d62e-c620-4844-b618-7193618b4d9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_61205d35-cd39-44d6-bbdc-8fffb49e61ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c4e31869-8654-46ac-a7c3-41b0255f0a57" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_61205d35-cd39-44d6-bbdc-8fffb49e61ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c01906f4-84e6-487d-af9b-14f27e378b20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_1425025f-c3dd-4b2d-9a71-215a7901195f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c01906f4-84e6-487d-af9b-14f27e378b20" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_1425025f-c3dd-4b2d-9a71-215a7901195f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_dfadb40d-4a8f-4614-8364-2ab4ea9e40e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c01906f4-84e6-487d-af9b-14f27e378b20" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_dfadb40d-4a8f-4614-8364-2ab4ea9e40e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCapitalImprovements_c744a38a-898f-445b-b32d-9f0d7910466d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForCapitalImprovements"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c01906f4-84e6-487d-af9b-14f27e378b20" xlink:to="loc_us-gaap_PaymentsForCapitalImprovements_c744a38a-898f-445b-b32d-9f0d7910466d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware_14e3f86f-40fd-464c-b9c0-fb347c892fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForSoftware"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c01906f4-84e6-487d-af9b-14f27e378b20" xlink:to="loc_us-gaap_PaymentsForSoftware_14e3f86f-40fd-464c-b9c0-fb347c892fdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_36534d32-c0ac-4480-8418-5776fddcb4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2208adf8-fb28-4eed-8c19-72c1220b851b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_36534d32-c0ac-4480-8418-5776fddcb4f5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2208adf8-fb28-4eed-8c19-72c1220b851b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8756d770-0709-4776-9741-9160d393904b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_36534d32-c0ac-4480-8418-5776fddcb4f5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8756d770-0709-4776-9741-9160d393904b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_40a3b8f7-a9cb-48d3-a97b-9b91fed41f81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_36534d32-c0ac-4480-8418-5776fddcb4f5" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_40a3b8f7-a9cb-48d3-a97b-9b91fed41f81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aed6347b-148b-4ec7-86e6-1f31efebc661" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_36534d32-c0ac-4480-8418-5776fddcb4f5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aed6347b-148b-4ec7-86e6-1f31efebc661" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#CashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e64d5649-db3b-43f3-9562-3a0e529f2e20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_ed21fac0-c27f-4040-9f06-2182f5ffc79e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e64d5649-db3b-43f3-9562-3a0e529f2e20" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_ed21fac0-c27f-4040-9f06-2182f5ffc79e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_12305449-7798-4c58-942e-496b938f88e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e64d5649-db3b-43f3-9562-3a0e529f2e20" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_12305449-7798-4c58-942e-496b938f88e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_861c92f3-d2d5-4be5-9c16-140718c6489c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e64d5649-db3b-43f3-9562-3a0e529f2e20" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_861c92f3-d2d5-4be5-9c16-140718c6489c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/InventoryScheduleofInventoryDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#InventoryScheduleofInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/InventoryScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_3cbd1a4b-96e1-4b7b-8737-7a06eefceadf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_376aad76-5403-4f79-80c7-3bf153a61fac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_3cbd1a4b-96e1-4b7b-8737-7a06eefceadf" xlink:to="loc_us-gaap_InventoryRawMaterials_376aad76-5403-4f79-80c7-3bf153a61fac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_be0d4c4a-63e0-472e-86fb-5ac80966f274" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_3cbd1a4b-96e1-4b7b-8737-7a06eefceadf" xlink:to="loc_us-gaap_InventoryWorkInProcess_be0d4c4a-63e0-472e-86fb-5ac80966f274" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_5f058d7d-ac7b-4d7e-8fb6-7584befc0846" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_3cbd1a4b-96e1-4b7b-8737-7a06eefceadf" xlink:to="loc_us-gaap_InventoryFinishedGoods_5f058d7d-ac7b-4d7e-8fb6-7584befc0846" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseLiabilityNoncurrent_db4bb743-780f-428f-86e2-974f6464a258" xlink:href="nvax-20231231.xsd#nvax_LeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_cdcd9ec8-d927-40f9-9118-42e644ade17d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nvax_LeaseLiabilityNoncurrent_db4bb743-780f-428f-86e2-974f6464a258" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_cdcd9ec8-d927-40f9-9118-42e644ade17d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3077aba8-b988-4d3a-a623-b9cf2f03ba40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nvax_LeaseLiabilityNoncurrent_db4bb743-780f-428f-86e2-974f6464a258" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3077aba8-b988-4d3a-a623-b9cf2f03ba40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseLiabilityCurrent_72d05267-0266-4cb6-9c8b-9d8ba9aaa87e" xlink:href="nvax-20231231.xsd#nvax_LeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b426f077-5d96-4700-9ec5-dfbc305a7203" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nvax_LeaseLiabilityCurrent_72d05267-0266-4cb6-9c8b-9d8ba9aaa87e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b426f077-5d96-4700-9ec5-dfbc305a7203" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_7c71b0cd-4b42-48fd-9169-69a76255e549" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nvax_LeaseLiabilityCurrent_72d05267-0266-4cb6-9c8b-9d8ba9aaa87e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_7c71b0cd-4b42-48fd-9169-69a76255e549" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseRightOfUseAsset_1c18c9c1-3a70-4876-89e3-34fee02c5b29" xlink:href="nvax-20231231.xsd#nvax_LeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_486f4ef0-042f-4f07-99ed-2c16600eca4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nvax_LeaseRightOfUseAsset_1c18c9c1-3a70-4876-89e3-34fee02c5b29" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_486f4ef0-042f-4f07-99ed-2c16600eca4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_17968e95-e2b9-49f0-aa8f-7c9657a5de8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nvax_LeaseRightOfUseAsset_1c18c9c1-3a70-4876-89e3-34fee02c5b29" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_17968e95-e2b9-49f0-aa8f-7c9657a5de8a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#LeasesScheduleofOperatingLeaseExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_c4a82651-9f74-41d9-8f54-269e41561ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_490fb061-f65e-4dca-bb08-d57b3869fe15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_c4a82651-9f74-41d9-8f54-269e41561ff6" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_490fb061-f65e-4dca-bb08-d57b3869fe15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_88409566-996b-4591-8d0e-781690df5b59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_c4a82651-9f74-41d9-8f54-269e41561ff6" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_88409566-996b-4591-8d0e-781690df5b59" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3f78b109-599a-493e-980e-9179c13c834b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6201b372-b4ba-459d-8c69-9b3d7a5e72a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3f78b109-599a-493e-980e-9179c13c834b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6201b372-b4ba-459d-8c69-9b3d7a5e72a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_19919b3a-c2b3-4e76-9ce9-4e22ad40f8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3f78b109-599a-493e-980e-9179c13c834b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_19919b3a-c2b3-4e76-9ce9-4e22ad40f8bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_39dc5221-d778-40ca-a3c7-f19f0d9ab636" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3f78b109-599a-493e-980e-9179c13c834b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_39dc5221-d778-40ca-a3c7-f19f0d9ab636" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ebdb5e02-b46d-4444-8523-91d8eccc772a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3f78b109-599a-493e-980e-9179c13c834b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ebdb5e02-b46d-4444-8523-91d8eccc772a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ff4c2a53-25a5-4131-a719-b3f0a0defd06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3f78b109-599a-493e-980e-9179c13c834b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ff4c2a53-25a5-4131-a719-b3f0a0defd06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f827d76d-afa2-4bbe-b38c-9bf0bd03d694" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3f78b109-599a-493e-980e-9179c13c834b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f827d76d-afa2-4bbe-b38c-9bf0bd03d694" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="nvax-20231231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6c4c4e9e-ce87-4bd1-a78c-b9c5587b97df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3fd6ae59-a37d-4289-9b54-214bdd262b55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6c4c4e9e-ce87-4bd1-a78c-b9c5587b97df" xlink:to="loc_us-gaap_OperatingLeaseLiability_3fd6ae59-a37d-4289-9b54-214bdd262b55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_807aa9a5-3507-40f6-b3d1-1690681a1491" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6c4c4e9e-ce87-4bd1-a78c-b9c5587b97df" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_807aa9a5-3507-40f6-b3d1-1690681a1491" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#LongTermDebtScheduleofNotesPayableDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_cd4636d0-bb07-457b-bfe7-b03b8e2e9438" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DebtInstrumentFaceAmountCurrent_070847b2-2748-4015-b7b5-8932a4776c95" xlink:href="nvax-20231231.xsd#nvax_DebtInstrumentFaceAmountCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleNotesPayableCurrent_cd4636d0-bb07-457b-bfe7-b03b8e2e9438" xlink:to="loc_nvax_DebtInstrumentFaceAmountCurrent_070847b2-2748-4015-b7b5-8932a4776c95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_18ccc637-fecd-4738-b9cb-8c082e7e3916" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleNotesPayableCurrent_cd4636d0-bb07-457b-bfe7-b03b8e2e9438" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_18ccc637-fecd-4738-b9cb-8c082e7e3916" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_99939c81-4cad-4b75-910d-aceb7860764f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_adef1dc7-7e5f-4a92-b94e-dc90277e5e07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable_99939c81-4cad-4b75-910d-aceb7860764f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_adef1dc7-7e5f-4a92-b94e-dc90277e5e07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_92ac00fa-f814-4548-832c-45586bc10e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable_99939c81-4cad-4b75-910d-aceb7860764f" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_92ac00fa-f814-4548-832c-45586bc10e5a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#LongTermDebtScheduleofInterestExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_5d9bddb7-44b3-4730-82b7-dd9f15360676" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_b5b2ff42-2435-435c-8f47-4c6dd3a8d606" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_5d9bddb7-44b3-4730-82b7-dd9f15360676" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_b5b2ff42-2435-435c-8f47-4c6dd3a8d606" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_acc917f1-0bb5-4a43-9228-9af42f56c5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_5d9bddb7-44b3-4730-82b7-dd9f15360676" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_acc917f1-0bb5-4a43-9228-9af42f56c5eb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c0c77062-2918-4e65-8086-70da3c834df5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_1728952b-e0a9-4563-a22b-fb794185a82c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c0c77062-2918-4e65-8086-70da3c834df5" xlink:to="loc_us-gaap_OtherAssetsCurrent_1728952b-e0a9-4563-a22b-fb794185a82c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Supplies_10913aec-35c7-484b-9ab1-cc808f17e0df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Supplies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c0c77062-2918-4e65-8086-70da3c834df5" xlink:to="loc_us-gaap_Supplies_10913aec-35c7-484b-9ab1-cc808f17e0df" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_238e02eb-c810-4674-a6cd-801bf3265255" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_34663b28-316b-4863-b719-124a2bf3853a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_238e02eb-c810-4674-a6cd-801bf3265255" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_34663b28-316b-4863-b719-124a2bf3853a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_dbe94896-92dd-4c7f-bc10-04851eab6c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_238e02eb-c810-4674-a6cd-801bf3265255" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_dbe94896-92dd-4c7f-bc10-04851eab6c9b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/OtherFinancialInformationScheduleofAccruedExpensesDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#OtherFinancialInformationScheduleofAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/OtherFinancialInformationScheduleofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b4bf1a33-69e6-495b-af4c-26c42f8b11ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_49a8da11-a4c5-4f5e-b433-33c5eba31274" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b4bf1a33-69e6-495b-af4c-26c42f8b11ec" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_49a8da11-a4c5-4f5e-b433-33c5eba31274" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccruedGrossToNetDeductionsCurrent_414a71a9-4b25-4077-8106-8a6fb21ffec3" xlink:href="nvax-20231231.xsd#nvax_AccruedGrossToNetDeductionsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b4bf1a33-69e6-495b-af4c-26c42f8b11ec" xlink:to="loc_nvax_AccruedGrossToNetDeductionsCurrent_414a71a9-4b25-4077-8106-8a6fb21ffec3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentAccrualsCurrent_d5426a40-321b-4e69-8df6-cc6ec3ed5a8b" xlink:href="nvax-20231231.xsd#nvax_ResearchAndDevelopmentAccrualsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b4bf1a33-69e6-495b-af4c-26c42f8b11ec" xlink:to="loc_nvax_ResearchAndDevelopmentAccrualsCurrent_d5426a40-321b-4e69-8df6-cc6ec3ed5a8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_U.S.ProductSalesReturnsAccrual_1b51f8fa-4917-4d5c-963c-dcebdb37f6a8" xlink:href="nvax-20231231.xsd#nvax_U.S.ProductSalesReturnsAccrual"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b4bf1a33-69e6-495b-af4c-26c42f8b11ec" xlink:to="loc_nvax_U.S.ProductSalesReturnsAccrual_1b51f8fa-4917-4d5c-963c-dcebdb37f6a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_5144b00a-8211-4bf3-8dd4-f80d42ca237a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b4bf1a33-69e6-495b-af4c-26c42f8b11ec" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_5144b00a-8211-4bf3-8dd4-f80d42ca237a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/OtherFinancialInformationScheduleofOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#OtherFinancialInformationScheduleofOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/OtherFinancialInformationScheduleofOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0f33ff6e-80f4-4d19-9493-9f1a4b6f483e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_74581b88-9f62-4e90-ab09-4a6f1a790ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_0f33ff6e-80f4-4d19-9493-9f1a4b6f483e" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_74581b88-9f62-4e90-ab09-4a6f1a790ad1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements_1e1f10e4-f017-4807-93a0-e3ed9b88fa2a" xlink:href="nvax-20231231.xsd#nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_0f33ff6e-80f4-4d19-9493-9f1a4b6f483e" xlink:to="loc_nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements_1e1f10e4-f017-4807-93a0-e3ed9b88fa2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_8c2d2409-b517-46bb-a597-0c519da9c356" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_0f33ff6e-80f4-4d19-9493-9f1a4b6f483e" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_8c2d2409-b517-46bb-a597-0c519da9c356" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_16da0636-94f2-484b-86ee-9a3a9c203cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_c30f18db-cfe5-4a28-81f1-c6a44acf4ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_16da0636-94f2-484b-86ee-9a3a9c203cbe" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_c30f18db-cfe5-4a28-81f1-c6a44acf4ab9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_fba9c2c7-f561-4d69-997e-09a6ee76a5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_16da0636-94f2-484b-86ee-9a3a9c203cbe" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_fba9c2c7-f561-4d69-997e-09a6ee76a5d7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1d4fa649-2c8a-4562-9e99-1e325d0b684c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_31448d44-4d1b-4908-9da8-34e233788af5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1d4fa649-2c8a-4562-9e99-1e325d0b684c" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_31448d44-4d1b-4908-9da8-34e233788af5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_6cb271bb-8998-4254-99ea-4070634ef491" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1d4fa649-2c8a-4562-9e99-1e325d0b684c" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_6cb271bb-8998-4254-99ea-4070634ef491" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_29bdfb27-a533-4886-8d30-3ac925ad3cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_f45b28af-9d5f-4312-bc12-e941c3dae04e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_29bdfb27-a533-4886-8d30-3ac925ad3cc9" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_f45b28af-9d5f-4312-bc12-e941c3dae04e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_73967dd6-6831-4a5b-aca3-916459d6ac9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_29bdfb27-a533-4886-8d30-3ac925ad3cc9" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_73967dd6-6831-4a5b-aca3-916459d6ac9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_1876c93c-9b2e-4d91-b317-309dc1cd91c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_29bdfb27-a533-4886-8d30-3ac925ad3cc9" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_1876c93c-9b2e-4d91-b317-309dc1cd91c6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#IncomeTaxesScheduleofTaxRateDifferencesDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_013bc8ee-d5d8-4cb3-b6ff-4ee3e50c9d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_194a5f8d-045c-47ba-a4a8-b4839eb33625" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_013bc8ee-d5d8-4cb3-b6ff-4ee3e50c9d0a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_194a5f8d-045c-47ba-a4a8-b4839eb33625" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_aca8c124-14d2-47b0-9b2f-7d89b65e891c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_013bc8ee-d5d8-4cb3-b6ff-4ee3e50c9d0a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_aca8c124-14d2-47b0-9b2f-7d89b65e891c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations_6130c85e-10c5-4157-a87e-ac0923ca2234" xlink:href="nvax-20231231.xsd#nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_013bc8ee-d5d8-4cb3-b6ff-4ee3e50c9d0a" xlink:to="loc_nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations_6130c85e-10c5-4157-a87e-ac0923ca2234" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_0d20eb82-69e1-4d83-a803-044e08cd149b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_013bc8ee-d5d8-4cb3-b6ff-4ee3e50c9d0a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_0d20eb82-69e1-4d83-a803-044e08cd149b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_ec6526ca-92d5-40b9-9da5-207e0b1e56b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_013bc8ee-d5d8-4cb3-b6ff-4ee3e50c9d0a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_ec6526ca-92d5-40b9-9da5-207e0b1e56b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent_c29682a9-26cc-4eb3-9030-46ea425cbc28" xlink:href="nvax-20231231.xsd#nvax_EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_013bc8ee-d5d8-4cb3-b6ff-4ee3e50c9d0a" xlink:to="loc_nvax_EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent_c29682a9-26cc-4eb3-9030-46ea425cbc28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_cc8293b7-1e66-477c-9fa1-a9fd47b14896" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_013bc8ee-d5d8-4cb3-b6ff-4ee3e50c9d0a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_cc8293b7-1e66-477c-9fa1-a9fd47b14896" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_6bbed894-5667-4198-aa36-09b0ac9eb7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_013bc8ee-d5d8-4cb3-b6ff-4ee3e50c9d0a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_6bbed894-5667-4198-aa36-09b0ac9eb7e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4b030241-8879-484f-8f1a-0911b3dce20b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_013bc8ee-d5d8-4cb3-b6ff-4ee3e50c9d0a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4b030241-8879-484f-8f1a-0911b3dce20b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_18523bf9-9e6d-435b-bb97-4aafb92cfc7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_013bc8ee-d5d8-4cb3-b6ff-4ee3e50c9d0a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_18523bf9-9e6d-435b-bb97-4aafb92cfc7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent_cde9fa13-9f2a-451a-a364-d2da2038c7f4" xlink:href="nvax-20231231.xsd#nvax_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_013bc8ee-d5d8-4cb3-b6ff-4ee3e50c9d0a" xlink:to="loc_nvax_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent_cde9fa13-9f2a-451a-a364-d2da2038c7f4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_ed8fa335-7b2c-4bfe-a166-d489f4ea4e56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0e9a17b4-4057-452c-87e3-6cec59b0cda4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_ed8fa335-7b2c-4bfe-a166-d489f4ea4e56" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0e9a17b4-4057-452c-87e3-6cec59b0cda4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_8fc11826-c344-4453-9b07-f4d0aa9c218b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_ed8fa335-7b2c-4bfe-a166-d489f4ea4e56" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_8fc11826-c344-4453-9b07-f4d0aa9c218b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_98a691cd-d228-4881-bf08-a74a9d81b871" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_2fdb1101-ef7a-4144-9890-bc1eaf048721" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_98a691cd-d228-4881-bf08-a74a9d81b871" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_2fdb1101-ef7a-4144-9890-bc1eaf048721" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_42c22ecb-d861-4a5e-8d3e-6e3adf2ab8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_98a691cd-d228-4881-bf08-a74a9d81b871" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_42c22ecb-d861-4a5e-8d3e-6e3adf2ab8c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_e160e64d-fd2e-4f17-8912-a5bec8d14b74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_96134230-5b91-4e6b-83be-01e2e694bb6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_e160e64d-fd2e-4f17-8912-a5bec8d14b74" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_96134230-5b91-4e6b-83be-01e2e694bb6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_2bb522d5-3b9a-4d9d-bfc4-2f652337654f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_e160e64d-fd2e-4f17-8912-a5bec8d14b74" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_2bb522d5-3b9a-4d9d-bfc4-2f652337654f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_bcd6171c-3d35-455a-9648-a468821c1828" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_3fd6166c-6ea5-498c-a8b4-9f8164c87949" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_bcd6171c-3d35-455a-9648-a468821c1828" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_3fd6166c-6ea5-498c-a8b4-9f8164c87949" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_6f15f702-2721-4497-8b06-377e069ff365" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_bcd6171c-3d35-455a-9648-a468821c1828" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_6f15f702-2721-4497-8b06-377e069ff365" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_64aff8c3-3a67-4139-b261-c9badad55c63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_bcd6171c-3d35-455a-9648-a468821c1828" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_64aff8c3-3a67-4139-b261-c9badad55c63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_e5f0aae3-64b1-45ba-8f46-1323fba0633c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_bcd6171c-3d35-455a-9648-a468821c1828" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_e5f0aae3-64b1-45ba-8f46-1323fba0633c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_29e8005f-6457-46d0-b7f7-1d7a70d27d40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_55ba1c7a-0449-4d9b-abcd-eee66a8dd399" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_29e8005f-6457-46d0-b7f7-1d7a70d27d40" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_55ba1c7a-0449-4d9b-abcd-eee66a8dd399" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_602fa2b1-0019-43a8-95b1-7cd383bab140" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_29e8005f-6457-46d0-b7f7-1d7a70d27d40" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_602fa2b1-0019-43a8-95b1-7cd383bab140" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_8b638684-1615-4410-8250-e465f109d1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_29e8005f-6457-46d0-b7f7-1d7a70d27d40" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_8b638684-1615-4410-8250-e465f109d1f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_c3b3a7f8-bfb2-427a-84d0-7c25a2cc6fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_29e8005f-6457-46d0-b7f7-1d7a70d27d40" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_c3b3a7f8-bfb2-427a-84d0-7c25a2cc6fd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_99837d1a-0a78-412f-b079-236e49be019f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_29e8005f-6457-46d0-b7f7-1d7a70d27d40" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_99837d1a-0a78-412f-b079-236e49be019f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_c32485f0-3aeb-47cc-b621-580260ed6633" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_29e8005f-6457-46d0-b7f7-1d7a70d27d40" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_c32485f0-3aeb-47cc-b621-580260ed6633" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DeferredTaxAssetLeasingLiability_481e9e16-d3bb-46aa-a63d-7c7f0c598aa2" xlink:href="nvax-20231231.xsd#nvax_DeferredTaxAssetLeasingLiability"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_29e8005f-6457-46d0-b7f7-1d7a70d27d40" xlink:to="loc_nvax_DeferredTaxAssetLeasingLiability_481e9e16-d3bb-46aa-a63d-7c7f0c598aa2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_c6c64a01-dfea-4a7e-b3fd-102628e01228" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_29e8005f-6457-46d0-b7f7-1d7a70d27d40" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_c6c64a01-dfea-4a7e-b3fd-102628e01228" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_ad6edaac-bdb2-474c-9547-5d7b93ac23db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_29e8005f-6457-46d0-b7f7-1d7a70d27d40" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_ad6edaac-bdb2-474c-9547-5d7b93ac23db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_b44f854d-de62-4dc9-a32f-a5b38e851cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_29e8005f-6457-46d0-b7f7-1d7a70d27d40" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_b44f854d-de62-4dc9-a32f-a5b38e851cc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_548a7c63-eb88-4c28-b971-e3a80ed1a87b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_29e8005f-6457-46d0-b7f7-1d7a70d27d40" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_548a7c63-eb88-4c28-b971-e3a80ed1a87b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RestructuringScheduleofImpairmentChargesDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#RestructuringScheduleofImpairmentChargesDetails"/>
  <link:calculationLink xlink:role="http://www.novavax.com/role/RestructuringScheduleofImpairmentChargesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_1f6dcb8b-8222-407c-8bf5-dd4ab78994d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_d8a8a6fe-653e-4f40-b22e-c28f278edd6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_1f6dcb8b-8222-407c-8bf5-dd4ab78994d4" xlink:to="loc_us-gaap_SeveranceCosts1_d8a8a6fe-653e-4f40-b22e-c28f278edd6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_84dadc82-8d87-4e2c-9c64-42d38d49b768" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_1f6dcb8b-8222-407c-8bf5-dd4ab78994d4" xlink:to="loc_us-gaap_AssetImpairmentCharges_84dadc82-8d87-4e2c-9c64-42d38d49b768" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>20
<FILENAME>nvax-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:02f62cea-2ee5-4f46-a427-e5f89894c0b1,g:b653a9b6-e98d-435f-a6cb-06522e8cacbf-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="nvax-20231231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_307afb4d-10ca-4ac1-ad72-26b6b4686c76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5585347f-638b-49d7-ae44-6fca19e6063e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_307afb4d-10ca-4ac1-ad72-26b6b4686c76" xlink:to="loc_us-gaap_StatementTable_5585347f-638b-49d7-ae44-6fca19e6063e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ac7142d9-c2ed-4500-ab2b-1b606a5587af" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5585347f-638b-49d7-ae44-6fca19e6063e" xlink:to="loc_srt_ProductOrServiceAxis_ac7142d9-c2ed-4500-ab2b-1b606a5587af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ac7142d9-c2ed-4500-ab2b-1b606a5587af_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ac7142d9-c2ed-4500-ab2b-1b606a5587af" xlink:to="loc_srt_ProductsAndServicesDomain_ac7142d9-c2ed-4500-ab2b-1b606a5587af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f69b6533-3de0-4c5b-b50b-596f66045db9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ac7142d9-c2ed-4500-ab2b-1b606a5587af" xlink:to="loc_srt_ProductsAndServicesDomain_f69b6533-3de0-4c5b-b50b-596f66045db9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_3887ac64-3973-4c41-a7f2-b8547b6612ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f69b6533-3de0-4c5b-b50b-596f66045db9" xlink:to="loc_us-gaap_ProductMember_3887ac64-3973-4c41-a7f2-b8547b6612ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_3aa043d4-329c-4229-af8b-4850c10aca13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f69b6533-3de0-4c5b-b50b-596f66045db9" xlink:to="loc_us-gaap_GrantMember_3aa043d4-329c-4229-af8b-4850c10aca13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RoyaltiesAndOtherMember_bd9f80de-e5c8-4615-8fe9-67cb28f2ac7a" xlink:href="nvax-20231231.xsd#nvax_RoyaltiesAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f69b6533-3de0-4c5b-b50b-596f66045db9" xlink:to="loc_nvax_RoyaltiesAndOtherMember_bd9f80de-e5c8-4615-8fe9-67cb28f2ac7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_91ed51a1-6758-43ec-9b0f-fccba062514c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_307afb4d-10ca-4ac1-ad72-26b6b4686c76" xlink:to="loc_us-gaap_RevenuesAbstract_91ed51a1-6758-43ec-9b0f-fccba062514c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7dd005ec-877a-45e0-8e5f-267ef5e0b0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_91ed51a1-6758-43ec-9b0f-fccba062514c" xlink:to="loc_us-gaap_Revenues_7dd005ec-877a-45e0-8e5f-267ef5e0b0ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_cf5dfb78-99ca-4795-a022-1ebb23cc0a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_307afb4d-10ca-4ac1-ad72-26b6b4686c76" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_cf5dfb78-99ca-4795-a022-1ebb23cc0a3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_12c81df8-8c84-4449-bfc7-14111c2513dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_cf5dfb78-99ca-4795-a022-1ebb23cc0a3c" xlink:to="loc_us-gaap_CostOfRevenue_12c81df8-8c84-4449-bfc7-14111c2513dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_cd74e510-c76f-4c74-be77-dcd52b3ef530" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_cf5dfb78-99ca-4795-a022-1ebb23cc0a3c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_cd74e510-c76f-4c74-be77-dcd52b3ef530" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_95225b1f-f070-46c8-8850-be32aa66f8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_cf5dfb78-99ca-4795-a022-1ebb23cc0a3c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_95225b1f-f070-46c8-8850-be32aa66f8ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b4ad316e-b8b4-4048-920e-c30b7fb436a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_cf5dfb78-99ca-4795-a022-1ebb23cc0a3c" xlink:to="loc_us-gaap_CostsAndExpenses_b4ad316e-b8b4-4048-920e-c30b7fb436a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9169f6ff-0fdb-439a-ba7d-a1d0460ca0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_307afb4d-10ca-4ac1-ad72-26b6b4686c76" xlink:to="loc_us-gaap_OperatingIncomeLoss_9169f6ff-0fdb-439a-ba7d-a1d0460ca0f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_cdd632a9-b0f7-4843-988f-4aa5ceb3acc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_307afb4d-10ca-4ac1-ad72-26b6b4686c76" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_cdd632a9-b0f7-4843-988f-4aa5ceb3acc2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4126f9aa-00ce-4c84-adce-8d6ba659b03f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_cdd632a9-b0f7-4843-988f-4aa5ceb3acc2" xlink:to="loc_us-gaap_InterestExpense_4126f9aa-00ce-4c84-adce-8d6ba659b03f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4a739bca-5bf8-4bcf-8ec0-c7a13ff9a005" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_cdd632a9-b0f7-4843-988f-4aa5ceb3acc2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4a739bca-5bf8-4bcf-8ec0-c7a13ff9a005" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_04f9e22a-2786-4fa4-9d4f-85a54eac2552" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_307afb4d-10ca-4ac1-ad72-26b6b4686c76" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_04f9e22a-2786-4fa4-9d4f-85a54eac2552" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bd0cb7a6-72a0-4a50-82d6-732ce43d45ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_307afb4d-10ca-4ac1-ad72-26b6b4686c76" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_bd0cb7a6-72a0-4a50-82d6-732ce43d45ad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ca67e736-c4fe-4735-944b-a23181bc05b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_307afb4d-10ca-4ac1-ad72-26b6b4686c76" xlink:to="loc_us-gaap_NetIncomeLoss_ca67e736-c4fe-4735-944b-a23181bc05b8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_77f9aa62-2d5d-4afc-b684-9eec78097e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_307afb4d-10ca-4ac1-ad72-26b6b4686c76" xlink:to="loc_us-gaap_EarningsPerShareAbstract_77f9aa62-2d5d-4afc-b684-9eec78097e6a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_595d6033-67c9-4ff7-8682-81e8c1699de7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_77f9aa62-2d5d-4afc-b684-9eec78097e6a" xlink:to="loc_us-gaap_EarningsPerShareBasic_595d6033-67c9-4ff7-8682-81e8c1699de7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_bca51188-9846-4ea8-bf31-a7d0500bf07a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_77f9aa62-2d5d-4afc-b684-9eec78097e6a" xlink:to="loc_us-gaap_EarningsPerShareDiluted_bca51188-9846-4ea8-bf31-a7d0500bf07a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_122bf029-e681-44b9-8a4e-a68edd610cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_307afb4d-10ca-4ac1-ad72-26b6b4686c76" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_122bf029-e681-44b9-8a4e-a68edd610cc1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_553a85a1-ac59-433c-9815-9144bb85b698" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_122bf029-e681-44b9-8a4e-a68edd610cc1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_553a85a1-ac59-433c-9815-9144bb85b698" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ae0174b1-02e7-4bef-a106-34fb5ace10c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_122bf029-e681-44b9-8a4e-a68edd610cc1" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ae0174b1-02e7-4bef-a106-34fb5ace10c4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="nvax-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6664f1f2-9073-4728-a344-bdb14586d861" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_82ee52b4-fd71-463b-b7aa-d98cb33e2e79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6664f1f2-9073-4728-a344-bdb14586d861" xlink:to="loc_us-gaap_StatementTable_82ee52b4-fd71-463b-b7aa-d98cb33e2e79" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_32aade4e-1f68-4203-913e-7df99f12c6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_82ee52b4-fd71-463b-b7aa-d98cb33e2e79" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_32aade4e-1f68-4203-913e-7df99f12c6e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_32aade4e-1f68-4203-913e-7df99f12c6e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_32aade4e-1f68-4203-913e-7df99f12c6e1" xlink:to="loc_us-gaap_EquityComponentDomain_32aade4e-1f68-4203-913e-7df99f12c6e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e635254c-63cc-4ce1-9263-23614a44d1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_32aade4e-1f68-4203-913e-7df99f12c6e1" xlink:to="loc_us-gaap_EquityComponentDomain_e635254c-63cc-4ce1-9263-23614a44d1dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0c8ce3e8-153f-47a0-ae9a-c1a9daf16e08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e635254c-63cc-4ce1-9263-23614a44d1dd" xlink:to="loc_us-gaap_CommonStockMember_0c8ce3e8-153f-47a0-ae9a-c1a9daf16e08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f582d3df-c83d-48bd-a381-76efac2fb25f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e635254c-63cc-4ce1-9263-23614a44d1dd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f582d3df-c83d-48bd-a381-76efac2fb25f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_94836934-e52b-4b24-a09c-1408ac82af82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e635254c-63cc-4ce1-9263-23614a44d1dd" xlink:to="loc_us-gaap_RetainedEarningsMember_94836934-e52b-4b24-a09c-1408ac82af82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_b3a812f9-9713-4f87-bee1-ffdaa719e85a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e635254c-63cc-4ce1-9263-23614a44d1dd" xlink:to="loc_us-gaap_TreasuryStockCommonMember_b3a812f9-9713-4f87-bee1-ffdaa719e85a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d55d5035-f456-4ca6-9311-2c3b920d6636" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e635254c-63cc-4ce1-9263-23614a44d1dd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d55d5035-f456-4ca6-9311-2c3b920d6636" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd9ebfb-6b72-46b9-a2f4-10e5d8af5380" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6664f1f2-9073-4728-a344-bdb14586d861" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd9ebfb-6b72-46b9-a2f4-10e5d8af5380" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d4d1e6e4-94f1-4a36-93bf-69849c583033" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd9ebfb-6b72-46b9-a2f4-10e5d8af5380" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d4d1e6e4-94f1-4a36-93bf-69849c583033" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_56598d35-2db1-4311-9e04-fadacd804805" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd9ebfb-6b72-46b9-a2f4-10e5d8af5380" xlink:to="loc_us-gaap_StockholdersEquity_56598d35-2db1-4311-9e04-fadacd804805" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f014228f-de4c-48a1-bd6e-7f4e453d9b25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd9ebfb-6b72-46b9-a2f4-10e5d8af5380" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f014228f-de4c-48a1-bd6e-7f4e453d9b25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram_9ed4fe1a-c91d-40da-b203-1755c5fca5e2" xlink:href="nvax-20231231.xsd#nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd9ebfb-6b72-46b9-a2f4-10e5d8af5380" xlink:to="loc_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram_9ed4fe1a-c91d-40da-b203-1755c5fca5e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CompensationStockIssuedUnderIncentiveProgram_737f5690-5c64-4234-a4e5-ca2fb200340e" xlink:href="nvax-20231231.xsd#nvax_CompensationStockIssuedUnderIncentiveProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd9ebfb-6b72-46b9-a2f4-10e5d8af5380" xlink:to="loc_nvax_CompensationStockIssuedUnderIncentiveProgram_737f5690-5c64-4234-a4e5-ca2fb200340e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_07c31189-0fd1-4adf-8796-3fa22d1d2f15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd9ebfb-6b72-46b9-a2f4-10e5d8af5380" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_07c31189-0fd1-4adf-8796-3fa22d1d2f15" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f7461c52-814b-4571-8b6e-715d21a110f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd9ebfb-6b72-46b9-a2f4-10e5d8af5380" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f7461c52-814b-4571-8b6e-715d21a110f6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_015d925e-12ac-4d5a-a332-b6ce0228a9b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd9ebfb-6b72-46b9-a2f4-10e5d8af5380" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_015d925e-12ac-4d5a-a332-b6ce0228a9b0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_340f31f4-bfa9-477a-9da2-ca68a31f1bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd9ebfb-6b72-46b9-a2f4-10e5d8af5380" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_340f31f4-bfa9-477a-9da2-ca68a31f1bf1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_414ea054-7664-4df5-a06f-1589b9bd21ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd9ebfb-6b72-46b9-a2f4-10e5d8af5380" xlink:to="loc_us-gaap_NetIncomeLoss_414ea054-7664-4df5-a06f-1589b9bd21ce" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_86129319-94f3-4e6e-b724-424c4472238b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ff9adc77-da6a-4b0d-85da-78f9fff9e28e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:href="nvax-20231231.xsd#nvax_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_3adf0823-5f07-45a9-ad49-d57e798a226c" xlink:href="nvax-20231231.xsd#nvax_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_3adf0823-5f07-45a9-ad49-d57e798a226c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4b5e5109-cf3c-4592-bf4b-b65f0d788861" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_3adf0823-5f07-45a9-ad49-d57e798a226c" xlink:to="loc_srt_RangeAxis_4b5e5109-cf3c-4592-bf4b-b65f0d788861" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4b5e5109-cf3c-4592-bf4b-b65f0d788861_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4b5e5109-cf3c-4592-bf4b-b65f0d788861" xlink:to="loc_srt_RangeMember_4b5e5109-cf3c-4592-bf4b-b65f0d788861_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_78c99b6a-8a57-4a1d-831e-30400a12611c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4b5e5109-cf3c-4592-bf4b-b65f0d788861" xlink:to="loc_srt_RangeMember_78c99b6a-8a57-4a1d-831e-30400a12611c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4ac1c7a0-ae7e-4ca3-9c80-f4e303018bc9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_78c99b6a-8a57-4a1d-831e-30400a12611c" xlink:to="loc_srt_MinimumMember_4ac1c7a0-ae7e-4ca3-9c80-f4e303018bc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_da73537c-ec65-4970-9a1e-315e77724eb9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_78c99b6a-8a57-4a1d-831e-30400a12611c" xlink:to="loc_srt_MaximumMember_da73537c-ec65-4970-9a1e-315e77724eb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1921d5bf-1621-44f7-af31-2cbe50a1b1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_3adf0823-5f07-45a9-ad49-d57e798a226c" xlink:to="loc_us-gaap_DebtInstrumentAxis_1921d5bf-1621-44f7-af31-2cbe50a1b1cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1921d5bf-1621-44f7-af31-2cbe50a1b1cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1921d5bf-1621-44f7-af31-2cbe50a1b1cf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1921d5bf-1621-44f7-af31-2cbe50a1b1cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_989b9635-e4a6-4355-b55e-e775fed7e0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1921d5bf-1621-44f7-af31-2cbe50a1b1cf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_989b9635-e4a6-4355-b55e-e775fed7e0e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_2fdd401b-7f1d-4930-aa69-eb115998a38f" xlink:href="nvax-20231231.xsd#nvax_FivePointZeroConvertibleNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_989b9635-e4a6-4355-b55e-e775fed7e0e1" xlink:to="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_2fdd401b-7f1d-4930-aa69-eb115998a38f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_caa9fed0-d1f1-4a8c-bf3c-2d641b9e4e06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_3adf0823-5f07-45a9-ad49-d57e798a226c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_caa9fed0-d1f1-4a8c-bf3c-2d641b9e4e06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_caa9fed0-d1f1-4a8c-bf3c-2d641b9e4e06_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_caa9fed0-d1f1-4a8c-bf3c-2d641b9e4e06" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_caa9fed0-d1f1-4a8c-bf3c-2d641b9e4e06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b594e277-3edb-4213-ad2d-abff813031de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_caa9fed0-d1f1-4a8c-bf3c-2d641b9e4e06" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b594e277-3edb-4213-ad2d-abff813031de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_cb6748d5-71d7-411b-a71a-e446ccbc5436" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b594e277-3edb-4213-ad2d-abff813031de" xlink:to="loc_us-gaap_UnsecuredDebtMember_cb6748d5-71d7-411b-a71a-e446ccbc5436" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_54e98b5c-1a43-4d04-9615-1aac0b5b551e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_3adf0823-5f07-45a9-ad49-d57e798a226c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_54e98b5c-1a43-4d04-9615-1aac0b5b551e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54e98b5c-1a43-4d04-9615-1aac0b5b551e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_54e98b5c-1a43-4d04-9615-1aac0b5b551e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54e98b5c-1a43-4d04-9615-1aac0b5b551e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ea777138-f839-47d5-bb1e-385002ef8512" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_54e98b5c-1a43-4d04-9615-1aac0b5b551e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ea777138-f839-47d5-bb1e-385002ef8512" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CanadaAdvancePurchaseAgreementMember_18a8c121-71fe-41f5-a6f3-35b24532a441" xlink:href="nvax-20231231.xsd#nvax_CanadaAdvancePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ea777138-f839-47d5-bb1e-385002ef8512" xlink:to="loc_nvax_CanadaAdvancePurchaseAgreementMember_18a8c121-71fe-41f5-a6f3-35b24532a441" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_1af95ae4-d288-43b8-bdb7-b14effb60f16" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_3adf0823-5f07-45a9-ad49-d57e798a226c" xlink:to="loc_srt_StatementScenarioAxis_1af95ae4-d288-43b8-bdb7-b14effb60f16" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1af95ae4-d288-43b8-bdb7-b14effb60f16_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_1af95ae4-d288-43b8-bdb7-b14effb60f16" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1af95ae4-d288-43b8-bdb7-b14effb60f16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_ea103805-9fd5-417c-a926-d122769a0452" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_1af95ae4-d288-43b8-bdb7-b14effb60f16" xlink:to="loc_srt_ScenarioUnspecifiedDomain_ea103805-9fd5-417c-a926-d122769a0452" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_151dafe3-5cf8-4b36-891e-5bae7effe9b2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_ea103805-9fd5-417c-a926-d122769a0452" xlink:to="loc_srt_ScenarioForecastMember_151dafe3-5cf8-4b36-891e-5bae7effe9b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_271cb20b-9f63-476a-9801-da73042c89ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_271cb20b-9f63-476a-9801-da73042c89ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InstallmentChargesOfTheCompany_5e2eb990-f9f4-48a6-a5bb-7b482c8f7e86" xlink:href="nvax-20231231.xsd#nvax_InstallmentChargesOfTheCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_nvax_InstallmentChargesOfTheCompany_5e2eb990-f9f4-48a6-a5bb-7b482c8f7e86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_967711e0-594c-45ef-b78c-8ff3e67d3bee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_us-gaap_NetIncomeLoss_967711e0-594c-45ef-b78c-8ff3e67d3bee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5f92ac14-944b-4a53-9302-03eee0c542f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5f92ac14-944b-4a53-9302-03eee0c542f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_35a04b9c-10e2-4d45-b895-f8ffda1c744c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_35a04b9c-10e2-4d45-b895-f8ffda1c744c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_bc7cecc9-d795-41db-909a-04e0df310f28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_us-gaap_SeveranceCosts1_bc7cecc9-d795-41db-909a-04e0df310f28" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_6c80b25b-7fa3-473e-b812-975fb7570f89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_us-gaap_AssetImpairmentCharges_6c80b25b-7fa3-473e-b812-975fb7570f89" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_64525cc3-2944-4381-a211-1eba142f69f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_us-gaap_AdvertisingExpense_64525cc3-2944-4381-a211-1eba142f69f2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_b4176c17-6b0d-48cb-914f-e838a085dac1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_b4176c17-6b0d-48cb-914f-e838a085dac1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_e82dd88a-6156-468c-91f4-0e6c97256bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_us-gaap_NumberOfReportingUnits_e82dd88a-6156-468c-91f4-0e6c97256bb8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_fe343123-c2cc-4480-b818-8f21fb3738b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_fe343123-c2cc-4480-b818-8f21fb3738b7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_290c9c6a-fe45-426c-8266-3e7fb610f39a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_290c9c6a-fe45-426c-8266-3e7fb610f39a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_aac99837-e5dd-4f55-a423-de55fa5420a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_aac99837-e5dd-4f55-a423-de55fa5420a0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_0a1d285f-3d27-43c9-b13e-86470a176d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_0a1d285f-3d27-43c9-b13e-86470a176d4d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax_7cbd7bb1-8f7a-4204-afe1-9cc2a6ecf41c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax_7cbd7bb1-8f7a-4204-afe1-9cc2a6ecf41c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_c44d237d-fdf0-4200-afe2-3c02b31e1588" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_us-gaap_NumberOfOperatingSegments_c44d237d-fdf0-4200-afe2-3c02b31e1588" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_ae250e11-20a5-49f2-935a-23b82a2bde68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_ad304fde-1a7a-43d9-876f-7296959b348f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ae250e11-20a5-49f2-935a-23b82a2bde68" xlink:to="loc_us-gaap_ConcentrationRiskTable_ad304fde-1a7a-43d9-876f-7296959b348f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_4ff5d038-ca6d-4a3e-8d32-daf1d4ff1968" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_ad304fde-1a7a-43d9-876f-7296959b348f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_4ff5d038-ca6d-4a3e-8d32-daf1d4ff1968" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4ff5d038-ca6d-4a3e-8d32-daf1d4ff1968_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_4ff5d038-ca6d-4a3e-8d32-daf1d4ff1968" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4ff5d038-ca6d-4a3e-8d32-daf1d4ff1968_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c45164ba-c99a-4797-800b-1a0b4e523c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_4ff5d038-ca6d-4a3e-8d32-daf1d4ff1968" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c45164ba-c99a-4797-800b-1a0b4e523c9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a7c225f6-e633-439a-ba62-13e21f6ec5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c45164ba-c99a-4797-800b-1a0b4e523c9a" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a7c225f6-e633-439a-ba62-13e21f6ec5ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b84defa8-7239-4850-91ec-ff42c5c30b72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_ad304fde-1a7a-43d9-876f-7296959b348f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b84defa8-7239-4850-91ec-ff42c5c30b72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b84defa8-7239-4850-91ec-ff42c5c30b72_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b84defa8-7239-4850-91ec-ff42c5c30b72" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b84defa8-7239-4850-91ec-ff42c5c30b72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f0038078-e27a-48d1-ad25-917d0353cef3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b84defa8-7239-4850-91ec-ff42c5c30b72" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f0038078-e27a-48d1-ad25-917d0353cef3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_30ac42da-c749-43ee-b3f9-95ac8377661a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f0038078-e27a-48d1-ad25-917d0353cef3" xlink:to="loc_us-gaap_SalesRevenueNetMember_30ac42da-c749-43ee-b3f9-95ac8377661a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_d6c79041-e717-43b3-b139-f5d2a7806a35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f0038078-e27a-48d1-ad25-917d0353cef3" xlink:to="loc_us-gaap_AccountsReceivableMember_d6c79041-e717-43b3-b139-f5d2a7806a35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_0c526f32-89d6-4a7d-9501-404676441dee" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_ad304fde-1a7a-43d9-876f-7296959b348f" xlink:to="loc_srt_MajorCustomersAxis_0c526f32-89d6-4a7d-9501-404676441dee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0c526f32-89d6-4a7d-9501-404676441dee_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_0c526f32-89d6-4a7d-9501-404676441dee" xlink:to="loc_srt_NameOfMajorCustomerDomain_0c526f32-89d6-4a7d-9501-404676441dee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_72016f8b-8174-4aed-b2de-d0bed02a87dd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_0c526f32-89d6-4a7d-9501-404676441dee" xlink:to="loc_srt_NameOfMajorCustomerDomain_72016f8b-8174-4aed-b2de-d0bed02a87dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EuropeanCommissionMember_2472432a-dd8b-4105-b705-62dc3e3cae5a" xlink:href="nvax-20231231.xsd#nvax_EuropeanCommissionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_72016f8b-8174-4aed-b2de-d0bed02a87dd" xlink:to="loc_nvax_EuropeanCommissionMember_2472432a-dd8b-4105-b705-62dc3e3cae5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GovernmentOfAustraliaMember_6c6ed3d5-d635-4669-8b95-5a779111cf2f" xlink:href="nvax-20231231.xsd#nvax_GovernmentOfAustraliaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_72016f8b-8174-4aed-b2de-d0bed02a87dd" xlink:to="loc_nvax_GovernmentOfAustraliaMember_6c6ed3d5-d635-4669-8b95-5a779111cf2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GovernmentOfCanadaMember_b8833950-1982-4598-8aa7-b31d2e83af61" xlink:href="nvax-20231231.xsd#nvax_GovernmentOfCanadaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_72016f8b-8174-4aed-b2de-d0bed02a87dd" xlink:to="loc_nvax_GovernmentOfCanadaMember_b8833950-1982-4598-8aa7-b31d2e83af61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GovernmentOfIsraelMember_f4cfff88-177f-4215-acdf-1e6d4987a720" xlink:href="nvax-20231231.xsd#nvax_GovernmentOfIsraelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_72016f8b-8174-4aed-b2de-d0bed02a87dd" xlink:to="loc_nvax_GovernmentOfIsraelMember_f4cfff88-177f-4215-acdf-1e6d4987a720" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentMember_00432610-8e2d-42ea-be18-48fc8bd662fe" xlink:href="nvax-20231231.xsd#nvax_USGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_72016f8b-8174-4aed-b2de-d0bed02a87dd" xlink:to="loc_nvax_USGovernmentMember_00432610-8e2d-42ea-be18-48fc8bd662fe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CoalitionForEpidemicPreparednessInnovationsMember_f4f7d3c4-2ff7-46d8-9af1-87cbf6d97280" xlink:href="nvax-20231231.xsd#nvax_CoalitionForEpidemicPreparednessInnovationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_72016f8b-8174-4aed-b2de-d0bed02a87dd" xlink:to="loc_nvax_CoalitionForEpidemicPreparednessInnovationsMember_f4f7d3c4-2ff7-46d8-9af1-87cbf6d97280" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SKBioscienceCoLtdMember_1e2e0111-bc7f-4e90-88d5-78937360e11d" xlink:href="nvax-20231231.xsd#nvax_SKBioscienceCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_72016f8b-8174-4aed-b2de-d0bed02a87dd" xlink:to="loc_nvax_SKBioscienceCoLtdMember_1e2e0111-bc7f-4e90-88d5-78937360e11d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_51308a2e-8243-4551-ad73-280254f44733" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ae250e11-20a5-49f2-935a-23b82a2bde68" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_51308a2e-8243-4551-ad73-280254f44733" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9c2451da-a09e-4da7-96e0-49e4de2bb84e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4ea4c104-b5cf-4673-ace3-71b86e4d5e85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9c2451da-a09e-4da7-96e0-49e4de2bb84e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4ea4c104-b5cf-4673-ace3-71b86e4d5e85" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e5b420e5-04cd-4562-ac34-ca6302feb582" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4ea4c104-b5cf-4673-ace3-71b86e4d5e85" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e5b420e5-04cd-4562-ac34-ca6302feb582" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e5b420e5-04cd-4562-ac34-ca6302feb582_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e5b420e5-04cd-4562-ac34-ca6302feb582" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e5b420e5-04cd-4562-ac34-ca6302feb582_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4fcd6685-1f9b-43ed-a51b-92f798b66bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e5b420e5-04cd-4562-ac34-ca6302feb582" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4fcd6685-1f9b-43ed-a51b-92f798b66bb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_cfb60d1b-470a-4deb-9882-0164f1d171fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4fcd6685-1f9b-43ed-a51b-92f798b66bb4" xlink:to="loc_us-gaap_BuildingMember_cfb60d1b-470a-4deb-9882-0164f1d171fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_ce4505b6-ec4e-47d8-b3a0-abda434b6d68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4fcd6685-1f9b-43ed-a51b-92f798b66bb4" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_ce4505b6-ec4e-47d8-b3a0-abda434b6d68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_1d2b3a56-75c6-4fa8-8b02-2c01a7c35dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4fcd6685-1f9b-43ed-a51b-92f798b66bb4" xlink:to="loc_us-gaap_ComputerEquipmentMember_1d2b3a56-75c6-4fa8-8b02-2c01a7c35dfc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f51fcfa1-0b79-4018-ab3a-3b870b891c68" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4ea4c104-b5cf-4673-ace3-71b86e4d5e85" xlink:to="loc_srt_RangeAxis_f51fcfa1-0b79-4018-ab3a-3b870b891c68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f51fcfa1-0b79-4018-ab3a-3b870b891c68_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f51fcfa1-0b79-4018-ab3a-3b870b891c68" xlink:to="loc_srt_RangeMember_f51fcfa1-0b79-4018-ab3a-3b870b891c68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9219d57b-aee8-464a-ace8-06fbc5a28804" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f51fcfa1-0b79-4018-ab3a-3b870b891c68" xlink:to="loc_srt_RangeMember_9219d57b-aee8-464a-ace8-06fbc5a28804" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8940c2bd-4b2c-43b5-8415-1609fe7689ff" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9219d57b-aee8-464a-ace8-06fbc5a28804" xlink:to="loc_srt_MinimumMember_8940c2bd-4b2c-43b5-8415-1609fe7689ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1c684a72-6901-4fe2-9981-90e088b0d228" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9219d57b-aee8-464a-ace8-06fbc5a28804" xlink:to="loc_srt_MaximumMember_1c684a72-6901-4fe2-9981-90e088b0d228" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_95f312ea-2009-4736-b8fe-8e3a2807cadd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9c2451da-a09e-4da7-96e0-49e4de2bb84e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_95f312ea-2009-4736-b8fe-8e3a2807cadd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#RevenueAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/RevenueAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_15203e6a-b6d5-4718-92a3-4cedc97e855b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_15203e6a-b6d5-4718-92a3-4cedc97e855b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_cc0b22b4-b91f-4be4-a001-b1361868b276" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_15203e6a-b6d5-4718-92a3-4cedc97e855b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_cc0b22b4-b91f-4be4-a001-b1361868b276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9ddb5bf0-4d62-4bf5-a04f-5384cb87f478" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_15203e6a-b6d5-4718-92a3-4cedc97e855b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9ddb5bf0-4d62-4bf5-a04f-5384cb87f478" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9ddb5bf0-4d62-4bf5-a04f-5384cb87f478_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9ddb5bf0-4d62-4bf5-a04f-5384cb87f478" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9ddb5bf0-4d62-4bf5-a04f-5384cb87f478_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9ddb5bf0-4d62-4bf5-a04f-5384cb87f478" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementSIIPLMember_fb25eba2-dd95-4b4d-a013-9c2b3050ffd1" xlink:href="nvax-20231231.xsd#nvax_GaviAdvancePurchaseAgreementSIIPLMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_GaviAdvancePurchaseAgreementSIIPLMember_fb25eba2-dd95-4b4d-a013-9c2b3050ffd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_01d6cb13-8a9b-46ca-aa33-1fb534b634e1" xlink:href="nvax-20231231.xsd#nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_01d6cb13-8a9b-46ca-aa33-1fb534b634e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EuropeanCommissionsECMember_e1cf4180-166f-4707-a4b2-56c9f6116c69" xlink:href="nvax-20231231.xsd#nvax_EuropeanCommissionsECMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_EuropeanCommissionsECMember_e1cf4180-166f-4707-a4b2-56c9f6116c69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CanadaAdvancePurchaseAgreementMember_ba1b3218-d6b3-4982-ae35-1b0ba58b9c4c" xlink:href="nvax-20231231.xsd#nvax_CanadaAdvancePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_CanadaAdvancePurchaseAgreementMember_ba1b3218-d6b3-4982-ae35-1b0ba58b9c4c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_af873946-406f-4818-8e79-aba1c5ae7f0a" xlink:href="nvax-20231231.xsd#nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_af873946-406f-4818-8e79-aba1c5ae7f0a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentPartnershipMember_41e1ef8b-cb07-44d5-85df-6b43f86a24c3" xlink:href="nvax-20231231.xsd#nvax_USGovernmentPartnershipMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_USGovernmentPartnershipMember_41e1ef8b-cb07-44d5-85df-6b43f86a24c3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentAgreementMember_60bd5a7c-fe8b-4598-9eb5-7b7e7218b43f" xlink:href="nvax-20231231.xsd#nvax_USGovernmentAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_USGovernmentAgreementMember_60bd5a7c-fe8b-4598-9eb5-7b7e7218b43f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember_671e1416-e629-4796-aea5-a31d506e91d8" xlink:href="nvax-20231231.xsd#nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember_671e1416-e629-4796-aea5-a31d506e91d8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CEPIGrantFundingMember_a2582746-10d7-4ce6-bb39-9a24f663b04e" xlink:href="nvax-20231231.xsd#nvax_CEPIGrantFundingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_CEPIGrantFundingMember_a2582746-10d7-4ce6-bb39-9a24f663b04e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_MatrixMAdjuvantSalesMember_2cda059d-a268-458f-a66d-cf1af8b167e4" xlink:href="nvax-20231231.xsd#nvax_MatrixMAdjuvantSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_MatrixMAdjuvantSalesMember_2cda059d-a268-458f-a66d-cf1af8b167e4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementMember_52bbe463-4b85-4da2-8a4c-852dbde7920b" xlink:href="nvax-20231231.xsd#nvax_SettlementAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_SettlementAgreementMember_52bbe463-4b85-4da2-8a4c-852dbde7920b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AustralianAPAMember_cd53adc1-3819-4f45-9d40-49e2f9b58b56" xlink:href="nvax-20231231.xsd#nvax_AustralianAPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_AustralianAPAMember_cd53adc1-3819-4f45-9d40-49e2f9b58b56" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis_8de9e936-5f94-461b-a3b3-00aa882113b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_15203e6a-b6d5-4718-92a3-4cedc97e855b" xlink:to="loc_us-gaap_SupplyCommitmentAxis_8de9e936-5f94-461b-a3b3-00aa882113b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_8de9e936-5f94-461b-a3b3-00aa882113b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SupplyCommitmentAxis_8de9e936-5f94-461b-a3b3-00aa882113b5" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_8de9e936-5f94-461b-a3b3-00aa882113b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_9422cb6c-8783-4780-a081-45910be563cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SupplyCommitmentAxis_8de9e936-5f94-461b-a3b3-00aa882113b5" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_9422cb6c-8783-4780-a081-45910be563cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember_e662f9b8-dec6-47e9-952f-59450e1e6c17" xlink:href="nvax-20231231.xsd#nvax_AmendedAndRestatedUKSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_9422cb6c-8783-4780-a081-45910be563cd" xlink:to="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember_e662f9b8-dec6-47e9-952f-59450e1e6c17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0d0a9843-9c47-4f43-b6d5-88ae8495c020" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_15203e6a-b6d5-4718-92a3-4cedc97e855b" xlink:to="loc_srt_RangeAxis_0d0a9843-9c47-4f43-b6d5-88ae8495c020" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0d0a9843-9c47-4f43-b6d5-88ae8495c020_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0d0a9843-9c47-4f43-b6d5-88ae8495c020" xlink:to="loc_srt_RangeMember_0d0a9843-9c47-4f43-b6d5-88ae8495c020_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9b4492e9-eb3e-4f35-91cf-f27b0efebfa1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0d0a9843-9c47-4f43-b6d5-88ae8495c020" xlink:to="loc_srt_RangeMember_9b4492e9-eb3e-4f35-91cf-f27b0efebfa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_95ee7d80-4841-4031-8604-9ef127180b5c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9b4492e9-eb3e-4f35-91cf-f27b0efebfa1" xlink:to="loc_srt_MinimumMember_95ee7d80-4841-4031-8604-9ef127180b5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_91e01c1d-641c-4bd7-a8cc-eb2c07fb1e54" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9b4492e9-eb3e-4f35-91cf-f27b0efebfa1" xlink:to="loc_srt_MaximumMember_91e01c1d-641c-4bd7-a8cc-eb2c07fb1e54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b8d2cb4c-ae66-4c7c-94a1-375bed680d25" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_15203e6a-b6d5-4718-92a3-4cedc97e855b" xlink:to="loc_srt_ProductOrServiceAxis_b8d2cb4c-ae66-4c7c-94a1-375bed680d25" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b8d2cb4c-ae66-4c7c-94a1-375bed680d25_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b8d2cb4c-ae66-4c7c-94a1-375bed680d25" xlink:to="loc_srt_ProductsAndServicesDomain_b8d2cb4c-ae66-4c7c-94a1-375bed680d25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2bd6aeec-0520-40c0-88bd-02df702759b1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b8d2cb4c-ae66-4c7c-94a1-375bed680d25" xlink:to="loc_srt_ProductsAndServicesDomain_2bd6aeec-0520-40c0-88bd-02df702759b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SalesBasedRoyaltiesMember_c5b91f69-8868-43f9-b6be-a61a52c9bbaa" xlink:href="nvax-20231231.xsd#nvax_SalesBasedRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2bd6aeec-0520-40c0-88bd-02df702759b1" xlink:to="loc_nvax_SalesBasedRoyaltiesMember_c5b91f69-8868-43f9-b6be-a61a52c9bbaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_MilestonePaymentsMember_0e904b24-724b-4733-b8c2-ab48a9ab9b94" xlink:href="nvax-20231231.xsd#nvax_MilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2bd6aeec-0520-40c0-88bd-02df702759b1" xlink:to="loc_nvax_MilestonePaymentsMember_0e904b24-724b-4733-b8c2-ab48a9ab9b94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_9857cf06-2444-46e6-bdc0-524c4a5a057e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2bd6aeec-0520-40c0-88bd-02df702759b1" xlink:to="loc_us-gaap_ProductMember_9857cf06-2444-46e6-bdc0-524c4a5a057e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_d2eaf049-e958-479b-819c-cadede746708" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_15203e6a-b6d5-4718-92a3-4cedc97e855b" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_d2eaf049-e958-479b-819c-cadede746708" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_d2eaf049-e958-479b-819c-cadede746708_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_d2eaf049-e958-479b-819c-cadede746708" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_d2eaf049-e958-479b-819c-cadede746708_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_6436b745-53e6-4c7a-9e3b-0f3ce7dc8de9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_d2eaf049-e958-479b-819c-cadede746708" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_6436b745-53e6-4c7a-9e3b-0f3ce7dc8de9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CanadaRevenueAgencyMember_0b51332c-144e-48dd-a4f6-b8d9f5151d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CanadaRevenueAgencyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_6436b745-53e6-4c7a-9e3b-0f3ce7dc8de9" xlink:to="loc_us-gaap_CanadaRevenueAgencyMember_0b51332c-144e-48dd-a4f6-b8d9f5151d3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fa2659f1-c576-451a-879f-9c7e96309404" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_15203e6a-b6d5-4718-92a3-4cedc97e855b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fa2659f1-c576-451a-879f-9c7e96309404" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fa2659f1-c576-451a-879f-9c7e96309404_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fa2659f1-c576-451a-879f-9c7e96309404" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fa2659f1-c576-451a-879f-9c7e96309404_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7ba3f60f-1845-4603-b47c-d319774f69f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fa2659f1-c576-451a-879f-9c7e96309404" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7ba3f60f-1845-4603-b47c-d319774f69f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ef19ab8d-5c71-4aa5-a0f0-9becaba0aafc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7ba3f60f-1845-4603-b47c-d319774f69f4" xlink:to="loc_us-gaap_SubsequentEventMember_ef19ab8d-5c71-4aa5-a0f0-9becaba0aafc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_00c55fd6-79fa-46f6-b7d1-c64e702f1b87" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_15203e6a-b6d5-4718-92a3-4cedc97e855b" xlink:to="loc_srt_StatementScenarioAxis_00c55fd6-79fa-46f6-b7d1-c64e702f1b87" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_00c55fd6-79fa-46f6-b7d1-c64e702f1b87_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_00c55fd6-79fa-46f6-b7d1-c64e702f1b87" xlink:to="loc_srt_ScenarioUnspecifiedDomain_00c55fd6-79fa-46f6-b7d1-c64e702f1b87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_7334eff0-c00b-4fc9-a202-f4c175813eb0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_00c55fd6-79fa-46f6-b7d1-c64e702f1b87" xlink:to="loc_srt_ScenarioUnspecifiedDomain_7334eff0-c00b-4fc9-a202-f4c175813eb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_a6606d1f-68ff-4d5c-83c1-b3c35a18abf7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_7334eff0-c00b-4fc9-a202-f4c175813eb0" xlink:to="loc_srt_ScenarioForecastMember_a6606d1f-68ff-4d5c-83c1-b3c35a18abf7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables_8c9dcc4f-7031-4174-a7bd-62ae2aae83f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BilledContractReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_BilledContractReceivables_8c9dcc4f-7031-4174-a7bd-62ae2aae83f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_fabaa3b9-23e5-47da-9646-02ebe230f6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_UnbilledContractsReceivable_fabaa3b9-23e5-47da-9646-02ebe230f6ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_c60d90e0-6d91-4445-8ae3-3bdd382f11a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_c60d90e0-6d91-4445-8ae3-3bdd382f11a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_e03d9713-153a-4188-be64-33cd0016d174" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_ContractWithCustomerLiability_e03d9713-153a-4188-be64-33cd0016d174" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_fcd38e5b-fc94-485e-a928-e558d0724b64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_fcd38e5b-fc94-485e-a928-e558d0724b64" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesToBeDistributed_99c59c9b-e845-4fe0-9bb7-94a31a7d6e28" xlink:href="nvax-20231231.xsd#nvax_NumberOfDosesToBeDistributed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_NumberOfDosesToBeDistributed_99c59c9b-e845-4fe0-9bb7-94a31a7d6e28" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount_c3e3afd8-7a8f-4032-b3f7-ae4f29c06653" xlink:href="nvax-20231231.xsd#nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount_c3e3afd8-7a8f-4032-b3f7-ae4f29c06653" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_5e11dc15-22ab-43b9-acfd-4cd15087de40" xlink:href="nvax-20231231.xsd#nvax_CollaborationAgreementUpfrontPaymentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_5e11dc15-22ab-43b9-acfd-4cd15087de40" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ea486202-4adb-405e-9c91-bff80075942b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ea486202-4adb-405e-9c91-bff80075942b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_172b3666-f176-40b2-8314-99be031572cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_LitigationSettlementExpense_172b3666-f176-40b2-8314-99be031572cc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_90b0cee5-456d-4f2a-bed1-0e3f89afda8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_GrantsReceivable_90b0cee5-456d-4f2a-bed1-0e3f89afda8a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_f9be9764-6b30-4803-aa9f-175d0b3c2bec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_36e85ac5-6b5a-4c8d-87e5-826142dc6abe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_36e85ac5-6b5a-4c8d-87e5-826142dc6abe" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AmountsChargedAgainstProductSales_70b09845-4a09-4f4e-b473-63f788fcf572" xlink:href="nvax-20231231.xsd#nvax_AmountsChargedAgainstProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_AmountsChargedAgainstProductSales_70b09845-4a09-4f4e-b473-63f788fcf572" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption_eebdea6f-9cd2-4929-894f-d6b085d39dbe" xlink:href="nvax-20231231.xsd#nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption_eebdea6f-9cd2-4929-894f-d6b085d39dbe" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfDosesCancelled_da55f0ec-b7dd-4a2b-9f55-4d28b916357f" xlink:href="nvax-20231231.xsd#nvax_PurchaseAgreementNumberOfDosesCancelled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_PurchaseAgreementNumberOfDosesCancelled_da55f0ec-b7dd-4a2b-9f55-4d28b916357f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfVaccineDoses_5b401aa3-f397-412d-8cba-bc74c56aae10" xlink:href="nvax-20231231.xsd#nvax_PurchaseAgreementNumberOfVaccineDoses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_PurchaseAgreementNumberOfVaccineDoses_5b401aa3-f397-412d-8cba-bc74c56aae10" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesOfVaccineCandidate_db8ae70c-4e4c-4b08-8446-0d53e6b71e29" xlink:href="nvax-20231231.xsd#nvax_NumberOfDosesOfVaccineCandidate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_NumberOfDosesOfVaccineCandidate_db8ae70c-4e4c-4b08-8446-0d53e6b71e29" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f50f31ff-e303-4239-b3d4-958ec3e4517e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f50f31ff-e303-4239-b3d4-958ec3e4517e" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InstallmentChargesOfTheCompany_cf11991f-81f9-4052-bc93-6d3bc1a63f9c" xlink:href="nvax-20231231.xsd#nvax_InstallmentChargesOfTheCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_InstallmentChargesOfTheCompany_cf11991f-81f9-4052-bc93-6d3bc1a63f9c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e88ea45b-0bb1-4227-8cb6-3333fd23f7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e88ea45b-0bb1-4227-8cb6-3333fd23f7cb" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8aa85966-6e81-4424-8385-465cc253e038" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8aa85966-6e81-4424-8385-465cc253e038" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_efef3603-fc55-4b20-adde-026cd31b490b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_efef3603-fc55-4b20-adde-026cd31b490b" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ContractWithCustomerObligationToDeliverTerms_2ae703b6-c945-44e2-b53b-67faf4d9e85b" xlink:href="nvax-20231231.xsd#nvax_ContractWithCustomerObligationToDeliverTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_ContractWithCustomerObligationToDeliverTerms_2ae703b6-c945-44e2-b53b-67faf4d9e85b" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PercentOfRemainingAmountToBePaid_956ee948-ad12-4fe7-b401-06e606203dee" xlink:href="nvax-20231231.xsd#nvax_PercentOfRemainingAmountToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_PercentOfRemainingAmountToBePaid_956ee948-ad12-4fe7-b401-06e606203dee" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EscrowDepositsRelatedToSalesHold_e2d2db42-acfe-4d7c-bdaa-c61a0d3a650e" xlink:href="nvax-20231231.xsd#nvax_EscrowDepositsRelatedToSalesHold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_EscrowDepositsRelatedToSalesHold_e2d2db42-acfe-4d7c-bdaa-c61a0d3a650e" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RevenueFromContractWithCustomerCommitment_5e133ae9-8704-49aa-8b0d-4d3f9b6205b2" xlink:href="nvax-20231231.xsd#nvax_RevenueFromContractWithCustomerCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_RevenueFromContractWithCustomerCommitment_5e133ae9-8704-49aa-8b0d-4d3f9b6205b2" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_ea1239ab-334a-4618-86f2-59f233f21287" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_ea1239ab-334a-4618-86f2-59f233f21287" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding_83992cf0-cdbc-4715-92e5-1ca329f1829c" xlink:href="nvax-20231231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding_83992cf0-cdbc-4715-92e5-1ca329f1829c" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant_7bb5f623-18bf-4590-b95e-3aea2fa7af29" xlink:href="nvax-20231231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant_7bb5f623-18bf-4590-b95e-3aea2fa7af29" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans_ebedb6d5-d18e-4926-b822-5043b773d201" xlink:href="nvax-20231231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans_ebedb6d5-d18e-4926-b822-5043b773d201" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9c6f7ab6-25da-4454-b90c-616792e90bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_Revenues_9c6f7ab6-25da-4454-b90c-616792e90bb8" xlink:type="arc" order="31"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueAdditionalInformationDetails_1" xlink:type="simple" xlink:href="nvax-20231231.xsd#RevenueAdditionalInformationDetails_1"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/RevenueAdditionalInformationDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_15203e6a-b6d5-4718-92a3-4cedc97e855b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_15203e6a-b6d5-4718-92a3-4cedc97e855b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9ddb5bf0-4d62-4bf5-a04f-5384cb87f478" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_15203e6a-b6d5-4718-92a3-4cedc97e855b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9ddb5bf0-4d62-4bf5-a04f-5384cb87f478" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9ddb5bf0-4d62-4bf5-a04f-5384cb87f478_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9ddb5bf0-4d62-4bf5-a04f-5384cb87f478" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9ddb5bf0-4d62-4bf5-a04f-5384cb87f478_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9ddb5bf0-4d62-4bf5-a04f-5384cb87f478" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementSIIPLMember_fb25eba2-dd95-4b4d-a013-9c2b3050ffd1" xlink:href="nvax-20231231.xsd#nvax_GaviAdvancePurchaseAgreementSIIPLMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_GaviAdvancePurchaseAgreementSIIPLMember_fb25eba2-dd95-4b4d-a013-9c2b3050ffd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_01d6cb13-8a9b-46ca-aa33-1fb534b634e1" xlink:href="nvax-20231231.xsd#nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_01d6cb13-8a9b-46ca-aa33-1fb534b634e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EuropeanCommissionsECMember_e1cf4180-166f-4707-a4b2-56c9f6116c69" xlink:href="nvax-20231231.xsd#nvax_EuropeanCommissionsECMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_EuropeanCommissionsECMember_e1cf4180-166f-4707-a4b2-56c9f6116c69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CanadaAdvancePurchaseAgreementMember_ba1b3218-d6b3-4982-ae35-1b0ba58b9c4c" xlink:href="nvax-20231231.xsd#nvax_CanadaAdvancePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_CanadaAdvancePurchaseAgreementMember_ba1b3218-d6b3-4982-ae35-1b0ba58b9c4c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_af873946-406f-4818-8e79-aba1c5ae7f0a" xlink:href="nvax-20231231.xsd#nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_af873946-406f-4818-8e79-aba1c5ae7f0a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentPartnershipMember_41e1ef8b-cb07-44d5-85df-6b43f86a24c3" xlink:href="nvax-20231231.xsd#nvax_USGovernmentPartnershipMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_USGovernmentPartnershipMember_41e1ef8b-cb07-44d5-85df-6b43f86a24c3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentAgreementMember_60bd5a7c-fe8b-4598-9eb5-7b7e7218b43f" xlink:href="nvax-20231231.xsd#nvax_USGovernmentAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_USGovernmentAgreementMember_60bd5a7c-fe8b-4598-9eb5-7b7e7218b43f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember_671e1416-e629-4796-aea5-a31d506e91d8" xlink:href="nvax-20231231.xsd#nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember_671e1416-e629-4796-aea5-a31d506e91d8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CEPIGrantFundingMember_a2582746-10d7-4ce6-bb39-9a24f663b04e" xlink:href="nvax-20231231.xsd#nvax_CEPIGrantFundingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_CEPIGrantFundingMember_a2582746-10d7-4ce6-bb39-9a24f663b04e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_MatrixMAdjuvantSalesMember_2cda059d-a268-458f-a66d-cf1af8b167e4" xlink:href="nvax-20231231.xsd#nvax_MatrixMAdjuvantSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_MatrixMAdjuvantSalesMember_2cda059d-a268-458f-a66d-cf1af8b167e4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementMember_52bbe463-4b85-4da2-8a4c-852dbde7920b" xlink:href="nvax-20231231.xsd#nvax_SettlementAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_SettlementAgreementMember_52bbe463-4b85-4da2-8a4c-852dbde7920b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AustralianAPAMember_cd53adc1-3819-4f45-9d40-49e2f9b58b56" xlink:href="nvax-20231231.xsd#nvax_AustralianAPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_AustralianAPAMember_cd53adc1-3819-4f45-9d40-49e2f9b58b56" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis_8de9e936-5f94-461b-a3b3-00aa882113b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_15203e6a-b6d5-4718-92a3-4cedc97e855b" xlink:to="loc_us-gaap_SupplyCommitmentAxis_8de9e936-5f94-461b-a3b3-00aa882113b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_8de9e936-5f94-461b-a3b3-00aa882113b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SupplyCommitmentAxis_8de9e936-5f94-461b-a3b3-00aa882113b5" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_8de9e936-5f94-461b-a3b3-00aa882113b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_9422cb6c-8783-4780-a081-45910be563cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SupplyCommitmentAxis_8de9e936-5f94-461b-a3b3-00aa882113b5" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_9422cb6c-8783-4780-a081-45910be563cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember_e662f9b8-dec6-47e9-952f-59450e1e6c17" xlink:href="nvax-20231231.xsd#nvax_AmendedAndRestatedUKSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_9422cb6c-8783-4780-a081-45910be563cd" xlink:to="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember_e662f9b8-dec6-47e9-952f-59450e1e6c17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0d0a9843-9c47-4f43-b6d5-88ae8495c020" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_15203e6a-b6d5-4718-92a3-4cedc97e855b" xlink:to="loc_srt_RangeAxis_0d0a9843-9c47-4f43-b6d5-88ae8495c020" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0d0a9843-9c47-4f43-b6d5-88ae8495c020_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0d0a9843-9c47-4f43-b6d5-88ae8495c020" xlink:to="loc_srt_RangeMember_0d0a9843-9c47-4f43-b6d5-88ae8495c020_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9b4492e9-eb3e-4f35-91cf-f27b0efebfa1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0d0a9843-9c47-4f43-b6d5-88ae8495c020" xlink:to="loc_srt_RangeMember_9b4492e9-eb3e-4f35-91cf-f27b0efebfa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_95ee7d80-4841-4031-8604-9ef127180b5c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9b4492e9-eb3e-4f35-91cf-f27b0efebfa1" xlink:to="loc_srt_MinimumMember_95ee7d80-4841-4031-8604-9ef127180b5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_91e01c1d-641c-4bd7-a8cc-eb2c07fb1e54" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9b4492e9-eb3e-4f35-91cf-f27b0efebfa1" xlink:to="loc_srt_MaximumMember_91e01c1d-641c-4bd7-a8cc-eb2c07fb1e54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b8d2cb4c-ae66-4c7c-94a1-375bed680d25" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_15203e6a-b6d5-4718-92a3-4cedc97e855b" xlink:to="loc_srt_ProductOrServiceAxis_b8d2cb4c-ae66-4c7c-94a1-375bed680d25" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b8d2cb4c-ae66-4c7c-94a1-375bed680d25_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b8d2cb4c-ae66-4c7c-94a1-375bed680d25" xlink:to="loc_srt_ProductsAndServicesDomain_b8d2cb4c-ae66-4c7c-94a1-375bed680d25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2bd6aeec-0520-40c0-88bd-02df702759b1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b8d2cb4c-ae66-4c7c-94a1-375bed680d25" xlink:to="loc_srt_ProductsAndServicesDomain_2bd6aeec-0520-40c0-88bd-02df702759b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SalesBasedRoyaltiesMember_c5b91f69-8868-43f9-b6be-a61a52c9bbaa" xlink:href="nvax-20231231.xsd#nvax_SalesBasedRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2bd6aeec-0520-40c0-88bd-02df702759b1" xlink:to="loc_nvax_SalesBasedRoyaltiesMember_c5b91f69-8868-43f9-b6be-a61a52c9bbaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_MilestonePaymentsMember_0e904b24-724b-4733-b8c2-ab48a9ab9b94" xlink:href="nvax-20231231.xsd#nvax_MilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2bd6aeec-0520-40c0-88bd-02df702759b1" xlink:to="loc_nvax_MilestonePaymentsMember_0e904b24-724b-4733-b8c2-ab48a9ab9b94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_9857cf06-2444-46e6-bdc0-524c4a5a057e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2bd6aeec-0520-40c0-88bd-02df702759b1" xlink:to="loc_us-gaap_ProductMember_9857cf06-2444-46e6-bdc0-524c4a5a057e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_d2eaf049-e958-479b-819c-cadede746708" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_15203e6a-b6d5-4718-92a3-4cedc97e855b" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_d2eaf049-e958-479b-819c-cadede746708" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_d2eaf049-e958-479b-819c-cadede746708_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_d2eaf049-e958-479b-819c-cadede746708" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_d2eaf049-e958-479b-819c-cadede746708_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_6436b745-53e6-4c7a-9e3b-0f3ce7dc8de9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_d2eaf049-e958-479b-819c-cadede746708" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_6436b745-53e6-4c7a-9e3b-0f3ce7dc8de9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CanadaRevenueAgencyMember_0b51332c-144e-48dd-a4f6-b8d9f5151d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CanadaRevenueAgencyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_6436b745-53e6-4c7a-9e3b-0f3ce7dc8de9" xlink:to="loc_us-gaap_CanadaRevenueAgencyMember_0b51332c-144e-48dd-a4f6-b8d9f5151d3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fa2659f1-c576-451a-879f-9c7e96309404" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_15203e6a-b6d5-4718-92a3-4cedc97e855b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fa2659f1-c576-451a-879f-9c7e96309404" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fa2659f1-c576-451a-879f-9c7e96309404_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fa2659f1-c576-451a-879f-9c7e96309404" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fa2659f1-c576-451a-879f-9c7e96309404_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7ba3f60f-1845-4603-b47c-d319774f69f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fa2659f1-c576-451a-879f-9c7e96309404" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7ba3f60f-1845-4603-b47c-d319774f69f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ef19ab8d-5c71-4aa5-a0f0-9becaba0aafc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7ba3f60f-1845-4603-b47c-d319774f69f4" xlink:to="loc_us-gaap_SubsequentEventMember_ef19ab8d-5c71-4aa5-a0f0-9becaba0aafc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_00c55fd6-79fa-46f6-b7d1-c64e702f1b87" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_15203e6a-b6d5-4718-92a3-4cedc97e855b" xlink:to="loc_srt_StatementScenarioAxis_00c55fd6-79fa-46f6-b7d1-c64e702f1b87" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_00c55fd6-79fa-46f6-b7d1-c64e702f1b87_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_00c55fd6-79fa-46f6-b7d1-c64e702f1b87" xlink:to="loc_srt_ScenarioUnspecifiedDomain_00c55fd6-79fa-46f6-b7d1-c64e702f1b87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_7334eff0-c00b-4fc9-a202-f4c175813eb0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_00c55fd6-79fa-46f6-b7d1-c64e702f1b87" xlink:to="loc_srt_ScenarioUnspecifiedDomain_7334eff0-c00b-4fc9-a202-f4c175813eb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_a6606d1f-68ff-4d5c-83c1-b3c35a18abf7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_7334eff0-c00b-4fc9-a202-f4c175813eb0" xlink:to="loc_srt_ScenarioForecastMember_a6606d1f-68ff-4d5c-83c1-b3c35a18abf7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables_8c9dcc4f-7031-4174-a7bd-62ae2aae83f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BilledContractReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_BilledContractReceivables_8c9dcc4f-7031-4174-a7bd-62ae2aae83f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_fabaa3b9-23e5-47da-9646-02ebe230f6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_UnbilledContractsReceivable_fabaa3b9-23e5-47da-9646-02ebe230f6ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_c60d90e0-6d91-4445-8ae3-3bdd382f11a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_c60d90e0-6d91-4445-8ae3-3bdd382f11a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_e03d9713-153a-4188-be64-33cd0016d174" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_ContractWithCustomerLiability_e03d9713-153a-4188-be64-33cd0016d174" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_fcd38e5b-fc94-485e-a928-e558d0724b64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_fcd38e5b-fc94-485e-a928-e558d0724b64" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesToBeDistributed_99c59c9b-e845-4fe0-9bb7-94a31a7d6e28" xlink:href="nvax-20231231.xsd#nvax_NumberOfDosesToBeDistributed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_NumberOfDosesToBeDistributed_99c59c9b-e845-4fe0-9bb7-94a31a7d6e28" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount_c3e3afd8-7a8f-4032-b3f7-ae4f29c06653" xlink:href="nvax-20231231.xsd#nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount_c3e3afd8-7a8f-4032-b3f7-ae4f29c06653" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_5e11dc15-22ab-43b9-acfd-4cd15087de40" xlink:href="nvax-20231231.xsd#nvax_CollaborationAgreementUpfrontPaymentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_5e11dc15-22ab-43b9-acfd-4cd15087de40" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ea486202-4adb-405e-9c91-bff80075942b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ea486202-4adb-405e-9c91-bff80075942b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_172b3666-f176-40b2-8314-99be031572cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_LitigationSettlementExpense_172b3666-f176-40b2-8314-99be031572cc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_90b0cee5-456d-4f2a-bed1-0e3f89afda8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_GrantsReceivable_90b0cee5-456d-4f2a-bed1-0e3f89afda8a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_f9be9764-6b30-4803-aa9f-175d0b3c2bec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_36e85ac5-6b5a-4c8d-87e5-826142dc6abe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_36e85ac5-6b5a-4c8d-87e5-826142dc6abe" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AmountsChargedAgainstProductSales_70b09845-4a09-4f4e-b473-63f788fcf572" xlink:href="nvax-20231231.xsd#nvax_AmountsChargedAgainstProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_AmountsChargedAgainstProductSales_70b09845-4a09-4f4e-b473-63f788fcf572" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption_eebdea6f-9cd2-4929-894f-d6b085d39dbe" xlink:href="nvax-20231231.xsd#nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption_eebdea6f-9cd2-4929-894f-d6b085d39dbe" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfDosesCancelled_da55f0ec-b7dd-4a2b-9f55-4d28b916357f" xlink:href="nvax-20231231.xsd#nvax_PurchaseAgreementNumberOfDosesCancelled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_PurchaseAgreementNumberOfDosesCancelled_da55f0ec-b7dd-4a2b-9f55-4d28b916357f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfVaccineDoses_5b401aa3-f397-412d-8cba-bc74c56aae10" xlink:href="nvax-20231231.xsd#nvax_PurchaseAgreementNumberOfVaccineDoses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_PurchaseAgreementNumberOfVaccineDoses_5b401aa3-f397-412d-8cba-bc74c56aae10" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesOfVaccineCandidate_db8ae70c-4e4c-4b08-8446-0d53e6b71e29" xlink:href="nvax-20231231.xsd#nvax_NumberOfDosesOfVaccineCandidate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_NumberOfDosesOfVaccineCandidate_db8ae70c-4e4c-4b08-8446-0d53e6b71e29" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f50f31ff-e303-4239-b3d4-958ec3e4517e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f50f31ff-e303-4239-b3d4-958ec3e4517e" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InstallmentChargesOfTheCompany_cf11991f-81f9-4052-bc93-6d3bc1a63f9c" xlink:href="nvax-20231231.xsd#nvax_InstallmentChargesOfTheCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_InstallmentChargesOfTheCompany_cf11991f-81f9-4052-bc93-6d3bc1a63f9c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e88ea45b-0bb1-4227-8cb6-3333fd23f7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e88ea45b-0bb1-4227-8cb6-3333fd23f7cb" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8aa85966-6e81-4424-8385-465cc253e038" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8aa85966-6e81-4424-8385-465cc253e038" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_efef3603-fc55-4b20-adde-026cd31b490b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_efef3603-fc55-4b20-adde-026cd31b490b" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ContractWithCustomerObligationToDeliverTerms_2ae703b6-c945-44e2-b53b-67faf4d9e85b" xlink:href="nvax-20231231.xsd#nvax_ContractWithCustomerObligationToDeliverTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_ContractWithCustomerObligationToDeliverTerms_2ae703b6-c945-44e2-b53b-67faf4d9e85b" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PercentOfRemainingAmountToBePaid_956ee948-ad12-4fe7-b401-06e606203dee" xlink:href="nvax-20231231.xsd#nvax_PercentOfRemainingAmountToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_PercentOfRemainingAmountToBePaid_956ee948-ad12-4fe7-b401-06e606203dee" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EscrowDepositsRelatedToSalesHold_e2d2db42-acfe-4d7c-bdaa-c61a0d3a650e" xlink:href="nvax-20231231.xsd#nvax_EscrowDepositsRelatedToSalesHold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_EscrowDepositsRelatedToSalesHold_e2d2db42-acfe-4d7c-bdaa-c61a0d3a650e" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RevenueFromContractWithCustomerCommitment_5e133ae9-8704-49aa-8b0d-4d3f9b6205b2" xlink:href="nvax-20231231.xsd#nvax_RevenueFromContractWithCustomerCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_RevenueFromContractWithCustomerCommitment_5e133ae9-8704-49aa-8b0d-4d3f9b6205b2" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_ea1239ab-334a-4618-86f2-59f233f21287" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_ea1239ab-334a-4618-86f2-59f233f21287" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding_83992cf0-cdbc-4715-92e5-1ca329f1829c" xlink:href="nvax-20231231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding_83992cf0-cdbc-4715-92e5-1ca329f1829c" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant_7bb5f623-18bf-4590-b95e-3aea2fa7af29" xlink:href="nvax-20231231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant_7bb5f623-18bf-4590-b95e-3aea2fa7af29" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans_ebedb6d5-d18e-4926-b822-5043b773d201" xlink:href="nvax-20231231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans_ebedb6d5-d18e-4926-b822-5043b773d201" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9c6f7ab6-25da-4454-b90c-616792e90bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_Revenues_9c6f7ab6-25da-4454-b90c-616792e90bb8" xlink:type="arc" order="31"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_18a33957-7ada-4b84-8094-4adae2e83bee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_09f17c85-5bb6-4167-a76c-3b3bd81a3ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_18a33957-7ada-4b84-8094-4adae2e83bee" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_09f17c85-5bb6-4167-a76c-3b3bd81a3ac5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_443f1dc1-abc1-4fb8-b142-cd8e10d48299" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_09f17c85-5bb6-4167-a76c-3b3bd81a3ac5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_443f1dc1-abc1-4fb8-b142-cd8e10d48299" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_443f1dc1-abc1-4fb8-b142-cd8e10d48299_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_443f1dc1-abc1-4fb8-b142-cd8e10d48299" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_443f1dc1-abc1-4fb8-b142-cd8e10d48299_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_72cfdf10-c12b-4a9e-93ed-31812e60ef80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_443f1dc1-abc1-4fb8-b142-cd8e10d48299" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_72cfdf10-c12b-4a9e-93ed-31812e60ef80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_d6eea238-e4b6-4d42-9fbd-3d51f17d0b4a" xlink:href="nvax-20231231.xsd#nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_72cfdf10-c12b-4a9e-93ed-31812e60ef80" xlink:to="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_d6eea238-e4b6-4d42-9fbd-3d51f17d0b4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember_daf3646e-f1ba-49e1-87de-dd2fc382df00" xlink:href="nvax-20231231.xsd#nvax_AmendedAndRestatedUKSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_72cfdf10-c12b-4a9e-93ed-31812e60ef80" xlink:to="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember_daf3646e-f1ba-49e1-87de-dd2fc382df00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_93505add-fee4-4416-b3ac-918763dfed64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_09f17c85-5bb6-4167-a76c-3b3bd81a3ac5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_93505add-fee4-4416-b3ac-918763dfed64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_93505add-fee4-4416-b3ac-918763dfed64_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_93505add-fee4-4416-b3ac-918763dfed64" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_93505add-fee4-4416-b3ac-918763dfed64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_887d6260-84de-48df-b213-5d2b056da02a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_93505add-fee4-4416-b3ac-918763dfed64" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_887d6260-84de-48df-b213-5d2b056da02a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RevenueMember_e298c08c-8ff9-4f2c-8ac5-3d89e494a9ea" xlink:href="nvax-20231231.xsd#nvax_RevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_887d6260-84de-48df-b213-5d2b056da02a" xlink:to="loc_nvax_RevenueMember_e298c08c-8ff9-4f2c-8ac5-3d89e494a9ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableAllowanceForCreditLossAdditions_ad0e8c3e-2ea3-4745-bad7-2b49f241c3b3" xlink:href="nvax-20231231.xsd#nvax_AccountsReceivableAllowanceForCreditLossAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_18a33957-7ada-4b84-8094-4adae2e83bee" xlink:to="loc_nvax_AccountsReceivableAllowanceForCreditLossAdditions_ad0e8c3e-2ea3-4745-bad7-2b49f241c3b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableAllowanceForCreditLossDeductions_4eeddff7-398e-41f5-a6a3-faf6f70db9f5" xlink:href="nvax-20231231.xsd#nvax_AccountsReceivableAllowanceForCreditLossDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_18a33957-7ada-4b84-8094-4adae2e83bee" xlink:to="loc_nvax_AccountsReceivableAllowanceForCreditLossDeductions_4eeddff7-398e-41f5-a6a3-faf6f70db9f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_02d6bd0f-226d-4bc3-bf7c-b60e05e407c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_18a33957-7ada-4b84-8094-4adae2e83bee" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_02d6bd0f-226d-4bc3-bf7c-b60e05e407c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_cb347760-5a63-4ce7-ba4d-6810352874a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_18a33957-7ada-4b84-8094-4adae2e83bee" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_cb347760-5a63-4ce7-ba4d-6810352874a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2a514630-05f5-4f74-b2df-0341432bc5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_18a33957-7ada-4b84-8094-4adae2e83bee" xlink:to="loc_us-gaap_ContractWithCustomerLiability_2a514630-05f5-4f74-b2df-0341432bc5f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_e9aa4c7a-a35a-4739-bf38-9ccb89b7faa0" xlink:href="nvax-20231231.xsd#nvax_CollaborationAgreementUpfrontPaymentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_18a33957-7ada-4b84-8094-4adae2e83bee" xlink:to="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_e9aa4c7a-a35a-4739-bf38-9ccb89b7faa0" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#RevenueScheduleofProductRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a45ac87c-241b-4930-95c0-f3738d519235" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_72d8ffc5-6ff1-43bd-9969-428be507f5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a45ac87c-241b-4930-95c0-f3738d519235" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_72d8ffc5-6ff1-43bd-9969-428be507f5e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_28acb214-aaa7-4bf4-a1e5-c68475c63c60" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_72d8ffc5-6ff1-43bd-9969-428be507f5e9" xlink:to="loc_srt_ProductOrServiceAxis_28acb214-aaa7-4bf4-a1e5-c68475c63c60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_28acb214-aaa7-4bf4-a1e5-c68475c63c60_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_28acb214-aaa7-4bf4-a1e5-c68475c63c60" xlink:to="loc_srt_ProductsAndServicesDomain_28acb214-aaa7-4bf4-a1e5-c68475c63c60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8603995b-6809-471b-87a7-d90115430d32" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_28acb214-aaa7-4bf4-a1e5-c68475c63c60" xlink:to="loc_srt_ProductsAndServicesDomain_8603995b-6809-471b-87a7-d90115430d32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_dd946436-022f-4e66-8231-ddc277bd71c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8603995b-6809-471b-87a7-d90115430d32" xlink:to="loc_us-gaap_ProductMember_dd946436-022f-4e66-8231-ddc277bd71c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_be6b8734-9c0a-4c82-8ffc-a2fb80d3d7f7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_72d8ffc5-6ff1-43bd-9969-428be507f5e9" xlink:to="loc_srt_StatementGeographicalAxis_be6b8734-9c0a-4c82-8ffc-a2fb80d3d7f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_be6b8734-9c0a-4c82-8ffc-a2fb80d3d7f7_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_be6b8734-9c0a-4c82-8ffc-a2fb80d3d7f7" xlink:to="loc_srt_SegmentGeographicalDomain_be6b8734-9c0a-4c82-8ffc-a2fb80d3d7f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8f61885a-5478-41c9-b412-615efe383db8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_be6b8734-9c0a-4c82-8ffc-a2fb80d3d7f7" xlink:to="loc_srt_SegmentGeographicalDomain_8f61885a-5478-41c9-b412-615efe383db8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NorthAmericaMember_c4dc1d38-a088-4a69-ae31-da672e07d5f8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NorthAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8f61885a-5478-41c9-b412-615efe383db8" xlink:to="loc_srt_NorthAmericaMember_c4dc1d38-a088-4a69-ae31-da672e07d5f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_bbdd1cf3-c6ac-4e53-90b6-95aa8a9d1bbc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8f61885a-5478-41c9-b412-615efe383db8" xlink:to="loc_srt_EuropeMember_bbdd1cf3-c6ac-4e53-90b6-95aa8a9d1bbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RestOfTheWorldMember_38b5c903-e231-4ab8-9c34-241dc6990632" xlink:href="nvax-20231231.xsd#nvax_RestOfTheWorldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8f61885a-5478-41c9-b412-615efe383db8" xlink:to="loc_nvax_RestOfTheWorldMember_38b5c903-e231-4ab8-9c34-241dc6990632" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ad93378a-6546-4b34-aa96-f5ec52fdc3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a45ac87c-241b-4930-95c0-f3738d519235" xlink:to="loc_us-gaap_Revenues_ad93378a-6546-4b34-aa96-f5ec52fdc3b7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e6f4f50d-2bc8-4998-b78f-cd217c4ed447" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_07ccbff5-73ac-4ab4-8409-095fc8337cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e6f4f50d-2bc8-4998-b78f-cd217c4ed447" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_07ccbff5-73ac-4ab4-8409-095fc8337cf0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0a8b57e5-2d5c-4c89-aad8-1155d396a003" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_07ccbff5-73ac-4ab4-8409-095fc8337cf0" xlink:to="loc_srt_ProductOrServiceAxis_0a8b57e5-2d5c-4c89-aad8-1155d396a003" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0a8b57e5-2d5c-4c89-aad8-1155d396a003_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0a8b57e5-2d5c-4c89-aad8-1155d396a003" xlink:to="loc_srt_ProductsAndServicesDomain_0a8b57e5-2d5c-4c89-aad8-1155d396a003_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dc779b7a-5010-43a0-896d-6d27c491aa7d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0a8b57e5-2d5c-4c89-aad8-1155d396a003" xlink:to="loc_srt_ProductsAndServicesDomain_dc779b7a-5010-43a0-896d-6d27c491aa7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_da559977-be5c-46d5-9471-5e218cac690d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc779b7a-5010-43a0-896d-6d27c491aa7d" xlink:to="loc_us-gaap_ProductMember_da559977-be5c-46d5-9471-5e218cac690d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_20ffffa2-38ff-4baa-9166-6df2e14d251f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerBasisOfPricingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_07ccbff5-73ac-4ab4-8409-095fc8337cf0" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_20ffffa2-38ff-4baa-9166-6df2e14d251f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_20ffffa2-38ff-4baa-9166-6df2e14d251f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_20ffffa2-38ff-4baa-9166-6df2e14d251f" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_20ffffa2-38ff-4baa-9166-6df2e14d251f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_3fd24a9b-5984-46d6-bc1c-66379d2d18fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_20ffffa2-38ff-4baa-9166-6df2e14d251f" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_3fd24a9b-5984-46d6-bc1c-66379d2d18fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember_ae0e4885-beb2-42ab-8b75-2aed1b7d722a" xlink:href="nvax-20231231.xsd#nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_3fd24a9b-5984-46d6-bc1c-66379d2d18fc" xlink:to="loc_nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember_ae0e4885-beb2-42ab-8b75-2aed1b7d722a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ProductReturnsMember_e1af7bc1-9992-403b-9bf0-d35c32f448f0" xlink:href="nvax-20231231.xsd#nvax_ProductReturnsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_3fd24a9b-5984-46d6-bc1c-66379d2d18fc" xlink:to="loc_nvax_ProductReturnsMember_e1af7bc1-9992-403b-9bf0-d35c32f448f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3a8bc02d-79f7-4410-96f1-a08ecbd4f403" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_07ccbff5-73ac-4ab4-8409-095fc8337cf0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3a8bc02d-79f7-4410-96f1-a08ecbd4f403" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3a8bc02d-79f7-4410-96f1-a08ecbd4f403_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3a8bc02d-79f7-4410-96f1-a08ecbd4f403" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3a8bc02d-79f7-4410-96f1-a08ecbd4f403_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9a5b8396-6d72-48d2-923f-1abe909a889f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3a8bc02d-79f7-4410-96f1-a08ecbd4f403" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9a5b8396-6d72-48d2-923f-1abe909a889f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_b275862d-c9ba-42ed-9af0-6a734e21ce26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9a5b8396-6d72-48d2-923f-1abe909a889f" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_b275862d-c9ba-42ed-9af0-6a734e21ce26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_100520d1-4e55-48cc-8f64-7681a0a4cab7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9a5b8396-6d72-48d2-923f-1abe909a889f" xlink:to="loc_us-gaap_AccountsReceivableMember_100520d1-4e55-48cc-8f64-7681a0a4cab7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ContractWithCustomerLiabilityRollForward_359d439a-fed2-4fbc-b49b-0b783fbd80eb" xlink:href="nvax-20231231.xsd#nvax_ContractWithCustomerLiabilityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e6f4f50d-2bc8-4998-b78f-cd217c4ed447" xlink:to="loc_nvax_ContractWithCustomerLiabilityRollForward_359d439a-fed2-4fbc-b49b-0b783fbd80eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_da9ca8b7-cf4c-4952-944f-c3d85bb86cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_ContractWithCustomerLiabilityRollForward_359d439a-fed2-4fbc-b49b-0b783fbd80eb" xlink:to="loc_us-gaap_ContractWithCustomerLiability_da9ca8b7-cf4c-4952-944f-c3d85bb86cc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AmountsChargedAgainstProductSales_dc22d916-56d8-4048-b4ff-2336a1cd298e" xlink:href="nvax-20231231.xsd#nvax_AmountsChargedAgainstProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_ContractWithCustomerLiabilityRollForward_359d439a-fed2-4fbc-b49b-0b783fbd80eb" xlink:to="loc_nvax_AmountsChargedAgainstProductSales_dc22d916-56d8-4048-b4ff-2336a1cd298e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_88d5df6e-9b73-4775-bec2-0b4101f61a26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_ContractWithCustomerLiabilityRollForward_359d439a-fed2-4fbc-b49b-0b783fbd80eb" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_88d5df6e-9b73-4775-bec2-0b4101f61a26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_7d89970f-5102-405d-be83-923548149d21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#RevenueScheduleofGrantRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_17bf7779-db27-425a-be6b-04311ad34af3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_277f2de6-bf1d-437b-9f0a-1bf0e76d261e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_17bf7779-db27-425a-be6b-04311ad34af3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_277f2de6-bf1d-437b-9f0a-1bf0e76d261e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_99b129eb-a7f0-43a9-8073-ea26ae454554" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_277f2de6-bf1d-437b-9f0a-1bf0e76d261e" xlink:to="loc_srt_ProductOrServiceAxis_99b129eb-a7f0-43a9-8073-ea26ae454554" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_99b129eb-a7f0-43a9-8073-ea26ae454554_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_99b129eb-a7f0-43a9-8073-ea26ae454554" xlink:to="loc_srt_ProductsAndServicesDomain_99b129eb-a7f0-43a9-8073-ea26ae454554_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4ced246a-56d7-4ef1-8632-0d8439d69cb4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_99b129eb-a7f0-43a9-8073-ea26ae454554" xlink:to="loc_srt_ProductsAndServicesDomain_4ced246a-56d7-4ef1-8632-0d8439d69cb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_0cfab287-0378-43f3-8883-07e91e9c87bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4ced246a-56d7-4ef1-8632-0d8439d69cb4" xlink:to="loc_us-gaap_GrantMember_0cfab287-0378-43f3-8883-07e91e9c87bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_36e57239-d9aa-4bb3-8e4e-1ae234348d86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_277f2de6-bf1d-437b-9f0a-1bf0e76d261e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_36e57239-d9aa-4bb3-8e4e-1ae234348d86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_36e57239-d9aa-4bb3-8e4e-1ae234348d86_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_36e57239-d9aa-4bb3-8e4e-1ae234348d86" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_36e57239-d9aa-4bb3-8e4e-1ae234348d86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_143e32e7-b239-4ac7-8f18-96bf925d4ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_36e57239-d9aa-4bb3-8e4e-1ae234348d86" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_143e32e7-b239-4ac7-8f18-96bf925d4ee7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentAgreementMember_f3bf6e0b-2a41-4afc-8bd4-260f64ecc933" xlink:href="nvax-20231231.xsd#nvax_USGovernmentAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_143e32e7-b239-4ac7-8f18-96bf925d4ee7" xlink:to="loc_nvax_USGovernmentAgreementMember_f3bf6e0b-2a41-4afc-8bd4-260f64ecc933" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USDepartmentOfDefenseDoDContractMember_58131291-375f-4a32-8167-09ba683635e4" xlink:href="nvax-20231231.xsd#nvax_USDepartmentOfDefenseDoDContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_143e32e7-b239-4ac7-8f18-96bf925d4ee7" xlink:to="loc_nvax_USDepartmentOfDefenseDoDContractMember_58131291-375f-4a32-8167-09ba683635e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember_543fb63e-9f4f-4d7e-8899-e7298c6d4cc0" xlink:href="nvax-20231231.xsd#nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_143e32e7-b239-4ac7-8f18-96bf925d4ee7" xlink:to="loc_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember_543fb63e-9f4f-4d7e-8899-e7298c6d4cc0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_OtherGrantRevenueMember_aab24a3f-7406-4ed3-b626-b1b2b31f79e5" xlink:href="nvax-20231231.xsd#nvax_OtherGrantRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_143e32e7-b239-4ac7-8f18-96bf925d4ee7" xlink:to="loc_nvax_OtherGrantRevenueMember_aab24a3f-7406-4ed3-b626-b1b2b31f79e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_39cf7d15-7c6a-412a-a1e5-a8ea93224f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_17bf7779-db27-425a-be6b-04311ad34af3" xlink:to="loc_us-gaap_Revenues_39cf7d15-7c6a-412a-a1e5-a8ea93224f4b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#CollaborationLicenseandSupplyAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6f60eeff-ced8-4ec2-95e3-2ceb7ebf07d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6f60eeff-ced8-4ec2-95e3-2ceb7ebf07d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bcaf6472-3050-4051-81e0-8255a813380c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6f60eeff-ced8-4ec2-95e3-2ceb7ebf07d0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bcaf6472-3050-4051-81e0-8255a813380c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bcaf6472-3050-4051-81e0-8255a813380c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bcaf6472-3050-4051-81e0-8255a813380c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bcaf6472-3050-4051-81e0-8255a813380c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f931af2-06b9-49c5-8ec7-0dd26804046d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bcaf6472-3050-4051-81e0-8255a813380c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f931af2-06b9-49c5-8ec7-0dd26804046d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TakedaArrangementMember_f47ba44f-df01-46d0-99f1-be3c7343665a" xlink:href="nvax-20231231.xsd#nvax_TakedaArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f931af2-06b9-49c5-8ec7-0dd26804046d" xlink:to="loc_nvax_TakedaArrangementMember_f47ba44f-df01-46d0-99f1-be3c7343665a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementMember_d786369a-17a1-40b0-80f8-6496222df2c4" xlink:href="nvax-20231231.xsd#nvax_SettlementAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f931af2-06b9-49c5-8ec7-0dd26804046d" xlink:to="loc_nvax_SettlementAgreementMember_d786369a-17a1-40b0-80f8-6496222df2c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SecuritiesSubscriptionArrangementMember_90f85116-764e-4b9d-8a34-59ba9f6745cf" xlink:href="nvax-20231231.xsd#nvax_SecuritiesSubscriptionArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f931af2-06b9-49c5-8ec7-0dd26804046d" xlink:to="loc_nvax_SecuritiesSubscriptionArrangementMember_90f85116-764e-4b9d-8a34-59ba9f6745cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e21d0df4-a539-4142-9354-536b336062fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6f60eeff-ced8-4ec2-95e3-2ceb7ebf07d0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e21d0df4-a539-4142-9354-536b336062fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e21d0df4-a539-4142-9354-536b336062fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e21d0df4-a539-4142-9354-536b336062fd" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e21d0df4-a539-4142-9354-536b336062fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cbfdbb17-6c4c-4bf0-a896-6a79b4535507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e21d0df4-a539-4142-9354-536b336062fd" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cbfdbb17-6c4c-4bf0-a896-6a79b4535507" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_25e56f14-b273-463a-b252-e95902dd8ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cbfdbb17-6c4c-4bf0-a896-6a79b4535507" xlink:to="loc_us-gaap_PrivatePlacementMember_25e56f14-b273-463a-b252-e95902dd8ad4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_373985b8-7431-4a6e-9b24-8d01074d0e06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6f60eeff-ced8-4ec2-95e3-2ceb7ebf07d0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_373985b8-7431-4a6e-9b24-8d01074d0e06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_373985b8-7431-4a6e-9b24-8d01074d0e06_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_373985b8-7431-4a6e-9b24-8d01074d0e06" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_373985b8-7431-4a6e-9b24-8d01074d0e06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a45f2fb7-2abe-40f7-b634-1ac580bdfb5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_373985b8-7431-4a6e-9b24-8d01074d0e06" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a45f2fb7-2abe-40f7-b634-1ac580bdfb5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_e7743efe-8a91-4dd0-b5c2-de150c7ee75a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a45f2fb7-2abe-40f7-b634-1ac580bdfb5c" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_e7743efe-8a91-4dd0-b5c2-de150c7ee75a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfExpenseAxis_8ebc9222-8141-449f-8518-9ac5180b992c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfExpenseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6f60eeff-ced8-4ec2-95e3-2ceb7ebf07d0" xlink:to="loc_us-gaap_NatureOfExpenseAxis_8ebc9222-8141-449f-8518-9ac5180b992c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_8ebc9222-8141-449f-8518-9ac5180b992c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_NatureOfExpenseAxis_8ebc9222-8141-449f-8518-9ac5180b992c" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_8ebc9222-8141-449f-8518-9ac5180b992c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_83fdaaa3-ade3-4654-b967-b64351b7c95c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_NatureOfExpenseAxis_8ebc9222-8141-449f-8518-9ac5180b992c" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_83fdaaa3-ade3-4654-b967-b64351b7c95c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_27d3c7de-7513-4ba5-8964-3810685a5513" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_83fdaaa3-ade3-4654-b967-b64351b7c95c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_27d3c7de-7513-4ba5-8964-3810685a5513" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_c2857706-33a7-40de-a62e-50cf5d1a497b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_83fdaaa3-ade3-4654-b967-b64351b7c95c" xlink:to="loc_us-gaap_CostOfSalesMember_c2857706-33a7-40de-a62e-50cf5d1a497b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RoyaltyPeriod_35baf022-f02d-4dfb-9bc0-0561e3d0c296" xlink:href="nvax-20231231.xsd#nvax_RoyaltyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_nvax_RoyaltyPeriod_35baf022-f02d-4dfb-9bc0-0561e3d0c296" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesToBeDistributed_0eb32588-a669-495e-86c0-6520f918768f" xlink:href="nvax-20231231.xsd#nvax_NumberOfDosesToBeDistributed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_nvax_NumberOfDosesToBeDistributed_0eb32588-a669-495e-86c0-6520f918768f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a46b360b-4182-446e-8d4e-a26d8d423203" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_us-gaap_Revenues_a46b360b-4182-446e-8d4e-a26d8d423203" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4fb04133-fb97-473d-a575-57382ee7613c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4fb04133-fb97-473d-a575-57382ee7613c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementPayment_29917f84-8c68-4fde-b1ae-a341a0574995" xlink:href="nvax-20231231.xsd#nvax_SettlementPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_nvax_SettlementPayment_29917f84-8c68-4fde-b1ae-a341a0574995" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementInitialReservationFee_a308c2ee-bfc8-4405-99d3-81d4fb46b372" xlink:href="nvax-20231231.xsd#nvax_SettlementAgreementInitialReservationFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_nvax_SettlementAgreementInitialReservationFee_a308c2ee-bfc8-4405-99d3-81d4fb46b372" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_389ab211-7c56-41c4-84ae-5c3e729771bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_us-gaap_ContractWithCustomerLiability_389ab211-7c56-41c4-84ae-5c3e729771bb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_eb650734-e3f3-4b6b-83c1-2dac24a32baf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_eb650734-e3f3-4b6b-83c1-2dac24a32baf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1b9bdbdf-f8fe-4eed-bf59-e47b2ddedbad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1b9bdbdf-f8fe-4eed-bf59-e47b2ddedbad" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_39e7237d-bc78-4189-8e9a-dd1f5307a922" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_39e7237d-bc78-4189-8e9a-dd1f5307a922" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_841867a5-edbb-45ad-b849-ca7280090daa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_841867a5-edbb-45ad-b849-ca7280090daa" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CommonStockQuotedMarketPrice_0e04ee72-25c3-4a07-a32e-47530a987767" xlink:href="nvax-20231231.xsd#nvax_CommonStockQuotedMarketPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_nvax_CommonStockQuotedMarketPrice_0e04ee72-25c3-4a07-a32e-47530a987767" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CommonStockPremiumPaid_e3bfe930-86ae-4344-b3eb-4690675c42c4" xlink:href="nvax-20231231.xsd#nvax_CommonStockPremiumPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_nvax_CommonStockPremiumPaid_e3bfe930-86ae-4344-b3eb-4690675c42c4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementBenefit_97ec2737-c5db-43d0-adcb-8e9ffd635a9d" xlink:href="nvax-20231231.xsd#nvax_SettlementAgreementBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_nvax_SettlementAgreementBenefit_97ec2737-c5db-43d0-adcb-8e9ffd635a9d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfQuarterlyInstallmentPayments_824fff18-75ce-4e31-8b76-851eecc11ed1" xlink:href="nvax-20231231.xsd#nvax_NumberOfQuarterlyInstallmentPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_nvax_NumberOfQuarterlyInstallmentPayments_824fff18-75ce-4e31-8b76-851eecc11ed1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementQuarterlyInstallmentAmount_5398a064-3367-4e3c-a3e3-6532e2efbbac" xlink:href="nvax-20231231.xsd#nvax_SettlementAgreementQuarterlyInstallmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_nvax_SettlementAgreementQuarterlyInstallmentAmount_5398a064-3367-4e3c-a3e3-6532e2efbbac" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_954f06f3-e4ac-4313-bdb8-e59a6b66b7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d13eb032-13fe-4781-a31b-d8414f96d6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_954f06f3-e4ac-4313-bdb8-e59a6b66b7a5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d13eb032-13fe-4781-a31b-d8414f96d6ef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c2be3af8-7ab5-42f0-9d0b-2c68239e9a12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d13eb032-13fe-4781-a31b-d8414f96d6ef" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c2be3af8-7ab5-42f0-9d0b-2c68239e9a12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c2be3af8-7ab5-42f0-9d0b-2c68239e9a12_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c2be3af8-7ab5-42f0-9d0b-2c68239e9a12" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c2be3af8-7ab5-42f0-9d0b-2c68239e9a12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b770c5b0-6915-4408-b2cc-34f842cfc2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c2be3af8-7ab5-42f0-9d0b-2c68239e9a12" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b770c5b0-6915-4408-b2cc-34f842cfc2fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b214675d-6429-411a-9869-12ed47a2c2af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b770c5b0-6915-4408-b2cc-34f842cfc2fd" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b214675d-6429-411a-9869-12ed47a2c2af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6a48b3be-320a-4987-a54d-36602f228a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b770c5b0-6915-4408-b2cc-34f842cfc2fd" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6a48b3be-320a-4987-a54d-36602f228a3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_038ebbc1-98d3-4e85-9e0e-becc6e0af8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b770c5b0-6915-4408-b2cc-34f842cfc2fd" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_038ebbc1-98d3-4e85-9e0e-becc6e0af8cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_c5613e30-94c6-496a-a399-dab8b8b6d399" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d13eb032-13fe-4781-a31b-d8414f96d6ef" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_c5613e30-94c6-496a-a399-dab8b8b6d399" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c5613e30-94c6-496a-a399-dab8b8b6d399_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_c5613e30-94c6-496a-a399-dab8b8b6d399" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c5613e30-94c6-496a-a399-dab8b8b6d399_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a9d3d610-0dfb-4b7b-bd5b-ef008cfc798b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_c5613e30-94c6-496a-a399-dab8b8b6d399" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a9d3d610-0dfb-4b7b-bd5b-ef008cfc798b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7dae93e9-9113-4606-b319-f16d2f46bbf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a9d3d610-0dfb-4b7b-bd5b-ef008cfc798b" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7dae93e9-9113-4606-b319-f16d2f46bbf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_167775ca-5737-477e-9b96-a239cadd657b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a9d3d610-0dfb-4b7b-bd5b-ef008cfc798b" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_167775ca-5737-477e-9b96-a239cadd657b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_23151f13-9b85-4e5e-98ac-fa00d98577b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a9d3d610-0dfb-4b7b-bd5b-ef008cfc798b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_23151f13-9b85-4e5e-98ac-fa00d98577b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_51a24eeb-6ce0-49bc-a324-bed6360eea8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a9d3d610-0dfb-4b7b-bd5b-ef008cfc798b" xlink:to="loc_us-gaap_AgencySecuritiesMember_51a24eeb-6ce0-49bc-a324-bed6360eea8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9877ec2f-c09c-4d8b-8d80-9e5ece16a591" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d13eb032-13fe-4781-a31b-d8414f96d6ef" xlink:to="loc_us-gaap_DebtInstrumentAxis_9877ec2f-c09c-4d8b-8d80-9e5ece16a591" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9877ec2f-c09c-4d8b-8d80-9e5ece16a591_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9877ec2f-c09c-4d8b-8d80-9e5ece16a591" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9877ec2f-c09c-4d8b-8d80-9e5ece16a591_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_087c6389-3b27-47ac-9548-0ac7ad5fdde7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9877ec2f-c09c-4d8b-8d80-9e5ece16a591" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_087c6389-3b27-47ac-9548-0ac7ad5fdde7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_cd59b784-588e-4ebd-9d0a-c83773fa1907" xlink:href="nvax-20231231.xsd#nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_087c6389-3b27-47ac-9548-0ac7ad5fdde7" xlink:to="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_cd59b784-588e-4ebd-9d0a-c83773fa1907" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_ba52fabf-1792-4eac-ae07-b13507d05e7c" xlink:href="nvax-20231231.xsd#nvax_FivePointZeroConvertibleNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_087c6389-3b27-47ac-9548-0ac7ad5fdde7" xlink:to="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_ba52fabf-1792-4eac-ae07-b13507d05e7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fc1d2142-5b27-4e61-8c16-d6dff2a00c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d13eb032-13fe-4781-a31b-d8414f96d6ef" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fc1d2142-5b27-4e61-8c16-d6dff2a00c3a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fc1d2142-5b27-4e61-8c16-d6dff2a00c3a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fc1d2142-5b27-4e61-8c16-d6dff2a00c3a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fc1d2142-5b27-4e61-8c16-d6dff2a00c3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0dcd84be-c09a-415a-b97a-1cabf4d805de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fc1d2142-5b27-4e61-8c16-d6dff2a00c3a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0dcd84be-c09a-415a-b97a-1cabf4d805de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_85cd4583-ee54-46ac-827c-e978fe16ac86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0dcd84be-c09a-415a-b97a-1cabf4d805de" xlink:to="loc_us-gaap_UnsecuredDebtMember_85cd4583-ee54-46ac-827c-e978fe16ac86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_ac4cc1f8-a0d8-4679-8cd8-9723cfacc08f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_954f06f3-e4ac-4313-bdb8-e59a6b66b7a5" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_ac4cc1f8-a0d8-4679-8cd8-9723cfacc08f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_8c4d934e-a941-44cb-9427-b42324dbbc55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ac4cc1f8-a0d8-4679-8cd8-9723cfacc08f" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_8c4d934e-a941-44cb-9427-b42324dbbc55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8c174225-ebbe-4af9-9264-cc932858810e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_954f06f3-e4ac-4313-bdb8-e59a6b66b7a5" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8c174225-ebbe-4af9-9264-cc932858810e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_3eff2179-f2bb-4b82-a2dd-47a367f18255" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8c174225-ebbe-4af9-9264-cc932858810e" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_3eff2179-f2bb-4b82-a2dd-47a367f18255" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_f1cc7fd6-84d7-448b-95c7-8458827ea73b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_954f06f3-e4ac-4313-bdb8-e59a6b66b7a5" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_f1cc7fd6-84d7-448b-95c7-8458827ea73b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/InventoryAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#InventoryAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/InventoryAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_38c7cff6-51b6-445e-b41b-025d4c1cff2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_571c0054-65e6-457d-aea1-cebec94d2e99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_38c7cff6-51b6-445e-b41b-025d4c1cff2c" xlink:to="loc_us-gaap_InventoryCurrentTable_571c0054-65e6-457d-aea1-cebec94d2e99" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseImpairmentChargeAxis_9a8b6056-cda6-4f18-82b6-bea42f8c061d" xlink:href="nvax-20231231.xsd#nvax_LeaseImpairmentChargeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_571c0054-65e6-457d-aea1-cebec94d2e99" xlink:to="loc_nvax_LeaseImpairmentChargeAxis_9a8b6056-cda6-4f18-82b6-bea42f8c061d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseImpairmentChargeDomain_9a8b6056-cda6-4f18-82b6-bea42f8c061d_default" xlink:href="nvax-20231231.xsd#nvax_LeaseImpairmentChargeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nvax_LeaseImpairmentChargeAxis_9a8b6056-cda6-4f18-82b6-bea42f8c061d" xlink:to="loc_nvax_LeaseImpairmentChargeDomain_9a8b6056-cda6-4f18-82b6-bea42f8c061d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseImpairmentChargeDomain_e33651b3-8d34-4078-8e40-cfede80da74f" xlink:href="nvax-20231231.xsd#nvax_LeaseImpairmentChargeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nvax_LeaseImpairmentChargeAxis_9a8b6056-cda6-4f18-82b6-bea42f8c061d" xlink:to="loc_nvax_LeaseImpairmentChargeDomain_e33651b3-8d34-4078-8e40-cfede80da74f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CMOAgreementMember_aa6f7735-aa94-4db3-96df-5eb589014ef3" xlink:href="nvax-20231231.xsd#nvax_CMOAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_LeaseImpairmentChargeDomain_e33651b3-8d34-4078-8e40-cfede80da74f" xlink:to="loc_nvax_CMOAgreementMember_aa6f7735-aa94-4db3-96df-5eb589014ef3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_4dc32362-6a5c-40be-85b1-6ca7eda74a21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_38c7cff6-51b6-445e-b41b-025d4c1cff2c" xlink:to="loc_us-gaap_InventoryWriteDown_4dc32362-6a5c-40be-85b1-6ca7eda74a21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_8f3a7b82-2d67-4102-98db-bc59c4a108bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFirmPurchaseCommitmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_38c7cff6-51b6-445e-b41b-025d4c1cff2c" xlink:to="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_8f3a7b82-2d67-4102-98db-bc59c4a108bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InventoryFirmPurchaseCommitmentRecoveries_b1da0a26-a8f3-48e7-8756-13b86ba71237" xlink:href="nvax-20231231.xsd#nvax_InventoryFirmPurchaseCommitmentRecoveries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_38c7cff6-51b6-445e-b41b-025d4c1cff2c" xlink:to="loc_nvax_InventoryFirmPurchaseCommitmentRecoveries_b1da0a26-a8f3-48e7-8756-13b86ba71237" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_6e85a394-70ea-45ef-8d05-3d234dd7aebc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_38c7cff6-51b6-445e-b41b-025d4c1cff2c" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_6e85a394-70ea-45ef-8d05-3d234dd7aebc" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#LeasesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_fdee4684-b763-4435-847a-f6e985ce96fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_5c7d06e5-2ed1-446d-9db6-5cbdae5ff17c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fdee4684-b763-4435-847a-f6e985ce96fb" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_5c7d06e5-2ed1-446d-9db6-5cbdae5ff17c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d937faf0-ce19-4254-8be8-16889d61d9de" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5c7d06e5-2ed1-446d-9db6-5cbdae5ff17c" xlink:to="loc_srt_CounterpartyNameAxis_d937faf0-ce19-4254-8be8-16889d61d9de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d937faf0-ce19-4254-8be8-16889d61d9de_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d937faf0-ce19-4254-8be8-16889d61d9de" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d937faf0-ce19-4254-8be8-16889d61d9de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e37ccf65-582a-43d6-ae98-2812bc7ff069" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d937faf0-ce19-4254-8be8-16889d61d9de" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e37ccf65-582a-43d6-ae98-2812bc7ff069" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CMOAndCMDAgreementsMember_9633b64d-473f-48cd-ad87-e4609ee805ac" xlink:href="nvax-20231231.xsd#nvax_CMOAndCMDAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e37ccf65-582a-43d6-ae98-2812bc7ff069" xlink:to="loc_nvax_CMOAndCMDAgreementsMember_9633b64d-473f-48cd-ad87-e4609ee805ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_A700QuinceOrchardRoadAgreementMember_1dbe3ac0-1b2e-4f15-9564-c83997059ea6" xlink:href="nvax-20231231.xsd#nvax_A700QuinceOrchardRoadAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e37ccf65-582a-43d6-ae98-2812bc7ff069" xlink:to="loc_nvax_A700QuinceOrchardRoadAgreementMember_1dbe3ac0-1b2e-4f15-9564-c83997059ea6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FacilityLeaseAgreementMember_d68d1a7a-9657-4326-ad72-5e01446f7d8c" xlink:href="nvax-20231231.xsd#nvax_FacilityLeaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e37ccf65-582a-43d6-ae98-2812bc7ff069" xlink:to="loc_nvax_FacilityLeaseAgreementMember_d68d1a7a-9657-4326-ad72-5e01446f7d8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_30f4e0f0-a606-45a3-8112-669438a8d129" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5c7d06e5-2ed1-446d-9db6-5cbdae5ff17c" xlink:to="loc_srt_RangeAxis_30f4e0f0-a606-45a3-8112-669438a8d129" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_30f4e0f0-a606-45a3-8112-669438a8d129_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_30f4e0f0-a606-45a3-8112-669438a8d129" xlink:to="loc_srt_RangeMember_30f4e0f0-a606-45a3-8112-669438a8d129_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_20200277-f15a-4501-b259-c04cd2764d34" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_30f4e0f0-a606-45a3-8112-669438a8d129" xlink:to="loc_srt_RangeMember_20200277-f15a-4501-b259-c04cd2764d34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8733949c-8444-4bd3-8d0e-344b3a4d87be" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_20200277-f15a-4501-b259-c04cd2764d34" xlink:to="loc_srt_MinimumMember_8733949c-8444-4bd3-8d0e-344b3a4d87be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_37f7f435-1e2d-4aa8-9aea-3df9f4774269" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_20200277-f15a-4501-b259-c04cd2764d34" xlink:to="loc_srt_MaximumMember_37f7f435-1e2d-4aa8-9aea-3df9f4774269" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseImpairmentChargeAxis_f021c482-3904-43f1-8a6b-3dad171ddbba" xlink:href="nvax-20231231.xsd#nvax_LeaseImpairmentChargeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5c7d06e5-2ed1-446d-9db6-5cbdae5ff17c" xlink:to="loc_nvax_LeaseImpairmentChargeAxis_f021c482-3904-43f1-8a6b-3dad171ddbba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseImpairmentChargeDomain_f021c482-3904-43f1-8a6b-3dad171ddbba_default" xlink:href="nvax-20231231.xsd#nvax_LeaseImpairmentChargeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nvax_LeaseImpairmentChargeAxis_f021c482-3904-43f1-8a6b-3dad171ddbba" xlink:to="loc_nvax_LeaseImpairmentChargeDomain_f021c482-3904-43f1-8a6b-3dad171ddbba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseImpairmentChargeDomain_cdd7a861-3812-431d-96c3-488201b1fb98" xlink:href="nvax-20231231.xsd#nvax_LeaseImpairmentChargeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nvax_LeaseImpairmentChargeAxis_f021c482-3904-43f1-8a6b-3dad171ddbba" xlink:to="loc_nvax_LeaseImpairmentChargeDomain_cdd7a861-3812-431d-96c3-488201b1fb98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ROUFacilityLeasesMember_413c349f-527c-4ff4-8e13-288469d05337" xlink:href="nvax-20231231.xsd#nvax_ROUFacilityLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_LeaseImpairmentChargeDomain_cdd7a861-3812-431d-96c3-488201b1fb98" xlink:to="loc_nvax_ROUFacilityLeasesMember_413c349f-527c-4ff4-8e13-288469d05337" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CMOAgreementMember_ace43555-6b9f-46b8-bb11-e6b8bc3d973e" xlink:href="nvax-20231231.xsd#nvax_CMOAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_LeaseImpairmentChargeDomain_cdd7a861-3812-431d-96c3-488201b1fb98" xlink:to="loc_nvax_CMOAgreementMember_ace43555-6b9f-46b8-bb11-e6b8bc3d973e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability_9bd40dc9-0d30-4dc0-836b-ced9e62a98c5" xlink:href="nvax-20231231.xsd#nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fdee4684-b763-4435-847a-f6e985ce96fb" xlink:to="loc_nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability_9bd40dc9-0d30-4dc0-836b-ced9e62a98c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FacilityNumberOfSquareFeet_18882af0-5949-4462-98dc-c881113d68ab" xlink:href="nvax-20231231.xsd#nvax_FacilityNumberOfSquareFeet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fdee4684-b763-4435-847a-f6e985ce96fb" xlink:to="loc_nvax_FacilityNumberOfSquareFeet_18882af0-5949-4462-98dc-c881113d68ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_fddca6a0-4bbf-4e94-8061-1572b2e36fba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fdee4684-b763-4435-847a-f6e985ce96fb" xlink:to="loc_us-gaap_OperatingLeaseExpense_fddca6a0-4bbf-4e94-8061-1572b2e36fba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c700ec78-6d8c-4ad4-a6f9-569999967ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fdee4684-b763-4435-847a-f6e985ce96fb" xlink:to="loc_us-gaap_OperatingLeaseLiability_c700ec78-6d8c-4ad4-a6f9-569999967ee3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ff2966e2-d6e4-4c64-8828-e7dd5bea16c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fdee4684-b763-4435-847a-f6e985ce96fb" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ff2966e2-d6e4-4c64-8828-e7dd5bea16c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_3ceeaee8-df8d-485e-89ce-fb96577e22b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fdee4684-b763-4435-847a-f6e985ce96fb" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_3ceeaee8-df8d-485e-89ce-fb96577e22b4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9c250ae9-0f40-490b-986a-25a994a586bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fdee4684-b763-4435-847a-f6e985ce96fb" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9c250ae9-0f40-490b-986a-25a994a586bf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_8587f5a6-8df5-467d-80cb-507c63a2fe80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fdee4684-b763-4435-847a-f6e985ce96fb" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_8587f5a6-8df5-467d-80cb-507c63a2fe80" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#LongTermDebtScheduleofNotesPayableDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5f222498-65c3-4d51-aa69-20d1657cffc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_13a31bd7-8ff3-4e62-8d0a-80b349552ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f222498-65c3-4d51-aa69-20d1657cffc3" xlink:to="loc_us-gaap_DebtInstrumentTable_13a31bd7-8ff3-4e62-8d0a-80b349552ac1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ea4600f1-1059-48be-baa2-48160b45dce6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_13a31bd7-8ff3-4e62-8d0a-80b349552ac1" xlink:to="loc_us-gaap_DebtInstrumentAxis_ea4600f1-1059-48be-baa2-48160b45dce6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ea4600f1-1059-48be-baa2-48160b45dce6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ea4600f1-1059-48be-baa2-48160b45dce6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ea4600f1-1059-48be-baa2-48160b45dce6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_be6bf303-c549-470f-b3f7-26dd0229b4b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ea4600f1-1059-48be-baa2-48160b45dce6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_be6bf303-c549-470f-b3f7-26dd0229b4b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_dbb3749d-e149-4d54-94f2-09d2e5ddabf6" xlink:href="nvax-20231231.xsd#nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_be6bf303-c549-470f-b3f7-26dd0229b4b7" xlink:to="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_dbb3749d-e149-4d54-94f2-09d2e5ddabf6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_18f068f9-887a-418d-a6da-2c54cd742671" xlink:href="nvax-20231231.xsd#nvax_FivePointZeroConvertibleNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_be6bf303-c549-470f-b3f7-26dd0229b4b7" xlink:to="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_18f068f9-887a-418d-a6da-2c54cd742671" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_58810bf9-0e04-4e7c-a94a-ec2a5c86a8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_13a31bd7-8ff3-4e62-8d0a-80b349552ac1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_58810bf9-0e04-4e7c-a94a-ec2a5c86a8dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_58810bf9-0e04-4e7c-a94a-ec2a5c86a8dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_58810bf9-0e04-4e7c-a94a-ec2a5c86a8dc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_58810bf9-0e04-4e7c-a94a-ec2a5c86a8dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7aa4529b-237c-4898-83b2-14b1fb7a864c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_58810bf9-0e04-4e7c-a94a-ec2a5c86a8dc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7aa4529b-237c-4898-83b2-14b1fb7a864c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_9b5e42d3-24a5-435d-8a36-a40efe19bdd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7aa4529b-237c-4898-83b2-14b1fb7a864c" xlink:to="loc_us-gaap_UnsecuredDebtMember_9b5e42d3-24a5-435d-8a36-a40efe19bdd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ConvertibleNotesPayableCurrentAbstract_c6b0e410-6569-45b1-b7d4-beb352ee8c57" xlink:href="nvax-20231231.xsd#nvax_ConvertibleNotesPayableCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f222498-65c3-4d51-aa69-20d1657cffc3" xlink:to="loc_nvax_ConvertibleNotesPayableCurrentAbstract_c6b0e410-6569-45b1-b7d4-beb352ee8c57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DebtInstrumentFaceAmountCurrent_b7f4d00a-011a-4aa8-82dd-f488a40daa10" xlink:href="nvax-20231231.xsd#nvax_DebtInstrumentFaceAmountCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_ConvertibleNotesPayableCurrentAbstract_c6b0e410-6569-45b1-b7d4-beb352ee8c57" xlink:to="loc_nvax_DebtInstrumentFaceAmountCurrent_b7f4d00a-011a-4aa8-82dd-f488a40daa10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_e515029c-8e7b-4f06-a389-a880767084a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_ConvertibleNotesPayableCurrentAbstract_c6b0e410-6569-45b1-b7d4-beb352ee8c57" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_e515029c-8e7b-4f06-a389-a880767084a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_8928a0c1-c3c0-4574-b4a0-eb393b2db022" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_ConvertibleNotesPayableCurrentAbstract_c6b0e410-6569-45b1-b7d4-beb352ee8c57" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_8928a0c1-c3c0-4574-b4a0-eb393b2db022" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ConvertibleNotesPayableNoncurrentAbstract_6cdb7ca5-b423-4127-8006-32f5eb1d6828" xlink:href="nvax-20231231.xsd#nvax_ConvertibleNotesPayableNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f222498-65c3-4d51-aa69-20d1657cffc3" xlink:to="loc_nvax_ConvertibleNotesPayableNoncurrentAbstract_6cdb7ca5-b423-4127-8006-32f5eb1d6828" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_736bdcc7-b031-4a99-9a00-80665af9ed6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_ConvertibleNotesPayableNoncurrentAbstract_6cdb7ca5-b423-4127-8006-32f5eb1d6828" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_736bdcc7-b031-4a99-9a00-80665af9ed6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_3e631bb1-d683-4421-a69b-6e99cc308b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_ConvertibleNotesPayableNoncurrentAbstract_6cdb7ca5-b423-4127-8006-32f5eb1d6828" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_3e631bb1-d683-4421-a69b-6e99cc308b5b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_8b17c259-7ef8-4f40-99ac-c83ff5e21ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_ConvertibleNotesPayableNoncurrentAbstract_6cdb7ca5-b423-4127-8006-32f5eb1d6828" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_8b17c259-7ef8-4f40-99ac-c83ff5e21ca3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_9dc5a630-2523-4a0a-a419-9e3aef9e74a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f222498-65c3-4d51-aa69-20d1657cffc3" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_9dc5a630-2523-4a0a-a419-9e3aef9e74a9" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#LongTermDebtAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_bfcda809-9dbb-412a-bbcc-a7500b4d633e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_DebtInstrumentTable_bfcda809-9dbb-412a-bbcc-a7500b4d633e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_af02b535-7534-46e4-9158-f78997fecbfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bfcda809-9dbb-412a-bbcc-a7500b4d633e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_af02b535-7534-46e4-9158-f78997fecbfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_af02b535-7534-46e4-9158-f78997fecbfd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_af02b535-7534-46e4-9158-f78997fecbfd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_af02b535-7534-46e4-9158-f78997fecbfd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5fa2cd39-f17f-4815-be69-7ac9b19a449c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_af02b535-7534-46e4-9158-f78997fecbfd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5fa2cd39-f17f-4815-be69-7ac9b19a449c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_6fe3539b-cdcb-4a38-b669-28ce0670dacb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5fa2cd39-f17f-4815-be69-7ac9b19a449c" xlink:to="loc_us-gaap_UnsecuredDebtMember_6fe3539b-cdcb-4a38-b669-28ce0670dacb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_572651a1-b28e-4733-a3b5-ab9dcc8b2a65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bfcda809-9dbb-412a-bbcc-a7500b4d633e" xlink:to="loc_us-gaap_DebtInstrumentAxis_572651a1-b28e-4733-a3b5-ab9dcc8b2a65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_572651a1-b28e-4733-a3b5-ab9dcc8b2a65_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_572651a1-b28e-4733-a3b5-ab9dcc8b2a65" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_572651a1-b28e-4733-a3b5-ab9dcc8b2a65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ccf85481-d8fe-4c58-962d-549ff4c768e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_572651a1-b28e-4733-a3b5-ab9dcc8b2a65" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ccf85481-d8fe-4c58-962d-549ff4c768e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_9d8df834-96b5-42ba-9a13-7cd49c49852e" xlink:href="nvax-20231231.xsd#nvax_FivePointZeroConvertibleNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ccf85481-d8fe-4c58-962d-549ff4c768e9" xlink:to="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_9d8df834-96b5-42ba-9a13-7cd49c49852e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember_2c3d1099-83a1-4fad-835b-9c7f64337b03" xlink:href="nvax-20231231.xsd#nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_9d8df834-96b5-42ba-9a13-7cd49c49852e" xlink:to="loc_nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember_2c3d1099-83a1-4fad-835b-9c7f64337b03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_1a618e10-85d2-4f61-8bca-f024f0732697" xlink:href="nvax-20231231.xsd#nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ccf85481-d8fe-4c58-962d-549ff4c768e9" xlink:to="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_1a618e10-85d2-4f61-8bca-f024f0732697" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_d8f39e3c-0129-40c9-925a-8154b2d34e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bfcda809-9dbb-412a-bbcc-a7500b4d633e" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_d8f39e3c-0129-40c9-925a-8154b2d34e5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_d8f39e3c-0129-40c9-925a-8154b2d34e5c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_d8f39e3c-0129-40c9-925a-8154b2d34e5c" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_d8f39e3c-0129-40c9-925a-8154b2d34e5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_615b30a4-6f34-4ed8-868e-87f74a55e01c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_d8f39e3c-0129-40c9-925a-8154b2d34e5c" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_615b30a4-6f34-4ed8-868e-87f74a55e01c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CallOptionMember_4d9ca8e7-c9ea-44a3-adb6-efe8d3957f92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CallOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_615b30a4-6f34-4ed8-868e-87f74a55e01c" xlink:to="loc_us-gaap_CallOptionMember_4d9ca8e7-c9ea-44a3-adb6-efe8d3957f92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_db6b0321-8bfa-482c-af20-ada7c1455764" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bfcda809-9dbb-412a-bbcc-a7500b4d633e" xlink:to="loc_srt_RangeAxis_db6b0321-8bfa-482c-af20-ada7c1455764" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_db6b0321-8bfa-482c-af20-ada7c1455764_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_db6b0321-8bfa-482c-af20-ada7c1455764" xlink:to="loc_srt_RangeMember_db6b0321-8bfa-482c-af20-ada7c1455764_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_50930d82-171f-4ccf-a0e1-d0c0594f9e2d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_db6b0321-8bfa-482c-af20-ada7c1455764" xlink:to="loc_srt_RangeMember_50930d82-171f-4ccf-a0e1-d0c0594f9e2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7529a2aa-a61d-405e-8ad2-307b365a625d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_50930d82-171f-4ccf-a0e1-d0c0594f9e2d" xlink:to="loc_srt_MaximumMember_7529a2aa-a61d-405e-8ad2-307b365a625d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_ec74cf52-7a70-467d-8768-79c02c3012ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bfcda809-9dbb-412a-bbcc-a7500b4d633e" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_ec74cf52-7a70-467d-8768-79c02c3012ac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_ec74cf52-7a70-467d-8768-79c02c3012ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_ec74cf52-7a70-467d-8768-79c02c3012ac" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_ec74cf52-7a70-467d-8768-79c02c3012ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e1ceee49-322a-437c-baf6-ac60fc3bf4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_ec74cf52-7a70-467d-8768-79c02c3012ac" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e1ceee49-322a-437c-baf6-ac60fc3bf4d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_cc6a04c8-6307-4183-bfb0-8accd1a123e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e1ceee49-322a-437c-baf6-ac60fc3bf4d4" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_cc6a04c8-6307-4183-bfb0-8accd1a123e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_eaf58b7b-1cfc-4bf4-8b5f-6d0899cecf19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e1ceee49-322a-437c-baf6-ac60fc3bf4d4" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_eaf58b7b-1cfc-4bf4-8b5f-6d0899cecf19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_f6fd32e0-d8bc-49dd-b632-8e9aea139778" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_f6fd32e0-d8bc-49dd-b632-8e9aea139778" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_d96c828c-76b6-4107-b256-08cea2218e30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_d96c828c-76b6-4107-b256-08cea2218e30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_9c2dc021-f464-4076-af25-00a0e0878e32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_9c2dc021-f464-4076-af25-00a0e0878e32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_6a47f85c-c3d6-47ac-a23b-eb3474b5fa34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_6a47f85c-c3d6-47ac-a23b-eb3474b5fa34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_a6538d1d-2d54-4ce9-9247-4fc066d6d452" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_a6538d1d-2d54-4ce9-9247-4fc066d6d452" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_36e07d04-e75a-46fb-ad0c-f76d09acd19e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_36e07d04-e75a-46fb-ad0c-f76d09acd19e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_4232c34c-f0be-440b-b27d-6db1122289cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_4232c34c-f0be-440b-b27d-6db1122289cb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ConvertibleDebtConversionRate_26ba7755-d234-4c2b-b022-5b7473f5fed2" xlink:href="nvax-20231231.xsd#nvax_ConvertibleDebtConversionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_nvax_ConvertibleDebtConversionRate_26ba7755-d234-4c2b-b022-5b7473f5fed2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_303d899f-b302-4d07-9674-cd013aae4b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_303d899f-b302-4d07-9674-cd013aae4b1b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ConversionPremiumPercentage_2f6ad457-1063-4cae-9584-bad3f2e0a88b" xlink:href="nvax-20231231.xsd#nvax_ConversionPremiumPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_nvax_ConversionPremiumPercentage_2f6ad457-1063-4cae-9584-bad3f2e0a88b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_16477682-b35b-4878-8103-b24dd107a1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_16477682-b35b-4878-8103-b24dd107a1ce" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage_72458814-cb23-40b6-ba17-2fc2af4c5bb1" xlink:href="nvax-20231231.xsd#nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage_72458814-cb23-40b6-ba17-2fc2af4c5bb1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_fb90e175-10ad-42f0-9b97-f6723a0f90b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_fb90e175-10ad-42f0-9b97-f6723a0f90b1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_d4d4323e-611e-4b16-bd96-513d2bf6a6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_DebtInstrumentTerm_d4d4323e-611e-4b16-bd96-513d2bf6a6ef" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3f803501-e674-408c-8749-51a453ea8031" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3f803501-e674-408c-8749-51a453ea8031" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_f56d200b-d12f-47b3-af02-87e5969d3446" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_RepaymentsOfDebt_f56d200b-d12f-47b3-af02-87e5969d3446" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_d7e5bb9b-f288-47b9-ae39-f51101c16c01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_d7e5bb9b-f288-47b9-ae39-f51101c16c01" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_63a7f3b2-f29f-4487-8d80-43cf9cd9e03e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_63a7f3b2-f29f-4487-8d80-43cf9cd9e03e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_70ca0e53-6f17-42ae-ba21-35a2ef3cbf6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_70ca0e53-6f17-42ae-ba21-35a2ef3cbf6b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PaymentForCappedCallTransactions_d21cae85-0119-4a4f-8ad2-9ace30db5b03" xlink:href="nvax-20231231.xsd#nvax_PaymentForCappedCallTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_nvax_PaymentForCappedCallTransactions_d21cae85-0119-4a4f-8ad2-9ace30db5b03" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DebtCapPrice_1e59ee39-a32f-44bb-a3de-96e02bb4f141" xlink:href="nvax-20231231.xsd#nvax_DebtCapPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_nvax_DebtCapPrice_1e59ee39-a32f-44bb-a3de-96e02bb4f141" xlink:type="arc" order="20"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockholdersDeficitDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#StockholdersDeficitDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/StockholdersDeficitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_417e0bd5-f420-4035-9c82-8cd4fc8e9ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_e5df99b9-6a00-467e-8612-27fd8b060bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_417e0bd5-f420-4035-9c82-8cd4fc8e9ea2" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_e5df99b9-6a00-467e-8612-27fd8b060bf6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b7913b52-9963-40d5-9f8b-e9ee63dcb82b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_e5df99b9-6a00-467e-8612-27fd8b060bf6" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b7913b52-9963-40d5-9f8b-e9ee63dcb82b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b7913b52-9963-40d5-9f8b-e9ee63dcb82b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b7913b52-9963-40d5-9f8b-e9ee63dcb82b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b7913b52-9963-40d5-9f8b-e9ee63dcb82b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2b1d73b8-b3f7-4c50-b190-6601bb8cc268" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b7913b52-9963-40d5-9f8b-e9ee63dcb82b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2b1d73b8-b3f7-4c50-b190-6601bb8cc268" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_June2021AndAugust2023SalesAgreementMember_cfd39a79-ac86-41c2-9964-e6a3b33c67b2" xlink:href="nvax-20231231.xsd#nvax_June2021AndAugust2023SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2b1d73b8-b3f7-4c50-b190-6601bb8cc268" xlink:to="loc_nvax_June2021AndAugust2023SalesAgreementMember_cfd39a79-ac86-41c2-9964-e6a3b33c67b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_August2023SalesAgreementMember_ec0524ef-9d8a-4984-b7c9-78cb969345ae" xlink:href="nvax-20231231.xsd#nvax_August2023SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_June2021AndAugust2023SalesAgreementMember_cfd39a79-ac86-41c2-9964-e6a3b33c67b2" xlink:to="loc_nvax_August2023SalesAgreementMember_ec0524ef-9d8a-4984-b7c9-78cb969345ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_June2021SalesAgreementMember_2e60a808-6690-42f5-b306-a1bcb0eb3b2c" xlink:href="nvax-20231231.xsd#nvax_June2021SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_June2021AndAugust2023SalesAgreementMember_cfd39a79-ac86-41c2-9964-e6a3b33c67b2" xlink:to="loc_nvax_June2021SalesAgreementMember_2e60a808-6690-42f5-b306-a1bcb0eb3b2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_3de89088-7f58-439f-90d2-f3f286720b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2b1d73b8-b3f7-4c50-b190-6601bb8cc268" xlink:to="loc_us-gaap_PrivatePlacementMember_3de89088-7f58-439f-90d2-f3f286720b5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PublicOfferingMember_4ce4e6c0-94dc-422b-9b75-ba00bf0ce765" xlink:href="nvax-20231231.xsd#nvax_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2b1d73b8-b3f7-4c50-b190-6601bb8cc268" xlink:to="loc_nvax_PublicOfferingMember_4ce4e6c0-94dc-422b-9b75-ba00bf0ce765" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_UnderwriterMember_7dc6268f-048b-49f5-9df3-7f842fae0b77" xlink:href="nvax-20231231.xsd#nvax_UnderwriterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2b1d73b8-b3f7-4c50-b190-6601bb8cc268" xlink:to="loc_nvax_UnderwriterMember_7dc6268f-048b-49f5-9df3-7f842fae0b77" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_fd958f4d-b38d-4f76-84e0-6e3bdffe7a20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_e5df99b9-6a00-467e-8612-27fd8b060bf6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_fd958f4d-b38d-4f76-84e0-6e3bdffe7a20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fd958f4d-b38d-4f76-84e0-6e3bdffe7a20_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fd958f4d-b38d-4f76-84e0-6e3bdffe7a20" xlink:to="loc_us-gaap_ClassOfStockDomain_fd958f4d-b38d-4f76-84e0-6e3bdffe7a20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ae901b46-97ab-4121-9611-949efcbd54c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fd958f4d-b38d-4f76-84e0-6e3bdffe7a20" xlink:to="loc_us-gaap_ClassOfStockDomain_ae901b46-97ab-4121-9611-949efcbd54c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4f23424f-9f93-4137-9b3e-682307f0f9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ae901b46-97ab-4121-9611-949efcbd54c6" xlink:to="loc_us-gaap_CommonStockMember_4f23424f-9f93-4137-9b3e-682307f0f9fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2c870b44-fec4-4f4a-aa03-6b51ae67d582" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_e5df99b9-6a00-467e-8612-27fd8b060bf6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2c870b44-fec4-4f4a-aa03-6b51ae67d582" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2c870b44-fec4-4f4a-aa03-6b51ae67d582_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2c870b44-fec4-4f4a-aa03-6b51ae67d582" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2c870b44-fec4-4f4a-aa03-6b51ae67d582_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e686b900-9f09-45bc-af30-fe695a062cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2c870b44-fec4-4f4a-aa03-6b51ae67d582" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e686b900-9f09-45bc-af30-fe695a062cc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SecuritiesSubscriptionArrangementMember_8bd065df-bf06-45dc-91d2-0723b14684be" xlink:href="nvax-20231231.xsd#nvax_SecuritiesSubscriptionArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e686b900-9f09-45bc-af30-fe695a062cc1" xlink:to="loc_nvax_SecuritiesSubscriptionArrangementMember_8bd065df-bf06-45dc-91d2-0723b14684be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_345423c6-a0cf-4c19-b097-be2072c3e13b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_e5df99b9-6a00-467e-8612-27fd8b060bf6" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_345423c6-a0cf-4c19-b097-be2072c3e13b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_345423c6-a0cf-4c19-b097-be2072c3e13b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_345423c6-a0cf-4c19-b097-be2072c3e13b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_345423c6-a0cf-4c19-b097-be2072c3e13b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5ea96d17-d9cf-4c9f-92f5-8ab00b672f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_345423c6-a0cf-4c19-b097-be2072c3e13b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5ea96d17-d9cf-4c9f-92f5-8ab00b672f3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_6218e064-032a-41c1-8686-3d2cc8bb636b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5ea96d17-d9cf-4c9f-92f5-8ab00b672f3e" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_6218e064-032a-41c1-8686-3d2cc8bb636b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_abdc56d6-ef16-402f-8d54-aec3e1a83ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_417e0bd5-f420-4035-9c82-8cd4fc8e9ea2" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_abdc56d6-ef16-402f-8d54-aec3e1a83ed0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2d3153c6-f345-4702-af30-a45bc3318d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_417e0bd5-f420-4035-9c82-8cd4fc8e9ea2" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2d3153c6-f345-4702-af30-a45bc3318d5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_42deb196-75e6-4566-8e67-b4b24395b8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_417e0bd5-f420-4035-9c82-8cd4fc8e9ea2" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_42deb196-75e6-4566-8e67-b4b24395b8e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SaleOfStockAmountOfRemainingUnissuedShares_a56bd6cb-072b-4f39-812d-73d88a439453" xlink:href="nvax-20231231.xsd#nvax_SaleOfStockAmountOfRemainingUnissuedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_417e0bd5-f420-4035-9c82-8cd4fc8e9ea2" xlink:to="loc_nvax_SaleOfStockAmountOfRemainingUnissuedShares_a56bd6cb-072b-4f39-812d-73d88a439453" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_6aa31ac5-1e26-4058-bfd7-1b2fb1ee1fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_417e0bd5-f420-4035-9c82-8cd4fc8e9ea2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_6aa31ac5-1e26-4058-bfd7-1b2fb1ee1fa6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_189a5d2b-a941-4781-9913-16423410ec38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_417e0bd5-f420-4035-9c82-8cd4fc8e9ea2" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_189a5d2b-a941-4781-9913-16423410ec38" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_57e3ceb2-0094-4668-8954-d7ceba1ffcd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_417e0bd5-f420-4035-9c82-8cd4fc8e9ea2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_57e3ceb2-0094-4668-8954-d7ceba1ffcd8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_7b47d2b6-97c7-45cd-9a3b-c290190272dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_417e0bd5-f420-4035-9c82-8cd4fc8e9ea2" xlink:to="loc_us-gaap_StockIssued1_7b47d2b6-97c7-45cd-9a3b-c290190272dd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_cf0163d4-b04f-4548-8ff0-61868c92a2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_417e0bd5-f420-4035-9c82-8cd4fc8e9ea2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_cf0163d4-b04f-4548-8ff0-61868c92a2a9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_fa96cdf9-3b44-4a4e-a6f1-d9326d972b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_417e0bd5-f420-4035-9c82-8cd4fc8e9ea2" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_fa96cdf9-3b44-4a4e-a6f1-d9326d972b9b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_924e9e3f-86ea-4553-9d1f-b5900d4b6b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_417e0bd5-f420-4035-9c82-8cd4fc8e9ea2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_924e9e3f-86ea-4553-9d1f-b5900d4b6b6c" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96844a3e-cec7-4082-81f5-278191be2e30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96844a3e-cec7-4082-81f5-278191be2e30" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9446b9c5-c562-4d4a-a631-6bac0bfc869d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96844a3e-cec7-4082-81f5-278191be2e30" xlink:to="loc_us-gaap_PlanNameAxis_9446b9c5-c562-4d4a-a631-6bac0bfc869d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9446b9c5-c562-4d4a-a631-6bac0bfc869d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_9446b9c5-c562-4d4a-a631-6bac0bfc869d" xlink:to="loc_us-gaap_PlanNameDomain_9446b9c5-c562-4d4a-a631-6bac0bfc869d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_dfc2eeee-9498-48c8-ae8e-28d31b52dda5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_9446b9c5-c562-4d4a-a631-6bac0bfc869d" xlink:to="loc_us-gaap_PlanNameDomain_dfc2eeee-9498-48c8-ae8e-28d31b52dda5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandTwentyThreeStockInducementPlanMember_92306e9c-527e-471b-b20f-fbdf281dfaf4" xlink:href="nvax-20231231.xsd#nvax_TwoThousandTwentyThreeStockInducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_dfc2eeee-9498-48c8-ae8e-28d31b52dda5" xlink:to="loc_nvax_TwoThousandTwentyThreeStockInducementPlanMember_92306e9c-527e-471b-b20f-fbdf281dfaf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_8b161226-61e0-48ba-8f36-9b342835eab0" xlink:href="nvax-20231231.xsd#nvax_TwoThousandFifteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_dfc2eeee-9498-48c8-ae8e-28d31b52dda5" xlink:to="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_8b161226-61e0-48ba-8f36-9b342835eab0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bb8cd966-f172-4cc6-ab77-284fd08471cb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96844a3e-cec7-4082-81f5-278191be2e30" xlink:to="loc_srt_RangeAxis_bb8cd966-f172-4cc6-ab77-284fd08471cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bb8cd966-f172-4cc6-ab77-284fd08471cb_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bb8cd966-f172-4cc6-ab77-284fd08471cb" xlink:to="loc_srt_RangeMember_bb8cd966-f172-4cc6-ab77-284fd08471cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1e20afcf-d354-42a5-8ec1-88d405af4d38" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bb8cd966-f172-4cc6-ab77-284fd08471cb" xlink:to="loc_srt_RangeMember_1e20afcf-d354-42a5-8ec1-88d405af4d38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_431f2c59-0c74-4408-bc2c-6d472ee02633" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1e20afcf-d354-42a5-8ec1-88d405af4d38" xlink:to="loc_srt_MinimumMember_431f2c59-0c74-4408-bc2c-6d472ee02633" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f3cde41a-0567-4c0e-96e3-19eaa61ddd53" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1e20afcf-d354-42a5-8ec1-88d405af4d38" xlink:to="loc_srt_MaximumMember_f3cde41a-0567-4c0e-96e3-19eaa61ddd53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_eda9b263-6e51-45f5-b940-c4d95cbc3dff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96844a3e-cec7-4082-81f5-278191be2e30" xlink:to="loc_us-gaap_AwardTypeAxis_eda9b263-6e51-45f5-b940-c4d95cbc3dff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eda9b263-6e51-45f5-b940-c4d95cbc3dff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_eda9b263-6e51-45f5-b940-c4d95cbc3dff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eda9b263-6e51-45f5-b940-c4d95cbc3dff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81718a03-5876-463e-8cf1-d0d7eec1174d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_eda9b263-6e51-45f5-b940-c4d95cbc3dff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81718a03-5876-463e-8cf1-d0d7eec1174d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_1c3f6beb-321a-44f9-846b-45e229e82d04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81718a03-5876-463e-8cf1-d0d7eec1174d" xlink:to="loc_us-gaap_EmployeeStockMember_1c3f6beb-321a-44f9-846b-45e229e82d04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7ef005d2-b323-4593-96ed-b25370f142d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7ef005d2-b323-4593-96ed-b25370f142d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance_e68ae046-2d9a-47fe-98df-0a6f08d4d6d6" xlink:href="nvax-20231231.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance_e68ae046-2d9a-47fe-98df-0a6f08d4d6d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3ed183b5-ccdd-4474-a574-a1c9e9989206" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3ed183b5-ccdd-4474-a574-a1c9e9989206" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3f49b07d-9ff6-4e3f-9837-119a7481e8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3f49b07d-9ff6-4e3f-9837-119a7481e8ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_72ea45e0-97ad-4f16-b93c-aa32cb1d11ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_72ea45e0-97ad-4f16-b93c-aa32cb1d11ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent_8855c6a9-f0b5-4f89-a2f3-853e7b364351" xlink:href="nvax-20231231.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent_8855c6a9-f0b5-4f89-a2f3-853e7b364351" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6de57da0-f28d-4b27-969c-04d80628bd3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6de57da0-f28d-4b27-969c-04d80628bd3c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_a9d05f2b-8d57-4fe9-b4e7-1a05d067954d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_a9d05f2b-8d57-4fe9-b4e7-1a05d067954d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f5aba64b-fdc9-4e91-8523-b9ad503f4524" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f5aba64b-fdc9-4e91-8523-b9ad503f4524" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1321ddd3-8d6b-4975-a7b6-646f1edb87f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1321ddd3-8d6b-4975-a7b6-646f1edb87f5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_675dd161-84e3-4208-b513-f98300574ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_675dd161-84e3-4208-b513-f98300574ee0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9a4d3aa5-d307-433f-a928-73b570b477cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9a4d3aa5-d307-433f-a928-73b570b477cd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_03466517-978e-4a12-a1ba-9478e7f2b312" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_03466517-978e-4a12-a1ba-9478e7f2b312" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_edb9b7a1-4fef-48c3-9559-36a0d6793be0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_edb9b7a1-4fef-48c3-9559-36a0d6793be0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_40aa70b1-6d13-46d3-be6f-f56f6611b34a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_40aa70b1-6d13-46d3-be6f-f56f6611b34a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease_558b9fe8-41b6-4c30-9030-e0f4321856f4" xlink:href="nvax-20231231.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease_558b9fe8-41b6-4c30-9030-e0f4321856f4" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_MaximumContributionOfEmployeesAsPayrollDeductions_e06a7810-210f-4da2-bce7-bfd10c3b6b7b" xlink:href="nvax-20231231.xsd#nvax_MaximumContributionOfEmployeesAsPayrollDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_nvax_MaximumContributionOfEmployeesAsPayrollDeductions_e06a7810-210f-4da2-bce7-bfd10c3b6b7b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PercentageOfMarketPriceForStockPurchase_a4e8fbad-f4d8-4581-9a3d-5ee20bbdddcc" xlink:href="nvax-20231231.xsd#nvax_PercentageOfMarketPriceForStockPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_nvax_PercentageOfMarketPriceForStockPurchase_a4e8fbad-f4d8-4581-9a3d-5ee20bbdddcc" xlink:type="arc" order="17"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_aa951031-87e3-4284-bfd5-19a33e396bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3835d72d-425d-4e62-840e-89d8ad0dc76d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_aa951031-87e3-4284-bfd5-19a33e396bf8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3835d72d-425d-4e62-840e-89d8ad0dc76d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fc86e54f-be09-4e9f-ab27-07cbbe0ccfce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3835d72d-425d-4e62-840e-89d8ad0dc76d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fc86e54f-be09-4e9f-ab27-07cbbe0ccfce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fc86e54f-be09-4e9f-ab27-07cbbe0ccfce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fc86e54f-be09-4e9f-ab27-07cbbe0ccfce" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fc86e54f-be09-4e9f-ab27-07cbbe0ccfce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_04548159-9b37-463a-8a58-654c377861c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fc86e54f-be09-4e9f-ab27-07cbbe0ccfce" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_04548159-9b37-463a-8a58-654c377861c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_437d4e72-1879-43d8-9368-bf8eb39d329c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_04548159-9b37-463a-8a58-654c377861c0" xlink:to="loc_us-gaap_CostOfSalesMember_437d4e72-1879-43d8-9368-bf8eb39d329c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9cc7eeb9-31f8-4941-a34f-12c5e4637d96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_04548159-9b37-463a-8a58-654c377861c0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9cc7eeb9-31f8-4941-a34f-12c5e4637d96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_306af303-4eb9-4493-9c52-8adde802381e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_04548159-9b37-463a-8a58-654c377861c0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_306af303-4eb9-4493-9c52-8adde802381e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_446f8125-ffca-4a89-be22-80ce5c82777c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_aa951031-87e3-4284-bfd5-19a33e396bf8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_446f8125-ffca-4a89-be22-80ce5c82777c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a49db98-232b-41cc-98ae-2b120ed4672f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00a2ff8c-f20b-4e95-8a97-51475785e441" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a49db98-232b-41cc-98ae-2b120ed4672f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00a2ff8c-f20b-4e95-8a97-51475785e441" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e48de2f3-0c96-4c19-91cf-63bd35bd515a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00a2ff8c-f20b-4e95-8a97-51475785e441" xlink:to="loc_us-gaap_PlanNameAxis_e48de2f3-0c96-4c19-91cf-63bd35bd515a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e48de2f3-0c96-4c19-91cf-63bd35bd515a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_e48de2f3-0c96-4c19-91cf-63bd35bd515a" xlink:to="loc_us-gaap_PlanNameDomain_e48de2f3-0c96-4c19-91cf-63bd35bd515a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6c922bec-7f42-4763-84ff-4dd6f3ece3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_e48de2f3-0c96-4c19-91cf-63bd35bd515a" xlink:to="loc_us-gaap_PlanNameDomain_6c922bec-7f42-4763-84ff-4dd6f3ece3ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandTwentyThreeStockInducementPlanMember_963911f8-2c04-4a1a-a64a-5a176cefae11" xlink:href="nvax-20231231.xsd#nvax_TwoThousandTwentyThreeStockInducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6c922bec-7f42-4763-84ff-4dd6f3ece3ae" xlink:to="loc_nvax_TwoThousandTwentyThreeStockInducementPlanMember_963911f8-2c04-4a1a-a64a-5a176cefae11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_b0e59d3a-14dd-4ea8-9849-468c21894b52" xlink:href="nvax-20231231.xsd#nvax_TwoThousandFifteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6c922bec-7f42-4763-84ff-4dd6f3ece3ae" xlink:to="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_b0e59d3a-14dd-4ea8-9849-468c21894b52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFiveStockIncentivePlanMember_ffb8bd4d-ea17-4d6c-8f4b-6549c6ef2ab2" xlink:href="nvax-20231231.xsd#nvax_TwoThousandFiveStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6c922bec-7f42-4763-84ff-4dd6f3ece3ae" xlink:to="loc_nvax_TwoThousandFiveStockIncentivePlanMember_ffb8bd4d-ea17-4d6c-8f4b-6549c6ef2ab2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e3eef298-9ab6-4c8b-b4e7-0b0cf260d5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a49db98-232b-41cc-98ae-2b120ed4672f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e3eef298-9ab6-4c8b-b4e7-0b0cf260d5ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_571863db-a242-40b0-941a-54e4021216c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e3eef298-9ab6-4c8b-b4e7-0b0cf260d5ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_571863db-a242-40b0-941a-54e4021216c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dad71d28-5b20-480b-afd1-a154c7202a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e3eef298-9ab6-4c8b-b4e7-0b0cf260d5ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dad71d28-5b20-480b-afd1-a154c7202a0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_26bc61df-f1ef-48e4-9e8d-8c2bd4c306d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e3eef298-9ab6-4c8b-b4e7-0b0cf260d5ea" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_26bc61df-f1ef-48e4-9e8d-8c2bd4c306d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_555461e3-dd00-49f1-b0be-2157e6df8db4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e3eef298-9ab6-4c8b-b4e7-0b0cf260d5ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_555461e3-dd00-49f1-b0be-2157e6df8db4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a8ea0c00-155a-4685-b7b2-26f0dadb2dee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_dd0b6dbe-1019-478a-94f9-4e680bf2d67b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a49db98-232b-41cc-98ae-2b120ed4672f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_dd0b6dbe-1019-478a-94f9-4e680bf2d67b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcd1eb1b-fd1e-4008-8776-bb2899fb5da2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a49db98-232b-41cc-98ae-2b120ed4672f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcd1eb1b-fd1e-4008-8776-bb2899fb5da2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_43fdb01f-4645-40c8-9530-d52b49b47e92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcd1eb1b-fd1e-4008-8776-bb2899fb5da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_43fdb01f-4645-40c8-9530-d52b49b47e92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_dc5dc393-5b5f-4c06-9345-fb0e2ae52f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcd1eb1b-fd1e-4008-8776-bb2899fb5da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_dc5dc393-5b5f-4c06-9345-fb0e2ae52f7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3dced04d-ac51-459c-ac2a-588f9429c542" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcd1eb1b-fd1e-4008-8776-bb2899fb5da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3dced04d-ac51-459c-ac2a-588f9429c542" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_806e6c5c-bd6f-4cb8-9e73-6df280e8bca6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcd1eb1b-fd1e-4008-8776-bb2899fb5da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_806e6c5c-bd6f-4cb8-9e73-6df280e8bca6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cab6cfe5-178b-48e1-8c89-338d05da1e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e5306e00-5803-4726-9530-f5747a13ec15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a49db98-232b-41cc-98ae-2b120ed4672f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e5306e00-5803-4726-9530-f5747a13ec15" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67a35c14-f8d1-4de3-9f2b-80914a08761b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_342991ed-afa8-49c2-8e33-fae8bf13df9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67a35c14-f8d1-4de3-9f2b-80914a08761b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_342991ed-afa8-49c2-8e33-fae8bf13df9c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2f0ef06e-762a-40ed-86f2-ac1374b9e444" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_342991ed-afa8-49c2-8e33-fae8bf13df9c" xlink:to="loc_us-gaap_AwardTypeAxis_2f0ef06e-762a-40ed-86f2-ac1374b9e444" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f0ef06e-762a-40ed-86f2-ac1374b9e444_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2f0ef06e-762a-40ed-86f2-ac1374b9e444" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f0ef06e-762a-40ed-86f2-ac1374b9e444_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be91a51c-6754-4cad-afdb-86f800ed7795" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2f0ef06e-762a-40ed-86f2-ac1374b9e444" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be91a51c-6754-4cad-afdb-86f800ed7795" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d9f48f81-aa5b-4f6d-aad3-d4e22ca213a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be91a51c-6754-4cad-afdb-86f800ed7795" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d9f48f81-aa5b-4f6d-aad3-d4e22ca213a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3ff4aca3-c02d-46b8-b88d-1ac6795079af" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_342991ed-afa8-49c2-8e33-fae8bf13df9c" xlink:to="loc_srt_RangeAxis_3ff4aca3-c02d-46b8-b88d-1ac6795079af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3ff4aca3-c02d-46b8-b88d-1ac6795079af_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3ff4aca3-c02d-46b8-b88d-1ac6795079af" xlink:to="loc_srt_RangeMember_3ff4aca3-c02d-46b8-b88d-1ac6795079af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_809878f9-3aff-40e2-b677-2b4f5998f461" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3ff4aca3-c02d-46b8-b88d-1ac6795079af" xlink:to="loc_srt_RangeMember_809878f9-3aff-40e2-b677-2b4f5998f461" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_54063f7f-1c40-4a07-a172-3cd9f8826b09" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_809878f9-3aff-40e2-b677-2b4f5998f461" xlink:to="loc_srt_MinimumMember_54063f7f-1c40-4a07-a172-3cd9f8826b09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0d46b7e2-db5c-4842-837b-a5747f008222" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_809878f9-3aff-40e2-b677-2b4f5998f461" xlink:to="loc_srt_MaximumMember_0d46b7e2-db5c-4842-837b-a5747f008222" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_adbc4a96-ea4f-4ea1-adb3-8717faa7dc0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67a35c14-f8d1-4de3-9f2b-80914a08761b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_adbc4a96-ea4f-4ea1-adb3-8717faa7dc0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_fe75441e-f442-4e1e-aab5-2e5e6e3f6ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67a35c14-f8d1-4de3-9f2b-80914a08761b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_fe75441e-f442-4e1e-aab5-2e5e6e3f6ae7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_fecc26d7-8f7d-498b-a605-eee166187893" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67a35c14-f8d1-4de3-9f2b-80914a08761b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_fecc26d7-8f7d-498b-a605-eee166187893" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bec03503-bc22-4a5a-a778-f2ee636e0ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67a35c14-f8d1-4de3-9f2b-80914a08761b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bec03503-bc22-4a5a-a778-f2ee636e0ae1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_9b0e1955-449d-4017-bdcf-39df9c91ad3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67a35c14-f8d1-4de3-9f2b-80914a08761b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_9b0e1955-449d-4017-bdcf-39df9c91ad3c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_fc1d29d0-ff11-4e8e-a3cf-1bb168f834a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67a35c14-f8d1-4de3-9f2b-80914a08761b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_fc1d29d0-ff11-4e8e-a3cf-1bb168f834a4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_584327e7-2047-4cb6-b3d8-a1fa0a5ac1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67a35c14-f8d1-4de3-9f2b-80914a08761b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_584327e7-2047-4cb6-b3d8-a1fa0a5ac1fa" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9d16d6d-1aec-4066-8ee3-a6c7bef03633" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe4530e4-197d-49c4-ab07-e88a13065e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9d16d6d-1aec-4066-8ee3-a6c7bef03633" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe4530e4-197d-49c4-ab07-e88a13065e8c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f71e51fd-4962-4bf4-ac22-cac6571059ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe4530e4-197d-49c4-ab07-e88a13065e8c" xlink:to="loc_us-gaap_AwardTypeAxis_f71e51fd-4962-4bf4-ac22-cac6571059ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f71e51fd-4962-4bf4-ac22-cac6571059ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f71e51fd-4962-4bf4-ac22-cac6571059ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f71e51fd-4962-4bf4-ac22-cac6571059ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19e7a343-3145-42db-b29d-c50a9e703baf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f71e51fd-4962-4bf4-ac22-cac6571059ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19e7a343-3145-42db-b29d-c50a9e703baf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3bc84ab1-3e49-4a94-b4f7-99b1ba8992eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19e7a343-3145-42db-b29d-c50a9e703baf" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3bc84ab1-3e49-4a94-b4f7-99b1ba8992eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6b81fe52-47ea-472b-bff7-cb620717a0de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe4530e4-197d-49c4-ab07-e88a13065e8c" xlink:to="loc_us-gaap_PlanNameAxis_6b81fe52-47ea-472b-bff7-cb620717a0de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6b81fe52-47ea-472b-bff7-cb620717a0de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6b81fe52-47ea-472b-bff7-cb620717a0de" xlink:to="loc_us-gaap_PlanNameDomain_6b81fe52-47ea-472b-bff7-cb620717a0de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_54f35933-2c6f-470d-8430-540b947e41ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6b81fe52-47ea-472b-bff7-cb620717a0de" xlink:to="loc_us-gaap_PlanNameDomain_54f35933-2c6f-470d-8430-540b947e41ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandTwentyThreeStockInducementPlanMember_5e1cd91c-9621-4749-acf8-4567b3a1ad3e" xlink:href="nvax-20231231.xsd#nvax_TwoThousandTwentyThreeStockInducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_54f35933-2c6f-470d-8430-540b947e41ae" xlink:to="loc_nvax_TwoThousandTwentyThreeStockInducementPlanMember_5e1cd91c-9621-4749-acf8-4567b3a1ad3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_f8784d04-fe84-4b72-9921-e128175238ef" xlink:href="nvax-20231231.xsd#nvax_TwoThousandFifteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_54f35933-2c6f-470d-8430-540b947e41ae" xlink:to="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_f8784d04-fe84-4b72-9921-e128175238ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_55158acd-548e-4c45-bd3a-934e7cbe0ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9d16d6d-1aec-4066-8ee3-a6c7bef03633" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_55158acd-548e-4c45-bd3a-934e7cbe0ee4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_09dbc26e-7386-4094-97f0-254abeb90d27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_55158acd-548e-4c45-bd3a-934e7cbe0ee4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_09dbc26e-7386-4094-97f0-254abeb90d27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_715b85ad-a4d5-4768-80f1-f8822479716e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_55158acd-548e-4c45-bd3a-934e7cbe0ee4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_715b85ad-a4d5-4768-80f1-f8822479716e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a34975d6-cf33-42b8-ab68-97bf51e2414b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_55158acd-548e-4c45-bd3a-934e7cbe0ee4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a34975d6-cf33-42b8-ab68-97bf51e2414b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_68815217-6c90-4f3a-a55e-3853a5e78e83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_55158acd-548e-4c45-bd3a-934e7cbe0ee4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_68815217-6c90-4f3a-a55e-3853a5e78e83" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a97a5d3c-e981-45fd-a0f6-63db7dd1733d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be6c6508-8856-45f7-9834-a62a6569a7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9d16d6d-1aec-4066-8ee3-a6c7bef03633" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be6c6508-8856-45f7-9834-a62a6569a7dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_886d7978-57f4-428c-aa4f-1338be8f128d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be6c6508-8856-45f7-9834-a62a6569a7dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_886d7978-57f4-428c-aa4f-1338be8f128d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2e2d0d46-c3ad-486a-bef4-1943259c7db0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be6c6508-8856-45f7-9834-a62a6569a7dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2e2d0d46-c3ad-486a-bef4-1943259c7db0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c5617680-d4a2-448c-a406-51356e31220f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be6c6508-8856-45f7-9834-a62a6569a7dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c5617680-d4a2-448c-a406-51356e31220f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_707acad1-ce2a-4e12-a682-c9272eb25753" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be6c6508-8856-45f7-9834-a62a6569a7dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_707acad1-ce2a-4e12-a682-c9272eb25753" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fb616a5b-c76f-4efa-bf1c-8972f5781efe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/EmployeeBenefitsDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#EmployeeBenefitsDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/EmployeeBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3085a9b9-7ebe-40b4-94db-583492d26d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMultiemployerPlansTable_56432414-6938-4804-afd2-3c9969678501" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMultiemployerPlansTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3085a9b9-7ebe-40b4-94db-583492d26d3b" xlink:to="loc_us-gaap_ScheduleOfMultiemployerPlansTable_56432414-6938-4804-afd2-3c9969678501" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollectiveBargainingArrangementAxis_003393d0-5562-43a7-bbc2-5257a48ad1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollectiveBargainingArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfMultiemployerPlansTable_56432414-6938-4804-afd2-3c9969678501" xlink:to="loc_us-gaap_CollectiveBargainingArrangementAxis_003393d0-5562-43a7-bbc2-5257a48ad1b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollectiveBargainingArrangementDomain_003393d0-5562-43a7-bbc2-5257a48ad1b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollectiveBargainingArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CollectiveBargainingArrangementAxis_003393d0-5562-43a7-bbc2-5257a48ad1b0" xlink:to="loc_us-gaap_CollectiveBargainingArrangementDomain_003393d0-5562-43a7-bbc2-5257a48ad1b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollectiveBargainingArrangementDomain_60ce2a04-ef51-4ea7-a9d1-dc9d67ba9866" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollectiveBargainingArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CollectiveBargainingArrangementAxis_003393d0-5562-43a7-bbc2-5257a48ad1b0" xlink:to="loc_us-gaap_CollectiveBargainingArrangementDomain_60ce2a04-ef51-4ea7-a9d1-dc9d67ba9866" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FirstThreePercentOfParticipantsDeferralMemberMember_c13b6454-da5c-4197-af08-f652b2139f10" xlink:href="nvax-20231231.xsd#nvax_FirstThreePercentOfParticipantsDeferralMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollectiveBargainingArrangementDomain_60ce2a04-ef51-4ea7-a9d1-dc9d67ba9866" xlink:to="loc_nvax_FirstThreePercentOfParticipantsDeferralMemberMember_c13b6454-da5c-4197-af08-f652b2139f10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NextTwoPercentOfParticipantsDeferralMemberMember_0702d0f7-890c-4e03-89fc-f5fbd4fc06d0" xlink:href="nvax-20231231.xsd#nvax_NextTwoPercentOfParticipantsDeferralMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollectiveBargainingArrangementDomain_60ce2a04-ef51-4ea7-a9d1-dc9d67ba9866" xlink:to="loc_nvax_NextTwoPercentOfParticipantsDeferralMemberMember_0702d0f7-890c-4e03-89fc-f5fbd4fc06d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_6c0bf09a-86a0-484f-ae92-68c04a9bd4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfMultiemployerPlansTable_56432414-6938-4804-afd2-3c9969678501" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_6c0bf09a-86a0-484f-ae92-68c04a9bd4f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_6c0bf09a-86a0-484f-ae92-68c04a9bd4f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_6c0bf09a-86a0-484f-ae92-68c04a9bd4f8" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_6c0bf09a-86a0-484f-ae92-68c04a9bd4f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_b2d478fa-501c-410d-b4e2-ac8d6ff12b11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_6c0bf09a-86a0-484f-ae92-68c04a9bd4f8" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_b2d478fa-501c-410d-b4e2-ac8d6ff12b11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_056f18ef-0cd2-4270-a62c-019b8e81195f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_b2d478fa-501c-410d-b4e2-ac8d6ff12b11" xlink:to="loc_us-gaap_ForeignPlanMember_056f18ef-0cd2-4270-a62c-019b8e81195f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_bdcce365-23e9-4c20-8fb5-5d4c566c2eac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfMultiemployerPlansTable_56432414-6938-4804-afd2-3c9969678501" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_bdcce365-23e9-4c20-8fb5-5d4c566c2eac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_bdcce365-23e9-4c20-8fb5-5d4c566c2eac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_bdcce365-23e9-4c20-8fb5-5d4c566c2eac" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_bdcce365-23e9-4c20-8fb5-5d4c566c2eac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_5b720af4-78e9-43aa-be93-9478e6523c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_bdcce365-23e9-4c20-8fb5-5d4c566c2eac" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_5b720af4-78e9-43aa-be93-9478e6523c2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_64d90bfc-3922-465f-b082-0b53870a70f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_5b720af4-78e9-43aa-be93-9478e6523c2e" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_64d90bfc-3922-465f-b082-0b53870a70f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_ef461fb8-1548-430b-9d95-dce3c5afb470" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3085a9b9-7ebe-40b4-94db-583492d26d3b" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_ef461fb8-1548-430b-9d95-dce3c5afb470" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_9c8abaf7-ba8d-45aa-b9e2-9f61971f9d57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3085a9b9-7ebe-40b4-94db-583492d26d3b" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_9c8abaf7-ba8d-45aa-b9e2-9f61971f9d57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_87bf1d19-b815-4fcf-b4d6-d1072974b72a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3085a9b9-7ebe-40b4-94db-583492d26d3b" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_87bf1d19-b815-4fcf-b4d6-d1072974b72a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_96732014-97fb-4378-b049-5776d2db6904" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3085a9b9-7ebe-40b4-94db-583492d26d3b" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_96732014-97fb-4378-b049-5776d2db6904" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_178e9409-3029-4d81-9888-6e4e11b9954a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_876b911f-0ff0-4109-a54f-5f99278a5cce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_178e9409-3029-4d81-9888-6e4e11b9954a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_876b911f-0ff0-4109-a54f-5f99278a5cce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5e7d7311-ab4a-4521-bacd-bb571852e1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_876b911f-0ff0-4109-a54f-5f99278a5cce" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5e7d7311-ab4a-4521-bacd-bb571852e1a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5e7d7311-ab4a-4521-bacd-bb571852e1a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5e7d7311-ab4a-4521-bacd-bb571852e1a7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5e7d7311-ab4a-4521-bacd-bb571852e1a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b87db3f8-4bcd-431b-b6e5-2faaf931f13b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5e7d7311-ab4a-4521-bacd-bb571852e1a7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b87db3f8-4bcd-431b-b6e5-2faaf931f13b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember_4365aace-06eb-41a7-b6d3-76064a303b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b87db3f8-4bcd-431b-b6e5-2faaf931f13b" xlink:to="loc_us-gaap_LandAndLandImprovementsMember_4365aace-06eb-41a7-b6d3-76064a303b3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_185e97ad-050b-4f2a-ac9e-867c53ef1dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b87db3f8-4bcd-431b-b6e5-2faaf931f13b" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_185e97ad-050b-4f2a-ac9e-867c53ef1dd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_3480b17c-fbb7-4454-8e0d-d85bf41bd5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b87db3f8-4bcd-431b-b6e5-2faaf931f13b" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_3480b17c-fbb7-4454-8e0d-d85bf41bd5ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ComputerSoftwareAndHardwareMemberMember_61e6680a-4398-4989-9306-74f52e6e4cd5" xlink:href="nvax-20231231.xsd#nvax_ComputerSoftwareAndHardwareMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b87db3f8-4bcd-431b-b6e5-2faaf931f13b" xlink:to="loc_nvax_ComputerSoftwareAndHardwareMemberMember_61e6680a-4398-4989-9306-74f52e6e4cd5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_fb05badf-48ee-4056-aa8a-9898889193ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b87db3f8-4bcd-431b-b6e5-2faaf931f13b" xlink:to="loc_us-gaap_ConstructionInProgressMember_fb05badf-48ee-4056-aa8a-9898889193ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_bb072174-0173-4e4e-902c-ce393e0f284a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_178e9409-3029-4d81-9888-6e4e11b9954a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_bb072174-0173-4e4e-902c-ce393e0f284a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c4935d3f-30b7-41dc-8220-b8465839ec74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_178e9409-3029-4d81-9888-6e4e11b9954a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c4935d3f-30b7-41dc-8220-b8465839ec74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_88ba7725-4744-4970-aeee-9e79f5ab015b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_178e9409-3029-4d81-9888-6e4e11b9954a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_88ba7725-4744-4970-aeee-9e79f5ab015b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/OtherFinancialInformationAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#OtherFinancialInformationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/OtherFinancialInformationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_010b878d-53d6-4f8a-9f14-84de4dc4656e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f0d1737d-6ed7-4d26-9d50-2706aa15ff79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_010b878d-53d6-4f8a-9f14-84de4dc4656e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f0d1737d-6ed7-4d26-9d50-2706aa15ff79" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2fe69fe7-7d23-486d-a385-bb06aacf4913" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f0d1737d-6ed7-4d26-9d50-2706aa15ff79" xlink:to="loc_srt_StatementGeographicalAxis_2fe69fe7-7d23-486d-a385-bb06aacf4913" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2fe69fe7-7d23-486d-a385-bb06aacf4913_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_2fe69fe7-7d23-486d-a385-bb06aacf4913" xlink:to="loc_srt_SegmentGeographicalDomain_2fe69fe7-7d23-486d-a385-bb06aacf4913_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f4cbb87d-f437-4f92-9d89-a242b96fade3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_2fe69fe7-7d23-486d-a385-bb06aacf4913" xlink:to="loc_srt_SegmentGeographicalDomain_f4cbb87d-f437-4f92-9d89-a242b96fade3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CZ_334ddbe1-d5d5-4a6e-a405-4bed93a1ca34" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CZ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f4cbb87d-f437-4f92-9d89-a242b96fade3" xlink:to="loc_country_CZ_334ddbe1-d5d5-4a6e-a405-4bed93a1ca34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_77ac7c2f-73d9-40f0-a09f-6c5faea0e437" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_010b878d-53d6-4f8a-9f14-84de4dc4656e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_77ac7c2f-73d9-40f0-a09f-6c5faea0e437" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_e38f96b9-341f-4dbd-9e31-4eb85b075cce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_010b878d-53d6-4f8a-9f14-84de4dc4656e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_e38f96b9-341f-4dbd-9e31-4eb85b075cce" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_48f4858f-99ee-447b-9c9d-31b1886d35d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_70c1be57-9d72-4ca2-8490-08d2a6704374" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48f4858f-99ee-447b-9c9d-31b1886d35d8" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_70c1be57-9d72-4ca2-8490-08d2a6704374" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_e5dac692-de13-468d-896a-a911fc15ba32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_70c1be57-9d72-4ca2-8490-08d2a6704374" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_e5dac692-de13-468d-896a-a911fc15ba32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e5dac692-de13-468d-896a-a911fc15ba32_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e5dac692-de13-468d-896a-a911fc15ba32" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e5dac692-de13-468d-896a-a911fc15ba32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_44ed1ae8-29b6-4b42-90f7-bc7efd4f4ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e5dac692-de13-468d-896a-a911fc15ba32" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_44ed1ae8-29b6-4b42-90f7-bc7efd4f4ca0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_33bddc4a-0011-4f53-8f64-87cba45f0d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_44ed1ae8-29b6-4b42-90f7-bc7efd4f4ca0" xlink:to="loc_us-gaap_DomesticCountryMember_33bddc4a-0011-4f53-8f64-87cba45f0d6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_c859ecd9-3973-4c9f-9e3e-f244417d520b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_44ed1ae8-29b6-4b42-90f7-bc7efd4f4ca0" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_c859ecd9-3973-4c9f-9e3e-f244417d520b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_8f8f6ef5-a3c5-40a3-b58c-e1afa338eb69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_70c1be57-9d72-4ca2-8490-08d2a6704374" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_8f8f6ef5-a3c5-40a3-b58c-e1afa338eb69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_8f8f6ef5-a3c5-40a3-b58c-e1afa338eb69_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_8f8f6ef5-a3c5-40a3-b58c-e1afa338eb69" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_8f8f6ef5-a3c5-40a3-b58c-e1afa338eb69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_6775e1c2-649e-4050-8ba8-52bb778e81d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_8f8f6ef5-a3c5-40a3-b58c-e1afa338eb69" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_6775e1c2-649e-4050-8ba8-52bb778e81d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_2ebaf273-264b-4985-b376-0fad9bac03c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_6775e1c2-649e-4050-8ba8-52bb778e81d7" xlink:to="loc_us-gaap_ResearchMember_2ebaf273-264b-4985-b376-0fad9bac03c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_b3493260-c659-4ca4-96d9-d7eae617fb87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_6775e1c2-649e-4050-8ba8-52bb778e81d7" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_b3493260-c659-4ca4-96d9-d7eae617fb87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_229b8690-a037-4abf-93e4-32ec27317cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_70c1be57-9d72-4ca2-8490-08d2a6704374" xlink:to="loc_us-gaap_TaxPeriodAxis_229b8690-a037-4abf-93e4-32ec27317cb6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_229b8690-a037-4abf-93e4-32ec27317cb6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_229b8690-a037-4abf-93e4-32ec27317cb6" xlink:to="loc_us-gaap_TaxPeriodDomain_229b8690-a037-4abf-93e4-32ec27317cb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_c5839beb-e214-4659-9ea4-79a6a497a9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_229b8690-a037-4abf-93e4-32ec27317cb6" xlink:to="loc_us-gaap_TaxPeriodDomain_c5839beb-e214-4659-9ea4-79a6a497a9c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SubjectToExpirationMember_3ca7f97a-4e8d-4576-9f21-db0e21575ef3" xlink:href="nvax-20231231.xsd#nvax_SubjectToExpirationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_c5839beb-e214-4659-9ea4-79a6a497a9c7" xlink:to="loc_nvax_SubjectToExpirationMember_3ca7f97a-4e8d-4576-9f21-db0e21575ef3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NoExpirationMember_298629e2-534a-49cc-aa57-f0f56f9e1e78" xlink:href="nvax-20231231.xsd#nvax_NoExpirationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_c5839beb-e214-4659-9ea4-79a6a497a9c7" xlink:to="loc_nvax_NoExpirationMember_298629e2-534a-49cc-aa57-f0f56f9e1e78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ea7a00e6-e6bf-4e21-9c0a-13bb3004a98f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_70c1be57-9d72-4ca2-8490-08d2a6704374" xlink:to="loc_srt_StatementGeographicalAxis_ea7a00e6-e6bf-4e21-9c0a-13bb3004a98f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ea7a00e6-e6bf-4e21-9c0a-13bb3004a98f_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_ea7a00e6-e6bf-4e21-9c0a-13bb3004a98f" xlink:to="loc_srt_SegmentGeographicalDomain_ea7a00e6-e6bf-4e21-9c0a-13bb3004a98f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_884d4eb9-b879-44d8-9e19-ca5d9145c78e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_ea7a00e6-e6bf-4e21-9c0a-13bb3004a98f" xlink:to="loc_srt_SegmentGeographicalDomain_884d4eb9-b879-44d8-9e19-ca5d9145c78e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_90fa5736-b14c-48a0-9493-ba8f7f05f496" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_884d4eb9-b879-44d8-9e19-ca5d9145c78e" xlink:to="loc_us-gaap_NonUsMember_90fa5736-b14c-48a0-9493-ba8f7f05f496" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_c0155f17-d522-49c3-8286-2a574535ced0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48f4858f-99ee-447b-9c9d-31b1886d35d8" xlink:to="loc_us-gaap_OperatingLossCarryforwards_c0155f17-d522-49c3-8286-2a574535ced0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_71905108-4a9c-4457-af40-62c42ae949f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48f4858f-99ee-447b-9c9d-31b1886d35d8" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_71905108-4a9c-4457-af40-62c42ae949f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_805c17c0-8256-40b2-a046-f5c71b7317d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48f4858f-99ee-447b-9c9d-31b1886d35d8" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_805c17c0-8256-40b2-a046-f5c71b7317d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_f8e0522d-401b-4338-a09c-602f4ce30bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48f4858f-99ee-447b-9c9d-31b1886d35d8" xlink:to="loc_us-gaap_DeferredTaxLiabilities_f8e0522d-401b-4338-a09c-602f4ce30bbc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_0b9024d3-3dd2-4a3e-86c9-582ec18d2d01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48f4858f-99ee-447b-9c9d-31b1886d35d8" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_0b9024d3-3dd2-4a3e-86c9-582ec18d2d01" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CommitmentandContingenciesDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#CommitmentandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/CommitmentandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_554a2e34-c84d-4930-b8d6-4d0f301db549" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_1ae989f4-e36c-4cce-9ed6-10fb6c9d3da3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_554a2e34-c84d-4930-b8d6-4d0f301db549" xlink:to="loc_us-gaap_LossContingenciesTable_1ae989f4-e36c-4cce-9ed6-10fb6c9d3da3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9987e75a-b47a-4ebc-b352-8d90a2df1a57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1ae989f4-e36c-4cce-9ed6-10fb6c9d3da3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9987e75a-b47a-4ebc-b352-8d90a2df1a57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9987e75a-b47a-4ebc-b352-8d90a2df1a57_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9987e75a-b47a-4ebc-b352-8d90a2df1a57" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9987e75a-b47a-4ebc-b352-8d90a2df1a57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b0c16a72-b553-45b7-8385-bdb5a2387455" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9987e75a-b47a-4ebc-b352-8d90a2df1a57" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b0c16a72-b553-45b7-8385-bdb5a2387455" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_a3a60df6-3081-49c9-8580-05d4083c1e6d" xlink:href="nvax-20231231.xsd#nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b0c16a72-b553-45b7-8385-bdb5a2387455" xlink:to="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_a3a60df6-3081-49c9-8580-05d4083c1e6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementMember_65c76021-9afb-4c9a-8a84-c278d4d4cc84" xlink:href="nvax-20231231.xsd#nvax_SettlementAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b0c16a72-b553-45b7-8385-bdb5a2387455" xlink:to="loc_nvax_SettlementAgreementMember_65c76021-9afb-4c9a-8a84-c278d4d4cc84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_b0aab848-f84b-4c37-ad5f-95e55e31fac9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1ae989f4-e36c-4cce-9ed6-10fb6c9d3da3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_b0aab848-f84b-4c37-ad5f-95e55e31fac9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b0aab848-f84b-4c37-ad5f-95e55e31fac9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b0aab848-f84b-4c37-ad5f-95e55e31fac9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b0aab848-f84b-4c37-ad5f-95e55e31fac9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b0b258bc-134d-415a-abd6-8a67e342dcfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b0aab848-f84b-4c37-ad5f-95e55e31fac9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b0b258bc-134d-415a-abd6-8a67e342dcfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_f6852f24-f2bb-49d7-943f-5e0c03824b22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b0b258bc-134d-415a-abd6-8a67e342dcfe" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_f6852f24-f2bb-49d7-943f-5e0c03824b22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_18e985c7-8768-45bc-94e0-145365a2fecb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1ae989f4-e36c-4cce-9ed6-10fb6c9d3da3" xlink:to="loc_srt_StatementScenarioAxis_18e985c7-8768-45bc-94e0-145365a2fecb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_18e985c7-8768-45bc-94e0-145365a2fecb_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_18e985c7-8768-45bc-94e0-145365a2fecb" xlink:to="loc_srt_ScenarioUnspecifiedDomain_18e985c7-8768-45bc-94e0-145365a2fecb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_75864596-0656-491a-af4a-33ef14aee5f8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_18e985c7-8768-45bc-94e0-145365a2fecb" xlink:to="loc_srt_ScenarioUnspecifiedDomain_75864596-0656-491a-af4a-33ef14aee5f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_2d83594b-e779-4552-8206-ffe230d57e37" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_75864596-0656-491a-af4a-33ef14aee5f8" xlink:to="loc_srt_ScenarioForecastMember_2d83594b-e779-4552-8206-ffe230d57e37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8f6e25d8-7dfd-4527-ae42-2be59c652136" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1ae989f4-e36c-4cce-9ed6-10fb6c9d3da3" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8f6e25d8-7dfd-4527-ae42-2be59c652136" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8f6e25d8-7dfd-4527-ae42-2be59c652136_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8f6e25d8-7dfd-4527-ae42-2be59c652136" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8f6e25d8-7dfd-4527-ae42-2be59c652136_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2f4fac06-3d3a-4af0-8300-08c3a6f197d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8f6e25d8-7dfd-4527-ae42-2be59c652136" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2f4fac06-3d3a-4af0-8300-08c3a6f197d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ef48e220-384c-488a-ad5d-fd295742829d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2f4fac06-3d3a-4af0-8300-08c3a6f197d2" xlink:to="loc_us-gaap_SubsequentEventMember_ef48e220-384c-488a-ad5d-fd295742829d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfDefendants_1582aa04-2f25-4ab3-9efa-23d0839576d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNumberOfDefendants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_554a2e34-c84d-4930-b8d6-4d0f301db549" xlink:to="loc_us-gaap_LossContingencyNumberOfDefendants_1582aa04-2f25-4ab3-9efa-23d0839576d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LossContingencyPeriodToAnswer_d8f47e4b-2540-4eec-943d-66186eda28e9" xlink:href="nvax-20231231.xsd#nvax_LossContingencyPeriodToAnswer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_554a2e34-c84d-4930-b8d6-4d0f301db549" xlink:to="loc_nvax_LossContingencyPeriodToAnswer_d8f47e4b-2540-4eec-943d-66186eda28e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesToBeDistributed_726139e2-0a76-492d-88c7-2dd8c7d0a59f" xlink:href="nvax-20231231.xsd#nvax_NumberOfDosesToBeDistributed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_554a2e34-c84d-4930-b8d6-4d0f301db549" xlink:to="loc_nvax_NumberOfDosesToBeDistributed_726139e2-0a76-492d-88c7-2dd8c7d0a59f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfVaccineDoses_5a4e9260-98d9-45a7-98a9-e568b5bc1e3c" xlink:href="nvax-20231231.xsd#nvax_PurchaseAgreementNumberOfVaccineDoses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_554a2e34-c84d-4930-b8d6-4d0f301db549" xlink:to="loc_nvax_PurchaseAgreementNumberOfVaccineDoses_5a4e9260-98d9-45a7-98a9-e568b5bc1e3c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementRemainingPaymentAmount_4ae4c4b3-b589-4466-8be8-f8d61ac5c386" xlink:href="nvax-20231231.xsd#nvax_CollaborationAgreementRemainingPaymentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_554a2e34-c84d-4930-b8d6-4d0f301db549" xlink:to="loc_nvax_CollaborationAgreementRemainingPaymentAmount_4ae4c4b3-b589-4466-8be8-f8d61ac5c386" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ec4ea502-a2aa-4ef6-a50e-dd899234bb09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_554a2e34-c84d-4930-b8d6-4d0f301db549" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ec4ea502-a2aa-4ef6-a50e-dd899234bb09" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_40839979-9dfc-414b-9f9e-538e515d5291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_554a2e34-c84d-4930-b8d6-4d0f301db549" xlink:to="loc_us-gaap_LitigationSettlementExpense_40839979-9dfc-414b-9f9e-538e515d5291" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_f8c23884-65bb-4b2f-93a4-0c10229dcd1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_554a2e34-c84d-4930-b8d6-4d0f301db549" xlink:to="loc_us-gaap_GrantsReceivable_f8c23884-65bb-4b2f-93a4-0c10229dcd1e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementPayment_7e72e364-9b67-460d-965b-081dc0876924" xlink:href="nvax-20231231.xsd#nvax_SettlementPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_554a2e34-c84d-4930-b8d6-4d0f301db549" xlink:to="loc_nvax_SettlementPayment_7e72e364-9b67-460d-965b-081dc0876924" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfQuarterlyInstallmentPayments_6e850ff7-1de9-4457-aa8d-3a3d3451e130" xlink:href="nvax-20231231.xsd#nvax_NumberOfQuarterlyInstallmentPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_554a2e34-c84d-4930-b8d6-4d0f301db549" xlink:to="loc_nvax_NumberOfQuarterlyInstallmentPayments_6e850ff7-1de9-4457-aa8d-3a3d3451e130" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfSettlementPayments_ca426467-a3d5-414c-92f0-7cdccc955362" xlink:href="nvax-20231231.xsd#nvax_NumberOfSettlementPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_554a2e34-c84d-4930-b8d6-4d0f301db549" xlink:to="loc_nvax_NumberOfSettlementPayments_ca426467-a3d5-414c-92f0-7cdccc955362" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementQuarterlyInstallmentAmount_31e227f6-752b-40bd-824c-04ff9094bfb9" xlink:href="nvax-20231231.xsd#nvax_SettlementAgreementQuarterlyInstallmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_554a2e34-c84d-4930-b8d6-4d0f301db549" xlink:to="loc_nvax_SettlementAgreementQuarterlyInstallmentAmount_31e227f6-752b-40bd-824c-04ff9094bfb9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_0703b633-c3b8-47e4-946d-17b5c030378f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_554a2e34-c84d-4930-b8d6-4d0f301db549" xlink:to="loc_us-gaap_PurchaseObligation_0703b633-c3b8-47e4-946d-17b5c030378f" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RestructuringScheduleofImpairmentChargesDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#RestructuringScheduleofImpairmentChargesDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/RestructuringScheduleofImpairmentChargesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_c8cec2b1-7fea-40ad-8c64-dde5f0e0eb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bc5b818c-8da0-4752-a2e7-063ceac4135d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c8cec2b1-7fea-40ad-8c64-dde5f0e0eb7a" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bc5b818c-8da0-4752-a2e7-063ceac4135d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e21c8115-c35e-4414-b5c6-a82995bc56d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bc5b818c-8da0-4752-a2e7-063ceac4135d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e21c8115-c35e-4414-b5c6-a82995bc56d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e21c8115-c35e-4414-b5c6-a82995bc56d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e21c8115-c35e-4414-b5c6-a82995bc56d1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e21c8115-c35e-4414-b5c6-a82995bc56d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ad976387-0b3a-4622-b6ba-931e678ed1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e21c8115-c35e-4414-b5c6-a82995bc56d1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ad976387-0b3a-4622-b6ba-931e678ed1f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_07e20fab-bcb6-4a71-997d-eee3e960d0de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ad976387-0b3a-4622-b6ba-931e678ed1f5" xlink:to="loc_us-gaap_CostOfSalesMember_07e20fab-bcb6-4a71-997d-eee3e960d0de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a8020c13-be9e-4e35-b4b9-2cf76da0c261" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ad976387-0b3a-4622-b6ba-931e678ed1f5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a8020c13-be9e-4e35-b4b9-2cf76da0c261" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_159eb37e-2959-4703-9652-7f845eae2cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ad976387-0b3a-4622-b6ba-931e678ed1f5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_159eb37e-2959-4703-9652-7f845eae2cd8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_16dab8e8-e155-4d15-92e9-c02ee92076ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c8cec2b1-7fea-40ad-8c64-dde5f0e0eb7a" xlink:to="loc_us-gaap_SeveranceCosts1_16dab8e8-e155-4d15-92e9-c02ee92076ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_68965667-cbee-4b7c-aa49-d57ad1815be4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c8cec2b1-7fea-40ad-8c64-dde5f0e0eb7a" xlink:to="loc_us-gaap_AssetImpairmentCharges_68965667-cbee-4b7c-aa49-d57ad1815be4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_c73705af-00d7-4d02-950b-f1c0f31dca93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c8cec2b1-7fea-40ad-8c64-dde5f0e0eb7a" xlink:to="loc_us-gaap_RestructuringCharges_c73705af-00d7-4d02-950b-f1c0f31dca93" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#RestructuringNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/RestructuringNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_70da10e6-ab08-403d-a189-00a8282aadf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c3ff20ca-36ba-4058-a12b-2e47119b875e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_70da10e6-ab08-403d-a189-00a8282aadf8" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c3ff20ca-36ba-4058-a12b-2e47119b875e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_4f035e36-8dbb-47a1-b67d-f4a250acc5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c3ff20ca-36ba-4058-a12b-2e47119b875e" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_4f035e36-8dbb-47a1-b67d-f4a250acc5f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_4f035e36-8dbb-47a1-b67d-f4a250acc5f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_4f035e36-8dbb-47a1-b67d-f4a250acc5f0" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_4f035e36-8dbb-47a1-b67d-f4a250acc5f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_e64f2491-af09-41e0-8769-cecbb5d7b3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_4f035e36-8dbb-47a1-b67d-f4a250acc5f0" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_e64f2491-af09-41e0-8769-cecbb5d7b3a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_9220c1d3-89dd-4434-b331-db43d8d60948" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e64f2491-af09-41e0-8769-cecbb5d7b3a4" xlink:to="loc_us-gaap_EmployeeSeveranceMember_9220c1d3-89dd-4434-b331-db43d8d60948" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseImpairmentChargeAxis_85725439-662a-4e03-9d3f-2bbc978340ad" xlink:href="nvax-20231231.xsd#nvax_LeaseImpairmentChargeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c3ff20ca-36ba-4058-a12b-2e47119b875e" xlink:to="loc_nvax_LeaseImpairmentChargeAxis_85725439-662a-4e03-9d3f-2bbc978340ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseImpairmentChargeDomain_85725439-662a-4e03-9d3f-2bbc978340ad_default" xlink:href="nvax-20231231.xsd#nvax_LeaseImpairmentChargeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nvax_LeaseImpairmentChargeAxis_85725439-662a-4e03-9d3f-2bbc978340ad" xlink:to="loc_nvax_LeaseImpairmentChargeDomain_85725439-662a-4e03-9d3f-2bbc978340ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseImpairmentChargeDomain_8dad07b0-998c-45c0-8732-aedf5e3688b6" xlink:href="nvax-20231231.xsd#nvax_LeaseImpairmentChargeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nvax_LeaseImpairmentChargeAxis_85725439-662a-4e03-9d3f-2bbc978340ad" xlink:to="loc_nvax_LeaseImpairmentChargeDomain_8dad07b0-998c-45c0-8732-aedf5e3688b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ROUFacilityLeasesMember_1eac6580-05ad-4357-9fb4-412dac59f50c" xlink:href="nvax-20231231.xsd#nvax_ROUFacilityLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nvax_LeaseImpairmentChargeDomain_8dad07b0-998c-45c0-8732-aedf5e3688b6" xlink:to="loc_nvax_ROUFacilityLeasesMember_1eac6580-05ad-4357-9fb4-412dac59f50c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_b15bf761-32fd-4b3a-b68c-eddf4011ade9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_70da10e6-ab08-403d-a189-00a8282aadf8" xlink:to="loc_us-gaap_SeveranceCosts1_b15bf761-32fd-4b3a-b68c-eddf4011ade9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_4162fda5-6fa4-4161-8086-88e66ad26e44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_70da10e6-ab08-403d-a189-00a8282aadf8" xlink:to="loc_us-gaap_AssetImpairmentCharges_4162fda5-6fa4-4161-8086-88e66ad26e44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_fbe2a91c-f1ee-436d-9619-2089e9153cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_70da10e6-ab08-403d-a189-00a8282aadf8" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_fbe2a91c-f1ee-436d-9619-2089e9153cc4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.novavax.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_21a36f47-a828-4481-ae25-28214dbef9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_5af27726-94b1-4a6c-a1f4-55f5008b8d71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_21a36f47-a828-4481-ae25-28214dbef9a0" xlink:to="loc_us-gaap_SubsequentEventTable_5af27726-94b1-4a6c-a1f4-55f5008b8d71" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3dc4cb21-ce41-43e6-802c-f37cd6f0aa28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5af27726-94b1-4a6c-a1f4-55f5008b8d71" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3dc4cb21-ce41-43e6-802c-f37cd6f0aa28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3dc4cb21-ce41-43e6-802c-f37cd6f0aa28_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3dc4cb21-ce41-43e6-802c-f37cd6f0aa28" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3dc4cb21-ce41-43e6-802c-f37cd6f0aa28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_34af4ccb-bc45-4c4e-8e7d-615a1edc78ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3dc4cb21-ce41-43e6-802c-f37cd6f0aa28" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_34af4ccb-bc45-4c4e-8e7d-615a1edc78ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_32d42d28-af7a-42ec-ae62-ff53c2c07f80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_34af4ccb-bc45-4c4e-8e7d-615a1edc78ae" xlink:to="loc_us-gaap_SubsequentEventMember_32d42d28-af7a-42ec-ae62-ff53c2c07f80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RestructuringAndRelatedCostNumberOfPositionsEliminatedGlobalPercent_a74af135-16c4-413a-8556-d910b42bef11" xlink:href="nvax-20231231.xsd#nvax_RestructuringAndRelatedCostNumberOfPositionsEliminatedGlobalPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_21a36f47-a828-4481-ae25-28214dbef9a0" xlink:to="loc_nvax_RestructuringAndRelatedCostNumberOfPositionsEliminatedGlobalPercent_a74af135-16c4-413a-8556-d910b42bef11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_dee3e4bb-77e7-49af-a35a-f73882d17b78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_21a36f47-a828-4481-ae25-28214dbef9a0" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_dee3e4bb-77e7-49af-a35a-f73882d17b78" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseRightOfUseAsset_0820f771-4a13-4df9-a8c7-2f47791384b0" xlink:href="nvax-20231231.xsd#nvax_LeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_nvax_LeaseRightOfUseAsset_0820f771-4a13-4df9-a8c7-2f47791384b0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockMember" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FilipDubovskyMDMember_f6bce82a-4467-49c8-9245-9f0553996d7d" xlink:href="nvax-20231231.xsd#nvax_FilipDubovskyMDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_nvax_FilipDubovskyMDMember_f6bce82a-4467-49c8-9245-9f0553996d7d" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>21
<FILENAME>nvax-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:02f62cea-2ee5-4f46-a427-e5f89894c0b1,g:b653a9b6-e98d-435f-a6cb-06522e8cacbf-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_d993a173-f974-4151-9d12-d516f57af804_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_d0543297-58fa-466b-b86c-174db9fb84cc_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_5d1459ca-0117-48e5-9175-690895fbccf9_periodStartLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at January 1,</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_eaed36c7-5d35-4a27-83ef-064ffdd96843_periodEndLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31,</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_FacilityLeaseAgreementMember_d8a634a8-8483-4727-807c-ca4ffc152bcb_terseLabel_en-US" xlink:label="lab_nvax_FacilityLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Lease Agreement</link:label>
    <link:label id="lab_nvax_FacilityLeaseAgreementMember_label_en-US" xlink:label="lab_nvax_FacilityLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Lease Agreement [Member]</link:label>
    <link:label id="lab_nvax_FacilityLeaseAgreementMember_documentation_en-US" xlink:label="lab_nvax_FacilityLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Lease Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FacilityLeaseAgreementMember" xlink:href="nvax-20231231.xsd#nvax_FacilityLeaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_FacilityLeaseAgreementMember" xlink:to="lab_nvax_FacilityLeaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_EuropeanCommissionsECMember_71cfd57b-5050-4cc5-b9bf-4b3584f0ed35_terseLabel_en-US" xlink:label="lab_nvax_EuropeanCommissionsECMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Commissions ("EC")</link:label>
    <link:label id="lab_nvax_EuropeanCommissionsECMember_label_en-US" xlink:label="lab_nvax_EuropeanCommissionsECMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Commissions ("EC") [Member]</link:label>
    <link:label id="lab_nvax_EuropeanCommissionsECMember_documentation_en-US" xlink:label="lab_nvax_EuropeanCommissionsECMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Commissions ("EC")</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EuropeanCommissionsECMember" xlink:href="nvax-20231231.xsd#nvax_EuropeanCommissionsECMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_EuropeanCommissionsECMember" xlink:to="lab_nvax_EuropeanCommissionsECMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_00affc74-b063-44d9-9e84-fe1a648d66b4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fd5a7554-d7f7-46a7-a62b-94ff70ef8465_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_7892b0f8-2124-495e-be40-a2a26a437bce_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment award, terms of award</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption_1551cdf7-d134-4814-8420-d3b37b40d133_terseLabel_en-US" xlink:label="lab_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional purchase option, number of doses</link:label>
    <link:label id="lab_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption_label_en-US" xlink:label="lab_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Doses Of Vaccine Candidate, Additional Purchase Option</link:label>
    <link:label id="lab_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption_documentation_en-US" xlink:label="lab_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Doses Of Vaccine Candidate, Additional Purchase Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption" xlink:href="nvax-20231231.xsd#nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption" xlink:to="lab_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_RestructuringAndRelatedCostNumberOfPositionsEliminatedGlobalPercent_eb9bf0ad-91cb-4743-ad3f-6f7f645a830f_terseLabel_en-US" xlink:label="lab_nvax_RestructuringAndRelatedCostNumberOfPositionsEliminatedGlobalPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global workforce percent</link:label>
    <link:label id="lab_nvax_RestructuringAndRelatedCostNumberOfPositionsEliminatedGlobalPercent_label_en-US" xlink:label="lab_nvax_RestructuringAndRelatedCostNumberOfPositionsEliminatedGlobalPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Global Percent</link:label>
    <link:label id="lab_nvax_RestructuringAndRelatedCostNumberOfPositionsEliminatedGlobalPercent_documentation_en-US" xlink:label="lab_nvax_RestructuringAndRelatedCostNumberOfPositionsEliminatedGlobalPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Global Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RestructuringAndRelatedCostNumberOfPositionsEliminatedGlobalPercent" xlink:href="nvax-20231231.xsd#nvax_RestructuringAndRelatedCostNumberOfPositionsEliminatedGlobalPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_RestructuringAndRelatedCostNumberOfPositionsEliminatedGlobalPercent" xlink:to="lab_nvax_RestructuringAndRelatedCostNumberOfPositionsEliminatedGlobalPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_FirstThreePercentOfParticipantsDeferralMemberMember_cf39f510-d4f8-4fef-a16d-a2ef2ba78c5b_terseLabel_en-US" xlink:label="lab_nvax_FirstThreePercentOfParticipantsDeferralMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Three Percent Of Participants Deferral</link:label>
    <link:label id="lab_nvax_FirstThreePercentOfParticipantsDeferralMemberMember_label_en-US" xlink:label="lab_nvax_FirstThreePercentOfParticipantsDeferralMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Three Percent Of Participants Deferral Member [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FirstThreePercentOfParticipantsDeferralMemberMember" xlink:href="nvax-20231231.xsd#nvax_FirstThreePercentOfParticipantsDeferralMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_FirstThreePercentOfParticipantsDeferralMemberMember" xlink:to="lab_nvax_FirstThreePercentOfParticipantsDeferralMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02e44a78-315c-4a6a-80a9-aa2026be7955_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_b8510978-c493-4fae-ad67-a2974efced71_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_add73bcf-e104-4cfe-a001-095d5a2f9ab1_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_InventoryReserveRollForward_2987862b-e2cb-4d1d-95e5-234537171394_terseLabel_en-US" xlink:label="lab_nvax_InventoryReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Reserve [Roll Forward]</link:label>
    <link:label id="lab_nvax_InventoryReserveRollForward_label_en-US" xlink:label="lab_nvax_InventoryReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Reserve [Roll Forward]</link:label>
    <link:label id="lab_nvax_InventoryReserveRollForward_documentation_en-US" xlink:label="lab_nvax_InventoryReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InventoryReserveRollForward" xlink:href="nvax-20231231.xsd#nvax_InventoryReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_InventoryReserveRollForward" xlink:to="lab_nvax_InventoryReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance_a59df585-63b0-4432-996a-5c0ade5cda65_terseLabel_en-US" xlink:label="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for issuance (in shares)</link:label>
    <link:label id="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance_label_en-US" xlink:label="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number of Shares Available For Issuance</link:label>
    <link:label id="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance_documentation_en-US" xlink:label="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number of Shares Available For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance" xlink:href="nvax-20231231.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance" xlink:to="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CommonStockQuotedMarketPrice_ad7cb7c2-07e8-4486-9668-599e8ef75ce6_terseLabel_en-US" xlink:label="lab_nvax_CommonStockQuotedMarketPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, quoted market price</link:label>
    <link:label id="lab_nvax_CommonStockQuotedMarketPrice_label_en-US" xlink:label="lab_nvax_CommonStockQuotedMarketPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, Quoted Market Price</link:label>
    <link:label id="lab_nvax_CommonStockQuotedMarketPrice_documentation_en-US" xlink:label="lab_nvax_CommonStockQuotedMarketPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, Quoted Market Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CommonStockQuotedMarketPrice" xlink:href="nvax-20231231.xsd#nvax_CommonStockQuotedMarketPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CommonStockQuotedMarketPrice" xlink:to="lab_nvax_CommonStockQuotedMarketPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_19a06d1d-30e9-44d8-a22a-893f2cc699e9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares exercisable at end of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_7f972986-eb53-4312-acd5-05d8fd9f65f9_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_18f213a0-603f-4c86-832a-a54645d65eb1_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4106d40c-62f3-4962-8c22-0f73821e72eb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_bc634dd7-dd77-491e-a3ca-53f211e305e3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; Deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_bc8e0d40-c947-4923-9767-879029f07bcc_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_InventoryReserveOtherAdditions_d2759593-45ed-4b9b-a8df-ec5674721a9e_terseLabel_en-US" xlink:label="lab_nvax_InventoryReserveOtherAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other additions</link:label>
    <link:label id="lab_nvax_InventoryReserveOtherAdditions_label_en-US" xlink:label="lab_nvax_InventoryReserveOtherAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Reserve, Other Additions</link:label>
    <link:label id="lab_nvax_InventoryReserveOtherAdditions_documentation_en-US" xlink:label="lab_nvax_InventoryReserveOtherAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Reserve, Other Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InventoryReserveOtherAdditions" xlink:href="nvax-20231231.xsd#nvax_InventoryReserveOtherAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_InventoryReserveOtherAdditions" xlink:to="lab_nvax_InventoryReserveOtherAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_fe00902f-fa62-433a-9cbf-d692c4c365b4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_30479940-4cbd-41ee-9f8f-e79ebba22648_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total convertible notes payable</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_SecuritiesSubscriptionArrangementMember_0639143f-25d3-4ef2-b147-8caf8e659238_terseLabel_en-US" xlink:label="lab_nvax_SecuritiesSubscriptionArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Subscription Arrangement</link:label>
    <link:label id="lab_nvax_SecuritiesSubscriptionArrangementMember_label_en-US" xlink:label="lab_nvax_SecuritiesSubscriptionArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Subscription Arrangement [Member]</link:label>
    <link:label id="lab_nvax_SecuritiesSubscriptionArrangementMember_documentation_en-US" xlink:label="lab_nvax_SecuritiesSubscriptionArrangementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Subscription Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SecuritiesSubscriptionArrangementMember" xlink:href="nvax-20231231.xsd#nvax_SecuritiesSubscriptionArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_SecuritiesSubscriptionArrangementMember" xlink:to="lab_nvax_SecuritiesSubscriptionArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_0abf1d1e-7a7f-4b41-ba00-0ad657adc9ab_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_d0d74c61-aec4-4dce-815c-906a9f299fb7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_6aad3dd6-d7aa-4734-b04f-25bc3e7b4bc1_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.01 par value, 2,000,000 shares authorized at December&#160;31, 2023 and 2022; no shares issued and outstanding at December&#160;31, 2023 and 2022</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_77b64d47-0fa3-4503-a8a6-a208e0a5b07d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_bb6ed3f8-2fb7-4edc-b60e-3effc040c60e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities_0763d86c-2e95-4f4c-86fb-99541160fe45_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements of tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandAndLandImprovementsMember_aa26a608-e18b-4a3d-ad56-deb030bf2ce1_terseLabel_en-US" xlink:label="lab_us-gaap_LandAndLandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land and buildings</link:label>
    <link:label id="lab_us-gaap_LandAndLandImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LandAndLandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land and Land Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandAndLandImprovementsMember" xlink:to="lab_us-gaap_LandAndLandImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_51230707-761e-405b-88c4-3d80de5e608a_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_LeaseImpairmentChargeAxis_84e1530f-3f61-4ad0-b128-b43e7fc6e87f_terseLabel_en-US" xlink:label="lab_nvax_LeaseImpairmentChargeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Impairment Charge [Axis]</link:label>
    <link:label id="lab_nvax_LeaseImpairmentChargeAxis_label_en-US" xlink:label="lab_nvax_LeaseImpairmentChargeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Impairment Charge [Axis]</link:label>
    <link:label id="lab_nvax_LeaseImpairmentChargeAxis_documentation_en-US" xlink:label="lab_nvax_LeaseImpairmentChargeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Impairment Charge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseImpairmentChargeAxis" xlink:href="nvax-20231231.xsd#nvax_LeaseImpairmentChargeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_LeaseImpairmentChargeAxis" xlink:to="lab_nvax_LeaseImpairmentChargeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_313d1b38-7284-4c0d-8929-628af6be94ed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d9e12f42-a5cf-4562-89aa-6cf72776e404_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_5283e23d-fc4e-4d2f-9cfc-2b6c34e5f139_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_6cacbee3-9e24-47df-bc98-f5aa5eb75b48_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_59acd22a-fe82-42f0-afec-384c923ab917_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_d57a523a-8684-47bc-9227-cf2984b68505_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_5ba6e036-e2b5-410e-bf1b-512e42c20151_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; deficit:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_75e22e16-4e58-44ef-a2e1-7119cfffc751_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_21a36f11-c22f-449f-8a92-ce9f8f29e50a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_3f99fe47-3437-430c-85d8-4b15f0ff1ae9_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_91457204-2cd5-4183-ac36-8d4526b08a76_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_cc3ac5c9-d311-48eb-a63a-19cadeae74a3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease_f745a833-21d0-48be-b42e-10d2d769fc2f_terseLabel_en-US" xlink:label="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage increase of shares each anniversary</link:label>
    <link:label id="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease_label_en-US" xlink:label="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Annual Increase</link:label>
    <link:label id="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease_documentation_en-US" xlink:label="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Annual Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" xlink:href="nvax-20231231.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" xlink:to="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3430cab1-985b-4621-9e1c-a089be60bf96_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b3176b51-6b21-4ee1-b84d-38167ff80e99_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_bcccdb6e-4cc8-4786-bb54-d742f1c101c5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_2008e613-9439-4260-a165-429402fde7f9_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_d199a8f4-5905-40c1-89cf-a19cb3a2dae4_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_0be2c960-ac31-484e-b3db-c0bdefa38bb3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_ef9e54ab-6eee-4a79-9a56-af4c42023a3a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7408d809-7b16-44a2-b453-905e9dd93b29_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_124f0219-7e85-4f17-bb18-ae0f34a67f7d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_fd9d2ec5-07e0-4042-ac81-ee171f317eed_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_12c7aeb6-bea0-4687-8b94-2a1f9dddc6e5_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_SummaryOfSignificantAccountingPoliciesLineItems_cd3ca539-b5b3-4d87-a917-acea8d82f48b_terseLabel_en-US" xlink:label="lab_nvax_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_nvax_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_nvax_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="nvax-20231231.xsd#nvax_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_nvax_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_4dc97782-62d4-4b52-9700-eda4bd499a1e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations_4eb3f79e-b9ae-4d36-9ceb-4abe855bc551_terseLabel_en-US" xlink:label="lab_nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. taxation of foreign operations</link:label>
    <link:label id="lab_nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations_label_en-US" xlink:label="lab_nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, US Taxation Of Foreign Operations</link:label>
    <link:label id="lab_nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations_documentation_en-US" xlink:label="lab_nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, US Taxation Of Foreign Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations" xlink:href="nvax-20231231.xsd#nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations" xlink:to="lab_nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_3dd37894-0217-4eb5-9b40-62097d718f63_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_637245ef-cf01-406e-8039-8763d6be3ccc_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_6b7a50cc-7a6f-4106-9a54-9b0af9c4f3d4_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_f4ae481c-a52a-4099-9842-a0b012dee3bd_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_eade6d1e-876f-4581-a88b-78ccedccf5f4_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_90eeec3c-fdcc-4fa8-9e88-dc46b42ccc02_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ComputerSoftwareAndHardwareMemberMember_bec28f30-2432-4610-a92c-6e3f3ee325cc_terseLabel_en-US" xlink:label="lab_nvax_ComputerSoftwareAndHardwareMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer hardware</link:label>
    <link:label id="lab_nvax_ComputerSoftwareAndHardwareMemberMember_label_en-US" xlink:label="lab_nvax_ComputerSoftwareAndHardwareMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software And Hardware Member [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ComputerSoftwareAndHardwareMemberMember" xlink:href="nvax-20231231.xsd#nvax_ComputerSoftwareAndHardwareMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ComputerSoftwareAndHardwareMemberMember" xlink:to="lab_nvax_ComputerSoftwareAndHardwareMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_d1ba85bf-a4c0-4964-82df-19a021111e52_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development and other tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0d1d330c-5d62-48dc-811b-f5cf00400415_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_20765542-5a31-4808-9de9-4044805f2afd_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_8e3c3b6e-2ecf-4b93-8e2e-7106f4395664_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_f0b8c97c-5547-4480-a028-01ff2bbe1920_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_be655ee3-b5be-4b7c-bc61-914e9f2ab521_netLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_f0ffef64-5478-47d8-8f02-efb813bc18a7_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_763066c9-e671-4ffe-83c5-b27b03e78a04_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total interest expense on convertible notes payable</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_b41d6b1a-5e54-4628-ae8a-d0d7fe35631a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_810974dd-0f4e-4a04-b61e-8fc03d6799c6_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CanadaRevenueAgencyMember_2773428d-f51f-4b19-80ab-37d055b12168_terseLabel_en-US" xlink:label="lab_us-gaap_CanadaRevenueAgencyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada Revenue Agency</link:label>
    <link:label id="lab_us-gaap_CanadaRevenueAgencyMember_label_en-US" xlink:label="lab_us-gaap_CanadaRevenueAgencyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada Revenue Agency [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CanadaRevenueAgencyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CanadaRevenueAgencyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CanadaRevenueAgencyMember" xlink:to="lab_us-gaap_CanadaRevenueAgencyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_98d4cf12-7766-459e-9896-85378b1f7e4a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b0702eb8-d55d-4237-b5ee-e0c3c35fb688_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_961839c5-05ac-449a-8ccc-9b69373059d2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_6e7afea5-1903-463f-84c0-33e3e1e00546_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_2cb37490-f5f6-4f5b-ac81-b8b587849d9a_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_03f9d351-c8e6-45ce-b6ee-714a0b8c1cfc_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_69d4fea4-ce20-4fcc-a3e1-cf1961cb569f_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU assets obtained in exchange for operating lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_8caf1a8d-4e1f-4193-a3d3-5f42b0a6cfca_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts:</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_48240834-28e1-4525-8755-01b45d9b8dc9_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_830f2b7a-e6bc-4938-8cdd-1ddbeeff13df_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6448f5b4-166e-4172-b00b-b173f584e27a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_b9119b78-329a-4007-8b8a-f3be166ef09e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_f284e9b0-be26-4094-ba42-023b4d3c6482_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_GovernmentOfIsraelMember_9e4d6b48-7701-4988-b429-efacef84833d_terseLabel_en-US" xlink:label="lab_nvax_GovernmentOfIsraelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government of Israel</link:label>
    <link:label id="lab_nvax_GovernmentOfIsraelMember_label_en-US" xlink:label="lab_nvax_GovernmentOfIsraelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government of Israel [Member]</link:label>
    <link:label id="lab_nvax_GovernmentOfIsraelMember_documentation_en-US" xlink:label="lab_nvax_GovernmentOfIsraelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government of Israel</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GovernmentOfIsraelMember" xlink:href="nvax-20231231.xsd#nvax_GovernmentOfIsraelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_GovernmentOfIsraelMember" xlink:to="lab_nvax_GovernmentOfIsraelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_e0446e9d-c25d-494e-a96a-448da82c9081_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7afff0cf-2d5f-4959-9981-75a4b0b748c0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset_28c570da-79a3-465d-bd0d-d2aab3822fa2_terseLabel_en-US" xlink:label="lab_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets from new lease agreements</link:label>
    <link:label id="lab_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash Related Transactions For Finance Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash Related Transactions For Finance Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" xlink:href="nvax-20231231.xsd#nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" xlink:to="lab_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_5f66f738-6006-45f4-a559-b782d797b6cb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3698c9c1-6d50-4e72-b303-25f14c0732b5_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfDefendants_d0e34764-042e-4320-bcb4-088a12e8fde0_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfDefendants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of defendants</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfDefendants_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfDefendants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Defendants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfDefendants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNumberOfDefendants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfDefendants" xlink:to="lab_us-gaap_LossContingencyNumberOfDefendants" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_1b1e6abe-0d18-42a5-afe0-2982f51aac82_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_64790a95-4f30-4c45-8091-f5a5d8a674d7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableGross_371b1dc9-73bf-4bfa-a778-f9a912ee3343_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGross" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, beginning balance</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGross_a81a6a72-89fa-488b-9f01-094d8cfe7974_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGross" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, ending balance</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGross_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGross" xlink:to="lab_us-gaap_AccountsReceivableGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_a51fe6be-b15e-43c5-8b2f-2741d9b0658f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_c6517b3d-ab05-465c-b365-fa09501b2ae7_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_8d733af9-7ed8-47c5-a8a9-36e34fe7bdbb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_7b686a42-6ca3-431c-adbf-73d0c176baf3_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_0e291d39-f592-442d-88f5-8481fcee21f5_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7fdc779f-8fa3-4c3d-955d-2b185f1abd06_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions Used in Estimation of Fair Value of Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_07371ac3-09a0-46e4-9d8b-5ef3f62dda5c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram_400d6d6c-0600-4fff-9170-c3e5c1862308_terseLabel_en-US" xlink:label="lab_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued under incentive programs (in shares)</link:label>
    <link:label id="lab_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram_label_en-US" xlink:label="lab_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Stock Issued Under Incentive Program</link:label>
    <link:label id="lab_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram_documentation_en-US" xlink:label="lab_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Stock Issued Under Incentive Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram" xlink:href="nvax-20231231.xsd#nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram" xlink:to="lab_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fec999ae-c750-4fc7-bb21-9dd38fb33ba7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_28183f23-123f-46f1-88c0-9c8a22143486_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration, License, and Supply Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_4e46f97b-b8e8-4ca6-8cad-0b8094a23e61_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_LossContingencyPeriodToAnswer_b7f6a142-b7df-4c24-a59e-a20d2beb2c90_terseLabel_en-US" xlink:label="lab_nvax_LossContingencyPeriodToAnswer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period to answer</link:label>
    <link:label id="lab_nvax_LossContingencyPeriodToAnswer_label_en-US" xlink:label="lab_nvax_LossContingencyPeriodToAnswer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Period To Answer</link:label>
    <link:label id="lab_nvax_LossContingencyPeriodToAnswer_documentation_en-US" xlink:label="lab_nvax_LossContingencyPeriodToAnswer" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Period To Answer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LossContingencyPeriodToAnswer" xlink:href="nvax-20231231.xsd#nvax_LossContingencyPeriodToAnswer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_LossContingencyPeriodToAnswer" xlink:to="lab_nvax_LossContingencyPeriodToAnswer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_788b5e1c-0172-42c7-a4ab-3e8ca22216e4_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_d5f5f914-2885-4835-b42c-d4b6e64632bd_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_24416f5b-05da-4e45-85b5-a2e2a65b6e76_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e341b414-9e74-43de-9759-f34b3ddf88cc_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e5109a39-786c-41b0-b018-02d3e5ff0664_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_DeferredTaxAssetLeasingLiability_fdf8fda5-c1f7-42d8-bf5c-ae7ee038eea3_terseLabel_en-US" xlink:label="lab_nvax_DeferredTaxAssetLeasingLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_nvax_DeferredTaxAssetLeasingLiability_label_en-US" xlink:label="lab_nvax_DeferredTaxAssetLeasingLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Leasing Liability</link:label>
    <link:label id="lab_nvax_DeferredTaxAssetLeasingLiability_documentation_en-US" xlink:label="lab_nvax_DeferredTaxAssetLeasingLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Leasing Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DeferredTaxAssetLeasingLiability" xlink:href="nvax-20231231.xsd#nvax_DeferredTaxAssetLeasingLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_DeferredTaxAssetLeasingLiability" xlink:to="lab_nvax_DeferredTaxAssetLeasingLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_34be4bd8-3b88-49e8-b4f8-7d22516d544a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Related Commitment Fees and Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:to="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_c2a0d5c9-3043-44ce-a90a-1ec031c39b57_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantsReceivable_3733e66b-0546-4887-96d7-932ff0ccfcb7_terseLabel_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants additional credit</link:label>
    <link:label id="lab_us-gaap_GrantsReceivable_label_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantsReceivable" xlink:to="lab_us-gaap_GrantsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a8256f09-e3f9-43e5-b483-069395335a5d_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_09abe96e-2862-4f82-920b-26ca92343581_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2e932db3-4d38-4034-aaef-a117d85d4354_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_1a5e4f83-6b1a-406d-86ee-846531da7ac2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other items, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_MilestonePaymentsMember_e4ecb499-a8e3-4a07-9dd0-8559eda9b09b_terseLabel_en-US" xlink:label="lab_nvax_MilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments</link:label>
    <link:label id="lab_nvax_MilestonePaymentsMember_label_en-US" xlink:label="lab_nvax_MilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments [Member]</link:label>
    <link:label id="lab_nvax_MilestonePaymentsMember_documentation_en-US" xlink:label="lab_nvax_MilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_MilestonePaymentsMember" xlink:href="nvax-20231231.xsd#nvax_MilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_MilestonePaymentsMember" xlink:to="lab_nvax_MilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_2bbba22d-9fc0-4bf9-8f71-3712cdedac4c_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c49edf20-29ea-45e2-9cb7-c5f180421dbd_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued expenses, and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_9c873a1e-5e8b-4b08-b359-68c117896634_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_75716ce4-ab81-49e5-9b84-bafde612bbb6_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_230a6d26-1ea5-4243-8b2d-0ef29577108e_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_d8e26425-432e-450a-96ee-6a7f461415af_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_2256792e-ee69-47dd-8080-44703b445551_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMultiemployerPlansTable_2557ffec-0bbd-4d73-8bc8-0333d65edf9c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMultiemployerPlansTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Multiemployer Plan [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMultiemployerPlansTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMultiemployerPlansTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Multiemployer Plan [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMultiemployerPlansTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMultiemployerPlansTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMultiemployerPlansTable" xlink:to="lab_us-gaap_ScheduleOfMultiemployerPlansTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f523e256-6169-4261-81f9-372b70b70502_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding and unvested at beginning of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6b638598-7f3a-41e5-b46c-2e84f6fe2a45_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding and unvested at end of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_204492ce-0fd5-414a-a660-0dad18b76c49_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fd071b71-2503-4ee9-a708-7cf85362df74_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f92ecfab-e339-447c-acde-c72dae577a2b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_9581cf5a-5789-4be0-86b8-c1d5942a155a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_467479d5-f9b1-4fb6-ae55-1b0d4435ef70_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total finance lease expense</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_f63a923e-5183-48f4-800d-4b1cf3ad317a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued for debt converted (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_aa01923b-6878-46f7-bda9-8d57288625a6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory reserve</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_970d64d8-fb83-47cd-8450-44f19c4a29be_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_15a34b18-fba5-4d26-ab58-2c95d5e7a4fa_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation capitalized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_923680d7-2ff5-4d0d-893c-376896d8422c_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_991b8dc2-61de-43b1-8df2-5e2c44c1997b_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coupon interest</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_d70a5d0b-d8a3-4ab4-99c1-66d69c280fc4_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_22c678e4-fbff-4fa0-b564-b4a4b729886c_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ContractWithCustomerLiabilityDeductions_d8454ffd-f215-4de4-bfe6-238a20a9a79f_negatedTerseLabel_en-US" xlink:label="lab_nvax_ContractWithCustomerLiabilityDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_nvax_ContractWithCustomerLiabilityDeductions_label_en-US" xlink:label="lab_nvax_ContractWithCustomerLiabilityDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Deductions</link:label>
    <link:label id="lab_nvax_ContractWithCustomerLiabilityDeductions_documentation_en-US" xlink:label="lab_nvax_ContractWithCustomerLiabilityDeductions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Deductions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ContractWithCustomerLiabilityDeductions" xlink:href="nvax-20231231.xsd#nvax_ContractWithCustomerLiabilityDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ContractWithCustomerLiabilityDeductions" xlink:to="lab_nvax_ContractWithCustomerLiabilityDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_cfd78cb5-9d32-4cb0-951b-fe84102bad32_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_9b3a91e2-f07c-45cf-9b07-d516c236f5ec_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_384b1862-325f-41f9-9811-66137652c739_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_0ae18e01-b61b-4f01-a994-afba65b859c3_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5dfa2705-429c-480d-94f5-b247cec4940c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a7ad65d8-60d2-4ea4-9c85-f5c4c958dda0_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_721fd46b-35ce-4b5d-bcab-38a01d3b12b2_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_fbf1c401-e6ea-46a4-85f9-c47e596d127f_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_7502ac4e-2567-4588-8ac8-3f34770aae88_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets (Liabilities)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_896d912a-7742-486a-a92e-75bb127bff94_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_0853620f-2144-4a61-badc-17d573fed4cf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows used in operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_df6c2605-a8bd-4f71-9dc7-aaf5817a825f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9fed8db5-01b2-4d4f-9d72-ba2c2e3a13b8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ec0d1c63-277d-444e-9513-af0e6e8beeca_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance ending (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_836022d9-adb4-45ad-8756-9b2b8a9f23e4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, impairment loss</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions_83424130-3f98-4b09-b1b8-03c1d6634f3b_negatedTerseLabel_en-US" xlink:label="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions_label_en-US" xlink:label="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Before Allowance For Credit Loss, Deductions</link:label>
    <link:label id="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions_documentation_en-US" xlink:label="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Before Allowance For Credit Loss, Deductions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions" xlink:href="nvax-20231231.xsd#nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions" xlink:to="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_ad5457d8-cf8d-46b3-bf4f-dd5b15dbf9e0_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_e2fd0c1a-03b4-4d81-8de6-1577beaa3614_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_842b5eb5-06df-406a-9d00-7604c5600b41_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_cf3f894b-4997-458b-aab0-62a03d1bd966_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefits</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableCurrent_94f41dc9-c575-4c32-8ca8-c9d17f3007c2_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableCurrent_87e5e65d-b0a7-4515-8961-2c544348b80f_totalLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current convertible notes payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableCurrent" xlink:to="lab_us-gaap_ConvertibleNotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_66fa646d-caa6-46c5-b1fc-1886a494f365_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_c8cd8a97-4d8c-4398-a459-5aab1b3da3f0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold percentage of stock price</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract_a50cd520-9f13-4cde-9df7-8a751eb682f8_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Pension and Other Postretirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Pension and Other Postretirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CallOptionMember_7a17cbd3-85c0-4acf-bb95-8b6beb366971_terseLabel_en-US" xlink:label="lab_us-gaap_CallOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call Option</link:label>
    <link:label id="lab_us-gaap_CallOptionMember_label_en-US" xlink:label="lab_us-gaap_CallOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CallOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CallOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CallOptionMember" xlink:to="lab_us-gaap_CallOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_d30e1e55-e515-4115-a750-6182955ffd1b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CZ_17f35581-a04a-4008-9d52-a26bf3dcbe8d_terseLabel_en-US" xlink:label="lab_country_CZ" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Czech Republic</link:label>
    <link:label id="lab_country_CZ_label_en-US" xlink:label="lab_country_CZ" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CZECHIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CZ" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CZ"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CZ" xlink:to="lab_country_CZ" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_fc3a7049-bbb7-446a-b664-d92f82d9f368_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_070801d4-ad61-4ffa-8925-0b54701a2461_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_d94dba98-a529-4655-926f-20f499b32582_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_SalesBasedRoyaltiesMember_5d1ebbb6-6b85-40b0-8de8-3ba850f8ec6c_terseLabel_en-US" xlink:label="lab_nvax_SalesBasedRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Royalties</link:label>
    <link:label id="lab_nvax_SalesBasedRoyaltiesMember_label_en-US" xlink:label="lab_nvax_SalesBasedRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Royalties [Member]</link:label>
    <link:label id="lab_nvax_SalesBasedRoyaltiesMember_documentation_en-US" xlink:label="lab_nvax_SalesBasedRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SalesBasedRoyaltiesMember" xlink:href="nvax-20231231.xsd#nvax_SalesBasedRoyaltiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_SalesBasedRoyaltiesMember" xlink:to="lab_nvax_SalesBasedRoyaltiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ScheduleOfInventoryReserveTableTextBlock_d37718d5-d76c-402e-b460-c5f61cde9f6b_terseLabel_en-US" xlink:label="lab_nvax_ScheduleOfInventoryReserveTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory Reserve</link:label>
    <link:label id="lab_nvax_ScheduleOfInventoryReserveTableTextBlock_label_en-US" xlink:label="lab_nvax_ScheduleOfInventoryReserveTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory Reserve [Table Text Block]</link:label>
    <link:label id="lab_nvax_ScheduleOfInventoryReserveTableTextBlock_documentation_en-US" xlink:label="lab_nvax_ScheduleOfInventoryReserveTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfInventoryReserveTableTextBlock" xlink:href="nvax-20231231.xsd#nvax_ScheduleOfInventoryReserveTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ScheduleOfInventoryReserveTableTextBlock" xlink:to="lab_nvax_ScheduleOfInventoryReserveTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_5b7782f8-6330-4b29-892e-ea1ca4656e9e_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember_75dc8d22-4854-42a0-be8d-0e3bec6c768a_terseLabel_en-US" xlink:label="lab_nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Notes, Make-Whole Fundamental Change</link:label>
    <link:label id="lab_nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember_label_en-US" xlink:label="lab_nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Zero Convertible Notes Due 2027, Make-Whole Fundamental Change [Member]</link:label>
    <link:label id="lab_nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember_documentation_en-US" xlink:label="lab_nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Zero Convertible Notes Due 2027, Make-Whole Fundamental Change</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember" xlink:href="nvax-20231231.xsd#nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember" xlink:to="lab_nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_8d276d8b-febb-48c5-b461-efe07a73bad0_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_5f848c2e-f868-4833-83fc-996d2e5ea2ca_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage_04ff5509-580b-4959-a7c5-987ed7eb4871_terseLabel_en-US" xlink:label="lab_nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase percentage of principal amount</link:label>
    <link:label id="lab_nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage_label_en-US" xlink:label="lab_nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Of Principal Amount, Percentage</link:label>
    <link:label id="lab_nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage_documentation_en-US" xlink:label="lab_nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Of Principal Amount, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage" xlink:href="nvax-20231231.xsd#nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage" xlink:to="lab_nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_FacilityNumberOfSquareFeet_d6735069-ee01-433a-b9e1-094cb5dadd5e_terseLabel_en-US" xlink:label="lab_nvax_FacilityNumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility, number of square feet</link:label>
    <link:label id="lab_nvax_FacilityNumberOfSquareFeet_label_en-US" xlink:label="lab_nvax_FacilityNumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Number Of Square Feet</link:label>
    <link:label id="lab_nvax_FacilityNumberOfSquareFeet_documentation_en-US" xlink:label="lab_nvax_FacilityNumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Number Of Square Feet</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FacilityNumberOfSquareFeet" xlink:href="nvax-20231231.xsd#nvax_FacilityNumberOfSquareFeet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_FacilityNumberOfSquareFeet" xlink:to="lab_nvax_FacilityNumberOfSquareFeet" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_PublicOfferingMember_d2f97d00-f3df-499c-aef4-a3565fd872fb_terseLabel_en-US" xlink:label="lab_nvax_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_nvax_PublicOfferingMember_label_en-US" xlink:label="lab_nvax_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_nvax_PublicOfferingMember_documentation_en-US" xlink:label="lab_nvax_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PublicOfferingMember" xlink:href="nvax-20231231.xsd#nvax_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_PublicOfferingMember" xlink:to="lab_nvax_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_7e737b61-a4d2-4ea8-8290-751bd8687549_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coupon interest rate</link:label>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_label_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_SummaryOfSignificantAccountingPoliciesTable_443ca8a9-65c6-4038-b39d-64a6138f4d37_terseLabel_en-US" xlink:label="lab_nvax_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nvax_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_nvax_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SummaryOfSignificantAccountingPoliciesTable" xlink:href="nvax-20231231.xsd#nvax_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_nvax_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_104ccebe-2a07-4cb5-8fd0-ffb72cc98299_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research costs</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForSoftware_c13e5231-ff1f-4b48-9ba4-828532853282_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForSoftware" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal-use software</link:label>
    <link:label id="lab_us-gaap_PaymentsForSoftware_label_en-US" xlink:label="lab_us-gaap_PaymentsForSoftware" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForSoftware"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForSoftware" xlink:to="lab_us-gaap_PaymentsForSoftware" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NorthAmericaMember_2ef708c6-e2b0-4f4f-adf3-64d17ecb2cba_terseLabel_en-US" xlink:label="lab_srt_NorthAmericaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">North America</link:label>
    <link:label id="lab_srt_NorthAmericaMember_label_en-US" xlink:label="lab_srt_NorthAmericaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">North America [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NorthAmericaMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NorthAmericaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NorthAmericaMember" xlink:to="lab_srt_NorthAmericaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_019e1edb-f099-4481-afc6-02498d9c031b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_d049d6c6-0557-4135-b64a-1f9fbc3eaebe_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_SettlementAgreementMember_f10d2586-67b5-4a72-854f-7251e686ed53_terseLabel_en-US" xlink:label="lab_nvax_SettlementAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Agreement</link:label>
    <link:label id="lab_nvax_SettlementAgreementMember_label_en-US" xlink:label="lab_nvax_SettlementAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Agreement [Member]</link:label>
    <link:label id="lab_nvax_SettlementAgreementMember_documentation_en-US" xlink:label="lab_nvax_SettlementAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementMember" xlink:href="nvax-20231231.xsd#nvax_SettlementAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_SettlementAgreementMember" xlink:to="lab_nvax_SettlementAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_d42c8d7d-6d14-42cf-aa98-332ce6b7f0e5_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForCapitalImprovements_ad9f24de-2ef9-4545-82a4-fdfd71907fbc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForCapitalImprovements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsForCapitalImprovements_label_en-US" xlink:label="lab_us-gaap_PaymentsForCapitalImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Capital Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCapitalImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForCapitalImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForCapitalImprovements" xlink:to="lab_us-gaap_PaymentsForCapitalImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_c2431162-f7c5-410a-b043-bd4b9bc9feac_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_41958df7-1474-4e5b-a53d-dc8e062a4c76_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_cf69d21e-a8ea-4d67-a3f9-335d74087ce8_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_PurchaseAgreementNumberOfVaccineDoses_87b3dee2-5617-4154-a150-e40d3c7f2542_terseLabel_en-US" xlink:label="lab_nvax_PurchaseAgreementNumberOfVaccineDoses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase agreement, number of vaccine doses</link:label>
    <link:label id="lab_nvax_PurchaseAgreementNumberOfVaccineDoses_label_en-US" xlink:label="lab_nvax_PurchaseAgreementNumberOfVaccineDoses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement, Number Of Vaccine Doses</link:label>
    <link:label id="lab_nvax_PurchaseAgreementNumberOfVaccineDoses_documentation_en-US" xlink:label="lab_nvax_PurchaseAgreementNumberOfVaccineDoses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement, Number Of Vaccine Doses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfVaccineDoses" xlink:href="nvax-20231231.xsd#nvax_PurchaseAgreementNumberOfVaccineDoses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_PurchaseAgreementNumberOfVaccineDoses" xlink:to="lab_nvax_PurchaseAgreementNumberOfVaccineDoses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_1f594172-7c86-44c9-9980-a02c70aa9d78_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_59c4c75f-b301-40dc-8957-fb69f9e93e63_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of assets</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_222d40f3-72cd-480b-9603-3a820896e7de_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_f01c0609-4aa2-43dc-8fc7-e8c2d48d49f7_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_d566673f-9111-4aeb-99df-a8718c1105a6_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_be8c0e56-188b-4cf9-8c07-5dea8b7f5ed8_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_f8fbffec-6805-441b-a83a-8549081fec6e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_InventoryFirmPurchaseCommitmentRecoveries_d672b09d-595b-41a8-b8d5-402e0847f31e_terseLabel_en-US" xlink:label="lab_nvax_InventoryFirmPurchaseCommitmentRecoveries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, firm purchase commitment, recoveries</link:label>
    <link:label id="lab_nvax_InventoryFirmPurchaseCommitmentRecoveries_label_en-US" xlink:label="lab_nvax_InventoryFirmPurchaseCommitmentRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Firm Purchase Commitment, Recoveries</link:label>
    <link:label id="lab_nvax_InventoryFirmPurchaseCommitmentRecoveries_documentation_en-US" xlink:label="lab_nvax_InventoryFirmPurchaseCommitmentRecoveries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Firm Purchase Commitment, Recoveries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InventoryFirmPurchaseCommitmentRecoveries" xlink:href="nvax-20231231.xsd#nvax_InventoryFirmPurchaseCommitmentRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_InventoryFirmPurchaseCommitmentRecoveries" xlink:to="lab_nvax_InventoryFirmPurchaseCommitmentRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_2e55c55d-e71b-4a4c-a20b-11d0dfa2b09a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ShortTermLeaseCostBenefit_4122fa68-1bad-49ba-b990-5dbed058c375_terseLabel_en-US" xlink:label="lab_nvax_ShortTermLeaseCostBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease expense (benefit(1))</link:label>
    <link:label id="lab_nvax_ShortTermLeaseCostBenefit_label_en-US" xlink:label="lab_nvax_ShortTermLeaseCostBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Cost (Benefit)</link:label>
    <link:label id="lab_nvax_ShortTermLeaseCostBenefit_documentation_en-US" xlink:label="lab_nvax_ShortTermLeaseCostBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Cost (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShortTermLeaseCostBenefit" xlink:href="nvax-20231231.xsd#nvax_ShortTermLeaseCostBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ShortTermLeaseCostBenefit" xlink:to="lab_nvax_ShortTermLeaseCostBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_b85e3f1a-1a1d-4977-9550-ad107bb18c31_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_60cbdf2f-1935-40ac-84d5-638eb51e3c0d_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6d2dbd84-50c8-4e13-a8c9-d0b07f4c1a6d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_AmendedAndRestatedUKSupplyAgreementMember_927df6fc-78ac-4fd1-9fd0-91531bebe91a_terseLabel_en-US" xlink:label="lab_nvax_AmendedAndRestatedUKSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated UK Supply Agreement</link:label>
    <link:label id="lab_nvax_AmendedAndRestatedUKSupplyAgreementMember_label_en-US" xlink:label="lab_nvax_AmendedAndRestatedUKSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated UK Supply Agreement [Member]</link:label>
    <link:label id="lab_nvax_AmendedAndRestatedUKSupplyAgreementMember_documentation_en-US" xlink:label="lab_nvax_AmendedAndRestatedUKSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated UK Supply Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember" xlink:href="nvax-20231231.xsd#nvax_AmendedAndRestatedUKSupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember" xlink:to="lab_nvax_AmendedAndRestatedUKSupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_af55e89b-c327-4c34-964d-b73afe7f252a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_ba46b098-692d-4d9b-83e3-ed7f31ced2ef_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_8d23d46f-eff4-43fa-b163-074d6ac88ef6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0f1f2266-8917-4e79-bb1e-f17d528d07f3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ba85b6f4-a0a3-40e5-85b1-0a042068524f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of stock options and stock appreciation rights exercisable (less than)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_439eadc8-2a76-4e0c-a670-6c35494282d9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant_24533666-ef77-4a94-93c2-581d926d6ccb_terseLabel_en-US" xlink:label="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract to perform for others grant</link:label>
    <link:label id="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant_label_en-US" xlink:label="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement Contract To Perform For Others Grant</link:label>
    <link:label id="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant_documentation_en-US" xlink:label="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement Contract To Perform For Others Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant" xlink:href="nvax-20231231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant" xlink:to="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_693121ce-6f09-4a9d-abf7-d4393718089d_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled_2c49952c-9f68-46bb-a46e-5924d7c9a37c_terseLabel_en-US" xlink:label="lab_nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock under the Sales Agreement not settled at year-end</link:label>
    <link:label id="lab_nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled_label_en-US" xlink:label="lab_nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Or Sale Of Equity Not Settled</link:label>
    <link:label id="lab_nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled_documentation_en-US" xlink:label="lab_nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of proceeds from issuance or sale of equity not settled.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled" xlink:href="nvax-20231231.xsd#nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled" xlink:to="lab_nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_7637ba3c-2a7d-45d1-a79e-64053c776780_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_68909b13-4da4-4f93-94d2-2d5819c31b2d_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_c5637054-2e7f-45a2-8bec-5c525f6f224a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19356d45-01c2-4564-abd1-08b43b1907e6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_NumberOfDosesOfVaccineCandidate_301e64b5-8fac-4318-947a-cdbaa323e875_terseLabel_en-US" xlink:label="lab_nvax_NumberOfDosesOfVaccineCandidate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of doses</link:label>
    <link:label id="lab_nvax_NumberOfDosesOfVaccineCandidate_label_en-US" xlink:label="lab_nvax_NumberOfDosesOfVaccineCandidate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Doses Of Vaccine Candidate</link:label>
    <link:label id="lab_nvax_NumberOfDosesOfVaccineCandidate_documentation_en-US" xlink:label="lab_nvax_NumberOfDosesOfVaccineCandidate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Doses Of Vaccine Candidate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesOfVaccineCandidate" xlink:href="nvax-20231231.xsd#nvax_NumberOfDosesOfVaccineCandidate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_NumberOfDosesOfVaccineCandidate" xlink:to="lab_nvax_NumberOfDosesOfVaccineCandidate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_591a5b44-4c5e-4aa2-a049-a8f31b38ce61_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_GaviAdvancePurchaseAgreementSIIPLMember_2b552121-a7ed-4e0a-acf9-649c4407a71d_terseLabel_en-US" xlink:label="lab_nvax_GaviAdvancePurchaseAgreementSIIPLMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gavi Advance Purchase Agreement SIIPL</link:label>
    <link:label id="lab_nvax_GaviAdvancePurchaseAgreementSIIPLMember_label_en-US" xlink:label="lab_nvax_GaviAdvancePurchaseAgreementSIIPLMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gavi Advance Purchase Agreement SIIPL [Member]</link:label>
    <link:label id="lab_nvax_GaviAdvancePurchaseAgreementSIIPLMember_documentation_en-US" xlink:label="lab_nvax_GaviAdvancePurchaseAgreementSIIPLMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gavi Advance Purchase Agreement SIIPL</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementSIIPLMember" xlink:href="nvax-20231231.xsd#nvax_GaviAdvancePurchaseAgreementSIIPLMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_GaviAdvancePurchaseAgreementSIIPLMember" xlink:to="lab_nvax_GaviAdvancePurchaseAgreementSIIPLMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_June2021AndAugust2023SalesAgreementMember_864a92b8-46c3-46a4-b209-8f68b1c6a822_terseLabel_en-US" xlink:label="lab_nvax_June2021AndAugust2023SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2021 and August 2023 Sales Agreement</link:label>
    <link:label id="lab_nvax_June2021AndAugust2023SalesAgreementMember_label_en-US" xlink:label="lab_nvax_June2021AndAugust2023SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2021 and August 2023 Sales Agreement [Member]</link:label>
    <link:label id="lab_nvax_June2021AndAugust2023SalesAgreementMember_documentation_en-US" xlink:label="lab_nvax_June2021AndAugust2023SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2021 and August 2023 Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_June2021AndAugust2023SalesAgreementMember" xlink:href="nvax-20231231.xsd#nvax_June2021AndAugust2023SalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_June2021AndAugust2023SalesAgreementMember" xlink:to="lab_nvax_June2021AndAugust2023SalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_A700QuinceOrchardRoadAgreementMember_8c0dff69-670c-4e40-aca5-0fca86437dbb_terseLabel_en-US" xlink:label="lab_nvax_A700QuinceOrchardRoadAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">700 Quince Orchard Road Agreement</link:label>
    <link:label id="lab_nvax_A700QuinceOrchardRoadAgreementMember_label_en-US" xlink:label="lab_nvax_A700QuinceOrchardRoadAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">700 Quince Orchard Road Agreement [Member]</link:label>
    <link:label id="lab_nvax_A700QuinceOrchardRoadAgreementMember_documentation_en-US" xlink:label="lab_nvax_A700QuinceOrchardRoadAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">700 Quince Orchard Road Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_A700QuinceOrchardRoadAgreementMember" xlink:href="nvax-20231231.xsd#nvax_A700QuinceOrchardRoadAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_A700QuinceOrchardRoadAgreementMember" xlink:to="lab_nvax_A700QuinceOrchardRoadAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1d4f319a-a002-458e-9433-eb091f5e92f8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_7f625080-c23b-490b-907e-ac7696cf2643_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_5d9abd4f-6b3c-4341-a2f1-59ff31ec7233_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_012787ba-8cfc-4a80-a96b-a50db0b374fd_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_236036ae-ed4b-4b46-9cde-c7e1dcc9ba21_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_TwoThousandFifteenStockIncentivePlanMember_deae5236-5fe1-4259-9700-8cc26b1ca87e_terseLabel_en-US" xlink:label="lab_nvax_TwoThousandFifteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Plan</link:label>
    <link:label id="lab_nvax_TwoThousandFifteenStockIncentivePlanMember_label_en-US" xlink:label="lab_nvax_TwoThousandFifteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Fifteen Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFifteenStockIncentivePlanMember" xlink:href="nvax-20231231.xsd#nvax_TwoThousandFifteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_TwoThousandFifteenStockIncentivePlanMember" xlink:to="lab_nvax_TwoThousandFifteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1d287cec-28cd-4629-a602-e74a082e2c5b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_5b8069a8-306b-4b94-a7e7-e00af4288f97_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_d4d93a40-342c-4780-9ced-7dcf889fbf01_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_0b96c444-c6a8-4097-a330-c609e71ebad7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock_f2ddc13d-9f67-4b04-ba1f-23cefb32a444_verboseLabel_en-US" xlink:label="lab_nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Cash Flow Information of Leases</link:label>
    <link:label id="lab_nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock_label_en-US" xlink:label="lab_nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Cash Flow information of Lease [Table Text Block]</link:label>
    <link:label id="lab_nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock_documentation_en-US" xlink:label="lab_nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of supplemental cash flow information of lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock" xlink:href="nvax-20231231.xsd#nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock" xlink:to="lab_nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ConvertibleNotesPayableCurrentAbstract_86c2619f-4100-49d0-9a2c-ee24897e3624_terseLabel_en-US" xlink:label="lab_nvax_ConvertibleNotesPayableCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion:</link:label>
    <link:label id="lab_nvax_ConvertibleNotesPayableCurrentAbstract_label_en-US" xlink:label="lab_nvax_ConvertibleNotesPayableCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable, Current [Abstract]</link:label>
    <link:label id="lab_nvax_ConvertibleNotesPayableCurrentAbstract_documentation_en-US" xlink:label="lab_nvax_ConvertibleNotesPayableCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ConvertibleNotesPayableCurrentAbstract" xlink:href="nvax-20231231.xsd#nvax_ConvertibleNotesPayableCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ConvertibleNotesPayableCurrentAbstract" xlink:to="lab_nvax_ConvertibleNotesPayableCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ContractWithCustomerLiabilityAdditions_4ee4d4a4-bace-4506-8526-5ecd668d0806_terseLabel_en-US" xlink:label="lab_nvax_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_nvax_ContractWithCustomerLiabilityAdditions_label_en-US" xlink:label="lab_nvax_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Additions</link:label>
    <link:label id="lab_nvax_ContractWithCustomerLiabilityAdditions_documentation_en-US" xlink:label="lab_nvax_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ContractWithCustomerLiabilityAdditions" xlink:href="nvax-20231231.xsd#nvax_ContractWithCustomerLiabilityAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ContractWithCustomerLiabilityAdditions" xlink:to="lab_nvax_ContractWithCustomerLiabilityAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_NumberOfDosesToBeDistributed_a7779ea0-ba9c-4486-9a6d-fb3e26ff6935_terseLabel_en-US" xlink:label="lab_nvax_NumberOfDosesToBeDistributed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of doses to be distributed</link:label>
    <link:label id="lab_nvax_NumberOfDosesToBeDistributed_label_en-US" xlink:label="lab_nvax_NumberOfDosesToBeDistributed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Doses, To Be Distributed</link:label>
    <link:label id="lab_nvax_NumberOfDosesToBeDistributed_documentation_en-US" xlink:label="lab_nvax_NumberOfDosesToBeDistributed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Doses, To Be Distributed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesToBeDistributed" xlink:href="nvax-20231231.xsd#nvax_NumberOfDosesToBeDistributed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_NumberOfDosesToBeDistributed" xlink:to="lab_nvax_NumberOfDosesToBeDistributed" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_ce80a400-d8cb-4478-84ea-0baab97079d2_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3d2be21c-220a-4b7f-ab3a-020d8fb45d05_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e119defe-3a83-428c-a070-d03708f70c6d_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_June2021SalesAgreementMember_4e56b363-beba-4d04-9e1d-3cb3532aebfd_terseLabel_en-US" xlink:label="lab_nvax_June2021SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2021 Sales Agreement</link:label>
    <link:label id="lab_nvax_June2021SalesAgreementMember_label_en-US" xlink:label="lab_nvax_June2021SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2021 Sales Agreement [Member]</link:label>
    <link:label id="lab_nvax_June2021SalesAgreementMember_documentation_en-US" xlink:label="lab_nvax_June2021SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2021 Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_June2021SalesAgreementMember" xlink:href="nvax-20231231.xsd#nvax_June2021SalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_June2021SalesAgreementMember" xlink:to="lab_nvax_June2021SalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_af7286da-709f-406c-9649-dce540b52113_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_8bf412e4-8e1a-4524-9998-37ce349a00d5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1ce9a0c8-75ca-4698-8039-83714a4f06fe_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in operating lease liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BilledContractReceivables_b9808d85-fa6e-47d8-b949-5d7ecb8798d1_terseLabel_en-US" xlink:label="lab_us-gaap_BilledContractReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Billed contracts receivable</link:label>
    <link:label id="lab_us-gaap_BilledContractReceivables_label_en-US" xlink:label="lab_us-gaap_BilledContractReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Billed Contracts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BilledContractReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BilledContractReceivables" xlink:to="lab_us-gaap_BilledContractReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_110d9ccc-0962-4741-8c1d-cea0f71a3254_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_U.S.ProductSalesReturnsAccrual_c2da260b-6385-4360-b26a-37b93a92b798_terseLabel_en-US" xlink:label="lab_nvax_U.S.ProductSalesReturnsAccrual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. product sales returns accrual</link:label>
    <link:label id="lab_nvax_U.S.ProductSalesReturnsAccrual_label_en-US" xlink:label="lab_nvax_U.S.ProductSalesReturnsAccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Product Sales Returns Accrual</link:label>
    <link:label id="lab_nvax_U.S.ProductSalesReturnsAccrual_documentation_en-US" xlink:label="lab_nvax_U.S.ProductSalesReturnsAccrual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Product Sales Returns Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_U.S.ProductSalesReturnsAccrual" xlink:href="nvax-20231231.xsd#nvax_U.S.ProductSalesReturnsAccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_U.S.ProductSalesReturnsAccrual" xlink:to="lab_nvax_U.S.ProductSalesReturnsAccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_3a6556d5-1f34-4e92-9ca5-4a1cd7e38d4f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_6eb8ea6c-6f78-4beb-9d3e-dff580747e4c_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ConversionPremiumPercentage_b0d18630-0407-4960-b7a0-4168f1d2dd01_terseLabel_en-US" xlink:label="lab_nvax_ConversionPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion premium percentage</link:label>
    <link:label id="lab_nvax_ConversionPremiumPercentage_label_en-US" xlink:label="lab_nvax_ConversionPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Premium Percentage</link:label>
    <link:label id="lab_nvax_ConversionPremiumPercentage_documentation_en-US" xlink:label="lab_nvax_ConversionPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represents the rate of premium based on the last reported sales price of stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ConversionPremiumPercentage" xlink:href="nvax-20231231.xsd#nvax_ConversionPremiumPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ConversionPremiumPercentage" xlink:to="lab_nvax_ConversionPremiumPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_da33aee4-0b22-456b-b697-9ee74ef7d8cd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_cce17822-008d-4fef-96a1-57df7d6b4b9c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_58b292d0-ca12-4a20-a308-708ef9c63592_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CEPIGrantFundingMember_f03578a7-3ee0-4a5f-8b78-c06cf9e5e9d3_terseLabel_en-US" xlink:label="lab_nvax_CEPIGrantFundingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CEPI Grant Funding</link:label>
    <link:label id="lab_nvax_CEPIGrantFundingMember_label_en-US" xlink:label="lab_nvax_CEPIGrantFundingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CEPI Grant Funding [Member]</link:label>
    <link:label id="lab_nvax_CEPIGrantFundingMember_documentation_en-US" xlink:label="lab_nvax_CEPIGrantFundingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CEPI Grant Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CEPIGrantFundingMember" xlink:href="nvax-20231231.xsd#nvax_CEPIGrantFundingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CEPIGrantFundingMember" xlink:to="lab_nvax_CEPIGrantFundingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_950d0dbe-74e9-438c-b4de-ea540c8f7104_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_53320fde-4c8a-4706-a23c-5f20d272f889_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_b93f2185-1814-4e86-9862-db408d99dbd1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_333d3045-1746-483f-939c-895080c5fdf5_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Name of Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability_a483444a-3f26-4beb-a0d6-0f36f522529f_terseLabel_en-US" xlink:label="lab_nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability and right of use assets recognized</link:label>
    <link:label id="lab_nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability_label_en-US" xlink:label="lab_nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance and Operating Lease Liability</link:label>
    <link:label id="lab_nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability_documentation_en-US" xlink:label="lab_nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance and Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability" xlink:href="nvax-20231231.xsd#nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability" xlink:to="lab_nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_28740c86-2827-4f42-8b24-395eeed557c5_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets (liabilities)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_59bc26a1-f33c-4c08-a5fd-fbd037366d8f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of stock options and stock appreciation rights exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_LeaseImpairmentChargeDomain_f6f6cac0-47ec-4a71-a566-7a3216307e5e_terseLabel_en-US" xlink:label="lab_nvax_LeaseImpairmentChargeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Impairment Charge [Domain]</link:label>
    <link:label id="lab_nvax_LeaseImpairmentChargeDomain_label_en-US" xlink:label="lab_nvax_LeaseImpairmentChargeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Impairment Charge [Domain]</link:label>
    <link:label id="lab_nvax_LeaseImpairmentChargeDomain_documentation_en-US" xlink:label="lab_nvax_LeaseImpairmentChargeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Impairment Charge [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseImpairmentChargeDomain" xlink:href="nvax-20231231.xsd#nvax_LeaseImpairmentChargeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_LeaseImpairmentChargeDomain" xlink:to="lab_nvax_LeaseImpairmentChargeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_af3520d9-a023-4a7f-ac5b-623afa3fc3d7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CollaborationAgreementUpfrontPaymentAmount_d6355cf3-5dff-4ef4-8949-4eb56d192f45_terseLabel_en-US" xlink:label="lab_nvax_CollaborationAgreementUpfrontPaymentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement upfront payment amount</link:label>
    <link:label id="lab_nvax_CollaborationAgreementUpfrontPaymentAmount_label_en-US" xlink:label="lab_nvax_CollaborationAgreementUpfrontPaymentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Upfront Payment Amount</link:label>
    <link:label id="lab_nvax_CollaborationAgreementUpfrontPaymentAmount_documentation_en-US" xlink:label="lab_nvax_CollaborationAgreementUpfrontPaymentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Upfront Payment Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementUpfrontPaymentAmount" xlink:href="nvax-20231231.xsd#nvax_CollaborationAgreementUpfrontPaymentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CollaborationAgreementUpfrontPaymentAmount" xlink:to="lab_nvax_CollaborationAgreementUpfrontPaymentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_762e49f8-2057-487a-84cc-3f274b5de89a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_1a6a6f6b-ea01-4d21-bd5f-2e9f232e8f79_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_78c839e6-3960-4fd1-a5cb-51e54871126e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ConvertibleNotesPayableNoncurrentAbstract_c6eda6d9-42eb-4704-b3c9-06d6cc0cbe70_terseLabel_en-US" xlink:label="lab_nvax_ConvertibleNotesPayableNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion:</link:label>
    <link:label id="lab_nvax_ConvertibleNotesPayableNoncurrentAbstract_label_en-US" xlink:label="lab_nvax_ConvertibleNotesPayableNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable, Noncurrent [Abstract]</link:label>
    <link:label id="lab_nvax_ConvertibleNotesPayableNoncurrentAbstract_documentation_en-US" xlink:label="lab_nvax_ConvertibleNotesPayableNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ConvertibleNotesPayableNoncurrentAbstract" xlink:href="nvax-20231231.xsd#nvax_ConvertibleNotesPayableNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ConvertibleNotesPayableNoncurrentAbstract" xlink:to="lab_nvax_ConvertibleNotesPayableNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_368ea5e5-3564-4bb1-bcca-4a530e9fb7f9_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_7e2db0d5-a87e-4490-bc4e-166254f2e836_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember" xlink:to="lab_us-gaap_UnsecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_AccruedGrossToNetDeductionsCurrent_fb894715-9f1e-409f-8f34-62fb8c837479_terseLabel_en-US" xlink:label="lab_nvax_AccruedGrossToNetDeductionsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross-to-net deductions</link:label>
    <link:label id="lab_nvax_AccruedGrossToNetDeductionsCurrent_label_en-US" xlink:label="lab_nvax_AccruedGrossToNetDeductionsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Gross-To-Net Deductions, Current</link:label>
    <link:label id="lab_nvax_AccruedGrossToNetDeductionsCurrent_documentation_en-US" xlink:label="lab_nvax_AccruedGrossToNetDeductionsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Gross-To-Net Deductions, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccruedGrossToNetDeductionsCurrent" xlink:href="nvax-20231231.xsd#nvax_AccruedGrossToNetDeductionsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_AccruedGrossToNetDeductionsCurrent" xlink:to="lab_nvax_AccruedGrossToNetDeductionsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans_428b3801-ab99-45da-8c89-7d9757da19c7_terseLabel_en-US" xlink:label="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract to perform for others forgivable no interest term loans</link:label>
    <link:label id="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans_label_en-US" xlink:label="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement Contract To Perform For Others Forgivable No Interest Term Loans</link:label>
    <link:label id="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans_documentation_en-US" xlink:label="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement Contract To Perform For Others Forgivable No Interest Term Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans" xlink:href="nvax-20231231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans" xlink:to="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_10cba448-c4ee-49d6-bdba-8ab67ddbc7bd_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_17f24410-5e56-4c52-addf-babf6799958b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_273e753a-31dd-451c-9e4a-96a8543a2482_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Grant Revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_97d2e94f-afc1-4722-a32e-903612635694_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance, deferred tax asset, amount increase</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_5a0c9328-e080-498c-ad83-bbb3e0c1f61f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_3eacce5f-df6f-46a3-96b2-ecc4896f22fb_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse stock split conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_SKBioscienceCoLtdMember_76569c19-9394-45dc-8346-8e93e024f14c_terseLabel_en-US" xlink:label="lab_nvax_SKBioscienceCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SK bioscience, Co., Ltd.</link:label>
    <link:label id="lab_nvax_SKBioscienceCoLtdMember_label_en-US" xlink:label="lab_nvax_SKBioscienceCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SK Bioscience, Co. Ltd [Member]</link:label>
    <link:label id="lab_nvax_SKBioscienceCoLtdMember_documentation_en-US" xlink:label="lab_nvax_SKBioscienceCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SK Bioscience, Co. Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SKBioscienceCoLtdMember" xlink:href="nvax-20231231.xsd#nvax_SKBioscienceCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_SKBioscienceCoLtdMember" xlink:to="lab_nvax_SKBioscienceCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ce2a0aa8-59d5-4915-83e6-bb5c4f9094fa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_de421884-5447-44f7-a4db-ad4284cf7f72_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_443060b3-5523-4953-b35e-817152309fc6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_76ffb553-6d81-4229-be5c-bc7e85a29270_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b0de7627-207b-4c10-8a64-5964de3d3e62_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_ce786df3-a5b1-4442-b884-3b68d67e286d_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0da4ae0a-cbcf-49db-8c69-33fc6db8ec23_negatedNetLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_4c054e4d-bc0a-4439-963d-cbe20f4d6cc9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, employer matching contribution, percent of employees' gross pay</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_5351d5bd-aa94-401a-a35a-1d1727711f91_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts, beginning balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_c1b95b66-5602-4565-af3c-315f29d74b44_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts, end balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_e4017e89-b235-4162-8eb8-59624e2864cd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_SettlementAgreementBenefit_781f2bb9-2062-4fb7-a730-21d7b33d4282_terseLabel_en-US" xlink:label="lab_nvax_SettlementAgreementBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement agreement, benefit</link:label>
    <link:label id="lab_nvax_SettlementAgreementBenefit_label_en-US" xlink:label="lab_nvax_SettlementAgreementBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Agreement, Benefit</link:label>
    <link:label id="lab_nvax_SettlementAgreementBenefit_documentation_en-US" xlink:label="lab_nvax_SettlementAgreementBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Agreement, Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementBenefit" xlink:href="nvax-20231231.xsd#nvax_SettlementAgreementBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_SettlementAgreementBenefit" xlink:to="lab_nvax_SettlementAgreementBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_77c61ecb-0c73-4778-9232-69aed1d6682a_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_2d2f095c-29b5-4951-a697-1a94d12af1f1_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_f6f17d8e-6cbf-4f1c-bf70-6481cb9048bc_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_4d02b435-a218-42b7-a12f-1b540fd5e366_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_a820ca0c-d4ed-42d2-a8e5-86c8231f5ac6_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_f60f8e22-9577-48a7-929b-39bf8fb22805_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_3e5d0683-e463-4e41-a500-5626864e1ce7_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_405eed0c-ff7a-4d1e-a808-de8847fdb9f7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_bd92486c-eb58-46f9-88b3-2278d849e8e7_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_5590572a-02a0-4605-a383-20d73ebc0ac9_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_b5193841-2271-49e3-bd7f-bd6abdcabeee_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_c98679a7-7053-4459-8ddb-54aa57303ab4_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU assets, finance, net</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_ef77364c-2222-4f1c-9682-8be41651866d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_2cd46158-609c-4fce-b979-9005d8d01b30_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_RoyaltyPeriod_eb4e16da-8a67-4a0c-baa0-3302174ce511_terseLabel_en-US" xlink:label="lab_nvax_RoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty period</link:label>
    <link:label id="lab_nvax_RoyaltyPeriod_label_en-US" xlink:label="lab_nvax_RoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Period</link:label>
    <link:label id="lab_nvax_RoyaltyPeriod_documentation_en-US" xlink:label="lab_nvax_RoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RoyaltyPeriod" xlink:href="nvax-20231231.xsd#nvax_RoyaltyPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_RoyaltyPeriod" xlink:to="lab_nvax_RoyaltyPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_be676c63-42c2-44ce-9656-0267c33a0082_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5585a3b7-e14f-47f3-bc5c-bf664eca5d40_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_06bf5e6d-753a-4d70-b2d5-bf6659739fc0_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CoalitionForEpidemicPreparednessInnovationsMember_346cf5e9-3d0f-4976-9459-f83791b97e39_terseLabel_en-US" xlink:label="lab_nvax_CoalitionForEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CEPI</link:label>
    <link:label id="lab_nvax_CoalitionForEpidemicPreparednessInnovationsMember_label_en-US" xlink:label="lab_nvax_CoalitionForEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:label id="lab_nvax_CoalitionForEpidemicPreparednessInnovationsMember_documentation_en-US" xlink:label="lab_nvax_CoalitionForEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CoalitionForEpidemicPreparednessInnovationsMember" xlink:href="nvax-20231231.xsd#nvax_CoalitionForEpidemicPreparednessInnovationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CoalitionForEpidemicPreparednessInnovationsMember" xlink:to="lab_nvax_CoalitionForEpidemicPreparednessInnovationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_a4e7f5ce-011e-4f1c-a5be-37ad42ea6944_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_PaymentForCappedCallTransactions_6e11c433-0b60-40be-8777-4d16c5fb0310_terseLabel_en-US" xlink:label="lab_nvax_PaymentForCappedCallTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for capped call transactions</link:label>
    <link:label id="lab_nvax_PaymentForCappedCallTransactions_label_en-US" xlink:label="lab_nvax_PaymentForCappedCallTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PaymentForCappedCallTransactions</link:label>
    <link:label id="lab_nvax_PaymentForCappedCallTransactions_documentation_en-US" xlink:label="lab_nvax_PaymentForCappedCallTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of payment which is made for entering into privately negotiated capped call transactions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PaymentForCappedCallTransactions" xlink:href="nvax-20231231.xsd#nvax_PaymentForCappedCallTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_PaymentForCappedCallTransactions" xlink:to="lab_nvax_PaymentForCappedCallTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_81084671-061c-4470-9573-ea838591cb06_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_SaleOfStockAmountOfRemainingUnissuedShares_ca94cae0-328b-45ee-9c19-202343d2cb4d_terseLabel_en-US" xlink:label="lab_nvax_SaleOfStockAmountOfRemainingUnissuedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining unissued capital</link:label>
    <link:label id="lab_nvax_SaleOfStockAmountOfRemainingUnissuedShares_label_en-US" xlink:label="lab_nvax_SaleOfStockAmountOfRemainingUnissuedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Amount Of Remaining Unissued Shares</link:label>
    <link:label id="lab_nvax_SaleOfStockAmountOfRemainingUnissuedShares_documentation_en-US" xlink:label="lab_nvax_SaleOfStockAmountOfRemainingUnissuedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Amount Of Remaining Unissued Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SaleOfStockAmountOfRemainingUnissuedShares" xlink:href="nvax-20231231.xsd#nvax_SaleOfStockAmountOfRemainingUnissuedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_SaleOfStockAmountOfRemainingUnissuedShares" xlink:to="lab_nvax_SaleOfStockAmountOfRemainingUnissuedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_2307b651-8949-4eb0-a3f2-7e8075726d5e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_RoyaltiesAndOtherMember_15d74467-9744-4edb-a3c6-97898c6d4d4b_terseLabel_en-US" xlink:label="lab_nvax_RoyaltiesAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties and other</link:label>
    <link:label id="lab_nvax_RoyaltiesAndOtherMember_label_en-US" xlink:label="lab_nvax_RoyaltiesAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties and Other [Member]</link:label>
    <link:label id="lab_nvax_RoyaltiesAndOtherMember_documentation_en-US" xlink:label="lab_nvax_RoyaltiesAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties and Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RoyaltiesAndOtherMember" xlink:href="nvax-20231231.xsd#nvax_RoyaltiesAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_RoyaltiesAndOtherMember" xlink:to="lab_nvax_RoyaltiesAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_fa53d8ca-534d-4aa1-87a3-37b4c88807c8_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_b2101209-b254-4db4-9c47-839b5fde5497_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Unsecured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_ca27b61b-b562-4521-898f-4e2f0b076fad_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU assets obtained in exchange for finance lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_28bbb7fa-7ca5-42df-8af4-1c4592d92ec3_terseLabel_en-US" xlink:label="lab_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Committee on Vaccination and Immunization (JCVI)</link:label>
    <link:label id="lab_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_label_en-US" xlink:label="lab_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Committee on Vaccination and Immunization (JCVI) [Member]</link:label>
    <link:label id="lab_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_documentation_en-US" xlink:label="lab_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Committee on Vaccination and Immunization (JCVI)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember" xlink:href="nvax-20231231.xsd#nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember" xlink:to="lab_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_24c19447-1e80-4e09-8eb8-7a7ebdfabfc1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7a9c391b-b8b7-4c3d-99b8-4ed4c4ec00f7_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_7cfd8d89-001b-4027-b29e-a2513f4bdca5_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_6081494c-5fff-4c98-ad4e-e9e2aecbf97c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for sales returns</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_074a29ea-acc5-4736-bc67-f1051938c487_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_7b2ef17d-a537-430c-97b1-2d869c47f975_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_389b4850-6803-4c1e-b850-f92f0597cf2c_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_e889bbc7-7ae6-4eb4-8d04-f2e46aed231f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_ad298fce-e3b6-420f-88cf-337c03e25f0f_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_a8f5169e-8751-429e-9df7-7c06b80c3607_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_98af6901-d9b3-4fbd-9ded-cfadde9c64de_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_fe60562c-b3be-4b11-a3fa-582de8d4b105_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_4614a6f3-4a13-48a4-bba5-85c921a83f58_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_688f8232-2b21-472a-b041-1dc5dbf7191f_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_SettlementPayment_f7a9dac0-029e-4e82-881e-7cd5ce7645d8_terseLabel_en-US" xlink:label="lab_nvax_SettlementPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement payment</link:label>
    <link:label id="lab_nvax_SettlementPayment_label_en-US" xlink:label="lab_nvax_SettlementPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Payment</link:label>
    <link:label id="lab_nvax_SettlementPayment_documentation_en-US" xlink:label="lab_nvax_SettlementPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementPayment" xlink:href="nvax-20231231.xsd#nvax_SettlementPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_SettlementPayment" xlink:to="lab_nvax_SettlementPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_d1cc32fa-e1c6-40ea-b68a-29b025c81eab_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation to be satisfied</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_b3001c9a-9bc6-4402-8fe3-e13e7e9856e4_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and related cost, annual impact percent</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent_7b42eb17-ed17-490e-8c85-3cc8216e3dc3_terseLabel_en-US" xlink:label="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum grant price, percent of common stock fair value</link:label>
    <link:label id="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent_label_en-US" xlink:label="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grant Date Exercise Price Minimum Percent</link:label>
    <link:label id="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent_documentation_en-US" xlink:label="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The minimum grant-date exercise price of incentive stock options granted as a percent of the common stock share price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" xlink:href="nvax-20231231.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" xlink:to="lab_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_b5a66730-5ebf-4f14-9866-0b595cf33664_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_0300b2ee-f871-4964-ba36-c1a20da60124_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU assets expensed</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7fba69ce-fdad-4131-aa69-54275628a313_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_DebtInstrumentFaceAmountCurrent_416f1bb2-6e0e-4f7a-a5fc-3b8b48ae6286_terseLabel_en-US" xlink:label="lab_nvax_DebtInstrumentFaceAmountCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.75% Convertible notes due 2023</link:label>
    <link:label id="lab_nvax_DebtInstrumentFaceAmountCurrent_label_en-US" xlink:label="lab_nvax_DebtInstrumentFaceAmountCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount, Current</link:label>
    <link:label id="lab_nvax_DebtInstrumentFaceAmountCurrent_documentation_en-US" xlink:label="lab_nvax_DebtInstrumentFaceAmountCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DebtInstrumentFaceAmountCurrent" xlink:href="nvax-20231231.xsd#nvax_DebtInstrumentFaceAmountCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_DebtInstrumentFaceAmountCurrent" xlink:to="lab_nvax_DebtInstrumentFaceAmountCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_4c5898d5-1fd2-494d-ac41-534e5d1c35e8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_e8f023e2-89f7-43eb-ba5c-971ad74e93d6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_97fffaf1-b57e-4d74-a0d0-d9b0996dabcf_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_976c3e9b-ba0f-4539-aab4-95b8d278298a_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_19d2d1ae-8c18-4ae2-bdc6-655fd371c318_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_08c072d3-e740-4ef1-82a1-b04c931db12a_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_805b59cf-de2b-4137-bc5e-2dbb129711ca_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_85ab3c45-f293-44af-965f-8f066bf6ed13_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AgencySecuritiesMember_506ad760-d32c-4395-a1af-5694edaf2592_terseLabel_en-US" xlink:label="lab_us-gaap_AgencySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agency securities</link:label>
    <link:label id="lab_us-gaap_AgencySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AgencySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agency Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AgencySecuritiesMember" xlink:to="lab_us-gaap_AgencySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_fa919360-4bf1-4eb2-91ed-19f8871b4df5_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_TwoThousandTwentyThreeStockInducementPlanMember_55f56bb3-06b4-454e-a665-991cec8655cc_terseLabel_en-US" xlink:label="lab_nvax_TwoThousandTwentyThreeStockInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Inducement Plan</link:label>
    <link:label id="lab_nvax_TwoThousandTwentyThreeStockInducementPlanMember_label_en-US" xlink:label="lab_nvax_TwoThousandTwentyThreeStockInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty Three Stock Inducement Plan [Member]</link:label>
    <link:label id="lab_nvax_TwoThousandTwentyThreeStockInducementPlanMember_documentation_en-US" xlink:label="lab_nvax_TwoThousandTwentyThreeStockInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty Three Stock Inducement Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandTwentyThreeStockInducementPlanMember" xlink:href="nvax-20231231.xsd#nvax_TwoThousandTwentyThreeStockInducementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_TwoThousandTwentyThreeStockInducementPlanMember" xlink:to="lab_nvax_TwoThousandTwentyThreeStockInducementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_30110738-e25a-4578-b2f2-bccef2a1b172_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_LiquidityAndGoingConcernPolicyTextBlock_4012390c-9a9c-4646-b00e-80bb185da775_terseLabel_en-US" xlink:label="lab_nvax_LiquidityAndGoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity and Going Concern</link:label>
    <link:label id="lab_nvax_LiquidityAndGoingConcernPolicyTextBlock_label_en-US" xlink:label="lab_nvax_LiquidityAndGoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity and Going Concern [Policy Text Block]</link:label>
    <link:label id="lab_nvax_LiquidityAndGoingConcernPolicyTextBlock_documentation_en-US" xlink:label="lab_nvax_LiquidityAndGoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity and Going Concern</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LiquidityAndGoingConcernPolicyTextBlock" xlink:href="nvax-20231231.xsd#nvax_LiquidityAndGoingConcernPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="lab_nvax_LiquidityAndGoingConcernPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_d092a0f6-5a16-4aa4-80a4-656ddfa712e9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of principal amount redeemed</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_506c3b2e-76d8-4313-a439-bd049bbc932f_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_da53222f-64d4-4f66-9227-cc705aebdccb_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_1bf152d4-ad62-47a7-85d3-05c1054d59b5_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ProvisionForExcessAndObsoleteInventory_95e8b0e3-093e-46bb-8ca0-59a32b928357_terseLabel_en-US" xlink:label="lab_nvax_ProvisionForExcessAndObsoleteInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for excess and obsolete inventory</link:label>
    <link:label id="lab_nvax_ProvisionForExcessAndObsoleteInventory_label_en-US" xlink:label="lab_nvax_ProvisionForExcessAndObsoleteInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Excess And Obsolete Inventory</link:label>
    <link:label id="lab_nvax_ProvisionForExcessAndObsoleteInventory_documentation_en-US" xlink:label="lab_nvax_ProvisionForExcessAndObsoleteInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Excess And Obsolete Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ProvisionForExcessAndObsoleteInventory" xlink:href="nvax-20231231.xsd#nvax_ProvisionForExcessAndObsoleteInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ProvisionForExcessAndObsoleteInventory" xlink:to="lab_nvax_ProvisionForExcessAndObsoleteInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_SettlementAgreementQuarterlyInstallmentAmount_894d8a3b-c8fe-4d13-ad92-2d736db5c270_terseLabel_en-US" xlink:label="lab_nvax_SettlementAgreementQuarterlyInstallmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement agreement, quarterly installment amount</link:label>
    <link:label id="lab_nvax_SettlementAgreementQuarterlyInstallmentAmount_label_en-US" xlink:label="lab_nvax_SettlementAgreementQuarterlyInstallmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Agreement, Quarterly Installment Amount</link:label>
    <link:label id="lab_nvax_SettlementAgreementQuarterlyInstallmentAmount_documentation_en-US" xlink:label="lab_nvax_SettlementAgreementQuarterlyInstallmentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Agreement, Quarterly Installment Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementQuarterlyInstallmentAmount" xlink:href="nvax-20231231.xsd#nvax_SettlementAgreementQuarterlyInstallmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_SettlementAgreementQuarterlyInstallmentAmount" xlink:to="lab_nvax_SettlementAgreementQuarterlyInstallmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_b0d65ea2-5d56-4921-ba71-0b8dc7b3a822_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock_9f3638f6-e3b9-4f9d-84f3-58df9390498b_terseLabel_en-US" xlink:label="lab_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Units Activity</link:label>
    <link:label id="lab_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock_label_en-US" xlink:label="lab_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation Restricted Stock Awards Activity [Table Text Block]</link:label>
    <link:label id="lab_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock_documentation_en-US" xlink:label="lab_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation, Restricted Stock Awards, Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" xlink:href="nvax-20231231.xsd#nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" xlink:to="lab_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_FilipDubovskyMDMember_label_en-US" xlink:label="lab_nvax_FilipDubovskyMDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Filip Dubovsky, MD [Member]</link:label>
    <link:label id="lab_nvax_FilipDubovskyMDMember_documentation_en-US" xlink:label="lab_nvax_FilipDubovskyMDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Filip Dubovsky, MD</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FilipDubovskyMDMember" xlink:href="nvax-20231231.xsd#nvax_FilipDubovskyMDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_FilipDubovskyMDMember" xlink:to="lab_nvax_FilipDubovskyMDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_843ec616-c15b-475b-9415-93b136be78a5_terseLabel_en-US" xlink:label="lab_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gavi Advance Purchase Agreement- COVAX Facility</link:label>
    <link:label id="lab_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_label_en-US" xlink:label="lab_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gavi Advance Purchase Agreement- COVAX Facility [Member]</link:label>
    <link:label id="lab_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_documentation_en-US" xlink:label="lab_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gavi Advance Purchase Agreement- COVAX Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember" xlink:href="nvax-20231231.xsd#nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember" xlink:to="lab_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_41346a4f-145a-4ed9-8f83-eed007856f62_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements_d6d35ad2-d709-400f-80a5-a4e164644952_terseLabel_en-US" xlink:label="lab_nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liability related to Gavi (see Note 3)</link:label>
    <link:label id="lab_nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements_label_en-US" xlink:label="lab_nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liability Related To Advance Purchase Agreements</link:label>
    <link:label id="lab_nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements_documentation_en-US" xlink:label="lab_nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liability Related To Advance Purchase Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements" xlink:href="nvax-20231231.xsd#nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements" xlink:to="lab_nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_d4770206-be50-456c-891b-3fb8c29bfd73_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_NetProceedsFromTheExerciseOfStockBasedAwards_0870b8b1-e148-4f25-b561-3169d3bd5b86_terseLabel_en-US" xlink:label="lab_nvax_NetProceedsFromTheExerciseOfStockBasedAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from the exercise of stock-based awards</link:label>
    <link:label id="lab_nvax_NetProceedsFromTheExerciseOfStockBasedAwards_label_en-US" xlink:label="lab_nvax_NetProceedsFromTheExerciseOfStockBasedAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Proceeds From The Exercise Of Stock-Based Awards</link:label>
    <link:label id="lab_nvax_NetProceedsFromTheExerciseOfStockBasedAwards_documentation_en-US" xlink:label="lab_nvax_NetProceedsFromTheExerciseOfStockBasedAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Proceeds From The Exercise Of Stock-Based Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NetProceedsFromTheExerciseOfStockBasedAwards" xlink:href="nvax-20231231.xsd#nvax_NetProceedsFromTheExerciseOfStockBasedAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_NetProceedsFromTheExerciseOfStockBasedAwards" xlink:to="lab_nvax_NetProceedsFromTheExerciseOfStockBasedAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_0668d014-f862-4087-a01f-a2abd82b5875_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_22272042-4778-4677-bda0-d940ab30e81f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding and unvested beginning of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ff5d4dde-ec3e-464f-a715-16f3259a2ae2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding and unvested at end of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_0dc6830e-5add-46f7-a0ba-56573a7a72be_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplyCommitmentArrangementMember_949d60ed-3c47-4b89-82ce-8b2289fb88e5_terseLabel_en-US" xlink:label="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment Arrangement [Domain]</link:label>
    <link:label id="lab_us-gaap_SupplyCommitmentArrangementMember_label_en-US" xlink:label="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment Arrangement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember" xlink:to="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_d2a297d8-f275-4e7c-8449-88eb49af274e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_e91e4319-e8a2-4b4b-b9c1-080ae45888cc_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ContractWithCustomerObligationToDeliverTerms_738408ca-2c6b-468c-8ca4-7bf474bc2b7a_terseLabel_en-US" xlink:label="lab_nvax_ContractWithCustomerObligationToDeliverTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, obligation to deliver, terms</link:label>
    <link:label id="lab_nvax_ContractWithCustomerObligationToDeliverTerms_label_en-US" xlink:label="lab_nvax_ContractWithCustomerObligationToDeliverTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Obligation To Deliver, Terms</link:label>
    <link:label id="lab_nvax_ContractWithCustomerObligationToDeliverTerms_documentation_en-US" xlink:label="lab_nvax_ContractWithCustomerObligationToDeliverTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Obligation To Deliver, Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ContractWithCustomerObligationToDeliverTerms" xlink:href="nvax-20231231.xsd#nvax_ContractWithCustomerObligationToDeliverTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ContractWithCustomerObligationToDeliverTerms" xlink:to="lab_nvax_ContractWithCustomerObligationToDeliverTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_11ee4bd8-8c71-49f4-92f8-cf29d4de7b48_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate on cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_25f1fc00-ea62-4d33-8f75-02a0fe5be946_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_86236a80-4252-4764-9c42-2468e51a7002_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual term of stock options and stock appreciation rights exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_6881028f-3a12-4193-8d18-293b3def8994_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_b6907431-28c7-4056-888e-eaaa9bbd851c_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6c10066b-265a-4dc3-84cb-017523b68896_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory federal tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_d90d4074-c076-41cf-b773-13e434166ec8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 16)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_d5b8c741-2bef-4bad-ac76-26d8906c9363_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from sales of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_cbc6da0b-351b-4219-a1e7-551b18dfe4c5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from sales of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_32d494df-02f2-4aff-a92c-190df01dad39_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_528095c6-1e12-4e49-9031-a7964220b88b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Requisite service period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_7f23d510-9f45-42d2-b14e-f1dccbe6679b_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_de1ba996-c0b4-44a7-bedd-98ef4781c57f_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_92adf401-3f75-4224-9d64-7c17d2322138_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7b3a9cfe-c500-4ee0-9222-3bbca08efd8f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in contract with customer, liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d191547b-8eba-4456-85f4-3a3f558c69e9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_f18277e8-87f7-4da1-9126-de7fd81fd38b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash non-current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_6c5a0cbd-c3d1-40da-b8b9-610a055f3d99_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_53086754-a22c-4155-b31d-7084eae453e0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases Accounting</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_76ee16c7-7b15-40a9-8357-0705faecae8b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_a3cf2465-d09b-45d7-adaf-a4b21c60d3fc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par or stated value per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e01db188-e70d-4149-8236-fdacb33d67db_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per Share Weighted-Average Grant-Date Fair Value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dc554c28-c26a-4f46-80da-c4a088eebb65_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6448b257-b0a1-44dc-8f1d-7a7df5e8dd63_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment, Net [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplyCommitmentAxis_9e9a2ef7-bd8d-4192-af53-60b649b56090_terseLabel_en-US" xlink:label="lab_us-gaap_SupplyCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment [Axis]</link:label>
    <link:label id="lab_us-gaap_SupplyCommitmentAxis_label_en-US" xlink:label="lab_us-gaap_SupplyCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentAxis" xlink:to="lab_us-gaap_SupplyCommitmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_1b774a12-cd3b-4d83-851a-21d7c0ae445c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_983feaea-b5fc-47c3-b100-265fa0a8061b_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refunds due to APA customers</link:label>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_OperatingAndFinanceLeaseWriteOff_845786e4-10fa-46ba-9645-69ed1f31af0b_verboseLabel_en-US" xlink:label="lab_nvax_OperatingAndFinanceLeaseWriteOff" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets expensed, net of credits received</link:label>
    <link:label id="lab_nvax_OperatingAndFinanceLeaseWriteOff_label_en-US" xlink:label="lab_nvax_OperatingAndFinanceLeaseWriteOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Finance Lease, Write-off</link:label>
    <link:label id="lab_nvax_OperatingAndFinanceLeaseWriteOff_documentation_en-US" xlink:label="lab_nvax_OperatingAndFinanceLeaseWriteOff" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Finance Lease, Write-off</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_OperatingAndFinanceLeaseWriteOff" xlink:href="nvax-20231231.xsd#nvax_OperatingAndFinanceLeaseWriteOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_OperatingAndFinanceLeaseWriteOff" xlink:to="lab_nvax_OperatingAndFinanceLeaseWriteOff" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_GovernmentOfAustraliaMember_7aea39eb-2a1d-4583-9adb-92747f38a9aa_terseLabel_en-US" xlink:label="lab_nvax_GovernmentOfAustraliaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government of Australia</link:label>
    <link:label id="lab_nvax_GovernmentOfAustraliaMember_label_en-US" xlink:label="lab_nvax_GovernmentOfAustraliaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government of Australia [Member]</link:label>
    <link:label id="lab_nvax_GovernmentOfAustraliaMember_documentation_en-US" xlink:label="lab_nvax_GovernmentOfAustraliaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government of Australia</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GovernmentOfAustraliaMember" xlink:href="nvax-20231231.xsd#nvax_GovernmentOfAustraliaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_GovernmentOfAustraliaMember" xlink:to="lab_nvax_GovernmentOfAustraliaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_19cefe1d-4c4c-481c-bed9-a2ab7f5096c0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_69f9eab5-8fad-4aa2-afd7-6df241578a54_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_665a55d1-7f8d-44a2-a97f-0822fa629124_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_38c444bb-b9c5-400a-9471-7f7d06588a1e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_b4e53eaf-1756-4e60-a306-3d77b1d9e472_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4f9516ce-2cf5-4abb-ae8a-ece792ccfb56_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Black-Scholes fair value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_EuropeanCommissionMember_1aee2ba9-42f4-4ab6-a481-87cf1b798001_terseLabel_en-US" xlink:label="lab_nvax_EuropeanCommissionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Commission</link:label>
    <link:label id="lab_nvax_EuropeanCommissionMember_label_en-US" xlink:label="lab_nvax_EuropeanCommissionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Commission [Member]</link:label>
    <link:label id="lab_nvax_EuropeanCommissionMember_documentation_en-US" xlink:label="lab_nvax_EuropeanCommissionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Commission</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EuropeanCommissionMember" xlink:href="nvax-20231231.xsd#nvax_EuropeanCommissionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_EuropeanCommissionMember" xlink:to="lab_nvax_EuropeanCommissionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_b977f20b-4bb9-4fe8-a412-0401a28c36ad_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_0b2ce013-ea32-4255-81b0-4ea23aea6c60_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_bd4581b1-e02d-4d73-bc09-5b26b85e0932_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_205cfa92-e214-49c2-ae5d-4b3358b5e168_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_4a20c052-07b4-4701-9c25-14d814abacab_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_894216f9-d3ca-45ec-a54c-1fa6cfb8cc38_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2f7dfbba-dff5-463c-8af9-732c3a64b5dc_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_3fcd3e59-f7b5-4cd2-9b77-a44b0c74ff52_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of 2023 Convertible notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_43b9482d-60ab-4c49-8f84-f9911dee9390_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_abab55b0-4ff5-41b4-8865-d80f55072e3d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d307e854-c142-4545-baa6-425a2d01085c_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_35b80a56-9c35-4969-ade5-52e14ed5f3be_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_5fd98e5f-e94c-47f9-baed-bb0b664e5b4b_totalLabel_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current convertible notes payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:to="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_0d7f7fe4-5027-4264-a426-97bb7cd6c946_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4c9d2a58-c621-4406-9096-e2f2db88f7eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_TwoThousandFiveStockIncentivePlanMember_d67f88b6-773a-440a-82ae-ff15ff75c202_terseLabel_en-US" xlink:label="lab_nvax_TwoThousandFiveStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2005 Plan</link:label>
    <link:label id="lab_nvax_TwoThousandFiveStockIncentivePlanMember_label_en-US" xlink:label="lab_nvax_TwoThousandFiveStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Five Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFiveStockIncentivePlanMember" xlink:href="nvax-20231231.xsd#nvax_TwoThousandFiveStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_TwoThousandFiveStockIncentivePlanMember" xlink:to="lab_nvax_TwoThousandFiveStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_ca410722-0d51-4deb-8c73-294030965348_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_4d819cad-2c7b-447e-8534-063a3e23a34d_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_25691fb4-bd7a-4a09-830b-d6f670b1d6fe_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_9177ac2f-8456-465d-a646-70828aa16806_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_ec32bd39-fc9a-4b7a-b86d-ef69793216af_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_USGovernmentMember_2923b363-2a2f-4f00-b516-a0875002a487_terseLabel_en-US" xlink:label="lab_nvax_USGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government</link:label>
    <link:label id="lab_nvax_USGovernmentMember_label_en-US" xlink:label="lab_nvax_USGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government [Member]</link:label>
    <link:label id="lab_nvax_USGovernmentMember_documentation_en-US" xlink:label="lab_nvax_USGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentMember" xlink:href="nvax-20231231.xsd#nvax_USGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_USGovernmentMember" xlink:to="lab_nvax_USGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_8efea658-aedd-4f21-979d-fa86d9760095_terseLabel_en-US" xlink:label="lab_nvax_GrantsUSGovernmentContractAndJointVentureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants, U.S. Government Contract and Joint Venture</link:label>
    <link:label id="lab_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_label_en-US" xlink:label="lab_nvax_GrantsUSGovernmentContractAndJointVentureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants, U.S. Government Contract and Joint Venture [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract" xlink:href="nvax-20231231.xsd#nvax_GrantsUSGovernmentContractAndJointVentureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract" xlink:to="lab_nvax_GrantsUSGovernmentContractAndJointVentureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CompensationStockIssuedUnderIncentiveProgram_9182f810-8d09-4f22-aaae-ef290237d78d_terseLabel_en-US" xlink:label="lab_nvax_CompensationStockIssuedUnderIncentiveProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued under incentive programs</link:label>
    <link:label id="lab_nvax_CompensationStockIssuedUnderIncentiveProgram_label_en-US" xlink:label="lab_nvax_CompensationStockIssuedUnderIncentiveProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Stock Issued Under Incentive Program</link:label>
    <link:label id="lab_nvax_CompensationStockIssuedUnderIncentiveProgram_documentation_en-US" xlink:label="lab_nvax_CompensationStockIssuedUnderIncentiveProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Stock Issued Under Incentive Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CompensationStockIssuedUnderIncentiveProgram" xlink:href="nvax-20231231.xsd#nvax_CompensationStockIssuedUnderIncentiveProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CompensationStockIssuedUnderIncentiveProgram" xlink:to="lab_nvax_CompensationStockIssuedUnderIncentiveProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_64b69e9c-9f52-4e75-81b2-c56e3368aeaa_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ffcc503b-ac1f-4993-8d99-86beedbca447_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_92d12f79-a03a-4620-9e04-1a767d8d4b1e_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gains (losses) on marketable securities available-for-sale, net of reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_71be232a-9c52-4b0f-a325-f9da305b75a8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_PercentageOfMarketPriceForStockPurchase_4ba7fbf2-4ae8-41b4-a0c9-23c99c7d4565_terseLabel_en-US" xlink:label="lab_nvax_PercentageOfMarketPriceForStockPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of market price for stock purchase</link:label>
    <link:label id="lab_nvax_PercentageOfMarketPriceForStockPurchase_label_en-US" xlink:label="lab_nvax_PercentageOfMarketPriceForStockPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Market Price For Stock Purchase</link:label>
    <link:label id="lab_nvax_PercentageOfMarketPriceForStockPurchase_documentation_en-US" xlink:label="lab_nvax_PercentageOfMarketPriceForStockPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of market price for stock purchase.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PercentageOfMarketPriceForStockPurchase" xlink:href="nvax-20231231.xsd#nvax_PercentageOfMarketPriceForStockPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_PercentageOfMarketPriceForStockPurchase" xlink:to="lab_nvax_PercentageOfMarketPriceForStockPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_d92a95fa-7e64-4bba-8571-dbc1fd04bdc6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_89f41183-3f83-46dc-a649-554397991a3c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_cb49eccf-617c-478c-bcbb-ed48ed497d06_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f3512089-4b61-4328-858f-b02559aba317_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent_d2461dc7-5d49-46f5-9b32-6ea4a334bda0_terseLabel_en-US" xlink:label="lab_nvax_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash stock-based compensation</link:label>
    <link:label id="lab_nvax_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent_label_en-US" xlink:label="lab_nvax_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Non-Cash Share-Based Payment Arrangement, Percent</link:label>
    <link:label id="lab_nvax_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent_documentation_en-US" xlink:label="lab_nvax_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Non-Cash Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent" xlink:href="nvax-20231231.xsd#nvax_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent" xlink:to="lab_nvax_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_NumberOfQuarterlyInstallmentPayments_f973ded9-c4f6-4b39-b9c5-0766d8def779_terseLabel_en-US" xlink:label="lab_nvax_NumberOfQuarterlyInstallmentPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of quarterly installment payments</link:label>
    <link:label id="lab_nvax_NumberOfQuarterlyInstallmentPayments_label_en-US" xlink:label="lab_nvax_NumberOfQuarterlyInstallmentPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Quarterly Installment Payments</link:label>
    <link:label id="lab_nvax_NumberOfQuarterlyInstallmentPayments_documentation_en-US" xlink:label="lab_nvax_NumberOfQuarterlyInstallmentPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Quarterly Installment Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfQuarterlyInstallmentPayments" xlink:href="nvax-20231231.xsd#nvax_NumberOfQuarterlyInstallmentPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_NumberOfQuarterlyInstallmentPayments" xlink:to="lab_nvax_NumberOfQuarterlyInstallmentPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4d70fbd8-af75-4a14-b1d0-dd553d9e6e7b_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_e730137b-13e8-4ef0-9d8b-644d97f11019_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_39332988-5a52-4a6f-a31b-4063881a8f76_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_8bb037b9-8be5-4c67-8612-9835e70b6f8f_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract_1fbfbe4e-5c84-4cdf-8028-c59dac57a8bd_terseLabel_en-US" xlink:label="lab_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract_label_en-US" xlink:label="lab_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Operating and Financing Activities Lessee [Abstract]</link:label>
    <link:label id="lab_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract_documentation_en-US" xlink:label="lab_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Operating and Financing Activities Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract" xlink:href="nvax-20231231.xsd#nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract" xlink:to="lab_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_bde102fe-dabf-4893-b97b-2a0fbc08d8d4_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_c6003265-4e8d-4cfe-b197-1b7e3e918b96_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CanadaAdvancePurchaseAgreementMember_3d8c40cc-13da-47f9-8a22-84d961d5346a_terseLabel_en-US" xlink:label="lab_nvax_CanadaAdvancePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada Advance Purchase Agreement</link:label>
    <link:label id="lab_nvax_CanadaAdvancePurchaseAgreementMember_label_en-US" xlink:label="lab_nvax_CanadaAdvancePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada Advance Purchase Agreement [Member]</link:label>
    <link:label id="lab_nvax_CanadaAdvancePurchaseAgreementMember_documentation_en-US" xlink:label="lab_nvax_CanadaAdvancePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada Advance Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CanadaAdvancePurchaseAgreementMember" xlink:href="nvax-20231231.xsd#nvax_CanadaAdvancePurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CanadaAdvancePurchaseAgreementMember" xlink:to="lab_nvax_CanadaAdvancePurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_e53ece09-8848-4e5b-a775-6d2a0f9f7822_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Lease Expenses</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_4fc0bf16-122c-492c-ad39-ba02f9328f6e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_7bf8f822-c994-463e-bdc5-ac0c6e362080_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_006f13bc-76f0-4a7b-8661-8552d39374ef_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward_beade6b1-7a38-44b3-aecd-8db8964fb00d_terseLabel_en-US" xlink:label="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable:</link:label>
    <link:label id="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward_label_en-US" xlink:label="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Before Allowance For Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward_documentation_en-US" xlink:label="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Before Allowance For Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward" xlink:href="nvax-20231231.xsd#nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward" xlink:to="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_2f6d62b0-f140-4bdc-9b79-47c31dbc8622_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_37676739-ef9c-4108-bbd5-324108748b1b_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_7d24d43e-b915-41b0-8ea4-f5feda9064f5_verboseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock_a9716eeb-fba8-455d-ad40-23049fcbcb89_verboseLabel_en-US" xlink:label="lab_nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Balance Sheet Information Related to Leases</link:label>
    <link:label id="lab_nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock_label_en-US" xlink:label="lab_nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Balance Sheet Information Related to Lease [Table Text Block]</link:label>
    <link:label id="lab_nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock_documentation_en-US" xlink:label="lab_nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of balance sheet information related to lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock" xlink:href="nvax-20231231.xsd#nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock" xlink:to="lab_nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock_69cc4efb-ffc1-471b-83bf-060eda7935f7_terseLabel_en-US" xlink:label="lab_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Receivable, Unbilled Services, and Deferred Revenue</link:label>
    <link:label id="lab_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock_label_en-US" xlink:label="lab_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Increase (Decrease) In Accounts Receivable, Unbilled Services, and Deferred Revenue [Table Text Block]</link:label>
    <link:label id="lab_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock_documentation_en-US" xlink:label="lab_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Increase (Decrease) In Accounts Receivable, Unbilled Services, and Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" xlink:href="nvax-20231231.xsd#nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" xlink:to="lab_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_21180430-8314-4e38-bd03-383a88c5a442_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2cd686d7-400b-4395-be1f-4d1c1e99262b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_da6aaaba-bef3-47b6-b31b-b8a44ffa54d4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual term of stock options and stock appreciation rights outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_5c334f17-9db4-48e9-8da6-3369c63964e3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_ac00e0a2-5939-41f4-8f9d-d62174d30240_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_USGovernmentPartnershipMember_285770d1-3282-429b-8244-6f87d32e5e54_terseLabel_en-US" xlink:label="lab_nvax_USGovernmentPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Partnership</link:label>
    <link:label id="lab_nvax_USGovernmentPartnershipMember_label_en-US" xlink:label="lab_nvax_USGovernmentPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Partnership [Member]</link:label>
    <link:label id="lab_nvax_USGovernmentPartnershipMember_documentation_en-US" xlink:label="lab_nvax_USGovernmentPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Partnership</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentPartnershipMember" xlink:href="nvax-20231231.xsd#nvax_USGovernmentPartnershipMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_USGovernmentPartnershipMember" xlink:to="lab_nvax_USGovernmentPartnershipMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_01e03ae2-ae8f-4a19-99d8-ea170fe46913_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_c1d10027-16e5-40bd-8419-ed7bad76f558_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_57990715-9188-47f6-ae0c-926f5e122f4c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_26edf451-bcc8-4737-9908-c7e5dd889381_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0309e7ee-539d-4594-b2de-eca0cc602c85_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_3f65aae4-5560-481d-989c-f16624b54e97_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for tax positions of prior year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_e1a4bb60-e42c-48db-92c2-1fdec43dea22_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_AuditInformationAbstract_label_en-US" xlink:label="lab_nvax_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_nvax_AuditInformationAbstract_documentation_en-US" xlink:label="lab_nvax_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AuditInformationAbstract" xlink:href="nvax-20231231.xsd#nvax_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_AuditInformationAbstract" xlink:to="lab_nvax_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_130dc744-9af3-49ee-bec2-07e219d4d382_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Supplies_4e60d298-6b17-41e6-93a1-93fcdcf32480_verboseLabel_en-US" xlink:label="lab_us-gaap_Supplies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_Supplies_label_en-US" xlink:label="lab_us-gaap_Supplies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Supplies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Supplies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Supplies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Supplies" xlink:to="lab_us-gaap_Supplies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_9ef01c4a-fb2e-4666-a28b-c76cec0fe235_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_LeaseLiabilityNoncurrent_808ba08c-76e0-41a0-b03f-151ffcfde9a4_totalLabel_en-US" xlink:label="lab_nvax_LeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current lease liabilities</link:label>
    <link:label id="lab_nvax_LeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_nvax_LeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liability, Noncurrent</link:label>
    <link:label id="lab_nvax_LeaseLiabilityNoncurrent_documentation_en-US" xlink:label="lab_nvax_LeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseLiabilityNoncurrent" xlink:href="nvax-20231231.xsd#nvax_LeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_LeaseLiabilityNoncurrent" xlink:to="lab_nvax_LeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_f91a9af9-fc5a-4e22-890f-7cf39ff86223_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for tax positions of current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_54bc728d-e4d9-40ab-a969-65d403f67603_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7c36b67f-02af-4821-9070-a23da70991bb_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c47d1efc-81cf-4965-92ab-35af92824a33_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cb113ed5-07c0-437b-a7d2-1627d712cd90_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_UnderwriterMember_db9dc57d-2229-4a52-8315-968d2c332dcc_terseLabel_en-US" xlink:label="lab_nvax_UnderwriterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriter</link:label>
    <link:label id="lab_nvax_UnderwriterMember_label_en-US" xlink:label="lab_nvax_UnderwriterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriter [Member]</link:label>
    <link:label id="lab_nvax_UnderwriterMember_documentation_en-US" xlink:label="lab_nvax_UnderwriterMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_UnderwriterMember" xlink:href="nvax-20231231.xsd#nvax_UnderwriterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_UnderwriterMember" xlink:to="lab_nvax_UnderwriterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_e330bd2e-df4c-417b-8cb8-1c8fc41a8e5c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_548d0e78-0d67-48fc-8434-eaf771fe940a_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease expense</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_8adb1753-e3e4-4b68-8225-fcd68b6f2121_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_880a4b32-b8b2-4800-a992-8ff6a9db80b1_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_868492a0-0b61-4acb-9c9e-b23f8fc0ab03_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b862ae38-b622-44a0-937c-b2743e4b83c0_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_032641c6-34f3-4026-8b28-e080a86d1075_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_0227cd21-26af-49d1-8e51-9d2af10f6f2c_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance and employee benefit costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_08bab111-e8c0-4364-8b6c-38974194ce29_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, 1,000,323 shares, cost basis at December&#160;31, 2023 and 766,631 shares, cost basis at December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_SubjectToExpirationMember_2b083f54-fa0e-42a2-b958-9e9ed192e975_terseLabel_en-US" xlink:label="lab_nvax_SubjectToExpirationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subject to Expiration</link:label>
    <link:label id="lab_nvax_SubjectToExpirationMember_label_en-US" xlink:label="lab_nvax_SubjectToExpirationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subject to Expiration [Member]</link:label>
    <link:label id="lab_nvax_SubjectToExpirationMember_documentation_en-US" xlink:label="lab_nvax_SubjectToExpirationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SubjectToExpirationMember" xlink:href="nvax-20231231.xsd#nvax_SubjectToExpirationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_SubjectToExpirationMember" xlink:to="lab_nvax_SubjectToExpirationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_348028bb-f79f-4cfe-a53c-ee82059d43ee_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received on transaction, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding_242ee80d-85ed-4abb-850f-04fa54095e1d_terseLabel_en-US" xlink:label="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract to perform for others funding</link:label>
    <link:label id="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding_label_en-US" xlink:label="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement Contract To Perform For Others Funding</link:label>
    <link:label id="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding_documentation_en-US" xlink:label="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement Contract To Perform For Others Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding" xlink:href="nvax-20231231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding" xlink:to="lab_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_db77b5d9-6db5-4676-8cf1-89167d77d855_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, employer matching contribution, percent of match</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4daac3c3-7728-4075-86b9-e90702d523b8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense, recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_b3cdb8bc-b436-4afe-a661-18f101bd24d9_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_28840f80-145b-4544-a5b6-7aef8c7f3150_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_USGovernmentAgreementMember_1a6a9c4a-fbb7-4aec-b87d-ed085eab5444_terseLabel_en-US" xlink:label="lab_nvax_USGovernmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">USG Agreement</link:label>
    <link:label id="lab_nvax_USGovernmentAgreementMember_label_en-US" xlink:label="lab_nvax_USGovernmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agreement [Member]</link:label>
    <link:label id="lab_nvax_USGovernmentAgreementMember_documentation_en-US" xlink:label="lab_nvax_USGovernmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentAgreementMember" xlink:href="nvax-20231231.xsd#nvax_USGovernmentAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_USGovernmentAgreementMember" xlink:to="lab_nvax_USGovernmentAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_3b93c09d-a438-4042-8840-c3a424a07457_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CollaborativeArrangementAbstract_label_en-US" xlink:label="lab_nvax_CollaborativeArrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Abstract]</link:label>
    <link:label id="lab_nvax_CollaborativeArrangementAbstract_documentation_en-US" xlink:label="lab_nvax_CollaborativeArrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborativeArrangementAbstract" xlink:href="nvax-20231231.xsd#nvax_CollaborativeArrangementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CollaborativeArrangementAbstract" xlink:to="lab_nvax_CollaborativeArrangementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_242aa80b-4e6b-4f28-a656-edafdb8a1b06_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14b1932b-c63c-4513-a4fd-4258a500c04c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_GovernmentOfCanadaMember_e417b2a3-03fb-4814-935e-13df54bc7a09_terseLabel_en-US" xlink:label="lab_nvax_GovernmentOfCanadaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government of Canada</link:label>
    <link:label id="lab_nvax_GovernmentOfCanadaMember_label_en-US" xlink:label="lab_nvax_GovernmentOfCanadaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government of Canada [Member]</link:label>
    <link:label id="lab_nvax_GovernmentOfCanadaMember_documentation_en-US" xlink:label="lab_nvax_GovernmentOfCanadaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government of Canada</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GovernmentOfCanadaMember" xlink:href="nvax-20231231.xsd#nvax_GovernmentOfCanadaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_GovernmentOfCanadaMember" xlink:to="lab_nvax_GovernmentOfCanadaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_281a2a7a-b605-40d1-b395-4a012fa97873_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_8ccc807b-55b0-409e-8cb1-489545592ce4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_8b426c3e-9660-413f-9f21-17a1de4210c3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_12cdcc9d-acab-41d9-8d8c-573cbb366ad1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_4f23e985-aad9-41c8-87e6-2125c2248157_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_ce4c57b2-f476-4c4a-8c03-5b6818b1fcd4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_WeightedAverageRemainingLeaseTermAbstract_78514b80-aaa9-438b-91d3-dc57006d039c_terseLabel_en-US" xlink:label="lab_nvax_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (years):</link:label>
    <link:label id="lab_nvax_WeightedAverageRemainingLeaseTermAbstract_label_en-US" xlink:label="lab_nvax_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:label id="lab_nvax_WeightedAverageRemainingLeaseTermAbstract_documentation_en-US" xlink:label="lab_nvax_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_WeightedAverageRemainingLeaseTermAbstract" xlink:href="nvax-20231231.xsd#nvax_WeightedAverageRemainingLeaseTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_WeightedAverageRemainingLeaseTermAbstract" xlink:to="lab_nvax_WeightedAverageRemainingLeaseTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerBasisOfPricingAxis_9f1bb549-2394-4fcc-a7ac-bdb035eb8bcf_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerBasisOfPricingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Basis of Pricing [Axis]</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerBasisOfPricingAxis_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerBasisOfPricingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Basis of Pricing [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerBasisOfPricingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis" xlink:to="lab_us-gaap_ContractWithCustomerBasisOfPricingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f05bd135-c401-41de-9715-52a1ca6dbc36_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b14c14cd-b1cd-47bf-939e-34f3bddeed5e_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock_ed29f656-115d-40f8-bccd-eeecd847dfb2_terseLabel_en-US" xlink:label="lab_nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development Expenses</link:label>
    <link:label id="lab_nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock_label_en-US" xlink:label="lab_nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development Expenses, Policy [Policy Text Block]</link:label>
    <link:label id="lab_nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for accrued research and development expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" xlink:href="nvax-20231231.xsd#nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" xlink:to="lab_nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_OtherGrantRevenueMember_f2fa1b50-1f54-42ab-8a55-dd4c3decec96_terseLabel_en-US" xlink:label="lab_nvax_OtherGrantRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other grant revenue</link:label>
    <link:label id="lab_nvax_OtherGrantRevenueMember_label_en-US" xlink:label="lab_nvax_OtherGrantRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Grant Revenue [Member]</link:label>
    <link:label id="lab_nvax_OtherGrantRevenueMember_documentation_en-US" xlink:label="lab_nvax_OtherGrantRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Grant Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_OtherGrantRevenueMember" xlink:href="nvax-20231231.xsd#nvax_OtherGrantRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_OtherGrantRevenueMember" xlink:to="lab_nvax_OtherGrantRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_151495e6-845d-4286-b0a9-fe43405fc6e5_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_74e6bc08-2739-4fa3-9d4b-71b742f91af3_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6b005193-3b62-4af3-aae3-daa890b70360_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_6cabbff8-f3ed-4abf-a56b-34f7cbe6a472_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_cab0fa83-b78a-4312-870a-566a37fbde34_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_c1fc2207-a95e-4da6-abe8-06abe6942847_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_29b803b7-feb0-48ec-95b2-7fd1849911cc_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_74504724-738a-43f8-b2c2-ff468f24348e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_048dc905-450a-42b7-9652-f308486d2caa_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_619b5e98-ab9b-43fe-a892-d1bd209d4761_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1d4f6d61-c404-4f07-8058-c372ca172b2c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ContractWithCustomerLiabilityRollForward_9cafea44-5a70-4382-8d39-8503cede6e81_terseLabel_en-US" xlink:label="lab_nvax_ContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_nvax_ContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_nvax_ContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_nvax_ContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_nvax_ContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ContractWithCustomerLiabilityRollForward" xlink:href="nvax-20231231.xsd#nvax_ContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ContractWithCustomerLiabilityRollForward" xlink:to="lab_nvax_ContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_MaximumContributionOfEmployeesAsPayrollDeductions_23f125c1-c56c-43c2-ad56-f604c90b7b76_terseLabel_en-US" xlink:label="lab_nvax_MaximumContributionOfEmployeesAsPayrollDeductions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum contribution of employees as payroll deductions</link:label>
    <link:label id="lab_nvax_MaximumContributionOfEmployeesAsPayrollDeductions_label_en-US" xlink:label="lab_nvax_MaximumContributionOfEmployeesAsPayrollDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Contribution Of Employees As Payroll Deductions</link:label>
    <link:label id="lab_nvax_MaximumContributionOfEmployeesAsPayrollDeductions_documentation_en-US" xlink:label="lab_nvax_MaximumContributionOfEmployeesAsPayrollDeductions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum contribution of employees as payroll deductions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_MaximumContributionOfEmployeesAsPayrollDeductions" xlink:href="nvax-20231231.xsd#nvax_MaximumContributionOfEmployeesAsPayrollDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_MaximumContributionOfEmployeesAsPayrollDeductions" xlink:to="lab_nvax_MaximumContributionOfEmployeesAsPayrollDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent_e681104c-6282-4798-a471-d97670e4af0b_terseLabel_en-US" xlink:label="lab_nvax_EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation of Indebtedness</link:label>
    <link:label id="lab_nvax_EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent_label_en-US" xlink:label="lab_nvax_EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Cancellation Of Indebtedness, Percent</link:label>
    <link:label id="lab_nvax_EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent_documentation_en-US" xlink:label="lab_nvax_EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Cancellation Of Indebtedness, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent" xlink:href="nvax-20231231.xsd#nvax_EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent" xlink:to="lab_nvax_EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_504b66d5-26fe-41e9-8dfd-6134c3fee25a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount of notes issued</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0d258595-341f-4aa4-84d9-7dfb1d41e431_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_9f3aa98c-3bb7-450f-9d4d-a1e44702dcf1_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b279ddd7-c671-4cf0-9c8a-a101fe6cb7ee_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_159e5268-db5c-4534-ba42-6c594ca25ba4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_338f7337-ed6f-4abe-ae31-59ef6efdbf78_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_1406165f-8c9d-4094-90b2-29d10a117702_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, conversion price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfExpenseAxis_63aab21a-bf0b-4eb7-b152-bd1af9edd16a_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfExpenseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Expense [Axis]</link:label>
    <link:label id="lab_us-gaap_NatureOfExpenseAxis_label_en-US" xlink:label="lab_us-gaap_NatureOfExpenseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Expense [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfExpenseAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfExpenseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfExpenseAxis" xlink:to="lab_us-gaap_NatureOfExpenseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6632c4b3-f59d-4f8b-9bfa-fbf30538fa57_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_eb5f4bbb-7128-4dee-9d7d-30fe69c849be_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum contribution, percentage of compensation</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_96b7fbf1-0842-4355-9a19-c16d7da8aba6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_71bfd47a-e9c6-42be-9a13-d2be97be0727_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_8af830d7-7aaf-4362-ba5c-347b79156747_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ROUFacilityLeasesMember_99b9a867-5125-4af4-a53e-4a5f06155f89_terseLabel_en-US" xlink:label="lab_nvax_ROUFacilityLeasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU Facility Leases</link:label>
    <link:label id="lab_nvax_ROUFacilityLeasesMember_label_en-US" xlink:label="lab_nvax_ROUFacilityLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU Facility Leases [Member]</link:label>
    <link:label id="lab_nvax_ROUFacilityLeasesMember_documentation_en-US" xlink:label="lab_nvax_ROUFacilityLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU Facility Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ROUFacilityLeasesMember" xlink:href="nvax-20231231.xsd#nvax_ROUFacilityLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ROUFacilityLeasesMember" xlink:to="lab_nvax_ROUFacilityLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_26fa1662-2ffb-419a-b912-750dabfed7c7_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_a8379eff-13aa-4add-8273-7b027f3d6cb8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_SettlementAgreementInitialReservationFee_b18673f6-0e1e-4153-a5b9-70638180b37d_terseLabel_en-US" xlink:label="lab_nvax_SettlementAgreementInitialReservationFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial reservation fee</link:label>
    <link:label id="lab_nvax_SettlementAgreementInitialReservationFee_label_en-US" xlink:label="lab_nvax_SettlementAgreementInitialReservationFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Agreement, Initial Reservation Fee</link:label>
    <link:label id="lab_nvax_SettlementAgreementInitialReservationFee_documentation_en-US" xlink:label="lab_nvax_SettlementAgreementInitialReservationFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Agreement, Initial Reservation Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementInitialReservationFee" xlink:href="nvax-20231231.xsd#nvax_SettlementAgreementInitialReservationFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_SettlementAgreementInitialReservationFee" xlink:to="lab_nvax_SettlementAgreementInitialReservationFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_93ff5758-5d56-4804-bfa7-bac854d32c60_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options &amp; SARs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_fc3375c0-0465-4b57-b8e6-dbf6acd8b39a_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement expense</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8a90b5e5-ebe2-43f0-bca0-3ecc0a7e723a_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_3c09e238-ed39-48e7-aaa4-e5621ff9ca69_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease obligation</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_f9a93025-a666-4f37-8761-4fa8389255ef_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollectiveBargainingArrangementDomain_f5363bd2-dbbc-44d0-a60c-5d583a687e3e_terseLabel_en-US" xlink:label="lab_us-gaap_CollectiveBargainingArrangementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collective Bargaining Arrangement [Domain]</link:label>
    <link:label id="lab_us-gaap_CollectiveBargainingArrangementDomain_label_en-US" xlink:label="lab_us-gaap_CollectiveBargainingArrangementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collective-Bargaining Arrangement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollectiveBargainingArrangementDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollectiveBargainingArrangementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollectiveBargainingArrangementDomain" xlink:to="lab_us-gaap_CollectiveBargainingArrangementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f306ebb5-6518-4a5e-9b8b-f65d1bd9f6f2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9063a7a5-8764-4da1-b02d-ce2003803c63_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, prepaid expenses, and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_42ba70e8-101f-4018-9bc6-5e4cd6f36e80_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_fb4e46fd-5f79-456f-9f5a-243a534db77d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_77fbf032-14f3-4304-aed2-cfc6b284d18a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, cost</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_ab24079a-a40c-4819-a59a-d3f06842633f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_ceae7737-a8cc-410d-bae5-eb244a06b262_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, noncurrent</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_FivePointZeroConvertibleNotesDue2027Member_26ccb5bf-460b-4f72-a2a6-2c384de0d2af_terseLabel_en-US" xlink:label="lab_nvax_FivePointZeroConvertibleNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Convertible notes due 2027</link:label>
    <link:label id="lab_nvax_FivePointZeroConvertibleNotesDue2027Member_c6106049-a8ad-41ac-a698-63f385681f7b_verboseLabel_en-US" xlink:label="lab_nvax_FivePointZeroConvertibleNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Notes</link:label>
    <link:label id="lab_nvax_FivePointZeroConvertibleNotesDue2027Member_label_en-US" xlink:label="lab_nvax_FivePointZeroConvertibleNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Zero Convertible Notes Due 2027 [Member]</link:label>
    <link:label id="lab_nvax_FivePointZeroConvertibleNotesDue2027Member_documentation_en-US" xlink:label="lab_nvax_FivePointZeroConvertibleNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Point Zero Convertible Notes Due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FivePointZeroConvertibleNotesDue2027Member" xlink:href="nvax-20231231.xsd#nvax_FivePointZeroConvertibleNotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_FivePointZeroConvertibleNotesDue2027Member" xlink:to="lab_nvax_FivePointZeroConvertibleNotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_da2f0d94-b046-451d-9b06-3e53fa1137c0_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_e27a517a-a71a-463d-9b66-bb31d6a7df3d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_MatrixMAdjuvantSalesMember_27797c34-a5c4-4005-b40d-5a8358d688be_terseLabel_en-US" xlink:label="lab_nvax_MatrixMAdjuvantSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Matrix-M Adjuvant Sales</link:label>
    <link:label id="lab_nvax_MatrixMAdjuvantSalesMember_label_en-US" xlink:label="lab_nvax_MatrixMAdjuvantSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Matrix-M Adjuvant Sales [Member]</link:label>
    <link:label id="lab_nvax_MatrixMAdjuvantSalesMember_documentation_en-US" xlink:label="lab_nvax_MatrixMAdjuvantSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Matrix-M Adjuvant Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_MatrixMAdjuvantSalesMember" xlink:href="nvax-20231231.xsd#nvax_MatrixMAdjuvantSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_MatrixMAdjuvantSalesMember" xlink:to="lab_nvax_MatrixMAdjuvantSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_10882e55-ad69-420f-92c3-0402764fd36e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_LeaseLiabilityCurrent_7aa88cf4-5ea3-453d-8df3-5f10e7b1952b_totalLabel_en-US" xlink:label="lab_nvax_LeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current lease liabilities</link:label>
    <link:label id="lab_nvax_LeaseLiabilityCurrent_label_en-US" xlink:label="lab_nvax_LeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liability, Current</link:label>
    <link:label id="lab_nvax_LeaseLiabilityCurrent_documentation_en-US" xlink:label="lab_nvax_LeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseLiabilityCurrent" xlink:href="nvax-20231231.xsd#nvax_LeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_LeaseLiabilityCurrent" xlink:to="lab_nvax_LeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_8f18727b-f651-4f0d-b3da-279e66a39552_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value, 600,000,000 shares authorized at December&#160;31, 2023 and 2022; and 140,506,093 shares issued and 139,505,770 shares outstanding at December&#160;31, 2023 and 86,806,554 shares issued and 86,039,923 shares outstanding at December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_86a198f1-8151-4824-8e17-6d76a15e4aed_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_dca75b64-5153-4589-a000-5182fda87816_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_LeaseRightOfUseAsset_59eaa4c0-b128-4da7-853b-2bba48187447_verboseLabel_en-US" xlink:label="lab_nvax_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use asset, net</link:label>
    <link:label id="lab_nvax_LeaseRightOfUseAsset_99d8d0a1-6ed9-4989-b742-9a4ac57ff883_totalLabel_en-US" xlink:label="lab_nvax_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current ROU assets</link:label>
    <link:label id="lab_nvax_LeaseRightOfUseAsset_label_en-US" xlink:label="lab_nvax_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_nvax_LeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_nvax_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseRightOfUseAsset" xlink:href="nvax-20231231.xsd#nvax_LeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_LeaseRightOfUseAsset" xlink:to="lab_nvax_LeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ba4258e-8738-4691-9deb-e8f8136f454f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_6bcbde70-1768-4d14-82ea-7dc864ba7925_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_52232e42-f0ee-4a64-be7e-0ae0cf20dda6_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Loss Carryforward</link:label>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_label_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Loss Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLossCarryforwardMember" xlink:to="lab_us-gaap_CapitalLossCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_d0e323e2-c408-432b-a27b-a1d8065c8685_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_3d206f99-7884-4c7a-bd34-6ea93e103e65_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal and state net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_AmountsChargedAgainstProductSales_43063244-ed7f-4e64-8fda-2487fbe08a62_verboseLabel_en-US" xlink:label="lab_nvax_AmountsChargedAgainstProductSales" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract value no longer available</link:label>
    <link:label id="lab_nvax_AmountsChargedAgainstProductSales_cfd14c2e-a7aa-41e3-8b97-d3db5cab3584_terseLabel_en-US" xlink:label="lab_nvax_AmountsChargedAgainstProductSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts charged against product sales</link:label>
    <link:label id="lab_nvax_AmountsChargedAgainstProductSales_label_en-US" xlink:label="lab_nvax_AmountsChargedAgainstProductSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Charged Against Product Sales</link:label>
    <link:label id="lab_nvax_AmountsChargedAgainstProductSales_documentation_en-US" xlink:label="lab_nvax_AmountsChargedAgainstProductSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Charged Against Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AmountsChargedAgainstProductSales" xlink:href="nvax-20231231.xsd#nvax_AmountsChargedAgainstProductSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_AmountsChargedAgainstProductSales" xlink:to="lab_nvax_AmountsChargedAgainstProductSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_7b952afb-2e4b-4446-9616-9e28b6a9e3df_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_32686334-5903-45bc-87a3-2dd1d85d765e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_340d706f-ab99-4937-817a-9fba4878a2bf_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash flows used in finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_6816baf0-2a88-468a-b97e-08ed360e80fd_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_TakedaArrangementMember_15d3fcf3-ed78-4d06-8640-b5d20d5e8b1b_terseLabel_en-US" xlink:label="lab_nvax_TakedaArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Arrangement</link:label>
    <link:label id="lab_nvax_TakedaArrangementMember_label_en-US" xlink:label="lab_nvax_TakedaArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Arrangement [Member]</link:label>
    <link:label id="lab_nvax_TakedaArrangementMember_documentation_en-US" xlink:label="lab_nvax_TakedaArrangementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TakedaArrangementMember" xlink:href="nvax-20231231.xsd#nvax_TakedaArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_TakedaArrangementMember" xlink:to="lab_nvax_TakedaArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_385afdee-1228-430e-bc33-4f6dbb8c2e4a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_4fbd4dc9-34b2-4c18-989d-e6ce3a8b5fdb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_d8515f3f-594e-4f83-8487-95fc32a57a70_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_3cf4af73-0157-44a5-93f9-3c50636914ab_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_ca45ce56-95a4-43e1-930f-6d1e1fb76c8d_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_593f7e0f-7b8c-458c-a7d3-441aaa36dd0b_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_440f53f1-4292-4aca-984a-b7129cc42cf3_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Tax Rate Differences</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_f4ae705d-c3df-45ae-8d75-3564bb1349ef_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits balance at January 1</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_e6ad12d4-0424-4302-a5f3-3ae883bbf019_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits balance at December 31,</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_a0ffcf28-2d6b-45f4-bd44-c113be03b35a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_b4da456b-33a9-4850-a3c9-3593e1577c2e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_88e63b74-0547-4e13-9ac5-099d20ad91e6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sundry Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_c576f46d-c7b9-4049-962e-c4c43253025a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_PurchaseAgreementNumberOfDosesCancelled_d674b31f-9c95-499f-94f1-8b4a239e2366_terseLabel_en-US" xlink:label="lab_nvax_PurchaseAgreementNumberOfDosesCancelled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of doses, cancelled</link:label>
    <link:label id="lab_nvax_PurchaseAgreementNumberOfDosesCancelled_label_en-US" xlink:label="lab_nvax_PurchaseAgreementNumberOfDosesCancelled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement, Number of Doses, Cancelled</link:label>
    <link:label id="lab_nvax_PurchaseAgreementNumberOfDosesCancelled_documentation_en-US" xlink:label="lab_nvax_PurchaseAgreementNumberOfDosesCancelled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement, Number of Doses, Cancelled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfDosesCancelled" xlink:href="nvax-20231231.xsd#nvax_PurchaseAgreementNumberOfDosesCancelled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_PurchaseAgreementNumberOfDosesCancelled" xlink:to="lab_nvax_PurchaseAgreementNumberOfDosesCancelled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_e8c351d9-c61d-4e6a-a0bf-6fb294525f0e_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_3cbefc06-63c4-4ec4-9523-3c3f16817cc8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_bb116a8d-c3a7-4105-aeda-62a8d8e41623_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_46748234-6b3f-47bc-856c-2a999cd81613_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_29fe36ba-afe9-46d9-b826-07886e1732ea_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_df3b9ff8-b0f7-4e47-a0f5-accb09be1774_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization &amp; Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e077c325-6269-4e7f-a4e7-9e0a97da039e_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial settlement payment</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock_0f4eea6d-2474-4910-9991-0ff94f5c97f6_verboseLabel_en-US" xlink:label="lab_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Interest Expense</link:label>
    <link:label id="lab_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock_label_en-US" xlink:label="lab_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense Related to Convertible Notes [Table Text Block]</link:label>
    <link:label id="lab_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock_documentation_en-US" xlink:label="lab_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of interest expense related to convertible notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock" xlink:href="nvax-20231231.xsd#nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock" xlink:to="lab_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_NumberOfSettlementPayments_bf29e57b-42c9-460b-8966-81447d70e4ae_terseLabel_en-US" xlink:label="lab_nvax_NumberOfSettlementPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of settlement payments</link:label>
    <link:label id="lab_nvax_NumberOfSettlementPayments_label_en-US" xlink:label="lab_nvax_NumberOfSettlementPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Settlement Payments</link:label>
    <link:label id="lab_nvax_NumberOfSettlementPayments_documentation_en-US" xlink:label="lab_nvax_NumberOfSettlementPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Settlement Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfSettlementPayments" xlink:href="nvax-20231231.xsd#nvax_NumberOfSettlementPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_NumberOfSettlementPayments" xlink:to="lab_nvax_NumberOfSettlementPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_01ba18af-de81-4fe7-9624-83af0ad05a2b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_516f176d-2d36-4ad7-a0e6-52fc91b5b502_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_0eeb138e-1f9c-40ef-8e61-9e0f83e401ba_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance beginning</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_9544ab90-c869-492e-934e-4a3cf4052081_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance ending</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_9a9257f6-fdda-47d8-9730-ed413bf1bf12_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CMOAgreementMember_864665a7-d178-4a00-b7f4-2c0a2873cd6c_terseLabel_en-US" xlink:label="lab_nvax_CMOAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMO Agreement</link:label>
    <link:label id="lab_nvax_CMOAgreementMember_label_en-US" xlink:label="lab_nvax_CMOAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMO Agreement [Member]</link:label>
    <link:label id="lab_nvax_CMOAgreementMember_documentation_en-US" xlink:label="lab_nvax_CMOAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMO Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CMOAgreementMember" xlink:href="nvax-20231231.xsd#nvax_CMOAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CMOAgreementMember" xlink:to="lab_nvax_CMOAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_InventoryReserveChargedToCostsOfSales_7f51c63f-0157-4532-b11f-efc9fed5539d_terseLabel_en-US" xlink:label="lab_nvax_InventoryReserveChargedToCostsOfSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged to Cost of sales, including impairments</link:label>
    <link:label id="lab_nvax_InventoryReserveChargedToCostsOfSales_label_en-US" xlink:label="lab_nvax_InventoryReserveChargedToCostsOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Reserve, Charged to Costs of sales</link:label>
    <link:label id="lab_nvax_InventoryReserveChargedToCostsOfSales_documentation_en-US" xlink:label="lab_nvax_InventoryReserveChargedToCostsOfSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Reserve, Charged to Costs of sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InventoryReserveChargedToCostsOfSales" xlink:href="nvax-20231231.xsd#nvax_InventoryReserveChargedToCostsOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_InventoryReserveChargedToCostsOfSales" xlink:to="lab_nvax_InventoryReserveChargedToCostsOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_76501c5c-c417-4fd8-b593-80b709a176a1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ce01559f-e6fb-4d85-98d8-20900dde82d4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3b704647-4f42-4c19-ba95-f1ef8ab42e05_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_2cd54bdd-32d1-457c-806e-077c094493bd_terseLabel_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled contracts receivable</link:label>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_label_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled Contracts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledContractsReceivable" xlink:to="lab_us-gaap_UnbilledContractsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_273e56ea-8533-411d-979f-fa34f8c3bfe4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_6396d35c-a485-4cd1-8547-81f95c62c2cb_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_65e25ae9-14b4-4d7a-a99b-ffd405ee1849_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_PercentOfRemainingAmountToBePaid_698f0df6-10fe-4659-856a-417687b04ddf_terseLabel_en-US" xlink:label="lab_nvax_PercentOfRemainingAmountToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of remaining amount to be paid</link:label>
    <link:label id="lab_nvax_PercentOfRemainingAmountToBePaid_label_en-US" xlink:label="lab_nvax_PercentOfRemainingAmountToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent Of Remaining Amount To Be Paid</link:label>
    <link:label id="lab_nvax_PercentOfRemainingAmountToBePaid_documentation_en-US" xlink:label="lab_nvax_PercentOfRemainingAmountToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent Of Remaining Amount To Be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PercentOfRemainingAmountToBePaid" xlink:href="nvax-20231231.xsd#nvax_PercentOfRemainingAmountToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_PercentOfRemainingAmountToBePaid" xlink:to="lab_nvax_PercentOfRemainingAmountToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember_3a0d1dce-c35e-4436-abee-99ac234d07ca_terseLabel_en-US" xlink:label="lab_nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesale Distributor Fees, Discounts, and Chargebacks</link:label>
    <link:label id="lab_nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember_label_en-US" xlink:label="lab_nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesale Distributor Fees, Discounts, and Chargebacks [Member]</link:label>
    <link:label id="lab_nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember_documentation_en-US" xlink:label="lab_nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesale Distributor Fees, Discounts, and Chargebacks</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember" xlink:href="nvax-20231231.xsd#nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember" xlink:to="lab_nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_7cdd7aac-f8c8-4408-8c5c-60529ccfa303_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, interest rate, effective percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a940cb91-fe6a-4749-9c37-18472a9f9c2b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_5b546c57-b99c-4137-bdf9-cd35271dbc3f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of costs related to issuance of 2027 Convertible notes</link:label>
    <link:label id="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Financing and Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_c99f0630-fae3-4757-9ad9-0593aa6aaa3b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_0dfc9b0c-458b-4de6-8792-64518a23bc44_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_833ae679-8af7-4330-aa30-1aac5025d0f5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d864ddf2-4534-428c-9bbc-08e9dcac7c4a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of year (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6a1badfe-87ef-40ef-b96a-acd2c0685450_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of year (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis_61c1ad48-a694-426b-867d-cecb77660a1d_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity [Axis]</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_1b8366cb-21c3-4485-8ab0-9b59fe9416b0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_633147f7-588c-4226-b0f5-f78d259cc7b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollectiveBargainingArrangementAxis_8250ee78-c540-4515-89ba-4dacb7521d17_terseLabel_en-US" xlink:label="lab_us-gaap_CollectiveBargainingArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collective Bargaining Arrangement [Axis]</link:label>
    <link:label id="lab_us-gaap_CollectiveBargainingArrangementAxis_label_en-US" xlink:label="lab_us-gaap_CollectiveBargainingArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collective-Bargaining Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollectiveBargainingArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollectiveBargainingArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollectiveBargainingArrangementAxis" xlink:to="lab_us-gaap_CollectiveBargainingArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_2ec6df2b-0d5d-440e-bb06-9a6fea5cd62a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_InstallmentChargesOfTheCompany_0277c836-2f10-430d-995f-3a7fe14acef8_terseLabel_en-US" xlink:label="lab_nvax_InstallmentChargesOfTheCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Installment charges</link:label>
    <link:label id="lab_nvax_InstallmentChargesOfTheCompany_label_en-US" xlink:label="lab_nvax_InstallmentChargesOfTheCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Installment Charges Of The Company</link:label>
    <link:label id="lab_nvax_InstallmentChargesOfTheCompany_documentation_en-US" xlink:label="lab_nvax_InstallmentChargesOfTheCompany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Installment Charges Of The Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InstallmentChargesOfTheCompany" xlink:href="nvax-20231231.xsd#nvax_InstallmentChargesOfTheCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_InstallmentChargesOfTheCompany" xlink:to="lab_nvax_InstallmentChargesOfTheCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_3bc107fa-bca8-47e8-b1da-930f26813219_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_f910669f-9ff4-4846-8e07-47629842ea61_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_289c3d94-4e08-4d53-9139-af6cdb9555d0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember_d10345a8-222a-430b-a35b-a3e2df0b0324_terseLabel_en-US" xlink:label="lab_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CEPI</link:label>
    <link:label id="lab_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember_label_en-US" xlink:label="lab_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition For Epidemic Preparedness Innovations Award [Member]</link:label>
    <link:label id="lab_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember_documentation_en-US" xlink:label="lab_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">n/a</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember" xlink:href="nvax-20231231.xsd#nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember" xlink:to="lab_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_66f52561-1399-4190-9963-171e1c09b34d_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_4a60e52c-749e-4503-84a5-15590557ed5f_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expiration</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_dd5cd411-cb81-46a3-b99d-a0d9d4b3d2c1_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ProductReturnsMember_2107ef9b-6a21-4134-ad15-8737c42f0ad0_terseLabel_en-US" xlink:label="lab_nvax_ProductReturnsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Returns</link:label>
    <link:label id="lab_nvax_ProductReturnsMember_label_en-US" xlink:label="lab_nvax_ProductReturnsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Returns [Member]</link:label>
    <link:label id="lab_nvax_ProductReturnsMember_documentation_en-US" xlink:label="lab_nvax_ProductReturnsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Returns</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ProductReturnsMember" xlink:href="nvax-20231231.xsd#nvax_ProductReturnsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ProductReturnsMember" xlink:to="lab_nvax_ProductReturnsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_AustralianAPAMember_8ce76ba0-aff0-43ae-8b90-8bb2a9ace057_terseLabel_en-US" xlink:label="lab_nvax_AustralianAPAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australian APA</link:label>
    <link:label id="lab_nvax_AustralianAPAMember_label_en-US" xlink:label="lab_nvax_AustralianAPAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australian APA [Member]</link:label>
    <link:label id="lab_nvax_AustralianAPAMember_documentation_en-US" xlink:label="lab_nvax_AustralianAPAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australian APA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AustralianAPAMember" xlink:href="nvax-20231231.xsd#nvax_AustralianAPAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_AustralianAPAMember" xlink:to="lab_nvax_AustralianAPAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b5c9ef16-cda7-419d-8d14-2125e8e91d5e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Option and Appreciation Rights Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_DebtCapPrice_0830cb41-59c7-45cd-8e6e-c7c43ddab6b6_terseLabel_en-US" xlink:label="lab_nvax_DebtCapPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt cap price (in usd per share)</link:label>
    <link:label id="lab_nvax_DebtCapPrice_label_en-US" xlink:label="lab_nvax_DebtCapPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Cap Price</link:label>
    <link:label id="lab_nvax_DebtCapPrice_documentation_en-US" xlink:label="lab_nvax_DebtCapPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cap rate on a debt . A payment or receipt is triggered if the market rate exceeds the cap rate on the debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DebtCapPrice" xlink:href="nvax-20231231.xsd#nvax_DebtCapPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_DebtCapPrice" xlink:to="lab_nvax_DebtCapPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4aa0af17-a01e-4b05-9dd5-ca8cdcdbd551_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_August2023SalesAgreementMember_20d32b57-ec87-4707-a304-5cc7ff0de889_terseLabel_en-US" xlink:label="lab_nvax_August2023SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2023 Sales Agreement</link:label>
    <link:label id="lab_nvax_August2023SalesAgreementMember_label_en-US" xlink:label="lab_nvax_August2023SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2023 Sales Agreement [Member]</link:label>
    <link:label id="lab_nvax_August2023SalesAgreementMember_documentation_en-US" xlink:label="lab_nvax_August2023SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2023 Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_August2023SalesAgreementMember" xlink:href="nvax-20231231.xsd#nvax_August2023SalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_August2023SalesAgreementMember" xlink:to="lab_nvax_August2023SalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerBasisOfPricingDomain_799e70f5-11f1-4e4a-a47f-3d5826a2a37e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Basis of Pricing [Domain]</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerBasisOfPricingDomain_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Basis of Pricing [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:to="lab_us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_WeightedAverageDiscountRateAbstract_77309b42-503b-4e04-9a7c-4e5e3300f080_terseLabel_en-US" xlink:label="lab_nvax_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate:</link:label>
    <link:label id="lab_nvax_WeightedAverageDiscountRateAbstract_label_en-US" xlink:label="lab_nvax_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Discount Rate [Abstract]</link:label>
    <link:label id="lab_nvax_WeightedAverageDiscountRateAbstract_documentation_en-US" xlink:label="lab_nvax_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_WeightedAverageDiscountRateAbstract" xlink:href="nvax-20231231.xsd#nvax_WeightedAverageDiscountRateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_WeightedAverageDiscountRateAbstract" xlink:to="lab_nvax_WeightedAverageDiscountRateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_c5f296b1-5236-4ef8-a496-56a237d2c327_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1f18bec6-03d5-4d20-87e0-23668b83b7de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_93181cff-b7bf-4b78-b84d-d8544e4b3eae_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_2bdbb77a-0429-4470-bd86-107f2289c3d4_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_DeferredRevenueIncreaseDecreaseAbstract_5199a28f-a67d-4711-a22d-4791cb5de7eb_terseLabel_en-US" xlink:label="lab_nvax_DeferredRevenueIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_nvax_DeferredRevenueIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_nvax_DeferredRevenueIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Increase (Decrease) [Abstract]</link:label>
    <link:label id="lab_nvax_DeferredRevenueIncreaseDecreaseAbstract_documentation_en-US" xlink:label="lab_nvax_DeferredRevenueIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract" xlink:href="nvax-20231231.xsd#nvax_DeferredRevenueIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract" xlink:to="lab_nvax_DeferredRevenueIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_8dd8a669-dd5e-43b7-90dd-afd05fe01d3a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use asset, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_28fb6b0b-9d1f-47c6-96a6-11a86446301e_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU assets, operating, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_da1e27a8-eac6-4610-84e4-bcfbd349264f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_3f4a49c8-fd83-486c-8ec7-b7cb8be26512_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and related cost percent</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_37b72c27-6759-4a79-9273-f159543b83bd_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_label_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:to="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_fa2cc19b-6e95-4e84-b4f4-98e9a236bc95_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_692ba177-2f52-4831-885a-66397d0a9d8c_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_49fb5f73-8991-412f-acb3-965970d292c5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions_a2ebf826-4f0a-4975-8fcb-82e61b0f6b46_terseLabel_en-US" xlink:label="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions_label_en-US" xlink:label="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Before Allowance For Credit Loss, Additions</link:label>
    <link:label id="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions_documentation_en-US" xlink:label="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Before Allowance For Credit Loss, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions" xlink:href="nvax-20231231.xsd#nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions" xlink:to="lab_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_EscrowDepositsRelatedToSalesHold_d77b42df-549b-427b-acc3-631ddb6901ca_terseLabel_en-US" xlink:label="lab_nvax_EscrowDepositsRelatedToSalesHold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow to sales hold</link:label>
    <link:label id="lab_nvax_EscrowDepositsRelatedToSalesHold_label_en-US" xlink:label="lab_nvax_EscrowDepositsRelatedToSalesHold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow Deposits Related To Sales Hold</link:label>
    <link:label id="lab_nvax_EscrowDepositsRelatedToSalesHold_documentation_en-US" xlink:label="lab_nvax_EscrowDepositsRelatedToSalesHold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow Deposits Related To Sales Hold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EscrowDepositsRelatedToSalesHold" xlink:href="nvax-20231231.xsd#nvax_EscrowDepositsRelatedToSalesHold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_EscrowDepositsRelatedToSalesHold" xlink:to="lab_nvax_EscrowDepositsRelatedToSalesHold" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_200224af-83f5-4867-a169-040c324e42e0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_c041eb8f-4358-4ccc-8cef-09abd9f3210e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_166ba9ba-40a7-42d0-8673-3b1ada91ccb8_totalLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Restructuring charge</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_1f2b7274-df73-4eeb-a640-704cc6ebc219_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_1bd7eeed-f453-45f1-8f62-b3dffbc26299_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_0e753210-f270-404c-b9f4-386ca9494142_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42fd211f-7784-4268-b577-14b5c275421c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ConvertibleDebtConversionRate_0efcbf7d-4e52-4afb-a6b2-0c36e2721dce_terseLabel_en-US" xlink:label="lab_nvax_ConvertibleDebtConversionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt conversion rate</link:label>
    <link:label id="lab_nvax_ConvertibleDebtConversionRate_label_en-US" xlink:label="lab_nvax_ConvertibleDebtConversionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Conversion Rate</link:label>
    <link:label id="lab_nvax_ConvertibleDebtConversionRate_documentation_en-US" xlink:label="lab_nvax_ConvertibleDebtConversionRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt conversion rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ConvertibleDebtConversionRate" xlink:href="nvax-20231231.xsd#nvax_ConvertibleDebtConversionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ConvertibleDebtConversionRate" xlink:to="lab_nvax_ConvertibleDebtConversionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax_4634f4f6-9208-4186-8be8-bb418e579b60_terseLabel_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency transaction (losses) gain</link:label>
    <link:label id="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax_label_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translation Adjustment Functional to Reporting Currency, Gain (Loss), Reclassified to Earnings, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" xlink:to="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock_c03b6e3d-16bf-4b5e-8d3b-847c53ebe86c_terseLabel_en-US" xlink:label="lab_nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Gross to Net Deductions Balances</link:label>
    <link:label id="lab_nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock_label_en-US" xlink:label="lab_nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Revenue Gross To Net Deductions Balances [Table Text Block]</link:label>
    <link:label id="lab_nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock_documentation_en-US" xlink:label="lab_nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Revenue Gross To Net Deductions Balances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock" xlink:href="nvax-20231231.xsd#nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock" xlink:to="lab_nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_541cfb4a-2386-45bd-a417-4071d045e982_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_RevenueFromContractWithCustomerCommitment_2bb2d2e6-4c15-4af3-b53b-9b01bc2d56a8_terseLabel_en-US" xlink:label="lab_nvax_RevenueFromContractWithCustomerCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from contract with customer</link:label>
    <link:label id="lab_nvax_RevenueFromContractWithCustomerCommitment_label_en-US" xlink:label="lab_nvax_RevenueFromContractWithCustomerCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer Commitment</link:label>
    <link:label id="lab_nvax_RevenueFromContractWithCustomerCommitment_documentation_en-US" xlink:label="lab_nvax_RevenueFromContractWithCustomerCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RevenueFromContractWithCustomerCommitment" xlink:href="nvax-20231231.xsd#nvax_RevenueFromContractWithCustomerCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_RevenueFromContractWithCustomerCommitment" xlink:to="lab_nvax_RevenueFromContractWithCustomerCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_NoExpirationMember_c823d339-0c21-4157-8517-f16deb6bf87e_terseLabel_en-US" xlink:label="lab_nvax_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No Expiration</link:label>
    <link:label id="lab_nvax_NoExpirationMember_label_en-US" xlink:label="lab_nvax_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No Expiration [Member]</link:label>
    <link:label id="lab_nvax_NoExpirationMember_documentation_en-US" xlink:label="lab_nvax_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NoExpirationMember" xlink:href="nvax-20231231.xsd#nvax_NoExpirationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_NoExpirationMember" xlink:to="lab_nvax_NoExpirationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_58c9eefe-a67c-470c-9ae5-10bdad05a6dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_1086253d-c537-40b9-8684-08c3b49aefe1_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a0a11c30-5954-4e50-a8cd-cee3f7868102_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f520903d-0c18-4445-958f-5c6425ce2e8d_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_c20282a4-6305-42ad-b33f-3b67eb106377_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Semi-finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_AccountsReceivableAllowanceForCreditLossDeductions_f3fe3615-13f1-48ad-bbf4-3df4e39e81df_negatedTerseLabel_en-US" xlink:label="lab_nvax_AccountsReceivableAllowanceForCreditLossDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_nvax_AccountsReceivableAllowanceForCreditLossDeductions_label_en-US" xlink:label="lab_nvax_AccountsReceivableAllowanceForCreditLossDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Deductions</link:label>
    <link:label id="lab_nvax_AccountsReceivableAllowanceForCreditLossDeductions_documentation_en-US" xlink:label="lab_nvax_AccountsReceivableAllowanceForCreditLossDeductions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Deductions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableAllowanceForCreditLossDeductions" xlink:href="nvax-20231231.xsd#nvax_AccountsReceivableAllowanceForCreditLossDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_AccountsReceivableAllowanceForCreditLossDeductions" xlink:to="lab_nvax_AccountsReceivableAllowanceForCreditLossDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_cbc440bc-1340-4a05-94f0-55cf8d57d285_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount_88ea0de4-1770-462a-b628-68a4c783c446_terseLabel_en-US" xlink:label="lab_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation, variable consideration amount</link:label>
    <link:label id="lab_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount_label_en-US" xlink:label="lab_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:label id="lab_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount_documentation_en-US" xlink:label="lab_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:href="nvax-20231231.xsd#nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:to="lab_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f723aa1d-077c-4d64-b651-3c1072c773a7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of stock options and stock appreciation rights outstanding (less than)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_d125c3e4-e220-4765-865d-9d91676ad6ac_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_NextTwoPercentOfParticipantsDeferralMemberMember_e24b6b4a-b693-4a6f-aaac-bb4ba604c0e3_terseLabel_en-US" xlink:label="lab_nvax_NextTwoPercentOfParticipantsDeferralMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Next Two Percent Of Participants Deferral</link:label>
    <link:label id="lab_nvax_NextTwoPercentOfParticipantsDeferralMemberMember_label_en-US" xlink:label="lab_nvax_NextTwoPercentOfParticipantsDeferralMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Next Two Percent Of Participants Deferral Member [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NextTwoPercentOfParticipantsDeferralMemberMember" xlink:href="nvax-20231231.xsd#nvax_NextTwoPercentOfParticipantsDeferralMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_NextTwoPercentOfParticipantsDeferralMemberMember" xlink:to="lab_nvax_NextTwoPercentOfParticipantsDeferralMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_53e4e72c-d8fb-44f3-b289-c4ac2f2ab02a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ResearchAndDevelopmentAccrualsCurrent_7692e854-36c9-4979-b08d-863a4cca3514_terseLabel_en-US" xlink:label="lab_nvax_ResearchAndDevelopmentAccrualsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development accruals</link:label>
    <link:label id="lab_nvax_ResearchAndDevelopmentAccrualsCurrent_label_en-US" xlink:label="lab_nvax_ResearchAndDevelopmentAccrualsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Accruals, Current</link:label>
    <link:label id="lab_nvax_ResearchAndDevelopmentAccrualsCurrent_documentation_en-US" xlink:label="lab_nvax_ResearchAndDevelopmentAccrualsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Accruals.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentAccrualsCurrent" xlink:href="nvax-20231231.xsd#nvax_ResearchAndDevelopmentAccrualsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ResearchAndDevelopmentAccrualsCurrent" xlink:to="lab_nvax_ResearchAndDevelopmentAccrualsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_RevenueMember_8773e387-336e-4c20-99aa-c2a53fe871f9_terseLabel_en-US" xlink:label="lab_nvax_RevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_nvax_RevenueMember_label_en-US" xlink:label="lab_nvax_RevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Member]</link:label>
    <link:label id="lab_nvax_RevenueMember_documentation_en-US" xlink:label="lab_nvax_RevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RevenueMember" xlink:href="nvax-20231231.xsd#nvax_RevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_RevenueMember" xlink:to="lab_nvax_RevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_4ca8ffd3-4d33-408c-9967-85d085e25075_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_b05033e0-2996-4efe-b748-a22755a1be87_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_fe6280a6-3809-4ed9-b395-7e8a34f8a381_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_InventoryReserveDeductions_81b3d867-9a1f-4a4a-8adc-1fee2140ee57_negatedTerseLabel_en-US" xlink:label="lab_nvax_InventoryReserveDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_nvax_InventoryReserveDeductions_label_en-US" xlink:label="lab_nvax_InventoryReserveDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Reserve, Deductions</link:label>
    <link:label id="lab_nvax_InventoryReserveDeductions_documentation_en-US" xlink:label="lab_nvax_InventoryReserveDeductions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Reserve, Deductions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InventoryReserveDeductions" xlink:href="nvax-20231231.xsd#nvax_InventoryReserveDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_InventoryReserveDeductions" xlink:to="lab_nvax_InventoryReserveDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CommonStockPremiumPaid_49052c3c-4032-4b9b-9f6c-eb45da3c2926_terseLabel_en-US" xlink:label="lab_nvax_CommonStockPremiumPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, premium paid</link:label>
    <link:label id="lab_nvax_CommonStockPremiumPaid_label_en-US" xlink:label="lab_nvax_CommonStockPremiumPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Premium Paid</link:label>
    <link:label id="lab_nvax_CommonStockPremiumPaid_documentation_en-US" xlink:label="lab_nvax_CommonStockPremiumPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Premium Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CommonStockPremiumPaid" xlink:href="nvax-20231231.xsd#nvax_CommonStockPremiumPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CommonStockPremiumPaid" xlink:to="lab_nvax_CommonStockPremiumPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_7deca141-c476-4484-8854-98bdb127e0b3_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b5cf759e-977f-4361-9838-e1a656a6cf7e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_AccountsReceivableAllowanceForCreditLossAdditions_00220183-4d5c-4411-901a-179265e5c508_negatedLabel_en-US" xlink:label="lab_nvax_AccountsReceivableAllowanceForCreditLossAdditions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_nvax_AccountsReceivableAllowanceForCreditLossAdditions_f8d5322b-93e0-457d-be91-afbf2d8e4c88_verboseLabel_en-US" xlink:label="lab_nvax_AccountsReceivableAllowanceForCreditLossAdditions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bad debt expense</link:label>
    <link:label id="lab_nvax_AccountsReceivableAllowanceForCreditLossAdditions_label_en-US" xlink:label="lab_nvax_AccountsReceivableAllowanceForCreditLossAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Additions</link:label>
    <link:label id="lab_nvax_AccountsReceivableAllowanceForCreditLossAdditions_documentation_en-US" xlink:label="lab_nvax_AccountsReceivableAllowanceForCreditLossAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableAllowanceForCreditLossAdditions" xlink:href="nvax-20231231.xsd#nvax_AccountsReceivableAllowanceForCreditLossAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_AccountsReceivableAllowanceForCreditLossAdditions" xlink:to="lab_nvax_AccountsReceivableAllowanceForCreditLossAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7b3f90da-1eab-4fe1-86a1-20fc4170992e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares exercisable at end of year (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_146aa27f-b017-41ad-8970-22cbe692e07d_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_9da57524-f4d8-4392-9cab-20b17beae6ee_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_b3351898-3736-444e-9b7b-e8fb1c78839a_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_252f8893-7edc-4bcd-8281-f5818ccb793b_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_9e94704c-bd31-4550-8768-a984cb0ca77f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible expenses</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_1b7c319a-501d-4355-a189-9eb2853afe69_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_d2969433-a2a7-4830-9ac4-6f18a11c1704_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefits and compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_28d659f3-3c0d-4844-bce8-a7bcc01b9141_verboseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Company's Income (Loss) from Operations Before Income Tax Provision (Benefit) by Jurisdiction</link:label>
    <link:label id="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Operating Loss Carryforwards [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_f83b568d-ac40-4fd6-9602-a3a6228708d3_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c19b2385-c185-4a61-a055-bdc8348a5a25_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_7d76a2a5-9ce3-4d79-b74f-c84048cda1ff_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_3758a5ab-524c-48e5-ba3d-f006aba1b04e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CMOAndCMDAgreementsMember_13078a9c-b9b3-4378-90f6-8cd337f1cb1a_terseLabel_en-US" xlink:label="lab_nvax_CMOAndCMDAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMO and CMD Agreements</link:label>
    <link:label id="lab_nvax_CMOAndCMDAgreementsMember_label_en-US" xlink:label="lab_nvax_CMOAndCMDAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMO and CMD Agreements [Member]</link:label>
    <link:label id="lab_nvax_CMOAndCMDAgreementsMember_documentation_en-US" xlink:label="lab_nvax_CMOAndCMDAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMO and CMD Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CMOAndCMDAgreementsMember" xlink:href="nvax-20231231.xsd#nvax_CMOAndCMDAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CMOAndCMDAgreementsMember" xlink:to="lab_nvax_CMOAndCMDAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c1d338ba-5327-4d98-a2fb-a8972302e4fd_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_b24b7f3d-5fae-4709-98cf-35e4b1942242_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_0d95201a-59fd-4f1f-80cf-d0eb31ed23da_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_8b27a774-1e91-4570-a0ba-17c078519fc6_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_abd0690d-c869-436d-90e7-0180ab8d665e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_977e9c46-7c15-46c0-93c5-93bfd2c29f91_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash interest payments, net of amounts capitalized</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_2d5c4f44-328d-4d6a-8f79-cc284f8a0a46_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_RestOfTheWorldMember_810452e3-63cf-4e1b-a3de-c0fef4ca10d9_terseLabel_en-US" xlink:label="lab_nvax_RestOfTheWorldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of the world</link:label>
    <link:label id="lab_nvax_RestOfTheWorldMember_label_en-US" xlink:label="lab_nvax_RestOfTheWorldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of the World [Member]</link:label>
    <link:label id="lab_nvax_RestOfTheWorldMember_documentation_en-US" xlink:label="lab_nvax_RestOfTheWorldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of the World</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RestOfTheWorldMember" xlink:href="nvax-20231231.xsd#nvax_RestOfTheWorldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_RestOfTheWorldMember" xlink:to="lab_nvax_RestOfTheWorldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_d312b68e-770f-4fea-8538-ec37bae4b29e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sell and issue</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillDisclosureTextBlock_bb1b7871-9e5a-462a-9820-ced427565168_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_cd2ada36-8237-48f6-91f5-35f0ce0c7431_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_f709c33c-546f-4199-adc0-3f535717de10_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember_64a47eac-bd39-4d48-9b29-23cd8add6b13_terseLabel_en-US" xlink:label="lab_nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations ("CEPI")</link:label>
    <link:label id="lab_nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember_label_en-US" xlink:label="lab_nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition For Epidemic Preparedness Innovations (CEPI) Agreement [Member]</link:label>
    <link:label id="lab_nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember_documentation_en-US" xlink:label="lab_nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition For Epidemic Preparedness Innovations (CEPI) Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember" xlink:href="nvax-20231231.xsd#nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember" xlink:to="lab_nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_85a72a61-c8b3-425b-b32e-1cae0113d9a1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_dae8a142-1522-42ac-a5d5-69a28e802834_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets (liabilities)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ba920c96-51d6-46c2-bc8e-6d7fa2679db4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_b4e61792-ad89-4bb6-8966-8c03238bede1_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_4b0ad80d-6424-4e64-9d17-ac839faa916f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_77b48ea2-8eb6-471d-9008-dd8d7d217756_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proposal to increase authorized shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_594d25de-a190-4ea7-b9b3-982aa936328c_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease expense:</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_340d7292-1c02-455a-9918-5784c66afa9d_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_a567dc6b-12a9-4cd5-8d1b-e94f85ec4ddd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of 2027 Convertible notes</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e7246392-2e57-4bc9-a4b8-9c37c923fcf4_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_USDepartmentOfDefenseDoDContractMember_10ba15c1-edce-4c50-b110-ce3681ba02d1_terseLabel_en-US" xlink:label="lab_nvax_USDepartmentOfDefenseDoDContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. DoD</link:label>
    <link:label id="lab_nvax_USDepartmentOfDefenseDoDContractMember_label_en-US" xlink:label="lab_nvax_USDepartmentOfDefenseDoDContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Department of Defense ("DoD Contract") [Member]</link:label>
    <link:label id="lab_nvax_USDepartmentOfDefenseDoDContractMember_documentation_en-US" xlink:label="lab_nvax_USDepartmentOfDefenseDoDContractMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Department of Defense ("DoD Contract")</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USDepartmentOfDefenseDoDContractMember" xlink:href="nvax-20231231.xsd#nvax_USDepartmentOfDefenseDoDContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_USDepartmentOfDefenseDoDContractMember" xlink:to="lab_nvax_USDepartmentOfDefenseDoDContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_ca22ace5-8102-48ae-977f-eb72df8b5a6c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows used in finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3976a2e6-65d9-4daa-8dac-cfd6d443bc3a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_de4e8e88-3cf9-41b2-bbb4-40684b4d8ad5_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_7c138c92-3c1f-46f3-866a-74fecf34a7e8_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3efe6ccc-ce29-4daa-b0d3-cafd411bf283_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_493b5636-f5f9-4771-9607-d98d7c7b652d_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_ce029c5e-cefb-48a3-9f2d-b289189dc98c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_61ffb2a1-7bab-4ea7-beb1-1b8a3e58800f_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0fee93e7-78b1-4226-8219-f410563655c6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_dd2c3135-3cf7-4cfe-83ba-d688c5fc8c9a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_label_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1c398fa6-0cc2-4d7d-a538-8b21945be221_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_dfc1361b-cfa2-49c9-8460-8504de721a69_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_4df0edb0-4834-489d-9e68-104cbf925091_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_ddaad678-8dd9-4ba4-988b-20a2d5b15189_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_63519fc7-f066-4c24-990d-d49b0ec9c018_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss_6c970e7c-2993-4ff6-89d8-e162f5af7663_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Firm purchase commitment loss</link:label>
    <link:label id="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss_label_en-US" xlink:label="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Firm Purchase Commitment, Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFirmPurchaseCommitmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:to="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_772179f3-3d43-49b7-9ff1-6b8af924bddc_verboseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_099b31d9-31a8-4eea-b379-6b6376346e33_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_ed596f42-2759-49de-a280-c65507ae0397_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_095fb32d-834e-4bf7-906d-71e1074c25e1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterimPeriodCostsNotAllocableDomain_6a0afe25-7233-4587-bfab-bf4113f24962_terseLabel_en-US" xlink:label="lab_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interim Period, Costs Not Allocable [Domain]</link:label>
    <link:label id="lab_us-gaap_InterimPeriodCostsNotAllocableDomain_label_en-US" xlink:label="lab_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interim Period, Costs Not Allocable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="lab_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_36a1f6ba-10b1-4d43-80cf-522821ad3577_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Convertible Notes Payable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_CollaborationAgreementRemainingPaymentAmount_db35187e-3b8b-477d-b3a5-d83cb1a81cb0_terseLabel_en-US" xlink:label="lab_nvax_CollaborationAgreementRemainingPaymentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining payment amount</link:label>
    <link:label id="lab_nvax_CollaborationAgreementRemainingPaymentAmount_label_en-US" xlink:label="lab_nvax_CollaborationAgreementRemainingPaymentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Remaining Payment Amount</link:label>
    <link:label id="lab_nvax_CollaborationAgreementRemainingPaymentAmount_documentation_en-US" xlink:label="lab_nvax_CollaborationAgreementRemainingPaymentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Remaining Payment Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementRemainingPaymentAmount" xlink:href="nvax-20231231.xsd#nvax_CollaborationAgreementRemainingPaymentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_CollaborationAgreementRemainingPaymentAmount" xlink:to="lab_nvax_CollaborationAgreementRemainingPaymentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_e90be625-2ef2-49ab-940c-95ab31144ada_terseLabel_en-US" xlink:label="lab_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.75% Convertible notes due 2023</link:label>
    <link:label id="lab_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_069f02c0-fa3d-4abf-864e-41b5a601dd4e_verboseLabel_en-US" xlink:label="lab_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Notes</link:label>
    <link:label id="lab_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_label_en-US" xlink:label="lab_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Seventy Five Convertible Notes Due 2023 [Member]</link:label>
    <link:label id="lab_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_documentation_en-US" xlink:label="lab_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Seventy Five Convertible Notes Due 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member" xlink:href="nvax-20231231.xsd#nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member" xlink:to="lab_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_968270ad-ac2b-4976-843f-64089a1b8e49_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>22
<FILENAME>nvax-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:02f62cea-2ee5-4f46-a427-e5f89894c0b1,g:b653a9b6-e98d-435f-a6cb-06522e8cacbf-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.novavax.com/role/CoverPage" xlink:type="simple" xlink:href="nvax-20231231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_aeb753f8-1659-4ed6-b3f3-a1bd52632c21" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_DocumentType_aeb753f8-1659-4ed6-b3f3-a1bd52632c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_a523a1e4-fd6e-42e4-9dbe-73a0fa5073d1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_DocumentAnnualReport_a523a1e4-fd6e-42e4-9dbe-73a0fa5073d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ac19a37a-3bf1-44e6-b031-b08fbad94638" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_DocumentPeriodEndDate_ac19a37a-3bf1-44e6-b031-b08fbad94638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_712a533a-2a25-4bfa-b601-870678e583b1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_CurrentFiscalYearEndDate_712a533a-2a25-4bfa-b601-870678e583b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_f592b304-c1bc-495a-9326-f0c237daec20" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_DocumentTransitionReport_f592b304-c1bc-495a-9326-f0c237daec20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_c8e64120-5fa2-432b-ad93-a2ac2be1548e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_EntityFileNumber_c8e64120-5fa2-432b-ad93-a2ac2be1548e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_96d830f3-97d8-4d7d-a9c7-ce3bec38592c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_EntityRegistrantName_96d830f3-97d8-4d7d-a9c7-ce3bec38592c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d37e9f23-def4-4570-9b5a-6ff2cca722c4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d37e9f23-def4-4570-9b5a-6ff2cca722c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_dedc0969-1ba6-4d69-b778-5b66b3a96552" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_EntityTaxIdentificationNumber_dedc0969-1ba6-4d69-b778-5b66b3a96552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_500a8b47-b1e5-4e6e-84ee-fc649d776ec3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_EntityAddressAddressLine1_500a8b47-b1e5-4e6e-84ee-fc649d776ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_1bd0e07a-c33a-4818-94fe-0da74714787c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_EntityAddressCityOrTown_1bd0e07a-c33a-4818-94fe-0da74714787c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_86782b1f-1852-4f29-a04f-177ea442dfdb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_EntityAddressStateOrProvince_86782b1f-1852-4f29-a04f-177ea442dfdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ddaebf97-5173-410a-a771-9479f3e25f0a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_EntityAddressPostalZipCode_ddaebf97-5173-410a-a771-9479f3e25f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_02ee0aef-e01e-4ae0-b2ee-d4255c05df7d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_CityAreaCode_02ee0aef-e01e-4ae0-b2ee-d4255c05df7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_db36e064-2bf6-4932-9746-7666916d183d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_LocalPhoneNumber_db36e064-2bf6-4932-9746-7666916d183d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_37427953-4228-489e-b846-ba339bd39662" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_Security12bTitle_37427953-4228-489e-b846-ba339bd39662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7a6565e6-0435-4f10-b8c1-e04524bd8865" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_TradingSymbol_7a6565e6-0435-4f10-b8c1-e04524bd8865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_63b71235-4654-4be0-bb6b-64ed7b986b35" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_SecurityExchangeName_63b71235-4654-4be0-bb6b-64ed7b986b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_0bc1d9be-902d-4e09-b711-5172c479ca69" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_0bc1d9be-902d-4e09-b711-5172c479ca69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_b224a68d-8d63-4600-9218-8a96c6b6a66d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_EntityVoluntaryFilers_b224a68d-8d63-4600-9218-8a96c6b6a66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_9693a3f0-ee22-45b6-a027-1e247cf18e4e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_EntityCurrentReportingStatus_9693a3f0-ee22-45b6-a027-1e247cf18e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_de5ffbf0-5a63-420f-9cae-5ac6e9c9eef3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_EntityInteractiveDataCurrent_de5ffbf0-5a63-420f-9cae-5ac6e9c9eef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_213ab4e8-7eb7-439a-8ccb-ebcee79dece8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_EntityFilerCategory_213ab4e8-7eb7-439a-8ccb-ebcee79dece8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_2af641a2-bb70-4556-964f-e9df2bf72b81" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_EntitySmallBusiness_2af641a2-bb70-4556-964f-e9df2bf72b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_8b639610-614f-47bb-a53c-6aabde3e08e6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_EntityEmergingGrowthCompany_8b639610-614f-47bb-a53c-6aabde3e08e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_4fbac696-8ddf-4bc5-a054-b82b562074d7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_IcfrAuditorAttestationFlag_4fbac696-8ddf-4bc5-a054-b82b562074d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_e336b260-4e95-4693-a794-db79a4856435" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_e336b260-4e95-4693-a794-db79a4856435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_c9afefd5-9ec2-4ad4-9af3-b5772aa88f1b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_EntityShellCompany_c9afefd5-9ec2-4ad4-9af3-b5772aa88f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_cfa175da-cfaa-4dd5-99cc-9536fa5fccf5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_EntityPublicFloat_cfa175da-cfaa-4dd5-99cc-9536fa5fccf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_a587856a-604e-49e4-b32e-2d9314c9b509" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_a587856a-604e-49e4-b32e-2d9314c9b509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_7cdef5b6-073e-43aa-b079-0e79f7668c2c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_7cdef5b6-073e-43aa-b079-0e79f7668c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_fdd19f5b-9758-4f43-8ab3-76d5e8538c85" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_AmendmentFlag_fdd19f5b-9758-4f43-8ab3-76d5e8538c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_62c7b1c1-a5f4-4330-9660-2f57c312ab27" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_DocumentFiscalYearFocus_62c7b1c1-a5f4-4330-9660-2f57c312ab27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6ec2643b-2b11-404d-9f44-651300dd6757" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_DocumentFiscalPeriodFocus_6ec2643b-2b11-404d-9f44-651300dd6757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5b0a0018-11c0-44d2-91dc-1dd84f680f41" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6f9ed5cb-22c3-4156-86d5-6725bd10113f" xlink:to="loc_dei_EntityCentralIndexKey_5b0a0018-11c0-44d2-91dc-1dd84f680f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/AuditInformation" xlink:type="simple" xlink:href="nvax-20231231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AuditInformationAbstract_b3f5c431-2f13-4380-bb11-f17354f6d0a5" xlink:href="nvax-20231231.xsd#nvax_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_382b58b3-4f1f-4ff6-8713-9114bed2ecae" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_AuditInformationAbstract_b3f5c431-2f13-4380-bb11-f17354f6d0a5" xlink:to="loc_dei_AuditorName_382b58b3-4f1f-4ff6-8713-9114bed2ecae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_3b2d51a8-a2d7-48e2-b6ad-26fa2669468f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_AuditInformationAbstract_b3f5c431-2f13-4380-bb11-f17354f6d0a5" xlink:to="loc_dei_AuditorLocation_3b2d51a8-a2d7-48e2-b6ad-26fa2669468f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_9f792e2a-4a44-41b4-bd26-2b58af47c7fc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_AuditInformationAbstract_b3f5c431-2f13-4380-bb11-f17354f6d0a5" xlink:to="loc_dei_AuditorFirmId_9f792e2a-4a44-41b4-bd26-2b58af47c7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="nvax-20231231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_f5b7547c-b1cd-4323-829e-a22c087ac15d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5585347f-638b-49d7-ae44-6fca19e6063e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f5b7547c-b1cd-4323-829e-a22c087ac15d" xlink:to="loc_us-gaap_StatementTable_5585347f-638b-49d7-ae44-6fca19e6063e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ac7142d9-c2ed-4500-ab2b-1b606a5587af" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5585347f-638b-49d7-ae44-6fca19e6063e" xlink:to="loc_srt_ProductOrServiceAxis_ac7142d9-c2ed-4500-ab2b-1b606a5587af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f69b6533-3de0-4c5b-b50b-596f66045db9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ac7142d9-c2ed-4500-ab2b-1b606a5587af" xlink:to="loc_srt_ProductsAndServicesDomain_f69b6533-3de0-4c5b-b50b-596f66045db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_3887ac64-3973-4c41-a7f2-b8547b6612ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f69b6533-3de0-4c5b-b50b-596f66045db9" xlink:to="loc_us-gaap_ProductMember_3887ac64-3973-4c41-a7f2-b8547b6612ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_3aa043d4-329c-4229-af8b-4850c10aca13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f69b6533-3de0-4c5b-b50b-596f66045db9" xlink:to="loc_us-gaap_GrantMember_3aa043d4-329c-4229-af8b-4850c10aca13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RoyaltiesAndOtherMember_bd9f80de-e5c8-4615-8fe9-67cb28f2ac7a" xlink:href="nvax-20231231.xsd#nvax_RoyaltiesAndOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f69b6533-3de0-4c5b-b50b-596f66045db9" xlink:to="loc_nvax_RoyaltiesAndOtherMember_bd9f80de-e5c8-4615-8fe9-67cb28f2ac7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_307afb4d-10ca-4ac1-ad72-26b6b4686c76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5585347f-638b-49d7-ae44-6fca19e6063e" xlink:to="loc_us-gaap_StatementLineItems_307afb4d-10ca-4ac1-ad72-26b6b4686c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_91ed51a1-6758-43ec-9b0f-fccba062514c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_307afb4d-10ca-4ac1-ad72-26b6b4686c76" xlink:to="loc_us-gaap_RevenuesAbstract_91ed51a1-6758-43ec-9b0f-fccba062514c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7dd005ec-877a-45e0-8e5f-267ef5e0b0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_91ed51a1-6758-43ec-9b0f-fccba062514c" xlink:to="loc_us-gaap_Revenues_7dd005ec-877a-45e0-8e5f-267ef5e0b0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_cf5dfb78-99ca-4795-a022-1ebb23cc0a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_307afb4d-10ca-4ac1-ad72-26b6b4686c76" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_cf5dfb78-99ca-4795-a022-1ebb23cc0a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_12c81df8-8c84-4449-bfc7-14111c2513dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_cf5dfb78-99ca-4795-a022-1ebb23cc0a3c" xlink:to="loc_us-gaap_CostOfRevenue_12c81df8-8c84-4449-bfc7-14111c2513dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_cd74e510-c76f-4c74-be77-dcd52b3ef530" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_cf5dfb78-99ca-4795-a022-1ebb23cc0a3c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_cd74e510-c76f-4c74-be77-dcd52b3ef530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_95225b1f-f070-46c8-8850-be32aa66f8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_cf5dfb78-99ca-4795-a022-1ebb23cc0a3c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_95225b1f-f070-46c8-8850-be32aa66f8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b4ad316e-b8b4-4048-920e-c30b7fb436a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_cf5dfb78-99ca-4795-a022-1ebb23cc0a3c" xlink:to="loc_us-gaap_CostsAndExpenses_b4ad316e-b8b4-4048-920e-c30b7fb436a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9169f6ff-0fdb-439a-ba7d-a1d0460ca0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_307afb4d-10ca-4ac1-ad72-26b6b4686c76" xlink:to="loc_us-gaap_OperatingIncomeLoss_9169f6ff-0fdb-439a-ba7d-a1d0460ca0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_cdd632a9-b0f7-4843-988f-4aa5ceb3acc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_307afb4d-10ca-4ac1-ad72-26b6b4686c76" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_cdd632a9-b0f7-4843-988f-4aa5ceb3acc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4126f9aa-00ce-4c84-adce-8d6ba659b03f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_cdd632a9-b0f7-4843-988f-4aa5ceb3acc2" xlink:to="loc_us-gaap_InterestExpense_4126f9aa-00ce-4c84-adce-8d6ba659b03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4a739bca-5bf8-4bcf-8ec0-c7a13ff9a005" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_cdd632a9-b0f7-4843-988f-4aa5ceb3acc2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4a739bca-5bf8-4bcf-8ec0-c7a13ff9a005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_04f9e22a-2786-4fa4-9d4f-85a54eac2552" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_307afb4d-10ca-4ac1-ad72-26b6b4686c76" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_04f9e22a-2786-4fa4-9d4f-85a54eac2552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bd0cb7a6-72a0-4a50-82d6-732ce43d45ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_307afb4d-10ca-4ac1-ad72-26b6b4686c76" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_bd0cb7a6-72a0-4a50-82d6-732ce43d45ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ca67e736-c4fe-4735-944b-a23181bc05b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_307afb4d-10ca-4ac1-ad72-26b6b4686c76" xlink:to="loc_us-gaap_NetIncomeLoss_ca67e736-c4fe-4735-944b-a23181bc05b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_77f9aa62-2d5d-4afc-b684-9eec78097e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_307afb4d-10ca-4ac1-ad72-26b6b4686c76" xlink:to="loc_us-gaap_EarningsPerShareAbstract_77f9aa62-2d5d-4afc-b684-9eec78097e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_595d6033-67c9-4ff7-8682-81e8c1699de7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_77f9aa62-2d5d-4afc-b684-9eec78097e6a" xlink:to="loc_us-gaap_EarningsPerShareBasic_595d6033-67c9-4ff7-8682-81e8c1699de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_bca51188-9846-4ea8-bf31-a7d0500bf07a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_77f9aa62-2d5d-4afc-b684-9eec78097e6a" xlink:to="loc_us-gaap_EarningsPerShareDiluted_bca51188-9846-4ea8-bf31-a7d0500bf07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_122bf029-e681-44b9-8a4e-a68edd610cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_307afb4d-10ca-4ac1-ad72-26b6b4686c76" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_122bf029-e681-44b9-8a4e-a68edd610cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_553a85a1-ac59-433c-9815-9144bb85b698" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_122bf029-e681-44b9-8a4e-a68edd610cc1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_553a85a1-ac59-433c-9815-9144bb85b698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ae0174b1-02e7-4bef-a106-34fb5ace10c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_122bf029-e681-44b9-8a4e-a68edd610cc1" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ae0174b1-02e7-4bef-a106-34fb5ace10c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="nvax-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_410130a7-19dd-4bdf-a2f2-2e77436af35d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4d9aaae3-683d-46ba-9a0f-7eeec8676732" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_410130a7-19dd-4bdf-a2f2-2e77436af35d" xlink:to="loc_us-gaap_NetIncomeLoss_4d9aaae3-683d-46ba-9a0f-7eeec8676732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_dfce9480-1610-4a54-9abf-ecb944d04e70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_410130a7-19dd-4bdf-a2f2-2e77436af35d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_dfce9480-1610-4a54-9abf-ecb944d04e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_851c01d0-da0b-489f-b1c3-bdb246c17c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_dfce9480-1610-4a54-9abf-ecb944d04e70" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_851c01d0-da0b-489f-b1c3-bdb246c17c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_20bfa280-beb0-4ad6-a1de-8c47638c0dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_dfce9480-1610-4a54-9abf-ecb944d04e70" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_20bfa280-beb0-4ad6-a1de-8c47638c0dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3df45e51-ec49-4cbc-9210-8f5e115dae5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_dfce9480-1610-4a54-9abf-ecb944d04e70" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3df45e51-ec49-4cbc-9210-8f5e115dae5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_73ead265-4665-4307-a1f3-7d20ec5720cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_410130a7-19dd-4bdf-a2f2-2e77436af35d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_73ead265-4665-4307-a1f3-7d20ec5720cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="nvax-20231231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_84ff1866-ff93-46bd-9374-adeb1e8c0fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_bf7aa88a-9303-4594-be71-03b788f1f53c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_84ff1866-ff93-46bd-9374-adeb1e8c0fa7" xlink:to="loc_us-gaap_AssetsAbstract_bf7aa88a-9303-4594-be71-03b788f1f53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_522939f6-3a2d-49c1-95c5-2136ff8b285d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bf7aa88a-9303-4594-be71-03b788f1f53c" xlink:to="loc_us-gaap_AssetsCurrentAbstract_522939f6-3a2d-49c1-95c5-2136ff8b285d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a3ce440b-3fb7-4a6d-aca0-d5ec29a0ff8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_522939f6-3a2d-49c1-95c5-2136ff8b285d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a3ce440b-3fb7-4a6d-aca0-d5ec29a0ff8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_47f83fef-9a44-4ca6-979d-88520faa24a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_522939f6-3a2d-49c1-95c5-2136ff8b285d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_47f83fef-9a44-4ca6-979d-88520faa24a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_333d0a53-3a03-47af-9d83-b92f745fc456" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_522939f6-3a2d-49c1-95c5-2136ff8b285d" xlink:to="loc_us-gaap_AccountsReceivableNet_333d0a53-3a03-47af-9d83-b92f745fc456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ab7ba596-7573-4dbb-abbc-1d49258f4b25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_522939f6-3a2d-49c1-95c5-2136ff8b285d" xlink:to="loc_us-gaap_InventoryNet_ab7ba596-7573-4dbb-abbc-1d49258f4b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b4f91c31-d920-4e4b-ac37-e309c1cb3ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_522939f6-3a2d-49c1-95c5-2136ff8b285d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b4f91c31-d920-4e4b-ac37-e309c1cb3ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_54910d1e-971f-419a-bb73-9cbcdbd33cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_522939f6-3a2d-49c1-95c5-2136ff8b285d" xlink:to="loc_us-gaap_AssetsCurrent_54910d1e-971f-419a-bb73-9cbcdbd33cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_78de0a1b-28ae-41a9-8fb3-45105f84a802" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bf7aa88a-9303-4594-be71-03b788f1f53c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_78de0a1b-28ae-41a9-8fb3-45105f84a802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseRightOfUseAsset_d0fab807-7f80-41e2-8caf-e7413056583b" xlink:href="nvax-20231231.xsd#nvax_LeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bf7aa88a-9303-4594-be71-03b788f1f53c" xlink:to="loc_nvax_LeaseRightOfUseAsset_d0fab807-7f80-41e2-8caf-e7413056583b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f0c39b2e-d5f8-4bf4-88b7-1e3a1087a37e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bf7aa88a-9303-4594-be71-03b788f1f53c" xlink:to="loc_us-gaap_Goodwill_f0c39b2e-d5f8-4bf4-88b7-1e3a1087a37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_18dd644f-3882-4eae-b6ad-f79e8944eb98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bf7aa88a-9303-4594-be71-03b788f1f53c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_18dd644f-3882-4eae-b6ad-f79e8944eb98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c678c837-9762-4407-8117-969d907205c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bf7aa88a-9303-4594-be71-03b788f1f53c" xlink:to="loc_us-gaap_Assets_c678c837-9762-4407-8117-969d907205c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_612b0782-fda0-4f55-b732-365832225c11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_84ff1866-ff93-46bd-9374-adeb1e8c0fa7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_612b0782-fda0-4f55-b732-365832225c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_1e028d76-ea37-4867-b59b-a86c564bd4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_612b0782-fda0-4f55-b732-365832225c11" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_1e028d76-ea37-4867-b59b-a86c564bd4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6e89eec2-e7b3-453c-8e2e-9fae43bc60f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1e028d76-ea37-4867-b59b-a86c564bd4a3" xlink:to="loc_us-gaap_AccountsPayableCurrent_6e89eec2-e7b3-453c-8e2e-9fae43bc60f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_dd4a27ca-3bd5-4681-a3c2-de8c4b7cf287" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1e028d76-ea37-4867-b59b-a86c564bd4a3" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_dd4a27ca-3bd5-4681-a3c2-de8c4b7cf287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3552b32b-a96d-417e-af4a-32b927018144" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1e028d76-ea37-4867-b59b-a86c564bd4a3" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3552b32b-a96d-417e-af4a-32b927018144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_53c4b441-1c34-4c12-994a-193689d1213b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1e028d76-ea37-4867-b59b-a86c564bd4a3" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_53c4b441-1c34-4c12-994a-193689d1213b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_0947339e-5357-4180-b8ab-8e2b0aed55f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1e028d76-ea37-4867-b59b-a86c564bd4a3" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_0947339e-5357-4180-b8ab-8e2b0aed55f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ec9bd259-71f1-46f0-99a2-5471b27f9ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1e028d76-ea37-4867-b59b-a86c564bd4a3" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ec9bd259-71f1-46f0-99a2-5471b27f9ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_eac8440e-5b2e-44c1-a968-0214735f8f18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1e028d76-ea37-4867-b59b-a86c564bd4a3" xlink:to="loc_us-gaap_LiabilitiesCurrent_eac8440e-5b2e-44c1-a968-0214735f8f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_567d0cce-cd90-4724-88c2-109808d27282" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_612b0782-fda0-4f55-b732-365832225c11" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_567d0cce-cd90-4724-88c2-109808d27282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_99f5a295-5f9e-4326-b531-f8f0e8d338e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_612b0782-fda0-4f55-b732-365832225c11" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_99f5a295-5f9e-4326-b531-f8f0e8d338e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1e6c44b7-3e37-4113-8365-cae0c867b1b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_612b0782-fda0-4f55-b732-365832225c11" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1e6c44b7-3e37-4113-8365-cae0c867b1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_9098764c-f56d-4af6-a1a6-9a86b0aa508f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_612b0782-fda0-4f55-b732-365832225c11" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_9098764c-f56d-4af6-a1a6-9a86b0aa508f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_dcc0dfd3-0911-4036-a559-9a3bc566fa46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_612b0782-fda0-4f55-b732-365832225c11" xlink:to="loc_us-gaap_Liabilities_dcc0dfd3-0911-4036-a559-9a3bc566fa46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_91a4049c-8496-4844-8068-26726c34e697" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_612b0782-fda0-4f55-b732-365832225c11" xlink:to="loc_us-gaap_CommitmentsAndContingencies_91a4049c-8496-4844-8068-26726c34e697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_da7109ed-7a19-4b39-9e01-ace1906800d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_612b0782-fda0-4f55-b732-365832225c11" xlink:to="loc_us-gaap_PreferredStockValue_da7109ed-7a19-4b39-9e01-ace1906800d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_44b39171-5d0b-4a52-b667-050f9e3331bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_612b0782-fda0-4f55-b732-365832225c11" xlink:to="loc_us-gaap_StockholdersEquityAbstract_44b39171-5d0b-4a52-b667-050f9e3331bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_8159a99d-1e04-47b9-8005-61d1130191ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_44b39171-5d0b-4a52-b667-050f9e3331bd" xlink:to="loc_us-gaap_CommonStockValue_8159a99d-1e04-47b9-8005-61d1130191ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_4844689e-bd2c-4438-b8b6-f26d9a988251" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_44b39171-5d0b-4a52-b667-050f9e3331bd" xlink:to="loc_us-gaap_AdditionalPaidInCapital_4844689e-bd2c-4438-b8b6-f26d9a988251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f43f994f-e791-494c-890b-f1a6b20e1358" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_44b39171-5d0b-4a52-b667-050f9e3331bd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f43f994f-e791-494c-890b-f1a6b20e1358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_251b7c97-020f-4862-93f8-b70637a35ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_44b39171-5d0b-4a52-b667-050f9e3331bd" xlink:to="loc_us-gaap_TreasuryStockCommonValue_251b7c97-020f-4862-93f8-b70637a35ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cffcb56d-e10a-4202-bdb2-dfedcada589f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_44b39171-5d0b-4a52-b667-050f9e3331bd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cffcb56d-e10a-4202-bdb2-dfedcada589f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_db02b1d7-360c-46ce-8a70-986045d67a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_44b39171-5d0b-4a52-b667-050f9e3331bd" xlink:to="loc_us-gaap_StockholdersEquity_db02b1d7-360c-46ce-8a70-986045d67a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c33c0ff5-5ca3-4de2-8fae-acfc4aeaaabd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_612b0782-fda0-4f55-b732-365832225c11" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_c33c0ff5-5ca3-4de2-8fae-acfc4aeaaabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="nvax-20231231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0675ea28-908c-45bc-b816-8a7ae35a1e80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0a35c6f0-55df-4b87-bcb3-c6a8a81ecc34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0675ea28-908c-45bc-b816-8a7ae35a1e80" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0a35c6f0-55df-4b87-bcb3-c6a8a81ecc34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_f3ba4f26-bede-4734-b680-067c614939ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0675ea28-908c-45bc-b816-8a7ae35a1e80" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_f3ba4f26-bede-4734-b680-067c614939ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6806678f-f619-4cdd-bfcf-e4d5535d8f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0675ea28-908c-45bc-b816-8a7ae35a1e80" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6806678f-f619-4cdd-bfcf-e4d5535d8f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f5674a0a-6eee-4ea8-8f41-030d1b1363be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0675ea28-908c-45bc-b816-8a7ae35a1e80" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f5674a0a-6eee-4ea8-8f41-030d1b1363be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_5aa902e4-16b7-4c41-aa01-d8f56fc70e65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0675ea28-908c-45bc-b816-8a7ae35a1e80" xlink:to="loc_us-gaap_CommonStockSharesIssued_5aa902e4-16b7-4c41-aa01-d8f56fc70e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_88591a42-ed95-48bc-9723-193469121238" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0675ea28-908c-45bc-b816-8a7ae35a1e80" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_88591a42-ed95-48bc-9723-193469121238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_09829cb8-9596-45a8-adaf-3ab3d5b04467" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0675ea28-908c-45bc-b816-8a7ae35a1e80" xlink:to="loc_us-gaap_TreasuryStockCommonShares_09829cb8-9596-45a8-adaf-3ab3d5b04467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="nvax-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_bdb230e1-4bf9-45ff-9396-09c2db3a1d29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_82ee52b4-fd71-463b-b7aa-d98cb33e2e79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_bdb230e1-4bf9-45ff-9396-09c2db3a1d29" xlink:to="loc_us-gaap_StatementTable_82ee52b4-fd71-463b-b7aa-d98cb33e2e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_32aade4e-1f68-4203-913e-7df99f12c6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_82ee52b4-fd71-463b-b7aa-d98cb33e2e79" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_32aade4e-1f68-4203-913e-7df99f12c6e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e635254c-63cc-4ce1-9263-23614a44d1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_32aade4e-1f68-4203-913e-7df99f12c6e1" xlink:to="loc_us-gaap_EquityComponentDomain_e635254c-63cc-4ce1-9263-23614a44d1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0c8ce3e8-153f-47a0-ae9a-c1a9daf16e08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e635254c-63cc-4ce1-9263-23614a44d1dd" xlink:to="loc_us-gaap_CommonStockMember_0c8ce3e8-153f-47a0-ae9a-c1a9daf16e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f582d3df-c83d-48bd-a381-76efac2fb25f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e635254c-63cc-4ce1-9263-23614a44d1dd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f582d3df-c83d-48bd-a381-76efac2fb25f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_94836934-e52b-4b24-a09c-1408ac82af82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e635254c-63cc-4ce1-9263-23614a44d1dd" xlink:to="loc_us-gaap_RetainedEarningsMember_94836934-e52b-4b24-a09c-1408ac82af82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_b3a812f9-9713-4f87-bee1-ffdaa719e85a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e635254c-63cc-4ce1-9263-23614a44d1dd" xlink:to="loc_us-gaap_TreasuryStockCommonMember_b3a812f9-9713-4f87-bee1-ffdaa719e85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d55d5035-f456-4ca6-9311-2c3b920d6636" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e635254c-63cc-4ce1-9263-23614a44d1dd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d55d5035-f456-4ca6-9311-2c3b920d6636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6664f1f2-9073-4728-a344-bdb14586d861" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_82ee52b4-fd71-463b-b7aa-d98cb33e2e79" xlink:to="loc_us-gaap_StatementLineItems_6664f1f2-9073-4728-a344-bdb14586d861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd9ebfb-6b72-46b9-a2f4-10e5d8af5380" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6664f1f2-9073-4728-a344-bdb14586d861" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd9ebfb-6b72-46b9-a2f4-10e5d8af5380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d4d1e6e4-94f1-4a36-93bf-69849c583033" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd9ebfb-6b72-46b9-a2f4-10e5d8af5380" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d4d1e6e4-94f1-4a36-93bf-69849c583033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_56598d35-2db1-4311-9e04-fadacd804805" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd9ebfb-6b72-46b9-a2f4-10e5d8af5380" xlink:to="loc_us-gaap_StockholdersEquity_56598d35-2db1-4311-9e04-fadacd804805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f014228f-de4c-48a1-bd6e-7f4e453d9b25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd9ebfb-6b72-46b9-a2f4-10e5d8af5380" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f014228f-de4c-48a1-bd6e-7f4e453d9b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram_9ed4fe1a-c91d-40da-b203-1755c5fca5e2" xlink:href="nvax-20231231.xsd#nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd9ebfb-6b72-46b9-a2f4-10e5d8af5380" xlink:to="loc_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram_9ed4fe1a-c91d-40da-b203-1755c5fca5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CompensationStockIssuedUnderIncentiveProgram_737f5690-5c64-4234-a4e5-ca2fb200340e" xlink:href="nvax-20231231.xsd#nvax_CompensationStockIssuedUnderIncentiveProgram"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd9ebfb-6b72-46b9-a2f4-10e5d8af5380" xlink:to="loc_nvax_CompensationStockIssuedUnderIncentiveProgram_737f5690-5c64-4234-a4e5-ca2fb200340e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_07c31189-0fd1-4adf-8796-3fa22d1d2f15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd9ebfb-6b72-46b9-a2f4-10e5d8af5380" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_07c31189-0fd1-4adf-8796-3fa22d1d2f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f7461c52-814b-4571-8b6e-715d21a110f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd9ebfb-6b72-46b9-a2f4-10e5d8af5380" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f7461c52-814b-4571-8b6e-715d21a110f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_015d925e-12ac-4d5a-a332-b6ce0228a9b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd9ebfb-6b72-46b9-a2f4-10e5d8af5380" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_015d925e-12ac-4d5a-a332-b6ce0228a9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_340f31f4-bfa9-477a-9da2-ca68a31f1bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd9ebfb-6b72-46b9-a2f4-10e5d8af5380" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_340f31f4-bfa9-477a-9da2-ca68a31f1bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_414ea054-7664-4df5-a06f-1589b9bd21ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd9ebfb-6b72-46b9-a2f4-10e5d8af5380" xlink:to="loc_us-gaap_NetIncomeLoss_414ea054-7664-4df5-a06f-1589b9bd21ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_86129319-94f3-4e6e-b724-424c4472238b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd9ebfb-6b72-46b9-a2f4-10e5d8af5380" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_86129319-94f3-4e6e-b724-424c4472238b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ff9adc77-da6a-4b0d-85da-78f9fff9e28e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd9ebfb-6b72-46b9-a2f4-10e5d8af5380" xlink:to="loc_us-gaap_StockholdersEquity_ff9adc77-da6a-4b0d-85da-78f9fff9e28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical" xlink:type="simple" xlink:href="nvax-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_27a8e1f4-3858-4e50-8df4-365671da0612" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_7f34b085-7916-4b10-85ac-6d0e4a4e55b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_27a8e1f4-3858-4e50-8df4-365671da0612" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_7f34b085-7916-4b10-85ac-6d0e4a4e55b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="nvax-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_25e867ca-8f81-4c22-b793-ad11eb006dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4f7409ce-7702-4984-80cd-2434994d203b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_25e867ca-8f81-4c22-b793-ad11eb006dc5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4f7409ce-7702-4984-80cd-2434994d203b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_84b4583a-1c6e-4cf1-8b88-9e8548f1169f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4f7409ce-7702-4984-80cd-2434994d203b" xlink:to="loc_us-gaap_NetIncomeLoss_84b4583a-1c6e-4cf1-8b88-9e8548f1169f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f05a9f29-cbb7-4f96-b697-b96baead62c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4f7409ce-7702-4984-80cd-2434994d203b" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f05a9f29-cbb7-4f96-b697-b96baead62c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_b977be06-0951-4ce8-88b2-4e33649410a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f05a9f29-cbb7-4f96-b697-b96baead62c0" xlink:to="loc_us-gaap_DepreciationAndAmortization_b977be06-0951-4ce8-88b2-4e33649410a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_OperatingAndFinanceLeaseWriteOff_b342e707-01e0-44e9-86ce-ef3ad63cf6f3" xlink:href="nvax-20231231.xsd#nvax_OperatingAndFinanceLeaseWriteOff"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f05a9f29-cbb7-4f96-b697-b96baead62c0" xlink:to="loc_nvax_OperatingAndFinanceLeaseWriteOff_b342e707-01e0-44e9-86ce-ef3ad63cf6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ccaa7c08-05de-480b-af3c-2fc506017e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f05a9f29-cbb7-4f96-b697-b96baead62c0" xlink:to="loc_us-gaap_ShareBasedCompensation_ccaa7c08-05de-480b-af3c-2fc506017e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ProvisionForExcessAndObsoleteInventory_4b5bc622-c8d6-43c4-a2af-c5abffa46cad" xlink:href="nvax-20231231.xsd#nvax_ProvisionForExcessAndObsoleteInventory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f05a9f29-cbb7-4f96-b697-b96baead62c0" xlink:to="loc_nvax_ProvisionForExcessAndObsoleteInventory_4b5bc622-c8d6-43c4-a2af-c5abffa46cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_aa58ab80-5f6b-4e03-91b8-9e87314315f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f05a9f29-cbb7-4f96-b697-b96baead62c0" xlink:to="loc_us-gaap_AssetImpairmentCharges_aa58ab80-5f6b-4e03-91b8-9e87314315f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_1acc63b9-276f-419c-9cf1-df8773f02280" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f05a9f29-cbb7-4f96-b697-b96baead62c0" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_1acc63b9-276f-419c-9cf1-df8773f02280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e039e471-97bf-40a0-b2c2-e760c1e9c78b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f05a9f29-cbb7-4f96-b697-b96baead62c0" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e039e471-97bf-40a0-b2c2-e760c1e9c78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_b93bb0d8-efb3-4a7c-bfd2-8b2c1aa4a850" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e039e471-97bf-40a0-b2c2-e760c1e9c78b" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_b93bb0d8-efb3-4a7c-bfd2-8b2c1aa4a850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f73d59b6-e347-4990-b708-eedd86455f59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e039e471-97bf-40a0-b2c2-e760c1e9c78b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f73d59b6-e347-4990-b708-eedd86455f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_d3ccc66d-0a77-4372-a094-44fa87939b80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e039e471-97bf-40a0-b2c2-e760c1e9c78b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_d3ccc66d-0a77-4372-a094-44fa87939b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_5571a06e-aa7e-4a56-b68f-15b30bd5aa9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e039e471-97bf-40a0-b2c2-e760c1e9c78b" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_5571a06e-aa7e-4a56-b68f-15b30bd5aa9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6d7b274a-377f-4b80-88bc-d7f749422a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4f7409ce-7702-4984-80cd-2434994d203b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6d7b274a-377f-4b80-88bc-d7f749422a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_57507743-d37e-4fe9-ad74-6439a943be5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_25e867ca-8f81-4c22-b793-ad11eb006dc5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_57507743-d37e-4fe9-ad74-6439a943be5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCapitalImprovements_2d29b305-775b-45e1-8d04-419a1a70109d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForCapitalImprovements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_57507743-d37e-4fe9-ad74-6439a943be5a" xlink:to="loc_us-gaap_PaymentsForCapitalImprovements_2d29b305-775b-45e1-8d04-419a1a70109d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware_96fb1fbe-b510-4cbe-924e-abd441fbba40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForSoftware"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_57507743-d37e-4fe9-ad74-6439a943be5a" xlink:to="loc_us-gaap_PaymentsForSoftware_96fb1fbe-b510-4cbe-924e-abd441fbba40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_f62f8324-26a6-4d28-9a81-fac6037aa6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_57507743-d37e-4fe9-ad74-6439a943be5a" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_f62f8324-26a6-4d28-9a81-fac6037aa6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_266dfab2-b190-4b2a-a553-5a857e468c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_57507743-d37e-4fe9-ad74-6439a943be5a" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_266dfab2-b190-4b2a-a553-5a857e468c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c776c493-b2d6-4d90-8296-4368d9ccbac1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_57507743-d37e-4fe9-ad74-6439a943be5a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c776c493-b2d6-4d90-8296-4368d9ccbac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0c1da664-c01c-489f-a532-bad3bda7c131" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_25e867ca-8f81-4c22-b793-ad11eb006dc5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0c1da664-c01c-489f-a532-bad3bda7c131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0122c3bd-3529-4fad-a4fb-8e1a99ab419a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0c1da664-c01c-489f-a532-bad3bda7c131" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0122c3bd-3529-4fad-a4fb-8e1a99ab419a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_ac851964-fb95-415c-906b-c45894cce6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0c1da664-c01c-489f-a532-bad3bda7c131" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_ac851964-fb95-415c-906b-c45894cce6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_e7bd90b2-0a4c-44d4-97c5-c8f844200fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0c1da664-c01c-489f-a532-bad3bda7c131" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_e7bd90b2-0a4c-44d4-97c5-c8f844200fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NetProceedsFromTheExerciseOfStockBasedAwards_a60337a7-a25a-4a39-9728-9d60413cea70" xlink:href="nvax-20231231.xsd#nvax_NetProceedsFromTheExerciseOfStockBasedAwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0c1da664-c01c-489f-a532-bad3bda7c131" xlink:to="loc_nvax_NetProceedsFromTheExerciseOfStockBasedAwards_a60337a7-a25a-4a39-9728-9d60413cea70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_b0b803a5-10f9-4749-b2ca-f4b6fffd871a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0c1da664-c01c-489f-a532-bad3bda7c131" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_b0b803a5-10f9-4749-b2ca-f4b6fffd871a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_f7b8101f-10d0-4dd4-a162-2f0b09aee888" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0c1da664-c01c-489f-a532-bad3bda7c131" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_f7b8101f-10d0-4dd4-a162-2f0b09aee888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_429a5d66-7acb-42bb-b297-871ae031d4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0c1da664-c01c-489f-a532-bad3bda7c131" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_429a5d66-7acb-42bb-b297-871ae031d4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eb8a6e9f-7674-4e8a-9b0c-0b7e4403c2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_25e867ca-8f81-4c22-b793-ad11eb006dc5" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eb8a6e9f-7674-4e8a-9b0c-0b7e4403c2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_12b68b1c-9add-49c0-b224-5306791dbd52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_25e867ca-8f81-4c22-b793-ad11eb006dc5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_12b68b1c-9add-49c0-b224-5306791dbd52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5a3247b7-39cd-40e5-86ab-9a00b5405cab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_25e867ca-8f81-4c22-b793-ad11eb006dc5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5a3247b7-39cd-40e5-86ab-9a00b5405cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_79507bcf-e936-44c1-bb83-087782fde853" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_25e867ca-8f81-4c22-b793-ad11eb006dc5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_79507bcf-e936-44c1-bb83-087782fde853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5ba85e3a-4684-426a-9f34-9a730bcc97c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_25e867ca-8f81-4c22-b793-ad11eb006dc5" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5ba85e3a-4684-426a-9f34-9a730bcc97c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled_510faae2-961b-4726-ac1a-2462faa1886f" xlink:href="nvax-20231231.xsd#nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5ba85e3a-4684-426a-9f34-9a730bcc97c0" xlink:to="loc_nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled_510faae2-961b-4726-ac1a-2462faa1886f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_771a975a-1cee-43ed-90e1-45cd0c15b3b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5ba85e3a-4684-426a-9f34-9a730bcc97c0" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_771a975a-1cee-43ed-90e1-45cd0c15b3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset_bdff9462-5227-4cb1-9635-948355a63d0f" xlink:href="nvax-20231231.xsd#nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5ba85e3a-4684-426a-9f34-9a730bcc97c0" xlink:to="loc_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset_bdff9462-5227-4cb1-9635-948355a63d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_57cd753c-1683-4b37-8cea-d6e60dd1cf72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_25e867ca-8f81-4c22-b793-ad11eb006dc5" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_57cd753c-1683-4b37-8cea-d6e60dd1cf72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_6865ba79-c28c-4226-9856-d5906a7c0bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_57cd753c-1683-4b37-8cea-d6e60dd1cf72" xlink:to="loc_us-gaap_InterestPaidNet_6865ba79-c28c-4226-9856-d5906a7c0bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_aee1d45e-8082-4ce1-8685-d45711f09ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_57cd753c-1683-4b37-8cea-d6e60dd1cf72" xlink:to="loc_us-gaap_IncomeTaxesPaid_aee1d45e-8082-4ce1-8685-d45711f09ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/OrganizationBusiness" xlink:type="simple" xlink:href="nvax-20231231.xsd#OrganizationBusiness"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/OrganizationBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9fac50b9-c47d-4836-8361-cc5a3eb27243" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_d620b219-281c-42a9-a8e2-7f02beca53a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9fac50b9-c47d-4836-8361-cc5a3eb27243" xlink:to="loc_us-gaap_NatureOfOperations_d620b219-281c-42a9-a8e2-7f02beca53a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="nvax-20231231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fd23f73b-4677-457d-b928-f76ebe7183f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_f38e3cc0-1ca1-4a0d-a5a1-9a02130f783f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fd23f73b-4677-457d-b928-f76ebe7183f1" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_f38e3cc0-1ca1-4a0d-a5a1-9a02130f783f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/Revenue" xlink:type="simple" xlink:href="nvax-20231231.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_417ce33a-25f7-4ed9-9d76-c79817819360" xlink:href="nvax-20231231.xsd#nvax_GrantsUSGovernmentContractAndJointVentureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_478d45b4-da7f-4905-9535-eeb879a7da35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_417ce33a-25f7-4ed9-9d76-c79817819360" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_478d45b4-da7f-4905-9535-eeb879a7da35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CollaborationLicenseandSupplyAgreements" xlink:type="simple" xlink:href="nvax-20231231.xsd#CollaborationLicenseandSupplyAgreements"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CollaborationLicenseandSupplyAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborativeArrangementAbstract_9942d7cb-9d2f-4f81-b9cc-0227b969f4e8" xlink:href="nvax-20231231.xsd#nvax_CollaborativeArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_2dafe067-a3fd-42f3-9e15-a754e7072e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_CollaborativeArrangementAbstract_9942d7cb-9d2f-4f81-b9cc-0227b969f4e8" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_2dafe067-a3fd-42f3-9e15-a754e7072e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCash" xlink:type="simple" xlink:href="nvax-20231231.xsd#CashCashEquivalentsandRestrictedCash"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCash" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_33ad6d0d-f599-4ed0-ada6-f5e0c50d0b48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_4d54bca8-69b1-4f13-be25-8f3dcaa9e3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_33ad6d0d-f599-4ed0-ada6-f5e0c50d0b48" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_4d54bca8-69b1-4f13-be25-8f3dcaa9e3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="nvax-20231231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_be1436cc-0b68-4636-bea3-b700902a2712" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_c962aca3-593a-4c14-b39d-4c7b772567ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_be1436cc-0b68-4636-bea3-b700902a2712" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_c962aca3-593a-4c14-b39d-4c7b772567ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/Inventory" xlink:type="simple" xlink:href="nvax-20231231.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_42e0bbfe-047d-4907-9cef-8de8e017f0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_9ea0dfe5-34a8-429c-b473-98e7f8baf7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_42e0bbfe-047d-4907-9cef-8de8e017f0f5" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_9ea0dfe5-34a8-429c-b473-98e7f8baf7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/Goodwill" xlink:type="simple" xlink:href="nvax-20231231.xsd#Goodwill"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/Goodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7531ead6-ca95-4a6c-b342-19fd5370b0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillDisclosureTextBlock_20fc1f96-9742-466b-a04e-b8330d7b477f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7531ead6-ca95-4a6c-b342-19fd5370b0ef" xlink:to="loc_us-gaap_GoodwillDisclosureTextBlock_20fc1f96-9742-466b-a04e-b8330d7b477f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/Leases" xlink:type="simple" xlink:href="nvax-20231231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_003c3927-fae7-4e13-8159-226742810c58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_391905ef-b07d-4543-8c2b-52387c4725bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_003c3927-fae7-4e13-8159-226742810c58" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_391905ef-b07d-4543-8c2b-52387c4725bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_0fd3de2d-e034-48aa-843b-20157c18a1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_003c3927-fae7-4e13-8159-226742810c58" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_0fd3de2d-e034-48aa-843b-20157c18a1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LongTermDebt" xlink:type="simple" xlink:href="nvax-20231231.xsd#LongTermDebt"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/LongTermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_73b0f129-2724-45f2-9154-64f230928719" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_885aab65-d6f7-40bf-878a-54174c6e5f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_73b0f129-2724-45f2-9154-64f230928719" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_885aab65-d6f7-40bf-878a-54174c6e5f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockholdersDeficit" xlink:type="simple" xlink:href="nvax-20231231.xsd#StockholdersDeficit"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockholdersDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_e0a2b1e8-b21c-42fc-b34c-7bf504f44d39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f62c34e4-2c2c-4ac5-b174-ca9f94d130b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_e0a2b1e8-b21c-42fc-b34c-7bf504f44d39" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f62c34e4-2c2c-4ac5-b174-ca9f94d130b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="nvax-20231231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_72b24105-bc60-4440-8683-06b7010d0e33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d92ab35e-ac20-43f5-8f1d-61e1e1dd9f59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_72b24105-bc60-4440-8683-06b7010d0e33" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d92ab35e-ac20-43f5-8f1d-61e1e1dd9f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/EmployeeBenefits" xlink:type="simple" xlink:href="nvax-20231231.xsd#EmployeeBenefits"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/EmployeeBenefits" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract_0fef59bc-e7d0-4820-87a3-590dd4540f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_c0203329-45be-42ab-8f7b-468dc0ddd88b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract_0fef59bc-e7d0-4820-87a3-590dd4540f4d" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_c0203329-45be-42ab-8f7b-468dc0ddd88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/OtherFinancialInformation" xlink:type="simple" xlink:href="nvax-20231231.xsd#OtherFinancialInformation"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/OtherFinancialInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5345ed92-700a-4e83-8abb-3b7698066f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_2ad3d644-3a4e-4844-935b-c4999616344e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5345ed92-700a-4e83-8abb-3b7698066f8d" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_2ad3d644-3a4e-4844-935b-c4999616344e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IncomeTaxes" xlink:type="simple" xlink:href="nvax-20231231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_607eff16-801c-4bff-8592-c6b2120393b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_37411add-dc1d-4f54-862f-5a934fb21fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_607eff16-801c-4bff-8592-c6b2120393b6" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_37411add-dc1d-4f54-862f-5a934fb21fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="nvax-20231231.xsd#CommitmentandContingencies"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CommitmentandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2007090d-6b75-4165-bb51-7c2290863f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_91b1432f-dce2-4777-872b-e1b36d46a045" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2007090d-6b75-4165-bb51-7c2290863f9f" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_91b1432f-dce2-4777-872b-e1b36d46a045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/Restructuring" xlink:type="simple" xlink:href="nvax-20231231.xsd#Restructuring"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/Restructuring" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e2c3970a-01db-4cd4-8270-9f20898c20ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_db2db97b-ce5f-4790-ab62-bbddfa76096c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_e2c3970a-01db-4cd4-8270-9f20898c20ee" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_db2db97b-ce5f-4790-ab62-bbddfa76096c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SubsequentEvents" xlink:type="simple" xlink:href="nvax-20231231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_06ad7c97-300f-4a67-a6d0-018f4a3143e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_713c739f-f869-4ba1-82e0-fab277a736dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_06ad7c97-300f-4a67-a6d0-018f4a3143e9" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_713c739f-f869-4ba1-82e0-fab277a736dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nvax-20231231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a8d9413f-e3a2-4db0-b5ab-788853231249" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a6c813a8-cb3b-4ccf-846f-23786cf5374f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8d9413f-e3a2-4db0-b5ab-788853231249" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a6c813a8-cb3b-4ccf-846f-23786cf5374f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LiquidityAndGoingConcernPolicyTextBlock_a9bdaebb-5277-4f6c-a17c-0b5063eabd69" xlink:href="nvax-20231231.xsd#nvax_LiquidityAndGoingConcernPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8d9413f-e3a2-4db0-b5ab-788853231249" xlink:to="loc_nvax_LiquidityAndGoingConcernPolicyTextBlock_a9bdaebb-5277-4f6c-a17c-0b5063eabd69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_c5ea487b-fbf4-4c4b-8e85-f5cbeca2a3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8d9413f-e3a2-4db0-b5ab-788853231249" xlink:to="loc_us-gaap_UseOfEstimates_c5ea487b-fbf4-4c4b-8e85-f5cbeca2a3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_5d659be8-42f5-4dc6-8dd6-6ff1a6bd2751" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8d9413f-e3a2-4db0-b5ab-788853231249" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_5d659be8-42f5-4dc6-8dd6-6ff1a6bd2751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_eeee8592-3e4b-49d0-8358-8e07f2ea824c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8d9413f-e3a2-4db0-b5ab-788853231249" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_eeee8592-3e4b-49d0-8358-8e07f2ea824c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_05900184-b480-4f47-a35b-7d505f436ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8d9413f-e3a2-4db0-b5ab-788853231249" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_05900184-b480-4f47-a35b-7d505f436ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock_31e79532-dc36-49fd-b161-fac0a6519e1f" xlink:href="nvax-20231231.xsd#nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8d9413f-e3a2-4db0-b5ab-788853231249" xlink:to="loc_nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock_31e79532-dc36-49fd-b161-fac0a6519e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_89ad7aa2-c44e-4a6c-afe0-1cca7a2535ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8d9413f-e3a2-4db0-b5ab-788853231249" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_89ad7aa2-c44e-4a6c-afe0-1cca7a2535ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_389a5a51-ae57-4d16-8ca8-e1644ea584f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8d9413f-e3a2-4db0-b5ab-788853231249" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_389a5a51-ae57-4d16-8ca8-e1644ea584f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_44d88c08-4d65-4d96-9df2-138cfa98e969" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8d9413f-e3a2-4db0-b5ab-788853231249" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_44d88c08-4d65-4d96-9df2-138cfa98e969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_61f2a484-64c2-4136-aff6-350941ea80ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8d9413f-e3a2-4db0-b5ab-788853231249" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_61f2a484-64c2-4136-aff6-350941ea80ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_223dadd3-128f-4a91-99a2-c31d2e5018c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8d9413f-e3a2-4db0-b5ab-788853231249" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_223dadd3-128f-4a91-99a2-c31d2e5018c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_f8ee8f3c-db73-48e1-9a3e-c6f697f79a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8d9413f-e3a2-4db0-b5ab-788853231249" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_f8ee8f3c-db73-48e1-9a3e-c6f697f79a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_a600dfe3-2961-4c66-92d5-7f4f8e626a98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8d9413f-e3a2-4db0-b5ab-788853231249" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_a600dfe3-2961-4c66-92d5-7f4f8e626a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_8cce53f0-85ed-4c87-a097-dd9587216567" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8d9413f-e3a2-4db0-b5ab-788853231249" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_8cce53f0-85ed-4c87-a097-dd9587216567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ddbe9f8b-93c8-4829-969c-ee29293e3d70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8d9413f-e3a2-4db0-b5ab-788853231249" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ddbe9f8b-93c8-4829-969c-ee29293e3d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_f45ef96f-2b70-4bda-bf87-e09cce4ffe68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8d9413f-e3a2-4db0-b5ab-788853231249" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_f45ef96f-2b70-4bda-bf87-e09cce4ffe68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_80ac8a4c-634f-483b-9090-a00fe857855b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8d9413f-e3a2-4db0-b5ab-788853231249" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_80ac8a4c-634f-483b-9090-a00fe857855b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_937fe39f-86c1-4cf2-9126-265bf151f292" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8d9413f-e3a2-4db0-b5ab-788853231249" xlink:to="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_937fe39f-86c1-4cf2-9126-265bf151f292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_241d3c15-5570-45eb-8e6a-1d3693f6eaa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8d9413f-e3a2-4db0-b5ab-788853231249" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_241d3c15-5570-45eb-8e6a-1d3693f6eaa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_85874c13-f79d-46d6-853a-67254a182388" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8d9413f-e3a2-4db0-b5ab-788853231249" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_85874c13-f79d-46d6-853a-67254a182388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_57690ded-69e9-41fd-be5b-0d431f9fede9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8d9413f-e3a2-4db0-b5ab-788853231249" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_57690ded-69e9-41fd-be5b-0d431f9fede9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0b87d710-5db7-496b-bd06-e557008269d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8d9413f-e3a2-4db0-b5ab-788853231249" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0b87d710-5db7-496b-bd06-e557008269d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_cb0ca0b8-6ab0-41b2-a107-65dd644d22a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8d9413f-e3a2-4db0-b5ab-788853231249" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_cb0ca0b8-6ab0-41b2-a107-65dd644d22a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_324988ff-bafb-4ddd-b441-cbaa265aeb59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8d9413f-e3a2-4db0-b5ab-788853231249" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_324988ff-bafb-4ddd-b441-cbaa265aeb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="nvax-20231231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_78154f55-d856-4860-baee-a504c0f1dd71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_adbc8c20-de0a-43dc-9d1f-733cf11894a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_78154f55-d856-4860-baee-a504c0f1dd71" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_adbc8c20-de0a-43dc-9d1f-733cf11894a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2d295d7a-c4a8-4a14-b258-f2baf1232d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_78154f55-d856-4860-baee-a504c0f1dd71" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2d295d7a-c4a8-4a14-b258-f2baf1232d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueTables" xlink:type="simple" xlink:href="nvax-20231231.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_7e91e49c-1b96-4350-bf3e-148eb5e4fae4" xlink:href="nvax-20231231.xsd#nvax_GrantsUSGovernmentContractAndJointVentureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock_80a4257b-304b-4ce5-9fd0-ece6019d88be" xlink:href="nvax-20231231.xsd#nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_7e91e49c-1b96-4350-bf3e-148eb5e4fae4" xlink:to="loc_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock_80a4257b-304b-4ce5-9fd0-ece6019d88be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_69401da2-89be-470f-8578-0056b6158e58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_7e91e49c-1b96-4350-bf3e-148eb5e4fae4" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_69401da2-89be-470f-8578-0056b6158e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_43ca3981-8fa1-4322-9c0e-cc08d65d0f76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_7e91e49c-1b96-4350-bf3e-148eb5e4fae4" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_43ca3981-8fa1-4322-9c0e-cc08d65d0f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock_3222e8de-c227-4698-b680-d4287a360181" xlink:href="nvax-20231231.xsd#nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_7e91e49c-1b96-4350-bf3e-148eb5e4fae4" xlink:to="loc_nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock_3222e8de-c227-4698-b680-d4287a360181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashTables" xlink:type="simple" xlink:href="nvax-20231231.xsd#CashCashEquivalentsandRestrictedCashTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_4b26bfd8-7a4b-4a84-aca7-1357983e87f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_3e7502ca-a9a3-4b40-8517-cdb5b7c34a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_4b26bfd8-7a4b-4a84-aca7-1357983e87f5" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_3e7502ca-a9a3-4b40-8517-cdb5b7c34a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="nvax-20231231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_85b37f7b-21d3-4682-9d36-cb630f1acd64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_a26c29ea-4deb-4ad0-bea2-950a6152f6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_85b37f7b-21d3-4682-9d36-cb630f1acd64" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_a26c29ea-4deb-4ad0-bea2-950a6152f6e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/InventoryTables" xlink:type="simple" xlink:href="nvax-20231231.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_663f7bab-0df9-407b-91aa-450dd9d5e730" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0922fd76-4fc3-4abb-90b4-e8e520740de7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_663f7bab-0df9-407b-91aa-450dd9d5e730" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0922fd76-4fc3-4abb-90b4-e8e520740de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfInventoryReserveTableTextBlock_ccfcf532-2fd5-499b-ab23-3878b4287c6f" xlink:href="nvax-20231231.xsd#nvax_ScheduleOfInventoryReserveTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_663f7bab-0df9-407b-91aa-450dd9d5e730" xlink:to="loc_nvax_ScheduleOfInventoryReserveTableTextBlock_ccfcf532-2fd5-499b-ab23-3878b4287c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/GoodwillTables" xlink:type="simple" xlink:href="nvax-20231231.xsd#GoodwillTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/GoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bcd83090-3ae8-463d-bc57-cc7dfd9f47ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_343b818f-f9d0-4408-8009-1a7a006cad78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bcd83090-3ae8-463d-bc57-cc7dfd9f47ec" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_343b818f-f9d0-4408-8009-1a7a006cad78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LeasesTables" xlink:type="simple" xlink:href="nvax-20231231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b4470066-09e3-405d-9a76-bddd2a70d15c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock_0c0c94f5-a3a9-4d71-84d8-d35410e16721" xlink:href="nvax-20231231.xsd#nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b4470066-09e3-405d-9a76-bddd2a70d15c" xlink:to="loc_nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock_0c0c94f5-a3a9-4d71-84d8-d35410e16721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_84725d49-b2a2-4e85-84ed-7e652861eb69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b4470066-09e3-405d-9a76-bddd2a70d15c" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_84725d49-b2a2-4e85-84ed-7e652861eb69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock_6d17a98f-3ab3-4860-83ba-d382c28edd3a" xlink:href="nvax-20231231.xsd#nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b4470066-09e3-405d-9a76-bddd2a70d15c" xlink:to="loc_nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock_6d17a98f-3ab3-4860-83ba-d382c28edd3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f1f5558a-be31-4ff7-bde5-71531ce3d039" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b4470066-09e3-405d-9a76-bddd2a70d15c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f1f5558a-be31-4ff7-bde5-71531ce3d039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LongTermDebtTables" xlink:type="simple" xlink:href="nvax-20231231.xsd#LongTermDebtTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/LongTermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f9625ac2-6c41-48a8-9073-367bbd382783" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_b430cc77-866d-4349-8818-d7a25293c34c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f9625ac2-6c41-48a8-9073-367bbd382783" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_b430cc77-866d-4349-8818-d7a25293c34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock_53c9db5f-7370-4460-a39c-3e42952c7b80" xlink:href="nvax-20231231.xsd#nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f9625ac2-6c41-48a8-9073-367bbd382783" xlink:to="loc_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock_53c9db5f-7370-4460-a39c-3e42952c7b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="nvax-20231231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7bc8b384-838c-43a3-ab84-6297d6d83fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7bf6b0f7-9118-4aac-8cb7-0bd71c34e388" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7bc8b384-838c-43a3-ab84-6297d6d83fbc" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7bf6b0f7-9118-4aac-8cb7-0bd71c34e388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_427e996c-ec78-4616-914b-a3897fb7aece" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7bc8b384-838c-43a3-ab84-6297d6d83fbc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_427e996c-ec78-4616-914b-a3897fb7aece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3db48570-8d7a-488a-b736-ebaa3580aa21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7bc8b384-838c-43a3-ab84-6297d6d83fbc" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3db48570-8d7a-488a-b736-ebaa3580aa21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock_d2c4575b-6c33-4943-9160-61c86b74b2a5" xlink:href="nvax-20231231.xsd#nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7bc8b384-838c-43a3-ab84-6297d6d83fbc" xlink:to="loc_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock_d2c4575b-6c33-4943-9160-61c86b74b2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/OtherFinancialInformationTables" xlink:type="simple" xlink:href="nvax-20231231.xsd#OtherFinancialInformationTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/OtherFinancialInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_14c351dc-92e7-4be3-a179-110a8ce6a108" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_5fa81af0-a9a5-44e7-99dd-3ec95fa60595" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_14c351dc-92e7-4be3-a179-110a8ce6a108" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_5fa81af0-a9a5-44e7-99dd-3ec95fa60595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_3cdf9be9-bd2e-4215-89b6-cd97aaa52ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_14c351dc-92e7-4be3-a179-110a8ce6a108" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_3cdf9be9-bd2e-4215-89b6-cd97aaa52ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_f2241534-10b1-4f5e-ae86-3b1cc398b6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_14c351dc-92e7-4be3-a179-110a8ce6a108" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_f2241534-10b1-4f5e-ae86-3b1cc398b6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_e07bfffa-0e89-4b53-8006-3dba3b23574b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_14c351dc-92e7-4be3-a179-110a8ce6a108" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_e07bfffa-0e89-4b53-8006-3dba3b23574b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="nvax-20231231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fca084f6-16f9-4ac9-b2ad-9b7071e31966" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_7cbdcfd5-9005-4863-809e-6a0a39b55c53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fca084f6-16f9-4ac9-b2ad-9b7071e31966" xlink:to="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_7cbdcfd5-9005-4863-809e-6a0a39b55c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_872223f4-a89e-4fb8-ad75-f3aa4d158931" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fca084f6-16f9-4ac9-b2ad-9b7071e31966" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_872223f4-a89e-4fb8-ad75-f3aa4d158931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_cbdfe730-bb28-4142-8ac6-7b19d48ff6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fca084f6-16f9-4ac9-b2ad-9b7071e31966" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_cbdfe730-bb28-4142-8ac6-7b19d48ff6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e87aa3ec-19fb-4a29-b405-ae9fc7f39187" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fca084f6-16f9-4ac9-b2ad-9b7071e31966" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e87aa3ec-19fb-4a29-b405-ae9fc7f39187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_c8b4ad29-5c8e-4627-9090-a276d8f6f464" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fca084f6-16f9-4ac9-b2ad-9b7071e31966" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_c8b4ad29-5c8e-4627-9090-a276d8f6f464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RestructuringTables" xlink:type="simple" xlink:href="nvax-20231231.xsd#RestructuringTables"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/RestructuringTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_c93673c1-9eb9-49f5-8056-6d55ec4d006a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_d1ddb5c5-3272-47a7-8b64-7237b374bb4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_c93673c1-9eb9-49f5-8056-6d55ec4d006a" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_d1ddb5c5-3272-47a7-8b64-7237b374bb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bb8faaeb-23c0-4c77-8e29-4c00e846ac23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_3adf0823-5f07-45a9-ad49-d57e798a226c" xlink:href="nvax-20231231.xsd#nvax_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bb8faaeb-23c0-4c77-8e29-4c00e846ac23" xlink:to="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_3adf0823-5f07-45a9-ad49-d57e798a226c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4b5e5109-cf3c-4592-bf4b-b65f0d788861" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_3adf0823-5f07-45a9-ad49-d57e798a226c" xlink:to="loc_srt_RangeAxis_4b5e5109-cf3c-4592-bf4b-b65f0d788861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_78c99b6a-8a57-4a1d-831e-30400a12611c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4b5e5109-cf3c-4592-bf4b-b65f0d788861" xlink:to="loc_srt_RangeMember_78c99b6a-8a57-4a1d-831e-30400a12611c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4ac1c7a0-ae7e-4ca3-9c80-f4e303018bc9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_78c99b6a-8a57-4a1d-831e-30400a12611c" xlink:to="loc_srt_MinimumMember_4ac1c7a0-ae7e-4ca3-9c80-f4e303018bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_da73537c-ec65-4970-9a1e-315e77724eb9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_78c99b6a-8a57-4a1d-831e-30400a12611c" xlink:to="loc_srt_MaximumMember_da73537c-ec65-4970-9a1e-315e77724eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1921d5bf-1621-44f7-af31-2cbe50a1b1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_3adf0823-5f07-45a9-ad49-d57e798a226c" xlink:to="loc_us-gaap_DebtInstrumentAxis_1921d5bf-1621-44f7-af31-2cbe50a1b1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_989b9635-e4a6-4355-b55e-e775fed7e0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1921d5bf-1621-44f7-af31-2cbe50a1b1cf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_989b9635-e4a6-4355-b55e-e775fed7e0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_2fdd401b-7f1d-4930-aa69-eb115998a38f" xlink:href="nvax-20231231.xsd#nvax_FivePointZeroConvertibleNotesDue2027Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_989b9635-e4a6-4355-b55e-e775fed7e0e1" xlink:to="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_2fdd401b-7f1d-4930-aa69-eb115998a38f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_caa9fed0-d1f1-4a8c-bf3c-2d641b9e4e06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_3adf0823-5f07-45a9-ad49-d57e798a226c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_caa9fed0-d1f1-4a8c-bf3c-2d641b9e4e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b594e277-3edb-4213-ad2d-abff813031de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_caa9fed0-d1f1-4a8c-bf3c-2d641b9e4e06" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b594e277-3edb-4213-ad2d-abff813031de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_cb6748d5-71d7-411b-a71a-e446ccbc5436" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b594e277-3edb-4213-ad2d-abff813031de" xlink:to="loc_us-gaap_UnsecuredDebtMember_cb6748d5-71d7-411b-a71a-e446ccbc5436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_54e98b5c-1a43-4d04-9615-1aac0b5b551e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_3adf0823-5f07-45a9-ad49-d57e798a226c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_54e98b5c-1a43-4d04-9615-1aac0b5b551e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ea777138-f839-47d5-bb1e-385002ef8512" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_54e98b5c-1a43-4d04-9615-1aac0b5b551e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ea777138-f839-47d5-bb1e-385002ef8512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CanadaAdvancePurchaseAgreementMember_18a8c121-71fe-41f5-a6f3-35b24532a441" xlink:href="nvax-20231231.xsd#nvax_CanadaAdvancePurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ea777138-f839-47d5-bb1e-385002ef8512" xlink:to="loc_nvax_CanadaAdvancePurchaseAgreementMember_18a8c121-71fe-41f5-a6f3-35b24532a441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_1af95ae4-d288-43b8-bdb7-b14effb60f16" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_3adf0823-5f07-45a9-ad49-d57e798a226c" xlink:to="loc_srt_StatementScenarioAxis_1af95ae4-d288-43b8-bdb7-b14effb60f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_ea103805-9fd5-417c-a926-d122769a0452" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_1af95ae4-d288-43b8-bdb7-b14effb60f16" xlink:to="loc_srt_ScenarioUnspecifiedDomain_ea103805-9fd5-417c-a926-d122769a0452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_151dafe3-5cf8-4b36-891e-5bae7effe9b2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_ea103805-9fd5-417c-a926-d122769a0452" xlink:to="loc_srt_ScenarioForecastMember_151dafe3-5cf8-4b36-891e-5bae7effe9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:href="nvax-20231231.xsd#nvax_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesTable_3adf0823-5f07-45a9-ad49-d57e798a226c" xlink:to="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_271cb20b-9f63-476a-9801-da73042c89ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_271cb20b-9f63-476a-9801-da73042c89ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InstallmentChargesOfTheCompany_5e2eb990-f9f4-48a6-a5bb-7b482c8f7e86" xlink:href="nvax-20231231.xsd#nvax_InstallmentChargesOfTheCompany"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_nvax_InstallmentChargesOfTheCompany_5e2eb990-f9f4-48a6-a5bb-7b482c8f7e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_967711e0-594c-45ef-b78c-8ff3e67d3bee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_us-gaap_NetIncomeLoss_967711e0-594c-45ef-b78c-8ff3e67d3bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5f92ac14-944b-4a53-9302-03eee0c542f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5f92ac14-944b-4a53-9302-03eee0c542f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_35a04b9c-10e2-4d45-b895-f8ffda1c744c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent_35a04b9c-10e2-4d45-b895-f8ffda1c744c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_bc7cecc9-d795-41db-909a-04e0df310f28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_us-gaap_SeveranceCosts1_bc7cecc9-d795-41db-909a-04e0df310f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_6c80b25b-7fa3-473e-b812-975fb7570f89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_us-gaap_AssetImpairmentCharges_6c80b25b-7fa3-473e-b812-975fb7570f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_64525cc3-2944-4381-a211-1eba142f69f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_us-gaap_AdvertisingExpense_64525cc3-2944-4381-a211-1eba142f69f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_b4176c17-6b0d-48cb-914f-e838a085dac1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_b4176c17-6b0d-48cb-914f-e838a085dac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_e82dd88a-6156-468c-91f4-0e6c97256bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_us-gaap_NumberOfReportingUnits_e82dd88a-6156-468c-91f4-0e6c97256bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_fe343123-c2cc-4480-b818-8f21fb3738b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_fe343123-c2cc-4480-b818-8f21fb3738b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_290c9c6a-fe45-426c-8266-3e7fb610f39a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_290c9c6a-fe45-426c-8266-3e7fb610f39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_aac99837-e5dd-4f55-a423-de55fa5420a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_aac99837-e5dd-4f55-a423-de55fa5420a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_0a1d285f-3d27-43c9-b13e-86470a176d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_0a1d285f-3d27-43c9-b13e-86470a176d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax_7cbd7bb1-8f7a-4204-afe1-9cc2a6ecf41c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax_7cbd7bb1-8f7a-4204-afe1-9cc2a6ecf41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_c44d237d-fdf0-4200-afe2-3c02b31e1588" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_SummaryOfSignificantAccountingPoliciesLineItems_97de76c2-50b6-43f5-aaf2-97c771841c10" xlink:to="loc_us-gaap_NumberOfOperatingSegments_c44d237d-fdf0-4200-afe2-3c02b31e1588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6be35e35-97ce-417d-9239-36bef25be084" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_ad304fde-1a7a-43d9-876f-7296959b348f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6be35e35-97ce-417d-9239-36bef25be084" xlink:to="loc_us-gaap_ConcentrationRiskTable_ad304fde-1a7a-43d9-876f-7296959b348f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_4ff5d038-ca6d-4a3e-8d32-daf1d4ff1968" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_ad304fde-1a7a-43d9-876f-7296959b348f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_4ff5d038-ca6d-4a3e-8d32-daf1d4ff1968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c45164ba-c99a-4797-800b-1a0b4e523c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_4ff5d038-ca6d-4a3e-8d32-daf1d4ff1968" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c45164ba-c99a-4797-800b-1a0b4e523c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a7c225f6-e633-439a-ba62-13e21f6ec5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c45164ba-c99a-4797-800b-1a0b4e523c9a" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a7c225f6-e633-439a-ba62-13e21f6ec5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b84defa8-7239-4850-91ec-ff42c5c30b72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_ad304fde-1a7a-43d9-876f-7296959b348f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b84defa8-7239-4850-91ec-ff42c5c30b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f0038078-e27a-48d1-ad25-917d0353cef3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b84defa8-7239-4850-91ec-ff42c5c30b72" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f0038078-e27a-48d1-ad25-917d0353cef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_30ac42da-c749-43ee-b3f9-95ac8377661a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f0038078-e27a-48d1-ad25-917d0353cef3" xlink:to="loc_us-gaap_SalesRevenueNetMember_30ac42da-c749-43ee-b3f9-95ac8377661a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_d6c79041-e717-43b3-b139-f5d2a7806a35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f0038078-e27a-48d1-ad25-917d0353cef3" xlink:to="loc_us-gaap_AccountsReceivableMember_d6c79041-e717-43b3-b139-f5d2a7806a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_0c526f32-89d6-4a7d-9501-404676441dee" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_ad304fde-1a7a-43d9-876f-7296959b348f" xlink:to="loc_srt_MajorCustomersAxis_0c526f32-89d6-4a7d-9501-404676441dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_72016f8b-8174-4aed-b2de-d0bed02a87dd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_0c526f32-89d6-4a7d-9501-404676441dee" xlink:to="loc_srt_NameOfMajorCustomerDomain_72016f8b-8174-4aed-b2de-d0bed02a87dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EuropeanCommissionMember_2472432a-dd8b-4105-b705-62dc3e3cae5a" xlink:href="nvax-20231231.xsd#nvax_EuropeanCommissionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_72016f8b-8174-4aed-b2de-d0bed02a87dd" xlink:to="loc_nvax_EuropeanCommissionMember_2472432a-dd8b-4105-b705-62dc3e3cae5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GovernmentOfAustraliaMember_6c6ed3d5-d635-4669-8b95-5a779111cf2f" xlink:href="nvax-20231231.xsd#nvax_GovernmentOfAustraliaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_72016f8b-8174-4aed-b2de-d0bed02a87dd" xlink:to="loc_nvax_GovernmentOfAustraliaMember_6c6ed3d5-d635-4669-8b95-5a779111cf2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GovernmentOfCanadaMember_b8833950-1982-4598-8aa7-b31d2e83af61" xlink:href="nvax-20231231.xsd#nvax_GovernmentOfCanadaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_72016f8b-8174-4aed-b2de-d0bed02a87dd" xlink:to="loc_nvax_GovernmentOfCanadaMember_b8833950-1982-4598-8aa7-b31d2e83af61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GovernmentOfIsraelMember_f4cfff88-177f-4215-acdf-1e6d4987a720" xlink:href="nvax-20231231.xsd#nvax_GovernmentOfIsraelMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_72016f8b-8174-4aed-b2de-d0bed02a87dd" xlink:to="loc_nvax_GovernmentOfIsraelMember_f4cfff88-177f-4215-acdf-1e6d4987a720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentMember_00432610-8e2d-42ea-be18-48fc8bd662fe" xlink:href="nvax-20231231.xsd#nvax_USGovernmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_72016f8b-8174-4aed-b2de-d0bed02a87dd" xlink:to="loc_nvax_USGovernmentMember_00432610-8e2d-42ea-be18-48fc8bd662fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CoalitionForEpidemicPreparednessInnovationsMember_f4f7d3c4-2ff7-46d8-9af1-87cbf6d97280" xlink:href="nvax-20231231.xsd#nvax_CoalitionForEpidemicPreparednessInnovationsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_72016f8b-8174-4aed-b2de-d0bed02a87dd" xlink:to="loc_nvax_CoalitionForEpidemicPreparednessInnovationsMember_f4f7d3c4-2ff7-46d8-9af1-87cbf6d97280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SKBioscienceCoLtdMember_1e2e0111-bc7f-4e90-88d5-78937360e11d" xlink:href="nvax-20231231.xsd#nvax_SKBioscienceCoLtdMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_72016f8b-8174-4aed-b2de-d0bed02a87dd" xlink:to="loc_nvax_SKBioscienceCoLtdMember_1e2e0111-bc7f-4e90-88d5-78937360e11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_ae250e11-20a5-49f2-935a-23b82a2bde68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_ad304fde-1a7a-43d9-876f-7296959b348f" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_ae250e11-20a5-49f2-935a-23b82a2bde68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_51308a2e-8243-4551-ad73-280254f44733" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ae250e11-20a5-49f2-935a-23b82a2bde68" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_51308a2e-8243-4551-ad73-280254f44733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ada4600b-f3a0-4194-9a48-d80021a1aa1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4ea4c104-b5cf-4673-ace3-71b86e4d5e85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ada4600b-f3a0-4194-9a48-d80021a1aa1f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4ea4c104-b5cf-4673-ace3-71b86e4d5e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e5b420e5-04cd-4562-ac34-ca6302feb582" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4ea4c104-b5cf-4673-ace3-71b86e4d5e85" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e5b420e5-04cd-4562-ac34-ca6302feb582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4fcd6685-1f9b-43ed-a51b-92f798b66bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e5b420e5-04cd-4562-ac34-ca6302feb582" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4fcd6685-1f9b-43ed-a51b-92f798b66bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_cfb60d1b-470a-4deb-9882-0164f1d171fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4fcd6685-1f9b-43ed-a51b-92f798b66bb4" xlink:to="loc_us-gaap_BuildingMember_cfb60d1b-470a-4deb-9882-0164f1d171fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_ce4505b6-ec4e-47d8-b3a0-abda434b6d68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4fcd6685-1f9b-43ed-a51b-92f798b66bb4" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_ce4505b6-ec4e-47d8-b3a0-abda434b6d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_1d2b3a56-75c6-4fa8-8b02-2c01a7c35dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4fcd6685-1f9b-43ed-a51b-92f798b66bb4" xlink:to="loc_us-gaap_ComputerEquipmentMember_1d2b3a56-75c6-4fa8-8b02-2c01a7c35dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f51fcfa1-0b79-4018-ab3a-3b870b891c68" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4ea4c104-b5cf-4673-ace3-71b86e4d5e85" xlink:to="loc_srt_RangeAxis_f51fcfa1-0b79-4018-ab3a-3b870b891c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9219d57b-aee8-464a-ace8-06fbc5a28804" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f51fcfa1-0b79-4018-ab3a-3b870b891c68" xlink:to="loc_srt_RangeMember_9219d57b-aee8-464a-ace8-06fbc5a28804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8940c2bd-4b2c-43b5-8415-1609fe7689ff" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9219d57b-aee8-464a-ace8-06fbc5a28804" xlink:to="loc_srt_MinimumMember_8940c2bd-4b2c-43b5-8415-1609fe7689ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1c684a72-6901-4fe2-9981-90e088b0d228" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9219d57b-aee8-464a-ace8-06fbc5a28804" xlink:to="loc_srt_MaximumMember_1c684a72-6901-4fe2-9981-90e088b0d228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9c2451da-a09e-4da7-96e0-49e4de2bb84e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4ea4c104-b5cf-4673-ace3-71b86e4d5e85" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9c2451da-a09e-4da7-96e0-49e4de2bb84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_95f312ea-2009-4736-b8fe-8e3a2807cadd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9c2451da-a09e-4da7-96e0-49e4de2bb84e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_95f312ea-2009-4736-b8fe-8e3a2807cadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#RevenueAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/RevenueAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_7dca9ff5-55b1-4bb8-b452-27a0188178b3" xlink:href="nvax-20231231.xsd#nvax_GrantsUSGovernmentContractAndJointVentureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_15203e6a-b6d5-4718-92a3-4cedc97e855b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_7dca9ff5-55b1-4bb8-b452-27a0188178b3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_15203e6a-b6d5-4718-92a3-4cedc97e855b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_cc0b22b4-b91f-4be4-a001-b1361868b276" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_15203e6a-b6d5-4718-92a3-4cedc97e855b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_cc0b22b4-b91f-4be4-a001-b1361868b276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9ddb5bf0-4d62-4bf5-a04f-5384cb87f478" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_15203e6a-b6d5-4718-92a3-4cedc97e855b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9ddb5bf0-4d62-4bf5-a04f-5384cb87f478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9ddb5bf0-4d62-4bf5-a04f-5384cb87f478" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementSIIPLMember_fb25eba2-dd95-4b4d-a013-9c2b3050ffd1" xlink:href="nvax-20231231.xsd#nvax_GaviAdvancePurchaseAgreementSIIPLMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_GaviAdvancePurchaseAgreementSIIPLMember_fb25eba2-dd95-4b4d-a013-9c2b3050ffd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_01d6cb13-8a9b-46ca-aa33-1fb534b634e1" xlink:href="nvax-20231231.xsd#nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_01d6cb13-8a9b-46ca-aa33-1fb534b634e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EuropeanCommissionsECMember_e1cf4180-166f-4707-a4b2-56c9f6116c69" xlink:href="nvax-20231231.xsd#nvax_EuropeanCommissionsECMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_EuropeanCommissionsECMember_e1cf4180-166f-4707-a4b2-56c9f6116c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CanadaAdvancePurchaseAgreementMember_ba1b3218-d6b3-4982-ae35-1b0ba58b9c4c" xlink:href="nvax-20231231.xsd#nvax_CanadaAdvancePurchaseAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_CanadaAdvancePurchaseAgreementMember_ba1b3218-d6b3-4982-ae35-1b0ba58b9c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_af873946-406f-4818-8e79-aba1c5ae7f0a" xlink:href="nvax-20231231.xsd#nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember_af873946-406f-4818-8e79-aba1c5ae7f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentPartnershipMember_41e1ef8b-cb07-44d5-85df-6b43f86a24c3" xlink:href="nvax-20231231.xsd#nvax_USGovernmentPartnershipMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_USGovernmentPartnershipMember_41e1ef8b-cb07-44d5-85df-6b43f86a24c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentAgreementMember_60bd5a7c-fe8b-4598-9eb5-7b7e7218b43f" xlink:href="nvax-20231231.xsd#nvax_USGovernmentAgreementMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_USGovernmentAgreementMember_60bd5a7c-fe8b-4598-9eb5-7b7e7218b43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember_671e1416-e629-4796-aea5-a31d506e91d8" xlink:href="nvax-20231231.xsd#nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember_671e1416-e629-4796-aea5-a31d506e91d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CEPIGrantFundingMember_a2582746-10d7-4ce6-bb39-9a24f663b04e" xlink:href="nvax-20231231.xsd#nvax_CEPIGrantFundingMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_CEPIGrantFundingMember_a2582746-10d7-4ce6-bb39-9a24f663b04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_MatrixMAdjuvantSalesMember_2cda059d-a268-458f-a66d-cf1af8b167e4" xlink:href="nvax-20231231.xsd#nvax_MatrixMAdjuvantSalesMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_MatrixMAdjuvantSalesMember_2cda059d-a268-458f-a66d-cf1af8b167e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementMember_52bbe463-4b85-4da2-8a4c-852dbde7920b" xlink:href="nvax-20231231.xsd#nvax_SettlementAgreementMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_SettlementAgreementMember_52bbe463-4b85-4da2-8a4c-852dbde7920b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AustralianAPAMember_cd53adc1-3819-4f45-9d40-49e2f9b58b56" xlink:href="nvax-20231231.xsd#nvax_AustralianAPAMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbc98d0b-7185-4d97-b393-de1856c3e189" xlink:to="loc_nvax_AustralianAPAMember_cd53adc1-3819-4f45-9d40-49e2f9b58b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis_8de9e936-5f94-461b-a3b3-00aa882113b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_15203e6a-b6d5-4718-92a3-4cedc97e855b" xlink:to="loc_us-gaap_SupplyCommitmentAxis_8de9e936-5f94-461b-a3b3-00aa882113b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_9422cb6c-8783-4780-a081-45910be563cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentAxis_8de9e936-5f94-461b-a3b3-00aa882113b5" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_9422cb6c-8783-4780-a081-45910be563cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember_e662f9b8-dec6-47e9-952f-59450e1e6c17" xlink:href="nvax-20231231.xsd#nvax_AmendedAndRestatedUKSupplyAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_9422cb6c-8783-4780-a081-45910be563cd" xlink:to="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember_e662f9b8-dec6-47e9-952f-59450e1e6c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0d0a9843-9c47-4f43-b6d5-88ae8495c020" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_15203e6a-b6d5-4718-92a3-4cedc97e855b" xlink:to="loc_srt_RangeAxis_0d0a9843-9c47-4f43-b6d5-88ae8495c020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9b4492e9-eb3e-4f35-91cf-f27b0efebfa1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0d0a9843-9c47-4f43-b6d5-88ae8495c020" xlink:to="loc_srt_RangeMember_9b4492e9-eb3e-4f35-91cf-f27b0efebfa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_95ee7d80-4841-4031-8604-9ef127180b5c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9b4492e9-eb3e-4f35-91cf-f27b0efebfa1" xlink:to="loc_srt_MinimumMember_95ee7d80-4841-4031-8604-9ef127180b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_91e01c1d-641c-4bd7-a8cc-eb2c07fb1e54" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9b4492e9-eb3e-4f35-91cf-f27b0efebfa1" xlink:to="loc_srt_MaximumMember_91e01c1d-641c-4bd7-a8cc-eb2c07fb1e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b8d2cb4c-ae66-4c7c-94a1-375bed680d25" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_15203e6a-b6d5-4718-92a3-4cedc97e855b" xlink:to="loc_srt_ProductOrServiceAxis_b8d2cb4c-ae66-4c7c-94a1-375bed680d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2bd6aeec-0520-40c0-88bd-02df702759b1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b8d2cb4c-ae66-4c7c-94a1-375bed680d25" xlink:to="loc_srt_ProductsAndServicesDomain_2bd6aeec-0520-40c0-88bd-02df702759b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SalesBasedRoyaltiesMember_c5b91f69-8868-43f9-b6be-a61a52c9bbaa" xlink:href="nvax-20231231.xsd#nvax_SalesBasedRoyaltiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2bd6aeec-0520-40c0-88bd-02df702759b1" xlink:to="loc_nvax_SalesBasedRoyaltiesMember_c5b91f69-8868-43f9-b6be-a61a52c9bbaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_MilestonePaymentsMember_0e904b24-724b-4733-b8c2-ab48a9ab9b94" xlink:href="nvax-20231231.xsd#nvax_MilestonePaymentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2bd6aeec-0520-40c0-88bd-02df702759b1" xlink:to="loc_nvax_MilestonePaymentsMember_0e904b24-724b-4733-b8c2-ab48a9ab9b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_9857cf06-2444-46e6-bdc0-524c4a5a057e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2bd6aeec-0520-40c0-88bd-02df702759b1" xlink:to="loc_us-gaap_ProductMember_9857cf06-2444-46e6-bdc0-524c4a5a057e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_d2eaf049-e958-479b-819c-cadede746708" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_15203e6a-b6d5-4718-92a3-4cedc97e855b" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_d2eaf049-e958-479b-819c-cadede746708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_6436b745-53e6-4c7a-9e3b-0f3ce7dc8de9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_d2eaf049-e958-479b-819c-cadede746708" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_6436b745-53e6-4c7a-9e3b-0f3ce7dc8de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CanadaRevenueAgencyMember_0b51332c-144e-48dd-a4f6-b8d9f5151d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CanadaRevenueAgencyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_6436b745-53e6-4c7a-9e3b-0f3ce7dc8de9" xlink:to="loc_us-gaap_CanadaRevenueAgencyMember_0b51332c-144e-48dd-a4f6-b8d9f5151d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fa2659f1-c576-451a-879f-9c7e96309404" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_15203e6a-b6d5-4718-92a3-4cedc97e855b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fa2659f1-c576-451a-879f-9c7e96309404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7ba3f60f-1845-4603-b47c-d319774f69f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fa2659f1-c576-451a-879f-9c7e96309404" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7ba3f60f-1845-4603-b47c-d319774f69f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ef19ab8d-5c71-4aa5-a0f0-9becaba0aafc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7ba3f60f-1845-4603-b47c-d319774f69f4" xlink:to="loc_us-gaap_SubsequentEventMember_ef19ab8d-5c71-4aa5-a0f0-9becaba0aafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_00c55fd6-79fa-46f6-b7d1-c64e702f1b87" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_15203e6a-b6d5-4718-92a3-4cedc97e855b" xlink:to="loc_srt_StatementScenarioAxis_00c55fd6-79fa-46f6-b7d1-c64e702f1b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_7334eff0-c00b-4fc9-a202-f4c175813eb0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_00c55fd6-79fa-46f6-b7d1-c64e702f1b87" xlink:to="loc_srt_ScenarioUnspecifiedDomain_7334eff0-c00b-4fc9-a202-f4c175813eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_a6606d1f-68ff-4d5c-83c1-b3c35a18abf7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_7334eff0-c00b-4fc9-a202-f4c175813eb0" xlink:to="loc_srt_ScenarioForecastMember_a6606d1f-68ff-4d5c-83c1-b3c35a18abf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_15203e6a-b6d5-4718-92a3-4cedc97e855b" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables_8c9dcc4f-7031-4174-a7bd-62ae2aae83f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BilledContractReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_BilledContractReceivables_8c9dcc4f-7031-4174-a7bd-62ae2aae83f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_fabaa3b9-23e5-47da-9646-02ebe230f6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_UnbilledContractsReceivable_fabaa3b9-23e5-47da-9646-02ebe230f6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_c60d90e0-6d91-4445-8ae3-3bdd382f11a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_c60d90e0-6d91-4445-8ae3-3bdd382f11a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_e03d9713-153a-4188-be64-33cd0016d174" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_ContractWithCustomerLiability_e03d9713-153a-4188-be64-33cd0016d174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_fcd38e5b-fc94-485e-a928-e558d0724b64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_fcd38e5b-fc94-485e-a928-e558d0724b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesToBeDistributed_99c59c9b-e845-4fe0-9bb7-94a31a7d6e28" xlink:href="nvax-20231231.xsd#nvax_NumberOfDosesToBeDistributed"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_NumberOfDosesToBeDistributed_99c59c9b-e845-4fe0-9bb7-94a31a7d6e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount_c3e3afd8-7a8f-4032-b3f7-ae4f29c06653" xlink:href="nvax-20231231.xsd#nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount_c3e3afd8-7a8f-4032-b3f7-ae4f29c06653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_5e11dc15-22ab-43b9-acfd-4cd15087de40" xlink:href="nvax-20231231.xsd#nvax_CollaborationAgreementUpfrontPaymentAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_5e11dc15-22ab-43b9-acfd-4cd15087de40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ea486202-4adb-405e-9c91-bff80075942b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ea486202-4adb-405e-9c91-bff80075942b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_172b3666-f176-40b2-8314-99be031572cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_LitigationSettlementExpense_172b3666-f176-40b2-8314-99be031572cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_90b0cee5-456d-4f2a-bed1-0e3f89afda8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantsReceivable"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_GrantsReceivable_90b0cee5-456d-4f2a-bed1-0e3f89afda8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_f9be9764-6b30-4803-aa9f-175d0b3c2bec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_36e85ac5-6b5a-4c8d-87e5-826142dc6abe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_36e85ac5-6b5a-4c8d-87e5-826142dc6abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AmountsChargedAgainstProductSales_70b09845-4a09-4f4e-b473-63f788fcf572" xlink:href="nvax-20231231.xsd#nvax_AmountsChargedAgainstProductSales"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_AmountsChargedAgainstProductSales_70b09845-4a09-4f4e-b473-63f788fcf572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption_eebdea6f-9cd2-4929-894f-d6b085d39dbe" xlink:href="nvax-20231231.xsd#nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption_eebdea6f-9cd2-4929-894f-d6b085d39dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfDosesCancelled_da55f0ec-b7dd-4a2b-9f55-4d28b916357f" xlink:href="nvax-20231231.xsd#nvax_PurchaseAgreementNumberOfDosesCancelled"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_PurchaseAgreementNumberOfDosesCancelled_da55f0ec-b7dd-4a2b-9f55-4d28b916357f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfVaccineDoses_5b401aa3-f397-412d-8cba-bc74c56aae10" xlink:href="nvax-20231231.xsd#nvax_PurchaseAgreementNumberOfVaccineDoses"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_PurchaseAgreementNumberOfVaccineDoses_5b401aa3-f397-412d-8cba-bc74c56aae10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesOfVaccineCandidate_db8ae70c-4e4c-4b08-8446-0d53e6b71e29" xlink:href="nvax-20231231.xsd#nvax_NumberOfDosesOfVaccineCandidate"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_NumberOfDosesOfVaccineCandidate_db8ae70c-4e4c-4b08-8446-0d53e6b71e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f50f31ff-e303-4239-b3d4-958ec3e4517e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f50f31ff-e303-4239-b3d4-958ec3e4517e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InstallmentChargesOfTheCompany_cf11991f-81f9-4052-bc93-6d3bc1a63f9c" xlink:href="nvax-20231231.xsd#nvax_InstallmentChargesOfTheCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_InstallmentChargesOfTheCompany_cf11991f-81f9-4052-bc93-6d3bc1a63f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e88ea45b-0bb1-4227-8cb6-3333fd23f7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e88ea45b-0bb1-4227-8cb6-3333fd23f7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8aa85966-6e81-4424-8385-465cc253e038" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8aa85966-6e81-4424-8385-465cc253e038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_efef3603-fc55-4b20-adde-026cd31b490b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_efef3603-fc55-4b20-adde-026cd31b490b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ContractWithCustomerObligationToDeliverTerms_2ae703b6-c945-44e2-b53b-67faf4d9e85b" xlink:href="nvax-20231231.xsd#nvax_ContractWithCustomerObligationToDeliverTerms"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_ContractWithCustomerObligationToDeliverTerms_2ae703b6-c945-44e2-b53b-67faf4d9e85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PercentOfRemainingAmountToBePaid_956ee948-ad12-4fe7-b401-06e606203dee" xlink:href="nvax-20231231.xsd#nvax_PercentOfRemainingAmountToBePaid"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_PercentOfRemainingAmountToBePaid_956ee948-ad12-4fe7-b401-06e606203dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EscrowDepositsRelatedToSalesHold_e2d2db42-acfe-4d7c-bdaa-c61a0d3a650e" xlink:href="nvax-20231231.xsd#nvax_EscrowDepositsRelatedToSalesHold"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_EscrowDepositsRelatedToSalesHold_e2d2db42-acfe-4d7c-bdaa-c61a0d3a650e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RevenueFromContractWithCustomerCommitment_5e133ae9-8704-49aa-8b0d-4d3f9b6205b2" xlink:href="nvax-20231231.xsd#nvax_RevenueFromContractWithCustomerCommitment"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_RevenueFromContractWithCustomerCommitment_5e133ae9-8704-49aa-8b0d-4d3f9b6205b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_ea1239ab-334a-4618-86f2-59f233f21287" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_ea1239ab-334a-4618-86f2-59f233f21287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding_83992cf0-cdbc-4715-92e5-1ca329f1829c" xlink:href="nvax-20231231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding_83992cf0-cdbc-4715-92e5-1ca329f1829c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant_7bb5f623-18bf-4590-b95e-3aea2fa7af29" xlink:href="nvax-20231231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant_7bb5f623-18bf-4590-b95e-3aea2fa7af29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans_ebedb6d5-d18e-4926-b822-5043b773d201" xlink:href="nvax-20231231.xsd#nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans_ebedb6d5-d18e-4926-b822-5043b773d201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9c6f7ab6-25da-4454-b90c-616792e90bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87f4cdfe-02ee-42d6-8f29-8b1af83d1623" xlink:to="loc_us-gaap_Revenues_9c6f7ab6-25da-4454-b90c-616792e90bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueAdditionalInformationDetails_1" xlink:type="simple" xlink:href="nvax-20231231.xsd#RevenueAdditionalInformationDetails_1"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/RevenueAdditionalInformationDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_1b7981cd-1d7f-4153-856a-50b5ca0efa9a" xlink:href="nvax-20231231.xsd#nvax_GrantsUSGovernmentContractAndJointVentureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward_383545c9-047c-40fa-a19d-2d52ba277b9a" xlink:href="nvax-20231231.xsd#nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_1b7981cd-1d7f-4153-856a-50b5ca0efa9a" xlink:to="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward_383545c9-047c-40fa-a19d-2d52ba277b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGross_cd827d8b-78fe-4865-82b4-6bd341a361ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward_383545c9-047c-40fa-a19d-2d52ba277b9a" xlink:to="loc_us-gaap_AccountsReceivableGross_cd827d8b-78fe-4865-82b4-6bd341a361ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions_241a4b1f-229f-4cd5-a067-0718e0221444" xlink:href="nvax-20231231.xsd#nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward_383545c9-047c-40fa-a19d-2d52ba277b9a" xlink:to="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions_241a4b1f-229f-4cd5-a067-0718e0221444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions_7785b67b-838e-495b-817a-671c2cbb793f" xlink:href="nvax-20231231.xsd#nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward_383545c9-047c-40fa-a19d-2d52ba277b9a" xlink:to="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions_7785b67b-838e-495b-817a-671c2cbb793f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGross_eaf4b92d-7eeb-46df-a171-63163085aa0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward_383545c9-047c-40fa-a19d-2d52ba277b9a" xlink:to="loc_us-gaap_AccountsReceivableGross_eaf4b92d-7eeb-46df-a171-63163085aa0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_aaa364a6-5d48-463f-b0e7-7e8ec37447dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_1b7981cd-1d7f-4153-856a-50b5ca0efa9a" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_aaa364a6-5d48-463f-b0e7-7e8ec37447dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_f32a4194-967d-429a-8f1d-5f7b6c83a0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_aaa364a6-5d48-463f-b0e7-7e8ec37447dc" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_f32a4194-967d-429a-8f1d-5f7b6c83a0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableAllowanceForCreditLossAdditions_3d651c6c-206d-4aa5-be28-66dd87b03889" xlink:href="nvax-20231231.xsd#nvax_AccountsReceivableAllowanceForCreditLossAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_aaa364a6-5d48-463f-b0e7-7e8ec37447dc" xlink:to="loc_nvax_AccountsReceivableAllowanceForCreditLossAdditions_3d651c6c-206d-4aa5-be28-66dd87b03889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableAllowanceForCreditLossDeductions_2985d30d-ea9d-41b0-8fd3-ca19a3b67253" xlink:href="nvax-20231231.xsd#nvax_AccountsReceivableAllowanceForCreditLossDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_aaa364a6-5d48-463f-b0e7-7e8ec37447dc" xlink:to="loc_nvax_AccountsReceivableAllowanceForCreditLossDeductions_2985d30d-ea9d-41b0-8fd3-ca19a3b67253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_e0682a7b-47be-4771-8178-8485abe10548" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_aaa364a6-5d48-463f-b0e7-7e8ec37447dc" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_e0682a7b-47be-4771-8178-8485abe10548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract_08f1aadd-9796-48f7-9888-c6dfe3777a32" xlink:href="nvax-20231231.xsd#nvax_DeferredRevenueIncreaseDecreaseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_1b7981cd-1d7f-4153-856a-50b5ca0efa9a" xlink:to="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract_08f1aadd-9796-48f7-9888-c6dfe3777a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_b198aa23-5a78-4708-b6f8-92afeb664ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract_08f1aadd-9796-48f7-9888-c6dfe3777a32" xlink:to="loc_us-gaap_ContractWithCustomerLiability_b198aa23-5a78-4708-b6f8-92afeb664ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ContractWithCustomerLiabilityAdditions_7da66d1c-6a5e-4672-9a4d-bab97aca838b" xlink:href="nvax-20231231.xsd#nvax_ContractWithCustomerLiabilityAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract_08f1aadd-9796-48f7-9888-c6dfe3777a32" xlink:to="loc_nvax_ContractWithCustomerLiabilityAdditions_7da66d1c-6a5e-4672-9a4d-bab97aca838b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ContractWithCustomerLiabilityDeductions_77707085-237e-4446-9867-955460dbbc86" xlink:href="nvax-20231231.xsd#nvax_ContractWithCustomerLiabilityDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract_08f1aadd-9796-48f7-9888-c6dfe3777a32" xlink:to="loc_nvax_ContractWithCustomerLiabilityDeductions_77707085-237e-4446-9867-955460dbbc86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_a468d714-0273-4e39-9cca-7ce51b6b99d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_DeferredRevenueIncreaseDecreaseAbstract_08f1aadd-9796-48f7-9888-c6dfe3777a32" xlink:to="loc_us-gaap_ContractWithCustomerLiability_a468d714-0273-4e39-9cca-7ce51b6b99d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_09f17c85-5bb6-4167-a76c-3b3bd81a3ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_1b7981cd-1d7f-4153-856a-50b5ca0efa9a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_09f17c85-5bb6-4167-a76c-3b3bd81a3ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_443f1dc1-abc1-4fb8-b142-cd8e10d48299" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_09f17c85-5bb6-4167-a76c-3b3bd81a3ac5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_443f1dc1-abc1-4fb8-b142-cd8e10d48299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_72cfdf10-c12b-4a9e-93ed-31812e60ef80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_443f1dc1-abc1-4fb8-b142-cd8e10d48299" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_72cfdf10-c12b-4a9e-93ed-31812e60ef80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_d6eea238-e4b6-4d42-9fbd-3d51f17d0b4a" xlink:href="nvax-20231231.xsd#nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_72cfdf10-c12b-4a9e-93ed-31812e60ef80" xlink:to="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_d6eea238-e4b6-4d42-9fbd-3d51f17d0b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember_daf3646e-f1ba-49e1-87de-dd2fc382df00" xlink:href="nvax-20231231.xsd#nvax_AmendedAndRestatedUKSupplyAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_72cfdf10-c12b-4a9e-93ed-31812e60ef80" xlink:to="loc_nvax_AmendedAndRestatedUKSupplyAgreementMember_daf3646e-f1ba-49e1-87de-dd2fc382df00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_93505add-fee4-4416-b3ac-918763dfed64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_09f17c85-5bb6-4167-a76c-3b3bd81a3ac5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_93505add-fee4-4416-b3ac-918763dfed64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_887d6260-84de-48df-b213-5d2b056da02a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_93505add-fee4-4416-b3ac-918763dfed64" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_887d6260-84de-48df-b213-5d2b056da02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RevenueMember_e298c08c-8ff9-4f2c-8ac5-3d89e494a9ea" xlink:href="nvax-20231231.xsd#nvax_RevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_887d6260-84de-48df-b213-5d2b056da02a" xlink:to="loc_nvax_RevenueMember_e298c08c-8ff9-4f2c-8ac5-3d89e494a9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_18a33957-7ada-4b84-8094-4adae2e83bee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_09f17c85-5bb6-4167-a76c-3b3bd81a3ac5" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_18a33957-7ada-4b84-8094-4adae2e83bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableAllowanceForCreditLossAdditions_ad0e8c3e-2ea3-4745-bad7-2b49f241c3b3" xlink:href="nvax-20231231.xsd#nvax_AccountsReceivableAllowanceForCreditLossAdditions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_18a33957-7ada-4b84-8094-4adae2e83bee" xlink:to="loc_nvax_AccountsReceivableAllowanceForCreditLossAdditions_ad0e8c3e-2ea3-4745-bad7-2b49f241c3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccountsReceivableAllowanceForCreditLossDeductions_4eeddff7-398e-41f5-a6a3-faf6f70db9f5" xlink:href="nvax-20231231.xsd#nvax_AccountsReceivableAllowanceForCreditLossDeductions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_18a33957-7ada-4b84-8094-4adae2e83bee" xlink:to="loc_nvax_AccountsReceivableAllowanceForCreditLossDeductions_4eeddff7-398e-41f5-a6a3-faf6f70db9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_02d6bd0f-226d-4bc3-bf7c-b60e05e407c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_18a33957-7ada-4b84-8094-4adae2e83bee" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_02d6bd0f-226d-4bc3-bf7c-b60e05e407c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_cb347760-5a63-4ce7-ba4d-6810352874a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_18a33957-7ada-4b84-8094-4adae2e83bee" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_cb347760-5a63-4ce7-ba4d-6810352874a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2a514630-05f5-4f74-b2df-0341432bc5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_18a33957-7ada-4b84-8094-4adae2e83bee" xlink:to="loc_us-gaap_ContractWithCustomerLiability_2a514630-05f5-4f74-b2df-0341432bc5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_e9aa4c7a-a35a-4739-bf38-9ccb89b7faa0" xlink:href="nvax-20231231.xsd#nvax_CollaborationAgreementUpfrontPaymentAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_18a33957-7ada-4b84-8094-4adae2e83bee" xlink:to="loc_nvax_CollaborationAgreementUpfrontPaymentAmount_e9aa4c7a-a35a-4739-bf38-9ccb89b7faa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#RevenueScheduleofProductRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_93e128ac-5282-49f3-912c-dc1c91e24d3e" xlink:href="nvax-20231231.xsd#nvax_GrantsUSGovernmentContractAndJointVentureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_72d8ffc5-6ff1-43bd-9969-428be507f5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_93e128ac-5282-49f3-912c-dc1c91e24d3e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_72d8ffc5-6ff1-43bd-9969-428be507f5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_28acb214-aaa7-4bf4-a1e5-c68475c63c60" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_72d8ffc5-6ff1-43bd-9969-428be507f5e9" xlink:to="loc_srt_ProductOrServiceAxis_28acb214-aaa7-4bf4-a1e5-c68475c63c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8603995b-6809-471b-87a7-d90115430d32" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_28acb214-aaa7-4bf4-a1e5-c68475c63c60" xlink:to="loc_srt_ProductsAndServicesDomain_8603995b-6809-471b-87a7-d90115430d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_dd946436-022f-4e66-8231-ddc277bd71c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8603995b-6809-471b-87a7-d90115430d32" xlink:to="loc_us-gaap_ProductMember_dd946436-022f-4e66-8231-ddc277bd71c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_be6b8734-9c0a-4c82-8ffc-a2fb80d3d7f7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_72d8ffc5-6ff1-43bd-9969-428be507f5e9" xlink:to="loc_srt_StatementGeographicalAxis_be6b8734-9c0a-4c82-8ffc-a2fb80d3d7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8f61885a-5478-41c9-b412-615efe383db8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_be6b8734-9c0a-4c82-8ffc-a2fb80d3d7f7" xlink:to="loc_srt_SegmentGeographicalDomain_8f61885a-5478-41c9-b412-615efe383db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NorthAmericaMember_c4dc1d38-a088-4a69-ae31-da672e07d5f8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NorthAmericaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8f61885a-5478-41c9-b412-615efe383db8" xlink:to="loc_srt_NorthAmericaMember_c4dc1d38-a088-4a69-ae31-da672e07d5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_bbdd1cf3-c6ac-4e53-90b6-95aa8a9d1bbc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8f61885a-5478-41c9-b412-615efe383db8" xlink:to="loc_srt_EuropeMember_bbdd1cf3-c6ac-4e53-90b6-95aa8a9d1bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RestOfTheWorldMember_38b5c903-e231-4ab8-9c34-241dc6990632" xlink:href="nvax-20231231.xsd#nvax_RestOfTheWorldMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8f61885a-5478-41c9-b412-615efe383db8" xlink:to="loc_nvax_RestOfTheWorldMember_38b5c903-e231-4ab8-9c34-241dc6990632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a45ac87c-241b-4930-95c0-f3738d519235" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_72d8ffc5-6ff1-43bd-9969-428be507f5e9" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_a45ac87c-241b-4930-95c0-f3738d519235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ad93378a-6546-4b34-aa96-f5ec52fdc3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a45ac87c-241b-4930-95c0-f3738d519235" xlink:to="loc_us-gaap_Revenues_ad93378a-6546-4b34-aa96-f5ec52fdc3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_20c0cd7a-61f4-4d4a-b753-e9e89318e8d2" xlink:href="nvax-20231231.xsd#nvax_GrantsUSGovernmentContractAndJointVentureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_07ccbff5-73ac-4ab4-8409-095fc8337cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_20c0cd7a-61f4-4d4a-b753-e9e89318e8d2" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_07ccbff5-73ac-4ab4-8409-095fc8337cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0a8b57e5-2d5c-4c89-aad8-1155d396a003" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_07ccbff5-73ac-4ab4-8409-095fc8337cf0" xlink:to="loc_srt_ProductOrServiceAxis_0a8b57e5-2d5c-4c89-aad8-1155d396a003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dc779b7a-5010-43a0-896d-6d27c491aa7d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0a8b57e5-2d5c-4c89-aad8-1155d396a003" xlink:to="loc_srt_ProductsAndServicesDomain_dc779b7a-5010-43a0-896d-6d27c491aa7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_da559977-be5c-46d5-9471-5e218cac690d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc779b7a-5010-43a0-896d-6d27c491aa7d" xlink:to="loc_us-gaap_ProductMember_da559977-be5c-46d5-9471-5e218cac690d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_20ffffa2-38ff-4baa-9166-6df2e14d251f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerBasisOfPricingAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_07ccbff5-73ac-4ab4-8409-095fc8337cf0" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_20ffffa2-38ff-4baa-9166-6df2e14d251f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_3fd24a9b-5984-46d6-bc1c-66379d2d18fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_20ffffa2-38ff-4baa-9166-6df2e14d251f" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_3fd24a9b-5984-46d6-bc1c-66379d2d18fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember_ae0e4885-beb2-42ab-8b75-2aed1b7d722a" xlink:href="nvax-20231231.xsd#nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_3fd24a9b-5984-46d6-bc1c-66379d2d18fc" xlink:to="loc_nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember_ae0e4885-beb2-42ab-8b75-2aed1b7d722a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ProductReturnsMember_e1af7bc1-9992-403b-9bf0-d35c32f448f0" xlink:href="nvax-20231231.xsd#nvax_ProductReturnsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_3fd24a9b-5984-46d6-bc1c-66379d2d18fc" xlink:to="loc_nvax_ProductReturnsMember_e1af7bc1-9992-403b-9bf0-d35c32f448f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3a8bc02d-79f7-4410-96f1-a08ecbd4f403" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_07ccbff5-73ac-4ab4-8409-095fc8337cf0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3a8bc02d-79f7-4410-96f1-a08ecbd4f403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9a5b8396-6d72-48d2-923f-1abe909a889f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3a8bc02d-79f7-4410-96f1-a08ecbd4f403" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9a5b8396-6d72-48d2-923f-1abe909a889f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_b275862d-c9ba-42ed-9af0-6a734e21ce26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9a5b8396-6d72-48d2-923f-1abe909a889f" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_b275862d-c9ba-42ed-9af0-6a734e21ce26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_100520d1-4e55-48cc-8f64-7681a0a4cab7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9a5b8396-6d72-48d2-923f-1abe909a889f" xlink:to="loc_us-gaap_AccountsReceivableMember_100520d1-4e55-48cc-8f64-7681a0a4cab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e6f4f50d-2bc8-4998-b78f-cd217c4ed447" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_07ccbff5-73ac-4ab4-8409-095fc8337cf0" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_e6f4f50d-2bc8-4998-b78f-cd217c4ed447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ContractWithCustomerLiabilityRollForward_359d439a-fed2-4fbc-b49b-0b783fbd80eb" xlink:href="nvax-20231231.xsd#nvax_ContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e6f4f50d-2bc8-4998-b78f-cd217c4ed447" xlink:to="loc_nvax_ContractWithCustomerLiabilityRollForward_359d439a-fed2-4fbc-b49b-0b783fbd80eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_da9ca8b7-cf4c-4952-944f-c3d85bb86cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_ContractWithCustomerLiabilityRollForward_359d439a-fed2-4fbc-b49b-0b783fbd80eb" xlink:to="loc_us-gaap_ContractWithCustomerLiability_da9ca8b7-cf4c-4952-944f-c3d85bb86cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AmountsChargedAgainstProductSales_dc22d916-56d8-4048-b4ff-2336a1cd298e" xlink:href="nvax-20231231.xsd#nvax_AmountsChargedAgainstProductSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_ContractWithCustomerLiabilityRollForward_359d439a-fed2-4fbc-b49b-0b783fbd80eb" xlink:to="loc_nvax_AmountsChargedAgainstProductSales_dc22d916-56d8-4048-b4ff-2336a1cd298e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_88d5df6e-9b73-4775-bec2-0b4101f61a26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_ContractWithCustomerLiabilityRollForward_359d439a-fed2-4fbc-b49b-0b783fbd80eb" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_88d5df6e-9b73-4775-bec2-0b4101f61a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_7d89970f-5102-405d-be83-923548149d21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_ContractWithCustomerLiabilityRollForward_359d439a-fed2-4fbc-b49b-0b783fbd80eb" xlink:to="loc_us-gaap_ContractWithCustomerLiability_7d89970f-5102-405d-be83-923548149d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#RevenueScheduleofGrantRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_b6c69461-0cd9-4602-a134-f44e9adda50c" xlink:href="nvax-20231231.xsd#nvax_GrantsUSGovernmentContractAndJointVentureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_277f2de6-bf1d-437b-9f0a-1bf0e76d261e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_GrantsUSGovernmentContractAndJointVentureAbstract_b6c69461-0cd9-4602-a134-f44e9adda50c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_277f2de6-bf1d-437b-9f0a-1bf0e76d261e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_99b129eb-a7f0-43a9-8073-ea26ae454554" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_277f2de6-bf1d-437b-9f0a-1bf0e76d261e" xlink:to="loc_srt_ProductOrServiceAxis_99b129eb-a7f0-43a9-8073-ea26ae454554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4ced246a-56d7-4ef1-8632-0d8439d69cb4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_99b129eb-a7f0-43a9-8073-ea26ae454554" xlink:to="loc_srt_ProductsAndServicesDomain_4ced246a-56d7-4ef1-8632-0d8439d69cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_0cfab287-0378-43f3-8883-07e91e9c87bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4ced246a-56d7-4ef1-8632-0d8439d69cb4" xlink:to="loc_us-gaap_GrantMember_0cfab287-0378-43f3-8883-07e91e9c87bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_36e57239-d9aa-4bb3-8e4e-1ae234348d86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_277f2de6-bf1d-437b-9f0a-1bf0e76d261e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_36e57239-d9aa-4bb3-8e4e-1ae234348d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_143e32e7-b239-4ac7-8f18-96bf925d4ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_36e57239-d9aa-4bb3-8e4e-1ae234348d86" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_143e32e7-b239-4ac7-8f18-96bf925d4ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USGovernmentAgreementMember_f3bf6e0b-2a41-4afc-8bd4-260f64ecc933" xlink:href="nvax-20231231.xsd#nvax_USGovernmentAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_143e32e7-b239-4ac7-8f18-96bf925d4ee7" xlink:to="loc_nvax_USGovernmentAgreementMember_f3bf6e0b-2a41-4afc-8bd4-260f64ecc933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_USDepartmentOfDefenseDoDContractMember_58131291-375f-4a32-8167-09ba683635e4" xlink:href="nvax-20231231.xsd#nvax_USDepartmentOfDefenseDoDContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_143e32e7-b239-4ac7-8f18-96bf925d4ee7" xlink:to="loc_nvax_USDepartmentOfDefenseDoDContractMember_58131291-375f-4a32-8167-09ba683635e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember_543fb63e-9f4f-4d7e-8899-e7298c6d4cc0" xlink:href="nvax-20231231.xsd#nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_143e32e7-b239-4ac7-8f18-96bf925d4ee7" xlink:to="loc_nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember_543fb63e-9f4f-4d7e-8899-e7298c6d4cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_OtherGrantRevenueMember_aab24a3f-7406-4ed3-b626-b1b2b31f79e5" xlink:href="nvax-20231231.xsd#nvax_OtherGrantRevenueMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_143e32e7-b239-4ac7-8f18-96bf925d4ee7" xlink:to="loc_nvax_OtherGrantRevenueMember_aab24a3f-7406-4ed3-b626-b1b2b31f79e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_17bf7779-db27-425a-be6b-04311ad34af3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_277f2de6-bf1d-437b-9f0a-1bf0e76d261e" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_17bf7779-db27-425a-be6b-04311ad34af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_39cf7d15-7c6a-412a-a1e5-a8ea93224f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_17bf7779-db27-425a-be6b-04311ad34af3" xlink:to="loc_us-gaap_Revenues_39cf7d15-7c6a-412a-a1e5-a8ea93224f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#CollaborationLicenseandSupplyAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborativeArrangementAbstract_47f161e6-b3aa-470c-923a-af18c62b8d96" xlink:href="nvax-20231231.xsd#nvax_CollaborativeArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6f60eeff-ced8-4ec2-95e3-2ceb7ebf07d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_CollaborativeArrangementAbstract_47f161e6-b3aa-470c-923a-af18c62b8d96" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6f60eeff-ced8-4ec2-95e3-2ceb7ebf07d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bcaf6472-3050-4051-81e0-8255a813380c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6f60eeff-ced8-4ec2-95e3-2ceb7ebf07d0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bcaf6472-3050-4051-81e0-8255a813380c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f931af2-06b9-49c5-8ec7-0dd26804046d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bcaf6472-3050-4051-81e0-8255a813380c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f931af2-06b9-49c5-8ec7-0dd26804046d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TakedaArrangementMember_f47ba44f-df01-46d0-99f1-be3c7343665a" xlink:href="nvax-20231231.xsd#nvax_TakedaArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f931af2-06b9-49c5-8ec7-0dd26804046d" xlink:to="loc_nvax_TakedaArrangementMember_f47ba44f-df01-46d0-99f1-be3c7343665a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementMember_d786369a-17a1-40b0-80f8-6496222df2c4" xlink:href="nvax-20231231.xsd#nvax_SettlementAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f931af2-06b9-49c5-8ec7-0dd26804046d" xlink:to="loc_nvax_SettlementAgreementMember_d786369a-17a1-40b0-80f8-6496222df2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SecuritiesSubscriptionArrangementMember_90f85116-764e-4b9d-8a34-59ba9f6745cf" xlink:href="nvax-20231231.xsd#nvax_SecuritiesSubscriptionArrangementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f931af2-06b9-49c5-8ec7-0dd26804046d" xlink:to="loc_nvax_SecuritiesSubscriptionArrangementMember_90f85116-764e-4b9d-8a34-59ba9f6745cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e21d0df4-a539-4142-9354-536b336062fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6f60eeff-ced8-4ec2-95e3-2ceb7ebf07d0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e21d0df4-a539-4142-9354-536b336062fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cbfdbb17-6c4c-4bf0-a896-6a79b4535507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e21d0df4-a539-4142-9354-536b336062fd" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cbfdbb17-6c4c-4bf0-a896-6a79b4535507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_25e56f14-b273-463a-b252-e95902dd8ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cbfdbb17-6c4c-4bf0-a896-6a79b4535507" xlink:to="loc_us-gaap_PrivatePlacementMember_25e56f14-b273-463a-b252-e95902dd8ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_373985b8-7431-4a6e-9b24-8d01074d0e06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6f60eeff-ced8-4ec2-95e3-2ceb7ebf07d0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_373985b8-7431-4a6e-9b24-8d01074d0e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a45f2fb7-2abe-40f7-b634-1ac580bdfb5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_373985b8-7431-4a6e-9b24-8d01074d0e06" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a45f2fb7-2abe-40f7-b634-1ac580bdfb5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_e7743efe-8a91-4dd0-b5c2-de150c7ee75a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a45f2fb7-2abe-40f7-b634-1ac580bdfb5c" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_e7743efe-8a91-4dd0-b5c2-de150c7ee75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfExpenseAxis_8ebc9222-8141-449f-8518-9ac5180b992c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfExpenseAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6f60eeff-ced8-4ec2-95e3-2ceb7ebf07d0" xlink:to="loc_us-gaap_NatureOfExpenseAxis_8ebc9222-8141-449f-8518-9ac5180b992c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_83fdaaa3-ade3-4654-b967-b64351b7c95c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NatureOfExpenseAxis_8ebc9222-8141-449f-8518-9ac5180b992c" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_83fdaaa3-ade3-4654-b967-b64351b7c95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_27d3c7de-7513-4ba5-8964-3810685a5513" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_83fdaaa3-ade3-4654-b967-b64351b7c95c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_27d3c7de-7513-4ba5-8964-3810685a5513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_c2857706-33a7-40de-a62e-50cf5d1a497b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_83fdaaa3-ade3-4654-b967-b64351b7c95c" xlink:to="loc_us-gaap_CostOfSalesMember_c2857706-33a7-40de-a62e-50cf5d1a497b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6f60eeff-ced8-4ec2-95e3-2ceb7ebf07d0" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RoyaltyPeriod_35baf022-f02d-4dfb-9bc0-0561e3d0c296" xlink:href="nvax-20231231.xsd#nvax_RoyaltyPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_nvax_RoyaltyPeriod_35baf022-f02d-4dfb-9bc0-0561e3d0c296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesToBeDistributed_0eb32588-a669-495e-86c0-6520f918768f" xlink:href="nvax-20231231.xsd#nvax_NumberOfDosesToBeDistributed"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_nvax_NumberOfDosesToBeDistributed_0eb32588-a669-495e-86c0-6520f918768f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a46b360b-4182-446e-8d4e-a26d8d423203" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_us-gaap_Revenues_a46b360b-4182-446e-8d4e-a26d8d423203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4fb04133-fb97-473d-a575-57382ee7613c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4fb04133-fb97-473d-a575-57382ee7613c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementPayment_29917f84-8c68-4fde-b1ae-a341a0574995" xlink:href="nvax-20231231.xsd#nvax_SettlementPayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_nvax_SettlementPayment_29917f84-8c68-4fde-b1ae-a341a0574995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementInitialReservationFee_a308c2ee-bfc8-4405-99d3-81d4fb46b372" xlink:href="nvax-20231231.xsd#nvax_SettlementAgreementInitialReservationFee"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_nvax_SettlementAgreementInitialReservationFee_a308c2ee-bfc8-4405-99d3-81d4fb46b372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_389ab211-7c56-41c4-84ae-5c3e729771bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_us-gaap_ContractWithCustomerLiability_389ab211-7c56-41c4-84ae-5c3e729771bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_eb650734-e3f3-4b6b-83c1-2dac24a32baf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_eb650734-e3f3-4b6b-83c1-2dac24a32baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1b9bdbdf-f8fe-4eed-bf59-e47b2ddedbad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1b9bdbdf-f8fe-4eed-bf59-e47b2ddedbad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_39e7237d-bc78-4189-8e9a-dd1f5307a922" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_39e7237d-bc78-4189-8e9a-dd1f5307a922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_841867a5-edbb-45ad-b849-ca7280090daa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_841867a5-edbb-45ad-b849-ca7280090daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CommonStockQuotedMarketPrice_0e04ee72-25c3-4a07-a32e-47530a987767" xlink:href="nvax-20231231.xsd#nvax_CommonStockQuotedMarketPrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_nvax_CommonStockQuotedMarketPrice_0e04ee72-25c3-4a07-a32e-47530a987767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CommonStockPremiumPaid_e3bfe930-86ae-4344-b3eb-4690675c42c4" xlink:href="nvax-20231231.xsd#nvax_CommonStockPremiumPaid"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_nvax_CommonStockPremiumPaid_e3bfe930-86ae-4344-b3eb-4690675c42c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementBenefit_97ec2737-c5db-43d0-adcb-8e9ffd635a9d" xlink:href="nvax-20231231.xsd#nvax_SettlementAgreementBenefit"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_nvax_SettlementAgreementBenefit_97ec2737-c5db-43d0-adcb-8e9ffd635a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfQuarterlyInstallmentPayments_824fff18-75ce-4e31-8b76-851eecc11ed1" xlink:href="nvax-20231231.xsd#nvax_NumberOfQuarterlyInstallmentPayments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_nvax_NumberOfQuarterlyInstallmentPayments_824fff18-75ce-4e31-8b76-851eecc11ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementQuarterlyInstallmentAmount_5398a064-3367-4e3c-a3e3-6532e2efbbac" xlink:href="nvax-20231231.xsd#nvax_SettlementAgreementQuarterlyInstallmentAmount"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_48d9bb1f-1ada-4109-81a9-57afaab06cb5" xlink:to="loc_nvax_SettlementAgreementQuarterlyInstallmentAmount_5398a064-3367-4e3c-a3e3-6532e2efbbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#CashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_6387a34a-a06d-4c17-96ac-1cca73ce6a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4cbdc797-78f0-4a29-bfa6-376914de9d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_6387a34a-a06d-4c17-96ac-1cca73ce6a3a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4cbdc797-78f0-4a29-bfa6-376914de9d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_aee3f60d-9e91-42cd-86f7-cee97b2b03fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_6387a34a-a06d-4c17-96ac-1cca73ce6a3a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_aee3f60d-9e91-42cd-86f7-cee97b2b03fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_05de9a34-5251-4a9d-acad-25717be9a291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_6387a34a-a06d-4c17-96ac-1cca73ce6a3a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_05de9a34-5251-4a9d-acad-25717be9a291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1fae6dfa-7a8e-4780-84b0-9379367c8808" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_6387a34a-a06d-4c17-96ac-1cca73ce6a3a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1fae6dfa-7a8e-4780-84b0-9379367c8808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f7a503e5-a6eb-42d7-9b19-c28924312b24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d13eb032-13fe-4781-a31b-d8414f96d6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f7a503e5-a6eb-42d7-9b19-c28924312b24" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d13eb032-13fe-4781-a31b-d8414f96d6ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c2be3af8-7ab5-42f0-9d0b-2c68239e9a12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d13eb032-13fe-4781-a31b-d8414f96d6ef" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c2be3af8-7ab5-42f0-9d0b-2c68239e9a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b770c5b0-6915-4408-b2cc-34f842cfc2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c2be3af8-7ab5-42f0-9d0b-2c68239e9a12" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b770c5b0-6915-4408-b2cc-34f842cfc2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b214675d-6429-411a-9869-12ed47a2c2af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b770c5b0-6915-4408-b2cc-34f842cfc2fd" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b214675d-6429-411a-9869-12ed47a2c2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6a48b3be-320a-4987-a54d-36602f228a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b770c5b0-6915-4408-b2cc-34f842cfc2fd" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6a48b3be-320a-4987-a54d-36602f228a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_038ebbc1-98d3-4e85-9e0e-becc6e0af8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b770c5b0-6915-4408-b2cc-34f842cfc2fd" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_038ebbc1-98d3-4e85-9e0e-becc6e0af8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_c5613e30-94c6-496a-a399-dab8b8b6d399" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d13eb032-13fe-4781-a31b-d8414f96d6ef" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_c5613e30-94c6-496a-a399-dab8b8b6d399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a9d3d610-0dfb-4b7b-bd5b-ef008cfc798b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_c5613e30-94c6-496a-a399-dab8b8b6d399" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a9d3d610-0dfb-4b7b-bd5b-ef008cfc798b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7dae93e9-9113-4606-b319-f16d2f46bbf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a9d3d610-0dfb-4b7b-bd5b-ef008cfc798b" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7dae93e9-9113-4606-b319-f16d2f46bbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_167775ca-5737-477e-9b96-a239cadd657b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a9d3d610-0dfb-4b7b-bd5b-ef008cfc798b" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_167775ca-5737-477e-9b96-a239cadd657b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_23151f13-9b85-4e5e-98ac-fa00d98577b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a9d3d610-0dfb-4b7b-bd5b-ef008cfc798b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_23151f13-9b85-4e5e-98ac-fa00d98577b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_51a24eeb-6ce0-49bc-a324-bed6360eea8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a9d3d610-0dfb-4b7b-bd5b-ef008cfc798b" xlink:to="loc_us-gaap_AgencySecuritiesMember_51a24eeb-6ce0-49bc-a324-bed6360eea8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9877ec2f-c09c-4d8b-8d80-9e5ece16a591" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d13eb032-13fe-4781-a31b-d8414f96d6ef" xlink:to="loc_us-gaap_DebtInstrumentAxis_9877ec2f-c09c-4d8b-8d80-9e5ece16a591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_087c6389-3b27-47ac-9548-0ac7ad5fdde7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9877ec2f-c09c-4d8b-8d80-9e5ece16a591" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_087c6389-3b27-47ac-9548-0ac7ad5fdde7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_cd59b784-588e-4ebd-9d0a-c83773fa1907" xlink:href="nvax-20231231.xsd#nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_087c6389-3b27-47ac-9548-0ac7ad5fdde7" xlink:to="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_cd59b784-588e-4ebd-9d0a-c83773fa1907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_ba52fabf-1792-4eac-ae07-b13507d05e7c" xlink:href="nvax-20231231.xsd#nvax_FivePointZeroConvertibleNotesDue2027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_087c6389-3b27-47ac-9548-0ac7ad5fdde7" xlink:to="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_ba52fabf-1792-4eac-ae07-b13507d05e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fc1d2142-5b27-4e61-8c16-d6dff2a00c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d13eb032-13fe-4781-a31b-d8414f96d6ef" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fc1d2142-5b27-4e61-8c16-d6dff2a00c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0dcd84be-c09a-415a-b97a-1cabf4d805de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fc1d2142-5b27-4e61-8c16-d6dff2a00c3a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0dcd84be-c09a-415a-b97a-1cabf4d805de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_85cd4583-ee54-46ac-827c-e978fe16ac86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0dcd84be-c09a-415a-b97a-1cabf4d805de" xlink:to="loc_us-gaap_UnsecuredDebtMember_85cd4583-ee54-46ac-827c-e978fe16ac86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_954f06f3-e4ac-4313-bdb8-e59a6b66b7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d13eb032-13fe-4781-a31b-d8414f96d6ef" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_954f06f3-e4ac-4313-bdb8-e59a6b66b7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_ac4cc1f8-a0d8-4679-8cd8-9723cfacc08f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_954f06f3-e4ac-4313-bdb8-e59a6b66b7a5" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_ac4cc1f8-a0d8-4679-8cd8-9723cfacc08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_8c4d934e-a941-44cb-9427-b42324dbbc55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ac4cc1f8-a0d8-4679-8cd8-9723cfacc08f" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_8c4d934e-a941-44cb-9427-b42324dbbc55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8c174225-ebbe-4af9-9264-cc932858810e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_954f06f3-e4ac-4313-bdb8-e59a6b66b7a5" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8c174225-ebbe-4af9-9264-cc932858810e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_3eff2179-f2bb-4b82-a2dd-47a367f18255" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_8c174225-ebbe-4af9-9264-cc932858810e" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_3eff2179-f2bb-4b82-a2dd-47a367f18255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_f1cc7fd6-84d7-448b-95c7-8458827ea73b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_954f06f3-e4ac-4313-bdb8-e59a6b66b7a5" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_f1cc7fd6-84d7-448b-95c7-8458827ea73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/InventoryScheduleofInventoryDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#InventoryScheduleofInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/InventoryScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_2b2b17f3-00b9-487a-9b9b-325e0ada7269" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_34d987b5-2b39-4f6d-8329-3d07a775a791" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2b2b17f3-00b9-487a-9b9b-325e0ada7269" xlink:to="loc_us-gaap_InventoryRawMaterials_34d987b5-2b39-4f6d-8329-3d07a775a791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_18e3006e-6752-4ce4-9a5f-2215095ca6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2b2b17f3-00b9-487a-9b9b-325e0ada7269" xlink:to="loc_us-gaap_InventoryWorkInProcess_18e3006e-6752-4ce4-9a5f-2215095ca6ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_043515f6-76d6-4628-8f38-6694f01c79a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2b2b17f3-00b9-487a-9b9b-325e0ada7269" xlink:to="loc_us-gaap_InventoryFinishedGoods_043515f6-76d6-4628-8f38-6694f01c79a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0f949be8-9250-497e-b84e-2cbeabe647ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2b2b17f3-00b9-487a-9b9b-325e0ada7269" xlink:to="loc_us-gaap_InventoryNet_0f949be8-9250-497e-b84e-2cbeabe647ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/InventoryAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#InventoryAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/InventoryAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_be039d20-b152-49c8-900f-057d70173c38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_571c0054-65e6-457d-aea1-cebec94d2e99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_be039d20-b152-49c8-900f-057d70173c38" xlink:to="loc_us-gaap_InventoryCurrentTable_571c0054-65e6-457d-aea1-cebec94d2e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseImpairmentChargeAxis_9a8b6056-cda6-4f18-82b6-bea42f8c061d" xlink:href="nvax-20231231.xsd#nvax_LeaseImpairmentChargeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_571c0054-65e6-457d-aea1-cebec94d2e99" xlink:to="loc_nvax_LeaseImpairmentChargeAxis_9a8b6056-cda6-4f18-82b6-bea42f8c061d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseImpairmentChargeDomain_e33651b3-8d34-4078-8e40-cfede80da74f" xlink:href="nvax-20231231.xsd#nvax_LeaseImpairmentChargeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_LeaseImpairmentChargeAxis_9a8b6056-cda6-4f18-82b6-bea42f8c061d" xlink:to="loc_nvax_LeaseImpairmentChargeDomain_e33651b3-8d34-4078-8e40-cfede80da74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CMOAgreementMember_aa6f7735-aa94-4db3-96df-5eb589014ef3" xlink:href="nvax-20231231.xsd#nvax_CMOAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_LeaseImpairmentChargeDomain_e33651b3-8d34-4078-8e40-cfede80da74f" xlink:to="loc_nvax_CMOAgreementMember_aa6f7735-aa94-4db3-96df-5eb589014ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_38c7cff6-51b6-445e-b41b-025d4c1cff2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_571c0054-65e6-457d-aea1-cebec94d2e99" xlink:to="loc_us-gaap_InventoryLineItems_38c7cff6-51b6-445e-b41b-025d4c1cff2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_4dc32362-6a5c-40be-85b1-6ca7eda74a21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_38c7cff6-51b6-445e-b41b-025d4c1cff2c" xlink:to="loc_us-gaap_InventoryWriteDown_4dc32362-6a5c-40be-85b1-6ca7eda74a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_8f3a7b82-2d67-4102-98db-bc59c4a108bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFirmPurchaseCommitmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_38c7cff6-51b6-445e-b41b-025d4c1cff2c" xlink:to="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_8f3a7b82-2d67-4102-98db-bc59c4a108bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InventoryFirmPurchaseCommitmentRecoveries_b1da0a26-a8f3-48e7-8756-13b86ba71237" xlink:href="nvax-20231231.xsd#nvax_InventoryFirmPurchaseCommitmentRecoveries"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_38c7cff6-51b6-445e-b41b-025d4c1cff2c" xlink:to="loc_nvax_InventoryFirmPurchaseCommitmentRecoveries_b1da0a26-a8f3-48e7-8756-13b86ba71237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_6e85a394-70ea-45ef-8d05-3d234dd7aebc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_38c7cff6-51b6-445e-b41b-025d4c1cff2c" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_6e85a394-70ea-45ef-8d05-3d234dd7aebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/InventoryScheduleofInventoryReservesDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#InventoryScheduleofInventoryReservesDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/InventoryScheduleofInventoryReservesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_d3fc61d3-9293-4920-849b-76ef7e7a1925" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InventoryReserveRollForward_a940a2cc-592d-4f6b-85e6-aa2f014443ee" xlink:href="nvax-20231231.xsd#nvax_InventoryReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d3fc61d3-9293-4920-849b-76ef7e7a1925" xlink:to="loc_nvax_InventoryReserveRollForward_a940a2cc-592d-4f6b-85e6-aa2f014443ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_56a98215-841f-4264-b4e6-a4c98c24f118" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_InventoryReserveRollForward_a940a2cc-592d-4f6b-85e6-aa2f014443ee" xlink:to="loc_us-gaap_InventoryValuationReserves_56a98215-841f-4264-b4e6-a4c98c24f118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InventoryReserveChargedToCostsOfSales_d01c5107-1749-475b-8521-1611fa9ee66e" xlink:href="nvax-20231231.xsd#nvax_InventoryReserveChargedToCostsOfSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_InventoryReserveRollForward_a940a2cc-592d-4f6b-85e6-aa2f014443ee" xlink:to="loc_nvax_InventoryReserveChargedToCostsOfSales_d01c5107-1749-475b-8521-1611fa9ee66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InventoryReserveOtherAdditions_38f38eef-0eb8-457a-b9de-c3186d6663d9" xlink:href="nvax-20231231.xsd#nvax_InventoryReserveOtherAdditions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_InventoryReserveRollForward_a940a2cc-592d-4f6b-85e6-aa2f014443ee" xlink:to="loc_nvax_InventoryReserveOtherAdditions_38f38eef-0eb8-457a-b9de-c3186d6663d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_InventoryReserveDeductions_d2c571f8-8af7-4a98-b2e2-06aaebef7720" xlink:href="nvax-20231231.xsd#nvax_InventoryReserveDeductions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_InventoryReserveRollForward_a940a2cc-592d-4f6b-85e6-aa2f014443ee" xlink:to="loc_nvax_InventoryReserveDeductions_d2c571f8-8af7-4a98-b2e2-06aaebef7720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_56d495ef-ada2-4066-a2f2-a451230f5b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_InventoryReserveRollForward_a940a2cc-592d-4f6b-85e6-aa2f014443ee" xlink:to="loc_us-gaap_InventoryValuationReserves_56d495ef-ada2-4066-a2f2-a451230f5b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/GoodwillDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#GoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/GoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_661a2dda-40a6-4bd2-a7b2-f59f25bd9ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_d68e6e7f-c1f2-4567-9925-32f2f746ff14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_661a2dda-40a6-4bd2-a7b2-f59f25bd9ed9" xlink:to="loc_us-gaap_NumberOfReportingUnits_d68e6e7f-c1f2-4567-9925-32f2f746ff14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_b54655a1-8760-485b-a791-a15254f4996d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_661a2dda-40a6-4bd2-a7b2-f59f25bd9ed9" xlink:to="loc_us-gaap_GoodwillRollForward_b54655a1-8760-485b-a791-a15254f4996d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9533c807-6d63-4b51-ad9e-ff3fb05817f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_b54655a1-8760-485b-a791-a15254f4996d" xlink:to="loc_us-gaap_Goodwill_9533c807-6d63-4b51-ad9e-ff3fb05817f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_26d37be2-9e67-4a80-a7ee-df994844cf0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_b54655a1-8760-485b-a791-a15254f4996d" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_26d37be2-9e67-4a80-a7ee-df994844cf0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_da4a2c41-7e91-4d08-9671-8257e1f4931f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_b54655a1-8760-485b-a791-a15254f4996d" xlink:to="loc_us-gaap_Goodwill_da4a2c41-7e91-4d08-9671-8257e1f4931f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#LeasesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a2fc0a39-8d53-4800-8ebd-799de16a32bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_5c7d06e5-2ed1-446d-9db6-5cbdae5ff17c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a2fc0a39-8d53-4800-8ebd-799de16a32bb" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_5c7d06e5-2ed1-446d-9db6-5cbdae5ff17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d937faf0-ce19-4254-8be8-16889d61d9de" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5c7d06e5-2ed1-446d-9db6-5cbdae5ff17c" xlink:to="loc_srt_CounterpartyNameAxis_d937faf0-ce19-4254-8be8-16889d61d9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e37ccf65-582a-43d6-ae98-2812bc7ff069" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d937faf0-ce19-4254-8be8-16889d61d9de" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e37ccf65-582a-43d6-ae98-2812bc7ff069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CMOAndCMDAgreementsMember_9633b64d-473f-48cd-ad87-e4609ee805ac" xlink:href="nvax-20231231.xsd#nvax_CMOAndCMDAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e37ccf65-582a-43d6-ae98-2812bc7ff069" xlink:to="loc_nvax_CMOAndCMDAgreementsMember_9633b64d-473f-48cd-ad87-e4609ee805ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_A700QuinceOrchardRoadAgreementMember_1dbe3ac0-1b2e-4f15-9564-c83997059ea6" xlink:href="nvax-20231231.xsd#nvax_A700QuinceOrchardRoadAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e37ccf65-582a-43d6-ae98-2812bc7ff069" xlink:to="loc_nvax_A700QuinceOrchardRoadAgreementMember_1dbe3ac0-1b2e-4f15-9564-c83997059ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FacilityLeaseAgreementMember_d68d1a7a-9657-4326-ad72-5e01446f7d8c" xlink:href="nvax-20231231.xsd#nvax_FacilityLeaseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e37ccf65-582a-43d6-ae98-2812bc7ff069" xlink:to="loc_nvax_FacilityLeaseAgreementMember_d68d1a7a-9657-4326-ad72-5e01446f7d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_30f4e0f0-a606-45a3-8112-669438a8d129" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5c7d06e5-2ed1-446d-9db6-5cbdae5ff17c" xlink:to="loc_srt_RangeAxis_30f4e0f0-a606-45a3-8112-669438a8d129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_20200277-f15a-4501-b259-c04cd2764d34" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_30f4e0f0-a606-45a3-8112-669438a8d129" xlink:to="loc_srt_RangeMember_20200277-f15a-4501-b259-c04cd2764d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8733949c-8444-4bd3-8d0e-344b3a4d87be" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_20200277-f15a-4501-b259-c04cd2764d34" xlink:to="loc_srt_MinimumMember_8733949c-8444-4bd3-8d0e-344b3a4d87be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_37f7f435-1e2d-4aa8-9aea-3df9f4774269" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_20200277-f15a-4501-b259-c04cd2764d34" xlink:to="loc_srt_MaximumMember_37f7f435-1e2d-4aa8-9aea-3df9f4774269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseImpairmentChargeAxis_f021c482-3904-43f1-8a6b-3dad171ddbba" xlink:href="nvax-20231231.xsd#nvax_LeaseImpairmentChargeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5c7d06e5-2ed1-446d-9db6-5cbdae5ff17c" xlink:to="loc_nvax_LeaseImpairmentChargeAxis_f021c482-3904-43f1-8a6b-3dad171ddbba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseImpairmentChargeDomain_cdd7a861-3812-431d-96c3-488201b1fb98" xlink:href="nvax-20231231.xsd#nvax_LeaseImpairmentChargeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_LeaseImpairmentChargeAxis_f021c482-3904-43f1-8a6b-3dad171ddbba" xlink:to="loc_nvax_LeaseImpairmentChargeDomain_cdd7a861-3812-431d-96c3-488201b1fb98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ROUFacilityLeasesMember_413c349f-527c-4ff4-8e13-288469d05337" xlink:href="nvax-20231231.xsd#nvax_ROUFacilityLeasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_LeaseImpairmentChargeDomain_cdd7a861-3812-431d-96c3-488201b1fb98" xlink:to="loc_nvax_ROUFacilityLeasesMember_413c349f-527c-4ff4-8e13-288469d05337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CMOAgreementMember_ace43555-6b9f-46b8-bb11-e6b8bc3d973e" xlink:href="nvax-20231231.xsd#nvax_CMOAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_LeaseImpairmentChargeDomain_cdd7a861-3812-431d-96c3-488201b1fb98" xlink:to="loc_nvax_CMOAgreementMember_ace43555-6b9f-46b8-bb11-e6b8bc3d973e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_fdee4684-b763-4435-847a-f6e985ce96fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5c7d06e5-2ed1-446d-9db6-5cbdae5ff17c" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_fdee4684-b763-4435-847a-f6e985ce96fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability_9bd40dc9-0d30-4dc0-836b-ced9e62a98c5" xlink:href="nvax-20231231.xsd#nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fdee4684-b763-4435-847a-f6e985ce96fb" xlink:to="loc_nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability_9bd40dc9-0d30-4dc0-836b-ced9e62a98c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FacilityNumberOfSquareFeet_18882af0-5949-4462-98dc-c881113d68ab" xlink:href="nvax-20231231.xsd#nvax_FacilityNumberOfSquareFeet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fdee4684-b763-4435-847a-f6e985ce96fb" xlink:to="loc_nvax_FacilityNumberOfSquareFeet_18882af0-5949-4462-98dc-c881113d68ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_fddca6a0-4bbf-4e94-8061-1572b2e36fba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fdee4684-b763-4435-847a-f6e985ce96fb" xlink:to="loc_us-gaap_OperatingLeaseExpense_fddca6a0-4bbf-4e94-8061-1572b2e36fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c700ec78-6d8c-4ad4-a6f9-569999967ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fdee4684-b763-4435-847a-f6e985ce96fb" xlink:to="loc_us-gaap_OperatingLeaseLiability_c700ec78-6d8c-4ad4-a6f9-569999967ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ff2966e2-d6e4-4c64-8828-e7dd5bea16c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fdee4684-b763-4435-847a-f6e985ce96fb" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ff2966e2-d6e4-4c64-8828-e7dd5bea16c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_3ceeaee8-df8d-485e-89ce-fb96577e22b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fdee4684-b763-4435-847a-f6e985ce96fb" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_3ceeaee8-df8d-485e-89ce-fb96577e22b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9c250ae9-0f40-490b-986a-25a994a586bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fdee4684-b763-4435-847a-f6e985ce96fb" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9c250ae9-0f40-490b-986a-25a994a586bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_8587f5a6-8df5-467d-80cb-507c63a2fe80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fdee4684-b763-4435-847a-f6e985ce96fb" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_8587f5a6-8df5-467d-80cb-507c63a2fe80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c6af1424-4d02-4ffc-b97d-0b563ca0802e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bd498ba7-38da-4f28-a3f1-500b1d9372cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6af1424-4d02-4ffc-b97d-0b563ca0802e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bd498ba7-38da-4f28-a3f1-500b1d9372cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_a8bb730b-3482-4eb1-859f-f1791c2a978c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_bd498ba7-38da-4f28-a3f1-500b1d9372cc" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_a8bb730b-3482-4eb1-859f-f1791c2a978c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_52dd50fb-f5d0-4cd0-aa6b-fab143614b04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6af1424-4d02-4ffc-b97d-0b563ca0802e" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_52dd50fb-f5d0-4cd0-aa6b-fab143614b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_3ca8c9de-bbad-49ee-b8dd-bfacb6c46749" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset_52dd50fb-f5d0-4cd0-aa6b-fab143614b04" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_3ca8c9de-bbad-49ee-b8dd-bfacb6c46749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseRightOfUseAsset_69988ccd-881f-4752-840f-0536d297a569" xlink:href="nvax-20231231.xsd#nvax_LeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6af1424-4d02-4ffc-b97d-0b563ca0802e" xlink:to="loc_nvax_LeaseRightOfUseAsset_69988ccd-881f-4752-840f-0536d297a569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ba761daa-1fbc-403d-ae89-4a1e9ff2d6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6af1424-4d02-4ffc-b97d-0b563ca0802e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ba761daa-1fbc-403d-ae89-4a1e9ff2d6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_1421bb90-fdd5-4538-9807-c0ff97a32ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_ba761daa-1fbc-403d-ae89-4a1e9ff2d6fa" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_1421bb90-fdd5-4538-9807-c0ff97a32ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_f654e41d-abd7-4723-87fd-cb30e856d1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6af1424-4d02-4ffc-b97d-0b563ca0802e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_f654e41d-abd7-4723-87fd-cb30e856d1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseLiabilityCurrent_8df4753d-6ba9-4c46-a5ae-727de62476d4" xlink:href="nvax-20231231.xsd#nvax_LeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6af1424-4d02-4ffc-b97d-0b563ca0802e" xlink:to="loc_nvax_LeaseLiabilityCurrent_8df4753d-6ba9-4c46-a5ae-727de62476d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_aa9f6df2-fa9c-447e-9223-1f5d235ca4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6af1424-4d02-4ffc-b97d-0b563ca0802e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_aa9f6df2-fa9c-447e-9223-1f5d235ca4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_d66e5abb-fd1f-486f-ad2d-e7c6472606e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_aa9f6df2-fa9c-447e-9223-1f5d235ca4bc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_d66e5abb-fd1f-486f-ad2d-e7c6472606e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_47b6030f-e298-4bb1-b548-3031a717caba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6af1424-4d02-4ffc-b97d-0b563ca0802e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_47b6030f-e298-4bb1-b548-3031a717caba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseLiabilityNoncurrent_a36f607b-accb-494a-a955-33aff6de3e8b" xlink:href="nvax-20231231.xsd#nvax_LeaseLiabilityNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6af1424-4d02-4ffc-b97d-0b563ca0802e" xlink:to="loc_nvax_LeaseLiabilityNoncurrent_a36f607b-accb-494a-a955-33aff6de3e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_WeightedAverageRemainingLeaseTermAbstract_5a1e90e2-d993-41e9-9c7a-98eb6b6cf023" xlink:href="nvax-20231231.xsd#nvax_WeightedAverageRemainingLeaseTermAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6af1424-4d02-4ffc-b97d-0b563ca0802e" xlink:to="loc_nvax_WeightedAverageRemainingLeaseTermAbstract_5a1e90e2-d993-41e9-9c7a-98eb6b6cf023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_dc1ed4af-291e-48e7-b721-dd1ce9758f41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_WeightedAverageRemainingLeaseTermAbstract_5a1e90e2-d993-41e9-9c7a-98eb6b6cf023" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_dc1ed4af-291e-48e7-b721-dd1ce9758f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_1293931e-9971-4a40-b281-d31b982396ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_WeightedAverageRemainingLeaseTermAbstract_5a1e90e2-d993-41e9-9c7a-98eb6b6cf023" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_1293931e-9971-4a40-b281-d31b982396ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_WeightedAverageDiscountRateAbstract_67e704cd-518a-4790-9a4b-c3a193582b8b" xlink:href="nvax-20231231.xsd#nvax_WeightedAverageDiscountRateAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6af1424-4d02-4ffc-b97d-0b563ca0802e" xlink:to="loc_nvax_WeightedAverageDiscountRateAbstract_67e704cd-518a-4790-9a4b-c3a193582b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_096fdd21-ace8-4183-be40-eee586677637" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_WeightedAverageDiscountRateAbstract_67e704cd-518a-4790-9a4b-c3a193582b8b" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_096fdd21-ace8-4183-be40-eee586677637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_bfb92bfe-6d09-4c2e-aaf1-fb733af9b1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_WeightedAverageDiscountRateAbstract_67e704cd-518a-4790-9a4b-c3a193582b8b" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_bfb92bfe-6d09-4c2e-aaf1-fb733af9b1a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#LeasesScheduleofOperatingLeaseExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_489bf1ab-4056-45f4-8863-703c48df8e78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_2883cf1c-c78e-41a5-b3e2-63003d304eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_489bf1ab-4056-45f4-8863-703c48df8e78" xlink:to="loc_us-gaap_OperatingLeaseCost_2883cf1c-c78e-41a5-b3e2-63003d304eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShortTermLeaseCostBenefit_56996d10-2c85-45c9-9a81-95ac6af4a873" xlink:href="nvax-20231231.xsd#nvax_ShortTermLeaseCostBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_489bf1ab-4056-45f4-8863-703c48df8e78" xlink:to="loc_nvax_ShortTermLeaseCostBenefit_56996d10-2c85-45c9-9a81-95ac6af4a873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_cc1199fd-ecc8-43b7-b97c-f8bebf4a59b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_489bf1ab-4056-45f4-8863-703c48df8e78" xlink:to="loc_us-gaap_VariableLeaseCost_cc1199fd-ecc8-43b7-b97c-f8bebf4a59b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_809d2f73-b42e-41e0-9712-229870156713" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_489bf1ab-4056-45f4-8863-703c48df8e78" xlink:to="loc_us-gaap_LeaseCostAbstract_809d2f73-b42e-41e0-9712-229870156713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_45d9f59d-a954-4313-9ac9-259b51f52f98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_809d2f73-b42e-41e0-9712-229870156713" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_45d9f59d-a954-4313-9ac9-259b51f52f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_32c4f121-c8c0-412a-bfbe-2d9bec148313" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_809d2f73-b42e-41e0-9712-229870156713" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_32c4f121-c8c0-412a-bfbe-2d9bec148313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_a4ad6640-8d61-4d5f-8a1f-d4ab6c7b6fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_489bf1ab-4056-45f4-8863-703c48df8e78" xlink:to="loc_us-gaap_LeaseCost_a4ad6640-8d61-4d5f-8a1f-d4ab6c7b6fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LeasesScheduleofSupplementalCashFlowInformationofLeasesDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#LeasesScheduleofSupplementalCashFlowInformationofLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/LeasesScheduleofSupplementalCashFlowInformationofLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b34b0d07-ce98-48dd-b6bf-48185001a5a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract_6d692ecf-68b0-4b79-b2a2-f54108d2fcdf" xlink:href="nvax-20231231.xsd#nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b34b0d07-ce98-48dd-b6bf-48185001a5a6" xlink:to="loc_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract_6d692ecf-68b0-4b79-b2a2-f54108d2fcdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_1cb3932a-9b71-4782-8bba-bd6ee4c07f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract_6d692ecf-68b0-4b79-b2a2-f54108d2fcdf" xlink:to="loc_us-gaap_OperatingLeasePayments_1cb3932a-9b71-4782-8bba-bd6ee4c07f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_ee36b6a5-cadc-4dd0-a8c3-db89540b2ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract_6d692ecf-68b0-4b79-b2a2-f54108d2fcdf" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_ee36b6a5-cadc-4dd0-a8c3-db89540b2ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_9368a4a7-a0eb-4bbc-a40f-ca7476761134" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract_6d692ecf-68b0-4b79-b2a2-f54108d2fcdf" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_9368a4a7-a0eb-4bbc-a40f-ca7476761134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7569477c-dfb5-4e29-ab2e-30386f41ec82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b34b0d07-ce98-48dd-b6bf-48185001a5a6" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7569477c-dfb5-4e29-ab2e-30386f41ec82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_9e45bc7b-62e8-4d56-a2de-560c8935f36d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b34b0d07-ce98-48dd-b6bf-48185001a5a6" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_9e45bc7b-62e8-4d56-a2de-560c8935f36d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_80c0c51c-68ed-4a88-8870-e9a491b21074" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_119f8f10-92db-40a7-ac2f-0d3d7ff825f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_80c0c51c-68ed-4a88-8870-e9a491b21074" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_119f8f10-92db-40a7-ac2f-0d3d7ff825f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0ba08327-efcf-4732-b9dc-569e52117f94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_80c0c51c-68ed-4a88-8870-e9a491b21074" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0ba08327-efcf-4732-b9dc-569e52117f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ae9a1ca0-f26a-4f19-b60f-bea17325e07d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_80c0c51c-68ed-4a88-8870-e9a491b21074" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ae9a1ca0-f26a-4f19-b60f-bea17325e07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c3dbf219-6dc1-43ae-8d68-efaac061e9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_80c0c51c-68ed-4a88-8870-e9a491b21074" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c3dbf219-6dc1-43ae-8d68-efaac061e9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6956e387-9439-4800-9f4d-86c3b06ccbc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_80c0c51c-68ed-4a88-8870-e9a491b21074" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6956e387-9439-4800-9f4d-86c3b06ccbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_74bfa041-4974-4231-b2ff-dd7583f9b632" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_80c0c51c-68ed-4a88-8870-e9a491b21074" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_74bfa041-4974-4231-b2ff-dd7583f9b632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_35bb8b8d-7efd-4097-bf05-f936e223f65c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_80c0c51c-68ed-4a88-8870-e9a491b21074" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_35bb8b8d-7efd-4097-bf05-f936e223f65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6731b143-12c5-4df8-827c-26992c2f239a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_80c0c51c-68ed-4a88-8870-e9a491b21074" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6731b143-12c5-4df8-827c-26992c2f239a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_21bdaea1-ae93-4fae-8fca-20313ab777d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_80c0c51c-68ed-4a88-8870-e9a491b21074" xlink:to="loc_us-gaap_OperatingLeaseLiability_21bdaea1-ae93-4fae-8fca-20313ab777d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="nvax-20231231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#LongTermDebtScheduleofNotesPayableDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_53226727-8d09-474d-abb5-1777aa52edcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_13a31bd7-8ff3-4e62-8d0a-80b349552ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_53226727-8d09-474d-abb5-1777aa52edcd" xlink:to="loc_us-gaap_DebtInstrumentTable_13a31bd7-8ff3-4e62-8d0a-80b349552ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ea4600f1-1059-48be-baa2-48160b45dce6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_13a31bd7-8ff3-4e62-8d0a-80b349552ac1" xlink:to="loc_us-gaap_DebtInstrumentAxis_ea4600f1-1059-48be-baa2-48160b45dce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_be6bf303-c549-470f-b3f7-26dd0229b4b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ea4600f1-1059-48be-baa2-48160b45dce6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_be6bf303-c549-470f-b3f7-26dd0229b4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_dbb3749d-e149-4d54-94f2-09d2e5ddabf6" xlink:href="nvax-20231231.xsd#nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_be6bf303-c549-470f-b3f7-26dd0229b4b7" xlink:to="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_dbb3749d-e149-4d54-94f2-09d2e5ddabf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_18f068f9-887a-418d-a6da-2c54cd742671" xlink:href="nvax-20231231.xsd#nvax_FivePointZeroConvertibleNotesDue2027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_be6bf303-c549-470f-b3f7-26dd0229b4b7" xlink:to="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_18f068f9-887a-418d-a6da-2c54cd742671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_58810bf9-0e04-4e7c-a94a-ec2a5c86a8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_13a31bd7-8ff3-4e62-8d0a-80b349552ac1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_58810bf9-0e04-4e7c-a94a-ec2a5c86a8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7aa4529b-237c-4898-83b2-14b1fb7a864c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_58810bf9-0e04-4e7c-a94a-ec2a5c86a8dc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7aa4529b-237c-4898-83b2-14b1fb7a864c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_9b5e42d3-24a5-435d-8a36-a40efe19bdd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7aa4529b-237c-4898-83b2-14b1fb7a864c" xlink:to="loc_us-gaap_UnsecuredDebtMember_9b5e42d3-24a5-435d-8a36-a40efe19bdd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5f222498-65c3-4d51-aa69-20d1657cffc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_13a31bd7-8ff3-4e62-8d0a-80b349552ac1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_5f222498-65c3-4d51-aa69-20d1657cffc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ConvertibleNotesPayableCurrentAbstract_c6b0e410-6569-45b1-b7d4-beb352ee8c57" xlink:href="nvax-20231231.xsd#nvax_ConvertibleNotesPayableCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f222498-65c3-4d51-aa69-20d1657cffc3" xlink:to="loc_nvax_ConvertibleNotesPayableCurrentAbstract_c6b0e410-6569-45b1-b7d4-beb352ee8c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DebtInstrumentFaceAmountCurrent_b7f4d00a-011a-4aa8-82dd-f488a40daa10" xlink:href="nvax-20231231.xsd#nvax_DebtInstrumentFaceAmountCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_ConvertibleNotesPayableCurrentAbstract_c6b0e410-6569-45b1-b7d4-beb352ee8c57" xlink:to="loc_nvax_DebtInstrumentFaceAmountCurrent_b7f4d00a-011a-4aa8-82dd-f488a40daa10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_e515029c-8e7b-4f06-a389-a880767084a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_ConvertibleNotesPayableCurrentAbstract_c6b0e410-6569-45b1-b7d4-beb352ee8c57" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_e515029c-8e7b-4f06-a389-a880767084a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_8928a0c1-c3c0-4574-b4a0-eb393b2db022" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_ConvertibleNotesPayableCurrentAbstract_c6b0e410-6569-45b1-b7d4-beb352ee8c57" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_8928a0c1-c3c0-4574-b4a0-eb393b2db022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ConvertibleNotesPayableNoncurrentAbstract_6cdb7ca5-b423-4127-8006-32f5eb1d6828" xlink:href="nvax-20231231.xsd#nvax_ConvertibleNotesPayableNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f222498-65c3-4d51-aa69-20d1657cffc3" xlink:to="loc_nvax_ConvertibleNotesPayableNoncurrentAbstract_6cdb7ca5-b423-4127-8006-32f5eb1d6828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_736bdcc7-b031-4a99-9a00-80665af9ed6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_ConvertibleNotesPayableNoncurrentAbstract_6cdb7ca5-b423-4127-8006-32f5eb1d6828" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_736bdcc7-b031-4a99-9a00-80665af9ed6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_3e631bb1-d683-4421-a69b-6e99cc308b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_ConvertibleNotesPayableNoncurrentAbstract_6cdb7ca5-b423-4127-8006-32f5eb1d6828" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_3e631bb1-d683-4421-a69b-6e99cc308b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_8b17c259-7ef8-4f40-99ac-c83ff5e21ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_ConvertibleNotesPayableNoncurrentAbstract_6cdb7ca5-b423-4127-8006-32f5eb1d6828" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_8b17c259-7ef8-4f40-99ac-c83ff5e21ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_9dc5a630-2523-4a0a-a419-9e3aef9e74a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f222498-65c3-4d51-aa69-20d1657cffc3" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_9dc5a630-2523-4a0a-a419-9e3aef9e74a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#LongTermDebtScheduleofInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0ed0e977-3f65-40f5-856d-c9475c4ccf89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_06bf40a5-5189-488b-8292-290feb1f7896" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0ed0e977-3f65-40f5-856d-c9475c4ccf89" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_06bf40a5-5189-488b-8292-290feb1f7896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_9a4a3a71-9096-4381-8818-d346d41c667c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0ed0e977-3f65-40f5-856d-c9475c4ccf89" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_9a4a3a71-9096-4381-8818-d346d41c667c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_79bc79e1-e29c-45db-8729-6aab3d414597" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0ed0e977-3f65-40f5-856d-c9475c4ccf89" xlink:to="loc_us-gaap_InterestExpenseDebt_79bc79e1-e29c-45db-8729-6aab3d414597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#LongTermDebtAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0dd156ad-c28c-4906-af83-73993a9314ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_bfcda809-9dbb-412a-bbcc-a7500b4d633e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0dd156ad-c28c-4906-af83-73993a9314ad" xlink:to="loc_us-gaap_DebtInstrumentTable_bfcda809-9dbb-412a-bbcc-a7500b4d633e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_af02b535-7534-46e4-9158-f78997fecbfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bfcda809-9dbb-412a-bbcc-a7500b4d633e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_af02b535-7534-46e4-9158-f78997fecbfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5fa2cd39-f17f-4815-be69-7ac9b19a449c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_af02b535-7534-46e4-9158-f78997fecbfd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5fa2cd39-f17f-4815-be69-7ac9b19a449c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_6fe3539b-cdcb-4a38-b669-28ce0670dacb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5fa2cd39-f17f-4815-be69-7ac9b19a449c" xlink:to="loc_us-gaap_UnsecuredDebtMember_6fe3539b-cdcb-4a38-b669-28ce0670dacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_572651a1-b28e-4733-a3b5-ab9dcc8b2a65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bfcda809-9dbb-412a-bbcc-a7500b4d633e" xlink:to="loc_us-gaap_DebtInstrumentAxis_572651a1-b28e-4733-a3b5-ab9dcc8b2a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ccf85481-d8fe-4c58-962d-549ff4c768e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_572651a1-b28e-4733-a3b5-ab9dcc8b2a65" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ccf85481-d8fe-4c58-962d-549ff4c768e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_9d8df834-96b5-42ba-9a13-7cd49c49852e" xlink:href="nvax-20231231.xsd#nvax_FivePointZeroConvertibleNotesDue2027Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ccf85481-d8fe-4c58-962d-549ff4c768e9" xlink:to="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_9d8df834-96b5-42ba-9a13-7cd49c49852e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember_2c3d1099-83a1-4fad-835b-9c7f64337b03" xlink:href="nvax-20231231.xsd#nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_FivePointZeroConvertibleNotesDue2027Member_9d8df834-96b5-42ba-9a13-7cd49c49852e" xlink:to="loc_nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember_2c3d1099-83a1-4fad-835b-9c7f64337b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_1a618e10-85d2-4f61-8bca-f024f0732697" xlink:href="nvax-20231231.xsd#nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ccf85481-d8fe-4c58-962d-549ff4c768e9" xlink:to="loc_nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member_1a618e10-85d2-4f61-8bca-f024f0732697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_d8f39e3c-0129-40c9-925a-8154b2d34e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bfcda809-9dbb-412a-bbcc-a7500b4d633e" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_d8f39e3c-0129-40c9-925a-8154b2d34e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_615b30a4-6f34-4ed8-868e-87f74a55e01c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_d8f39e3c-0129-40c9-925a-8154b2d34e5c" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_615b30a4-6f34-4ed8-868e-87f74a55e01c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CallOptionMember_4d9ca8e7-c9ea-44a3-adb6-efe8d3957f92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CallOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_615b30a4-6f34-4ed8-868e-87f74a55e01c" xlink:to="loc_us-gaap_CallOptionMember_4d9ca8e7-c9ea-44a3-adb6-efe8d3957f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_db6b0321-8bfa-482c-af20-ada7c1455764" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bfcda809-9dbb-412a-bbcc-a7500b4d633e" xlink:to="loc_srt_RangeAxis_db6b0321-8bfa-482c-af20-ada7c1455764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_50930d82-171f-4ccf-a0e1-d0c0594f9e2d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_db6b0321-8bfa-482c-af20-ada7c1455764" xlink:to="loc_srt_RangeMember_50930d82-171f-4ccf-a0e1-d0c0594f9e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7529a2aa-a61d-405e-8ad2-307b365a625d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_50930d82-171f-4ccf-a0e1-d0c0594f9e2d" xlink:to="loc_srt_MaximumMember_7529a2aa-a61d-405e-8ad2-307b365a625d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_ec74cf52-7a70-467d-8768-79c02c3012ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bfcda809-9dbb-412a-bbcc-a7500b4d633e" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_ec74cf52-7a70-467d-8768-79c02c3012ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e1ceee49-322a-437c-baf6-ac60fc3bf4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_ec74cf52-7a70-467d-8768-79c02c3012ac" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e1ceee49-322a-437c-baf6-ac60fc3bf4d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_cc6a04c8-6307-4183-bfb0-8accd1a123e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e1ceee49-322a-437c-baf6-ac60fc3bf4d4" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_cc6a04c8-6307-4183-bfb0-8accd1a123e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_eaf58b7b-1cfc-4bf4-8b5f-6d0899cecf19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e1ceee49-322a-437c-baf6-ac60fc3bf4d4" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_eaf58b7b-1cfc-4bf4-8b5f-6d0899cecf19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bfcda809-9dbb-412a-bbcc-a7500b4d633e" xlink:to="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_f6fd32e0-d8bc-49dd-b632-8e9aea139778" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_f6fd32e0-d8bc-49dd-b632-8e9aea139778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_d96c828c-76b6-4107-b256-08cea2218e30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_d96c828c-76b6-4107-b256-08cea2218e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_9c2dc021-f464-4076-af25-00a0e0878e32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_9c2dc021-f464-4076-af25-00a0e0878e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_6a47f85c-c3d6-47ac-a23b-eb3474b5fa34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_6a47f85c-c3d6-47ac-a23b-eb3474b5fa34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_a6538d1d-2d54-4ce9-9247-4fc066d6d452" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_a6538d1d-2d54-4ce9-9247-4fc066d6d452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_36e07d04-e75a-46fb-ad0c-f76d09acd19e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_36e07d04-e75a-46fb-ad0c-f76d09acd19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_4232c34c-f0be-440b-b27d-6db1122289cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_4232c34c-f0be-440b-b27d-6db1122289cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ConvertibleDebtConversionRate_26ba7755-d234-4c2b-b022-5b7473f5fed2" xlink:href="nvax-20231231.xsd#nvax_ConvertibleDebtConversionRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_nvax_ConvertibleDebtConversionRate_26ba7755-d234-4c2b-b022-5b7473f5fed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_303d899f-b302-4d07-9674-cd013aae4b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_303d899f-b302-4d07-9674-cd013aae4b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ConversionPremiumPercentage_2f6ad457-1063-4cae-9584-bad3f2e0a88b" xlink:href="nvax-20231231.xsd#nvax_ConversionPremiumPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_nvax_ConversionPremiumPercentage_2f6ad457-1063-4cae-9584-bad3f2e0a88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_16477682-b35b-4878-8103-b24dd107a1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_16477682-b35b-4878-8103-b24dd107a1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage_72458814-cb23-40b6-ba17-2fc2af4c5bb1" xlink:href="nvax-20231231.xsd#nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage_72458814-cb23-40b6-ba17-2fc2af4c5bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_fb90e175-10ad-42f0-9b97-f6723a0f90b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_fb90e175-10ad-42f0-9b97-f6723a0f90b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_d4d4323e-611e-4b16-bd96-513d2bf6a6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_DebtInstrumentTerm_d4d4323e-611e-4b16-bd96-513d2bf6a6ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3f803501-e674-408c-8749-51a453ea8031" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3f803501-e674-408c-8749-51a453ea8031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_f56d200b-d12f-47b3-af02-87e5969d3446" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_RepaymentsOfDebt_f56d200b-d12f-47b3-af02-87e5969d3446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_d7e5bb9b-f288-47b9-ae39-f51101c16c01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_d7e5bb9b-f288-47b9-ae39-f51101c16c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_63a7f3b2-f29f-4487-8d80-43cf9cd9e03e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_63a7f3b2-f29f-4487-8d80-43cf9cd9e03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_70ca0e53-6f17-42ae-ba21-35a2ef3cbf6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_70ca0e53-6f17-42ae-ba21-35a2ef3cbf6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PaymentForCappedCallTransactions_d21cae85-0119-4a4f-8ad2-9ace30db5b03" xlink:href="nvax-20231231.xsd#nvax_PaymentForCappedCallTransactions"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_nvax_PaymentForCappedCallTransactions_d21cae85-0119-4a4f-8ad2-9ace30db5b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DebtCapPrice_1e59ee39-a32f-44bb-a3de-96e02bb4f141" xlink:href="nvax-20231231.xsd#nvax_DebtCapPrice"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9274ffcb-f31c-4416-84a8-44bc24a656ec" xlink:to="loc_nvax_DebtCapPrice_1e59ee39-a32f-44bb-a3de-96e02bb4f141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockholdersDeficitDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#StockholdersDeficitDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockholdersDeficitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_d1482ffb-c58a-4614-a1f2-1b15f297a42f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_e5df99b9-6a00-467e-8612-27fd8b060bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_d1482ffb-c58a-4614-a1f2-1b15f297a42f" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_e5df99b9-6a00-467e-8612-27fd8b060bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b7913b52-9963-40d5-9f8b-e9ee63dcb82b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_e5df99b9-6a00-467e-8612-27fd8b060bf6" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b7913b52-9963-40d5-9f8b-e9ee63dcb82b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2b1d73b8-b3f7-4c50-b190-6601bb8cc268" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b7913b52-9963-40d5-9f8b-e9ee63dcb82b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2b1d73b8-b3f7-4c50-b190-6601bb8cc268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_June2021AndAugust2023SalesAgreementMember_cfd39a79-ac86-41c2-9964-e6a3b33c67b2" xlink:href="nvax-20231231.xsd#nvax_June2021AndAugust2023SalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2b1d73b8-b3f7-4c50-b190-6601bb8cc268" xlink:to="loc_nvax_June2021AndAugust2023SalesAgreementMember_cfd39a79-ac86-41c2-9964-e6a3b33c67b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_August2023SalesAgreementMember_ec0524ef-9d8a-4984-b7c9-78cb969345ae" xlink:href="nvax-20231231.xsd#nvax_August2023SalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_June2021AndAugust2023SalesAgreementMember_cfd39a79-ac86-41c2-9964-e6a3b33c67b2" xlink:to="loc_nvax_August2023SalesAgreementMember_ec0524ef-9d8a-4984-b7c9-78cb969345ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_June2021SalesAgreementMember_2e60a808-6690-42f5-b306-a1bcb0eb3b2c" xlink:href="nvax-20231231.xsd#nvax_June2021SalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_June2021AndAugust2023SalesAgreementMember_cfd39a79-ac86-41c2-9964-e6a3b33c67b2" xlink:to="loc_nvax_June2021SalesAgreementMember_2e60a808-6690-42f5-b306-a1bcb0eb3b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_3de89088-7f58-439f-90d2-f3f286720b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2b1d73b8-b3f7-4c50-b190-6601bb8cc268" xlink:to="loc_us-gaap_PrivatePlacementMember_3de89088-7f58-439f-90d2-f3f286720b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PublicOfferingMember_4ce4e6c0-94dc-422b-9b75-ba00bf0ce765" xlink:href="nvax-20231231.xsd#nvax_PublicOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2b1d73b8-b3f7-4c50-b190-6601bb8cc268" xlink:to="loc_nvax_PublicOfferingMember_4ce4e6c0-94dc-422b-9b75-ba00bf0ce765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_UnderwriterMember_7dc6268f-048b-49f5-9df3-7f842fae0b77" xlink:href="nvax-20231231.xsd#nvax_UnderwriterMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2b1d73b8-b3f7-4c50-b190-6601bb8cc268" xlink:to="loc_nvax_UnderwriterMember_7dc6268f-048b-49f5-9df3-7f842fae0b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_fd958f4d-b38d-4f76-84e0-6e3bdffe7a20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_e5df99b9-6a00-467e-8612-27fd8b060bf6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_fd958f4d-b38d-4f76-84e0-6e3bdffe7a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ae901b46-97ab-4121-9611-949efcbd54c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fd958f4d-b38d-4f76-84e0-6e3bdffe7a20" xlink:to="loc_us-gaap_ClassOfStockDomain_ae901b46-97ab-4121-9611-949efcbd54c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4f23424f-9f93-4137-9b3e-682307f0f9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ae901b46-97ab-4121-9611-949efcbd54c6" xlink:to="loc_us-gaap_CommonStockMember_4f23424f-9f93-4137-9b3e-682307f0f9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2c870b44-fec4-4f4a-aa03-6b51ae67d582" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_e5df99b9-6a00-467e-8612-27fd8b060bf6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2c870b44-fec4-4f4a-aa03-6b51ae67d582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e686b900-9f09-45bc-af30-fe695a062cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2c870b44-fec4-4f4a-aa03-6b51ae67d582" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e686b900-9f09-45bc-af30-fe695a062cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SecuritiesSubscriptionArrangementMember_8bd065df-bf06-45dc-91d2-0723b14684be" xlink:href="nvax-20231231.xsd#nvax_SecuritiesSubscriptionArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e686b900-9f09-45bc-af30-fe695a062cc1" xlink:to="loc_nvax_SecuritiesSubscriptionArrangementMember_8bd065df-bf06-45dc-91d2-0723b14684be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_345423c6-a0cf-4c19-b097-be2072c3e13b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_e5df99b9-6a00-467e-8612-27fd8b060bf6" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_345423c6-a0cf-4c19-b097-be2072c3e13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5ea96d17-d9cf-4c9f-92f5-8ab00b672f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_345423c6-a0cf-4c19-b097-be2072c3e13b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5ea96d17-d9cf-4c9f-92f5-8ab00b672f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_6218e064-032a-41c1-8686-3d2cc8bb636b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5ea96d17-d9cf-4c9f-92f5-8ab00b672f3e" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_6218e064-032a-41c1-8686-3d2cc8bb636b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_417e0bd5-f420-4035-9c82-8cd4fc8e9ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_e5df99b9-6a00-467e-8612-27fd8b060bf6" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_417e0bd5-f420-4035-9c82-8cd4fc8e9ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_abdc56d6-ef16-402f-8d54-aec3e1a83ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_417e0bd5-f420-4035-9c82-8cd4fc8e9ea2" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_abdc56d6-ef16-402f-8d54-aec3e1a83ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2d3153c6-f345-4702-af30-a45bc3318d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_417e0bd5-f420-4035-9c82-8cd4fc8e9ea2" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2d3153c6-f345-4702-af30-a45bc3318d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_42deb196-75e6-4566-8e67-b4b24395b8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_417e0bd5-f420-4035-9c82-8cd4fc8e9ea2" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_42deb196-75e6-4566-8e67-b4b24395b8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SaleOfStockAmountOfRemainingUnissuedShares_a56bd6cb-072b-4f39-812d-73d88a439453" xlink:href="nvax-20231231.xsd#nvax_SaleOfStockAmountOfRemainingUnissuedShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_417e0bd5-f420-4035-9c82-8cd4fc8e9ea2" xlink:to="loc_nvax_SaleOfStockAmountOfRemainingUnissuedShares_a56bd6cb-072b-4f39-812d-73d88a439453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_6aa31ac5-1e26-4058-bfd7-1b2fb1ee1fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_417e0bd5-f420-4035-9c82-8cd4fc8e9ea2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_6aa31ac5-1e26-4058-bfd7-1b2fb1ee1fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_189a5d2b-a941-4781-9913-16423410ec38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_417e0bd5-f420-4035-9c82-8cd4fc8e9ea2" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_189a5d2b-a941-4781-9913-16423410ec38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_57e3ceb2-0094-4668-8954-d7ceba1ffcd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_417e0bd5-f420-4035-9c82-8cd4fc8e9ea2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_57e3ceb2-0094-4668-8954-d7ceba1ffcd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_7b47d2b6-97c7-45cd-9a3b-c290190272dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_417e0bd5-f420-4035-9c82-8cd4fc8e9ea2" xlink:to="loc_us-gaap_StockIssued1_7b47d2b6-97c7-45cd-9a3b-c290190272dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_cf0163d4-b04f-4548-8ff0-61868c92a2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_417e0bd5-f420-4035-9c82-8cd4fc8e9ea2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_cf0163d4-b04f-4548-8ff0-61868c92a2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_fa96cdf9-3b44-4a4e-a6f1-d9326d972b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_417e0bd5-f420-4035-9c82-8cd4fc8e9ea2" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_fa96cdf9-3b44-4a4e-a6f1-d9326d972b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_924e9e3f-86ea-4553-9d1f-b5900d4b6b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_417e0bd5-f420-4035-9c82-8cd4fc8e9ea2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_924e9e3f-86ea-4553-9d1f-b5900d4b6b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee53e81a-9690-42d6-8832-93f2bb3f1f64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96844a3e-cec7-4082-81f5-278191be2e30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee53e81a-9690-42d6-8832-93f2bb3f1f64" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96844a3e-cec7-4082-81f5-278191be2e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9446b9c5-c562-4d4a-a631-6bac0bfc869d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96844a3e-cec7-4082-81f5-278191be2e30" xlink:to="loc_us-gaap_PlanNameAxis_9446b9c5-c562-4d4a-a631-6bac0bfc869d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_dfc2eeee-9498-48c8-ae8e-28d31b52dda5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_9446b9c5-c562-4d4a-a631-6bac0bfc869d" xlink:to="loc_us-gaap_PlanNameDomain_dfc2eeee-9498-48c8-ae8e-28d31b52dda5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandTwentyThreeStockInducementPlanMember_92306e9c-527e-471b-b20f-fbdf281dfaf4" xlink:href="nvax-20231231.xsd#nvax_TwoThousandTwentyThreeStockInducementPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_dfc2eeee-9498-48c8-ae8e-28d31b52dda5" xlink:to="loc_nvax_TwoThousandTwentyThreeStockInducementPlanMember_92306e9c-527e-471b-b20f-fbdf281dfaf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_8b161226-61e0-48ba-8f36-9b342835eab0" xlink:href="nvax-20231231.xsd#nvax_TwoThousandFifteenStockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_dfc2eeee-9498-48c8-ae8e-28d31b52dda5" xlink:to="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_8b161226-61e0-48ba-8f36-9b342835eab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bb8cd966-f172-4cc6-ab77-284fd08471cb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96844a3e-cec7-4082-81f5-278191be2e30" xlink:to="loc_srt_RangeAxis_bb8cd966-f172-4cc6-ab77-284fd08471cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1e20afcf-d354-42a5-8ec1-88d405af4d38" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_bb8cd966-f172-4cc6-ab77-284fd08471cb" xlink:to="loc_srt_RangeMember_1e20afcf-d354-42a5-8ec1-88d405af4d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_431f2c59-0c74-4408-bc2c-6d472ee02633" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1e20afcf-d354-42a5-8ec1-88d405af4d38" xlink:to="loc_srt_MinimumMember_431f2c59-0c74-4408-bc2c-6d472ee02633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f3cde41a-0567-4c0e-96e3-19eaa61ddd53" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1e20afcf-d354-42a5-8ec1-88d405af4d38" xlink:to="loc_srt_MaximumMember_f3cde41a-0567-4c0e-96e3-19eaa61ddd53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_eda9b263-6e51-45f5-b940-c4d95cbc3dff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96844a3e-cec7-4082-81f5-278191be2e30" xlink:to="loc_us-gaap_AwardTypeAxis_eda9b263-6e51-45f5-b940-c4d95cbc3dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81718a03-5876-463e-8cf1-d0d7eec1174d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_eda9b263-6e51-45f5-b940-c4d95cbc3dff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81718a03-5876-463e-8cf1-d0d7eec1174d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_1c3f6beb-321a-44f9-846b-45e229e82d04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81718a03-5876-463e-8cf1-d0d7eec1174d" xlink:to="loc_us-gaap_EmployeeStockMember_1c3f6beb-321a-44f9-846b-45e229e82d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96844a3e-cec7-4082-81f5-278191be2e30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7ef005d2-b323-4593-96ed-b25370f142d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7ef005d2-b323-4593-96ed-b25370f142d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance_e68ae046-2d9a-47fe-98df-0a6f08d4d6d6" xlink:href="nvax-20231231.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance_e68ae046-2d9a-47fe-98df-0a6f08d4d6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3ed183b5-ccdd-4474-a574-a1c9e9989206" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3ed183b5-ccdd-4474-a574-a1c9e9989206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3f49b07d-9ff6-4e3f-9837-119a7481e8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3f49b07d-9ff6-4e3f-9837-119a7481e8ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_72ea45e0-97ad-4f16-b93c-aa32cb1d11ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_72ea45e0-97ad-4f16-b93c-aa32cb1d11ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent_8855c6a9-f0b5-4f89-a2f3-853e7b364351" xlink:href="nvax-20231231.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent_8855c6a9-f0b5-4f89-a2f3-853e7b364351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6de57da0-f28d-4b27-969c-04d80628bd3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6de57da0-f28d-4b27-969c-04d80628bd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_a9d05f2b-8d57-4fe9-b4e7-1a05d067954d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_a9d05f2b-8d57-4fe9-b4e7-1a05d067954d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f5aba64b-fdc9-4e91-8523-b9ad503f4524" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f5aba64b-fdc9-4e91-8523-b9ad503f4524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1321ddd3-8d6b-4975-a7b6-646f1edb87f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1321ddd3-8d6b-4975-a7b6-646f1edb87f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_675dd161-84e3-4208-b513-f98300574ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_675dd161-84e3-4208-b513-f98300574ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9a4d3aa5-d307-433f-a928-73b570b477cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9a4d3aa5-d307-433f-a928-73b570b477cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_03466517-978e-4a12-a1ba-9478e7f2b312" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_03466517-978e-4a12-a1ba-9478e7f2b312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_edb9b7a1-4fef-48c3-9559-36a0d6793be0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_edb9b7a1-4fef-48c3-9559-36a0d6793be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_40aa70b1-6d13-46d3-be6f-f56f6611b34a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_40aa70b1-6d13-46d3-be6f-f56f6611b34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease_558b9fe8-41b6-4c30-9030-e0f4321856f4" xlink:href="nvax-20231231.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease_558b9fe8-41b6-4c30-9030-e0f4321856f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_MaximumContributionOfEmployeesAsPayrollDeductions_e06a7810-210f-4da2-bce7-bfd10c3b6b7b" xlink:href="nvax-20231231.xsd#nvax_MaximumContributionOfEmployeesAsPayrollDeductions"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_nvax_MaximumContributionOfEmployeesAsPayrollDeductions_e06a7810-210f-4da2-bce7-bfd10c3b6b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PercentageOfMarketPriceForStockPurchase_a4e8fbad-f4d8-4581-9a3d-5ee20bbdddcc" xlink:href="nvax-20231231.xsd#nvax_PercentageOfMarketPriceForStockPurchase"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22d6de73-40b0-4416-bf39-d790e4f7bc00" xlink:to="loc_nvax_PercentageOfMarketPriceForStockPurchase_a4e8fbad-f4d8-4581-9a3d-5ee20bbdddcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f84207e4-fb48-4516-b843-5baecd454da7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3835d72d-425d-4e62-840e-89d8ad0dc76d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f84207e4-fb48-4516-b843-5baecd454da7" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3835d72d-425d-4e62-840e-89d8ad0dc76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fc86e54f-be09-4e9f-ab27-07cbbe0ccfce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3835d72d-425d-4e62-840e-89d8ad0dc76d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fc86e54f-be09-4e9f-ab27-07cbbe0ccfce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_04548159-9b37-463a-8a58-654c377861c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fc86e54f-be09-4e9f-ab27-07cbbe0ccfce" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_04548159-9b37-463a-8a58-654c377861c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_437d4e72-1879-43d8-9368-bf8eb39d329c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_04548159-9b37-463a-8a58-654c377861c0" xlink:to="loc_us-gaap_CostOfSalesMember_437d4e72-1879-43d8-9368-bf8eb39d329c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9cc7eeb9-31f8-4941-a34f-12c5e4637d96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_04548159-9b37-463a-8a58-654c377861c0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9cc7eeb9-31f8-4941-a34f-12c5e4637d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_306af303-4eb9-4493-9c52-8adde802381e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_04548159-9b37-463a-8a58-654c377861c0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_306af303-4eb9-4493-9c52-8adde802381e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_aa951031-87e3-4284-bfd5-19a33e396bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3835d72d-425d-4e62-840e-89d8ad0dc76d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_aa951031-87e3-4284-bfd5-19a33e396bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_446f8125-ffca-4a89-be22-80ce5c82777c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_aa951031-87e3-4284-bfd5-19a33e396bf8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_446f8125-ffca-4a89-be22-80ce5c82777c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8c2e103c-9f72-460f-9dfc-6d69ccbb7c99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00a2ff8c-f20b-4e95-8a97-51475785e441" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8c2e103c-9f72-460f-9dfc-6d69ccbb7c99" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00a2ff8c-f20b-4e95-8a97-51475785e441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e48de2f3-0c96-4c19-91cf-63bd35bd515a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00a2ff8c-f20b-4e95-8a97-51475785e441" xlink:to="loc_us-gaap_PlanNameAxis_e48de2f3-0c96-4c19-91cf-63bd35bd515a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6c922bec-7f42-4763-84ff-4dd6f3ece3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_e48de2f3-0c96-4c19-91cf-63bd35bd515a" xlink:to="loc_us-gaap_PlanNameDomain_6c922bec-7f42-4763-84ff-4dd6f3ece3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandTwentyThreeStockInducementPlanMember_963911f8-2c04-4a1a-a64a-5a176cefae11" xlink:href="nvax-20231231.xsd#nvax_TwoThousandTwentyThreeStockInducementPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6c922bec-7f42-4763-84ff-4dd6f3ece3ae" xlink:to="loc_nvax_TwoThousandTwentyThreeStockInducementPlanMember_963911f8-2c04-4a1a-a64a-5a176cefae11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_b0e59d3a-14dd-4ea8-9849-468c21894b52" xlink:href="nvax-20231231.xsd#nvax_TwoThousandFifteenStockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6c922bec-7f42-4763-84ff-4dd6f3ece3ae" xlink:to="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_b0e59d3a-14dd-4ea8-9849-468c21894b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFiveStockIncentivePlanMember_ffb8bd4d-ea17-4d6c-8f4b-6549c6ef2ab2" xlink:href="nvax-20231231.xsd#nvax_TwoThousandFiveStockIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6c922bec-7f42-4763-84ff-4dd6f3ece3ae" xlink:to="loc_nvax_TwoThousandFiveStockIncentivePlanMember_ffb8bd4d-ea17-4d6c-8f4b-6549c6ef2ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a49db98-232b-41cc-98ae-2b120ed4672f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00a2ff8c-f20b-4e95-8a97-51475785e441" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a49db98-232b-41cc-98ae-2b120ed4672f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e3eef298-9ab6-4c8b-b4e7-0b0cf260d5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a49db98-232b-41cc-98ae-2b120ed4672f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e3eef298-9ab6-4c8b-b4e7-0b0cf260d5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_571863db-a242-40b0-941a-54e4021216c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e3eef298-9ab6-4c8b-b4e7-0b0cf260d5ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_571863db-a242-40b0-941a-54e4021216c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dad71d28-5b20-480b-afd1-a154c7202a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e3eef298-9ab6-4c8b-b4e7-0b0cf260d5ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dad71d28-5b20-480b-afd1-a154c7202a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_26bc61df-f1ef-48e4-9e8d-8c2bd4c306d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e3eef298-9ab6-4c8b-b4e7-0b0cf260d5ea" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_26bc61df-f1ef-48e4-9e8d-8c2bd4c306d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_555461e3-dd00-49f1-b0be-2157e6df8db4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e3eef298-9ab6-4c8b-b4e7-0b0cf260d5ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_555461e3-dd00-49f1-b0be-2157e6df8db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a8ea0c00-155a-4685-b7b2-26f0dadb2dee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e3eef298-9ab6-4c8b-b4e7-0b0cf260d5ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a8ea0c00-155a-4685-b7b2-26f0dadb2dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_dd0b6dbe-1019-478a-94f9-4e680bf2d67b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a49db98-232b-41cc-98ae-2b120ed4672f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_dd0b6dbe-1019-478a-94f9-4e680bf2d67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcd1eb1b-fd1e-4008-8776-bb2899fb5da2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a49db98-232b-41cc-98ae-2b120ed4672f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcd1eb1b-fd1e-4008-8776-bb2899fb5da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_43fdb01f-4645-40c8-9530-d52b49b47e92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcd1eb1b-fd1e-4008-8776-bb2899fb5da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_43fdb01f-4645-40c8-9530-d52b49b47e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_dc5dc393-5b5f-4c06-9345-fb0e2ae52f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcd1eb1b-fd1e-4008-8776-bb2899fb5da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_dc5dc393-5b5f-4c06-9345-fb0e2ae52f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3dced04d-ac51-459c-ac2a-588f9429c542" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcd1eb1b-fd1e-4008-8776-bb2899fb5da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3dced04d-ac51-459c-ac2a-588f9429c542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_806e6c5c-bd6f-4cb8-9e73-6df280e8bca6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcd1eb1b-fd1e-4008-8776-bb2899fb5da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_806e6c5c-bd6f-4cb8-9e73-6df280e8bca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cab6cfe5-178b-48e1-8c89-338d05da1e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcd1eb1b-fd1e-4008-8776-bb2899fb5da2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cab6cfe5-178b-48e1-8c89-338d05da1e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e5306e00-5803-4726-9530-f5747a13ec15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a49db98-232b-41cc-98ae-2b120ed4672f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e5306e00-5803-4726-9530-f5747a13ec15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0fafe335-ef94-4b22-bc67-bb69d301145b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_342991ed-afa8-49c2-8e33-fae8bf13df9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0fafe335-ef94-4b22-bc67-bb69d301145b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_342991ed-afa8-49c2-8e33-fae8bf13df9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2f0ef06e-762a-40ed-86f2-ac1374b9e444" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_342991ed-afa8-49c2-8e33-fae8bf13df9c" xlink:to="loc_us-gaap_AwardTypeAxis_2f0ef06e-762a-40ed-86f2-ac1374b9e444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be91a51c-6754-4cad-afdb-86f800ed7795" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2f0ef06e-762a-40ed-86f2-ac1374b9e444" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be91a51c-6754-4cad-afdb-86f800ed7795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d9f48f81-aa5b-4f6d-aad3-d4e22ca213a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be91a51c-6754-4cad-afdb-86f800ed7795" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d9f48f81-aa5b-4f6d-aad3-d4e22ca213a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3ff4aca3-c02d-46b8-b88d-1ac6795079af" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_342991ed-afa8-49c2-8e33-fae8bf13df9c" xlink:to="loc_srt_RangeAxis_3ff4aca3-c02d-46b8-b88d-1ac6795079af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_809878f9-3aff-40e2-b677-2b4f5998f461" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3ff4aca3-c02d-46b8-b88d-1ac6795079af" xlink:to="loc_srt_RangeMember_809878f9-3aff-40e2-b677-2b4f5998f461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_54063f7f-1c40-4a07-a172-3cd9f8826b09" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_809878f9-3aff-40e2-b677-2b4f5998f461" xlink:to="loc_srt_MinimumMember_54063f7f-1c40-4a07-a172-3cd9f8826b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0d46b7e2-db5c-4842-837b-a5747f008222" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_809878f9-3aff-40e2-b677-2b4f5998f461" xlink:to="loc_srt_MaximumMember_0d46b7e2-db5c-4842-837b-a5747f008222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67a35c14-f8d1-4de3-9f2b-80914a08761b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_342991ed-afa8-49c2-8e33-fae8bf13df9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67a35c14-f8d1-4de3-9f2b-80914a08761b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_adbc4a96-ea4f-4ea1-adb3-8717faa7dc0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67a35c14-f8d1-4de3-9f2b-80914a08761b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_adbc4a96-ea4f-4ea1-adb3-8717faa7dc0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_fe75441e-f442-4e1e-aab5-2e5e6e3f6ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67a35c14-f8d1-4de3-9f2b-80914a08761b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_fe75441e-f442-4e1e-aab5-2e5e6e3f6ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_fecc26d7-8f7d-498b-a605-eee166187893" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67a35c14-f8d1-4de3-9f2b-80914a08761b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_fecc26d7-8f7d-498b-a605-eee166187893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bec03503-bc22-4a5a-a778-f2ee636e0ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67a35c14-f8d1-4de3-9f2b-80914a08761b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bec03503-bc22-4a5a-a778-f2ee636e0ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_9b0e1955-449d-4017-bdcf-39df9c91ad3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67a35c14-f8d1-4de3-9f2b-80914a08761b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_9b0e1955-449d-4017-bdcf-39df9c91ad3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_fc1d29d0-ff11-4e8e-a3cf-1bb168f834a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67a35c14-f8d1-4de3-9f2b-80914a08761b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_fc1d29d0-ff11-4e8e-a3cf-1bb168f834a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_584327e7-2047-4cb6-b3d8-a1fa0a5ac1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67a35c14-f8d1-4de3-9f2b-80914a08761b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_584327e7-2047-4cb6-b3d8-a1fa0a5ac1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dd962dca-3173-4202-b908-f633f9ba36d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe4530e4-197d-49c4-ab07-e88a13065e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dd962dca-3173-4202-b908-f633f9ba36d1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe4530e4-197d-49c4-ab07-e88a13065e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f71e51fd-4962-4bf4-ac22-cac6571059ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe4530e4-197d-49c4-ab07-e88a13065e8c" xlink:to="loc_us-gaap_AwardTypeAxis_f71e51fd-4962-4bf4-ac22-cac6571059ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19e7a343-3145-42db-b29d-c50a9e703baf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f71e51fd-4962-4bf4-ac22-cac6571059ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19e7a343-3145-42db-b29d-c50a9e703baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3bc84ab1-3e49-4a94-b4f7-99b1ba8992eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19e7a343-3145-42db-b29d-c50a9e703baf" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3bc84ab1-3e49-4a94-b4f7-99b1ba8992eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6b81fe52-47ea-472b-bff7-cb620717a0de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe4530e4-197d-49c4-ab07-e88a13065e8c" xlink:to="loc_us-gaap_PlanNameAxis_6b81fe52-47ea-472b-bff7-cb620717a0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_54f35933-2c6f-470d-8430-540b947e41ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_6b81fe52-47ea-472b-bff7-cb620717a0de" xlink:to="loc_us-gaap_PlanNameDomain_54f35933-2c6f-470d-8430-540b947e41ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandTwentyThreeStockInducementPlanMember_5e1cd91c-9621-4749-acf8-4567b3a1ad3e" xlink:href="nvax-20231231.xsd#nvax_TwoThousandTwentyThreeStockInducementPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_54f35933-2c6f-470d-8430-540b947e41ae" xlink:to="loc_nvax_TwoThousandTwentyThreeStockInducementPlanMember_5e1cd91c-9621-4749-acf8-4567b3a1ad3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_f8784d04-fe84-4b72-9921-e128175238ef" xlink:href="nvax-20231231.xsd#nvax_TwoThousandFifteenStockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_54f35933-2c6f-470d-8430-540b947e41ae" xlink:to="loc_nvax_TwoThousandFifteenStockIncentivePlanMember_f8784d04-fe84-4b72-9921-e128175238ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9d16d6d-1aec-4066-8ee3-a6c7bef03633" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe4530e4-197d-49c4-ab07-e88a13065e8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9d16d6d-1aec-4066-8ee3-a6c7bef03633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_55158acd-548e-4c45-bd3a-934e7cbe0ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9d16d6d-1aec-4066-8ee3-a6c7bef03633" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_55158acd-548e-4c45-bd3a-934e7cbe0ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_09dbc26e-7386-4094-97f0-254abeb90d27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_55158acd-548e-4c45-bd3a-934e7cbe0ee4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_09dbc26e-7386-4094-97f0-254abeb90d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_715b85ad-a4d5-4768-80f1-f8822479716e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_55158acd-548e-4c45-bd3a-934e7cbe0ee4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_715b85ad-a4d5-4768-80f1-f8822479716e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a34975d6-cf33-42b8-ab68-97bf51e2414b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_55158acd-548e-4c45-bd3a-934e7cbe0ee4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a34975d6-cf33-42b8-ab68-97bf51e2414b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_68815217-6c90-4f3a-a55e-3853a5e78e83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_55158acd-548e-4c45-bd3a-934e7cbe0ee4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_68815217-6c90-4f3a-a55e-3853a5e78e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a97a5d3c-e981-45fd-a0f6-63db7dd1733d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_55158acd-548e-4c45-bd3a-934e7cbe0ee4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a97a5d3c-e981-45fd-a0f6-63db7dd1733d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be6c6508-8856-45f7-9834-a62a6569a7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9d16d6d-1aec-4066-8ee3-a6c7bef03633" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be6c6508-8856-45f7-9834-a62a6569a7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_886d7978-57f4-428c-aa4f-1338be8f128d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be6c6508-8856-45f7-9834-a62a6569a7dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_886d7978-57f4-428c-aa4f-1338be8f128d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2e2d0d46-c3ad-486a-bef4-1943259c7db0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be6c6508-8856-45f7-9834-a62a6569a7dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2e2d0d46-c3ad-486a-bef4-1943259c7db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c5617680-d4a2-448c-a406-51356e31220f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be6c6508-8856-45f7-9834-a62a6569a7dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c5617680-d4a2-448c-a406-51356e31220f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_707acad1-ce2a-4e12-a682-c9272eb25753" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be6c6508-8856-45f7-9834-a62a6569a7dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_707acad1-ce2a-4e12-a682-c9272eb25753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fb616a5b-c76f-4efa-bf1c-8972f5781efe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be6c6508-8856-45f7-9834-a62a6569a7dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fb616a5b-c76f-4efa-bf1c-8972f5781efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/EmployeeBenefitsDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#EmployeeBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/EmployeeBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract_1ed7ae67-fa08-4972-9e1d-275921d7a22d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMultiemployerPlansTable_56432414-6938-4804-afd2-3c9969678501" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMultiemployerPlansTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract_1ed7ae67-fa08-4972-9e1d-275921d7a22d" xlink:to="loc_us-gaap_ScheduleOfMultiemployerPlansTable_56432414-6938-4804-afd2-3c9969678501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollectiveBargainingArrangementAxis_003393d0-5562-43a7-bbc2-5257a48ad1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollectiveBargainingArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfMultiemployerPlansTable_56432414-6938-4804-afd2-3c9969678501" xlink:to="loc_us-gaap_CollectiveBargainingArrangementAxis_003393d0-5562-43a7-bbc2-5257a48ad1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollectiveBargainingArrangementDomain_60ce2a04-ef51-4ea7-a9d1-dc9d67ba9866" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollectiveBargainingArrangementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollectiveBargainingArrangementAxis_003393d0-5562-43a7-bbc2-5257a48ad1b0" xlink:to="loc_us-gaap_CollectiveBargainingArrangementDomain_60ce2a04-ef51-4ea7-a9d1-dc9d67ba9866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FirstThreePercentOfParticipantsDeferralMemberMember_c13b6454-da5c-4197-af08-f652b2139f10" xlink:href="nvax-20231231.xsd#nvax_FirstThreePercentOfParticipantsDeferralMemberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollectiveBargainingArrangementDomain_60ce2a04-ef51-4ea7-a9d1-dc9d67ba9866" xlink:to="loc_nvax_FirstThreePercentOfParticipantsDeferralMemberMember_c13b6454-da5c-4197-af08-f652b2139f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NextTwoPercentOfParticipantsDeferralMemberMember_0702d0f7-890c-4e03-89fc-f5fbd4fc06d0" xlink:href="nvax-20231231.xsd#nvax_NextTwoPercentOfParticipantsDeferralMemberMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollectiveBargainingArrangementDomain_60ce2a04-ef51-4ea7-a9d1-dc9d67ba9866" xlink:to="loc_nvax_NextTwoPercentOfParticipantsDeferralMemberMember_0702d0f7-890c-4e03-89fc-f5fbd4fc06d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_6c0bf09a-86a0-484f-ae92-68c04a9bd4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfMultiemployerPlansTable_56432414-6938-4804-afd2-3c9969678501" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_6c0bf09a-86a0-484f-ae92-68c04a9bd4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_b2d478fa-501c-410d-b4e2-ac8d6ff12b11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_6c0bf09a-86a0-484f-ae92-68c04a9bd4f8" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_b2d478fa-501c-410d-b4e2-ac8d6ff12b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_056f18ef-0cd2-4270-a62c-019b8e81195f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_b2d478fa-501c-410d-b4e2-ac8d6ff12b11" xlink:to="loc_us-gaap_ForeignPlanMember_056f18ef-0cd2-4270-a62c-019b8e81195f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_bdcce365-23e9-4c20-8fb5-5d4c566c2eac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfMultiemployerPlansTable_56432414-6938-4804-afd2-3c9969678501" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_bdcce365-23e9-4c20-8fb5-5d4c566c2eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_5b720af4-78e9-43aa-be93-9478e6523c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_bdcce365-23e9-4c20-8fb5-5d4c566c2eac" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_5b720af4-78e9-43aa-be93-9478e6523c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_64d90bfc-3922-465f-b082-0b53870a70f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_5b720af4-78e9-43aa-be93-9478e6523c2e" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_64d90bfc-3922-465f-b082-0b53870a70f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3085a9b9-7ebe-40b4-94db-583492d26d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfMultiemployerPlansTable_56432414-6938-4804-afd2-3c9969678501" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3085a9b9-7ebe-40b4-94db-583492d26d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_ef461fb8-1548-430b-9d95-dce3c5afb470" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3085a9b9-7ebe-40b4-94db-583492d26d3b" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_ef461fb8-1548-430b-9d95-dce3c5afb470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_9c8abaf7-ba8d-45aa-b9e2-9f61971f9d57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3085a9b9-7ebe-40b4-94db-583492d26d3b" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_9c8abaf7-ba8d-45aa-b9e2-9f61971f9d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_87bf1d19-b815-4fcf-b4d6-d1072974b72a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3085a9b9-7ebe-40b4-94db-583492d26d3b" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_87bf1d19-b815-4fcf-b4d6-d1072974b72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_96732014-97fb-4378-b049-5776d2db6904" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3085a9b9-7ebe-40b4-94db-583492d26d3b" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_96732014-97fb-4378-b049-5776d2db6904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5f90ed9d-9d95-477b-ac93-757e22b5788f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Supplies_576433c6-7eb7-4ffd-bc67-fb511d7054ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Supplies"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5f90ed9d-9d95-477b-ac93-757e22b5788f" xlink:to="loc_us-gaap_Supplies_576433c6-7eb7-4ffd-bc67-fb511d7054ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_d7b430a4-f86a-449a-bc83-7cfbcb5d81fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5f90ed9d-9d95-477b-ac93-757e22b5788f" xlink:to="loc_us-gaap_OtherAssetsCurrent_d7b430a4-f86a-449a-bc83-7cfbcb5d81fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bf665aca-648d-44eb-8ee3-f26f46d825e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5f90ed9d-9d95-477b-ac93-757e22b5788f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bf665aca-648d-44eb-8ee3-f26f46d825e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a4e4ab7c-99f8-4c6a-8b03-75f340539893" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_876b911f-0ff0-4109-a54f-5f99278a5cce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a4e4ab7c-99f8-4c6a-8b03-75f340539893" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_876b911f-0ff0-4109-a54f-5f99278a5cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5e7d7311-ab4a-4521-bacd-bb571852e1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_876b911f-0ff0-4109-a54f-5f99278a5cce" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5e7d7311-ab4a-4521-bacd-bb571852e1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b87db3f8-4bcd-431b-b6e5-2faaf931f13b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5e7d7311-ab4a-4521-bacd-bb571852e1a7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b87db3f8-4bcd-431b-b6e5-2faaf931f13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember_4365aace-06eb-41a7-b6d3-76064a303b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b87db3f8-4bcd-431b-b6e5-2faaf931f13b" xlink:to="loc_us-gaap_LandAndLandImprovementsMember_4365aace-06eb-41a7-b6d3-76064a303b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_185e97ad-050b-4f2a-ac9e-867c53ef1dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b87db3f8-4bcd-431b-b6e5-2faaf931f13b" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_185e97ad-050b-4f2a-ac9e-867c53ef1dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_3480b17c-fbb7-4454-8e0d-d85bf41bd5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b87db3f8-4bcd-431b-b6e5-2faaf931f13b" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_3480b17c-fbb7-4454-8e0d-d85bf41bd5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ComputerSoftwareAndHardwareMemberMember_61e6680a-4398-4989-9306-74f52e6e4cd5" xlink:href="nvax-20231231.xsd#nvax_ComputerSoftwareAndHardwareMemberMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b87db3f8-4bcd-431b-b6e5-2faaf931f13b" xlink:to="loc_nvax_ComputerSoftwareAndHardwareMemberMember_61e6680a-4398-4989-9306-74f52e6e4cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_fb05badf-48ee-4056-aa8a-9898889193ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b87db3f8-4bcd-431b-b6e5-2faaf931f13b" xlink:to="loc_us-gaap_ConstructionInProgressMember_fb05badf-48ee-4056-aa8a-9898889193ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_178e9409-3029-4d81-9888-6e4e11b9954a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_876b911f-0ff0-4109-a54f-5f99278a5cce" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_178e9409-3029-4d81-9888-6e4e11b9954a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_bb072174-0173-4e4e-902c-ce393e0f284a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_178e9409-3029-4d81-9888-6e4e11b9954a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_bb072174-0173-4e4e-902c-ce393e0f284a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c4935d3f-30b7-41dc-8220-b8465839ec74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_178e9409-3029-4d81-9888-6e4e11b9954a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c4935d3f-30b7-41dc-8220-b8465839ec74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_88ba7725-4744-4970-aeee-9e79f5ab015b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_178e9409-3029-4d81-9888-6e4e11b9954a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_88ba7725-4744-4970-aeee-9e79f5ab015b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/OtherFinancialInformationAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#OtherFinancialInformationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/OtherFinancialInformationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d8671bab-50ea-4b08-8569-cb7acaa0617b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f0d1737d-6ed7-4d26-9d50-2706aa15ff79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d8671bab-50ea-4b08-8569-cb7acaa0617b" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f0d1737d-6ed7-4d26-9d50-2706aa15ff79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2fe69fe7-7d23-486d-a385-bb06aacf4913" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f0d1737d-6ed7-4d26-9d50-2706aa15ff79" xlink:to="loc_srt_StatementGeographicalAxis_2fe69fe7-7d23-486d-a385-bb06aacf4913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f4cbb87d-f437-4f92-9d89-a242b96fade3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_2fe69fe7-7d23-486d-a385-bb06aacf4913" xlink:to="loc_srt_SegmentGeographicalDomain_f4cbb87d-f437-4f92-9d89-a242b96fade3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CZ_334ddbe1-d5d5-4a6e-a405-4bed93a1ca34" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CZ"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f4cbb87d-f437-4f92-9d89-a242b96fade3" xlink:to="loc_country_CZ_334ddbe1-d5d5-4a6e-a405-4bed93a1ca34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_010b878d-53d6-4f8a-9f14-84de4dc4656e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f0d1737d-6ed7-4d26-9d50-2706aa15ff79" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_010b878d-53d6-4f8a-9f14-84de4dc4656e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_77ac7c2f-73d9-40f0-a09f-6c5faea0e437" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_010b878d-53d6-4f8a-9f14-84de4dc4656e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_77ac7c2f-73d9-40f0-a09f-6c5faea0e437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_e38f96b9-341f-4dbd-9e31-4eb85b075cce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_010b878d-53d6-4f8a-9f14-84de4dc4656e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_e38f96b9-341f-4dbd-9e31-4eb85b075cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/OtherFinancialInformationScheduleofAccruedExpensesDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#OtherFinancialInformationScheduleofAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/OtherFinancialInformationScheduleofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e967cdad-b68e-4186-8aa6-8c3dd724ec87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2c41d8f5-b661-4b8e-a8d6-0fbc4972424e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e967cdad-b68e-4186-8aa6-8c3dd724ec87" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2c41d8f5-b661-4b8e-a8d6-0fbc4972424e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_AccruedGrossToNetDeductionsCurrent_022ee921-7e9d-432a-a5c7-4132046332d0" xlink:href="nvax-20231231.xsd#nvax_AccruedGrossToNetDeductionsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e967cdad-b68e-4186-8aa6-8c3dd724ec87" xlink:to="loc_nvax_AccruedGrossToNetDeductionsCurrent_022ee921-7e9d-432a-a5c7-4132046332d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_U.S.ProductSalesReturnsAccrual_9d05cc19-acb8-41fc-9acb-cd0b225085a2" xlink:href="nvax-20231231.xsd#nvax_U.S.ProductSalesReturnsAccrual"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e967cdad-b68e-4186-8aa6-8c3dd724ec87" xlink:to="loc_nvax_U.S.ProductSalesReturnsAccrual_9d05cc19-acb8-41fc-9acb-cd0b225085a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ResearchAndDevelopmentAccrualsCurrent_2190334e-dc50-43b3-89fe-b1a4c6cfe02d" xlink:href="nvax-20231231.xsd#nvax_ResearchAndDevelopmentAccrualsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e967cdad-b68e-4186-8aa6-8c3dd724ec87" xlink:to="loc_nvax_ResearchAndDevelopmentAccrualsCurrent_2190334e-dc50-43b3-89fe-b1a4c6cfe02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1c598435-fe4a-4f25-81ae-0ce2a8359a83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e967cdad-b68e-4186-8aa6-8c3dd724ec87" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1c598435-fe4a-4f25-81ae-0ce2a8359a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f72f9ae8-c4f1-4119-9073-b4d909f01a73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e967cdad-b68e-4186-8aa6-8c3dd724ec87" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f72f9ae8-c4f1-4119-9073-b4d909f01a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/OtherFinancialInformationScheduleofOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#OtherFinancialInformationScheduleofOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/OtherFinancialInformationScheduleofOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b8a57049-cbee-4560-99b9-91f127671d14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_a96af06a-8ef3-44e5-9281-5b4e67a715b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b8a57049-cbee-4560-99b9-91f127671d14" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_a96af06a-8ef3-44e5-9281-5b4e67a715b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements_42335acb-45bb-45cd-abf1-1fb22b38e988" xlink:href="nvax-20231231.xsd#nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b8a57049-cbee-4560-99b9-91f127671d14" xlink:to="loc_nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements_42335acb-45bb-45cd-abf1-1fb22b38e988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_27dcc056-14c9-437c-b854-8a785f7bf54a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b8a57049-cbee-4560-99b9-91f127671d14" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_27dcc056-14c9-437c-b854-8a785f7bf54a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_52868aa2-cfac-46d6-9a72-2624bb3f044b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b8a57049-cbee-4560-99b9-91f127671d14" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_52868aa2-cfac-46d6-9a72-2624bb3f044b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ea119861-fb67-47c4-8e80-d848586a2ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_47667c51-74b6-4562-80f1-59fdcaf3cbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ea119861-fb67-47c4-8e80-d848586a2ee4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_47667c51-74b6-4562-80f1-59fdcaf3cbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_dcd6a055-a9e9-44ff-9913-f7ba9fdcfaae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ea119861-fb67-47c4-8e80-d848586a2ee4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_dcd6a055-a9e9-44ff-9913-f7ba9fdcfaae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_30815416-2347-43db-82ca-59aa7715b432" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ea119861-fb67-47c4-8e80-d848586a2ee4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_30815416-2347-43db-82ca-59aa7715b432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6c14aa77-aee2-4994-9372-bbeacfb26746" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_589f29c9-8e71-434b-beba-a6285ca344d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6c14aa77-aee2-4994-9372-bbeacfb26746" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_589f29c9-8e71-434b-beba-a6285ca344d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_a281f9ab-26aa-42c0-b385-ad7bb68e1ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_589f29c9-8e71-434b-beba-a6285ca344d4" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_a281f9ab-26aa-42c0-b385-ad7bb68e1ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6aaab038-b047-4c22-ab90-c6aa150de0db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_589f29c9-8e71-434b-beba-a6285ca344d4" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6aaab038-b047-4c22-ab90-c6aa150de0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_68db55e3-2cea-4675-8541-7ceec3727f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_589f29c9-8e71-434b-beba-a6285ca344d4" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_68db55e3-2cea-4675-8541-7ceec3727f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ae997f8b-e88c-42d0-bc25-c349efb61997" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_589f29c9-8e71-434b-beba-a6285ca344d4" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ae997f8b-e88c-42d0-bc25-c349efb61997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_0f11c148-2d21-47d7-a2bc-bee70f97b783" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6c14aa77-aee2-4994-9372-bbeacfb26746" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_0f11c148-2d21-47d7-a2bc-bee70f97b783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_44046f94-e059-44d8-8490-2d69286f3433" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_0f11c148-2d21-47d7-a2bc-bee70f97b783" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_44046f94-e059-44d8-8490-2d69286f3433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a34fdea9-4649-49cf-bf0f-5635b5fdc10f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6c14aa77-aee2-4994-9372-bbeacfb26746" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a34fdea9-4649-49cf-bf0f-5635b5fdc10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2ef2454a-5e30-4a9b-a578-29516ff6a3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_70c1be57-9d72-4ca2-8490-08d2a6704374" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2ef2454a-5e30-4a9b-a578-29516ff6a3bc" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_70c1be57-9d72-4ca2-8490-08d2a6704374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_e5dac692-de13-468d-896a-a911fc15ba32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_70c1be57-9d72-4ca2-8490-08d2a6704374" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_e5dac692-de13-468d-896a-a911fc15ba32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_44ed1ae8-29b6-4b42-90f7-bc7efd4f4ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e5dac692-de13-468d-896a-a911fc15ba32" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_44ed1ae8-29b6-4b42-90f7-bc7efd4f4ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_33bddc4a-0011-4f53-8f64-87cba45f0d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_44ed1ae8-29b6-4b42-90f7-bc7efd4f4ca0" xlink:to="loc_us-gaap_DomesticCountryMember_33bddc4a-0011-4f53-8f64-87cba45f0d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_c859ecd9-3973-4c9f-9e3e-f244417d520b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_44ed1ae8-29b6-4b42-90f7-bc7efd4f4ca0" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_c859ecd9-3973-4c9f-9e3e-f244417d520b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_8f8f6ef5-a3c5-40a3-b58c-e1afa338eb69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_70c1be57-9d72-4ca2-8490-08d2a6704374" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_8f8f6ef5-a3c5-40a3-b58c-e1afa338eb69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_6775e1c2-649e-4050-8ba8-52bb778e81d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_8f8f6ef5-a3c5-40a3-b58c-e1afa338eb69" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_6775e1c2-649e-4050-8ba8-52bb778e81d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_2ebaf273-264b-4985-b376-0fad9bac03c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_6775e1c2-649e-4050-8ba8-52bb778e81d7" xlink:to="loc_us-gaap_ResearchMember_2ebaf273-264b-4985-b376-0fad9bac03c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_b3493260-c659-4ca4-96d9-d7eae617fb87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_6775e1c2-649e-4050-8ba8-52bb778e81d7" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_b3493260-c659-4ca4-96d9-d7eae617fb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_229b8690-a037-4abf-93e4-32ec27317cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_70c1be57-9d72-4ca2-8490-08d2a6704374" xlink:to="loc_us-gaap_TaxPeriodAxis_229b8690-a037-4abf-93e4-32ec27317cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_c5839beb-e214-4659-9ea4-79a6a497a9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_229b8690-a037-4abf-93e4-32ec27317cb6" xlink:to="loc_us-gaap_TaxPeriodDomain_c5839beb-e214-4659-9ea4-79a6a497a9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SubjectToExpirationMember_3ca7f97a-4e8d-4576-9f21-db0e21575ef3" xlink:href="nvax-20231231.xsd#nvax_SubjectToExpirationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_c5839beb-e214-4659-9ea4-79a6a497a9c7" xlink:to="loc_nvax_SubjectToExpirationMember_3ca7f97a-4e8d-4576-9f21-db0e21575ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NoExpirationMember_298629e2-534a-49cc-aa57-f0f56f9e1e78" xlink:href="nvax-20231231.xsd#nvax_NoExpirationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_c5839beb-e214-4659-9ea4-79a6a497a9c7" xlink:to="loc_nvax_NoExpirationMember_298629e2-534a-49cc-aa57-f0f56f9e1e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ea7a00e6-e6bf-4e21-9c0a-13bb3004a98f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_70c1be57-9d72-4ca2-8490-08d2a6704374" xlink:to="loc_srt_StatementGeographicalAxis_ea7a00e6-e6bf-4e21-9c0a-13bb3004a98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_884d4eb9-b879-44d8-9e19-ca5d9145c78e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_ea7a00e6-e6bf-4e21-9c0a-13bb3004a98f" xlink:to="loc_srt_SegmentGeographicalDomain_884d4eb9-b879-44d8-9e19-ca5d9145c78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_90fa5736-b14c-48a0-9493-ba8f7f05f496" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_884d4eb9-b879-44d8-9e19-ca5d9145c78e" xlink:to="loc_us-gaap_NonUsMember_90fa5736-b14c-48a0-9493-ba8f7f05f496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_48f4858f-99ee-447b-9c9d-31b1886d35d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_70c1be57-9d72-4ca2-8490-08d2a6704374" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_48f4858f-99ee-447b-9c9d-31b1886d35d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_c0155f17-d522-49c3-8286-2a574535ced0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48f4858f-99ee-447b-9c9d-31b1886d35d8" xlink:to="loc_us-gaap_OperatingLossCarryforwards_c0155f17-d522-49c3-8286-2a574535ced0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_71905108-4a9c-4457-af40-62c42ae949f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48f4858f-99ee-447b-9c9d-31b1886d35d8" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_71905108-4a9c-4457-af40-62c42ae949f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_805c17c0-8256-40b2-a046-f5c71b7317d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48f4858f-99ee-447b-9c9d-31b1886d35d8" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_805c17c0-8256-40b2-a046-f5c71b7317d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_f8e0522d-401b-4338-a09c-602f4ce30bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48f4858f-99ee-447b-9c9d-31b1886d35d8" xlink:to="loc_us-gaap_DeferredTaxLiabilities_f8e0522d-401b-4338-a09c-602f4ce30bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_0b9024d3-3dd2-4a3e-86c9-582ec18d2d01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48f4858f-99ee-447b-9c9d-31b1886d35d8" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_0b9024d3-3dd2-4a3e-86c9-582ec18d2d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#IncomeTaxesScheduleofTaxRateDifferencesDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9baee5b9-dd50-495e-8fde-de461f85d072" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_10811cc8-f644-476b-b3cd-5468e0ea40df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9baee5b9-dd50-495e-8fde-de461f85d072" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_10811cc8-f644-476b-b3cd-5468e0ea40df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_96f382e6-27fa-46d1-8cdb-349aa7df329b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9baee5b9-dd50-495e-8fde-de461f85d072" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_96f382e6-27fa-46d1-8cdb-349aa7df329b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_50d2c6ee-56ec-45b4-8f03-c5bdb79ff3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9baee5b9-dd50-495e-8fde-de461f85d072" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_50d2c6ee-56ec-45b4-8f03-c5bdb79ff3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_b8debd07-5346-4236-8e9e-0656b9d327a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9baee5b9-dd50-495e-8fde-de461f85d072" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_b8debd07-5346-4236-8e9e-0656b9d327a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent_6d9493bb-db38-4b9d-b6dc-f8363300b22a" xlink:href="nvax-20231231.xsd#nvax_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9baee5b9-dd50-495e-8fde-de461f85d072" xlink:to="loc_nvax_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent_6d9493bb-db38-4b9d-b6dc-f8363300b22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations_82f66364-46a9-46c7-ae48-071bec698d06" xlink:href="nvax-20231231.xsd#nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9baee5b9-dd50-495e-8fde-de461f85d072" xlink:to="loc_nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations_82f66364-46a9-46c7-ae48-071bec698d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent_0fe00a1a-1f53-4bf0-91c5-51956518c426" xlink:href="nvax-20231231.xsd#nvax_EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9baee5b9-dd50-495e-8fde-de461f85d072" xlink:to="loc_nvax_EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent_0fe00a1a-1f53-4bf0-91c5-51956518c426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_215d461c-d3a6-467d-b8e8-018ced3d63b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9baee5b9-dd50-495e-8fde-de461f85d072" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_215d461c-d3a6-467d-b8e8-018ced3d63b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_8626ea92-66b6-401b-a7fa-8ae0b0be6167" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9baee5b9-dd50-495e-8fde-de461f85d072" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_8626ea92-66b6-401b-a7fa-8ae0b0be6167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_0cf4c9cf-2db9-4a14-b0f5-365009f4146a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9baee5b9-dd50-495e-8fde-de461f85d072" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_0cf4c9cf-2db9-4a14-b0f5-365009f4146a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_cf165947-e746-44c6-a850-2d7f28ae8d33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9baee5b9-dd50-495e-8fde-de461f85d072" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_cf165947-e746-44c6-a850-2d7f28ae8d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0888b43b-7773-4536-ae32-7b9023e44c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9baee5b9-dd50-495e-8fde-de461f85d072" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0888b43b-7773-4536-ae32-7b9023e44c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0eb1400b-65db-4b52-ac7f-e81d7f650bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_fea23ee7-b627-429d-a6d0-82456754c0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0eb1400b-65db-4b52-ac7f-e81d7f650bc2" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_fea23ee7-b627-429d-a6d0-82456754c0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_66bbb8a7-934f-42e0-8d71-8ca29c31cff4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_fea23ee7-b627-429d-a6d0-82456754c0e1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_66bbb8a7-934f-42e0-8d71-8ca29c31cff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_8a9a3948-fa91-42a2-bc4b-b357a89759c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_fea23ee7-b627-429d-a6d0-82456754c0e1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_8a9a3948-fa91-42a2-bc4b-b357a89759c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_d0ac9c4b-c8b0-4fb6-b43f-774b5df7d5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_fea23ee7-b627-429d-a6d0-82456754c0e1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_d0ac9c4b-c8b0-4fb6-b43f-774b5df7d5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_DeferredTaxAssetLeasingLiability_d9b541d0-29b7-4b8b-9ae4-04892a4d2830" xlink:href="nvax-20231231.xsd#nvax_DeferredTaxAssetLeasingLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_fea23ee7-b627-429d-a6d0-82456754c0e1" xlink:to="loc_nvax_DeferredTaxAssetLeasingLiability_d9b541d0-29b7-4b8b-9ae4-04892a4d2830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_2c672d26-4826-4e45-a520-f075c5a702e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_fea23ee7-b627-429d-a6d0-82456754c0e1" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_2c672d26-4826-4e45-a520-f075c5a702e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_a4295b0c-d80c-4c1e-aeb7-ca44653c2bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_fea23ee7-b627-429d-a6d0-82456754c0e1" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_a4295b0c-d80c-4c1e-aeb7-ca44653c2bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_a4f50d1e-f0fa-4a52-9751-4c96ece0b7da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_fea23ee7-b627-429d-a6d0-82456754c0e1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_a4f50d1e-f0fa-4a52-9751-4c96ece0b7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_98c171e3-7fb0-4462-b923-a5ae24c878f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_fea23ee7-b627-429d-a6d0-82456754c0e1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_98c171e3-7fb0-4462-b923-a5ae24c878f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_85f8f01f-74df-4b47-8b8f-b9a9bf8653d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_fea23ee7-b627-429d-a6d0-82456754c0e1" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_85f8f01f-74df-4b47-8b8f-b9a9bf8653d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_a80783a3-4ac2-4032-ae27-6f5af0fef4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_fea23ee7-b627-429d-a6d0-82456754c0e1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_a80783a3-4ac2-4032-ae27-6f5af0fef4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_ea1d828c-df5b-43d0-8d73-9d7c48e0df58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_fea23ee7-b627-429d-a6d0-82456754c0e1" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_ea1d828c-df5b-43d0-8d73-9d7c48e0df58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_4635e8f7-5ac4-487b-90ba-4ff038e27cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_fea23ee7-b627-429d-a6d0-82456754c0e1" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_4635e8f7-5ac4-487b-90ba-4ff038e27cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f3ac50f7-4bd5-4392-97fc-bcf7576952dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_fea23ee7-b627-429d-a6d0-82456754c0e1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f3ac50f7-4bd5-4392-97fc-bcf7576952dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_71db91e1-51f4-4844-b169-8d522407f669" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_fea23ee7-b627-429d-a6d0-82456754c0e1" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_71db91e1-51f4-4844-b169-8d522407f669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_0943acc4-e9d3-49b4-a408-0ed48fdea02e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0eb1400b-65db-4b52-ac7f-e81d7f650bc2" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_0943acc4-e9d3-49b4-a408-0ed48fdea02e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_b4c1e821-00da-4b8e-a95c-92a89f55b4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_0943acc4-e9d3-49b4-a408-0ed48fdea02e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_b4c1e821-00da-4b8e-a95c-92a89f55b4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_3d83122c-2762-4f87-bcfa-26c52a7bf97c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_0943acc4-e9d3-49b4-a408-0ed48fdea02e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_3d83122c-2762-4f87-bcfa-26c52a7bf97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_28f11e74-afa4-48f6-8b23-eb09be2d7d33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_0943acc4-e9d3-49b4-a408-0ed48fdea02e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_28f11e74-afa4-48f6-8b23-eb09be2d7d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_356a324a-c196-4078-aa28-9385896c56ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_0943acc4-e9d3-49b4-a408-0ed48fdea02e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_356a324a-c196-4078-aa28-9385896c56ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_ca696f22-00b3-42ef-8536-b76ac82338ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_0943acc4-e9d3-49b4-a408-0ed48fdea02e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_ca696f22-00b3-42ef-8536-b76ac82338ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_7d8794b7-fefb-4344-9e69-730bcefd0240" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0eb1400b-65db-4b52-ac7f-e81d7f650bc2" xlink:to="loc_us-gaap_DeferredTaxLiabilities_7d8794b7-fefb-4344-9e69-730bcefd0240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_91654fc2-8a71-4045-a34c-a44a8c9f1382" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0eb1400b-65db-4b52-ac7f-e81d7f650bc2" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_91654fc2-8a71-4045-a34c-a44a8c9f1382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollforwardDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollforwardDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b97f7183-c644-402f-af95-af27086863ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_cf921009-6d8e-4923-b9b5-cbf9e95b74cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b97f7183-c644-402f-af95-af27086863ba" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_cf921009-6d8e-4923-b9b5-cbf9e95b74cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_40fb2ba2-5817-4450-80c3-673ba0b51627" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_cf921009-6d8e-4923-b9b5-cbf9e95b74cc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_40fb2ba2-5817-4450-80c3-673ba0b51627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_9d0f9e19-a24f-49a1-ab45-9d0785f2c2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_cf921009-6d8e-4923-b9b5-cbf9e95b74cc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_9d0f9e19-a24f-49a1-ab45-9d0785f2c2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_8f285c90-2060-4aee-9f96-8db53430b108" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_cf921009-6d8e-4923-b9b5-cbf9e95b74cc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_8f285c90-2060-4aee-9f96-8db53430b108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_f39be8c4-3eba-4358-97ed-2a18cc26e1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_cf921009-6d8e-4923-b9b5-cbf9e95b74cc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_f39be8c4-3eba-4358-97ed-2a18cc26e1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities_9e4605f4-79f7-4448-8879-d31e1f104eca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_cf921009-6d8e-4923-b9b5-cbf9e95b74cc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities_9e4605f4-79f7-4448-8879-d31e1f104eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_c9f4ca3c-1c3c-4438-8bab-678464d4e155" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_cf921009-6d8e-4923-b9b5-cbf9e95b74cc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_c9f4ca3c-1c3c-4438-8bab-678464d4e155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/CommitmentandContingenciesDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#CommitmentandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/CommitmentandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3ed37225-6ea0-4f91-bb9c-e347bb3db074" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_1ae989f4-e36c-4cce-9ed6-10fb6c9d3da3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3ed37225-6ea0-4f91-bb9c-e347bb3db074" xlink:to="loc_us-gaap_LossContingenciesTable_1ae989f4-e36c-4cce-9ed6-10fb6c9d3da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9987e75a-b47a-4ebc-b352-8d90a2df1a57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1ae989f4-e36c-4cce-9ed6-10fb6c9d3da3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9987e75a-b47a-4ebc-b352-8d90a2df1a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b0c16a72-b553-45b7-8385-bdb5a2387455" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9987e75a-b47a-4ebc-b352-8d90a2df1a57" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b0c16a72-b553-45b7-8385-bdb5a2387455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_a3a60df6-3081-49c9-8580-05d4083c1e6d" xlink:href="nvax-20231231.xsd#nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b0c16a72-b553-45b7-8385-bdb5a2387455" xlink:to="loc_nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember_a3a60df6-3081-49c9-8580-05d4083c1e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementMember_65c76021-9afb-4c9a-8a84-c278d4d4cc84" xlink:href="nvax-20231231.xsd#nvax_SettlementAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b0c16a72-b553-45b7-8385-bdb5a2387455" xlink:to="loc_nvax_SettlementAgreementMember_65c76021-9afb-4c9a-8a84-c278d4d4cc84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_b0aab848-f84b-4c37-ad5f-95e55e31fac9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1ae989f4-e36c-4cce-9ed6-10fb6c9d3da3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_b0aab848-f84b-4c37-ad5f-95e55e31fac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b0b258bc-134d-415a-abd6-8a67e342dcfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b0aab848-f84b-4c37-ad5f-95e55e31fac9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b0b258bc-134d-415a-abd6-8a67e342dcfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_f6852f24-f2bb-49d7-943f-5e0c03824b22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b0b258bc-134d-415a-abd6-8a67e342dcfe" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_f6852f24-f2bb-49d7-943f-5e0c03824b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_18e985c7-8768-45bc-94e0-145365a2fecb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1ae989f4-e36c-4cce-9ed6-10fb6c9d3da3" xlink:to="loc_srt_StatementScenarioAxis_18e985c7-8768-45bc-94e0-145365a2fecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_75864596-0656-491a-af4a-33ef14aee5f8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_18e985c7-8768-45bc-94e0-145365a2fecb" xlink:to="loc_srt_ScenarioUnspecifiedDomain_75864596-0656-491a-af4a-33ef14aee5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_2d83594b-e779-4552-8206-ffe230d57e37" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_75864596-0656-491a-af4a-33ef14aee5f8" xlink:to="loc_srt_ScenarioForecastMember_2d83594b-e779-4552-8206-ffe230d57e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8f6e25d8-7dfd-4527-ae42-2be59c652136" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1ae989f4-e36c-4cce-9ed6-10fb6c9d3da3" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8f6e25d8-7dfd-4527-ae42-2be59c652136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2f4fac06-3d3a-4af0-8300-08c3a6f197d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8f6e25d8-7dfd-4527-ae42-2be59c652136" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2f4fac06-3d3a-4af0-8300-08c3a6f197d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ef48e220-384c-488a-ad5d-fd295742829d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2f4fac06-3d3a-4af0-8300-08c3a6f197d2" xlink:to="loc_us-gaap_SubsequentEventMember_ef48e220-384c-488a-ad5d-fd295742829d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_554a2e34-c84d-4930-b8d6-4d0f301db549" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1ae989f4-e36c-4cce-9ed6-10fb6c9d3da3" xlink:to="loc_us-gaap_LossContingenciesLineItems_554a2e34-c84d-4930-b8d6-4d0f301db549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfDefendants_1582aa04-2f25-4ab3-9efa-23d0839576d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNumberOfDefendants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_554a2e34-c84d-4930-b8d6-4d0f301db549" xlink:to="loc_us-gaap_LossContingencyNumberOfDefendants_1582aa04-2f25-4ab3-9efa-23d0839576d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LossContingencyPeriodToAnswer_d8f47e4b-2540-4eec-943d-66186eda28e9" xlink:href="nvax-20231231.xsd#nvax_LossContingencyPeriodToAnswer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_554a2e34-c84d-4930-b8d6-4d0f301db549" xlink:to="loc_nvax_LossContingencyPeriodToAnswer_d8f47e4b-2540-4eec-943d-66186eda28e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfDosesToBeDistributed_726139e2-0a76-492d-88c7-2dd8c7d0a59f" xlink:href="nvax-20231231.xsd#nvax_NumberOfDosesToBeDistributed"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_554a2e34-c84d-4930-b8d6-4d0f301db549" xlink:to="loc_nvax_NumberOfDosesToBeDistributed_726139e2-0a76-492d-88c7-2dd8c7d0a59f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_PurchaseAgreementNumberOfVaccineDoses_5a4e9260-98d9-45a7-98a9-e568b5bc1e3c" xlink:href="nvax-20231231.xsd#nvax_PurchaseAgreementNumberOfVaccineDoses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_554a2e34-c84d-4930-b8d6-4d0f301db549" xlink:to="loc_nvax_PurchaseAgreementNumberOfVaccineDoses_5a4e9260-98d9-45a7-98a9-e568b5bc1e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_CollaborationAgreementRemainingPaymentAmount_4ae4c4b3-b589-4466-8be8-f8d61ac5c386" xlink:href="nvax-20231231.xsd#nvax_CollaborationAgreementRemainingPaymentAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_554a2e34-c84d-4930-b8d6-4d0f301db549" xlink:to="loc_nvax_CollaborationAgreementRemainingPaymentAmount_4ae4c4b3-b589-4466-8be8-f8d61ac5c386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ec4ea502-a2aa-4ef6-a50e-dd899234bb09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_554a2e34-c84d-4930-b8d6-4d0f301db549" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ec4ea502-a2aa-4ef6-a50e-dd899234bb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_40839979-9dfc-414b-9f9e-538e515d5291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_554a2e34-c84d-4930-b8d6-4d0f301db549" xlink:to="loc_us-gaap_LitigationSettlementExpense_40839979-9dfc-414b-9f9e-538e515d5291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_f8c23884-65bb-4b2f-93a4-0c10229dcd1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantsReceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_554a2e34-c84d-4930-b8d6-4d0f301db549" xlink:to="loc_us-gaap_GrantsReceivable_f8c23884-65bb-4b2f-93a4-0c10229dcd1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementPayment_7e72e364-9b67-460d-965b-081dc0876924" xlink:href="nvax-20231231.xsd#nvax_SettlementPayment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_554a2e34-c84d-4930-b8d6-4d0f301db549" xlink:to="loc_nvax_SettlementPayment_7e72e364-9b67-460d-965b-081dc0876924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfQuarterlyInstallmentPayments_6e850ff7-1de9-4457-aa8d-3a3d3451e130" xlink:href="nvax-20231231.xsd#nvax_NumberOfQuarterlyInstallmentPayments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_554a2e34-c84d-4930-b8d6-4d0f301db549" xlink:to="loc_nvax_NumberOfQuarterlyInstallmentPayments_6e850ff7-1de9-4457-aa8d-3a3d3451e130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_NumberOfSettlementPayments_ca426467-a3d5-414c-92f0-7cdccc955362" xlink:href="nvax-20231231.xsd#nvax_NumberOfSettlementPayments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_554a2e34-c84d-4930-b8d6-4d0f301db549" xlink:to="loc_nvax_NumberOfSettlementPayments_ca426467-a3d5-414c-92f0-7cdccc955362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_SettlementAgreementQuarterlyInstallmentAmount_31e227f6-752b-40bd-824c-04ff9094bfb9" xlink:href="nvax-20231231.xsd#nvax_SettlementAgreementQuarterlyInstallmentAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_554a2e34-c84d-4930-b8d6-4d0f301db549" xlink:to="loc_nvax_SettlementAgreementQuarterlyInstallmentAmount_31e227f6-752b-40bd-824c-04ff9094bfb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_0703b633-c3b8-47e4-946d-17b5c030378f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_554a2e34-c84d-4930-b8d6-4d0f301db549" xlink:to="loc_us-gaap_PurchaseObligation_0703b633-c3b8-47e4-946d-17b5c030378f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RestructuringScheduleofImpairmentChargesDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#RestructuringScheduleofImpairmentChargesDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/RestructuringScheduleofImpairmentChargesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_572649bc-aa11-480b-a89c-4a888d6bb44a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bc5b818c-8da0-4752-a2e7-063ceac4135d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_572649bc-aa11-480b-a89c-4a888d6bb44a" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bc5b818c-8da0-4752-a2e7-063ceac4135d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e21c8115-c35e-4414-b5c6-a82995bc56d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bc5b818c-8da0-4752-a2e7-063ceac4135d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e21c8115-c35e-4414-b5c6-a82995bc56d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ad976387-0b3a-4622-b6ba-931e678ed1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e21c8115-c35e-4414-b5c6-a82995bc56d1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ad976387-0b3a-4622-b6ba-931e678ed1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_07e20fab-bcb6-4a71-997d-eee3e960d0de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ad976387-0b3a-4622-b6ba-931e678ed1f5" xlink:to="loc_us-gaap_CostOfSalesMember_07e20fab-bcb6-4a71-997d-eee3e960d0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a8020c13-be9e-4e35-b4b9-2cf76da0c261" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ad976387-0b3a-4622-b6ba-931e678ed1f5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a8020c13-be9e-4e35-b4b9-2cf76da0c261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_159eb37e-2959-4703-9652-7f845eae2cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ad976387-0b3a-4622-b6ba-931e678ed1f5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_159eb37e-2959-4703-9652-7f845eae2cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_c8cec2b1-7fea-40ad-8c64-dde5f0e0eb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bc5b818c-8da0-4752-a2e7-063ceac4135d" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_c8cec2b1-7fea-40ad-8c64-dde5f0e0eb7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_16dab8e8-e155-4d15-92e9-c02ee92076ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c8cec2b1-7fea-40ad-8c64-dde5f0e0eb7a" xlink:to="loc_us-gaap_SeveranceCosts1_16dab8e8-e155-4d15-92e9-c02ee92076ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_68965667-cbee-4b7c-aa49-d57ad1815be4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c8cec2b1-7fea-40ad-8c64-dde5f0e0eb7a" xlink:to="loc_us-gaap_AssetImpairmentCharges_68965667-cbee-4b7c-aa49-d57ad1815be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_c73705af-00d7-4d02-950b-f1c0f31dca93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c8cec2b1-7fea-40ad-8c64-dde5f0e0eb7a" xlink:to="loc_us-gaap_RestructuringCharges_c73705af-00d7-4d02-950b-f1c0f31dca93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#RestructuringNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/RestructuringNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4d4819ac-db45-46ed-84b0-0799bcd07303" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c3ff20ca-36ba-4058-a12b-2e47119b875e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4d4819ac-db45-46ed-84b0-0799bcd07303" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c3ff20ca-36ba-4058-a12b-2e47119b875e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_4f035e36-8dbb-47a1-b67d-f4a250acc5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c3ff20ca-36ba-4058-a12b-2e47119b875e" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_4f035e36-8dbb-47a1-b67d-f4a250acc5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_e64f2491-af09-41e0-8769-cecbb5d7b3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_4f035e36-8dbb-47a1-b67d-f4a250acc5f0" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_e64f2491-af09-41e0-8769-cecbb5d7b3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_9220c1d3-89dd-4434-b331-db43d8d60948" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e64f2491-af09-41e0-8769-cecbb5d7b3a4" xlink:to="loc_us-gaap_EmployeeSeveranceMember_9220c1d3-89dd-4434-b331-db43d8d60948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseImpairmentChargeAxis_85725439-662a-4e03-9d3f-2bbc978340ad" xlink:href="nvax-20231231.xsd#nvax_LeaseImpairmentChargeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c3ff20ca-36ba-4058-a12b-2e47119b875e" xlink:to="loc_nvax_LeaseImpairmentChargeAxis_85725439-662a-4e03-9d3f-2bbc978340ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_LeaseImpairmentChargeDomain_8dad07b0-998c-45c0-8732-aedf5e3688b6" xlink:href="nvax-20231231.xsd#nvax_LeaseImpairmentChargeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_LeaseImpairmentChargeAxis_85725439-662a-4e03-9d3f-2bbc978340ad" xlink:to="loc_nvax_LeaseImpairmentChargeDomain_8dad07b0-998c-45c0-8732-aedf5e3688b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_ROUFacilityLeasesMember_1eac6580-05ad-4357-9fb4-412dac59f50c" xlink:href="nvax-20231231.xsd#nvax_ROUFacilityLeasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nvax_LeaseImpairmentChargeDomain_8dad07b0-998c-45c0-8732-aedf5e3688b6" xlink:to="loc_nvax_ROUFacilityLeasesMember_1eac6580-05ad-4357-9fb4-412dac59f50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_70da10e6-ab08-403d-a189-00a8282aadf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c3ff20ca-36ba-4058-a12b-2e47119b875e" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_70da10e6-ab08-403d-a189-00a8282aadf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_b15bf761-32fd-4b3a-b68c-eddf4011ade9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_70da10e6-ab08-403d-a189-00a8282aadf8" xlink:to="loc_us-gaap_SeveranceCosts1_b15bf761-32fd-4b3a-b68c-eddf4011ade9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_4162fda5-6fa4-4161-8086-88e66ad26e44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_70da10e6-ab08-403d-a189-00a8282aadf8" xlink:to="loc_us-gaap_AssetImpairmentCharges_4162fda5-6fa4-4161-8086-88e66ad26e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_fbe2a91c-f1ee-436d-9619-2089e9153cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_70da10e6-ab08-403d-a189-00a8282aadf8" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_fbe2a91c-f1ee-436d-9619-2089e9153cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.novavax.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="nvax-20231231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.novavax.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_8c848198-16a9-4197-a493-5e3d295b0e43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_5af27726-94b1-4a6c-a1f4-55f5008b8d71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_8c848198-16a9-4197-a493-5e3d295b0e43" xlink:to="loc_us-gaap_SubsequentEventTable_5af27726-94b1-4a6c-a1f4-55f5008b8d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3dc4cb21-ce41-43e6-802c-f37cd6f0aa28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5af27726-94b1-4a6c-a1f4-55f5008b8d71" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3dc4cb21-ce41-43e6-802c-f37cd6f0aa28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_34af4ccb-bc45-4c4e-8e7d-615a1edc78ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3dc4cb21-ce41-43e6-802c-f37cd6f0aa28" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_34af4ccb-bc45-4c4e-8e7d-615a1edc78ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_32d42d28-af7a-42ec-ae62-ff53c2c07f80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_34af4ccb-bc45-4c4e-8e7d-615a1edc78ae" xlink:to="loc_us-gaap_SubsequentEventMember_32d42d28-af7a-42ec-ae62-ff53c2c07f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_21a36f47-a828-4481-ae25-28214dbef9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5af27726-94b1-4a6c-a1f4-55f5008b8d71" xlink:to="loc_us-gaap_SubsequentEventLineItems_21a36f47-a828-4481-ae25-28214dbef9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_RestructuringAndRelatedCostNumberOfPositionsEliminatedGlobalPercent_a74af135-16c4-413a-8556-d910b42bef11" xlink:href="nvax-20231231.xsd#nvax_RestructuringAndRelatedCostNumberOfPositionsEliminatedGlobalPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_21a36f47-a828-4481-ae25-28214dbef9a0" xlink:to="loc_nvax_RestructuringAndRelatedCostNumberOfPositionsEliminatedGlobalPercent_a74af135-16c4-413a-8556-d910b42bef11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_dee3e4bb-77e7-49af-a35a-f73882d17b78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_21a36f47-a828-4481-ae25-28214dbef9a0" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_dee3e4bb-77e7-49af-a35a-f73882d17b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_nvax_FilipDubovskyMDMember" xlink:href="nvax-20231231.xsd#nvax_FilipDubovskyMDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_nvax_FilipDubovskyMDMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image.jpg
<TEXT>
begin 644 image.jpg
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M[Z!G;AM'G[Z?VET,1/VZGIA$0>$; B<^U>9D^H8(HS!VTK0Z?2SR,WN4[8P
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M$[<!1H 1<!P"3$R.JQ)6B!%@!)B8N VX!X& ET(E7U*X_ !1.'7[@V<Z8.%
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MZC(QI0][SID18 04"# Q*8#ARXP (Y ^!)B8TH<]Y\P(, (*!)B8%,#P94:
M$4@? DQ,Z<.><V8$& $% DQ,"F#X,B/ "*0/ 2:F]&'/.3,"C( " 28F!3!\
MF1%@!-*' !-3^K#GG!D!1D"! !.3 AB^S @P NE#@(DI?=ASSHP (Z! @(E)
M 0Q?9@08@?0AP,24/NPY9T: $5 @P,2D (8O,P*,0/H08&)*'_:<,R/ ""@0
M8&)2 ,.7&0%&('T(,#&E#WO.F1%@!!0(,#$I@.'+C  CD#X$_A_'E*.=:L)G
-@P    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image1a.jpg
<TEXT>
begin 644 image1a.jpg
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ME#FLN:0T(;#9%XKW8<KVT>]RDQ?EIJEXQV<+>Y-V&)=X/LBA2UV8G!S?M5A
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M.4LJ@LHNV5QRPHX2B?66_4ZGS4G@@UEB&,;3'3Q#3NBXLL;"->P<F8J@LN-
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M,^]T:83+=AUM0U5WU75\UATSM[+[1N2$1=ZJ%V/#Y(6Y[4F@Z>KY1<'/RTY
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M=1@U6YZ(AX<=T^;X]!36L6$:&SC@PZ/P&8,_EBI@2)HH-WZGBD 2\X<&G*F
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M,#EE$FTN*S4(A-6+D5-3 .?B! 28G)S0"BP#(\ ()"' Y)0$"5]@!!@!)R#
MY.2$5F 9& %&( D!)J<D2/@"(\ (. $!)B<GM ++P @P DD(,#DE0<(77(U
MR$^1XB\I6K:?*)J^_<9=C1$114,AJCY\,'9T:EV8G)S:,BR7902B_K,Q[W'A
MJ%FW]E&BJ/6OC%@NV(4)BL:/H-S?=:-#KXUTK/1,3HYM&A;,*@+A+<\U>9 +
M@HH4;[::3:N(7YHUE?;]OBL5S)[FV/HR.3FV:5@PJPC4?O*')'(*YRVWFDVK
MB1^J+"=*P=>,T@48DU.ZD.5\,XY .']%$CE%_249EX,+3 T"3$ZIP9%S<00"
M48H<6TC!9=TIF/U0@U'<$7*Q$'808'*R@QJG8008@;0CP.24=HBY ,<B@)F\
MX'F*UE4Z5L36+!B34VMN_59<]\C9;11<>7N3C2JTX6FBD,MW.XB$*;0OA\+'
M]WFB99F</-&,7 DK"$2K"II(2;@<Q([K!\ ]T4I6CHI;-?8IJGCT)[&_NO6+
M'26;'6&8G.R@QFE<C4!X]R@Y.2WO2E%_L3OK%HTV$1,("D3E]L#DY/869/DM
M(Q#:,%!-3N5'+.?GE 2!16\U$53XZUU.$<NV'$Q.MJ'CA&Y%('1XKIJ<](SC
MD1"%"W=2:/]*BIQRYMJ]2'DI16N\8>!G<G+K$\9RVT<@%*#@BCN3""IT<+HR
MSVCU6:J9<3L%QG>FP.NWD'_DS11\\VZ*!JN5:9IS(UKIH\K1_<G7]WKR3QE,
MT3J7&^MM@,'D9 ,T3N(!!$(U5+]O0LQALW9M'XJ<V:"N5#1"_G=[4G!REP9R
M&M- 3OY_=Z+JMWJITS7>"1_>18$Y(RGXWF@*YQTPC$_A$%4,Z-PT1(,-J7+(
M?<;I/!:#R<EC#<K523T"4=]Q"DZ[C8*3NE#@S<[D!SF]<C/5_+L3U0SI2-$J
MG[)0_\RA5-'WNH:_/M=119_K*+!PO#(^;H2+CL81DYB!\\IP3;?RFIM,3AHP
M^)01D"$0.;V;@E,;R6G<K>1_#>3T,ZH9WD!.D=)"63(*%QZFBGZ-Q 2" CDU
M3O5'SI^1IL'%2.GIIG@B/HZM;6C'Y*3L(GR#$6A (%ISCH)3?D[!B5TH '(:
M?0OY7[Y(3E07D$)5NWKN1:TI@9SJMZZ1IA$7J\8\&4=0@47ZVI9(YZ4CDY.7
M6I/KDC8$:K.'4."M+A1XHY&<7OH9U0SK1'6?O*,LLV[=XHODU#BD$YI0:/=Z
M9;K8C6B40OLV4W#5; H=VZL?UZ-WF9P\VK!<K10C$(U0W?KQ%!A[*_E?O86J
M7KF%ZC?-T]T/"3-NL:&<(*;&89VOS_44K?6G6$#O9<?DY+TVY1JE$X%P/5%$
M]L<   %C241!5$4#E401<]O_AO9O(5_?&YI(RO?8C>9F[-)9!Y?DS>3DDH9B
M,5V,0%TMA4]\1>'\@T2A>A=7)+.B,SEE%F\NC1%@!$PBP.1D$BB.Q@@P IE%
M@,DILWAS:8P (V 2 28GDT!Q-$: $<@L DQ.F<6;2V,$& &3"# YF02*HS$"
MC$!F$6!RRBS>7!HCP B81(#)R210'(T18 0RBP"34V;QYM(8 4; ) ),3B:!
MXFB, ".06028G#*+-Y?&"# ")A%@<C()%$=C!!B!S"+ Y)19O+DT1H 1,(D
MDY-)H#@:(\ (9!8!)J?,XLVE,0*,@$D$F)Q, L71& %&(+,(,#EE%F\NC1%@
M!$PBP.1D$BB.Q@@P IE%@,DILWAS:8P (V 2 28GDT!Q-$: $<@L DQ.F<6;
M2V,$& &3"# YF02*HS$"C$!F$6!RRBS>7!HCP B81(#)R210'(T18 0RB\#_
5 ZS$(PINCP 5     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>image_01a.jpg
<TEXT>
begin 644 image_01a.jpg
MB5!.1PT*&@H    -24A$4@  #XP    $" 8   #/VR--    "7!(67,  $SE
M  !,Y0%USO"5    :TE$051XG.W.L0D   @$L=]_:04WL!(A!^DO20H
M             (!WINL)                    ]J;K"0
M     /8D29(D29(D29(D29(D29(D29(D29(D25]KK;%U$J3 *)T     245.
%1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>image_02a.jpg
<TEXT>
begin 644 image_02a.jpg
MB5!.1PT*&@H    -24A$4@   8L   %2" 8    #T?-L    !F)+1T0 _P#_
M /^@O:>3    "7!(67,   [$   .Q &5*PX;   @ $E$051XG.R]:9!<UW7G
M^3_O9695UH(J+$0!(,"=$B62[;;<LMP1X^D9N=OA"$],1'^8=H?;X+X)8!5
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MK91Q_J82SM]4PLEG#]!?'NY>DWWKB7%Z:<K\;JAD;" )LCP.G1(KF_A#UM9
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MQR9XOXY6"NP9CK%G.$:+UY%3O(!3SQZ@OIA0BO*+PN&U:F]CD4O<8>PPI^H
M@;'[IN(87'M&*VA9'=K$X!(QH;B#)FZ_<KFXUW.>U;V3[+1B<HTMWIG<>?H=
M "(,]^CB<?&MD[QSP.;P<.O<[;LY$=FVA!2$X1)PU>9V^Y2/D91?*^_P-AZS
M,6%@9[5W7XN_>.0V&HP9@R5&ZHQ,1-E87D'7+Q'PYER*A<;Z-/A&*\7??-1
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M(GRX1(B=K.4E+[>$5KS8#77VX>,=)X]/=,[<Z\=.?B,CMGW2R[)Q1S,%%EM
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MQ6K+O#LML\^M2U]KOO#9YR:(.<OJL*),*]T\O,_+6DHP;+O^,)]93A')N$:
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MULD/0S#[O(E/<L66$IJI6[-N?21\?!HIQIG"6RGP9^\LX\_>60Y@&3@  "
M241!5"ZN;4YK=#:1M<;:<3X;]L?BH#+FC8C3XG]X;DT5;01V(P[Z9+5UVMVP
MI0]9WI)<O[NR\[%J&$!?O/9<Q;^VLP^+200OQ%I? ';BK,C#D((P6@;FZHR_
MGER;#:$S80-EK@C9HGZ"+:\"+'2AZ[]\9#\MU!/L'C#VE4S?%^?2R?BW3BX9
MB7#)2(1F*FQK*Q5A*Y4PL'U@[?\V'(Q3I-(70,0-R\R'I@V;"7#I2&E]>:#]
M?2>T]3B/&&?S=/>59@HTU^'282YQ>=TC'-_V/!GK+*<#)Y;-*\[94+)V1OAR
M=;+U8@(J,8$WT =D+>B3A:(HBE*(3A:*HBA*(3I9*(JB*(5T]+/PDF>7VO>/
M#X_3*V=:J,2AYD\^%KX(>F*UN3@"3M2 V?H*6FYN#3(S>QN%TS*=[2*+G+("
M)&11=U"OT3LAWHG/0KQW:]C/M>FB0_MWS#>>W]1#7=]_VOA:=+2'=(*!A!D[
M!B+L6*,6_A_>;0#,B"#\$IBM28@R_1U 1,!"R[QZX>J)8]Q,X75@YXL3O%P?
MV_%4.'Y68+'E[&;9N&<9QZS-3F98C]_.8MWZJP3Y3(2?C/01(D(I MZ99U3W
M%I=YY>U'>6RPA"1UW9$;"-;? M:?JAP#U2C!ZS-)3^=RY?C1-;1#YA]#8#12
MXVNP5GY\>)R&2EF\L3:;G/LL[1?>Q$H8O;:[N%HK,7+=) ?WH+P=4O8;Q+9<
M-1>;C N&8UP]?NR<W97TR4)1%$4I1"<+15$4I1"=+!1%491"1 [N3/IJ<UMP
MR^_E>NX5].RQ?G2(=V(_2)TPT 2!I82P^Z8.NJ#;U^J_0;YD7U_JK/7E^' )
M*(E\$(%_A;2E^(-G:\O/\9)F ,"EFR(TD\R6PIU.4L:QRC:"49S?/,]O[*FT
MK]4/E[T'GV,RN<EC)+ARW^KQ<SYW\!@W$OCV9*(LK;/0]9D(K90QUL\8JW93
M^XSJ-9/\VDP+I=B= -MQL[(8'!'02+OOY+>>'*>!.$7D[5O&!F+&I.@OYWMA
MMS,S!F/&MNN[U\)?GMI/"TU&+'T#@- ^TF&-?B-E7+FMA']RQV.KECE=2S%=
M2Q%'8?Z'T)@)K^>[OVLOKBU.4YXW9E.\,9NB',NMHHKBGM-,&)>,Q+AD).[:
MI^/D\0F2OE\,<>WD7\):4T\)=>[IU *J>Z>XD1 H=VU1<,\1=+*MV+]+$>'G
M<RW\?.[<Y;30)PM%412E$)TL%$51E$)TLE 415$*$3FX,_T^6*YM-7$IYZ_&
M6T^.4Z8'RF_$CZ66:[7(*%IE37U>1Y=U%AIM43Z+K'QTUN([:?.BS%XUV5Z9
M7DX01UF'9+%L:.6Z6OO+FMLB3UXW)6'/DGJX>V/@I[.$:E]EU<.^<KJ%B@L+
M!0;9\4%2)R8",2,BDZ=[J84>8PV9SJ1\A;,3"OT@!">/'^BICS^[K8)&FAW?
MV[SD2_@G$ @++4*3S=K[7LJ\S,6'6LVF)IJ@$A%>.M7$2Z=6#X"U8[B$$S5K
MAW'&2N]_8#K+_==,&9\>C='D>-5CKD1G7Q.V32@O5!,+J1P3!J+>@S7M&23K
M6F/'1SX6$]R[-0B):VLM/BHK,7+=%%=B^+0MX>W0WB_],.%<7=H_$UE;2@K\
M]MV/GQ-?"WVR4!1%40K1R4)1%$4I1"<+15$4I9!LLA!K>N6R7Y/C.A?61N8Q
M[L".*H7VA#R4%PG-IUI"..^&4+_UL7HZ+8_W>N+J]6G_H1/+,YM,VVZ<-08S
MHT(I1J[=N%R\:^%,@Q!Y_11"8^]07]N!J5W._R\OK^)?7MZ=H\(?WW\;=8J/
M%*P#S[<]C +?2%9NFJKP]_"VK%PO.U\$ALF%O6NH-PW\XEN/\ Z?WSCOCV++
MLO:<_->SS_66B^'MIP[03TXUC$T&@#&@"?\*L1GD$B^;/WOQ[0" 4\].T&MS
M*<IQA]^S;.!0_R893ZH#_].=1_FG9UK9<5>X[MS56XX)?]]C3"@ &*LR$I&7
MPU6=B(0]R[:7_?S2&5YSGO0\KSYV.PV6&6F:'QNV?%A[EF@WDS^"48E[N_Q_
MYWM/<S-EU!-KJW/7@+RL 7\9D+O&I4&/1>/XZIDX>?_AW29&KIOD7FU?:T6?
M+!1%491"=+)0%$51"M')0E$412FD8SX+\0; K4FVVX, 49UYZ\EQVMZ7!AIG
MMKO3!.&7,KM79-?T;[M>V 8Z'2/O ^'M*N+8'=@S'*$EZL_LLMB2D'B=-FAU
M9YL_HY%&:*3G;FZ]Z-8I'JN:W,ZFBI2U%<3GP/Y#B+!&\\T*7#92RM:>!X-
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M>+"\*T*G=I+[ 9AOI/CKPSWDEG#MX<T++@]USNA#!% 4Q/'R=0GN!Q36U\>
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M>#[]2"8Q[#MT-R=)8L,R$#8-]&-^J8Z$&7WE$@:K_3@U,X?^2AD#?17,+M;
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M?OA!.O*C^^F\D4W&7A!%J*UB*WG\H1_0 ]_Y)@' 0+6*[9M'4.KKPS7[#C
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M[8% 6%I:A-OMXO&]_6&C1>(P\[$<^;6B.WW@U.H:Y2S+&QL7 "D%)26TX/H
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M$[^&A90:<K8%I0B:$'BG-'T\^<&=6R*?S>+$0@F*" ("><>>NOR;^L-7.P(
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LXD=GW]#)\V4" $WU ,W\OVX.8XS](OX7+,2Z?/PF;38     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
MB5!.1PT*&@H    -24A$4@  #+(    +" 8   #15442    "7!(67,  $SE
M  !,Y0%USO"5    S$E$051XG.W.L0V  ! #L8S^F\,4D"(^R?WE[AX
M          #X6MH#                ;$A[                @ UI#P
M             + A[0$                VI#T               # AK0'
M                V)#V                 !O2'@               &!#
MV@,               !LB"1)DB1)DB1)DB1)DB1)DB1)DO1'+V93]9'.=V')
,     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>image_0b.jpg
<TEXT>
begin 644 image_0b.jpg
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MLB^]M<]Z$% LD7W9K?W6@X!BFNP+;NV]'@04H;(OM77.>A!0A,B^S-9YZT%
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HG$9 '40X<1H!=1"AQ&D$%%#6OP$OTS8IZ(MGC@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>image_1a.jpg
<TEXT>
begin 644 image_1a.jpg
MB5!.1PT*&@H    -24A$4@  $'(    $" 8   #\4*]J    "7!(67,  $SE
M  !,Y0%USO"5    ;4E$051XG.W.P0D   @#L>Z_M"Y1$"0'^5^2#
M               5YP,                     7YP/
M     'PA29(D29(D29(D29(D29(D29(D29(D29*D1@M9V2>*&S:G.P    !)
'14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>image_2a.jpg
<TEXT>
begin 644 image_2a.jpg
MB5!.1PT*&@H    -24A$4@  $$H    $" 8   "'=&VF    "7!(67,  $SE
M  !,Y0%USO"5    ;$E$051XG.W.L0D   S#L/S_=/M"ME*00;N39
M              ">.!\                     :)T/
M     +0D29(D29(D29(D29(D29(D29(D29(D29)^M!OBK_-XF=$K     $E%
&3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>nvax-20231231_g1.jpg
<TEXT>
begin 644 nvax-20231231_g1.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +U#;X# 2(  A$! Q$!_\0
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MO_QVC_AK:R_Y^/$?_?:__':^7:*/[,P_9_>'UFH?47_#6UE_S\>(_P#OM?\
MX[1_PUM9?\_'B/\ [[7_ ..U\NT4?V9A^S^\/K-0^HO^&MK+_GX\1_\ ?:__
M !VC_AK:R_Y^/$?_ 'VO_P =KY=HH_LS#]G]X?6:A]1?\-;67_/QXC_[[7_X
M[1_PUM9?\_'B/_OM?_CM?+M%']F8?L_O#ZS4/J+_ (:VLO\ GX\1_P#?:_\
MQVC_ (:VLO\ GX\1_P#?:_\ QVOEVBC^S,/V?WA]9J'U%_PUM9?\_'B/_OM?
M_CM'_#6UE_S\>(_^^U_^.U\NT4?V9A^S^\/K-0^HO^&MK+_GX\1_]]K_ /':
M/^&MK+_GX\1_]]K_ /':^7:*/[,P_9_>'UFH?47_  UM9?\ /QXC_P"^U_\
MCM'_  UM9?\ /QXC_P"^U_\ CM?+M%']F8?L_O#ZS4/J+_AK:R_Y^/$?_?:_
M_':/^&MK+_GX\1_]]K_\=KY=HH_LS#]G]X?6:A]1?\-;67_/QXC_ .^U_P#C
MM'_#6UE_S\>(_P#OM?\ X[7R[11_9F'[/[P^LU#ZB_X:VLO^?CQ'_P!]K_\
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MUE_S\>(_^^U_^.U\NT4?V9A^S^\/K-0^HO\ AK:R_P"?CQ'_ -]K_P#':/\
MAK:R_P"?CQ'_ -]K_P#':^7:*/[,P_9_>'UFH?47_#6UE_S\>(_^^U_^.T?\
M-;67_/QXC_[[7_X[7R[11_9F'[/[P^LU#ZB_X:VLO^?CQ'_WVO\ \=H_X:VL
MO^?CQ'_WVO\ \=KY=HH_LS#]G]X?6:A]1?\ #6UE_P _'B/_ +[7_P".T?\
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M/_OM?_CM?+M%']F8?L_O#ZS4/J+_ (:VLO\ GX\1_P#?:_\ QVC_ (:VLO\
MGX\1_P#?:_\ QVOEVBC^S,/V?WA]9J'U%_PUM9?\_'B/_OM?_CM'_#6UE_S\
M>(_^^U_^.U\NT4?V9A^S^\/K-0^HO^&MK+_GX\1_]]K_ /':/^&MK+_GX\1_
M]]K_ /':^7:*/[,P_9_>'UFH?47_  UM9?\ /QXC_P"^U_\ CM'_  UM9?\
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M_?:__':^7:*/[,P_9_>'UFH?47_#6UE_S\>(_P#OM?\ X[1_PUM9?\_'B/\
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MM?\ X[7R[11_9F'[/[P^LU#ZB_X:VLO^?CQ'_P!]K_\ ':/^&MK+_GX\1_\
M?:__ !VOEVBC^S,/V?WA]9J'U%_PUM9?\_'B/_OM?_CM'_#6UE_S\>(_^^U_
M^.U\NT4?V9A^S^\/K-0^HO\ AK:R_P"?CQ'_ -]K_P#':/\ AK:R_P"?CQ'_
M -]K_P#':^7:*/[,P_9_>'UFH?47_#6UE_S\>(_^^U_^.T?\-;67_/QXC_[[
M7_X[7R[11_9F'[/[P^LU#ZB_X:VLO^?CQ'_WVO\ \=H_X:VLO^?CQ'_WVO\
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M[7R[11_9F'[/[P^LU#ZB_P"&MK+_ )^/$?\ WVO_ ,=H_P"&MK+_ )^/$?\
MWVO_ ,=KY=HH_LS#]G]X?6:A]1?\-;67_/QXC_[[7_X[1_PUM9?\_'B/_OM?
M_CM?+M%']F8?L_O#ZS4/J+_AK:R_Y^/$?_?:_P#QVC_AK:R_Y^/$?_?:_P#Q
MVOEVBC^S,/V?WA]9J'U%_P -;67_ #\>(_\ OM?_ ([1_P -;67_ #\>(_\
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M=KY=HH_LS#]G]X?6:A]1?\-;67_/QXC_ .^U_P#CM'_#6UE_S\>(_P#OM?\
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MM?+M%']F8?L_O#ZS4/J+_AK:R_Y^/$?_ 'VO_P =H_X:VLO^?CQ'_P!]K_\
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M']F8?L_O#ZS4/J+_ (:VLO\ GX\1_P#?:_\ QVC_ (:VLO\ GX\1_P#?:_\
MQVOEVBC^S,/V?WA]9J'U%_PUM9?\_'B/_OM?_CM'_#6UE_S\>(_^^U_^.U\N
MT4?V9A^S^\/K-0^HO^&MK+_GX\1_]]K_ /':/^&MK+_GX\1_]]K_ /':^7:*
M/[,P_9_>'UFH?47_  UM9?\ /QXC_P"^U_\ CM'_  UM9?\ /QXC_P"^U_\
MCM?+M%']F8?L_O#ZS4/J+_AK:R_Y^/$?_?:__':/^&MK+_GX\1_]]K_\=KY=
MHH_LS#]G]X?6:A]1?\-;67_/QXC_ .^U_P#CM'_#6UE_S\>(_P#OM?\ X[7R
M[11_9F'[/[P^LU#ZB_X:VLO^?CQ'_P!]K_\ ':/^&MK+_GX\1_\ ?:__ !VO
MEVBC^S,/V?WA]9J'U%_PUM9?\_'B/_OM?_CM'_#6UE_S\>(_^^U_^.U\NT4?
MV9A^S^\/K-0^HO\ AK:R_P"?CQ'_ -]K_P#':/\ AK:R_P"?CQ'_ -]K_P#'
M:^7:*/[,P_9_>'UFH?47_#6UE_S\>(_^^U_^.T?\-;67_/QXC_[[7_X[7R[1
M1_9F'[/[P^LU#ZB_X:VLO^?CQ'_WVO\ \=H_X:VLO^?CQ'_WVO\ \=KY=HH_
MLS#]G]X?6:A]1?\ #6UE_P _'B/_ +[7_P".T?\ #6UE_P _'B/_ +[7_P".
MU\NT4?V9A^S^\/K-0^HO^&MK+_GX\1_]]K_\=H_X:VLO^?CQ'_WVO_QVOEVB
MC^S,/V?WA]9J'U%_PUM9?\_'B/\ [[7_ ..T?\-;67_/QXC_ .^U_P#CM?+M
M%']F8?L_O#ZS4/J+_AK:R_Y^/$?_ 'VO_P =H_X:VLO^?CQ'_P!]K_\ ':^7
M:*/[,P_9_>'UFH?47_#6UE_S\>(_^^U_^.T?\-;67_/QXC_[[7_X[7R[11_9
MF'[/[P^LU#ZB_P"&MK+_ )^/$?\ WVO_ ,=H_P"&MK+_ )^/$?\ WVO_ ,=K
MY=HH_LS#]G]X?6:A]1?\-;67_/QXC_[[7_X[1_PUM9?\_'B/_OM?_CM?+M%'
M]F8?L_O#ZS4/J+_AK:R_Y^/$?_?:_P#QVC_AK:R_Y^/$?_?:_P#QVOEVBC^S
M,/V?WA]9J'U%_P -;67_ #\>(_\ OM?_ ([1_P -;67_ #\>(_\ OM?_ ([7
MR[11_9F'[/[P^LU#ZB_X:VLO^?CQ'_WVO_QVC_AK:R_Y^/$?_?:__':^7:*/
M[,P_9_>'UFH?47_#6UE_S\>(_P#OM?\ X[1_PUM9?\_'B/\ [[7_ ..U\NT4
M?V9A^S^\/K-0^HO^&MK+_GX\1_\ ?:__ !VC_AK:R_Y^/$?_ 'VO_P =KY=H
MH_LS#]G]X?6:A]1?\-;67_/QXC_[[7_X[1_PUM9?\_'B/_OM?_CM?+M%']F8
M?L_O#ZS4/J+_ (:VLO\ GX\1_P#?:_\ QVC_ (:VLO\ GX\1_P#?:_\ QVOE
MVBC^S,/V?WA]9J'U%_PUM9?\_'B/_OM?_CM'_#6UE_S\>(_^^U_^.U\NT4?V
M9A^S^\/K-0^HO^&MK+_GX\1_]]K_ /':/^&MK+_GX\1_]]K_ /':^7:*/[,P
M_9_>'UFH?47_  UM9?\ /QXC_P"^U_\ CM'_  UM9?\ /QXC_P"^U_\ CM?+
MM%']F8?L_O#ZS4/J+_AK:R_Y^/$?_?:__':/^&MK+_GX\1_]]K_\=KY=HH_L
MS#]G]X?6:A]1?\-;67_/QXC_ .^U_P#CM'_#6UE_S\>(_P#OM?\ X[7R[11_
M9F'[/[P^LU#ZB_X:VLO^?CQ'_P!]K_\ ':/^&MK+_GX\1_\ ?:__ !VOEVBC
M^S,/V?WA]9J'U%_PUM9?\_'B/_OM?_CM'_#6UE_S\>(_^^U_^.U\NT4?V9A^
MS^\/K-0^HO\ AK:R_P"?CQ'_ -]K_P#':/\ AK:R_P"?CQ'_ -]K_P#':^7:
M*/[,P_9_>'UFH?47_#6UE_S\>(_^^U_^.T?\-;67_/QXC_[[7_X[7R[11_9F
M'[/[P^LU#ZB_X:VLO^?CQ'_WVO\ \=H_X:VLO^?CQ'_WVO\ \=KY=HH_LS#]
MG]X?6:A]1?\ #6UE_P _'B/_ +[7_P".T?\ #6UE_P _'B/_ +[7_P".U\NT
M4?V9A^S^\/K-0^HO^&MK+_GX\1_]]K_\=H_X:VLO^?CQ'_WVO_QVOEVBC^S,
M/V?WA]9J'U%_PUM9?\_'B/\ [[7_ ..T?\-;67_/QXC_ .^U_P#CM?+M%']F
M8?L_O#ZS4/J+_AK:R_Y^/$?_ 'VO_P =H_X:VLO^?CQ'_P!]K_\ ':^7:*/[
M,P_9_>'UFH?47_#6UE_S\>(_^^U_^.T?\-;67_/QXC_[[7_X[7R[11_9F'[/
M[P^LU#ZB_P"&MK+_ )^/$?\ WVO_ ,=H_P"&MK+_ )^/$?\ WVO_ ,=KY=HH
M_LS#]G]X?6:A]1?\-;67_/QXC_[[7_X[1_PUM9?\_'B/_OM?_CM?+M%']F8?
ML_O#ZS4/J+_AK:R_Y^/$?_?:_P#QVC_AK:R_Y^/$?_?:_P#QVOEVBC^S,/V?
MWA]9J'U%_P -;67_ #\>(_\ OM?_ ([1_P -;67_ #\>(_\ OM?_ ([7R[11
M_9F'[/[P^LU#ZB_X:VLO^?CQ'_WVO_QVC_AK:R_Y^/$?_?:__':^7:*/[,P_
M9_>'UFH?47_#6UE_S\>(_P#OM?\ X[1_PUM9?\_'B/\ [[7_ ..U\NT4?V9A
M^S^\/K-0^HO^&MK+_GX\1_\ ?:__ !VC_AK:R_Y^/$?_ 'VO_P =KY=HH_LS
M#]G]X?6:A]1?\-;67_/QXC_[[7_X[1_PUM9?\_'B/_OM?_CM?+M%']F8?L_O
M#ZS4/J+_ (:VLO\ GX\1_P#?:_\ QVC_ (:VLO\ GX\1_P#?:_\ QVOEVBC^
MS,/V?WA]9J'U%_PUM9?\_'B/_OM?_CM'_#6UE_S\>(_^^U_^.U\NT4?V9A^S
M^\/K-0^HO^&MK+_GX\1_]]K_ /':/^&MK+_GX\1_]]K_ /':^7:*/[,P_9_>
M'UFH?47_  UM9?\ /QXC_P"^U_\ CM'_  UM9?\ /QXC_P"^U_\ CM?+M%']
MF8?L_O#ZS4/J+_AK:R_Y^/$?_?:__':/^&MK+_GX\1_]]K_\=KY=HH_LS#]G
M]X?6:A]1?\-;67_/QXC_ .^U_P#CM'_#6UE_S\>(_P#OM?\ X[7R[11_9F'[
M/[P^LU#ZB_X:VLO^?CQ'_P!]K_\ ':/^&MK+_GX\1_\ ?:__ !VOEVBC^S,/
MV?WA]9J'U%_PUM9?\_'B/_OM?_CM'_#6UE_S\>(_^^U_^.U\NT4?V9A^S^\/
MK-0^HO\ AK:R_P"?CQ'_ -]K_P#':/\ AK:R_P"?CQ'_ -]K_P#':^7:*/[,
MP_9_>'UFH?47_#6UE_S\>(_^^U_^.T?\-;67_/QXC_[[7_X[7R[11_9F'[/[
MP^LU#ZB_X:VLO^?CQ'_WVO\ \=H_X:VLO^?CQ'_WVO\ \=KY=HH_LS#]G]X?
M6:A]1?\ #6UE_P _'B/_ +[7_P".T?\ #6UE_P _'B/_ +[7_P".U\NT4?V9
MA^S^\/K-0^HO^&MK+_GX\1_]]K_\=H_X:VLO^?CQ'_WVO_QVOEVBC^S,/V?W
MA]9J'U%_PUM9?\_'B/\ [[7_ ..T?\-;67_/QXC_ .^U_P#CM?+M%']F8?L_
MO#ZS4/J+_AK:R_Y^/$?_ 'VO_P =H_X:VLO^?CQ'_P!]K_\ ':^7:*/[,P_9
M_>'UFH?47_#6UE_S\>(_^^U_^.T?\-;67_/QXC_[[7_X[7R[11_9F'[/[P^L
MU#ZB_P"&MK+_ )^/$?\ WVO_ ,=H_P"&MK+_ )^/$?\ WVO_ ,=KY=HH_LS#
M]G]X?6:A]1?\-;67_/QXC_[[7_X[1_PUM9?\_'B/_OM?_CM?+M%']F8?L_O#
MZS4/J+_AK:R_Y^/$?_?:_P#QVC_AK:R_Y^/$?_?:_P#QVOEVBC^S,/V?WA]9
MJ'U%_P -;67_ #\>(_\ OM?_ ([1_P -;67_ #\>(_\ OM?_ ([7R[11_9F'
M[/[P^LU#ZB_X:VLO^?CQ'_WVO_QVC_AK:R_Y^/$?_?:__':^7:*/[,P_9_>'
MUFH?47_#6UE_S\>(_P#OM?\ X[7Z _L ?$A/B?\ !K5]3C>\=+?7IK0&^.9.
M+>W?^\W'[SUK\7*_67_@DS_R;GXC_P"QKN?_ $CLZX,;@J-"CSPW-Z-:<YV9
M^</[2G_)QGQ4_P"QKU7_ -+):\XKT?\ :4_Y.,^*G_8UZK_Z62UYQ7T%/X(^
MAP2^)A117U7\*O\ @G#\2OB]\/=$\8Z-KGA2VTS5H3/!%?7=RDRJ&*X8+;LH
M.5/1C14J1I1YYNR)C[TN1;_U_F?*E%?:-Q_P2>^,$,99-<\&SL/X([^Z!/\
MWU; ?K7@7QB_9?\ B7\!U2;QCX8N+'3I'\N/4[=UN+5SG@>9&2%)[*^UCSQQ
M6,,50F^6,U<U=*HE>QY715C3["XU6_MK*TB:>ZN95AAB7J[L0%4>Y)%?:OC[
M_@EKXK\$_"6^\51>+K+5==T^R-[=Z%%9,B!47=(L<Y<[V !QF-=V.U76KT\.
ME*J[)DTX2JRY(*[/B*BBBMR HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/3&,"OERL*->GB$Y4W=+0TG3E3LI+<****W,PHHHH **** "BOI;]D']C/\
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MMQOQ]X],^U8>WINJZ%_>2O;RT_S12BW#VBVO;\_\F>>T445N2%%%% !1110
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ML)(4&,*>A)SCBO *FG5A67-3=T5*,H:204445J0%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%>R?LX_LL>+/VG[[7+7PMJ&C6$FCQQ2SG6)I8PPD+!=GEQ/D_(<YQVKW%O\
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M%%%%;&84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]BI+_P"B*\VKB'4P5.52*D[M:WZ:=+;V5SJ5/DQ?N:75]/E^3O;MT/Q1\#^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_:VAW+R1Q77]I6<.YD8JPVR3*PPP(Y%?<'_!7/\ Y)?X$_[#,O\ Z(->I_\
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MGSEIG['7Q?UCX<KX\L_"/G>%&L'U,:A_:5FO^C*I9G\LS!^%4G&W/'2H+_\
M9&^+ND_#J;QU?>"KNQ\,0V_VN2[NKB"*1(O[YA:02@?\ [U^N?[(%O%>?LI_
M#B"XC2:"70XDDCD *LI!!!!Z@BOAS]M#]OZP^+/A+Q5\,_#>A3VVGG48X#KD
MEV&%Y##(6;$07Y SHA!W'*]0"<5Z7US$2KSH4XIV?W*]KO77^OEPTJ5.5"%:
M;M=:^K5TE^/X;=?AK2]+O=;U"WL-.M)[^^N'$<-K:Q-)+*YZ*JJ"6)]!7O&E
M?L!_'W6-/BO+?X=W,<,JAU6ZU"SMY #ZQR3*ZGV(!K[U_P""=?[-NC_#'X2Z
M;X_U&R2X\7>([;[6MRZ;WM;-N8HXN,C>N';')W ?PBM+QS^VUXTT;7I;3PO^
MSE\1/$FFQN4.H7FFW5CYF#C<D?V:0E2.1NVGU K3$8Z:JNC0BFUO?;]/S(I4
M5*'M)Z)['Y5_$SX*^.O@[?):>,_"^HZ \AVQ2W,68)3C)$<JY1R!UVL<5Q5?
MNSX7US1/VK/ACJVD^+_A[XA\/6LZ^1>:-XLTJ2T<$C*R0.P ;!Y#J0RD D+Q
MG\D_$/[,>K:;^U1)\&K2=I+F35EM+>]D7/\ HK@2+.PXSB$[B!W!%:83&2K5
M'1JJTEKY6_IA5I1C3]K!^[U/-O OPW\5?$[5_P"R_"?A_4?$-]P6BT^W:7RP
M3@,Y PBY_B8@>]>RM_P3V_:!2W,Q^'LFS&<#5;$M_P!\B?/Z5^HMY=?"_P#8
M9^"*R&%=(T&SVQA8$#WFI71'X>9*VTG)(  _A5>/FBV_X*\^'G\1"&X^'&I1
M:%OP;Z/4XWN=OKY!C"Y]O-_&L/KM>O)_5872ZO\ X=%*C&$5*L[7Z'YP^+O!
M>O> =:ET?Q)HU]H6J1<O::A;M#)CLV& R#C@C@]J_2#_ ()#_P#(D_$7_L(6
MG_HMZ9^W)^TI\ ?BM\%;>T2[_P"$I\3W=N+K17TN,"XTV1AUG=A^[4D;7B.6
M/'RCA@__ ()#_P#(D_$7_L(6G_HMZJI6G6P-9U(<K5O_ $I&-2G"&(H.$KIM
M_P#I,CRSXV>*/&?A'_@IE>WW@'3XM7\3M-:PV^FW$JQ1W:M8QAXF9F4*"N[D
MD8(![5N?\%!OBI\:O$7PPT?3_&'PRA^''A.XU%%ED77;;4Y+RX5':-,Q$%$
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MC1_VIOAOJ^D>+_ASXB\.6\RB"^T7Q;I,EMNW#(>&1E ?!'#+AE(!PORD^?\
M7\3%>TE!<OX_G^AT^PI<W(Y._P#7];GX345Z/^T1\(9O@5\9/$O@R25[B#3[
MC-I<2#YI;=U#Q,<<9VL <<9!KSBO=IU(U8*I'9ZG'4A*G)PENCZ@_88_:.^'
MW[-/B'Q+KWB_1]:U/5KVWBM-/DTFVAE\B+<S39,DR8+$1= ?NFO2?CQ_P5%\
M7^(_%%DOPH\WPQX?MU5G.J6%O-=W<G\2N"9%1.@ 0[NIW<X'PM7Z3_\ !+6[
M^'5KX'U<ZU-X7A\<-K;BQ^WM;+J1A\B' BW?O-F[?]WC.[WKCQ5&E=XF<>9Q
M2T_#;YW*I3E']W%VYNO]>EC[ :ZE^(O[,TEUX_TN/2YM6\,M-K-C*I1;=FMR
MT@PV2F#DX/*X]17X,5^UO[<OP]^)_P 2/@YJ6E_#W5+6*V,3-J>DB!A=ZA"!
MDQ13;L 'O'M!;&-^"5;\4W5HV964JRG!5A@@^E>?E5I3JU%I>VG;?_/\#LQ*
M<:5.+UM?7[OQT$HHHKZ \T**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** .S^#/PWN_B]\5/#'@ZSW+)JUZD#R(
M,F*+.Z63_@*!F_"OWNMYM$\%6>@:$DMOIL,FW3=,M20N\QPLPC0=R(XF./13
M7YQ?\$F_A"-2\3>)_B1>P[H=-C_LG3V8?\MI 'F8>ZIL7Z2FC_@H?^TO?^'_
M -I+P5IGA^Y)_P"$#EBU.:-6*K)>2%7*-CJ/)"+])7%>'CKXG$4\)%^;\K]_
M16^;L=6'7+"I7MMHO/\ X=[^A7_X*P?"#^Q_&GASXC64&VVU>'^S-0=5  N(
MAF)B>Y:/</I"*^ Z_<']HCP5I_[4G[*VI#1PMX^I:9'K6C28R?.5!+$!Z%AF
M,_[YK\/V4JQ!&"."#5974?)*A/>#_!_\&Z-<4E)1K1VDOR_X%OQ/<M%_8B^-
M7B#P9:>+-/\ !?VCP_=60U&&\_M6R7=;E-X?89@P^7G!&?:O#*_<SX-?\F9^
M%/\ L2H?_2,5^&==&'Q4ZV)K49)6A:WWR6OW&,Z:C1IU%O+_ "7^9[E>_L1_
M&G3_  3+XNN/!GE^'HK ZH]Y_:MD<6PC\S?L$V_[G.,9]LU[_P#\$PO@GXTM
M_B;8_$J31MO@JXT^\LX]4^U0G=*&5=OE;_,'*L,E<<=:^V/&G_)D^K?]B$__
M *05\O\ _!,G]IC[9:Z3\%_^$;V?9(+W4?[<^W9W9EW[/(\OC[^,[^W2N66)
MK58UX12]VZ^6M^O9$QIP=&A6F_B:OZ^ZU^+.L_X*7_L_^/?C,W@K4?!V@_VQ
M9Z';:A)J$GVRW@\A6\EE.)9%+<1O]T'I[BNZ_P""97_)J.C_ /82O?\ T::L
M?MO_ +6O_#-VF:1H_P#PBO\ PD7_  E%G>Q>=_:/V7[-L6-,[?*??GSL]5^[
M[\5_^"97_)J.C_\ 82O?_1IKRZ<JOU&46O<6S[OF?-]WI]YV5E'ZQ3=_>OKZ
M<NA^>GBC]G+XD_&[XZ?$V3P5X1OM:MH?$NI*]YE(+8,+J3*^=*RH6Y'R[L\]
M*XGXK?LS_$[X(VD%WXT\(7NCV,S;%O%>.YMPW96EA9T5CV!()P<=*_2;]H#_
M (*)>$?V>_'DW@G1?"4GB6[L9/\ B9-;726<%M(_SLJ?NW\R3YB6X49/WLYQ
M]$>&]=\+?M)_!FVU%;4WOA?Q1I[![6\0!PC JZ. 2 RL",@\%<@]#78L;B*-
M"%14_<T7KI^%^F@G2IRJN$Y>\[OT_P [?U8_ .N]^%_P&^(/QHN)(O!?A34-
M=2,[9+F)!';QM@':TSE8U;!'!;-=M^SY^SB?C#^TDOP\FN9$TNPN[@ZE=18#
M_9H'*L5]"YVJ#V+YP<5^J7QD^.'PY_8J^&ND6K::+:V(:VTCP_I,:J\VW!9N
M2 %!8%G.3EOXB>?2Q&-C3C#V:YI3U7IW_K\#EA1E*<HO11W/RR\3_L*_';PC
MI4NHZA\.[^2VB&6&GW-O?2 >OEP2.Y_ 5X3+$\,CQR(T<B$JR,,%2.H(]:_5
MKX._\%3O"'Q \86>@^)_"UUX,6^F6WMM0%\MY;AV.%\X^7&8P3@9 8#/.!DU
MD_\ !3+]F'1]8\#7/Q7T&QCLO$&F/&-7^SI@7UNS!!(P'61"5^;J5SG.U<<\
M<97HU(QQ4+*6S7_#OY]C94:=5-4G=KI_7X=SX@\(_L<_%_QUX#M_&FA^$?MW
MAJ>"2YCOO[3LX]T:%@[;'F#C!5N"N>*K1?LC_%R3X<3>/#X*NH/"L-HU\][<
MW$$+"W5=QD\IY!(5V\@A>1R,U^K7[!\$=U^R'X!AF198I+2X1T<9#*;B4$$>
MF*^3OVTOV_;#QAX?\=_"?PWH5Q;PBY73FUXW0 F6*4><JQ!>%)3:#N.5)X%*
MIC,1]:J8>E%.SLO1.S;U]-O/?I%&E"=&%:H[)K7Y]OQ_#8])^"/QL_:4_P"&
M==!CTGX.V7B(+I2II7B>7Q%:0(T"IMBDEM6?>S  9^9-V.@K\_OAA\!_B5^T
MEJ&OWO@_1&\27=I*L^I2M>V]N5>8N0Q\V1,[BC_=SC'..*_7S]DW_DT;P!_V
M+Z_^@M7YA?L?_MA?\,HGQ4?^$2_X2G^W?LO_ #$OL?D>3YO_ $QDW9\WVQM[
MYX5&3=?%.G%<\;6\_>=[Z]E?2VHE_NU&[T?^2_S\Q?\ AW;^T)_T3_\ \K6G
M_P#R16'XV_8C^-'PX\*ZEXD\2>#X]*T33HO-N;N76+!@BY 'RK.68DD * 22
M0 ":_5#]DW]I35_VG?#&J^(KCP/_ ,(CHUM<"UM+AM3-V;R0#,FT>3'A5RHW
M9.22/X37Q_\ \%2OVBO[:UVS^$VBW.;/362]UIXVXDN",Q0'U"*=Y'JR]UJ(
MXS%^W6'E%)]?)=]^WXZ&T:-&4'43=E_7;N? =C8W.J7L%G9V\MW=W#K%#;P(
M7DD<G 55'))/  KWC1/V"/CWX@TV&_M?AW=QP2J'5;V]M+64 ^L<LJNI]B :
M^X?^":_[-.D>"_AG8_$S5K)+GQ3KR-)9R3(&-E:9*KY?HT@!8L.2K*/7/8_$
M;]M+QCX=\03V'A/]GCXA^*[*"1HVU&XTRZL8Y<'&Z)?L\C,I[%MI]JWQ&-G&
MJZ%!)M;WV_0PHT>>'M9NT>A^5/Q.^!7C_P"#-PD7C3PIJ.@K(VR.XFC#V\C8
M)VI,A,;' / 8FN$K]V/ ?C/2_P!J#X?ZQH_B_P"&WB+PU#(BP7VB^+M)DMUD
M##(>&1E < CAAAU*@X7Y2?R?^(G[+M_X5_:N'P@L9I9([[5((+"]E3+?99L,
MLK 8R40G=C&3&W2M,+C)5:KH5E:7X#K4HQI^V@]%OY?U_EW/._AE\&?&_P 9
M-4DL/!?AF_\ $$\>/->VCQ##D$CS)6(1,X.-S#..*[WQI^Q'\;_ .AS:OK'P
M_OEL(1NEDL;BWO61>[%()'8*.YQ@=Z_6K5=4^'7[%OP.21XAI'AG2$6*.&V0
M-<7L[= !QOE<@DDD=R2 ,CYBT'_@KGX7O/$PM=6\ :GIF@L^U=2@OTN)PN>&
M:#8H'J0)&/IFN?Z]7KR?U:%XKO\ \.ON+5&-.*E6=K]OZ9]&_LF_\FC> /\
ML7U_]!:OPTK^AG1]2T;6O <6I>'7MY=$O;(W5I):*%B>.12X90!QG=G\:_GF
MK/+I.>)Q$VK7MIVUD%6*AAZ44[VZ_*(4445] <04444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ]QX=NI9;G3+12\LL,JJ#(B#EV0H.!SAF/:ORX\"_"OQ;\2O%$?AWPUX?O\
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MMDG(XX'1!D DDEC@CRGX _'KQ)^SM\0;;Q3X==)3M\B\L)R?)O("06C?'3D
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M&*_7#]F/PK??"/\ 9<\(Z7KT/]FW^FZ2]S>12GF!F+RLK>A4-@CL0:XW3O\
M@H]\ ;VQBGF\97&GRNH9K6XT>\,B'^Z2D3+GZ,1[U\Q?MB?\%'-+^('@W4?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUS:OYRVDC=(9\?ZM^G^R<X#$@@?:_P#P2'_Y$GXB_P#80M/_ $6]>4?M>?\
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M5+]8W;\O^"=6%C2HU6W+5I>EM?Q_X!+_ ,$C?^26^.O^PS'_ .B%KX\_;_\
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M445ZYQA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@N8_X@7;S5;Z%7QG_9/I7@G[9_\ P4,\/_$3P'J'@#X:Q74]AJ2B'4-;N83
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M4JCFKK9?/9:_,\,HHHKVCSPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#]=/\ @E9_R;3>_P#8
M?NO_ $7#7YW_ +8W_)T7Q+_[#,W]*^L_V ?VLOA3\$_@?<^'_&GBK^QM7?5Y
M[I;?^SKN?,;)$%;=%$R\E6XSGBOC/]I3QAI'Q ^/7CCQ'H%W]OT;4M3DN+6Y
M\IX_,C.,':X##Z$ UX\:<_[3E4L^7EWZ?9.NG)+!<C>O-M\Y'FE?HY_P1_\
MO?%7Z:9_[=5^<=?:O_!-_P#:(^'OP$;X@?\ "=^(/["_M3[#]C_T*XN/-\O[
M1O\ ]3&^,>8G7&<\=Z]#%)RPM6*U;2_]*B<]/2<6^YS/_!3B>2;]JO4U=MRQ
M:99H@]!L)Q^9/YU]&_\ !(B=V\!_$.$M^[74K9U7'0F)@3_XZ/RKY#_;F^*7
MACXQ?M!:EXE\(:G_ &OHDUE:Q)=?9Y8,LD>&&V55;@^U>U_\$Y?VEOAO\!_"
M_C2T\=>(_P"P[C4;RWEM4^PW-QYBJCACF&-P,$CKBO,A3FLL=-Q]ZVW7XD;X
MB2>,IRB]+_\ MC_7\2/XQ^*++P9_P5*L]7U%ECLH=7TU)9'.%C62UBCWD]@N
M_/X5];_\%"_@OXB^-7P$%IX7MY-0U71]1CU0:?#]^ZC6.1'5!_$P$FX#J=N!
MDD"OS-_;,^(WA[XK_M&>*O%'A74/[4T*]%M]GN_)DAW[+>-&^2158892.0.E
M?57[*_\ P4VLM!\.V/A;XLQWDALT6"V\2VL9G+1@8 N4'S%@ !O0,6R,KG+'
M&>&JRPM"<%[T$M/N_P CHE5A#%3D]8R27X?\'Y'P3I'P]\4:]XH'AK3O#VJ7
MGB#?Y9TR*TD-PK9P0R8RN.^<8[U^X/[-'PUU/X0_L[>%/">LN&U:PL'-TJOO
M$<DC/(T8.<$*7VY''R\5YIXF_P""E?P)T/1YKO3_ !%?>(KM!\EA8:5<QRN?
M3=.D:#\6_.J'@K_@I)\'/$'@>SO/$WB1?#FOW,4AN-)33[ZX%L2S!4\U("KG
M;MRPXR3TZ5CC*N*Q6'=/V32Z[W;L[6\M^_05&%*G64W/^M-_Z[GY6?#8^,!\
M5M(_X0'[;_PF/V__ (EO]G_Z[S<GIGC;C.[=\NW=NXS7Z.? W_@HU>-XTM?A
MW\8_"TWAOQ5]J33FU&TC(C\]FVJ)H#\T>25^9"RDMG"KS7QA^R'^TQI_[-/Q
M4O\ 7M1\/1Z]IFHQ&VFFA51>VR;MVZ L0.>-RDC=@<C%?H)-^W%^RWXCU#3?
M$NJ:C8OXALT#6MQ?^&;B6]M#_=240-M/^Z^/>N_&7?+&5+FC;ING_7]:&6CJ
M5)1E9WT[-?U_6IY?_P %0_V=_#4'@>'XHZ/I\.F:_#?16NIM;J$6]CDR%=U'
M!D5@HW=2&.<X7'U%^R;XFM_$W[+OP\O=(,5TT&A06?EE]B^?!&(G1C@[?G0@
MG!]<&OSH_;F_;>M?VC+>Q\*>$[*YLO"-C<_:I;J\ 2:^F4%4.P$[(P&8@$Y)
M8$A<8KE?V/\ ]M76OV8[V?2KRS?7_!5]-YUQIRN%FMY#@&6!CQD@#*'AL#E3
MS7)3PE>I@72EH[W2\K6M^+:-:U:$:\9QUTL_OW\^A]7^/O\ @IIXK^%NORZ-
MXJ^ U]HFH1NR".ZUYE67!QNC;['B13V920>QK4N?^"A7Q&L_!1\73_LVZ[#X
M;4_-J,FK2+&%V[O,.;/(CQ_RTQMSQG->B:+_ ,%)/@'JFG0W-UXLN]'F=<M9
MWND7;2QGT)BC=,_1B*\L^/'_  5,\(:/H=WI_P ,+6Y\1:U-&4BU2^MF@L[?
M(/S['Q)(P_NE5'N>AY52=E'ZM[WJ[?U\S7F3=_:67R_K\#X3_:D^/R?M)_%
M^,4\/?\ "-,UC#9O9_;?M6XQEOGW^6G4,!C;_#UYKR&K.I:E<ZQJ5U?WDIGN
M[J5YYI6 !=V)9FX]235:OJ*-.-&"A%61YM23G)R;N?8_[,O_  3UM_VD/A3:
M>,H?B,-#DDN9K6;3QHOVGR7C; R_VA,Y4JWW1C=7S1\7?AEJGP=^)&O^#]72
M076EW3PK,\?EBXBS^[F49.%==K#D]>M>\?L,_MC+^S7KU]HWB*&>\\$ZQ*LL
MYMQNEL9P-OGJO\2E<!EZX52.1M;]&K[XS_LV_%>TT[5]:\3_  [ULPJ)+5O$
M4MH+B#OQ'<8DC/M@&O-Q%;$8:OS6YJ;_  _K7?=&M&,*E-Q>D_Z_KU.:_P""
M<^K>+]8_9ETF;Q:]S,$NYH]*FO&9I9+$;?+)+<E0WF*O^RJXXQ7Y7_M.0Z;;
M?M$?$B+20!8+K]X$5<8!\UMP&.P;=CVK]&?VG/\ @HUX(\ ^%[[1/AKJ<'B?
MQ7+&T$-Y9)NL;#( \SS"-LA /RJFX9'S$8P?R>NKJ:^NIKFYE>>XF=I))9&+
M,[$Y+$GJ23G-98.-2KB9XJ4>5-6]=M?PWZMFU3EHX=4+W=[^F_\ GMY$5%%%
M>X< 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4JJ78*H+,QP !R:2O3OV:;KP;IGQO\*:GX_U1=)\+:;="^N9FMY9
M][1#?''LB1V.Z0(#QC&>:>F[V)DVEIN?L1^S7\.]/_9T_9R\.Z5J]Q;:3]AL
M?M^L7=W,L<44T@\R9G=L *I.W)[(*PM:UO\ 96\2:I<ZGJU_\'M4U*Z?S)[R
M]FTJ::5C_$[L26/N37S+^W=^W!X"^)7P5;P?\.?$3:U=:M=QKJ+"RN;;RK5#
MOQF6-,EG"# SP&SUK\X*^9HX.IBISKU;Q;?]?+I\CTY3C0IQIPUT_KY]?F?T
M#?#/QC\.M:T[^QOA[KGA>_L-,0?\2_PS=VTD5JC$X_=PDA 3N[#)S7X[?MR?
M"'_A3O[1WB6QMXO*TG57_MBP]/+F)+*/0+()% ]%%'[$?QXL_P!G_P".VGZU
MK5TUIX9OH)-/U618WDV1, RR;$!8[9%0\ G&['6O<O\ @HA\</@W^T!X3\-Z
MGX+\6KJGBK1[EX3;?V;=P&6UE&6^>2%5RKHA )Z,U:1P\\'BH2C>49:-]KO_
M #L[]KBC5C6I3IRLK:KY+_AU;T/MS]F&6'QM^R#X&M[:52MQX:33RRG[KK&8
M6'U#*?RK\9IO@[XU@^(A\"-X:U'_ (2P7'V8:6(&\TMG&X<<IWW_ '<<YQS7
MTE^Q/^W</V>=-E\'^+K&ZU3P=+.T]M/9X:XL';[X",0'C8_,0"""6(SG%?<?
M_#QC]G[[/YG_  G,F_&?)_L:^W?3_4XS^-5*-;!XJI5A#F4_\V^GJ_4SA)5:
M$:4G9Q_K\;+T.D_:!5/ /['7C&SGE2$V/A.33PV<CS#;B%0">N6('XU^=O\
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M<94#N6P!WQ7WY^R[_P %.].TOP_8^&?BW'=B>T188/$UI$9_-0# ^TQCY]P
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_AT/X:_Z*)JW_@OB_P#BZ/\ AT/X:_Z*)JW_ (+XO_BZ_-+^V]1_Y_[K_O\
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M]U_W^;_&CZOBO^?WX(/:4_Y/Q/TM_P"'0_AK_HHFK?\ @OB_^+H_X=#^&O\
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M^KXK_G]^"#VE/^3\3]+?^'0_AK_HHFK?^"^+_P"+H_X=#^&O^BB:M_X+XO\
MXNOS2_MO4?\ G_NO^_S?XT?VWJ/_ #_W7_?YO\:/J^*_Y_?@@]I3_D_$_2W_
M (=#^&O^BB:M_P""^+_XNC_AT/X:_P"BB:M_X+XO_BZ_-+^V]1_Y_P"Z_P"_
MS?XT?VWJ/_/_ '7_ '^;_&CZOBO^?WX(/:4_Y/Q/TM_X=#^&O^BB:M_X+XO_
M (NC_AT/X:_Z*)JW_@OB_P#BZ_-+^V]1_P"?^Z_[_-_C1_;>H_\ /_=?]_F_
MQH^KXK_G]^"#VE/^3\3]+?\ AT/X:_Z*)JW_ (+XO_BZ/^'0_AK_ **)JW_@
MOB_^+K\TO[;U'_G_ +K_ +_-_C1_;>H_\_\ =?\ ?YO\:/J^*_Y_?@@]I3_D
M_$_2W_AT/X:_Z*)JW_@OB_\ BZ/^'0_AK_HHFK?^"^+_ .+K\TO[;U'_ )_[
MK_O\W^-']MZC_P _]U_W^;_&CZOBO^?WX(/:4_Y/Q/TM_P"'0_AK_HHFK?\
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M:M_X+XO_ (NC_AT/X:_Z*)JW_@OB_P#BZ_-+^V]1_P"?^Z_[_-_C1_;>H_\
M/_=?]_F_QH^KXK_G]^"#VE/^3\3]+?\ AT/X:_Z*)JW_ (+XO_BZ/^'0_AK_
M **)JW_@OB_^+K\TO[;U'_G_ +K_ +_-_C1_;>H_\_\ =?\ ?YO\:/J^*_Y_
M?@@]I3_D_$_2W_AT/X:_Z*)JW_@OB_\ BZ/^'0_AK_HHFK?^"^+_ .+K\TO[
M;U'_ )_[K_O\W^-']MZC_P _]U_W^;_&CZOBO^?WX(/:4_Y/Q/TM_P"'0_AK
M_HHFK?\ @OB_^+H_X=#^&O\ HHFK?^"^+_XNOS2_MO4?^?\ NO\ O\W^-']M
MZC_S_P!U_P!_F_QH^KXK_G]^"#VE/^3\3]+?^'0_AK_HHFK?^"^+_P"+H_X=
M#^&O^BB:M_X+XO\ XNOS2_MO4?\ G_NO^_S?XT?VWJ/_ #_W7_?YO\:/J^*_
MY_?@@]I3_D_$_2W_ (=#^&O^BB:M_P""^+_XNC_AT/X:_P"BB:M_X+XO_BZ_
M-+^V]1_Y_P"Z_P"_S?XT?VWJ/_/_ '7_ '^;_&CZOBO^?WX(/:4_Y/Q/TM_X
M=#^&O^BB:M_X+XO_ (NC_AT/X:_Z*)JW_@OB_P#BZ_-+^V]1_P"?^Z_[_-_C
M1_;>H_\ /_=?]_F_QH^KXK_G]^"#VE/^3\3]+?\ AT/X:_Z*)JW_ (+XO_BZ
M/^'0_AK_ **)JW_@OB_^+K\TO[;U'_G_ +K_ +_-_C1_;>H_\_\ =?\ ?YO\
M:/J^*_Y_?@@]I3_D_$_2W_AT/X:_Z*)JW_@OB_\ BZ/^'0_AK_HHFK?^"^+_
M .+K\TO[;U'_ )_[K_O\W^-']MZC_P _]U_W^;_&CZOBO^?WX(/:4_Y/Q/TM
M_P"'0_AK_HHFK?\ @OB_^+H_X=#^&O\ HHFK?^"^+_XNOS2_MO4?^?\ NO\
MO\W^-']MZC_S_P!U_P!_F_QH^KXK_G]^"#VE/^3\3]+?^'0_AK_HHFK?^"^+
M_P"+H_X=#^&O^BB:M_X+XO\ XNOS2_MO4?\ G_NO^_S?XT?VWJ/_ #_W7_?Y
MO\:/J^*_Y_?@@]I3_D_$_2W_ (=#^&O^BB:M_P""^+_XNC_AT/X:_P"BB:M_
MX+XO_BZ_-+^V]1_Y_P"Z_P"_S?XT?VWJ/_/_ '7_ '^;_&CZOBO^?WX(/:4_
MY/Q/TM_X=#^&O^BB:M_X+XO_ (NC_AT/X:_Z*)JW_@OB_P#BZ_-+^V]1_P"?
M^Z_[_-_C1_;>H_\ /_=?]_F_QH^KXK_G]^"#VE/^3\3]+?\ AT/X:_Z*)JW_
M (+XO_BZ/^'0_AK_ **)JW_@OB_^+K\TO[;U'_G_ +K_ +_-_C1_;>H_\_\
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M/^3\3]+?^'0_AK_HHFK?^"^+_P"+H_X=#^&O^BB:M_X+XO\ XNOS2_MO4?\
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MO_BZ/^'0_AK_ **)JW_@OB_^+K\TO[;U'_G_ +K_ +_-_C1_;>H_\_\ =?\
M?YO\:/J^*_Y_?@@]I3_D_$_2W_AT/X:_Z*)JW_@OB_\ BZ/^'0_AK_HHFK?^
M"^+_ .+K\TO[;U'_ )_[K_O\W^-']MZC_P _]U_W^;_&CZOBO^?WX(/:4_Y/
MQ/TM_P"'0_AK_HHFK?\ @OB_^+H_X=#^&O\ HHFK?^"^+_XNOS2_MO4?^?\
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MZ_-+^V]1_P"?^Z_[_-_C1_;>H_\ /_=?]_F_QH^KXK_G]^"#VE/^3\3]+?\
MAT/X:_Z*)JW_ (+XO_BZ/^'0_AK_ **)JW_@OB_^+K\TO[;U'_G_ +K_ +_-
M_C1_;>H_\_\ =?\ ?YO\:/J^*_Y_?@@]I3_D_$_2W_AT/X:_Z*)JW_@OB_\
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M]U_W^;_&CZOBO^?WX(/:4_Y/Q/TM_P"'0_AK_HHFK?\ @OB_^+H_X=#^&O\
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M^KXK_G]^"#VE/^3\3]+?^'0_AK_HHFK?^"^+_P"+H_X=#^&O^BB:M_X+XO\
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MK_O\W^-']MZC_P _]U_W^;_&CZOBO^?WX(/:4_Y/Q/TM_P"'0_AK_HHFK?\
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M:M_X+XO_ (NC_AT/X:_Z*)JW_@OB_P#BZ_-+^V]1_P"?^Z_[_-_C1_;>H_\
M/_=?]_F_QH^KXK_G]^"#VE/^3\3]+?\ AT/X:_Z*)JW_ (+XO_BZ/^'0_AK_
M **)JW_@OB_^+K\TO[;U'_G_ +K_ +_-_C1_;>H_\_\ =?\ ?YO\:/J^*_Y_
M?@@]I3_D_$_2W_AT/X:_Z*)JW_@OB_\ BZ/^'0_AK_HHFK?^"^+_ .+K\TO[
M;U'_ )_[K_O\W^-']MZC_P _]U_W^;_&CZOBO^?WX(/:4_Y/Q/TM_P"'0_AK
M_HHFK?\ @OB_^+H_X=#^&O\ HHFK?^"^+_XNOS2_MO4?^?\ NO\ O\W^-']M
MZC_S_P!U_P!_F_QH^KXK_G]^"#VE/^3\3]+?^'0_AK_HHFK?^"^+_P"+H_X=
M#^&O^BB:M_X+XO\ XNOS2_MO4?\ G_NO^_S?XT?VWJ/_ #_W7_?YO\:/J^*_
MY_?@@]I3_D_$_2W_ (=#^&O^BB:M_P""^+_XNC_AT/X:_P"BB:M_X+XO_BZ_
M-+^V]1_Y_P"Z_P"_S?XT?VWJ/_/_ '7_ '^;_&CZOBO^?WX(/:4_Y/Q/TM_X
M=#^&O^BB:M_X+XO_ (NC_AT/X:_Z*)JW_@OB_P#BZ_-+^V]1_P"?^Z_[_-_C
M1_;>H_\ /_=?]_F_QH^KXK_G]^"#VE/^3\3]+?\ AT/X:_Z*)JW_ (+XO_BZ
M/^'0_AK_ **)JW_@OB_^+K\TO[;U'_G_ +K_ +_-_C1_;>H_\_\ =?\ ?YO\
M:/J^*_Y_?@@]I3_D_$_2W_AT/X:_Z*)JW_@OB_\ BZ/^'0_AK_HHFK?^"^+_
M .+K\TO[;U'_ )_[K_O\W^-']MZC_P _]U_W^;_&CZOBO^?WX(/:4_Y/Q/TM
M_P"'0_AK_HHFK?\ @OB_^+H_X=#^&O\ HHFK?^"^+_XNOS2_MO4?^?\ NO\
MO\W^-']MZC_S_P!U_P!_F_QH^KXK_G]^"#VE/^3\3]+?^'0_AK_HHFK?^"^+
M_P"+H_X=#^&O^BB:M_X+XO\ XNOS2_MO4?\ G_NO^_S?XT?VWJ/_ #_W7_?Y
MO\:/J^*_Y_?@@]I3_D_$_2W_ (=#^&O^BB:M_P""^+_XNC_AT/X:_P"BB:M_
MX+XO_BZ_-+^V]1_Y_P"Z_P"_S?XT?VWJ/_/_ '7_ '^;_&CZOBO^?WX(/:4_
MY/Q/TM_X=#^&O^BB:M_X+XO_ (NC_AT/X:_Z*)JW_@OB_P#BZ_-+^V]1_P"?
M^Z_[_-_C1_;>H_\ /_=?]_F_QH^KXK_G]^"#VE/^3\3]+?\ AT/X:_Z*)JW_
M (+XO_BZ/^'0_AK_ **)JW_@OB_^+K\TO[;U'_G_ +K_ +_-_C1_;>H_\_\
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M/^3\3]+?^'0_AK_HHFK?^"^+_P"+H_X=#^&O^BB:M_X+XO\ XNOS2_MO4?\
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MO_BZ/^'0_AK_ **)JW_@OB_^+K\TO[;U'_G_ +K_ +_-_C1_;>H_\_\ =?\
M?YO\:/J^*_Y_?@@]I3_D_$_2W_AT/X:_Z*)JW_@OB_\ BZ/^'0_AK_HHFK?^
M"^+_ .+K\TO[;U'_ )_[K_O\W^-']MZC_P _]U_W^;_&CZOBO^?WX(/:4_Y/
MQ/TM_P"'0_AK_HHFK?\ @OB_^+H_X=#^&O\ HHFK?^"^+_XNOS2_MO4?^?\
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MZ_-+^V]1_P"?^Z_[_-_C1_;>H_\ /_=?]_F_QH^KXK_G]^"#VE/^3\3]+?\
MAT/X:_Z*)JW_ (+XO_BZ/^'0_AK_ **)JW_@OB_^+K\TO[;U'_G_ +K_ +_-
M_C1_;>H_\_\ =?\ ?YO\:/J^*_Y_?@@]I3_D_$_2W_AT/X:_Z*)JW_@OB_\
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M]U_W^;_&CZOBO^?WX(/:4_Y/Q/TM_P"'0_AK_HHFK?\ @OB_^+H_X=#^&O\
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M^KXK_G]^"#VE/^3\3]+?^'0_AK_HHFK?^"^+_P"+H_X=#^&O^BB:M_X+XO\
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MK_O\W^-']MZC_P _]U_W^;_&CZOBO^?WX(/:4_Y/Q/TM_P"'0_AK_HHFK?\
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M:M_X+XO_ (NC_AT/X:_Z*)JW_@OB_P#BZ_-+^V]1_P"?^Z_[_-_C1_;>H_\
M/_=?]_F_QH^KXK_G]^"#VE/^3\3]+?\ AT/X:_Z*)JW_ (+XO_BZ/^'0_AK_
M **)JW_@OB_^+K\TO[;U'_G_ +K_ +_-_C1_;>H_\_\ =?\ ?YO\:/J^*_Y_
M?@@]I3_D_$_2W_AT/X:_Z*)JW_@OB_\ BZ/^'0_AK_HHFK?^"^+_ .+K\TO[
M;U'_ )_[K_O\W^-']MZC_P _]U_W^;_&CZOBO^?WX(/:4_Y/Q/TM_P"'0_AK
M_HHFK?\ @OB_^+H_X=#^&O\ HHFK?^"^+_XNOS2_MO4?^?\ NO\ O\W^-']M
MZC_S_P!U_P!_F_QH^KXK_G]^"#VE/^3\3]+?^'0_AK_HHFK?^"^+_P"+H_X=
M#^&O^BB:M_X+XO\ XNOS2_MO4?\ G_NO^_S?XT?VWJ/_ #_W7_?YO\:/J^*_
MY_?@@]I3_D_$_2W_ (=#^&O^BB:M_P""^+_XNC_AT/X:_P"BB:M_X+XO_BZ_
M-+^V]1_Y_P"Z_P"_S?XT?VWJ/_/_ '7_ '^;_&CZOBO^?WX(/:4_Y/Q/TM_X
M=#^&O^BB:M_X+XO_ (NC_AT/X:_Z*)JW_@OB_P#BZ_-+^V]1_P"?^Z_[_-_C
M1_;>H_\ /_=?]_F_QH^KXK_G]^"#VE/^3\3]+?\ AT/X:_Z*)JW_ (+XO_BZ
M/^'0_AK_ **)JW_@OB_^+K\TO[;U'_G_ +K_ +_-_C1_;>H_\_\ =?\ ?YO\
M:/J^*_Y_?@@]I3_D_$_2W_AT/X:_Z*)JW_@OB_\ BZ/^'0_AK_HHFK?^"^+_
M .+K\TO[;U'_ )_[K_O\W^-']MZC_P _]U_W^;_&CZOBO^?WX(/:4_Y/Q/TM
M_P"'0_AK_HHFK?\ @OB_^+H_X=#^&O\ HHFK?^"^+_XNOS2_MO4?^?\ NO\
MO\W^-']MZC_S_P!U_P!_F_QH^KXK_G]^"#VE/^3\3]+?^'0_AK_HHFK?^"^+
M_P"+H_X=#^&O^BB:M_X+XO\ XNOS2_MO4?\ G_NO^_S?XT?VWJ/_ #_W7_?Y
MO\:/J^*_Y_?@@]I3_D_$_2W_ (=#^&O^BB:M_P""^+_XNC_AT/X:_P"BB:M_
MX+XO_BZ_-+^V]1_Y_P"Z_P"_S?XT?VWJ/_/_ '7_ '^;_&CZOBO^?WX(/:4_
MY/Q/TM_X=#^&O^BB:M_X+XO_ (NC_AT/X:_Z*)JW_@OB_P#BZ_-+^V]1_P"?
M^Z_[_-_C1_;>H_\ /_=?]_F_QH^KXK_G]^"#VE/^3\3]+?\ AT/X:_Z*)JW_
M (+XO_BZ/^'0_AK_ **)JW_@OB_^+K\TO[;U'_G_ +K_ +_-_C1_;>H_\_\
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MA(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU[7O_I-)7Z7WUKX-_;=_9Q>,'.F:W;G:W!FTZ\0X_P"^XY!]&'J&K\\_V(O
M.L?"W]N[3_"FOV_V;5M*%_;S+SM;%LY5U)ZJRD,#W# UE@:\O95<-5^*,9?=
MRO\ +_(Z<;!2Y:T=G*-_6Z_/\[GL_P#P5^_Y!/PO_P"N^H_^@V]?FO7Z4?\
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MS")0&*-L;)Z+OKXE_8X^"P^.OQ]\/:#=0^=HMJYU+5 1E3;1$$H?9V*1_P#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJKJ?.D&#D;8]P![,Z5^+589>IXFM+%5=6K)?=K^%OO9MB.6C3]G'[3;^5_\
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MR2*20$@SL26,C!<_,=V-O;%?DE_P40_Y.[\<?2S_ /22&BA6C7S%U(JR<?\
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M +8 PP=\#7]E65N>UG^G]=?4=1K$4W[-_"W\_/\ 7T[,^%:***^F/*"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXE%KN^S_ -L:C-=^3NQNV>8QVYVC..N!Z5S=%#2;3:!-K8*.G(HHIB.]@_:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K]9?^"3/_)N?B/\ [&NY
M_P#2.SK\FJ_67_@DS_R;GXC_ .QKN?\ TCLZ\K,_]W?JCJPW\0_/O]HWP3XB
MNOVA/BA/!H.IS0R>*=4=)([.1E93=RD$$+R".]>=_P#"!>)O^A<U;_P!E_\
MB:_=G4/@3X;U*_N;N5[Y9+B5I6"3* "Q)./EZ<U7_P"&?/"__/34/^_R_P#Q
M->9'-IQBH\FWF=+PL6[\Q^%W_"!>)O\ H7-6_P# &7_XFC_A O$W_0N:M_X
MR_\ Q-?NC_PSYX7_ .>FH?\ ?Y?_ (FC_AGSPO\ \]-0_P"_R_\ Q-5_:\_Y
M/Q#ZI'^8_"[_ (0+Q-_T+FK?^ ,O_P 31_P@7B;_ *%S5O\ P!E_^)K]T?\
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MGA?_ )Z:A_W^7_XFC_AGSPO_ ,]-0_[_ "__ !-']KS_ )/Q#ZI'^8_"[_A
MO$W_ $+FK?\ @#+_ /$T?\(%XF_Z%S5O_ &7_P")K]T?^&?/"_\ STU#_O\
M+_\ $T?\,^>%_P#GIJ'_ '^7_P")H_M>?\GXA]4C_,?A=_P@7B;_ *%S5O\
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M $+FK?\ @#+_ /$T?\(%XF_Z%S5O_ &7_P")K]T?^&?/"_\ STU#_O\ +_\
M$T?\,^>%_P#GIJ'_ '^7_P")H_M>?\GXA]4C_,?A=_P@7B;_ *%S5O\ P!E_
M^)H_X0+Q-_T+FK?^ ,O_ ,37[H_\,^>%_P#GIJ'_ '^7_P")H_X9\\+_ //3
M4/\ O\O_ ,31_:\_Y/Q#ZI'^8_"[_A O$W_0N:M_X R__$T?\(%XF_Z%S5O_
M  !E_P#B:_='_AGSPO\ \]-0_P"_R_\ Q-'_  SYX7_YZ:A_W^7_ .)H_M>?
M\GXA]4C_ #'X7?\ "!>)O^A<U;_P!E_^)H_X0+Q-_P!"YJW_ ( R_P#Q-?NC
M_P ,^>%_^>FH?]_E_P#B:/\ AGSPO_STU#_O\O\ \31_:\_Y/Q#ZI'^8_"[_
M (0+Q-_T+FK?^ ,O_P 31_P@7B;_ *%S5O\ P!E_^)K]T?\ AGSPO_STU#_O
M\O\ \31_PSYX7_YZ:A_W^7_XFC^UY_R?B'U2/\Q^%W_"!>)O^A<U;_P!E_\
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MX0+Q-_T+FK?^ ,O_ ,37[H_\,^>%_P#GIJ'_ '^7_P")H_X9\\+_ //34/\
MO\O_ ,31_:\_Y/Q#ZI'^8_"[_A O$W_0N:M_X R__$T?\(%XF_Z%S5O_  !E
M_P#B:_='_AGSPO\ \]-0_P"_R_\ Q-'_  SYX7_YZ:A_W^7_ .)H_M>?\GXA
M]4C_ #'X7?\ "!>)O^A<U;_P!E_^)H_X0+Q-_P!"YJW_ ( R_P#Q-?NC_P ,
M^>%_^>FH?]_E_P#B:/\ AGSPO_STU#_O\O\ \31_:\_Y/Q#ZI'^8_"[_ (0+
MQ-_T+FK?^ ,O_P 31_P@7B;_ *%S5O\ P!E_^)K]T?\ AGSPO_STU#_O\O\
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M7_XFC_AGSPO_ ,]-0_[_ "__ !-']KS_ )/Q#ZI'^8_"[_A O$W_ $+FK?\
M@#+_ /$T?\(%XF_Z%S5O_ &7_P")K]T?^&?/"_\ STU#_O\ +_\ $T?\,^>%
M_P#GIJ'_ '^7_P")H_M>?\GXA]4C_,?A=_P@7B;_ *%S5O\ P!E_^)H_X0+Q
M-_T+FK?^ ,O_ ,37[H_\,^>%_P#GIJ'_ '^7_P")H_X9\\+_ //34/\ O\O_
M ,31_:\_Y/Q#ZI'^8_"[_A O$W_0N:M_X R__$U+#\.?%ER2(?"^LRE1DA-/
MF.!^"U^YG_#/GA?_ )Z:A_W^7_XFN0^(WPGT3PK;V#V3W1,\I1_-D!X '3Y1
M1_:\_P"3\0^J1_F/Q=_X0+Q-_P!"YJW_ ( R_P#Q-'_"!>)O^A<U;_P!E_\
MB:_='_AGSPO_ ,]-0_[_ "__ !-'_#/GA?\ YZ:A_P!_E_\ B:/[7G_)^(?5
M(_S'X7?\(%XF_P"A<U;_ , 9?_B:/^$"\3?]"YJW_@#+_P#$U^Z/_#/GA?\
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M:A_W^7_XFC_AGSPO_P ]-0_[_+_\31_:\_Y/Q#ZI'^8_"[_A O$W_0N:M_X
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M^7_XFC_AGSPO_P ]-0_[_+_\31_:\_Y/Q#ZI'^8_"[_A O$W_0N:M_X R_\
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M^>FH?]_E_P#B:/[7G_)^(?5(_P Q^%W_  @7B;_H7-6_\ 9?_B:/^$"\3?\
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M_P"A<U;_ , 9?_B:/^$"\3?]"YJW_@#+_P#$U^Z/_#/GA?\ YZ:A_P!_E_\
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M_P#B:/[7G_)^(?5(_P Q^%W_  @7B;_H7-6_\ 9?_B:/^$"\3?\ 0N:M_P"
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MN_X0+Q-_T+FK?^ ,O_Q-'_"!>)O^A<U;_P  9?\ XFOW1_X9]\+_ //34/\
MO^O_ ,32?\,^^%_^>FH?]_U_^)H_M>?\GXA]4C_,?A?_ ,(%XF_Z%S5O_ &7
M_P")H_X0+Q-_T+FK?^ ,O_Q-?NA_PS_X7_YZ:A_W_7_XFC_AG[PO_P ]-0_[
M_K_\31_:\_Y/Q#ZI'^8_"_\ X0+Q-_T+FK?^ ,O_ ,31_P (%XF_Z%S5O_ &
M7_XFOW1_X9]\+_\ /34/^_Z__$T?\,^>%_\ GIJ'_?Y?_B:/[7G_ "?B'U2/
M\Q^%W_"!>)O^A<U;_P  9?\ XFC_ (0+Q-_T+FK?^ ,O_P 37[H_\,^>%_\
MGIJ'_?Y?_B:/^&?/"_\ STU#_O\ +_\ $T?VO/\ D_$/JD?YC\+O^$"\3?\
M0N:M_P" ,O\ \31_P@7B;_H7-6_\ 9?_ (FOW1_X9\\+_P#/34/^_P O_P 3
M1_PSYX7_ .>FH?\ ?Y?_ (FC^UY_R?B'U2/\Q^%W_"!>)O\ H7-6_P# &7_X
MFC_A O$W_0N:M_X R_\ Q-?NC_PSYX7_ .>FH?\ ?Y?_ (FC_AGSPO\ \]-0
M_P"_R_\ Q-']KS_D_$/JD?YC\+O^$"\3?]"YJW_@#+_\31_P@7B;_H7-6_\
M &7_ .)K]T?^&?/"_P#STU#_ +_+_P#$T?\ #/GA?_GIJ'_?Y?\ XFC^UY_R
M?B'U2/\ ,?A=_P (%XF_Z%S5O_ &7_XFC_A O$W_ $+FK?\ @#+_ /$U^Z/_
M  SYX7_YZ:A_W^7_ .)H_P"&?/"__/34/^_R_P#Q-']KS_D_$/JD?YC\+O\
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M_B:/^&?/"_\ STU#_O\ +_\ $T?VO/\ D_$/JD?YC\+O^$"\3?\ 0N:M_P"
M,O\ \31_P@7B;_H7-6_\ 9?_ (FOW1_X9\\+_P#/34/^_P O_P 31_PSYX7_
M .>FH?\ ?Y?_ (FC^UY_R?B'U2/\Q^%W_"!>)O\ H7-6_P# &7_XFC_A O$W
M_0N:M_X R_\ Q-?NC_PSYX7_ .>FH?\ ?Y?_ (FC_AGSPO\ \]-0_P"_R_\
MQ-']KS_D_$/JD?YC\+O^$"\3?]"YJW_@#+_\31_P@7B;_H7-6_\  &7_ .)K
M]T?^&?/"_P#STU#_ +_+_P#$T?\ #/GA?_GIJ'_?Y?\ XFC^UY_R?B'U2/\
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M^&?/"_\ STU#_O\ +_\ $T?VO/\ D_$/JD?YC\+O^$"\3?\ 0N:M_P" ,O\
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MJ1_F/PN_X0+Q-_T+FK?^ ,O_ ,31_P (%XF_Z%S5O_ &7_XFOW1_X9\\+_\
M/34/^_R__$T?\,^>%_\ GIJ'_?Y?_B:/[7G_ "?B'U2/\Q^%W_"!>)O^A<U;
M_P  9?\ XFC_ (0+Q-_T+FK?^ ,O_P 37[H_\,^>%_\ GIJ'_?Y?_B:/^&?/
M"_\ STU#_O\ +_\ $T?VO/\ D_$/JD?YC\+O^$"\3?\ 0N:M_P" ,O\ \31_
MP@7B;_H7-6_\ 9?_ (FOW1_X9\\+_P#/34/^_P O_P 31_PSYX7_ .>FH?\
M?Y?_ (FC^UY_R?B'U2/\Q^%W_"!>)O\ H7-6_P# &7_XFC_A O$W_0N:M_X
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M^_R__$T?\,^>%_\ GIJ'_?Y?_B:/[7G_ "?B'U2/\Q^%W_"!>)O^A<U;_P
M9?\ XFC_ (0+Q-_T+FK?^ ,O_P 37[H_\,^>%_\ GIJ'_?Y?_B:/^&?/"_\
MSTU#_O\ +_\ $T?VO/\ D_$/JD?YC\+O^$"\3?\ 0N:M_P" ,O\ \31_P@7B
M;_H7-6_\ 9?_ (FOW1_X9\\+_P#/34/^_P O_P 31_PSYX7_ .>FH?\ ?Y?_
M (FC^UY_R?B'U2/\Q^%W_"!>)O\ H7-6_P# &7_XFC_A O$W_0N:M_X R_\
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M_$T?\,^>%_\ GIJ'_?Y?_B:/[7G_ "?B'U2/\Q^%W_"!>)O^A<U;_P  9?\
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M (0+Q-_T+FK?^ ,O_P 37[H_\,^>%_\ GIJ'_?Y?_B:/^&?/"_\ STU#_O\
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M_/34/^_R_P#Q-']KS_D_$/JD?YC\+O\ A O$W_0N:M_X R__ !-'_"!>)O\
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MQ-_T+FK?^ ,O_P 37[H_\,^>%_\ GIJ'_?Y?_B:/^&?/"_\ STU#_O\ +_\
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M ,O_ ,31_P (%XF_Z%S5O_ &7_XFOW1_X9\\+_\ /34/^_R__$T?\,^>%_\
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MJW_@#+_\31_P@7B;_H7-6_\  &7_ .)K]T?^&?/"_P#STU#_ +_+_P#$T?\
M#/GA?_GIJ'_?Y?\ XFC^UY_R?B'U2/\ ,?A=_P (%XF_Z%S5O_ &7_XFC_A
MO$W_ $+FK?\ @#+_ /$U^Z/_  SYX7_YZ:A_W^7_ .)H_P"&?/"__/34/^_R
M_P#Q-']KS_D_$/JD?YC\+O\ A O$W_0N:M_X R__ !-'_"!>)O\ H7-6_P#
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M^ ,O_P 37[H_\,^>%_\ GIJ'_?Y?_B:/^&?/"_\ STU#_O\ +_\ $T?VO/\
MD_$/JD?YC\+O^$"\3?\ 0N:M_P" ,O\ \31_P@7B;_H7-6_\ 9?_ (FOW1_X
M9\\+_P#/34/^_P O_P 31_PSYX7_ .>FH?\ ?Y?_ (FC^UY_R?B'U2/\Q^%W
M_"!>)O\ H7-6_P# &7_XFC_A O$W_0N:M_X R_\ Q-?NC_PSYX7_ .>FH?\
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M34/^_P O_P 31_PSYX7_ .>FH?\ ?Y?_ (FC^UY_R?B'U2/\Q^%W_"!>)O\
MH7-6_P# &7_XFC_A O$W_0N:M_X R_\ Q-?NC_PSYX7_ .>FH?\ ?Y?_ (FC
M_AGSPO\ \]-0_P"_R_\ Q-']KS_D_$/JD?YC\+O^$"\3?]"YJW_@#+_\31_P
M@7B;_H7-6_\  &7_ .)K]T?^&?/"_P#STU#_ +_+_P#$T?\ #/GA?_GIJ'_?
MY?\ XFC^UY_R?B'U2/\ ,?A=_P (%XF_Z%S5O_ &7_XFC_A O$W_ $+FK?\
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M_H7-6_\  &7_ .)K]T?^&?/"_P#STU#_ +_+_P#$T?\ #/GA?_GIJ'_?Y?\
MXFC^UY_R?B'U2/\ ,?A=_P (%XF_Z%S5O_ &7_XFC_A O$W_ $+FK?\ @#+_
M /$U^Z/_  SYX7_YZ:A_W^7_ .)H_P"&?/"__/34/^_R_P#Q-']KS_D_$/JD
M?YC\+O\ A O$W_0N:M_X R__ !-'_"!>)O\ H7-6_P# &7_XFOW1_P"&?/"_
M_/34/^_R_P#Q-'_#/GA?_GIJ'_?Y?_B:/[7G_)^(?5(_S'X7?\(%XF_Z%S5O
M_ &7_P")H_X0+Q-_T+FK?^ ,O_Q-?NC_ ,,^>%_^>FH?]_E_^)H_X9\\+_\
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M_P 31_PSYX7_ .>FH?\ ?Y?_ (FC^UY_R?B'U2/\Q^%W_"!>)O\ H7-6_P#
M&7_XFC_A O$W_0N:M_X R_\ Q-?NC_PSYX7_ .>FH?\ ?Y?_ (FC_AGSPO\
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M\Q^%W_"!>)O^A<U;_P  9?\ XFC_ (0+Q-_T+FK?^ ,O_P 37[H_\,^>%_\
MGIJ'_?Y?_B:/^&?/"_\ STU#_O\ +_\ $T?VO/\ D_$/JD?YC\+O^$"\3?\
M0N:M_P" ,O\ \31_P@7B;_H7-6_\ 9?_ (FOW1_X9\\+_P#/34/^_P O_P 3
M1_PSYX7_ .>FH?\ ?Y?_ (FC^UY_R?B'U2/\Q^%W_"!>)O\ H7-6_P# &7_X
MFC_A O$W_0N:M_X R_\ Q-?NC_PSYX7_ .>FH?\ ?Y?_ (FC_AGSPO\ \]-0
M_P"_R_\ Q-']KS_D_$/JD?YC\+O^$"\3?]"YJW_@#+_\31_P@7B;_H7-6_\
M &7_ .)K]T?^&?/"_P#STU#_ +_+_P#$T?\ #/GA?_GIJ'_?Y?\ XFC^UY_R
M?B'U2/\ ,?A=_P (%XF_Z%S5O_ &7_XFC_A O$W_ $+FK?\ @#+_ /$U^Z/_
M  SYX7_YZ:A_W^7_ .)H_P"&?/"__/34/^_R_P#Q-']KS_D_$/JD?YC\+O\
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MT%\+O^BD^$/_  >VO_QRC_AH+X7?]%)\(?\ @]M?_CE'LJG\K^X.278[^BN
M_P"&@OA=_P!%)\(?^#VU_P#CE'_#07PN_P"BD^$/_![:_P#QRCV53^5_<')+
ML=_17 ?\-!?"[_HI/A#_ ,'MK_\ '*/^&@OA=_T4GPA_X/;7_P".4>RJ?RO[
M@Y)=COZ*X#_AH+X7?]%)\(?^#VU_^.4?\-!?"[_HI/A#_P 'MK_\<H]E4_E?
MW!R2['?T5P'_  T%\+O^BD^$/_![:_\ QRC_ (:"^%W_ $4GPA_X/;7_ ..4
M>RJ?RO[@Y)=COZ*X#_AH+X7?]%)\(?\ @]M?_CE'_#07PN_Z*3X0_P#![:__
M !RCV53^5_<')+L=_17 ?\-!?"[_ **3X0_\'MK_ /'*/^&@OA=_T4GPA_X/
M;7_XY1[*I_*_N#DEV._HK@/^&@OA=_T4GPA_X/;7_P".4?\ #07PN_Z*3X0_
M\'MK_P#'*/95/Y7]P<DNQW]%<!_PT%\+O^BD^$/_  >VO_QRC_AH+X7?]%)\
M(?\ @]M?_CE'LJG\K^X.278[^BN _P"&@OA=_P!%)\(?^#VU_P#CE'_#07PN
M_P"BD^$/_![:_P#QRCV53^5_<')+L=_17 ?\-!?"[_HI/A#_ ,'MK_\ '*/^
M&@OA=_T4GPA_X/;7_P".4>RJ?RO[@Y)=COZ*X#_AH+X7?]%)\(?^#VU_^.4?
M\-!?"[_HI/A#_P 'MK_\<H]E4_E?W!R2['?T5P'_  T%\+O^BD^$/_![:_\
MQRC_ (:"^%W_ $4GPA_X/;7_ ..4>RJ?RO[@Y)=COZ*X#_AH+X7?]%)\(?\
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M_P#'*/95/Y7]P<DNQW]%<!_PT%\+O^BD^$/_  >VO_QRC_AH+X7?]%)\(?\
M@]M?_CE'LJG\K^X.278[^BN _P"&@OA=_P!%)\(?^#VU_P#CE'_#07PN_P"B
MD^$/_![:_P#QRCV53^5_<')+L=_17 ?\-!?"[_HI/A#_ ,'MK_\ '*/^&@OA
M=_T4GPA_X/;7_P".4>RJ?RO[@Y)=COZ*X#_AH+X7?]%)\(?^#VU_^.4?\-!?
M"[_HI/A#_P 'MK_\<H]E4_E?W!R2['?T5P'_  T%\+O^BD^$/_![:_\ QRC_
M (:"^%W_ $4GPA_X/;7_ ..4>RJ?RO[@Y)=COZ*X#_AH+X7?]%)\(?\ @]M?
M_CE'_#07PN_Z*3X0_P#![:__ !RCV53^5_<')+L=_17 ?\-!?"[_ **3X0_\
M'MK_ /'*/^&@OA=_T4GPA_X/;7_XY1[*I_*_N#DEV._HK@/^&@OA=_T4GPA_
MX/;7_P".4?\ #07PN_Z*3X0_\'MK_P#'*/95/Y7]P<DNQW]%<!_PT%\+O^BD
M^$/_  >VO_QRC_AH+X7?]%)\(?\ @]M?_CE'LJG\K^X.278[^BN _P"&@OA=
M_P!%)\(?^#VU_P#CE'_#07PN_P"BD^$/_![:_P#QRCV53^5_<')+L=_17 ?\
M-!?"[_HI/A#_ ,'MK_\ '*/^&@OA=_T4GPA_X/;7_P".4>RJ?RO[@Y)=COZ*
MX#_AH+X7?]%)\(?^#VU_^.4?\-!?"[_HI/A#_P 'MK_\<H]E4_E?W!R2['?T
M5P'_  T%\+O^BD^$/_![:_\ QRC_ (:"^%W_ $4GPA_X/;7_ ..4>RJ?RO[@
MY)=COZ*X#_AH+X7?]%)\(?\ @]M?_CE'_#07PN_Z*3X0_P#![:__ !RCV53^
M5_<')+L=_17 ?\-!?"[_ **3X0_\'MK_ /'*/^&@OA=_T4GPA_X/;7_XY1[*
MI_*_N#DEV._HK@/^&@OA=_T4GPA_X/;7_P".4?\ #07PN_Z*3X0_\'MK_P#'
M*/95/Y7]P<DNQW]%<!_PT%\+O^BD^$/_  >VO_QRC_AH+X7?]%)\(?\ @]M?
M_CE'LJG\K^X.278[^BN _P"&@OA=_P!%)\(?^#VU_P#CE'_#07PN_P"BD^$/
M_![:_P#QRCV53^5_<')+L=_17 ?\-!?"[_HI/A#_ ,'MK_\ '*/^&@OA=_T4
MGPA_X/;7_P".4>RJ?RO[@Y)=COZ*X#_AH+X7?]%)\(?^#VU_^.4?\-!?"[_H
MI/A#_P 'MK_\<H]E4_E?W!R2['?T5P'_  T%\+O^BD^$/_![:_\ QRC_ (:"
M^%W_ $4GPA_X/;7_ ..4>RJ?RO[@Y)=COZ*X#_AH+X7?]%)\(?\ @]M?_CE'
M_#07PN_Z*3X0_P#![:__ !RCV53^5_<')+L=_17 ?\-!?"[_ **3X0_\'MK_
M /'*/^&@OA=_T4GPA_X/;7_XY1[*I_*_N#DEV._HK@/^&@OA=_T4GPA_X/;7
M_P".4?\ #07PN_Z*3X0_\'MK_P#'*/95/Y7]P<DNQW]%<!_PT%\+O^BD^$/_
M  >VO_QRC_AH+X7?]%)\(?\ @]M?_CE'LJG\K^X.278[^BN _P"&@OA=_P!%
M)\(?^#VU_P#CE'_#07PN_P"BD^$/_![:_P#QRCV53^5_<')+L=_17 ?\-!?"
M[_HI/A#_ ,'MK_\ '*/^&@OA=_T4GPA_X/;7_P".4>RJ?RO[@Y)=COZ*X#_A
MH+X7?]%)\(?^#VU_^.4?\-!?"[_HI/A#_P 'MK_\<H]E4_E?W!R2['?T5P'_
M  T%\+O^BD^$/_![:_\ QRC_ (:"^%W_ $4GPA_X/;7_ ..4>RJ?RO[@Y)=C
MOZ*X#_AH+X7?]%)\(?\ @]M?_CE'_#07PN_Z*3X0_P#![:__ !RCV53^5_<'
M)+L=_17 ?\-!?"[_ **3X0_\'MK_ /'*/^&@OA=_T4GPA_X/;7_XY1[*I_*_
MN#DEV._HK@/^&@OA=_T4GPA_X/;7_P".4?\ #07PN_Z*3X0_\'MK_P#'*/95
M/Y7]P<DNQW]%<!_PT%\+O^BD^$/_  >VO_QRC_AH+X7?]%)\(?\ @]M?_CE'
MLJG\K^X.278[^BN _P"&@OA=_P!%)\(?^#VU_P#CE'_#07PN_P"BD^$/_![:
M_P#QRCV53^5_<')+L=_17 ?\-!?"[_HI/A#_ ,'MK_\ '*/^&@OA=_T4GPA_
MX/;7_P".4>RJ?RO[@Y)=COZ*X#_AH+X7?]%)\(?^#VU_^.4?\-!?"[_HI/A#
M_P 'MK_\<H]E4_E?W!R2['?T5P'_  T%\+O^BD^$/_![:_\ QRC_ (:"^%W_
M $4GPA_X/;7_ ..4>RJ?RO[@Y)=COZ*X#_AH+X7?]%)\(?\ @]M?_CE'_#07
MPN_Z*3X0_P#![:__ !RCV53^5_<')+L=_17 ?\-!?"[_ **3X0_\'MK_ /'*
M/^&@OA=_T4GPA_X/;7_XY1[*I_*_N#DEV._HK@/^&@OA=_T4GPA_X/;7_P".
M4?\ #07PN_Z*3X0_\'MK_P#'*/95/Y7]P<DNQW]%<!_PT%\+O^BD^$/_  >V
MO_QRC_AH+X7?]%)\(?\ @]M?_CE'LJG\K^X.278[^BN _P"&@OA=_P!%)\(?
M^#VU_P#CE'_#07PN_P"BD^$/_![:_P#QRCV53^5_<')+L=_17 ?\-!?"[_HI
M/A#_ ,'MK_\ '*/^&@OA=_T4GPA_X/;7_P".4>RJ?RO[@Y)=COZ*X#_AH+X7
M?]%)\(?^#VU_^.4?\-!?"[_HI/A#_P 'MK_\<H]E4_E?W!R2['?T5P'_  T%
M\+O^BD^$/_![:_\ QRC_ (:"^%W_ $4GPA_X/;7_ ..4>RJ?RO[@Y)=COZ*X
M#_AH+X7?]%)\(?\ @]M?_CE'_#07PN_Z*3X0_P#![:__ !RCV53^5_<')+L=
M_17 ?\-!?"[_ **3X0_\'MK_ /'*/^&@OA=_T4GPA_X/;7_XY1[*I_*_N#DE
MV._HK@/^&@OA=_T4GPA_X/;7_P".4?\ #07PN_Z*3X0_\'MK_P#'*/95/Y7]
MP<DNQW]%<!_PT%\+O^BD^$/_  >VO_QRC_AH+X7?]%)\(?\ @]M?_CE'LJG\
MK^X.278[^BN _P"&@OA=_P!%)\(?^#VU_P#CE'_#07PN_P"BD^$/_![:_P#Q
MRCV53^5_<')+L=_17 ?\-!?"[_HI/A#_ ,'MK_\ '*/^&@OA=_T4GPA_X/;7
M_P".4>RJ?RO[@Y)=COZ*X#_AH+X7?]%)\(?^#VU_^.4?\-!?"[_HI/A#_P '
MMK_\<H]E4_E?W!R2['?T5P'_  T%\+O^BD^$/_![:_\ QRC_ (:"^%W_ $4G
MPA_X/;7_ ..4>RJ?RO[@Y)=COZ*X#_AH+X7?]%)\(?\ @]M?_CE'_#07PN_Z
M*3X0_P#![:__ !RCV53^5_<')+L=_17 ?\-!?"[_ **3X0_\'MK_ /'*/^&@
MOA=_T4GPA_X/;7_XY1[*I_*_N#DEV._HK@/^&@OA=_T4GPA_X/;7_P".4?\
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M+X7?]%)\(?\ @]M?_CE'_#07PN_Z*3X0_P#![:__ !RCV53^5_<')+L=_17
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M07PN_P"BD^$/_![:_P#QRCV53^5_<')+L=_17 ?\-!?"[_HI/A#_ ,'MK_\
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MT%\+O^BD^$/_  >VO_QRC_AH+X7?]%)\(?\ @]M?_CE'LJG\K^X.278[^BN
M_P"&@OA=_P!%)\(?^#VU_P#CE'_#07PN_P"BD^$/_![:_P#QRCV53^5_<')+
ML=_17 ?\-!?"[_HI/A#_ ,'MK_\ '*/^&@OA=_T4GPA_X/;7_P".4>RJ?RO[
M@Y)=COZ*X#_AH+X7?]%)\(?^#VU_^.4?\-!?"[_HI/A#_P 'MK_\<H]E4_E?
MW!R2['?T5R&@_&+P%XJU:#2]%\;^'-7U.?=Y5E8:M;SS2;5+-M17).%4DX'
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MM%&T5+MHVT 1;11M%2[:-M $6T4;14NVC;0!%M%&T5+MHVT 1;11M%2[:-M
M$6T4;14NVC;0!%M%&T5+MHVT 1;11M%2[:-M $6T4;14NVC;0!%M%&T5+MHV
MT 1;11M%2[:-M $6T4;14NVC;0!%M%&T5+MHVT 1;11M%2[:-M $6T4;14NV
MC;0!%M%&T5+MHVT 1;11M%2[:-M $6T4;14NVC;0!%M%&T5+MHVT 1;11M%2
M[:-M $6T4;14NVC;0!%M%&T5+MHVT 1;11M%2[:-M $6T4;14NVC;0!%M%&T
M5+MHVT 1;11M%2[:-M $6T4;14NVC;0!%M%&T5+MHVT 1;11M%2[:-M $6T4
M;14NVC;0!%M%&T5+MHVT 1;11M%2[:-M $6T4;14NVC;0!%M%&T5+MHVT 1;
M11M%2[:-M $6T4;14NVC;0!%M%&T5+MHVT 1;11M%2[:-M $6T4;14NVC;0!
M%M%&T5+MHVT 1;11M%2[:-M $6T4;14NVC;0!%M%&T5+MHVT 1;11M%2[:-M
M $6T4;14NVC;0!%M%&T5+MHVT 1;11M%2[:-M $6T4;14NVC;0!%M%&T5+MH
MVT 1;11M%2[:-M $6T4;14NVC;0!%M%&T5+MHVT 1;11M%2[:-M $6T4;14N
MVC;0!%M%&T5+MHVT 1;11M%2[:-M $6T4;14NVC;0!%M%&T5+MHVT 1;11M%
M2[:-M $6T4;14NVC;0!%M%&T5+MHVT 1;11M%2[:-M $6T4;14NVC;0![O\
ML(C_ (RL\#_]OW_I#<5^NM?D=^PFO_&57@C_ +?O_2&XK]<:^1S?^/'T_5GA
M8_\ BKT_S"BBBO#/-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/C)!I'PXUG6M*TQIA8:7:Z7>26K71)YFDV,.O7YN%4=OFK] OA+X)O\ X?\
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M^U:^9S*$*>*G&GMI^6I\KB(QA7G&&R?]?<[H****\PYPHHHH **** "BBB@
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M4;?:@!FVC;3]OM1M]J &;:-M/V^U&WVH 9MHVT_;[4;?:@!FVC;3]OM1M]J
M&;:-M/V^U&WVH 9MHVT_;[4;?:@!FVC;3]OM1M]J &;:-M/V^U&WVH 9MHVT
M_;[4;?:@!FVC;3]OM1M]J &;:-M/V^U&WVH 9MHVT_;[4;?:@!FVC;3]OM1M
M]J &;:-M/V^U&WVH 9MHVT_;[4;?:@!FVC;3]OM1M]J &;:-M/V^U&WVH 9M
MHVT_;[4;?:@!FVC;3]OM1M]J &;:-M/V^U&WVH 9MHVT_;[4;?:@!FVC;3]O
MM1M]J &;:-M/V^U&WVH 9MHVT_;[4;?:@!FVC;3]OM1M]J &;:-M/V^U&WVH
M 9MHVT_;[4;?:@!FVC;3]OM1M]J &;:-M/V^U&WVH 9MHVT_;[4;?:@!FVC;
M3]OM1M]J &;:-M/V^U&WVH 9MHVT_;[4;?:@!FVC;3]OM1M]J &;:-M/V^U&
MWVH 9MHVT_;[4;?:@!FVC;3]OM1M]J &;:-M/V^U&WVH 9MHVT_;[4;?:@!F
MVC;3]OM1M]J &;:-M/V^U&WVH 9MHVT_;[4;?:@!FVC;3]OM1M]J &;:-M/V
M^U&WVH 9MHVT_;[4;?:@!FVC;3]OM1M]J &;:-M/V^U&WVH 9MHVT_;[4;?:
M@!FVC;3]OM1M]J &;:-M/V^U&WVH 9MHVT_;[4;?:@!FVC;3]OM1M]J &;:-
MM/V^U&WVH 9MHVT_;[4;?:@!FVC;3]OM1M]J &;:-M/V^U&WVH 9MHVT_;[4
M;?:@!FVC;3]OM1M]J &;:-M/V^U&WVH 9MHVT_;[4;?:@!FVC;3]OM1M]J &
M;:-M/V^U&WVH 9MHVT_;[4;?:@!FVC;3]OM1M]J &;:-M/V^U&WVH ]W_84'
M_&57@C_M^_\ 2&XK];Z_)/\ 867'[5'@C_M^_P#2&XK];*^.SC_>(^GZL\#'
M_P 5>G^84445X1YH445POQ>^,_ACX)>&3K/B6\,2N2EM9P@-<73@?=C7(S[D
MD =S3C%R:C%7;+A"522C%7;.ZHK\V?B!_P %$OB!K]Y*GA>TT_PM8;OW3&$7
M5SC_ &FD!3\ G'J:YG0_V]?C%I-XLUWKEEK40/-O?:; J'\85C;]:]N.3XJ4
M>9V7E<]3^R\1:^GWGZF45\T_L]_MN>'/C#?P:#K=LOACQ-+A88VEWVUVWI&Y
MP5;_ &&_ L:^EJ\NM0J8>7)55F>94ISI2Y)JS"BBBN<S"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **9-)Y,3OM9]JEMJC)..PK\YO"_[>7Q'U
M+XQ60N?LTGAV\U!+7^P5M4!CC>0(-LF/,,@![L03VQQ79A<)4QDI1I=#JI8:
MI6A.I':)^CE%%%<9RA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5YM\:O^//2/\ KNW\A7I->;?&K_CS
MTC_KNW\A0!Z31110!R/Q>_Y)/XT_[ MY_P"B'K\\O^">O_)PB?\ 8*NOYI7Z
M&_%[_DD_C3_L"WG_ *(>OSR_X)Z_\G")_P!@JZ_FE?099_ Q/^'])'LT?]PJ
M^O\ D;?[>'[/Y\ >+AX[T.W,>A:U-F[2(8%K>'DGCH).6'^T&]17C?QF^--W
M\9M+\&2ZKN?6M'T]M/N[ANEQAR4D^I4C/N">]?K+X\\$Z7\1_!^J^&]:@\_3
MM0A,,@[J>JNOHRD!@>Q K\>?BO\ #35?A%X\U7POJZ?Z19R?NY@,+/$>4D7V
M8?D<CJ*[LJQ$:ZC1J?%#6/I:WX7_ "['J8"M'$Q3G\<?R_K<_1CX:ZE=Z/\
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M&K]HSP9\";&)O$-Y)-J,Z[K?2K%1)<RKG&[!("KG^)B <'&2,5)X#^#O@?\
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M -+#730HX>6+JTZ:M&*MHW\^O_ %3A2J4\3*"LDM-7V?WWM?4^SOVB/VT?\
MA0?Q 3PQ_P (=_;NZSCN_M7]J?9_OLPV[?)?IMZY[UF:E^W[HLWQ'TSPIX:\
M+7/B/[5=1637R7JQ)YKL%/E+L;S%!.-Q*YQD<<U\\?\ !1+_ ). A_[ UM_Z
M'+7T;^R?^ROX,T/P+X)\<7UA)>^+9H4U6.\>XD"Q>8I*((PVP@*P.2"=W.>U
M8PH82GA(8BM%MN^W5ZVZ]+%8BCAJ-"$W'WI1T];+5Z]_SV-;]I+]L3_AGOQM
M8>'_ /A$?[?^U:>E]]H_M+[-MW22)LV^2^?]7G.>_3BO;/AKXR_X6%X!\/\
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MH(/45)10W?5DG'6_P;\ 6=\+V#P-X;@O%;<+B/2+=9 ?7<$SFNP50J@ 8 X
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MS;7R'C<='1ARK#/4>I'0D5W8+%/!U?:)76S7D>A@\2L/)J:O&6YX=\%?VYO
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M[/\ [(QG]\9?+\SS_?&[;[X[5R9;B*="I.55VNCEPM:G3H5H2=G):?<SY_\
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M\>O^&A?!>H:__87]@?9;]K'[/]K^T[L1QONW>6F/]9C&.W6MC]H;_DA/C_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]I:?Y?Y?,]G+9ISE0GM-?U^%SZE^*7Q8L?!OP1U;QU:3I)!_9HN;%B>)))5
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M:)9MTA55+9D9B.$48!QQ7S=*O&&'J4GO*UODSR/;1^K*CUYK_A8ZVBBBN$Y
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH BF^Z:\I\;?'O3/ACXVAT/6;28V5Q:)=+>0?,4):52"O<?NT
MQCU->KR]#7S9^TI\']=\::W;Z_HXBNA;V:VSV>[;*=KNVY<\'[_3(/'&:]O)
MZ6$KXI4\:[0:>M[:]-?\]#Y3B;$9EA,O=?*H\U6+3M:]UUTZ_+7L?0?A[Q1I
M/BRQ%YH^H6^H6Q_C@<'')'(ZCE3U]*U*_-K3-:U_P#K#O9W-YHNHQ'#J,QL#
M@CYE/LQZCO7T+\/?VPON6OB^Q]?]/L5_WC\T?_?"C'N37OYAPIB*"]IA'[2/
MX_Y/Y?<?&9+XC8'%M4,SC["IM?[-_P X_/1=SZ@HK+\/>*-)\66(O-'U"WU&
MV/\ ' X..2.1U'*GKZ5J5\/*,J<G&:LT?K5.I"M!5*<DXO9K5/YA1114F@44
M44 %%%% !1167XB\4:3X1T]K[6=0M].M5_Y:3N!D^BCJQ]ADU48RJ248*[9G
M4J0HP=2I)**W;T2^9J5E^(O%&D^$=/:^UG4+?3K5?^6D[@9/HHZL?89-?.?Q
M$_;"_P!;9^#K+_9_M*^7]4C_ *M_WS7SGXB\4:MXNU!K[6=0N-1NF_Y:3N3@
M>BCHH]AQ7W.7<)XG$6GBG[./;[7_  /G]Q^1YWXD8# WI9<O;3[[07SWE\M/
M,]B_:'^/FE?$S2[?0M&LYOL=M=K=&^G^0R%4= %3J!\Y.20>.E?#?[2GWO#?
M_;S_ .TJ]AU;6+'0[-KK4+N*SMUZR3,%'T'J?85\\?&#X@:=XZO=.CTQ)C#9
M>;F:1=HDW[.@ZX&WOCKTK[7&4,+EN7/!T7;:RO=O5-O^M#Y'@JIFO$'%5'.,
M13<HQYE*25HKW))*_JUIJ^K.,L>U;]IT%8EBO2MVU7I7RU(_KN!>2G4BTM=J
M.@****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% 'NO[#O_)T7@K_ +??_2&XK]8:_)_]AW_DZ+P5_P!O
MO_I#<5^L%?%9W_O$?\*_-GSV8_Q5Z?JPHHHKY\\L**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0:^UG4+C4;IO^6D[DX'HHZ*/8<5]MEW">)Q%IXI^SCV^U_P/G]Q^3YWXD8#
MWI9<O;3[[07SWE\M/,^C/B)^V%_K;/P=9?[/]I7R_JD?]6_[YKYS\1>*-6\7
M:@U]K.H7&HW3?\M)W)P/11T4>PXK.AADN) D:,['LHS6[I_A1Y,-<MM'_/-.
MOXFOM[93P[#HI??)_K^2/R7FXDXXK6UE"_\ AIQ_2_WR.2U;6+'0K-KK4+N*
MSMUZR3,%'T'J?85X]XP_:(1=]OX<M?,/3[;=*0OU5.OXMCZ5]23?#70-::-[
M_0=.OW0;5>ZM$E8#TRP)K2L?@CX/DQGPAH9_[AL/_P 37R>+XOG5O&A!Q7?K
M_P #^M3]>R#PXRW 6K9H_;3[;07RWE\[+^Z?G3K&M:EXDO#=:G>37L_9I&X7
MV Z >PIEO;G/2OU TSX!^"Y,;O!N@GZZ7!_\378:3^SWX$.W=X(\.GZZ3!_\
M17SG]J1D^:46V?ME&M1P\%2I0Y8K9*R2]$C\I[.'&*V+=, 5^N6E_L^_#Q<;
MO 7AEOKH]O\ _$5TEK\ OALJC/P]\*GZZ+;?_$5O'.*<?L,ZXYA!?9/QS6EK
M]F5^ OPS_P"B=^$__!);?_$4[_A0OPS_ .B=>$__  1VO_Q%;?VY3_D9?]I0
M_E/QDHK]F_\ A0OPS_Z)UX3_ /!':_\ Q%'_  H7X9_]$Z\)_P#@CM?_ (BC
M^W*?\C#^TH?RGXR45^S?_"A?AG_T3KPG_P"".U_^(H_X4+\,_P#HG7A/_P $
M=K_\11_;E/\ D8?VE#^4_&2BOV;_ .%"_#/_ *)UX3_\$=K_ /$4?\*%^&?_
M $3KPG_X([7_ .(H_MRG_(P_M*'\I^,E%?LW_P *%^&?_1.O"?\ X([7_P"(
MH_X4+\,_^B=>$_\ P1VO_P 11_;E/^1A_:4/Y3\9**_9O_A0OPS_ .B=>$__
M  1VO_Q%'_"A?AG_ -$Z\)_^".U_^(H_MRG_ ",/[2A_*?C)17[-_P#"A?AG
M_P!$Z\)_^".U_P#B*/\ A0OPS_Z)UX3_ /!':_\ Q%']N4_Y&']I0_E/QDHK
M]F_^%"_#/_HG7A/_ ,$=K_\ $4?\*%^&?_1.O"?_ (([7_XBC^W*?\C#^TH?
MRGXR45^S?_"A?AG_ -$Z\)_^".U_^(H_X4+\,_\ HG7A/_P1VO\ \11_;E/^
M1A_:4/Y3\9**_9O_ (4+\,_^B=>$_P#P1VO_ ,11_P *%^&?_1.O"?\ X([7
M_P"(H_MRG_(P_M*'\I^,E%?LW_PH7X9_]$Z\)_\ @CM?_B*/^%"_#/\ Z)UX
M3_\ !':__$4?VY3_ )&']I0_E/QDHK]F_P#A0OPS_P"B=>$__!':_P#Q%'_"
MA?AG_P!$Z\)_^".U_P#B*/[<I_R,/[2A_*?C)17[-_\ "A?AG_T3KPG_ .".
MU_\ B*/^%"_#/_HG7A/_ ,$=K_\ $4?VY3_D8?VE#^4_&2BOV;_X4+\,_P#H
MG7A/_P $=K_\11_PH7X9_P#1.O"?_@CM?_B*/[<I_P C#^TH?RGXR45^S?\
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M .B=>$__  1VO_Q%']N4_P"1A_:4/Y3\9**_9O\ X4+\,_\ HG7A/_P1VO\
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M=>$__!':_P#Q%'_"A?AG_P!$Z\)_^".U_P#B*/[<I_R,/[2A_*?C)17[-_\
M"A?AG_T3KPG_ .".U_\ B*/^%"_#/_HG7A/_ ,$=K_\ $4?VY3_D8?VE#^4_
M&2BOV;_X4+\,_P#HG7A/_P $=K_\11_PH7X9_P#1.O"?_@CM?_B*/[<I_P C
M#^TH?RGXR45^S?\ PH7X9_\ 1.O"?_@CM?\ XBC_ (4+\,_^B=>$_P#P1VO_
M ,11_;E/^1A_:4/Y3\9**_9O_A0OPS_Z)UX3_P#!':__ !%'_"A?AG_T3KPG
M_P"".U_^(H_MRG_(P_M*'\I^,E%?LW_PH7X9_P#1.O"?_@CM?_B*/^%"_#/_
M *)UX3_\$=K_ /$4?VY3_D8?VE#^4_&2BOV;_P"%"_#/_HG7A/\ \$=K_P#$
M4?\ "A?AG_T3KPG_ .".U_\ B*/[<I_R,/[2A_*?C)17[-_\*%^&?_1.O"?_
M (([7_XBC_A0OPS_ .B=>$__  1VO_Q%']N4_P"1A_:4/Y3\9**_9O\ X4+\
M,_\ HG7A/_P1VO\ \11_PH7X9_\ 1.O"?_@CM?\ XBC^W*?\C#^TH?RGXR45
M^S?_  H7X9_]$Z\)_P#@CM?_ (BC_A0OPS_Z)UX3_P#!':__ !%']N4_Y&']
MI0_E/QDHK]F_^%"_#/\ Z)UX3_\ !':__$4?\*%^&?\ T3KPG_X([7_XBC^W
M*?\ (P_M*'\I^,E%?LW_ ,*%^&?_ $3KPG_X([7_ .(H_P"%"_#/_HG7A/\
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M/[2A_*?C)17[-_\ "A?AG_T3KPG_ .".U_\ B*/^%"_#/_HG7A/_ ,$=K_\
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M':__ !%']N4_Y&']I0_E/QDHK]F_^%"_#/\ Z)UX3_\ !':__$4?\*%^&?\
MT3KPG_X([7_XBC^W*?\ (P_M*'\I^,E%?LW_ ,*%^&?_ $3KPG_X([7_ .(H
M_P"%"_#/_HG7A/\ \$=K_P#$4?VY3_D8?VE#^4_&2BOV;_X4+\,_^B=>$_\
MP1VO_P 11_PH7X9_]$Z\)_\ @CM?_B*/[<I_R,/[2A_*?C)17[-_\*%^&?\
MT3KPG_X([7_XBC_A0OPS_P"B=>$__!':_P#Q%']N4_Y&']I0_E/QDHK]F_\
MA0OPS_Z)UX3_ /!':_\ Q%'_  H7X9_]$Z\)_P#@CM?_ (BC^W*?\C#^TH?R
MGXR45^S?_"A?AG_T3KPG_P"".U_^(H_X4+\,_P#HG7A/_P $=K_\11_;E/\
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MO_Q%']N4_P"1A_:4/Y3\9**_9O\ X4+\,_\ HG7A/_P1VO\ \11_PH7X9_\
M1.O"?_@CM?\ XBC^W*?\C#^TH?RGXR45^S?_  H7X9_]$Z\)_P#@CM?_ (BC
M_A0OPS_Z)UX3_P#!':__ !%']N4_Y&']I0_E/QDHK]F_^%"_#/\ Z)UX3_\
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M;E/^1A_:4/Y3\9**_9O_ (4+\,_^B=>$_P#P1VO_ ,11_P *%^&?_1.O"?\
MX([7_P"(H_MRG_(P_M*'\I^,E%?LW_PH7X9_]$Z\)_\ @CM?_B*/^%"_#/\
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M[2A_*?C)17[-_P#"A?AG_P!$Z\)_^".U_P#B*/\ A0OPS_Z)UX3_ /!':_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU %6WLPF.*N)'MIX7%.H 0<4M%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%>4ZIK7Q
M2CU*[6ST:T>T69Q"Q\O)3<=I_P!9Z8JK_;GQ:_Z EG_Y#_\ CE ['L%%>/\
M]N?%K_H"6?\ Y#_^.4?VY\6O^@)9_P#D/_XY0%CV"BO'_P"W/BU_T!+/_P A
M_P#QRC^W/BU_T!+/_P A_P#QR@+'L%%>/_VY\6O^@)9_^0__ (Y1_;GQ:_Z
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M*\?_ +<^+7_0$L__ "'_ /'*/[<^+7_0$L__ "'_ /'* L>P45X__;GQ:_Z
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MK_H"6?\ Y#_^.4!8]@HKQ_\ MSXM?] 2S_\ (?\ \<H_MSXM?] 2S_\ (?\
M\<H"Q[!17C_]N?%K_H"6?_D/_P".4?VY\6O^@)9_^0__ (Y0%CV"BO'_ .W/
MBU_T!+/_ ,A__'*/[<^+7_0$L_\ R'_\<H"Q[!17C_\ ;GQ:_P"@)9_^0_\
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M?_QRC^W/BU_T!+/_ ,A__'* L>P45X__ &Y\6O\ H"6?_D/_ ..4?VY\6O\
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M<^+7_0$L_P#R'_\ '* L>P45X_\ VY\6O^@)9_\ D/\ ^.4?VY\6O^@)9_\
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M $!+/_R'_P#'* L>P45X_P#VY\6O^@)9_P#D/_XY1_;GQ:_Z EG_ .0__CE
M6/8**\?_ +<^+7_0$L__ "'_ /'*/[<^+7_0$L__ "'_ /'* L>P45X__;GQ
M:_Z EG_Y#_\ CE']N?%K_H"6?_D/_P".4!8]@HKQ_P#MSXM?] 2S_P#(?_QR
MC^W/BU_T!+/_ ,A__'* L>P45X__ &Y\6O\ H"6?_D/_ ..4?VY\6O\ H"6?
M_D/_ ..4!8]@HKQ_^W/BU_T!+/\ \A__ !RC^W/BU_T!+/\ \A__ !R@+'L%
M%>/_ -N?%K_H"6?_ )#_ /CE']N?%K_H"6?_ )#_ /CE 6/8**\?_MSXM?\
M0$L__(?_ ,<H_MSXM?\ 0$L__(?_ ,<H"Q[!17C_ /;GQ:_Z EG_ .0__CE'
M]N?%K_H"6?\ Y#_^.4!8]@HKQ_\ MSXM?] 2S_\ (?\ \<H_MSXM?] 2S_\
M(?\ \<H"Q[!17C_]N?%K_H"6?_D/_P".4?VY\6O^@)9_^0__ (Y0%CV"BO'_
M .W/BU_T!+/_ ,A__'*/[<^+7_0$L_\ R'_\<H"Q[!17C_\ ;GQ:_P"@)9_^
M0_\ XY1_;GQ:_P"@)9_^0_\ XY0%CV"BO'_[<^+7_0$L_P#R'_\ '*/[<^+7
M_0$L_P#R'_\ '* L>P45X_\ VY\6O^@)9_\ D/\ ^.4?VY\6O^@)9_\ D/\
M^.4!8]@HKQ_^W/BU_P! 2S_\A_\ QRC^W/BU_P! 2S_\A_\ QR@+'L%%>/\
M]N?%K_H"6?\ Y#_^.4?VY\6O^@)9_P#D/_XY0%CV"BFIN*+N&&QR/>G4""BB
MB@ HHHH 3;4;1!JEHH HS68;M69=:4KY^6N@VBHVB#=J .$U#P^KY^6N:OO"
MX8GY*]7FLPW:J$VEJW:@#R)O"?S?<JW9^%-K#Y/TKTAM'3^Z*FATE5["@#E=
M/\-A<?+70V>C+'CY:V(;$+VJVD(7M0!3@L0F.*N1PA:E5<4Z@!H4"G444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5YM\:O^//2/^N[?R%>DUYM\:O\ CSTC_KNW\A0!Z31110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1124 +24<_2B@!"N[VIDD.X?+U]ZEH
MH SY&\LX9=I]_P /\:1)US6@RAAA@&'H16=<:1NY@?RS_=;D=O\ Z_YTQ%F.
M4&IE8&N>:XGLF"SHR>_4=N_XBKMOJ ?'-(9K4M5H[@-WJ=7S0 ZBDI: "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *\V^-7_'GI'_7=OY"O2:\V^-7_'GI'_7=OY"@#TFBBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_@S@_P#BJ/JN(_Y]O[F']HX+_G]'_P "7^9U-%<M_P +4\%?]#?H/_@S@_\
MBJ/^%J>"O^AOT'_P9P?_ !5'U7$?\^W]S#^T<%_S^C_X$O\ ,ZFBN6_X6IX*
M_P"AOT'_ ,&<'_Q5'_"U/!7_ $-^@_\ @S@_^*H^JXC_ )]O[F']HX+_ )_1
M_P# E_F=317+?\+4\%?]#?H/_@S@_P#BJ/\ A:G@K_H;]!_\&<'_ ,51]5Q'
M_/M_<P_M'!?\_H_^!+_,ZFBN6_X6IX*_Z&_0?_!G!_\ %4?\+4\%?]#?H/\
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MC@O^?T?_  )?YG4T5RW_  M3P5_T-^@_^#.#_P"*H_X6IX*_Z&_0?_!G!_\
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MP5_T-^@_^#.#_P"*H^JXC_GV_N8?VC@O^?T?_ E_F=317+?\+4\%?]#?H/\
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M\"7^9U-%<M_PM3P5_P!#?H/_ (,X/_BJ/^%J>"O^AOT'_P &<'_Q5'U7$?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME^VK:_\ )!_PS^+&A?%/2VN=*E:*ZA ^T6,V!+"3WQW4]F''T/%=I7EGP7^
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M444 %%%% !1110 4444 %%%% ')_%JWCN?A;XOCFC65/[(NVVN,C(A8@_4$
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXG>#K>9XI?%FAQRHQ5T?4H0RD<$$;N#4]C\0/"VJ3"*S\2:1=RG@)!?Q.Q_
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MS3+\+EO%V7/!4U34D[J*27VELM-G9G,?M/>,KKQ)\3[ZP>1A8Z3BV@BS\H;
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M _1KX5_\DP\(?]@>S_\ 1"5U-<M\*_\ DF'A#_L#V?\ Z(2NIK^;,5_O%3U?
MYG]X9=_N5'_#'\D%%%%<IZ 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=1GR;BW-MN]@0SC/UQ7UDJK&H50%51@*!@ 4ZG5XKS&57GIM1C_+9/\ '?\
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M#'MM]6ARY4<><F%;\QM/YU](_!'QC_PG'PST749)/,NTB^S7))R?-C^4D^[
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M[V?/:35KVWG+K9_D?;5%?"4&D_$_XT:1%+:6UYJ&C6,26T4*2K!; (H7"JS
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M?^N-O_Z*6OM?0?\ D!Z=_P!>T?\ Z"*^*/VIO^2S:K_UQM__ $4M>Z_M(_\
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MK4(U/^P+UV?Y_,NKB..8^Y5W#Y_"NC^&_P </%?PG\3)HWBMKZXTL.([BUU
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MV:A\^7=/UM^7F?,O_!3KX%_#;X?_  [\,^(?#7A_2?"^ORZF++[/I-NELES
M8G9B8D 4E65/FQGYL$\BK?\ P46\.Z5_PRO\+=<_LRS_ +;W:?9_VE]G3[3Y
M'V.1_*\S&[9N^;;G&><5TGBW_@E_?>/-+BD\2_&SQ#XB\2Q2 )JFKVCW4:6^
M#F)8GN"P)8J=WF8XQMYS7MW[17[)_P#PO[X.>%O ?_"4_P!A?V'+;R_VA_9_
MVCSO*@:+'E^:FW.[/WCC&.>M)5H4X0C[3F:FGUT77^O4T47*IS<MER27SZ?U
MY(^-?VN?A]X=3Q9^S)X<L]'L]+TC5+2V2[M=/@2W20S2VXE<A /F;)RW4FO0
M_P#@J'X/T+P+\%?A_I'AS1['0M+CUV1DL].MT@B5C"Q)"J ,D\D]Z]S^+?[&
MO_"TO%?PFUK_ (2_^S/^$#CMX_(_LSSOMWE/$^=WG+Y>?*QT;&[OBMW]K?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% 'Z-?"O_DF'A#_L#V?_ *(2
MNIKEOA7_ ,DP\(?]@>S_ /1"5U-?S9BO]XJ>K_,_O#+O]RH_X8_D@HHHKE/0
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB)X>KO'^D_F>UE694,WP5/'8?X9KYI]4_-/0****XCU@HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#]&OA7_P DP\(?]@>S_P#1"5U-<M\*_P#DF'A#_L#V?_HA*ZFOYLQ7
M^\5/5_F?WAEW^Y4?\,?R04445RGH!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]M4]&UK^9';V\=G;Q00H(X8E"(B]%4#  _"I***X=]6>LDHJR"BBBD,****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** /T:^%?_ "3#PA_V![/_ -$)74UR
MWPK_ .28>$/^P/9_^B$KJ:_FS%?[Q4]7^9_>&7?[E1_PQ_)!1117*>@%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5;V]1M>BZ_>VOD%%%%?#GZT%%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /T:^%?_),/"'_8'L__ $0E=37+?"O_ ))AX0_[ ]G_ .B$KJ:_
MFS%?[Q4]7^9_>&7?[E1_PQ_)!1117*>@%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH/\ X+(/_B:/^%5^"O\ H4-!_P#!9!_\374T4_K6(_Y^/[V+^S\'_P ^8_\
M@*_R.6_X57X*_P"A0T'_ ,%D'_Q-'_"J_!7_ $*&@_\ @L@_^)KJ:*/K6(_Y
M^/[V']GX/_GS'_P%?Y'+?\*K\%?]"AH/_@L@_P#B:/\ A5?@K_H4-!_\%D'_
M ,374T4?6L1_S\?WL/[/P?\ SYC_ . K_(Y;_A5?@K_H4-!_\%D'_P 31_PJ
MOP5_T*&@_P#@L@_^)KJ:*/K6(_Y^/[V']GX/_GS'_P !7^1RW_"J_!7_ $*&
M@_\ @L@_^)H_X57X*_Z%#0?_  60?_$UU-%'UK$?\_'][#^S\'_SYC_X"O\
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MR#_XFC_A5?@K_H4-!_\ !9!_\374T4?6L1_S\?WL/[/P?_/F/_@*_P CEO\
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M?\_'][#^S\'_ ,^8_P#@*_R.6_X57X*_Z%#0?_!9!_\ $T?\*K\%?]"AH/\
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M_'][#^S\'_SYC_X"O\CEO^%5^"O^A0T'_P %D'_Q-'_"J_!7_0H:#_X+(/\
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M_!9!_P#$T?\ "J_!7_0H:#_X+(/_ (FNIHH^M8C_ )^/[V']GX/_ )\Q_P#
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MCZUB/^?C^]A_9^#_ .?,?_ 5_D16MK!8VL-M;0QV]M"BQQ0Q*%1% P%4#@
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M/!G_ $&1_P" TW_Q% 69V]>;?&K_ (\](_Z[M_(5I?\ "Z/!G_09'_@--_\
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M?Q@\%K_S&!_X#3?_ !% 69T]OIRKCBK\=N%[5QZ_&7P8/^8R/_ :;_XBG_\
M"Z/!G_09'_@--_\ $4!9G:+'3L5Q/_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'
M_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G
M;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_
M $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q
M%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'
M_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G
M;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_
M $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q
M%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'
M_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G
M;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_
M $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q
M%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'
M_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G
M;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_
M $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q
M%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'
M_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G
M;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_
M $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q
M%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'
M_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G
M;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_
M $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q
M%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'
M_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G
M;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_
M $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q
M%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'
M_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G
M;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_
M $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q
M%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'
M_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G
M;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_
M $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q
M%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'
M_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G
M;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_
M $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q
M%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'
M_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G
M;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_
M $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q
M%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'
M_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G
M;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_
M $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q
M%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'
M_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G
M;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_
M $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q
M%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'
M_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G
M;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_
M $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q
M%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'
M_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G
M;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_
M $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q
M%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'
M_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G
M;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_
M $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q
M%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'
M_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G
M;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_
M $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q
M%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'
M_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G
M;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_
M $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q
M%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'
M_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G
M;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_
M $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q
M%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'
M_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G
M;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_
M $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q
M%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'
M_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G
M;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_
M $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q
M%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'
M_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G
M;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_
M $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q
M%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'
M_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G
M;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_
M $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q
M%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'
M_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G
M;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_
M $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q
M%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'
M_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G
M;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_
M $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q
M%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'
M_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G
M;T5Q'_"Z/!G_ $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_
M $&1_P" TW_Q%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q
M%'_"Z/!G_09'_@--_P#$4!9G;T5Q'_"Z/!G_ $&1_P" TW_Q%='X>\3:;XJL
M6O-*N?M5LLAB+[&3Y@ 2,, >A% C\5_V@OC=X[T?X]?$FPLO$]];65KXEU*"
M"&-P%CC6ZD55''0  ?A7 ?\ #0'Q$_Z&[4?^^Q_A4_[2G_)QGQ4_[&O5?_2R
M6O.*^[IT:7)'W5MV/$E.5WJ>@?\ #0'Q$_Z&[4?^^Q_A1_PT!\1/^ANU'_OL
M?X5Y_16GL*7\B^Y$^TGW/0/^&@/B)_T-VH_]]C_"C_AH#XB?]#=J/_?8_P *
M\_HH]A2_D7W(/:3[GH'_  T!\1/^ANU'_OL?X4?\- ?$3_H;M1_[['^%>?T4
M>PI?R+[D'M)]ST#_ (: ^(G_ $-VH_\ ?8_PH_X: ^(G_0W:C_WV/\*\_HH]
MA2_D7W(/:3[GH'_#0'Q$_P"ANU'_ +['^%'_  T!\1/^ANU'_OL?X5Y_11["
ME_(ON0>TGW/0/^&@/B)_T-VH_P#?8_PH_P"&@/B)_P!#=J/_ 'V/\*\_HH]A
M2_D7W(/:3[GH'_#0'Q$_Z&[4?^^Q_A1_PT!\1/\ H;M1_P"^Q_A7G]%'L*7\
MB^Y![2?<] _X: ^(G_0W:C_WV/\ "C_AH#XB?]#=J/\ WV/\*\_HH]A2_D7W
M(/:3[GH'_#0'Q$_Z&[4?^^Q_A1_PT!\1/^ANU'_OL?X5Y_11["E_(ON0>TGW
M/0/^&@/B)_T-VH_]]C_"C_AH#XB?]#=J/_?8_P *\_HH]A2_D7W(/:3[GH'_
M  T!\1/^ANU'_OL?X4?\- ?$3_H;M1_[['^%>?T4>PI?R+[D'M)]ST#_ (:
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M_P!#=J/_ 'V/\*\_HH]A2_D7W(/:3[GH'_#0'Q$_Z&[4?^^Q_A1_PT!\1/\
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M  T!\1/^ANU'_OL?X4?\- ?$3_H;M1_[['^%>?T4>PI?R+[D'M)]ST#_ (:
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M_P!#=J/_ 'V/\*\_HH]A2_D7W(/:3[GH'_#0'Q$_Z&[4?^^Q_A1_PT!\1/\
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M  T!\1/^ANU'_OL?X4?\- ?$3_H;M1_[['^%>?T4>PI?R+[D'M)]ST#_ (:
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M_P!#=J/_ 'V/\*\_HH]A2_D7W(/:3[GH'_#0'Q$_Z&[4?^^Q_A1_PT!\1/\
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M_P!#=J/_ 'V/\*/^&@/B)_T-VH_]]C_"O/Z*/84OY%]R#VD^YZ!_PT!\1/\
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M_H;M1_[['^%>?T4>PI?R+[D'M)]ST#_AH#XB?]#=J/\ WV/\*/\ AH#XB?\
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M_P!#=J/_ 'V/\*/^&@/B)_T-VH_]]C_"O/Z*/84OY%]R#VD^YZ!_PT!\1/\
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M_H;M1_[['^%>?T4>PI?R+[D'M)]ST#_AH#XB?]#=J/\ WV/\*/\ AH#XB?\
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M_P!#=J/_ 'V/\*/^&@/B)_T-VH_]]C_"O/Z*/84OY%]R#VD^YZ!_PT!\1/\
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M_H;M1_[['^%>?T4>PI?R+[D'M)]ST#_AH#XB?]#=J/\ WV/\*/\ AH#XB?\
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M_P!#=J/_ 'V/\*/^&@/B)_T-VH_]]C_"O/Z*/84OY%]R#VD^YZ!_PT!\1/\
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M_H;M1_[['^%>?T4>PI?R+[D'M)]ST#_AH#XB?]#=J/\ WV/\*/\ AH#XB?\
M0W:C_P!]C_"O/Z*/84OY%]R#VD^YZ!_PT!\1/^ANU'_OL?X4?\- ?$3_ *&[
M4?\ OL?X5Y_11["E_(ON0>TGW/0/^&@/B)_T-VH_]]C_  H_X: ^(G_0W:C_
M -]C_"O/Z*/84OY%]R#VD^YZ!_PT!\1/^ANU'_OL?X4?\- ?$3_H;M1_[['^
M%>?T4>PI?R+[D'M)]ST#_AH#XB?]#=J/_?8_PH_X: ^(G_0W:C_WV/\ "O/Z
M*/84OY%]R#VD^YZ!_P - ?$3_H;M1_[['^%'_#0'Q$_Z&[4?^^Q_A7G]%'L*
M7\B^Y![2?<] _P"&@/B)_P!#=J/_ 'V/\*/^&@/B)_T-VH_]]C_"O/Z*/84O
MY%]R#VD^YZ!_PT!\1/\ H;M1_P"^Q_A1_P - ?$3_H;M1_[['^%>?T4>PI?R
M+[D'M)]ST#_AH#XB?]#=J/\ WV/\*/\ AH#XB?\ 0W:C_P!]C_"O/Z*/84OY
M%]R#VD^YZ!_PT!\1/^ANU'_OL?X4?\- ?$3_ *&[4?\ OL?X5Y_11["E_(ON
M0>TGW/0/^&@/B)_T-VH_]]C_  H_X: ^(G_0W:C_ -]C_"O/Z*/84OY%]R#V
MD^YZ!_PT!\1/^ANU'_OL?X4?\- ?$3_H;M1_[['^%>?T4>PI?R+[D'M)]ST#
M_AH#XB?]#=J/_?8_PH_X: ^(G_0W:C_WV/\ "O/Z*/84OY%]R#VD^YZ!_P -
M ?$3_H;M1_[['^%'_#0'Q$_Z&[4?^^Q_A7G]%'L*7\B^Y![2?<] _P"&@/B)
M_P!#=J/_ 'V/\*/^&@/B)_T-VH_]]C_"O/Z*/84OY%]R#VD^YZ!_PT!\1/\
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M_H;M1_[['^%>?T4>PI?R+[D'M)]ST#_AH#XB?]#=J/\ WV/\*/\ AH#XB?\
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M_P!#=J/_ 'V/\*/^&@/B)_T-VH_]]C_"O/Z*/84OY%]R#VD^YZ!_PT!\1/\
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M?P[\*6NK0^$)KF*_@T2V2=)A:%A(L@3<&SSN!SGFOQMKCH8E5Y3BE;E_X/\
MD:.%J<:G\W_ _P PHHHKL,PHHHH **** "BBB@ HHHH **** "BBB@ HK[@_
MX);_  ]\*_$'QEX[@\4^&='\2PVUA;/!'K%A%=K$QD8$J)%.TD#J*Y'_ (*7
M>"_#W@/]H+3M.\,Z#IGAW3V\/VTS6FDV<=K$9#-< N4C4#<0JC.,\#TKCEB5
M&NJ%M6:0ASPE/M_P/\SY-HHHKL,PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVIO3=/#J;4KMJUODU^OY#_V;?V8?%O[3/BJ33- 6.QTRSVMJ.L70/DVJD\#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K]9?^"3/_)N?B/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "OUE_X),_\FY^(_P#L:[G_ -([.OR:K]9?^"3/_)N?
MB/\ [&NY_P#2.SKRLS_W=^J.K#?Q#\X?VE/^3C/BI_V->J_^EDM><5Z/^TI_
MR<9\5/\ L:]5_P#2R6O.*]&G\$?0YY?$PHHHK0D**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA[_P50?_ !%=911SR[A9')_\*C\#?]"7X>_\%4'_ ,11_P *C\#?]"7X>_\
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M')_\*C\#?]"7X>_\%4'_ ,11_P *C\#?]"7X>_\ !5!_\17644<\NX61R?\
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MA[_P50?_ !%=911SR[A9')_\*C\#?]"7X>_\%4'_ ,11_P *C\#?]"7X>_\
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M !YZ1_UW;^0HYY=PLC=_X5'X&_Z$OP]_X*H/_B*/^%1^!O\ H2_#W_@J@_\
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M(H_X5'X&_P"A+\/?^"J#_P"(KK**.>7<+(Y/_A4?@;_H2_#W_@J@_P#B*/\
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MCD_^%1^!O^A+\/?^"J#_ .(H_P"%1^!O^A+\/?\ @J@_^(KK**.>7<+(Y/\
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M1^!O^A+\/?\ @J@_^(KK**.>7<+(Y/\ X5'X&_Z$OP]_X*H/_B*/^%1^!O\
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MX*H/_B*/^%1^!O\ H2_#W_@J@_\ B*ZRBCGEW"R.3_X5'X&_Z$OP]_X*H/\
MXBC_ (5'X&_Z$OP]_P""J#_XBNLHHYY=PLCD_P#A4?@;_H2_#W_@J@_^(H_X
M5'X&_P"A+\/?^"J#_P"(KK**.>7<+(Y/_A4?@;_H2_#W_@J@_P#B*/\ A4?@
M;_H2_#W_ (*H/_B*ZRBCGEW"R.3_ .%1^!O^A+\/?^"J#_XBC_A4?@;_ *$O
MP]_X*H/_ (BNLHHYY=PLCD_^%1^!O^A+\/?^"J#_ .(H_P"%1^!O^A+\/?\
M@J@_^(KK**.>7<+(Y/\ X5'X&_Z$OP]_X*H/_B*/^%1^!O\ H2_#W_@J@_\
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M(H_X5'X&_P"A+\/?^"J#_P"(KK**.>7<+(Y/_A4?@;_H2_#W_@J@_P#B*/\
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MCD_^%1^!O^A+\/?^"J#_ .(H_P"%1^!O^A+\/?\ @J@_^(KK**.>7<+(Y/\
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M1^!O^A+\/?\ @J@_^(KK**.>7<+(Y/\ X5'X&_Z$OP]_X*H/_B*/^%1^!O\
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MX*H/_B*/^%1^!O\ H2_#W_@J@_\ B*ZRBCGEW"R.3_X5'X&_Z$OP]_X*H/\
MXBC_ (5'X&_Z$OP]_P""J#_XBNLHHYY=PLCD_P#A4?@;_H2_#W_@J@_^(H_X
M5'X&_P"A+\/?^"J#_P"(KK**.>7<+(Y/_A4?@;_H2_#W_@J@_P#B*/\ A4?@
M;_H2_#W_ (*H/_B*ZRBCGEW"R.3_ .%1^!O^A+\/?^"J#_XBC_A4?@;_ *$O
MP]_X*H/_ (BNLHHYY=PLCD_^%1^!O^A+\/?^"J#_ .(H_P"%1^!O^A+\/?\
M@J@_^(KK**.>7<+(Y/\ X5'X&_Z$OP]_X*H/_B*/^%1^!O\ H2_#W_@J@_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "O-OC5_QYZ1_UW;^0KTFO-OC
M5_QYZ1_UW;^0H ])HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M +EH_P"'KW_5+?\ RX?_ +EH_LG&_P GXK_,/K%+N?H%17Y^_P##U[_JEO\
MY</_ -RT?\/7O^J6_P#EP_\ W+1_9.-_D_%?YA]8I=S] J*_/W_AZ]_U2W_R
MX?\ [EH_X>O?]4M_\N'_ .Y:/[)QO\GXK_,/K%+N?H%17Y^_\/7O^J6_^7#_
M /<M'_#U[_JEO_EP_P#W+1_9.-_D_%?YA]8I=S] J*_/W_AZ]_U2W_RX?_N6
MC_AZ]_U2W_RX?_N6C^R<;_)^*_S#ZQ2[GZ!45^?O_#U[_JEO_EP__<M'_#U[
M_JEO_EP__<M']DXW^3\5_F'UBEW/T"HK\_?^'KW_ %2W_P N'_[EH_X>O?\
M5+?_ "X?_N6C^R<;_)^*_P P^L4NY^@5%?G[_P /7O\ JEO_ )</_P!RT?\
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M (>O?]4M_P#+A_\ N6C^R<;_ "?BO\P^L4NY^@5%?G[_ ,/7O^J6_P#EP_\
MW+1_P]>_ZI;_ .7#_P#<M']DXW^3\5_F'UBEW/T"HK\_?^'KW_5+?_+A_P#N
M6C_AZ]_U2W_RX?\ [EH_LG&_R?BO\P^L4NY^@5%?G[_P]>_ZI;_Y</\ ]RT?
M\/7O^J6_^7#_ /<M']DXW^3\5_F'UBEW/T"HK\_?^'KW_5+?_+A_^Y:/^'KW
M_5+?_+A_^Y:/[)QO\GXK_,/K%+N?H%17Y^_\/7O^J6_^7#_]RT?\/7O^J6_^
M7#_]RT?V3C?Y/Q7^8?6*7<_0*BOS]_X>O?\ 5+?_ "X?_N6C_AZ]_P!4M_\
M+A_^Y:/[)QO\GXK_ ##ZQ2[GZ!45^?O_  ]>_P"J6_\ EP__ '+1_P /7O\
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MH_LG&_R?BO\ ,/K%+N?H%17Y^_\ #U[_ *I;_P"7#_\ <M'_  ]>_P"J6_\
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M_P!RT?V3C?Y/Q7^8?6*7<_0*BOS]_P"'KW_5+?\ RX?_ +EH_P"'KW_5+?\
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M_)^*_P P^L4NY^@5%?G[_P /7O\ JEO_ )</_P!RT?\ #U[_ *I;_P"7#_\
M<M']DXW^3\5_F'UBEW/T"HK\_?\ AZ]_U2W_ ,N'_P"Y:/\ AZ]_U2W_ ,N'
M_P"Y:/[)QO\ )^*_S#ZQ2[GZ!45^?O\ P]>_ZI;_ .7#_P#<M'_#U[_JEO\
MY</_ -RT?V3C?Y/Q7^8?6*7<_0*BOS]_X>O?]4M_\N'_ .Y:/^'KW_5+?_+A
M_P#N6C^R<;_)^*_S#ZQ2[GZ!45^?O_#U[_JEO_EP_P#W+1_P]>_ZI;_Y</\
M]RT?V3C?Y/Q7^8?6*7<_0*BOS]_X>O?]4M_\N'_[EH_X>O?]4M_\N'_[EH_L
MG&_R?BO\P^L4NY^@5%?G[_P]>_ZI;_Y</_W+1_P]>_ZI;_Y</_W+1_9.-_D_
M%?YA]8I=S] J*_/W_AZ]_P!4M_\ +A_^Y:/^'KW_ %2W_P N'_[EH_LG&_R?
MBO\ ,/K%+N?H%17Y^_\ #U[_ *I;_P"7#_\ <M'_  ]>_P"J6_\ EP__ '+1
M_9.-_D_%?YA]8I=S] J*_/W_ (>O?]4M_P#+A_\ N6C_ (>O?]4M_P#+A_\
MN6C^R<;_ "?BO\P^L4NY^@5%?G[_ ,/7O^J6_P#EP_\ W+1_P]>_ZI;_ .7#
M_P#<M']DXW^3\5_F'UBEW/T"HK\_?^'KW_5+?_+A_P#N6C_AZ]_U2W_RX?\
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M_LG&_P GXK_,/K%+N?H%17Y^_P##U[_JEO\ Y</_ -RT?\/7O^J6_P#EP_\
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M?H%17Y^_\/7O^J6_^7#_ /<M'_#U[_JEO_EP_P#W+1_9.-_D_%?YA]8I=S]
MJ*_/W_AZ]_U2W_RX?_N6C_AZ]_U2W_RX?_N6C^R<;_)^*_S#ZQ2[GZ!45^?O
M_#U[_JEO_EP__<M'_#U[_JEO_EP__<M']DXW^3\5_F'UBEW/T"HK\_?^'KW_
M %2W_P N'_[EKZA_9=_:#_X:2\ :AXF_L#_A'?LFIR:=]E^V?:MVV**3?N\M
M,9\W&,?P]>>,*V Q.'ASU8V7JO\ ,N-:$W:+/8:***\\V"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "O-OC5_QYZ1_P!=V_D*])KS;XU?\>>D?]=V_D* /2:*** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBDH *.3THQ2T )MI:** "BBB@ HHHH
M**** "L3Q=X)T#Q]I$FE^(]'L]:T^3[UO>0B1>H;OTY4'CTK;HJHR<7S1=F3
M*,9KEDKH^!?C9_P3#M+KS=1^&.K?8I>O]C:K(6B/W!\DW++_ !L=V>P&*^%O
M'OPT\5_"W5SIGBO0KS1+O^$7,>$?@'Y''RMPRYP3C/-?O'6)XN\$Z!X^TB32
M_$>CV>M:?)]ZWO(A(O4'OTY4'CTKZ'"YS4I^[67,N_7_ (/]:GG3P;6M)_)_
MY[K\3\%5:I!7WW^T/_P3<TW2=%U7Q+\/-6:RBLK=[J71]28NA1%4MY<O4' D
M;YL\X Q7PAK7A_4_#5U]GU*SDM7_ (2P^5O=6'!_"OL,-B(8JG[6EJOR/*E6
MITZRP]1VFU=)M7:[KO\ +YE7;[T;::K9J08KJ-1NVC;3]M&VJL S;1MI^VC;
M18!FVC;3]M&VBP#-M&VG[:-M%@&;:-M/VT;:+ ,VT;:?MHVT6 9MHVT_;1MH
ML S;1MI^VC;18!FVC;3]M&VBP#-M&VG[:-M%@&;:-M/VT;:+ ,VT;:?MHVT6
M 9MHVT_;1MHL S;1MI^VC;18!FVC;3]M&VBP#-M&VG[:-M%@&;:-M/VT;:+
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M-4_-2M44;?O3]* )J*** "BBB@ HHHH **** "BBB@ HHHH **** .7^*?\
MR3'Q?_V![S_T0]?EA\:,#X;ZLQ )4PD9'0^<@_K7ZG_%/_DF/B__ + ]Y_Z(
M>ORM^-S;?A?K1_ZX?^CXZ_3^%O\ D7XK^OLGX9QM_P E'E7^*/\ Z<1\W0S;
ML5<C;-8MK,>*U;=B:Z:<KGZG)%L?2EV^U"=J?M-=)F,V^U&WVI^TT;33L(9M
M]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6
M9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT
M6 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&
MTT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M
M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J
M?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1M
M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM
M1M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-
MOM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP
M#-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]IHVF
MBP#-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]IH
MVFBP#-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]
MIHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM
M3]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-
MOM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]
MJ-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9
MM]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6
M 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&T
MT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M-
M&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?
MM-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]
MJ?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1
MM]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-O
MM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP#
M-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]IHVFB
MP#-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]IHV
MFBP#-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]I
MHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM3
M]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-O
MM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]J
M-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9M
M]J-OM3]IHVFBP#-OM1M]J?M-&TT6 9M]J-OM3]IHVFBP#-OM1M]J?M-&TT6
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MF_4FOV)_8O\ $@\4?LQ^ [G?O>WLC8M[>3(T0'Y(*[L=EL,+A85%\6B?W/\
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M=M&VG44 -VT;:=10 W;1MIU% #=M&VG44 -VT;:=10 W;1MIU% #=M&VG44
M-VT;:=10 W;1MIU% #=M&VG44 -VT;:=10 W;1MIU% #=M&VG44 -VT;:=10
M W;1MIU% #=M&VG44 -VT;:=10 W;1MIU% #=M&VG44 -VT;:=10 W;1MIU%
M #=M&VG44 -VT;:=10 W;1MIU% #=M&VG44 -VT;:=10 W;1MIU% #=M&VG4
M4 -VT;:=10 W;1MIU% #=M&VG44 -VT;:=10 W;1MIU% #=M&VG44 -VT;:=
M10 W;1MIU% #=M&VG44 -VT;:=10 W;1MIU% #=M&VG44 -VT;:=10 W;1MI
MU% #=M&VG44 -VT;:=10 W;1MIU% #=M&VG44 -VT;:=10 W;1MIU% #=M&V
MG44 -VT;:=10 W;1MIU% #=M&VG44 -VT;:=10 W;1MIU% #=M&VG44 -VT;
M:=10 W;1MIU% #=M&VG44 -VT;:=10 W;1MIU% #=M&VG44 -VT;:=10 W;1
MMIU% #=M&VG44 -VT;:=10 W;1MIU% #=M&VG44 -VT;:=10 W;1MIU% #=M
M&VG44 -VT;:=10 W;1MIU% #=M&VG44 -VT;:=10 W;1MIU% #=M&VG44 -V
MT;:=10 W;1MIU% #=M&VG44 -VT;:=10 W;1MIU% #=M&VG44 -VT;:=10 W
M;1MIU% #=M&VG44 -VT;:=10 W;1MIU% #=M&VG44 -VT;:=10 W;1MIU% #
M=M&VG44 -VT;:=10 W;1MIU% #=M&VG44 -VT;:=10 W;1MIU% #=M&VG44
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M2?\ R*/RKXXUKQ9XB^-FM>"="F)N+RRL[7P[I\8).Y0Y5,^Y+@'Z"O5PU/\
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M >>GO?\ P3__ .32[3_KYO\ _P!#:HQ=:K7RB52JM7^.N_\ 7J.22JTK=_\
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M2<9*Y4Y897L<5]&_\$I_^1;^(G_7W9_^@2UTO_!1SXT>%[/X2W'@.#4;>_\
M$NI7,#M:6[B1K6.-PY>3'W"2H4 \G<3T!KFO^"4__(M_$3_K[L__ $"6M/K%
M;$975G6WNK/NKQU_3Y$5TDZ?K^C/O&BBBOD1A1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRJ'IPS<8#?-/['7[(VH_';Q /'_CL7$GA47#3@73$RZQ/NRV2>3'NSN;^(Y
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M=TA_&O(O^"5/B(QZQX_T%FXE@M;Y%_W&=&/_ (^E16K_ %W"8EK[,M/1<O\
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M\X_D37!?\$J_^1%\=_\ 82M__134_K%3%Y95G6U<6O\ VW_-H51\DJ4X[_\
M#_Y'Q'\?OA'_ ,*-^*VL>"_[5_MO^SQ"?MWV;[/YGF0I)]S>V,;\?>.<9K[?
M\.Z#9?\ !.?X1:WXFGUE_&>H^*7M8M/LA8&T2.=8Y''F-YKY0!B21@_+@=<C
MYC_;\_Y.M\8?[EE_Z20U^MWAO_D7=+_Z]8O_ $ 5>,Q526 H2J._.ES=+[/M
MI\AU5&-:*:TM?YV7^9^-_A7]H2&;XP3_ !$^)'AV3XC:KN$MM:3Z@+6VA<'Y
M?D\J0,B_PIP >3FOT7_93_:[_P"&G-0\16O_  B?_"-?V1%#)N_M+[5YOF%Q
MC'E)MQL]\YKZ*HKR\3CJ&(AR^QLTK+WG9?*UB)>\W+JPHHHKQAA1110 4444
M -;[M0Q?\?!_W?\ "IF^[4,7_'P?]W_"@#X)T-A\2O\ @JUJEQ_K;;PGIKA>
MX!2V6,_E)<M7SG^T'\%-<TS]L'6/A7I$LUMH?C;7+/4H[>/[C)(SMO(](C+<
M#Z*:_8JBO2HXQT94Y*-U&/+;OK>_WZF%2G[15%>W,]/*RLO72_WGY\_MTZ5;
M?"'X]?L[^+]/A%II^F31::=@P$@MYXB$^FR5Q^=1_M :7XJ_95_;";XZV7AV
MZ\3^"-9MQ%J36:EFMLQ)%(K'^ _NT=6;"GE<CK7Z%45G3Q<J<8*UVN:_FIN[
M7_!'*E&3?9J*]''9K^N_<_*#]N#]L"/]I+X8Z-9^%_"&O:9X/MM36:XUK6+=
M8UDNA%($A0HSK]UI&/S9X' KUW_@HK_R9S\+O^OK3_\ TADK] J*KZS",8QI
MPLE)2WWL-0ES\\G?W7'[S\UOVMO^2K?LG?\ 7OI__H^VKN?^"MW_ "2[P)_V
M&W_]$-7WA15+&6=)\OP2<M][RYK?H1"ERWUWBH_<K7/AG]MGXV:QXZU32/V>
M/AJ%U#Q1X@6.+69HSE;6 @-Y+$9VY4%Y#_"@_P!KC@/A+J6N?\$Y_CJG@3QC
MJ U#X9>+2DMOK?E^7'#. JF;;D[-I(209^[L;M@_I+14TL4J4?9\MT[\WGV]
M+=/\Q2H\R2OLE;R[OSOU^X^;?CM^PC\/OVCO'0\8^(-:\1VM_):16P32;JW2
M QIDJ0'@<Y.[KNQ7D'_!12QL?@]^R'X-^'FDSW$]G]NM=/A>[96FD@MXG;+E
M54$[A'G  ]J^\:*PA7E'DC)WC%IV]'<WY5=RZM-?>K'YX?MT?"&]\!_LY_!S
MQ=H9:SUGP#'963W,0P\2F./;)_P&:-.O>0U'\"?@7(?^"<WQ%U&]A:76?%MI
M=:WND&79+?YH/KDQ,X_ZZ5^B=%;2QDY49TK:RE>_;6]O_ M3.%)0G2E_(E\[
M:+\'8^.OV,_%G_"3_L!W<+OYDVDZ?JVG/D]-JR.@_!)$KY(^.7_)+=;_ .V'
M_H^.OU4^*?\ R3'Q?_V![S_T0]?E7\<O^26ZU_VP_P#1\=?HW#]55\'C*MK7
MN_\ R4_#.,*?LN(,IA>]I1_].(^6[,=*W;3H*Q+/M6Y:+TI43];D:$?2I*;&
MM2UZ2,!E%/HJ@&44^B@!E%/HH 913Z* &44^B@!E%/HH 913Z* &44^B@!E%
M/HH 913Z* &44^B@!E%/HH 913Z* &44^B@!E%/HH 913Z* &44^B@!E%/HH
M 913Z* &44^B@!E%/HH 913Z* &44^B@!E%/HH 913Z* &44^B@!E%/HH 91
M3Z* &44^B@!E%/HH 913Z* &44^B@!E%/HH 913Z* &44^B@!E%/HH 913Z*
M &44^B@!E%/HH 913Z* &44^B@!E%/HH 913Z* &44^B@!E%/HH 913Z* &4
M4^B@!E%/HH 913Z* &44^B@!E%/HH 913Z* &44^B@!E%/HH 913Z* &44^B
M@!E%/HH 913Z* &44^B@!E%/HH 913Z* &44^B@!E%/HH 913Z* &44^B@!E
M%/HH 913Z* &44^B@!E%/HH 913Z* &44^B@!E%/HH 913Z* &44^B@!E%/H
MH 913Z* &44^B@!E%/HH 913Z* &44^B@!E%/HH 913Z* &44^B@!E%/HH 9
M13Z* &44^B@!E%/HH 913Z* &44^B@!E%/HH 913Z* &44^B@!E%/HH 913Z
M* &44^B@!E%/HH 913Z* &44^B@!E%/HH 913Z* &44^B@!E%/HH 913Z* &
M44^B@!E%/HH 913Z* &44^B@!E%/HH 913Z* &44^B@!E%/HH 913Z* &44^
MB@!E%/HH 913Z* &44^B@!E%/HH 913Z* &44^B@!E%/HH 913Z* &44^B@!
ME%/HH 913Z* &44^B@!E%/HH 913Z* &5^FO_!,G_D@VO?\ 8RW'_I+:U^9M
M?IG_ ,$R_P#D@^O?]C+<?^DMK7SV>?[F_5'7A?XA]<4445^<'M'/_$*/5)O
M?B.+1+8WFLR:=<)96ZNJ&28QL(UW,0HRQ')( KX/_8O_ &0_B3\,OCKI_B;Q
MGX8&DZ78VEP8IS?VL_[YT\M1MBE9NCMSC'%?HA17;A\7/#1J1@E[ZL_QV^\)
M>_#D>U[_ )?Y'EG[3OPKE^,OP1\3>&;2%9M4F@$]@K,%S<QD/&-Q( W$;<DX
MPQKXV_9!_8J^(?@OXXZ/XD\=^&UTC1](CDNHG:^MI_,N-NV-=L4C$8+%\D8^
M3K7Z.45>'QU7"TYTZ>TO\K703]^'(]OZT]/\V>=?M$>!;SXE_!'QEX:TZW%U
MJ5_I[K:0LZH'F7#QKN8@#+*.20!7RU^P7^SU\4_@?\2M=N?%WA@Z3H>HZ68?
MM'V^UG_?+*C(-L<K-]TR<XQ7W5144<5.A3G2BE:6X2]^"@^CO^7^1\]?M6_L
MAZ/^T=IL%_;7*:)XPL8S';:@R;HYH\DB*8#DKDG##E<G@]*^#[[_ ()Z?&^S
MU5K2+PU9WUN&VB^@U6V$)']X!W5\?\ S[5^NM%;X7,J^$CR0=UV9;DVK,_++
MQE_P3=^)'A_PGHT^CQ0^*/$5S+(;^TLKJ&&WLXP%\L!YV0R,26R0,#&.>I^T
M?V/_ (7^)OA;^SS;^&?$^F?V9KBSW;FU\^*; =B4.Z-F7D'UKWRBC$9C7Q5&
M5&K:S^\CK%_R_P!?J?FW^RC^R)\6OAK^T-X7\3>)/"?]G:'927+3W7]I6DNP
M/;RHORI*S'+,HX'>OLO]HS]G/P_^T9X-72=5=K#4[0M+IVJPH&DMI",$$<;D
M; W+D9P.00#7K-%1B<=5Q-2-66CCM;UOY]QIM3=1;O\ K]3\D_%'_!.OXT:'
MJKVVG:+8^(K0'Y+VQU*")".Q*S,C ^V#]37177_!-GXC6'PYN=586VI>+'GB
M2VT&QNHE5(CGS'EFE94R.,*I/7.3TK]2J*[/[:Q5DM-/+<+ZW/E+]@/X(>-?
M@GX2\767C31?[&N;^]AEMT^U03[U6,@G,3L!R>^*\#^ 7[(/Q;\$_M)>'O%.
MM>$_L>@VNJ2W$UW_ &E:2;8RK@-L64L?O#@#/-?I316"S*M&M.O97FDGOT^9
M-OW<J71_\'_,:X+(P'7%?FO^S+^R!\7/A[^T-X7\3>(/"7V#0[*[FDGNO[2M
M)-BM%(H.U)2QY8=!WK]*J*YL+BYX3GY$O>5G?Y_YE2?-3=-[,\L_:&_9[\/?
MM%>"_P"Q-99K.]MV,NGZI"H:2UD(P3@_>0\;ER,X'((!'YT^*_\ @G3\9M!U
M:2VTO2+'Q)9[ODO;'488E*]B5F9&!]0 ?J:_6FBM,+CZ^#35-Z=GL5S.UF?E
MJ_\ P39^(UG\.K[5I1;7WBLR1+9^'[&ZB&$+?O'EFD94R%SA5)SG.[M7TK_P
M3]^!?CCX(Z)XSM_&NB?V+-J%Q;26R_:X)_,5%D#']T[8P6'7'6OK6BMJV:8B
MO2G2G:TOPVV^[S,G'FM?I_P?\PHHHKR"@HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS;
MXU?\>>D?]=V_D*])KS;XU?\ 'GI'_7=OY"@#TFBBB@#F_B5I%WX@^'/BG2["
M+S[Z]TNZMK>+<%WR/$RJN20!DD<DXKX=_8B_97^*/PA^-R:_XM\,?V3I TVX
MM_M']H6LWSMLVC;'*S<X/.,5^@U%=N'Q4\/"I""5IJS_ !V^\<O>@H/9._Y?
MY'R5^WA^ROJWQPTO1O$/@W3H[WQ;IS?99;?SHX3=6K$D?/(RKE&R1DCAV]A6
M?^SEX2^//PQ_9[\8^#K[PTUCKUE;R2^%[A]0LYAODSNAXE(7:V7!?"_,1V K
M[%HIQQE2.'>&:3C>^O3T_KJQRES.,GO'^M?R/R$U+]AG]H+6=0N;^_\ !TMY
M>W,C2S7$^M6+O([')9B9\DDU6_X8'^.__0B_^5>P_P#C]?L)17IK/,0E91C]
MS_S#F;U9^?/[$7[*_P 4?A#\;DU_Q;X8_LG2!IMQ;_:/[0M9OG;9M&V.5FYP
M><8K]!J**\O%XN>,FJE1)-*VG]>9FHV;?<_-?]J[]D'XM_$KX_>*?$GAOPG_
M &CHMZ\!M[K^TK2+>%@C4_*\JL/F4CD#I7Z-Z+;R6>C6$$J[)8K>-'7(.&"@
M$<5=HHJXN=:A3H22M#;OM;4N;YY\[W/D/_@I1\4O^$1^#MGX3M9=M_XFN=DB
MJ>1;1$._YL8U]P37L/[*GPN_X5#\"?"^A2Q>5J+V_P!MO_7[1+\[ _[H(3_@
M KC_ (P?LA?\+G^.'A[QUK/BW&CZ/]G6/PZ-.W!TC<R,IF\T??8\G9TP/>OH
MNM)5H1P<:,'JVW+\DON_$53WI12V2_%[_=L4]8DNHM)O7LH?M%ZL#F"'(7?)
MM.U<DX&3@<\5^<W[*_['/Q4\&_M!>&_%'C/PO_9NCV,L]U-=-J-K,?,,3A/E
MCE9B=[#M7Z2T5GAL7/"J:II>\K?GM]X2]Z#IO9G"?'/X=)\6/A'XI\*%5:;4
M;)TMR^,+.OS1'GIAU6O@;]F?]AKXE:!\;?#&L^-_"ZZ7X>TNX^W2RM?VL^Z2
M,%HEVQRLW+A3TQ@&OTTHJ\+CJN$C.-/[7X>:\_\ )!+WX>S>W^9R7Q;\)R>.
M_A=XM\.PH))]3TNYM858@ R/&P3D\#YL=:^*OV'_ -FGXL_!7XU'6/$_A4Z7
MH5UIL]G/<?VC:3!22CI\L<K,?F0#@=Z_0*BHH8J>'A4IQ2:FK._SV^\)>]!0
M>R=_R_R/#OVH?V5]#_:2\/VZS7']D>)=/5A8:JJ;P >3%(O&Y"??*GD=P?S^
MUG_@GC\;=+U1[6V\/66KVX; OK/5+=8F'KB5T?\ \=K]<J*VPN85\''D@[KL
MRW)M69^6?B/_ ()M_$?1? 5E?6*6_B'Q7<7@6;2K&ZABAM;?8Q+-+,R!WW;!
MA>!S][.1]?\ ["?PE\5_!OX/W^B>,-*_L?5)=7END@^T13YC:.)0VZ)V7JK<
M9SQ7T;15ULSKXBE*E4M9F4H\W+?I_P '_,_-?]I3]D'XM_$#]HSQ-XHT'PG]
MOT*\O()8+K^TK2/>JQ1JQV/*&'*GJ.U?4'[;WPH\5?%_X(VV@>$=+_M;5TU.
MWN&M_M$4.(U20,=TCJO!8<9SS7T116,L=4E"C!I6I6M\K;Z^7D:<S]JZO5W_
M !/EK]@/X*^,_@GX%\3Z?XTT;^QKR\U);B"/[5#/O01*I.8G8#D'@G-:_P"W
M=\)?%GQF^#^FZ)X.TK^V-4AUF&[>#[1%!B)89E+;I75>KKQG/-?1U%15Q<ZN
M(^LR2YKI^6EO\A4W[/;S_&_^9\>?LG?#'XI?L\_ 3QK;3^"S=>,;C4#/I>E?
MVA:%9288T5WD$VP*&!)!8,0.!S7BGPI_87^)WQ ^,_\ ;_Q@TUK+2))VU#49
MY+^VGDOI-P(A BD8J&/4X "@@<XK]+J*ZEF=:-2=9)<TM+ZZ65M-?GZDV]SV
M?1ZG@/[67[,-A\>?AK'9Z5;V]EXFT6,MHTJA8TP  ;9CCA&  '92%/3.?#OV
M*OA9\>/@#XPETO7O!LG_  @^K,/M>-5LI/L<H&%N%59B3Q\K #)&#R5 K[OH
MK"CC:E*E*A9.,N_Z?GZZCE[\5%] HHHKSP/DW_@H!\'?B#\:O#_A'2/!&@'6
MH;6ZGN[UOMEO;B-MBK'_ *V1<Y#2=,XQ[UVG[$?P?UWX+?!&/1O$VG#2]=N-
M0N+RYMQ-'-MSM1/FC9E/RHIX/>O?J*[5BIK#?5DERWOY_P!?()^_RW^S_P '
M_,^&_P!O3]DWQE\7/'FA>*/ FAKK%Q)9&TU&,7<%N5,;9B?]ZZ[LAV7C/W!7
MK7[#?P'U;X%_"6YMO$EBNG^)=4OGN;N 2QRF-% 2)-\;,IX!;@G[YKZ*HJ_K
MU7ZM]5^S^.]PG^\:;Z?Y6/BC]O[]F?QS\:O%'A/5_!&@C6I+6SFM;S_2X+<Q
M@.&C_P!;(N<[GZ9QBO?_ -E;POXF\$_ 7PKX?\7:<=+UW38I+:6W,\<V$$K^
M6=T;,I^0KWKUBBH>*F\,L*TN5._GU_S[!/WY*3W04445Q %%%% !1110 5\O
M_M:?L4Z?^T!,/$>@WD.A^,XHA$TLZG[/?(H^59=H)5AT#@'C@@\8^H**UI59
MT9JI3=FBHR<=C\B?^'>OQP_M3[)_PC-IY&_;]N_M6V\G']['F;\?\ S[5TOQ
M _X)P_$KPWI^@KX<M8_%VHSQ2/JCVUW;V]O;/D;(X_.=&?C<2V/P&.?U1HKV
MGG6*;3TT\M_77\K"OK<\K_9=\$ZU\.O@'X0\.>(;+^S]9L+>2.YMO-278QFD
M8#<C,IX8=">M?-'[3_\ P3NE\9>(;WQ5\-;BTL[N\D:>\T.\;RHFD/+/ X!"
MDGDHV!DDAATK[KHKS8XRK"O+$0=I-M^6NHJ?[N/(MC\DO#?_  3M^-.M:LEK
MJ&AV/A^U)^:^OM2@DC ]0L+NQ/X?E5[X@?\ !/'XJ:%XPNK+PIH,GB30H1$(
M=4DO[.W-PWEJ9&$;S!E&_< #S@#D]:_5^BO36>8I34TEITMI^=_Q'W/GS]N;
M]Q^R5XR20A&\JS3!/?[5#Q^E?-__  2G_P"1@^(G_7K9?^AS5P'[5'PO^.NM
M?%+Q78QZ+XSUOP?>:K-=Z?9V?VB]L=C.2C".,LB'GN 1FOJ/]@']G3Q!\$_"
M.NZMXKM1I^MZ])#ML&8-);P1AMN\@D!F+L=O8 9YX&])4\/EM1N:;J6=O7ET
M^5M2:J4(1H1UL_\ +_(ZG]KC]DNS_:1T6SN[&]BTCQ;IB,EI>3*3#-&3GR9<
M<A<\A@"5R>#FO@R^_P""?/QQL[][>+PI;WL2M@74&JV@C8>H#R*V/JN:_7FB
MO,PN95\)'DA9KLS1R;5F?%G[(O[!=S\)_$]OXT\=W5I>:Y:9;3]-LF,D5LY&
M/,D<@;G )  &!UR3C'VG117-B<55Q4^>JS)1MJ?(7[?'[+NO_&ZV\.Z_X+TQ
M=2\26#-9W-MY\4!EMFRRMND95^1\\9S^\/I7=?L3_ &]^ OPE:VUVU6U\4ZM
M<M=:A&LB2>4!\L46]"5;"C=P2,NU?0=%4L956&^J_9O?S[V]+ZE3]]Q;Z"=>
M#R*^!OVE/^"<=WKOB"]\2?#">TA%V[37'A^\?RE1R<DP/C: 3_ V .<-C 'W
MU16>'Q%3"S]I2=F6I-*W0_);PG_P3I^,NO:M';:KI%CX:L]WSWM[J$$RA>^%
MA=V)] 0/J*TO$/\ P3]^*GAOXE&+PYX>DUOPW9W<)@U2;4+.%IT&TN_EF8,H
MW;L*1G&.O4_JO17KK.\4IJ5EZ6T_._XF4H\\7%]3Q']LGX<^(OBM\ ]:\.>%
MM/\ [4UJXN+5XK;SXX=RI,C,=TC*HP 3R:\O_P""?GP&\=?!&U\:IXUT/^Q6
MU%[0VH^UP3^9L$N[_5.V,;EZXZU]?45YE/%3I8>>&BERR=WWZ?Y%3_>**?0\
M"_;;^%_B;XO? ^;P_P"$M,_M;5VU&WG%OY\4/R+NW'=(RKQD=\UR'[ /P1\:
M_!+PIXLL_&FB_P!C7-]>PS6Z?:H)]ZK&03F)V Y/?%?5E%*&*G3P\\,DN63O
MY]/\@E[_ "WZ?\'_ #/S@_:]_9'^+'Q0_:"\2>)?#'A3^T]$O%M1!=?VC:1;
M]EO&C?+)*K##*1R.U?HEHMO)9Z-802KLEBMXT=<@X8* 1Q5VBG4Q4ZM"GAY)
M6AMWVMJ.;YY*;Z*WY?Y!1117$(**** "BBB@ HHHH :WW:AB_P"/@_[O^%3-
M]VH8O^/@_P"[_A0!8HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y?XI_\
MDQ\7_P#8'O/_ $0]?E9\<O\ DENM?]L/_1\=?JG\4_\ DF/B_P#[ ]Y_Z(>O
MRL^./_)+=:_[8?\ H^.OT[A?_D7XKY_^DGX9QM_R4>5?XH_^G$?+EGU%;MGV
MK$L^U;MGT%;T#]4D:$=24V+H*DKTT8#:*=13#4;13J* U&T4ZB@-1M%.HH#4
M;13J* U&T4ZB@-1M%.HH#4;13J* U&T4ZB@-1M%.HH#4;13J* U&T4ZB@-1M
M%.HH#4;13J* U&T4ZB@-1M%.HH#4;13J* U&T4ZB@-1M%.HH#4;13J* U&T4
MZB@-1M%.HH#4;13J* U&T4ZB@-1M%.HH#4;13J* U&T4ZB@-1M%.HH#4;13J
M* U&T4ZB@-1M%.HH#4;13J* U&T4ZB@-1M%.HH#4;13J* U&T4ZB@-1M%.HH
M#4;13J* U&T4ZB@-1M%.HH#4;13J* U&T4ZB@-1M%.HH#4;13J* U&T4ZB@-
M1M%.HH#4;13J* U&T4ZB@-1M%.HH#4;13J* U&T4ZB@-1M%.HH#4;13J* U&
MT4ZB@-1M%.HH#4;13J* U&T4ZB@-1M%.HH#4;13J* U&T4ZB@-1M%.HH#4;1
M3J* U&T4ZB@-1M%.HH#4;13J* U&T4ZB@-1M%.HH#4;13J* U&T4ZB@-1M%.
MHH#4;13J* U&T4ZB@-1M%.HH#4;13J* U&T4ZB@-1M%.HH#4;13J* U&T4ZB
M@-1M%.HH#4;13J* U&T4ZB@-1M%.HH#4;13J* U&T4ZB@-1M%.HH#4;13J*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7FWQJ_P"//2/^
MN[?R%>DUYM\:O^//2/\ KNW\A0!Z31110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 UONUYK\?->U#PS\+]:U+2[J2QOH?(\N>(X9=T\:G'U!(_&O2VZ5CZ]IEKJ
M]A-9WMM%=VLPVR0S('1A[@UTX6I&C7IU9JZBTVNZ3V.#,*%3%8.MAZ4N64XR
M2?9M-)Z=MSYX^'O[87W+7Q?9>O\ I]BO^\?FC_[X48]R:^C/#WBC2?%EB+S1
M]0M]0MC_ !P.#CDCD=1RIZ^E?,GQ(_9LT^1Y;KPY,=/EY/V.8EHC_NGJOZ_A
M7BJMXI^%NL>9#+=Z-=@D"6%OD?@C@CY6X)^F:^_>5Y5G2Y\NJ>SJ?RO_ "_R
MNO(_&8\0<1\*25+.Z/MJ/_/Q;_\ @77TDDWW/T9HKY?^'O[87W+7Q?9>O^GV
M*_[Q^:/_ +X48]R:^C/#WBC2?%EB+S1]0M]0MC_' X..2.1U'*GKZ5\;CLJQ
M>72MB(67?=??_3/U'*.(LMSR'-@JJ<NL7I)?+]5=>9J4445Y)](%%%% !111
M0 445Y?\1/VB?"7P_P#-M_M7]L:JG'V*Q8-M/H[_ '5^G)]JZL/A:^+G[.A!
MR?D>?CLPPF6TG7QE10CW;_+N_):GJ%>7_$3]HGPE\/\ S;?[5_;&JIQ]BL6#
M;3Z._P!U?IR?:OE_XB?M$^+?B!YMO]I_L?2FX^Q6+%=P]'?[S?3@>U>7XS[F
MOT3+^$-JF/E_VZOU?^7WGX?G?B;O1R>G_P!OR7Y1_P __ 3T[XC_ +0WBOXB
M+-:-<#2=(D!4V-D2 ZGM(_5^.HX!]*^=OCA_R2[6O^V'_H^.NP\06_B.SLPV
MC>')M9N7'RK]IA@1?]XNX/Y"O'O%'PI^-GCZ0I>Z(4LR<K9P7ULD0YR,CS?F
M^IS7OU\PRO T)87#RBKIJR:]-7_3/"R7A_B#.<QHYMF',HQE&5YWNTFG:,>B
M^278\0LQR*W;/M7I&F_LA_%BX(\OPGN_[B-H/_:M=5I_[%'QGG4;/!N[_N*6
M0_\ :U?/4<5AEO4C]Z/Z!E3G_*SQ^+H*DKW2']AGXW,!CP3G_N+6/_Q^IO\
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M_P "7^8>RJ?RO[CP6BO>O^&%?CC_ -"1_P"5:Q_^/T?\,*_''_H2/_*M8_\
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MK\<?^A(_\JUC_P#'Z/KV$_Y^Q_\  E_F'LJG\K^X\%HKWK_AA7XX_P#0D?\
ME6L?_C]'_#"OQQ_Z$C_RK6/_ ,?H^O83_G['_P "7^8>RJ?RO[CP6BO>O^&%
M?CC_ -"1_P"5:Q_^/T?\,*_''_H2/_*M8_\ Q^CZ]A/^?L?_  )?YA[*I_*_
MN/!:*]Z_X85^./\ T)'_ )5K'_X_1_PPK\<?^A(_\JUC_P#'Z/KV$_Y^Q_\
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M/T?\,*_''_H2/_*M8_\ Q^CZ]A/^?L?_  )?YA[*I_*_N/!:*]Z_X85^./\
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M_P "7^8>RJ?RO[CP6BO>O^&%?CC_ -"1_P"5:Q_^/T?\,*_''_H2/_*M8_\
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MK\<?^A(_\JUC_P#'Z/KV$_Y^Q_\  E_F'LJG\K^X\%HKWK_AA7XX_P#0D?\
ME6L?_C]'_#"OQQ_Z$C_RK6/_ ,?H^O83_G['_P "7^8>RJ?RO[CP6BO>O^&%
M?CC_ -"1_P"5:Q_^/T?\,*_''_H2/_*M8_\ Q^CZ]A/^?L?_  )?YA[*I_*_
MN/!:*]Z_X85^./\ T)'_ )5K'_X_1_PPK\<?^A(_\JUC_P#'Z/KV$_Y^Q_\
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M/T?\,*_''_H2/_*M8_\ Q^CZ]A/^?L?_  )?YA[*I_*_N/!:*]Z_X85^./\
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M_P "7^8>RJ?RO[CP6BO>O^&%?CC_ -"1_P"5:Q_^/T?\,*_''_H2/_*M8_\
MQ^CZ]A/^?L?_  )?YA[*I_*_N/!:*]Z_X85^./\ T)'_ )5K'_X_1_PPK\<?
M^A(_\JUC_P#'Z/KV$_Y^Q_\  E_F'LJG\K^X\%HKWK_AA7XX_P#0D?\ E6L?
M_C]'_#"OQQ_Z$C_RK6/_ ,?H^O83_G['_P "7^8>RJ?RO[CP6BO>O^&%?CC_
M -"1_P"5:Q_^/T?\,*_''_H2/_*M8_\ Q^CZ]A/^?L?_  )?YA[*I_*_N/!:
M*]Z_X85^./\ T)'_ )5K'_X_1_PPK\<?^A(_\JUC_P#'Z/KV$_Y^Q_\  E_F
M'LJG\K^X\%HKWK_AA7XX_P#0D?\ E6L?_C]'_#"OQQ_Z$C_RK6/_ ,?H^O83
M_G['_P "7^8>RJ?RO[CP6BO>O^&%?CC_ -"1_P"5:Q_^/T?\,*_''_H2/_*M
M8_\ Q^CZ]A/^?L?_  )?YA[*I_*_N/!:*]Z_X85^./\ T)'_ )5K'_X_1_PP
MK\<?^A(_\JUC_P#'Z/KV$_Y^Q_\  E_F'LJG\K^X\%HKWK_AA7XX_P#0D?\
ME6L?_C]'_#"OQQ_Z$C_RK6/_ ,?H^O83_G['_P "7^8>RJ?RO[CP6BO>O^&%
M?CC_ -"1_P"5:Q_^/T?\,*_''_H2/_*M8_\ Q^CZ]A/^?L?_  )?YA[*I_*_
MN/!:*]Z_X85^./\ T)'_ )5K'_X_1_PPK\<?^A(_\JUC_P#'Z/KV$_Y^Q_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH 0U6N(]RFK5,=<T <GK%CYBMQ7FWB
MCPO%J$,D4\*31-U2100?PKV>ZM1(#Q6!J&CB3/%--Q=UN3*,9Q<9*Z9\E>*O
M@V@9Y=+<V[=?)DR4_ ]1^M<-9WOB3X<ZH)[2XNM(NATEA8A6X(^AX)^F:^PM
M4\-!L_+7&:YX-BNHGCF@66-NJNN0:^RP/$^)H1]EBE[6'GO]_7Y_>?EV;^'^
M QD_K.72>'JK5./PW].G_;K7HS.^'O[87W+7Q?9>O^GV*_[Q^:/_ +X48]R:
M^C/#WBC2?%EB+S1]0M]0MC_' X..2.1U'*GKZ5\5^)O@ZNYY=-<P/U\F3)0_
M0]1^M<39WOB3X<ZH)[2XNM(NATEA;"MP1]#P3],UZKRO*LZ7/EU3V=3^5_Y?
MY77D?.QX@XCX4DJ6=T?;4?\ GXM__ NOI))ON?H]17R_\/?VPON6OB^R]?\
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MW;^0KTFO-OC5_P >>D?]=V_D* /2:*** "BBB@ HHHH **** "BBB@ HHHH
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M=N%J=5IV*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\-T-_P!"4/\ P:__ &FC_ANAO^A*'_@U_P#M-?2G_"'Z#_T!--_\!(_\*/\
MA#]!_P"@)IO_ ("1_P"% 'S7_P -T-_T)0_\&O\ ]IH_X;H;_H2A_P"#7_[3
M7TI_PA^@_P#0$TW_ ,!(_P#"C_A#]!_Z FF_^ D?^% 'S7_PW0W_ $)0_P#!
MK_\ ::/^&Z&_Z$H?^#7_ .TU]*?\(?H/_0$TW_P$C_PH_P"$/T'_ * FF_\
M@)'_ (4 ?-?_  W0W_0E#_P:_P#VFC_ANAO^A*'_ (-?_M-?2G_"'Z#_ - 3
M3?\ P$C_ ,*/^$/T'_H":;_X"1_X4 ?-?_#=#?\ 0E#_ ,&O_P!IH_X;H;_H
M2A_X-?\ [37TI_PA^@_] 33?_ 2/_"C_ (0_0?\ H":;_P" D?\ A0!\U_\
M#=#?]"4/_!K_ /::/^&Z&_Z$H?\ @U_^TU]*?\(?H/\ T!--_P# 2/\ PH_X
M0_0?^@)IO_@)'_A0!\U_\-T-_P!"4/\ P:__ &FC_ANAO^A*'_@U_P#M-?2G
M_"'Z#_T!--_\!(_\*/\ A#]!_P"@)IO_ ("1_P"% 'S7_P -T-_T)0_\&O\
M]IH_X;H;_H2A_P"#7_[37TI_PA^@_P#0$TW_ ,!(_P#"C_A#]!_Z FF_^ D?
M^% 'S7_PW0W_ $)0_P#!K_\ ::/^&Z&_Z$H?^#7_ .TU]*?\(?H/_0$TW_P$
MC_PH_P"$/T'_ * FF_\ @)'_ (4 ?-?_  W0W_0E#_P:_P#VFC_ANAO^A*'_
M (-?_M-?2G_"'Z#_ - 33?\ P$C_ ,*/^$/T'_H":;_X"1_X4 ?-?_#=#?\
M0E#_ ,&O_P!IH_X;H;_H2A_X-?\ [37TI_PA^@_] 33?_ 2/_"C_ (0_0?\
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M\-T-_P!"4/\ P:__ &FC_ANAO^A*'_@U_P#M-?2G_"'Z#_T!--_\!(_\*/\
MA#]!_P"@)IO_ ("1_P"% 'S7_P -T-_T)0_\&O\ ]IH_X;H;_H2A_P"#7_[3
M7TI_PA^@_P#0$TW_ ,!(_P#"C_A#]!_Z FF_^ D?^% 'S7_PW0W_ $)0_P#!
MK_\ ::/^&Z&_Z$H?^#7_ .TU]*?\(?H/_0$TW_P$C_PH_P"$/T'_ * FF_\
M@)'_ (4 ?-?_  W0W_0E#_P:_P#VFC_ANAO^A*'_ (-?_M-?2G_"'Z#_ - 3
M3?\ P$C_ ,*/^$/T'_H":;_X"1_X4 ?-?_#=#?\ 0E#_ ,&O_P!IH_X;H;_H
M2A_X-?\ [37TI_PA^@_] 33?_ 2/_"C_ (0_0?\ H":;_P" D?\ A0!\U_\
M#=#?]"4/_!K_ /::/^&Z&_Z$H?\ @U_^TU]*?\(?H/\ T!--_P# 2/\ PH_X
M0_0?^@)IO_@)'_A0!\U_\-T-_P!"4/\ P:__ &FC_ANAO^A*'_@U_P#M-?2G
M_"'Z#_T!--_\!(_\*/\ A#]!_P"@)IO_ ("1_P"% 'S7_P -T-_T)0_\&O\
M]IH_X;H;_H2A_P"#7_[37TI_PA^@_P#0$TW_ ,!(_P#"C_A#]!_Z FF_^ D?
M^% 'S7_PW0W_ $)0_P#!K_\ ::/^&Z&_Z$H?^#7_ .TU]*?\(?H/_0$TW_P$
MC_PH_P"$/T'_ * FF_\ @)'_ (4 ?-?_  W0W_0E#_P:_P#VFC_ANAO^A*'_
M (-?_M-?2G_"'Z#_ - 33?\ P$C_ ,*/^$/T'_H":;_X"1_X4 ?-?_#=#?\
M0E#_ ,&O_P!IH_X;H;_H2A_X-?\ [37TI_PA^@_] 33?_ 2/_"C_ (0_0?\
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M#_P:_P#VFN8\=?M='Q7:VP/A06OV5S)_R$=^[CI_JABOKO\ X0_0?^@)IO\
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M%?4G_"$^'O\ H Z9_P" <?\ \31_PA/A[_H Z9_X!Q__ !- 778^6_\ AO\
M;_H1!_X-_P#[11_PW^W_ $(@_P#!O_\ :*^I/^$)\/?] '3/_ ./_P")H_X0
MGP]_T =,_P# ./\ ^)H"Z['RW_PW^W_0B#_P;_\ VBC_ (;_ &_Z$0?^#?\
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M^@#IG_@''_\ $T?\(3X>_P"@#IG_ (!Q_P#Q- 778^6_^&_V_P"A$'_@W_\
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MQ\M_\-_M_P!"(/\ P;__ &BC_AO]O^A$'_@W_P#M%?4G_"$^'O\ H Z9_P"
M<?\ \31_PA/A[_H Z9_X!Q__ !- 778^6_\ AO\ ;_H1!_X-_P#[11_PW^W_
M $(@_P#!O_\ :*^I/^$)\/?] '3/_ ./_P")H_X0GP]_T =,_P# ./\ ^)H"
MZ['RW_PW^W_0B#_P;_\ VBC_ (;_ &_Z$0?^#?\ ^T5]2?\ "$^'O^@#IG_@
M''_\31_PA/A[_H Z9_X!Q_\ Q- 778^6_P#AO]O^A$'_ (-__M%'_#?[?]"(
M/_!O_P#:*^I/^$)\/?\ 0!TS_P  X_\ XFC_ (0GP]_T =,_\ X__B: NNQ\
MM_\ #?[?]"(/_!O_ /:*/^&_V_Z$0?\ @W_^T5]2?\(3X>_Z .F?^ <?_P 3
M1_PA/A[_ * .F?\ @''_ /$T!==CY;_X;_;_ *$0?^#?_P"T4?\ #?[?]"(/
M_!O_ /:*^I/^$)\/?] '3/\ P#C_ /B:/^$)\/?] '3/_ ./_P")H"Z['RW_
M ,-_M_T(@_\ !O\ _:*/^&_V_P"A$'_@W_\ M%?4G_"$^'O^@#IG_@''_P#$
MT?\ "$^'O^@#IG_@''_\30%UV/EO_AO]O^A$'_@W_P#M%'_#?[?]"(/_  ;_
M /VBOJ3_ (0GP]_T =,_\ X__B:/^$)\/?\ 0!TS_P  X_\ XF@+KL?+?_#?
M[?\ 0B#_ ,&__P!HH_X;^/\ T(@_\&__ -HKZD_X0GP]_P! '3/_  #C_P#B
M:/\ A"?#W_0!TS_P#C_^)H"Z['RRW[?9;_F1!_X-_P#[14,G[>F[_F1!_P"#
M;_[17U9_PA/A[_H Z9_X!Q__ !-'_"$^'?\ H Z9_P" <?\ \30%UV/D:X_;
MH$G_ #(H'_<6_P#M%9=Q^VNLN?\ BAQ_X-?_ +37V4W@?PZ?^8#IG_@''_\
M$U$_@/PZW_,!TS_P#C_^)H"Z['Q3)^V4C'_D21_X-/\ [32Q?ME(I_Y$@?\
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M%?4G_"$^'O\ H Z9_P" <?\ \31_PA/A[_H Z9_X!Q__ !- 778^6_\ AO\
M;_H1!_X-_P#[11_PW^W_ $(@_P#!O_\ :*^I/^$)\/?] '3/_ ./_P")H_X0
MGP]_T =,_P# ./\ ^)H"Z['RW_PW^W_0B#_P;_\ VBC_ (;_ &_Z$0?^#?\
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M^@#IG_@''_\ $T?\(3X>_P"@#IG_ (!Q_P#Q- 778^6_^&_V_P"A$'_@W_\
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MQ\M_\-_M_P!"(/\ P;__ &BC_AO]O^A$'_@W_P#M%?4G_"$^'O\ H Z9_P"
M<?\ \31_PA/A[_H Z9_X!Q__ !- 778^6_\ AO\ ;_H1!_X-_P#[11_PW^W_
M $(@_P#!O_\ :*^I/^$)\/?] '3/_ ./_P")H_X0GP]_T =,_P# ./\ ^)H"
MZ['RW_PW^W_0B#_P;_\ VBC_ (;_ &_Z$0?^#?\ ^T5]2?\ "$^'O^@#IG_@
M''_\31_PA/A[_H Z9_X!Q_\ Q- 778^6_P#AO]O^A$'_ (-__M%'_#?[?]"(
M/_!O_P#:*^I/^$)\/?\ 0!TS_P  X_\ XFC_ (0GP]_T =,_\ X__B: NNQ\
MM_\ #?[?]"(/_!O_ /:*/^&_V_Z$0?\ @W_^T5]2?\(3X>_Z .F?^ <?_P 3
M1_PA/A[_ * .F?\ @''_ /$T!==CY;_X;_;_ *$0?^#?_P"T4?\ #?[?]"(/
M_!O_ /:*^I/^$)\/?] '3/\ P#C_ /B:/^$)\/?] '3/_ ./_P")H"Z['RW_
M ,-_M_T(@_\ !O\ _:*/^&_V_P"A$'_@W_\ M%?4G_"$^'O^@#IG_@''_P#$
MT?\ "$^'O^@#IG_@''_\30%UV/EO_AO]O^A$'_@W_P#M%'_#?[?]"(/_  ;_
M /VBOJ3_ (0GP]_T =,_\ X__B:/^$)\/?\ 0!TS_P  X_\ XF@+KL?+?_#?
M[?\ 0B#_ ,&__P!HH_X;_;_H1!_X-_\ [17U)_PA/A[_ * .F?\ @''_ /$T
M?\(3X>_Z .F?^ <?_P 30%UV/EO_ (;_ &_Z$0?^#?\ ^T4?\-_M_P!"(/\
MP;__ &BOJ3_A"?#W_0!TS_P#C_\ B:/^$)\/?] '3/\ P#C_ /B: NNQ\M_\
M-_M_T(@_\&__ -HH_P"&_P!O^A$'_@W_ /M%?4G_  A/A[_H Z9_X!Q__$T?
M\(3X>_Z .F?^ <?_ ,30%UV/EO\ X;_;_H1!_P"#?_[11_PW^W_0B#_P;_\
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M\/?] '3/_ ./_P")H_X0GP]_T =,_P# ./\ ^)H"Z['RW_PW^W_0B#_P;_\
MVBC_ (;_ &_Z$0?^#?\ ^T5]2?\ "$^'O^@#IG_@''_\31_PA/A[_H Z9_X!
MQ_\ Q- 778^6_P#AO]O^A$'_ (-__M%'_#?[?]"(/_!O_P#:*^I/^$)\/?\
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M%UV/EO\ X;_;_H1!_P"#?_[11_PW^W_0B#_P;_\ VBOJ3_A"?#W_ $ =,_\
M ./_ .)H_P"$)\/?] '3/_ ./_XF@+KL?+?_  W^W_0B#_P;_P#VBC_AO]O^
MA$'_ (-__M%?4G_"$^'O^@#IG_@''_\ $T?\(3X>_P"@#IG_ (!Q_P#Q- 77
M8^6_^&_V_P"A$'_@W_\ M%'_  W^W_0B#_P;_P#VBOJ3_A"?#W_0!TS_ , X
M_P#XFC_A"?#W_0!TS_P#C_\ B: NNQ\M_P##?[?]"(/_  ;_ /VBC_AO]O\
MH1!_X-__ +17U)_PA/A[_H Z9_X!Q_\ Q-'_  A/A[_H Z9_X!Q__$T!==CY
M;_X;_;_H1!_X-_\ [11_PW^W_0B#_P &_P#]HKZD_P"$)\/?] '3/_ ./_XF
MC_A"?#W_ $ =,_\  ./_ .)H"Z['RW_PW^W_ $(@_P#!O_\ :*/^&_V_Z$0?
M^#?_ .T5]2?\(3X>_P"@#IG_ (!Q_P#Q-'_"$^'O^@#IG_@''_\ $T!==CY;
M_P"&_P!O^A$'_@W_ /M%'_#?[?\ 0B#_ ,&__P!HKZD_X0GP]_T =,_\ X__
M (FC_A"?#W_0!TS_ , X_P#XF@+KL?+?_#?[?]"(/_!O_P#:*/\ AO\ ;_H1
M!_X-_P#[17U)_P (3X>_Z .F?^ <?_Q-'_"$^'O^@#IG_@''_P#$T!==CY;_
M .&_V_Z$0?\ @W_^T4?\-_M_T(@_\&__ -HKZD_X0GP]_P! '3/_  #C_P#B
M:/\ A"?#W_0!TS_P#C_^)H"Z['RW_P -_M_T(@_\&_\ ]HH_X;_;_H1!_P"#
M?_[17U)_PA/A[_H Z9_X!Q__ !-'_"$^'O\ H Z9_P" <?\ \30%UV/EO_AO
M]O\ H1!_X-__ +11_P -_M_T(@_\&_\ ]HKZD_X0GP]_T =,_P# ./\ ^)H_
MX0GP]_T =,_\ X__ (F@+KL?+?\ PW^W_0B#_P &_P#]HH_X;_;_ *$0?^#?
M_P"T5]2?\(3X>_Z .F?^ <?_ ,31_P (3X>_Z .F?^ <?_Q- 778^6_^&_V_
MZ$0?^#?_ .T4?\-_M_T(@_\ !O\ _:*^I/\ A"?#W_0!TS_P#C_^)H_X0GP]
M_P! '3/_  #C_P#B: NNQ\M_\-_M_P!"(/\ P;__ &BC_AO]O^A$'_@W_P#M
M%?4G_"$^'O\ H Z9_P" <?\ \31_PA/A[_H Z9_X!Q__ !- 778^6_\ AO\
M;_H1!_X-_P#[11_PW^W_ $(@_P#!O_\ :*^I/^$)\/?] '3/_ ./_P")H_X0
MGP]_T =,_P# ./\ ^)H"Z['RW_PW^W_0B#_P;_\ VBC_ (;_ &_Z$0?^#?\
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M^@#IG_@''_\ $T?\(3X>_P"@#IG_ (!Q_P#Q- 778^6_^&_V_P"A$'_@W_\
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MQ\M_\-_M_P!"(/\ P;__ &BC_AO]O^A$'_@W_P#M%?4G_"$^'O\ H Z9_P"
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M?\(3X>_Z .F?^ <?_P 30%UV/EO_ (;_ &_Z$0?^#?\ ^T4?\-_M_P!"(/\
MP;__ &BOJ3_A"?#W_0!TS_P#C_\ B:/^$)\/?] '3/\ P#C_ /B: NNQ\M_\
M-_M_T(@_\&__ -HH_P"&_P!O^A$'_@W_ /M%?4G_  A/A[_H Z9_X!Q__$T?
M\(3X>_Z .F?^ <?_ ,30%UV/EO\ X;_;_H1!_P"#?_[11_PW^W_0B#_P;_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 FVC;11
M0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
I%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>nvax-20231231_g2.jpg
<TEXT>
begin 644 nvax-20231231_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/X<UE[>&RG\5Z;+-/#IT=TENB0I<"X2*&66&.-")T98@0V0#]0J*_)7X4_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPEI=UKOC"*Q;>VD:?IESH+74MQC_ %(WV%Q""^,R@(,M@5_097/^%?A/\+/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y1^W/_R:
M/X]_[ +_ /H:UW7PN_Y)GX=_[ 5I_P"B4KA?VY_^31_'O_8!?_T-:[KX7?\
M),_#O_8"M/\ T2E &[1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'E'[<__ ":/X]_[ +_^AK7=?"[_
M ))GX=_[ 5I_Z)2N%_;G_P"31_'O_8!?_P!#6NZ^%W_),_#O_8"M/_1*4 ;M
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 >4?MS_P#)H_CW_L O_P"AK7=?"[_DF?AW_L!6G_HE*X7]
MN?\ Y-'\>_\ 8!?_ -#6NZ^%W_),_#O_ & K3_T2E &[1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
ME'[<_P#R:/X]_P"P"_\ Z&M=U\+O^29^'?\ L!6G_HE*X7]N?_DT?Q[_ -@%
M_P#T-:[KX7?\DS\._P#8"M/_ $2E &[1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT+5C"X$T<<!W(&;;7Z]44 ?C#\,O^":W[3G[4?C'_@GA\,?BA\#/$/@VP_9
MTZ]N_BSJ/B*T$5K)J%M/IAL+.PE#%-1$TFF+(98"\212?,X?]V?V>HHH *I:
MSX<\/>(XD@\0Z#97Z1MNC2]M4E"'U 8'!J[10!XA^VQ\/O .E_LI>.=0TSP1
MH]O<1:&[13P:9$CH=R\A@N0:]1^%B)'\,?#B(H55T&S  & !Y"5PW[<__)H_
MCW_L O\ ^AK7=?"[_DF?AW_L!6G_ *)2@#=HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RC]N?_DT?
MQ[_V 7_]#6NZ^%W_ "3/P[_V K3_ -$I7"_MS_\ )H_CW_L O_Z&M=U\+O\
MDF?AW_L!6G_HE* -VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /*/VY_\ DT?Q[_V 7_\ 0UKNOA=_
MR3/P[_V K3_T2E<+^W/_ ,FC^/?^P"__ *&M=U\+O^29^'?^P%:?^B4H W:*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH \H_;G_ .31_'O_ & 7_P#0UKNOA=_R3/P[_P!@*T_]$I7"
M_MS_ /)H_CW_ + +_P#H:UW7PN_Y)GX=_P"P%:?^B4H W:*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI&944N[
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!Y1^W/_P FC^/?^P"__H:UW7PN_P"29^'?^P%:?^B4KA?VY_\
MDT?Q[_V 7_\ 0UKNOA=_R3/P[_V K3_T2E &[1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#RC]N?_DT?Q[_V 7_]#6NZ^%W_ "3/P[_V
M K3_ -$I7"_MS_\ )H_CW_L O_Z&M=U\+O\ DF?AW_L!6G_HE* -VBBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWPS_ &8?"]S]_P .?"#P^WB'Q T)ZQ3:A?$0P2_]-;;(&!QUKI_A/_P;T_\
M!.WPOXLB^*7[1>B>+_V@O&Z8,GBWX]>+;CQ!*YSDC[-(5M2F>BM"Q XR><_<
ME% &9X.\$^#/AWX<M?!WP_\ ".F:%I%E'LLM*T:PCM;:W7^ZD4:JJ#V %:=%
M% !1110 4444 %%%% !1110 4444 ))''-&T4J!E8$,K#((/4$5^8-LTW_!
M/]M06$A:#]C?X_>*3]G<Y%M\)_&%P?N$](=+O"..B0L/X!&3-^G]<9^T/^S]
M\)?VJ?@EXE_9X^.GA&WUWPGXLTN2PUG3;@??C;D.C=8Y$8*Z2+AD=%92"H-
M'9(Z2*'1@RL,@@Y!%+7YX_\ !,']H'XM?L5?'^X_X(I_MP>+KC5-9T'37OOV
M=?B1J1VCQSX5CSMLW8\?VA9(NQXQR8XR0"L8DE_0Z@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#RC]N?_DT?Q[_V 7_]#6NZ^%W_ "3/P[_V
M K3_ -$I7"_MS_\ )H_CW_L O_Z&M=U\+O\ DF?AW_L!6G_HE* -VBBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP(JY]\9KJ:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH _,;X_:/JW_!"?]L^]_;7^'>EW#?LJ_&WQ
M#%'\<_#5A"SQ> /$<[".'Q);Q*#LM9V*I<*HX8C&XF"-?TPT?6-)\0Z1:Z_H
M&J6]]87ULEQ97MI,LD5Q"ZADD1U)#JRD$,"00016;\2?AQX$^,/P_P!:^%7Q
M0\*V>N>'/$6F3:=K>CZA%O@O+65"DD3KW!4D>OI@U^>?[ _Q'\=_\$F?VL+3
M_@CU^TYXJO-2^&7BQY[S]D[XC:S+N,MJ&W2^%;J8\?:;<L/(S]]&51MWPQ*
M?I/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8ZC96/AQXIIH]RY5'+?*<XYKZ5^$BW"?"KPREW(KRCP]9"5T& S>0F2!V&:
M.AHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ^ _^#D#_DQ3P=_V<!X(_P#3HE 'IG[,O_!#S_@E_P#LJ:N/&'@?]E71-?\
M%+2^?<>,_B TGB#59KCO/YU^TGE2'N8EC^G)KZQCC2)%BB0*J@!548 'H*6B
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1\7_  IO?'T\OAV]FN)&>X'D%?.6.4L1*@FVS)^[E#IE3]<44 >4?M(_L7?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !45]?66EV4VIZG>16]
MM;Q-+<7$\@1(D499F8\*  22> !4DDB1(TLKA54$LS'  ]37YA?&SXI_$O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /+?VT/V/O@M^WC^S;XF_9>^/F@_;
M= \26>SSX<"YTZY7YH+RW<@^7/%(%=6Z<%6#*S*?F+_@E#^V#\:?"'Q#U_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP@T#X"_ CP+8^&_"?AC3UL]&T?3X\)#&.223EG=F+.\C$N[LS,2S$G._9?\
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M=,\<>#M:M]2TC6=/AOM*U&TD#Q75M,@DBE1A]Y61E8'N"*T* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \H_;G_Y-'\>_
M]@%__0UKNOA=_P DS\._]@*T_P#1*5PO[<__ ":/X]_[ +_^AK7=?"[_ ))G
MX=_[ 5I_Z)2@#=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKX!_X*#?MR?'K]H3X]3?
M\$F_^"7.NQQ_$V[M5?XO?%F-#+8_"S1Y.&8LIP^J2J2(800R$AOE/SQ@&=^W
M3^V)\>OVY?VA-4_X),_\$P_&#Z7JEDJQ_M!_'.R!>V^'VG.2KZ?:2*0)=6F
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MTA\*VVBG4(C,YMU^R0-Y<;K%Y:L=WS,&.>:^4-%_X+Y> /AGXDM/ W_!0/\
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MU%=!^,O@>3"FWOE!$>H6XS\]G=*IEC=<J/F4,RA7< ^KZ*** "BBB@ HHHH
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MKA?VY_\ DT?Q[_V 7_\ 0UKNOA=_R3/P[_V K3_T2E &[1110 4444 %%%%
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M9W_9R\">!%GA$4__  AWA*STTRH"#M<V\:%QD \YY&>M 'AW[87_  5<T?\
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MP]]H^,WPQTXVWC;P=:Y5/B3X3!#7.ES*H.^YB4&2W?!;*!0'980OV9J/Q?\
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M)*Q">[EEF=5SA0SG:H55PJ@#L** "BBB@ HHHH **** "BBB@ HHHH ****
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M! (- '64444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_@@'X6^.<Z:Q_P %,_V\_C7^T5.SA[GPWJOB9_#_ (89QR3'I6FL@BR?2;&
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M<3I'G+)&]U;JS#@&9/6MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML=4LY=.U*SBN+>>,I/!/&'212,%64\$$=C7RK^T/_P $-_\ @E!^T[<R:O\
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M/P \ >"+'4TN-:^'_P -?"U]JUYJEH,[K66]OV40.?\ GK#D @$ C*U]KT4
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M#@8%>^5D>,_A_P" _B-I)T'XA>"=(UZQ;.;+6=-BNHCGK\DJL/TH \W^$O\
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M_P#1*5PO[<__ ":/X]_[ +_^AK7=?"[_ ))GX=_[ 5I_Z)2@#=HHHH ****
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MW7[;2-6M[RYT+68?,M-1CCD5VMIEZF.104;&#AC@@X-?VD_\$J_A-_P3_P!
M_9AT3]H?_@GE\&-%\&^%/BOHMCK5U;:*7 DD5&7RYE+LHFA=Y87Q@AD93G:,
M 'TS1110 4444 %%%% !1110 445R?QU^.GPE_9G^$6O_'?XZ^.;'PWX3\,:
M>][K6LZA)MC@B7@  9+NS%42-06=V55!9@" 9W[3?[3/P2_8\^!WB#]HO]H?
MQU:^'?"?AJR-QJ6H7)R6/1(8D'S2S2,0B1J"SLP '-?#/['W[,WQL_X*J_M
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M*0Q,=^0-I)"L>U<]\)?^"Y?_  2&^-GE+X'_ ."A/PTA>?'E0^(]>&BR,3T
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M!>%T\(?'SX2ZBN@_&7P/)A3;WR@B/4+<9^>SNE4RQNN5'S*&90KO]7U\&?\
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MFS<0"Q%87_#EK]J/Q!_R4+_@NK^U/<[O]9_PC>NV6D9^GE0-MK[_ ** //\
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M "@"'7]?T+PIH5[XH\4:U::;IFFVDEUJ.HW]PL,%K!&I>261W(5$506+$@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4217ZGT4 ? /_#0__!QQ_P!(ZOV?_P#P[MQ_\;H_X:'_ .#CC_I'5^S_ /\
MAW;C_P"-U]_44 ?DA\:_@=_P7J^//[:/P._;.U+]BKX.^$_$?PAUJ>.^OO#?
MQ3:277?#]V E]I<RRQA65DWM$QSY<C%@,G-?K>.G2BB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "OQQ_;5_X-$O!7[:/[67Q!_:L\3?MYZYI-YX\\3W.KR:5#X!@F2Q65LI
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M))(D2-+*X55!+,QP /4U^87QL^*?Q+_X+V_&W6?V-/V5_&&H>'_V4?!FJ_8O
MC?\ %W1IC'+X]NXR"_AW1YA]ZVZ"XN5RK*>,H4%Q=_:<^//Q<_X+2_'?7O\
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M^7XC?!'X5?M9^%;;[VL>!-3_ .$1\4M&/O2RVEP#9R-CD16X);D9Y&/T+HH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^:W[=OP^\;?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_"3PC^T-HG_!9+XT>-?/^+'AK0KWP]KMG80VUQ;7M^D4H9HDW?=R,>]?K]0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!Y1^W/_R:/X]_[ +_ /H:UW7PN_Y)GX=_[ 5I
M_P"B4KA?VY_^31_'O_8!?_T-:[KX7?\ ),_#O_8"M/\ T2E &[1110 4444
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M4]P?RK\T_P#@X$_X)R_\$_\ X5_L=>%_&GPJ_8E^%/A75[OXV>$=.NM2\,>
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MX]_[ +_^AK7=?"[_ ))GX=_[ 5I_Z)2@#=HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /&_VI?\ @GG^
MQ!^VQIKZ?^U1^RYX-\:2-%Y::GJFCH-0A3&,17D>VXAX_N2+V]*_)S_@M5_P
M2#T[]AK]E+PWXF_8Z_;"^+.B^%9OB]X7L;'X3>+_ !0^N^&["ZDOU%M<VT5S
MF6 PR;6(WOO VGBOW'KX!_X.0/\ DQ3P=_V<!X(_].B4 4O^&U?^"X7['O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)Y]ZXCQ!_P $0O\ @D1XEW?VC_P3I^$T>[K_ &?X1@M/3IY 3'3^?J:^IJ*
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MNA(. RN".G8UB0?!;_@JSH\":3X<_:J^&$&G6J"&P@F\$2N\<*C:BLV[YB%
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MY?\ XNOJ:B@#Y9_X5/\ \%<O^CM/A9_X0<O_ ,71_P *G_X*Y?\ 1VGPL_\
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M_P 71_PJ?_@KE_T=I\+/_"#E_P#BZ^IJ* /EG_A4_P#P5R_Z.T^%G_A!R_\
MQ='_  J?_@KE_P!':?"S_P (.7_XNOJ:B@#Y9_X5/_P5R_Z.T^%G_A!R_P#Q
M='_"I_\ @KE_T=I\+/\ P@Y?_BZ^IJ* /EG_ (5/_P %<O\ H[3X6?\ A!R_
M_%T?\*G_ ."N7_1VGPL_\(.7_P"+KZFHH ^6?^%3_P#!7+_H[3X6?^$'+_\
M%T?\*G_X*Y?]':?"S_P@Y?\ XNOJ:B@#Y9_X5/\ \%<O^CM/A9_X0<O_ ,71
M_P *G_X*Y?\ 1VGPL_\ "#E_^+KZFHH ^6?^%3_\%<O^CM/A9_X0<O\ \77S
M?_P5,_8)_P""R'[6'[,]E\/?"_QI^%WBW4-*\<:/K]GHRZ,VE!Y;*X\Y6,[D
MC:& RN/FS7Z;44 ?E=_PE_\ P=H_]$?_ &?_ /PH8O\ XFND^&_Q6_X.CO#-
M]<S_ !#_ &4/V?\ Q/#+$%MX/^$[-EY#9R6W1(2V1Q@U^EM% 'P#_P -#_\
M!QQ_TCJ_9_\ _#NW'_QNM_\ X(\_LN?MG_!+Q[^T/\<OVV/A]X7\,>(?C'\2
M+;Q%::/X3\0?VC;6\:V8A=?,(!'S*.O/-?;]% !1110 4444 %%%% !1110
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MF)CWL8=XA;:T910#[IHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA<^#]5%C<3:YK5\-2N;>><1^<$A^U-:A8GC&R, YVK@ _4VBOR)T?]H3X_\
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MPL^H0-$=:\,3PQ7UNI!!,4DL4@C;G[P7<.H(/- '045^27_!GW\1OBG\8_\
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M_$ETZR7!TN!5ADNK,W"RH+8SJQC0AHUD6? .3D _56BOR"_X-_\ Q#\2;_\
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MRP)(!]>T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M64%GXX\4>)+SQ3XLTRWN5G73KBXC@@CM3(A*NZ6]K!O*DJ)"X4L &/W3110
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MMJ?P_P!<U/308KV!-1U&8>:(F=K8M%<QN/-"#JI(;"G]5*** "BBB@ HHHH
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M/RV^L>-A<^([;2]/\6ZG&R36EG(#O>:QMY LTL115GG2-3^ZB=9_KW_@G?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?B-\/?B-%?3_  ]\=Z-KR:7J,EAJ;Z-JD5T+2[CQYEO*8F;RY5R-R-AAGD4
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MQ7I'Q,\->./$MS\;[@SRWK>.8I-4E']CWJ&=(X(H[>*W$""-DABGW1QJVU@
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M$?[.-]^U#XFT?Q!<>'M/\/Q:Q/8Z7HDMSJ302*C!5M4&]I<.,H.00?2OG#X
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MP.WA'QKX1\4N]QX8N(6BE'A[4=UYH=YM;EEDLG5/,'RR- TBX61!7R#^WO\
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M%I]B%X,D:2\J2^7E=I0KO&-^WYJ^Z/"?B2P\9>%=,\7Z7#<1VNJZ?#>6T=W
M8I5CE0.H=#RC ,,J>0<BOPV_:(;X^Q?\'=NM77[+\OA?_A.[?X+RS>';;QG9
M3SZ==W"^'69+>;R)X7B$A 3S0Q\O=N*/C:0#]'/V-O\ @KS\./VF_P!LOXA_
M\$[_ (E?![7?AK\9?AQ ;O4O#>JW\%]9ZE98A87%G=PD"0;+BWDV.D;;)E8
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "O@'_@Y _Y,4\'?]G >"/\ TZ)7W]7@'_!2C]@G1/\ @H[^S<G[/.M_
M%?6/!7D>*--UVR\0Z%:Q37-O<V4OFQ%5E^7[V#GMB@#W^BO@'_AS]^W7_P!)
MZ?V@/_!3I?\ \11_PY^_;K_Z3T_M ?\ @ITO_P"(H /VA_\ E8X_9U_[-_\
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M]G?PSJ=AJWQB\3+KGC*34-8END:X62XD1(5<XBC5[NX8#D_O2"Q"J%][HHH
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M%8[5TEBFL8X1+)+)]K+&-(ED-?H2B)&@CC0*JC"JHP /2EHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
@* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253656481040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 23, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-26770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NOVAVAX,&#160;INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-2816046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">700 Quince Orchard Road,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Gaithersburg,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(240)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">268-2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NVAX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 699,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,953,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Documents incorporated by reference: Portions of the Registrant&#8217;s Definitive Proxy Statement to be filed no later than 120 days after the fiscal year ended December&#160;31, 2023 in connection with the Registrant&#8217;s 2024 Annual Meeting of Stockholders are incorporated by reference into Part&#160;III of this Annual Report on Form&#160;10-K to the extent indicated herein.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001000694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253656484464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst&#160;& Young LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tysons, Virginia<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253657559648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 983,705<span></span>
</td>
<td class="nump">$ 1,981,872<span></span>
</td>
<td class="nump">$ 1,146,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="nump">343,768<span></span>
</td>
<td class="nump">902,639<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">737,502<span></span>
</td>
<td class="nump">1,235,278<span></span>
</td>
<td class="nump">2,534,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="nump">468,946<span></span>
</td>
<td class="nump">488,691<span></span>
</td>
<td class="nump">298,358<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">1,550,216<span></span>
</td>
<td class="nump">2,626,608<span></span>
</td>
<td class="nump">2,832,866<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(566,511)<span></span>
</td>
<td class="num">(644,736)<span></span>
</td>
<td class="num">(1,686,576)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(14,416)<span></span>
</td>
<td class="num">(19,880)<span></span>
</td>
<td class="num">(21,127)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="nump">37,896<span></span>
</td>
<td class="nump">10,969<span></span>
</td>
<td class="num">(6,833)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">(543,031)<span></span>
</td>
<td class="num">(653,647)<span></span>
</td>
<td class="num">(1,714,536)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(2,031)<span></span>
</td>
<td class="num">(4,292)<span></span>
</td>
<td class="num">(29,215)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (545,062)<span></span>
</td>
<td class="num">$ (657,939)<span></span>
</td>
<td class="num">$ (1,743,751)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in usd per share)</a></td>
<td class="num">$ (5.41)<span></span>
</td>
<td class="num">$ (8.42)<span></span>
</td>
<td class="num">$ (23.44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in usd per share)</a></td>
<td class="num">$ (5.41)<span></span>
</td>
<td class="num">$ (8.42)<span></span>
</td>
<td class="num">$ (23.44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted average number of common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">100,768<span></span>
</td>
<td class="nump">78,183<span></span>
</td>
<td class="nump">74,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">100,768<span></span>
</td>
<td class="nump">78,183<span></span>
</td>
<td class="nump">74,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 531,389<span></span>
</td>
<td class="nump">$ 1,554,961<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">427,323<span></span>
</td>
<td class="nump">382,921<span></span>
</td>
<td class="nump">948,709<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nvax_RoyaltiesAndOtherMember', window );">Royalties and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 24,993<span></span>
</td>
<td class="nump">$ 43,990<span></span>
</td>
<td class="nump">$ 197,581<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nvax_RoyaltiesAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nvax_RoyaltiesAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253656272736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (545,062)<span></span>
</td>
<td class="num">$ (657,939)<span></span>
</td>
<td class="num">$ (1,743,751)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gains (losses) on marketable securities available-for-sale, net of reclassifications</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">9,099<span></span>
</td>
<td class="num">(5,024)<span></span>
</td>
<td class="num">(8,368)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">9,099<span></span>
</td>
<td class="num">(5,024)<span></span>
</td>
<td class="num">(8,377)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (535,963)<span></span>
</td>
<td class="num">$ (662,963)<span></span>
</td>
<td class="num">$ (1,752,128)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253656145424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 568,505<span></span>
</td>
<td class="nump">$ 1,336,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">10,424<span></span>
</td>
<td class="nump">10,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">297,240<span></span>
</td>
<td class="nump">82,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">41,696<span></span>
</td>
<td class="nump">36,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">226,023<span></span>
</td>
<td class="nump">237,147<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,143,888<span></span>
</td>
<td class="nump">1,703,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">305,771<span></span>
</td>
<td class="nump">294,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_LeaseRightOfUseAsset', window );">Right of use asset, net</a></td>
<td class="nump">185,218<span></span>
</td>
<td class="nump">106,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">127,454<span></span>
</td>
<td class="nump">126,331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">35,159<span></span>
</td>
<td class="nump">28,469<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,797,490<span></span>
</td>
<td class="nump">2,258,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">132,610<span></span>
</td>
<td class="nump">216,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">394,668<span></span>
</td>
<td class="nump">591,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">241,310<span></span>
</td>
<td class="nump">370,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease liabilities</a></td>
<td class="nump">5,142<span></span>
</td>
<td class="nump">27,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">324,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">861,408<span></span>
</td>
<td class="nump">930,055<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,635,138<span></span>
</td>
<td class="nump">2,459,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">622,210<span></span>
</td>
<td class="nump">179,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes payable</a></td>
<td class="nump">168,016<span></span>
</td>
<td class="nump">166,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Non-current finance lease liabilities</a></td>
<td class="nump">55,923<span></span>
</td>
<td class="nump">31,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">33,130<span></span>
</td>
<td class="nump">55,695<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,514,417<span></span>
</td>
<td class="nump">2,892,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 16)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value, 2,000,000 shares authorized at December&#160;31, 2023 and 2022; no shares issued and outstanding at December&#160;31, 2023 and 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value, 600,000,000 shares authorized at December&#160;31, 2023 and 2022; and 140,506,093 shares issued and 139,505,770 shares outstanding at December&#160;31, 2023 and 86,806,554 shares issued and 86,039,923 shares outstanding at December&#160;31, 2022</a></td>
<td class="nump">1,405<span></span>
</td>
<td class="nump">868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">4,192,164<span></span>
</td>
<td class="nump">3,737,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(4,820,951)<span></span>
</td>
<td class="num">(4,275,889)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, 1,000,323 shares, cost basis at December&#160;31, 2023 and 766,631 shares, cost basis at December&#160;31, 2022</a></td>
<td class="num">(92,267)<span></span>
</td>
<td class="num">(90,659)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">2,722<span></span>
</td>
<td class="num">(6,377)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(716,927)<span></span>
</td>
<td class="num">(634,078)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="nump">$ 1,797,490<span></span>
</td>
<td class="nump">$ 2,258,679<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_LeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_LeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480833/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481058/954-310-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253656091136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value per share (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">140,506,093<span></span>
</td>
<td class="nump">86,806,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">139,505,770<span></span>
</td>
<td class="nump">86,039,923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, shares (in shares)</a></td>
<td class="nump">1,000,323<span></span>
</td>
<td class="nump">766,631<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253654381248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance beginning (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,433,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance beginning at Dec. 31, 2020</a></td>
<td class="nump">$ 627,209<span></span>
</td>
<td class="nump">$ 714<span></span>
</td>
<td class="nump">$ 2,535,476<span></span>
</td>
<td class="num">$ (1,874,199)<span></span>
</td>
<td class="num">$ (41,806)<span></span>
</td>
<td class="nump">$ 7,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">183,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram', window );">Stock issued under incentive programs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,503,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CompensationStockIssuedUnderIncentiveProgram', window );">Stock issued under incentive programs</a></td>
<td class="nump">24,761<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">68,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,295)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,578,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">564,859<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">564,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(8,368)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,368)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,743,751)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,743,751)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance ending (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,350,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance ending at Dec. 31, 2021</a></td>
<td class="num">$ (351,673)<span></span>
</td>
<td class="nump">$ 764<span></span>
</td>
<td class="nump">3,351,967<span></span>
</td>
<td class="num">(3,617,950)<span></span>
</td>
<td class="num">(85,101)<span></span>
</td>
<td class="num">(1,353)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance beginning (in shares) at Dec. 31, 2022</a></td>
<td class="nump">86,039,923<span></span>
</td>
<td class="nump">86,806,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 131,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram', window );">Stock issued under incentive programs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">701,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CompensationStockIssuedUnderIncentiveProgram', window );">Stock issued under incentive programs</a></td>
<td class="num">(639)<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">4,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,558)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,672,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">249,230<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
<td class="nump">249,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(5,024)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,024)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(657,939)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(657,939)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance ending (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,433,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance ending at Dec. 31, 2022</a></td>
<td class="num">$ (634,078)<span></span>
</td>
<td class="nump">$ 868<span></span>
</td>
<td class="nump">3,737,979<span></span>
</td>
<td class="num">(4,275,889)<span></span>
</td>
<td class="num">(90,659)<span></span>
</td>
<td class="num">(6,377)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance beginning (in shares) at Dec. 31, 2023</a></td>
<td class="nump">139,505,770<span></span>
</td>
<td class="nump">140,506,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 85,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram', window );">Stock issued under incentive programs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">902,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CompensationStockIssuedUnderIncentiveProgram', window );">Stock issued under incentive programs</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">1,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,608)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,796,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">367,105<span></span>
</td>
<td class="nump">$ 528<span></span>
</td>
<td class="nump">366,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">9,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (545,062)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(545,062)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance ending (in shares) at Dec. 31, 2022</a></td>
<td class="nump">86,039,923<span></span>
</td>
<td class="nump">86,806,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance ending at Dec. 31, 2023</a></td>
<td class="num">$ (716,927)<span></span>
</td>
<td class="nump">$ 1,405<span></span>
</td>
<td class="nump">$ 4,192,164<span></span>
</td>
<td class="num">$ (4,820,951)<span></span>
</td>
<td class="num">$ (92,267)<span></span>
</td>
<td class="nump">$ 2,722<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_CompensationStockIssuedUnderIncentiveProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Compensation Stock Issued Under Incentive Program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_CompensationStockIssuedUnderIncentiveProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Stock Issued Under Incentive Program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253656439184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of common stock, issuance costs</a></td>
<td class="nump">$ 6,171<span></span>
</td>
<td class="nump">$ 7,216<span></span>
</td>
<td class="nump">$ 7,292<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253657586400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (545,062)<span></span>
</td>
<td class="num">$ (657,939)<span></span>
</td>
<td class="num">$ (1,743,751)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Reconciliation of net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">41,225<span></span>
</td>
<td class="nump">29,054<span></span>
</td>
<td class="nump">12,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_OperatingAndFinanceLeaseWriteOff', window );">Right-of-use assets expensed, net of credits received</a></td>
<td class="nump">6,113<span></span>
</td>
<td class="nump">18,104<span></span>
</td>
<td class="nump">144,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">85,357<span></span>
</td>
<td class="nump">130,300<span></span>
</td>
<td class="nump">183,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ProvisionForExcessAndObsoleteInventory', window );">Provision for excess and obsolete inventory</a></td>
<td class="nump">72,197<span></span>
</td>
<td class="nump">447,597<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="nump">10,081<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other items, net</a></td>
<td class="num">(7,042)<span></span>
</td>
<td class="num">(21,903)<span></span>
</td>
<td class="num">(7,641)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(74,457)<span></span>
</td>
<td class="num">(477,801)<span></span>
</td>
<td class="num">(8,872)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Accounts receivable, prepaid expenses, and other assets</a></td>
<td class="num">(274,442)<span></span>
</td>
<td class="nump">249,166<span></span>
</td>
<td class="num">(183,393)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses, and other liabilities</a></td>
<td class="num">(378,805)<span></span>
</td>
<td class="nump">913,399<span></span>
</td>
<td class="nump">600,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">350,868<span></span>
</td>
<td class="num">(1,045,914)<span></span>
</td>
<td class="nump">1,325,557<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(713,967)<span></span>
</td>
<td class="num">(415,937)<span></span>
</td>
<td class="nump">322,946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForCapitalImprovements', window );">Capital expenditures</a></td>
<td class="num">(53,771)<span></span>
</td>
<td class="num">(89,056)<span></span>
</td>
<td class="num">(54,501)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForSoftware', window );">Internal-use software</a></td>
<td class="num">(5,035)<span></span>
</td>
<td class="num">(3,929)<span></span>
</td>
<td class="num">(2,985)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,167)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">159,807<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(58,806)<span></span>
</td>
<td class="num">(92,985)<span></span>
</td>
<td class="nump">100,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sales of common stock</a></td>
<td class="nump">360,243<span></span>
</td>
<td class="nump">249,230<span></span>
</td>
<td class="nump">564,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of 2027 Convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">175,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Payments of costs related to issuance of 2027 Convertible notes</a></td>
<td class="num">(3,591)<span></span>
</td>
<td class="num">(5,258)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NetProceedsFromTheExerciseOfStockBasedAwards', window );">Net proceeds from the exercise of stock-based awards</a></td>
<td class="nump">159<span></span>
</td>
<td class="num">(639)<span></span>
</td>
<td class="nump">24,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of 2023 Convertible notes</a></td>
<td class="num">(325,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Finance lease payments</a></td>
<td class="num">(27,345)<span></span>
</td>
<td class="num">(93,595)<span></span>
</td>
<td class="num">(127,907)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">4,466<span></span>
</td>
<td class="nump">324,988<span></span>
</td>
<td class="nump">461,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate on cash, cash equivalents, and restricted cash</a></td>
<td class="nump">3,272<span></span>
</td>
<td class="nump">4,520<span></span>
</td>
<td class="num">(5,292)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(765,035)<span></span>
</td>
<td class="num">(179,414)<span></span>
</td>
<td class="nump">879,521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of year</a></td>
<td class="nump">1,348,845<span></span>
</td>
<td class="nump">1,528,259<span></span>
</td>
<td class="nump">648,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of year</a></td>
<td class="nump">583,810<span></span>
</td>
<td class="nump">1,348,845<span></span>
</td>
<td class="nump">1,528,259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled', window );">Sale of common stock under the Sales Agreement not settled at year-end</a></td>
<td class="nump">6,862<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures included in accounts payable and accrued expenses</a></td>
<td class="nump">7,899<span></span>
</td>
<td class="nump">17,665<span></span>
</td>
<td class="nump">10,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset', window );">Right-of-use assets from new lease agreements</a></td>
<td class="nump">103,299<span></span>
</td>
<td class="nump">91,855<span></span>
</td>
<td class="nump">179,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash interest payments, net of amounts capitalized</a></td>
<td class="nump">17,349<span></span>
</td>
<td class="nump">18,035<span></span>
</td>
<td class="nump">19,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">$ 190<span></span>
</td>
<td class="nump">$ 17,980<span></span>
</td>
<td class="nump">$ 12,606<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_NetProceedsFromTheExerciseOfStockBasedAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Proceeds From The Exercise Of Stock-Based Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_NetProceedsFromTheExerciseOfStockBasedAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash Related Transactions For Finance Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_OperatingAndFinanceLeaseWriteOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating and Finance Lease, Write-off</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_OperatingAndFinanceLeaseWriteOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of proceeds from issuance or sale of equity not settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ProvisionForExcessAndObsoleteInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision For Excess And Obsolete Inventory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ProvisionForExcessAndObsoleteInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForCapitalImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of or capital improvements to properties held for investment (operating, managed, leased) or for use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForCapitalImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253659939424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization &amp; Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization &amp; Business</a></td>
<td class="text">Organization &amp; Business<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novavax, Inc. (&#8220;Novavax,&#8221; and together with its wholly owned subsidiaries, the &#8220;Company&#8221;) is a biotechnology company that promotes improved health by discovering, developing, and commercializing innovative vaccines to prevent serious infectious diseases. Novavax offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and patented Matrix-M&#8482; adjuvant to enhance the immune response. Novavax currently has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid&#8482; prototype COVID-19 vaccine ("NVX-CoV2373,&#8221; or &#8220;prototype vaccine&#8221;) and Nuvaxovid&#8482; updated COVID-19 vaccine (&#8220;NVX-CoV2601,&#8221; or &#8220;updated vaccine&#8221;) (collectively, &#8220;COVID-19 Vaccine&#8221;). Local regulatory authorities have also specified nomenclature for the prototype and updated vaccines within their territories (e.g., &#8220;Novavax COVID-19 Vaccine, Adjuvanted&#8221; and &#8220;Novavax COVID-19, Adjuvanted (2023-2024 Formula)&#8221;, respectively, for the U.S.). The Company&#8217;s partner, Serum Institute of India Pvt. Ltd. (&#8220;SIIPL&#8221;), markets NVX-CoV2373 as &#8220;Covovax&#8482;.&#8221; </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2022, the Company received approval, interim authorization, provisional approval, conditional marketing authorization, and emergency use authorization (&#8220;EUA&#8221;) from multiple regulatory authorities globally for its prototype vaccine for both adult and adolescent populations as a primary series and for both homologous and heterologous booster indications in select territories. In October 2023, the U.S. Food and Drug Administration (&#8220;U.S. FDA&#8221;) amended the EUA for its prototype vaccine to include its updated vaccine. The amended EUA authorizes use of the Company&#8217;s updated vaccine in individuals 12 years and older. In October 2023, the European Commission (&#8220;EC&#8221;) granted approval for the Company&#8217;s updated vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 and older. Currently, the Company significantly depends on its supply agreement with SIIPL and its subsidiary, Serum Life Sciences Limited (&#8220;SLS&#8221;), for co-formulation, filling and finishing (other than in Europe) and on its service agreement with PCI Pharma Services for finishing in Europe. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novavax is advancing development of other vaccine candidates, including its COVID19-Influenza Combination (&#8220;CIC&#8221;) vaccine candidate and additional vaccine candidates. The Company&#8217;s COVID-19 Vaccine and its other vaccine candidates incorporate the Company&#8217;s proprietary Matrix-M&#8482; adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253781114000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Novavax,&#160;Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Going Concern</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern within one year after the date that the financial statements are issued and contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainty described below. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company had $568.5 million in cash and cash equivalents and had a working capital deficiency. In January 2024, pursuant to the June 2023 Amendment to the advance purchase agreement between the Company and the Canadian government (the &#8220;Canada APA&#8221;), the Company received the second installment of $174.8&#160;million from the Canadian government that was contingent and payable upon the Company&#8217;s delivery of vaccine doses (see Note 3). During the year ended December&#160;31, 2023, the Company incurred a net loss of $545.1 million and had net cash flows used in operating activities of $714.0&#160;million.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 205-40</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Presentation of Financial Statements - Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that these consolidated financial </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements are issued. While the Company&#8217;s current cash flow forecast for the one-year going concern look forward period estimates that there will be sufficient capital available to fund operations, this forecast is subject to significant uncertainty, including as it relates to revenue for the next 12 months and the Company&#8217;s ability to execute on certain cost-reduction initiatives. The Company&#8217;s revenue projections depend on its ability to successfully develop, manufacture, distribute and market its updated vaccine for the 2024-2025 vaccination season, which is inherently uncertain and subject to a number of risks, including the Company&#8217;s ability to obtain regulatory authorizations, introduce a single-dose vial or pre-filled syringe  product presentation for the U.S. commercial and certain other markets, the incidence of COVID-19 during the 2024-2025 vaccination season, the Company&#8217;s ability to timely deliver doses and achieve commercial adoption and market acceptance of its updated vaccine. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to meet regulatory milestones or achieve product volume or delivery timing obligations under the Company&#8217;s advance purchase agreements (&#8220;APAs&#8221;) may require the Company to refund portions of upfront and other payments or result in reduced future payments which would adversely affect the Company&#8217;s ability to continue as a going concern. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that, given the history of recurring losses, negative working capital and accumulated deficit, conditions or events exist that raise substantial doubt about the Company&#8217;s ability to continue as a going concern through one year from the date that these financial statements are issued. Management&#8217;s plans to alleviate the conditions that exist include restructuring and cost reduction measures and successful execution of its commercial plans. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, the Company announced a global restructuring and cost reduction plan (the &#8220;Restructuring Plan&#8221;), which includes a more focused investment in its COVID-19 Vaccine, reduction to its pipeline spending, the continued rationalization of its manufacturing network, a reduction to the Company&#8217;s global workforce, as well as the consolidation of facilities, and infrastructure. In January 2024, as part of reducing combined research and development and selling, general and administrative expenses, the Company announced further reductions in its global workforce (the &#8220;2024 Cost Reduction Plan&#8221;) (see Note 18). The Company intends to prioritize improvements to its long-term supply chain efficiency. The Company expects the full annual impact of the Restructuring Plan to be realized in 2024 and the full annual impact of the 2024 Cost Reduction Plan to be realized in 2025 and approximately 85% of the annual impact, excluding one-time charges, to be realized in 2024. During the year ended December&#160;31, 2023, the Company recorded a charge of $4.5&#160;million related to one-time employee severance and benefit costs and recorded an impairment charge of $10.1&#160;million related to the consolidation of facilities and infrastructure (see Note 17) and expects to record an additional charge of approximately $4&#160;million to $7&#160;million related to one-time employee severance and benefit costs, the majority of which is expected to be incurred in the first quarter of 2024. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Management&#8217;s plans may also include raising additional capital through a combination of equity and debt financing, collaborations, strategic alliances, asset sales, and marketing, distribution, or licensing arrangements. New financings may not be available to the Company on commercially acceptable terms, or at all. Also, any collaborations, strategic alliances, asset sales and marketing, distribution, or licensing arrangements may require the Company to give up some or all of its rights to a product or technology, which in some cases may be at less than the full potential value of such rights. If the Company is unable to obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate some or all of its operations, or further downsize its organization, any of which may have a material adverse effect on its business, financial condition, results of operations, and ability to operate as a going concern.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Due to the uncertainties associated with management&#8217;s plans, there is substantial doubt about the Company&#8217;s ability to continue as a going concern for at least one year from the date that these financial statements are issued.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company analyzes its revenue arrangements to determine the appropriate accounting under U.S. GAAP. Currently, the Company&#8217;s revenue arrangements represent customer contracts within the scope of ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 606&#8221;), or are contributions subject to the guidance in ASC Topic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities &#8211; Revenue Recognition </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 958-605&#8221;). The Company recognizes revenue from arrangements within the </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">scope of ASC 606 following the five-step model: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) it satisfies a performance obligation. The Company only recognizes revenue under the five-step model when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to its customer. The Company recognizes contribution revenue within the scope of ASC 958-605 when the funder-imposed conditions have been substantially met. Contributions are recorded as deferred revenue until the period in which research and development activities are performed that satisfy the funder-imposed conditions.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Sales - Advance Purchase Agreements </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales include sales associated with COVID-19 Vaccine supply agreements, sometimes referred to as APAs, with various international governments. The Company recognizes revenue from product sales related to these APA&#8217;s based on the transaction price per dose calculated in accordance with ASC 606 at the point in time when control of the product transfers to the customer and customer acceptance has occurred, unless such acceptance provisions are deemed perfunctory. The APAs typically contain terms that include upfront payments which are reflected in Deferred revenue. The Company constrains the transaction price for APA&#8217;s until it is probable that a significant reversal in revenue recognized will not occur. Specifically, if an APA includes a provision whereby the customer may request a discount, return, or refund, or includes a term that may have the effect of decreasing the price per dose of previously delivered shipments, revenue is constrained based on an estimate of the impact of the transaction price until it is probable that a significant reversal in revenue recognized will not occur. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Sales - U.S. Commercial </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2023, the Company commenced sales of COVID-19 Vaccine to the U.S. commercial market. Product sales in the U.S. are primarily made through large pharmaceutical wholesale distributors at the wholesale acquisition cost (&#8220;WAC&#8221;). The Company recognizes revenue upon title transfer (which is typically at time of delivery), provided all other revenue recognition criteria have been met. The transaction price includes estimates of variable consideration for which reserves are established that primarily result from invoice discounts for prompt payment, wholesale distributor fees, chargebacks, and product returns (collectively, &#8220;gross-to-net deductions&#8221;). These estimates are based on the amounts earned or to be claimed for related sales and are classified as either reductions of gross accounts receivable or a current liability based on the nature of the estimate, the expected settlement method, and net position by individual customer. Where appropriate, these estimates are based on factors such as industry data and forecasted customer buying and payment patterns, the Company&#8217;s experience, current contractual and statutory requirements, specific known market events, and trends. Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. If actual results vary from estimates, the Company will adjust the estimates, which would affect product sales in the period such variances become known. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross-to-net deductions include the following:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Wholesale distributor fees, discounts, and chargebacks: The Company has arrangements under which indirect customers such as retailers, healthcare providers, and others receive discounts to the WAC. The chargeback represents the difference between the WAC and this negotiated discounted price. For distribution and related services, the Company incurs service fees to its wholesale distributors. In addition, the Company typically offers wholesale distributor customers invoice discounts on product sales for prompt payments. The Company estimates chargebacks, discounts, and fees it will owe and deducts these amounts from gross product sales at the time the revenue is recognized based on the contractual terms and the Company&#8217;s expectations regarding future customer behaviors. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product returns: The Company offers U.S. customers the right to return COVID-19 Vaccine. These return rights include the right of wholesale distributors to return unsold and expired doses and the right of indirect customers to return any partial or unused vials upon expiry. Estimated returns for COVID-19 Vaccine are determined considering levels of inventory in the distribution channel, projected market demand, utilization data, returns claims received, and product shelf life. The estimated amount for product returns is deducted from gross product sales in the period the related product sales are recognized.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Other: Fees payable to retailers, healthcare providers, and buying groups, including certain patient assistance programs, are deducted from gross product sales in the period the related product sales are recognized.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Grants</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant revenue includes both revenue from government contracts and grants from organizations such as the Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;). The Company performs research and development under government funding, grant, license, and clinical development agreements. The revenue primarily consists of funding under U.S. government contracts and other arrangements to advance the clinical development and manufacturing of COVID-19 Vaccine.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under U.S. government contracts, the Company is entitled to receive funding on a cost-reimbursable or cost-reimbursable-plus-fixed-fee basis, to support certain activities related to the development, manufacture, and delivery of COVID-19 Vaccine to the U.S. government. The Company analyzed these contracts and determined that they are within the scope of ASC 606. The obligations under each of the contracts are not distinct in the context of the contract as they are highly interdependent or interrelated and, as such, they are accounted for as a single performance obligation. The transaction price under these arrangements is the consideration the Company is expecting to receive and consists of the funded contract amount and the unfunded variable amount to the extent that it is probable that a significant reversal of revenue will not occur. The Company recognizes revenue for these contracts over time as the Company transfers control over the goods and services and satisfies the performance obligation. The Company measures progress toward satisfaction of the performance obligation using an Estimate-at-Completion (&#8220;EAC&#8221;) process, which is a cost-based input method that reviews and monitors the progress towards the completion of the Company&#8217;s performance obligation. Under this process, management considers the costs that have been incurred to-date, as well as projections to completion using various inputs and assumptions, including, but not limited to, progress towards completion, labor costs and level of effort, material and subcontractor costs, indirect administrative costs, and other identified risks. Estimating the total allowable cost at completion of the performance obligation under a contract is subjective and requires the Company to make assumptions about future activity and cost drivers. Changes in these estimates can occur for a variety of reasons and, if significant, may impact the timing of revenue and fee recognition on the Company&#8217;s contracts. Allowable contract costs include direct costs incurred on the contract and indirect costs that are applied in the form of rates to the direct costs. Progress billings under the contracts are initially based on provisional indirect billing rates, agreed upon between the Company and the U.S. government. These indirect rates are subject to review on an annual basis. The Company records the impact of changes in the indirect billing rates in the period when such changes are identified. These changes reflect the difference between actual indirect costs incurred compared to the estimated amounts used to determine the provisional indirect billing rates agreed upon with the U.S. government. The Company recognizes revenue on the U.S. government contracts based on reimbursable allowable contract costs incurred in the period up to the transaction price. For cost-reimbursable-plus-fixed-fee contracts, the Company recognizes the fixed-fee based on the proportion of reimbursable contract costs incurred to total estimated allowable contract costs expected to be incurred on completion of the underlying performance obligation as determined under the EAC process. The Company recognizes changes in estimates related to the EAC process in the period when such changes are made on a cumulative catch-up basis. The Company includes the transaction price comprising both funded and unfunded portions of customer contracts in this estimate.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:28.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s other funding agreements currently include funding from CEPI in the form of a grant (&#8220;CEPI Grant Funding&#8221;) and one or more forgivable no interest term loans (&#8220;CEPI Forgivable Loan Funding&#8221;). Under the Company&#8217;s grant funding arrangements, including the CEPI arrangement, the Company is primarily entitled to reimbursement for costs that support development related activities of COVID-19 Vaccine. The Company analyzed these other funding arrangements and determined that they are not within the scope of ASC 606 as they do not provide a direct economic benefit to the grantor. Payments received under the grant funding arrangements are considered conditional contributions under the scope of ASC 958-605 and are recorded as deferred revenue until the period in which such research and development activities are actually performed in a manner that satisfies the funder-imposed conditions. Payments received under the CEPI Forgivable Loan Funding are only repayable if project vaccine, as defined under the CEPI funding agreement, manufactured by the contract manufacturing organization (&#8220;CMO&#8221;) network funded by CEPI is sold to one or more third parties (which could include sales credited under the Gavi Settlement Agreement), and such sales cover the Company&#8217;s costs of manufacturing such vaccine, not including manufacturing costs funded by CEPI. As the financial risk remains with CEPI, the Company determined that the use of the funds from the CEPI agreement is outside the scope of ASC Topic 470, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The research and development risk was considered substantive, such that it was not probable that the development would be successful at the inception of the contract. Therefore, the Company concluded that ASC Topic 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 730&#8221;) was considered applicable and most appropriate. Given the financial risk associated with the research and development activities lies with CEPI because repayment of any funds provided by CEPI depends solely on the results of the research and development activities having future economic benefit, the Company has accounted for the obligation under the CEPI Forgivable Loan Funding as a contract to perform research and development for others. The Company has determined that payments received under these agreements should be recorded as revenue under ASC 958-605 rather than a reduction to research and development expenses. This is consistent with the Company&#8217;s policy of presenting such amounts as revenue. In reaching this determination, the Company </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">considered a number of factors, including whether it is principal under the arrangement, and whether the arrangement is significant to, and part of, the Company&#8217;s core operations. The Company will record revenue as it performs the contractual research and development services.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments received in advance related to arrangements where revenue is recognized under ASC 958-605 that are related to future performance are deferred and recognized as revenue when the research and development activities are performed. Such cash payments are restricted as to their use and are reflected in Restricted cash until expenditures contemplated in the funding agreements are incurred.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Royalties and Other</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has various arrangements that include a right for a customer to use the Company's intellectual property as a functional license, where the Company&#8217;s performance obligation is satisfied at the point in time at which the license is granted. These licensing arrangements include sales-based royalties, certain development and commercial milestone payments, and the sale of proprietary Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> adjuvant. Because development milestone payments are contingent on the achievement of milestones, such as regulatory approvals, that are not within the Company or licensee's control, the payments are not considered probable of being achieved and are excluded from the transaction price until the milestone is achieved, at which point the Company recognizes revenue. For arrangements that include sales-based royalties related to a previously granted license, including milestone payments based upon the achievement of a certain level of product sales, the license is deemed to be the sole or predominant item to which the royalties relate and the Company recognizes revenue when the related sales occur.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the transaction price to each performance obligation based on a relative standalone selling price basis. It develops assumptions that require judgment to determine the standalone selling price for each performance obligation in consideration of applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales includes cost of raw materials, production, and manufacturing overhead costs associated with the Company&#8217;s product sales during the period. Cost of sales also includes adjustments for excess, obsolete, or expired inventory; idle capacity; and losses on firm purchase commitments to the extent the cost cannot be recovered based on estimates about future demand. Cost of sales does not include certain expenses related to raw materials, production, and manufacturing overhead costs that were expensed prior to regulatory authorization as described under the caption &#8220;Inventory.&#8221;</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include salaries; stock-based compensation; laboratory supplies; consultants and subcontractors, including external contract research organizations (&#8220;CROs&#8221;), CMOs, and contract development and manufacturing organizations (&#8220;CDMOs&#8221;); and other expenses associated with the Company&#8217;s process development, manufacturing, clinical, regulatory, and quality assurance activities for its clinical development programs. In addition, related indirect costs such as fringe benefits and overhead expenses are also included in research and development expenses. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates its research and development expense related to services performed under its contracts with external service providers based on an estimate of the level of service performed in the period. Research and development activities are expensed as incurred.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development Expenses</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues research and development expenses, including clinical trial-related expenses, as the services are performed, which may include estimates of those expenses incurred, but not invoiced. The Company uses information provided by third-party service providers and CRO, CMO, and CDMO invoices and internal estimates to determine the progress of work performed on the Company&#8217;s behalf. Assumptions based on clinical trial protocols, contracts, and participant enrollment data are also used to estimate these accruals.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed as incurred. The Company had advertising costs of $91.5&#160;million, $84.0&#160;million and $8.9&#160;million during the years ended December&#160;31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation related to grants of stock options, stock appreciation rights (&#8220;SARs&#8221;), and restricted stock awards (&#8220;RSUs&#8221;), and purchases under the Company&#8217;s Employee Stock Purchase Plan (&#8220;ESPP&#8221;), at fair value. The Company recognizes compensation expense related to such awards on a straight-line basis over the requisite service period (generally the vesting period) of the equity awards, based on the award's fair value at the grant date. The requisite service period is typically <span style="-sec-ix-hidden:f-398">one</span> to four years. Forfeitures for all awards are recognized as incurred. The Company generally settles stock-based awards with newly issued shares.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options and SARs is measured on the date of grant using the Black-Scholes option pricing model. The expected term of stock options and SARs is based on the Company&#8217;s historical option exercise experience and post-vesting forfeiture experience using the historical expected term from the vesting date, and the expected term for purchases under the ESPP is based on the purchase periods included in the offering. The expected volatility is determined using historical volatilities based on stock prices over a look-back period corresponding to the expected term. The risk-free interest rate is determined using the yield available for zero-coupon U.S. government issues with a remaining term equal to the expected term. The Company has never paid a dividend and the Company does not intend to pay dividends in the foreseeable future, and as such, the expected dividend yield is zero.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of highly liquid investments with maturities of three months or less from the date of purchase. Cash equivalents are recorded at cost, which approximates fair value due to their short-term nature.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), for financial and non-financial assets and liabilities. ASC 820 discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The statement utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Unobservable inputs that reflect the reporting entity&#8217;s own assumptions.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s current and non-current restricted cash includes payments received under grant agreements and cash collateral accounts under letters of credit that serve as security deposits for certain facility leases. Payments received under grant agreements become unrestricted as the Company incurs expenses for services performed under these agreements. As of December&#160;31, 2023 and 2022, restricted cash balances (both current and non-current) consisted primarily of payments under the CEPI funding agreements and letter of credits.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes amounts due from customers as accounts receivable when its right to payment is unconditional. Gross-to-net deductions are classified as reductions of gross accounts receivable if settlement is expected to occur through a reduction in the amount paid to Novavax by its customer. Account receivables are recorded net of any </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allowance for credit losses. The Company&#8217;s estimate for the allowance for credit losses, which has not been significant to date, is determined based on the credit risk of its customers based on historical loss experience, economic conditions, the aging of receivables, and customer-specific risks.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments expose the Company to concentration of credit risk and consist primarily of cash and cash equivalents. The Company&#8217;s investment policy limits investments to certain types of instruments, including asset-backed securities, high-grade corporate debt securities, and money market funds; places restrictions on maturities and concentrations in certain industries; and requires the Company to maintain a certain level of liquidity. At times, the Company maintains cash balances in financial institutions that may exceed federally insured limits. The Company has not experienced any losses relating to such accounts and believes it is not exposed to a significant credit risk on its cash and cash equivalents.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's accounts receivable arise from revenue arrangements with customers in different countries. The Company's revenue is primarily due to product sales, grants made by government-sponsored and private organizations, and royalties from its collaboration and license partners. The following customers accounted for more than 10% of total revenue or accounts receivable for the periods presented:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Revenue<br/>&#160;for Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Accounts Receivable as of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European Commission</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government of Australia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government of Canada</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government of Israel</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CEPI</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SK bioscience, Co., Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Amounts represent less than 10%</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Including the USG Agreement (as defined in Note 3) and the U.S. Department of Defense.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently depends significantly on one supplier for co-formulation, filling, and finishing of COVID-19 Vaccine. The loss of this supplier could prevent or delay the Company&#8217;s delivery of customer orders.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is recorded at the lower of cost or net realizable value under the First In, First Out methodology, taking into consideration the expiration of the inventory item. The Company determines the cost of raw materials using moving average costs and the cost of semi-finished and finished goods using a standard cost method adjusted on a periodic basis to reflect the deviation in the actual cost from the standard cost estimate. Standard costs consist primarily of the cost of manufacturing goods, including direct materials, direct labor, and the services and products of third-party suppliers. Manufacturing overhead costs are applied to semi-finished and finished goods based on expected production levels. The Company utilizes third-party CMOs, CDMOs, and other suppliers and service organizations to support the procurement and processing of raw materials, management of inventory, packaging, and the delivery process. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess, obsolete, or expired inventory through cost of sales. At each reporting period, the Company assesses whether there are excess firm, non-cancelable, purchase commitment liabilities, resulting from supply agreements with third-party CMOs and CDMOs. The determination of net realizable value of inventory and firm purchase commitment liabilities requires judgment, including consideration of many factors, such as estimates of future product demand, current and future market conditions, potential product obsolescence, expiration and utilization of raw materials under firm purchase commitments, and contractual minimums.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to initial regulatory authorization for its product candidates, the Company expenses costs relating to raw materials, production, and manufacturing overhead costs as research and development expenses in the consolidated statements of operations, in the period incurred. Subsequent to initial regulatory authorization for a product candidate, the Company </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capitalizes the costs of production for a particular supply chain as inventory when the Company determines that it has a present right to the economic benefit associated with the product.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, net of accumulated depreciation. and are depreciated using the straight-line method over the estimated useful lives of the assets. Repairs and maintenance costs are expensed as incurred. The estimated useful lives of property and equipment are described below:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.316%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or remaining term of the lease</span></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Accounting</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into manufacturing supply agreements with CMOs and CDMOs to manufacture its vaccine candidates. Certain of these manufacturing supply agreements include the use of identified manufacturing facilities and equipment that are controlled by the Company and for which the Company obtains substantially all the output and may qualify as an embedded lease. The Company treats manufacturing supply agreements that contain an embedded lease as lease arrangements in their entirety. The evaluation of leases that are embedded in the Company&#8217;s CMO and CDMO agreements is complex and requires judgment in determining whether the contract, either explicitly or implicitly, is for the use of an identified asset and the Company has the right to direct the use of, and obtain substantially all of the benefit from, the identified asset which generally is the use of a portion of the manufacturing facility of the CMO or CDMO, the term of the lease, and the fixed lease payments under the contract. Depending on the contract, the lease commencement date, defined as the date on which the lessor makes the underlying asset available for use by the lessee and on which the Company is required to accrue lease expenses, may be different than the inception date of the contract. The Company determines the non-cancellable lease term of its embedded leases based on the impact of certain expected milestones on its option to terminate the lease where it is reasonably certain to not exercise that option. The Company evaluates changes to the terms and conditions of a lease contract to determine if they result in a new lease or a modification of an existing lease. For lease modifications, the Company remeasures and reallocates the remaining consideration in the contract and reassesses the lease classification at the effective date of the modification. Leases are classified as either operating or finance leases based on the economic substance of the agreement. The Company also enters into non-cancelable lease agreements for facilities and certain equipment.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For leases that have a lease term of more than 12 months at the lease commencement date, the Company recognizes lease liabilities, which represent the Company&#8217;s obligation to make lease payments arising from the lease, and corresponding right-of-use (&#8220;ROU&#8221;) assets, which represent the right to use an underlying asset for the lease term, based on the present value of the fixed future payments over the lease term. The Company calculates the present value of future payments using the discount rate implicit in the lease, if available, or the Company&#8217;s incremental borrowing rate. For all leases that have a lease term of 12 months or less at the commencement date (referred to as &#8220;short-term&#8221; leases), the Company has elected to apply the practical expedient in ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 842&#8221;), to not recognize a lease liability or ROU asset but, instead, recognize lease payments as an expense on a straight-line basis over the lease term and variable lease payments that do not depend on an index or rate as an expense in the period in which the variable lease costs are incurred based on performance or usage in accordance with contractual agreements. In determining the lease period, the Company evaluates facts and circumstances that could affect the period over which it is reasonably certain to use the underlying asset while taking into consideration the non-cancelable period over which it has the right to use the underlying asset and any option period to extend or terminate the lease if it is reasonably certain to exercise the option. The Company re-evaluates short-term leases that are modified and if they no longer meet the requirements to be treated as a short-term lease, recognizes and measures the lease liability and ROU asset as if the date of the modification is the lease commencement date. For short-term leases that are modified and continue to meet the requirements to be treated as a short-term lease, the Company remeasures the fixed lease payments under the modified lease and recognize lease payments as an expense on a straight-line basis over the modified lease term.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For operating leases, the Company recognizes lease expense related to fixed payments on a straight-line basis from the lease commencement date through the end of the lease term and lease expense related to variable payments as incurred based on performance or usage in accordance with the contractual agreements. For finance leases, the Company recognizes the amortization of the ROU asset over the shorter of the lease term or useful life of the underlying asset. The Company expenses ROU assets acquired for research and development activities under ASC 730 if they do not have an alternative future use, in research and development projects or otherwise.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses significant assumptions and judgment in evaluating its lease contracts and other agreements under ASC 842, including the determination of whether an agreement is or contains a lease; whether a change in the terms and conditions of a lease contract represent a new or modified lease; whether a lease represents an operating or finance lease; the discount rate used to determine the present value of lease obligations; the term of a lease embedded in its manufacturing supply agreements; and the Company&#8217;s incremental borrowing rate, which is determined using estimates such as the estimated value of the underlying leased asset and financial profile of comparable companies.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, including property and equipment, internal-use software, and ROU assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable based on the criteria for accounting for the impairment or disposal of long-lived assets under ASC Topic 360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If such events or changes in circumstances occur, the Company assesses the recoverability of the long-lived assets (or asset group) by comparing their projected future undiscounted net cash flows over their remaining lives against their respective carrying amounts. If the cash flows are not expected to be sufficient to recover the carrying amount of the assets (or asset group), they are written down to their estimated fair values.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes restructuring charges when such costs are incurred. The Company&#8217;s restructuring charges consist of employee severance and other termination benefits related to the reduction of its workforce, the consolidation of facilities and infrastructure and other costs. Termination benefits are expensed on the date the Company notifies the employee, unless the employee must provide future service, in which case the benefits are expensed ratably over the future service period. Ongoing benefits are expensed when restructuring activities are probable and the benefit estimable. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 17 for additional information on the severance and employee benefit costs for terminated employees and impairment of long-lived assets in connection with the Company&#8217;s Restructuring Plan and Note 18 for information on the expected severance and employee benefit costs as a result of the Company&#8217;s workforce reduction announced on January 31, 2024.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Goodwill is subject to impairment tests annually or more frequently should indicators of impairment arise. The Company has determined that, because its only business is the development and commercialization of innovative vaccines, it operates as a single operating segment and has one reporting unit. The one-step impairment test, which requires a comparison of the fair value of a reporting unit to its carrying value, including goodwill, is required to be applied to all reporting units including reporting units with zero or negative carrying value. A reporting unit with a zero or negative carrying value likely will not have an impairment. If the carrying value of the reporting unit exceeds its fair value, step two of the impairment analysis is performed. In step two of the analysis, an impairment loss is recorded equal to the excess of the carrying value of the reporting unit&#8217;s goodwill over its implied fair value, should such a circumstance arise. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and 2022, the Company had a negative carrying value and did not have any impairment of goodwill.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes in accordance with ASC Topic 740,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the liability method, deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect of changes in tax rates on deferred tax assets and </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liabilities is recognized in income in the period such changes are enacted. A valuation allowance is established when necessary to reduce net deferred tax assets to the amount expected to be realized.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Global Intangible Low-Taxed Income (&#8220;GILTI&#8221;) provisions under the Tax Cuts and Jobs Act of 2017 impose U.S. tax on certain foreign income in excess of a deemed return on tangible assets of foreign corporations. The Company has elected to treat any potential GILTI inclusions as period costs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax benefits associated with uncertain tax positions are recognized in the period in which one of the following conditions is satisfied: (1) the more-likely-than-not recognition threshold is satisfied; (2) the position is ultimately settled through negotiation or litigation; or (3) the statute of limitations for the taxing authority to examine and challenge the position has expired. Tax benefits associated with an uncertain tax position are reversed in the period in which the more-likely-than-not recognition threshold is no longer satisfied.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically generated significant federal, state, and foreign tax net operating losses, which may be subject to limitation in future periods. Management has fully reserved the related deferred tax assets with a valuation allowance in the current reporting period as it is more likely than not that the related benefit will not be realized. The Company is currently subject to examination in all open tax years.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted net loss per share is computed using the treasury stock method by dividing net loss by the weighted-average number of common shares outstanding after giving consideration to the dilutive effect of certain securities outstanding during the period. As of December&#160;31, 2023, the Company's 2027 Notes (see Note 10) would have been convertible into approximately 14&#160;million shares of the Company's common stock assuming the common stock price is equal to or greater than $12.50. These shares, after giving effect to the add back of interest expense and unamortized discounts and debt issuance costs on the Notes and any shares due to the Company upon settlement of its capped call transactions, are excluded from the computation, as their effect is antidilutive under the if-converted method. In addition, all stock options, SARs, and unvested RSUs are excluded from the computation as their effect is antidilutive. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements are presented in U.S. dollars. The functional currency of the Company&#8217;s international subsidiaries is generally the local currency. The financial statements of international subsidiaries are translated to U.S. dollars using the exchange rate in effect at the consolidated balance sheet date for assets and liabilities, historical rates for equity accounts, and average exchange rates for the consolidated statement of operations. Cash flows from operations are translated at the average exchange rate in effect for the period, while cash flows from investing and financing activities are translated at the exchange rate in effect at the date of the underlying transaction. Translation gains and losses are recognized as a component of accumulated other comprehensive income (loss) in the accompanying consolidated balance sheets. The foreign currency translation adjustment balance included in accumulated other comprehensive income (loss) was $2.7 million of income and $6.4 million losses at December&#160;31, 2023 and 2022, respectively. The aggregate foreign currency transaction gains and losses resulting from the conversion of the transaction currency to functional currency were $7.9&#160;million of gains, $2.5&#160;million of losses, and $5.3&#160;million of losses for the years ended December&#160;31, 2023, 2022, and 2021, respectively, which are reflected in Other income (expense).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages its business as one operating segment, the development and commercialization of innovative vaccines. The Company does not operate separate lines of business with respect to its vaccine or vaccine candidates. Accordingly, the Company does not have separately reportable segments as defined by ASC Topic 280, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Not Yet Adopted</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-06, Disclosure Improvements (&#8220;ASU 2023-06&#8221;), to clarify or improve disclosure and presentation requirements of a variety of topics and align the requirements in the FASB ASC with the SEC's regulations. The Company is currently evaluating ASU 2023-06 to determine its impact on the Company's consolidated financial statements and disclosures.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (&#8220;ASU 2023-09&#8221;). The standard enhances transparency in income tax disclosures by requiring, on an annual basis, certain disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation and income taxes paid. The ASU also requires disaggregated disclosure related to pre-tax income (or loss) and income tax expense (or benefit) and eliminates certain disclosures related to the balance of an entity&#8217;s unrecognized tax benefit and the cumulative amount of certain temporary differences. The ASU is effective for the Company beginning on January 1, 2025. The Company is currently evaluating ASU 2023-09 to determine its impact on the Company's disclosures.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline">Adopted</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;), with amendments in 2018, 2019, 2020, and 2022. The ASU sets forth a &#8220;current expected credit loss&#8221; model that requires companies to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. ASU 2016-13 applies to financial instruments that are not measured at fair value, including receivables that result from revenue transactions. The Company adopted ASU 2020-06 on January 1, 2023, using a modified retrospective approach, and it did not have a material impact on the Company&#8217;s consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253751544320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_GrantsUSGovernmentContractAndJointVentureAbstract', window );"><strong>Grants, U.S. Government Contract and Joint Venture [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's accounts receivable, net, included $286.4 million and $53.8 million related to amounts that were billed to customers and $10.8 million and $28.6 million related to amounts which had not yet been billed to customers as of December&#160;31, 2023 and 2022, respectively. During the years ended December&#160;31, 2023 and 2022, changes in the Company's accounts receivables, deferred revenue, and allowance for doubtful accounts balances were as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance, Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deductions </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance, End of Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2023</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,472,768&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,264,062)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,768,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,127,240)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allowance for doubtful accounts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,835)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,676)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,835)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,835)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(267,599)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,092,829)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Bad debt expense was $13.8&#160;million in the year ended 2022. There was no bad debt expense in the year ended December 31, 2023 or 2021. There was a $6.2&#160;million reversal of a bad debt expense during the year ended December&#160;31, 2023 due to the collection of a previously recognized allowance for doubtful accounts. To estimate the allowance for doubtful accounts, the Company evaluates the credit risk related to its customers based on historical loss experience, economic conditions, the aging of receivables, and customer-specific risks.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Deductions from Deferred revenue generally related to the recognition of revenue once performance obligations on a contract with a customer are met. Amount is comprised of $241.3&#160;million, $0.4&#160;billion, and $1.4&#160;billion current Deferred </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue and $622.2&#160;million, $179.4&#160;million, and $172.5&#160;million non-current Deferred revenue as of December&#160;31, 2023, 2022, and 2021 respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;In 2023, deductions from Deferred revenue included $151.1&#160;million that was realized in Revenue and $112.5&#160;million related to the Amended and Restated UK Supply Agreement (as described below), that was reclassified to Other current liabilities, as described below. In 2022, deduction from Deferred revenue included $273.8&#160;million that was realized in Revenue and $819.0&#160;million, including $697.4&#160;million related to the Advance Payment Amount (as described below) related to the Gavi arbitration and $112.5&#160;million related to the Amended and Restated UK Supply Agreement, that was reclassified to Other current liabilities, as described below.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the aggregate amount of the transaction price allocated to performance obligations that were unsatisfied (or partially unsatisfied), excluding amounts related to sales-based royalties, the Gavi APA, and the reduction in doses related to the Amended and Restated SARS-CoV-2 Vaccine Supply Agreement, dated as of July 1, 2022 (as amended on September 26, 2022, the &#8220;Amended and Restated UK Supply Agreement&#8221;) between the Company and The Secretary of State for Business, Energy and Industrial Strategy (as assigned to the UK Health Security Agency), acting on behalf of the government of the United Kingdom of Great Britain and Northern Ireland (the &#8220;Authority&#8221;), which amended and restated the Original UK Supply Agreement, was approximately $2&#160;billion of which $863.5&#160;million was included in Deferred revenue. Failure to meet regulatory milestones, obtain timely supportive recommendations from governmental advisory committees, or achieve product volume or delivery timing obligations under the Company&#8217;s APAs may require the Company to refund portions of upfront payments or result in reduced future payments, which could adversely impact the Company&#8217;s ability to realize revenue from its unsatisfied performance obligations. The timing to fulfill performance obligations related to APAs will depend on timing of product manufacturing, receipt of marketing authorizations for additional indications, delivery of doses based on customer demand, and the ability of the customer to request variant vaccine in place of the prototype vaccine under certain of the Company&#8217;s APAs. The remaining unfilled performance obligations not related to APAs are expected to be fulfilled in less than one year.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Gavi APA and a separate purchase agreement between Gavi and SIIPL, 1.1&#160;billion doses of the prototype vaccine were to be made available to countries participating in the COVAX Facility. The Company expected to manufacture and distribute 350&#160;million doses of the prototype vaccine to countries participating under the COVAX Facility. Under a separate purchase agreement with Gavi, SIIPL was expected to manufacture and deliver the balance of the 1.1&#160;billion doses of prototype vaccine for low- and middle-income countries participating in the COVAX Facility. The Company expected to deliver doses with antigen and adjuvant manufactured at facilities directly funded under the Company's funding agreement with CEPI, with initial doses supplied by SIIPL and SLS under a supply agreement. The Company expected to supply significant doses that Gavi would allocate to low-, middle- and high-income countries, subject to certain limitations, utilizing a tiered pricing schedule and Gavi could prioritize such doses to low- and middle- income countries, at lower prices. Additionally, the Company could provide additional doses of prototype vaccine, to the extent available from CEPI-funded manufacturing facilities, in the event that SIIPL could not materially deliver expected vaccine doses to the COVAX Facility. Under the agreement, the Company received an upfront payment of $350.0&#160;million from Gavi in 2021 and an additional payment of $350.0&#160;million in 2022 related to the Company&#8217;s achieving an emergency use license for the Company&#8217;s prototype vaccine by the World Health Organization (&#8220;WHO&#8221;) (the &#8220;Advance Payment Amount&#8221;). </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 18, 2022, the Company delivered written notice to Gavi to terminate the Gavi APA on the basis of Gavi&#8217;s failure to procure the purchase of 350&#160;million doses of the Company&#8217;s prototype vaccine from the Company as required by the Gavi APA. As of November 18, 2022, the Company had only received orders under the Gavi APA for approximately 2&#160;million doses. On December 2, 2022, Gavi issued a written notice purporting to terminate the Gavi APA based on Gavi&#8217;s contention that the Company repudiated the agreement and, therefore, materially breached the Gavi APA. Gavi also contended that, based on its purported termination of the Gavi APA, it was entitled to a refund of the Advance Payment Amount less any amounts that have been credited against the purchase price for binding orders placed by a buyer participating in the COVAX Facility. As of December&#160;31, 2023 and 2022, the remaining Gavi Advance Payment was $696.4&#160;million and $697.4&#160;million, respectively, pending resolution of the dispute with Gavi related to the return of the remaining Advance Payment Amount, and was classified within Other current liabilities in the Company&#8217;s consolidated balance sheet. On January 24, 2023, Gavi filed a demand for arbitration with the International Court of Arbitration based on the claims described above. The Company filed its Answer and Counterclaims on March 2, 2023. On April 5, 2023, Gavi filed its Reply to the Company&#8217;s Counterclaims. On February 16, 2024, the Company and Gavi entered into a Termination and Settlement Agreement (the &#8220;Gavi Settlement Agreement&#8221;) terminating the Gavi APA, settling the arbitration proceedings and releasing both parties of all claims arising from, under or otherwise in connection with the Gavi APA. Pursuant to the Gavi Settlement Agreement, the Company is responsible for payment to Gavi of (i) an initial settlement payment of $75&#160;million, which the Company paid on February 20, </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024, and (ii) deferred payments, in equal annual amounts of $80&#160;million payable each calendar year through a deferred payment term ending December 31, 2028. The deferred payments are due in variable quarterly installments beginning in the first quarter of 2024 and total $400&#160;million during the deferred payment term. Such deferred payments may be reduced through Gavi&#8217;s use of an annual vaccine credit equivalent to the unpaid balance of such deferred payments each year, which may be applied to qualifying sales of any of the Company&#8217;s vaccines for supply to certain low-income and lower-middle income countries. The Company has the right to price the vaccines offered to such low-income and lower-middle income countries in its discretion, and, when utilized by Gavi, the Company will credit the actual price per vaccine paid against the applicable credit. The Company intends to price vaccines offered via the tender process, consistent with its shared goal with Gavi to provide equitable access to those countries. Also, pursuant to the Gavi Settlement Agreement, the Company granted Gavi an additional credit of up to $225&#160;million that may be applied against qualifying sales of any of the Company&#8217;s vaccines for supply to such low-income and lower-middle income countries that exceed the $80&#160;million deferred payment amount in any calendar year during the deferred payment term. In addition, the Company and Gavi entered into a security agreement pursuant to which Novavax granted Gavi a security interest in accounts receivable from SIIPL under the SIIPL R21 Agreement (see Note 4), which will continue for the deferred payment term of the Gavi Settlement Agreement. On February 22, 2024, the claims and counterclaims were dismissed with prejudice.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue by the Company&#8217;s customer&#8217;s geographic location was as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.615%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt 0 7pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">North America</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rest of the world</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531,389&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554,961&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2023, the Company commenced sales of COVID-19 Vaccine to the U.S. commercial market, in addition to continuing sales to various international governments. Product sales in the U.S. are primarily made through large pharmaceutical wholesale distributors at the WAC. Product sales in the U.S. are recorded net of gross-to-net deductions, as described in Note 2.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, changes in the Company&#8217;s gross-to-net deductions balances were as follows (in thousands):</span></div><div style="padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.497%"><tr><td style="width:1.0%"></td><td style="width:51.727%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.247%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.827%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Wholesale Distributor Fees, Discounts, and Chargebacks</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Returns</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts charged against product sales</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131,716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,956)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26,028)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,072&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,616&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,688&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, $103.1&#160;million of gross-to-net deductions were included in Accrued expenses and $2.6&#160;million were included in Accounts receivable on the consolidated balance sheet. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has an APA with the Commonwealth of Australia for the purchase of doses of COVID-19 Vaccine (the &#8220;Australia APA&#8221;). In May 2023, the Company extended a credit for certain doses delivered and recognized within product revenue in 2022 that qualified for replacement under the Australia APA. This credit is the result of a single lot sold to the Australian government that upon pre-planned 6-month stability testing was found to have fallen below the defined specifications and the lot therefore was removed from the market. The credit will be applied against the future sale of doses to Australia and, during the year ended December&#160;31, 2023, the Company recorded a reduction of $64.7&#160;million in product sales, with a corresponding increase to Deferred revenue, non-current. In July 2023, the Company amended the Australia APA to provide for replacement doses and to extend the delivery schedule through 2025. As of February 2024, the Company had not yet received Therapeutic Goods Administration (&#8220;TGA&#8221;) authorization or delivered doses as contemplated in the July 2023 </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">amendment and is in active discussions with the Australian government on both the TGA authorization and delivery of the doses previously scheduled for the fourth quarter of 2023. In February 2024, the Company received notice from the Australian government purporting to cancel its order for such prototype vaccine doses. The Company believes the cancellation was not proper under the amended Australia APA. However, if such a cancellation were determined to be allowable, $6.0 million of the deferred revenue would become a credit towards future deliveries of doses and approximately $48 million of the contract value related to future deliverables would no longer be available.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an APA with the European Commission (&#8220;EC&#8221;) acting on behalf of various European Union member states to supply a minimum of 20&#160;million and up to 100&#160;million initial doses of prototype vaccine, with the option for the EC to purchase an additional 100&#160;million doses up to a maximum aggregate of 200&#160;million doses in one or more tranches, through 2023. Under the terms of the APA, the Company agreed to manufacture the vaccine in facilities located in the European Union and ensure continued efficacy of the vaccine against variants of the SARS-CoV-2 virus. Pursuant to the terms of the APA, the Company is prohibited from supplying prototype vaccine to any third party if such delivery would impede or limit the fulfillment of the Company&#8217;s obligations to the EC under the APA, except with respect to the Company&#8217;s obligations under the Gavi APA. In 2022, the Company was notified by the EC that it was cancelling approximately 7&#160;million doses of its prior commitment originally scheduled for delivery in the first and second quarters of 2022, in accordance with the APA, and reducing the order to approximately 63&#160;million doses. In January 2023, the Company finalized a revised delivery schedule for the remaining 20&#160;million committed doses under the APA that were originally scheduled for delivery during the first and second quarters of 2022. The APA expired in August 2023 and required that any open and outstanding orders from European Union member states be satisfied by February 2024. Since August 2023, any additional doses have been managed by amending outstanding orders with deliveries made by February 2024.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an APA with His Majesty the King in Right of Canada as represented by the Minister of Public Works and Government Services, as successor in interest to Her Majesty the Queen in Right of Canada, as represented by the Minister of Public Works and Government Services (the &#8220;Canadian government&#8221;), for the purchase of doses of COVID-19 Vaccine (the &#8220;Canada APA&#8221;). In April 2023, the Company amended the &#8220;Canada APA&#8221;, pursuant to which the Canadian government forfeited certain doses originally scheduled for delivery in 2022 for a payment of $100.4&#160;million, which the Company received in the second quarter of 2023. In June 2023, the Company entered into an additional amendment (the &#8220;June 2023 Amendment&#8221;) to the Canada APA. Pursuant to the June 2023 Amendment, (i) the Canadian government forfeited certain doses of COVID-19 Vaccine previously scheduled for delivery and agreed to pay a total amount of $349.6&#160;million to the Company in two equal installments, which total amount equaled the remaining balance owed by the Canadian government with respect to such forfeited vaccine doses, (ii) the amount of doses of COVID-19 Vaccine due for delivery was reduced, (iii) the delivery schedule for the remaining doses of COVID-19 Vaccine to be delivered was revised, and (iv) the parties agreed Novavax would use the Biologics Manufacturing Centre (&#8220;BMC&#8221;) Inc. to produce bulk antigen for doses in 2024 and 2025. The June 2023 Amendment maintained the total contract value of the original Canada APA. The first Installment of $174.8&#160;million was payable upon execution of the June 2023 Amendment and received by Novavax in July 2023, and the second installment of $174.8&#160;million was contingent and payable upon the delivery of vaccine doses in the second half of 2023 and received by Novavax in January 2024. The Canadian government may terminate the Canada APA, as amended, if the Company fails to receive regulatory approval for its COVID-19 Vaccine using bulk antigen produced at BMC on or before December 31, 2024. The Company&#8217;s 2024 plans do not currently anticipate the submission for regulatory approval of its COVID-19 Vaccine using bulk antigen produced at BMC, and it plans to work with the Canadian government on an amendment that addresses possible alternatives, which may not be achievable. As of December 31, 2023, $102.8&#160;million <span id="i6df5a9d3262e4de6b703aaf6230c4c93_96276"></span>was classified as short-term Deferred revenue and $485.3&#160;million was classified as long-term Deferred revenue with respect to the Canadian APA in the Company&#8217;s consolidated balance sheet. If the Canadian government terminates the Canada APA, $28.0&#160;million of the deferred revenue would become refundable and approximately $224&#160;million of the contract value related to future deliverables would no longer be available. Pursuant to the June 2023 Amendment, Novavax and the Canadian government will endeavor to expand the previously agreed in-country commitment to Canada and to further partner to provide health, economic, and future pandemic preparedness benefits to Canada, which value may be provided through a number of activities, including without limitation, capital investments, the performance of activities or services, or the provision of technology or intellectual property licenses. Further, the parties will endeavor to enter into a memorandum of understanding (the &#8220;MOU&#8221;) to illustrate the Company&#8217;s ability to deliver such benefits over a 15-year period with an aggregate value of not less than 100% of the amount remaining to be paid under the June 2023 Amendment and ultimately received by the Company. As of December&#160;31, 2023, discussions regarding the MOU were ongoing. The Company agreed to hold, when received, $20.0&#160;million of the second installment payment in escrow for the benefit of the Canadian government, which amount is the sole recourse available to the Canadian government in the event of non-performance under the MOU. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, the Company entered into an Amended and Restated SARS-CoV-2 Vaccine Supply Agreement (as amended on September 26, 2022, the &#8220;Amended and Restated UK Supply Agreement&#8221;) with The Secretary of State for </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business, Energy and Industrial Strategy (as assigned to the UK Health Security Agency), acting on behalf of the government of the United Kingdom of Great Britain and Northern Ireland (the &#8220;Authority&#8221;), which amended and restated in its entirety the SARS-CoV-2 Vaccine Supply Agreement, dated October 22, 2020, between the parties (the &#8220;Original UK Supply Agreement&#8221;). Under the Original UK Supply Agreement, the Authority agreed to purchase 60&#160;million doses of prototype vaccine and made an upfront payment to the Company. Under the terms of the Amended and Restated UK Supply Agreement, the Authority agreed to purchase a minimum of 1&#160;million doses and up to an additional 15&#160;million doses (the &#8220;Conditional Doses&#8221;) of prototype vaccine, with the number of Conditional Doses contingent on, and subject to reduction based on, the Company&#8217;s timely achievement of supportive recommendations from the Joint Committee on Vaccination and Immunisation (the &#8220;JCVI&#8221;) that is approved by the UK Secretary of State for Health, with respect to use of the vaccine for (a) the general adult population as part of a SARS-CoV-2 vaccine booster campaign in the United Kingdom or (b) the general adolescent population as part of a SARS-CoV-2 vaccine booster campaign in the United Kingdom or as a primary series SARS-CoV-2 vaccination, excluding where that recommendation relates only to one or more population groups comprising less than one million members in the United Kingdom. If the Authority did not purchase the Conditional Doses or the number of such Conditional Doses was reduced below 15&#160;million doses of prototype vaccine, the Company would have to repay up to $225.0&#160;million related to the upfront payment previously received from the Authority under the Original UK Supply Agreement. Under the Amended and Restated UK Supply Agreement, the Authority also has the option to purchase up to an additional 44&#160;million doses, in one or more tranches, through 2024.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November 30, 2022, the JCVI had not made a supportive recommendation with respect to prototype vaccine, thereby triggering, under the terms of the Amended and Restated UK Supply Agreement, (i) a reduction of the number of Conditional Doses from 15&#160;million doses to 7.5&#160;million doses, which reduced number of Conditional Doses are contingent on, and subject to further reduction based on, the Company&#8217;s timely achievement by November 30, 2023 of a supportive recommendation from JCVI that is approved by the UK Secretary of State for Health as described in the paragraph above, and (ii) an obligation for the Company to repay $112.5&#160;million related to the upfront payment previously received from the Authority under the Original UK Supply Agreement. In April 2023, the Company repaid the $112.5&#160;million related to the November 30, 2022 triggering event. As of November 30, 2023, the JCVI had not made a supportive recommendation with respect to the prototype vaccine, thereby triggering a reduction in the number of Conditional Doses from 7.5&#160;million doses to zero. As of February 2024, the Company is in discussions with the Authority regarding the treatment of the remaining upfront payment previously received of $112.5&#160;million, which is reflected in Other current liabilities. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grants</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized grant revenue as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt 0 7pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">USG Agreement</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788,953&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.S. DoD</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CEPI</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other grant revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,323&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,921&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">948,709&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Government</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. government agreement consists of a Project Agreement (the &#8220;Project Agreement&#8221;) and a Base Agreement with Advanced Technology International, the Consortium Management Firm acting on behalf of the Medical CBRN Defense Consortium in connection with the partnership formerly known as Operation Warp Speed (the Base Agreement together with the Project Agreement the &#8220;USG Agreement&#8221;). </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The original USG Agreement required the Company to conduct certain clinical, regulatory, and other activities, including a pivotal Phase 3 clinical trial to determine the safety and efficacy of prototype vaccine, and to manufacture and deliver to the U.S. government 100&#160;million doses of the vaccine candidate. Funding under the USG Agreement is payable to the Company for various development, clinical trial, manufacturing, regulatory, and other activities. The USG Agreement contains terms and conditions that are customary for U.S. government agreements of this nature, including provisions giving the U.S. government the right to terminate the Base Agreement or the Project Agreement based on a reasonable determination that the funded project will not produce beneficial results commensurate with the expenditure of resources and that termination would </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be in the U.S. government&#8217;s interest. If the Project Agreement is terminated prior to completion, the Company is entitled to be paid for work performed and costs or obligations incurred prior to termination and consistent with the terms of the USG Agreement. As of December 31, 2023, the Company has recognized the full $1.8&#160;billion funding under the USG Agreement in revenue. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coalition for Epidemic Preparedness Innovations</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:28.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company entered into a restated funding agreement which was amended in November 2020 with CEPI, under which CEPI agreed to provide funding of up to $399.5&#160;million to the Company to support the development of prototype vaccine. The agreement provided up to $257.0&#160;million in CEPI Grant Funding and up to $142.5&#160;million in CEPI Forgivable Loan Funding, which are loans in the form of one or more forgivable no-interest term loans to fund certain manufacturing activities and are not subject to restrictive or financial covenants. As of December&#160;31, 2023 and 2022, the Company had recognized total revenue related to CEPI of $358.6&#160;million, with the unused amounts primarily related to CEPI Forgivable Loan Funding. Payments received under the CEPI Forgivable Loan Funding are only repayable if project vaccine, as defined under the CEPI funding agreement, manufactured by the CMO network funded by CEPI is sold to one or more third parties (which could include sales credited under the Gavi Settlement Agreement), and such sales cover the Company&#8217;s costs of manufacturing such vaccine, not including manufacturing costs funded by CEPI.&#160;The timing and amount of any loan repayments is currently uncertain.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties and Other</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties and other includes royalty milestone payments, sales-based royalties, and Matrix-M&#8482; adjuvant sales. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, the Company recognized $8.5&#160;million in revenue related to license fees, and $16.5&#160;million in revenue related to a Matrix-M&#8482; adjuvant sales. During the year ended December&#160;31, 2023, the Company did not recognize revenue related to milestone payments.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, the Company recognized $9.0&#160;million in revenue related to sales-based royalties, $20.0&#160;million related to milestone payments, and $15.0&#160;million in revenue related to a Matrix-M&#8482; adjuvant sales.</span></div>During the year ended December&#160;31, 2021, the Company recognized $178.6&#160;million in revenue related to sales-based royalties and $20.0&#160;million related to milestone payments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_GrantsUSGovernmentContractAndJointVentureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_GrantsUSGovernmentContractAndJointVentureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253659969408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Supply Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CollaborativeArrangementAbstract', window );"><strong>Collaborative Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration, License, and Supply Agreements</a></td>
<td class="text">Collaboration, License, and Supply Agreements <div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SIIPL</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously granted SIIPL exclusive and non-exclusive licenses for the development, co-formulation, filling and finishing, registration, and commercialization of its prototype vaccine, its proprietary COVID-19 variant antigen candidate(s), and its CIC vaccine candidate. SIIPL agreed to purchase the Company's Matrix-M&#8482; adjuvant and the Company granted SIIPL a non-exclusive license to manufacture the antigen drug substance component of the Company&#8217;s COVID-19 Vaccine in SIIPL&#8217;s licensed territory solely for use in the manufacture of COVID-19 Vaccine. The Company and SIIPL equally split the revenue from SIIPL&#8217;s sale of COVID-19 Vaccine in its licensed territory, net of agreed costs. The Company also has a supply agreement with SIIPL and SLS under which SIIPL and SLS supply the Company with prototype vaccine, its proprietary COVID-19 variant antigen candidate(s), and its CIC vaccine candidate for commercialization and sale in certain territories, as well as a contract development manufacture agreement with SLS, under which SLS manufactures and supplies finished vaccine product to the Company using antigen drug substance and Matrix-M&#8482; adjuvant supplied by the Company. In March 2020, the Company entered into an agreement with SIIPL that granted SIIPL a non-exclusive license for the use of Matrix-M&#8482; adjuvant supplied by the Company to develop, manufacture, and commercialize R21/Matrix-M&#8482; adjuvant (&#8220;SIIPL R21 Agreement&#8221;), a malaria vaccine created by the Jenner Institute, University of Oxford (&#8220;R21/Matrix-M&#8482;&#8221;). In December 2023 received prequalification by the WHO. Under the SIIPL R21 Agreement, SIIPL purchases the Company's Matrix-M&#8482; adjuvant for use in development activities at cost and for commercial purposes at a tiered commercial supply price, and pays a royalty in the single-to low- double-digit range based on vaccine sales for a period of 15 years after the first commercial sale of the vaccine in each country. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a collaboration and license agreement with Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;) under which the Company granted Takeda an exclusive license to develop, manufacture, and commercialize the Company&#8217;s COVID-19 Vaccine in Japan. Under the agreement, Takeda purchases Matrix-M&#8482; adjuvant from the Company to manufacture doses of COVID-19 Vaccine, and the Company is entitled to receive milestone and sales-based royalty payments from Takeda based on the achievement of certain development and commercial milestones, as well as a portion of net profits from the sale of COVID-19 Vaccine. In September 2021, Takeda finalized an agreement with the Government of Japan&#8217;s Ministry of Health, Labour and Welfare ("MHLW") for the purchase of 150&#160;million doses of its prototype vaccine. In February 2023, MHLW canceled the remainder of doses under its agreement with Takeda. As a result, it is uncertain whether the Company will receive future sales-based royalty payments from Takeda under the terms and conditions of their current collaboration and licensing agreement. For the year ended December&#160;31, 2023, the Company recognized $6.0&#160;million of revenue as consideration for changes to certain terms of the license agreement which is included in Royalties and other revenue on the consolidated statements of operations. For the year ended December 31, 2022, the Company recognized $20.0&#160;million, upon the sale of prototype vaccine in Japan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which is included in Royalties and other revenue on the consolidated statements of operations. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bill &amp; Melinda Gates Medical Research Institute</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, the Company entered into a 3-year agreement with the Bill &amp; Melinda Gates Medical Research Institute to provide the Company&#8217;s Matrix-M&#8482; adjuvant for use in preclinical vaccine research. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SK bioscience, Co., Ltd.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company entered into a Collaboration and License Agreement (&#8220;CLA&#8221;) with SK bioscience, Co., Ltd. (&#8220;SK&#8221;) to manufacture and commercialize its prototype vaccine for sale to the government of South Korea. The CLA was amended in December 2021 and July 2022 to include the sale of its prototype vaccine to Thailand and Vietnam and to supply the Company with the antigen component of prototype vaccine for use in the final drug product globally, including product to be distributed by the COVAX Facility. Under the CLA, as amended, SK agreed to pay the Company a royalty on the sale of its prototype vaccine in the low to middle double-digit range. The CLA was in addition to the Company's existing manufacturing arrangement with SK under a Development and Supply Agreement (&#8220;DSA&#8221;) entered into in August 2020. In July 2022, the Company signed an additional agreement with SK for the technology transfer of the Company&#8217;s proprietary COVID-19 variant antigen materials so that SK can manufacture the drug substance targeting COVID-19 variants, including the Omicron subvariants. The companies also signed an agreement to manufacture and supply its prototype vaccine in a prefilled syringe.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, the Company entered into a material transfer agreement with SK for the use by SK of the Company&#8217;s Matrix-M&#8482; adjuvant in preclinical vaccine experiments for shingles, influenza, and pan-sarbecovirus vaccine.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company and SK entered into a Settlement Agreement and General Release (the &#8220;Settlement Agreement&#8221;) regarding mutual release by the parties of all claims arising from or in relation to statements of work (&#8220;SOWs&#8221;) canceled by the Company under the DSA and the CLA (collectively the &#8220;Business Agreements&#8221;), and other SOWs under the Business Agreements (collectively, the &#8220;Subject SOWs&#8221;), in each case, in connection with the cessation of all drug substance and drug product manufacturing activity at SK for supply to the Company. Subject SOWs canceled by the Company under the Settlement Agreement included (i) Statement of Work No. 1 dated as of December 23, 2021 as amended to date under the CLA; (ii) Statement of Work No. 5 dated as of July 18, 2022 under the DSA; and (iii) Statement of Work No. 6 dated as of July 18, 2022, and as amended as of December 28, 2022 under the DSA. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Settlement Agreement, the Company is responsible for payment of $149.8&#160;million to SK in connection with the cancellation of manufacturing activity for the SOWs under the Business Agreements, of which (i) $130.4&#160;million was paid in August 2023 and (ii) the remaining balance was paid in November 2023. Under the Settlement Agreement, the Company and SK agreed to a wind down plan with respect to the remaining products, materials and equipment under the SOWs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Settlement Agreement, the Company and SK agreed to remove certain restrictions under the CLA that have been triggered by the launch of SK&#8217;s competing vaccine SKYCovione&#8482; in the Republic of Korea. In addition, the Company agreed to extend the term of an exclusive license to SK under the CLA for the exploitation of antigen and vaccine products </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">utilizing Company&#8217;s proprietary coronavirus vaccine antigens and Matrix-M adjuvant in certain territories. The Company recorded $4.0&#160;million to Deferred revenue related to the extended licenses granted to SK under the Settlement Agreement. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company also entered into a Securities Subscription Agreement (the &#8220;Subscription Agreement&#8221;) with SK, pursuant to which the Company agreed to sell and issue to SK, in a private placement (the &#8220;Private Placement&#8221;), 6.5&#160;million shares of the Company&#8217;s common stock, par value $0.01 per share (the &#8220;Shares&#8221;) at a price of $13.00 per share for aggregate gross proceeds to the Company of approximately $84.5&#160;million. The closing of the Private Placement occurred on August 10, 2023. The fair value of the Company&#8217;s common stock on the date of closing, based on the quoted market price, was $46.5&#160;million, which results in a premium paid by SK of approximately $38&#160;million.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Settlement Agreement and the Subscription Agreement were negotiated concurrently between the parties, and therefore were combined for accounting purposes and analyzed as a single arrangement. As a result, the Company recorded the $46.5&#160;million fair value of common stock issued to SK, based on the quoted market price on the date of close, as an equity transaction. The remaining elements of the arrangement were deemed to relate to the settlement of the Company&#8217;s outstanding liabilities due to SK. These elements consist primarily of the cash payable to SK of $149.8&#160;million, offset by the premium paid on the common stock purchase by SK of $38.0&#160;million, which resulted in a net gain upon derecognition of the liabilities due to SK of $79.2&#160;million in connection with the settlement. As a result, during the year ended December&#160;31, 2023, the Company recorded this net gain of $79.2&#160;million between research and development expense, for $57.7&#160;million, and cost of sales, for $21.5&#160;million, proportionally based on the where the underlying costs were originally recorded.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Supply Agreements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, the Company, FUJIFILM Diosynth Biotechnologies UK Limited (&#8220;FDBK&#8221;), FUJIFILM Diosynth Biotechnologies Texas, LLC (&#8220;FDBT&#8221;), and FUJIFILM Diosynth Biotechnologies USA, Inc. (&#8220;FDBU&#8221; and together with FDBK and FDBT, &#8220;Fujifilm&#8221;) entered into a Confidential Settlement Agreement and Release (the &#8220;Fujifilm Settlement Agreement&#8221;) regarding amounts due to Fujifilm in connection with the termination of manufacturing activity at FDBT under the Commercial Supply Agreement (the &#8220;Fujifilm CSA&#8221;) dated August 20, 2021 and Master Services Agreement dated June 30, 2020 and associated statements of work (the &#8220;Fujifilm MSA&#8221;) by and between the Company and Fujifilm. The Fujifilm MSA and Fujifilm CSA established the general terms and conditions applicable to Fujifilm&#8217;s manufacturing and supply activities related to prototype vaccine under the associated statements of work.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Fujifilm Settlement Agreement, the Company agreed to pay up to $185.0&#160;million (the &#8220;Settlement Payment&#8221;) to Fujifilm in connection with cancellation of manufacturing activity at FDBT under the CSA, of which (i) $47.8&#160;million, constituting the initial reservation fee under the CSA, was credited against the Settlement Payment on September&#160;30, 2022 and (ii) the remaining balance was to be paid in four equal quarterly installments of $34.3&#160;million each, which began on March 31, 2023. Under the Fujifilm Settlement Agreement, the final two quarterly installments due to Fujifilm were subject to Fujifilm&#8217;s obligation to use commercially reasonable efforts to mitigate losses associated with the vacant manufacturing capacity caused by the termination of manufacturing activities at FDBT under the CSA. Any replacement revenue achieved by Fujifilm&#8217;s mitigation efforts between July 1, 2023 and December 31, 2023 would offset the final two settlement payments owed by the Company. On October 2, 2023, the Company sent a notice of breach under the Fujifilm Settlement Agreement to Fujifilm setting forth the Company&#8217;s position that Fujifilm had not used commercially reasonable efforts to mitigate losses. The Company withheld two installments of $34.3&#160;million due to Fujifilm on September&#160;30, 2023 and December&#160;31, 2023, pending resolution of the issues identified in the notice of breach. On October 30, 2023, FDBT filed a demand for arbitration with Judicial Arbitration and Mediation Services (&#8220;JAMS&#8221;) seeking payment of the third quarter installment of the Settlement Payment. As of December&#160;31, 2023, the remaining payment of $68.6&#160;million was reflected in Accrued expenses.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to assess its manufacturing needs and intends to modify its global manufacturing footprint consistent with its contractual obligations to supply, and anticipated demand for, its COVID-19 Vaccine, and in doing so, recognizes that significant costs may be incurred.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_CollaborativeArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_CollaborativeArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253659094592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, and Restricted Cash<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents, and Restricted Cash<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the consolidated balance sheets that sum to the total of the same such amounts shown in the statement of cash flows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336,883&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,515,116&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash non-current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583,810&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348,845&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528,259&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>(1)&#160;&#160;&#160;&#160;Classified as Other non-current assets as of December&#160;31, 2023 and 2022<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br> -Publisher SEC<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//946-320/tableOfContent<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//940-320/tableOfContent<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253659763440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the estimated fair value of the Company&#8217;s financial assets and liabilities (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-backed securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,824&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,622&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,834&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,536&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75% Convertible notes due 2023</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00% Convertible notes due 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total convertible notes payable</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,909&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494,900&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">All investments are classified as Cash and cash equivalents as of December&#160;31, 2023 and 2022, on the consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed-income investments categorized as Level 2 are valued at the custodian bank by a third-party pricing vendor&#8217;s valuation models that use verifiable observable market data, such as interest rates and yield curves observable at commonly quoted intervals and credit spreads, bids provided by brokers or dealers, or quoted prices of securities with similar characteristics.&#160;Pricing of the Company&#8217;s convertible notes has been estimated using observable inputs, including the price of the Company&#8217;s common stock, implied volatility, interest rates, and credit spreads.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2023 and 2022, the Company did not have any transfers between Levels.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount in the Company&#8217;s consolidated balance sheets for accounts payable and accrued expenses approximates its fair value due to its short-term nature.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253659650560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,912&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Semi-finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,696&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,683&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory write-downs as a result of excess, obsolescence, expiry, or other reasons, and losses on firm purchase commitments are recorded as a component of Cost of sales in the consolidated statements of operations. For the year ended December&#160;31, 2023, inventory write-downs were $72.4&#160;million and losses on firm purchase commitments were $73.5&#160;million. In addition, for the year ended December&#160;31, 2023, the Company recorded recoveries on firm purchase commitments of $40.2&#160;million related primarily to negotiated reductions to previously recognized firm purchase commitments. Also, during the year ended December&#160;31, 2023, the Company recorded an impairment charge of $6.1&#160;million in Cost of sales related to an embedded lease agreement with a CMO for production capacity in excess of production needs. For the year ended December 31, 2022, inventory write-downs and losses on firm purchase commitments were $447.6&#160;million and $155.9&#160;million respectively. There were no inventory write-downs or losses on firm purchase commitments during 2021. Inventory reserves for write-downs are relieved when the inventory is disposed of through scrap or sale. Activity in the reserve for excess and obsolete inventory was as follows (in thousands): </span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.306%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.908%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368,383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to Cost of sales, including impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other additions </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deductions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239,814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79,214)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31,</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,059&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368,383&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>Other additions include receipts of inventory previously recorded as losses on firm purchase commitments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253659775360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillDisclosureTextBlock', window );">Goodwill</a></td>
<td class="text">Goodwill<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one reporting unit, which has a negative carrying amount as of December&#160;31, 2023 and 2022, The change in the carrying amounts of goodwill was as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,479&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127,454&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126,331&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-20/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253656608304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases <div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has embedded leases related to multiple manufacturing supply agreements with CMOs and CMOS to manufacture COVID-19 Vaccine, as well as operating and finance leases for its research and development and manufacturing facilities, corporate headquarters and offices. During the year ended December&#160;31, 2023, the Company continued to align its global manufacturing footprint as a result of its ongoing assessment of manufacturing needs consistent with its contractual obligations related to the supply, and anticipated demand for, its COVID-19 Vaccine.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2023 and 2022, the Company modified certain of its CMO and CDMO agreements that had previously been determined to represent embedded leases and, in accordance with its policy, the Company remeasured and reallocated the remaining consideration under the contracts and reassessed the lease classification as of the effective dates of the respective modifications. During the year ended December&#160;31, 2023 and 2022, as a result of new or modified leases, the Company recognized ROU assets, net of credits on modifications, and a corresponding lease liability of $6.8&#160;million and $18.6&#160;million, respectively, for its long-term finance and operating leases embedded in CMO and CDMO manufacturing supply agreements. Also, during the year ended December&#160;31, 2023, the Company recorded an impairment charge of $6.1&#160;million in Cost of sales related to an embedded lease agreement with a CMO for production capacity in excess of production needs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the Company entered into a lease agreement for the premises located at 700 Quince Orchard Road, Gaithersburg, Maryland ("700QO"). The lease is for approximately 170,000 square feet of space that the Company is using for manufacturing, research and development, and offices. The term of the lease expires in 2035 with options to extend the lease. The lease provides for an annual base rent of $5.8&#160;million that is subject to future rent increases and obligates the Company to pay building operating costs. During the year ended December 31, 2022, the Company obtained the right to direct the use of, and obtain substantially all of the benefit from, certain floors located at the premises and recognized an ROU asset and related lease obligation of $73.2&#160;million as lease commencement for accounting purposes occurred in 2022. During the year ended December&#160;31, 2023, the Company obtained the right to direct the use of, and obtain substantially all of the benefit from, the remaining floors located at the premises and recognized a ROU asset and related lease obligation of $96.5&#160;million as the lease commencement dates for accounting purposes had occurred for such remaining floors. The lease obligation was reduced by $73.4&#160;million for prepaid rent and prior costs incurred on behalf of the landlord during 2023.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, facility leases, including the 700QO lease, have expirations that range from approximately <span style="-sec-ix-hidden:f-745">two</span> to thirteen years, some of which include options to extend the lease term. The facility leases contain provisions for future rent increases and obligate the Company to pay building operating costs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, the Company recorded an impairment charge of $5.9&#160;million related to ROU facility leases used for research and development, manufacturing and offices space that are impacted by the Restructuring Plan (see Note 17). </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases as of December&#160;31, 2023 and 2022 was as follows (in thousands, except weighted-average remaining lease term and discount rate):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease Assets and Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets, operating, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-749"><span style="-sec-ix-hidden:f-750">Right of use asset, net</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,985</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,384</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets, finance, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-753"><span style="-sec-ix-hidden:f-754">Right of use asset, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,233</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,857</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current ROU assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,218</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,241</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-759"><span style="-sec-ix-hidden:f-760">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,977</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,867</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,142</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,196</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,119</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,063</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-767"><span style="-sec-ix-hidden:f-768">Other non-current liabilities</span></span> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,577</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,085</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion of finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,923</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,238</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,500</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,323</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4%</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense for the operating and short-term leases for the years ended December&#160;31, 2023, 2022, and 2021 was as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,027&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease expense (benefit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,009)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease expense:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets expensed</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total finance lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,481&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,231&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119,769&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;During the year ended December&#160;31, 2023, the Company recognized a short-term lease benefit of $48.0&#160;million due to gains on the settlement of manufacturing supply agreements with CMOs and CDMOs that included embedded leases.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases for the year ended December&#160;31, 2023, 2022, and 2021 was as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows used in operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows used in finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows used in finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for operating lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, maturities of lease liabilities were as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,832&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,619&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases <div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has embedded leases related to multiple manufacturing supply agreements with CMOs and CMOS to manufacture COVID-19 Vaccine, as well as operating and finance leases for its research and development and manufacturing facilities, corporate headquarters and offices. During the year ended December&#160;31, 2023, the Company continued to align its global manufacturing footprint as a result of its ongoing assessment of manufacturing needs consistent with its contractual obligations related to the supply, and anticipated demand for, its COVID-19 Vaccine.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2023 and 2022, the Company modified certain of its CMO and CDMO agreements that had previously been determined to represent embedded leases and, in accordance with its policy, the Company remeasured and reallocated the remaining consideration under the contracts and reassessed the lease classification as of the effective dates of the respective modifications. During the year ended December&#160;31, 2023 and 2022, as a result of new or modified leases, the Company recognized ROU assets, net of credits on modifications, and a corresponding lease liability of $6.8&#160;million and $18.6&#160;million, respectively, for its long-term finance and operating leases embedded in CMO and CDMO manufacturing supply agreements. Also, during the year ended December&#160;31, 2023, the Company recorded an impairment charge of $6.1&#160;million in Cost of sales related to an embedded lease agreement with a CMO for production capacity in excess of production needs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the Company entered into a lease agreement for the premises located at 700 Quince Orchard Road, Gaithersburg, Maryland ("700QO"). The lease is for approximately 170,000 square feet of space that the Company is using for manufacturing, research and development, and offices. The term of the lease expires in 2035 with options to extend the lease. The lease provides for an annual base rent of $5.8&#160;million that is subject to future rent increases and obligates the Company to pay building operating costs. During the year ended December 31, 2022, the Company obtained the right to direct the use of, and obtain substantially all of the benefit from, certain floors located at the premises and recognized an ROU asset and related lease obligation of $73.2&#160;million as lease commencement for accounting purposes occurred in 2022. During the year ended December&#160;31, 2023, the Company obtained the right to direct the use of, and obtain substantially all of the benefit from, the remaining floors located at the premises and recognized a ROU asset and related lease obligation of $96.5&#160;million as the lease commencement dates for accounting purposes had occurred for such remaining floors. The lease obligation was reduced by $73.4&#160;million for prepaid rent and prior costs incurred on behalf of the landlord during 2023.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, facility leases, including the 700QO lease, have expirations that range from approximately <span style="-sec-ix-hidden:f-745">two</span> to thirteen years, some of which include options to extend the lease term. The facility leases contain provisions for future rent increases and obligate the Company to pay building operating costs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, the Company recorded an impairment charge of $5.9&#160;million related to ROU facility leases used for research and development, manufacturing and offices space that are impacted by the Restructuring Plan (see Note 17). </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases as of December&#160;31, 2023 and 2022 was as follows (in thousands, except weighted-average remaining lease term and discount rate):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease Assets and Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets, operating, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-749"><span style="-sec-ix-hidden:f-750">Right of use asset, net</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,985</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,384</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets, finance, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-753"><span style="-sec-ix-hidden:f-754">Right of use asset, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,233</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,857</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current ROU assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,218</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,241</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-759"><span style="-sec-ix-hidden:f-760">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,977</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,867</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,142</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,196</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,119</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,063</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-767"><span style="-sec-ix-hidden:f-768">Other non-current liabilities</span></span> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,577</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,085</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion of finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,923</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,238</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,500</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,323</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4%</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense for the operating and short-term leases for the years ended December&#160;31, 2023, 2022, and 2021 was as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,027&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease expense (benefit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,009)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease expense:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets expensed</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total finance lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,481&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,231&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119,769&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;During the year ended December&#160;31, 2023, the Company recognized a short-term lease benefit of $48.0&#160;million due to gains on the settlement of manufacturing supply agreements with CMOs and CDMOs that included embedded leases.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases for the year ended December&#160;31, 2023, 2022, and 2021 was as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows used in operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows used in finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows used in finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for operating lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, maturities of lease liabilities were as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,832&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,619&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253659809824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-Term Debt</a></td>
<td class="text">Long-Term Debt<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s long-term debt consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75% Convertible notes due 2023</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current convertible notes payable</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,881&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00% Convertible notes due 2027</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,784)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current convertible notes payable</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,016&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,466&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense incurred in connection with the convertible notes payable consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coupon interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,542&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense on convertible notes payable</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,468&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,039&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,612&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2027 Convertible Notes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company issued $175.3 million aggregate principal amount of convertible senior unsecured notes that will mature on December 15, 2027 (the &#8220;2027 Notes&#8221;), unless earlier converted, redeemed, or repurchased. The 2027 Notes were issued in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended, and pursuant to an indenture dated December 20, 2022 (the &#8220;2027 Indenture&#8221;) between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee. Concurrently with the issuance of the 2027 Notes, the Company completed a public offering of shares of its common stock (see Note 11). The Company received $166.4 million in net proceeds from the issuance of the 2027 Notes after deducting the initial purchasers&#8217; fees and the Company&#8217;s offering expenses. The 2027 Notes bear cash interest at a rate of 5.00% per year, payable semiannually in arrears on June 15 and December 15 of each year, beginning on June 15, 2023.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2027 Notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding September 15, 2027, only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2023 (and only during such calendar quarter), if the last reported sale price of the Company&#8217;s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for the 2027 Notes on each applicable trading day; (2) during the five business day period after any ten consecutive trading day period (the &#8220;measurement period&#8221;) in which the trading price (as defined in the 2027 Indenture) per $1,000 principal amount of the 2027 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company&#8217;s common stock and the conversion rate for the 2027 Notes on each such trading day; (3) if the Company calls such 2027 Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the 2027 Notes called (or deemed called) for redemption; and (4) upon the occurrence of specified corporate events as set forth in the 2027 Indenture. On or after September 15, 2027, until the close of business on the business day immediately preceding the maturity date (December 15, 2027), holders of the 2027 Notes may convert all or any portion of their 2027 Notes at any time, regardless of the foregoing conditions. Upon conversion, the Company may satisfy its conversion obligation by paying or delivering, as the case may be, cash, shares of the Company&#8217;s common stock, or a combination of cash and shares of the Company&#8217;s common stock, at the Company&#8217;s election, in the manner and subject to the terms and conditions provided in the 2027 Indenture.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conversion rate for the 2027 Notes will initially be 80.0000 shares of the Company&#8217;s common stock per $1,000 principal amount of 2027 Notes, which is equivalent to an initial conversion price of $12.50 per share of common stock. The initial conversion price of the 2027 Notes represents a conversion premium of 25% of the public offering price in the Company&#8217;s concurrent common stock offering that closed on December 20, 2022 (see Note 11). The conversion rate for the 2027 Notes is subject to adjustment under certain circumstances in accordance with the terms of the 2027 Indenture. In addition, following certain corporate events that occur prior to the maturity date of the 2027 Notes or if the Company delivers a notice of redemption in respect of the 2027 Notes, the Company will, under certain circumstances, increase the conversion rate of the 2027 Notes for a holder who elects to convert its 2027 Notes (or any portion thereof) in connection with such a corporate event or convert its 2027 Notes called (or deemed called) for redemption during the related redemption period (as defined in the 2027 Indenture), as the case may be.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not redeem the 2027 Notes prior to December 22, 2025. The Company may redeem for cash all or any portion of the 2027 Notes, at its option, on or after December 22, 2025, if the last reported sale price of the common stock has been at least 130% of the conversion price for the 2027 Notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the 2027 Notes to be redeemed, plus accrued and unpaid interest, to, but excluding, the redemption date. If the Company redeems less than all the outstanding 2027 Notes, at least $50&#160;million aggregate principal amount of 2027 Notes must be outstanding and not subject to redemption as of the date of the relevant notice of redemption. No sinking fund is provided for the 2027 Notes.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company undergoes a Fundamental Change (as defined in the 2027 Indenture), holders may require, subject to certain conditions and exceptions as set forth in the 2027 Indenture, the Company to repurchase for cash all or any portion of their 2027 Notes at a Fundamental Change repurchase price equal to 100% of the principal amount of the 2027 Notes to be repurchased, plus accrued and unpaid interest, to, but excluding, the Fundamental Change repurchase date. If a holder of the 2027 Notes converted upon a Make-Whole Fundamental Change (as described in the 2027 Indenture), they may be eligible to </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">receive a make-whole premium through an increase to the conversion rate up to a maximum of 20.0000 shares per $1,000 principal amount of 2027 Notes (subject to other adjustments as described in the 2027 Indenture).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accounting for the issuance of the 2027 Notes, the Company determined that the scope exceptions provided under ASC Topic 815-40,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(&#8220;ASC 815-40&#8221;) apply to all but one of the conversion features embedded in the 2027 Notes. This remaining conversion feature, which is associated with a Fundamental Change of the Company, was determined to have a de minimis value as of December&#160;31, 2023, and 2022.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial purchasers&#8217; fees and the Company&#8217;s issuance costs related to the 2027 Notes totaled $8.8 million, which were recorded as a reduction to the 2027 Notes on the consolidated balance sheet. The $8.8 million of debt issuance costs is being amortized and recognized as additional interest expense over the five-year contractual term of the 2027 Notes using an effective interest rate of 6.2%.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2023 Convertible Notes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company issued $325 million&#160;aggregate principal amount of convertible senior unsecured notes that matured on&#160;February&#160;1, 2023&#160;(the &#8220;2023 Notes&#8221;).&#160;The 2023 Notes were senior unsecured debt obligations and were issued at par. On January 31, 2023, the Company funded the outstanding principal amount of $325 million on the 2023 Notes, due February 1, 2023 and the indenture governing the 2023 Notes was subsequently satisfied and discharged in accordance with its terms. The Company&#8217;s related &#8220;capped call transactions&#8221; expired by their terms on January 27, 2023. The Company repaid the outstanding principal amount of $325 million together with accrued but unpaid interest on the maturity date. The repayment was funded by the issuance of the 2027 Notes and the concurrent common stock offering, as well as cash on hand.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Notes were issued pursuant to an indenture dated January&#160;29, 2016 (the &#8220;2023 Indenture&#8221;) between the Company and the trustee.&#160;The Company received $315.0 million in net proceeds from the offering after deducting underwriting fees and offering expenses. The 2023 Notes bore cash interest at a rate of 3.75%, payable on&#160;February&#160;1&#160;and&#160;August&#160;1&#160;of each year. The 2023 Notes were not redeemable prior to maturity and were convertible into shares of&#160;the Company&#8217;s&#160;common stock. As a result of the Company&#8217;s one-for-twenty reverse stock split in 2019 and pursuant to Section&#160;14.04(a)&#160;of the 2023 Indenture, the 2023 Notes were initially convertible into approximately 2,385,800 shares of the Company&#8217;s common stock based on the initial conversion rate of 7.3411 shares of the Company&#8217;s common stock per&#160;$1,000&#160;principal amount of the 2023 Notes. This represents an initial conversion price of approximately $136.20&#160;per share of the Company&#8217;s common stock,&#160;representing an approximate 22.5% conversion premium based on the last reported sale price of the Company&#8217;s common stock of $111.20 per share on January&#160;25, 2016. In addition, the holders of the 2023 Notes may have required the Company to repurchase the 2023 Notes at par value plus accrued and unpaid interest following the occurrence of a Fundamental Change (as described in the 2023 Indenture). If a holder of the 2023 Notes converted upon a Make-Whole Adjustment Event (as described in the 2023 Indenture), they may have been eligible to receive a make-whole premium through an increase to the conversion rate up to a maximum of 8.9928 shares per $1,000 principal amount of 2023 Notes (subject to other adjustments as described in the 2023 Indenture).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Notes are accounted for in accordance with ASC 470-20,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt with Conversion and Other Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(&#8220;ASC 470-20&#8221;) and ASC 815-40.&#160;Under ASC 815-40, to qualify for equity classification (or non-bifurcation, if embedded) the instrument (or embedded feature) must be both (1)&#160;indexed to the issuer&#8217;s stock and (2) meet the requirements of the equity classification guidance. Based upon the Company&#8217;s analysis, it was determined the 2023 Notes did contain embedded features indexed to its own stock, but did not meet the requirements for bifurcation, and therefore do not need to be separately accounted for as an equity component. Since the embedded conversion feature met the equity scope exception from derivative accounting, and also since the embedded conversion option did not need to be separately accounted for as an equity component under ASC 470-20,&#160;the proceeds received from the issuance of the convertible debt were recorded as a liability on the consolidated balance sheets.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the 2023 Notes,&#160;the Company&#160;also paid $38.5 million, including expenses, to enter into privately negotiated capped call transactions with certain financial institutions (the &#8220;capped call transactions&#8221;). The capped call transactions expired by their terms on January 27, 2023. The capped call transactions were generally expected to reduce the potential dilution upon conversion of the 2023 Notes in the event that the market price per share of the Company&#8217;s common stock, as measured under the terms of the capped call transactions, was greater than the strike price of the capped call transactions, which initially corresponded to the conversion price of the 2023 Notes, and was subject to anti-dilution adjustments generally similar to those applicable to the conversion rate of the 2023 Notes. The cap price of the capped call transactions was initially $194.60 per share, which represented a premium of approximately 75% based on the last reported sale </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">price of the Company&#8217;s common stock of $111.20 per share on January&#160;25, 2016, and was subject to certain adjustments under the terms of the capped call transactions. If, however, the market price per share of the Company&#8217;s common stock, as measured under the terms of the capped call transactions, exceeded the cap price, there would nevertheless have been dilution upon conversion of the 2023 Notes to the extent that such market price exceeded the cap price. The Company evaluated the capped call transactions under ASC Topic 815-10,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8211; Overall</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and determined that they should be accounted for as a separate transaction and that the capped call transactions would be classified as an equity instrument.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred approximately $10 million of debt issuance costs in 2016 relating to the issuance of the 2023 Notes, which were recorded as a reduction to the 2023 Notes on the consolidated balance sheet. The $10.0 million of debt issuance costs was amortized and recognized as additional interest expense over the seven-year contractual term of the 2023 Notes on a straight-line basis, which approximated the effective interest rate method. The Company also incurred $0.9 million of expenses related to the capped call transactions, which were recorded as a reduction to additional paid-in-capital.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253659907712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Deficit<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Deficit</a></td>
<td class="text">Stockholders&#8217; Deficit<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company entered into an At Market Issuance Sales Agreement (the "August 2023 Sales Agreement"), which allows it to issue and sell up to $500 million in gross proceeds of shares of its common stock, and terminated its then-existing At Market Issuance Sales agreement entered in June 2021 (the &#8220;June 2021 Sales Agreement&#8221;). During the year ended December&#160;31, 2023, the Company sold 38.3 million shares of its common stock under its August 2023 Sales Agreement and 7.9 million shares of its common stock under its June 2021 Sales Agreement, resulting in net proceeds of approximately $321 million, of which $6.9&#160;million was included in Prepaid expenses and other current assets as of December 31, 2023 and received in cash in January 2024. As of December&#160;31, 2023, the remaining balance available under the August 2023 Sales Agreement was approximately $242 million.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, the Company sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.2 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of its common stock resulting in net proceeds of approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$179 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under its June 2021 Sales Agreement. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, pursuant to the Securities Subscription Agreement with SK, the Company agreed to sell and issue to SK 6.5 million shares of the Company&#8217;s common stock at a price of $13.00 per share (the &#8220;Shares&#8221;) in a Private Placement for aggregate gross proceeds to the Company of approximately $84.5 million. The Company recognized the Shares at the settlement date fair value of $46.5 million (see Note 4 for additional discussion of the Securities Subscription Agreement with SK). The closing of the Private Placement occurred on August 10, 2023.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company completed a public offering of 7,475,000 shares of its common stock, including 975,000 shares of common stock that were issued upon the exercise in full of the option to purchase additional shares granted to the underwriters, at a price of $10.00 per share resulting in net proceeds, net of offering costs of $4.9 million, of approximately $70 million. The Company completed this public offering concurrent with the issuance of the 2027 Notes (see Note 10).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253659700048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Plans</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company established the 2023 Inducement Plan (the &#8220;2023 Inducement Plan&#8221;), which provides for the granting of share-based awards to individuals who were not previously employees, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with the Company. The Company reserved 1.0&#160;million shares of common stock for grants under the 2023 Inducement Plan. As of December&#160;31, 2023, there were 0.2&#160;million shares available for issuance under the 2023 Inducement Plan.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2015 Stock Incentive Plan, as amended (&#8220;2015 Plan&#8221;), was approved at the Company&#8217;s annual meeting of stockholders in June&#160;2015. Under the 2015 Plan, equity awards may be granted to officers, directors, employees, and consultants of and advisors to the Company and any present or future subsidiary.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2015 Plan authorizes the issuance of up to 21.0 million shares of common stock under equity awards granted under the 2015 Plan, which includes an increase of 6.2 million shares approved for issuance under the 2015 Plan at the Company&#8217;s 2023 annual meeting of stockholders. All such shares authorized for issuance under the 2015 Plan have been reserved.&#160;The 2015 Plan will expire on March&#160;30, 2033. As of December&#160;31, 2023, there were 6.9 million shares available for issuance under the 2015 Plan.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended and Restated 2005 Stock Incentive Plan (&#8220;2005 Plan&#8221;) expired in February&#160;2015 and no new awards may be made under such plan, although awards will continue to be outstanding in accordance with their terms.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2015 Plan permits and the 2005 Plan permitted the grant of stock options (including incentive stock options), restricted stock, SARs, and RSUs. In addition, under the 2015 Plan, unrestricted stock, stock units, and performance awards may be granted. Stock options and SARs generally have a maximum term of ten years and may be or were granted with an exercise price that is no less than 100% of the fair market value of the Company&#8217;s common stock at the time of grant. Grants of stock options are generally subject to vesting over periods ranging from <span style="-sec-ix-hidden:f-931">one</span> to four years.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the consolidated statements of operations as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,357&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,300&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,626&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023 and 2022, total stock-based compensation capitalized in inventory was $0.5 million and $1.7 million, respectively. No stock-based compensation was capitalized in inventory during the year ended December 31, 2021. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there was approximately $81.4 million of total unrecognized compensation expense related to unvested stock options, SARs, RSUs, and the ESPP. This unrecognized non-cash compensation expense is expected to be recognized over a weighted-average period of approximately 1.0 year and will be allocated between cost of sales, research and development, and general and administrative expenses accordingly. This estimate does not include the impact of other possible stock-based awards that may be made during future periods.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value represents the total intrinsic value (the difference between the Company&#8217;s closing stock price on the last trading day of the period and the exercise price, multiplied by the number of in-the-money stock options and SARs) that would have been received by the holders had all stock option and SARs holders exercised their stock options and SARs on December&#160;31, 2023. This amount is subject to change based on changes to the closing price of the Company&#8217;s common stock. The aggregate intrinsic value of stock options and SARs exercises and vesting of RSUs for the years ending December&#160;31, 2023, 2022, and 2021 was approximately $5 million, $21 million, and $454 million, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Stock Appreciation Rights</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock options and SARs activity under the 2023 Inducement Plan, 2015 Plan and the 2005 Plan for the year ended December&#160;31, 2023:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.212%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.460%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.460%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.460%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.460%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.460%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023 Inducement Plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2015 Plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2005 Plan</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options &amp; SARs</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock<br/>Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,053,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.07&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,021,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,483)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(278,361)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,787,042&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,275&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares exercisable at December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,436,339&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.51&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,275&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.79&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted under the 2023 Inducement Plan and the 2015 Plan was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:53.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average Black-Scholes fair value of stock<br/>options and SARs granted</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$55.32</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$158.02</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5%-4.8%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4%-4.3%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5%-1.3%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.4%-140.3%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.5%-140.1%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.7%-142.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9-6.4</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0-6.3</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1-6.1</span></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total aggregate intrinsic value and weighted-average remaining contractual term of stock options and SARs outstanding under the 2023 Inducement Plan, 2015 Plan and 2005 Plan as of December&#160;31, 2023 was less than $0.1 million and 6.9 years, respectively. The total aggregate intrinsic value and weighted-average remaining contractual term of stock options and SARs exercisable under the 2023 Inducement Plan, 2015 Plan and 2005 Plan as of December&#160;31, 2023 was less than $0.1 million and 5.9 years, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of RSU activity for the year ended December&#160;31, 2023:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.533%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023 Inducement Plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2015 Plan</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per Share<br/>Weighted-<br/>Average<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per Share<br/>Weighted-<br/>Average<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034,574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,314,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(696,553)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(937,603)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,990&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.66&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,714,870&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.43&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP was approved at the Company&#8217;s annual meeting of stockholders in June&#160;2013. The ESPP currently authorizes an aggregate of 1.2 million shares of common stock to be purchased, and the aggregate amount of shares will continue to increase 5% on each anniversary of its adoption up to a maximum of 1.65 million shares. The ESPP allows employees to purchase shares of common stock of the Company at each purchase date through payroll deductions of up to a maximum of 15% of their compensation, at 85% of the lesser of the market price of the shares at the time of purchase or the market price on the beginning date of an option period (or, if later, the date during the option period when the employee was first eligible to participate). At December&#160;31, 2023, there were 0.5 million shares available for issuance under the ESPP.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253659723760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract', window );"><strong>Payment for Pension and Other Postretirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefits</a></td>
<td class="text">Employee Benefits<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a defined contribution 401(k)&#160;retirement plan, pursuant to which employees may elect to contribute up to 100% of their compensation on a tax deferred basis up to the maximum amount permitted by the Internal Revenue Code of 1986, as amended. The Company matches 100% of the first 3% of the participants&#8217; deferral, and 50% on the next 2% of the participants&#8217; deferral, up to a potential 4% Company match. The Company&#8217;s matching contributions to the 401(k)&#160;plan vest immediately. Under its 401(k)&#160;plan, the Company has recorded expense of $7.0 million, $6.0 million, and $3.4 million in 2023, 2022, and 2021, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s foreign subsidiaries have pension plans under local tax and labor laws and are obligated to make contributions to the plan. Contributions and other expenses related to this plan were $3.0 million, $2.4 million, and $1.7 million in 2023, 2022, and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253659727184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Financial Information</a></td>
<td class="text">Other Financial Information <div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following as of (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">160,773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">155,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">226,023&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">237,147&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is comprised of the following as of (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and buildings</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,916&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">380,739&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">341,539&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,968)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">305,771&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">294,247&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, approximately $155 million and $170 million, respectively, of net assets used in operations were located in the Czech Republic. Depreciation expense was approximately $41 million, $29 million, and $13 million for the years ended December&#160;31, 2023, 2022, and 2021, respectively.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following as of (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee benefits and compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,952&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52,569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross-to-net deductions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. product sales returns accrual </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">468,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">394,668&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">591,158&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consist of the following as of (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refunds due to APA customers </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,362&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liability related to Gavi (see Note 3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">861,408&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">930,055&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253659717600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s loss before income tax expense by jurisdiction is as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(628,984)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(712,183)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,633,016)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(81,520)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(543,031)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(653,647)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,714,536)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the current and deferred income tax expense (benefit) are as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current income tax expense (benefit)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,292&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,215&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred: </span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total income tax expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,031&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,292&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,215&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense to the amount computed by applying the U.S. federal statutory tax rate to the Company&#8217;s effective tax rate is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Statutory federal tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development and other tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-deductible expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxation of foreign operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancellation of Indebtedness</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-US tax credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company has available federal and state net operating losses of $2.4&#160;billion, $877.6&#160;million, respectively, that may be applied against future taxable income in the respective jurisdiction. The federal net operating losses of $2.4&#160;billion can be carried forward indefinitely, with all but $11.3&#160;million, which expires in 2037, limited to 80% of annual taxable income. State net operating losses of $457.4&#160;million have various expiration dates between 2028 and 2042. The remaining state net operating losses of $420.2&#160;million can be carried forward indefinitely. The Company also has research tax credits of $51.9&#160;million that will begin to expire in 2024 through 2043 and a foreign tax credit carryforward of $18.7&#160;million that will expire in 2030.&#160;Utilization of the federal and state net operating loss carryforwards and research tax credits may be subject to an annual limitation due to potential ownership changes of the Company. As of December&#160;31, 2023, the Company does not expect such limitation, if any, to impact the use of its net operating losses and research tax credits.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the U.S. federal jurisdiction and in various states, as well as in multiple foreign jurisdictions including Sweden and the Czech Republic. The Company has U.S. federal and state net operating losses and credit carryforwards that are subject to examination from 2003 through 2023. The returns in Sweden are subject to examination from 2016 through 2023 and the returns for the Czech Republic are subject to examination from 2019 through 2023.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company&#8217;s deferred tax assets and liabilities as of December 31 were as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">550,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">479,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign net operating loss carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">266,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowance for sales returns</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign tax credit carryforward</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,186,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,056,799&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,128,941)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,020,123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57,852&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(41,456)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23,330)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,587)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,279)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,055)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(704)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(59,895)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(36,676)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,043)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the positive and negative evidence bearing upon the realization of its deferred tax assets, including its history of significant losses in every year since inception and, in accordance with U.S GAAP, has fully reserved the net deferred tax asset. The Company concluded that realization of its net deferred tax assets is not more-likely-than-not to be realized as of December&#160;31, 2023 and 2022. The valuation allowance increased by $108.8 million and $4.8 million for the years ended December&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net deferred tax liability of $2.0&#160;million at December&#160;31, 2023 is included within other non-current liabilities on the accompanying consolidated balance sheet.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the effect of an income tax position when it is more likely than not, based on the technical merits, that the income tax position will be sustained upon examination. A reconciliation of the beginning and ending amounts of unrecognized tax benefits in the year ended December&#160;31, 2023, 2022, and 2021 is as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized tax benefits balance at January 1</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,766&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions for tax positions of current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reductions for tax positions of prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,027)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Settlements of tax positions of prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized tax benefits balance at December 31,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,237&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,154&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense. As of December&#160;31, 2023 and 2022, the Company had no accruals for interest or penalties. The total amount of unrecognized tax benefits that, if recognized, could affect the effective tax rate was $4.2 million and $5.2 million as of December&#160;31, 2023 and 2022, respectively. However, the Company maintains a full valuation allowance as of December&#160;31, 2023 and 2022 and the recognition of any unrecognized tax benefits would be offset with a change in the valuation allowance and therefore there would be no income statement impact. As of December&#160;31, 2023, the Company does not expect a significant change in the recorded unrecognized tax benefits liability balance during the next twelve months. The unrecognized tax benefits are presented in the financial statements as a reduction to the deferred tax assets for all periods.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021 the Organization for Economic Cooperation and Development (&#8220;OECD&#8221;) developed guidance on Base Erosion and Profit Shifting (&#8220;BEPS&#8221;) Pillar Two Model Rules (&#8220;Pillar Two&#8221;), which addresses corporate tax planning strategies used by some large multinational corporations to shift profits from higher-tax jurisdictions to lower-tax jurisdictions or zero-tax locations. This guidance imposes a 15% minimum tax on the earnings of large multinational corporations. Pillar Two is expected to be effective in 2024 for the jurisdictions in which the Company operates. The Company is currently evaluating the application of Pillar Two and does not expect these rules to have a significant impact on its effective tax rate or its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253659695456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitment and Contingencies<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stockholder Litigation</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 12, 2021, Sothinathan Sinnathurai filed a purported securities class action in the U.S. District Court for the District of Maryland (the &#8220;Maryland Court&#8221;) against the Company and certain members of senior management, captioned Sothinathan Sinnathurai v. Novavax, Inc., et al., No. 8:21-cv-02910-TDC (the &#8220;Sinnathurai Action&#8221;). On January 26, 2022, the Maryland Court entered an order designating David Truong, Nuggehalli Balmukund Nandkumar, and Jeffrey Gabbert as co-lead plaintiffs in the Sinnathurai Action. The co-lead plaintiffs filed a consolidated amended complaint on March 11, 2022, alleging that the defendants made certain purportedly false and misleading statements concerning the Company&#8217;s ability to manufacture prototype vaccine on a commercial scale and to secure the prototype vaccine&#8217;s regulatory approval. The amended complaint defines the purported class as those stockholders who purchased the Company&#8217;s securities between February 24, 2021 and October 19, 2021. On April 25, 2022, the defendants filed a motion to dismiss the consolidated amended complaint. On December 12, 2022, the Maryland Court issued a ruling granting in part and denying in part defendants&#8217; motion to dismiss. The Maryland Court dismissed all claims against two individual defendants and claims based on certain public statements challenged in the consolidated amended complaint. The Maryland Court denied the motion to dismiss as to the remaining claims and defendants, and directed the Company and other remaining defendants to answer within fourteen days. On December 27, 2022, the Company filed its answer and affirmative defenses. On March 16, 2023, the plaintiffs filed a motion for class certification and to appoint class representatives and counsel. Due to the Maryland Court&#8217;s ruling on the dismissal motion, the motion sought to certify a class of stockholders who purchased the Company&#8217;s securities between May 11, 2021, and October 19, 2021. The Company filed its opposition to the plaintiffs&#8217; motion on September 22, 2023. On December 4, 2023, the parties agreed to a binding settlement in principle (the &#8220;Proposed Settlement&#8221;) to fully resolve the surviving claims in the Sinnathurai Action. Under the Proposed Settlement&#8217;s terms, the Company agreed to pay $47 million into a settlement fund, which will be funded by the Company&#8217;s directors and officers&#8217; liability insurance and paid to members of a putative settlement class. On January 12, 2024, after the parties negotiated and executed a written agreement governing the Proposed Settlement, plaintiffs filed an unopposed motion for the Proposed Settlement&#8217;s preliminary approval. On January 23, 2024, the Maryland Court granted the motion for preliminary approval and, as requested by the parties, preliminarily certified, for the purposes of settlement only, the settlement class. The court also scheduled a settlement hearing to consider final approval of the settlement for May 23, 2024.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">After the Sinnathurai Action was filed, eight derivative lawsuits were filed: (i) Robert E. Meyer v. Stanley C. Erck, et al., No. 8:21-cv-02996-TDC (the &#8220;Meyer Action&#8221;), (ii) Shui Shing Yung v. Stanley C. Erck, et al., No. 8:21-cv-03248-TDC (the &#8220;Yung Action&#8221;), (iii) William Kirst, et al. v. Stanley C. Erck, et al., No. C-15-CV-21-000618 (the &#8220;Kirst Action&#8221;), (iv) Amy Snyder v. Stanley C. Erck, et al., No. 8:22-cv-01415-TDC (the &#8220;Snyder Action&#8221;), (v) Charles R. Blackburn, et al. v. Stanley C. Erck, et al., No. 1:22-cv-01417-TDC (the &#8220;Blackburn Action&#8221;), (vi) Diego J. Mesa v. Stanley C. Erck, et al., No. 2022-0770-NAC (the &#8220;Mesa Action&#8221;), (vii) Sean Acosta v. Stanley C. Erck, et al., No. 2022-1133-NAC (the &#8220;Acosta Action&#8221;), and (viii) Jared Needelman v. Stanley C. Erck, et al., No. C-15-CV-23-001550 (the &#8220;Needelman Action&#8221;). The Meyer, Yung, Snyder, and Blackburn Actions were filed in the Maryland Court. The Kirst and Needelman Actions were filed in the Circuit Court for Montgomery County, Maryland. The Mesa and Acosta Actions were filed in the Delaware Court of Chancery (the &#8220;Delaware Court&#8221;). The derivative lawsuits name members of the Company&#8217;s board of directors and certain members of senior management as defendants. The Company is deemed a nominal defendant. The plaintiffs assert derivative claims arising out of </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">substantially the same alleged facts and circumstances as the Sinnathurai Action. Collectively, the derivative complaints assert claims for breach of fiduciary duty, insider selling, unjust enrichment, violation of federal securities law, abuse of control, waste, and mismanagement. Plaintiffs seek declaratory and injunctive relief, as well as an award of monetary damages and attorneys&#8217; fees.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 7, 2022, the Maryland Court entered an order consolidating the Meyer and Yung Actions (the &#8220;First Consolidated Derivative Action&#8221;). The plaintiffs in the First Consolidated Derivative Action filed their consolidated derivative complaint on April 25, 2022. On May 10, 2022, the Maryland Court entered an order granting the parties&#8217; request to stay all proceedings and deadlines pending the earlier of dismissal or the filing of an answer in the Sinnathurai Action. On June 10, 2022, the Snyder and Blackburn Actions were filed. On October 5, 2022, the Maryland Court entered an order granting a request by the plaintiffs in the First Consolidated Derivative Action and the Snyder and Blackburn Actions to consolidate all three actions and appoint co-lead plaintiffs and co-lead and liaison counsel (the &#8220;Second Consolidated Derivative Action&#8221;). The co-lead plaintiffs in the Second Consolidated Derivative Action filed a consolidated amended complaint on November 21, 2022. On February 10, 2023, defendants filed a motion to dismiss the Second Consolidated Derivative Action. The plaintiffs filed their opposition to the motion to dismiss on April 11, 2023. Defendants filed their reply brief in further support of their motion to dismiss on May 11, 2023. On August 21, 2023, the court entered an order granting in part and denying in part the motion to dismiss; the court allowed claims for alleged insider selling under Brophy v. Cities Service Co., et al., 70 A.2d 5 (Del. Ch. 1949) and unjust enrichment claims to proceed, but dismissed the remaining claims in the second consolidated amended complaint. On September 5, 2023, the Company filed an Answer to the consolidated amended complaint. On September 6, 2023, the court entered an order granting the individual defendants an extension of time to file their answer until November 6, 2023. On October 6, 2023, the Board of Directors of the Company formed a Special Litigation Committee (&#8220;SLC&#8221;) with full and exclusive power and authority of the Board to, among other things, investigate, review, and analyze the facts and circumstances surrounding the claims asserted in the pending derivative actions, including the claims that remain following the court&#8217;s order on the motion to dismiss in the Second Consolidated Derivative Action. On November 7, 2023, the court entered an order granting the parties&#8217; request to stay the Second Consolidated Derivative Action for up to six months from the date of entry of the order. This includes staying the deadline for the individual defendants to respond to the consolidated amended complaint.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Kirst Action was filed on December 28, 2021, and the defendants immediately removed the case to the Maryland Court. On July 21, 2022, the Maryland Court issued a memorandum opinion and order remanding the Kirst Action to state court. The plaintiffs filed an amended complaint on December 30, 2022. On January 23, 2023, defendants filed a motion to stay the Kirst action. On February 22, 2023, the parties in the Kirst Action filed for the Court&#8217;s approval of a stipulation staying the Kirst Action pending the resolution of defendants&#8217; motion to dismiss in the Second Consolidated Derivative Action. On March 22, 2023, the Court entered the parties&#8217; stipulated stay of the Kirst Action pending resolution of the motion to dismiss in the Second Consolidated Derivative Action.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2022, the Mesa Action was filed. On October 3, 2022, the Delaware Court entered an order granting the parties&#8217; request to stay all proceedings and deadlines in the Mesa Action pending the earlier of dismissal of the Sinnathurai Action or the filing of an answer to the operative complaint in the Sinnathurai Action. On January 18, 2023, defendants filed a motion to stay the Mesa Action pending a final judgment in the Second Consolidated Derivative Action. The plaintiff filed his opposition on February 8, 2023. Defendants filed their reply on February 22, 2023. On February 28, 2023, the court granted the defendants&#8217; motion to stay. On August 31, 2023, the plaintiff filed a motion to lift the stay. On October 6, 2023, the Company filed an opposition to plaintiff&#8217;s motion to lift the stay. Plaintiff filed his reply on October 17, 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 27, 2023, the parties filed a letter informing the Court that the Second Consolidated Derivative Action had been stayed for a period of six months and asked the Court to stay further proceedings in the Mesa Action until expiration of that stay.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2022, the Acosta Action was filed. On February 6, 2023, defendants accepted service of the complaint and summons in the Acosta Action. On March 9, 2023, the court entered an order granting the parties&#8217; request to stay the Acosta Action pending the entry of a final, non-appealable judgment in the Second Consolidated Derivative Action. On October 13, 2023, the parties filed, and the Delaware Court entered, a stipulated order providing that (i) if the Delaware Court declines to lift the stay in the Mesa Action, the Acosta Action will also remain stayed, and (ii) if the Delaware Court lifts the stay in the Mesa Action, the stay in the Acosta Action will also be lifted.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2023, the Needelman Action was filed. On July 12, 2023, the parties filed a stipulation and proposed order to stay the Needelman Action pending the Maryland Court&#8217;s decision on the motion to dismiss in the Second Consolidated Derivative Action. The court entered that order on July 17, 2023. The parties continue to discuss next steps in the litigation following the Maryland Court&#8217;s ruling on the motion to dismiss the Second Consolidated Derivative Action. The court entered that order on July 17, 2023.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2023, the court entered an order consolidating the Kirst and Needelman Actions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2023, the parties filed a stipulation (i) extending the plaintiffs&#8217; deadline to file a consolidated complaint until January 29, 2024, and (ii) otherwise staying all other proceedings in the case (including the defendants&#8217; deadline to respond to the consolidated complaint) until February 12, 2024. The stipulation entered by the court instructs the parties to discuss whether the stay should be further extended in light of the then-current status of the SLC&#8217;s investigation. The financial impact of the derivative claims is not estimable.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 18, 2022, the Company delivered written notice to Gavi to terminate the Gavi APA based on Gavi&#8217;s failure to procure the purchase of 350&#160;million doses of prototype vaccine from the Company as required by the Gavi APA. As of November 18, 2022, the Company had only received orders under the Gavi APA for approximately 2&#160;million doses. On December 2, 2022, Gavi issued a written notice purporting to terminate the Gavi APA based on Gavi&#8217;s contention that the Company repudiated the agreement and, therefore, materially breached the Gavi APA. Gavi also contended that, based on its purported termination of the Gavi APA, it was entitled to a refund of the Advance Payment Amount less any amounts that have been credited against the purchase price for binding orders placed by a buyer participating in the COVAX Facility. Since December 31, 2022, the remaining Gavi Advance Payment Amount, which is $696.4&#160;million as of December 31, 2023, pending resolution of the dispute with Gavi related to a return of the remaining Advance Payment Amount, has been classified within Other current liabilities in the Company&#8217;s consolidated balance sheet. On January 24, 2023, Gavi filed a demand for arbitration with the International Court of Arbitration based on the claims described above. The Company filed its Answer and Counterclaims on March 2, 2023. On April 5, 2023, Gavi filed its Reply to the Company&#8217;s Counterclaims. On February 16, 2024, the Company and Gavi entered into a Termination and Settlement Agreement (the &#8220;Gavi Settlement Agreement&#8221;) terminating the Gavi APA, settling the arbitration proceedings and releasing both parties of all claims arising from, under or otherwise in connection with the Gavi APA. Pursuant to the Gavi Settlement Agreement, the Company is responsible for payment to Gavi of (i) an initial settlement payment of $75&#160;million, which the Company paid on February 20, 2024, and (ii) deferred payments, in equal annual amounts of $80&#160;million payable each calendar year through a deferred payment term ending December 31, 2028. The deferred payments are due in variable quarterly installments beginning in the first quarter of 2024 and total $400&#160;million during the deferred payment term. Such deferred payments may be reduced through Gavi&#8217;s use of an annual vaccine credit equivalent to the unpaid balance of such deferred payments each year, which may be applied to qualifying sales of any of the Company&#8217;s vaccines funded by Gavi for supply to certain low-income and lower-middle income countries. The Company has the right to price the vaccines offered to such low-income and lower-middle income countries at its discretion, and, when utilized by Gavi, the Company will credit the actual price per vaccine paid against the applicable credit. The Company intends to price vaccines offered via the tender process, consistent with its shared goal with Gavi to provide equitable access to those countries. On February 22, 2024, the claims and counterclaims were dismissed with prejudice.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 30, 2022, the Company and Fujifilm entered into the Fujifilm Settlement Agreement regarding amounts due to Fujifilm in connection with the termination of manufacturing activity at FDBT under the CSA dated August 20, 2021 and the MSA by and between the Company and Fujifilm. The MSA and CSA established the general terms and conditions applicable to Fujifilm&#8217;s manufacturing and supply activities related to the Company&#8217;s prototype vaccine under the associated statements of work. Pursuant to the Fujifilm Settlement Agreement, the Company agreed to pay up to $185.0&#160;million (the &#8220;Settlement Payment&#8221;) to Fujifilm in connection with cancellation of manufacturing activity at FDBT. Under the Fujifilm Settlement Agreement, the final two quarterly installments due to Fujifilm were subject to Fujifilm&#8217;s obligation to use commercially reasonable efforts to mitigate losses associated with the vacant manufacturing capacity caused by the termination of manufacturing activities at FDBT under the CSA. Any replacement revenue achieved by Fujifilm&#8217;s mitigation efforts between July 1, 2023 and December 31, 2023 would offset the final two settlement payments owed by the Company. On October 2, 2023, the Company sent a notice of breach under the Fujifilm Settlement Agreement to Fujifilm setting forth the Company&#8217;s position that Fujifilm had not used commercially reasonable efforts to mitigate losses. The Company withheld two installments of $34.3&#160;million due to Fujifilm on September&#160;30, 2023 and December&#160;31, 2023, pending resolution of the issues identified in the notice of breach. On October 30, 2023, FDBT filed a demand for arbitration with Judicial Arbitration and Mediation Services (&#8220;JAMS&#8221;) seeking payment of the third quarter installment of the Settlement Payment. An arbitration hearing has been scheduled for May 2024. As of December&#160;31, 2023, the remaining payment of $68.6&#160;million was reflected in Accrued expenses. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also involved in various other legal proceedings arising in the normal course of business. Although the outcomes of these other legal proceedings are inherently difficult to predict, the Company does not expect the resolution of these other legal proceedings to have a material adverse effect on its financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into agreements in the normal course of business with CMOs and CDMOs supplying the Company with production capabilities, and with vendors for preclinical studies, clinical trials, and other goods or services. A number of these arrangements are within the scope of lease accounting (see Note 9). Certain agreements provide for termination rights subject to termination fees. Under such agreements, the Company is contractually obligated to make payments to vendors, mainly to reimburse them for their estimated unrecoverable expenses. The exact amount of such obligations are dependent on the timing of termination and the terms of the relevant agreement, and cannot be reasonably estimated. As of December&#160;31, 2023, most of these agreements were active ongoing arrangements and the Company expects to receive value from these arrangements in the future. The Company recognizes fees related to obligations for terminated contracts where such fees are reasonably estimable. The Company did not accrue obligations that were not reasonably estimable. As of December&#160;31, 2023, the Company had no non-cancelable purchase commitments with a remaining term of more than one year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253659691872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring </span><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the restructuring charge recorded by the Company comprised (in thousands): </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:80.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.982%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severance and employee benefit costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,503&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Restructuring charge </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,584&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Restructuring charges of $0.5&#160;million, $2.3&#160;million and $11.5&#160;million are included in Cost of sales, Research and development and Selling, general, and administrative expenses, respectively, in the Consolidated Statements of Operations for the period ended December&#160;31, 2023. These charges reflect substantially all expected restructuring charges under the Restructuring Plan.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Severance and employee benefit costs</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employees affected by the reduction in force under the Restructuring Plan are entitled to receive severance payments and certain termination benefits. The Company recorded a severance and termination benefit cost in full for employees who were notified of their termination during the year ended December&#160;31, 2023 and had no requirements for future service. The Company fully paid $4.5&#160;million for severance and employee benefit costs during the year ended December&#160;31, 2023 and no remaining liability for the severance and employee benefit costs is included in the Company&#8217;s consolidated balance sheet as of December&#160;31, 2023. There were no severance and employee benefit costs during the year ended December 31, 2022 and 2021.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of long-lived assets</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Restructuring Plan, the Company evaluated its long-lived assets for impairment including certain leased laboratory and office spaces located in Gaithersburg, Maryland. The evaluation is subject to judgment and actual results may vary from the estimates, resulting in potential future adjustments to amounts recorded. During the year ended December&#160;31, 2023, the Company recorded an impairment charge of $10.1&#160;million related to the impairment of long-lived assets, including $5.9&#160;million related to ROU assets for facility leases. There were no impairment charges recorded during the year ended December 31, 2022 and 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//420/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253659913808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2024, the Company announced that the Board of Directors of the Company approved an approximately 12% reduction of its global workforce, comprised of an approximately 9% reduction in the Company&#8217;s full-time employees and the remainder comprised of contractors and consultants. </span></div>On February 16, 2024, the Company and Gavi entered into the Gavi Settlement Agreement terminating the Gavi APA, settling the arbitration proceedings and releasing both parties of all claims arising from, under or otherwise in connection with the Gavi APA. The terms of the Gavi Settlement Agreement are outlined in Note 3 and Note 16.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253656483184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (545,062)<span></span>
</td>
<td class="num">$ (657,939)<span></span>
</td>
<td class="num">$ (1,743,751)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253656503712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=nvax_FilipDubovskyMDMember', window );">Filip Dubovsky, MD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 12, 2023, Filip Dubovsky, MD, our President, Research &amp; Development, entered into a Rule 10b5-1 trading plan that is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides that Dr. Dubovsky, acting through a broker, may sell up to an aggregate of 13,365 shares of our common stock, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur from March 15, 2024 to June 14, 2024. The plan is scheduled to terminate on June 14, 2024, subject to earlier termination upon the sale of all shares subject to the plan or the expiration of all sale orders under the plan, upon termination by Dr. Dubovsky or the broker, or as otherwise provided in the plan.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Filip Dubovsky, MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">President, Research & Development<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">December 12, 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">185 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">13,365<span></span>
</td>
<td class="nump">13,365<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=nvax_FilipDubovskyMDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=nvax_FilipDubovskyMDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253656677488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Novavax,&#160;Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_LiquidityAndGoingConcernPolicyTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Going Concern</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern within one year after the date that the financial statements are issued and contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainty described below. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company had $568.5 million in cash and cash equivalents and had a working capital deficiency. In January 2024, pursuant to the June 2023 Amendment to the advance purchase agreement between the Company and the Canadian government (the &#8220;Canada APA&#8221;), the Company received the second installment of $174.8&#160;million from the Canadian government that was contingent and payable upon the Company&#8217;s delivery of vaccine doses (see Note 3). During the year ended December&#160;31, 2023, the Company incurred a net loss of $545.1 million and had net cash flows used in operating activities of $714.0&#160;million.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 205-40</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Presentation of Financial Statements - Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that these consolidated financial </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements are issued. While the Company&#8217;s current cash flow forecast for the one-year going concern look forward period estimates that there will be sufficient capital available to fund operations, this forecast is subject to significant uncertainty, including as it relates to revenue for the next 12 months and the Company&#8217;s ability to execute on certain cost-reduction initiatives. The Company&#8217;s revenue projections depend on its ability to successfully develop, manufacture, distribute and market its updated vaccine for the 2024-2025 vaccination season, which is inherently uncertain and subject to a number of risks, including the Company&#8217;s ability to obtain regulatory authorizations, introduce a single-dose vial or pre-filled syringe  product presentation for the U.S. commercial and certain other markets, the incidence of COVID-19 during the 2024-2025 vaccination season, the Company&#8217;s ability to timely deliver doses and achieve commercial adoption and market acceptance of its updated vaccine. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to meet regulatory milestones or achieve product volume or delivery timing obligations under the Company&#8217;s advance purchase agreements (&#8220;APAs&#8221;) may require the Company to refund portions of upfront and other payments or result in reduced future payments which would adversely affect the Company&#8217;s ability to continue as a going concern. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that, given the history of recurring losses, negative working capital and accumulated deficit, conditions or events exist that raise substantial doubt about the Company&#8217;s ability to continue as a going concern through one year from the date that these financial statements are issued. Management&#8217;s plans to alleviate the conditions that exist include restructuring and cost reduction measures and successful execution of its commercial plans. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, the Company announced a global restructuring and cost reduction plan (the &#8220;Restructuring Plan&#8221;), which includes a more focused investment in its COVID-19 Vaccine, reduction to its pipeline spending, the continued rationalization of its manufacturing network, a reduction to the Company&#8217;s global workforce, as well as the consolidation of facilities, and infrastructure. In January 2024, as part of reducing combined research and development and selling, general and administrative expenses, the Company announced further reductions in its global workforce (the &#8220;2024 Cost Reduction Plan&#8221;) (see Note 18). The Company intends to prioritize improvements to its long-term supply chain efficiency. The Company expects the full annual impact of the Restructuring Plan to be realized in 2024 and the full annual impact of the 2024 Cost Reduction Plan to be realized in 2025 and approximately 85% of the annual impact, excluding one-time charges, to be realized in 2024. During the year ended December&#160;31, 2023, the Company recorded a charge of $4.5&#160;million related to one-time employee severance and benefit costs and recorded an impairment charge of $10.1&#160;million related to the consolidation of facilities and infrastructure (see Note 17) and expects to record an additional charge of approximately $4&#160;million to $7&#160;million related to one-time employee severance and benefit costs, the majority of which is expected to be incurred in the first quarter of 2024. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Management&#8217;s plans may also include raising additional capital through a combination of equity and debt financing, collaborations, strategic alliances, asset sales, and marketing, distribution, or licensing arrangements. New financings may not be available to the Company on commercially acceptable terms, or at all. Also, any collaborations, strategic alliances, asset sales and marketing, distribution, or licensing arrangements may require the Company to give up some or all of its rights to a product or technology, which in some cases may be at less than the full potential value of such rights. If the Company is unable to obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate some or all of its operations, or further downsize its organization, any of which may have a material adverse effect on its business, financial condition, results of operations, and ability to operate as a going concern.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Due to the uncertainties associated with management&#8217;s plans, there is substantial doubt about the Company&#8217;s ability to continue as a going concern for at least one year from the date that these financial statements are issued.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div>The preparation of the consolidated financial statements in conformity with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company analyzes its revenue arrangements to determine the appropriate accounting under U.S. GAAP. Currently, the Company&#8217;s revenue arrangements represent customer contracts within the scope of ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 606&#8221;), or are contributions subject to the guidance in ASC Topic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities &#8211; Revenue Recognition </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 958-605&#8221;). The Company recognizes revenue from arrangements within the </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">scope of ASC 606 following the five-step model: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) it satisfies a performance obligation. The Company only recognizes revenue under the five-step model when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to its customer. The Company recognizes contribution revenue within the scope of ASC 958-605 when the funder-imposed conditions have been substantially met. Contributions are recorded as deferred revenue until the period in which research and development activities are performed that satisfy the funder-imposed conditions.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Sales - Advance Purchase Agreements </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales include sales associated with COVID-19 Vaccine supply agreements, sometimes referred to as APAs, with various international governments. The Company recognizes revenue from product sales related to these APA&#8217;s based on the transaction price per dose calculated in accordance with ASC 606 at the point in time when control of the product transfers to the customer and customer acceptance has occurred, unless such acceptance provisions are deemed perfunctory. The APAs typically contain terms that include upfront payments which are reflected in Deferred revenue. The Company constrains the transaction price for APA&#8217;s until it is probable that a significant reversal in revenue recognized will not occur. Specifically, if an APA includes a provision whereby the customer may request a discount, return, or refund, or includes a term that may have the effect of decreasing the price per dose of previously delivered shipments, revenue is constrained based on an estimate of the impact of the transaction price until it is probable that a significant reversal in revenue recognized will not occur. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Sales - U.S. Commercial </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2023, the Company commenced sales of COVID-19 Vaccine to the U.S. commercial market. Product sales in the U.S. are primarily made through large pharmaceutical wholesale distributors at the wholesale acquisition cost (&#8220;WAC&#8221;). The Company recognizes revenue upon title transfer (which is typically at time of delivery), provided all other revenue recognition criteria have been met. The transaction price includes estimates of variable consideration for which reserves are established that primarily result from invoice discounts for prompt payment, wholesale distributor fees, chargebacks, and product returns (collectively, &#8220;gross-to-net deductions&#8221;). These estimates are based on the amounts earned or to be claimed for related sales and are classified as either reductions of gross accounts receivable or a current liability based on the nature of the estimate, the expected settlement method, and net position by individual customer. Where appropriate, these estimates are based on factors such as industry data and forecasted customer buying and payment patterns, the Company&#8217;s experience, current contractual and statutory requirements, specific known market events, and trends. Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. If actual results vary from estimates, the Company will adjust the estimates, which would affect product sales in the period such variances become known. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross-to-net deductions include the following:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Wholesale distributor fees, discounts, and chargebacks: The Company has arrangements under which indirect customers such as retailers, healthcare providers, and others receive discounts to the WAC. The chargeback represents the difference between the WAC and this negotiated discounted price. For distribution and related services, the Company incurs service fees to its wholesale distributors. In addition, the Company typically offers wholesale distributor customers invoice discounts on product sales for prompt payments. The Company estimates chargebacks, discounts, and fees it will owe and deducts these amounts from gross product sales at the time the revenue is recognized based on the contractual terms and the Company&#8217;s expectations regarding future customer behaviors. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product returns: The Company offers U.S. customers the right to return COVID-19 Vaccine. These return rights include the right of wholesale distributors to return unsold and expired doses and the right of indirect customers to return any partial or unused vials upon expiry. Estimated returns for COVID-19 Vaccine are determined considering levels of inventory in the distribution channel, projected market demand, utilization data, returns claims received, and product shelf life. The estimated amount for product returns is deducted from gross product sales in the period the related product sales are recognized.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Other: Fees payable to retailers, healthcare providers, and buying groups, including certain patient assistance programs, are deducted from gross product sales in the period the related product sales are recognized.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Grants</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant revenue includes both revenue from government contracts and grants from organizations such as the Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;). The Company performs research and development under government funding, grant, license, and clinical development agreements. The revenue primarily consists of funding under U.S. government contracts and other arrangements to advance the clinical development and manufacturing of COVID-19 Vaccine.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under U.S. government contracts, the Company is entitled to receive funding on a cost-reimbursable or cost-reimbursable-plus-fixed-fee basis, to support certain activities related to the development, manufacture, and delivery of COVID-19 Vaccine to the U.S. government. The Company analyzed these contracts and determined that they are within the scope of ASC 606. The obligations under each of the contracts are not distinct in the context of the contract as they are highly interdependent or interrelated and, as such, they are accounted for as a single performance obligation. The transaction price under these arrangements is the consideration the Company is expecting to receive and consists of the funded contract amount and the unfunded variable amount to the extent that it is probable that a significant reversal of revenue will not occur. The Company recognizes revenue for these contracts over time as the Company transfers control over the goods and services and satisfies the performance obligation. The Company measures progress toward satisfaction of the performance obligation using an Estimate-at-Completion (&#8220;EAC&#8221;) process, which is a cost-based input method that reviews and monitors the progress towards the completion of the Company&#8217;s performance obligation. Under this process, management considers the costs that have been incurred to-date, as well as projections to completion using various inputs and assumptions, including, but not limited to, progress towards completion, labor costs and level of effort, material and subcontractor costs, indirect administrative costs, and other identified risks. Estimating the total allowable cost at completion of the performance obligation under a contract is subjective and requires the Company to make assumptions about future activity and cost drivers. Changes in these estimates can occur for a variety of reasons and, if significant, may impact the timing of revenue and fee recognition on the Company&#8217;s contracts. Allowable contract costs include direct costs incurred on the contract and indirect costs that are applied in the form of rates to the direct costs. Progress billings under the contracts are initially based on provisional indirect billing rates, agreed upon between the Company and the U.S. government. These indirect rates are subject to review on an annual basis. The Company records the impact of changes in the indirect billing rates in the period when such changes are identified. These changes reflect the difference between actual indirect costs incurred compared to the estimated amounts used to determine the provisional indirect billing rates agreed upon with the U.S. government. The Company recognizes revenue on the U.S. government contracts based on reimbursable allowable contract costs incurred in the period up to the transaction price. For cost-reimbursable-plus-fixed-fee contracts, the Company recognizes the fixed-fee based on the proportion of reimbursable contract costs incurred to total estimated allowable contract costs expected to be incurred on completion of the underlying performance obligation as determined under the EAC process. The Company recognizes changes in estimates related to the EAC process in the period when such changes are made on a cumulative catch-up basis. The Company includes the transaction price comprising both funded and unfunded portions of customer contracts in this estimate.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:28.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s other funding agreements currently include funding from CEPI in the form of a grant (&#8220;CEPI Grant Funding&#8221;) and one or more forgivable no interest term loans (&#8220;CEPI Forgivable Loan Funding&#8221;). Under the Company&#8217;s grant funding arrangements, including the CEPI arrangement, the Company is primarily entitled to reimbursement for costs that support development related activities of COVID-19 Vaccine. The Company analyzed these other funding arrangements and determined that they are not within the scope of ASC 606 as they do not provide a direct economic benefit to the grantor. Payments received under the grant funding arrangements are considered conditional contributions under the scope of ASC 958-605 and are recorded as deferred revenue until the period in which such research and development activities are actually performed in a manner that satisfies the funder-imposed conditions. Payments received under the CEPI Forgivable Loan Funding are only repayable if project vaccine, as defined under the CEPI funding agreement, manufactured by the contract manufacturing organization (&#8220;CMO&#8221;) network funded by CEPI is sold to one or more third parties (which could include sales credited under the Gavi Settlement Agreement), and such sales cover the Company&#8217;s costs of manufacturing such vaccine, not including manufacturing costs funded by CEPI. As the financial risk remains with CEPI, the Company determined that the use of the funds from the CEPI agreement is outside the scope of ASC Topic 470, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The research and development risk was considered substantive, such that it was not probable that the development would be successful at the inception of the contract. Therefore, the Company concluded that ASC Topic 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 730&#8221;) was considered applicable and most appropriate. Given the financial risk associated with the research and development activities lies with CEPI because repayment of any funds provided by CEPI depends solely on the results of the research and development activities having future economic benefit, the Company has accounted for the obligation under the CEPI Forgivable Loan Funding as a contract to perform research and development for others. The Company has determined that payments received under these agreements should be recorded as revenue under ASC 958-605 rather than a reduction to research and development expenses. This is consistent with the Company&#8217;s policy of presenting such amounts as revenue. In reaching this determination, the Company </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">considered a number of factors, including whether it is principal under the arrangement, and whether the arrangement is significant to, and part of, the Company&#8217;s core operations. The Company will record revenue as it performs the contractual research and development services.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments received in advance related to arrangements where revenue is recognized under ASC 958-605 that are related to future performance are deferred and recognized as revenue when the research and development activities are performed. Such cash payments are restricted as to their use and are reflected in Restricted cash until expenditures contemplated in the funding agreements are incurred.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Royalties and Other</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has various arrangements that include a right for a customer to use the Company's intellectual property as a functional license, where the Company&#8217;s performance obligation is satisfied at the point in time at which the license is granted. These licensing arrangements include sales-based royalties, certain development and commercial milestone payments, and the sale of proprietary Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> adjuvant. Because development milestone payments are contingent on the achievement of milestones, such as regulatory approvals, that are not within the Company or licensee's control, the payments are not considered probable of being achieved and are excluded from the transaction price until the milestone is achieved, at which point the Company recognizes revenue. For arrangements that include sales-based royalties related to a previously granted license, including milestone payments based upon the achievement of a certain level of product sales, the license is deemed to be the sole or predominant item to which the royalties relate and the Company recognizes revenue when the related sales occur.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the transaction price to each performance obligation based on a relative standalone selling price basis. It develops assumptions that require judgment to determine the standalone selling price for each performance obligation in consideration of applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Sales</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales includes cost of raw materials, production, and manufacturing overhead costs associated with the Company&#8217;s product sales during the period. Cost of sales also includes adjustments for excess, obsolete, or expired inventory; idle capacity; and losses on firm purchase commitments to the extent the cost cannot be recovered based on estimates about future demand. Cost of sales does not include certain expenses related to raw materials, production, and manufacturing overhead costs that were expensed prior to regulatory authorization as described under the caption &#8220;Inventory.&#8221;</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include salaries; stock-based compensation; laboratory supplies; consultants and subcontractors, including external contract research organizations (&#8220;CROs&#8221;), CMOs, and contract development and manufacturing organizations (&#8220;CDMOs&#8221;); and other expenses associated with the Company&#8217;s process development, manufacturing, clinical, regulatory, and quality assurance activities for its clinical development programs. In addition, related indirect costs such as fringe benefits and overhead expenses are also included in research and development expenses. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates its research and development expense related to services performed under its contracts with external service providers based on an estimate of the level of service performed in the period. Research and development activities are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock', window );">Accrued Research and Development Expenses</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development Expenses</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues research and development expenses, including clinical trial-related expenses, as the services are performed, which may include estimates of those expenses incurred, but not invoiced. The Company uses information provided by third-party service providers and CRO, CMO, and CDMO invoices and internal estimates to determine the progress of work performed on the Company&#8217;s behalf. Assumptions based on clinical trial protocols, contracts, and participant enrollment data are also used to estimate these accruals.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed as incurred. The Company had advertising costs of $91.5&#160;million, $84.0&#160;million and $8.9&#160;million during the years ended December&#160;31, 2023, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation related to grants of stock options, stock appreciation rights (&#8220;SARs&#8221;), and restricted stock awards (&#8220;RSUs&#8221;), and purchases under the Company&#8217;s Employee Stock Purchase Plan (&#8220;ESPP&#8221;), at fair value. The Company recognizes compensation expense related to such awards on a straight-line basis over the requisite service period (generally the vesting period) of the equity awards, based on the award's fair value at the grant date. The requisite service period is typically <span style="-sec-ix-hidden:f-398">one</span> to four years. Forfeitures for all awards are recognized as incurred. The Company generally settles stock-based awards with newly issued shares.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options and SARs is measured on the date of grant using the Black-Scholes option pricing model. The expected term of stock options and SARs is based on the Company&#8217;s historical option exercise experience and post-vesting forfeiture experience using the historical expected term from the vesting date, and the expected term for purchases under the ESPP is based on the purchase periods included in the offering. The expected volatility is determined using historical volatilities based on stock prices over a look-back period corresponding to the expected term. The risk-free interest rate is determined using the yield available for zero-coupon U.S. government issues with a remaining term equal to the expected term. The Company has never paid a dividend and the Company does not intend to pay dividends in the foreseeable future, and as such, the expected dividend yield is zero.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of highly liquid investments with maturities of three months or less from the date of purchase. Cash equivalents are recorded at cost, which approximates fair value due to their short-term nature.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), for financial and non-financial assets and liabilities. ASC 820 discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The statement utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Unobservable inputs that reflect the reporting entity&#8217;s own assumptions.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s current and non-current restricted cash includes payments received under grant agreements and cash collateral accounts under letters of credit that serve as security deposits for certain facility leases. Payments received under grant agreements become unrestricted as the Company incurs expenses for services performed under these agreements. As of December&#160;31, 2023 and 2022, restricted cash balances (both current and non-current) consisted primarily of payments under the CEPI funding agreements and letter of credits.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes amounts due from customers as accounts receivable when its right to payment is unconditional. Gross-to-net deductions are classified as reductions of gross accounts receivable if settlement is expected to occur through a reduction in the amount paid to Novavax by its customer. Account receivables are recorded net of any </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allowance for credit losses. The Company&#8217;s estimate for the allowance for credit losses, which has not been significant to date, is determined based on the credit risk of its customers based on historical loss experience, economic conditions, the aging of receivables, and customer-specific risks.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risk</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments expose the Company to concentration of credit risk and consist primarily of cash and cash equivalents. The Company&#8217;s investment policy limits investments to certain types of instruments, including asset-backed securities, high-grade corporate debt securities, and money market funds; places restrictions on maturities and concentrations in certain industries; and requires the Company to maintain a certain level of liquidity. At times, the Company maintains cash balances in financial institutions that may exceed federally insured limits. The Company has not experienced any losses relating to such accounts and believes it is not exposed to a significant credit risk on its cash and cash equivalents.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently depends significantly on one supplier for co-formulation, filling, and finishing of COVID-19 Vaccine. The loss of this supplier could prevent or delay the Company&#8217;s delivery of customer orders.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is recorded at the lower of cost or net realizable value under the First In, First Out methodology, taking into consideration the expiration of the inventory item. The Company determines the cost of raw materials using moving average costs and the cost of semi-finished and finished goods using a standard cost method adjusted on a periodic basis to reflect the deviation in the actual cost from the standard cost estimate. Standard costs consist primarily of the cost of manufacturing goods, including direct materials, direct labor, and the services and products of third-party suppliers. Manufacturing overhead costs are applied to semi-finished and finished goods based on expected production levels. The Company utilizes third-party CMOs, CDMOs, and other suppliers and service organizations to support the procurement and processing of raw materials, management of inventory, packaging, and the delivery process. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess, obsolete, or expired inventory through cost of sales. At each reporting period, the Company assesses whether there are excess firm, non-cancelable, purchase commitment liabilities, resulting from supply agreements with third-party CMOs and CDMOs. The determination of net realizable value of inventory and firm purchase commitment liabilities requires judgment, including consideration of many factors, such as estimates of future product demand, current and future market conditions, potential product obsolescence, expiration and utilization of raw materials under firm purchase commitments, and contractual minimums.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to initial regulatory authorization for its product candidates, the Company expenses costs relating to raw materials, production, and manufacturing overhead costs as research and development expenses in the consolidated statements of operations, in the period incurred. Subsequent to initial regulatory authorization for a product candidate, the Company </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capitalizes the costs of production for a particular supply chain as inventory when the Company determines that it has a present right to the economic benefit associated with the product.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div>Property and equipment are stated at cost, net of accumulated depreciation. and are depreciated using the straight-line method over the estimated useful lives of the assets. Repairs and maintenance costs are expensed as incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases Accounting</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Accounting</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into manufacturing supply agreements with CMOs and CDMOs to manufacture its vaccine candidates. Certain of these manufacturing supply agreements include the use of identified manufacturing facilities and equipment that are controlled by the Company and for which the Company obtains substantially all the output and may qualify as an embedded lease. The Company treats manufacturing supply agreements that contain an embedded lease as lease arrangements in their entirety. The evaluation of leases that are embedded in the Company&#8217;s CMO and CDMO agreements is complex and requires judgment in determining whether the contract, either explicitly or implicitly, is for the use of an identified asset and the Company has the right to direct the use of, and obtain substantially all of the benefit from, the identified asset which generally is the use of a portion of the manufacturing facility of the CMO or CDMO, the term of the lease, and the fixed lease payments under the contract. Depending on the contract, the lease commencement date, defined as the date on which the lessor makes the underlying asset available for use by the lessee and on which the Company is required to accrue lease expenses, may be different than the inception date of the contract. The Company determines the non-cancellable lease term of its embedded leases based on the impact of certain expected milestones on its option to terminate the lease where it is reasonably certain to not exercise that option. The Company evaluates changes to the terms and conditions of a lease contract to determine if they result in a new lease or a modification of an existing lease. For lease modifications, the Company remeasures and reallocates the remaining consideration in the contract and reassesses the lease classification at the effective date of the modification. Leases are classified as either operating or finance leases based on the economic substance of the agreement. The Company also enters into non-cancelable lease agreements for facilities and certain equipment.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For leases that have a lease term of more than 12 months at the lease commencement date, the Company recognizes lease liabilities, which represent the Company&#8217;s obligation to make lease payments arising from the lease, and corresponding right-of-use (&#8220;ROU&#8221;) assets, which represent the right to use an underlying asset for the lease term, based on the present value of the fixed future payments over the lease term. The Company calculates the present value of future payments using the discount rate implicit in the lease, if available, or the Company&#8217;s incremental borrowing rate. For all leases that have a lease term of 12 months or less at the commencement date (referred to as &#8220;short-term&#8221; leases), the Company has elected to apply the practical expedient in ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 842&#8221;), to not recognize a lease liability or ROU asset but, instead, recognize lease payments as an expense on a straight-line basis over the lease term and variable lease payments that do not depend on an index or rate as an expense in the period in which the variable lease costs are incurred based on performance or usage in accordance with contractual agreements. In determining the lease period, the Company evaluates facts and circumstances that could affect the period over which it is reasonably certain to use the underlying asset while taking into consideration the non-cancelable period over which it has the right to use the underlying asset and any option period to extend or terminate the lease if it is reasonably certain to exercise the option. The Company re-evaluates short-term leases that are modified and if they no longer meet the requirements to be treated as a short-term lease, recognizes and measures the lease liability and ROU asset as if the date of the modification is the lease commencement date. For short-term leases that are modified and continue to meet the requirements to be treated as a short-term lease, the Company remeasures the fixed lease payments under the modified lease and recognize lease payments as an expense on a straight-line basis over the modified lease term.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For operating leases, the Company recognizes lease expense related to fixed payments on a straight-line basis from the lease commencement date through the end of the lease term and lease expense related to variable payments as incurred based on performance or usage in accordance with the contractual agreements. For finance leases, the Company recognizes the amortization of the ROU asset over the shorter of the lease term or useful life of the underlying asset. The Company expenses ROU assets acquired for research and development activities under ASC 730 if they do not have an alternative future use, in research and development projects or otherwise.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses significant assumptions and judgment in evaluating its lease contracts and other agreements under ASC 842, including the determination of whether an agreement is or contains a lease; whether a change in the terms and conditions of a lease contract represent a new or modified lease; whether a lease represents an operating or finance lease; the discount rate used to determine the present value of lease obligations; the term of a lease embedded in its manufacturing supply agreements; and the Company&#8217;s incremental borrowing rate, which is determined using estimates such as the estimated value of the underlying leased asset and financial profile of comparable companies.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, including property and equipment, internal-use software, and ROU assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable based on the criteria for accounting for the impairment or disposal of long-lived assets under ASC Topic 360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If such events or changes in circumstances occur, the Company assesses the recoverability of the long-lived assets (or asset group) by comparing their projected future undiscounted net cash flows over their remaining lives against their respective carrying amounts. If the cash flows are not expected to be sufficient to recover the carrying amount of the assets (or asset group), they are written down to their estimated fair values.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy', window );">Restructuring</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes restructuring charges when such costs are incurred. The Company&#8217;s restructuring charges consist of employee severance and other termination benefits related to the reduction of its workforce, the consolidation of facilities and infrastructure and other costs. Termination benefits are expensed on the date the Company notifies the employee, unless the employee must provide future service, in which case the benefits are expensed ratably over the future service period. Ongoing benefits are expensed when restructuring activities are probable and the benefit estimable. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 17 for additional information on the severance and employee benefit costs for terminated employees and impairment of long-lived assets in connection with the Company&#8217;s Restructuring Plan and Note 18 for information on the expected severance and employee benefit costs as a result of the Company&#8217;s workforce reduction announced on January 31, 2024.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Goodwill is subject to impairment tests annually or more frequently should indicators of impairment arise. The Company has determined that, because its only business is the development and commercialization of innovative vaccines, it operates as a single operating segment and has one reporting unit. The one-step impairment test, which requires a comparison of the fair value of a reporting unit to its carrying value, including goodwill, is required to be applied to all reporting units including reporting units with zero or negative carrying value. A reporting unit with a zero or negative carrying value likely will not have an impairment. If the carrying value of the reporting unit exceeds its fair value, step two of the impairment analysis is performed. In step two of the analysis, an impairment loss is recorded equal to the excess of the carrying value of the reporting unit&#8217;s goodwill over its implied fair value, should such a circumstance arise. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and 2022, the Company had a negative carrying value and did not have any impairment of goodwill.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes in accordance with ASC Topic 740,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the liability method, deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect of changes in tax rates on deferred tax assets and </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liabilities is recognized in income in the period such changes are enacted. A valuation allowance is established when necessary to reduce net deferred tax assets to the amount expected to be realized.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Global Intangible Low-Taxed Income (&#8220;GILTI&#8221;) provisions under the Tax Cuts and Jobs Act of 2017 impose U.S. tax on certain foreign income in excess of a deemed return on tangible assets of foreign corporations. The Company has elected to treat any potential GILTI inclusions as period costs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax benefits associated with uncertain tax positions are recognized in the period in which one of the following conditions is satisfied: (1) the more-likely-than-not recognition threshold is satisfied; (2) the position is ultimately settled through negotiation or litigation; or (3) the statute of limitations for the taxing authority to examine and challenge the position has expired. Tax benefits associated with an uncertain tax position are reversed in the period in which the more-likely-than-not recognition threshold is no longer satisfied.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically generated significant federal, state, and foreign tax net operating losses, which may be subject to limitation in future periods. Management has fully reserved the related deferred tax assets with a valuation allowance in the current reporting period as it is more likely than not that the related benefit will not be realized. The Company is currently subject to examination in all open tax years.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div>Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted net loss per share is computed using the treasury stock method by dividing net loss by the weighted-average number of common shares outstanding after giving consideration to the dilutive effect of certain securities outstanding during the period.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div>The accompanying consolidated financial statements are presented in U.S. dollars. The functional currency of the Company&#8217;s international subsidiaries is generally the local currency. The financial statements of international subsidiaries are translated to U.S. dollars using the exchange rate in effect at the consolidated balance sheet date for assets and liabilities, historical rates for equity accounts, and average exchange rates for the consolidated statement of operations. Cash flows from operations are translated at the average exchange rate in effect for the period, while cash flows from investing and financing activities are translated at the exchange rate in effect at the date of the underlying transaction. Translation gains and losses are recognized as a component of accumulated other comprehensive income (loss) in the accompanying consolidated balance sheets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages its business as one operating segment, the development and commercialization of innovative vaccines. The Company does not operate separate lines of business with respect to its vaccine or vaccine candidates. Accordingly, the Company does not have separately reportable segments as defined by ASC Topic 280, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Not Yet Adopted</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-06, Disclosure Improvements (&#8220;ASU 2023-06&#8221;), to clarify or improve disclosure and presentation requirements of a variety of topics and align the requirements in the FASB ASC with the SEC's regulations. The Company is currently evaluating ASU 2023-06 to determine its impact on the Company's consolidated financial statements and disclosures.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (&#8220;ASU 2023-09&#8221;). The standard enhances transparency in income tax disclosures by requiring, on an annual basis, certain disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation and income taxes paid. The ASU also requires disaggregated disclosure related to pre-tax income (or loss) and income tax expense (or benefit) and eliminates certain disclosures related to the balance of an entity&#8217;s unrecognized tax benefit and the cumulative amount of certain temporary differences. The ASU is effective for the Company beginning on January 1, 2025. The Company is currently evaluating ASU 2023-09 to determine its impact on the Company's disclosures.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline">Adopted</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;), with amendments in 2018, 2019, 2020, and 2022. The ASU sets forth a &#8220;current expected credit loss&#8221; model that requires companies to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. ASU 2016-13 applies to financial instruments that are not measured at fair value, including receivables that result from revenue transactions. The Company adopted ASU 2020-06 on January 1, 2023, using a modified retrospective approach, and it did not have a material impact on the Company&#8217;s consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_LiquidityAndGoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity and Going Concern</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_LiquidityAndGoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org//705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3,4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253755537920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedules of Concentration of Risk</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's accounts receivable arise from revenue arrangements with customers in different countries. The Company's revenue is primarily due to product sales, grants made by government-sponsored and private organizations, and royalties from its collaboration and license partners. The following customers accounted for more than 10% of total revenue or accounts receivable for the periods presented:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Revenue<br/>&#160;for Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Accounts Receivable as of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European Commission</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government of Australia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government of Canada</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government of Israel</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CEPI</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SK bioscience, Co., Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Amounts represent less than 10%</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Including the USG Agreement (as defined in Note 3) and the U.S. Department of Defense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text">The estimated useful lives of property and equipment are described below:<div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.316%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or remaining term of the lease</span></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is comprised of the following as of (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and buildings</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,916&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">380,739&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">341,539&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,968)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">305,771&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">294,247&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253656409520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_GrantsUSGovernmentContractAndJointVentureAbstract', window );"><strong>Grants, U.S. Government Contract and Joint Venture [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock', window );">Schedule of Accounts Receivable, Unbilled Services, and Deferred Revenue</a></td>
<td class="text">During the years ended December&#160;31, 2023 and 2022, changes in the Company's accounts receivables, deferred revenue, and allowance for doubtful accounts balances were as follows (in thousands):<div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance, Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deductions </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance, End of Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2023</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,472,768&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,264,062)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,768,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,127,240)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allowance for doubtful accounts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,835)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,676)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,835)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,835)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(267,599)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,092,829)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Bad debt expense was $13.8&#160;million in the year ended 2022. There was no bad debt expense in the year ended December 31, 2023 or 2021. There was a $6.2&#160;million reversal of a bad debt expense during the year ended December&#160;31, 2023 due to the collection of a previously recognized allowance for doubtful accounts. To estimate the allowance for doubtful accounts, the Company evaluates the credit risk related to its customers based on historical loss experience, economic conditions, the aging of receivables, and customer-specific risks.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Deductions from Deferred revenue generally related to the recognition of revenue once performance obligations on a contract with a customer are met. Amount is comprised of $241.3&#160;million, $0.4&#160;billion, and $1.4&#160;billion current Deferred </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue and $622.2&#160;million, $179.4&#160;million, and $172.5&#160;million non-current Deferred revenue as of December&#160;31, 2023, 2022, and 2021 respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;In 2023, deductions from Deferred revenue included $151.1&#160;million that was realized in Revenue and $112.5&#160;million related to the Amended and Restated UK Supply Agreement (as described below), that was reclassified to Other current liabilities, as described below. In 2022, deduction from Deferred revenue included $273.8&#160;million that was realized in Revenue and $819.0&#160;million, including $697.4&#160;million related to the Advance Payment Amount (as described below) related to the Gavi arbitration and $112.5&#160;million related to the Amended and Restated UK Supply Agreement, that was reclassified to Other current liabilities, as described below.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Product Revenue</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue by the Company&#8217;s customer&#8217;s geographic location was as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.615%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt 0 7pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">North America</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rest of the world</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531,389&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554,961&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of Grant Revenue</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized grant revenue as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt 0 7pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">USG Agreement</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788,953&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.S. DoD</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CEPI</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other grant revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,323&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,921&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">948,709&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock', window );">Schedule of Revenue Gross to Net Deductions Balances</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, changes in the Company&#8217;s gross-to-net deductions balances were as follows (in thousands):</span></div><div style="padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.497%"><tr><td style="width:1.0%"></td><td style="width:51.727%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.247%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.827%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Wholesale Distributor Fees, Discounts, and Chargebacks</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Returns</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts charged against product sales</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131,716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,956)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26,028)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,072&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,616&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,688&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_GrantsUSGovernmentContractAndJointVentureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_GrantsUSGovernmentContractAndJointVentureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Increase (Decrease) In Accounts Receivable, Unbilled Services, and Deferred Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Revenue Gross To Net Deductions Balances</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -SubTopic 10<br> -Topic 280<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253659957632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, and Restricted Cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the consolidated balance sheets that sum to the total of the same such amounts shown in the statement of cash flows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336,883&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,515,116&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash non-current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583,810&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348,845&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528,259&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>(1)&#160;&#160;&#160;&#160;Classified as Other non-current assets as of December&#160;31, 2023 and 2022<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253656442048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock', window );">Schedule of Fair Value Hierarchy</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the estimated fair value of the Company&#8217;s financial assets and liabilities (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value at December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-backed securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,824&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,622&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,834&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,536&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75% Convertible notes due 2023</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00% Convertible notes due 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total convertible notes payable</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,909&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494,900&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">All investments are classified as Cash and cash equivalents as of December&#160;31, 2023 and 2022, on the consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a nonrecurring basis in periods after initial recognition (for example, impaired assets). Disclosures may include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253656030048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,912&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Semi-finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,696&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,683&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ScheduleOfInventoryReserveTableTextBlock', window );">Schedule of Inventory Reserve</a></td>
<td class="text">Activity in the reserve for excess and obsolete inventory was as follows (in thousands): <div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.306%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.908%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368,383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to Cost of sales, including impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other additions </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deductions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239,814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79,214)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31,</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,059&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368,383&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ScheduleOfInventoryReserveTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Inventory Reserve</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ScheduleOfInventoryReserveTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253659849424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text">The change in the carrying amounts of goodwill was as follows (in thousands):<div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,479&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127,454&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126,331&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253660079568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock', window );">Schedule of Supplemental Balance Sheet Information Related to Leases</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases as of December&#160;31, 2023 and 2022 was as follows (in thousands, except weighted-average remaining lease term and discount rate):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease Assets and Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets, operating, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-749"><span style="-sec-ix-hidden:f-750">Right of use asset, net</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,985</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,384</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets, finance, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-753"><span style="-sec-ix-hidden:f-754">Right of use asset, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,233</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,857</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current ROU assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,218</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,241</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-759"><span style="-sec-ix-hidden:f-760">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,977</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,867</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,142</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,196</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,119</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,063</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-767"><span style="-sec-ix-hidden:f-768">Other non-current liabilities</span></span> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,577</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,085</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion of finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,923</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,238</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,500</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,323</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Operating Lease Expenses</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense for the operating and short-term leases for the years ended December&#160;31, 2023, 2022, and 2021 was as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,027&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease expense (benefit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,009)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease expense:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets expensed</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total finance lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,481&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,231&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119,769&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;During the year ended December&#160;31, 2023, the Company recognized a short-term lease benefit of $48.0&#160;million due to gains on the settlement of manufacturing supply agreements with CMOs and CDMOs that included embedded leases.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock', window );">Schedule of Supplemental Cash Flow Information of Leases</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases for the year ended December&#160;31, 2023, 2022, and 2021 was as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows used in operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows used in finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows used in finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for operating lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Lease Liabilities</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, maturities of lease liabilities were as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,832&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,619&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of balance sheet information related to lease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental cash flow information of lease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253661435952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Convertible Notes Payable</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s long-term debt consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75% Convertible notes due 2023</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current convertible notes payable</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,881&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00% Convertible notes due 2027</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,784)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current convertible notes payable</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,016&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,466&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock', window );">Schedule of Interest Expense</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense incurred in connection with the convertible notes payable consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coupon interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,542&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense on convertible notes payable</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,468&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,039&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,612&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest expense related to convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253656551920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the consolidated statements of operations as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,357&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,300&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,626&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Option and Appreciation Rights Activity</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock options and SARs activity under the 2023 Inducement Plan, 2015 Plan and the 2005 Plan for the year ended December&#160;31, 2023:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.212%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.460%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.460%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.460%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.460%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.460%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023 Inducement Plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2015 Plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2005 Plan</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options &amp; SARs</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock<br/>Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,053,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.07&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,021,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,483)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(278,361)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,787,042&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,275&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares exercisable at December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,436,339&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.51&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,275&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.79&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used in Estimation of Fair Value of Stock</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted under the 2023 Inducement Plan and the 2015 Plan was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:53.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average Black-Scholes fair value of stock<br/>options and SARs granted</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$55.32</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$158.02</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5%-4.8%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4%-4.3%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5%-1.3%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.4%-140.3%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.5%-140.1%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.7%-142.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9-6.4</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0-6.3</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1-6.1</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock', window );">Schedule of Restricted Stock Units Activity</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of RSU activity for the year ended December&#160;31, 2023:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.533%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023 Inducement Plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2015 Plan</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per Share<br/>Weighted-<br/>Average<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per Share<br/>Weighted-<br/>Average<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034,574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,314,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(696,553)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(937,603)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,990&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.66&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,714,870&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.43&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Share Based Compensation, Restricted Stock Awards, Activity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253659039024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following as of (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">160,773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">155,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">226,023&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">237,147&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text">The estimated useful lives of property and equipment are described below:<div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.316%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 - 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or remaining term of the lease</span></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is comprised of the following as of (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and buildings</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,916&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">380,739&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">341,539&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,968)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">305,771&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">294,247&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following as of (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee benefits and compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,952&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52,569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross-to-net deductions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. product sales returns accrual </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">468,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">394,668&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">591,158&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Other Current Liabilities</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consist of the following as of (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refunds due to APA customers </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,362&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liability related to Gavi (see Note 3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">861,408&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">930,055&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253659049760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Schedule of Company's Income (Loss) from Operations Before Income Tax Provision (Benefit) by Jurisdiction</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s loss before income tax expense by jurisdiction is as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(628,984)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(712,183)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,633,016)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(81,520)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(543,031)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(653,647)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,714,536)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the current and deferred income tax expense (benefit) are as follows (in thousands):</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current income tax expense (benefit)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,292&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,215&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred: </span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total income tax expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,031&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,292&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,215&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Tax Rate Differences</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense to the amount computed by applying the U.S. federal statutory tax rate to the Company&#8217;s effective tax rate is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Statutory federal tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development and other tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-deductible expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxation of foreign operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancellation of Indebtedness</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-US tax credits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets (Liabilities)</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company&#8217;s deferred tax assets and liabilities as of December 31 were as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">550,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">479,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign net operating loss carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">266,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowance for sales returns</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign tax credit carryforward</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,186,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,056,799&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,128,941)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,020,123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57,852&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(41,456)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23,330)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,587)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,279)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,055)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(704)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(59,895)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(36,676)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,043)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Roll Forward</a></td>
<td class="text">A reconciliation of the beginning and ending amounts of unrecognized tax benefits in the year ended December&#160;31, 2023, 2022, and 2021 is as follows (in thousands):<div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized tax benefits balance at January 1</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,766&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions for tax positions of current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reductions for tax positions of prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,027)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Settlements of tax positions of prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized tax benefits balance at December 31,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,237&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,154&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253659978640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Restructuring and Related Costs</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the restructuring charge recorded by the Company comprised (in thousands): </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:80.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.982%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severance and employee benefit costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,503&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Restructuring charge </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,584&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Restructuring charges of $0.5&#160;million, $2.3&#160;million and $11.5&#160;million are included in Cost of sales, Research and development and Selling, general, and administrative expenses, respectively, in the Consolidated Statements of Operations for the period ended December&#160;31, 2023. These charges reflect substantially all expected restructuring charges under the Restructuring Plan.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253654341968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>segment </div>
<div>reporting_unit </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>reporting_unit </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 568,505,000<span></span>
</td>
<td class="nump">$ 1,336,883,000<span></span>
</td>
<td class="nump">$ 1,515,116,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(545,062,000)<span></span>
</td>
<td class="num">(657,939,000)<span></span>
</td>
<td class="num">(1,743,751,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (713,967,000)<span></span>
</td>
<td class="num">(415,937,000)<span></span>
</td>
<td class="nump">322,946,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent', window );">Restructuring and related cost, annual impact percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and employee benefit costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,503,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,081,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,500,000<span></span>
</td>
<td class="nump">$ 84,000,000<span></span>
</td>
<td class="nump">8,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | reporting_unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="num">(6,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax', window );">Foreign currency transaction (losses) gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,900,000<span></span>
</td>
<td class="num">$ (2,500,000)<span></span>
</td>
<td class="num">$ (5,300,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_CanadaAdvancePurchaseAgreementMember', window );">Canada Advance Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_InstallmentChargesOfTheCompany', window );">Installment charges</a></td>
<td class="nump">$ 174,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member', window );">5.00% Convertible notes due 2027 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares issued for debt converted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Requisite service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and employee benefit costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Requisite service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and employee benefit costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_InstallmentChargesOfTheCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Installment Charges Of The Company</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_InstallmentChargesOfTheCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the total number of positions eliminated as of the balance sheet date since inception of the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reclassification from other comprehensive income (loss) to earnings, after tax, related to translation from the functional currency to reporting currency, as a result of the sale or complete or substantially complete liquidation of an investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_CanadaAdvancePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_CanadaAdvancePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253652993440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue Benchmark | European Commission</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue Benchmark | Government of Australia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue Benchmark | Government of Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue Benchmark | U.S. government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">43.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue Benchmark | CEPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue Benchmark | SK bioscience, Co., Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts Receivable | European Commission</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts Receivable | Government of Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">59.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts Receivable | Government of Israel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts Receivable | U.S. government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481027/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nvax_EuropeanCommissionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nvax_EuropeanCommissionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nvax_GovernmentOfAustraliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nvax_GovernmentOfAustraliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nvax_GovernmentOfCanadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nvax_GovernmentOfCanadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nvax_USGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nvax_USGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nvax_CoalitionForEpidemicPreparednessInnovationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nvax_CoalitionForEpidemicPreparednessInnovationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nvax_SKBioscienceCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nvax_SKBioscienceCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=nvax_GovernmentOfIsraelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=nvax_GovernmentOfIsraelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253655587504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">25 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253644599664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 16, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>dose</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>dose</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>dose</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>dose</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>dose</div>
</th>
<th class="th">
<div>Nov. 18, 2022 </div>
<div>dose</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($) </div>
<div>dose</div>
</th>
<th class="th">
<div>Oct. 22, 2020 </div>
<div>dose</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BilledContractReceivables', window );">Billed contracts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 286,400,000<span></span>
</td>
<td class="nump">$ 53,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnbilledContractsReceivable', window );">Unbilled contracts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,800,000<span></span>
</td>
<td class="nump">28,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">863,521,000<span></span>
</td>
<td class="nump">549,551,000<span></span>
</td>
<td class="nump">$ 1,595,472,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfVaccineDoses', window );">Purchase agreement, number of vaccine doses | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,310,000<span></span>
</td>
<td class="nump">370,137,000<span></span>
</td>
<td class="nump">1,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">622,210,000<span></span>
</td>
<td class="nump">179,414,000<span></span>
</td>
<td class="nump">172,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Refunds due to APA customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,165,000<span></span>
</td>
<td class="nump">210,362,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">983,705,000<span></span>
</td>
<td class="nump">1,981,872,000<span></span>
</td>
<td class="nump">1,146,290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nvax_SalesBasedRoyaltiesMember', window );">Sales-Based Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,500,000<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
<td class="nump">178,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nvax_MilestonePaymentsMember', window );">Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,688,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (decrease) in contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,028,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AmountsChargedAgainstProductSales', window );">Contract value no longer available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,716,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 531,389,000<span></span>
</td>
<td class="nump">1,554,961,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=nvax_AmendedAndRestatedUKSupplyAgreementMember', window );">Amended and Restated UK Supply Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfDosesToBeDistributed', window );">Number of doses to be distributed | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=nvax_AmendedAndRestatedUKSupplyAgreementMember', window );">Amended and Restated UK Supply Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfDosesToBeDistributed', window );">Number of doses to be distributed | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementSIIPLMember', window );">Gavi Advance Purchase Agreement SIIPL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfDosesToBeDistributed', window );">Number of doses to be distributed | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Remaining performance obligation, variable consideration amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember', window );">Gavi Advance Purchase Agreement- COVAX Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfDosesToBeDistributed', window );">Number of doses to be distributed | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CollaborationAgreementUpfrontPaymentAmount', window );">Collaboration agreement upfront payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 696,400,000<span></span>
</td>
<td class="nump">697,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfVaccineDoses', window );">Purchase agreement, number of vaccine doses | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_EuropeanCommissionsECMember', window );">European Commissions ("EC")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfDosesToBeDistributed', window );">Number of doses to be distributed | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption', window );">Additional purchase option, number of doses | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfDosesCancelled', window );">Number of doses, cancelled | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfVaccineDoses', window );">Purchase agreement, number of vaccine doses | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfDosesOfVaccineCandidate', window );">Number of doses | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_EuropeanCommissionsECMember', window );">European Commissions ("EC") | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfDosesToBeDistributed', window );">Number of doses to be distributed | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_EuropeanCommissionsECMember', window );">European Commissions ("EC") | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfDosesToBeDistributed', window );">Number of doses to be distributed | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_CanadaAdvancePurchaseAgreementMember', window );">Canada Advance Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CollaborationAgreementUpfrontPaymentAmount', window );">Collaboration agreement upfront payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">349,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_InstallmentChargesOfTheCompany', window );">Installment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 485,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ContractWithCustomerObligationToDeliverTerms', window );">Contract with customer, obligation to deliver, terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_PercentOfRemainingAmountToBePaid', window );">Percent of remaining amount to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_EscrowDepositsRelatedToSalesHold', window );">Escrow to sales hold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_CanadaAdvancePurchaseAgreementMember', window );">Canada Advance Purchase Agreement | Canada Revenue Agency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Refunds due to APA customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember', window );">Joint Committee on Vaccination and Immunization (JCVI)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfDosesToBeDistributed', window );">Number of doses to be distributed | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CollaborationAgreementUpfrontPaymentAmount', window );">Collaboration agreement upfront payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_USGovernmentPartnershipMember', window );">US Government Partnership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Milestone payment recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_USGovernmentAgreementMember', window );">USG Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfDosesOfVaccineCandidate', window );">Number of doses | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember', window );">Coalition for Epidemic Preparedness Innovations ("CEPI")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding', window );">Contract to perform for others funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 399,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant', window );">Contract to perform for others grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans', window );">Contract to perform for others forgivable no interest term loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_CEPIGrantFundingMember', window );">CEPI Grant Funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_RevenueFromContractWithCustomerCommitment', window );">Revenue from contract with customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">358,600,000<span></span>
</td>
<td class="nump">358,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_MatrixMAdjuvantSalesMember', window );">Matrix-M Adjuvant Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,500,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SettlementAgreementMember', window );">Settlement Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SettlementAgreementMember', window );">Settlement Agreement | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Settlement expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SettlementAgreementMember', window );">Settlement Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Initial settlement payment</a></td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Settlement expense</a></td>
<td class="nump">80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants additional credit</a></td>
<td class="nump">$ 225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_AustralianAPAMember', window );">Australian APA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (decrease) in contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AmountsChargedAgainstProductSales', window );">Contract value no longer available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation to be satisfied</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_AmountsChargedAgainstProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts Charged Against Product Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_AmountsChargedAgainstProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_CollaborationAgreementUpfrontPaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Upfront Payment Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_CollaborationAgreementUpfrontPaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ContractWithCustomerObligationToDeliverTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Obligation To Deliver, Terms</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ContractWithCustomerObligationToDeliverTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_EscrowDepositsRelatedToSalesHold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Escrow Deposits Related To Sales Hold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_EscrowDepositsRelatedToSalesHold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_InstallmentChargesOfTheCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Installment Charges Of The Company</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_InstallmentChargesOfTheCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_NumberOfDosesOfVaccineCandidate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Doses Of Vaccine Candidate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_NumberOfDosesOfVaccineCandidate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Doses Of Vaccine Candidate, Additional Purchase Option</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_NumberOfDosesToBeDistributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Doses, To Be Distributed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_NumberOfDosesToBeDistributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_PercentOfRemainingAmountToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percent Of Remaining Amount To Be Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_PercentOfRemainingAmountToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_PurchaseAgreementNumberOfDosesCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Number of Doses, Cancelled</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_PurchaseAgreementNumberOfDosesCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_PurchaseAgreementNumberOfVaccineDoses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Number Of Vaccine Doses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_PurchaseAgreementNumberOfVaccineDoses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement Contract To Perform For Others Forgivable No Interest Term Loans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement Contract To Perform For Others Funding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement Contract To Perform For Others Grant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_RevenueFromContractWithCustomerCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer Commitment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_RevenueFromContractWithCustomerCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Variable Consideration Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BilledContractReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BilledContractReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledContractsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledContractsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nvax_SalesBasedRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nvax_SalesBasedRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nvax_MilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nvax_MilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=nvax_AmendedAndRestatedUKSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=nvax_AmendedAndRestatedUKSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementSIIPLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementSIIPLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_EuropeanCommissionsECMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_EuropeanCommissionsECMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_CanadaAdvancePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_CanadaAdvancePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CanadaRevenueAgencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CanadaRevenueAgencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_USGovernmentPartnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_USGovernmentPartnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_USGovernmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_USGovernmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_CEPIGrantFundingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_CEPIGrantFundingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_MatrixMAdjuvantSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_MatrixMAdjuvantSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_SettlementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_SettlementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_AustralianAPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_AustralianAPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253650380608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Schedule of Accounts Receivable, Unbilled Services, and Deferred Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward', window );"><strong>Accounts receivable:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Accounts receivable, beginning balance</a></td>
<td class="nump">$ 96,210<span></span>
</td>
<td class="nump">$ 454,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions', window );">Additions</a></td>
<td class="nump">1,472,768<span></span>
</td>
<td class="nump">1,768,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions', window );">Deductions</a></td>
<td class="num">(1,264,062)<span></span>
</td>
<td class="num">(2,127,240)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Accounts receivable, ending balance</a></td>
<td class="nump">304,916<span></span>
</td>
<td class="nump">96,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Allowance for doubtful accounts:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts, beginning balance</a></td>
<td class="num">(13,835)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AccountsReceivableAllowanceForCreditLossAdditions', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,835)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AccountsReceivableAllowanceForCreditLossDeductions', window );">Deductions</a></td>
<td class="nump">6,159<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts, end balance</a></td>
<td class="num">(7,676)<span></span>
</td>
<td class="num">(13,835)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_DeferredRevenueIncreaseDecreaseAbstract', window );"><strong>Deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, beginning balance</a></td>
<td class="nump">549,551<span></span>
</td>
<td class="nump">1,595,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ContractWithCustomerLiabilityAdditions', window );">Additions</a></td>
<td class="nump">581,569<span></span>
</td>
<td class="nump">46,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ContractWithCustomerLiabilityDeductions', window );">Deductions</a></td>
<td class="num">(267,599)<span></span>
</td>
<td class="num">(1,092,829)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, ending balance</a></td>
<td class="nump">863,521<span></span>
</td>
<td class="nump">549,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AccountsReceivableAllowanceForCreditLossAdditions', window );">Bad debt expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AccountsReceivableAllowanceForCreditLossDeductions', window );">Deductions</a></td>
<td class="nump">6,159<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">241,310<span></span>
</td>
<td class="nump">370,137<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="nump">622,210<span></span>
</td>
<td class="nump">179,414<span></span>
</td>
<td class="nump">172,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">863,521<span></span>
</td>
<td class="nump">549,551<span></span>
</td>
<td class="nump">$ 1,595,472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=nvax_RevenueMember', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_DeferredRevenueIncreaseDecreaseAbstract', window );"><strong>Deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, beginning balance</a></td>
<td class="nump">273,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, ending balance</a></td>
<td class="nump">151,100<span></span>
</td>
<td class="nump">273,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">151,100<span></span>
</td>
<td class="nump">273,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember', window );">Gavi Advance Purchase Agreement- COVAX Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CollaborationAgreementUpfrontPaymentAmount', window );">Collaboration agreement upfront payment amount</a></td>
<td class="nump">696,400<span></span>
</td>
<td class="nump">697,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_AmendedAndRestatedUKSupplyAgreementMember', window );">Amended and Restated UK Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CollaborationAgreementUpfrontPaymentAmount', window );">Collaboration agreement upfront payment amount</a></td>
<td class="nump">$ 112,500<span></span>
</td>
<td class="nump">$ 819,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_AccountsReceivableAllowanceForCreditLossAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance for Credit Loss, Additions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_AccountsReceivableAllowanceForCreditLossAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_AccountsReceivableAllowanceForCreditLossDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance for Credit Loss, Deductions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_AccountsReceivableAllowanceForCreditLossDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Before Allowance For Credit Loss, Additions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Before Allowance For Credit Loss, Deductions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Before Allowance For Credit Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_CollaborationAgreementUpfrontPaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Upfront Payment Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_CollaborationAgreementUpfrontPaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ContractWithCustomerLiabilityAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Additions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ContractWithCustomerLiabilityAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ContractWithCustomerLiabilityDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Deductions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ContractWithCustomerLiabilityDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_DeferredRevenueIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Revenue Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_DeferredRevenueIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=nvax_RevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=nvax_RevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_AmendedAndRestatedUKSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_AmendedAndRestatedUKSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253656335920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Schedule of Product Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 983,705<span></span>
</td>
<td class="nump">$ 1,981,872<span></span>
</td>
<td class="nump">$ 1,146,290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">531,389<span></span>
</td>
<td class="nump">1,554,961<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product | North America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">29,959<span></span>
</td>
<td class="nump">194,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">268,361<span></span>
</td>
<td class="nump">823,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product | Rest of the world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 233,069<span></span>
</td>
<td class="nump">$ 536,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_NorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=nvax_RestOfTheWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=nvax_RestOfTheWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253656560208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Schedule of Revenue Gross to Net Deductions Balances (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ContractWithCustomerLiabilityRollForward', window );"><strong>Contract with Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, beginning balance</a></td>
<td class="nump">$ 549,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, ending balance</a></td>
<td class="nump">863,521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ContractWithCustomerLiabilityRollForward', window );"><strong>Contract with Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, beginning balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AmountsChargedAgainstProductSales', window );">Amounts charged against product sales</a></td>
<td class="nump">131,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Payments</a></td>
<td class="num">(26,028)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, ending balance</a></td>
<td class="nump">105,688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales | Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ContractWithCustomerLiabilityRollForward', window );"><strong>Contract with Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, ending balance</a></td>
<td class="nump">103,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ContractWithCustomerLiabilityRollForward', window );"><strong>Contract with Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, ending balance</a></td>
<td class="nump">2,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales | Wholesale Distributor Fees, Discounts, and Chargebacks</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ContractWithCustomerLiabilityRollForward', window );"><strong>Contract with Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, beginning balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AmountsChargedAgainstProductSales', window );">Amounts charged against product sales</a></td>
<td class="nump">47,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Payments</a></td>
<td class="num">(25,956)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, ending balance</a></td>
<td class="nump">21,072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales | Product Returns</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ContractWithCustomerLiabilityRollForward', window );"><strong>Contract with Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, beginning balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AmountsChargedAgainstProductSales', window );">Amounts charged against product sales</a></td>
<td class="nump">84,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Payments</a></td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, ending balance</a></td>
<td class="nump">$ 84,616<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_AmountsChargedAgainstProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts Charged Against Product Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_AmountsChargedAgainstProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerBasisOfPricingAxis=nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerBasisOfPricingAxis=nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerBasisOfPricingAxis=nvax_ProductReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerBasisOfPricingAxis=nvax_ProductReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253653203392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Schedule of Grant Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 983,705<span></span>
</td>
<td class="nump">$ 1,981,872<span></span>
</td>
<td class="nump">$ 1,146,290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">427,323<span></span>
</td>
<td class="nump">382,921<span></span>
</td>
<td class="nump">948,709<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grants | USG Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">427,323<span></span>
</td>
<td class="nump">380,996<span></span>
</td>
<td class="nump">788,953<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grants | U.S. DoD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,925<span></span>
</td>
<td class="nump">21,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grants | CEPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">135,445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grants | Other grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,628<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_USGovernmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_USGovernmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_USDepartmentOfDefenseDoDContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_USDepartmentOfDefenseDoDContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_OtherGrantRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_OtherGrantRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253655659232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Supply Agreements (Details)<br> $ / shares in Units, $ in Thousands, shares in Millions, dose in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>installment </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>dose</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_RoyaltyPeriod', window );">Royalty period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 983,705<span></span>
</td>
<td class="nump">$ 1,981,872<span></span>
</td>
<td class="nump">$ 1,146,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 863,521<span></span>
</td>
<td class="nump">$ 549,551<span></span>
</td>
<td class="nump">1,595,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sales of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 360,243<span></span>
</td>
<td class="nump">$ 249,230<span></span>
</td>
<td class="nump">$ 564,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_TakedaArrangementMember', window );">Takeda Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfDosesToBeDistributed', window );">Number of doses to be distributed | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Milestone payment recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SettlementAgreementMember', window );">Settlement Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SettlementPayment', window );">Settlement payment</a></td>
<td class="nump">$ 149,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SettlementAgreementInitialReservationFee', window );">Initial reservation fee</a></td>
<td class="nump">130,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfQuarterlyInstallmentPayments', window );">Number of quarterly installment payments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SettlementAgreementQuarterlyInstallmentAmount', window );">Settlement agreement, quarterly installment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SettlementAgreementMember', window );">Settlement Agreement | Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SettlementPayment', window );">Settlement payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SecuritiesSubscriptionArrangementMember', window );">Securities Subscription Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SettlementAgreementBenefit', window );">Settlement agreement, benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SecuritiesSubscriptionArrangementMember', window );">Securities Subscription Arrangement | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SettlementAgreementBenefit', window );">Settlement agreement, benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SecuritiesSubscriptionArrangementMember', window );">Securities Subscription Arrangement | Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SettlementAgreementBenefit', window );">Settlement agreement, benefit</a></td>
<td class="nump">$ 21,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SecuritiesSubscriptionArrangementMember', window );">Securities Subscription Arrangement | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares sell and issue | shares</a></td>
<td class="nump">6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock (in usd per share) | $ / shares</a></td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sales of common stock</a></td>
<td class="nump">$ 84,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CommonStockQuotedMarketPrice', window );">Common stock, quoted market price</a></td>
<td class="nump">46,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CommonStockPremiumPaid', window );">Common stock, premium paid</a></td>
<td class="nump">$ 38,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_CommonStockPremiumPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Premium Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_CommonStockPremiumPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_CommonStockQuotedMarketPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock, Quoted Market Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_CommonStockQuotedMarketPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_NumberOfDosesToBeDistributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Doses, To Be Distributed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_NumberOfDosesToBeDistributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_NumberOfQuarterlyInstallmentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Quarterly Installment Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_NumberOfQuarterlyInstallmentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_RoyaltyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_RoyaltyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_SettlementAgreementBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement Agreement, Benefit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_SettlementAgreementBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_SettlementAgreementInitialReservationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement Agreement, Initial Reservation Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_SettlementAgreementInitialReservationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_SettlementAgreementQuarterlyInstallmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement Agreement, Quarterly Installment Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_SettlementAgreementQuarterlyInstallmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_SettlementPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_SettlementPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_TakedaArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_TakedaArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_SettlementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_SettlementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_SecuritiesSubscriptionArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_SecuritiesSubscriptionArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253644363776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents, and Restricted Cash - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 568,505<span></span>
</td>
<td class="nump">$ 1,336,883<span></span>
</td>
<td class="nump">$ 1,515,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash current</a></td>
<td class="nump">10,424<span></span>
</td>
<td class="nump">10,303<span></span>
</td>
<td class="nump">11,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash non-current</a></td>
<td class="nump">4,881<span></span>
</td>
<td class="nump">1,659<span></span>
</td>
<td class="nump">1,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash</a></td>
<td class="nump">$ 583,810<span></span>
</td>
<td class="nump">$ 1,348,845<span></span>
</td>
<td class="nump">$ 1,528,259<span></span>
</td>
<td class="nump">$ 648,738<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253654140976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member', window );">3.75% Convertible notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Coupon interest rate</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member', window );">5.00% Convertible notes due 2027 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Coupon interest rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">$ 171,824<span></span>
</td>
<td class="nump">$ 398,834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total convertible notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | 3.75% Convertible notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total convertible notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | 5.00% Convertible notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total convertible notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">171,824<span></span>
</td>
<td class="nump">398,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Government-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">245,622<span></span>
</td>
<td class="nump">400,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total convertible notes payable</a></td>
<td class="nump">100,909<span></span>
</td>
<td class="nump">494,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | 3.75% Convertible notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total convertible notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">322,111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | 5.00% Convertible notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total convertible notes payable</a></td>
<td class="nump">100,909<span></span>
</td>
<td class="nump">172,789<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Government-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">296,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">45,622<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">104,536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total convertible notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | 3.75% Convertible notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total convertible notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | 5.00% Convertible notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total convertible notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Government-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253656661456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Schedule of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 6,614<span></span>
</td>
<td class="nump">$ 13,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Semi-finished goods</a></td>
<td class="nump">7,392<span></span>
</td>
<td class="nump">21,410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">27,690<span></span>
</td>
<td class="nump">1,361<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 41,696<span></span>
</td>
<td class="nump">$ 36,683<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253661625408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="nump">$ 72,400,000<span></span>
</td>
<td class="nump">$ 447,600,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFirmPurchaseCommitmentLoss', window );">Firm purchase commitment loss</a></td>
<td class="num">(73,500,000)<span></span>
</td>
<td class="nump">$ 155,900,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_InventoryFirmPurchaseCommitmentRecoveries', window );">Inventory, firm purchase commitment, recoveries</a></td>
<td class="nump">40,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_LeaseImpairmentChargeAxis=nvax_CMOAgreementMember', window );">CMO Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Operating lease, impairment loss</a></td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_InventoryFirmPurchaseCommitmentRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory, Firm Purchase Commitment, Recoveries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_InventoryFirmPurchaseCommitmentRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFirmPurchaseCommitmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss recognized on firm purchase commitment for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -SubTopic 10<br> -Topic 330<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFirmPurchaseCommitmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_LeaseImpairmentChargeAxis=nvax_CMOAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_LeaseImpairmentChargeAxis=nvax_CMOAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253661676864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory - Schedule of Inventory Reserves (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_InventoryReserveRollForward', window );"><strong>Inventory Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Balance at January 1,</a></td>
<td class="nump">$ 368,383<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_InventoryReserveChargedToCostsOfSales', window );">Charged to Cost of sales, including impairments</a></td>
<td class="nump">72,441<span></span>
</td>
<td class="nump">447,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_InventoryReserveOtherAdditions', window );">Other additions</a></td>
<td class="nump">65,049<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_InventoryReserveDeductions', window );">Deductions</a></td>
<td class="num">(239,814)<span></span>
</td>
<td class="num">(79,214)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Balance at December 31,</a></td>
<td class="nump">$ 266,059<span></span>
</td>
<td class="nump">$ 368,383<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_InventoryReserveChargedToCostsOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory Reserve, Charged to Costs of sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_InventoryReserveChargedToCostsOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_InventoryReserveDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory Reserve, Deductions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_InventoryReserveDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_InventoryReserveOtherAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory Reserve, Other Additions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_InventoryReserveOtherAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_InventoryReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory Reserve</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_InventoryReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253656447984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>reporting_unit</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>reporting_unit</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | reporting_unit</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">$ 126,331<span></span>
</td>
<td class="nump">$ 131,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Currency translation adjustments</a></td>
<td class="nump">1,123<span></span>
</td>
<td class="num">(5,148)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">$ 127,454<span></span>
</td>
<td class="nump">$ 126,331<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253657627408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease obligation</a></td>
<td class="nump">$ 112,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset, net</a></td>
<td class="nump">24,985<span></span>
</td>
<td class="nump">$ 36,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_LeaseImpairmentChargeAxis=nvax_ROUFacilityLeasesMember', window );">ROU Facility Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Operating lease, impairment loss</a></td>
<td class="nump">5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_LeaseImpairmentChargeAxis=nvax_CMOAgreementMember', window );">CMO Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Operating lease, impairment loss</a></td>
<td class="nump">6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nvax_CMOAndCMDAgreementsMember', window );">CMO and CMD Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability', window );">Lease liability and right of use assets recognized</a></td>
<td class="nump">6,800<span></span>
</td>
<td class="nump">18,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nvax_A700QuinceOrchardRoadAgreementMember', window );">700 Quince Orchard Road Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_FacilityNumberOfSquareFeet', window );">Facility, number of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease obligation</a></td>
<td class="nump">96,500<span></span>
</td>
<td class="nump">73,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset, net</a></td>
<td class="nump">96,500<span></span>
</td>
<td class="nump">$ 73,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Increase (decrease) in operating lease liability</a></td>
<td class="num">$ (73,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nvax_FacilityLeaseAgreementMember', window );">Facility Lease Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease expiration</a></td>
<td class="text">1 year 8 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nvax_FacilityLeaseAgreementMember', window );">Facility Lease Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease expiration</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_FacilityNumberOfSquareFeet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Facility Number Of Square Feet</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_FacilityNumberOfSquareFeet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-of-Use Asset Obtained in Exchange for Finance and Operating Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_LeaseImpairmentChargeAxis=nvax_ROUFacilityLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_LeaseImpairmentChargeAxis=nvax_ROUFacilityLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_LeaseImpairmentChargeAxis=nvax_CMOAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_LeaseImpairmentChargeAxis=nvax_CMOAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nvax_CMOAndCMDAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nvax_CMOAndCMDAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nvax_A700QuinceOrchardRoadAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nvax_A700QuinceOrchardRoadAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nvax_FacilityLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nvax_FacilityLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253653079056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU assets, operating, net</a></td>
<td class="nump">$ 24,985<span></span>
</td>
<td class="nump">$ 36,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Total non-current ROU assets<span></span>
</td>
<td class="text">Total non-current ROU assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">ROU assets, finance, net</a></td>
<td class="nump">$ 160,233<span></span>
</td>
<td class="nump">$ 69,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Total non-current ROU assets<span></span>
</td>
<td class="text">Total non-current ROU assets<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_LeaseRightOfUseAsset', window );">Total non-current ROU assets</a></td>
<td class="nump">$ 185,218<span></span>
</td>
<td class="nump">$ 106,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">$ 22,977<span></span>
</td>
<td class="nump">$ 16,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease liabilities</a></td>
<td class="nump">$ 5,142<span></span>
</td>
<td class="nump">$ 27,196<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_LeaseLiabilityCurrent', window );">Total current lease liabilities</a></td>
<td class="nump">28,119<span></span>
</td>
<td class="nump">44,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion of operating lease liabilities</a></td>
<td class="nump">$ 28,577<span></span>
</td>
<td class="nump">$ 50,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other non-current liabilities<span></span>
</td>
<td class="text">Other non-current liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Non-current portion of finance lease liabilities</a></td>
<td class="nump">$ 55,923<span></span>
</td>
<td class="nump">$ 31,238<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_LeaseLiabilityNoncurrent', window );">Total non-current lease liabilities</a></td>
<td class="nump">$ 84,500<span></span>
</td>
<td class="nump">$ 81,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_WeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted-average remaining lease term (years):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases</a></td>
<td class="text">11 years 7 months 6 days<span></span>
</td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_WeightedAverageDiscountRateAbstract', window );"><strong>Weighted-average discount rate:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases</a></td>
<td class="nump">8.90%<span></span>
</td>
<td class="nump">5.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_LeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_LeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_LeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_LeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_LeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_LeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_WeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_WeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_WeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Lease Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_WeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253655587376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Operating Lease Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 6,929<span></span>
</td>
<td class="nump">$ 6,903<span></span>
</td>
<td class="nump">$ 37,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ShortTermLeaseCostBenefit', window );">Short-term lease expense (benefit(1))</a></td>
<td class="num">(48,009)<span></span>
</td>
<td class="nump">94,726<span></span>
</td>
<td class="nump">468,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="nump">10,292<span></span>
</td>
<td class="nump">6,836<span></span>
</td>
<td class="nump">116,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Finance lease expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">ROU assets expensed</a></td>
<td class="nump">12,876<span></span>
</td>
<td class="nump">7,759<span></span>
</td>
<td class="nump">112,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest expense</a></td>
<td class="nump">2,605<span></span>
</td>
<td class="nump">1,472<span></span>
</td>
<td class="nump">7,241<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total finance lease expense</a></td>
<td class="nump">$ 15,481<span></span>
</td>
<td class="nump">$ 9,231<span></span>
</td>
<td class="nump">$ 119,769<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ShortTermLeaseCostBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-Term Lease, Cost (Benefit)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ShortTermLeaseCostBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253655748880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Supplemental Cash Flow Information of Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows used in operating leases</a></td>
<td class="nump">$ 101,297<span></span>
</td>
<td class="nump">$ 190,158<span></span>
</td>
<td class="nump">$ 203,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows used in finance leases</a></td>
<td class="nump">2,605<span></span>
</td>
<td class="nump">1,472<span></span>
</td>
<td class="nump">7,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows used in finance leases</a></td>
<td class="nump">27,345<span></span>
</td>
<td class="nump">93,595<span></span>
</td>
<td class="nump">127,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">ROU assets obtained in exchange for operating lease obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,675<span></span>
</td>
<td class="nump">66,682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">ROU assets obtained in exchange for finance lease obligations</a></td>
<td class="nump">$ 103,299<span></span>
</td>
<td class="nump">$ 73,240<span></span>
</td>
<td class="nump">$ 112,528<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flow Operating and Financing Activities Lessee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253656025168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 34,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">17,192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">13,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">14,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">14,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">67,296<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">160,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">48,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total current lease liabilities</a></td>
<td class="nump">$ 112,619<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253656557264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Schedule of Notes Payable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ConvertibleNotesPayableCurrentAbstract', window );"><strong>Current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (119)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Total current convertible notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">324,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ConvertibleNotesPayableNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="num">(7,234)<span></span>
</td>
<td class="num">(8,784)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Total non-current convertible notes payable</a></td>
<td class="nump">$ 168,016<span></span>
</td>
<td class="nump">$ 166,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member', window );">3.75% Convertible notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ConvertibleNotesPayableNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Coupon interest rate</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member', window );">3.75% Convertible notes due 2023 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ConvertibleNotesPayableCurrentAbstract', window );"><strong>Current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_DebtInstrumentFaceAmountCurrent', window );">3.75% Convertible notes due 2023</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ConvertibleNotesPayableNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member', window );">5.00% Convertible notes due 2027 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ConvertibleNotesPayableNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="nump">$ 175,250<span></span>
</td>
<td class="nump">$ 175,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Coupon interest rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ConvertibleNotesPayableCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Notes Payable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ConvertibleNotesPayableCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ConvertibleNotesPayableNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Notes Payable, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ConvertibleNotesPayableNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_DebtInstrumentFaceAmountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Face Amount, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_DebtInstrumentFaceAmountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253656112704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Schedule of Interest Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Coupon interest</a></td>
<td class="nump">$ 9,779<span></span>
</td>
<td class="nump">$ 12,542<span></span>
</td>
<td class="nump">$ 12,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">1,689<span></span>
</td>
<td class="nump">1,497<span></span>
</td>
<td class="nump">1,424<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense on convertible notes payable</a></td>
<td class="nump">$ 11,468<span></span>
</td>
<td class="nump">$ 14,039<span></span>
</td>
<td class="nump">$ 13,612<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253653810128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>day</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 25, 2016 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member', window );">2023 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Coupon interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member', window );">2023 Notes | Call Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ConversionPremiumPercentage', window );">Conversion premium percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_PaymentForCappedCallTransactions', window );">Payment for capped call transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_DebtCapPrice', window );">Debt cap price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194.60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 2027 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,250,000<span></span>
</td>
<td class="nump">$ 175,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt', window );">Net proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Coupon interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ConvertibleDebtConversionRate', window );">Convertible debt conversion rate | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ConversionPremiumPercentage', window );">Conversion premium percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage', window );">Repurchase percentage of principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, interest rate, effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares issued for debt converted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 2027 Notes | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Percentage of principal amount redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 2027 Notes | Debt Instrument, Redemption, Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage of stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 2027 Notes, Make-Whole Fundamental Change | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ConvertibleDebtConversionRate', window );">Convertible debt conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 2023 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt', window );">Net proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 315,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ConvertibleDebtConversionRate', window );">Convertible debt conversion rate | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0073411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ConversionPremiumPercentage', window );">Conversion premium percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 325,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares issued for debt converted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,385,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 2023 Notes | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ConvertibleDebtConversionRate', window );">Convertible debt conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0089928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ConversionPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents the rate of premium based on the last reported sales price of stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ConversionPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ConvertibleDebtConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible debt conversion rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ConvertibleDebtConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_DebtCapPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cap rate on a debt . A payment or receipt is triggered if the market rate exceeds the cap rate on the debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_DebtCapPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Of Principal Amount, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_PaymentForCappedCallTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment which is made for entering into privately negotiated capped call transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_PaymentForCappedCallTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -SubTopic 470<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the charge against earnings during the period for commitment fees and debt issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_CallOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_CallOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253655632016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Deficit (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sales of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 360,243,000<span></span>
</td>
<td class="nump">$ 249,230,000<span></span>
</td>
<td class="nump">$ 564,859,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">367,105,000<span></span>
</td>
<td class="nump">$ 249,230,000<span></span>
</td>
<td class="nump">$ 564,859,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nvax_June2021AndAugust2023SalesAgreementMember', window );">June 2021 and August 2023 Sales Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nvax_June2021AndAugust2023SalesAgreementMember', window );">June 2021 and August 2023 Sales Agreement | Common Stock | Prepaid Expenses and Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nvax_August2023SalesAgreementMember', window );">August 2023 Sales Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized amount</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SaleOfStockAmountOfRemainingUnissuedShares', window );">Remaining unissued capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 242,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nvax_June2021SalesAgreementMember', window );">June 2021 Sales Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,900,000<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 179,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Securities Subscription Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares sell and issue</a></td>
<td class="nump">6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock (in usd per share)</a></td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sales of common stock</a></td>
<td class="nump">$ 84,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Stock Issued</a></td>
<td class="nump">$ 46,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nvax_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nvax_UnderwriterMember', window );">Underwriter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">975,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_SaleOfStockAmountOfRemainingUnissuedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Amount Of Remaining Unissued Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_SaleOfStockAmountOfRemainingUnissuedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nvax_June2021AndAugust2023SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nvax_June2021AndAugust2023SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nvax_August2023SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nvax_August2023SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nvax_June2021SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nvax_June2021SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_SecuritiesSubscriptionArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_SecuritiesSubscriptionArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nvax_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nvax_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nvax_UnderwriterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nvax_UnderwriterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253652883552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock-based compensation capitalized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense, recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock options and stock appreciation rights exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="nump">$ 21.0<span></span>
</td>
<td class="nump">$ 454.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of stock options and stock appreciation rights outstanding (less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual term of stock options and stock appreciation rights outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of stock options and stock appreciation rights exercisable (less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual term of stock options and stock appreciation rights exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Proposal to increase authorized shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease', window );">Percentage increase of shares each anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_MaximumContributionOfEmployeesAsPayrollDeductions', window );">Maximum contribution of employees as payroll deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_PercentageOfMarketPriceForStockPurchase', window );">Percentage of market price for stock purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nvax_TwoThousandTwentyThreeStockInducementPlanMember', window );">2023 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance', window );">Number of shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember', window );">2015 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Proposal to increase authorized shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based payment award, terms of award</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent', window );">Minimum grant price, percent of common stock fair value</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember', window );">2015 Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember', window );">2015 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_MaximumContributionOfEmployeesAsPayrollDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum contribution of employees as payroll deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_MaximumContributionOfEmployeesAsPayrollDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_PercentageOfMarketPriceForStockPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of market price for stock purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_PercentageOfMarketPriceForStockPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Number of Shares Available For Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum grant-date exercise price of incentive stock options granted as a percent of the common stock share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Annual Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nvax_TwoThousandTwentyThreeStockInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nvax_TwoThousandTwentyThreeStockInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253650470992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 85,357<span></span>
</td>
<td class="nump">$ 130,300<span></span>
</td>
<td class="nump">$ 183,626<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">3,417<span></span>
</td>
<td class="nump">1,032<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">41,211<span></span>
</td>
<td class="nump">66,565<span></span>
</td>
<td class="nump">86,928<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Selling, general, and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 40,729<span></span>
</td>
<td class="nump">$ 62,703<span></span>
</td>
<td class="nump">$ 96,698<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253656632624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Option and Appreciation Rights Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nvax_TwoThousandTwentyThreeStockInducementPlanMember', window );">2023 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options &amp; SARs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">422,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding (in shares) | shares</a></td>
<td class="nump">422,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares exercisable at end of year (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of year (in usd per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">10.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of year (in usd per share) | $ / shares</a></td>
<td class="nump">10.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Shares exercisable at end of year (in usd per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember', window );">2015 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options &amp; SARs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding (in shares) | shares</a></td>
<td class="nump">4,053,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,021,596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(9,483)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares) | shares</a></td>
<td class="num">(278,361)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding (in shares) | shares</a></td>
<td class="nump">4,787,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares exercisable at end of year (in shares) | shares</a></td>
<td class="nump">3,436,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of year (in usd per share) | $ / shares</a></td>
<td class="nump">$ 46.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">7.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">6.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in usd per share) | $ / shares</a></td>
<td class="nump">41.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of year (in usd per share) | $ / shares</a></td>
<td class="nump">38.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Shares exercisable at end of year (in usd per share) | $ / shares</a></td>
<td class="nump">$ 41.51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nvax_TwoThousandFiveStockIncentivePlanMember', window );">2005 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options &amp; SARs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding (in shares) | shares</a></td>
<td class="nump">63,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares) | shares</a></td>
<td class="num">(5,450)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding (in shares) | shares</a></td>
<td class="nump">58,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares exercisable at end of year (in shares) | shares</a></td>
<td class="nump">58,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of year (in usd per share) | $ / shares</a></td>
<td class="nump">$ 112.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in usd per share) | $ / shares</a></td>
<td class="nump">39.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of year (in usd per share) | $ / shares</a></td>
<td class="nump">119.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Shares exercisable at end of year (in usd per share) | $ / shares</a></td>
<td class="nump">$ 119.79<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nvax_TwoThousandTwentyThreeStockInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nvax_TwoThousandTwentyThreeStockInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nvax_TwoThousandFiveStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nvax_TwoThousandFiveStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253656239760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Assumptions Used in Estimation of Fair Value of Stock (Details) - Options - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Black-Scholes fair value (in usd per share)</a></td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="nump">$ 55.32<span></span>
</td>
<td class="nump">$ 158.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="nump">120.40%<span></span>
</td>
<td class="nump">120.50%<span></span>
</td>
<td class="nump">124.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="nump">140.30%<span></span>
</td>
<td class="nump">140.10%<span></span>
</td>
<td class="nump">142.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253655669856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">2023 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and unvested beginning of year (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted (in shares) | shares</a></td>
<td class="nump">363,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock units vested (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock units forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and unvested at end of year (in shares) | shares</a></td>
<td class="nump">363,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Per Share Weighted-Average Grant-Date Fair Value (in usd per share)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding and unvested at beginning of year (in shares) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock units granted (in usd per share) | $ / shares</a></td>
<td class="nump">10.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock units vested (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Restricted stock units forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding and unvested at end of year (in shares) | $ / shares</a></td>
<td class="nump">$ 10.66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">2015 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and unvested beginning of year (in shares) | shares</a></td>
<td class="nump">2,034,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted (in shares) | shares</a></td>
<td class="nump">3,314,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock units vested (in shares) | shares</a></td>
<td class="num">(696,553)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock units forfeited (in shares) | shares</a></td>
<td class="num">(937,603)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and unvested at end of year (in shares) | shares</a></td>
<td class="nump">3,714,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Per Share Weighted-Average Grant-Date Fair Value (in usd per share)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding and unvested at beginning of year (in shares) | $ / shares</a></td>
<td class="nump">$ 61.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock units granted (in usd per share) | $ / shares</a></td>
<td class="nump">7.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock units vested (in usd per share) | $ / shares</a></td>
<td class="nump">73.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Restricted stock units forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">27.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding and unvested at end of year (in shares) | $ / shares</a></td>
<td class="nump">$ 19.43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nvax_TwoThousandTwentyThreeStockInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nvax_TwoThousandTwentyThreeStockInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nvax_TwoThousandFifteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253657605728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum contribution, percentage of compensation</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Defined contribution plan, employer matching contribution, percent of match</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan, cost</a></td>
<td class="nump">$ 7.0<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan | Pension Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan, cost</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollectiveBargainingArrangementAxis=nvax_FirstThreePercentOfParticipantsDeferralMemberMember', window );">First Three Percent Of Participants Deferral</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined contribution plan, employer matching contribution, percent of employees' gross pay</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Defined contribution plan, employer matching contribution, percent of match</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollectiveBargainingArrangementAxis=nvax_NextTwoPercentOfParticipantsDeferralMemberMember', window );">Next Two Percent Of Participants Deferral</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined contribution plan, employer matching contribution, percent of employees' gross pay</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Defined contribution plan, employer matching contribution, percent of match</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollectiveBargainingArrangementAxis=nvax_FirstThreePercentOfParticipantsDeferralMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollectiveBargainingArrangementAxis=nvax_FirstThreePercentOfParticipantsDeferralMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollectiveBargainingArrangementAxis=nvax_NextTwoPercentOfParticipantsDeferralMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollectiveBargainingArrangementAxis=nvax_NextTwoPercentOfParticipantsDeferralMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253659652944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Supplies', window );">Prepaid expenses</a></td>
<td class="nump">$ 70,297<span></span>
</td>
<td class="nump">$ 160,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">155,726<span></span>
</td>
<td class="nump">76,374<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 226,023<span></span>
</td>
<td class="nump">$ 237,147<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Supplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Supplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253656667872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 380,739<span></span>
</td>
<td class="nump">$ 341,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(74,968)<span></span>
</td>
<td class="num">(47,292)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">305,771<span></span>
</td>
<td class="nump">294,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember', window );">Land and buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">102,916<span></span>
</td>
<td class="nump">101,342<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">148,243<span></span>
</td>
<td class="nump">134,809<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">48,310<span></span>
</td>
<td class="nump">18,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nvax_ComputerSoftwareAndHardwareMemberMember', window );">Computer hardware</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">5,114<span></span>
</td>
<td class="nump">4,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 76,156<span></span>
</td>
<td class="nump">$ 81,566<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nvax_ComputerSoftwareAndHardwareMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nvax_ComputerSoftwareAndHardwareMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253660887520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 305,771<span></span>
</td>
<td class="nump">$ 294,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expense</a></td>
<td class="nump">41,000<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CZ', window );">Czech Republic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 155,000<span></span>
</td>
<td class="nump">$ 170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CZ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CZ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253644584896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee benefits and compensation</a></td>
<td class="nump">$ 55,952<span></span>
</td>
<td class="nump">$ 52,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_AccruedGrossToNetDeductionsCurrent', window );">Gross-to-net deductions</a></td>
<td class="nump">20,616<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_U.S.ProductSalesReturnsAccrual', window );">U.S. product sales returns accrual</a></td>
<td class="nump">82,506<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_ResearchAndDevelopmentAccrualsCurrent', window );">Research and development accruals</a></td>
<td class="nump">131,027<span></span>
</td>
<td class="nump">468,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">104,567<span></span>
</td>
<td class="nump">70,375<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 394,668<span></span>
</td>
<td class="nump">$ 591,158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_AccruedGrossToNetDeductionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Gross-To-Net Deductions, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_AccruedGrossToNetDeductionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ResearchAndDevelopmentAccrualsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_ResearchAndDevelopmentAccrualsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_U.S.ProductSalesReturnsAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>U.S. Product Sales Returns Accrual</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_U.S.ProductSalesReturnsAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253656394688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Schedule of Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Refunds due to APA customers</a></td>
<td class="nump">$ 142,165<span></span>
</td>
<td class="nump">$ 210,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements', window );">Other current liability related to Gavi (see Note 3)</a></td>
<td class="nump">696,390<span></span>
</td>
<td class="nump">697,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">22,853<span></span>
</td>
<td class="nump">22,309<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total other current liabilities</a></td>
<td class="nump">$ 861,408<span></span>
</td>
<td class="nump">$ 930,055<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Current Liability Related To Advance Purchase Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481573/470-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253656435472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Company's Income (Loss) from Operations Before Income Tax Provision (Benefit) by Jurisdiction (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (628,984)<span></span>
</td>
<td class="num">$ (712,183)<span></span>
</td>
<td class="num">$ (1,633,016)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">85,953<span></span>
</td>
<td class="nump">58,536<span></span>
</td>
<td class="num">(81,520)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">$ (543,031)<span></span>
</td>
<td class="num">$ (653,647)<span></span>
</td>
<td class="num">$ (1,714,536)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253656307360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Domestic</a></td>
<td class="num">$ (1,300)<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State and local</a></td>
<td class="num">(157)<span></span>
</td>
<td class="nump">503<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">1,445<span></span>
</td>
<td class="nump">2,489<span></span>
</td>
<td class="nump">29,215<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax expense (benefit)</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">4,292<span></span>
</td>
<td class="nump">29,215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">2,043<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 2,031<span></span>
</td>
<td class="nump">$ 4,292<span></span>
</td>
<td class="nump">$ 29,215<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253655600944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance, deferred tax asset, amount increase</a></td>
<td class="nump">$ 108,800<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liability</a></td>
<td class="nump">2,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">4,200<span></span>
</td>
<td class="nump">$ 5,194<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">51,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward | Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">18,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember', window );">Capital Loss Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">11,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">877,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | Subject to Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">457,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | No Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 420,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=nvax_SubjectToExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=nvax_SubjectToExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=nvax_NoExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=nvax_NoExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253655675760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Tax Rate Differences (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory federal tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development and other tax credits</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible expenses</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent', window );">Non-cash stock-based compensation</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations', window );">U.S. taxation of foreign operations</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent', window );">Cancellation of Indebtedness</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Non-US tax credits</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Change in tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(20.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(20.00%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="num">(30.00%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax expense</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Cancellation Of Indebtedness, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Non-Cash Share-Based Payment Arrangement, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, US Taxation Of Foreign Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253653143504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Federal and state net operating loss carryforward</a></td>
<td class="nump">$ 550,272<span></span>
</td>
<td class="nump">$ 479,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Foreign net operating loss carryforward</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research tax credits</a></td>
<td class="nump">51,878<span></span>
</td>
<td class="nump">45,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_DeferredTaxAssetLeasingLiability', window );">Lease liability</a></td>
<td class="nump">25,207<span></span>
</td>
<td class="nump">27,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">266,392<span></span>
</td>
<td class="nump">195,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory reserve</a></td>
<td class="nump">79,386<span></span>
</td>
<td class="nump">213,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Allowance for sales returns</a></td>
<td class="nump">20,756<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Non-cash stock-based compensation</a></td>
<td class="nump">30,727<span></span>
</td>
<td class="nump">27,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research costs</a></td>
<td class="nump">132,500<span></span>
</td>
<td class="nump">49,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign', window );">Foreign tax credit carryforward</a></td>
<td class="nump">18,679<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">10,996<span></span>
</td>
<td class="nump">13,695<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">1,186,793<span></span>
</td>
<td class="nump">1,056,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(1,128,941)<span></span>
</td>
<td class="num">(1,020,123)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">57,852<span></span>
</td>
<td class="nump">36,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">ROU assets</a></td>
<td class="num">(41,456)<span></span>
</td>
<td class="num">(23,330)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(17,160)<span></span>
</td>
<td class="num">(11,587)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangibles</a></td>
<td class="num">(1,279)<span></span>
</td>
<td class="num">(1,055)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(704)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(59,895)<span></span>
</td>
<td class="num">(36,676)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax assets (liabilities)</a></td>
<td class="nump">$ 2,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets (liabilities)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_DeferredTaxAssetLeasingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset, Leasing Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_DeferredTaxAssetLeasingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253656025424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits Rollforward (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits balance at January 1</a></td>
<td class="nump">$ 5,194<span></span>
</td>
<td class="nump">$ 11,154<span></span>
</td>
<td class="nump">$ 8,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions for tax positions of current year</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">1,260<span></span>
</td>
<td class="nump">4,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions of prior years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">807<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior year</a></td>
<td class="num">(1,228)<span></span>
</td>
<td class="num">(8,027)<span></span>
</td>
<td class="num">(1,770)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements of tax positions of prior years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits balance at December 31,</a></td>
<td class="nump">$ 4,237<span></span>
</td>
<td class="nump">$ 5,194<span></span>
</td>
<td class="nump">$ 11,154<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253654196272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies (Details)<br> dose in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 16, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 12, 2022 </div>
<div>defendant</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 18, 2022 </div>
<div>dose</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>payment </div>
<div>installment</div>
</th>
<th class="th">
<div>Oct. 22, 2020 </div>
<div>dose</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfDefendants', window );">Number of defendants | defendant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_LossContingencyPeriodToAnswer', window );">Period to answer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfVaccineDoses', window );">Purchase agreement, number of vaccine doses | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember', window );">Gavi Advance Purchase Agreement- COVAX Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfDosesToBeDistributed', window );">Number of doses to be distributed | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_PurchaseAgreementNumberOfVaccineDoses', window );">Purchase agreement, number of vaccine doses | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_CollaborationAgreementRemainingPaymentAmount', window );">Remaining payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 696,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SettlementAgreementMember', window );">Settlement Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SettlementPayment', window );">Settlement payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfQuarterlyInstallmentPayments', window );">Number of quarterly installment payments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_NumberOfSettlementPayments', window );">Number of settlement payments | payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SettlementAgreementQuarterlyInstallmentAmount', window );">Settlement agreement, quarterly installment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SettlementAgreementMember', window );">Settlement Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Initial settlement payment</a></td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Settlement expense</a></td>
<td class="nump">80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants additional credit</a></td>
<td class="nump">$ 225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SettlementAgreementMember', window );">Settlement Agreement | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Settlement expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nvax_SettlementAgreementMember', window );">Settlement Agreement | Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_SettlementPayment', window );">Settlement payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_CollaborationAgreementRemainingPaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Remaining Payment Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_CollaborationAgreementRemainingPaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_LossContingencyPeriodToAnswer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Period To Answer</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_LossContingencyPeriodToAnswer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_NumberOfDosesToBeDistributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Doses, To Be Distributed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_NumberOfDosesToBeDistributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_NumberOfQuarterlyInstallmentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Quarterly Installment Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_NumberOfQuarterlyInstallmentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_NumberOfSettlementPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Settlement Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_NumberOfSettlementPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_PurchaseAgreementNumberOfVaccineDoses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Number Of Vaccine Doses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_PurchaseAgreementNumberOfVaccineDoses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_SettlementAgreementQuarterlyInstallmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement Agreement, Quarterly Installment Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_SettlementAgreementQuarterlyInstallmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_SettlementPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_SettlementPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfDefendants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of defendants named in a legal action.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfDefendants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nvax_SettlementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nvax_SettlementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253653130192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Schedule of Impairment Charges (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and employee benefit costs</a></td>
<td class="nump">$ 4,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of assets</a></td>
<td class="nump">10,081<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total Restructuring charge</a></td>
<td class="nump">14,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total Restructuring charge</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total Restructuring charge</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general, and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total Restructuring charge</a></td>
<td class="nump">$ 11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253644537680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and employee benefit costs</a></td>
<td class="nump">$ 4,503,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of assets</a></td>
<td class="nump">10,081,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_LeaseImpairmentChargeAxis=nvax_ROUFacilityLeasesMember', window );">ROU Facility Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Operating lease, impairment loss</a></td>
<td class="nump">5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and employee benefit costs</a></td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_LeaseImpairmentChargeAxis=nvax_ROUFacilityLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_LeaseImpairmentChargeAxis=nvax_ROUFacilityLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140253659623376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event<br></strong></div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvax_RestructuringAndRelatedCostNumberOfPositionsEliminatedGlobalPercent', window );">Global workforce percent</a></td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Restructuring and related cost percent</a></td>
<td class="nump">9.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_RestructuringAndRelatedCostNumberOfPositionsEliminatedGlobalPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Number of Positions Eliminated, Global Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvax_RestructuringAndRelatedCostNumberOfPositionsEliminatedGlobalPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvax_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>121
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( -<[7%@'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #7.UQ8^*YS6>\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9)1
M2\,P$,>_BN2]O395D=#E9<,G!<&!XEM(;EM8DX;DI-VW-ZU;A^@'\#%W__SN
M=W"M#D+W$5]B'S"2Q70SNLXGH<.*'8B" $CZ@$ZE,B=\;N[ZZ!3E9]Q#4/JH
M]@B\JN[!(2FC2,$$+,)"9+(U6NB(BOIXQAN]X,-G[&:8T8 =.O24H"YK8'*:
M&$YCU\(5,,$(HTO?!30+<:[^B9T[P,[),=DE-0Q#.31S+N]0P_OST^N\;F%]
M(N4UYE_)"CH%7+'+Y+=FO=D^,LDK?EM4O. /VYJ+IA+\[F-R_>%W%7:]L3O[
MCXTO@K*%7W<AOP!02P,$%     @ USM<6)E<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MR''])NBF+.0"IB+1L_($S16L8H@+-.894^(5?D=FGG;UR:T1H#6H-4!':E6
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M6ZYTN=MAJ?LK"!.@]W><J_W$'-!W[/0O4$L#!!0    ( -<[7%BQ,7UW/08
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M^>?,AW.*Q6<2VXEET,4R>#4?5D26R[+X%S*TD&62-U$$?H%D69*E\!D$GI6
M.*0K5H@".,)K7)1JLB?K;H_C$CXA O5199"6F/-B7J18%39MJC6;"K92P]I+
MLE<1\2&B%^D3*^R"$9X,AJRCLDH26748 Y+^0?)V(;S$37W.?LIBI"XDG:'P
M8#.1%>T=B/$AJ.=;CK?G2X/JNT%?;ZW?6>N?M/;JF=&9ZK_%U"%(9TJ#ZKMA
MJ#<5=::BDZ9VJ\*Q:RW27&NN'P7NGA$-+@B< URLP=FA[]C._B<RMYJ2"MBB
M;NZX_ @K(IJJWLUV_>-UW3;MS=_(OK)I _^7:9K2.\P6ZL26,)>2UF4HM\6:
M1J\9"+JL6Y\9%;*1JE]SV1L#4P#Y_YQ2\3)0"W3=]N@_4$L#!!0    ( -<[
M7%CS:]VE"@<   $>   8    >&PO=V]R:W-H965T<R]S:&5E=#4N>&ULK5EA
M<YLX$/TK&E^GT\XX,9) 0)IX)G5RU\[TDDR3WGTF6(Z98N0BX33WZV\%CK&1
MD.UI/[0!LUJ]75;[GL3YLRB_RSGG"OU<Y(6\&,R56IZ-1C*=\T4B3\62%_!D
M)LI%HN"V?!K)9<F3:3UHD8^(Y['1(LF*P?B\_NVN')^+2N59P>]*)*O%(BE?
M/O)</%\,\.#UAZ_9TUSI'T;C\V7RQ.^Y^K:\*^%NM/$RS1:\D)DH4,EG%X-+
M?#:A3 ^H+?[)^+/<ND8ZE$<AONN;S].+@:<1\9RG2KM(X,^*3WB>:T^ X\?:
MZ6 SIQZX??WJ_<\Z> CF,9%\(O)_LZF:7PRB 9KR65+EZJMX_L37 07:7RIR
M6?^/GM>VW@"EE51BL1X,"!99T?Q-?JX3L34 ^ST#R'H .70 70^@=: -LCJL
MJT0EX_-2/*-26X,W?5'GIAX-T62%?HWWJH2G&8Q3X\GMS?WME\]7EP_75^CC
MY9?+F\DUNO]T??UPCT[0M_LK].[->_0&905ZF(M*)L54GH\4S*S'C]+U+!^;
M64C/+%<\/444#Q'Q"+4,GQP^G.P.'T&\FZ#))FA2^Z-]05=ER0N%$BFYDF>V
M>!H'OMV!7EMG<IFD_&( BT?R<L4'X[=_8.9]L$7WFYSMQ$HWL5*7]_$DD7,$
M;PVE^H+_J+)5DD/PUK?8N IJ5[H!K,8!BP(O.!^MMN,QS3"E+(KHQFX'JK^!
MZCNA?N52E5FJ> /6!K!QP+9G]GSB=_#9K*C7@R[8H N<Z"[35%20-VA>*8<D
M/N;<AC PYB9Q2'RO ]$TBP@- SM$MH'(G! _%RMXLZ)\L0%CQHP^9C'KX#*M
M*&-]+S;<X J=N.Y*ODRR*>(_@7TDEW4]"C7G);2X[:5HPQV:"26L;B,[P"UF
M-,1^:$<>;9!'3N0/0B7Y 2 CL^*P3Z,HZJ"TV(4>I3&VPXPW,.,]"09>+]5+
MG5B]QI? M&J("JYL:&/S)7M!&.(.6-.,Q+#8>E**O99R//<ZU]2*Q Q5DC<Y
M[46Z]K23L"@@N)M7FYW'B-^35[Q%C]B)]2\AIL]9GEO!87-2$OI!MQU9[1BE
M?>!:&L-.YAC?UDNH$,7)_@I=N]IYZ0$.XBY6TXQ$/HM[H+8LA-TTU"PD!SQJ
M61EQZ,?=QFDQ)"2(6-@'L64?[!^D"O(L><SR3&7<+@VPD\6.U0:_R]MNT"VI
MX0-9;9F\]%$:-LD*4\*P\6HLW(=9@/L:1DMKV,UK +*L>,L?5I 6YHI]X*XN
M2-,NB#$.HAZ0+<=A-\E=\1F' IJ"/@ 6KNR9M+"4CZF92=..AAZF?9ELZ0R[
M^>RUQI>BK'=1T(1G69$4*4<YA]W0=O%; S )+, ^Z<(WK4B(M[3&+OJ6Y;";
MYB8"! X ASJ%KJ>XNVI-^C+2;"%"XD=13V,F+<,1-\/=[FB;/3DE)G=%#/M>
MMW(M=C'UO*!'-)*6XXB;XW9%SCZT%C)CP"34@&L:$C^(8]_OP;NU>W/3WB$K
MC9@\Q@@AQDJSV 'O^+@/9$MX9,^^ZYA:)1;V8Y&'N^K<:L>@R_6@;;F/N+=>
M-UL:XJB&0,R]5A#$ACJWF%%,:$_3)2U]$3=]F0IH'UZ3HT"(4:,L3+,@8''?
M4FN9C+B9K%EJ^S":%$6@R_I;1+I&:3&,8A(&/3Q!6C(C;C*;B,4B4WH3T6S6
M4E&HK'CB10J8T;L;*&B$V7LK>J=GNZ!!UE.37W>T&WW+DL3-DK!?77<8J43Z
M?8C>>*<>A@5<HE625WR(R-#S//T/R7E2ZAUMI>:BS/Z#,8E"5SSEBT=>-D+M
M]>"KSJ0^POH %?LZ,)-22YMZ1UPIJ> "$GV $VON3>(U*MMELINOEI=)[%3.
M]SI+<Y%/>2G?_A$1''[01ZE9FBG[X9J3YH\^7?M-WG:/UUJNIVZNUTL%E%1?
MI;"F3GZA5O05R(%AX+&A%U-+X6 :P]-@&(:;.0ZOI8@-(_ <!+[%,SSTP#DT
M]&,<6VN36K;HOGFT:!-#/31!6X5#W0KG<CK-M-Z%WJL/HDZR J7),H->;$5J
M*A<?Q["5Z6[L+88TI+!M[=F+TE;B4+?$@1U/M:CR1)^%KE>2%:FI7D[\B'AQ
MT#W+L5H"4T11']:M ^8]6_L2A$)5OKPN 5S7.]V4S!#80RK]L263>VHQ9&S(
M*#YFH+W63)UT$A/"N@1JM?-8T)>35D]1MY[:?G_K@TZQ@/8SUQ_ 5AQE!=QS
M]"X74EI9E)J"B82DN]&R6)TP&O;0/VUE%77+JD:FR/ZV;H5L:J:3$#/0(UW4
M%D-&?2_L6^>MO*)'RJNZJHZ-@YF?-ZQ'419#^U'4:.O[G/XX^G=2/F6%!(4]
M@Y'>:0@NRN9[8W.CQ++^9/<HE!*+^G+.$\"O#>#Y3(  6]_HKX";K[[C_P%0
M2P,$%     @ USM<6!MANJ 5 P  L0D  !@   !X;"]W;W)K<VAE971S+W-H
M965T-BYX;6RMEFUOFS 0Q[^*Q::ID[K@0(#0)4AITJJ5NC9JNNW%M!<.7()5
MP,PV2;M//QM2E@?:)-/R(MCF[OS_G<_8O27CCR(&D.@I33+1-V(I\S/3%&$,
M*1$MED.FWLP83XE473XW1<Z!1*53FI@6QJZ9$IH90:\<&_.@QPJ9T S&'(DB
M30E_/H>$+?M&VW@9N*?S6.H!,^CE9 X3D%_S,5<]LXX2T10R05F&.,SZQJ!]
M-O2U?6GPC<)2K+61)IDR]J@[UU'?P%H0)!!*'8&HQP*&D"0ZD)+Q:Q73J*?4
MCNOME^B7);MBF1(!0Y9\IY&,^T;70!',2)'(>[:\@A6/H^.%+!'E/UI6MJYK
MH+ 0DJ4K9Z4@I5GU)$^K/*PYM#NO.%@K!^M0!WOE8)>@E;(2:T0D"7J<+1'7
MUBJ:;I2Y*;T5#<WT*DXD5V^I\I/!\.YV<G=S/1H\7(S0^>!F<#N\0).KBXN'
M"3H9$PZ9C$'2D"0?T2?T'IE(Q&I4]$RI9M<QS' UTWDUD_7*3",(6\ANGR(+
M6W:#^_!P=VO3W53,-;A5@UME//N5>!-))*ARE(C-T"7-2!92DJ Q$[2LKQ^#
MJ9!<5=G/)M0J=J<YMMYY9R(G(?0-M;4$\ 48P8=W;1=_;@+_3\$VTF#7:;#?
MBAZ,U:X!SB%"JM3"QU.4$XZ8VN8Z/1%:D*0 E .OEAV=T P5(OH[\K$I.]64
M7CFE_HPL MS"[9ZY6*?>8[1!TZEI.L?15,6*2"%CQNEO]4(35*.-TJOX[IHJ
M]3W4ORWU^^TV )P:P'D38,C25!7?VEK\VPHXAZS 'J,- +<&<(\ .#K][DY:
M78P;%^ 0RPT"KR;PCB>@0A3[U7L[FMH=[& 7^_:6^EW+KMO%KN-TFL5W:_'=
MX\6KPUMMYRRBV7P?07>7P/8=['C>=OYW+;LNMGW?LIL)_)K ?Y/@0=U%1,&?
MMQCVZ/9W=:M"L*WMO._:>:[KVMM%;ZX=J/HR\X7P.<T$2F"F'''+4UN'5Q>$
MJB-97IZQ4R;5B5TV8W6G JX-U/L98_*EHX_M^I86_ %02P,$%     @ USM<
M6!HN:2(4"0  )$@  !@   !X;"]W;W)K<VAE971S+W-H965T-RYX;6R]G&US
MV[@1Q[\*1KUIXYE31  D0::V9Q**9#R7L]/8::?3Z0M:@BTV%.DC*?MRG_Y
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M"+E.4/MSQN0FT ?4WS3O+U!+ P04    " #7.UQ8@7%<NE,)   K*P  &
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;*U::V_;.!;]*T1VL.@ =2T^].HF
M 5*KQ128-D'=V?G,R'0L5)8\$ITT\^OW4G(LF[QBDEE_22S[\$KG\CX.29T_
MU,V/=J64)C_79=5>G*VTWKR?3MM\I=:R?5=O5 6_+.MF+35<-G?3=M,HN>@&
MK<LI"X)HNI9%=79YWGUWTUR>UUM=%I6Z:4B[7:]E\_A!E?7#Q1D]>_KB6W&W
MTN:+Z>7Y1MZIN=)_;&X:N)KNK2R*M:K:HJY(HY879U?T?2:8&= A_ENHA_;@
M,S%4;NOZA[GXO+@X"\P3J5+EVIB0\.]>S519&DOP''_MC)[M[VD&'GY^LOZI
M(P]D;F6K9G7Y9['0JXNSY(PLU%)N2_VM?OA-[0B%QEY>EVWWESSTV!CNF&];
M7:]W@^%Z753]?_ESYXB# 30:&<!V Y@]0(P,X+L!_*4#Q&Z Z#S34^G\D$DM
M+\^;^H$T!@W6S(?.F=UHH%]49M[GNH%?"QBG+V?77^?7OW_.KKY_S,C\._S[
M\O'K]SFY_D1F5_/?R*??K_^<DPGY8YZ1-[_\2GXA146^K^IM*ZM%>S[5\ S&
MTC3?W>]#?S\V<C_*R)>ZTJN6?*P6:G%L8 H/OV? GAA\8%Z+F<K?$4[?$A8P
MCCS0[.7#&3(\>_EPZF'#]_/!.WM\Q-[U1C52%]4=N3(94>A"M>\Q-_=F!&[&
M5(OW[4;FZN(,RD&KFGMU=OGO?]$H^ _FHE,:RTYD[,A]8N\^X;-^^14J95FW
M:&#V(\-NI"F']Y>34(1!!+-^?^@,!!>%<<K38UR&X&@L>!S2/?"(0[CG$'I#
MX)O*ZRHORD)VE;%>DFK'BNBZ^YS+=D6VK5J89*SW$2/]$1.>,F).:2P[D;$C
M;T=[;T?>B,D4&,UWOH::1N2Z;G3Q=_<%YL;>7'0P[8(R%EI!Y*)8&H3""B$7
M15D4C<1/O&<4>QEUO7M2+R<0(42VK=(M43]!*$# O.WB!T(J;]2B@!^ NX+&
MN\"8QL[3191RBZ@+H@D-;*((2@C!.<XTV3--_-E>5Y,N%Z!-YC\FIO\O2%ZO
M#=?1^4N<1TE"'L86+1=%><"#P.*%P!(>L0CGE>YYI5Y>-TU]7W3*"H0=S%VN
M(/=-;-:W;5TJK2#O[U6EZ^818Y@Z#Q4SFMH,7900<6C#,A<6X.1H,$B.P$OO
M\WHCBP;$8Q>)95W=34H3@[M@145%X#HZ"!)J<4)@]HQY(<>$#C04]1*ZUBO5
MD$*K==LE&,J .O>=Q(&PFP\&@\D+N$T#,Q>)D=)!V4"%>9O/;"6K.]5:C:4O
M(B8"H2O=0FL:;3([\R?J,B>UEIW*VK%K!V5'O<KG\K,O9W=CC^=3"*<N83@1
MQTE [0!!@$D2LY$ &006]2NLJSROM]6^<\C;4KTEX"](Z<53FX$LZ*I5EQ:>
MI!9(K -I-RE<(!,IC2*;,V(0ZC%/1_H,'209]6J0@?5&/O:499XW6X53/D@2
ME'?H/B:/DR2P100"3"G0L94H@HN"@(^U(3IH(_J<.%JJ!I0"3#;$[E:A;%P1
MP\,@B1*;C(N;@% (4VJ+!01).0O#@V0XYC,H(^J71E^?Q//&=%A8?Y+;1_)F
MIZ1_1:4T2MF5,Y.8\C1RLA4!"AJFW.ZR") SEHJQ&1P4$DV\]=P4G?8EZTGJ
ME5JO+MRGM):=RMJQ#P<U1OUR;"8WA99EG^J@FK?-2%BX6FD2\CAV5 J"2V!U
MX)0SS!ZL6$>:/!L$&'M&@%5:-94LNQ5"6R_U@VS0W&:N6)J$ ;?K% ;C*;/+
M% 9C:1*.T!GD%_/+KYMMDZ] ^[=&3JYE\T-I4Z-)J_)M,YK$S%50@<WK64B&
M0$"O12.5B@TZC'G%B%D"Y$HM6K)LZC60TCLFKZ/(GJ?X+"1#(%#"DF",XR"(
MF%\0/5.-BWWI\E=CABB=$+II9%-%<.E1_.WXNCA8:]"#Q?LQWT$Z,>&MQ9^*
M2E;Y"VHQ\TJPU];BDUK+3F7MV(>#$&-^(69B9G.4&ZTL^[2 A?\:ELS=7@#J
M55<E\2A@PM[10'"@-AEW\L+%A9%(PG0D3@;5Q?RJZSCWB[;=0M@H0Y$%+":S
M&A*CT87)_ZK6(TGA:B@G]1&9%8<L='CZ3!U3'(08\PNQ&_EHUO^[>6N[Y40I
M-62^KO\I8T1K<5"7-FL$!J03F[0+&R,]:#'VS':5$[NP6@!5H9J\:#NVA_M8
M$IHR?L+"D%VG,+5YNJ!)Y.QA(R@FXK$=2#9()N:73-]@/?CXM,-C#F9>.(>(
MX@'E']C[;C,$Z(3MBW>N^""<N%\X]15<D5+!%)$=190)Q[1.S(4MG3!<"F%K
M-R4,1UF<CG5A/J@G[E=/:!=>[EN5O_=R5_X(8:_+9PB*0TE-[*3#K$4TIB/+
M=SZH*>Y74Q^72Y5WL:A^YMT.%X&%'J1<U5%_VSM _;4M[J&;P)3VJWEH8+HI
M<E.6# !U@"N..(OM#0P$)4)F1RR"@M*4CFS9\(,CQ>=UUIN%RAL3M497]9_,
M'M__RQ[;M8J0%0(&I'$JG+4_ DSB-&0C%8D/XHO[]ZUF+V=*I":WZJZH*I,
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M';TY:I$%BS5.-EOK'2UB.!6/+)6%BI5X;*?!<&WM]6"XQUJS?=?6 7@X'C3
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M]^951[CJ.EJ]!%O$*R"X&!?*^(CI&'W' O@^MQ@UZQ<VT/Y/X/Q?4$L#!!0
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M)@O8^K-+."ZH66G8;,;GR""@EV C_IRO4K6)> FT_$@YN^$G56WQ=TV?B$!
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M$29@8V8!I$54B81%D\8"&E9I-;3CB'7_JD$@Q6,$1B##_]G4P5'MTPCWSL_
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M6&N'/@6;*D$#J8/1&K/QP0862NQZ%A9CP4XGA9,=P@6=Q@/3L*D-4HOYR$P
M4CB%"5'A@S4ZQMB:$#.Q<6NZ?\C2Z'1//JJB+KN9W^-;4E1CW*H558W(CK ,
MH CU]JY01]I6%0GEKI^M\EKCQT*N=GN9$.NIVT#[8^HD<EL5VV&"U\R:&Q%Q
M$ ]N /,A>YUSTG6A0]6$_O:[)D]NVZ*]5!L;,D9?.@9'045(I&MWVE!1-=RS
M$?-N89<J@]@RH;L(>?^Z8;+C%2P?O1PQ"DN)MQ,2XRM*[2S"P*1.BH1 =./&
M3'<N 10#<=CFXT%Z=,_&[3KNG5.1ZH"--=+.%SW0TM(=@BYF,%K>5-D<8V):
M*HT;]PY9-)W,ISGE +B3W&(SBRM '*,*':?4&W!-3?'2%M2)"LKS[77#45Y7
M8"Z]ZBEIS5'+ND(0:AHD0: \USX0#PK/S2$BX!ION^.EJ?."_8DVNF*[TQ6+
M'LI(%!S?1@F'[OK'',_W8"'>1[\ RF<]^+LN7] U8XJJ@)0DXC8$NJ!):3ZM
M->\)W#&PN:]!%V-L^?C,SM6Y._H@BT=L!Z(\!)@33 S#"6.ZW.0'06*_AXE<
M6OZK1EYTB0G^(&J\ )&F]H%5TQW]^^-.S;YVT,D%U.,@_] ,04\:EN;H[@ )
M7TNR_7[H^B+S1,$JU:.]PA^X;;=RWZW]6?BJ39ROJAX(_J$&?O5$WUXFV@,-
M#=AWV6SGX4L(?E4W;]@3]9=/>QX/J SZF_G:(PX' P3+:X*B%GP K[%7CQ)9
MS:V1\_%DZ>1B?'](G'[*=>W4+4K:\W&GHV$R:=EN6^I[:E2J;^]MOTSPH&&(
M%UL$7.GE*,%LY3"K$IW&;\ &:3H5-FDJ/==+7-'A53C0</K#:!%R<J8Z_<CK
MF/*]/AQ3[& (A#55''2C\C3?J!@-J=MS> O, O]F(/S-^P;#WV7Q0(?MN#>Q
MJM//MN^5[T=J?&LKQAR7?^H75H&;1C'4A\JGW0I>-"0SJN\IQ"?K6^\:X6%M
MGT^<6V+(*E-\I^R1_")CKT&GCSJ='F.C ))E^*B\9(=)%&ESH4X2PK!Z8U;P
MZ/*DA"(DMVW3-TPFBG+P03^M#5PR7K5'/;#"Z/>X-8PFSZ5M/,7%'N:"2+'D
MRP2TO'O?A< <'",)!P+.CE#7W'3B"I*6+NJ7!ND3G%Y9<0*NG?_R<8(%V"1_
MF!XL@744_NM4%8:1F>XAXVV6]<J$K9R&ZE*OT?+O()[% ] YTX*.#UR[DS/N
M.0D*PAR'P6@O2<!V4>(F+[D-)DIUJ>=1EFX3 ^X60WAJC.48_ECB/73$TTGC
MA<==V^^]-/=G7XTCSJ)$_/\].,TMW=R!;9W D.=V?'[J=N.'N,KI>+BT/ R\
MVX?&T[CD';MTUZ#))KMQ_)(>YP_UAEVX83#MK*=IN9LBH/9_NH'3[5SW0<GA
MQ,MON*-[@F8ODS5JT=^DLUIYIVEKH ?8S9L!8. ;_-9JQ(G,5U:3]B'@:$_A
M>BIS/=ZYM]$4&$P#IV<RK"W6-QSUY42C":<N/))3IM?UW)I+CJA<+*Y-<OMN
MMZLA?-)Y>A=:W_YTUV!IRI'HVYZ/#4[$T^NW$ZSG00<UZHXT-PF&PR\B1E[Z
MQ0EP;%C?VN?[6F>-([YPQ"4O-SUF;A[D.<6 <03, Z-C2^8M8P%+K=I+804Z
MIHSZG[$>O;R#NP, N'+$WIDPXOZ<YMKV$[WY@_CN'Z].1I?<VP\<=5.AS@8V
M15[O[;L@<$K_DI]1!4YIE/WT0["V;FECHK@"9'611;8M^AJ7-]I!X4)WG(/T
M=4VQHZ8';@2YF3T"YI1'(;W"4*KI!'.J":VF\;8A\]]YPEC0*<(8%M0O,KVN
M'?S=I@_O)ICV19UC=^U@GYF;3'S^!2_*ET\ZMTK&0Q=/H#FPU3]V!(=-4$?K
M^\^OD&A&@(4;R;=[Z__4<5 +LU^Y/66CZ7P[,@<TSP?3-B,9)1AQ/39K9-/_
MAZS_NB:$\I]X 0Y3O-,:ZYZ @R=#VZ7#_+TVO=-3I'%,1+UJ?-W Z?9&<V.S
M]>VK9(VZ'G^]QY^LJ$<R<TB=TDV:1TGLZ(TCV7SI\)"&C?\(#:-#>(F6>?JA
M3^^D?G1T 9?\51;Y"UH&N#!_H")O3@K+?45BTOT5XGD7\CO7WU\@"90V<,_*
M:"[=@UBG?*/SV%6?@>#7(7HY=*?3A]I>W=<8'6IOHY>1O3WP]BV2$KK7^>/#
M.R?$.Q>3<!Z,J1ELO!@&RR4V@<T7BV Y'7,3X)O\C>U;&P7+<(I=8[/%F.["
MVF_LB/$TF$RF>K\^\>VQ83 +%[J?SA_IDQ7"JB-\K=UD$<R'R\Y[(_NR"C3&
M">B:#F/=<\X-V-C=1V:R_T)/Y]NF1DZO)+A!SWCMW_C6U\ 2\4G&VPP3=\_^
MS2HCLUF)^@:!Q7NJQ= ,WZEB=S ^?2\3ZNF\O?GX3^KRP1NSSCP'[O0@N 3\
M66[5'HWBCJZ5?,[R)X*>'_92M\[\'!5[\;#' (AXT-I<E6\D':J=N,L[AW6>
MG#6QY"<W/^C+HE,S\ZPV9M"P_\GDP>,4]#-&/C8)(/8"=+V)&W/L36S[<B*Q
M5X\D:O>$9\9V'L'I!'I5@&X5X6Q3M,8@G*KL3E&]Q_3I[J>#;T=P6H8=D>PV
M)[2BE1AK<1C:#\1W^NT"C9OQ>:>:I&DK;X]NT#1O)*!>:;YG .-O/^B^_N0X
M;_DH?2H0AF"7@<94W,UN7H.GDV.%>:T)FG D[J"F:G[ UD!S:KQFVYPF=:.Q
MB=^H1V/,VU.1/3<W<?R,:4NX-5;H2K2]\(B^+"I!?Y''1E B_]ZP?C' 7L]"
MG86ZGXF3\! '@B"AM'%;9:E;SLN:7LEA-8LZ9(%O*$GYFBZI @XW?7:TG+.^
M:5#R>K?](B/91%,)M:%6=[NJ;/BD7]/ *KC;I[)[L4/Y=Y!7^NX0'BLE3_6+
M8S2@CO.2WS+D]E3 F=9%X2Y6M:Y=MB\)=4"[)X0G7I?F5JD=+\NG!\=U/AHL
M['M+UJ>T+FM>)76;1ZFRP//M7B427P-YCZ@.MH>)3' #6?ZH]]WT!0^/I6^;
MY&#/"T;XBHJ3I57..PMP9O<=)+P)?H9<MY/L,KV=>HGF=M-XN73P6,NTZ'8O
M\#ZZ&&*M2Z^=9(OA7/7A51,;/T_G_CLEB$I"1];^-0FW\]'$A<AF^'=YL=%]
MXO_((2#0#]JT:X%MPE%FDQ HGDBM&[6NFSFR_*KI'\!+/OPP!5594YKU7P72
M&$F&"84D*^#EXS"'S0VDL"KVPF1D%F(XO2RB.R ONQOO=LNZ\DR>SL I)WX@
M)O$;/)RW.SM)QCJKT>*9:['-79/V) <X/6@N)UB4[+POY\B3Q"C]&@GCS-3:
M6M/&VY:V$;PU<4=% O^M/J;D_/X#WF8A"Z5--GQ#,X!!,YWM7A[#MJM1!MU]
M!9J^K:"O;-C7)[1:Q?KN@UV:0!WFTD_GYF5*W8O_&K'ZDD;/6L:@D#4NTA_)
M$_B[]=ZH1I)J"^@H4BCJ?!1\G'@UP%;FZDS+_D!\-.]UI#D8^/N?,7;0G"KU
MBR"=5^PYU[,/O# 29WD?@<Y\N7H/3)DL('RP;VZB9W[#12,_Z+8Z<[[P[4F/
M]MC7U$A#U/EH=O*IZ,\AW:1'[1;ZUN[R^*6KA8<9M?3M=,^R!X[Q/!SVITC[
M1('9.SVYUDGV]KWE_Y7SEQGH343X]R=*OGS)?Z3!?BK,G[BXYK_LT SGOX_Q
M/@)S!DXAE6MX=#B83\\8=9I?JGQ/?^=AE5> >^G'K8S /N  ^'Z=YY7Y!1>P
M?_CC];\!4$L#!!0    ( -<[7%A(WWDV"!$   XU   9    >&PO=V]R:W-H
M965T<R]S:&5E=#$S+GAM;+U;:W/;QI+]*U.ZJJQ315,D)=M*_*B2Y>M$EG2M
MLNQXM[;VPQ 8DA.#& 8#Z)%??T_W/#  05FY=W<_)!:)F9Y^]^D>\-6MJ;[9
ME5*UN%L7I7V]MZKKS<\'!S9;J;6T8[-1)9XL3+66-3Y6RP.[J93,>=.Z.)A-
M)L\/UE*7>V]>\7=7U9M7IJD+7:JK2MAFO9;5_5M5F-O7>].]\,4GO5S5],7!
MFU<;N537JOZRN:KPZ2!2R?5:E5:;4E1J\7KO9/KSVR-:SPM^T^K6)G\+DF1N
MS#?Z<):_WIL00ZI064T4)/ZY4:>J*(@0V/C#T]R+1]+&].] _3W+#EGFTJI3
M4WS5>;UZO7>\)W*UD$U1?S*WORHOSS.BEYG"\O_%K5M[]'Q/9(VMS=IO!@=K
M7;I_Y9W70[+A>+)CP\QOF#'?[B#F\IVLY9M7E;D5%:T&-?J#1>7=8$Z79)3K
MNL)3C7WU&TA3R+FI).EH)"YT!H6KD9!E+JZ;S::X%R?+2BG8H;:O#FH<21L/
M,D_^K2,_VT%^.A.7IJQ75OR]S%7>)7  7B/#L\#PV]F#%-^I;"P.IR,QF\P.
M'Z!W&!5PR/0.OZ^ &R5.JDJ62Y96_/?)W-85W.9_AN1V5(^&J5(H_6PW,E.O
M]Q K5E4W:N_-#W^;/I^\?(#GH\CST4/4_WVC_2^2%]=G9U<7XO-*B5.SWLCR
M7D#B&VT:BW5+J+-6N5^D[K*BL:1G(E6:\FG[3>%.L0*)1M2@EJL;I(P-'3(2
MF7E*":@I/$\+78#K)=-9Z%+;%3Z-D"66FFSF%M'#S*S7JLJT+/2?_+4P"Z'!
M]J8RM:GO-TK<R"R#!D;AZTVE58T$)4X__G;V[NGT)ZRH-.0 P5HO52DR4-:Y
MK-43^Z,[AK:>GIT&6NV*L1==DL)R41NQ::ILA3S"0GJ5_8<5E[*N]-W3RQ_^
M=GQT/'LI9/Y[<^,.S=.E/97*837206M9-@NX;U.YLP+W>=4LD83AW++,%&EH
M8TIR>&@F.0B,S*8O7MI6#;]YX73I#H\K_*'@4U65K@UT9TVA8'\R9F-Y"Y%.
M6<)I?<KCCANQNSF_^:.1!:C93:%K)@0/4V6CQ*(RZQXS5A:#Q(D',M,VLR-1
M*I;>&RDS%H6NRTMAC8#5H&_K(D"&"$#"KE?!&L3RQ;5HD.PJ<;O26?^)WYT:
ME/?_/[DC&V0[)F@/ZPTZRE152[*75X]6%D2MN$7E%*R!#!F=\F(:HAW3]G5S
M<3WJJ@2*2-9;=SYI1E,"X'B&'0+W4$+>X#CX=*HW.#QG@$&O)HH[0\H?E8MY
MQQ)C<59B$\*3BLMDU#D-TJ@*6W0)-F0Y;/]Z)>M'!FA(<Q0=<+V_RBLIPZM_
ME.IR.^LI\6DV/=A)_PD%SFSRTG&+I6UNYR?3E^13.*(@KVL]"@BP;KGZH,H2
MYCTK;:WKI@8;7TI(6UE=WY-X'^\@;QX/&^ H',9&0)%7ZSD(4I%'L&<*Q'(J
M+)0)]$)GSF_]Z5]__3C&@>1@]'% E)'_,B1?^]CLFR2PU-L93.J:W!46IX3A
M2E$GNNBTC;%NC1187:G4-B$9(,(S;[B-O*<(J\R]+* YGS;)T0OU%"8'AGXJ
M<M/,\3'72V1#QBL,3',!C03[4#2[6BK%1E7:Y&2&Z3-QKV2%(Q:U5]9"5[;N
M,.7S)SV\:5.GD@B+S#0(?03*9_E-Y5)<K220<:::&A8IHF]>Z+4FYT@SZ,JG
MC@1:L,0A'GKQ]+@#@C^YU<&%.KEFJ'1ZXHCBP<+YV+AZ;+'\(+$D=5#9NJ5G
MI?7+W9Y(I:Z7 =*DF[.G#12^T1:$T);2F:X+ATA\?*&]@,_4P *Q'MBGSK&"
M/\(]'>AC9CSOT?=8M&REH;ZUQQ.AF'1BIZ/(]M1^F=F8*@ VJL^H @L=CN:H
MV%'H.8-<JTT=4\@TZAFUA6V7#Z1PHOF+0=(J _=LN&C:2ZI+\'YZ\JN"/E;
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MU<;#(XSMS35:O(B@;3L79) G! T5W^+X5.SIOJ5)D+(VF4HGHXL(2NCXA/S
MKNX1H_2,ZV;^.QZ(5(91VQ=+FH_3\,R4I;]OBO4APR%Q]$R*'!A5=>I +P&Z
M4<.]<#'/_N:K42>% C0D/#Y"OX,.%9'=$_VCN ZV),Z_DBG_8<9B*AR0DVSA
MM@(?CGP5;BLT-=,T=6S2HO02M'<2?]8ASKEX>NPP;=<U7K+>0&DGJ>>[23FW
M2!CMRS)XY%A<-95M9!E'D4,J[,8RP#)0W8:Z"I1&MIYOD^C _>G13^/CV(J
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M.P,^GG[L)<=X>'K\,]FMR9-><BIJXTE>4/1#-NR/RMY(I6F4)$E/=CR,XU?
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M;.B+O_T+-I1#C)^$L(DB[U:+TYPH%U4F.F 5*7=62+2\49?9<ZQ<G:S'P64
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MWYC:$9[:32OC$\ 3\<-WD>NX/Q(/V%:XH+H@#*TP<K](]C2RQI(=>,B-8['
MEV\/,?MHM0S$ =N<,O8M&^JM6CX)HA<,"I+HDT&^Y06,(#B,<C4#"2SD6:$3
M4GLA')^/#]".J.W! =A38/^\0MR*$.LT9/@M<M2V[6,9VV<3>50-19Z+%*$!
M+M2Q;6,.20PW^<2.7B=B7WHDSX2H#@Y<!03#54#PC5<!!\<=KP*.5P''JX#C
M5<#Q*N!X%7"\"CA>!1RO HY7 <>K@.-5P/$JX'@5<+P*.%X%'*\"CE<!QZN
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;)U7;6_;-A#^*P<UZ!;
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MN['3(PI#,:E-B/\,RP6:3NA/J;=4+1B?Q>,._\M0H:&(QB\?(-[S,8W??5_
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MNK#LYO$1[4^^$CX1OV,=\XAS[3RU;RSY+C?UTPPL1ONRF77&%R1O*P[9Z+8
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M<^V0:S?!UG&PK&V@,167%?TO0,<*)-]8JMQNPP[Z?QJ+_P!02P,$%     @
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M3H#NYXI(Z3?.P?;A/OD74$L#!!0    ( -<[7%AK2T0E% P  #DA   9
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M8-@3AY,T'8W17=2_4=6V+@*R>Z(G+3J.>W@@AY>&T>4*[5YIQ;*R5$[)PL1
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MD6@%9:7'I=S7JB9R%E71K'QS=0<'P @*RV_XS93SK\?1T7S%[W%RRUM^MU]
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M%G0&2!>'A,=6N%$FA[<GY3LUBE8:%=(#7:P;A+- )NP8"J+U>X(<6_Q6(IA
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M.6$)VTP\B'GE_$24C1L^QT=T/YM[0U'4LQ2B1F6%5F"PG+"KY&(Z\ODAX9?
MI=T:@Z]DIO63#[X5$Q9[02@Q=YZ!TV^!URBE)R(9SVM.UF_I@=OC#?N74#O5
M,N,6K[7\+0I73=@9@P)+WDKWH)=?<5W/L>?+M;3A"\LN-SUGD+?6Z7H-)@6U
M4-V?OZS/80MP%K\#2-> -.CN-@HJ;[CCV=CH)1B?36Q^$$H-:!(GE+^41V=H
M51#.98_MS.)SB\K![8*^=APYHO6+4;ZFF'84Z3L420IW6KG*PJTJL'A-$)&>
M7E2Z$35-]S+>8#Z 87($:9P.]_ -^R*'@6_XT2+AS]7,.D-/XN^N>CNVT6XV
M;Y,+V_ <)XQ\8-$LD&6'!\E)?+E'ZZC7.MK'_K$+V4NQ6^#;,_BAX#M7+5EQ
M<]:C(W 5PK6N&ZY6P)72K<JQH%GNPM)4<U. +N%&&/*5-M8'KT!-8_2",%QU
MXQ=!WD&Y@B3]1#8NVLZ.!!,D8B[UC,M@7>HP.1Y!3D1&6 S;O"$YW^80:GOK
MPX.S-#F]M%"V4GYVU#H ZT;J%:(EHB+D&O2=JD#S>I^<'K!_#KX@GTJQ)5]S
M.J<![+K5:,MR-9IY:"R6<*URG?OZV;YW7766_9_>-;X[;N9"69!8$C0>G!XS
M,%TSZ0*GFV#@F7;4#L*PHOZ+QB?0>JFUVP1^@[ZC9_\ 4$L#!!0    ( -<[
M7%A+4 ],7@(  (,&   9    >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;*U5
M76^;,!3]*Q:KIDU:PW>R9H#4A%7;0Z>H6;=G!VZ"5;"9;9+VW\\VA"45B:*I
M+^![?<^Y'S:':,?XDR@ )'JN2BIBJY"RGMJVR JHL!BQ&JC:63->8:E,OK%%
MS0'G!E25MN<X8[O"A%I)9'P+GD2LD26AL.!(-%6%^<L,2K:++=?:.Q[(II#:
M82=1C3>P!/E8+[BR[)XE)Q5001A%'-:Q=>M.TT#'FX!?!';B8(UT)RO&GK3Q
M/8\M1Q<$)612,V#UVL(<RE(3J3+^=)Q6GU(##]=[]CO3N^IEA07,6?F;Y+*(
MK<\6RF&-FU(^L-TWZ/H)-5_&2F&>:-?&AJ&%LD9(5G5@54%%:/O&S]T<#@#N
M^ 3 ZP#>:T!P N!W /]20- !S*CMMA4SAQ1+G$2<[1#7T8I-+\PP#5JU3Z@^
M]J7D:I<HG$P6^ 5M!5H -U>(9H!2(K*2B88#ND:/RQ1]N/J(KA"AZ&?!&H%I
M+B);JMR:P<ZZ/+,VCW<BC^NA>T9E(=!7FD-^3&"KHOO*O7WE,^\L8PK9"/GN
M)^0YGC]0T/QRN#< 3R^'NV>Z\?MS\ V?_S_G,#3NEBX8IM-B,14USB"VE!H(
MX%NPDO?OW+'S96A4;TF6OA'9T1B#?HS!.?;DAQ)*-;/!"]HB0X/4:KA-KL,@
M=,;J]+>'PQB(&X>3&__F."X=B',G@3\)W3ZP[<$^^#PKX!LC<P)EK*&RO>^]
MMU?26R,@K_PSI;"M(/ZC:>7Y'O,-H0*5L%:4SFBBRN*MY+6&9+41@1632E+,
MLE!_"> Z0.VO&9-[0R?H_SO)7U!+ P04    " #7.UQ8Q1Q9@^,$   !$P
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MF%""F<%TP.]+(?2N80:H;[VF_P)02P,$%     @ USM<6-LY7HJ3-@  +KX
M !D   !X;"]W;W)K<VAE971S+W-H965T,S N>&ULM7UM<]O&LN9?0?EF[[&K
M2%F27V,GKE)D.^M4?.*RDG-J:VL_@,101 P"# !*5G[]]OOT@  EV^=^260)
M&,ST]/3KTST_7#?MIVX=0I]]WE1U]^.]==]O7SQ\V"W789-W1\TVU/"75=-N
M\A[^V5X^[+9MR MZ:5,]/#T^?OIPDY?UO5<_T.\^M*]^:'9]5=;A0YMUN\TF
M;V]^"E5S_>.]DWOZBX_EY;K'7SQ\]<,VOPP7H?]C^Z&%?SVT48IR$^JN;.JL
M#:L?[YV=O/CI]#F^0$_\JPS7G?LYPZ4LFN83_N-=\>.]8YQ1J,*RQR%R^-]5
M. ]5A2/!//Z20>_9-_%%_[.._I86#XM9Y%TX;ZI_ET6__O'>\WM9$5;YKNH_
M-M?_.\B"GN!XRZ;JZ+_9-3_[Y/&];+GK^F8C+\,,-F7-_\\_"R'<"\^/)UXX
ME1=.:=[\(9KEZ[S/7_W0-M=9BT_#:/@#+97>ALF5->[*1=_"7TMXKW]UP;N1
M-:OLHKRLRU6YS.L^.ULNFUW=E_5E]J&IRF49NNR^_O3@AX<]?!H'>+B4S_S$
MGSF=^,S):?:^J?MUE[VIBU"D SR$.=O$3W7B/YT>'/%U6!YECTYFV>GQZ:,#
MXSTR0CRB\1Y-C#>VXO][MNCZ%ACG_XVMF,=[/#X>GJ87W39?AA_OP7'I0GL5
M[KWZ[_\Z>7K\\L!L']ML'Q\:_=5/>5=VN&D?<.RZSY'%QR;Y%<-DOZ]#MFSJ
M#LA0Y'THLE59Y_6RS*NL@T<"',J^R\IZ6>V*D/7P=,[$HZ'^V5SE5_GG6?:N
MAAW*ZR(KX0_7ZZ:J@,VN:QBOVRVZLBCS%HA\E)U5%0S6AW;9;+9Y?1-'PY>!
M_G67TQ'NLG5^%;)%"'46JA). \VNK-ULX;&C _1]8O1]<I POY9_[6"&_0W-
MX><&V>*\J9>A':7R5P]&M,;UTLKQ#[<3/A(!&&N;M_!<WH%4Q;?[==[3CIP+
M+:]+H"Z,"8R]@R\!3;/+1KY#$[@N^S50L*E#=A/R-LM7L!,T!$XA#C@Z%?AX
M5L*W<0JP-/Q.V&PK^'M'+X&>J,J_F:N -6":0;:U@U]V*]Y7_%-5YHNR*GL\
M=C =?+EI"_@FR";@AK8+^-1BUP%M.V":N_%HT61UTQNK$G,5?X)4Y3^W :9*
M9&MDNLOF*K0\$]ZM9063)JFH,\6'VH*)#EHSWPCG,]'TG^/O^E4293>H-&#(
M#I1(MFJ;#:]\UP-'T(KQGSO<J1XT+,RI"-VR+1?P^05J5#@]=.A &H;- C9.
M)>(LX8)U7F3?/7GZ_.@)?+&J<#9X:O)NS1/%'P(PZ55>!9T]OI.33B5VR;=E
M#\0%A8>RL5[>',$!SW[)ZQUN$7SR\2S;PC[M4'T(/7_9 5?A;+(S('B!1-<_
MY<45;%? 5Y9KT*I9?MD&VC586'^-W.T70)( _YW7.0B.&I@8-JJFY^_C'_[[
MOYZ?GAZ_I+_GV=F',_K%R<L'*2%@\P)8 3Q8!SN)XJD&CJDJ&@M(^=W)L\='
MSXU.MBECGZ8]O(93Q2?L$G^'4]WF-_FB@IW;-LDZ<%(GSUX"8X+\@E%([U[!
M^0>N!F;M4,MV(8 ,A:/WZ,%1]GK7\K&6TQE0>]ZVV\#NNY;$0E8#AU9-1SSR
MW9/'3XY.;&&ZQ_@(,< *^*G+=AV+5+#[6CX<9#@QS^(HSTX>'QWK*,0$*+_:
M@K83I8DW'BYZ^$S>%AU,KHA'X;YLU]G%N>Y3]GNS+9>PFB?SQ\?9+-5(\-VW
M=KXOXOF>#Z1I2H< [+PCX7"]#O '.J$@L5!JX<Z7K%20$.$*QYN12"F+T#(-
MB%$O@3$O8909[W:;E\"MJ,%@:3W.IVAV"]CV!9Q:4G4J/H#3_P."M[N+G(MR
M^"C[][JLPBC3$5?4;K<SL.H#_*O''UCRU&%.LTGG6H%5C<]<PU9FP!AE R3K
M^G(CDIZGV@96-PNDSXKE1&^2 XR"LJ)3 819[8#HPF*P.J0M&"(V'?@9*/PG
M6.[X<.<,4R<+9R+7B4=!:_0LSW%"#?P(.PJ$UX75X7.?@16Z82O4Y,F 1&[O
MPN>PW/5(DDP^">3H^CGPQH[55ED#!^7H58A"&HZFD]BVS9]!3)@B@$-5X*@#
M7NEVRR6HMM4.[:0"WJR:[0Q,_7J':G+7 @,6)9BCY0)GA0L P_U38)[;;9D[
M5);HLE$NS^$_3^0O?)RZD'=-/8-C42[72.RRQMVK>_BR$9C5=-P%$"8[$CJH
M \ON4^?I?PLMFP6-" =I!SO4@-S+=_VZ:<4VH*'ZM@'"PLI@O^O+*LQ1'F97
MR.FP&#!UYBM@+K0>;U F$E5Q)[*MEQ2Z\#^.+HY@OS8;,"MQ"%)SLK"&9 %3
MKV.1 2N!8X\2#%9W_MN_WKV>GWR?%5'Z'B;D+<N'@Q)H4TGHBZ#'&>7+=0D[
MG4RT:+:]RF?98?ABV/:Y3&]DOX^RMW"X@$?P:QMTYAVI053#686334:*?E*I
M=]54.S0UVJB3^I)LR691E9>\/\ 5A0BGO65.*O(NBOD/9YW)^4V.:AB,C3:1
M4GQH22YLFY:_"HO=;4$!BU;E?0/=RJ/#E,5P(M9"Y@'QN,.C$A]B%K]N=E6!
M4PU@2,).Y*L5<?7A;3L@O8^R]V .7*K!4B%)61#.LDN@(NL.D&FT VPU@O3%
M$5 =!V"[&K4*/+IG8C%C+'<;W$!8$IM<_<SK+%@[JRP04_"1NZBFKU\LO-HV
MN\MUU%5F% U5U:W:*9+-)@'^0DTR&XRP .>]9[YPJZ4/\$+5E(>=[]L=RD42
M_^1\='T6A?,&CB9P@G@;)EM%K(M1@4?)G3V:"9DT[_.;$<,JK^L&Y2-:5I=5
MLX!7;IT'CIF8J!^3-S[ GZ.I*@*9UXC[L &-"#)M*589,!FY+LCQ.'>35/]B
M.3!S'P:"XB/;<AO0(<TZU#OPR9E2E[:[R%@%)WX:OA<5#TX3C$1DTQE,*?G"
M&%,)9?!YD,9+F!2PU'4 PR#O]-O16\?OP7?$*YIQP*!>M;E2*8PX&C 0.+X]
M'RR8#C/K9E%B= '500["B(821;I1RQR.?T5$ %L=K \Y;04(/-2M?"##9R 5
MG='QS5_M6I)$1HE.]V.X]&3C<>HP&G#'1R.AWWYG^I\\?Y!8%!0?J0LZ)5NP
MOEH@UM]PJ#8@Q:_DE,E^5TU].0=+<@-,O]V"K .I#+,+J^BW^8%QK<N>]P5-
M#USF#I8 0\/FJP>ZS[/XN84Z^&PMT_K4L)H>:XH,XR,^X0W:PD(_D[D)*WK^
MY'_I8,D79K :-4C0D$6UB\MO+VDO1R?\E2Y6# +(!\@U>NS\:[9%"[)^="X8
M&VEN GJ>&&9 M8FK6P KKL!\1<G!\BH.7]/:RI88V'WJY-BY<NY;MYROD>/E
MV>[9 _:&E"D:F0G.(R]8' .YXSS2C?GNL4T)7OWNV3<3@XF^R?]$CB<]:B8K
MSY''7(3H\XK;MBI;X+"_0&;T;++R9D^J'[1*\JIKHH(!94HBW2U;%+2JPUQD
MCM$9K1J)&Q4!%*]H0Q0WRZ8"YZ<Q?X>$3;@$CQ>T7HFK1]E'$:4NKU00LOU'
M YCM7Z+!"?J_*I>8',$IMD ^7A5HKW^&Z_AA7AC&P(!&B0?FN1E='-."U8W:
MF_0D2)*.O@<J&/Z(X=JNF5$H[4O7])5+.F0QHJT%-F+6-6S#PH=5@;486F.[
MPHQ== ["<ETW57-Y$]4MOPZ>9^"/(:WZ#&9,ID<=!=H63@E;5AA:H!, IL5:
MO@6*:I4&8M!P5H*+#[3/3ZED(0\:B=9U;)X(TX%6:\#$-BK>L#0CJM A /,]
MOQ$#@.G4+<'#ACD2;2U@/D8K[XG#7U3!%<TU; <J&C*W+_-:C 3>?SN..!N*
M2H/! E]HV8\A8QL5#YK:XN]J '?F+$4S]&9BSY/A[Z=$*L!YD_2G<;/\]<ZX
M.X8*2/!U7;,L.1J$0:K-A"28222#0Q#_:4MZQ0>I"ACE^'9S^D"FXZEE.IX>
M3$[\P9'U-QK-&4MO?,L(R:2>V:2>'1SRHP1./H+VN:S+J>36%P^2G?6T/9C3
M0TD?MLQWJ9V75S=_!SY]&L%)Y!$=-A2,:%:3%8):$.PR8LH8_&2GF2(1/Y^=
M?3C*SCD 5]V,1PQ&/]8&B6](-AA&U!5T&D/TAST[NSB76.K3XZ>S3*E /':>
MO GSX1$['Y#%UZ)'@OS*X5(3U4EL#C]]N2LY^@M3B5___LGS^=/C)S,T+>;
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M3@KZ _[ZP(HUI=D9?6XVJ#C%7_ZC<VO2H!GGF0N#0$Q.(BDI1M\8GW;C#1F
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MO>"7#"O/T$G E[VG?U/T!AH[I9U&KI8"$991@M?,[2V88+)"\,_ T#FS;LJ
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M8^\5_(2O'D*FX^P5B>#! $E&+4E&SR;)>PM<^[^[A1GE"1(<1G7[A=L/C*6
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M Y!& =]O!48R;(R#\7]C_1=02P,$%     @ USM<6!T?&UK0!0  0P\  !D
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MV,Z8!%'FL2BD((R\S)_L\AY28>!3D'G9)-X2O-@+@H@B;\+2MK=9W72'()P
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M[:318'$YB6;9Y=6([8/!5XEKMS<'SF1AS",O;LM)E#(A5%AX1A T/.$U*L5
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M\T4W83?<>_M^US[EE_DSX;HI[S9@2&_ !/K/P9;,J(,5/E@'2%K8T#KM_%"
MDTEBJ#IUY?%:>;R/CC:2H35CZ2O-,J,45M!@*2!I84,+CH\DT>DD,52=NE*T
MFW_7NL%<QHP3M>M'2<DY*9(W)-5,+K+:^\+IOTLA\R/++SMYL#:@^_V&MM\'
MO)EQM.HGO)A.C*/5S]BIN^U6W;7OU<U"X=K"KO:11)RC-::%42O0W3LH+73[
M6^W9PJA5/^&%9YJ#8E/*P+=-+>WFW3VQ>]]-+>W&L;$2]>S27!HU -W3@])"
MM[__[DTKD 7&4+2NBJTEX-H]@3M<X!0CM2RK]BV/)4\V6!!TL^:$'!40U (
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MJ,\[% 5[*@KV6!3LN2C8@U$_P_KR6^O+M[]O];^NI>W8P7(;WHTRKJ5!BXU
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M0K48U1)4$Y0FIV3;ZYBH>QU1OLS6=5EDSS/<*IN7MT7^SZRSIJ;F>D<>6MU
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M4)J<>4:;>>KE,;8?5&C.=L2FV:=GI&JD=XJA10M4LU#-1C4'U5Q4\U#-1[4
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M1I/J[9;@D&1E /]\32E[OBB_H#U_N/@?4$L#!!0    ( -@[7%@;_S? S@,
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M@0KGUL1" 6QI&JDU/_X&Y8+<S)_/(YG_HF/YKF,A/Y6*QZ6Q1A"SI/BGW\I
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MJOPF@=*[,_Y=)I0#F9 "=$%__:8XP8.DN?B[;X&J"7C]$]#GS8U8DP6=6NI
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M=A#_WR3B'E3]* HX+M"[^#]02P,$%     @ V#M<6#;0S(,  P  H0H  !D
M  !X;"]W;W)K<VAE971S+W-H965T-3(N>&ULK99?3]LP%,6_BI6A":1"_H?
MVDC0%&T/DQ =V\.T!S>Y;2R2N-A.R[[];">$-@U=00BIM9-S#KZ_6R<>KBE[
MX!F 0$]%7O*1D0FQO#1-GF108'Y&EU#*.W/*"BSDE"U,OF2 4VTJ<M.QK, L
M,"F-:*BOW;)H2"N1DQ)N&>)546#V]QIRNAX9MO%\X8XL,J$NF-%PB1<P!7&_
MO&5R9K8I*2F@Y(26B,%\9%S9EY- Z;7@)X$UWQ@C5<F,T@<U^9:.#$LM"')(
MA$K \FL%8\AS%227\=AD&NV_5,;-\7/ZC:Y=UC+#',8T_T52D8V,T$ IS'&5
MBSNZ_@I-/;[*2VC.]2=:-UK+0$G%!2T:LUQ!0<KZ&S\U'#8,MO>*P6D,SJ$&
MMS&XAQJ\QN =:O ;@R[=K&O7X&(L<#1D=(V84LLT-=#TM5OR(J7ZG4P%DW>)
M](EHC'DV0.H331XKLL(YE((/$"Y3= =<,)((2&O!*9K*GVE:Y8#H7-Y-:)F0
MG&#=<7GE+5G',0A,<GXB4^^G,3H^.D%'B)3H1T8K+AU\: I9GUJEF32U7->U
M.*_4$D-RAEQ[@!S+<7OLX\/M3H\]/MQN]]@GA]NM;;LI>]HVUFD;Z^@\=T]C
M-?EN/]#OJYGLA=RA?_H0UZE>?ZIZ:EWR)4Y@9,C'$@>V B/Z_,D.K"]]P#\R
M+/[(L,D'A6VUQFU;X^Y+?VE-H@;PTIJ^?M11OHY2#_U5Y >A;_E#<[5)>E=F
MNVX0ANZV+N[1^?+/#K9UD[T5O)./U_+Q]O+9>%9H0DG%F,331Z<."C;+L3S'
MZ\#I4[E6%TV/RO8NK Z8O4M_)QB_!>._"4Q)R],]</R=@KPPM#ML=D5VX%]T
MT/2*.OPF>]?^3C)!2R;X[Y8:[.RG^M7#MJGUD0IV-UGHAG:G]^-=F>U*I%YG
M,\8].M\)G2[6R:XN\,)S-VQE-0MSX_6N#F_?,5N0DJ,<YM)HG9W+!%8?B.J)
MH$O]QI]1(<\/>IC),R0P)9#WYY2*YXDZ1+2GTN@?4$L#!!0    ( -@[7%A/
ML<\H>0<  !%#   9    >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;+5<:V^;
M2!3]*R-O=[65MC', ^QN8JE-U-V56JGJ:S]C>Q*C8'!AG#32_O@%[/HR,;X\
M?.F'QG;N'-_#/<#A!/OR,4GOLY76AOU81W%V-5H9LWD]'F>+E5X'V46RT7'^
MF]LD70<F?YK>C;--JH-EN6@=C;GC>.-U$,:CV67YVL=T=IEL313&^F/*LNUZ
M':1/;W64/%Z-W-'/%SZ%=RM3O#">76Z"._U9FZ^;CVG^;'Q 689K'6=A$K-4
MWUZ-WKBOKWVO6%!6? OU8U9YS HJ\R2Y+Y[\L[P:.45'.M(+4T $^8\'?:VC
MJ$#*^_B^!QT=WK-86'W\$_U=23XG,P\R?9U$_X9+L[H:349LJ6^#;60^)8]_
MZSTA5> MDB@K_V>/NUHU';'%-C/)>K\X[V =QKN?P8_]AJ@L<.6)!7R_@+==
M(/8+1$ETUUE)ZR8PP>PR31Y96E3G:,6#<MN4JW,V85R,\;-)\]^&^3HS>Q>$
M*?L61%O-/N@@VZ8ZGY')V.\WV@1AE+UDK]C7SS?L]Q<OV0L6QNS+*MEF0;S,
M+L<F?_\"9;S8O]?;W7OQ$^]UHQ<73+A_,.YP4;/\NOUR;B\?YZP/U/F!.B_Q
MY D\<>&K7]EU$C_HU(3S2+,X,3ICRWQ;G.CP+8I8['*OLTVPT%>C?)_*=/J@
M1[/??G$]Y\\ZND1@%GEQ("]*='&"_/LPF(=1:$)=.TA!R9,(S.(I#SPE.N3K
M9+O)CQ9A;'0.;E@:&%U'>(?B.B5,<>Q[F#D7CO#5Y?BARJ6YSFI3'=I4:)OJ
MPG$0+?KL/_8USO0BWS^7[$;/31T']"VZ#HT(S-H:WF%K>.>(TZ/D201F\?0/
M/'T2<>Y0)K;FGBNSH<AJ<')H<((V^%X_Z(BY=3VA"[L.@0C,XC@]<)RB8GN3
M9=K4ZFQ*29$(S*+H.G"6=]!!?DE,$+%%D*V8_KX-'X*H.,O7GL)W0*JB(]=W
M)UP^DUM-G9A.)D+6*\ZM&!+WG)U_OYIH*E1H-E=P("YN0?9C.3KL;X*G(']6
MRW^'Z%7W\^>CP4KL3L$NN.A9^N>1(#\/];%-.'CGH0UA*%QP%*X\2Z"H(>G,
ME0C-Y@JVQ,5]21^!JF:!8B5VIV 97/1,71%HDY>J;9K44U"AV9L"7(7KGR50
MU)1TYDJ$9G,%@^+B#J6/0"?- L5*[$[!9KCH*;XBT ])K)_RB_CT7AMVNSUU
M+4UJ/ZC0["MM\!_<Z6FR.&I<.E]2$Z'9-,&[<-0O=+!9>Z"JPFIM5DT=9K-X
M)?S K0?(\:\DWW?B(O9Y-0\6]_D%9GFA>?+X@0-WGM@0*0@'7\/Q' 01)JEG
MH4*S:8)GX7@,TD&8LO'HB);8#8+1X+C1 #E>)^DF*:Z$V5+/39,623,/*C1[
M&X"%X7CL@6B1U)Y0H=DTP9YP//7HH$6_68M8B=T@> K>*O7(M?CF3L>+IR8-
MDD8A5&@V=W IO&\:PDG]"!6:'7Z#'Q%4><@>"-,@6F(W"$Y"X$YBIT%>VQ%I
M D*%9O,$&R)X3[T)4IM!A6;3K/RU!8]/.NA-'(F)2^45?_&R17=<)QU'">^$
M\L JB+/B#4$:;U"AV5S!=0CR>$,<9Q>NXTR=Z?/Y'-?)J9PZIXX,X!)$FZ"#
M]TSB</#.XQO"20AP$N*LH$.0!AU4:#97,"6"/.@0S4%'38G@W'7=$RH%'R':
MI!V\9QR'@W>>W!!>0X+7D'CVT:!221J 4*'97,&VR%8!2!>5RIHDI.Z 6E?G
M<W\RK9>J! LBVR0AO'4PA\-U'M@0QD2",9%]\P])FG]0H=DT*W>!4.4?LCG_
M0$OL!L&)R#;Y!^\1Q^' G><T1 0BP=S(OA&()#4N5&@V33 NDBH"D<?Y!G>*
M?\\U65,W]9Q3=E."[Y!MPA#>-9C#43N/:XA01(*9D7U#$4EJ5*C0[%O0P*@H
MJE!$'2<>==>H-64G]*C 8:A6P4C;< Y'ZWQ3W!!AB0*GHOJ&)8K4DU"AV33!
MDRBJL$0=AR#/#XPU):XC3^8D"BR%PBW%3HBU%]GXRL[3&"(C494[4U5?T='>
M<#J$\U#@/!0>JW00G=<L.JS$;A \@SHK[%"D80<5FLT53(<B#SM4<]B!EMB=
M@C50;7(.T3.-P\$[#VT(^^"!??#.RCD\TIR#"LWF"B[$(\\YO./\XKE T1*[
M4_ ,7IMT0_0,XG#PSD,;PE=XX"N\LS[SXI$&'E1H-E=P)UZKP*.30)N3#[3$
M[A3\A=<F^1"MXS<<KO.8!OF<2^6#+GWS#H_V4RY#Y!T>>!>/*N_PFF_Y0$OL
M!L%P>&U2#M$C?L.!.\]IB*## S?C]0TZ/%*G0H5F?^H*G(I/%73XS7=_H"5V
M@V O_#8AA^@:NN&H78=$A69O S N?M^PPR<U)51H-DTP)3Y5V.$WAQUHB=T@
M. F_5<[1-G##T3H/9XCLPP=OXO?-/GQ2%T*%9M,$%^)391][((5I$"O9-3BN
M?%]!\641'X+T+HPS%NG;?(US46R.=/?]"[LG)MF47V$P3XQ)UN7#E0Z6.BT*
M\M_?)KFYW3\IOA7A\"T8L_\!4$L#!!0    ( -@[7%A%(IA5BP(  .,&   9
M    >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;*U574_;,!3]*U:&)I &^:RA
M+(T$K=!XF%11V!ZF/;C)36/AV)GM-O#O9R<A*VTH/.PE\<<]YY[C7-_$M9"/
MJ@#0Z*ED7$V<0NOJTG556D!)U)FH@)N=7,B2:#.5*U=5$DC6@$KF!IZ'W9)0
M[B1QLS:722S6FE$.<XG4NBR)?+X&)NJ)XSLO"W=T56B[X"9Q15:P /U0S:69
MN3U+1DO@B@J.).03Y\J_G&(;WP3\H%"KK3&R3I9"/-K);39Q/"L(&*3:,A#S
MVL 4&+-$1L:?CM/I4UK@]OB%_:;Q;KPLB8*I8#]IIHN)<^&@#'*R9OI.U-^@
M\S.R?*E@JGFBNHW%8P>E:Z5%V8&-@I+R]DV>NG/8 OC1&X"@ P0?!80=(&R,
MMLH:6S.B21)+42-IHPV;'31GTZ"-&\KM5UQH:7:IP>GDEF^ :R&?T2E:F!+)
MU@R0R-&_]>,9:$*9.C$1#XL9.CXZ04>(<G1?B+4B/%.QJXT2R^>F7=;K-FOP
M1M89I&<H]+^@P O" ?CTX_#@-=PU_OM#"/I#"!J^\-U#F%&5,J'6$M"OJZ72
MTI39[R%_+6$T3&BOWJ6J2 H3Q]PM!7(#3O+YDX^]KT-N_Q/9*^]A[ST\Q)[<
MD=K4DP9)"1O\DBU\U,!M3]@D&/M1[&ZV'>P'^>'8#_JH5]*B7EIT4-H"2GJ:
M4TY->6=H)<1PJ;4D>"OW>3@.=@3N!P5^Y'O# D>]P-%!@3?O:AOMISW'8V]'
MW'Z4'V)_6!ONM>&#VNZ%)LQ<TZZRA\3AO8\6^7B,=\3M1X487X0[ZMRM%F3;
M_W<B5Y0KQ" W.._LW!#(MJ6V$RVJIBLMA38]KAD6YB\$T@:8_5P(_3*QC:[_
MKR5_ 5!+ P04    " #8.UQ8K@KA12(#   K#   &0   'AL+W=O<FMS:&5E
M=',O<VAE970U-2YX;6RM5UUOVC 4_2M6-DVM1)L/D@ =( %9-:15K5IU>YCV
MX"87L)K8F6U(^^]G)R&%$C(JA0>PG7N.[SE.;B[#C/%GL0*0Z"6)J1@9*RG3
M*],4X0H2+"Y9"E1=63">8*FF?&F*E ..<E 2FXYE^6:""37&PWSMCH^';"UC
M0N&.([%.$LQ?IQ"S;&38QG;AGBQ74B^8XV&*E_  \C&]XVIF5BP128 *PBCB
ML!@9$_LJ&.CX/. G@4SLC)%6\L38LY[,HY%AZ80@AE!J!JQ^-C"#.-9$*HV_
M):=1;:F!N^,M^W6N76EYP@)F+/Y%(KD:&7T#1;# ZUC>L^P[E'H\S1>R6.3?
M*"MB/<] X5I(EI1@E4%":/&+7TH?=@"V?P3@E #G/< ] NB6@.ZI +<$N+DS
MA93<AP!+/!YREB&NHQ6;'N1FYF@EGU!][ ^2JZM$X>1X3C= )>.OZ )-HHCH
MP\ QFM/BCM)'<Q: Q"06YRKD\2% 9Y_/AZ94>VL&,RSWF1;[.$?VL1UTPZA<
M"?2-1A#M$Y@JZ2IS9YOYU&ED#""\1%V[@QS+Z=8D-#L=[M3 @]/A=H.:;G4.
MW9RO^]]S^/U#74)S"8GX4^=SP>/6\^@J<252',+(4&5  -^ ,?[RR?:MKW4>
MM4D6M$2VYY];^><VL>_XEW$BX2)B&:USKV#Q<A9=$C?CGN-:^C,T-[O.' :Z
M;L^OB0P.(]\B]K1XE1:O4<LUX0E*USQ<J8*&0I8D1*I**U',A*@35=#Y.QE<
M]+I>G2KO(%?;\P9UJ@XCCZCR*U7^:2?408LC COJ11*R#7 "M3K] YVNY=3)
M;,SDH[=U2V1[IO4JTWJ-ILUN;M%DR0&T/766-,(_6@W:) M:(MNSK5_9UF^I
MFO;;]*]-LJ ELCW_!I5_@\;;[C8%KE[^=(EB4(]H!Y$DQ>JA;2I"@X."X=MU
MSV;CSA\UJ26RPB1SIXU*@"_S=E2H^K2FLNA+JM6JXYWDC=Z[]:GJA(O&]8VF
M:*-O,%\2*I2M"T5I7?:47[QH38N)9&G>K#TQJ5J_?+A2W3QP':"N+QB3VXG>
MH/I_,/X'4$L#!!0    ( -@[7%@E]VLP P,  %H(   9    >&PO=V]R:W-H
M965T<R]S:&5E=#4V+GAM;*U6WT_;,!#^5ZP,32 !^=FDL#82;3>-26@(QO8P
M[<$DU\;"L3O;:>&_WSEI0VG3;@][:6SG[KOONYSO.EA*]:0+ $.>2R[TT"F,
MF5^ZKLX***D^EW,0^&8J54D-;M7,U7,%-*^=2NX&GA>[)67"20?UV:U*![(R
MG FX541794G5RPBX7 X=WUD?W+%98>R!FP[F= ;W8![FMPIW;HN2LQ*$9E(0
M!=.A<^5?COO6OC;XSF"I-];$*GF4\LENKO.AXUE"P"$S%H'B8P%CX-P"(8W?
M*TRG#6D=-]=K]$^U=M3R2#6,)?_!<E,,G;Y#<IC2BIL[N?P,*ST]BY=)KNM?
MLFQL$S3.*FUDN7)&!B43S9,^K_*PX>#'>QR"E4.P[1#M<0A7#F$MM&%6RYI0
M0].!DDNBK#6BV46=F]H;U3!AO^*]4?B6H9])K\4"A)'JA9R1>RR1O.) Y)2\
MGM^!!K4 38XG8"CC^@1-'^XGY/CHA!P1)LBW0E::BEP/7(.4++";K<*/FO#!
MGO!^0&ZD,(4F'T4.^5L %[6T@H*UH%%P$'$"V3D)_5,2>$'806C\[^[! 3IA
MF]^PQ@O_FM]5'LG/.\DYP1I<4I7_ZDI9@QAU(]IK?:GG-(.A@_>VQG32]^_\
MV/O0)?<_@;T1'[7BHT/HZ8AR*C(@U) O5%38)8A_VJ6X@>G5,+;O+-(P[H=]
M_'Z+32V[9EYK\89@KR78.TAP7% U@YP82<92&UOXFG+0IUC6&:]R)F:$E7/*
M%#8NTUG?38!X@U,21)&_Q7S7*HJ2WD7233]NZ<<'Z7\U!2A"\YS9EMA)+]X)
M'/>\Z&*+WJ[5GL0F+;/D(+,)-I)L+ZED)]Q9$%[T_6B+5H==<A%LF+WAUF^Y
M]?^U*O&V0_F(.0R[Z[*_4W!!''N][?3MFFV5;\/3W6C3)6#AV>FE228K89H&
MUYZV _*JG@M;YR,<G,V<>X5IINX-UC,3FG"8(J1WGB IU4RR9F/DO!X&C]+@
M:*F7!0Y_4-8 WT^E-.N-#=#^G4C_ %!+ P04    " #8.UQ8?(>GO_D"  #:
M"   &0   'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6RM5EUOFS 4_2L6JZ9.
MZDJ D&1=@I2/??2A4]6NVT,U309N@E=C,]N$5MJ/GVT2FJ0TS4-?P#;WGGON
MN;8OPXJ+.YD!*'2?4R9'3J94<>:Z,LD@Q_*4%\#TESD7.59Z*A:N+ 3@U#KE
MU/4[G9Z;8\*<:&C7+D4TY*6BA,&E0++,<RP>)D!Y-7(\9[UP11:9,@MN-"SP
M JY!W1270L_<!B4E.3!).$,"YB-G[)U-!\;>&OP@4,F-,3*9Q)S?F<EY.G(Z
MAA!02)1!P/JUA"E0:H TC;\K3*<):1PWQVOTSS9WG4N,)4PY_4E2E8V<@8-2
MF..2JBM>?855/J'!2SB5]HFJVC8,')244O%\Y:P9Y(35;WR_TF'#(>@_X^"O
M'/Q#'8*50V 3K9G9M&98X6@H>(6$L=9H9F"UL=XZ&\),%:^5T%^)]E/1%\[3
MBE"*CF>@,*'R'3I"A*'O&2\E9JD<NDJ',<9NLH*<U)#^,Y">CRXX4YE$GU@*
MZ3: J_DU)/TUR8F_%W$&R2D*O!/D=_P W5S/T/'1.[V'"BX488O?)2.JA>?T
M<%3_(-0M\D&C<&##!"\IK-5$YTQAMB Q!326$I1$,R(3RF4I -V.8ZF$WMB_
MVD2OHW3;HYC#?B8+G,#(T:=9@EB"$[U]X_4Z']N4>26P+4&ZC2#=?>C1MS*/
M02 ^?]0:&:TE^O=R32<U=L]BFRMJ&7E#=[F9VSZ++<)A0S@\K(*W5UP_]?51
M89&V%BE\S2*]$MA6SKTFY][>(JUS/D$Q+ ACID@QII@ET)9W#19N:N[W@F"W
M-"UF@=?M?VBO3[_AVM_+=5H* 2QY0/KP,$EQW1_2/_KVU/U&M5YA_:>;Q/.#
M';I/C=Z'7G?0SG;0L!T<J"RP] 59!RVR]KMA=X=GF]F6^C51=Z--Y" 6MGM*
ME/"2J?HR;E:;!CVV?6EG?:(;=]UG'V'JKG^!A=XM$E&8:\C.:5^3$G4GK2>*
M%[89Q5SIUF:'F?[Y &$,]/<YYVH],0&:WYGH/U!+ P04    " #8.UQ8ODA<
ML9P%  #G*@  &0   'AL+W=O<FMS:&5E=',O<VAE970U."YX;6RUFEMOHS@8
MAO^*E1VM9J3.$#O'=M)(;6&TE:;J['2[>[':"Q><Q!K &=OI8;4_?LVA$ ?B
M!NG+30L$/S;O"Q^\X-F3D#_4BC&-GI,X5>>]E=;K,\]3X8HE5'T2:Y::7Q9"
M)E2;5;GTU%HR&N6-DM@C_?[82RA/>_-9ONV;G,_$1L<\9=\D4ILDH?+EDL7B
MZ;R'>Z\;OO/E2F<;O/EL39?LCNG[]3=IUKR*$O&$I8J+%$FV..]=X+. 3+(&
M^1Y_<O:DMI91=B@/0OS(5JZC\UX_&Q&+6:@S!#7_'MD5B^.,9,;QLX3VJCZS
MAMO+K_0O^<&;@WF@BEV)^"\>Z=5Y;]I#$5O03:R_BZ??6'E HXP7BECE?]%3
ML>]HTD/A1FF1E(W-"!*>%O_I<RG$5@-"]C0@90-R:(-!V6!P:(-AV6"XTP!/
M]S08E0WR0_>*8\^%\ZFF\YD43TAF>QM:MI"KG[<V>O$T.U'NM#2_<M-.S[\R
MH[)"']%%%/',.AJCZ[0X 3,CW_M,4QZK#^@=XBGZ8R4VBJ:1FGG:])XQO+#L
MZ;+HB>SI"1-T(U*]4BA((Q;9 ,\,NQH[>1W[)7$2?19^0@-\@DB?#-#]G8_>
MO_O0,K"KPS'$@?$/QV ')C@<TT<+_>LO>#+][%!K4#D]R,&#O4XKQ=@)RAT_
M03Y3H>3KW.2_OYI]T;5FB?JGS=@"/&P'9Z7L3*UIR,Y[IE8I)A]9;VZ&/>Y_
M;C,#$N9#P@(@F.7.L')GZ*(7UR$2#S%?YA=>FPT%8903LAO XQQC,L:G,^]Q
M6V!G1UT%AH0%0#!+X%$E\,@I<'X+1&*!-D9G:BX%?8)2IMMT+D#C+9W)\'0Z
MVI%YU'!C,!Y,A_9>OG-07?4#@EGZC2O]QF[];N_1%QKRF.N7HH:TW@.<D*ZE
M A+F0\("()CEQ*1R8G*L0CZ!= <2YD/" B"8Y<ZT<F?JO$YNUTR:"IXN45SX
MPY,UY=(\6VL4"]5ZT4P;!6=TVN_OU!MGMUWEAH0%0#!+[M-*[E.GW%<WM^AB
M*1G+!&[3UMF\ZRD/"?,A80$0S/( ]^L0T3]622K)0 :!TGQ06@!%LSW:"GH8
MO#"5R.W*-,:-RN3NN+/HD+0 BF:+3FK1R9OER<1E='7CUV6J76HGJ/-U $GS
M06D!%,VVI([!^&@Y&(,&85":#TH+H&BV1W48QH>DX9C3AR)O9)>0; 0XA20+
MQ3+E_^Z^3BKM&C:KU[19O9I[X>EX=S??/>+.^AXC"N,Z"V-W&)[T^^CW#4]#
MAFYEN*(R0M\%C=Q/4FYFY[,?DN:#T@(HFNU.G;3Q^&@5"C1_@])\4%H 1;,]
MJC,X=H;(^>NKD!.4;I(')K/"I'YNJ&1HD7W?^6_/J]O2)M @#DKS06E!2;.J
MJZD^6^75-J".V;ACSF;/:Y8JUBHW9-R] J7Y)6W[/>*H<9,*H/JTQ:Y#-G:G
M[$/>3I>(;:=/QZ/F[;:YVV1 FK=;T'0,1;,_4]7QF#BC79=WSR7I+17+W49O
MJ.@>5U<5H6BVBG6 )>X >YV&,C\/WT>L6/J0?9(4=B&HGQI;Y<4-W3Y.!L.F
MOJ"1%I060-%L&^I(2]R1UOX(4#\RFEO>#4]YLDE:A0>-MZ T'Y060-%L>^IX
M2XX6;PEHO 6E^:"T (IF>U3'6^*.MSO/+MFC"Y=[;ZQOP#!Z852B*4KRV16M
M5H!^$@:E!5 TVXHZ"1-W$G95,_J\MYJ!1F%0F@]*"Z!HMCUU%"9'B\($- J#
MTGQ06@!%LSVJHS!Q1^&.U<P-PX.\G+67,="<"TH+H&B%!][6A+Z$R64^DU*A
M4&Q27<R/J[96LS4O\CF*.]LO\5E0S+FL,<44T!LJESQ5QK.%0?8_3<R%+HM9
ME<6*%NM\VN"#T%HD^>**T8C); ?S^T((_;J2=5#-;9W_#U!+ P04    " #8
M.UQ8VZ@G:,8$  #Z%   &0   'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6RM
M6&UOXC@0_BM6;G7J2K2)G1!"#Y!:NM6NU+M697O[874?##$0;1)SMBGMOS_;
MA+QA7#CQI20P\^29>6:F$P\VE/WB2T($>,O2G ^=I1"K:]?ELR7),+^B*Y++
M7^:495C(6[9P^8H1'&NG+'61YX5NAI/<&0WT=T]L-*!KD28Y>6* K[,,L_=;
MDM+-T('.[HOG9+$4Z@MW-%CA!9D0\;)Z8O+.+5'B)",Y3V@.&)D/G1MX/4;:
M05O\G9 -KUT#%<J4TE_JYEL\=#S%B*1D)A0$EA^O9$S25"%)'O\6H$[Y3.58
MO]ZAW^O@93!3S,F8IC^26"R'3N2 F,SQ.A7/=/.5% %U%=Z,IES_!9O"UG/
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M- TD2 LPZSLA],O ;M"WI.M_ 5!+ P04    " #8.UQ8>%@BO+\"  #0!P
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M9"26&@*KPYZL299I)#6/?QI0IWVF3CP]_X[^:U6\*N8)"[)FV=]I(G=+)W)
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MU/T-4RW0#/1WYO:'B-4W4$L#!!0    ( -@[7%B3N<RQ] (  %8(   9
M>&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;*U676_:,!3]*U9639VT-I\$VD$D
M()U6:96JTFX/TQY,<@&KB9W9#K3[];M.T@QH0'WH"[&=<T[NN;;O9;@1\E&M
M #1YRC.N1M9*Z^+2ME6R@IRJ<U$ QS<+(7.J<2J7MBHDT+0BY9GM.4YHYY1Q
M*QI6:[<R&HI29XS#K22JS',JGR>0B<W(<JV7A3NV7&FS8$?#@BYA!OJAN)4X
MLUN5E.7 %1.<2%B,K+%[&8<&7P%^,-BHK3$Q3N9"/)K)=3JR'!,09)!HHT#Q
ML88I9)D1PC#^-)I6^TE#W!Z_J'^MO*.7.54P%=E/ENK5R!I8)(4%+3-])S;?
MH/'3,WJ)R%3U2S8-UK%(4BHM\H:,$>2,UT_ZU.1AB^"&!PA>0_#V"<$!@M\0
M_+<2@H805)FIK51YB*FFT5"*#9$&C6IF4"6S8J-]QLVVS[3$MPQY.OHN^/+L
M'F1.8IAK<D9F>+#2,@,B%N2::Y"@-+EZPF.F@)S&H"G+U"<$/LQB<GKRB9P0
MQLG]2I2*\E0-;8U1&6T[:2*8U!%X!R)P/7(CN%XI<L532'<%;+33>O)>/$V\
MHXHQ).?$=S\3S_'\CH"F;Z=['?3X[73WB!N_W2&_TO,/ZN&^Q$PEF5"E!/)K
M/%=:XGWYW97K6BOHUC(UY%(5-(&1A45"@5R#%7W\X(;.EZX\O:=8_$YB.SD,
MVAP&Q]2CJ2@++#*L.<]=B:L%>I6 J97KZ*+?OQC:Z^V$O :Y7B_P=E%Q%\H=
M#%K4CH5>:Z%WU,(X%U*SO[2JEG@W4W,LF%(EY0F01"C=>?=JT7 [EG"P;ZL#
M%%ST]UQU@;R@VU38F@J/FKH7FF;MMA!HR@PZ3 1? QJ>8R7B0H,B!7VF..LR
M&;Y.N!N$@SV7':C \?=R$7>@_-#U]GS:6Q4W![FL.I?"J$NNZT+5KK;-<5SU
MA+WU"3;-NL?]EZD[[@V52\85R6"!DLYY'V.2=1>K)UH455V?"XU=HAJNL/&#
M- !\OQ"8MV9B/M#^E8C^ 5!+ P04    " #8.UQ8N)"#<"8*  !19@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6RUG5UOVS@6AO\*X1TL.D :6U^V
MTTT"M!&)[6+:"=)VYF*P%XI-VT(MR2O)20O,CU_J(Z8H2R=6^Z873>R(#RF]
M$G7X\E"Z?$S2K]E&RIQ]B[9Q=C7:Y/GNS7B<+38R"K+S9"=C]9=5DD9!KCZF
MZW&V2V6P+ M%V[$]F4S'41#&H^O+\KO;]/HRV>?;,):W*<OV412DW]_);?)X
M-;)&3U_<A>M-7GPQOK[<!6OY2>9?=K>I^C0^4)9A).,L3&*6RM75Z*WU1GA>
M4:#<XH]0/F:-WUFQ*_=)\K7X\'YY-9H4+9);N<@+1*!^/,@;N=T6)-6._]70
MT:'.HF#S]R>Z*'=>[<Q]D,F;9/MGN,PW5Z/YB"WE*MAO\[OD\=^RWJ&R@8MD
MFY7_L\=JV]G%B"WV69Y$=6'5@BB,JY_!M_I - K8=D\!NRY@MPHXLYX"3EW
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MWBRN>:Q'6W4!_?NR+-7C2IU@^Q&)^;]02P,$%     @ V#M<6.?<##@$"
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M0'X_RW/Q^D%5L'[YR^0?4$L#!!0    ( -@[7%B.0'D0Q@,  - 1   9
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M1; A^U3<T^,?4!8T5GPA3;G^1<<RUC)0N.>"9B589I E>?%/GDHA:@#;NP#
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MME0#:W,[+ =9%H-X3PSB>NB:4;D5Z!V-(&H*V,KCRFWOX/;2ZU4,(!P@W[U
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ME4I9G-NVB%/(L3AE!5"U,V4\QU)-^<P6!0><&%">V9[C=.T<$VJ% [,VYN&
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M0;7ML9T8V;@.LY8&^Y4;5OA% <H:X/.-E.9Q8IM6_XV2_PM02P,$%     @
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MBZ(=O>[616D_4I^H6C*A"8<% KV34V10]<5?3XQ<57?G7!ILX&J8X[<2E"W
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M36*^'3O0>7WP0)<K91ZXD]$:+\F,J,?UO=!W;H$2T80P23D#@BS&SA6\G*+
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M@/Y^P;EZO3$-%,=ODW\!4$L#!!0    ( -@[7%A CH:=%@0  (X0   9
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M[(5V*^]!#DU.SS-R;(=\>S_TV'9"AY)J3(.A7;F<:;L?2Q'I0W875??DHE8
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M]_%H=Z/XNOG^<L^5XF5SN:)$G[%K _U^R;EZO:D_Z72?\!;_ 5!+ P04
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M9.H>]!.5.X9IS6&+DLY-B#')NJ^K!UH<JDYG(S3V3=7C'EMAD,8 U[="Z-/
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M2E=IM6E[+TY]X85)0#68VB9IO_V-#4M"PJ*-Y'V3@/'\[?G9'H:9[;CX(5,
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MH7%I7P2V%N@1OPBL^=8U4JE,*7U6C=MH:%@J(H@A% J!Y=\*KB".%4G&\:^
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MDBA*$C\"F-]!%&$(/(TX@CD #Q@21?8]N/<^"C?OJ7#[7\KQ'U!+ P04
M" #8.UQ8EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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MQ R4$!L(Q?2Z3X(9*"$V$-Z:(XB)&2@A-A#>FEXOQPR4$!L(Q_1Z.;K+F-A
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M[_*=>@_CYZ$.MYZO-3[_.ZD>+_?6V^.ORZ^3$W:N.(?[BN'Y+U!+ P04
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MX1_'+\^T-^WPG)\M_^*X^0502P$"% ,4    " #7.UQ8!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M -<[7%CXKG-9[P   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( -<[7%B97)PC$ 8  )PG   3
M  "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ USM<6,_N
MQ)8&"   #S$  !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( -<[7%@SOG$5.@(  +T%   8
M  " @4H0  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #7
M.UQ8L3%]=ST&  "J(   &               @(&Z$@  >&PO=V]R:W-H965T
M<R]S:&5E=#,N>&UL4$L! A0#%     @ USM<6$Z)_'V2 P  >0L  !@
M         ("!+1D  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0
M   ( -<[7%CS:]VE"@<   $>   8              " @?4<  !X;"]W;W)K
M<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #7.UQ8&V&ZH!4#  "Q"0
M&               @($U)   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!
M A0#%     @ USM<6!HN:2(4"0  )$@  !@              ("!@"<  'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( -<[7%AA-46\O@(
M -\&   8              " @<HP  !X;"]W;W)K<VAE971S+W-H965T."YX
M;6Q02P$"% ,4    " #7.UQ8@7%<NE,)   K*P  &               @(&^
M,P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ USM<6/ [
M^&FP!@  'Q   !D              ("!1ST  'AL+W=O<FMS:&5E=',O<VAE
M970Q,"YX;6Q02P$"% ,4    " #7.UQ8JQ\.(,\I  #<A@  &0
M    @($N1   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (
M -<[7%CIZ<Y':!X   1D   9              " @31N  !X;"]W;W)K<VAE
M971S+W-H965T,3(N>&UL4$L! A0#%     @ USM<6$C?>38($0  #C4  !D
M             ("!TXP  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"
M% ,4    " #7.UQ8WLGK3/8"  #\!@  &0              @($2G@  >&PO
M=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( -<[7%A476(+_P0
M "@,   9              " @3^A  !X;"]W;W)K<VAE971S+W-H965T,34N
M>&UL4$L! A0#%     @ USM<6(F..7RN!   -@L  !D              ("!
M=:8  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #7.UQ8
M6L-,8+<"   $!@  &0              @(%:JP  >&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;%!+ 0(4 Q0    ( -<[7%A2TQF\10H   <T   9
M      " @4BN  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%
M  @ USM<6 V$1.% $0  _CH  !D              ("!Q+@  'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #7.UQ8]D,JD@P%   F#0
M&0              @($[R@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+
M 0(4 Q0    ( -<[7%@8#Q,TF L  #(A   9              " @7[/  !X
M;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ USM<6%>O#AZP
M P  =0@  !D              ("!3=L  'AL+W=O<FMS:&5E=',O<VAE970R
M,BYX;6Q02P$"% ,4    " #7.UQ8\^X:6?L$  #$"P  &0
M@($TWP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( -<[
M7%AK2T0E% P  #DA   9              " @6;D  !X;"]W;W)K<VAE971S
M+W-H965T,C0N>&UL4$L! A0#%     @ USM<6. 5?B]I%P  BDL  !D
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M=#(Y+GAM;%!+ 0(4 Q0    ( -<[7%C;.5Z*DS8  "Z^   9
M  " @>P7 0!X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @
MUSM<6'$!&DTF!0  60L  !D              ("!MDX! 'AL+W=O<FMS:&5E
M=',O<VAE970S,2YX;6Q02P$"% ,4    " #7.UQ8=6G_U50'  #I$P  &0
M            @($35 $ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4
M Q0    ( -<[7%@D,878"P,  /8&   9              " @9Y; 0!X;"]W
M;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ USM<6'E@Z F@ P
MS @  !D              ("!X%X! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX
M;6Q02P$"% ,4    " #7.UQ8FO3-[$ #  !H!P  &0              @(&W
M8@$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( -<[7%C,
MI(6FF@(  *4%   9              " @2YF 0!X;"]W;W)K<VAE971S+W-H
M965T,S8N>&UL4$L! A0#%     @ USM<6"FEQ5I%!@  D1$  !D
M     ("!_V@! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -<[7%AP)B]./ ,  !D'   9              "
M@>Z% 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ V#M<
M6*;2OUL5"   5S\  !D              ("!88D! 'AL+W=O<FMS:&5E=',O
M<VAE970T,RYX;6Q02P$"% ,4    " #8.UQ8Z-;MKS,%  "?*0  &0
M        @(&MD0$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0
M   ( -@[7%@*X%AFN0(  " +   9              " @1>7 0!X;"]W;W)K
M<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ V#M<6)CY>U@4'0  Q T"
M !D              ("!!YH! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q0
M2P$"% ,4    " #8.UQ8>%0+ZU<&  "+*   &0              @(%2MP$
M>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( -@[7%@;_S?
MS@,  '<4   9              " @>"] 0!X;"]W;W)K<VAE971S+W-H965T
M-#@N>&UL4$L! A0#%     @ V#M<6*01K9E,!   210  !D
M ("!Y<$! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " #8
M.UQ8<S3MRQP$   [&   &0              @(%HQ@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( -@[7%C_+Y?_#0D  *Q7   9
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M970U-2YX;6Q02P$"% ,4    " #8.UQ8)?=K, ,#  !:"   &0
M    @($!Y0$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    (
M -@[7%A\AZ>_^0(  -H(   9              " @3OH 0!X;"]W;W)K<VAE
M971S+W-H965T-3<N>&UL4$L! A0#%     @ V#M<6+Y(7+&<!0  YRH  !D
M             ("!:^L! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"
M% ,4    " #8.UQ8VZ@G:,8$  #Z%   &0              @($^\0$ >&PO
M=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( -@[7%A*+@"/< ,
M -X+   9              " @3OV 0!X;"]W;W)K<VAE971S+W-H965T-C N
M>&UL4$L! A0#%     @ V#M<6$PEV"%D P  G@H  !D              ("!
MXOD! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " #8.UQ8
M>%@BO+\"  #0!P  &0              @(%]_0$ >&PO=V]R:W-H965T<R]S
M:&5E=#8R+GAM;%!+ 0(4 Q0    ( -@[7%A/H(Y+,00  )08   9
M      " @7,  @!X;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%
M  @ V#M<6).YS+'T @  5@@  !D              ("!VP0" 'AL+W=O<FMS
M:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    " #8.UQ8N)"#<"8*  !19@
M&0              @($&" ( >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+
M 0(4 Q0    ( -@[7%C\]WAD- <  %!"   9              " @6,2 @!X
M;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ V#M<6.?<##@$
M"   "$8  !D              ("!SAD" 'AL+W=O<FMS:&5E=',O<VAE970V
M-RYX;6Q02P$"% ,4    " #8.UQ8CD!Y$,8#  #0$0  &0
M@($)(@( >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( -@[
M7%B5C=E51 4  *P>   9              " @08F @!X;"]W;W)K<VAE971S
M+W-H965T-CDN>&UL4$L! A0#%     @ V#M<6) R\28W!   WA(  !D
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M=#<T+GAM;%!+ 0(4 Q0    ( -@[7%C3:30 " ,  #0+   9
M  " @>0_ @!X;"]W;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @
MV#M<6(/9BG\F P  KP@  !D              ("!(T," 'AL+W=O<FMS:&5E
M=',O<VAE970W-BYX;6Q02P$"% ,4    " #8.UQ8+%J^'-T"  ")!P  &0
M            @(& 1@( >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4
M Q0    ( -@[7%C/K8'*$0,  (((   9              " @91) @!X;"]W
M;W)K<VAE971S+W-H965T-S@N>&UL4$L! A0#%     @ V#M<6'L/,S!$ P
MF L  !D              ("!W$P" 'AL+W=O<FMS:&5E=',O<VAE970W.2YX
M;6Q02P$"% ,4    " #8.UQ8-+,'A\\$  "*&P  &0              @(%7
M4 ( >&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4 Q0    ( -@[7%A
MCH:=%@0  (X0   9              " @5U5 @!X;"]W;W)K<VAE971S+W-H
M965T.#$N>&UL4$L! A0#%     @ V#M<6+$8Q)+C!   SA,  !D
M     ("!JED" 'AL+W=O<FMS:&5E=',O<VAE970X,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -@[7%BQOA=<%P(  *8$   9              "
M@2%R @!X;"]W;W)K<VAE971S+W-H965T.#<N>&UL4$L! A0#%     @ V#M<
M6%'18Z=- P  LA0   T              ( !;W0" 'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " #8.UQ8EXJ[',     3 @  "P              @ 'G=P(
M7W)E;',O+G)E;'-02P$"% ,4    " #8.UQ8UNL.]U8&  #<.   #P
M        @ '0> ( >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ V#M<6$#*
M==&. @  3#,  !H              ( !4W\" 'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ V#M<6"';^;$Q @  S3$  !,
M     ( !&8(" %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %\ 7P 0&@
&>X0"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>317</ContextCount>
  <ElementCount>477</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>113</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Organization &amp; Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/OrganizationBusiness</Role>
      <ShortName>Organization &amp; Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Collaboration, License, and Supply Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CollaborationLicenseandSupplyAgreements</Role>
      <ShortName>Collaboration, License, and Supply Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Cash, Cash Equivalents, and Restricted Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CashCashEquivalentsandRestrictedCash</Role>
      <ShortName>Cash, Cash Equivalents, and Restricted Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/Goodwill</Role>
      <ShortName>Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/LongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Stockholders??? Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockholdersDeficit</Role>
      <ShortName>Stockholders??? Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Employee Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/EmployeeBenefits</Role>
      <ShortName>Employee Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Other Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/OtherFinancialInformation</Role>
      <ShortName>Other Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CommitmentandContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/Restructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.novavax.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/Revenue</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Cash, Cash Equivalents, and Restricted Cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashTables</Role>
      <ShortName>Cash, Cash Equivalents, and Restricted Cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/CashCashEquivalentsandRestrictedCash</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/FairValueMeasurements</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/Inventory</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/GoodwillTables</Role>
      <ShortName>Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/Goodwill</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/Leases</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Long-Term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/LongTermDebtTables</Role>
      <ShortName>Long-Term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/LongTermDebt</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/StockBasedCompensation</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Other Financial Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/OtherFinancialInformationTables</Role>
      <ShortName>Other Financial Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/OtherFinancialInformation</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/IncomeTaxes</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Restructuring (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/RestructuringTables</Role>
      <ShortName>Restructuring (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.novavax.com/role/Restructuring</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Revenue - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/RevenueAdditionalInformationDetails</Role>
      <ShortName>Revenue - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Revenue - Schedule of Accounts Receivable, Unbilled Services, and Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails</Role>
      <ShortName>Revenue - Schedule of Accounts Receivable, Unbilled Services, and Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Revenue - Schedule of Product Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails</Role>
      <ShortName>Revenue - Schedule of Product Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Revenue - Schedule of Revenue Gross to Net Deductions Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails</Role>
      <ShortName>Revenue - Schedule of Revenue Gross to Net Deductions Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Revenue - Schedule of Grant Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails</Role>
      <ShortName>Revenue - Schedule of Grant Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Collaboration, License, and Supply Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails</Role>
      <ShortName>Collaboration, License, and Supply Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/CollaborationLicenseandSupplyAgreements</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Cash, Cash Equivalents, and Restricted Cash - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Cash, Cash Equivalents, and Restricted Cash - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Inventory - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/InventoryScheduleofInventoryDetails</Role>
      <ShortName>Inventory - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Inventory - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/InventoryAdditionalInformationDetails</Role>
      <ShortName>Inventory - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Inventory - Schedule of Inventory Reserves (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/InventoryScheduleofInventoryReservesDetails</Role>
      <ShortName>Inventory - Schedule of Inventory Reserves (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/GoodwillDetails</Role>
      <ShortName>Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/GoodwillTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails</Role>
      <ShortName>Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Leases - Schedule of Operating Lease Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails</Role>
      <ShortName>Leases - Schedule of Operating Lease Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information of Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/LeasesScheduleofSupplementalCashFlowInformationofLeasesDetails</Role>
      <ShortName>Leases - Schedule of Supplemental Cash Flow Information of Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Long-Term Debt - Schedule of Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails</Role>
      <ShortName>Long-Term Debt - Schedule of Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Long-Term Debt - Schedule of Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails</Role>
      <ShortName>Long-Term Debt - Schedule of Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Long-Term Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails</Role>
      <ShortName>Long-Term Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Stockholders??? Deficit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockholdersDeficitDetails</Role>
      <ShortName>Stockholders??? Deficit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/StockholdersDeficit</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Stock-Based Compensation - Schedule of Option and Appreciation Rights Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Option and Appreciation Rights Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used in Estimation of Fair Value of Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Assumptions Used in Estimation of Fair Value of Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Employee Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/EmployeeBenefitsDetails</Role>
      <ShortName>Employee Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/EmployeeBenefits</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - Other Financial Information - Schedule of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Other Financial Information - Schedule of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - Other Financial Information - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails</Role>
      <ShortName>Other Financial Information - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - Other Financial Information - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/OtherFinancialInformationAdditionalInformationDetails</Role>
      <ShortName>Other Financial Information - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - Other Financial Information - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/OtherFinancialInformationScheduleofAccruedExpensesDetails</Role>
      <ShortName>Other Financial Information - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - Other Financial Information - Schedule of Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/OtherFinancialInformationScheduleofOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Other Financial Information - Schedule of Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - Income Taxes - Schedule of Company's Income (Loss) from Operations Before Income Tax Provision (Benefit) by Jurisdiction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails</Role>
      <ShortName>Income Taxes - Schedule of Company's Income (Loss) from Operations Before Income Tax Provision (Benefit) by Jurisdiction (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9954520 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9954521 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9954522 - Disclosure - Income Taxes - Schedule of Tax Rate Differences (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails</Role>
      <ShortName>Income Taxes - Schedule of Tax Rate Differences (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9954523 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9954524 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollforwardDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits Rollforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9954525 - Disclosure - Commitment and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/CommitmentandContingenciesDetails</Role>
      <ShortName>Commitment and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/CommitmentandContingencies</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9954526 - Disclosure - Restructuring - Schedule of Impairment Charges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/RestructuringScheduleofImpairmentChargesDetails</Role>
      <ShortName>Restructuring - Schedule of Impairment Charges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9954527 - Disclosure - Restructuring - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/RestructuringNarrativeDetails</Role>
      <ShortName>Restructuring - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="nvax-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9954528 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.novavax.com/role/SubsequentEvents</ParentRole>
      <Position>87</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="nvax-20231231.htm">nvax-20231231.htm</File>
    <File>nvax-20231231.xsd</File>
    <File>nvax-20231231_cal.xml</File>
    <File>nvax-20231231_def.xml</File>
    <File>nvax-20231231_lab.xml</File>
    <File>nvax-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>nvax-20231231_g1.jpg</File>
    <File>nvax-20231231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1038">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="10">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>128
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "nvax-20231231.htm": {
   "nsprefix": "nvax",
   "nsuri": "http://www.novavax.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "nvax-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "nvax-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "nvax-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nvax-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "nvax-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nvax-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 397,
   "keyCustom": 80,
   "axisStandard": 37,
   "axisCustom": 1,
   "memberStandard": 54,
   "memberCustom": 54,
   "hidden": {
    "total": 21,
    "http://fasb.org/us-gaap/2023": 12,
    "http://www.novavax.com/20231231": 4,
    "http://xbrl.sec.gov/dei/2023": 4,
    "http://xbrl.sec.gov/ecd/2023": 1
   },
   "contextCount": 317,
   "entityCount": 1,
   "segmentCount": 113,
   "elementCount": 838,
   "unitCount": 12,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 1038,
    "http://xbrl.sec.gov/dei/2023": 40,
    "http://xbrl.sec.gov/ecd/2023": 10
   },
   "report": {
    "R1": {
     "role": "http://www.novavax.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.novavax.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "longName": "0000003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "longName": "0000004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
     "longName": "0000005 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:AccountsReceivableNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "longName": "0000006 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-32",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical",
     "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "0000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.novavax.com/role/OrganizationBusiness",
     "longName": "0000010 - Disclosure - Organization & Business",
     "shortName": "Organization & Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.novavax.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "0000011 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.novavax.com/role/Revenue",
     "longName": "0000012 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreements",
     "longName": "0000013 - Disclosure - Collaboration, License, and Supply Agreements",
     "shortName": "Collaboration, License, and Supply Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCash",
     "longName": "0000014 - Disclosure - Cash, Cash Equivalents, and Restricted Cash",
     "shortName": "Cash, Cash Equivalents, and Restricted Cash",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.novavax.com/role/FairValueMeasurements",
     "longName": "0000015 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.novavax.com/role/Inventory",
     "longName": "0000016 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.novavax.com/role/Goodwill",
     "longName": "0000017 - Disclosure - Goodwill",
     "shortName": "Goodwill",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.novavax.com/role/Leases",
     "longName": "0000018 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.novavax.com/role/LongTermDebt",
     "longName": "0000019 - Disclosure - Long-Term Debt",
     "shortName": "Long-Term Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.novavax.com/role/StockholdersDeficit",
     "longName": "0000020 - Disclosure - Stockholders\u2019 Deficit",
     "shortName": "Stockholders\u2019 Deficit",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.novavax.com/role/StockBasedCompensation",
     "longName": "0000021 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.novavax.com/role/EmployeeBenefits",
     "longName": "0000022 - Disclosure - Employee Benefits",
     "shortName": "Employee Benefits",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.novavax.com/role/OtherFinancialInformation",
     "longName": "0000023 - Disclosure - Other Financial Information",
     "shortName": "Other Financial Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.novavax.com/role/IncomeTaxes",
     "longName": "0000024 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.novavax.com/role/CommitmentandContingencies",
     "longName": "0000025 - Disclosure - Commitment and Contingencies",
     "shortName": "Commitment and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.novavax.com/role/Restructuring",
     "longName": "0000026 - Disclosure - Restructuring",
     "shortName": "Restructuring",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.novavax.com/role/SubsequentEvents",
     "longName": "0000027 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R29": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ecd:NonRule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrTrmntdFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "ecd:NonRule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrTrmntdFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.novavax.com/role/RevenueTables",
     "longName": "9954473 - Disclosure - Revenue (Tables)",
     "shortName": "Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "nvax:ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "nvax:ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashTables",
     "longName": "9954474 - Disclosure - Cash, Cash Equivalents, and Restricted Cash (Tables)",
     "shortName": "Cash, Cash Equivalents, and Restricted Cash (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.novavax.com/role/FairValueMeasurementsTables",
     "longName": "9954475 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.novavax.com/role/InventoryTables",
     "longName": "9954476 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.novavax.com/role/GoodwillTables",
     "longName": "9954477 - Disclosure - Goodwill (Tables)",
     "shortName": "Goodwill (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.novavax.com/role/LeasesTables",
     "longName": "9954478 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "nvax:ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "nvax:ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.novavax.com/role/LongTermDebtTables",
     "longName": "9954479 - Disclosure - Long-Term Debt (Tables)",
     "shortName": "Long-Term Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.novavax.com/role/StockBasedCompensationTables",
     "longName": "9954480 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.novavax.com/role/OtherFinancialInformationTables",
     "longName": "9954481 - Disclosure - Other Financial Information (Tables)",
     "shortName": "Other Financial Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.novavax.com/role/IncomeTaxesTables",
     "longName": "9954482 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.novavax.com/role/RestructuringTables",
     "longName": "9954483 - Disclosure - Restructuring (Tables)",
     "shortName": "Restructuring (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "9954484 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails",
     "longName": "9954485 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-63",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-63",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails",
     "longName": "9954486 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-78",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-78",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
     "longName": "9954487 - Disclosure - Revenue - Additional Information (Details)",
     "shortName": "Revenue - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:BilledContractReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:BilledContractReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails",
     "longName": "9954488 - Disclosure - Revenue - Schedule of Accounts Receivable, Unbilled Services, and Deferred Revenue (Details)",
     "shortName": "Revenue - Schedule of Accounts Receivable, Unbilled Services, and Deferred Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-20",
      "name": "us-gaap:AccountsReceivableGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-37",
      "name": "us-gaap:AccountsReceivableGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails",
     "longName": "9954489 - Disclosure - Revenue - Schedule of Product Revenue (Details)",
     "shortName": "Revenue - Schedule of Product Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-98",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails",
     "longName": "9954490 - Disclosure - Revenue - Schedule of Revenue Gross to Net Deductions Balances (Details)",
     "shortName": "Revenue - Schedule of Revenue Gross to Net Deductions Balances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-20",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-112",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails",
     "longName": "9954491 - Disclosure - Revenue - Schedule of Grant Revenue (Details)",
     "shortName": "Revenue - Schedule of Grant Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-129",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
     "longName": "9954492 - Disclosure - Collaboration, License, and Supply Agreements (Details)",
     "shortName": "Collaboration, License, and Supply Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "nvax:RoyaltyPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "nvax:RoyaltyPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails",
     "longName": "9954493 - Disclosure - Cash, Cash Equivalents, and Restricted Cash - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "shortName": "Cash, Cash Equivalents, and Restricted Cash - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-37",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.novavax.com/role/FairValueMeasurementsDetails",
     "longName": "9954494 - Disclosure - Fair Value Measurements (Details)",
     "shortName": "Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-197",
      "name": "us-gaap:LongTermDebtPercentageBearingFixedInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:LongTermDebtPercentageBearingFixedInterestRate",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-190",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.novavax.com/role/InventoryScheduleofInventoryDetails",
     "longName": "9954495 - Disclosure - Inventory - Schedule of Inventory (Details)",
     "shortName": "Inventory - Schedule of Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.novavax.com/role/InventoryAdditionalInformationDetails",
     "longName": "9954496 - Disclosure - Inventory - Additional Information (Details)",
     "shortName": "Inventory - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryWriteDown",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryWriteDown",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.novavax.com/role/InventoryScheduleofInventoryReservesDetails",
     "longName": "9954497 - Disclosure - Inventory - Schedule of Inventory Reserves (Details)",
     "shortName": "Inventory - Schedule of Inventory Reserves (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-20",
      "name": "us-gaap:InventoryValuationReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-37",
      "name": "us-gaap:InventoryValuationReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.novavax.com/role/GoodwillDetails",
     "longName": "9954498 - Disclosure - Goodwill (Details)",
     "shortName": "Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportingUnits",
      "unitRef": "reporting_unit",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-37",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.novavax.com/role/LeasesAdditionalInformationDetails",
     "longName": "9954499 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:OperatingLeaseLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-212",
      "name": "nvax:RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails",
     "longName": "9954500 - Disclosure - Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)",
     "shortName": "Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nvax:ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nvax:ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails",
     "longName": "9954501 - Disclosure - Leases - Schedule of Operating Lease Expenses (Details)",
     "shortName": "Leases - Schedule of Operating Lease Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.novavax.com/role/LeasesScheduleofSupplementalCashFlowInformationofLeasesDetails",
     "longName": "9954502 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information of Leases (Details)",
     "shortName": "Leases - Schedule of Supplemental Cash Flow Information of Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nvax:ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nvax:ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
     "longName": "9954503 - Disclosure - Leases - Maturities of Lease Liabilities (Details)",
     "shortName": "Leases - Maturities of Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails",
     "longName": "9954504 - Disclosure - Long-Term Debt - Schedule of Notes Payable (Details)",
     "shortName": "Long-Term Debt - Schedule of Notes Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:UnamortizedDebtIssuanceExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:UnamortizedDebtIssuanceExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails",
     "longName": "9954505 - Disclosure - Long-Term Debt - Schedule of Interest Expense (Details)",
     "shortName": "Long-Term Debt - Schedule of Interest Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nvax:InterestExpenseRelatedToConvertibleNotesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nvax:InterestExpenseRelatedToConvertibleNotesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
     "longName": "9954506 - Disclosure - Long-Term Debt - Additional Information (Details)",
     "shortName": "Long-Term Debt - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-196",
      "name": "us-gaap:LongTermDebtPercentageBearingFixedInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-235",
      "name": "us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.novavax.com/role/StockholdersDeficitDetails",
     "longName": "9954507 - Disclosure - Stockholders\u2019 Deficit (Details)",
     "shortName": "Stockholders\u2019 Deficit (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-241",
      "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
     "longName": "9954508 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails",
     "longName": "9954509 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails",
     "longName": "9954510 - Disclosure - Stock-Based Compensation - Schedule of Option and Appreciation Rights Activity (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Option and Appreciation Rights Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-265",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-265",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails",
     "longName": "9954511 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used in Estimation of Fair Value of Stock (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Assumptions Used in Estimation of Fair Value of Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-271",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-271",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails",
     "longName": "9954512 - Disclosure - Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-280",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nvax:ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-280",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nvax:ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.novavax.com/role/EmployeeBenefitsDetails",
     "longName": "9954513 - Disclosure - Employee Benefits (Details)",
     "shortName": "Employee Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.novavax.com/role/OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails",
     "longName": "9954514 - Disclosure - Other Financial Information - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Other Financial Information - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:Supplies",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:Supplies",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails",
     "longName": "9954515 - Disclosure - Other Financial Information - Schedule of Property and Equipment, Net (Details)",
     "shortName": "Other Financial Information - Schedule of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.novavax.com/role/OtherFinancialInformationAdditionalInformationDetails",
     "longName": "9954516 - Disclosure - Other Financial Information - Additional Information (Details)",
     "shortName": "Other Financial Information - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.novavax.com/role/OtherFinancialInformationScheduleofAccruedExpensesDetails",
     "longName": "9954517 - Disclosure - Other Financial Information - Schedule of Accrued Expenses (Details)",
     "shortName": "Other Financial Information - Schedule of Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.novavax.com/role/OtherFinancialInformationScheduleofOtherCurrentLiabilitiesDetails",
     "longName": "9954518 - Disclosure - Other Financial Information - Schedule of Other Current Liabilities (Details)",
     "shortName": "Other Financial Information - Schedule of Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:CustomerRefundLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "nvax:OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.novavax.com/role/IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails",
     "longName": "9954519 - Disclosure - Income Taxes - Schedule of Company's Income (Loss) from Operations Before Income Tax Provision (Benefit) by Jurisdiction (Details)",
     "shortName": "Income Taxes - Schedule of Company's Income (Loss) from Operations Before Income Tax Provision (Benefit) by Jurisdiction (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails",
     "longName": "9954520 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)",
     "shortName": "Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails",
     "longName": "9954521 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails",
     "longName": "9954522 - Disclosure - Income Taxes - Schedule of Tax Rate Differences (Details)",
     "shortName": "Income Taxes - Schedule of Tax Rate Differences (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails",
     "longName": "9954523 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.novavax.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollforwardDetails",
     "longName": "9954524 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Rollforward (Details)",
     "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits Rollforward (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-20",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.novavax.com/role/CommitmentandContingenciesDetails",
     "longName": "9954525 - Disclosure - Commitment and Contingencies (Details)",
     "shortName": "Commitment and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-312",
      "name": "us-gaap:LossContingencyNumberOfDefendants",
      "unitRef": "defendant",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-312",
      "name": "us-gaap:LossContingencyNumberOfDefendants",
      "unitRef": "defendant",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.novavax.com/role/RestructuringScheduleofImpairmentChargesDetails",
     "longName": "9954526 - Disclosure - Restructuring - Schedule of Impairment Charges (Details)",
     "shortName": "Restructuring - Schedule of Impairment Charges (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SeveranceCosts1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.novavax.com/role/RestructuringNarrativeDetails",
     "longName": "9954527 - Disclosure - Restructuring - Narrative (Details)",
     "shortName": "Restructuring - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SeveranceCosts1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-314",
      "name": "us-gaap:SeveranceCosts1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.novavax.com/role/SubsequentEventsDetails",
     "longName": "9954528 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-317",
      "name": "nvax:RestructuringAndRelatedCostNumberOfPositionsEliminatedGlobalPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-317",
      "name": "nvax:RestructuringAndRelatedCostNumberOfPositionsEliminatedGlobalPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvax-20231231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "nvax_A700QuinceOrchardRoadAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "A700QuinceOrchardRoadAgreementMember",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "700 Quince Orchard Road Agreement",
        "label": "700 Quince Orchard Road Agreement [Member]",
        "documentation": "700 Quince Orchard Road Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r833"
     ]
    },
    "nvax_AccountsReceivableAllowanceForCreditLossAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "AccountsReceivableAllowanceForCreditLossAdditions",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Additions",
        "verboseLabel": "Bad debt expense",
        "label": "Accounts Receivable, Allowance for Credit Loss, Additions",
        "documentation": "Accounts Receivable, Allowance for Credit Loss, Additions"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_AccountsReceivableAllowanceForCreditLossDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "AccountsReceivableAllowanceForCreditLossDeductions",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deductions",
        "label": "Accounts Receivable, Allowance for Credit Loss, Deductions",
        "documentation": "Accounts Receivable, Allowance for Credit Loss, Deductions"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_AccountsReceivableBeforeAllowanceForCreditLossAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "AccountsReceivableBeforeAllowanceForCreditLossAdditions",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Accounts Receivable, Before Allowance For Credit Loss, Additions",
        "documentation": "Accounts Receivable, Before Allowance For Credit Loss, Additions"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_AccountsReceivableBeforeAllowanceForCreditLossDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "AccountsReceivableBeforeAllowanceForCreditLossDeductions",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deductions",
        "label": "Accounts Receivable, Before Allowance For Credit Loss, Deductions",
        "documentation": "Accounts Receivable, Before Allowance For Credit Loss, Deductions"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_AccountsReceivableBeforeAllowanceForCreditLossRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "AccountsReceivableBeforeAllowanceForCreditLossRollForward",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable:",
        "label": "Accounts Receivable, Before Allowance For Credit Loss [Roll Forward]",
        "documentation": "Accounts Receivable, Before Allowance For Credit Loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableGross",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Accounts receivable, beginning balance",
        "periodEndLabel": "Accounts receivable, ending balance",
        "label": "Accounts Receivable, before Allowance for Credit Loss",
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r295",
      "r1046"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r715",
      "r771",
      "r839",
      "r1046"
     ]
    },
    "nvax_AccruedGrossToNetDeductionsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "AccruedGrossToNetDeductionsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross-to-net deductions",
        "label": "Accrued Gross-To-Net Deductions, Current",
        "documentation": "Accrued Gross-To-Net Deductions, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/CommitmentandContingenciesDetails",
      "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Liabilities",
        "label": "Accrued Liabilities [Member]",
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "nvax_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Research and Development Expenses",
        "label": "Accrued Research and Development Expenses, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accrued research and development expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r198",
      "r653"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustment",
        "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax",
        "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r214",
      "r215",
      "r216",
      "r593"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r115",
      "r206",
      "r649",
      "r671",
      "r672"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r12",
      "r35",
      "r578",
      "r581",
      "r626",
      "r667",
      "r668",
      "r943",
      "r944",
      "r945",
      "r953",
      "r954",
      "r955"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Financial Information",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r833",
      "r1051"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r535",
      "r536",
      "r682",
      "r953",
      "r954",
      "r955",
      "r1028",
      "r1053"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78",
      "r499"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICITParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock, issuance costs",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r141"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising Costs",
        "label": "Advertising Cost [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "us-gaap_AdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising costs",
        "label": "Advertising Expense",
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line."
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "us-gaap_AgencySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AgencySecuritiesMember",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agency securities",
        "label": "Agency Securities [Member]",
        "documentation": "Securities issued by government sponsored entities."
       }
      }
     },
     "auth_ref": [
      "r960",
      "r962"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r857",
      "r869",
      "r879",
      "r905"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r872",
      "r882",
      "r908"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r864",
      "r873",
      "r883",
      "r900",
      "r909",
      "r913",
      "r921"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r528",
      "r537"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedPeriodStartLabel": "Allowance for doubtful accounts, beginning balance",
        "negatedPeriodEndLabel": "Allowance for doubtful accounts, end balance",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r298",
      "r306",
      "r307",
      "r308",
      "r1046"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for doubtful accounts:",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "nvax_AmendedAndRestatedUKSupplyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "AmendedAndRestatedUKSupplyAgreementMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended and Restated UK Supply Agreement",
        "label": "Amended and Restated UK Supply Agreement [Member]",
        "documentation": "Amended and Restated UK Supply Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt issuance costs",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r605",
      "r807",
      "r808",
      "r948"
     ]
    },
    "nvax_AmountsChargedAgainstProductSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "AmountsChargedAgainstProductSales",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contract value no longer available",
        "terseLabel": "Amounts charged against product sales",
        "label": "Amounts Charged Against Product Sales",
        "documentation": "Amounts Charged Against Product Sales"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/CommitmentandContingenciesDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails",
      "http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails",
      "http://www.novavax.com/role/StockholdersDeficitDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetBackedSecuritiesMember",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government-backed securities",
        "label": "Asset-Backed Securities [Member]",
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans."
       }
      }
     },
     "auth_ref": [
      "r817",
      "r961",
      "r963",
      "r964"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/RestructuringScheduleofImpairmentChargesDetails": {
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.novavax.com/role/RestructuringNarrativeDetails",
      "http://www.novavax.com/role/RestructuringScheduleofImpairmentChargesDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Impairment of long-lived assets",
        "terseLabel": "Impairment of assets",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r59"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r201",
      "r239",
      "r271",
      "r285",
      "r289",
      "r303",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r573",
      "r575",
      "r594",
      "r645",
      "r720",
      "r833",
      "r846",
      "r985",
      "r986",
      "r1036"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r211",
      "r239",
      "r303",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r573",
      "r575",
      "r594",
      "r833",
      "r985",
      "r986",
      "r1036"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.novavax.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r851",
      "r852",
      "r865"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.novavax.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r851",
      "r852",
      "r865"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.novavax.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r851",
      "r852",
      "r865"
     ]
    },
    "nvax_August2023SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "August2023SalesAgreementMember",
     "presentation": [
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "August 2023 Sales Agreement",
        "label": "August 2023 Sales Agreement [Member]",
        "documentation": "August 2023 Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_AustralianAPAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "AustralianAPAMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Australian APA",
        "label": "Australian APA [Member]",
        "documentation": "Australian APA"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/CommitmentandContingenciesDetails",
      "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails",
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Axis]",
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/CommitmentandContingenciesDetails",
      "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails",
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Domain]",
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_BilledContractReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BilledContractReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Billed contracts receivable",
        "label": "Billed Contracts Receivable",
        "documentation": "Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingMember",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Building",
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "nvax_CEPIGrantFundingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "CEPIGrantFundingMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CEPI Grant Funding",
        "label": "CEPI Grant Funding [Member]",
        "documentation": "CEPI Grant Funding"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_CMOAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "CMOAgreementMember",
     "presentation": [
      "http://www.novavax.com/role/InventoryAdditionalInformationDetails",
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CMO Agreement",
        "label": "CMO Agreement [Member]",
        "documentation": "CMO Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_CMOAndCMDAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "CMOAndCMDAgreementsMember",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CMO and CMD Agreements",
        "label": "CMO and CMD Agreements [Member]",
        "documentation": "CMO and CMD Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "country_CZ": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "CZ",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Czech Republic",
        "label": "CZECHIA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CallOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CallOptionMember",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Call Option",
        "label": "Call Option [Member]",
        "documentation": "Financial contract between two parties, the buyer and the seller of the option, where the buyer has the right but not the obligation to buy an agreed quantity of a particular commodity or financial instrument (the underlying instrument) from the seller of the option for a certain price (the strike price). Seller is obligated to sell the asset to the buyer, if the buyer exercises the option."
       }
      }
     },
     "auth_ref": [
      "r760",
      "r761"
     ]
    },
    "nvax_CanadaAdvancePurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "CanadaAdvancePurchaseAgreementMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Canada Advance Purchase Agreement",
        "label": "Canada Advance Purchase Agreement [Member]",
        "documentation": "Canada Advance Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CanadaRevenueAgencyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CanadaRevenueAgencyMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Canada Revenue Agency",
        "label": "Canada Revenue Agency [Member]",
        "documentation": "Designated tax department of the government of Canada."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Capital expenditures included in accounts payable and accrued expenses",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r46"
     ]
    },
    "us-gaap_CapitalLossCarryforwardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalLossCarryforwardMember",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital Loss Carryforward",
        "label": "Capital Loss Carryforward [Member]",
        "documentation": "Deductions derived from capital losses that cannot be utilized on the tax return during a period that have been carried forward to reduce taxable income or taxes payable in a future year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r196",
      "r789"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r153"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of year",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of year",
        "totalLabel": "Cash, cash equivalents, and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r126",
      "r236"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (decrease) increase in cash, cash equivalents, and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r126"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash activities:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_CashFlowOperatingAndFinancingActivitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "CashFlowOperatingAndFinancingActivitiesLesseeAbstract",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalCashFlowInformationofLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:",
        "label": "Cash Flow Operating and Financing Activities Lessee [Abstract]",
        "documentation": "Cash Flow Operating and Financing Activities Lessee"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r202",
      "r203",
      "r204",
      "r239",
      "r261",
      "r262",
      "r264",
      "r266",
      "r269",
      "r270",
      "r303",
      "r342",
      "r344",
      "r345",
      "r346",
      "r349",
      "r350",
      "r382",
      "r383",
      "r386",
      "r389",
      "r395",
      "r594",
      "r676",
      "r677",
      "r678",
      "r679",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r707",
      "r729",
      "r748",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r928",
      "r949",
      "r957"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "nvax_CoalitionForEpidemicPreparednessInnovationsAwardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "CoalitionForEpidemicPreparednessInnovationsAwardMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CEPI",
        "label": "Coalition For Epidemic Preparedness Innovations Award [Member]",
        "documentation": "n/a"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Coalition for Epidemic Preparedness Innovations (\"CEPI\")",
        "label": "Coalition For Epidemic Preparedness Innovations (CEPI) Agreement [Member]",
        "documentation": "Coalition For Epidemic Preparedness Innovations (CEPI) Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_CoalitionForEpidemicPreparednessInnovationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "CoalitionForEpidemicPreparednessInnovationsMember",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CEPI",
        "label": "Coalition for Epidemic Preparedness Innovations [Member]",
        "documentation": "Coalition for Epidemic Preparedness Innovations"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_CollaborationAgreementRemainingPaymentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "CollaborationAgreementRemainingPaymentAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining payment amount",
        "label": "Collaboration Agreement Remaining Payment Amount",
        "documentation": "Collaboration Agreement Remaining Payment Amount"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_CollaborationAgreementUpfrontPaymentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "CollaborationAgreementUpfrontPaymentAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement upfront payment amount",
        "label": "Collaboration Agreement Upfront Payment Amount",
        "documentation": "Collaboration Agreement Upfront Payment Amount"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_CollaborativeArrangementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "CollaborativeArrangementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement [Abstract]",
        "documentation": "Collaborative Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Collaboration, License, and Supply Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r175",
      "r188"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_CollectiveBargainingArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollectiveBargainingArrangementAxis",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collective Bargaining Arrangement [Axis]",
        "label": "Collective-Bargaining Arrangement [Axis]",
        "documentation": "Information by arrangement collectively bargained between employer and its employees represented by union."
       }
      }
     },
     "auth_ref": [
      "r827",
      "r993"
     ]
    },
    "us-gaap_CollectiveBargainingArrangementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollectiveBargainingArrangementDomain",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collective Bargaining Arrangement [Domain]",
        "label": "Collective-Bargaining Arrangement [Domain]",
        "documentation": "Arrangement collectively bargained between employer and its employees represented by union."
       }
      }
     },
     "auth_ref": [
      "r827",
      "r993"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 16)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r96",
      "r646",
      "r706"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r334",
      "r335",
      "r773",
      "r980"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r837",
      "r838",
      "r840",
      "r841",
      "r842",
      "r843",
      "r953",
      "r954",
      "r1028",
      "r1050",
      "r1053"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value per share (in usd per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "nvax_CommonStockPremiumPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "CommonStockPremiumPaid",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, premium paid",
        "label": "Common Stock, Premium Paid",
        "documentation": "Common Stock, Premium Paid"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_CommonStockQuotedMarketPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "CommonStockQuotedMarketPrice",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, quoted market price",
        "label": "Common stock, Quoted Market Price",
        "documentation": "Common stock, Quoted Market Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r707"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodEndLabel": "Balance beginning (in shares)",
        "periodStartLabel": "Balance ending (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r106",
      "r707",
      "r726",
      "r1053",
      "r1054"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, $0.01 par value, 600,000,000 shares authorized at December\u00a031, 2023 and 2022; and 140,506,093 shares issued and 139,505,770 shares outstanding at December\u00a031, 2023 and 86,806,554 shares issued and 86,039,923 shares outstanding at December\u00a031, 2022",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r648",
      "r833"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "nvax_CompensationStockIssuedUnderIncentiveProgram": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "CompensationStockIssuedUnderIncentiveProgram",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issued under incentive programs",
        "label": "Compensation Stock Issued Under Incentive Program",
        "documentation": "Compensation Stock Issued Under Incentive Program"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Components of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Components of Deferred Tax Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r219",
      "r221",
      "r228",
      "r641",
      "r657"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other comprehensive income (loss):",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer Equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "nvax_ComputerSoftwareAndHardwareMemberMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "ComputerSoftwareAndHardwareMemberMember",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer hardware",
        "label": "Computer Software And Hardware Member [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r53",
      "r90",
      "r91",
      "r294",
      "r772"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r53",
      "r90",
      "r91",
      "r294",
      "r673",
      "r772"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r53",
      "r90",
      "r91",
      "r294",
      "r772",
      "r932"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Concentration of Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r177"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Line Items]",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk, percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r53",
      "r90",
      "r91",
      "r294"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Table]",
        "label": "Concentration Risk [Table]",
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r53",
      "r54",
      "r90",
      "r151",
      "r772"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r53",
      "r90",
      "r91",
      "r294",
      "r772"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerBasisOfPricingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerBasisOfPricingAxis",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with Customer, Basis of Pricing [Axis]",
        "label": "Contract with Customer, Basis of Pricing [Axis]",
        "documentation": "Information by basis of pricing for contract representing right to consideration in exchange for good or service transferred to customer."
       }
      }
     },
     "auth_ref": [
      "r813",
      "r988"
     ]
    },
    "us-gaap_ContractWithCustomerBasisOfPricingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerBasisOfPricingDomain",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with Customer, Basis of Pricing [Domain]",
        "label": "Contract with Customer, Basis of Pricing [Domain]",
        "documentation": "Basis of pricing for contract with customer. Includes, but is not limited to, fixed-price and time-and-materials contracts."
       }
      }
     },
     "auth_ref": [
      "r813",
      "r988"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails",
      "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "periodStartLabel": "Deferred revenue, beginning balance",
        "periodEndLabel": "Deferred revenue, ending balance",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r398",
      "r409"
     ]
    },
    "nvax_ContractWithCustomerLiabilityAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "ContractWithCustomerLiabilityAdditions",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Contract With Customer, Liability, Additions",
        "documentation": "Contract With Customer, Liability, Additions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Deferred revenue, current",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r398",
      "r409"
     ]
    },
    "nvax_ContractWithCustomerLiabilityDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "ContractWithCustomerLiabilityDeductions",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deductions",
        "label": "Contract With Customer, Liability, Deductions",
        "documentation": "Contract With Customer, Liability, Deductions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Deferred revenue, noncurrent",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r398",
      "r409"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment recognized",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "nvax_ContractWithCustomerLiabilityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "ContractWithCustomerLiabilityRollForward",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with Customer, Liability [Roll Forward]",
        "label": "Contract with Customer, Liability [Roll Forward]",
        "documentation": "Contract with Customer, Liability"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_ContractWithCustomerObligationToDeliverTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "ContractWithCustomerObligationToDeliverTerms",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with customer, obligation to deliver, terms",
        "label": "Contract With Customer, Obligation To Deliver, Terms",
        "documentation": "Contract With Customer, Obligation To Deliver, Terms"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_ConversionPremiumPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "ConversionPremiumPercentage",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion premium percentage",
        "label": "Conversion Premium Percentage",
        "documentation": "It represents the rate of premium based on the last reported sales price of stock."
       }
      }
     },
     "auth_ref": []
    },
    "nvax_ConvertibleDebtConversionRate": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "ConvertibleDebtConversionRate",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible debt conversion rate",
        "label": "Convertible Debt Conversion Rate",
        "documentation": "Convertible debt conversion rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleLongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes payable",
        "totalLabel": "Total non-current convertible notes payable",
        "label": "Convertible Notes Payable, Noncurrent",
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleNotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes payable",
        "totalLabel": "Total current convertible notes payable",
        "label": "Convertible Notes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "nvax_ConvertibleNotesPayableCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "ConvertibleNotesPayableCurrentAbstract",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion:",
        "label": "Convertible Notes Payable, Current [Abstract]",
        "documentation": "Convertible Notes Payable, Current"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_ConvertibleNotesPayableNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "ConvertibleNotesPayableNoncurrentAbstract",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current portion:",
        "label": "Convertible Notes Payable, Noncurrent [Abstract]",
        "documentation": "Convertible Notes Payable, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r817",
      "r819",
      "r1049"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales",
        "label": "Cost of Revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r239",
      "r303",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r594",
      "r985"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/RestructuringScheduleofImpairmentChargesDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales",
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Sales",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expenses:",
        "label": "Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring",
        "label": "Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r133",
      "r134"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243",
      "r355",
      "r384",
      "r627",
      "r792",
      "r794"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r935",
      "r952",
      "r1026"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r935",
      "r952"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current income tax expense (benefit)",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r561",
      "r566",
      "r952"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current:",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and local",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r935",
      "r952",
      "r1026"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r294"
     ]
    },
    "us-gaap_CustomerRefundLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerRefundLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofOtherCurrentLiabilitiesDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Refunds due to APA customers",
        "label": "Customer Refund Liability, Current",
        "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment."
       }
      }
     },
     "auth_ref": []
    },
    "nvax_DebtCapPrice": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "DebtCapPrice",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt cap price (in usd per share)",
        "label": "Debt Cap Price",
        "documentation": "The cap rate on a debt . A payment or receipt is triggered if the market rate exceeds the cap rate on the debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued for debt converted (in shares)",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r46"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Long-Term Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r237",
      "r351",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r367",
      "r374",
      "r375",
      "r377"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails",
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r100",
      "r101",
      "r155",
      "r157",
      "r244",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r358",
      "r363",
      "r364",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r606",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r950"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, convertible, conversion price (in usd per share)",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r354"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold consecutive trading days",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold percentage of stock price",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold trading days",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails": {
       "parentTag": "us-gaap_ConvertibleLongTermNotesPayable",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate principal amount of notes issued",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r95",
      "r352",
      "r606",
      "r805",
      "r806"
     ]
    },
    "nvax_DebtInstrumentFaceAmountCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "DebtInstrumentFaceAmountCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails": {
       "parentTag": "us-gaap_ConvertibleNotesPayableCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.75% Convertible notes due 2023",
        "label": "Debt Instrument, Face Amount, Current",
        "documentation": "Debt Instrument, Face Amount, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, interest rate, effective percentage",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r93",
      "r379",
      "r606"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r358",
      "r363",
      "r364",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r376",
      "r606",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r950"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails",
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r244",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r358",
      "r363",
      "r364",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r606",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r950"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Redemption, Period One",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Redemption, Period Two",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption price, percentage",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of principal amount redeemed",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "documentation": "Percentage of principal amount of debt redeemed."
       }
      }
     },
     "auth_ref": []
    },
    "nvax_DebtInstrumentRepurchaseOfPrincipalAmountPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "DebtInstrumentRepurchaseOfPrincipalAmountPercentage",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchase percentage of principal amount",
        "label": "Debt Instrument, Repurchase Of Principal Amount, Percentage",
        "documentation": "Debt Instrument, Repurchase Of Principal Amount, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r69",
      "r70",
      "r92",
      "r93",
      "r95",
      "r97",
      "r139",
      "r140",
      "r244",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r358",
      "r363",
      "r364",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r376",
      "r606",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r950"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, term",
        "label": "Debt Instrument, Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails": {
       "parentTag": "us-gaap_ConvertibleLongTermNotesPayable",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unamortized debt issuance costs",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r363",
      "r378",
      "r805",
      "r806"
     ]
    },
    "us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtRelatedCommitmentFeesAndDebtIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs",
        "label": "Debt Related Commitment Fees and Debt Issuance Costs",
        "documentation": "Represents the charge against earnings during the period for commitment fees and debt issuance expenses."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Prepaid Expenses and Other Current Assets",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r952",
      "r1025"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r156",
      "r555"
     ]
    },
    "nvax_DeferredRevenueIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "DeferredRevenueIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Revenue Increase (Decrease) [Abstract]",
        "documentation": "Deferred Revenue Increase (Decrease)"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_DeferredTaxAssetLeasingLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "DeferredTaxAssetLeasingLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Deferred Tax Asset, Leasing Liability",
        "documentation": "Deferred Tax Asset, Leasing Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Tax Assets, Deferred Income",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r1024"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research costs",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r1024"
     ]
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInventory",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory reserve",
        "label": "Deferred Tax Assets, Inventory",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r1024"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets (liabilities)",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign net operating loss carryforward",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r1024"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Federal and state net operating loss carryforward",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r1024"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r1024"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsForeign",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign tax credit carryforward",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Foreign",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r83",
      "r1024"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r83",
      "r1024"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-cash stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r1024"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for sales returns",
        "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r1024"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net deferred tax liability",
        "totalLabel": "Net deferred tax assets (liabilities)",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r1023"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Intangibles",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r1024"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "ROU assets",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r1024"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r1024"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Fixed assets",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r1024"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined contribution plan, cost",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined contribution plan, employer matching contribution, percent of employees' gross pay",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined contribution plan, employer matching contribution, percent of match",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Maximum contribution, percentage of compensation",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r60"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r275"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails",
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails",
      "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails",
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails",
      "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r501",
      "r530",
      "r531",
      "r533",
      "r828"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r851",
      "r852",
      "r865"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r851",
      "r852",
      "r865",
      "r901"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share:",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in usd per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r259",
      "r261",
      "r264",
      "r265",
      "r266",
      "r267",
      "r585",
      "r586",
      "r642",
      "r658",
      "r797"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in usd per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r261",
      "r264",
      "r265",
      "r266",
      "r267",
      "r585",
      "r586",
      "r642",
      "r658",
      "r797"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate on cash, cash equivalents, and restricted cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax expense",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory federal tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r546",
      "r568"
     ]
    },
    "nvax_EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancellation of Indebtedness",
        "label": "Effective Income Tax Rate Reconciliation, Cancellation Of Indebtedness, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Cancellation Of Indebtedness, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1021",
      "r1027"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r568",
      "r1021"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-US tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r1021",
      "r1027"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-deductible expenses",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r1021",
      "r1027"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1021",
      "r1027"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State income taxes, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1021",
      "r1027"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development and other tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r1021",
      "r1027"
     ]
    },
    "nvax_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash stock-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Non-Cash Share-Based Payment Arrangement, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Non-Cash Share-Based Payment Arrangement, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofTaxRateDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. taxation of foreign operations",
        "label": "Effective Income Tax Rate Reconciliation, US Taxation Of Foreign Operations",
        "documentation": "Effective Income Tax Rate Reconciliation, US Taxation Of Foreign Operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Employee benefits and compensation",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation capitalized",
        "label": "Share-Based Payment Arrangement, Amount Capitalized",
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense, recognition period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "us-gaap_EmployeeSeveranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeSeveranceMember",
     "presentation": [
      "http://www.novavax.com/role/RestructuringNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Severance",
        "label": "Employee Severance [Member]",
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ESPP",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r191",
      "r223",
      "r224",
      "r225",
      "r245",
      "r246",
      "r247",
      "r249",
      "r255",
      "r257",
      "r268",
      "r304",
      "r305",
      "r396",
      "r534",
      "r535",
      "r536",
      "r562",
      "r563",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r584",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r626",
      "r667",
      "r668",
      "r669",
      "r682",
      "r748"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r857",
      "r869",
      "r879",
      "r905"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r854",
      "r866",
      "r876",
      "r902"
     ]
    },
    "nvax_EscrowDepositsRelatedToSalesHold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "EscrowDepositsRelatedToSalesHold",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Escrow to sales hold",
        "label": "Escrow Deposits Related To Sales Hold",
        "documentation": "Escrow Deposits Related To Sales Hold"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EuropeMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Europe",
        "label": "Europe [Member]"
       }
      }
     },
     "auth_ref": [
      "r1055",
      "r1056",
      "r1057",
      "r1058"
     ]
    },
    "nvax_EuropeanCommissionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "EuropeanCommissionMember",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "European Commission",
        "label": "European Commission [Member]",
        "documentation": "European Commission"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_EuropeanCommissionsECMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "EuropeanCommissionsECMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "European Commissions (\"EC\")",
        "label": "European Commissions (\"EC\") [Member]",
        "documentation": "European Commissions (\"EC\")"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "nvax_FacilityLeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "FacilityLeaseAgreementMember",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facility Lease Agreement",
        "label": "Facility Lease Agreement [Member]",
        "documentation": "Facility Lease Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_FacilityNumberOfSquareFeet": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "FacilityNumberOfSquareFeet",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facility, number of square feet",
        "label": "Facility Number Of Square Feet",
        "documentation": "Facility Number Of Square Feet"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r588",
      "r589",
      "r590"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r588",
      "r589",
      "r590"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value Hierarchy",
        "label": "Fair Value Measurements, Nonrecurring [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a nonrecurring basis in periods after initial recognition (for example, impaired assets). Disclosures may include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r88",
      "r150"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Domain]",
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Axis]",
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r589",
      "r631",
      "r632",
      "r633",
      "r805",
      "r806",
      "r817",
      "r818",
      "r819"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r438",
      "r443",
      "r589",
      "r631",
      "r817",
      "r818",
      "r819"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r438",
      "r443",
      "r589",
      "r632",
      "r805",
      "r806",
      "r817",
      "r818",
      "r819"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r589",
      "r633",
      "r805",
      "r806",
      "r817",
      "r818",
      "r819"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r631",
      "r632",
      "r633",
      "r805",
      "r806",
      "r817",
      "r818",
      "r819"
     ]
    },
    "nvax_FilipDubovskyMDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "FilipDubovskyMDMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Filip Dubovsky, MD [Member]",
        "documentation": "Filip Dubovsky, MD"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Finance Lease, Interest Expense",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r611",
      "r618",
      "r832"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalCashFlowInformationofLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows used in finance leases",
        "label": "Finance Lease, Interest Payment on Liability",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r613",
      "r621"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "parentTag": "nvax_LeaseLiabilityCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of finance lease liabilities",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "parentTag": "nvax_LeaseLiabilityNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-current finance lease liabilities",
        "terseLabel": "Non-current portion of finance lease liabilities",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.novavax.com/role/LeasesScheduleofSupplementalCashFlowInformationofLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Finance lease payments",
        "terseLabel": "Financing cash flows used in finance leases",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r621"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "parentTag": "nvax_LeaseRightOfUseAsset",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ROU assets, finance, net",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ROU assets expensed",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r611",
      "r618",
      "r832"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance leases",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r624",
      "r832"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance leases",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r832"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total convertible notes payable",
        "label": "Financial Liabilities Fair Value Disclosure",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "nvax_FirstThreePercentOfParticipantsDeferralMemberMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "FirstThreePercentOfParticipantsDeferralMemberMember",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Three Percent Of Participants Deferral",
        "label": "First Three Percent Of Participants Deferral Member [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027 Notes, Make-Whole Fundamental Change",
        "label": "Five Point Zero Convertible Notes Due 2027, Make-Whole Fundamental Change [Member]",
        "documentation": "Five Point Zero Convertible Notes Due 2027, Make-Whole Fundamental Change"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_FivePointZeroConvertibleNotesDue2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "FivePointZeroConvertibleNotesDue2027Member",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails",
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "5.00% Convertible notes due 2027",
        "verboseLabel": "2027 Notes",
        "label": "Five Point Zero Convertible Notes Due 2027 [Member]",
        "documentation": "Five Point Zero Convertible Notes Due 2027"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign Currency",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_ForeignPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignPlanMember",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Plan",
        "label": "Foreign Plan [Member]",
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r991",
      "r992",
      "r994"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r861",
      "r873",
      "r883",
      "r909"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r861",
      "r873",
      "r883",
      "r909"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r861",
      "r873",
      "r883",
      "r909"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r861",
      "r873",
      "r883",
      "r909"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r861",
      "r873",
      "r883",
      "r909"
     ]
    },
    "nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "GaviAdvancePurchaseAgreementCOVAXFacilityMember",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gavi Advance Purchase Agreement- COVAX Facility",
        "label": "Gavi Advance Purchase Agreement- COVAX Facility [Member]",
        "documentation": "Gavi Advance Purchase Agreement- COVAX Facility"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_GaviAdvancePurchaseAgreementSIIPLMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "GaviAdvancePurchaseAgreementSIIPLMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gavi Advance Purchase Agreement SIIPL",
        "label": "Gavi Advance Purchase Agreement SIIPL [Member]",
        "documentation": "Gavi Advance Purchase Agreement SIIPL"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general, and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r731"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general, and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/GoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "periodStartLabel": "Goodwill, beginning balance",
        "periodEndLabel": "Goodwill, ending balance",
        "label": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r314",
      "r640",
      "r803",
      "r833",
      "r968",
      "r975"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r320",
      "r803"
     ]
    },
    "us-gaap_GoodwillDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillDisclosureTextBlock",
     "presentation": [
      "http://www.novavax.com/role/Goodwill"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r316",
      "r319",
      "r803"
     ]
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/GoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation adjustments",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment to goodwill",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r315",
      "r317",
      "r320",
      "r803"
     ]
    },
    "us-gaap_GoodwillRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillRollForward",
     "presentation": [
      "http://www.novavax.com/role/GoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Roll Forward]",
        "label": "Goodwill [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "nvax_GovernmentOfAustraliaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "GovernmentOfAustraliaMember",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government of Australia",
        "label": "Government of Australia [Member]",
        "documentation": "Government of Australia"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_GovernmentOfCanadaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "GovernmentOfCanadaMember",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government of Canada",
        "label": "Government of Canada [Member]",
        "documentation": "Government of Canada"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_GovernmentOfIsraelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "GovernmentOfIsraelMember",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government of Israel",
        "label": "Government of Israel [Member]",
        "documentation": "Government of Israel"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrantMember",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grants",
        "label": "Grant [Member]",
        "documentation": "Award of money not required to be repaid."
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "us-gaap_GrantsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrantsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grants additional credit",
        "label": "Grants Receivable",
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants."
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "nvax_GrantsUSGovernmentContractAndJointVentureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "GrantsUSGovernmentContractAndJointVentureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grants, U.S. Government Contract and Joint Venture",
        "label": "Grants, U.S. Government Contract and Joint Venture [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r851",
      "r852",
      "r865"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r132"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r567"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.novavax.com/role/IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income tax expense",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r116",
      "r160",
      "r271",
      "r284",
      "r288",
      "r290",
      "r643",
      "r655",
      "r799"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofCompanysIncomeLossfromOperationsBeforeIncomeTaxProvisionBenefitbyJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r567"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.novavax.com/role/RestructuringScheduleofImpairmentChargesDetails",
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r326",
      "r732"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.novavax.com/role/RestructuringScheduleofImpairmentChargesDetails",
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r732"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Axis]",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Domain]",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority, Name [Axis]",
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority, Name [Domain]",
        "label": "Income Tax Authority, Name [Domain]",
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r541",
      "r547",
      "r552",
      "r559",
      "r564",
      "r569",
      "r570",
      "r571",
      "r681"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax expense",
        "totalLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r185",
      "r256",
      "r257",
      "r276",
      "r545",
      "r565",
      "r659"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r543",
      "r544",
      "r552",
      "r553",
      "r558",
      "r560",
      "r675"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r43"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable, accrued expenses, and other liabilities",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Increase (decrease) in contract with customer, liability",
        "terseLabel": "Payments",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r636",
      "r947"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Deferred Revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in operating lease liability",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r933",
      "r947"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable, prepaid expenses, and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r864",
      "r873",
      "r883",
      "r900",
      "r909",
      "r913",
      "r921"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r925"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r925"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r925"
     ]
    },
    "nvax_InstallmentChargesOfTheCompany": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "InstallmentChargesOfTheCompany",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Installment charges",
        "label": "Installment Charges Of The Company",
        "documentation": "Installment Charges Of The Company"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r162",
      "r226",
      "r274",
      "r604",
      "r733",
      "r844",
      "r1052"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total interest expense on convertible notes payable",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r371",
      "r380",
      "r807",
      "r808"
     ]
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebtExcludingAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtScheduleofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Coupon interest",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r372",
      "r807",
      "r808"
     ]
    },
    "nvax_InterestExpenseRelatedToConvertibleNotesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "InterestExpenseRelatedToConvertibleNotesTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Interest Expense",
        "label": "Interest Expense Related to Convertible Notes [Table Text Block]",
        "documentation": "Tabular disclosure of interest expense related to convertible notes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash interest payments, net of amounts capitalized",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r234",
      "r235"
     ]
    },
    "us-gaap_InterimPeriodCostsNotAllocableDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterimPeriodCostsNotAllocableDomain",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interim Period, Costs Not Allocable [Domain]",
        "label": "Interim Period, Costs Not Allocable [Domain]",
        "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_InventoryCurrentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryCurrentTable",
     "presentation": [
      "http://www.novavax.com/role/InventoryAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, Current [Table]",
        "label": "Inventory, Current [Table]",
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.novavax.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/InventoryScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/InventoryScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Gross",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "us-gaap_InventoryFirmPurchaseCommitmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFirmPurchaseCommitmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/InventoryAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Firm purchase commitment loss",
        "label": "Inventory, Firm Purchase Commitment, Loss",
        "documentation": "Amount of loss recognized on firm purchase commitment for inventory."
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "nvax_InventoryFirmPurchaseCommitmentRecoveries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "InventoryFirmPurchaseCommitmentRecoveries",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/InventoryAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, firm purchase commitment, recoveries",
        "label": "Inventory, Firm Purchase Commitment, Recoveries",
        "documentation": "Inventory, Firm Purchase Commitment, Recoveries"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryLineItems",
     "presentation": [
      "http://www.novavax.com/role/InventoryAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory [Line Items]",
        "label": "Inventory [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.novavax.com/role/InventoryScheduleofInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/InventoryScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r790",
      "r833"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r195",
      "r208",
      "r309",
      "r310",
      "r312",
      "r638",
      "r795"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/InventoryScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/InventoryScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Gross",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "nvax_InventoryReserveChargedToCostsOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "InventoryReserveChargedToCostsOfSales",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/InventoryScheduleofInventoryReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charged to Cost of sales, including impairments",
        "label": "Inventory Reserve, Charged to Costs of sales",
        "documentation": "Inventory Reserve, Charged to Costs of sales"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_InventoryReserveDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "InventoryReserveDeductions",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/InventoryScheduleofInventoryReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deductions",
        "label": "Inventory Reserve, Deductions",
        "documentation": "Inventory Reserve, Deductions"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_InventoryReserveOtherAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "InventoryReserveOtherAdditions",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/InventoryScheduleofInventoryReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other additions",
        "label": "Inventory Reserve, Other Additions",
        "documentation": "Inventory Reserve, Other Additions"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_InventoryReserveRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "InventoryReserveRollForward",
     "presentation": [
      "http://www.novavax.com/role/InventoryScheduleofInventoryReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory Reserve [Roll Forward]",
        "label": "Inventory Reserve [Roll Forward]",
        "documentation": "Inventory Reserve"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryValuationReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryValuationReserves",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/InventoryScheduleofInventoryReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at January 1,",
        "periodEndLabel": "Balance at December 31,",
        "label": "Inventory Valuation Reserves",
        "documentation": "Amount of valuation reserve for inventory."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r941"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/InventoryScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/InventoryScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Semi-finished goods",
        "label": "Inventory, Work in Process, Gross",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/InventoryAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory write-down",
        "label": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total cash equivalents",
        "label": "Investments, Fair Value Disclosure",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCash"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash, Cash Equivalents, and Restricted Cash",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r163",
      "r164",
      "r190",
      "r300",
      "r301",
      "r591",
      "r592"
     ]
    },
    "nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "JointCommitteeOnVaccinationAndImmunizationJCVIMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Joint Committee on Vaccination and Immunization (JCVI)",
        "label": "Joint Committee on Vaccination and Immunization (JCVI) [Member]",
        "documentation": "Joint Committee on Vaccination and Immunization (JCVI)"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_June2021AndAugust2023SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "June2021AndAugust2023SalesAgreementMember",
     "presentation": [
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "June 2021 and August 2023 Sales Agreement",
        "label": "June 2021 and August 2023 Sales Agreement [Member]",
        "documentation": "June 2021 and August 2023 Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_June2021SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "June2021SalesAgreementMember",
     "presentation": [
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "June 2021 Sales Agreement",
        "label": "June 2021 Sales Agreement [Member]",
        "documentation": "June 2021 Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandAndLandImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LandAndLandImprovementsMember",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land and buildings",
        "label": "Land and Land Improvements [Member]",
        "documentation": "Real estate held and assets that are an addition or improvement to real estate held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total finance lease expense",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r832"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease expense:",
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Operating Lease Expenses",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "nvax_LeaseImpairmentChargeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "LeaseImpairmentChargeAxis",
     "presentation": [
      "http://www.novavax.com/role/InventoryAdditionalInformationDetails",
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails",
      "http://www.novavax.com/role/RestructuringNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Impairment Charge [Axis]",
        "label": "Lease Impairment Charge [Axis]",
        "documentation": "Lease Impairment Charge"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_LeaseImpairmentChargeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "LeaseImpairmentChargeDomain",
     "presentation": [
      "http://www.novavax.com/role/InventoryAdditionalInformationDetails",
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails",
      "http://www.novavax.com/role/RestructuringNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Impairment Charge [Domain]",
        "label": "Lease Impairment Charge [Domain]",
        "documentation": "Lease Impairment Charge [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_LeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "LeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current lease liabilities",
        "label": "Lease Liability, Current",
        "documentation": "Lease Liability, Current"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_LeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "LeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current lease liabilities",
        "label": "Lease Liability, Noncurrent",
        "documentation": "Lease Liability, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_LeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "LeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Right of use asset, net",
        "totalLabel": "Total non-current ROU assets",
        "label": "Lease, Right-Of-Use Asset",
        "documentation": "Lease, Right-Of-Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeFinanceLeasesTextBlock",
     "presentation": [
      "http://www.novavax.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Finance Leases [Text Block]",
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases Accounting",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Maturities of Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease expiration",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.novavax.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r239",
      "r303",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r574",
      "r575",
      "r576",
      "r594",
      "r705",
      "r798",
      "r846",
      "r985",
      "r1036",
      "r1037"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 deficit",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r159",
      "r651",
      "r833",
      "r951",
      "r965",
      "r1029"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r194",
      "r239",
      "r303",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r574",
      "r575",
      "r576",
      "r594",
      "r833",
      "r985",
      "r1036",
      "r1037"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Liabilities",
        "label": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_LiquidityAndGoingConcernPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "LiquidityAndGoingConcernPolicyTextBlock",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidity and Going Concern",
        "label": "Liquidity and Going Concern [Policy Text Block]",
        "documentation": "Liquidity and Going Concern"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial settlement payment",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "documentation": "Amount awarded to other party in judgment or settlement of litigation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationSettlementExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement expense",
        "label": "Litigation Settlement, Expense",
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtPercentageBearingFixedInterestRate",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails",
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Coupon interest rate",
        "label": "Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate",
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails",
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails",
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r67"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r341",
      "r981",
      "r982"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r341",
      "r981",
      "r982"
     ]
    },
    "us-gaap_LossContingencyNumberOfDefendants": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyNumberOfDefendants",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of defendants",
        "label": "Loss Contingency, Number of Defendants",
        "documentation": "Number of defendants named in a legal action."
       }
      }
     },
     "auth_ref": [
      "r981",
      "r982"
     ]
    },
    "nvax_LossContingencyPeriodToAnswer": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "LossContingencyPeriodToAnswer",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period to answer",
        "label": "Loss Contingency, Period To Answer",
        "documentation": "Loss Contingency, Period To Answer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Machinery and equipment",
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r294",
      "r812",
      "r988",
      "r1047",
      "r1048"
     ]
    },
    "nvax_MatrixMAdjuvantSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "MatrixMAdjuvantSalesMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Matrix-M Adjuvant Sales",
        "label": "Matrix-M Adjuvant Sales [Member]",
        "documentation": "Matrix-M Adjuvant Sales"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_MaximumContributionOfEmployeesAsPayrollDeductions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "MaximumContributionOfEmployeesAsPayrollDeductions",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum contribution of employees as payroll deductions",
        "label": "Maximum Contribution Of Employees As Payroll Deductions",
        "documentation": "Maximum contribution of employees as payroll deductions."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails",
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r340",
      "r490",
      "r635",
      "r666",
      "r697",
      "r698",
      "r753",
      "r755",
      "r757",
      "r758",
      "r762",
      "r783",
      "r784",
      "r801",
      "r809",
      "r827",
      "r835",
      "r987",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "nvax_MilestonePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "MilestonePaymentsMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Payments",
        "label": "Milestone Payments [Member]",
        "documentation": "Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r340",
      "r490",
      "r635",
      "r666",
      "r697",
      "r698",
      "r753",
      "r755",
      "r757",
      "r758",
      "r762",
      "r783",
      "r784",
      "r801",
      "r809",
      "r827",
      "r835",
      "r987",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r294",
      "r812",
      "r988",
      "r1047",
      "r1048"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_NatureOfExpenseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfExpenseAxis",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of Expense [Axis]",
        "label": "Nature of Expense [Axis]",
        "documentation": "Information by type of cost or expense."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.novavax.com/role/OrganizationBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization &amp; Business",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r186"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing Activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) operating activities",
        "terseLabel": "Net cash provided by (used in) operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r127",
      "r128"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating Activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "verboseLabel": "Net income (loss)",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r128",
      "r161",
      "r192",
      "r217",
      "r220",
      "r225",
      "r239",
      "r248",
      "r250",
      "r251",
      "r252",
      "r253",
      "r256",
      "r257",
      "r263",
      "r271",
      "r284",
      "r288",
      "r290",
      "r303",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r586",
      "r594",
      "r656",
      "r728",
      "r746",
      "r747",
      "r799",
      "r844",
      "r985"
     ]
    },
    "nvax_NetProceedsFromTheExerciseOfStockBasedAwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "NetProceedsFromTheExerciseOfStockBasedAwards",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from the exercise of stock-based awards",
        "label": "Net Proceeds From The Exercise Of Stock-Based Awards",
        "documentation": "Net Proceeds From The Exercise Of Stock-Based Awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "nvax_NextTwoPercentOfParticipantsDeferralMemberMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "NextTwoPercentOfParticipantsDeferralMemberMember",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Next Two Percent Of Participants Deferral",
        "label": "Next Two Percent Of Participants Deferral Member [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_NoExpirationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "NoExpirationMember",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "No Expiration",
        "label": "No Expiration [Member]",
        "documentation": "No Expiration"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets from new lease agreements",
        "label": "Non-cash Related Transactions For Finance Lease, Right-Of-Use Asset",
        "documentation": "Non-cash Related Transactions For Finance Lease, Right-Of-Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r861",
      "r873",
      "r883",
      "r900",
      "r909"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonUsMember",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-US",
        "label": "Non-US [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r1055",
      "r1056",
      "r1057",
      "r1058"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_NorthAmericaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NorthAmericaMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "North America",
        "label": "North America [Member]"
       }
      }
     },
     "auth_ref": [
      "r1055",
      "r1056",
      "r1057",
      "r1058"
     ]
    },
    "nvax_NumberOfDosesOfVaccineCandidate": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "NumberOfDosesOfVaccineCandidate",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of doses",
        "label": "Number Of Doses Of Vaccine Candidate",
        "documentation": "Number Of Doses Of Vaccine Candidate"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional purchase option, number of doses",
        "label": "Number Of Doses Of Vaccine Candidate, Additional Purchase Option",
        "documentation": "Number Of Doses Of Vaccine Candidate, Additional Purchase Option"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_NumberOfDosesToBeDistributed": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "NumberOfDosesToBeDistributed",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/CommitmentandContingenciesDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of doses to be distributed",
        "label": "Number Of Doses, To Be Distributed",
        "documentation": "Number Of Doses, To Be Distributed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "nvax_NumberOfQuarterlyInstallmentPayments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "NumberOfQuarterlyInstallmentPayments",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of quarterly installment payments",
        "label": "Number Of Quarterly Installment Payments",
        "documentation": "Number Of Quarterly Installment Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportingUnits": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportingUnits",
     "presentation": [
      "http://www.novavax.com/role/GoodwillDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reporting units",
        "label": "Number of Reporting Units",
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment."
       }
      }
     },
     "auth_ref": []
    },
    "nvax_NumberOfSettlementPayments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "NumberOfSettlementPayments",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of settlement payments",
        "label": "Number Of Settlement Payments",
        "documentation": "Number Of Settlement Payments"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_OperatingAndFinanceLeaseWriteOff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "OperatingAndFinanceLeaseWriteOff",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Right-of-use assets expensed, net of credits received",
        "label": "Operating and Finance Lease, Write-off",
        "documentation": "Operating and Finance Lease, Write-off"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r284",
      "r288",
      "r290",
      "r799"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease expense",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r619",
      "r832"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/InventoryAdditionalInformationDetails",
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails",
      "http://www.novavax.com/role/RestructuringNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, impairment loss",
        "label": "Operating Lease, Impairment Loss",
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails",
      "http://www.novavax.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease obligation",
        "verboseLabel": "Total current lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "parentTag": "nvax_LeaseLiabilityCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "parentTag": "nvax_LeaseLiabilityNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current portion of operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalCashFlowInformationofLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows used in operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r614",
      "r621"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "parentTag": "nvax_LeaseRightOfUseAsset",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails",
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use asset, net",
        "verboseLabel": "ROU assets, operating, net",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r624",
      "r832"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r832"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OptionIndexedToIssuersEquityEquityAxis",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Indexed to Issuer's Equity [Axis]",
        "label": "Option Indexed to Issuer's Equity [Axis]",
        "documentation": "Information by type of options indexed to an issuer's equity."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r86",
      "r87",
      "r149"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Indexed to Issuer's Equity, Type [Domain]",
        "label": "Option Indexed to Issuer's Equity, Type [Domain]",
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other accrued expenses",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r833"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other non-current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on marketable securities",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r11",
      "r148"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r11",
      "r148"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive income (loss)",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r11",
      "r148",
      "r218",
      "r221"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net unrealized gains (losses) on marketable securities available-for-sale, net of reclassifications",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214",
      "r302"
     ]
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Current Liabilities",
        "label": "Other Current Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "nvax_OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liability related to Gavi (see Note 3)",
        "label": "Other Current Liability Related To Advance Purchase Agreements",
        "documentation": "Other Current Liability Related To Advance Purchase Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_OtherGrantRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "OtherGrantRevenueMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other grant revenue",
        "label": "Other Grant Revenue [Member]",
        "documentation": "Other Grant Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "totalLabel": "Total other current liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r833"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other items, net",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense)",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherSundryLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Other Sundry Liabilities, Current",
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r66"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r859",
      "r871",
      "r881",
      "r907"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r862",
      "r874",
      "r884",
      "r910"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r862",
      "r874",
      "r884",
      "r910"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "nvax_PaymentForCappedCallTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "PaymentForCappedCallTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment for capped call transactions",
        "label": "PaymentForCappedCallTransactions",
        "documentation": "Amount of payment which is made for entering into privately negotiated capped call transactions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentOfFinancingAndStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments of costs related to issuance of 2027 Convertible notes",
        "label": "Payment of Financing and Stock Issuance Costs",
        "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_PaymentsForCapitalImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForCapitalImprovements",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Capital expenditures",
        "label": "Payments for Capital Improvements",
        "documentation": "The cash outflow for acquisition of or capital improvements to properties held for investment (operating, managed, leased) or for use."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_PaymentsForSoftware": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForSoftware",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Internal-use software",
        "label": "Payments for Software",
        "documentation": "The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitContributionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitContributionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment for Pension and Other Postretirement Benefits [Abstract]",
        "label": "Payment for Pension and Other Postretirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Employee Benefits",
        "label": "Retirement Benefits [Text Block]",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r435",
      "r437",
      "r443",
      "r461",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r482",
      "r483",
      "r484",
      "r819"
     ]
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionPlansDefinedBenefitMember",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Plan",
        "label": "Pension Plan [Member]",
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r459",
      "r460",
      "r462",
      "r465",
      "r468",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r484",
      "r485",
      "r496",
      "r819",
      "r820",
      "r824",
      "r825",
      "r826"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "nvax_PercentOfRemainingAmountToBePaid": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "PercentOfRemainingAmountToBePaid",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percent of remaining amount to be paid",
        "label": "Percent Of Remaining Amount To Be Paid",
        "documentation": "Percent Of Remaining Amount To Be Paid"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_PercentageOfMarketPriceForStockPurchase": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "PercentageOfMarketPriceForStockPurchase",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of market price for stock purchase",
        "label": "Percentage Of Market Price For Stock Purchase",
        "documentation": "Percentage of market price for stock purchase."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par or stated value per share (in usd per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r382"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r707"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, $0.01 par value, 2,000,000 shares authorized at December\u00a031, 2023 and 2022; no shares issued and outstanding at December\u00a031, 2023 and 2022",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r647",
      "r833"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "presentation": [
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid Expenses and Other Current Assets",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of 2027 Convertible notes",
        "label": "Proceeds from Convertible Debt",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net proceeds from sales of common stock",
        "terseLabel": "Net proceeds from sales of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfUnsecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfUnsecuredDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds received",
        "label": "Proceeds from Issuance of Unsecured Debt",
        "documentation": "The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "nvax_ProceedsFromIssuanceOrSaleOfEquityNotSettled": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "ProceedsFromIssuanceOrSaleOfEquityNotSettled",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of common stock under the Sales Agreement not settled at year-end",
        "label": "Proceeds From Issuance Or Sale Of Equity Not Settled",
        "documentation": "Represents the amount of proceeds from issuance or sale of equity not settled."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from maturities of marketable securities",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r231",
      "r959"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductMember",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails",
      "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product sales",
        "verboseLabel": "Product",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails",
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails",
      "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r291",
      "r639",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r787",
      "r810",
      "r834",
      "r934",
      "r983",
      "r984",
      "r988",
      "r1047"
     ]
    },
    "nvax_ProductReturnsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "ProductReturnsMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Returns",
        "label": "Product Returns [Member]",
        "documentation": "Product Returns"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails",
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails",
      "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r291",
      "r639",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r787",
      "r810",
      "r834",
      "r934",
      "r983",
      "r984",
      "r988",
      "r1047"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and equipment",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r197",
      "r654"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationAdditionalInformationDetails",
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/OtherFinancialInformationAdditionalInformationDetails",
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r644",
      "r654",
      "r833"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r178",
      "r184",
      "r652"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationTables",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Property and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "nvax_ProvisionForExcessAndObsoleteInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "ProvisionForExcessAndObsoleteInventory",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for excess and obsolete inventory",
        "label": "Provision For Excess And Obsolete Inventory",
        "documentation": "Provision For Excess And Obsolete Inventory"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_PublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "PublicOfferingMember",
     "presentation": [
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public Offering",
        "label": "Public Offering [Member]",
        "documentation": "Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_PurchaseAgreementNumberOfDosesCancelled": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "PurchaseAgreementNumberOfDosesCancelled",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of doses, cancelled",
        "label": "Purchase Agreement, Number of Doses, Cancelled",
        "documentation": "Purchase Agreement, Number of Doses, Cancelled"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_PurchaseAgreementNumberOfVaccineDoses": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "PurchaseAgreementNumberOfVaccineDoses",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase agreement, number of vaccine doses",
        "label": "Purchase Agreement, Number Of Vaccine Doses",
        "documentation": "Purchase Agreement, Number Of Vaccine Doses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase obligation",
        "label": "Purchase Obligation",
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "nvax_ROUFacilityLeasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "ROUFacilityLeasesMember",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails",
      "http://www.novavax.com/role/RestructuringNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ROU Facility Leases",
        "label": "ROU Facility Leases [Member]",
        "documentation": "ROU Facility Leases"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails",
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r340",
      "r435",
      "r490",
      "r524",
      "r525",
      "r526",
      "r634",
      "r635",
      "r666",
      "r697",
      "r698",
      "r753",
      "r755",
      "r757",
      "r758",
      "r762",
      "r783",
      "r784",
      "r801",
      "r809",
      "r827",
      "r835",
      "r838",
      "r978",
      "r987",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails",
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r340",
      "r435",
      "r490",
      "r524",
      "r525",
      "r526",
      "r634",
      "r635",
      "r666",
      "r697",
      "r698",
      "r753",
      "r755",
      "r757",
      "r758",
      "r762",
      "r783",
      "r784",
      "r801",
      "r809",
      "r827",
      "r835",
      "r838",
      "r978",
      "r987",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r854",
      "r866",
      "r876",
      "r902"
     ]
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfConvertibleDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayment of 2023 Convertible notes",
        "label": "Repayments of Convertible Debt",
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayments of debt",
        "label": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243",
      "r355",
      "r384",
      "r627",
      "r793",
      "r794"
     ]
    },
    "nvax_ResearchAndDevelopmentAccrualsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "ResearchAndDevelopmentAccrualsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development accruals",
        "label": "Research And Development Accruals, Current",
        "documentation": "Research And Development Accruals."
       }
      }
     },
     "auth_ref": []
    },
    "nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract to perform for others forgivable no interest term loans",
        "label": "Research And Development Arrangement Contract To Perform For Others Forgivable No Interest Term Loans",
        "documentation": "Research And Development Arrangement Contract To Perform For Others Forgivable No Interest Term Loans"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersFunding",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract to perform for others funding",
        "label": "Research And Development Arrangement Contract To Perform For Others Funding",
        "documentation": "Research And Development Arrangement Contract To Perform For Others Funding"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersGrant",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract to perform for others grant",
        "label": "Research And Development Arrangement Contract To Perform For Others Grant",
        "documentation": "Research And Development Arrangement Contract To Perform For Others Grant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r540",
      "r1044"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/RestructuringScheduleofImpairmentChargesDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Tax Credit Carryforward",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "nvax_RestOfTheWorldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "RestOfTheWorldMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rest of the world",
        "label": "Rest of the World [Member]",
        "documentation": "Rest of the World"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r855",
      "r867",
      "r877",
      "r903"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r856",
      "r868",
      "r878",
      "r904"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r863",
      "r875",
      "r885",
      "r911"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash current",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r196",
      "r236"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash non-current",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r169",
      "r236"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units (RSUs)",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.novavax.com/role/Restructuring"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r323",
      "r325",
      "r328",
      "r333"
     ]
    },
    "nvax_RestructuringAndRelatedCostNumberOfPositionsEliminatedGlobalPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedGlobalPercent",
     "presentation": [
      "http://www.novavax.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Global workforce percent",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Global Percent",
        "documentation": "Restructuring and Related Cost, Number of Positions Eliminated, Global Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and related cost, annual impact percent",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date Percent",
        "documentation": "Percentage of the total number of positions eliminated as of the balance sheet date since inception of the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://www.novavax.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and related cost percent",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/RestructuringScheduleofImpairmentChargesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.novavax.com/role/RestructuringScheduleofImpairmentChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Restructuring charge",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r329",
      "r330",
      "r979"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.novavax.com/role/RestructuringNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Type [Axis]",
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r330",
      "r331"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.novavax.com/role/RestructuringNarrativeDetails",
      "http://www.novavax.com/role/RestructuringScheduleofImpairmentChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost and Reserve [Line Items]",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r327",
      "r330",
      "r331",
      "r332"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r141",
      "r650",
      "r670",
      "r672",
      "r680",
      "r708",
      "r833"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r245",
      "r246",
      "r247",
      "r249",
      "r255",
      "r257",
      "r304",
      "r305",
      "r534",
      "r535",
      "r536",
      "r562",
      "r563",
      "r577",
      "r579",
      "r580",
      "r582",
      "r584",
      "r667",
      "r669",
      "r682",
      "r1053"
     ]
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetirementPlanSponsorLocationAxis",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Sponsor Location [Axis]",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r462",
      "r465",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r991",
      "r992",
      "r994"
     ]
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetirementPlanSponsorLocationDomain",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Sponsor Location [Domain]",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r462",
      "r465",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r991",
      "r992",
      "r994"
     ]
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetirementPlanTypeAxis",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Type [Axis]",
        "label": "Retirement Plan Type [Axis]",
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r459",
      "r460",
      "r462",
      "r465",
      "r468",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r484",
      "r485",
      "r486",
      "r496",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826"
     ]
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetirementPlanTypeDomain",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Type [Domain]",
        "label": "Retirement Plan Type [Domain]",
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r459",
      "r460",
      "r462",
      "r465",
      "r468",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r484",
      "r485",
      "r486",
      "r496",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826"
     ]
    },
    "nvax_RevenueFromContractWithCustomerCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "RevenueFromContractWithCustomerCommitment",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from contract with customer",
        "label": "Revenue From Contract With Customer Commitment",
        "documentation": "Revenue From Contract With Customer Commitment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product sales",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r273",
      "r283",
      "r286",
      "r287",
      "r291",
      "r292",
      "r294",
      "r407",
      "r408",
      "r639"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.novavax.com/role/Revenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r411"
     ]
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Product Revenue",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "nvax_RevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "RevenueMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue [Member]",
        "documentation": "Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r730",
      "r786",
      "r796"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining performance obligation to be satisfied",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining performance obligation, expected timing of satisfaction, period",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining performance obligation, variable consideration amount",
        "label": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails",
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenues",
        "terseLabel": "Total revenue",
        "netLabel": "Revenues",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r239",
      "r272",
      "r273",
      "r283",
      "r286",
      "r287",
      "r291",
      "r292",
      "r294",
      "r303",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r594",
      "r643",
      "r985"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability and right of use assets recognized",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance and Operating Lease Liability",
        "documentation": "Right-of-Use Asset Obtained in Exchange for Finance and Operating Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalCashFlowInformationofLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ROU assets obtained in exchange for finance lease obligations",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r832"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalCashFlowInformationofLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ROU assets obtained in exchange for operating lease obligations",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r832"
     ]
    },
    "nvax_RoyaltiesAndOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "RoyaltiesAndOtherMember",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties and other",
        "label": "Royalties and Other [Member]",
        "documentation": "Royalties and Other"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_RoyaltyPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "RoyaltyPeriod",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty period",
        "label": "Royalty Period",
        "documentation": "Royalty Period"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "nvax_SKBioscienceCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "SKBioscienceCoLtdMember",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SK bioscience, Co., Ltd.",
        "label": "SK Bioscience, Co. Ltd [Member]",
        "documentation": "SK Bioscience, Co. Ltd"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_SaleOfStockAmountOfRemainingUnissuedShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "SaleOfStockAmountOfRemainingUnissuedShares",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining unissued capital",
        "label": "Sale of Stock, Amount Of Remaining Unissued Shares",
        "documentation": "Sale of Stock, Amount Of Remaining Unissued Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration received on transaction, net of issuance costs",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock, Name of Transaction [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued in transaction (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock (in usd per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "nvax_SalesBasedRoyaltiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "SalesBasedRoyaltiesMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales-Based Royalties",
        "label": "Sales-Based Royalties [Member]",
        "documentation": "Sales-Based Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Benchmark",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r931"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r495",
      "r956"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Domain]",
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r258",
      "r495",
      "r929",
      "r956"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "nvax_ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Supplemental Balance Sheet Information Related to Leases",
        "label": "Schedule of Balance Sheet Information Related to Lease [Table Text Block]",
        "documentation": "Schedule of balance sheet information related to lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Convertible Notes Payable",
        "label": "Schedule of Debt [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Deferred Tax Assets (Liabilities)",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Tax Rate Differences",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://www.novavax.com/role/GoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Goodwill",
        "label": "Schedule of Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r803",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977"
     ]
    },
    "nvax_ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Receivable, Unbilled Services, and Deferred Revenue",
        "label": "Schedule of Increase (Decrease) In Accounts Receivable, Unbilled Services, and Deferred Revenue [Table Text Block]",
        "documentation": "Schedule of Increase (Decrease) In Accounts Receivable, Unbilled Services, and Deferred Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r112",
      "r113",
      "r114"
     ]
    },
    "nvax_ScheduleOfInventoryReserveTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "ScheduleOfInventoryReserveTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory Reserve",
        "label": "Schedule of Inventory Reserve [Table Text Block]",
        "documentation": "Schedule of Inventory Reserve"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfMultiemployerPlansTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfMultiemployerPlansTable",
     "presentation": [
      "http://www.novavax.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Multiemployer Plan [Table]",
        "label": "Multiemployer Plan [Table]",
        "documentation": "Disclosure of information about multiemployer plan."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationAdditionalInformationDetails",
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPropertyandEquipmentNetDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment, Net [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "presentation": [
      "http://www.novavax.com/role/CashCashEquivalentsandRestrictedCashTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r153",
      "r1045"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.novavax.com/role/RestructuringNarrativeDetails",
      "http://www.novavax.com/role/RestructuringScheduleofImpairmentChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r327",
      "r330",
      "r331",
      "r332"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://www.novavax.com/role/RestructuringTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring and Related Costs",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r65"
     ]
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Grant Revenue",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer."
       }
      }
     },
     "auth_ref": []
    },
    "nvax_ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue Gross to Net Deductions Balances",
        "label": "Schedule Of Revenue Gross To Net Deductions Balances [Table Text Block]",
        "documentation": "Schedule Of Revenue Gross To Net Deductions Balances"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r500",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527"
     ]
    },
    "nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Stock Units Activity",
        "label": "Schedule Of Share Based Compensation Restricted Stock Awards Activity [Table Text Block]",
        "documentation": "Schedule Of Share Based Compensation, Restricted Stock Awards, Activity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Option and Appreciation Rights Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r75"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assumptions Used in Estimation of Fair Value of Stock",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "nvax_ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Supplemental Cash Flow Information of Leases",
        "label": "Schedule of Supplemental Cash Flow information of Lease [Table Text Block]",
        "documentation": "Schedule of supplemental cash flow information of lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r831",
      "r1022"
     ]
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedules of Concentration of Risk",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r53",
      "r54",
      "r90",
      "r151"
     ]
    },
    "nvax_SecuritiesSubscriptionArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "SecuritiesSubscriptionArrangementMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities Subscription Arrangement",
        "label": "Securities Subscription Arrangement [Member]",
        "documentation": "Securities Subscription Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.novavax.com/role/OtherFinancialInformationAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r292",
      "r293",
      "r694",
      "r695",
      "r696",
      "r754",
      "r756",
      "r759",
      "r763",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r788",
      "r811",
      "r838",
      "r988",
      "r1047"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r292",
      "r800"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.novavax.com/role/RestructuringScheduleofImpairmentChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general, and administrative",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "nvax_SettlementAgreementBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "SettlementAgreementBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement agreement, benefit",
        "label": "Settlement Agreement, Benefit",
        "documentation": "Settlement Agreement, Benefit"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_SettlementAgreementInitialReservationFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "SettlementAgreementInitialReservationFee",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial reservation fee",
        "label": "Settlement Agreement, Initial Reservation Fee",
        "documentation": "Settlement Agreement, Initial Reservation Fee"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_SettlementAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "SettlementAgreementMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/CommitmentandContingenciesDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement Agreement",
        "label": "Settlement Agreement [Member]",
        "documentation": "Settlement Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_SettlementAgreementQuarterlyInstallmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "SettlementAgreementQuarterlyInstallmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement agreement, quarterly installment amount",
        "label": "Settlement Agreement, Quarterly Installment Amount",
        "documentation": "Settlement Agreement, Quarterly Installment Amount"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_SettlementPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "SettlementPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement payment",
        "label": "Settlement Payment",
        "documentation": "Settlement Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/RestructuringScheduleofImpairmentChargesDetails": {
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/RestructuringNarrativeDetails",
      "http://www.novavax.com/role/RestructuringScheduleofImpairmentChargesDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance and employee benefit costs",
        "label": "Severance Costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Requisite service period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedNetLabel": "Restricted stock units forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units forfeited (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units granted (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding and unvested beginning of year (in shares)",
        "periodEndLabel": "Outstanding and unvested at end of year (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r514"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding and unvested at beginning of year (in shares)",
        "periodEndLabel": "Outstanding and unvested at end of year (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r514"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Per Share Weighted-Average Grant-Date Fair Value (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Restricted stock units vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units vested (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r500",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proposal to increase authorized shares (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock reserved for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for grant (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares available for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number of Shares Available For Issuance",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number of Shares Available For Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Shares exercisable at end of year (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares exercisable at end of year (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of stock options and stock appreciation rights exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Canceled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum grant price, percent of common stock fair value",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grant Date Exercise Price Minimum Percent",
        "documentation": "The minimum grant-date exercise price of incentive stock options granted as a percent of the common stock share price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Black-Scholes fair value (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of stock options and stock appreciation rights outstanding (less than)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding (in shares)",
        "periodEndLabel": "Outstanding (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r506"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options &amp; SARs",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of year (in usd per share)",
        "periodEndLabel": "Outstanding at end of year (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r506"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage increase of shares each anniversary",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Annual Increase",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Annual Increase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Award [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Canceled (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "nvax_ShareBasedCompensationStockIssuedUnderIncentiveProgram": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "ShareBasedCompensationStockIssuedUnderIncentiveProgram",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issued under incentive programs (in shares)",
        "label": "Share-Based Compensation Stock Issued Under Incentive Program",
        "documentation": "Share-Based Compensation Stock Issued Under Incentive Program"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment award, terms of award",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofAssumptionsUsedinEstimationofFairValueofStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of stock options and stock appreciation rights exercisable (less than)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining contractual term of stock options and stock appreciation rights exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining contractual term of stock options and stock appreciation rights outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued (in usd per share)",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "nvax_ShortTermLeaseCostBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "ShortTermLeaseCostBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease expense (benefit(1))",
        "label": "Short-Term Lease, Cost (Benefit)",
        "documentation": "Short-Term Lease, Cost (Benefit)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and Local Jurisdiction",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r202",
      "r203",
      "r204",
      "r239",
      "r261",
      "r262",
      "r264",
      "r266",
      "r269",
      "r270",
      "r303",
      "r342",
      "r344",
      "r345",
      "r346",
      "r349",
      "r350",
      "r382",
      "r383",
      "r386",
      "r389",
      "r395",
      "r594",
      "r676",
      "r677",
      "r678",
      "r679",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r707",
      "r729",
      "r748",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r928",
      "r949",
      "r957"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r32",
      "r191",
      "r223",
      "r224",
      "r225",
      "r245",
      "r246",
      "r247",
      "r249",
      "r255",
      "r257",
      "r268",
      "r304",
      "r305",
      "r396",
      "r534",
      "r535",
      "r536",
      "r562",
      "r563",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r584",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r626",
      "r667",
      "r668",
      "r669",
      "r682",
      "r748"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.novavax.com/role/OtherFinancialInformationAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofProductRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r292",
      "r293",
      "r694",
      "r695",
      "r696",
      "r754",
      "r756",
      "r759",
      "r763",
      "r770",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r788",
      "r811",
      "r838",
      "r988",
      "r1047"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r268",
      "r639",
      "r674",
      "r693",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r707",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r716",
      "r717",
      "r718",
      "r719",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r727",
      "r730",
      "r731",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r748",
      "r839"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r258",
      "r495",
      "r929",
      "r930",
      "r956"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r268",
      "r639",
      "r674",
      "r693",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r707",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r716",
      "r717",
      "r718",
      "r719",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r727",
      "r730",
      "r731",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r748",
      "r839"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r858",
      "r870",
      "r880",
      "r906"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Issued",
        "label": "Stock Issued",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r46"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares sell and issue",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of issuance costs (in shares)",
        "verboseLabel": "Shares sold (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r105",
      "r106",
      "r141",
      "r676",
      "r748",
      "r765"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r105",
      "r106",
      "r141",
      "r510"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT",
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock, net of issuance costs",
        "terseLabel": "Issuance of common stock, net of issuance costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r105",
      "r106",
      "r141",
      "r682",
      "r748",
      "r765",
      "r845"
     ]
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Authorized amount",
        "label": "Stock Repurchase Program, Authorized Amount",
        "documentation": "Amount of stock repurchase plan authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 deficit",
        "periodStartLabel": "Balance beginning",
        "periodEndLabel": "Balance ending",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r109",
      "r110",
      "r130",
      "r709",
      "r726",
      "r749",
      "r750",
      "r833",
      "r846",
      "r951",
      "r965",
      "r1029",
      "r1053"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 deficit:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity Note [Abstract]",
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.novavax.com/role/StockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 Deficit",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r238",
      "r381",
      "r383",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r396",
      "r583",
      "r751",
      "r752",
      "r769"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split conversion ratio",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "nvax_SubjectToExpirationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "SubjectToExpirationMember",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subject to Expiration",
        "label": "Subject to Expiration [Member]",
        "documentation": "Subject to Expiration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.novavax.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r629"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r629"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.novavax.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r629"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r629"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.novavax.com/role/CommitmentandContingenciesDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r629"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.novavax.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r628",
      "r630"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "documentation": "Different names of stock transactions and the different attributes of each transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Company's Income (Loss) from Operations Before Income Tax Provision (Benefit) by Jurisdiction",
        "label": "Summary of Operating Loss Carryforwards [Table Text Block]",
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "nvax_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies [Line Items]",
        "label": "Summary of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies [Table]",
        "label": "Summary of Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Supplies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Supplies",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses",
        "label": "Prepaid Supplies",
        "documentation": "Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r791",
      "r802",
      "r966"
     ]
    },
    "us-gaap_SupplyCommitmentArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplyCommitmentArrangementMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supply Commitment Arrangement [Domain]",
        "label": "Supply Commitment Arrangement [Domain]",
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r158"
     ]
    },
    "us-gaap_SupplyCommitmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplyCommitmentAxis",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supply Commitment [Axis]",
        "label": "Supply Commitment [Axis]",
        "documentation": "Information by arrangements in which the entity has committed resources to supply goods or services to a customer."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r158"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "nvax_TakedaArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "TakedaArrangementMember",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Takeda Arrangement",
        "label": "Takeda Arrangement [Member]",
        "documentation": "Takeda Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforward",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Axis]",
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardLineItems",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Line Items]",
        "label": "Tax Credit Carryforward [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Name [Domain]",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period [Axis]",
        "label": "Tax Period [Axis]",
        "documentation": "Information about the period subject to enacted tax laws."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period [Domain]",
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": []
    },
    "nvax_ThreePointSeventyFiveConvertibleNotesDue2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "ThreePointSeventyFiveConvertibleNotesDue2023Member",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails",
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.75% Convertible notes due 2023",
        "verboseLabel": "2023 Notes",
        "label": "Three Point Seventy Five Convertible Notes Due 2023 [Member]",
        "documentation": "Three Point Seventy Five Convertible Notes Due 2023"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r296",
      "r297",
      "r299"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.novavax.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency transaction (losses) gain",
        "label": "Translation Adjustment Functional to Reporting Currency, Gain (Loss), Reclassified to Earnings, Net of Tax",
        "documentation": "Amount of reclassification from other comprehensive income (loss) to earnings, after tax, related to translation from the functional currency to reporting currency, as a result of the sale or complete or substantially complete liquidation of an investment in a foreign entity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r115",
      "r1030"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock, shares (in shares)",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_TreasuryStockCommonValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonValue",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Treasury stock, 1,000,323 shares, cost basis at December\u00a031, 2023 and 766,631 shares, cost basis at December\u00a031, 2022",
        "label": "Treasury Stock, Common, Value",
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r71",
      "r72"
     ]
    },
    "nvax_TwoThousandFifteenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "TwoThousandFifteenStockIncentivePlanMember",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2015 Plan",
        "label": "Two Thousand Fifteen Stock Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_TwoThousandFiveStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "TwoThousandFiveStockIncentivePlanMember",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2005 Plan",
        "label": "Two Thousand Five Stock Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_TwoThousandTwentyThreeStockInducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "TwoThousandTwentyThreeStockInducementPlanMember",
     "presentation": [
      "http://www.novavax.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofOptionandAppreciationRightsActivityDetails",
      "http://www.novavax.com/role/StockBasedCompensationScheduleofRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Inducement Plan",
        "label": "Two Thousand Twenty Three Stock Inducement Plan [Member]",
        "documentation": "Two Thousand Twenty Three Stock Inducement Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.novavax.com/role/CollaborationLicenseandSupplyAgreementsDetails",
      "http://www.novavax.com/role/CommitmentandContingenciesDetails",
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofAccountsReceivableUnbilledServicesandDeferredRevenueDetails",
      "http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails",
      "http://www.novavax.com/role/StockholdersDeficitDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.novavax.com/role/RestructuringNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Restructuring [Domain]",
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r330",
      "r331"
     ]
    },
    "nvax_U.S.ProductSalesReturnsAccrual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "U.S.ProductSalesReturnsAccrual",
     "crdr": "credit",
     "calculation": {
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/OtherFinancialInformationScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. product sales returns accrual",
        "label": "U.S. Product Sales Returns Accrual",
        "documentation": "U.S. Product Sales Returns Accrual"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_USDepartmentOfDefenseDoDContractMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "USDepartmentOfDefenseDoDContractMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. DoD",
        "label": "US Department of Defense (\"DoD Contract\") [Member]",
        "documentation": "US Department of Defense (\"DoD Contract\")"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_USGovernmentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "USGovernmentAgreementMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails",
      "http://www.novavax.com/role/RevenueScheduleofGrantRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "USG Agreement",
        "label": "US Government Agreement [Member]",
        "documentation": "US Government Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_USGovernmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "USGovernmentMember",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesScheduleofConcentrationRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government",
        "label": "US Government [Member]",
        "documentation": "US Government"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_USGovernmentPartnershipMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "USGovernmentPartnershipMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US Government Partnership",
        "label": "US Government Partnership [Member]",
        "documentation": "US Government Partnership"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnamortizedDebtIssuanceExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails": {
       "parentTag": "us-gaap_ConvertibleNotesPayableCurrent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unamortized debt issuance costs",
        "label": "Unamortized Debt Issuance Expense",
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnbilledContractsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnbilledContractsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unbilled contracts receivable",
        "label": "Unbilled Contracts Receivable",
        "documentation": "Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "nvax_UnderwriterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "UnderwriterMember",
     "presentation": [
      "http://www.novavax.com/role/StockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriter",
        "label": "Underwriter [Member]",
        "documentation": "Underwriter"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unrecognized tax benefits balance at January 1",
        "periodEndLabel": "Unrecognized tax benefits balance at December 31,",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r548"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Reductions for tax positions of prior year",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions for tax positions of current year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions for tax positions of prior years",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlements of tax positions of prior years",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Settlements with Taxing Authorities",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from settlements with taxing authorities."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_UnsecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnsecuredDebtMember",
     "presentation": [
      "http://www.novavax.com/role/FairValueMeasurementsDetails",
      "http://www.novavax.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.novavax.com/role/LongTermDebtScheduleofNotesPayableDetails",
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unsecured Debt",
        "label": "Unsecured Debt [Member]",
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.novavax.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r57",
      "r174",
      "r176",
      "r179",
      "r180"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.novavax.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance, deferred tax asset, amount increase",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofOperatingLeaseExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease expense",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r620",
      "r832"
     ]
    },
    "nvax_WeightedAverageDiscountRateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "WeightedAverageDiscountRateAbstract",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate:",
        "label": "Weighted Average Discount Rate [Abstract]",
        "documentation": "Weighted Average Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r266"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r266"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "presentation": [
      "http://www.novavax.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average number of common shares outstanding:",
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_WeightedAverageRemainingLeaseTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "WeightedAverageRemainingLeaseTermAbstract",
     "presentation": [
      "http://www.novavax.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term (years):",
        "label": "Weighted Average Remaining Lease Term [Abstract]",
        "documentation": "Weighted Average Remaining Lease Term"
       }
      }
     },
     "auth_ref": []
    },
    "nvax_WholesaleDistributorFeesDiscountsAndChargebacksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.novavax.com/20231231",
     "localname": "WholesaleDistributorFeesDiscountsAndChargebacksMember",
     "presentation": [
      "http://www.novavax.com/role/RevenueScheduleofRevenueGrosstoNetDeductionsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wholesale Distributor Fees, Discounts, and Chargebacks",
        "label": "Wholesale Distributor Fees, Discounts, and Chargebacks [Member]",
        "documentation": "Wholesale Distributor Fees, Discounts, and Chargebacks"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "e",
   "SubTopic": "470",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "a",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-8"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "330",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 5.P.3,4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-10"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "63",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481620/480-10-55-63"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b),(f(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-4"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-3"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//940-320/tableOfContent"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//942-320/tableOfContent"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//946-320/tableOfContent"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "SubTopic": "10",
   "Topic": "330",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-5"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "(b)",
   "Publisher": "SEC"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-20/tableOfContent"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//420/tableOfContent"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480606/715-80-35-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-9"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-5A"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481058/954-310-45-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-18"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//705/tableOfContent"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480606/715-80-35-1"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-9"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479365/842-20-25-6"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>129
<FILENAME>0001000694-24-000007-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001000694-24-000007-xbrl.zip
M4$L#!!0    ( -@[7%BDY$7LHN,# -+Z)  1    ;G9A>"TR,#(S,3(S,2YH
M=&WLO6EW&DF6/_Q^/D4>=<VT?1Z06;2[RO^#D633)4MJ(;NJY\V<(#. +">9
M="Z2Z$__W'MCR060D PBP#EGIL:")&.Y-^[RNTO\^O\>1IYUQ\/(#?S?_E[?
MK?W=XKX=.*X_^.WOK6Z[T_G[__OP7[\.8W@,'O6C$VX[O^T,XWA\\N[=0R_T
M=B-N[PZ"NW?PQ;M&K='<D0_:0>+'X63VP_++W \\U_^NG[Z_O]^E7P3A )ZJ
M-=_AUST6<?7XP]3S]TUZNGY\?/R.OM6/1NZL!^&U]7=_?KGHVD,^8E77CV+F
MVWH ]R&NPGQSOU3S=WUX/__SX\W%NSAD?M0/PA&+81/AI?7]:NVHVJQGWC-[
M68^]I%&KUAK5>D,O 7[D/K([A<G/WQ<DI7II$H=S7WG\#K[52XB"O4;]\+'Q
MQ1/IFN<]6V]FUJT>]^]8_@=^<,?@LUT[&!&/U!OI?B91=<#86#_?9U&/7BZ_
MR#&5P]W9' A?Y![$+YW"LW)U!^_$E^K1*(RG!X</T_>=> P.T [WJU^[.Q]^
M'7+F?/AUQ&-FX<^J_-^)>_?;3COP8^['U=O)&.AFB[]^VXGY0_R.R/3NPW_]
MUW_]&KNQQS_@%E755OSZ3GSXZSOQZE[@3#[\ZKAW5A1///[;CN-&8X]-3OS
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M8;M)+^+_3N"-9V#DS<#N"@^L&-P%VQ,.W<$BX&[AT1\!=X^-12M>F2O*)EO
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MC$/+1[>478P#4S:'7=H!7N[T2C&==>C\ ^/P'!.M\<:/( >)[XKMII]Y'DY
M;_J(LPC83RPK\X!ZE_I>_8TOFT?*C82 7M^Q6EZ7K(.-!(%6>!_U"KK&&T1M
M8U&E<^:&WYB7\(\3_<_/\$8T="87:.;DB: ?ZOCC)([HB?JR>" SF584\;CM
ML2C*C_\E\/GD"PN_<THUVB 6,!:[6@8+-$H66( %C 73EL$"S9(%%F !8W&R
M4A&\TJ6*A\;B9:4B>"T6,!:%*Q7!:[& L<C:IBD"^OPCL[]S)P7^-L8@.#06
M1%O1UANEC0SB V,1N$U3"1LN#XS%!4N]\*KVP28@AJ5>6#T?;#5LN-UZ8:E\
ML-78X6OJA780CH.0Q?R4]^)-M! V 4)<[N9OD6Y8)B<<;0*2N,&<\)1V,H@3
MMAI0W';ML$P[X6@3<,4-E@F;XSD<;3*RN &<L%KML%1.V&IL\54Q);H,= .=
MAJ--@!67M.M;I ^6R@*;@"AN!I*TL5)@J\'$K54$2[4%-@%'+!7!2EE@$P#$
M4A&LD@6.-P$Y7)DB,$<A'V\U;K<YMO'Q)J!FAB(52Z7#)F!6ALJEI>J'K4:,
M-L=4.]X$V,90N;14.AB+G2 ^WH&EA4FA5/=V&')^';A^W,4K7>+)N7O'VX%_
MQ\/8[7G\,HAY=)IPE.";0P=C 0SSZ;!4/;T)*,+Z@:2?C"FV&E=86F';3\44
MC=I6(PU+ YM^,J;8:MCC)U(?2[3MX&W;S!0_D?I8*E-L-2#T$ZF/I3*%L>C4
M7#K@MA,9_I>'P>S]/UP6,UP$_B#FX0@G@\V\\GSXU8\P7L4=_'IS+(:M!L)6
M;S$L@?\,8H;-0^->\_R;#Y$OE1DV#Q+<-&;8(,>RQ"77S9D&F8G&XI%;(QDV
M)I+:J!N+0VX-,VR. UDW#G\D@E]P%O'.: Q[BS]K#UDXR-Y'U_YR]5H7TZ_G
MOH%&W3@,$*\(; <)S#(<PQY,+MFH2!+?:7\YU839SHN"&W7C@#CC*+.>2]$:
M=>/0L"<HTSJLU?Z9N+[-KT"[L-"Y"9CS6H*MMCB1:C]")'US0_3O_O25#4D<
MGN 7ZL>+7]70J!N'A)E,[O5<J=JH&X=0&4:D51EVQH%!YN[[,G&7NG&XBV'[
M;H0)9QP>\@21SIF-%[U,R"]:VH4S..@-WFTC1L(_O[B^.TI&&W/<&L:!&<90
MDCUL%B4W$XFXN?J:(^F6.KT-X^"(Y<?X%Q[2_!R3I1Y,X_".DO2OY$0TC -4
MC H5K#6]J "XU1MK -P:QB$P1O%'?A(WW.$CNG_WFO8XSRV//WOE/W6M<LFT
M3P.0#IO,OC(6OG@!_M@P#MK:4NZ_O0]*[E^6R#8.%]Q2IMT6D;TJT](XG+3T
M*N:3OGZP3-(;A[Z6I'\:<VHNB#GE'OTA5=4T#MLM^>0Q/@$AL2@V690G/\8G
MQB'')9\\JDJ 2QK[2U$E36-AZ9^,#L9BQ%=DDG=\AS]PYS;H1%'"P^CLWPE,
M4ORWT&Z?>9[XS9:?2",DM['X<LDVKRQ -@])+H]OTS@ ],5Y$!MITBT$C+'O
M_(]AX'&\%)[A"YC7'N(6;6>B0M,X?//GXLE2*C:-13:[22]R'9>%DR[S^%6_
M&P?V]VPJ:#)(HA@I@]]'2\M.T^/'L*F4184-Y'/C:SLJ&(T"G[Y8<8),[6A9
M>&;36#SS9R>X"0IISU@4\RGN^$?BHYBNE[RQ,MXP%KE<E#=:OE,*D5=@%&-Q
MSFUEE(5'_<@\YMN\.^0\O@ALAAA0?M#KD(^9ZYP]C.&WL&[?N8J'/&PG88BV
M,]ZHLZ59XWO&PL(_NV6THESQ/6,!W=+867=U_IZQ$.]3O'&=]. -5_T^+-<?
M;&=>X)YQ6.ZBU/GJ.SR\#]V8AUM*&N,@32-(LZ+$Q#UCX;MK,#0+U:2W]\'M
M,$@BYCNW]XBV$OQ*9.CX3F*3SL'?K1I,JR]M^XT%TPS>_N5Q_[ZQ:-7CVW_N
M]F/.?;GU-@YWQS=KYXW%@HS9>1-<VGUCD1@CR53?K]8.%@S"T:/-VG+(9"SR
M8 R9,ID\A9W_,3EF+ 2PFIU_<OC7[+)BQ-$SSL]??0:&,8?:" 8P%DJ S0]&
M7(-QL^'Z=A#%X,HB#KBE)HRQ>()A]%D34+IO+ )A&'W6U-)RWUB(8B'ZW/"(
M8S/S%NP!-BL/QOBLC$YNI\0[,!;5,)YB:Y*!!\:B(<93;$U2\<!88&0ABGWB
M/@^9AVDJS@C<LR@.&9KIVRT7C45)-H!FZY*,QN(K&T"S=<E&XR 1XX-:RPSI
M'A@+2!B#&ZUJYXV%&I[:^3N^R=MN+()@EKPQP@8S%DTPXXB80*-#8_$#,VBT
MHI2(0V-!@-8]"YWI4MNST=@+)E)X+=0.8E,/A+'.OC&469-[>&BL2V\,9=;D
M!!X:Z[@OC3)/CKBN7(BUR4GC'/_5YT(8<\[717-CT8:?X)RO2^L:AW/\1.=\
M730W%F3Y"<[YNFPXX\":G^B<KXGF1QL*_OP0F/JCW''#HSAT[9@[-/97WXVC
MF^[7C4'0CXR%GM:4Q;[M]#86T"H/N1ENW9&QP-I/+A&,8 YCL;U2?*PL/'5D
M'+A72H25TGNC@;TM%;S& 6_KI<FJ6-]8K*L=>!ZW48)]9.& N;[K#UIAB(@(
MOBG7+3V,8M&>FH<H]:[ZU\"D\/HQ[$MTROL<?N>)H;;TM!@'7SV?C)>P'E!F
M/RT-CXV%HVYX[(;:>.R. S\*PME9X.=!R-V!OTRC(S_ZM."]%C_ +Y%/7)\[
M'[D/_WBJR=^F\HFQ"%;))R:%L8Z-1;Y*/C$I#')L+OX5!K"2>(*DB%N^@_=S
M4;WEQ\DTV2[  89G\/]U1N,PN",2KZ!2?466^+&Y2)/I9%AFO.#87.SG.63X
MPNPA2*YPDGUP<\Z"L8",X418ZDDP%H%YGD#B+.+#P-M0K6 L/F,X$99Z$HQ%
M5Q8B J$K[6 T3F(>=H-^?,]"#@]_9J&#_UP5J+*:(]&L&8N3; HUEG@VFC5C
MT8AG":AV0'<>VN)R8/CI(.31QJB)9LU87]]T*BSU+!CG26/6J.[;\8G#?K+Q
MT+69)_;=#A(_#B<G[?_=!!XWSD%>]^XNE7>-]7M%]YE;]M!*XF$0NL4;VD_A
MVRAV[;;8[LV1V<8ZN4_M./$\@CP!\/H_DM"-'-=>39[XJO;>6-\6=KT=<L>-
MVRP,)_T@Q&R#@I9D8S=FWD401=F'-F?SC?5I8?.O:2494[V;]/[B=GP;G#V,
MW9 MH[CF)SIGQGK.LTA]6=+X!32N&^N/+R!+53_/S=EM8_WMY>WVCQK>:KC+
MP/^Z.3Y\?>4^_ )K*R0NU/%_]1X]E;B0/OJ\@'3BNV(7'-Z'7\(.ZIT8<18E
M(1?R67^MWJ.^57_CBZ9>.F83).WL5\HO%WEAD5S&.?O/:M?9Y9[G^H,GNG9N
MYT4)S;IQ4$(NE3ZQXP0O),6&^T 9E)KAW;QT8WX'!/3M[6QDW*P;"TL82ZGU
MI)LUZ\;"&<92:CT)7\VZL> '7CO+_YW C\[NX#_3 8+" RNFSU[^^M/'Z%-X
M=%'ZO',?3D(>!4EH\TC\.>3,H<D[[MV'7^$_1#;W8'__N-YW&O6] [ZW?\"8
MO7]TW.,-UF>.?72P]W_H%Z2_B>*)!^0#E5X=<G<PC$_VCG?WQ_'[>]>)AR=
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MNR!2+X/=Y_H(9P3<X:_A8=!3ZJ@=$!Z)EU(=UE[B+!R]QC8U%O-IG[L;-WQ
M03L_QKY0:D<.=SY<7GUK?6O]61&;W+EL%W=F/@N]/LO,1@G?G#TP.Z8E6T'?
M2I=JL<B*QMQ&N-FQ7-]RX\BRARR$N;XU5;>#:MT[KC\7'VH<[1[N'2U%MS?V
M=QL'C^OVQ3_?WU^.P;%7WSUN-IYO<!R\W. 05%F3&'SN^<9@?CB6^"G%]&6>
M<SMP\N8]S,C&&$7,L<0.WY,:]T=HW'L,ZXM^P!K1:.&2++^-(L0M>^C($)?(
MI\CKH..=#XT&MA<^J.T=/+K'F\;.],83S#AV[46$-C$IRFLWR[IO7X7/9AG'
M>G_6H^&>NWV=W9O=[JXE8]&AE6<Z-)L*&B[+5(48P?XC,8)G;O:*'GOY83"0
MU$N5-RW'P>(W^?\NX'UUC8O7=C[ (-8_$SABW+H*T?1Q8)+,J3QN_R[O\#U.
MP84.:XB[L]$Z01*G#?^\"F^#>ZUO,4OW$W/!_PNC7A(.YI-E:1C NC;NF7A*
M;N-(55R%UV"O("<O;,Y@JNP7%DX\YCNE/?-#O'L=P!Y[_^N.A3TI][<)UDSM
MZ/#HIS9DY ZA*3,.@3_=,?,L_L#M!#-DX6-0RCQZ'<-F,W8,V,A"/GK[#,3N
MM7&8!8]3"C;\S]^.&O7#]Y$5<X^/AX'/+9],_PI:N%Z")+/ L6) 4H>?/"-.
MA'JC!3_,';T]V,?&7NWM=)AEX?=2+=$USC3OHV R;>/@J-J K3,6)UN0/ETX
MAJ$;N_#&D$C%0^Y8XR2,$@2(XL#J<JJCDLASXTU/8LYPG!&7;=GQB;%0T8M2
MB9I'NXVC_:6@,G680',Y  _,:O_P<0!KV1&EM>KA6S?VR/WES!Y:ML>BZ,>,
M/1/7&#*2>MW)J!=X6[>\2PDX$P7Y WA7_@ ^\*W[H0N?I/+F:7/(_"V8DZ"[
ML+*1@GA2;_2(];6R.1 Q']@V:HE?L:Y9:'UC7L*M7VJ[M3J&PZQH^&.0Y+;M
MICQ9XF#IK<1PSK?6G^4^37'=F3R=(OA5=!_Q[!8\QR.07J#]+UGDL'];G[R@
M!T9]EV./>@M<RN\\?MKG6<26-2KV^GQC:3!M+%F706RUQEAB@<M_20#ZKR2*
MW?YD3=S5\1U$4;G5FUCVD-O?+9CJ=\L52\Q$%]W(8M8]][SJ=S^XAWER%H$Q
M[< 748)V/XLL1W2&QN#C3>)QL5M[M7U+[EAFRV'S=I]AO0OW_ \8_G<<O2L'
M[]#8FH^/=S[\BT=33H+,6P1:63K[9)OIY -/AOS?B8L,#7S<Q]2"D#)THD<8
MO&D%838/)67S70NV5>W=LZGV+? 2/V8A)2F$D4XHK8$ #^81:VLH=#_DB'@6
MR'1BO:G+;1["P4$*.1;S/$VF+/UZ7#X ;UZ(9)ESIG0!DA&/(:8.60Y5_=&C
MXY#;G.S6>L.B-,C(>@,O!:UA10D8=M$PP P"E:<3#UE<9+E[%DWS&_U8KN8M
M2 ??L=XT,DON@0*"AZB/#/Z(GH=?XE3DRZ@A*LV$9LJBV#JN60Z;1,\7'3(9
M5.2IH3$1LSA)>;'^TTF.+%^&*2V1-$"5D1O'0$PR <+ 1UO(FUA8 CJQ.JBT
M&5U?8YVRF(G4I0+#IN_("IPIK0!<E'@BB->MWEIO\,O#]XUF8U>K#9>R6,:8
MQ;(4Q@WG,ZZ8M&9%'KU]/J-E=@<W1_*=9K3&3\=HH*(<-[*] )M(($D=#K^E
M>E7:Y#"ODSHQ'UFSN.-WI=J0!(SL#.!?[OI"N-R[(#WQ:V ^_40%WXA$[_$H
M5E;(#!0331H0L ..\*4P8USB[W$8/$Q0R+J^L*-Q+I'J(A%EPOE"/(=X)Q/'
M "2\!R]KDIEFG8YFYK00".MX\-W,GUC 1;Z#[Q0SGGIN=ZL58UBP,SU8"[>8
M;8, $GM+G(*4GODI$-ZOSO@B&H'<@C%")?:!-4:P!9.*V'<+R(B[-K &87 ?
M#]77NZ!".<U,\4+@4\P#.:8!BYPS/_JZ_EX]]N0#\^>G'D36E@_/F:MZ,F=T
MUQN]:D,Q?-8&V+7>M(D&8#Z_W3*LM]'</6X>+"<#K[';/-I;3H;A\F:UO]O<
M>WQ2+\?;UA@^_U'<(TV!#MMPU@9!.)D!>]!#= IM^5"*@#2:.Q\N9I]I\Y(4
MEE3N4=0GFY9T,9MK6M/T6_?ZEDFOO?>SX/5"AEN]L9DI;IO)<9>S3(^MYKK-
MIUEWGMVUPG7.-]4-KO03JI6VZV,2P8NBZ,DBO\;>TU5^3R7IEB+L-8_#V6S/
M8OV'?DW\KO;C$VU'6^S&TWR_E.K6%['A2X)O$A00'[D^9M13+Y-UH03]1_QQ
MA&4>BW_D $P)6X(J1C@H#JPD$KX\+%1T+9A1?AJ$-)8WP<'O71@:41D?UA:@
MFKAS(U+M/O-MEWGH)F#%$3Z,W6T=%CH1@D5WKL,?"[&\87FD/N^:_SCT9PPU
MGPTZRQ"(5,F86(+0!XMCCG ;D@IV$TL:86Y,W).NX3L61:"8"#V3^\K[?7'!
MNB^355T"ZV(>^D ]% !AX%D!B*<,45-K(($-#!7MK+W:WIO>6QW$9&&/P6NK
M5P\>GU!<Y4U]W_JZV\7F1(>- \RJ>XL+3U<I0\L]#Z1/AG7Z;C@2P/08QF;X
M$$*-&-1T:,8L<=Q8SFMW7MGS,R#JCMT/6_C.(&RE.WONL<&3[5\.YO9_>5&O
M"]/XM6]%:= ,*/%$3H!%N9.S +:YHBK+^YKGIK9N/<O/(-K!E$05";TBK"\F
M+X-T?4H0P8_L( SEQ@1"CH<AANT"9.P[-T@B;Z+X.CUOZ:C/";.HYA/GKM^-
M1_$9CM36X\_CY;RF/ES00M4$^?!K+WPW/Q_88,9^G!E1R1'% ]"1@F@I+=5!
MR' '"2L=,D-I;0<4% 2A[$TB-Y(UCHBVW?%JCZ':1,7*_4A(<0S;P5<4+=&C
M9_E-2_5B54$89>-_(2CY.V1//06IRK.G5803K<9>;;=>.ZW6X<S.U[*+4]IX
MLL[*W8F&W/.4066]F9>N,S=R\%9D@3S;=\1A%S:AC^8>3!T:_:$0F"G'$M/M
MV&  7(]$'%&.G75'>:!RZ^\",A'0",+@EOS3%LFC> #CB05;2^>(HE]]E,OP
MMF@ZSFF]$0<Q$ +<PTP*853 AQ'S,,X)!RS?3R)2@T68J8J__4?B2R9IUD3;
M*_7&1S('WU*4G8TQDNH"[3EH@E\D$YU3H!S>@5<*$ LED;-3X*G&#C"J#3_U
MHM]V:M,,=DUFU;D7L$+_(3\959V 6JWBK\&% D>4TSLDMQWO?#@X/JX J2N9
MZ@\UJT>:@6P.H[6('<YY+TQ8.!'4:S2)>GL5I!U(^'O\SUR24#9R5*1*,TN5
MSN7YC(P;XAY*<^[2*ZZ2F'PEX.-G$JI9V_E0;QY7CO>;E?I><XI0(F-Z!N-K
M79)GY70B!1(_VPB).ID$@(^3&Q7^OX7???1@,+T$^#F'=8U1AZ!=O:'\I!<^
M/_7AQ+I&-TI&S.<0Y#3-L;BF' M]-4<NX\T/0%K%I-$8&MTB_<MB_9C/:TE8
M;-@G)14H.:"G+ZU4\O#G3 V/AB5:8UI?.">Y"PLA3L;KNM$00</HL=P/6,/L
M[ _YWAOMY1;2062^"D$5L78E5*I+@5V+MNNF!_"-[ON\D'FH>DQ@7ZMQ(#"F
M$S!5Z?Z8J3[SZ11I;K7T)ZP7!5X23_]D_BR*#< 7ZY!_J#OD#\,48QR Z1YR
M]KU*!^V$>?=PZG!KRC;Z91O]G[R-OE%%+*JAG=6Y;&]>^\/;UL>+,VQHV;ZZ
MO#V[O.T:G(]V6#M\KCJKUW9K>\_K+3?O58<'NWL'2RICAA\<OZ"YW*H#JZ95
MX\UFV6O0C<^I<.TQ^_L@#!+?J<HIVC;G_?ZTU?'"WZ^FI?!R]ZQU<VMU%HB!
M+KY9S][U/OW/8[LV*UXM]NPQ4Z;?7]G&36DXBDKA4W.,G/7,97&5BQUT*+V_
MOCM#Y3Z'+4IJFD'-CU^[G<NS;G<MY'RBL1UU4ILO\9:TO0N9IJ]$ZF?.Y7FD
MWIM#XQ_5?^797</9/=A3DKCUHZ*X)*<9Y+SI='^WSEOMVZN;'Q7'+R-I*8Y?
M2QPCN1N'RY+'I2UEP $^5/+X8VD:;P<YOU[>G'6O+KZ)NQC/S^G*18%QE;;R
M^FF_.N$,M#\HC>4M.LW-H[VCQG'MX/CH:$_;S7-#'ANVFO:V+*3T8[;NI+7_
M]?'L1EZ#]J_2IS&!]"M3FP72+T^#EO;P^L_U84VJS4;IW6P'-:]OKJ[/;O!R
MRM*=,8'8*Y/+2.S2G=FJXZNBL,W29-X.:EZ<?6I=6""2VV=GIYW+3R7^;P3-
M5R>3FZ6!O&6G^$#*Y+W20-X.:G[I7)Y9W=;YV>V_K--.MWUQU?UZ4UK+9E!^
M=9(9*'_P1&2V4"I2WWNL=F75V:-+^_V/JIUG3^3IHV!F&NS+\F#G[5;I@1DS
ME\6EQ%%#:OO]T@/;#FI^:=W\?G9KG5_=6#=GGSK=VYO6Y:TL*.U2Y/_JTCK[
MY]?.[;\J\,1%ZY;2 J[:OW^^NC@]N[&^M&YOSVZZ%:MU>6IUNMVO\-GUUYOV
MYU;WK(L5,N+'EHR&_#CN5OIX9EL2R%4'1Z6/MT5R8E]*_0,3?;QF;;_>;YA!
MS?7-Y7G4!'_N[.;;V6GIU)EP<%<GBO>Q34P9 MDB47PD1?%A:8!O!S6_M"Y;
MG\XPOU9;W8BZ?>UV.V!YHU$-#US\J]LA8_J\<]FZ;'=:%UAX?@KFM'P&!/K7
MBUMZ!,/;+?RB-+2-X)[52?>C94KWTM!>OSRHUQ6^<OC#U6TE/0VAYS^_MBYO
M.[<@DK^=D:R&#R[4WYD B]7Z>/7UUI* #!;%E=:Y"=RQNMIDY(ZC,D-IJPZ\
M@DJ.2OM\2\B9FMQ=$-IDJ7=)CG>_7E]?T-^MFW]9IZW;5FEPF\ .*Q38P Y'
M^Z7%O4TG7 $JQZ7!O27D;']N77X">[HCH!$PL5N?;LZDX/ZC<_O9:K7;5U]!
M;.,'"*"(/SN7G^@'J<!/K?/2%#>!;U8HV8^6*=E+V\T 4="H*\E>=@K:%GIB
MM]6;JPMA?U/9P.D2<E-+N]MPZ8RD+^WN[3K-JA_%<=DW:%OH>77[^>P&S.[S
MJYLO%($LK683B+Y"N0Q$/SHHK>9M.L>JG]MQN[2:MX2>*8R!.=ZM&ZRTQ8SO
ML\ZG2^L?7V\ZW=-.FS)&K-O/K5LPK,^^G5W>@B3O7I^URU028]ADA9+\\&E)
M_F/E7TNNFEK:[\M;$)Z00[K\J[P'H50G37T10JUTV[:$GJ>=FS-JOEVQSOX\
M:W^EQ*2K\_-.6]=UM:]NKJ]N6K=GUJ>K;V<W&!\I0R)&L,8*;TYHEL[=MIUV
MU:RC_L/WV)3T-(2>J<AN7WVY/KOL+@-Y*_TUTX4S4/ZHO$AAJP[SL1+.9:_1
M;:&G:@%M7?UQ"<;TY\XUW1EZ=G/;ZEQ:'\\NS\#*QDPC\3W9VFE!F*SLFMMS
MH;3 3>"@%0KYXV4*^=)B,T H[*D"KWK9PW1;Z*G$.4EJ#): F._F9#<VU>FV
M1"2E(I-2!>9B=2Y/S\!J/SW[<42E--H-E^?(+*71OEWG7]5[U<O^I]M"S^N;
MSF6[<PU6>:8PX/SL3%9]G=U\Z[3+?JAF<,(*A?7^T\+ZQR+B94/4A<^"F1'Q
M;V5#U)]>8>RK*I-ZV1)U6^AY]N?GSL>.K/*>4?YM==N?STZ_7I2%)V9PP^J,
M .2&H[*7Z58=<'T1JI'=3$MZOH">6'!BU6O5WZWNUR]?6C<_>N5FZ9R9+I>!
MZ,>/.F?O8M;SN/H\0Q$YE[WCW7V8[CB(7)I&R#V8SQU_?^\Z\1#6@F9^]G>"
MNB>U]">L%P5>$L__R90#LW)O9=:.[WQH%#8I\]^A]F'';,"KO9"S[U76A[F>
M,.^>32+T3#)+&KE^-;^#Q<6O9XDSV7B%(TZQL1\\[[J5G0^WR*#6W$NLS9Y\
MT-_4F;=A"#B,T0SA4105(Q8.@-]!89_LY\7_7TD4N_W)FM '%7 Z/0/GI"/K
M<[(KF2V#Y*3%.EP0NWY\TCP8*YWTX==>^.[#$E[TVF>_Y7D6,  /N6_#6UW?
MBH=N9+5\/V&>=</'01A;@6^=!^%(6 EQ8&&SW4;M_65PQ^[80X7^K+^'7W+U
M53L8P6(F^BOY\3TO?I)$^A/F.^K3( G5IS0Y'%2-9G5\>Q<F:GL)&AB6&T?6
M_3#PO$DUN/>Y8T5)+W(=EX4N+.A-XGL\BFAN-G+O RP'_@COW8C#6QRP06(>
MO=VUGKT3BMK+)5MC(;)9JQE\,9X!8NQ<?ONSV@Z^-9J'34W (%3T&X=!',23
M,;?NF&W#"Z:H"12V+A.@9W#G.O#MWE'CO97^K'WUK7-:K1^KWU>(.UB>1!E.
ME+,YJ-5GS"89.T!CYWES43\JSF37^H/G?SJU6)IK8= *&L\>M]%,\B:PG(A^
MJXZ+&N1;;HJ[UD4 )C(,-TC P@K"B<62>!B$8$/!^H?L#L;RHL"*QMQV^RX,
MYP<CV!QX. FYU8<]0,9/9SAC9A$]YK$>]_ XW;O ]LC[W(4?\Q#&"L1)XKN#
MW4KA[%O%F5>LEO,7["6<-&?&P2[^+/NX]:91:S2K\)\].F2PY+>5E%BX1K5[
M:F%?=[N[<'1OX9]2XL@^X)$U9F'L\[!B=7F8C$!H@-B-P>"T0/MVX-@SZ_HN
MA@V.'5@4**OO'.1(AJN10EJ8W<&T'R1G[*HIS97V&=5')\H8W7=Y=9NM8KV]
M:9V>8<O<^1KPZ:68HL@D9TDB5:8.=,7ZPN+0?:A^*7R@_[P..3 -UW_?<'!1
M[M*_D8WALV]Z$ N>MN*0.1SY)T+.DK, ;>)/A)[)/D!B(P1.!\FQ@*:EUXOC
M.P9O>8(#B'.)BBZ,I,["3<!WP\;=<8?DDQ. ((AA#+#6'!(T"6@[.#2.&XT]
M1F\2L[/IV,#YE@='3-?R&9(FR,T>)ST:>R"#? M>&X01!UD3XU/1./ C^&#H
MCO'5263U)J"'[6'Z_@H^!P?4$LXB/(\/H[2A3\72(I[^8'?SSM?YU<T?<+:J
M%U=7O^,!RW7SV/@3=OL$NZ)YQ5R?],D]"YVJ%P3?4:5$,>@;9!4TPQBRY1T>
M+.#<"-B*5!+H\Q!_C'H-V!H^189.O!@98X0,TF<V*")@(V(KAJ\*@%TB'N-X
MP$6$A2B1?0.OML[%3[)JB'L1OP>^YPN<OPH=''A'0BH89Q/!7"9PB/JH_D>P
MJM %FP0F%P8C.2%09:[MCDG#"CT:\4=V9->Z]CB+E![GXL1'J.I@+J"R/*Z5
MYQ?FLP']3&NY4S>RDRC"9W%Y+9]YD\@E473N^LRW87Z@&D'?Q>J9&[D2>.0*
MQ(HXBTJI;=Z9DZ EIH9CV_>NU>IVK]H=2AVD?I577V^LCU^[G<NS;G=:9V^X
M^W8%'-I+(C3CP&6)T/?Y"W@'9;6?C'@8@"@6Q^Q^Z.*Y <YW!,\ 7XT"-!(3
MY&!Q>I#WAIR17_7(27KZ[)!-%JDC+IPUL U[24Q30.7DN2,W)EU8H7'[8!\'
M]P@9/X,.B[G?$HNN(O!,U'I*RE;K1VLC*6WRP?OU.7CO<]M5WT.D<N<#6!7"
MW[" \N2*@ #Q N C(<)15O83<CO 7NF[,>NYG@M&"_")%N_S=7I)VK62]MX%
M2Q(5N.LG'*5'R/^=N$#+"/81/$L;U!J0UR?) %^/4%?#_Q'9[02,6OC>X^"=
MD6FI]0JQ!OY.'/$D)*/3P0>#L; >^_0.Y3K#0(Z+_NDC]E_)*^OCE8_<9N1+
M9&@&Y]U)0.EDR<K[:)5%\-F87!#?\F%2R TA&[L.:!R.1B"Q$[>'/BQI0%["
M/?$ *H@>_$N(#6$VXI#JM<2O\  8@S:H/M!A);N8R"Z(S&31*Q^#R",P3,@P
ME=13,J"()<$O1^10I/K#^F/H>AR9A)11R&WN@M-+1HQ$<9"E)$KV'Q)"R)]W
M+MK( DH#]26D$V)RTC)F\W_]1J% 7UK2_GE+OBP8XN& ^_:$?.O9OSG[JG]#
MF%4>+IQ:K]*C\[!'-+P8&G8]$**P:7\E8%\Y+OD*XNB@>P+'(O$I/H8 98\.
M$.U/EA!CW!3P.:2/8GWUR1CKHF,2Z?DCOJ87@/,G\9T;5J^K "OBXWCD[W@8
MT7-R(&$CT X*N8$F17J,\TN-@3]!5 !K$I3G]BV0 ^!QE8?=U,.N3H5@9CAH
M?C1RP4&5QB P[1T#I]D7#B@R1+=UTT70M=JP[MPPB030AM\@\(3F [!*SP5F
M1;VB0.L*L3H#1QP4CSBZX*K;?!PS'!PQ*?C!7-%2T6>-A $?3/"P2 66Y]MY
MP@F>QZ.,X[,!BJE8JRN]1)RC5&6EIC*;><$(1L^4 :L%VB*92#A2:*X^L_,&
M,7JW**@DW\ [D2W]!+$JD)'X9U[CN?]!_2*U -I,PD!6!E1I_)K-(\KXO><9
MNS8>NJ%#X297Q"31J$!J1L&(*^GAL1YF7:#J!>H**P,Y \;%)#@0E, =4O2Q
M'(^Q49!,NTDY+J-?.6C6N+U$&#;2% !!C+\FE\MC$U+"&.PCY!2GARY?&(#3
M=L?#G(&=D8;X]B@9(_+_%-?.CXF5;+MVT3:$QX"&@G/)]?9E6L2B!KG@3V +
M_&&0#(;3AOA\6QOL9[+ZP";&__>HQ0YLJG3I;&-3SVPNX_R$J8K-,E71P)RY
M,E71]%3%173,FH[TM. %'U@)7:V-/1?D3B0"CKB6'*(156:!=3G?!(R06 0R
M$== 4T!!^!XO+5$353KA:B)\'D4!Z&Y$7BB90FM&PEI1V\$W [3O? 1F@2W&
M20\8!N-\'CP_#N /M%RSZ#]AL\!U(FB(G$(,E_CCD*,N)I'&R?F.E!D!+$,I
M6D))+V!49!Z!WPY"-BIYS41>^R+S<RC4 ^XP&&P8#!8LD7%50'P,P*Y ;R/D
M$3QMR] @?QC#;! 4RG*4SP=,Y/-A6A'X,FH Q13!&,/*B2^2'04HA(Z+FHJ,
M.HD($P4>I1PLW6<S&>E6)-Y$.?]6<90T^P7NEPL/LC2O5N)L.1G'\!4]U\]
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MTZD((N+5OG1_!XYZ+<B62[4Y35-M6LZ=&^%):,NL/(Y1^4XV+?8Z1##,SEP
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M85"T/[4LGIH%^66S]N_LJY@"V(PZ"Z+X[M102]^MD$=EHA4:P&"\<&'CZK'
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M?8>%XIK"-%6O^'HBI"4;0133:X^$Y)B:$FT55@C@A79X3Q,.*^ODJ&=R6O4
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MW*N9VQ5UEF3"+;9OPTIV 27/Z+:-A80"U79FW[B+'N1C0I'UN;R,S\42D6#
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M4.ZR[(S+4<,<N.*M51/;1/,YTZ(R*T\"T$C;//T:_)+$\QO)%@OS8$@6=;Y
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M+0;RRR8Q+.>LO@C^:BD'BE<C#Q%I#6(L:Z"P1 @XO$"3^Y:V;@$T$8Y6Y<N
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ML0!,AL+^I2LXZWF$XI 9O>BME0_@*4^C L CP9)WE\&=M')]AJU@,85EDCW
M^L*Z;9<"N2@K\-R(L,)51&Y%D.SD0J'"3T-ZK@$&C%>2TS+J56+R"M%"V,1)
MG: E9,53B^CHSETHA+ VXNG2!?:X;(R^TLI;&+,V&'%,HAO@8@V?W"DXOAW*
MLQB A0+';%+5-%IE-LY;*>@IY'N>K5-S32 ,+K4TIW*GM<'9UFE*UT>)A6@*
M 9VD]<<!_O..(Q; ]]#+*J;"(6%E5C[,T:@@Z8]LJC!O#:>MYSVRX9I1@X_.
M14*^*+MCGDD.@TVY9JE%3KN1I_)'AW00-FI^'U9HBD4HG,&HY.T#/-.$$2(1
M?2N](N6VGN970KYOJ%;:0 ',F:T3R6S=MBE=;;(T."(M#9"YL1&@5R"G3^7%
M]Y8R./E3 S44M<T8).=+IDEG3OR7C-OB.Z\F6;T4#<5';.+(PZPOG6-D6P5A
ME!)[4S=<9C2 <@85PW\-4:*\."];""B]P'V0B_J*$3,2S;-<T?$S'2Z#LO80
M/"JF%*O7U9O 9(4[BW5;'S4!L$E>,08)4M))9I+@2X]RBZB"XV\C!@G-+$$=
M(26F]PTT\J9%-0XNO[ )'W(,N#$[AH<#<&UT<[!^T&*;4$BCE3F- P]MS"VC
MI>3M6:XJK87$B7(%>J_UUA!R4G\<9O;XML',Q#PX%M#>;5,LXU-Z9H)WVZ:S
M <&?U,\)F31HH16JKJE,!,X.)[B:=SIZ>WSZZ-L79SC@P.1^*.G<0N,^^:_)
M6;TH)J]VG^Y"I[PYPS\*AX,887C]YVDL\@6OY<1,U&_L3EZ+1]$QUOZB;MZ3
MCF#8<_*8AX__*R@WIQ6@KCHE*SFF8B#+PJRV+.V4L\X?%3<Y6!OVX<%UWR>Z
MFDOHIZ"< $!OT*/'#*F,:<7-="<'"?T&6#DS]$^9_32AI5IZWE>:')@\^P"(
MJQ18J+T9QH>B<JVWDPP-DC&U4DZ><VN&Z27? +@1SQ/5*78MWYQ]Q6HR)N/0
M<O7\ F:H5):R8Y$L#;F;4N4N[R%S$Q>-/ YB@HUMN<'"K)0LY_BS6"A=TJ4D
M'O243J#FC 9<&+>0J6:#(TEF>]](YX#3IKX0J6#C?[!6\[QL!%_*N<J.3I22
M;-JZSNCV9-"XDH^2A/=\=_$R7\ NFIR4"X 73CIW7KK)T47>L! Q&R9$[0=^
MLRK'QM"R@ZX*D+W3&JTSAGP%.3^P<?,%E_R;(]>*SUF:,2[8;=4 ?MRW;4>O
M(!^IVE"3]#V9*FA1\%WL</_F%@LHC]LVYW$I?NU5>N,@ :12\ME[\#F44(_!
MBM(RA$R5*]G+M53@9W%E0E>O)O0PL/I#PD@[<H%+S!D8UI@4L2ZP%1N8,<?U
M[6ZQFBR=Z[0%3',9>%N'ZDC2S6Q9UMQ 8VQ"7-;F#V6,)E=@2IO496A9RDH9
MRQBLX,ZT\",,/"3/RLH[V!&6A*^S4I+E4JS\';Y3+UWL]G1G-/!3X?AHS^JF
MVY$"M+HZW4&K!027K";$,K+RB7+NPIM!"%)K=44+P(N_Q%9YB?\!1 &7A./"
M,7W0=X/5K_7+6*-IOE"6%#[P4JG7" 8&[PX4(FBSVJ\F,[+00<I0<",*)EKA
MVOQ9;BU6Y&Z%G\%UZ<(L$-+,84&Y-%_XHZ(O\,4M@39X%W0[[=35#BZI\+D5
M#;H2_X!I5U3 "C?5;B5T:Y5,=94+J9SQ$=\Z3;;Y5/NUTE+)\IRE7B!8N5_<
MREVT"]=U*% 45 @702@.,V$0$3D2'F=RZ^IZT=KAMUH@YBPJ1&/P 4YO0I*[
M0D]!J7P-9V3/X=]@^1"OEJEL:.?..4;+_1@0=5NM6N\IUA>#!W,<K*K4-:4%
MKRNL2M3<BXQ:<H)(J&N.FN52H1'9EO)L@*(BK4=RTL]8C_&GF=#Y W.?""@*
M7<Q:--JI"K+-*_N0@W*4:]*+.,]-&3V:>@KZ0QM_?%@M+Y)JJS!B(\Z6GEH1
M$PMK J88W_(@) GR1]L$^0W,U&X3Y-L$^7^&6).#)G*)2'GQOR2;E80)F.].
MC#C^P[][_DB<RXJ:OWG[3#_';$92+\O 9Q#\*Q@SOI? C39['_J%P2P9>%YT
MY^@S8\O8=Z?4I-&0+6<*4PJD-^K5#6F4DV>9_3MU3.6%YF :]^ >JN+"\3?]
M[*5P?A ]P.6'K6^56\D'WT.^+?Q*!\(+<,:$1[?/[Q_W$M^Z64,;)C&CI\/0
MU;M&PAZW;:Z;D^7J^/'!6HO4D=LG$?OT=)5M+)Y*>V#P4$TS\D$0 DJ76C)-
M6.')N3M#78'TU6 C,_(Q8V<A-#%)6HVP:&IZF M^L[C[25M+QT+R!G(0:Z*2
M7FW:=2.-M*QK&B/79#QKI2W\2.$(S88V\/N)[%QZ_O]C%&+B5[IJ=HE>)6XA
MR=TY+-13#MO ,)8A[TZ..J,>RV#/-9?P;7A%Y5,*%6>6 CR+1]OR5 37P7:Y
MM\D]J$2<1G_TPRLG[?L2;)F:A<'Z+#Q;0^P"W+H3O#%R%[>?0?!.8SL:]5Y&
MJC0*M(=KI2_C9"74,M-EDJ\@*K=QY7+:-ZT+)P4,[20]+.!=8[%1V9FY>*GP
M=J+4><U#1(%%F7;W(7>7QKW3KFH@)M"@$^XY!-W'N.7WIK7%<U"ZC9_*ZKTK
M2'1)2!L>Q:*<-M:S!2'&_8<9;0!>HQUK$+FA+P/^P@P@XBH)+YL*C]1T+5QQ
MJE[^U)&O4R)/&@&.+/">1=*71=B83-VJ )!YJ:WZ<CJ)^P?*UI?)B,!GU("K
MTEWXWC_"6U+(1.[O\40Z%I[IY3!FE-@,:5IA__#!,-@=;GJ)WB?+S\K,8ERT
MU<_\1L3(FC>COIVD7:5_$;\+>\*T?Q'F1"K5HF\A:<#CXB;6Z3/"]U37:KHZ
M.O*AO",./8E:10][6E,E=.$'L!UA014MQI.@V]4S]9&U@63R<>% 8@"W1*.+
MCT&DN8)?#H<<;"-.#*[HJV34*:8IT#KI.6.DG2:Q[ H1SFTI[A)%((02UYP6
M*G]00R.O4&K"4VZ40J?I\'XL;F\V'?2%'43H,\W3)- 8:.74$/-E&JU;S'<0
MNW=RKI)&G=GD['+:E-R'Z[WFK\*QXU-JF;!\UM-8;IV"'S?17L(,K:2)-"K4
M%#MYVR:W$5<CLI :37SM0UBT/PHW B$G0 *?#,+E#*=?COA&4<&EL] OV\%5
M0D(5_)F^.7>7:E*$\^MUB#[ F'W0/\^"\T$!1(>U<W280"!^2B:&>F7& #73
M<D\)L15A$/%[K86"W'"P07,F;#/ B._UC/"SF4YU;(9*:VK2IJ/L0S=;0,:E
M_REK)&8F>R:N)6;]LF+<7%W=MDENCG!'KFL1YNS"G$N;<X#%/@O=%A"?;K7?
M^HPQF][!T?N(_02I^K0+QWNV'@$AM;-.DKYJ2];3?TDB7(6?RPEWP  \H1%,
M@-M>YJMPC0@#](H,J;QI__%)+8RVQ!5_EKCBV7)*Z@7[PC@&;.-9R<B3PLW*
M-J0^C(/@CY-2;/?GC^R/ (V'SAC9OQ?JE$O*DC]QTJ]< _>9,U3"'2]E#HO>
M65\[3DH#TA"K$*\LMMO[9;>7]/4JMN)YD\(^ANAB#]0GTF0%V[*S?.4I.+WK
MK7G)05J2;@ ZW[?N?M\,K)YY;]ML-YJ?IR"IITCFYTR+H44'@N7AL+8%']@?
M+Q>%H)(,56\G0O+E<AO&FQ,RD8'S (B E5YX8$HP.E;IE%*XO-7'B3I%WQCV
MF>/XF3)X%L[WKA$.?3;_A!@XZ<\R9[#:4@W<95DAR,_>DT1UGD7V)LV"'72#
M8 ^#!<+&"I^W#?T85JY>25=*8YZI\J4#O<P[\1R/9B2YK88/R+F3G*]4KT6U
M+:\\R&#0FI-SY<;=S)B09E4+"S$N([0>GI5<&NWO)8LG_A1,:! -+Y*D0KUN
M<&AP5*PBLSXXJ^!$N?:60D<LJ^Y;#&B)>(;VROE KO3M.3[\Q'\ -E#.KG&@
MGI''<2%X<JS='<,7^T-FPM/"56/?R2!<BEG@54AR9.+5)7ZFA6.V5NJ7O29?
M036B]U?9\8DMZDIA.3&\V%B@H:I"SZ=ER6&GG0*&3S5 ]41 ..LAS/*0]E4-
M&5!SPY=YIX$VC2Z<EHA<;K$G,?;D\19[<@-!$%OLR2W$GFROD#][A3SO&UP'
M+H+P7IF G%J)'GL+4<YS0Z+3GJ;?"&G'Y T^_X-/CZ=9U,;@K@B>UB\DM4).
MY;99:!L*VJKSLJFY0AW%12?US)>+_\"UZ_ C;MM4K]W_&/X) X&Y4M':"\2@
MY<*ULZ9$D"Z?UN<,?>)NX'$?R/#I*-WLTH55M =GZORZ^M#PLY,??&@8&3B.
M-M ]S/E P*84.IT\=-+2^I(_[0,1EKM6R?7=W#37@* T^U51UD7PT)D9X.4H
M\DH&+'XPMQPMIXMA%8\6'HGO1\-Z[\ZT+QYRVTB,F!'7\8PDB9C#P0:^Q.-U
MU-D,Q0<^55)9VU372D0M@'K(,G4&]*)C'4B]XKU1V 4'Y>9CH] UYG8[UF'H
MD^CQ;Y7?F4C222))M]BY^L15N)EWY5N-'<8U(GP.&T<GH :.\I0;<!K)K(58
MK(HBY';0LHKQ#NJ&;?,'7W8KCZI( =:(U*&GC>:M0800(F_M0)^##[8I9QJ!
M(]^Y  8'FB\4"4IS,S:&^BD^O-W>+[J]/W$%#KJ IPBN1P+^:O_=XS:?UW47
M.,G+:O)#7C+#/%FOI]GD5=Y<+A@TU$W(2)O\3U_"-G@-X'93T,CS0LB#!&/U
MT[-G3ZT@5R+;"DT2Z$3EFM-+:1]5,NA3D%0#R<I;$D..OZP6^>S3T =;L?FS
M8G.,MNT-VV$7)#'-Y)[;/=W-X/0T#AO"@"QT3W-X*\JP^6/8!5@V2E U1\Z>
MTY-<=MD*(]ZRKD!B)"@W%@9<&/FLJ<F*$OL,OU@(LH6Y92X@/HK=^53F^*TT
M_.D[@JO?28G\]NRGG^R@&^4>&,&,#UJW;+M17VFCO)5,>]'FY @!B0M+C3TN
M<!4QT8^4 $R>DH/1=),?.5\,I^*]NY0>A2@Y580[Z7HZP__*Y7E,3GGOI,Y7
MT[QY_PV<S0[IP$I[-8**#N1&B\DQN(AV)R<ZBA)8(O$[A83-1:S3.Z]H.>\_
M/OC.TRK>GMC%)]KS+U,/^%?U@(^""_G2>\ _B <L[ JW[R =W V7Y_[N8W9Y
M#O:_'4JKL;5J',,#Y(0]AO-&E4'O<)Y>?Z ]EQL-C>?_Z2H<PY<5;4C7:Z(1
MWSIQ3;^,?D]??5D599X9TIU[ YM!%9^CP$M*!ZZJ+[05J6#R)7//=#U-Z-7F
M0K],'?1O+UYO]?:7O6"+\QH-=3U'9T"?T'\;E_=I;[;+09;2.)(:=\I-1$PT
MN$CSZ7%,,:()2P%[,/,M.I X:P'M:ZLBVGMZR,^Y5NPKU<NQ4"!EJL"0)?_?
MD,/G6#"3K>2+WR_0F_IG1,/;R9$69&WQ9%\<3Z8"QG%%@*&J00?C !8FFW]6
M5_6RG&63)F<RLU-WBXBF/_':.<+*%-L XXT0T^=!/-$95P%Y\QK*C;FV0G!8
M-%U5@U6-KK7&M[=4*+KO855(=;@KI9W-V67+4A]W*Y<>S^4L:CBNE,%;-?5%
M]Q^P#91/]TW5)E2!YWK?, <R(RSUJC/\%HB<.36*LK# >=24[?LX^:7/WF[K
M%]W6ES&::E@RBK_\:H<5>PX7LFA<-;GWZ_/C;ZR\T%(('';2 B6?G&OS.9!X
ME5."27L"IRLG^T^\I?2*"=_+8L?1[I53=!?H*V8* U%Y+PRZ_!-TPM&2?@19
M.)OAU;='B[Q]3S_^S&[O5HANEA =[C_:("Q^B]D^37:9*=E:C45S'K;UG1#^
MQWM(9OXR;$Y+O3WT8G'IU9.[ZE6@0[F:B&HK-U]#;A3J\'U3HG) 0S)6U/R\
MMF8QO\;]3=^A-(ZKM!4>$?M: >.SUB9,>0B9IZQ0_G_I#"R8#5^;,1?B6S*]
M[ZSE_8-';[P-Z(TM4#8"RC[9 F5O(&)S"Y3= F6WWCHMSAOI*=*X);>NM9R]
M]M]9D5W$+AH\LM!N2(L03Q'*1N,HTEX5/X0;=@3B$_16;COZ -<V,F<Q/^VT
MKHN);T(","YXN.(N3S^$+MN9;U?-7QNV3Q]^<_;#J]"@6P"&-2HYP-@\[84W
M;OUU3_UWMI;=EY4_W8L(_8ED2KD4BMFYD,;;?D6L:,Q\9KDX]$_2+Y&1#P!L
M*-D$V0%8@5IQ%?.I@+@U87+X=L?7(T[NO656W(R,F3DGA=XR8,*1#"K1C)Z&
MF? LLX? ;PUI<\-/G$KL'/N.%H)R:OBS[L.*EF_I"SY==\8.L)(336L^*)+]
ML6A(^,[6]?BR JH: M1)B%,=UX7+S%_P5'IGI&BF=?V>6Y8T8(>I(IV7\!'Q
M;K?2RZED5'>J>;?;^T6W]Y51V.<>M5YWS+ -O=(X1G73(>3+L&1<_:RF_T5P
M4S!Q+<H6N4N>L(3*J4=1>GDJ: '0X=<TQ^W1_6I[>^))-(_#1H8:%.;38E*G
MA-_="#<34X@;*ZCQLP4]?_%-/3XKW3S>Q== HZ*\>^'.0XI 2#"E$.?XV6N]
MMR<%[85#<XG*V5^/>G1,\ *PW<XONITOT)EK)F34.Q?<_'=P4QJM1^;[TRI#
M;WZ!4FTGS)UB/&TW[XMNWH_.K9C_M>K*G2DJV9I+Y82E7\SJINDE5JJ=*V/O
MTG%$G4&(-"AIX")U6&H.>SE@,N#MSG[1G3U1XQ5,BXVW8F;D'@'9CX/H/.O-
MCK+>;'?HB^+.IJ4T$E479'8Y!5WKK.>6 -[YR)C"C_'Z=C]&<1QK9RKEER%Z
ML]W+KV#3G$@"W.P9:XL0(0J18PKT[2L2@&4IK=>MX\.W@I80HE[NIX &2!'!
MF' ^RIM0O5YJ,6O@O#+0S58&OJ@,O*Y.:RFF5!H:3V<&1[1?%7QV548D:OO'
MN_T^N&W=?G\(.NMM<+UN35;UH[THDOX3BEL3]G9NLX>&?0ILF_*)9PM)/]<.
M*G.UK: DJV<@%2RX E3ZT24X=T->::W[L#5X P9B9GP5I\H6GD52E$@FU8#Y
M3"GN&9%.$DH/K_JE="T,%P[BLWUW9HQV<:O"T(?<H]R9!< 3@OM/1HD'Y;#S
MD.40<P/9<AN!^?'%YT^/I%A&:;05WJR :)[4B[Q!B9LVF+'TP,OC%R$;$35,
M1]JCY)65!C07@;3 ;ET_-WI&-+S0*YR;OAE;+W/HX>7M_'(MP5(&%JQHGM5P
MU1#T;IQ0(Z)G';?D"!T*=B<OZ@O$Q(6<L/$]WK1GSP?P'08&K1;]',\=[B%T
MWT6LZ]+V3=K\TH'YI;*:82V<@*I";5)1+R?WN"6R"@Z-1=JY?@^ZK[*B]92;
M1]J@+)VV939V1W ]3+C$F8N4VLZM9*&L1P-Z--K=A0P![;=UI12C!FO83.B>
MHQ^-P+N19$/A?"=D1&R+^ NZ?QKD6Z)5DJPS4@U#,;3M\5T=!*C2#0]VDKL:
M.=O"%+)*.MO*F#T2=G F28-IX\[H= IB#F\W%-3SNBZRR=.FU[<>U^V2WCJ;
M',VTB\>(6KGB_,L;.$$A-,*,N$7O#.T,RAUZI5Q!<5<GTH43;Y1&!'8D(57H
M:G@)_"<34L8V"GN$JF$"M4;0?%,RB<I.#HX.D#O#2)\GWK$.::)6MJ-#6!9K
M'[;"94A%N@7_NJ7]Y":PX&YOBIWWY.'*7A7GJ)UL_<:M/"\FC8K%T 8ETS/5
M!"CSU,31SUG:-_:-TW:'%5TEIK+!6%*WW4(FCQX?Y$I7 HV]/4"B*Z\\JYWS
M]0LQ.Q/IBV4-C\9K-&%,,;D@):'J,[D*\N[L BUMVTE!<MY&>MIDFW;F>T?K
M[9!<6UR:;36R*:"0E"ZY./CQYOC[E-6G:$O&MY=D7^.T+"&-59P!X$L&S\"X
M^-5:@!ONEY^?^I2U:>$%9X4T1AFNKTV"31J-H6A,9.E"74C]H9R)BZ"B#[\"
M8BK8N2@)+]E)?1QIA[.:ZX:3@V*W._N-]8*?V6JFA N(,[N&#90_U_9IZ6KH
M4='+M&=5(O<U>K'($T49ZJBY>12WAJ)GG^IK_,8A$E'(S2>L25Q#!^*=NN(+
M"\I$>$'/^<1Q4;246>FJC-I,6"$>AI@B2[A=W)I%UQ!-R$D;[0_J<+3K"QU(
MU^RT]&NG'SS@/QRN?9SWG)PY.N6<IX@48$:6S+*O:I+X<L9$3$.-&!5*1".W
M!A)L2TB7,]L,6S;Z'V,B,B(DF '*'JQ?0/)9:8,Q!4$UCIQ:E!-__],11D V
MD!X$C<8G>X4P@ZYY.&\Z,IL&MC]<C--<RTFBC_CV%R/7Q.[DI"2=E3>F$]"D
M1[L^B\D2Z893!XSHZNS*@O>_(&[Q8&^+6[R! +HM;O$6XA9OKAV6V.%,FRZ&
M^$H9TEFEEZER+MOXJI+N=W);96@(J]DYJ:S8G3P5G%Y\!7C=K8 GW#)X469%
M>V()I$ _!5A=BNMQ6L,5@J6S(V-ES(50]=-%4<AW)"J2W#[N RUC):&'PI%9
MOH@K!:-+TO,"2*?=L:%DWM,QLZBHN=E89Q2BOF0M>N*N)XX(UY]Z+QQ_;VU
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MW"EKA<C2S[,NS4:WG0^BYKD*(DV":G;2"/0<]5./9MWDC_(RWEP]2EM( XT
M02G:!;<(4H:Y8JVP+PG01HR "Z<FL1NU'[CA#MH*-MQQ"4\3_(*@.IFX+6\\
MM#.%(0 \5BZG: _(^Z"B&O UJ_R2O UHIN'O/&5)S"T>FQ.-S[]SCAH$5@:.
MD)8L](S($Z?5SF'72AT,2HD3PHZD\Z)IRO61LJ1I4(:>2F=J=D:"ZZI3JS'
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MIE4UCNU.>"2_U^? W0?R G[;'/[-F*\U-%-BVH3@98+.H&REV.RN".]X25Z
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MT(MT',@=1-1_T(U^"N<R0C:\#11BOOO4TS=O@_&I,>-CN@+H1569,]=7OW1
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MRK18DM8!XFOMJP5HV5Z3[8*-NC&RBPF$7$I<5=)C^5X/W7AW7MJ!7V78Q4"
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MUDT]689B5A@:* J8\#(@]U!>FU>AW_S)T=N3G>/ZUYV#R7G9 # )*57?UP(
M)!ZK3HB7FM!)<>R$!B":UFI=QI5:B4!N.N,"=^Z8<-OHMS33XP<?-0H,PKL5
MRYLHEL;.-<H^9C3KL]1T9,^/:Y<V$AP/Z\%"IO]*EN.MC-Q$&3$SD4ORS (,
MO25+H\IFM$!2O>MYEB]]#2%+1LJO;I5JL8SE2V[%-G H$BDS6G-?M^EO<>YM
M@B1B7.G:3!BUH.0=# >8,*8^-E('=:O2X224T6S%\P:*IZHP]+KG>#(DE)W1
M2HDRKVN_*J>^E.4S0GS-;OV(N0I;E9/L7-OANP]K'Q(+_?H+<]Q4O&)8PK_
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MO#N[R"\WAGTFI7?+.3IC*?9,(Y/D5.%7'/D<M''K*SA@S.8*KB?@#ET+ M3
M"+@5D9LH(H;+TE@ZDS T_D>_^6@N%(?<D^1QEJ2YAZU,-TI;+BP,@T:3,(P]
MU[99R6902^)1]),VW^-W^-%+2\'9F312O+HKW%;LOJYF6G 8!\6=M3486S7N
M'&3/I'SZ"CW2*NL<K+CC/# 1Q@1N4FB6SR2KG:HFZTT[Y)_%\XHFO\@7:0!
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MZ-4,Z[&*5LFQKY? ;J7B)DK%;\Z:@*6HS'X%0N@S,DH"='.SG3U5_TDZ;M!
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M^J@A@H)\NXZ'$BT$:NNNL<\[)K<?K3#VPAE6VW<:YZL[2HK>8R#8WG>_G/S
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M2\'/9W"4P)@XW:T!,2M3B"V"!QLDG /,<F(O71>$[]T/1VF<-0J6@^Y;QC#
M7^EA]'.4^?DT1"Y(=\X?NTTG21>ABM.%N$)J_<3ZP 37&8*!O!8\ONA4^=(-
MSU0ZKW%/3?Y-B]&)ZL"0UW*A]U63ZKK00J%*)U+38P,FPXZUGD3,9SAJ"PYJ
MU0UT.8; L8'U6#$/G*.&QAXLJ#D\8:&*DY9=4XPKUT37@TE3(DF[DQ?UA3"J
ME!J1R ?/0P6"Y0@UTHHD^**^@"^7329_?[B[-S&]:2ML:2XKU;:4),=5<P-
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MM+VS.\$GJ$B&DL_DL"ZC!6<UP;UIBTR(2"5BW (V90\Q<<.<ON ZWYF^TVC
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M+.5OBPJ2N)BAOWW_CU=_>_7E5[)<C(%XBEZ)6*R;Q7\\^\L?%ULZWYA_W:Z
MA&==L[!0I(K6CFZ9R$GW_X"W=7+']++T%/3@:RDBMLV/2CW_'W^-CU#R>"V:
M._[DR!F:>JADN$F/1:8T?)QN/DTF^.]8._6QC?,UI4X[LERD]W-"X=TLJ%-U
M)]JZ1\==>O0@_FJDA_?PY 05GD%5E#/Q$P&8F3@8-@K+Q;;$3&+"UHK<;/Y<
M35?3ST^M^,;QF-!<-"Q(BHB6\"&6_<@&ZD'N.Y*0F<W4Q.6; +V1ZQ^WKT]G
ML5"[\#0_$G/C]VIX(Z\Q*+%R)]W6MG2$LQ>$F7'@]H0HBT+GV3D@RB^ #I1C
M/;)3MTX28(HW;-FL'='$LMA P)K(B5:Y)F>=C(+9]C07H$>&)W?B?EEQY#'D
MQ,;H"P&E(^,<B P;MP"MKS(JM$XS@DNV6O.!$B3X1>MI$2-IM9.XC$2[?@V7
M0VYH-%2&Z_Q4#)[ :% 'G@Q.,SG+$L+6X41/.B/)^IAD=B4;/23\P,%S1G(X
M),>?SDB.$X04G)$<9R3'.Z[N1-043DMJ6R& *,=UN T)P+K$-KA&;W)Q2DC_
MY8)DD*([?U^ 0V>ALF^DY!MIZ,.GR%/R6)5;GT+?)K)T4K3=4B6HLVA!O<RH
MVCCO5=K,P"7=EQT$DL1=FZT%IR4_?XXO^^JM\RG&5;I,F2&UA2Q/GB@R?0G5
M"K_5]'+@ 4%Y9Y"YG,@;WSK'^%Y9RI^7%OGA7?QY2!23/QDU"-Q#NWQ5A :=
M&05.I^D 35A2.%U0X91FG,.><^O.Z4Q3=].TJ"VA?R>_&_#<2GGC/9RR=QRY
M]WSR2H:9Q"*5:!^RS0U&DER!6+=Z[V;Q\6X\97Q6G1+D)3IA''K_MMOCG:C(
M@PVOOX+J2W"].A5?5156% ,! CI/W^E,7W+ N68Q]+_5!6\\Z2U6P-F*Y7;+
M<YOQ24TE%Q&BB CA1U>$)"GJ3=.NA*;>H/_2:IE)\^6$7 4#[*@N>DN)4"J?
MYIPUKDEVE"6,HA@!/1Z2M0TI!ECIO!:*/ /!Z2E,85<IS#[\K+@A\_ZK^G1S
M5\N#SR=?"8G4G;NJ3VPUYCO"UR\V/6A2GU*JY3-S-]/< I=;A%K2"C2*M"]$
M-*I.6'$(S56'/8TRO8)%LIG:+$I?>7>SV%3-W6/+;CVP9X.J/&COU9J>994V
M Q!Z!"51;A*U>ZD^1<"TXR?V=HAK,6'H0Z3QV,;[7L;QFG31H07>A,U/9:[%
MK;4IS</C!==8LBJ?KG>7/$O8\^,4D!RK *S*5=@+E8@]8N5C#G>0SUL5_=ZD
M599E8[-Z\%) =5-?A*,+(KL)H)R^=4TPI)HQ*R+7=+GX7)^$ :<S#P)WR7BJ
MW87$#A(6=UU2H9LRT>/DY.7BM>DKQTLWK?9[H0PZN"=#YE2;L6PI4 H#Z$FV
MS(@D'3IBH:JJX&0PB1<7M*ZU<@@A2 7D\;4-#;\K=P!"AY-W8KS2Q^5\,UWM
MN@4XWZL7#VZ0/KRTR5.%GGO[Y!=XC*(3C1M/8T H4X\2%!(!T;BDKHHHW*?B
M.<%M.31&<.O:')I6(U!"J_GIX%H^T4,4Q5NDL9LUF1DO(S%C'WZ/%,TQE/.O
M;BU>$UA)MC7<R'?:2K_ZGK9D/ST>.-X7UWU."[1 G40Z0?V#TZIC)'28<;)(
MR0P+1W_80X3'IL]QPC\J62?K0; [)!(U:,_Q6)A8AAF,#^VF^%*#!YF!(.B]
MY!'E^<873J\FQ.A#_56I.UP(YF(.(_HNE#IX&4!C]TGOC5 FT67(@(;_M+)O
MNP*MV6CF=H>YM#L]M;-XN'6TF4B7%.O; "%KJTRG*E9%,<G1T[E7;%CDZ2>F
M$_3?1*F#$B-LK(=3LS8:U-7R_;DL=3I1F]O!7+RG/AS/CL796/S:*2YM?*>0
MQB%HT#?!6,W=F@+G@;%W8:%1OXH<_A/"P7'5B#0IH0#W:I."+U#45'5.Q*#F
M&EG'*S4[*@X\G]YZBN"L/Y_!62>($CJ#L]Y;<-;Y&/O5N%.I=TR/(SW1PA'1
M#-U+E;<2Z95ISY3C8IP/TC//ZNR%A(S3030K3)\K)*>S+!(G192-:R,:0,\M
MG C/4Z$0-P<NSV+10UB""/->+-9E6Z#@@C#0?K+\XE07A:A)VU,I2Y*[< D6
M](0RB<3;5 R,]9*3I)D\.CO] HE,HC C6Z+ 4$@-];+!*-;-EJ)M@J7MD;DI
M^8F0JCNOZ!-:T=RNRB+3C68SVOW((W<A/T5F(MDWXW,/)*%BQP6W9M\?%,XL
M=F XI,J1IGR#NXCD@+:GG)F23W*UK<LNXE1]9!;^L.MQ6-X*JP/5;5O*'@$_
M'--UT31QC1H283ZQJB0.,2L1Z>D5Y9VH+,Z++"K.EWD%!HG9X_FC=R*R,BF[
M2"/SA-).G+Q4U=8D-ZY9QN@N>>$XA_?G?"DS$J(4-YD-=?T!G6\HO'/]_ 8Z
M)PM&9]N>6/YTFK.4M6S(YG1\4@G0 )Z O2(29)$Q34Z7I$)X:3HB(L*("YD3
MCY34Q8>\"MGBNB394?I,E:^@/@EJJ,R+ -)J]<1@GJTI&]PVTFD\P$@_LA7\
M\*+Q/ 65'T<K"LRPRF2"M2GHBTU_'7MX32ST9ZF$CA4DTS]3)Z;P@*8RD?-D
M8?; S,3@Y;4[3;.A;.L:(OGI!L+E$1$4:P$E<:HR@PV4$!%3;4J4)Q[9DGL7
M"L!?8H'Q49A0.\$\U8GF?-0B);@Z@EU/'2&.%OCG6! <&>"W!:N84BG-M%S)
M&@T-1R2)[]*WR5W="F0ERZH8E0!8B>8.='?]@-,I,YY#;L8FV@C\>A>,([.O
M<+=8N=N9#//@L2X7 \*<<,^7G[]^9<5X.UH6JEP&1Q4!$7755U6S CC.=E-\
MJW73%;/3XXEXM^5Z716"E+A#(]P*W/_ T>'0,'(.:2=R#48#3]F*9#P[:!:R
M5#NS\%#?O9.SYLW)/HR3L;69T\[XN"$UM_X2I56&[F:+X(T) T8L]&$G'ZG;
M=9&;)(;,C;36>YETO;F 1PBBWYGGX*ETA,HEP3T],@/RP#/K\VBSDR1 6G8]
M2EF9*1];7C6L88Q.?E=29+8H8G+J:UG7^\.H(+-KPSQAZR88J7*[[-LN<L"P
MYL&*65XH)LV@"!(>S],2I&W_3*$DOAK]66!SQM^$-YRWGX_>TSEZ[ R8LVAJ
MBVC]HXD?T)(.!J^3:&HG'.#.-"F?8[[7HK!R>%/ZU!!-@JA(EE9,4C2Q+;++
M'.TQ73HL</Z)<$!F-HSW+)H%#=:R2+C-!XA?A:9.'7DIAH0XN_Q SR3$\^<:
M]>ED(1SH1=13!OH_X@IS[";" ;2ZK];!X:: /AQLVW)/*!]:"*_ J2^.\VND
M.U=\LN,01,F5'>?/6-:&J*ZL*>DU\Q>>Q?-.:HV$D^B6[((L$&C5%^?4]2E-
M$;-2$E"$<M<>KW>>I=.9)<%?$JE"75 XR-,&ZVO0RW.>_K0FC;'-B9O-'!#)
M-IMW@)\BN.DO9W#3":)LSN"FQPIN.MU@^;MQ%,CDAJCB!&/+U!'@U]%,)F4^
MPA.$7[?DTT#WE+)Q,0';N7(D,A42G%(^?K-!5G BFDW#5K <%G0%KF06ID<I
MZ5P2%V-(MQ09$ V'AZ.KKJHB!P2WBP&_\D]R<X"T_T8B2M<ID[0:2&DT'/PE
MW[#7VL JK+IU[$&F#.^%:;I$H<\P.B%&6Z.B9V\#!NXAS1=FX 5+  CQ*5V
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MMNH0Y-8]H^U7#6-3I)U]!<G,8#WD%&/5FZ@R@J%X4DF?,<ARP-H2'C$\<7N
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M#/VQ8[T( 7US*+3>2/"&"&9HBU7;EPD)$*XO;0/Q#NMXG;-W<#H+8F[2J3X
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MZ1JN]DW33FV3Q]#3]8[<*=^ZG(\PIQ#]SZH(6V(?=E/WN,Z+!Y;;7,EU$AF
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M*GF[=$YA(;8KD"?]\5]?J$K3F-5=TNO;\?(Y_34R=^Q@1?Q0B&U4C,*D@PX
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MEI/BR;7$P].8D%9W74Q<>K!BT0/!WL[QE_"=7#(#G 8EA@KT453RU=L"FT1
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M<W1(OWCXX\@(2[#BRNQ-=;X(K&J#_"/$<441E7Y0@9?QVI[ZWM3O\3UN+BN
M=T#!G@R&%CE;:V:&J12<-1C=[H@F8;,="#9);:9M-#X3(VSDIDG?\F!8\'J'
MBBXQ3N=3D=Z$&ROCT.%4*@EG\=2],]Q"T!3GE2NV];]PDZ+2%5@4[ ?.1UP:
M*. XPO3!_4WPFWH).N'\GA48O2^#U6>A89]%JBFI8%_**2W9WQ5RO2A+N7;_
M8>]!5K3"2W+!%.I6$I"G?F4OIJ\Q$MZKCF!0\6Q3:5K)#%8IC"-,@B+( ^D?
M=1MXM/;&[50H&GW$X$89$V^OZA4-X<X0Y7>N23(E<&)P[M4<3AA8+%LIJ=?K
MSS-C+2UOM^!:\7F-\;AU*6<Z)GAP2,PRG7N;[SJ;I;]F9+D7H3;D;@[=3L4U
M[ME+"IL4W&#<UHM  8T 3,RE>C<DF@;7H3J_W:F\!Y \+[-+V0P]J-.XOH@<
M/@E=:OC)#&ML,$4W=5V=5MY]_CP+X2/V=_<?:*%52(Y6MI.&"1^#\OENO;IH
M B(_.B\%:0=O&"?NF-+!F)S/='FN,BHZ<Y(%+V]2/6-DU4F7!UA'AT6!15*G
M*1YY9E]C-KJ[+C'7EFX;U36'T47@E^<MKO#51:J]815;2#:/5U&#0D-,>6PK
M^IZ:^/P<M[PA/Q[K5V*,#O;% PS>MN>,KY,)"6 ZD:"DC)6)%>(0^^V.#IOH
M>3I-YQ/XY8&KGJ*6J"3Z=G?\*(*QY H1@H?#G1*\"6!U7)L0J:",[ +\^SAZ
MSLK(/9*T%RX,%K<TW,, 2OG;AP\>CO>BN;P''X4OQZ^XTUA'!+R#L^5KD6P=
MI8ZDISS>>S#>_8__M?=H]YD\ZEX+,S>_]91=H-I<X1"(T Z)4"A@.5;8P7>N
MXBK1@"]L,L%3>)>):GKJ%AF4,W[/ E5RZ'_,6L*"\L8MZ2$WD#!0-ZQLEP'Y
M)F@U!;QR556^XO;/W_D%>F'%^4Z>SOAGSZYY],[>DR\F#!15??1,)_/7#^%9
ML%QP4A_J@IE,G6 /%.DW_Y=NTE.^2;_<J+_YOW^/\%(([O6$RCSJ@2JVP# 4
M.];:L' !$/5,-FD;)8NB# ;,JUTP<1)XJR4K5:8FE7]&)UD"X%S5V6NYH;-\
M]/:7D^<[>T^#0L<$7=[+C(F'P(_<F8%Z).=-V'4E%T-0JUK=J9IAAB6--'_W
M;'UU3>7;+G*$9L8%U4!C;[.>6C:>+*1=T=)E@^FSCK,^0&+];]/?W%EMK<E-
MW4QW?M=,*<]H"I/IG@O:0!V-_)^O7>YC#<K#;0W*!A9#;&M0MC4HGRONK[TS
M-4GS++T4JW$4G9,K3EUISM:;:N<4HIA9%WOT97SI^GKWZ3X[&&_#!2<#_XAR
M/4MCZ*-=P!831:\7U/;%AI0)G#B3@BC:E<*KVTS9*X+EYHR+H9YU+0,:J*HE
MM,D 0P ,EJ!)*GE&TD!=HJX"0FV!.:>%GW4BG2YCL,CC(F@OTYP:^OTT$)^^
M45=))3*VN1)\*?K8TAR9I"#V)M\3YLAL>L3ETD8R1ED"8WXR>(BB:]"HJBH6
MT!BP<%!&W+M6D*F[K%( H;^67_TPKTL&D_@31S^ /H'J!JO:F&VOHCZ=$+&%
M3%.5([0(74[?IT;YY^"O>C22N#$E4MPGBH -IM$_;TFM&1+&3B<A2YHW?(..
M/<L.CJ-U1KBDR9QAS!9JOQ'?FM=')T?];XP,]H,Q\:L,G>^:,@?8&-E(S];U
M_DFM+5ZUU^+KVUUZY\$G23#4C;/',(:<%=^:JTB6':X%P@(9:2V/A>@9!14S
M0])@(Q381EE>%;5V39;5>5R(1S+2WEU_S"D,$GM(/J7@]1V*-@U@4SHND#BR
M;(IV*(SI[GN.%@Q>TK_;ONY"G<\H.%%.RB0ZS\L)BX=)A/!IJAN6!F[Q0_UL
MRD5=.[C)W[IOUP+S##J9/AY.5+&3R]W=(\&6R677PN;X'@HKZ+2J7337@*-^
MY:8"Z+O7,%<7"/:;%M]JVZ3"$/]1;U7J9L$.U5DYE1"QYA8I6FQU9MAU?%[%
M\Y%Y@:!8+;)%FI,M(MT\(VFM9'L2A$"2L@8%11B$3:JR2)NK$E';X_X;9,;X
M=ZJ3#<ISY%U@>*!VEN?[9+[4#\RJ6)<KY>H87!,44?=4\UZ_5%(_^TD!AO<?
M_BWXWHKQ$<00D<XRE77G(;N=A^ =N$-5I5J^H;EF131-Y8J@;BK[< +B@U54
M7B)JR<_1].<J;T%6=3=MS(DL+604YCF4G#J^)--% 3_8L,/A832KGYRHT%M+
M2"0Y>TI)A0?CAT%*(:#V C&G6;I,.L/VH".#8Y^ 'IAEC2&>_G9O=[P7/H__
M:)YZ>P%0$MS?RDH*2;0:NS(Y%TE&U0C+DV#=5-5P% Y78'S+&.L1K.:DRGZ?
M5O@+PFB;JQ(/G=&34UXC^@GT![;H4ZPUU)&!B;2W;T^;*)\;'%G_A*>=XXIB
M(8Z;<V+\$?YCCNY[_PXYP_7O/L0/^8(-=-$34&CR@."I(ZEJIDB!GENIDABM
MT!%1PD4YW,2)CW4("%H\-4_CVE6]T$M]CP=WH=O"=5^0,I-UDM4/6L/Q0_$X
M&K7T.BM(5?92@D7H=*BZ.KOLE5BX0M\^<)E6^.FWCZ/?J]E6J9_.("=]733+
M*MCC4!6!9OZP8)\2BPN-AX3"1%Z,+(*_Z?IO"J=\ !=47EYA(1!W)\65U[78
M,ZN /0/C.;C7,9Z@KXI.QT@O> '*Q,*KD9PW;S^+@*!?+R>8KJTYU<.ZNB]N
M\ZG)S>2KS$7BV&\BF$(YA2T6W,/G:4%@.PA_P+%!<O>H!*,MG!B09 Y[G3(1
M;I%PCGJG;OJ\TE*M0 ^Y0.%MK-8082:]B4$8%(Q): 0Y^5SM@_J)83&9QS>]
MTF:Q?@'^F%*: W:B DHN$=RV4]"*RAR[OS@NHZ!D<=-4_+Y)ND2S8HT5RK!$
M[.VHFB/@HGBYTY0[26RCACS&/WF1>;;4$C5$E8F3BP7$ >&<8+Q4;4X P*9,
MJ.L+NM)9A_\RK02%I(?2?YU\.GG6 ^4E\(:K(H6#23HE&+B26XP(C=5<%D/[
M]35ZH;<,()RE<"'A=C-8<&JO:"NJLF^9Z?DQ>%<,SR/M#:6GVKF$JT4X>$$2
MYNQD4*AY +;5/EN@5,O:<\J*7*(]L6@;!4U*XGE\;MFG6.W=HUIL 08I,0>$
MUC,B(-4.C=L'VZ2S8VX0]P:*M7T06MI=X)>RBR-KWXZZ!BZ%LU-%?&E*@G M
M, -_24FEN$OV/(#@)QD/!VOH]']7-/!YIEAP"JO"V).$"@0*F^H0ZQ9-4:V#
M=@_S$_,#8HT5FP:/C)21>3';G]@06J%"P2D4/F.7A8.$?^VJ/),0"H:C=]LX
M.A/<J=[30.*Y7(/C%ZR5<5T;-'"9P*NBD&Z.?XVG'[';<HXJ@)C>0D85:C^)
MX7\H(5.PA3PON<)=,8SAJW5J5X@3,CN4!*3(,$6"\5[4-R/OVP+^))VL%S ,
MK$Y$^UA:6K$?D^KC]*N@8<ZKMFBP0L7B,%,_3,?OXOX5OA;+@D.^@Y60=)UQ
MPHT:?H0:C.5NG?IRT%[;FA13D_)H6Y.R@<41VYJ4KZ\FY0N=X $2=EM='.#\
MQHJ-+SPL#=WHRMJHMB+<"G1+NOQTF(#$SM"+LF04?,HA6$/;OX_ @A/LI0R[
M@YPJ'QF8/T0KH;X#]YI)@"=")@%8#I?Q5)"4=;2*.6[C4.2Y)[ M8&5@64T2
M5PGH_Z,EUF7R%<I5+EB  .[CCC0L,DL#>#J4GZS+!5S5C2)!D!E5L8](8T#/
MO%YDTAOE!J0AL]%-3.I^L%LB;:4W\M3,IB(1L6X\7^A\CK"P7)Q[X2:'J6LQ
M^?E.A=TFAAW*J%;@+"WHJL;0>RN8;AX1^^QE=*@8^RX!;UW 5<GZ$-L7'H&Y
M8BJ#)2O&K+]!LQ:;AKT&BU[M,LW6E> W2_I)1)01;/U"DX&J6*(.5B:F0@/B
MZVXG(%@Y)2>GR&@!GR%:SX@%J>#N%@01B@LN]Z6""40SCZN,>DSY88B>[# S
M,$OG_%%!')XO&GD-8GI@(2]#G6)M+Q&L(M8XMA.+=Z.=Y!([4"D>N38$GF[/
MX//<MLZ9,UX;?86.D /TZ7CJ_' R#;.4@_(J21K%0)L<#QX_UAJ/<S0''';X
M'#E40&HSF"!*7Y@(0,9<EF$>%1A,VFG!;D5@\3>T_>Q?R$9G?F;T3C0'.Q#!
M@;S)/$;6WS4.95_K8<L03YTEIUOVH%'\;KF#\0#0R.TV0++ L]B,5/#PO+NA
M:+N0D>21Z\H2D0:MV#(*$T$/J:OC_6,_9:)+)1!(-_'NK@>EZ7 'E7/<QU'O
M*%J??&1^K1M.&(J7C-N)GED A-U)_R$H5))YE0KB37A0#.M"NT]J@NA@B9B1
M60Z(QZD.\>X1!)>P<B0;CHEQI>L9^:""F24K.8\VKI<@ P+Q]8)H#^(PAGL1
MMK;#I2DXXN"^S;-V7G=J9H;%Y[JJF6O%Z%<1>DNPND#H(]E"@CQ0-\WOJCII
M,".A0Y".^UJ$DE'[G8:U-Y2#EZ#XF8G/^&@2;7V4A=#%+LTE 2,SP$(4#(EV
M"A/RH*/J69/*D4R*#WOPE:$_OV.AH%N&]S!3Q+6$K$PE!&SM)%I$I^0L+%O_
MPC6Y-9?1-]@.;%9=9)-LH(G31X>D89_?S"-"Q:]F!&*4"%LLI<"6YG8R7!V#
MP%@\XCR-2>C-T;?$A0*;0?5G6F-I9=0223 J>:][W<LX&U9(?7#').T:PNXR
MQWP0%X7#2J8)L361"2S SL/9W[[9;2K8!^UWQA^4BTGDB+0M,815J:"3C(QP
MV.MSQ%@IL]20J*@(*G2/*G.4L3%"_X:GHRMUXO XG@O!["-O!/[9,6'DPFC,
M$-=R#O@?U6^:D@5,;"=%#;Z$1,#@WV8Y9L,IT>6/I $IHDNF=AJT]KEE-@$R
MR2 O"9R0+"EBAJ%="9@_3&L!F*I8'_HIQM0S)S5?/G]WJC] E/YY:M L,RUK
MVWLR8KX0*D>;5&6<4$7RDD$BC5*9E<'R!VMOS0VR0QM:3F<)!0_R8N.%@M:U
M-?< /S7XG>! JR'-="(@EN!T)BW>,^0G8Y5<G?;V7VJE-?W'YJ8C()=RWFFY
M<"0D<TZ.<2*_)VS1!28:"3FO%.(Q&M6(T9OTFB^\F/?L/]*HY*X$-N,L,++H
M7>KO!8A Z"N G<31;=QKI4'AG;)M)^#)&ZHT!!2?^NO%8:92;EC\.O@0K(J#
M1P^>[>^Z*@OX[0,J49'+2*I4M"="FQ&9VP&WUYLXV*KB>P\'%-_^P=YL_T^E
M@X3S_.>\?_]V%6-?8O)2H'5OY\_@$'LHGO=V#5!%W-O)7X#*)Z(OKH9(DWN[
M$G#+??AY)!@4>!MQ7M6Q"L=7^(_'Q7E.EA'\YU=L;!M%9].R<9^]*2DN5D0G
MZ/\7=!->9E4C#4-RYQ[H4SML"-_]"E9-4L57<?X],3"P&8(!S#EC^PHD[7.\
M_=X9Z]!:>,=H.E1E ?<G>$OSMG $S]\9O/"TF8Z_C[X[_A =?\J:[Z-38];"
M:Y]&WYV=T#_\\&#OZ?>>6.IGNE,5TA<&E\/-ZPD.?W;EIITQNOGPQ2S/@3NT
MJH@EG8%M4L.S+89:-D['(_W;S2[D[[ >^^#9WN/Q0_WL^]XMW;15@>[4VNOW
M+^FXU*JXCG_(TV_,8EES_QJ+GDW7@;A4S$C)C$+LZ(Y3@GC,!81!8)(I?HLU
MHP%>&4%-X\,3]A2'S"GJXW.$C;8I-"M=QF+&#;_"S2?E&D'68\@COA52P]?N
ME09A=O7ZJL#+""I)IE5)Q24$!RN!C0DADU+3KD!3=O$[A*7;KS/#\1L/PS2S
M2*&&V5ZJL##1"$ID>$20L!":R:-)JJ_**D<6<*%T[T<0"Q<Y# /0)@JCD1>*
ME*M7'#HDL5?D0=3#5B8.^HCT4#UZ>IX(#<O!8M&4P#VA26F9HAM'SS=R[C*=
M$<,+>WQ\Z+(Z\,;W5(:.>.99/0]Q;+G:J9,ZH1(TZL-&7\-=*OQ.&4U-J*Q^
MEF<2K8B.I 8*79:C'*-#OO0=;H>=Z,.9ZG(^E2\JN(TP%?4]*0[J0/&<U1*Z
M]CCG1J8Z!,GXEM_ -YYRL>XT8\(FN>.8T!">^!.>20<DT+DSI8B),'P=C/#:
MN>$J!"OCNH#K*2BP*BLQ-<3=YA3Q(/OHNEF2@B1XKL;3&9TUCB=\X+9GYS7Q
MW-Z1,$RM7W6E_R.E'0Y#0+/BIC-!)TMZD)DDM/0@I9021)!,,!L:+EBRV<\@
MG4$\B0,/KTT?.?F\@_J*1A;(OJ[*L9"+1X>P,M%W8>WOM9)8]&E7:248R4P(
MJ6A(.ZP1>22$G1;J.LKNXT4@Y7NH\:@U>3JEFL3S?#E<Y>M:20C+"1?)A!/\
M'N#:D*+6@0SJ<G=N1T$NPB=CZ!*6L++M-==8L+V9V7KB:.5O4CY6NS((&SM<
MM6W;"C)30?9X6T&V@:5,VPJR;079C9U]KV@IH<&7D&/R1=BX0VRDM-AT<P+6
M'536JY[19ZQ&'3S,UC)@F-KL 5A%%$$?QD5BJ)R@AH02)CPF\)"?/GBVYO>*
MVY*ZTAKNDW'@"!8G ^^6M+K,J R (NN=4OK@,E8;M5.P@D;U,ZX]PKN7"A7J
MT/O4$AQS/4WCA<_-NNDA8DL/NYSPSZG#,>\9!NQ>8$4!V/&@-;(:[;!Z 28H
M/$*LJEZ.)[BSO5F]HG8BP!K\O:^F=<C+J4<H^$X3-EQ#&)I7A'(LE-I21>.+
M"C!;]ST9,-UE\?8+H2\X)^<R#9*>O;7H^!F$L<+58,Q)I[Y/GN+DS3#()ZNR
M\ZR0_K/ Y)1>K@YZ>C]U3<#W[%E@@FL*DP=KOJHE$F4+3=IJL+-.GS*(U!(Y
MBN60[?D>A2'>K8G'^)(T9B;@K@2O GNN]='1NT.5\-ID^.CT(P@!R%>1Q=R*
M,^>V%LG#5JU"B6F"E$U6+OH*#A^UTH!QI>HHQAA;4ONG1H; PR0_?>KS8P&>
M@4$(ST30$=:XS!-I?>1:2G;Q2NH)&X6/$8(]";2)0EQR C65YP[77@6/*1?-
M#G4'L1.,H&IK-4_P8\QLXEBYL<5A!!"G#1']9$R0IFK]"@D._ ZXY'$=^=@<
M/5Q*.7VPUFVPUVZU[\C-@]NPDWYUH4'IB\>GD%RY]*V\O-&981^\),DQ""TU
M >!SM^0)<2>=R(LHXB!M+"_R(J=R?LHY<8Q8:]S[Z-WIH0]Z2]F H?,0@($#
M[3>*!4Y8%V3$A1&,(W/EEU;2[U)%)"'<NM?YJCL)=EJ%M^C-)"8R$B,U!(,"
M@Q$[6+,Y5R=(( :,EX\.*F?HJ;(R]46,U[<6V^G,/';>H,'D[A"T&T#+P9+"
MU9B5E=8+-@2L-^H+LUY+D;*&=(H$7(_>T(O'T2]9!?=-%H\P.$0%Q-.6J[@^
M-/&%N9\7B%,F/9WI!3[U,@TCTW2DARI(&("&HJS*A(W?IV=3-$F>71*-"7PD
M:%^&9* .3!=M4K-Q6$',,75*9"!(-3]%> ).&L=Z0!4E!$TM 0Z>DL G45 _
M33]VLQ$DR' (1M$O1\]1GNE\>O0+,PX:[9J2/*[8D92"HO^42H3B2_+$CM/*
M<-_'P>.Z3S?P&54Z&3IU8OY,DK""48FG1@SVIV<[K+<*8M>D=QQ@@EB?6?W1
M]\$HZ*)YD8'CHEHHTVYC EXB3WQ]H^&FG;AI'0#Y=3G@L$87FSPQI%VGLS;W
MA?B^<+-#M\5O= FN'ZAAQ[&!^D99'\NC>6,[Z9WCN;IU0:T%[=0F:'+E'$(E
MF#5X=Y=7B .!<<4LR6)R&3R7FZ2_E0-NQ%H##$66&5^XK\;6V<G)NU>CZ'W\
M,4UX>\]^CB9964^I'2-0=O2L,*UE7,^@K]XV9A$-**C:$NQ]O-JX[)8:;;VW
M;4+1:+#>+6%8KU2N4K@[+W8F=) Z6WGT[Q3VZ33E2KS.=X[^ARZNU7(!@B/?
M'44GQ=27\'/3#>XDW7,$T4IM[4NIO9Z2RO<Y$=HSD94 8';X^R(KFE1<)5WF
MYC(_)4?!HL[2L[3\UQ=?=TDP'9N \Z5IPH1IV&.#:RCC%(1=M/5!#\E%MG!-
M3JY^$HUX:FEKPFB,N?KM"&%,> E@MSP^ME8[D+*NXX@I<AGBB]!!UIT)!W>L
MD:L .P:><AMNELV@8CG$$-GO*U?:- *6@S&M@*^?[FH^-.O(HP@MNSFB+BWR
M=&7VG^Q<EJUNZ'"($46*W?/<@WUGA4BHT&T\V\K+QLC+BNX4S!SN3*ILDE;B
M[M@HB89V2#$>@5.*>+?OG'EUJ+ IXO[T'^949A!4V\K%YL@%ABE".SHLWP@K
MN,!@3%+3"&[B%W +S69HILTG<75>4L M+ER@@],JUBL9.;0D^(/'@[<Z:2LH
MFR,H%KHO$G8HOH P'-/$\%<,Y!"\FN*:>9P;[OFVEKT/O6]W>7-VV>B!M+C,
MJI+L3&R.ODCC7-ATZWB62H!GNW>;LW>S'($V?#I+/1I&J)HB?"]O;T3 M'_\
MUMW'(J$GVR*A#:Q6V18);7J1T%;-_T46>_QI>U%OV YB2H*10+ P5^,L%);D
M(O:2?6F%<)[C%Q!8%(.'+HVCO?:U*:+F>#QF;GT?-J=V%7I2?Q5-TN8*DY2G
M;5UG'#O]\!$YHZ3,G9$V39]!Z9"8]1G?;X5J<X0JU;IZ(U/HH,]RD0+L=*AK
M#:F3SL"*%:H'M*;C=E,W9U.1@6K."B')B(X*ZPA-%R"A*@R $D=$=U@L.X$W
MW/KM]F[,]H*_0TA[D49%M.Y3(F.$*<T5+?<H8?F>2"0<Q;@"G#!8H10=QN?G
MB*/2.$RW/X##KUY!XL>AKKB^H#:B>UY(,-01I7P+5.=-!7@?TZ4E6G H?HYA
M830,#G<#?@R'>JE;C3GE/E7&W=JDZZA>/&PX([86&=7CIM.6\K@EAFZIB,)4
M6^ >49Z\H9ITTW6NF\25DXK>R-PN%G!(T!I-:LGTQ@G7'"DPQ]B;";N%.[1"
MWA%4>H>M%$02P^B(A.K'QW]Z@9S4ICB)&AA&(9:K[;:@M@2$BH=)"21 )(+J
MUTGC3[4A+<*D)H).(MB\EVA)]JO=CH6I.UAI&R&P+J96*;M&4+)2"MP%I;-5
MI=R,&-!-PK!QT[",0;GCX ;Q_#A&2;+N\[52,.5I:IE3;D0X(J57W/\YR$6H
M>\NEBTH+2;^S%&A=K"\M[*P_NA9GJEC,"6D9D8/)%<)"[)V+\LHK"TXVU2D\
MAIO3+8JKYVH!V8^KYIX=>$OKW-'"GNK&GE4LQ45A]R)>:FVXY7U&8N@QR2Q!
MGTH-KW^DYS;(&(& RG((EFN!ISF>IBV[M@2+DI4&&MI4N6BYK^J6@1<P^W2G
M.TOF.-)[ALH7D0*"*EY]3=@%K!:6H7\$00M&+7J'2?!Z#5)$7);V.JP"NG&G
M)Z\(9XWUC50\T!IJ.<0]DTBJ^R*( B8Z0A(ZIN!+^5[B8B.XJK,:VS6(8JE&
M[$!!_7-$U)(N7$O9Z[;(TY"L/Q6LW4AH!BZR8H#\W")5R"74 0L71)>OF[EY
MK;7']6.G'A7@+=UH!57NXUJ=L:GQ!LYY?;?D_99V\1DUU:CL/ASO[OX-C02W
M4&*3M04S\20HIRE3Y,&E^=BW2L5!\PRHUI9M''1  H0>%'2&/6C%4FB\EZ+8
MR2RRDWMU/9Y0:\8^(2ID=8W,S]_N/7XX/G#(4<Y[Q/:% L.LN5EI$F8F%S"W
MPQR)UVJ$\FCQ2H'%Y;(Y*;CT#T*R>EE]%V3#^!N"+J"&9*=&N<-P<]*DBUF.
M3Z1AC,2T=W#U J $Y@]UNU )M6/M--VW&@XTGNXH@#0W31W2SRM,@ Q76S15
MR0 BTN4I'1R!M2Z4G:)JF3T=[T\GA705&$_:B"HUH' CF@JI="-\Q I4O'")
M%BQ>X!D4!I"L<9RM> 0((@73W &/!Y6'4P=3D3)9!_4N2O')I6T%%.9WO(A2
MUS7A+&4:$YJC!(]*WS-M*_\BZU_'YZPILG$%00L&4)4,:R\620*N$HZA)U[K
MY$)1;WGRW'GT> 2Z),=-@$L2V<)4VR#E ZP"%CLG0ONP:.$:C8D,@BQO[RU2
M%:G,0(HV/9[U4 MMPTN'M_JJ&S<MSL%+XA*AI7<<#=,5^J;N2_V_%D@_DE6K
M[F)+I)&DLQC_1;D<:,,FN8?*Y^KQN0![S[!QQD'G,^<E(;66E1@(,==(HS7H
M\VL!\^/=4J2WO.5^[5P]Y(L;(8[1)J:&M19UEC_&).$JAUZ]183 ).>6H*UB
M^FG,54>R"09C7>#C<)\)AAI&C"9=!W6X[)ZM_IOOV#ZNO1#_4>:)8!CXE2=-
MX#8Q:&3&1C!NLPE7+A-#C_LZ4<G3EE%Z<2I51LQ;/;")$35&#WQNWL$MRBEZ
M@_AV+'SIWZ_^HO:3X8MH6YAD"I.>;@N3-K!"9EN8M.F%21N#7A38;8N\I4!=
MU0H,15LLXLRG\4?,/;,<1X=#.I;ZB#% @QU=X "TU" ><4 =MM79411F%]^&
M,7I'G9Y<#K]/TUR,>E7$9)YR<R\G=Y#Y:,?5(5F+EG$)P?8",P(L;\H=V,AP
MUZL-N(*X"WG$[%_P91OKX:8^_3ZA&K CIB;)=5</]C;CO29=K;4VK:,ERS=-
M3=<<-_!/EM&%7*VSP-!>;<J,HQ//1]/ITA9+$]?-UV]-X44(51U/#5D-^VT=
MYY'V?^3L,^:'&+K&929KQO@VS.K<[N>,*^*LNJNNT3X@=O#XNA7RMH8H[]!D
MPK=S/UK@$EMG8$02V5;%*)!L]V"/,NU@4(C3>.7Z$6(2&43N%"C%DP3![*]
M8GF%)N9,X '%NY2$QC ]PJ8( ,MYA1B/F,LHDWJT+I[#9C1O@8AQ\'[E]/D2
MUNW&A"2OI)D6=XKCD_,YR.994TX_WBTK_Y;>VH^IIX&J<35$RSDZ (HF4BZ.
M8<%M"S.(M,0L+@FQ1X&=.$R@:$)"R,XKSN^0V =H'TRQ2/A%GX&*OI!8TOW*
MTK]=M0F=51Y'R-7B,JK,W7$ ZU:5[?E%]!Q<:L+</I"_\*X@- [Q6L5YNF9O
M_,[7N$'X/]\^&#_91644(<0/QP7A8QP5_7EO?_S@B?^[(#'+3I,H("$JA?YR
ME]>3O^"MN"('2/$7QY+;9^F$3<,F0%T6\N09Z!>U.!AS/(^V,)#%Y(BZ0A(3
M(B7 $?\R-X@!W#),.@NE%S>]XP0ZJ<VUDQC:4R6GI3M0[A-',0N/2E**U+IB
M3:G0](2,IE;3Y?Z9K$I7VO;^4&2$3OZ-#BP?]NUY70/*?YY="CJXE%3,RFGK
MD;^Z6^GB509#!V').'=(@63_HTNF&!YUL;HHZL$$67#NBIC?EJ$YL$!I4= Z
MXK1"=L!I6U%!'!Z1BSA9J]T5>I_2LO]&&6/TGN\XTG%)=HKB0'SO"HN\_D)#
MU@_7',).DM1B!I!%;D&L&5YCCK!SOO91>3*Z-O@0+_.(2P+M0)1<C>+4^JS)
MTN4^*/?<>33'MKH[PN:5_ OZ*TF6,$ 7'K!Y&J-=RD4!!K0R6*/#[KF'[?,:
M;10MRW8HA$ZP"LO>08W)08LG8!/S7[,B8TJ.P(MA%7W3>QJ53LLZ=[*TQ .2
M%C)IJ2W^Q^:4#DLD')WHMI@JL@WA87H>98\]4S)BJSD$/?!!7_K:I.1[CCRO
MNS2K%.6EA[%A@$,]O:[L9=L^L#E"TJ$;ERW>[M#F[! 5%M7<K?&1RY_=]5BW
MDWE&-;/ULS^>#FF[9Y^_9PM/BTIJ%D.&6*Y67?X9;?7;G?K<G5+\9*G5$&A2
M9?RN,>8H"4M?UX'1M>T>;LX>6@M'**([),&*.#H-D/4Z.(+P[[^5X$A'EQQ9
MQK]+X0L:,5DCU5Q@7T]!6J1(>BL(FR,(IB#'(R!:C/KM9FW.9JE#/#,NA];1
M.XXJ&SNS==7R/?QUW_OV/.BI$IE02N>J&/CR5B0V1R0"U@_)=7(%#IQ=CX4:
M^JT:#)T)\Z)J^"UXT1\0XGRTNZT1VL!BE6V-T*;7"&TO@3_"FA>Z4:FW%GS!
M:4R<5!C1E^J&;#YIJYKM?V:]H+PBAA^#0#U'K>=QTQ#O#S-U2#].T%\L8;"1
M) MR,34X@3)=;FV&S1$7=.#9WS,TIUP [(IY.)LAGF'E*Z?H<ZW/,CRS[OL9
M,['0KQ[^+?C^%MEH@X0@R";6"[!$$LT_#*@3SD*Z3&R2U9A$WWH"&[2AGE5^
MNRN;LRM2:S MX3Q55"$D)34"]ROJ=IOGV[RM"Z*A:;,SB:<?)=]+FUE[<B]8
M.EA)QA(TU4%4H(1$+^EV7S=G7TTR,"N(0)=9M2ZS]*K+ZL4<B3:KSS@,CL;A
M^:'N^=GQT=>WRS=<[*]ZO\%DH6 7E4U>@NV+^0KQ<;Z^';O+YY(*7XI$JF$F
M06XQ+N)\67,RR>+IQ]3(4"-I:C:GZ/06CG&CMI7JAP-(A"1%.MV),FMG-3%J
M12_DSS6C<-ZGLM@3*4R-L>=L5F*3D11;8S,+I6Q\Q;94L79+$1T_LF./]:=G
M9$_2-(_K>D?8?[W7( 7@KI@]T\Z?)(K/8_PWGR2BGA[FU72_IV:?@1^UM:))
M<O6THZK'*(,)0##M"?%BS1!(@4I-8:S9O!:J6@1B,'!Q;IX8G"I<4L-TLUF
M ]P99L;LX>,-XE;:#KT.=.5(*8>IU/6N-;W?LAWF-":RX8!,54H ,!I4URV%
MAX(B$6V[6,5)2,^S7(*^]IZA/DKB!AP.2E'/8-ANGY.=A^5$./!:ZYY](28/
MJY_IO&-;NUX'#6"02F)06,U05U?)#G[(N''))97ZH#8*(")G 4B,N+A#)=]7
M'9YEAKJ8PZ^73D@Z5404C>3*(]>1BMT;[%7#4C*:)3>^\O/6BV:OC&GD Z J
M4S1(WT@396"G) 3!J?+H\62H_MOXCE0X7B%H$C<+QP:UD<OI>0!:.66E'7L)
M7".>-(+Z[LL3IG[*HU/L_6S3Z*A,:+GWGCYY1*BDV$.:8*>S)913BNGRDKC*
M:VS1@9-":!\:VC<X']KK5L!EX_N "&-P"H=T"7;U55PE NA+C;6WWP_=[!7G
MG\B^N]RB1GL@RJ@CR97.SPYXD=<"HP%8(6D5F,679>4Q&T=&8=3EW(GR]8K#
MMU[3Y>.A#94>7"$.N7S<-6O04M=I3I"J05.S0Z+WR,J^ 5U[2AQ6KYS)&K5@
MZ;<3.[8,U8&M8P_Y51M8[#J6%FI:[99;I);^I0QS4GHLV2F*;[X:8A!$#H&T
M1$4KB756127QM<.I;)/S]+Y?J._<P51Q.\.]3Z)#/LRTK*<IG>(D.D(H/%0T
M#4GG23$MJX6]40=_]>-RYU4LP8[GL'U7J/;A?T)@QBXZL*O@<]UV; J.J/<<
MS3]& #-?O%)<Z4E:I-A_S1@T5KF.I&,)OYC-%RFHL Y*U(\EZ)<[)A1KKV(C
M K($EK48+\)RVK(F5,CG.?:2R@U-NG 9F,?S!2,N3$DACICZH(8?5P@8%M[L
M%.&2'TD:67ZG"':,QN<%8,QMX>ZVO"A!9X"Y)1:$4*YX7+) N_2@K\H%DE>V
MA=+DHNYE](25JR H'+@4C$LFX$8$/H'-@JCAB'4[8V@Z!R4H(!;4]C.3!I\@
MZB#8>?!,,F8<8:-',^-685B)TI\.)[8.L0VNAR6HQ4YS[-J]%9IV!E+#:_O\
MG!$RZ,$2?*[2E#TZ3NDFL$WJ1E>7;!SK[^C+.S@*Q2@F_&LVX@1((2 OQA<'
M=E"#J(5S,+O(\M$WN45"9/*RALWXXP_K?2PDV]L6DFU@1=.VD&S3"\DV]V*G
MSF5G<!E3;:2^-[N(V&"=",:_YR4B!7\F'$7[NP=JAKD'OA3 B"-C X*=I[XI
M>;%JTH''1Q<]888*)4/L2[K@/IMD3*"CWC^3 S#$^%1QE;%Z+*Z;:._AWP;[
MH?GNXD FCQ<O++R#:I]*2X3,XD+?(<_7(*!YH -HU7N++\/PHF*2C$M8B2L$
MMB"@V?N%LW!8]#D^Q#2)U6RA-@*VYXQ!ULFO>$,&PSF6JH,=!?08;;J4]HVC
M<-9Y$!8 -P3[PJP0^>R%712:=IH2MG(0+H:GS[-V3KXC8XP@0!;C939A<'S&
M&=I,P%;NN7_Y:\JF=I'BRA'>78*8_18/6\,R<N0$'UTPJSV)(MK03'ZRY)/J
M'Z26=8G1@)2N3+:R[]CB7T?@T%UJZFKMK[?1<(SCQW),S!ANM0,X/^7JR'/5
MNRX5BO+>UNIO]4*SW<K=M=O:&>_J;;6H'+X+$!5Q.LU\@HC"!4,7A8L4,*\F
M\HQ0&@>_C)FDOC/2PH!S,S:\ 7&-^3V$U7>'$=OTKK>IT[MUM&ZIUUZ93&85
M!44^& %0]/)KF.VTQ4X[J?KIOU4<:O=)L9G(-"=SA\@R;6JXQUYCP_2&8($+
M!?*;;>4X.@UZ#2@K#A/B#2/MQ>ECRQXPH41#$Z2G;_B^(:A\3$K78M;</#5M
M&4<Z>0I)C)O:0R)IP/ .)\9),[N$/(;3>)8$LMG/X($1%F<Y$:[=;):T,Q*.
M[27I\XQ3"03S]BOEM:XH[\$!(+P 8C#@Z>U:D:-;H[]=!ATJ"YF2&1WG#3!$
MA4D5VKRLP?P9B-8$'TU#Q'*A*J%7<H&Z>S[?13[)9*&L)EADA!N J^*>1>&S
MFMTM9\SZ\?+>76+^QI4947K-<_&-HW^45WC-C_ 5#! YB["*OL)[FH*)=MKV
M<%!TW>&OTU7NWN*(&:^JLCB_8SKF]I9KJ;:^AKDS!<T%MW1.1BK3<,C)ZG-8
M8NJW0%1E)@"&8>[,D1$OR6KP8]5UX:IMZ9Z"(UV=,V6@)SD9A*B[8_MS+?1F
MMR:FN2AKCXNF.$DN(6@CW5055#"-6 !FU_T6^)!)R3P+>EO75## ]6,=(+RP
MI,0GA1,D@<PFK0M8"QOB=8(T\B?07%.SC+ N%$[S*HWI:9;T%F;<7/RK!:T(
M_[(@&,CZH@1E<(X?P'U)U8XMKA!?+@(-C?H7IVF_/<M+PC2^ *\ [P1ZPG)Q
M4;*ZCBM\ VH47&T$[\0RLAJ6 7]/9R:MJK+*ZKF9^MI#$'":?O9I(,B\#HF%
M9:]Q;@B\MVH7]I+MAJE:+@K(:;PAFQ=FBTS:Q8!Z$R""N_E]Z@9Q:N:.)IK=
M)>8J%"Q'T=J60$>2,#8"X8-:1-R#D]4%I-L)5 _?'2:JY@A.D28'EUAY1O&#
M*5L$&+O"CV!'0(!<XLPC?,=:S>;?A\Z1U'?PUXR%T;_&G4G!5RVA91DTU0&:
M+CUDJ6U7L04/)%@4:;,\4XY0L$7(;EG&%4]P!TVD <_WS,+/FI3X350'K0F_
M5[)_]@Z(UQX YLE<(?G+.Z;F;W\-TV)&30S+P7C$LE#UM&I!P)>>6\B)O@)C
MDG_%6] 6OMZ&'X#&V]U:V[57Z$L!P 4#URG/*EW@?4F$P#%",6, )4WX@Q;E
MK^F(Y104>U;+_<L1(M(I$C<-J)\=Y$?8QB+]$3 V"P-D+TIU7+!XHZ4$?2^V
M- P\*P>VCS&KPRPG!/'&%2I4A\+ NE8?XY6+VC%0^X+B&WA8*H ^+,R1YT\P
MTJF45.B+Z< [.%_B/E>P0$&[[<QPY#$\.U8'TD),O?."86=21\-S'_;4 CY<
M=B7EFB0^:N.6]98"R0H:K1_ \N:P]+E?'=:#U'U/36Q,/"P+:TA0?)?W(IT*
M,!0>8':XDRP>K8DU=F=/%>;D(862&5:X=T;H4EBI4B9:\8 ';@L'3.' _K9P
M8 ,SV-O"@:^O<. +G6 PB&-S^=H %I._HN]=G)?$9=3A5><(EVAQ5/D:Z:)K
MQ_4N@WN)=T-<444V05QSE2<%<8FZ4_-!"2*^PRNFE$WVC>OBRPV;\R/-W<O[
M^"KJQF-,)Y.+F8*QCZSAOLZT[C0-F*LM1]@*+%#$^QW7$>\.5_(GCY0K0[P"
M,C/LUWVMX$!>ZHZ9H[<T]=DL(,8,%#6):M8E93[HYD>WM4'IQ.@LV:TU88B0
MS<(FX0581RG5$TC?S1UE?5U[HL_LFF6U6=4<_2)9W83-&HT+Z<%<Q92B\JT!
MMM'@.53Z& 5MD4J; 1>>*)^9HYG,.$%]X5#,. KFL$#WF]A<] B%@W20"-:(
M3\'($Y9L S$:!,9I<-3[4J5"N89F":@YJIY]C^VB^!CN L-%)-XT%VB7:#UF
M14%4X;H@!R"C6B%AJ/ O-D1B'=D<22A$*J-\5L R;4A5ED\E=:I[)6+(SB_.
M*3@Y6&53(/"6[#G9S(54JMAF(Z)W4W4/6IWJ^3LH],J#3IY93'4!Z7GJ%&XD
M6_@K%LEPU]$E=]9@=(Y2$-*B9+J3KE(*2E( J"P(;%1\O 4(+5>%^04,WB0C
M(2?(,T<3O> @O;7T? 81 XGU\T7F;@>85B9Y)?50?%E"/'79)A\0Y?)DJ0=*
MB1FQ=K3J%(@(MB5IA9[/D A26)A7! =?8PL,G4Q/1R-S])P-MHUPN 6LQ'Y9
MDT.BDOR\).I&5+/8"46]3?;^-PPR3-.B%#4P8VV/9V&RS!5<A![,DQ[47)45
M.;U7Z01>QC9"$*,5.5%./I(7V4??U:1BLD(TS)'K91==EFW$V]<_7T)',VVK
MT-%UE(W4T'OCN^4^.H0'JQU"'&Z6_.<WU]O2C\"8WGJ17]J=V7J1F^Y%PEUS
M#O(N^H+ .S:F:NRD2>?1WH_CZ,.;T^.SMZ]^.7X>G;T_?/$B.GK[^O7QF_=G
M*_7FC:85F-L/=O&H?R&=]P:V>. 2N)FJ.WCRX,G^T]U'3Y\\>?#@FZ]RCX_&
MT=$_?SP^/3L^^G!Z\OZ?FU[1V#NCU.>.WV)VVNBU+SY'B^Z,^2F6O7G=R%&\
MO3!_0=_QO>^TI.!YG)24'0478CE!FWO*'.%D5)H:?3 LSZMX+A54%,1/J8A*
M^ *P/_R\D+(SG"3,>22U4"-Y$+N/:OZS5T\AJ/#5V-81-\Q!+@EMV!PVL-</
MDMK-R7)#YLVTZGUA!E-(T4QE7[2<ET1&+3 T.U?8(8E9?;&:P[=17XS'* X?
MC69Y2?Q^NB*R2%3(T3+0,?I2M"*:T\@4=0&?B/@&]"^R  [=409 12XS7MR8
MK5Q>&2TKD^B<:\_7?781P'I9PWE&QZ%$,YW _!63F4M7>5/@Q?K;H"I'&W3
MUVQC3"VA[0Y>8"H)LHH];?<T[?V0B1QU,85D.*4M_M'BQD7)R45TGVA0(E59
MFG"*24?8XF*_.3E[W]VN_B;Y_:<Q2:4>UGB&/Y56%L)LH'09A4\%6$!/0LKX
MU9<D$E0FB*4_&O<;.#]3.@IF(=B!HZ8I;+A%HL\DU4[=2JM(R/_C^A#-I/4D
M9@&#:*1.2?**O.%N,9S8]8=J^[57''OQM'@LYEF$)D4U50,G,R PE!A>36XC
MGF1/)9&7;>(JLU:44ZUVP;XJ[7OH:HL35\R:U1+@\&EL#&A8JN6N<H9EI=/
MVIB#2US!9JK04TG/%F$D1+B8EAJ4ZN%1P5X.5:1'S^%,9DWJ2F:P]@@A;YC
M=22UNSCT\S:N8I!3J;>E'P3CQ[ _?BFIPSY"]/VF%XR#0GY@4E[Y.AVI]K'B
M2GWI4W-F-(IIHQR&W%HTSLCPVN3+;L1')D<*CH*,E!D9NJ(L"S1'7^MR<8%
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M>2Y#(!<GETASTR&2\]QPJF+6,<E-X_HBFH$#.81-<D-,_4=K,/6;<L$;O%F
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M[L/!D9CU*X(<-ST<)*UK3<./Q7ZY2GD":G](]9'<86 H5'1 DB#Q!JM(8<3
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MKP67W.??"B/VL$4&*RJ]*W]!?8'(W5F3$'[./-H@T92",L]?AM.6A?3$$95
MDK)%D1S!:.(I:()I\ .55FX9TL;6& [KMJ>8"O+(4)#'Q:C9ID]\>;/*??>
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MI6&1%]DH%@SYR)_?QLEW&VTC9;'+8)%= H(LJ"O$K+5K);JT0,[!, H#,;:
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M[=[<UL/"*+&8"/XQWUR;/VE8.^=A@^(\F(<L\)Z$])%^7JGT<D09YY8#5*
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MS893^ONJ1SG-1M=IK?6HZM]W6NZ.#ZJ]]%'WL-8O9:!>_%@)Q33;\2_$,;U
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MP"(4VKN)&&& !4A>2,;97P(=D"K2T[,DN,%2DS-$^=;$Y!>_RQ79(B5)3_R
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ML%YA5?]#ZE11QE8/ZY#>3K97;IZI&0K!QQI?Y]VFL*N71-(GXY$S(QKFXUC
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M!L6%>99< X=!LY14U*>+ A0\'^BC/%*P7DAA'O.*')IB0NM\HA=QC8G!+ 3
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M^"M@60 8!-.=(6QN"<-9E05%+U*UM7107"SW(.M9Y1ZLQ9JN'!SK"X[5*/?
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M%P=1#^1/:YL#4:!+W >/I/_B F&>WX1KE J73MH>S?> 9Q@C5:6CL,3UP":
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MX#W[8'6T##XO6ZHF1B-C"*V/[WH!Q68P';T)?7L:$"P&ZP3P/34T81Y/1 B
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MXD67?S,7'GR[27#6<9=SZ[W:K_;/N-&>V]^HZ^.QMB2;]^XFC@NB&'<WRM8
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MIZH#S$@?7TNZ&^ <F?F.2S_J-RD<50[&U ";)"OJ/5JX/<HM?) T1S%;W2O
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M@#D/0&?%8.*GV=)3SJ=9Y2C*.4GOEP%YC@K@TT0K9UY?3O#.F]-*\,6X?JP
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MC _/N5A!P'>\*:9^89UC^E<8'@-:@K80$0"4NR'Q<<(#!_\&SSD8#1,/*$Q
M6T,=G4T=9O!$7V,+/F'_L%VZHI!@8MD$_F;W7\3TU. 7'NJ13A\.TQ1-<$43
M&Y$>7O?%#GWGY]D7(*+646 _!O^>ON+0L![BOM"&TTAR9SR>PJQ\$DQ -LAL
M'32*W UAMU[L0( S)T4MG!^HLV.1>B2S2'5Q]^WZ\DRV1-ARI_\29\L!$\(L
M?F)CLGABN%0O?)N0Y)F$5.]:M]_^<7;A?5/ :$\X"]X8\<GLT>B)A&.0%$MO
MFDX&=">6WQ/S</0V0Y(SWA8_OOBN=R!X(^0'X*TW,>'A^"7?YG_>%FX\L'N
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M?+S=Z<>_<]JI@<7\!( 72"I]W42K*8A(ETL9RIQH;&1T66%NS^+''Z$ZA_1
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MU(YZ:L?A+K5C W,,=JD=+RRU8]28VG&TMZ)A?190I =C8NB1:'?N#;99E;%
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MTR+@:?0TTNLZE9$7^.'?,N=,.BN(RR,#JA_Y-F\3I9DF)30%M)OLA]_WK\(
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M(00VG!9AS:^KB0.;JS(-OQM\F/EW?"LV&4S#F%)/54PY#DE< ;]9EK(%,.^
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MC>N#HA!CFRJ]>9MCWS%SP&@$AJ*NL-JGA!&FB4\MMARP2LN-C!MG-^W03(%
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MONU7=0VG@T-_L=3QV1#'JK[1$TR/7> 9!<@R7)[.6%]9!' 6Y4(1@%=D%#C
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M^K&8(MXK<7/\\??/QM-3<G\TNHKU3[O>=NBTGV/O-["^R5O6.W:]99I<A0O
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MXUQP/4?3Q_]8M77BDH??GE:7)\?S6UV*7K-J?]3AP3%87B>=D[4-_EWN9EY
M[]0'T-<+1[4%+??OC6HG>Z>]D\/.8:L=NCFX]@CCG[3FOR%H06+H8Y$F,]6J
MINS&3\ 3CT,,O0,<A7+<&8PV9=3$;F[)>A&G9;[.@Q&GMW=ZW!]TAH</GKOP
M<F>45'P')  V)6!*C!5+_;4#\!:SPG?C2Q823/^1"*8/G'8PZ!P\?+[9;@C
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MY* WLC>8$#=C_CI7Q1RCOSX/,\UZ2G9PU[L(D4J<373HG8["PA"B",18P4Y
M4OF7O!99HK2;^LZ(\!S+BKHYUMZ__6;$WT$@_NK_J;*<V?Y_RXCRK_@\1=$
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M4B&;<F+I,BG3 XBEX#"ST27+H;SV),DE]8TEH/V I.K^O/S]=2;>#C&^LQ3
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M"AW1+HK$DGGR[*L*2ECNT+D[H80MRY0LRX]#-6I!M,HTO[&-M1ET:'N_,?F
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M#+\Z**B+ZKI9IIMX.  DTW"KJM=5-=9^,^"2J((4R9T02PGUHGQ-R)\I&]%
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MH.J[KR%RQV@$5G2]O0<2I]@6&4L! L5)RP5F( Q4L04XOF2XZ^^!>>F%K8%
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M!"S-NF=!05A\"[2!>_&>DES@W:AQ5$Z-YY+W.];[X_&XN:ZW3>7]MJ<5KW]
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M7U>,>1\MSONI*Q(Q[&\V5U2RA\CIDU1^U+G*[J_HOR?3AMQDO/F@BT !_2:
M2E2.^5&]*JTZ"AM@R.2JWG@27R!;7('JZ@#KC!A,H9K&):/IDM$E828/-M"H
MK#Z=2TL,;=J?:&WK8Z'I?5VM-Y_O\(L"D3E66[BFXGXFS;2@..)EY]H/9-\F
M(.W*T,_.#R89)9''CANAOO/&9/D5H3NCQSE Y":6U]$<#"ZK>\G)>[Z<#\@&
M+Z#A2S:><+;RI@JJ[#0%XPSN;X0&CKZX]),;ZI# J];4OCIL#>IF&S71]+C
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M)KW95)?':KJ9;DVQU2%1&Y$H1^]I&(FFP(1&$UE5THDTI\&BE^#!^\MP3 K
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MG_ D>E2QS0BV'<B1M-DXBMJ-'__XD/(S@1*&2C&JH9^9@SS!N&>_,@,'[WW
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M&(%Y "U=!& 3MT="68;KVG.3_,#D><Y4I>-Q-)F2,J+(9DLK@SC*@DGPE?D
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M*-;!B?+</,?\GJPUS'\$3W^*.#H<K"2V>: MI:DFJ]R#&!"YAXQX)3: ]RH
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M#Q+:BNC!/ *JH"35S*CL)>$?M#RT-R)1DQ+I>1B!Q ;V>-K"BA?NZS<U!"N
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M#J&8 F L>.-C:;M! !C2 Y];LQ.:Q8!PE3V59!\TVQ^Y5$2NC#+D!'9%"-+
M_JJNQ 2'<Q%*/I;EX2+\'6$+R"4(_,%M"\1&;P5"ZQZ^-9X=&_!PP1;;.>]!
M#??7.8X\G!QEJ@&$D6(Z$;4Y-N^V^+S;I<_%W6OW,U_4NV!-V?B&$_\R$8X
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M\^%D>L=48VDLYI.1_C\JIDSOJ#$=OT,?*4A_V(">BB:1$J2\K=G2_3,@ :*
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MWH#U^@/#,/NC\83IQM2PS-&@]S]@#U+>N_++&^,2-^]-+W7G#\B+J6<S;+^
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M.R3-EDNL-&?,BASV>8K9A9Z+]:&?I_&UO.<6R:]\KN^Z)FKZZ\FS?(0]V5,
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M1MR%*@$&P53N> _ :"<$#'8+'+6'.P,F#8]NI\T?^S.T'?OON%%$.-M- <G
M*:!'"U%+2,,@FOP% @YO!5!7L#7B=X*T(X;?+;R0EW@HWHO+_&!F+Q23?+R!
MW)S Z+:RNWIE>?!SUPO)XP>;""+89+*XJMC(:5%^>XH-/\%]PL^C@.$*>(I"
M1K+NS.VL1_%2U=<T^YC:#@FJV'?J,]!FW$#J+]3>3:)-6H,A(%'(FW-S0J=
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M78(NF?'DJ"<9-P4D4>[BQYLO_A U-7V]V'B\O:XO6XRVX;HKM0/!^^# R*>
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M2.6PUZZ+:P7;%TM_N6[A":.W 1*^&MH37L,,^US-)%DA/C*\M$*K0S+<M/U
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M,S$N>'-D[5WK<QLWDO^>OV).5[6;5)G6PY9M>6-OT21E,Y%$1J3LO?N2 F=
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M#^$]_F\\;>Q@.JU.ZB0E-/5<)75]1I[@LFRRT9D!U7:G;L'S@%M5'>]IF,&
MAW>.>!_\-;_647X!Z97D:L@6G(R8_#UJ$_S8A4L>5$>3 R(QH[]@MWH/+R<T
M=39L!G0KI'JH(S&UFV)C2[,YRV('(M-?(J;Y*_LN(-)3I"T8/;<#4N6&3N%I
MPRCC2]%:2&T)F3%R\'J-B&R-VL>3G(#EDAE>P'6S"7*JS^>EA,;:N)FSAM\"
MILR=3#XYE0.*$B)#_6XJ,AR%4D3WV_H>:Y ?YE#8QPQ1X&[$/,BL[R*>+XG
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M_]P:YXX'RZ69C=CHQ[>THLNMXD0H3-51?0JHQ<14#X'2(QG,J/XVQR[D*2Y
M="8D;ACNX0$.*6\CYGJ%HRSU,\3[P3&WRKG(LS5&:.'P)J"N!TZ#L;GZ0O$A
MPVW\<H?TR.UI5'X^98-"F;FT !]_^#]02P,$%     @ V#M<6 WDE,PF*0
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M;Q</P;P6)*[_U"W,+S!9;G O#J'KSL;3H_.<_2RSC1Z9,5(R[62NM\02$R9
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M'D3IV\BUHK)7J]@2V&^=C3@2%B<0M23"&8%@)&YK)G,2K)(F:,VX3Y6W]&\
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M7BDS]YG3H1,DM]'G'0F2VXCQT F2-Z;P\K_/Q_.OSYO3LV:*7[9=%E&)34F
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M.<-MO]=TZZ&_>]T/*^R*)0 6T9G_]FS<M'$,746"U_.TJM\&'"AN^B3$LMB
M0^)VQ>6M$T;H$@F5>A%@PP#?O9IK"&Z ]/T;QS;+&B/^(["18H):SX%87JH[
M*U7.Z8P@R"^N9);2B,%O.:[@>0 GF:^'B>^[K] W^DN'##Q^4QS!V?RKGZ92
MLN^L;&I[C#V^;?C]AQ_W%D:E".35>&\F!=B502^9ZR*7I=HF\=0!D0E-?*>!
M(H=!)N A6%D[6N9N5#O?Q2TE?I(WCK4XD);@9614DJ BKK<:WRP?01##@M4H
M  6V]LU,7VS[BEJNS)$;-W5#J.*AQ#-OG-*5*#Q007(*BE 9T717FN.\A"Q!
M>8*BV1Z4K1URU /6H2Z&AJ%#,ZQ:!H@6V#S[RT"]/A 'BD;J >\P 4G55=N7
M.COJY4 4DCDFK:TB++M0(B(2\8H%XG@VS@:M0Y"/A3IW!"<]!.9LHXX!&//L
M?#Q):)BN>KZ5"OP)AR]YV[BM P*QEA/T:65FB95>*I7)\2V"_;MPU9745)/P
M  %)O_GX"8VXV=>K,UU! ZFH"II E%#Z\5@2A*?$A^2ED$&GZNE6M\!Y?$RH
M)?M!XEE/S\[G,+L.BR6.,)0F1D5-9(G3M(%RPB-EWD2A4JY=_V #E,='AQHR
MKWC-5HXUWY:J?-VVEQ7+,7M&:#".2,HL4E%X(H(U-%C'8K^UX([0E8L!'Z7S
M<7^1#J'7U>5 #Q@5 ]*N#+W_$+1["O^Z^G:07.58LZMP'&<N*1.(![#(2.D+
M(RVA.H>H/+>6]C+D#ZW 6^+)ZNIO&X'5#@!&29V>GRZ!6"=IY '=B<!CB416
MQ,K2%%-3E\%HZW*O,@AWQ?Y>'72_]V/W%GM30V85[>9%5..7*T *TZ0WG&A7
MPAA+S1?G+".. K6X42?>KYC]G8';7[YKY=U;9OL\%OG00CZ?O!YG&#F5!2M!
M%)S2THQ4:!)L!F)!X"RIB;Y?K&Z-8Y%+6 _(ZJUS]E];%7NYX%QF%1VE-%Y4
M%#N>YF9VVMW.[G!QV>>QNU](;@V^6JFC"7ZW*7?8G^%F:^"XX<=7^P1?4LZ:
M+&-"#E .2#F>=*GD6^))F<]6)*9Y_4"#>OCK75Y60+7P9YCB5(#V).C2GM&@
M0>5XZ0\1(45GT)M18;!KSEJSV%\9IP-Q>?/5Z4&(\% N69=KVELH6UH)JX!9
MMZ9-(YR$R?ACM[B5UA=Q#NE]:9;T\22_P^^V>3'W=W,_FY>.29US$2,-G ?T
M[1U#WSZ Q*T-#97 A&96V\!-K\[<6[P+=6=P^-.3P]#Q1@^M@]%B *NU'#.>
MY"O"ZD"YE((*I>1DTAQ!E6J65&:BA)4QE+7%U#ZD7POD!^4J*6F HB8WA>'7
MSW_EY/6 .U!4P990#Q-A4$')UY/4]Z"A 9:D;6'G$)U--!!\I_#-2JXD"[E2
MX!Z_UE'@A^I=WQX"H>Z(.S@\G[913/74//]Y?)0^EUWYS?DL?O(M''V<00?U
MW?'QF]<7&+F"X#E)J30R##*A/)@@+O(@J*(YIYZ9>OT&W/]9RZ!::P86>?54
MW%LP/C_YQ]%_OO)Q/!G/OZ[RGUC2$4TQ8GVY>M71$^^%("P'52[,A83=Z;%F
MX"=*DUU5,'PF?OOR^1(7L%*9WU+"M,XET,80+P,G.'F7-6,Z:M>+&K<,\HAI
M4$NTM7. %\G(FPBZ2E+V+ B.)GS2 4WXDJGL02C" @U>V>#B]0[7FQ(->XSV
MB$E07=BU,XC_M1F7[DI(T?D<X&3Z#Q]C:8I=Q#]-QZ>GY]/Q_W1?_NOS?QRO
MBI%F:X23FDA:Z-MUA /CB,>91.7!9-JO3,=]1G_$;!E<&;4SF*\F5+_QL_D4
M9NVG\=D2F63 H"1QQH +G)1)$:M2)CI(D:WV7$;1BR:W#O.(^5!/O+7SDZ\B
MN[Z<:1J2\B:2#*4232EPX2 H8H(!@\M<@;>UVI_.EE%+M!6SF+=-H'_^\LWQ
M#>@&Z2I9*6#-RW6TT[C)>73.!4N*:G LV7X6Q4XX'C%Q]JB@F]RZ=V_S!73$
M\RN*HK0;NQ+E[[FRW.#6QF@RY2!9DX"R( [7MJRU"/1Z"NTFSJQ]_F/FPNX"
MO:GC>W?\[B#]YN>S\9??2FLYM(;G7:'95>VRF#Q5+A'/M<5ES6;BM4XDYG*7
M&Y@V('OI>?,8CUC7E01[4]_W;NB]J,0!\_GBPOKZ2J-X"" UNCJAFZGGQ'H9
MT7KA*22T73D-O=2]<8A'K.TZ8EUSCK3;N>-%U;KIT9NC539.4L*GR(BP#'>4
M+!5Q2781;CR[@)ZMTKWTO.;ACUC#NXIRC6YWK\%^?G8V^;IP32^N6FP"!TYH
MHK*31&H6T%@(@E#JO;6<,1&JUWA8@^/''7H=%54\6MJ(Z7+RJX#T'@ 'NC2_
M$]QAKLEWU^-=Q*BBA"$:/=P)U$G.8]"XIQF+;X6QE'AJ6?&$&0V@M(BUP\L/
MQ)([[KX/0))M9%_[FNKHM(NEQN7T+;3STG3]P[\M$%\W@J!4;'3!XGM6TCX-
ME"85/!/E9*DC!CHRT\_FZ#OD_BV1RKIJ!A=TY4RBRWPVFJAW5I:K=6F*6206
M.Z>U'JQT*M+K96N_]_S:@YH:]Q=^Q8N'Z[E5?6 \ODS<K82_(9/S/I(;,A,W
M2.DXKB,0!" <43K5Q$PR-X%"AI ]^QX4V"L3MX;^MA'8H)FX3@&8A)N,M++T
MI!",6$TE<9 9QY6%!M6KOL5WDHF[C=@W9N)N([-!,W$= \HB2T1+%HD,R1!O
M8\39\4A-#@Q4C03XAY*)>U_EW5MFE=^\-[,FG<?YR>P=S#Z/(RS;_R6T]V0D
M'LTRW,)-)$YZ1H11 9*V-/%>)S%WZ'#=V#],HMU54O%V_@J>,O\EHO:B[^?=
MH"K:2AN![-]RVEU'-Q5>2<##+!!KP/&0M >(A"+1<<N)I09Z2(3RE WE1KE0
MP\#:L]9O,;?VI/1MY%K[9*2[[7OF6TAOFZ]^,A]?W/U%51+N2K<@6^[^2KO.
MH'%M]9IYQ:,+P?<+TMLXQ'YW\4KR;ZH+KW8(_V]C1#5OIO#&?^WVL96[!H[*
MP"4Q7);"AP)=!ALY\4%:[WQPP?6\)5\_P'>OSAJ"&Z9N2IGIRG2TRL1,->%2
MED/:$H*1<(J*RRB]\E29 <K"7P+XGK6\NT0'2!,]1@OS%-[[+T?G\T_-;#S_
M6MJ:=%M-XN SE>AL.&5+2%7I9^(BB3Y! B.UH;6SC#>C>>*&>F5U#= C9CVR
MY>O2!]M ]Z2WX3K,%6DM'?:BQ@X*&& SN16CED('(Q51^'84T]83!R(0FD4$
MDV*Y(/SNR7''S>@AN+&-W(<H.]PE&:TJ5'V$:;Q(+0R*"<$C8;+40[8I$2]S
M*0267%9,L21J&QL;P>S_GK2>SJ[7'*XB\ 'JDK\[#RW\]SENFB\_+TLL+^I^
M>JZ5RXQ$97"RBGEBC<O$10-."^IDOR*G6\5-K(7RPPJIIJB*0?BWP%J^+GV
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M/'OC<\^KNEV1_&#@'C2XAG^[-6S?Y?U!U2UB9']OCJ=SF$$[+\[LZP;E.X(
MJ:MME9B%$D-3ZJ%R7-NI%,$8D3AE@Z^-MR'\P=<#:GQ-3O;.I_9+^Z(=N:BS
M\4$3KA*:%5))?*%H))II4]J T1!J'\NOQGZ"I-I)_&MXL#Q8_^=?KHD04?[1
M_:#[?A'16\@_E8\?WAY?B////__\R[3Y[)'I?XG-Z2^=*)?05F7\FGP48Q=H
M>AGFORJ(LFI8X<O;D6$V@[3\ZQ<P]^-)^RWR=GQZ-KGS:*/J^+]<"N%;X2Q!
M?,.N/8L#OLR[5L(_[_8FOQBW_N/'&2Q.2LNA6#?D)4^9]4(X98CQA6+!2F)I
MR:#'+X&#%>'Z>>3.;_A=F'9=O38\?U$MDJ(9:J)51 5\KR2^2,0;'8D((B3+
MO/"Q5ZN_W>?[OG)ZD)],-J]M57EP?;VJ)O!U-9!^*A-.\[_&2=-"^MO/\]DY
M7'X3-UA\4UXNTM!P$8&/-T^JMF=0J4-[DJ^L\5W]02E%+DFYQ ?\1^9@26"2
MH[-C@=$DT;NIW1YB+9!#U6ZMI^:FMK@'*)YUTP#PZ_?\997!/G 'JO"^)=3#
MU'VOH.1F_QIZ ,0R/.:4&261\8#KL0/B!"0BF&4<-(5L>U5__=X(=4?=^,/S
M:1O%U.Y;^:O_/#Y*GTO*Q(T@^><G_SCZSU<^=D?%2ZQ) W@N+ %9EN>$(G$Y
M(-:D&"[<B0;9KYOEE@/OWXL;5(O-GE10NR?FT6GG3* \WD);BBNG#__V[OSL
M;/+U O(*I<]"2PTDLX!VH -&2K41DA+/45B>,NV7V-)[R$=,D6'$/EA;M(NR
MVZ_+'Q05E"75"4653XED /0'T+0C :TYXI@U6J0,J7IAO5O@/#KCMY;H!VO-
M>0/:LDIW'W"#ME3< .R0/14KJ+$?/7;0P?Z6CR5(BRN9YIH2*U/7U"V3P)D@
M*O% E4Z>\MI56 Y D%Y]%??-CVU$7]M$7:Z0J^X[W-E(;20VER27S/&S4I]"
M).M NK*I]C- OWGLH9HB5I'WFABC>PBKNJEXXP3[:#)I_BQF[JMF]GP&:8RS
M;MM5RG\[\HF"C0((A])VIS2%##X9PH-TF4L6<1OL9S)N._3^U3_(.>H>Y'XH
MEKR 4G"D@RL!4LK9$.'*I2;+BGA=LK9]UMG0%%Q656ER.?93Y,D])3]$?]T^
MB6J4)QT2S83S4ALL1$%"+J&WZ%Y1!9*:N-=Z\0=+U1GTIJ:Z*O;=5^!*UED,
M0AJ#>ZWRNNOV9G#YDXEHRZA0W!KI^3X9<\B4P<.1YIX*&:"3P.T%T;A73&I!
M"56Y% ,W$BTS-,^HD$P*'J+*>I]L>4H<V4KXM8OS;U%T&9SW72=S+TK1/%-*
M-&1AB8LQ6!=,]O[[+X4]G&4RD*0WEN8?-*YI62IO@(BE]4\>(!:IQQ3V%67D
MI?+1H@V!;DD@TN%2X%2D) LC;%+,<;&GJ)O7>XDR,CRAZU[*;^;,2OGV1)S3
MZ,IS&T!1DQ74#A7Y+J*,MN'!5E%&VPC\T%%&I57E\MT\F2W# KMS0&Y]#)Q)
MXKTWN/)F_(R!(E%;:534(NH:?5[7C?T@KU6V4FI34;B5>[TN\92[QE44Z/*\
ML ^HBHV=-P+9?V/GW75T4^&5!+PW[5M-A7,JH(=4*O :7!*M09C)4<:4%#2)
M7A[LP]+Z+7V=]Z3T;>0ZP'G7$MCJ9C\YJ:4H33]Y)A*T)A9M0Y)2Y,:$9%AD
ME4V!;P#LMZES):4TM21:\=S[F\;DOT+S<>;//HVCGW0L#J"#-4*B"T.[@NN\
M7-Y$XGD.%N>63)W&W9L /*H-O(Z8*YY-=J 65M]52$MJ]P%5<1??"&3_NW@E
M135#2;GR5KX9G,V:6:L\4=)8(EET)$C&B68*,@@K4K]$N8>E^ENV\GUJ?AOA
M5M;X[\UL_NGH%&8(9[G]1)DB2\(23RVB\;B>>2C;C]>& S5)Y1JJOCGR?G?R
M2NIHJLFR\E;^\GS6G*T"+D)(B<4LT.CTI52T$L31H(E3WEOO$@NA5^^?.W1Z
M=<SO79OWEE_].*-VWM73_8]F-DE+0,(&%1T5!(IE*'TH9\NX)G')4M3.47W=
MM=J<,W_CZ=^SZNJ(;(!KWXND9Y^<$,9ZHI74Z ^*XADZ3=!8C(KG%$6H797H
M<#GG@YZ8WDND&Y?90:];EM_X==:T[;SY'>:7X2O/_*0$M[0U[V"V&&Z BYG[
M3G9?MS6@L\R*)L)#Q'7%.4N"L9G$Q)F)$I*4M=_ P^:$FQA#SHJ8$G6+*Y\D
M5E)'J%,Y6GQS8JZ=8?==W-9LPX/M<L*W$/B#O:VA'C?,TE./)Q6+GX.VJT^6
M,*9*8ROM*145;,;OYK9F*Z7>=5NSC7#W=E[?!]03NJW92D>]#N[O(^"]:3]%
M8UPP:&U31HD4GA+K="(Z<5P,'?/>I.]/Z]O>UM17^C9R'?ZVQBOEG#$D0)E>
MJ<'EI&%$ 6<V>O2#:"\E?^^W-5LIY?;;FBTD6O&(Y[; Q&>^';<G^<UL'$MY
M\.X2DF;\SW,B;,[H(7E/'"L=+5+FP&3BBN7*>N^'[-%L]0,J9$]!Z-^B7 48
M], Y4!9L7XR'28@=0L];4VD')>TI$68MWM*:27H7B')6EC53DQ!9)%H+XQ)/
MS.9]M*+?'YGN2)Y]2%S:1C>UC[K_XQ/*K?43P-5Y/AN'<_S=5X";]KA=)(7A
M1K[H,!=\_&-5OL(#!6FMPATX<"*Y#\0&@Q:<A\2"289?S[_><!9^K^$/4<=S
M"%4V>]5#[7S-BUCP^?GLHJX),)]-J9/DG$- 5 3B0J8D"14%SU+:Z^=>FWK1
MK'GZ8]3[SE(<8%-9GAB_^P3P;54!@9Y:I#P1X[(I504H<3JS<M4*,2299;_S
MJ2TVD4U8'IT16T7H ^3 K<.U(GT/9 ,9JIM1'<8TK:.]'I380?1[6BE6=62\
M"E:X8BH97NI6<.*XR(3A4QQUWEI7V_W=-RGN,#'WS8EM)#Y$$<H89^=PT8!Q
M#*O=+'"CK,;I1E<*D7%(Q'G<S;0W0@)G$7CM/-E-6/9O0=32U_7"DC6$/<#9
MV,U2$DM<C%+%:6(EDD?A9&.I1*,E,=HR3[V,OGH(QB8LCXD$NPN[MD-Y>Y>I
M9C)YU<S^]+,T$LHE*9PG&5)IFA@B"=*5MM+&BAR2I7#_=J?K1GR H3CWN0X?
M3LI[.BN_3.)/WD7<"PV)6:*][!227TJ<ODA6A6!UC(^T@L* 2MRJC,(V&JB]
M4BP2]]O%J48Z^HCR:N=+?[CKG3E*D?/DF"9*)WP]J,370^9,N!#:,WQ)G.W7
MN?3.H1Z3Y@<0[C"50&?@6W@!BX_'T]N9:FU2*6L@+IA2FLR40Z_(41)H/[.L
MF:]N16X)\3%Q:!]:VGO!'I.L<X9FHA@MQVHJ(3@KBL&EI&72X:Z[_^UFT"#8
MKHG= !5'UCUW@+#6.^%7BE^MVJ>+F9"-,8XD=,;0!5.>E 0F0J5@S"<A?:Y]
M2EH3_Z[OX$I[)[D"JL6Y*C<F\P2:A,P2D<($XC+UA(5,P>C$-:O=4:K^+/85
M@WLP+E_?.PY,A <;Y>M<8-Q!(-[D+A#*$4MQMP3<&SU()97J59?R.XKR/305
M[HH-WD8E>XL.[0/J"<4&;Z6C7F&B]Q'PWK0O(UKK4OOBGN'*"YD1JP5:TLFB
M,9^TBZ'B*O%08X/K*WT;N0YP2])9M,MC6AJS#]P:0D5)MA19$&O1'Z$&' ,7
M+6Z^E<V:*\,_E+C@K132U)'F ">=ZYN'"0W*<('VD_.E\F5 4""!, ]<2"%M
MLK5/+1Y4@\<'LO'74]( )V';]H[J _='6\B=E+QC&[_[:.@!M(5D4H#@I<9V
MP2Y]-,1F9HG3(3NND@2H?D?[$ AUK[:0^^33-HJI?4OSX=VOS6>83;N)7VLQ
MET7(&F@@W,M2WR%'8D.2A&N:M808G>C7IN6601Y^+[^MM-,,(-K:D;T?WKV
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M[G"Z*5&"2#B^5$S1: #,]2/0IU&P;2M]]2W8MHVP!S X?O?S\QENJ2^_G)7
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MB9,1NC0]$!&W.1!$*]SL..00?+SO8K)YV*?*GN%TLX9&JG[5Q%=^/.M\^-_
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MT*@")=HQ54(D+ D\1B)DMI+''.M7/WH W+HC\>;!46L;+0U)J>/IV?F\[23
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MWLFWX*MY[=]P-L;Y*/(<6! &@JOS/!Q:<);.-"ZC,S%8VL6[I>%U?N2+5?Z
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MP)A?R?0D9/4_OUQ^G4V_K::>K*/"2AH=0D)@!LF9X#5/EUP4L(89%223\>&
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MU6P\S^-E"M1U@U^G/2;RN:6OF2V)?&[RHQ"*4$IQF[5@K2_HMT Z$S:T%/P
M.\*3-O9R_W.%^(E%0Y!)@V)!0M0N ?)0@I0.HVE],;H1S#F:CFTD/T!O@R>!
M_1XNKY,ON\ ;R(C< NTXMF0C17:AQYY:.-3^<0>FL58C3P*,\LN$6@8N!@=:
MQ&AM[;V96T?3CT*2+3;F<3C21_B#=#6<(WW@E_5))S"&(NB0$T;%FG6O(4IK
M@)60?0R)R=0Z$'$?P>$MBJ8*>M3'<&?I#F!?O@U?QXMP\?"<7(.+4GDI#(-D
M=.W7&!1X0S9/MAC0<%NB:[T+/ OHO)C03O;#'!"K ;JK% "RH)WQ]5:OWAN'
M2-:N1 528"+R<G*&6L\"N@?@3 W)'24\0&W3#9CKW)P.<(8S%N]".9IQN*MR
M-JEY#\D.^7ZO8:5::A Q @JN:JM43_XL[3G6!Q.4M\&G 0R^X16]W< ;2,]]
M!-I0O\N"RD]7\?_'M/AC^O/?7\>S<"=L(5.PA1X."I>M(,G2\$5PR)$13DV'
M67F0UK:A4G7C(XYR1N\N^6ESL36TTE;#G![#$=X943MX:EG;=_B4( 0ZA0HK
MVA2/'*WKI,7'G_V"U;>GH%JGEF[,I\1@ V-H $VL@[J)1SZQ %S&*%F=F.(Z
M30]Y:5GF0QA3[23=L"SX^1S,+J!>6W)Y+T5U2C'>1<H'2RYW3F6%L7;!M>3;
MJ>QHB^,>4M#9<Z43>8XO3_4[)9>WUWP?X0Y@6/\^G?QYW9; LT*GC300N4J@
M7&#@R:NO?;B++4P7Y5N[S7<>?RI)Y[T4,FTCS0%"99N/KU%B7.O"+61=YTSX
M),$)9T 07J6E3OAP<NF N7XG$B3[=>"$OUY"'X .3U\-7-;D@9'EGFG.'+F0
M/M6>177LKF)@1%(B(+&VZ,9\> ;.61&BE=@'V/G_%2ZN5M7B%Q?3O\(DX6K6
M+N::FS"?X^+MESKA]Y?)&J]C.G&;&/%6F]HW74!@RD"A+9''&F_(K6]6^F(\
M*^X,JJ!AIA5<H_MU'.+X@D2/\U%QR&C+RP2(UV;XTM5BFP2&B:(22A9CZ_F#
M3R,Y*W(T$/8 <?D_)[.;*0B$;#V(8?['E[#XS^G5LF%>2(N?2UE-$Z<_^4B6
M]HA%SX3*$F2N@S.#K&T4DP?M!"9._G1FK<?7[H;TK"AT &5MC%*TK(5Z.[V\
M'"^J-1\FR\D<9'_A)-'KL$<5U/8/W;_^J2?P1I5/2]/T[L-NV:2U"@*E@D0^
M$-FHLK9UJA5UF17)>(Y:M4[&VXQF[PZI#S]Y%;;C9%DY7Q2@-&1UI50[%-$:
M.2N1:)QE#JU[YCZ-Y%#U38WT_:@)ZO[B/962IMKR\7UY,YM5:ZI^X#+4X[VS
M:'6 J)8W*3%!E%J RYX%D0L/S4?(/0GD6/'O%@I^Z WM+>@!_* [<.9O)OGW
MZ23<_N0/^FH>EIG4-W&=#G 'RC7H"?5(N0C[*_EA[\(#:.@$B!59XB98 5%K
M"4I'"V[9N(3VX2"DLTJW#L.<!*&VY3P<G4]]%-,Z-^*?X=OX3?Y6O?\/5[/T
M)<SQS><9+J&^??^O-__ONY"J\W== !1D,"P7 Y(Y7L.,'L@_8,!T5LS)Q-'D
M;;;O+@\^O&<TJ!:G!U)!Z^R+3[A8K*RC&XC7W<AULH;5^ZI09Q(F'\ %1Z:?
ML"ZK3 >Y4YV(L?$19TR!-F(=X(SY1[BHO/ST!7'Q:_WK*N_E['H60G3*07$U
M43M)"R'K EZCUBAY":FU*[<)RQD9L$W$/4#H]2E<UTWL.R ;R%S=C.HXEFD;
M[76@Q!ZB/] ><8,P"NW(=N*R!@ XV5,ATKO@@K$HE<BIM*[)/C0IMEB7A^=$
M=XD/X9.D-+O"?.?*X'HDA7%:%*&@B%@+>[(%KV0!C2PQZ82*HO7EWB8LA[<C
M6NGK<<_]_87=T$*\E]KT*2%92^/IDNS<T9E(E@PX:UPUC!(!0@9<Z3K]3!1,
MG>KRN^9XWGWX&9@';03;\#YN"6B-X\_)_"NF<1GC=<IR%U M4SHW 3EB2N?N
M2IH.)>'6Z9P;P5GMC-+> #,U3<#S4/-. L@ZM4X%1%TZ];8[+;5W2><<6.M]
M!#N0MM]-9YC"_-H[%=E)[<E^05MS&74-D EFH!04DF5-1UBG.XR.JK[_] ,G
M=+91RQ.*WD.F0[38N8IS_*\K8O//W];CRM85_@:%S@YL+K7F1Y"]BDJ B*A]
M,EIPV3IY=P.4,SC06PI[@ %N3\"ZZ=>Q'=A WOY&4,=Q]INH;CL=]I#[ .[=
M9H"B*/)8:9N26090H3!PDM5JI22#*=RW3]X\,"&V./J'Y4,?<0_/@_7)A44Y
MK+/:I%M6)+A00QH92A9>6R6<\*V'?CX)Y/ .?B-%/:_^':0\@'UP_Q3\_OM5
M!?6^U'S120Z3!1F^VHD0F )1ZK2V$"4=B"6 D)DY21A-\ZU@*ZC#4^(@:5'[
MBK_U]> #=*M"YC^F;R;SOXBYV15ED2Q;H14#A5@](IG!&.X,YB#(8^IT1?CL
M8UZ\JAM+LG7&P WEIG,R@:?_P)_&\\5L'*\6F$=6&"YKA3D+MOI"(H-SY .+
MG.D_F07M2R<5/_>4\]!P,SDVO.]; GN4A'"-]%\A)5KW$O!(!X6^-F3RKLXX
MT<'25\$#:N.BCHFC3)TTW>EQYZ'R]I)M&--=SYZ_H!]-5UTC;F!^Q"HRDL2'
M\'V9I+"J!U)DR"85EZW^:B6K,> BUANM;'A(.DEG.E&@SU//@PF#R7F :,"O
M)-_/2Z!WTE26R-[48A&D8VDY*?9#F"V^CS I#)H)"&2%T-%4#-"W"+1Q>2^D
MBI$US_'O _#%\V=XM3SFD!Z"0S___95\:QS5I#7OK0>?"SDTG,P:7SR"E@XU
MUUD+W[HZZQDX9\V/743^F UF7S;\<U8]E8^8</QM-4C5)2&=4V!TO;".HG8:
M"PI8XDR0/YLR;YTG\A##V>A]+^$^5K9ME"^Z/M)&%BVMS"CPT5A0AF7P! R8
MXSDQ9XT7??-$UQ_]XC780&*/]>>:.'O_ZXI.$9Q=?/]E,E^$BXL[^.8C@TZS
M4BSPC'[=:""X##+(+)7FR"7KI-(N3SL/+3>7ZV/%^R:*?T3'^2@%)8PB*A(,
M70^/!%X4!C;EE)+76AK12]V/GW%>2MY3AD\$<)HG\3_%P[7W(3D*8<E>M%K$
MVO4A@Q.$EZE2//,JEM@M:M?KL>?!@.$D_00I]K[5N0Y/O(\7:\MQQ"R3T4@)
M248'->8(7ID,W$:=F&32=FO.V,,P>XSBQ7.AD8"?T+EHW^[@(\X7LZNTN)K1
MZC^E+YBO+G!::K>&\6Q9D_0ES#[OU?R@[R/V;X6PUZ(:-4:XA^'M=%Z'#=?Q
M![-O>$NOY!(F$3G8@J$.TJ ]()'MES/JPI!AM*'Q"]<%U]X7QFN1OR_WGK9\
MTD588*[/72?4Q*2CXRZ!RX'1*Z%KT (M,",3AJ2XU,VOD;O#.U1;A>9L>72[
M/)!*3J7KPFH.VDUNYKWB"Q0\.<XU[;JZMK7A"FB[-1"<\%[3:DUN'7)Z!LZQ
M$MH&8\"3<R3WU\0 B2P;H%UWS>T ;M!!LQN '7/:; ,U=J/''CHX.%%"]M9(
M1Z]#K%D^1@B()@;P9-(;ZS#SYATNCT"03A-H#\V//J(?@!=UBR0//US<%%\Q
MBX*5$"&F.F8S6 [>VPR(*-$;EEEN'<M^!.)84T>;*.GA7*B])#Q !MSUR#(Z
M)W_";W@Q_7KG:N6Z1X-C@B4N(6(=A(520U31@TC%&CI!DS"M#8P.L,Z)%JVU
M,$26+%[0KS[_$R<X"Q<$]$V^)(F3J15JP\,UUFM6<^TQ2HL@?)UP9IFL87Y!
MIKU3&@.*E#N53?5Q>_H /"?R#*>9 9HO?")ZSVK]\-(<YR-.U(T.'2#7&E2F
M4]4+])"80/2"65-:Q^0>0#@\%8;WAO<0\@!GS++]\J/HU,@X(IXQ%E*L[5BC
MK0-\E(>L;<C<<1U1-5;]TTC.D $-1#[ &7)_V6M,R4K+="C 6+8U\BS :Q:A
M\,2*Y#D%W[K'Z%,XSI $>XM[X_X_6(C^]]J3JIY:K0+RCSZP<?C]><"'#+9;
ME@.OTW9"K&,2F,P0N/.D9_)+:Q5%[E:I_H*#[4F60C9R %EM)\6T(Q&(" *5
MY=Q'9W5K;_6E!MO[L&6?8'L?E9Q*L/T9 2[C/ZHPJ5$:<+GFH-G R5@GE[VH
M(#0+*='.?+@W[:4$W7LQX=F3;#^-#&#7K+JNW@.Y]NNZ !MJUO(F4,<)N#=5
MX9.MLEO)_Z $0:.*4)Y#*(S<<8ZLME@AUPQ3C#K;*$-K)^C Q-@2:#\.+_J(
M?0 ^_$QV[/0[XHVC?MV,6]007Y;@?,Z@E%00I:RSB)7,+AOF56L;;@.4(PQO
M::.L:7M)-R\LQC#'A\[YJK^"MD(KZ<$840M;:G NRP(BQN2MD]7_ZY2>N/$1
MYVHI-!1LZQ+4)U%=MT+I@.MI^Z"/XH]Q[K=4R%8=[R'-UA7ES^++(3,;&7CO
M$BA=I\]9*2!@+O6,<RYVJS$]N)8W'.)'47(/(;96[L?W?U[WKU]"O+E4P9#,
MJFU]H--$UD'G)2HZJT0.2?NB6;?Z\0T/.-QIW%;\T\:R&Z)%W(.[DLAU+-9P
MD**V.*K7<='02C'GHACG(3_LZ_%*+J3VBACM(>3#74@I;@A.T&!*J/PC?(XY
M\CP<&A.R,*A>]874/@QH(/(!_+#;$=3W=[Q:,C$J$47P/$'A];),FEJJR#TI
MT7GT7,N46M/A.3QG2(IFXC_(1=6##F;[U(QL^JC]+Z<Z@6QT+?7@6;><$#Q(
M4Y2M&9'$">7(=4>A@?C 58Y8?&@=(-^$I763R*6#JD,1U@H#7D4.*IA$G"\*
MM"9CA;GHLFV=$/<4CD-=*#71\[9VD+T%>RJW19MZ9<J<5(J"0T)%:Y&T13HF
M:#N3-F536 BB>0K<:?48WE_%'3L,]Q'U01O)=@'VNCL,]U)=YXZRN\C]L,10
MH:B4:M:WTJ"20G!H,QBN \><K O-,Q5>1(?A@?C00]P'ZS L158BT\$92IW*
M*9!V0C0"2B';5B1FBQO82CJ]#L.]%-6IPW ?*;>^Z'GFJN.ZG<:'Z7PI[/G/
M%^/+\:3^^I\7TQ@N/M Y6QOF!$LBX5(#-ZEZR#* T]I ]IQ%)<C(XGR;N]$*
MS-&9LI_I>12=#%.SL\,25EUWKY>0:WF1BA&L10O*AP)!Z@#%2N=$YC;:0;,%
M=X/]P@EX+ 5N/-)V#(\\TOY2HHCY\C]^KJ&%^9@L_9\G5Y>XZ@GZZWB^Z! G
MZ<&P^L#Y+<7JH_L%3QHLH5$491D9G;^)M5XGM?8"'GSXWA>;'\>?ORS>ES_G
MN/SD$7."%6NK(\<EJ%P\O0^UM3.]&=9SZ53LUBWMJ4\_PHSD)W7Q^&IR'S&T
M?AF7:YYC^A^?I]_^ U/^CV7'U&4VS>3B>\^W[N[GK.B5\BVK[G]RK_>M#\I6
MX<DO88;_(&W1QGI9:^!6%=QWQF#_X_OMWUQW*:ZP;K#1WOSA(DQ^#Y?7OE)C
M>WP(B"VLBW&B ^?38IK^_2?I=?[QTY^_W7MU6IH$&Y]U^,-^0,8\:0-L$_,
M#;!O$N+J4P=1ZE-/.&M5/B/2C=VG6VWV2YG\,LGC;^-\%2[FS??\AY^]WZZ_
M'>Z>FS\]9/3FXN+.([9R_/GU;_S ?6RI=^.+\=>?KN+TV_S?WW_[Z6;2<4SH
M:J94;::I?'+@A=+@"]-:>F^R[9;]^>3''^X=W*:#>_;4_J+H>_F[_G'])]++
M_W__7_\'4$L#!!0    ( -@[7%A1BFL[!],! %@8!  4    ;G9A>"TR,#(S
M,3(S,5]G,2YJ<&?LNW=44]V[+KH0$ 4$Z9VH- 41Z4B+C2X@'6D1 0$1D-Z)
M@M(1 0$%-)\"(C52 E(CA(Z ] ZAB+1(0@F!M)/OM^_9^_[VWG?<??89X][S
MAVODS6"NK)4UYS/G^S[/PUJA3E'1P%E#70-=@(ZV&=(9 @!U%K@%T)\X\?>+
MMC'07HRG&!D9&!B9F9A.GF)E9F5E869A.</&>?8,&P<;"\M9WK,<7-P\/#RL
M['S\O-S\G-P\W']_"1T][1P&QM.,C*>YS["<X?Y?WJC? (Y3)P[.M-+370!.
M<-#1<]!1.P 0 - QTOUC _ZOC>X$K8\GF4Z=9F:A'8 X"YR@HZ<_P4#_=Z]I
MGT;1/@<8.!@YS\O?.,EEYLQTP8];X5GZAU-B-ZO:>,R'L>**#_QC3C/S\O$+
M"$I(2EV\)*VDK**J=DW]UFT=73U] T,+2RMK&]M[=BZN;@_=/3P?!00&!8>$
MAH7'/G\1%Y^0F)21^3HK.^?-V]R/!85%GXH_EY16U]0BZNJ_-C2VHSHZN[I[
M>OM&1L?&)R:GIF>6EE=6?Z[]6M_8Q.WN[1_@#PE'QW^/BPZ@I_N?VW\Z+@[:
MN$XP,- S,/T]+KH3(7\?P,' >%[^).<-,R9G/ZX+"L].<=],_U#5=EI,T1S+
M\\!_F)E77&E) O?WT/XQLO_:P&+^6R/[UX']V[AF %9Z.MKDT7, 8*";@"2:
MV!.\EB=3:Q-_(_ PTXF="O&K/2J\+T,LZA78%-30-F)4X(RW&Q4 B]+^:IVD
M B\G,Z)'8+M^,![PMM<X=+_:;B_I>,KM:YB."FPAS+S#TKA@4X[@Y25W1,"!
MR'@D*3CMGUJMCA_A1$7V:?+R\<"M_[<CT[:_@]T/XR<>@<R@*/M[T*'N!"JP
M@Z "*[7_KHW8Q7!#'SH3P<W:-7>/DRF",_V4:$T]*A %IP(B!?^N#<_Q*/A'
M)Y8.<N/'(-B)"<@>;AE,Q$ )&- _M2*;=$#3;Z*'=MC+Q[0_4H&XNFHJ $OC
MH *+7E2@V^,_[/'Z.7.1\AV%AX9&/?QPP$=21N202*%I%"*$HJ'W3RW(E6$]
M_$-0#1&UI<S^&;E448[\M=(!/9RA K@9\#\WCX*3P#57R; %T+W/43K_84Z&
M_^,L]=>:D=_&;U.P?V#^ _,?F/_ _ ?F/S#_@?D/S']@_@/S'YC_P/P'YC\P
M_X'Y#\Q_8/X#\Q^8_\#\!^8_,/^!^0_,?V#^ _,?F/_ _ ?F/S#_@?D/S']@
M_@/S'YC_P/S_(<R(8WHB$*EOFD@%3B*B3%2; ^LG/]6>)*R9R&(6B0/=.UI>
M.'_D/2@Z$[SK$TV[>%7E+RJ@O[T5*Q13<#--4U6UP"[@W=LC%-$0VML5:4D[
M &Y%!49ZO09E:)WV-#U2&TJ"X94WD<?W9,,ZHQC!,=KQ#*V2W&80*Y(T%8AY
M0C(DM& /;^->IE:&FL_>&?^@V,9S,-]WIY2_DE^VZ>(UB^%4'FG=UV%KVXEI
M+5=TD <4][[7-C.J(*S!3LK9KGO*0R<'400Q9",#;8*LOT4CT!!^) VJ1"C=
MN"0N+>[*Y< -4'^:17W05T3 >Z:W N<-MN&(-$T_6Q3/3=]L11OEP%*)"%$;
M'=O1[2O*]D0O&?W<B+*WUOP/G"JWKUN)KJ9#'A&(E-->RT@&DD0KSM+I2O5X
MT+QVS\+\NMD]A7.6CB.7 W(TI@"_-Y/!&E83<%.VUZ5-DL9JAN4-YRJ'$CY_
M3)I[^C'I(O!_7#2RQ[>>;B5DKJ2RM#>ZUF$?"7:N!M\U"/Y>)=/$R-A7=E8A
M@GX?7H%<&@7S0===L*84)B?HKJR+.4)=)4BDTO+!VDS:K>5<F4U(PB+6&)D*
M8@^\A]#?)RMV6F,O97B0P(&C=Y).&G#TI->0S\KCX=G3AO+6C+;"9\.3+DT4
MVU$&;:0M?[(GGM;AMNYRUN&^2_>/X%F'UE"!=@C!"<;7#$9#,9!M4XQ[EO8B
MWK<VS/Y\&'A\QWAZ.JU9?>UE*IY^Z"+\,Q7P@D_%4P0@[<>\553@=#%)G K,
MY*1ZKE(!MZC,OG:^^:;!3"WY%.8C_R\%3N_/7[,(,;IE,)JE<4FV/>EBQ7?:
MVU\G_A'']O@;Y!0JL%1V.=(X@/9=\:0+5&"JNDUT<7NH+FSA?D#^T3"F:RAR
MK7D6GT:0HP*L1%R$+1:,[\8?XL.O4P%?HMQT\Y "=Z:HTV&7ZLJ.\(IR<@6C
MS93JCAV>"-OT%/3/%]&OX#N:W=/LHUT[Y=^N_7]2R&PB7T"P)J!$"%^KZ/I[
M^6'$$+.]9VZM9.B%UJ8&@ZQ;/"C&>C<FZ7#Y\DW+U(M[ ],,41O^LE0 OJ=M
M^;'U^Q@2_1K)O^WMFBUBTZ[^/*GAK/TC/KJY8WJ)QLKH0N8C]V4I%)@[4@*G
M21'%!2<'?-C$/EU;0)\0,-73-;<:0Y/Z]-%[G>ZF'+IE/Y]G/JPN5BM#?/@^
MK,/SPY7;3 ?XMX"81/= JR D9>O$9:U;%"XY JUX5OV^$-M/Z2="\EKNU<#4
MM;[.CC)5Z!ATY8L8;".78L,N'D1$39+2]T1X]GD11-#66<JX0B37CX//05X=
M'OU>?+Q="THIL^4[8KH"/3.%*3[7S@4.B9AB;(@GMJ U>K';) NFQ \XIZ1#
M%J_@+5=OB;I@)N?9-357<8[\F-/" >FQG68..3G=]>_PE+?U53"E F\7Y*^C
M1Y$E.MPV9@EF.A'0[6*BS!8$H9J,.',%91E_<V2_AS>";.)QITMK-6%8C+5I
M.JG>&F"4TJ(SSTAQ**JF[[@(#R*7@UW)[G@;G$J66UC9+?B&8*VI1'81]\D3
MVR]N)^"RO<M5+Q$[SJ+>_Q5JY6Y8+G/#)*_1;9#STY$K@OGB1\2YBQ^3@'\$
MO 3LZDO+&,&"]IG?-?_(&#'0=$C9OR0,?*"/B98P:2)^*8*XQ1GZ)3G2163R
MP@6L*AZ.7\3?ZH#Y$L'3I'EL]Y7(EIUZ(=QAVAVBM>A"7NDZ9,$0OSM*&C:4
M1<W(PGV'2&]_U9KI^.B;Z7 #_\OA] RKB*YL(%Z/O(G AL17UA*U3)8%W V"
MKHF_/%M5N<;P4<-=1-ONV)XBHH@+H<3),8*(T<U48-6NO2C<TLY*PBOK5&/.
MZL0BE@J4X(QY]L%=IE.*R[_:M-BB?,U'O(-:.*<U^]_=NOE5];1/09FZ0ODS
M/?/9X&=C2;NP6"0[>.DQR0P[%(NL!5<CZ^#F0YA6TW>KORFR>3G!6JKL%5;J
M7\KAQG-67!\;/I6_5$\Z'L)_(<>"EW(HHK:A!10N&,$@>OSS)QC>=#NMVGM>
M. T)?7_4G9/B@G226>VS]+* BS[R61\INC9:KS!'FY:IGG^=GW^*UO<$12K
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M&=;[-<ZS'X]1)K(05O#>5939[.7%#@JGPJF7<!<A,?NJ;V::>MI.RT]./71
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MB%O/>=F4$4+PU<N^(?CHU:+L$HUU=SM_?K"BSZQM$'E6<OQ;C$/JP-;Q"A7
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MMR)7'ZV/F.,C%PX/ G"0Y>)V$"^)"Z=.B.C*-<6K?)G8")1M':7E4=.#-OM
MD_Y>ZY5KRXW@%\CJQ4[35'6O36TVK-OOLD\ETG*N&3*VPC$W3HL/)JUR#([X
M+;3L4)B]1<H7$9\R18AORB%Z5??F@FR_C_P&9WOM9W8G+\O1D?A#6]D)$0;C
MRM[:(_S[J9(_2676"3S\_*Y,IS-._NS=L3,"J3D[WRL:D)S,J*$@.;62LD(,
MM#A-=RC(*[^6NSM-I^'+OFT:H961GDLL&-$^"X0OO9Z?[]=]B\MW>OCQ##%>
MW[?V%Y?=2=PW'D>S>K4*XB91;VN'$O<*//="?:UJ_9S%?0J%,I&9?)#YU0R_
M.+'+VN%_JQ;*P#&D&Y)D<UR?*&M]B-(6>*F1^+A0X.7FTM21V=?N[T_%:MB(
MEL(Q7I5Q%\J>_W)2,=NLBX;%.\[7*Y;QZ^5D'$:)4H')C<KN3)(R.9-R)=)Q
M9-(""W]VP$)6?BJ_X* 4_*J//70A6,?O=^'XCFAT%TPP6G!#X5'NX5-E_G(Q
MQJ+W7?J^V1+T$K">D)F_H%SW(R:W]+HA,RQW"7)X;T44E)GDC*,W\Z O##^9
MI3IUWP$M,W?Y,=TWL+3,?3:_]/<TW8-Q7 8GBEZ(U:&).CF1T!,1V3)G#B;>
M^OD]8%/C_.Z<T@TS;XK2AX.W"$F)@_E\<GF3>Y#TX>U+H]6?#W8I;PDPG:A1
M6O:HD7-K87&4<R.MYPD/^[3 =R:+O1P-!QE/<X?D&94G%#Q;NQCYK&M5JDR0
M8-?R6.6"6NZCPD JH/@>(:7KT)06HQ/G,5]P+\M6_N4=S'WV6S%L[%4GD7I@
M5]CL83>4J_5JJ-S2P&*\ID0AP7_)%6$U\OCW@XQ3R_7!.FE!J(OT_69][V7V
M8EI?T"8%2I.2\R1M*E Y"3DV4/:R>RW=5E(VK;I7<]7\2>3P'%&1PCQ/!<3=
MVY!X$!68#?/:;41:0M$5B[NZD4(T4J,"Y/ILFI'M[8/&RD&&1::02=JP,N:+
M'UMJGO_G3WO]UX+,3.O=#9H+Z,<I4EHN0_>OE=&0>[PS6]"U6./>90QN/V9+
M_NM1^.U&2\'G%9]1U_*;^J45R@I+_WJ@W&5YH.7U'8Q^!=U5(-&$,-P(1&9[
M1(0LYVS#L? 5J:0*DO&**8LDHMQ^MJC4P2 J@#,A_6V6H9[T!X'@3;: @<A!
M!<NE%/-2N!#T[6*\B>6G@A9:3R ,A%A]<AG87<-8SV)$>Z"( #?*T'BG;;WX
M4_YR"L\7Q3ASJR_L %J0M$;KN^-LGNE,+N5$"'^M1L?\5J(S#QZ*D2?:18+)
MN=&"\Z$A[8>YCMU)8@@5=>MG10H*MJ0/5C\ME\6OWV!^8L]/7P*BZ9*VR[9(
MC%;@=R/Y'U=ZI9 [YPM80"$<YARU@G]; *3$6"D%(VVYJ=&WM6=#I *W)I'H
M4E'V2<T0',O2P]2E^0N']N/NM:V[V]OG/%U]WPOG7T2SK6(U)OO5)[>%<+]0
MQTHS19.HIFY$HF:7O4:3_=LJ#*MY[7,BHR32&NF9-J/8#JN1>G$?I]+P8"8;
M'FHW9%I5-U,SQ[&GL /VEV]S&510$W_F,+2=173W6$3<W%))][ @N#N.#$MF
M=QFE!PB_JI(6$6=^CDXY:^GBOQO09>N@>R%;<.Q#D- \4F4Q>W+O2NVYS1++
MX):*0_L],+=;XE+Z2KK@M;-9KLXQA4$,X1-#L22N9?8$NU5UU;A +TR(5=[K
MVB_/BB)=3W30M:>D5*%#E ]\23Q"2PMY2Z"9$RB;4=F5.IJ]3+YCW_1YF?_,
MDVJEQX2-[+MO#\Z]_]2Z3\YM90V%X(T)'"(3'_ 1++@'RF".+2[V-U^-?Q<U
M;J=PEA;\R'=[&>6>EO*DC'/BV'[ =Q?R<VXM6]00694&[YW%C9&Z6FELI+TQ
M\SAGA*39$.IR\^?]L<MK.8![PLB#52)=[B^*2'0W%>"CR'@>I^[$-?/YA;"]
M"S\.FIEWG+W7S]@N7:,[/'1![9PZ?N< 7G<P1) I?K%-NNL=B 0>A6<_K?96
M?SVYP;#=\#/[3 K[%P7ZK20B"QK9"6$F/<9JU:=$7B!N!_%*!F6<%\9]_TM&
M[ZK T1BCB/ZY2PPI@FO9BGR&>27FN?6F<H[0'J2;3G^Z$63+!>O2Y<0^3@$1
M"BRP:TA/_!EWXS>S\_9AB5(YYS95STM'_Y7N5(:&3A6ON'<XGCSC=0M[9KO1
MNST^SJL_.4+LPOM;TD,7Y,VOL9X\M>%4&ZA%WP'#6O2W:'0,W]).5TUZN'AF
MZ+A!G*/F9@H[@\"),\6Q^2'P'U1@QJ4;Q-,J2H 8CVOS$C1,<:_33;HM:QJN
MN.N?6 V3+R@)EA)+[?![_CC?TT)$;;A /$=I)-K(=ZM_<.D@"+-I8:]+@4-W
MCV#)8"YM-L(D>JT\US>%I!JU1"RADQ=Z??+2TZX[_I<N$GIHO)B[$F=*GPF)
MI$Q1@7K?>,H5DD MU@KV7!*!DUUAFI ]:/('W<Y5;=-/!&J?Q^ZAG8487+,<
M3?^^6S)4&)HAM)C4*EYMA*]N4@F70+2?3)6X+FB4+UK.PFA!$I??JGU9:IO8
ME5*Z+.;C-!^E#?U5E6KWQ#S%LZF> #6"?#O*;*,"5>S=(!%/^4?A-JB!Z_?Z
M^U0^:/)>1HV)[XJ=C1"^CZ\,689N=^.,T/.P64T(ND7/\,M*T"Y#0]V=?&"D
M?3#)0//$#>5C)*X&_P4'0D$Y3#\23-%I+TE0K1K&W./9.U_KJZ2$$SZ=[7'M
M_NS8^GQBIPV<Q@<1D8770G@C)7'NSRISIU,F%L1&)-2COKO_=+VWH&RMIEE6
MNBJJ&)NF0;S%N8*QY).K1,+6 R.8_2(S?6A,>M! <->)$B.&4@;QT)J=KH?Q
MMQ(_8KN:3H\I$=*, KXFWF?Z:MTFFK1YK<MK;1/_V?KEA=R2,[!]*L"54:%J
MZ,-*C*><-L(.=G>"^#1UEOO7K8.Q\Z^]/"H5JR-B^L1%E\1>0;]M32/1?X'J
MNE.BF0D3J&\+=._/2)/N%1W@*V2;0SC/;+==2!5GC7TAGE'X#L7?-O2STRO4
MM#T7^3+2H-A#\,SSF??PSW>^V-M]:_ 4I@+GU#-" <XGC $3;>4ZH>-YPX&4
MY@,1]=(4\8SQ TP548AXDC(2OH,YCT6:-^&TFL4<A^&,^8?!PT=^\S+GW*):
M>!IC^%[2?1N4V1/#CV!]\M"@&6CWC&ZZX*WBY/'&E_R4[8<>&0_O:@ C*DS.
M261#PGGL%@I9Q;X]JQ$:?_?%F=>^I5XA6X=N#?=/]NSU!^K_"'K )/#89J6X
MTS=!%<G3*AZ:UGD<L]TX(>?:*/]+VRYS5Y?]22D/E'GO2U5*U;C4C8A$^[YC
M:"84^\MH[26'=%,]!9KA*5S$;0:Y_N1_YT%D4"4,:SATI)*W2&2?AZY_]?I.
MD:'QAU&D)S:/9AX3FR\%+:4R66&[TDJTBG];A_HZR;^,1(E)[A#=8S%.;ZD
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MW$N3?^%%8YUP,(8#&^?[#"*@:83NE8A(4"*FS#CH:WMZS]_JZ!9V]P+\NF[
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M^/!=> PP_\&T(P5AB;.X5U#U6[.0$YWS4[=_%3;&06'NBPG"?@JPV-MK-]2
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M##\U$GS@4264FDP'M(:X/(J*9;J/V<=%J_Y^S^5KNGWFY&+C VH8$BI[ BZ
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MM.VYD.L_KNZK-S;J,3//Z8"\L?O).5'L]_6]8HQ:>JT?A<O:9GBW;\V:_77
MVXVR^@YJ)K1([W+[[#"\Q*E.<[0('('$/Y#EI<C%^VSR(?H.4L)RZ\/W(1Y8
M/@YS299QW-/QUA-\P(+PF=.!QQC2P"1N[$#@93S<6_3GB3O7_V";XZJNO3[
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M- F^QR>Y/BX8LWKA]1(YAX'<H=#F/^4YMW NU=O8H[K >"NG'P%+P7#MV<Q
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MHN9/0A^H,.4%F9/_;FHT_%H..C-*LI[K\4L04'@H4V_@QI=1_O@QVWO0]<>
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M(7*F499V%:. J=P%[=,!AA;!]-(4D.XKX&TZX$L'D.D4YX-&*1H2<5(C#[Q
M,1[ D7S H9@_V:XXDFP4'8C*^3>HJ]L&9"C#@*'(:#(%-Z]+G,ZA ^ ]R-X^
MICVN< ZSM#<3<LAUR'7(=<AUR'7(=<AUR'7(=<AUR'7(=<AUR'7(=<AUR'7(
M=<AUR'7(=<AUR'7(=<AUR'7(=<AUR'7(=<AUR'7(=<AUR'7(=<AUR'7(=<AU
MR'7(=<AUR'7(=<AUR'7(=<AUR'7(=<AUR'7(=<AUR'7(=<AUR'7(=<AUR'7(
M]9_+A?Y$!QR18W/=Q&?XJR6S!J>?!7FQ[/H-:?9[LK9VV4T?DWIUMVEK&Q5
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M(PSD&,@QD&,@QT".@1P#.09R#.08R#&08R#'0(Z!' ,Y!G(,Y!C(,9!C(,=
MCH$< SD&<@SD&,@QD&,@QT".@1P#.09R#.08R#&08R#W?S5R826P=HF=K T0
M(1A_AH?@SRT'/S-U)6%1-+XN2T?-\^;\\WT(\B]+LZX"FMT M_/9IRO[9]HD
MV]W@?2/'+5$VPC2NX6TK=\SV$DF1G\^HL_3IXOWI#S&2?<JW8\3?_?&?M;5,
MSD/(@2N@W6GD:X060H$X2@,$@S0I_AX+XH>&G#[$ .+_%5I^GEHJ8.@XE.%1
M+@6(8LS+?-F^SQ(V>,]V:HC>5$E09\]VK$0)*,F[QSC_U/66/(N<:!;F_);H
M)LO+^?6*/I#-V6DG=%V,MV0>:;(%6:R/690[-YA?F7P,\D"31>CYYF%;JP#W
M>V&NQW#7*0.=W +1''V[*DO"NUSF.FY@Q!KYVY;X5BD56:XV;W+C]?2JPVN^
MV5TDGS/U6+6BM3"R]H<4A*E"7FGHZ+/K\\$"1>D&[:M>8U7T/>*$B-)$='D<
M2R0E6,#P/I3L R%3TBI^9/?^$#I;DZ0>(J,:)AR@20-8ZI#DIX70B=-8?\H9
M^%$:,$M TX $@_4E,F)3)MDJ\=:'!@ZBDTPD<L<P1(@&/)^$4I4TR==X.K8.
M+JF=I 'M&P@:<*YHO10F27J>;)5 C9D%8]^U\< &M7#15 XW&/$7"/<#>ARY
MG$]4_]OG)3H8[4.GSB6O^^] F&@ VV'Z]HG1?P'&!;O2@%YQ>O"+^#/H:HAU
M@(BJM31@/C58 OZ5.KN088?\FSD8NCD7_E5S\L8?4B%[+,+- A2NS[#.6R'T
MF/LA!<M!%IR@QXZO?S50\&O1;V2#DLC/K>6*0U2^X_]="]C?I/A' PG&X#1*
M>Y]T+TS#\Q^=^P?SJDKH6K)K^=TXD S_G_CVC_:IING_@GD^U:G$#%JR_*-S
M_V A0WR&^ SQ&>(SQ&>(SQ"?(3Y#?(;X#/$9XC/$9XC/$)\A/D-\AO@,\1GB
M,\1GB/^_6_P+[\BV.)Z86J=KK3P]U'.CNTI[@28F?+4MVUJU.@HC$&'LPY1G
MGYG14 /QAN715\[E'3'B)2<--,X _UD;)"O$A08DJ@I1F^M_<ZW(+V+XD/.H
M>S2@8H,<"03I_K]Z">2X\#T[9V&'.P;ICZ\#02F63S#\:H(6T_S.(<'8EQ5,
M$S:AME/7U=[(9!;W& Y)_!+_:B%4\Z'L)V;2Q:]R:GQ*W=_M_%?=0]%W!=\E
ML)F6"(M_^*2BB6?IF.%(,K+&2R=]N'&B=!6"MTA6K?]4F.+^Q5G)*0FI84/T
MZ+7FPR=LOPN(UD;_$;JU/OFS0H'B)]OM_F!N;OV'JL ;NN,OSAAH /]J,]8U
M,JD:O.S0.N(AM7YYCC=Y;M4XX9I@P9MP29Y.Y&F5"W-K=;4_6B ?7"':5VV&
M:\\Z>JKZY9U^^&&B2?V77VN-LKGXA_Q;&F<>,/W[&UP;$$<5\(<Z.S$I' P-
M_KU%ZH&.'L46JJTCG%.3?9W=5UGN+JD\;U]LT_GSYI'Y%PZ<0)ZD\ZI# XZ:
M?/Q)^7;/O@K6H)2HI)]FL9F4/*Z$J"BNB+D>DRJPTOR'NTRF-.J V@QZA>$!
M.\J\!!W:O(=7B[QH2@/82YS?EH->T(#T\)"6)L2W(_J'Y)=8YY AB,L;N\<=
MZYLB;F3Y8^?>'LKSSKTUNPT5)3O3@ B? *%>:S?Z[BV@ 2]D3)Z$+0I?-0-/
MG>O-+OI:OG>O[TDV^@=V^YZ.=BD*IZILNJ*I74IUW87^V@.]<7$F0]Z%0"FY
M9'^<-%X(;Y+PP^SKY(61\JR!VK2ZLI,5RJ"LLX_8;_5X60=4L 4/)B<;QC:I
M!OE>,/:^-<TQ(3YQZ>'PYP&S$L'!NX.&&WEN@$:-0<W#9J?)FYQN9]RXI"<4
M?C!;:/!KZ-3%US!Q,P8Q!C$&,0;]?S]HDP9\>DD#XC[BP!0D;(6M.ZP)O>"_
M+HK$IUD?I0'U6Y0+#0@TW_XY#!&_0S'[\RV0,:W@;^(?8G"H:__'OR?R;S3)
M@39Y6&]N$@VPFMQGW<G<]HB'XI?R86@_ZNUP5=$8\7?LFG-[Y&08'^PG]S8-
MN*,:IAXB24PI)8O@%]/FXB]\::Q*D3EFRQV0R'$Z^,H7PNPNU\$V/IBJ!8X'
MKQ\/I.=Y@DBA,&ZRS$C;99>)PI0\\D%.798\F9O8E]WS\$UOHZ'7UK.9MBR1
M5#N^[\%FT.&9QIVW_D*=N@_'FT,)FFLT(%S%NR!$"Q>6,:?+[:664WQ;1)U\
M+^BJ8MXE9LY522R8>,F?G*I_%/;S$@W8\3;17Q<BW53LQ/""#JUE'%%E,<_B
M'I#MF)@19+&.(;+")B:WS#$XPZU]\5QZAOG)B 8L+Q;H',6]3;W8QA,<BOI]
MM?U'.NCL2G_]#!+1=8 BZ-& %&\<B/*\EQHUNF:\@*SR)V?!Z8GMNB!X1P'Q
MA@8X)TXB(;%=/&V\1#<OKK2<O#?N\M.QPBD-V!<7GAG??*KX*&7DT=.0U3=!
M;SXZ:/N,U</>+AIT/NP:*/91(WQ BM  K#+E_;58V3DM7_V75U9*5;;J+;,Z
M'>LKPKQ^;5 D5^#C1H29%GQ/J^/L%N@-N&;SIX;-QXX(D5R]P:]YOTY,'Q('
MLD\XIK1:EI9?5^K0-IGI&?W$=>G62*RA3C#(<1 J &N_">EIXZC^$6*'A7&M
M'2AD6Y"4J6C=D:(($>_T&-WBS_;D5;T;(D&:ZQ;X*%@LF,4MXV%K\EX7W^6H
M'H)9=DL5PK3 -E D(T+?,,XU=K4JP.-C][3U@!^UAO1-PF9*O*?*7Q^G2H@A
M)E)9F?![9KB*RO<!BAT3TX380#Z8DPN/LMMPN\Q 6LS%+[=Z%&4%EUTGP8_Y
MK1S;X<"&+PT0#(@V&)'QN!!JN[IDVIKN[>H.>2IM+US,&=[%ONX4 #EWM:MO
M7-$^VHA-P@>KL)O>C]BMGPF.Y-I/P5<3YO"H+M6@8(XC,U-$NTZJ8]J3="&W
M7[W73_SF>*NU7GQ7[GESN<TR\BS2R>.%&W=S,6INN]#=$(-+F;1$.8NCIJ6N
MS*N5?C[@VXPR,G]@F)UJ,2Y73;I:7IN\N!Y68@!-5>.CO&\)G0<E\.FBR2(S
MYRN'??5/=EX8LAO=9&LQT/(LZCO>P!8NT- C.]'VGIY.A6O.Z[,N'X#B6J3F
M<H(UJE[1@.K=XU9R!KE'VY[4&*;=/:0TE3^?_>YCJ4-UGO*#$N%L>N9'S]W6
M'^.DY4=9I,P;=S>XMM'KFOCD^;GZ#OFZ440^$L\>+5O3G#EW^_< [_Z'M%?"
MR7<A8LD/,K=!1'&.WE:[]KT@EN<M,N76RQ//90CQNV-93W':)W]=3 PZZ1GF
M)Z2:WD@M,EH#&Z_!B(JDA*#K9F,?E]='MWZK#7]H$2,\J$:'R.%$,5W62GCN
M@A)K%_&#FGJ^[O5J2CK:_<&A"S?N=L]X4;9<]GGF,S8&YO4%U]#*L @/=Q4Y
M[*CW&38GA1FK$[,WM/925--DXV93("<.:]?^NIV%E-YZ[W/%NTM;FT,#_?[
M1B/,>)D&\,"<8)&B4F$'\SW@\6>IS0')$XO!6CQ@G[?/ )#Q^0.^O$+J8"X8
M#^]Q4]X/,9MC4]0?J2T^MZ)PT-H[_D'SK?>IBEF%1TEQ/A7$A5$1R;O.%33@
M_>#E.J^XHF^9VDMK7%RSH-J]3AK %Q#[>:E+\!!>NCEOS5SY6O+*@4G>M6/!
M+";\G.%791X$)26A^A-SD7:P"0+I/IYYAHOX:HX_=EJ9^/;R;KSU2KZK<_BB
M8E+?C;/L5\,,P1/SW_.>IU^,*QU.F_*WTG-XD;H<['1CTG<4]"X5LNC8 YJP
MZ(4+J%V]E1]R?<RW7/*^<V14AFO!C)8+^D[NXQ0[]M8P=RY-CTSDS;931%'Z
MIJ<!SWRFA4S0M1RG5K\T;\E+::_J1">;_*K+$'[!$BGX?"13\M&OZ *^-('L
M)E\QSJ@ =V/%+;6<A)X&9"R&J\;CN=IA)%ZMIOM=.'/4S%7F##G%J?A0%.+1
ML0VK@K!06+LVV<[+>UZ&E6AF?W%HJ+N6Y6: L[#?3?T&T^_@&;7:!.[H,=>>
M#%C_4YRI[\N/>5+UCHG$_KG$;O#$9(\ZO2!N)OZR)<R AK5T3$^"6LCA7DEO
MA54/GCVS*D>23Q?-94\X-08CV=L5IC%VR00C<;6WIC&.U,.)00=(@B@14D16
M(XKEK;YRCS;#,TL66TUS[7]5E+W+L7?[T?Q(RDS;,X0'YYN6R],G+AO&^>SG
M^,I=ZK&L.65@ 4IRI'*CUU/F?M;3 *< 6^QD@.Z<A>2H@'>$W6L[P7G5^+"W
MY*/$^!*R"=$NGY@"^5&(HVP,A8S]#NV[N7(Y<+].T: 97MRNJAG3PO^>.*^G
MPW'262&S.]M;>.WPPFV-4Q>^?F(AO[ZG<DKRT#PT-I\8C(ONSMPM%&H8WAFW
MQAQBLI^L _?%H(](\E6F#J7)HZ:6RLWL'(\63^B.MRWUP6JW-MZ7.$_\HJ\>
MF2F8<,'%G$W3(IRZ\^6ZTWMP9_U[K^\!9WOTXX@L!!DB N_RS35Y\E;^K4#2
M0C.>K;]7I"=PND:R#V59%;<D).]*$"#:.>/5YYV:QVQYZI0OLY7HG,-<R73#
MVK'E(N7<]R:A)5PK)N7G2F7?WQ(3K<#L4H2:.6-,+X5"V>NFX:D@3J0#1PS\
MC_>"%X)]&ZNKU5Q=J*!&?Y(LJ"O ["3'EMOG740^S X^>6JOYR"M_EF(EZ?8
MF+!5DWO%3Z.G-U%I,F6SGICN.,% L$/_*5W^WHN7DQHDOG2>?S["N0)-@=?R
MA-L1>4DWK3NQ\P1^*]SJP=->&B!-2IC-^R%9QK1^6$5!Y+%_IZUA:PT,O=.K
MIW/U1<F N;.5W)\O#=W"(LFB<.;\,;>Y;1FRTO46PSSXA4_)B86LE33@:0N2
M>@R!%_()$\7)?VLIX2M/EEWW3&&B :]1<ZYK&]QSJ+GH3GY>Q$6SCR&W\O-T
M0;8IMQ4Y^N+#+,G71NG9V..M"=M!F:F>3+72 ]]M1Z=@/SM^Y+#SC%I$U6>-
ML3R+0U)[UDC<2NCB&=C$IZM%8\H(%!G]C>*!^ J>R.OA ?.!G:6T4?=%5Z^[
MY_VH66")DB"QJV::>.]<1&JJJ81H)&)A':!3Q#1[ ]76/*DB<)#__L5>Q+>O
M8>'HS]!/D,X>/+I7>&QSL+ :1Y:""=6?_SYN^FROSY&>KIB8W3=6-.)2?8<$
MT1,FV5GX*&Y7%BI""?IY4$;(Q(4BZ*'I)P*"^_7F#\S]JD]US#!.BS>'%$>R
MX3TMKM1C*33@ @H$0]?"J9%2H<=)],*\KY*(6J%7Z@6>:!04=Q^^SQY HK9^
MI*<[EUQPR=Z?;1VDII#WDI$+QC)XF>]'(.0SS51ML1?@]3,TX$"IK+M%BB01
M8HIWC'H2HO6>:*XS(/%;1GEF49+DX&B9]#KJP?S[>5[$GT\",F!]=W#1E @X
M#="4#W4DB<'Z&HD<U/9Y&J#NLE(0DWM:JLCPF*)?[6[2N,I#7(.+Y:L;%45+
M4<_P&?.@]94YIPT9C]HLEA=1H3S6I[0\)!RKE):]]GXDVD'S,7]0Y5;  BJ'
M7.>DKH3FANPKUEV>S!SS9+(7:U@X&1RA?.[9][ Q..L./7,&':[=S1P'&0^Y
MV8_XD.+SOB7<&ZD65TLH?9B0_?PGI ^,TP.=M72&<=7"V=_RKYM79 \'!C=L
MVSYZ.$\9"^K1RW6(RM$SYNVT4D:LT@"O_I?Q*B;\:U?B\W/@N]L4CL&OXA_:
MG/!'90K3)[X'OJ\/;LR+SY&:=S!)"__RP#22.5?IO'<?HI]C0@X+ZCD>;V%-
M3)Q'L<,<S2PMI??!-5*%%KZ/CYW1+I%4 "9:55%!%!-$+M)#?U^A-9C:]N>J
M!$'RPKMT.*Q52M0>I[>>=B&H/JFK+C*^);(5NA0+:Y>%S2_-B9'20=_GVE::
M&A.^3UB\RM8\<<_>3_6/9\DP":(%]5@L#0"!.<%3GZC^7'M'FHMRH.HCEXWK
M^,L"SY\(=C=LI+B&T%VSR&F6H8B<(];D*GQ(1T,/[NM_A<7 3ZO8D<Q"+&-U
MA^_LF>SQZ!Z)S9/<2!#O\5P_UC/WKEII;QU@(]:2I$+4*7"?:7!74,I$G_-B
M,<^!?']E348IBXA!ZH)GIY!0Q;WO_NV@<UHD)7)@]4C(K:)O=]-4",J158@M
MNQ/E_&G,<6EB:L2]@= +)*LP=!LS,1*7OM01QMF<9=X\*AQ9]+9<.%+*0-A,
M:9M+R_8A1RIG1.!Z6-33LN@T/M-[UEFU&)15J#S2)%2XP/SLR\$78'^/->@P
MXMLN?7ODS8_2@)[$Z'J_H'6D$YX]\N(MKZ=ANUUZQQ+NT@#77PYJS=XS;3&(
M&.1L9MCQYDK<5FR+@?)5\]73G0YN2?'4!X_]!,>3-$?X2"9MCE=?7)HKX@MV
MWG<)J;@H&QG8PR]&"?V^3"]_MMD]_YUO+67BT-900HTEJ^L^JY<,=?K#7/Q#
M..N_TE1X"-_C18D6A?DO*^++NGA-[3D7]-NY]J/Q\$YEQZB*G;Z:-2\7=S+F
MZC6P6'_U68$V_ JT"%.G3TX1D*-V<L*67ZUM*Q(24OH]V(,I>?0" [)J9FE'
MB5@<*X66@H6*8A":71+7G >*]01_ZXY/9$\TC8_G#RXF:36?&XU<K"I_/!TS
M_&*QT783IJ$QE>7&[_RUICFTS##*+<\-[%'+'UH2]WA"89A ,JB?".>EE[>4
MMA$WPKLC_]Q=S)3E-*D_N7$7XP(P!C(&,@8R!O[_=R"'/R62A>P B0!OD&C
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M1>/, Q:AOSRM5$'.YB)_>[ZB 8_*$(MI!_S_=O\.KR-.%HRE" =?@TU)'-"
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M*7)X>FHV<.WKSB&.DN]0DL+$1+JN3CEGO&X^+F#./-"Z;G40\?%HSX*[)J\
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MF]%F:,>B;!/[:K>QG>>;GXV_Q)VX^3/BM.PE/O6'HJ F(#-)?/KC#6!3/=>
M%'LE0\GM1$NVHG=,TQ*JG*TZDFNFNP\S!9/ :LJ_<'"MOTIPG0%QF:DXSP*9
M;-&[6]F)K-6I"+8F_B6%1]6QIWP9VJ OJ8"S;$'B32B&XW(G;!,P)%7/1P8B
M<>'%<=<>)1EJ?ZP&AI1&,TUP^P,UBP8<>HWR' 982>^/F3S2?3CA4W(S+?P:
MP-"C;F92J,7D>9)'1>;X&I??:TDT="(#)T%_Z?V+NPU+F;;]:N@O68/5-_W$
MIX%,7H(_$><(KAI]9WLPBBL>$J;>-:X5'BW<195S2K=@/N$BF4)"W@I!#C7%
M(56?5^JO#BP-NOLK3^@/+G%;E]6\L8YLJR[D_[R%#'9#G+"]F'0UV(HO.=/D
MFI&89<_0B00E#<58L')9ONJ-7R9@]ZBX0U/Q]/_))MIPIVI[40A+DZA$8^YY
MC4.&!%H[OB5P%:U-CM,29'3E;K1^_7*9T[E*X\1QR=:[.?'KV,KA@H( 4])Y
M HW_GKU&HQ1H1+,R&.WD]*D[L_Y6JZ7BJ.9GXH&S>'_N!X+H;*0^OH#P:HMQ
MIB"=*=9.F3%<O?Z9G$9:N,JE'[O;Z8%\OG%KT$QH"6I]8@8^CF@\3 B>\<W7
M.YQX6"M3HIVKQ1.[,993RC%WM_1D[X/Y5-B%:<2ZYS3H)>HW194YYK/MW[1R
MUD0%'=AVBQ1O%]766PE>MM)+OZS>91K,=[ _%Y&IXZ!NU**>V*%Y0X8$IPO)
MO#84Y*2A44,%A&C;[8LW'S3AM7;J>2EH#)#$XD"L0!GO,:HJGNV4^?A;&[$"
MFDDCA@UBIDVYL^"P=F08?3,54$[".-)A+71,N[?W71$R'B37?4ET?7D%^8.?
MF U1I1<7RTA^ KSPTY2<"I-*$B^Z7W__[17%_ /TMP JX"%SF3,M_GXL'@SD
M402+AY6).FC=&7'D]I\<"7KQCIR#JN-7=*RI,P* 76"I'$E^WVZAZDZWU.>T
M4, Y>2M5FGK0[JYZF%,BN/8 ,=OD)4O33KN>EPIHO((7EP4[D)%D1$4GT=%Z
M,J76:7QA8S.U=K':*1*S_1X9C,(S5U @[NOU9VFQC!=)E #'T352Q/NNC.9)
M\P(R8E3P8_,ABZK7_=J#6HV*)H.*WC]F.H:IQ4'6:V:@['Y^?<HW+.RYF@,$
M^RWOBV$?)UU^UE'_C#$GK I4YQ@ES]RZ,BL\&,^:;,\SJ8 YW.7/$-)'UYA^
M%*R'CD[Y96XY:90,H:9S$"P+U151GB7E5:ET_$$+[0L363.;96,!5\M(WFTD
MMJ#OC^%]EZB %=Y)?[$9Z+AG8STS80]),BT9DG[CIY%_;^NG2:^46K=!;>U[
MW=]>P-WJS/:DL*YXRZW6.N(=.P3'E:&R#XJZV2;)]\5FDH#%#A(:%V<C69Z,
MQ4=C6N_,<9X2>//:/Y[2K0Q9Z[QR&"_OJ%E6/U%-'#T LL$;M$WOX-1;-AF7
MIQ@+ZX>41>X^IXWLL^F!/6*UQ2O<W\ZVWJF9B K3<3G=U@?:TM9V_3Y*!90,
MEX4&6Q)O5-G(T:*K0,XPR;I!F_-QK]Y;T]E\UJN-%SQ4;T"-BS=@3OEYSS)S
MF4#7+ 1QAN5&/^WK+Z5>R]3NK@:+=X;?K(F2;)BYP\'SR.(,.<8/N(694\O!
M"35QI5:E05>#*>-IZ%[ X%7F3CJ6UX7<K10>R^K'SK_#!HW@N>987RK 9[\,
ME0A%/<PYHYE=IN4@-FDRND>6JEH:P;"@8%F$&+;W&$:_JZEGY0N#]TY61_=>
M5/9@JB0&>![ ;]]VI_ -+T(K*FD!S2OB([^36PR(6Y+NO-W-Y@$:CKI&,91Y
M9B@<$KV&*:;]AY\&\8XMAGVS[.P3,,O*S;R+(_>\ZAM9!<//@$4#X%[=37MM
MCJ(\ROQ2:WHYPIGM_A4^IGK?&CI2C++SXNNDJ0"!G;:YWO ]T#AP+K0-S&3W
ML/UBXMRDN#\BP2.L=I_I*=\/O@V)J'F#Z$C0&03>A\!.E":4WK$<?NY^:DB:
M+D(F15+5+=Q_^,DX%7 ,61>@1&F;.D%.5S28(<-;;JV^LUAN7^!?&53E,FNK
M!27>]!J+I_><%'F![<U6Q1'QWEN]6.YI7R=&KP3_>QV-Z V%L:R!C"BYF'[C
M.R?[6W_*_6C+=-=M;7TOC"J[B*1P3(J;<Q_$Z467YBB0Q$ D!@TH3EV "/VI
M[KV%4$N].LE:G7<C0B'H1#,7J8N<I;P?@L(N_=KOLB*#U?K2,H-X1>'HGT[U
M_>!&7#/]/6DA2(N_S>%6B O@9!BGX+%>>](X.;/^7S\TN3!"^8ZX\1-#= 'Q
M1<N0?C<3OTV*_LN;']'+ Q7YD(4\!;[A.KL^R$F!0Y.3P[IZ#EEMX()FMS?E
MD:6E^O_5'KP?73BZ\,^^H#2!YX82.J"_7O1L_N5%CUB -J4)ONV6RD %5&!^
ME3T9T21TK9%G03-DXYWQ4!PD^R"85=?BV$)P@#YE$,-8!A\GSKU.*DA<1*_L
M>R+0:*7M<RP5FQ)!@VY.K4JW4_<.B\Q&FX&ARGR$S)G<2/IF]'.?A!29[K)M
M/AE>7@Z7/,DAGYB^&/.QZ_H-P_@WYL]'8Y8?XT29KV8A.1V]/!N@$\G?ZY7[
M'1[CU-+I7Y/4PB[.*@SHC1C2)4;I;[^$5S>S#'YZ5K/)'C ,9?#CSM+P=IYS
M$-(5R<BOCW%)+/[A*VSTID$Y[\X>?[T5KHUT0>W <2&Q@7*C/'8\60*]YGQ+
MT:JOD\,!L]\X"DJC404IDK/2[ WD+()Y# UG+;?P[PI:CN1Y3 5@#%8U0\P-
M=EK3P[%D\1UY<L@ITE3_1,5N@2<5P 2?_GR!T#MWIW_O[)G\6M%O]Q.27"9:
M!\T;KMZ'O+OAN=DKDK[PO?6%!BVF.2E(@/G#83.]/,:-@R;& G:C+6I^G[NK
MA91;WA;X:QZ.UI).D^/]N+=X T8M>9)08>:W-?*@PK< ZJ+GHP3TL;$^%Z77
MJA.2[?)6]F^SX_NFQLU:^[6=Y.FC?A<X:0P^P8*N$GDBK-M\+^N\O#INY<"=
MQ"00GJU^ 6O;VH]N:T(5)V+S9YSH2:#"+7A4)D++7^R!8=(GCTU%/958 _.'
M%YFJVACN ES.WB4:4] 6[+BVETY^W-.AE4.C>N@*GXQ"*0G!NT'/55]P%(D<
M$P30/UB*&FS#;&E3 6>\@O02-IN4^>NV:EV*GI4D_+1H3&U/5*-;[=8C*=,8
ME3-!IBGI-23@ZJB3'V3A]D*9D6I*#5&6J4N]O\6S^J.#)L(XSK,.NT3V'EN-
MV&)=PLY.^$[\RE*EIYQIVNJA C3Z%=7G8,LFC/[:>AU-7@TQ+&_OSY%3)AX!
M#>P/4/BG5$#<MRTD.3B+"NA[BAQ>XU6>T"H,[.B8$M6Z+\"B>N(TB\##FVR/
M7@!X@_URMMKPC#1_[8HSU<1EDX1 :*!EC2^RD IXZFVZ?XK;\P ;73=JMZ*O
M<C-;9._;L(>>AGA\EV5X1,X37G4[&C&6IJ@/'8XD\E6D8^P&>52\3R1LJ.^;
M:R+Z1N<K@MQIC M,()787Q03FWKK>J5L,D<AH)\N,".'YLGN6X,TR1Y(,<(X
M4=9+<J[EDPJT-!:C7V&><)C_]D15I ]6,)#3E73]W"WG0%<+#WHVGNOSWT1;
M-7L/#TIXKO*SSHD8Q,\)A$$GYJ9W;)\0UF0Z/4L\\9:#63L[T34U3HD( I_2
MV@PH+%5D!&6_&0VU'2A=#%^#)"DH<"MNW&Q,!U3Q!;D6+<NMBZY "1[2B(D*
M&CMN0JS[ELS3[E[\8\4@/"6"B"6)+J,"X260P/H3#0++MV,G[4NNMI?!\.?-
MY/?0IP'\2\6O/C$M':\3<2_DN+K:YZBW$H ().MD0L\&1:1R5FGL^8,$NJ@
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M9!\[]]*7P;JNJE>3?&=0^1CAQ@/'+<? @&HS($G;@PN\OC^M4N$9J"@?4/T
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M3\+[,)]I!NAAIHA$?YL%+4T0/\!MIU%+N_"M*Q0;?547S-]J!?H;*_E#6*@
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M27U#_HE<A=WXR<;75B4)UY9$Z7T*J0BJVNP)D5]OU[;1>!6]/\VPZFOS_9Y
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M%?3U&8CL=3#^EV^M8QZT(6#P!(508CB(3@>M<QLBP#H+>XP#>)<#<Z9J-(_
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MW]B&V+%K78A*'V(R' [QTR8R9!>0'9N26RS(]+[FA@O>50TZ%M15C)H+K32
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M?!9]WPK=9^_=Z[79TGYF!4Y5D'.JJE?RJ$=>1_&]V/YUH^N9X:#S7GI03N&
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MHC'OMQ/_+KPQSE9BM^$H%1@K2IH-EP9PC!OL4YKDV4U0N<Y&=1!8:#$@'>L
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M%'//]K6IW /YD;GZ&DU0NOL^86IH$T)&<F&[E!YVCRISY>.&(T.1S &8"B6
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MN.5$!TH@2EFN2Z<W$3;:&\0X^&:)/&UP[10UD:;@A6D<O5C5O>EK+VNF%34
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M]W^5:5O%>W#NLKQYW<BC/PFB9-1X+H=;9E<CSLY1&&DZO2EY*+"C=0>>H?&
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MYHZ7O\J+9[<=AB)>K6R"@E2$NYT>F97&ZWY>##0>^LZ1^%+0CG;W^?M[YUB
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MSE;(&<VS<0UEFCD\D7YAZ4,P?:/G%OTSX+6N*EC@[_[ZTK]GZ\YA",)L"FK
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MJ1GP/MG_W?KC:BSIK#I%(N*5J<@SU/@N6B.MVSMN&3>L@HJ;KEWS[RC(=2^
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MN/:_\A;87[]+C='X\^Q9+-UVC'R]C2!7Z3R..+P0WS>D(92;Z"@^DK%_[Z#
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M9X1XT T2G Y< 7&CQL!I=$!P8,!37@-EN_>[U0MWM?RS#S\<C42W8SE0]I!
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MW$[GB%^;[_"JW4J9 Z[C2D;J8^[E'"SF^I!C,]3>>4A=G9J@!+'/<CCA-]1
MI32.MNH$7N6*K[9Y]_YYT94F!1%!U[E-:G85!ZJ6+4G*F<=,=7Q;PK)=\67.
M;+B&S974OM-V]1%/%J,RU66G<47F.-8J)3_6S@I8#JE?&W35=R)>/3BG<'Y%
MZM)A#.\5#F\]@0?/2_:R"GQ</W<[*@/BR-KZ*"EB97,-E_=HVVR@ X_=Z+A)
M?8>R3X008_&5M(_6:=J?%DP?9(%7$F4^(21=A'CN 0_U Y<.&Q ZT3:8-U#K
M+,@+'"OM,"FKGA],\!]X=5Y\%I?KB!Z4OQ"SUB.:X?REJ@%^WK5\54J$A:5'
MB9U\Q^\T*7+"%PKR\FV4LG3D>I%365$L;T2SWI7X,?4E7,E%.GJHI,&*#J!D
M@YY/6\*T5>@ ]F.H<VN;>&Z']:<\)?M)"XYQ7*!SQ?4)935Q,?4\[?6?F@?8
MI)\ M[6.W=QU13#ZB=@SDA-9GW*!5#EQ]0-)O3[*\3+F3<];_5OEH:(2%[^O
M'LL,OS(5&L6J;RZ5JI=B_O%X-T[[E8]8983QIQ"Q4VS;9@T0O"XN4.48(3!K
M?+%2K'YMQ+XDW[C-P]G^8>=Q];/?4]JY<Z]"'RLL(V +92]\=.*\_:6&V;,E
MI=&JAH*T9]@]'FUZVNZFO;(\I;%K$UI!=,#[1Q[-8]G&^++7MRA#N1!$!$5:
M9MJRK:J$D4E003@MW^"5Y8DD+I/3D=>3,YIM!$Y%U)8ZA^ X"IV?5^WN\[/
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MANZT$J/A,1/PZQC\-N,__3Z4C#L4G L78B3&^P"W@3(44=7#1:J[AS4("/(
M'X7]/;#D4E6>J%)W)8O7IERZ%#'U_!;MOO4,0X&HFAJIJ52R/A$7(2^A/&#W
M;8P)\.$OIP5CHA"S68UB#604T;,#)UQ5J6RZ:WBLXDHG7^_DPB1C(8P_3,O'
MN>NV7YNQAP<3H)Y#U[V -ZRJKX24'$IMAZN;UO3O3=J=O)8B9GP_\82CP\O8
MOXJ -X_!C5D>\K;F[1DI>I%JR?TNGX*)B;&SXKN+KTXP 8WYJA0\)'ZB!?@:
M5?UB#10F6(+G.;%UZMS"12:@0[#VR_U=1_'E+R:T+:QQ<H#1BX5:1 LC N9+
MD%C>:"#N&B3]HW.B(J&%]80?KAZ[A]?.\C"XL@IQAN-0HFCNC;[LMKP'3L'3
M'Q//H;NJ."NNTWJ,$#.JKUGN_0X92B^<19TB3\Q<^ID_514UR*HP13DN6[MI
M$$@::.0B"B&KME_6@B+J57UJE[2.#U=.:Y^7KCA,JD!V+-V1[*Q:>S1'+S2*
M-X1R>.X,P\VH8T.6LGJ8 X0$9A$]/CP#$TD"TU.?P*6[^3@P-#U_<D;-^(C0
M(5;$,H9VU'H:0O@'PBMA/FM:DE_GO-?@8FFY9R@5W\'0:BR##V#9YPBH#:!2
MU&;_/UGBY14?OB ;Y RB76E!!@C1'27R>?#+N- .Y)Z@]_F(D4,A>KN_(Q.
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MZ[E=YV2?+909MIRVEHD<:.1N9/G.4!BT8MAV0(G+!F<7/:'T<=CKA30BF#T
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MA%LL5>J:>,018*:V/$N/_&DNOP+<%2H;SG6TIH0U&D]*Z F_PSRV<M%C'P+
M"["V;NC+7REDE6'U0M?R![TCKHLE+$O DJ8-[4;C<+[@Z(R\\IUJ.+"\]N6C
MDW#B8KJ>1>>#.8L/RQIUU@-8 ACW''Z-+)43W(MKKY4A79J(:JM,Z29]E=D5
M$+S9<6 ZUO1H5,)SW5;>8[S@7(/L0"9:J<6K<?NJC*0GI) &W.6\F%,?$?&_
MUJ[S)<9Y=R'X6;+??*9BLY(VY<"XMKKF]5/['<U_/GV3/I*H+SW?*$%_B75&
MQ().P-4O8.=QIQ!.JVPF7VNH^J2H4IS&DXG?MN":)EZ PJ4;.$<T;VG..YM<
M4,H$2#02NV<B(L<U&) %6#(U&/Z#4M/!I:1'Y([T7]F&V16JCSO7[.:^F+8M
MEX;M*)>9?=$SF)L<LT)L+,XI(4&G$*Y88?(-:HN)(\;&KDLI:@MXM^(]-$DC
M>_Z>D*=S$TRI1_^A_(:M;(?(O6M!T>[79BA[>XS:\A\/>I7#.BBC.Z"_597&
M7$D1(P$G,ZA, +MQ2)B?E+%J*V7X=7U"Q_GW:3N&JG8,82 >2S^!/;1F,1G\
M/I5#-]13L_6\LS"]C]:2UF!SN$OE@?]@ OCA9VC>)HBV1F%&U\#Q#!\H";EY
MTJ8Q<+S2*\'*^VE(N_R>:*Q\=]O\<EQZL9GT0#5J-"T]/B.\[R=BHHYTBUQ#
ME,<?Q,(,Y[ <3(#;2@WF2$TM8Z#R=?!]*?.=^D\M2_>NL^7#XU>J=VQ61LX8
MU9V/G5$)Z+SV\"-/FWU.[-=O(]FF+Q(KU;:KJA2A6;!MOP4065:_38E\!WYZ
MG&PZ8E_#N/!M_%SQ@MT='>Q2N^K!T='/C!^HD]BYNS0.0F/4)0>K'!(3X(7=
MI][!:K Q5OX&S?[UE0F( WX1HBDB$B0EB2,5\U-N%-#X".ATO,93__B>N *H
M2CA),S/SLM;Z2NV 9;:XN%O3VJ0O+9&*Y;$XR.>O-B:&T2?Y]U\IY@Q '7X
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M8Q#?T3:2 W:5),\@'K(8="._XU0ZY6K+S,4!F,UC)97PV[B[U: .ML@$@X4
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M^%Q)D7CN?4[XMCX/J%'[9#QV?*6SO4T0#.]$"H6@)=M4(-_>@^\NF(K47$A
M'FER#UM8+'/*Z]ZDQ2=W @!6'N#%+&2Q1I ".'$00H$IY$)5%; WW>#+P@4'
MA2.)MH+ESR5V:''LC'7LU//M'J7]XT;ZFIGO.+EMXC![J0^_3 I<RKV%F+B
MD/98^$%O?S;\R.US\O+42PMOQB&Y#\_/NZ1HZQ-NP(D(U83H(8A@#XS"]9P/
M\T0GW?@WT!18[^C!UIMY<:4&+VVF)=GO<TKHU)$BD5+;\\]TG]E+O]TVOI:
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M;'=9?]\K-6*_V>R.!X>,]TO/K2!H1NWX2_AZA8[U_#2]]MQU8U!X!V[C\,B
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MDV.Q!]\1B$R^7Y_;9101;,0\W[5F$7--+?[I5IF@A>6 WJ<2$H0;0:]Y0,@
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M-H2'4'$7:!)6\F6F\G;O*M=QN!NR4>'YW]VJXCM>G"2:9NH'%8"Y_OU:\))
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M)3%U>"1+[7PP-W>^)5KT!5]+&0#WJ*89/432&W;"OT0X.1^GW-.WZASKBTH
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MG&#CP3Y7>M#9A?M??0U_EVZ\)H8LR)/5NS3,]!FBR'O4D6Z<M&W%V9E\-<[
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M7U-849JBAM&#.4;B&ZW.$":".S!\P)&/!4YU5$Q"T+WOLR*]0933:#DBGE@
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MZJ,760197)W.Z3,WMG]Y8NE"];&!S"XY2>$$IY<G8:K(;H8AAP3RTEA/VD$
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M[_ K4'2A-I=U*Y&*)GGF%OR5714#:H:7>G./U,%\X:EXZC]P0-4IEXS=C[S
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M7ZHT?#)*3.TA:</(/.U<;]J<]Z?WU)CTKO;9ZNKJ">W7$[5K-A4;&V078JQ
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M1TX@&/!HL*-T*NJ5KV]#XGA1S$KM,S:Y 74:X]1-8$#<3EB&WA4Q&^)@%VU
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M,=>PH@0MFIMTX<_,19PH&/QA>=_L_+#%M3L/#2>E$J,V^6S8W28: @L31I
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M]Q@)LL[C6';C/<+9YAPTE,XVX02S(QO_W#@#KJH-NA 4$+YAPMCB3\9U5^4
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M:_+Y'+\L !+S=URH,O+=YR)W=RQ;%I!U);_"!%&'>CDG^,]KS06 !#C3R18
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M&7OTUS(_Y[--$6E$XW$&6-\%JR.\]R4MY;[&@^:JO#7@D;JQ>=QV1S38C07
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M8=\()HN\:X"SG_F@VZ81A4D+#-&/#FW.,'6BS__1K=/J6OWQ*=;MN$Y")XS
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M0]<5B#63/]F/FQ-\5M:CO C8-ZNC\]\EMOQ)8)_@=1<9#D-A^#5:@FQ F-B
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M65S>.Y:BT-NAEB!D7*W9C;"Z@E^JM?T#]H6NUW:.YK'E[^7JH$Z=C\-H0(@
M062=49;)01HR%0'8(,;WR1<:=6/X\%815TM"/)+W'YK+.??:ZT1YU,3V.611
M/*8[<SLLYO'FMU&NM=AD4@.J;@.VC<E-X>VV8J*[BX0''ZS3+1N>XTAL^7:R
ME'. ?4WOC=S1*[V1;X=-[H=10\5D[W9K9(ZV(4!-4B(2'6Z;!:KU,;R %QQ=
MD'*YY&7UE%!PRW$#+_'.IBAW>$$91D;G1Y3T!](U1\\V:F-..*,,48@!+NAF
MT3&)Q(9U1CN0-YUM ^]P:W$LLWW6'4-"8;7.C&S_UF[R6C]/JJ_%_\"=7=9*
M0R3 JU*\$P%-W33E:]8[XG8IFQ:?T@\E%VYD?7WM7S?H.QK0F.UNN*)LK;.L
M<&O^5K/B<71X1.]52^!S6A3=7G1^9$3N.BE4M9?[^\>"A.&7KJ>35M>5]FG&
MVO[3]$:&]PD-N*!3T8 #=3>8Y07QJ>N\][D$;3!@JM#72\T^E2)&4+*92A,)
M7#E0:CX81AO$+H7OYC>;.7D;V1N7N#WT$?26%3"23DJET+)(M3M2@'"MYP9O
M3/CT6ER.Y_N_LO'-YL+VU"\8O#E;\DPELFHO%*:<3.QI;XF\G1E LQWPY+9\
MK[PK4R0OV2\^MG^R,'#I$@+1$39;'TY,R*O7X)OO&\.RZIE6C.U,=3JR#:-
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M0X(8L=5\ W81\Y7*$V! H48&/ C4T+$I!M&8L57Z[X9$E#A8Y3X40&G^<M%
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MG+-GC)EC"YIN'YP_P.OV^/A19XM.4YAD):-;L<%Q?)K[PH%_M G-V0,', Z
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MVWI]]E+?N2_\"W67,)*;[8[C*-NAI)IO"IEEXBI)24&IAZZ&*(KTE^PM>_M
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M__H_OS^MP%>1%\ML_6\_^'_T?@!BS3*^7#_\VP^_?7D/\0__\]__Z9_^]?^
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M"&Q?NY-%NQHHUPUL-7G\NOJ1RK1XNXN%: BE#5I#/H^I3V D(@11'.AJ'9A
M[O%$BC"*0W]04<F>/N?&%N>"1H95F.P#V]1-XA3"T3TH'?0Z\K96PHBU* T
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M&J50?>0^3"*"J$<3A)E5:4EK">9FB*JO-W88.W42=)L3RY&@G.@8L\\!5F:
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M?)E %' ,J8P8)"(1P@NQ$,3HPKU1;W.;E%6J8+!JQ;,X^[F(J\&AF4NTQI[
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M)"5Q1'&4LM#.U76FI[GQ7>.\T=+"OVEQ02MO?;O"^M+].81-W5T.<)O&WS4
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M>*5:\H.@.E]A?EAS]JE9JIVAR)])7KYH[U-U%J=3L:1^0&"2H  B'!-(TD#
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MQVG,612:G]B<ZV9VI+ 5%&PEM3F!.0NGR7F+"Y#&YH$3^ Q*37H6*)M,>2X
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MWLA4L\FFM -0BSQ16B4SF-QF5^KI\R.2+)G!<";7DN'+ T^H^&.;=J.LML'
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M,-FVCG=3E@G[_3]US/S;<>[_+$B8B 6%22JW9D@P'V:J F_F1Z%/..&9;W3
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M.4DYCBF,19)"1#B!&0LY9$)$J9>@A"-JXS(ZW<W<C,.=E$TYG,&%TL^@:D9
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M2 )5\=2&64[V,C<VT4*!7_("K&NF@@! K63]FQV=G ;4C$(NAFEDVMAZ5Z2
M0$MX!;2,[GBB$P)'W'"ZCTGYH%/-8P[H?GA@(AI*R[7VW]Z7RUQY<+?+'<E"
M$?AI!/W45W',*KM\&@>0$>2E+,L8L;M#>KZKN3' 3E*P$75P#JL.@,W(P UL
M8V]*AB%FG]VF%PQ7F6[.=S1MUIM>A=]EP.E_8V#:.ZR+R:F(H^_R4[@3#Q66
MNTVZ5ZLW#$,6>DA21H)BB-)0P"S,*$SE%B7U:"28L,ICU=_EW*A#2:S+7RJ9
MKX"26OUU3^Z!19(-T#?C$[>8CLPK!W".4"+9' Q7&?'Z.YPV+YXQ .^RXYF_
M.>#PYT?^^+2Z$[_+#8ZZ'WM'FM.EV^+S7_1)?B'\2UDU5R/X=<'.)8O!DH(0
M0AA*2R9N[C1@C\70$V$LHB"(@DP8GQ4Y$6EN?/7U,&N/#M:HE*)JUJWE/^$F
M55W%:?E8Y/]M52;&S2 :G%1-/C0CTY[6!Y8"2HV:F_E@HY-*";31"HBR:B]Z
M<3UR]KF"QAHTB].SR0=OHL.VZ0;1[JS.*=Z=1WMN>IKN)- I,@<'AVY;MC]G
M_%Q5ZE3BNL#+MSJOK8\8S[T_M^5,RED6O%S7AX=A&[G-3Q// M9_D.@"J[$=
M>-TPC7!FV ?*H./"LXU.=E+8I];^(6'OLX[R/&WX0N[\58&:($W4*6 ,@S1(
M(!(H@"D)$ RSB'/.HBBAD4TZ@I[^K!AAHAP$;)/H:(7_VABTORQW8ENZ]OL0
M-]N'.\1Q9+8XF2?*:2T@0RS&2A=UU-O'YHTZK7IO JDSKPUT];7'"RHOW6Y]
MN*XJ9:HHT_G7M]TC]_A-_4KGZKW3=UOJSW_QBN8UKV^+>U[E)7M0,_VV6%5Y
M4>?T'WBYYHLH(S10=T]$&%*(J)="' E5O595)POCF*5&F_,IA9Z;O7/]^%CQ
M1W5]--_("5Z5H-O+H:!LM--;B^8W^.5%;N?S9LW7F_T:\%9YP^W]I!^*H5]S
M9L,_MF=4Z0*U,D=&W$YCE1%F_[E6:Z#5O@*MXE=@J[K:ES;*7X&MYD"K[M#G
M.N% N?+:3B'RM'[?"0?AG>=XRKX'^)[UKOOV^07GE>KZ1LKRR-LS%A&+F&+J
M091PN6CAQ)>+5AS#!(>!'X=>PB.C?/!]'<UMH6E<43M902.LY6%6+[P&OEY'
MH(U,SQ/A9>%F=83;1,[3P?C9^4(-0.GT<':]/YW?TD"+ V^DR?,#-P[TB;.U
M.AC\P57A=KJ2)(_K)W5-5/Y/E2Z5YJFZ.+KSJ&$11H'',H@EO(I2!<0T(C .
M0BQP*&C($JM]@+T,<V/;C0K*BO_!U2<@MW:->=?6A[MJ<O_M*:,-_)W&^M\M
MC?D!@V=HFX\[)&.?QK4RZVV4' *-O+[5?CP$?SRHS.U@E#OM%V#HR@H>(,&T
M1NUPB-[9J!<T-2@CVU+^7%:-);RI5OK[B]2Q6&U,X&<5U[5@<1A%5(0P8D)
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M&54LX3;RHHT XNA.M*W,0 L-6JFOP$YNZVOEEMA:%U%PC/%D3C0#K)U62;#
MR:!F@DEK4U=0L-#P1#T%F[?MR)SQ?/&I_:STE5.]3OS0!3(689QR'/$(AE&,
M(")$[M(IQ2I-:.C)G3I)A-$NO:N3N1'U1DZP$Q0TDII12B>@W>3L"J:1J7@
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MXRC.J)_!+,R0NE5"81JB&*8\DUO"  D?4>-;)6<ZF=N\__F?@&SE5(OCWZ^
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M+#U@#KS98N<6QXDR'^X'ZNU)?05:N<VBD*P7"&NL''&X>;^3TJPU',=,:-_
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M(H0X(G)K@%  B?)UAB1.69SP0/ZK;666\]W-;6':5B#9U<K;F:Q:?K!3H*_
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M&?0SD::)3Q 35F5(3G<SMYF_2]!5;7>Z:R6H'0.<P=2, 2Y':NPSABU(.W?
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MMOR!AV8MWU=KJ?\$'[MKV2F+6#^B%_?@E_MO:!$Q7VYTA,/=BR@JP> Q+F[
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MEAUK862U9#S,PP1E%&)!B=+D=$!Q(A&,22R3!+,T%T9W"$.NU8AZ7F.JVY\
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M[H"-X?3U !CE*%$(A5 $$8>(9S&D+,AA0J.4XD0$>6SIW7*&;!QGE@9M7O<
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M+F"-UV>KI>X&4/$T7RZUP4_)0K>A=T0Q2M(\E!1!RC-E=9$@AS@.*.2I3+.
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M@.R2_4=G86JBJB4;@H9PT%(.*M)'JJ+E_DD8"L1)+_30XO;ZREK;VED=(&Y
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M0YR)%$9AE+ H0CC405_F"30^4!TA>:9*9JK+VPR'K:$&=SUB0ZMO%4P=$F]
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M*6$8$Z*4&\XACK(89C2(,AGSE%%L8\683CPU,=#279>A;"BWLVR,,3>S=X9
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MJ_YHSTSC%B.]S/)195*#5WS&I^DX\OERHP124\E"][C") ]H(A(HJ- !V3*
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M?91E><9BW2R((8B"(($4!1PF!,<)YBG&U*BVP(5YIB8$:DKA;Z"E%53$6I@
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M]_P 4^FXO%/3162>$8(QDP@F@L00)>JDA-7I""8R#$1&PSR)J$D]SNM36%'
M"'4WG91FZT#4P$:Z&2?/%%"7 SRX7[RWN;?MP,;"(KH9HY&,(6NL[*RA3A@Z
M#:'+;XYG W5*?F3^=#\Y-#SFY46']J[8'W\GBZV88QGB+,JJRBFZ!*4.S8@Y
M@5&6BS0E<9XDUJ$9QU-,[XJMEA"46L09^/^"OP0A>"5K\%6+.P-I$,R"^O]K
M6Z@$9+OYLEKK&$1 -N"M8)45^N__*TR#_XS#F;[EB*NL;?6'Z#^K/X4HF"5!
M.@ORN!VE*,MM4Y8CC'/UM\DLRW9SK Z:)'1/@M,95B,G";HPLOK+0 V>1['-
MP)%M[,G)S\C,S+OEI^&9VYO?Q.?Z-_'W^I?PH8+59>S(9?V=!8F<##]R-,AE
MY<[#/JX\-]S5_6&I[,#JJ_9)</%2=7YX7!=,-,6MR;,BNI2$N6([B$--=#A"
M$(LP@RG/U-\D A%A[?LVF'=J)[V]H.!52SK31[Y&5GMWN GPYOYQQW".X3#?
MBZS3N7;0/M;0/O9#.\B';@&40Z>ZR:RC>]DMH+CD=K=Y?1@_O2?%NN*YNJ;'
MK\JHVZX%?UA^7"W70I^WU'?Y#2F+<E\0DC.2)315IT_=3!(E.(=$62/J7W$D
M.<$9#E,;KAH@P]1XZ[!SJU:G_D2#_RK$6BW)%\M.N$,6Q8S'/$/MF=,.D&TD
MUUNCK")I=])[;9-[ WZ.J&Z(!*/2W@T0G5+@+4,-];5]*IZ_;![D;V4]Z3S)
M!2&(!9"&$=8%VS*(DYC"B%*"L#J=(I19Q'Y>FF-Z1]!*0,UE6UWN2\LX TMA
M[4DZQ3+/.>8!"6$J> Y1KCX<-$,1S DB+,FDQ#BV<UO>@.1X7LOE:@E;S^6G
MA]^L"M==!]/48WD#1&,X+)5AJ@6$#Q(J$>N*<K="8^NPO &B,?V55E -<%A>
M@:'?7WGZXLCNRBMRGWLKKSTXL!O1^IDLBW]6*W^_6I:K1<'K&J1+_J@;C3>_
MB@?YOEB2)2O(XK/Z+[7-LKN!C-1G)$JP@#B+U?<ES4.8<T&AP!*'<2I1@JPR
M_9Q(-37S^E IG1]_H%;E53Q4K#+!6]7 7K?!@75NUMG,/A]]]3Q3_%@+9]]9
MR"70KOH0.9%IW*Y%+F$\ZW'D=/"A-<8V17W,U/'/GU^U&.M?FA+333.>E#+*
M11; ,$OU$2%$$$>"P(PSG")*LCQ*[ J']<XY-8+>BUS5, &-T*"5>F S)!/T
MS8C5,::>:?-V. ?4TS(&R%F1K/X91ZY\90S!>3DK\U<'7HW7G1)T:=][LEY_
MEW6K\"9H-8FB.!+J*"T#(2 B*8)49 (&1 1,1@'GQ,HEVSG;U,BG$19H:<&A
MN):WQIT(&UXAN\+-]WWR-<@\%#HVPL35'7/G7.->.)NH?7;[;/22T^ZY^U(&
M.^/IP*!Z7)5%78IOHRLITX5ZL=S,>2#B*!819"A0)D\<44ATF X).0[21-D]
MV,KD<2C;U-CI>I_4PPH@L_V!Y_@<U"H)?M^K";2>MJ=8AZMO>);],6OJ^T3K
M83G?+;<O38MLET=<]_C[;;@[2+(I-.F]!5+#QKXW33&X*FI5"^J)?*OOW_:B
MG7R>RDHF=2K7%N]B'O,H2&6>PPQC!!'+"*0\1C 5)(]%&,0B3>R"-H>*,KV;
MM?="+8#B >W\*K6H^EX-K':D4J6YL,$V[. U,Z/T,=;!,W_O*IPI'9K^13-P
M0.JG!G'94'FU8I4R3DNSW@2GNVJMP\08NX#K36!=J.EZVW@#(@SJ?A'E_1>R
M?A;\3K=*+C>/ZQ7?LCI_<([B((TCA*#@F81(J(,\ECK@'>%,4A%@8EJ+T&S"
MZ3'DKG!>%>\.EBO%B<MGW>_M*RD6.K3'XGJX'W F>8A8)"#)"($H%#'$-,\@
MCSE-&*%Q@I%QPKE3N$<IQ%L+#%@M,2"UR."UEAF4EEGH_7@;A"TX1='SYZ0%
ML!$6--*"1ESK-/Y^ "V"&YP".5*DPVV VD4]&./3&0+1/\IX\1#&&AT%1YB_
M==M)HN["I3ZX33_!-V(I9+'1C%\LM[K%PVMS#-[?FV<T3R(B*8P$HA AE,(\
M#=4_1(1I2G(1<ZOXB!MDF1IYMZI8)L/?LAIVQP3/&(]U4FC:*NH#0]L"]:=&
ME9^KH(9&&[!7QU-]HIMA=7QB&"+)#SDTW #9M7/#+4,.S-6HW#VB<@P]KHLE
M*U[)HNFQ7L[C*,5I'".8Y('.RJ ,XHS$,.(\Y#CA69J(MK/TDT5R1M>D1KOU
MN(OTTPC$V,C<E EX;82US,'H!AL%/ M2"0G-=21SG$&L*]?E4D>%9YA$U.JK
M=#O*(WYW&K>C(CQ&RB] +E9_ECI2G.MFT?(0>Z>8FWU[G"'I^>O2_D:;6X2=
MJ."Q[^=JG[1B HFK])3.N<9-1#%1^RSEQ.BEP1VO*SO[TZ[!_4>QF:<X3"F1
M 8P(U@' F$":Z] -+'B<!@('TBKS]^(L4Z.05DBPWDEIW:_Z I9F%'$S0KY]
M"BTX>P%G@$BU+N!NH<BVX@VY6H-[9884F\IG[;0O]75TW/6@OC#'V/VFKZMY
MH;=TQ\.#^GU]6/+B:\&W9&'?Y^OLW<EM[\4"' AIU=;K')CN7>T"$]\;^A@.
M]]V[KBH_M&O7^8!C=NNZJLY)EZ[KSPVXFWDB?PA.[M9KM7+5_7KSZPL3'DLF
M8WTCHZ.[@Q3B% 60)CP*>"(P#:GQ!<&52::V?VLQP8&<%B[L:T :>/X=P.-Y
M*Y\C,Z3\[#6(+'S[#J :R:-O\6.R<]_W0-#IM+_V[GBN^A[ICQST?<_>[D\Z
M28VT" :,<4(D%P*&D4Z0CP,!*8MCB&3**<4L$LBJ+;(3J:9&J">G_3J/=W60
MQ^LA8-#CFMN[8D99R7%=-J,LXDW.GIM!]^ 4&B[3#W,>W0QCEY/I]L$'9@-L
MOHCUQ]5R%WI8WV<TEQES)"E'G.4P1C2"B(48YCCG4*1,Q 331'(CJ]=LNJG1
M=24M*.I[OY]$+>3/E@'WW0";4:@[V#QS8XW8H:3MM>E/[_K@LX]L-T+%5;!Z
M]V3CQI\;*7X64F[VEAV/<%',WRTWQ>;[^V(AUDV?[.]SCI,PD;&$28Z$,@)Q
M##'"&<P3R>*()!G)C+JM71E_:DQ1BP@J&=L&[8;5WJXAV,T,#G#Q3 5VD!AO
M_A[%.SQ=ZLUZHZL_[/?WM?%&V= ]RK0[N.\Q>\^SHH%'L?HH5G=?GZOJ5/>K
ME]>[EXVI]_G:^U/;ETI.^/CN 7Q4_W_W5?'>LP!U-2XML.*].H^^CGPS]T]?
MA:_?1^T".<\[UPUH5L[K/E0&.;"O#CJ:$[M/K4-'=N^SPPS\W4FB*H<YCYE$
M1&8Q#,(D@PB1!.:Q5/8]2X(T3O,0$2N#_GCXJ6W__3F\K@9JZ24YP<[,5A^.
MB.=M;0Z&M25^66='EO?)X*-:VI<5.[6LKSQE;TDW[3/>%R4CB_\GR/K=DK]5
M8\\900D32:KL9X(@BD6HMFT@8<I#$4J:I0P;18=T33*US=O("6I!@984*%&!
MEM7<M+X*:;]][0(HSWMZ$$96MG8?"(,,[JN#CF9U]ZEU:'KW/COTR[QB?WP2
MK^JW\*4*,UL]K\G+W:Z)2VU?A?-$?: SH39[1C'3==89)!F/U<<[)(3$*>>!
MY2?;:-ZIT<'=07<;"W/=%FW3C[QS#+U__97$8"\R:&2>@0-@79GT V%R9C"8
MS3JR)6$%Q;F)8??Z0$IJ^A<\R'=2"K8IOHI=?L,GQ7B?A-:V6!35";"R=O:M
M!Q *9!++$*(HCR BC, <(P)I%D8Y8RAB,K:K]W"+.#9;;YR,YL/F$#J)2&L
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M0<X<<>-+<$.ZQ.?MDJ^_MS6Y"U$V%\1SC$4:TPS!($$91"*,84Y8 H,\YU%
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M)G,7IRA-$Y)!'F98&4A! &DF$8Q80"*<Q8RGS-@#>S[^U,A/2;A/[;=P'UY
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M)98/LFV<V"8I&+8BO3["U.BF[<Q1M=PLJV*+YPX?\R:E'=#U^\7<H.:9/(P
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MY09DN5Z$R5ERZ_'H(^>T7E3M/)7U\F,#"Y25I=AT%N^+>,*01 C&$>80\91
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M&QV#*4>^TC$'X?Q.Q^+=@?X=]D7P[4+HGHQT4]F43^+;YHV:XX]YG))0II3
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MW,26[E1DN\.5G!18IDHS2CE79I&%)G#^6U,!=I^G=X,"L^H*3--8Y%![Y"I
M,$@F2Y(4!)>*&<R5+K'(7"^7.D]G0HWA=EF1'R$<<>I^A^U8Y(>E?H$<AZ4S
ML"AWX%&''O7PD<-_93.UZ__K\R?(5F'>0Z;#1B"26 ,BL9)>P^F;5&W L/&T
M&[[F@8+_8QA8,^CJ1;C=J7J9B20GRF!5).V.3>89%IR5..-$2$6UL-SK$-_H
M3+>FS2-7/X/N+ABG=UGC9Q720J=\&%_>#9]9+E;J]HS/$[75,[O<OWV>^0?&
M4L1EC![;;]O-Z9?V0ZM/N]W\ %!+ P04    " #8.UQ8(NL\LO_J  !#NPH
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M^I._*O?1UW< &@]?@,C1=>\"-Q&)!?3H7/8@18B:YMJY(MLI:09,!^GYD7>
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M>/GU]>5BB5'%_!:WTEB,(((DR9>&8(XJXI10!"!8X[Q)7M0>(KDK;<,8F2-
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MH$Y?BD=)JF2L[JS0-='O+D>WC-,"'H4SZ%M3E@*1,>&YQ0TE+G-JG8V<0NU
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MMT0RR8GU41,3F$O2YHRB[R^1X,7T#AN6] _6GC78F&F]OLY"-E=75N@R/^'
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M.08WRY%0&/T$%PFCP(E,4I%@G2(9]V'R+!I9?<Q/3?J;O\BJ ^;!5-X W,\
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M6&G=PF^W*8V2)EBE09.@JCV'Y/#+ *S(F&V*-<!Q$@#VT,.ZE<X'0>D !70
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M/$1C'8#O8A[@C0=9SP*+N;[%:D.'?!$((2<.+,OB/%D@Z%J_H-^F8>*F?=W
M["C==("MQU^W"FT(;XT"$V3MJL D(/H"W.K$@HPBY-9'VQY/D@?5D:PRKO.K
M?/'O-XO'^9<F.XU1$_\:R9IR"9PEW3IA..$D&EJB?6G)/B0.VX<_?[Q@3,WN
MOTW]Q39=Y$^UH=7'5NW)JC&U?OD95Y]R>O&)G-3U9E=5N"U&GEDZ>_SVU039
MME]DKFFJ$@PYH<Z56.AF&^2H/;G4,-C]O,&!$11R\&7P+:_"LOGCZ-MR,2TD
MO\1%FJ<ZO_1J!O?ET)JW7[=1N)Q#RFAJ)GTB@]Y7V7E5ZN@:YG22/MT^)8>\
MFPXG8!@8?]X7_9,I;^HWJSO#DGY@^F5]J*LY#+.$6A>68\V0)1L,10!?=&W'
M*USPW$AMATWQ&+C@, #^Y(_Z8RBG6\#MMM>6M9D.BG%$"45Z"XH+LB5B(+L_
M6A6U0<Q\V/OHH.6&@>TG?ZIOKYBIH?;$^3U+P6&V+(+*JK8X8PZ<JDE8J5;A
M!LNS&#;!\8F%AL'K)W]Z;ZF,#IS\76#K-4G[/J_HU[_BV7F=<O)B3>RNR6$A
M$13-BN2E0);D]2LA/029%'CM<I19:=Z\_<L!9 Y#Z\__^#ZVAJ<^'=^09X5G
M9U5X%^X6[<J/G_/+Y9>ON/@^BX5S[WD!QXNOT01!9[PG/RO)$#F2N^6'C2E]
M?)UAN<(_[]MZ:U5T<#0^^DKT\GQ5]3++SF54.@ +@9.LA*UVA %)_RM)D#,?
M6T<@A] U#(X__QM\<QU.^A0SB*LJWQUC#M%I;PR87/OM*Z' R3I[QN@8!=DC
M3+;NOS60M&'X_/EK*\;09!\0W3'S/I?S1;J[Y4HNLO9**+'Z]T$PP)2J"$U,
MD@?E;X\..QZ9CU(T#) _?["DH=ZF-@SOVUO7R7H?EZ_R&4ES]3&O2&:B.FV2
M#OWHZYN\RF2;:!G V()%)9^='C;+;I]5AX'N)P^5C*:FJ?'W+J\BB>MMN<H:
MO8@*U:SF=SA/,Z]-SEXYVD)<U'1F"_55"IC)AAG!9,K#@B-/K30,9S]Y%*2I
M.J;&UJ]K4L"_7N6OR_6\YIB<;8/)RVUH\7\NS](LBR124*(F>Y*8DHT0$B)$
MPY$EB4:S8=AZ:J5AV/K) QQ-U3$UMIYX,+H>]55SBZ7$3 *R3('RQ) ++!%_
MY,H'VC(Z#$LJ&+SD,+3]Y!&.<134^XO+50E&7'Y:S/\[TZ9"0I''0(ZZJGV/
MN -GB@#MBR#/77 QK,]8*_?V#H7#T/KS!DQ.H-?I#\MUIM4_DTA?$2-GRZ^W
MAB!>\OYQN:L9>KU<;9/=U[OY\3,GO1>Q=F9*(=;V-1J\R!IX1"E\X4X,?*$^
MGI9A@/UY8R93J/09(WB;X3RS(>A"P@3N0JE3/1D$KS/0Q8.BH,4R,/Q\+"7#
M^F/\Y#&8DZKS&6.7?O'I(B__C^6;!=&3UYOZQO#;DM0QRR&G;3>QQ%VNJ6^U
MV;B@*X@I&:R523 ^^IG\&(7#L/[S!GCZ47\'=O/.A%K/?#3%8C @="++26E%
M>Y=%,-S8.DJ1A= ZX'.Y]C! _OP1G8-TT0Q#_]__N"-^8NN?VS_:_DG]6^]S
M^7_JO_]\_^:'[R^6WY"VU?\;EU\NOGXYB^$J0?C-8EOU7G_S*F]P?K:>W=H'
MZ_F7KV=/OBP-^_#_N";[-D.[[]^!4 L6\E^;[=SQF^L?(K;+3I?+\B+&;3G
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ME"?XJ?74W_)JGM>SP!,R% ;0U2'Q+EMPEBP\+H,S 2W9*,,*[@8OV<F;[''
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MG4G&&)G\07#Y<9UI?*K3X>0(J?8&D%=D*%Z,K9XE$;6M54P.BZUC_&K7\"R
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MN)L+@Y_R+QE7\\6GU_._:NN.BX9:=7+,S*>HT4@&0E?)(?G7J#C=!EEBIGO
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MUBY(=0:QE1)0!@U8>V-&%P2:UHW3#BRY/6FMR3&7T9%2[@XG-VJXJF>H:=M
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MUP\MN[3]YYLYML4[(._YW>%Z(A\C@#:Z)"?-*5:1H^1XQF8&O^8,"6>C#UR
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MC33DKH[(,QL0U](BL/WYXIHS*HQ7P>&S,0)#M'=K[P3_6UF"(?'\HAV!^_G
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MAB$#NRU"R,& D\$QU-Y)=IB>GX7. 4)O #R;C/-J0T$\,9[&L,DS;\RIY,'
M*>\1,WDREA0).:PIPDXPK;!5./4:4K__E<5.FEH#TR&:?]BLL*0:&H#5?1XR
M6[=MYC_<//U@6 MP$PU2T47$L>,@K."0T(P;&J@,K/13]%Z$5:["&?3,*Z^9
M=N!V]VILY1&NYR.]FDZ7=G+OWNQSG%W?&&]2*Z.8N"3):40$!Z$R[) )1J
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M)'@!2KO>$LEAX6Q(B.N8K[^%1-9JBX IK;4AAL725UM/T5.WY=30MJF8)AI
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M@^A^1_#S@JE^$&>J2N1L[Z]4K:QT7Q=I"_NMJ.3;>'&T]WIOJ6HUI <JY9X
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MSW>JW9T6TG ?(3:H]C_&W60EYD_I/[O+^+I;3A>SJP_VSR%T_^3'ZMW&ED1
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M\Q/R&]ZB;WZ0?W%V'O_O_^O_ %!+ P04    " #8.UQ8=T[DA5>$  #S3@4
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MTW.5@L13!888L67;'^)'U29)701.6,,]\[CD8D8L0,0:1QW5]&5DWF(%#[G
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MJ,\I%;V &&NK-2&W%DN@ZS]U+"@*8%D@E7.!)I)WJJ[(M'A]I8$036$I5MG
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M(WS BLHORBIO6GVM+W' 1.P1 O"CV4-?(/9?Z97TG9K1KCY0,IF0Y!)1O+7
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MIPF_-\*K-<*S)P F=ZS^R4YYV@VKAL.2_$M--1^IHIWL<X^><KM2W-.-4YX
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M@O-@\B,NF;&=.B^U+^G$1S?!_?2@)[>_+QYTY4Y;&IT+A%OTNBSP.Z9E'!K
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M-_T?>*D@JE<\?PQ7C9^^5$7U$4@1WC/&EQIH<@.O\LU%4L2\\<$/.M-@IR9
M#/LUMD!S/F.IK4H#_YMNFMIR$K1.ERSP0 P\,/HN4QQT%KA?,W?PE(=&M3;R
MX-P$V(&S1.TN[JH =JX">'17!; /OFDH'(D>93V2[<F3)T\(=IX1K]MRN]N2
M]:(3@6EYEB';5>UHIW6<>Y:<0>AP1B'-+5M:=2&\QUTD*>-X4]>EA7[O\'HP
M&:MAG#J(7.(O]X8+AN/\/;Y]?#/S/ICSKE(&_"NPEU]P5TJ%B!?P*D&L%U0S
M?HW2+>&<R=\3>Y@LR_;N.E-+S&=AT)I=$C9I<H3$<'HZ;>2L.>F==I&'A^*
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MPJTLJNHA1Q8];!X\:W+CG?#BONL\FPSZ30*(DC9N8Z8,U2"5O2*DT>"CN>E
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M<QMM=T\;(XH<1+DU4/[(+>&=T-^73OV4BEPJ9R @6]8IYOP+K(=H8:NKL9J
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M$FKWW^\X^D-$\Z-7FZA]H?GU3U[0_-R##]Y@NE$RO-((T4=;W"]M_&AP[-N
MG&(8#.-#MH?G4&L.FV:%FQ1W$T6=@3DT4*2QT[ =(M%V^&&<E%%=EM8GR/0R
MA^TTV;6E*F*V"_M/D"RK)'YCMY<SR@LT&?*,<33T>_;QL9&CNL*LE[.2D>Q
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MW#6/>.]KR2..R)T]29DA\1L&W"<_+)N;[O-V!85:HVH!%A!%X^@.9I;0'S
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MD13Z,@$9(WA=S% 9K]ANO+,V'CM'[=SM.OW*-E<95% D?CM2[E)+:(Z^A;4
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ME&Z6X"HOWC$<>YJJ.=7V7\H,3,*KC[BR-$KA'",4^-5FG8,3M[[@/ZTM6"9
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M.5\6M8%<>I-?8>3Z,0B<'_)-6E;@E;#RIBM_R/$3X.2S(#@^/7GR!'QVN'1
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M1)* O))9'DNWRD6S[*7WYI'H'\HCL2_'PY$\0HN-<QE'JYGGT^F%6N["S=Y
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M8!8P"]!3#SV02Z68!98'\%"%L6\0>L L8!:@IQYZ()=*,0LL#^"A"F/?(/2
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M%:6@ \040^QDY7?IELK2G+-*)(.'G9CM=F+6#YS"V9H+Z:;]6J:;OOLY(4I
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ME(2"MQU\2MM=38O/I]"9DG]&R=A_]W]02P,$%     @ V#M<6)9_&Q\E(
MD+P  !@   !N=F%X+3(P,C,Q,C,Q>&5X,3 R."YH=&WM/6MW&LF5W_=7U,[L
MCJ4<1(3>DB=S#I:PK<0&1Y+'F4]["KH0-6ZZ23\DDU^_]U%57=TT"#M",([&
MB2U!=SUNW?>K?AYEX_"7GT=*!K_\U\__O;,C+N)!/E91)@:)DID*1)[JZ%9\
M"E3Z6>SLF*?.X\DTT;>C3.SM[AV(3W'R6=])_C[36:A^L>/\_&?^_><_TR0_
M]^-@^LO/@;X3.OC+#[I_..@/AR='PX.C_L%Q__2D)4_V]W:'P?#X:/?H9/!_
MK1_@57B<WTFS::C^\L-81SLCA?.?'>]-LI?W.LA&9ZW=W?_]H?1<IKYD.S+4
MM]$9K1:^'<91!JM(8%3^<6;PQWS)?CV(PS@Y^W&7_GN)W^P,Y5B'T[,7-WJL
M4M%5]^(J'LOH12.54;J3JD0/^<%4_TN=M5JP3?KUWNP;Q@EUI"P<>/.=+R/=
MUYEH[3;W3LJ+7;3D 1R42M:TYO->]_KCNYO+[AO1[EZ(]L6OE]>]J]]$^\U5
MI_.^T[U9!NBE'2Q]5+_G:::'TY5O_*!VXS_]V#K:?;G\WS<CG8H'H26V,GSN
MIQ_W#UZV;Q.ED KIMVT!GQ.<@*QUE,5"#8=JD F9BG@HNO&=&O=5(EK'#23K
M_8;H3X6, M%7V;U2$3XA[^27AKB,!LV&D.)"A?)>)DH,XF02)S+3<21&\@XY
MALY2,4ET-- 3&<+X0SU00F8"D$#\/8?/E>@E@Y%, H"E#,0;J;.12M)^GMR*
M]Q>P@I/C$[%%*S<3T\\B3@0\R!L\C\<3&4UY>PU:[%_C423:3?%6)0D<420N
M+R_Q&]@Q(($.<E@-C]KYH@9YIN\4O][\_C!FWM_?WT[MCFK6"J@,?U:XUD]O
M.U>=]G5#.(1"0DM4IA,DA&$2CP62I!I/PGA*PO4><)VPV" PDB 23#'"KT@N
M'Q*5Z@!>:(CSD59#\4[= OKVB)@20O=S0WE*7"L0V9E,I@:]KW !/O4SM>/@
M3/ 7:L $?\+TCIS#T%7'/7H!0_/[/_UX>/KO8\[*3^/):6'C=E2#CR,X<8G"
M(!# ]B7S?."),KC3*3+4N(2->CQ6@8:3#Z=B&(=A?(^(C#CL(Q6@ Z+@UP/P
M<>3SYL*]1-A H\4Y@!8-X$-PDQQF*4SRVHEJD:HL([X1)X9)P)-CHE@WT(L4
M1&Z4YB$]B7.8DYP"WPE)#J<C/:GA,_ HL(Y,ZDC$*&_%6&8P?FK>@]%@1;B@
M+ '0:9+HB#(%KB1QJ+Y!5GZGA][M?6J(&SSYU[VK3@-.E$X&N+91A^#8\  F
M0#4Z52F= 'XPSC-410:@=44RRO@+:;$@%7 VB@?#PU(!H]5$)IE6_"T>"SZ/
MM,Q4F@)1GGP#1UM\-A,9!( 8.Z$:9F>G $7[ 5DZ9X?-8_AL=FS^"+0NV,[9
MWE[S</+X5M'>4A9&J[E /5CQ["]+T-MO,1C."^*]5LD=2/.T*9YFD?5H7[ H
M0JD4:1Z&8EU!PB(C#:3?-BP 6),(216QW&,U:U^.9(FB8N9/RN=VP"59;2IV
M9U4G4)%.]H"1G'=Z]%,+]"-2IVK4+/?LN_*S:3X8&29:V!8IL( A?#UM(.0"
MA;P;R1=M*6]9G1[KA1D @J0O_IO M DBBV/1!1/>(?X,XQB((Z<9A#D]35P>
M5,4)&G/$K*?N8(JG$#"O8K2W4/<#,33(8GC [NY5[\+NCI9^K\(0_X7Q)DD,
MFU,5P3%/ *4&H4L2I7PJ?70JJ33%\1,ETSB2_1!%US]SE68,+'H#P$2G\JX.
M7%N 8"&KJ>&T41B%EJ*,62?J<#M0=S'HS"C6QG$..(MLF@8?@8VJ9Y:E$U:=
M)BH!Y!_39 7E=@$B9/-&+,P=&X>C 2CV%0$K2W(S2*+N\$N@(O@1ST=YBZ2-
MWJ-'#49$?K]#"T.RR\.0?T$"Q%/FDX YX53Q40"#.:R2UA'#IJ,X$W<Z1B0J
M*Q77"$(05$<-*W/Z"F1)4]R8IUB$E704VM8@!C41[7A4$>#9LM% !Z?@__"M
MLS1:NV1J'#1$'H6( $HFH<8M$)D0@LNTV(-9T)9G\#ND^P#<(@[L(=\0@E6^
M!"J8(O1!$,%*&*^,W+U/-!!(Y!V5%=0L8=?)C.=K5S7"9$EI_)\AZ?<V3M)?
M E0FBD"#^ D,'=GN6K&K9$8L-A<L^R*N& ^-&\UM:. V1-2.+,9[DOT=2AGB
M!%Z^99DY\7WFJML5$XFF_#T&RPA8KY.?K#*K;!2#(@R?2HV2%M\<*X %SFA8
MLQ5U!7>NC#V2\%,$4C*'T8 +3"OFF-U4RGOI:Z.P6YC 9CDV(N(^4 %#S_)
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M!K/ 9Y1<GY&?R>NV4(_(Y;)\<[BN+H^ 9A2LS/.Q>VF)75C#>3%A:9>TL3L
M@\UO-TA*,59MT927BX64:&.'TYGJYB6Y[^'!)@KV];+9A:[C)PU1'C1W%[J.
MS\L4L"E==I"M]+&UB!P.-:7C>$PVYM)9#V.7#=/#MU3I#8.&FE*$2&].X@RY
M$#:6\< !Y$^9 T1?6]5B;ZM@MW87,:WM(G\X4DB26+8<QJFR*4/ 4BC"I5S8
MR15P8W=1OQSX7IC60B9]#8MC*MD-R&*#W,7A2D7'FD&W&![;Y#=$LQ G(HY]
M']D2>?SJ%J28J>Z=!ZJXSQVYRF8E=CJEI@BF?YHG45S:-7#?>*!E.8'#ZRM
M_PPK2VY6J[$IT<HP.3)[;)*HB[/Y*9 (8H#$,#.R^($H'O<@HF)H<^SLR>$L
MRDIP<;%IMZ6WT2X>&;PS0)OI(\#2(&VX;5!%M<DB9[C=2]P!NB465B>L7$$J
MR2AGL*Z3HV 53!X!"66N$12"[1;%(XEYP%UYRUT'$A:04R*!.2]2GU[-CFO
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MIC;M/@?^8SS$1%H8B-+P1CCY-/B;#&#>UDW*._>7?M[17QCZ'U!+ P04
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MHXHXY*QN5U%'[\4#ZR%CX=BG2H''*(XQ5.JCLZO[WFP)5QAEINGB '4.PH:
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MEF=H0\ON@%7.,_-6_K :V,&7!#LA1 ,)X5AJQ0@370#,Q5)VKU)!K:: Y\Y
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M$/%R*K-*"QH*0NK[D@5E[5P*S,]![6/E%-Q2$R3VH36(6LRA4V=OC8D+['=
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MT4PLDG3U[.F'9"&+X%=Y&[Q3"Y$]#0N1%4>%S),97U@D_Y;/AD-X"7V\U7.
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MW3ED46H E(W7T!L#],?!CZW7;)%6,SD=M/-J01H^5(#C;L(:'N]03TSVAZY
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M9 01[29!O-:..T'H\5-P+0[B))8/0S"KK.8/ [_]S$XZQYU>^P/[T/X$O&_
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MA[N+*USV^GL'Z%O\_SF[_UGW;'#6_L!Z_4MVVFMW!]]/=.XO</$%(+@9DE8
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M<!85]BQUM/*[),]2TO=IA/FE,!"8/6&>^9G^:_>_++RF_]WA/U!+ P04
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MM47$\87,Y'P"?QV..P2QO3&JC BCF^M*!$#ZBQO(AMGLH_M"?)[)4D[AA+=
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MND-F6LLS;0, YXZY8H2+84SA?+D=+HX6M/C=OLV"W8-%USKTV?_^8?[W>TY
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M)68O"$?H:[+"&5V;>UABLGZH$$]R-E7K5?XZ7;&LBYS*<9[+^0Y02P,$%
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M1@Y$K UWV&$KGUZ6'NAE:=SVS8Y-O^[?4$L#!!0    ( -D[7%@I]71("0@
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M*P*T8(G, 1E"WQ(B=: 9XA@V*^,R3U#9N).81^:1*F/,"1BNX*$."$NC9JP
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M>P8Q>L#7%Z9Q<':GC5UP$?\%ILPRZ9P03[28L0;;H?%8PCX_R5L &A7=4L?
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MOFD_\W>BN\'!]\,O:_?]+WK_#U!+ P04    " #9.UQ8*JT6 @<(  !9+0
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M$+P/1E>S\9\!/D)J< EOKRZG5\.+V4\?T6P";A>N+L:SX RFL^$LF,)H<A;
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M=^;.!V_3AR;P!ZR?\WM'0O5&O)4L/8N;P/3^MN&^!*:V(K ?5.T^%;UY6XJ
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M]K(N228;D@H6E8*2_4-[CH9GOEY6>%%/PC*ZQE^"'BUCMF */-=RMQ'?C37
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M]:U"N+R8,N+G%?*/8K6=GE!<9%/Z]9"$:B'))6L7#A36G-:YX]Y0;'V%#<Y
MNDORXBG0\THU1;2N1R4L8V;(/;"TO,X8E SR:.;/:?.8&TJ>_Z4EF]]1GOC\
MX+^N_XW[=I\OC,ONONNP[W7-G^5J2R"RL6X(-ZY=746]-Z%;;KA+KD?&<UW
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MI."W6N(X,&30$""MI"!JH %H-UZQ$Y%937I;.LM*^,Y(KEBE*R10R5:=X-A
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M,C R,S$R,S%?9S(N:G!G4$L! A0#%     @ V#M<6,XI?%S$? $ P></ !4
M             ( !.*D' &YV87@M,C R,S$R,S%?;&%B+GAM;%!+ 0(4 Q0
M   ( -@[7%@BZSRR_^H  $.["@ 5              "  2\F"0!N=F%X+3(P
M,C,Q,C,Q7W!R92YX;6Q02P$"% ,4    " #8.UQ8=T[DA5>$  #S3@4 &0
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M-"YH=&U02P$"% ,4    " #8.UQ8YBG3D[(N  !3 @$ &
M@ &[!@L ;G9A>"TR,#(S,3(S,7AE>#$P,S4N:'1M4$L! A0#%     @ V#M<
M6%16<<S]#0  Y$$  !@              ( !HS4+ &YV87@M,C R,S$R,S%X
M97@Q,#,V+FAT;5!+ 0(4 Q0    ( -@[7%BAJ<@$]R8  %W7   8
M      "  =9#"P!N=F%X+3(P,C,Q,C,Q>&5X,3 S-RYH=&U02P$"% ,4
M" #8.UQ8^K%G(M "  #2$0  %@              @ $#:PL ;G9A>"TR,#(S
M,3(S,7AE>#(Q+FAT;5!+ 0(4 Q0    ( -D[7%A,;";AB@4  +8[   7
M          "  0=N"P!N=F%X+3(P,C,Q,C,Q>&5X,C,Q+FAT;5!+ 0(4 Q0
M   ( -D[7%@I]71("0@  -@K   7              "  <9S"P!N=F%X+3(P
M,C,Q,C,Q>&5X,S$Q+FAT;5!+ 0(4 Q0    ( -D[7%@JK18"!P@  %DM   7
M              "  01\"P!N=F%X+3(P,C,Q,C,Q>&5X,S$R+FAT;5!+ 0(4
M Q0    ( -D[7%@A!FE4AP4  'P6   7              "  4"$"P!N=F%X
M+3(P,C,Q,C,Q>&5X,S(Q+FAT;5!+ 0(4 Q0    ( -D[7%A!=SE3KP4  +87
M   7              "  ?R)"P!N=F%X+3(P,C,Q,C,Q>&5X,S(R+FAT;5!+
M 0(4 Q0    ( -D[7%BDG%05VA$  &)7   6              "  >"/"P!N
M=F%X+3(P,C,Q,C,Q>&5X-#0N:'1M4$L! A0#%     @ V3M<6"Z\'0K4#@
M'&L  !8              ( ![J$+ &YV87@M,C R,S$R,S%X97@Y-RYH=&U0
52P4&     !@ & !D!@  ]K +

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>nvax-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nvax="http://www.novavax.com/20231231"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nvax-20231231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <instant>2024-02-23</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nvax:FilipDubovskyMDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nvax:FilipDubovskyMDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">nvax:FilipDubovskyMDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:RoyaltiesAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:RoyaltiesAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:RoyaltiesAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CanadaAdvancePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:EuropeanCommissionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:EuropeanCommissionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:EuropeanCommissionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:EuropeanCommissionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:GovernmentOfAustraliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:GovernmentOfAustraliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:GovernmentOfCanadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:GovernmentOfCanadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:GovernmentOfIsraelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:USGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:USGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:USGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:USGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">nvax:SKBioscienceCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nvax:RevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:AmendedAndRestatedUKSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nvax:RevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:AmendedAndRestatedUKSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementCOVAXFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementSIIPLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementCOVAXFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-18</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementSIIPLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementSIIPLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:GaviAdvancePurchaseAgreementCOVAXFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-16</startDate>
            <endDate>2024-02-16</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-16</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nvax:RestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">nvax:RestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">nvax:WholesaleDistributorFeesDiscountsAndChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">nvax:ProductReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">nvax:WholesaleDistributorFeesDiscountsAndChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">nvax:ProductReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">nvax:WholesaleDistributorFeesDiscountsAndChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">nvax:ProductReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:AustralianAPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:AustralianAPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:EuropeanCommissionsECMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:EuropeanCommissionsECMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:EuropeanCommissionsECMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:EuropeanCommissionsECMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CanadaAdvancePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CanadaAdvancePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CanadaAdvancePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <instant>2020-10-22</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">nvax:AmendedAndRestatedUKSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">nvax:AmendedAndRestatedUKSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:JointCommitteeOnVaccinationAndImmunizationJCVIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">nvax:AmendedAndRestatedUKSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">nvax:AmendedAndRestatedUKSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USDepartmentOfDefenseDoDContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USDepartmentOfDefenseDoDContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USDepartmentOfDefenseDoDContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CoalitionForEpidemicPreparednessInnovationsAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CoalitionForEpidemicPreparednessInnovationsAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CoalitionForEpidemicPreparednessInnovationsAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:OtherGrantRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:OtherGrantRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:OtherGrantRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:USGovernmentPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CEPIGrantFundingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:CEPIGrantFundingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:SalesBasedRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:MatrixMAdjuvantSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:MilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:SalesBasedRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:MilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:MatrixMAdjuvantSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:SalesBasedRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nvax:MilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:TakedaArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:TakedaArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:TakedaArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SecuritiesSubscriptionArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SecuritiesSubscriptionArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SecuritiesSubscriptionArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SecuritiesSubscriptionArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SecuritiesSubscriptionArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nvax:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvax:LeaseImpairmentChargeAxis">nvax:CMOAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:CMOAndCMDAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:CMOAndCMDAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:A700QuinceOrchardRoadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:A700QuinceOrchardRoadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:A700QuinceOrchardRoadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:A700QuinceOrchardRoadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:A700QuinceOrchardRoadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:FacilityLeaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nvax:FacilityLeaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvax:LeaseImpairmentChargeAxis">nvax:ROUFacilityLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-31</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-25</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-25</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-25</instant>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:FivePointZeroConvertibleNotesDue2027MakeWholeFundamentalChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nvax:ThreePointSeventyFiveConvertibleNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:August2023SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:August2023SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:June2021SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:June2021AndAugust2023SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:June2021AndAugust2023SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:August2023SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:June2021SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:UnderwriterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nvax:UnderwriterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandTwentyThreeStockInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandTwentyThreeStockInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2015-06-30</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-06-30</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2015-06-30</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2015-06-30</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandTwentyThreeStockInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFiveStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandTwentyThreeStockInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFiveStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFiveStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandTwentyThreeStockInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandTwentyThreeStockInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandTwentyThreeStockInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nvax:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollectiveBargainingArrangementAxis">nvax:FirstThreePercentOfParticipantsDeferralMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollectiveBargainingArrangementAxis">nvax:NextTwoPercentOfParticipantsDeferralMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nvax:ComputerSoftwareAndHardwareMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nvax:ComputerSoftwareAndHardwareMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CZ</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CZ</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">nvax:SubjectToExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">nvax:NoExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
        </entity>
        <period>
            <startDate>2022-12-12</startDate>
            <endDate>2022-12-12</endDate>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001000694</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-31</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="reporting_unit">
        <measure>nvax:reporting_unit</measure>
    </unit>
    <unit id="segment">
        <measure>nvax:segment</measure>
    </unit>
    <unit id="dose">
        <measure>nvax:dose</measure>
    </unit>
    <unit id="installment">
        <measure>nvax:installment</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="day">
        <measure>nvax:day</measure>
    </unit>
    <unit id="defendant">
        <measure>nvax:defendant</measure>
    </unit>
    <unit id="payment">
        <measure>nvax:payment</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-32">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-33">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-34">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-35">0001000694</dei:EntityCentralIndexKey>
    <ecd:TrdArrDuration contextRef="c-6" id="f-45">P185D</ecd:TrdArrDuration>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c-61" id="f-398">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-219" id="f-745">P1Y8M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-19" id="f-749">http://www.novavax.com/20231231#LeaseRightOfUseAsset</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-20" id="f-750">http://www.novavax.com/20231231#LeaseRightOfUseAsset</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-19" id="f-753">http://www.novavax.com/20231231#LeaseRightOfUseAsset</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-20" id="f-754">http://www.novavax.com/20231231#LeaseRightOfUseAsset</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-20" id="f-759">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-19" id="f-760">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-20" id="f-767">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-19" id="f-768">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <nvax:ConvertibleDebtConversionRate
      contextRef="c-224"
      decimals="INF"
      id="f-900"
      unitRef="usdPerShare">0.08</nvax:ConvertibleDebtConversionRate>
    <nvax:ConvertibleDebtConversionRate contextRef="c-236" decimals="INF" id="f-901" unitRef="usd">0.02</nvax:ConvertibleDebtConversionRate>
    <nvax:ConvertibleDebtConversionRate
      contextRef="c-230"
      decimals="INF"
      id="f-902"
      unitRef="usdPerShare">0.0073411</nvax:ConvertibleDebtConversionRate>
    <nvax:ConvertibleDebtConversionRate contextRef="c-237" decimals="INF" id="f-903" unitRef="usd">0.0089928</nvax:ConvertibleDebtConversionRate>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-235" decimals="2" id="f-904" unitRef="number">0.05</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-254" id="f-931">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">000-26770</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">NOVAVAX,&#160;INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">22-2816046</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">700 Quince Orchard Road,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Gaithersburg,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">20878</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">(240)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">268-2000</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, Par Value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">NVAX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-19">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-26">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-27">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-28">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="0" id="f-29" unitRef="usd">699000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-30" unitRef="shares">139953143</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-31">&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Documents incorporated by reference: Portions of the Registrant&#x2019;s Definitive Proxy Statement to be filed no later than 120 days after the fiscal year ended December&#160;31, 2023 in connection with the Registrant&#x2019;s 2024 Annual Meeting of Stockholders are incorporated by reference into Part&#160;III of this Annual Report on Form&#160;10-K to the extent indicated herein.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-4" id="f-36">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-4" id="f-37">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-4" id="f-38">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-5" id="f-39">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On December 12, 2023, Filip Dubovsky, MD, our President, Research &amp;amp; Development, entered into a Rule 10b5-1 trading plan that is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides that Dr. Dubovsky, acting through a broker, may sell up to an aggregate of 13,365 shares of our common stock, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur from March 15, 2024 to June 14, 2024. The plan is scheduled to terminate on June 14, 2024, subject to earlier termination upon the sale of all shares subject to the plan or the expiration of all sale orders under the plan, upon termination by Dr. Dubovsky or the broker, or as otherwise provided in the plan.&lt;/span&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate contextRef="c-6" id="f-40">December 12, 2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName contextRef="c-6" id="f-41">Filip Dubovsky, MD</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-6" id="f-42">President, Research &amp; Development</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-6" id="f-43">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-7" decimals="INF" id="f-44" unitRef="shares">13365</ecd:TrdArrSecuritiesAggAvailAmt>
    <dei:AuditorFirmId contextRef="c-1" id="f-46">42</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-47">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-48">Tysons, Virginia</dei:AuditorLocation>
    <dei:AuditorName contextRef="c-1" id="f-49">Ernst&#160;&amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-50">Tysons, Virginia</dei:AuditorLocation>
    <us-gaap:Revenues contextRef="c-8" decimals="-3" id="f-51" unitRef="usd">531389000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-9" decimals="-3" id="f-52" unitRef="usd">1554961000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-10" decimals="-3" id="f-53" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-11" decimals="-3" id="f-54" unitRef="usd">427323000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-12" decimals="-3" id="f-55" unitRef="usd">382921000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-13" decimals="-3" id="f-56" unitRef="usd">948709000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-14" decimals="-3" id="f-57" unitRef="usd">24993000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-15" decimals="-3" id="f-58" unitRef="usd">43990000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-16" decimals="-3" id="f-59" unitRef="usd">197581000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-1" decimals="-3" id="f-60" unitRef="usd">983705000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-17" decimals="-3" id="f-61" unitRef="usd">1981872000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-18" decimals="-3" id="f-62" unitRef="usd">1146290000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue contextRef="c-1" decimals="-3" id="f-63" unitRef="usd">343768000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-17" decimals="-3" id="f-64" unitRef="usd">902639000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-18" decimals="-3" id="f-65" unitRef="usd">0</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-66" unitRef="usd">737502000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-17" decimals="-3" id="f-67" unitRef="usd">1235278000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-18" decimals="-3" id="f-68" unitRef="usd">2534508000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-69" unitRef="usd">468946000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-17" decimals="-3" id="f-70" unitRef="usd">488691000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-18" decimals="-3" id="f-71" unitRef="usd">298358000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-3" id="f-72" unitRef="usd">1550216000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-17" decimals="-3" id="f-73" unitRef="usd">2626608000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-18" decimals="-3" id="f-74" unitRef="usd">2832866000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-75" unitRef="usd">-566511000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-17" decimals="-3" id="f-76" unitRef="usd">-644736000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-18" decimals="-3" id="f-77" unitRef="usd">-1686576000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-3" id="f-78" unitRef="usd">14416000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-17" decimals="-3" id="f-79" unitRef="usd">19880000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-18" decimals="-3" id="f-80" unitRef="usd">21127000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-81" unitRef="usd">37896000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-17" decimals="-3" id="f-82" unitRef="usd">10969000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-18" decimals="-3" id="f-83" unitRef="usd">-6833000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-84" unitRef="usd">-543031000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-17" decimals="-3" id="f-85" unitRef="usd">-653647000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-18" decimals="-3" id="f-86" unitRef="usd">-1714536000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-87" unitRef="usd">2031000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-88" unitRef="usd">4292000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-18" decimals="-3" id="f-89" unitRef="usd">29215000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-90" unitRef="usd">-545062000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="-3" id="f-91" unitRef="usd">-657939000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-18" decimals="-3" id="f-92" unitRef="usd">-1743751000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-93"
      unitRef="usdPerShare">-5.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-94"
      unitRef="usdPerShare">-5.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-17"
      decimals="2"
      id="f-95"
      unitRef="usdPerShare">-8.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-17"
      decimals="2"
      id="f-96"
      unitRef="usdPerShare">-8.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-18"
      decimals="2"
      id="f-97"
      unitRef="usdPerShare">-23.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-18"
      decimals="2"
      id="f-98"
      unitRef="usdPerShare">-23.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-99" unitRef="shares">100768000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-100" unitRef="shares">100768000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-17" decimals="-3" id="f-101" unitRef="shares">78183000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-17" decimals="-3" id="f-102" unitRef="shares">78183000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-18" decimals="-3" id="f-103" unitRef="shares">74400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-18" decimals="-3" id="f-104" unitRef="shares">74400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-105" unitRef="usd">-545062000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="-3" id="f-106" unitRef="usd">-657939000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-18" decimals="-3" id="f-107" unitRef="usd">-1743751000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-108" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-17" decimals="-3" id="f-109" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-18" decimals="-3" id="f-110" unitRef="usd">-9000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-111" unitRef="usd">9099000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-17" decimals="-3" id="f-112" unitRef="usd">-5024000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-18" decimals="-3" id="f-113" unitRef="usd">-8368000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-114" unitRef="usd">9099000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-17" decimals="-3" id="f-115" unitRef="usd">-5024000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-18" decimals="-3" id="f-116" unitRef="usd">-8377000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-117" unitRef="usd">-535963000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-17" decimals="-3" id="f-118" unitRef="usd">-662963000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-18" decimals="-3" id="f-119" unitRef="usd">-1752128000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-19" decimals="-3" id="f-120" unitRef="usd">568505000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-20" decimals="-3" id="f-121" unitRef="usd">1336883000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-19" decimals="-3" id="f-122" unitRef="usd">10424000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-20" decimals="-3" id="f-123" unitRef="usd">10303000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNet contextRef="c-19" decimals="-3" id="f-124" unitRef="usd">297240000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="c-20" decimals="-3" id="f-125" unitRef="usd">82375000</us-gaap:AccountsReceivableNet>
    <us-gaap:InventoryNet contextRef="c-19" decimals="-3" id="f-126" unitRef="usd">41696000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-20" decimals="-3" id="f-127" unitRef="usd">36683000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-19" decimals="-3" id="f-128" unitRef="usd">226023000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-20" decimals="-3" id="f-129" unitRef="usd">237147000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-19" decimals="-3" id="f-130" unitRef="usd">1143888000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-20" decimals="-3" id="f-131" unitRef="usd">1703391000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-19" decimals="-3" id="f-132" unitRef="usd">305771000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-20" decimals="-3" id="f-133" unitRef="usd">294247000</us-gaap:PropertyPlantAndEquipmentNet>
    <nvax:LeaseRightOfUseAsset contextRef="c-19" decimals="-3" id="f-134" unitRef="usd">185218000</nvax:LeaseRightOfUseAsset>
    <nvax:LeaseRightOfUseAsset contextRef="c-20" decimals="-3" id="f-135" unitRef="usd">106241000</nvax:LeaseRightOfUseAsset>
    <us-gaap:Goodwill contextRef="c-19" decimals="-3" id="f-136" unitRef="usd">127454000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-20" decimals="-3" id="f-137" unitRef="usd">126331000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-19" decimals="-3" id="f-138" unitRef="usd">35159000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-20" decimals="-3" id="f-139" unitRef="usd">28469000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-19" decimals="-3" id="f-140" unitRef="usd">1797490000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-20" decimals="-3" id="f-141" unitRef="usd">2258679000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-19" decimals="-3" id="f-142" unitRef="usd">132610000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-20" decimals="-3" id="f-143" unitRef="usd">216517000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-19" decimals="-3" id="f-144" unitRef="usd">394668000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-20" decimals="-3" id="f-145" unitRef="usd">591158000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-19" decimals="-3" id="f-146" unitRef="usd">241310000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-20" decimals="-3" id="f-147" unitRef="usd">370137000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-19" decimals="-3" id="f-148" unitRef="usd">5142000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-20" decimals="-3" id="f-149" unitRef="usd">27196000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c-19" decimals="-3" id="f-150" unitRef="usd">0</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c-20" decimals="-3" id="f-151" unitRef="usd">324881000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-19" decimals="-3" id="f-152" unitRef="usd">861408000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-20" decimals="-3" id="f-153" unitRef="usd">930055000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-19" decimals="-3" id="f-154" unitRef="usd">1635138000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-20" decimals="-3" id="f-155" unitRef="usd">2459944000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-19" decimals="-3" id="f-156" unitRef="usd">622210000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-20" decimals="-3" id="f-157" unitRef="usd">179414000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c-19" decimals="-3" id="f-158" unitRef="usd">168016000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c-20" decimals="-3" id="f-159" unitRef="usd">166466000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-19" decimals="-3" id="f-160" unitRef="usd">55923000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-20" decimals="-3" id="f-161" unitRef="usd">31238000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-19" decimals="-3" id="f-162" unitRef="usd">33130000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-20" decimals="-3" id="f-163" unitRef="usd">55695000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-19" decimals="-3" id="f-164" unitRef="usd">2514417000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-20" decimals="-3" id="f-165" unitRef="usd">2892757000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-19" id="f-166" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-20" id="f-167" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-19"
      decimals="INF"
      id="f-168"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-20"
      decimals="INF"
      id="f-169"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-19"
      decimals="INF"
      id="f-170"
      unitRef="shares">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-20"
      decimals="INF"
      id="f-171"
      unitRef="shares">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockValue contextRef="c-19" decimals="-3" id="f-172" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-20" decimals="-3" id="f-173" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-19"
      decimals="INF"
      id="f-174"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-20"
      decimals="INF"
      id="f-175"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-20"
      decimals="INF"
      id="f-176"
      unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-19"
      decimals="INF"
      id="f-177"
      unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-19"
      decimals="INF"
      id="f-178"
      unitRef="shares">140506093</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-19"
      decimals="INF"
      id="f-179"
      unitRef="shares">139505770</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-20"
      decimals="INF"
      id="f-180"
      unitRef="shares">86806554</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-20"
      decimals="INF"
      id="f-181"
      unitRef="shares">86039923</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-19" decimals="-3" id="f-182" unitRef="usd">1405000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-20" decimals="-3" id="f-183" unitRef="usd">868000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-19" decimals="-3" id="f-184" unitRef="usd">4192164000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-20" decimals="-3" id="f-185" unitRef="usd">3737979000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-19" decimals="-3" id="f-186" unitRef="usd">-4820951000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-20" decimals="-3" id="f-187" unitRef="usd">-4275889000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c-19"
      decimals="INF"
      id="f-188"
      unitRef="shares">1000323</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c-20"
      decimals="INF"
      id="f-189"
      unitRef="shares">766631</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue contextRef="c-19" decimals="-3" id="f-190" unitRef="usd">92267000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue contextRef="c-20" decimals="-3" id="f-191" unitRef="usd">90659000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-19" decimals="-3" id="f-192" unitRef="usd">2722000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-20" decimals="-3" id="f-193" unitRef="usd">-6377000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-194" unitRef="usd">-716927000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-195" unitRef="usd">-634078000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-19" decimals="-3" id="f-196" unitRef="usd">1797490000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-20" decimals="-3" id="f-197" unitRef="usd">2258679000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-21"
      decimals="INF"
      id="f-198"
      unitRef="shares">71350365</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-199" unitRef="usd">714000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-200" unitRef="usd">2535476000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-201" unitRef="usd">-1874199000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-202" unitRef="usd">-41806000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-203" unitRef="usd">7024000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-204" unitRef="usd">627209000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-27" decimals="-3" id="f-205" unitRef="usd">183626000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-18" decimals="-3" id="f-206" unitRef="usd">183626000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <nvax:ShareBasedCompensationStockIssuedUnderIncentiveProgram
      contextRef="c-28"
      decimals="INF"
      id="f-207"
      unitRef="shares">2503819</nvax:ShareBasedCompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram contextRef="c-28" decimals="-3" id="f-208" unitRef="usd">24000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram contextRef="c-27" decimals="-3" id="f-209" unitRef="usd">68032000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram contextRef="c-29" decimals="-3" id="f-210" unitRef="usd">-43295000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram contextRef="c-18" decimals="-3" id="f-211" unitRef="usd">24761000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-18" decimals="-3" id="f-212" unitRef="usd">7292000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-28"
      decimals="INF"
      id="f-213"
      unitRef="shares">2578967</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-28" decimals="-3" id="f-214" unitRef="usd">26000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-27" decimals="-3" id="f-215" unitRef="usd">564833000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-18" decimals="-3" id="f-216" unitRef="usd">564859000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-30" decimals="-3" id="f-217" unitRef="usd">-9000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-18" decimals="-3" id="f-218" unitRef="usd">-9000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-30" decimals="-3" id="f-219" unitRef="usd">-8368000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-18" decimals="-3" id="f-220" unitRef="usd">-8368000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-31" decimals="-3" id="f-221" unitRef="usd">-1743751000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-18" decimals="-3" id="f-222" unitRef="usd">-1743751000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-32"
      decimals="INF"
      id="f-223"
      unitRef="shares">76433151</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-224" unitRef="usd">764000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-225" unitRef="usd">3351967000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-226" unitRef="usd">-3617950000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-227" unitRef="usd">-85101000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-3" id="f-228" unitRef="usd">-1353000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-229" unitRef="usd">-351673000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-38" decimals="-3" id="f-230" unitRef="usd">131967000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-17" decimals="-3" id="f-231" unitRef="usd">131967000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <nvax:ShareBasedCompensationStockIssuedUnderIncentiveProgram
      contextRef="c-39"
      decimals="INF"
      id="f-232"
      unitRef="shares">701005</nvax:ShareBasedCompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram contextRef="c-39" decimals="-3" id="f-233" unitRef="usd">7000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram contextRef="c-38" decimals="-3" id="f-234" unitRef="usd">4912000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram contextRef="c-40" decimals="-3" id="f-235" unitRef="usd">-5558000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram contextRef="c-17" decimals="-3" id="f-236" unitRef="usd">-639000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-17" decimals="-3" id="f-237" unitRef="usd">7216000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-39"
      decimals="INF"
      id="f-238"
      unitRef="shares">9672398</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-39" decimals="-3" id="f-239" unitRef="usd">97000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-38" decimals="-3" id="f-240" unitRef="usd">249133000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-17" decimals="-3" id="f-241" unitRef="usd">249230000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-41" decimals="-3" id="f-242" unitRef="usd">-5024000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-17" decimals="-3" id="f-243" unitRef="usd">-5024000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-42" decimals="-3" id="f-244" unitRef="usd">-657939000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="-3" id="f-245" unitRef="usd">-657939000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-43"
      decimals="INF"
      id="f-246"
      unitRef="shares">86806554</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="-3" id="f-247" unitRef="usd">868000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="-3" id="f-248" unitRef="usd">3737979000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-45" decimals="-3" id="f-249" unitRef="usd">-4275889000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-3" id="f-250" unitRef="usd">-90659000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="-3" id="f-251" unitRef="usd">-6377000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-252" unitRef="usd">-634078000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-48" decimals="-3" id="f-253" unitRef="usd">85850000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-254" unitRef="usd">85850000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <nvax:ShareBasedCompensationStockIssuedUnderIncentiveProgram
      contextRef="c-49"
      decimals="INF"
      id="f-255"
      unitRef="shares">902742</nvax:ShareBasedCompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram contextRef="c-49" decimals="-3" id="f-256" unitRef="usd">9000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram contextRef="c-48" decimals="-3" id="f-257" unitRef="usd">1758000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram contextRef="c-50" decimals="-3" id="f-258" unitRef="usd">-1608000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <nvax:CompensationStockIssuedUnderIncentiveProgram contextRef="c-1" decimals="-3" id="f-259" unitRef="usd">159000</nvax:CompensationStockIssuedUnderIncentiveProgram>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-1" decimals="-3" id="f-260" unitRef="usd">6171000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-49"
      decimals="INF"
      id="f-261"
      unitRef="shares">52796797</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-49" decimals="-3" id="f-262" unitRef="usd">528000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-48" decimals="-3" id="f-263" unitRef="usd">366577000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-264" unitRef="usd">367105000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-51" decimals="-3" id="f-265" unitRef="usd">9099000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-266" unitRef="usd">9099000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-52" decimals="-3" id="f-267" unitRef="usd">-545062000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-268" unitRef="usd">-545062000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-53"
      decimals="INF"
      id="f-269"
      unitRef="shares">140506093</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-53" decimals="-3" id="f-270" unitRef="usd">1405000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-54" decimals="-3" id="f-271" unitRef="usd">4192164000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-55" decimals="-3" id="f-272" unitRef="usd">-4820951000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-56" decimals="-3" id="f-273" unitRef="usd">-92267000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-57" decimals="-3" id="f-274" unitRef="usd">2722000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-275" unitRef="usd">-716927000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-276" unitRef="usd">-545062000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="-3" id="f-277" unitRef="usd">-657939000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-18" decimals="-3" id="f-278" unitRef="usd">-1743751000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-279" unitRef="usd">41225000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-17" decimals="-3" id="f-280" unitRef="usd">29054000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-18" decimals="-3" id="f-281" unitRef="usd">12661000</us-gaap:DepreciationAndAmortization>
    <nvax:OperatingAndFinanceLeaseWriteOff contextRef="c-1" decimals="-3" id="f-282" unitRef="usd">6113000</nvax:OperatingAndFinanceLeaseWriteOff>
    <nvax:OperatingAndFinanceLeaseWriteOff contextRef="c-17" decimals="-3" id="f-283" unitRef="usd">18104000</nvax:OperatingAndFinanceLeaseWriteOff>
    <nvax:OperatingAndFinanceLeaseWriteOff contextRef="c-18" decimals="-3" id="f-284" unitRef="usd">144433000</nvax:OperatingAndFinanceLeaseWriteOff>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-285" unitRef="usd">85357000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-17" decimals="-3" id="f-286" unitRef="usd">130300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-18" decimals="-3" id="f-287" unitRef="usd">183626000</us-gaap:ShareBasedCompensation>
    <nvax:ProvisionForExcessAndObsoleteInventory contextRef="c-1" decimals="-3" id="f-288" unitRef="usd">72197000</nvax:ProvisionForExcessAndObsoleteInventory>
    <nvax:ProvisionForExcessAndObsoleteInventory contextRef="c-17" decimals="-3" id="f-289" unitRef="usd">447597000</nvax:ProvisionForExcessAndObsoleteInventory>
    <nvax:ProvisionForExcessAndObsoleteInventory contextRef="c-18" decimals="-3" id="f-290" unitRef="usd">0</nvax:ProvisionForExcessAndObsoleteInventory>
    <us-gaap:AssetImpairmentCharges contextRef="c-1" decimals="-3" id="f-291" unitRef="usd">10081000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-17" decimals="-3" id="f-292" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-18" decimals="-3" id="f-293" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-3" id="f-294" unitRef="usd">7042000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-17" decimals="-3" id="f-295" unitRef="usd">21903000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-18" decimals="-3" id="f-296" unitRef="usd">7641000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-297" unitRef="usd">74457000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-17" decimals="-3" id="f-298" unitRef="usd">477801000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-18" decimals="-3" id="f-299" unitRef="usd">8872000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-300" unitRef="usd">274442000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-17" decimals="-3" id="f-301" unitRef="usd">-249166000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-18" decimals="-3" id="f-302" unitRef="usd">183393000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-3" id="f-303" unitRef="usd">-378805000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-17" decimals="-3" id="f-304" unitRef="usd">913399000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-18" decimals="-3" id="f-305" unitRef="usd">600326000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c-1" decimals="-3" id="f-306" unitRef="usd">350868000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c-17" decimals="-3" id="f-307" unitRef="usd">-1045914000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c-18" decimals="-3" id="f-308" unitRef="usd">1325557000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-309" unitRef="usd">-713967000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-17" decimals="-3" id="f-310" unitRef="usd">-415937000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-18" decimals="-3" id="f-311" unitRef="usd">322946000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsForCapitalImprovements contextRef="c-1" decimals="-3" id="f-312" unitRef="usd">53771000</us-gaap:PaymentsForCapitalImprovements>
    <us-gaap:PaymentsForCapitalImprovements contextRef="c-17" decimals="-3" id="f-313" unitRef="usd">89056000</us-gaap:PaymentsForCapitalImprovements>
    <us-gaap:PaymentsForCapitalImprovements contextRef="c-18" decimals="-3" id="f-314" unitRef="usd">54501000</us-gaap:PaymentsForCapitalImprovements>
    <us-gaap:PaymentsForSoftware contextRef="c-1" decimals="-3" id="f-315" unitRef="usd">5035000</us-gaap:PaymentsForSoftware>
    <us-gaap:PaymentsForSoftware contextRef="c-17" decimals="-3" id="f-316" unitRef="usd">3929000</us-gaap:PaymentsForSoftware>
    <us-gaap:PaymentsForSoftware contextRef="c-18" decimals="-3" id="f-317" unitRef="usd">2985000</us-gaap:PaymentsForSoftware>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-1" decimals="-3" id="f-318" unitRef="usd">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-17" decimals="-3" id="f-319" unitRef="usd">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-18" decimals="-3" id="f-320" unitRef="usd">2167000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-1" decimals="-3" id="f-321" unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-17" decimals="-3" id="f-322" unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-18" decimals="-3" id="f-323" unitRef="usd">159807000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-324" unitRef="usd">-58806000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-17" decimals="-3" id="f-325" unitRef="usd">-92985000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-18" decimals="-3" id="f-326" unitRef="usd">100154000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-327" unitRef="usd">360243000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-17" decimals="-3" id="f-328" unitRef="usd">249230000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-18" decimals="-3" id="f-329" unitRef="usd">564859000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c-1" decimals="-3" id="f-330" unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c-17" decimals="-3" id="f-331" unitRef="usd">175250000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c-18" decimals="-3" id="f-332" unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts contextRef="c-1" decimals="-3" id="f-333" unitRef="usd">3591000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts contextRef="c-17" decimals="-3" id="f-334" unitRef="usd">5258000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts contextRef="c-18" decimals="-3" id="f-335" unitRef="usd">0</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <nvax:NetProceedsFromTheExerciseOfStockBasedAwards contextRef="c-1" decimals="-3" id="f-336" unitRef="usd">159000</nvax:NetProceedsFromTheExerciseOfStockBasedAwards>
    <nvax:NetProceedsFromTheExerciseOfStockBasedAwards contextRef="c-17" decimals="-3" id="f-337" unitRef="usd">-639000</nvax:NetProceedsFromTheExerciseOfStockBasedAwards>
    <nvax:NetProceedsFromTheExerciseOfStockBasedAwards contextRef="c-18" decimals="-3" id="f-338" unitRef="usd">24761000</nvax:NetProceedsFromTheExerciseOfStockBasedAwards>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c-1" decimals="-3" id="f-339" unitRef="usd">325000000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c-17" decimals="-3" id="f-340" unitRef="usd">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c-18" decimals="-3" id="f-341" unitRef="usd">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-1" decimals="-3" id="f-342" unitRef="usd">27345000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-17" decimals="-3" id="f-343" unitRef="usd">93595000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-18" decimals="-3" id="f-344" unitRef="usd">127907000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-345" unitRef="usd">4466000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-17" decimals="-3" id="f-346" unitRef="usd">324988000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-18" decimals="-3" id="f-347" unitRef="usd">461713000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-348" unitRef="usd">3272000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-17" decimals="-3" id="f-349" unitRef="usd">4520000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-18" decimals="-3" id="f-350" unitRef="usd">-5292000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-351" unitRef="usd">-765035000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-17" decimals="-3" id="f-352" unitRef="usd">-179414000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-18" decimals="-3" id="f-353" unitRef="usd">879521000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-20" decimals="-3" id="f-354" unitRef="usd">1348845000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-37" decimals="-3" id="f-355" unitRef="usd">1528259000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-26" decimals="-3" id="f-356" unitRef="usd">648738000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-19" decimals="-3" id="f-357" unitRef="usd">583810000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-20" decimals="-3" id="f-358" unitRef="usd">1348845000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-37" decimals="-3" id="f-359" unitRef="usd">1528259000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <nvax:ProceedsFromIssuanceOrSaleOfEquityNotSettled contextRef="c-1" decimals="-3" id="f-360" unitRef="usd">6862000</nvax:ProceedsFromIssuanceOrSaleOfEquityNotSettled>
    <nvax:ProceedsFromIssuanceOrSaleOfEquityNotSettled contextRef="c-17" decimals="-3" id="f-361" unitRef="usd">0</nvax:ProceedsFromIssuanceOrSaleOfEquityNotSettled>
    <nvax:ProceedsFromIssuanceOrSaleOfEquityNotSettled contextRef="c-18" decimals="-3" id="f-362" unitRef="usd">0</nvax:ProceedsFromIssuanceOrSaleOfEquityNotSettled>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-363" unitRef="usd">7899000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-17" decimals="-3" id="f-364" unitRef="usd">17665000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-18" decimals="-3" id="f-365" unitRef="usd">10338000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <nvax:NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset contextRef="c-1" decimals="-3" id="f-366" unitRef="usd">103299000</nvax:NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset>
    <nvax:NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset contextRef="c-17" decimals="-3" id="f-367" unitRef="usd">91855000</nvax:NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset>
    <nvax:NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset contextRef="c-18" decimals="-3" id="f-368" unitRef="usd">179210000</nvax:NonCashRelatedTransactionsForFinanceLeaseRightOfUseAsset>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-369" unitRef="usd">17349000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-17" decimals="-3" id="f-370" unitRef="usd">18035000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-18" decimals="-3" id="f-371" unitRef="usd">19428000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid contextRef="c-1" decimals="-3" id="f-372" unitRef="usd">190000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-17" decimals="-3" id="f-373" unitRef="usd">17980000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-18" decimals="-3" id="f-374" unitRef="usd">12606000</us-gaap:IncomeTaxesPaid>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-375">Organization &amp;amp; Business&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Novavax, Inc. (&#x201c;Novavax,&#x201d; and together with its wholly owned subsidiaries, the &#x201c;Company&#x201d;) is a biotechnology company that promotes improved health by discovering, developing, and commercializing innovative vaccines to prevent serious infectious diseases. Novavax offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and patented Matrix-M&#x2122; adjuvant to enhance the immune response. Novavax currently has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid&#x2122; prototype COVID-19 vaccine ("NVX-CoV2373,&#x201d; or &#x201c;prototype vaccine&#x201d;) and Nuvaxovid&#x2122; updated COVID-19 vaccine (&#x201c;NVX-CoV2601,&#x201d; or &#x201c;updated vaccine&#x201d;) (collectively, &#x201c;COVID-19 Vaccine&#x201d;). Local regulatory authorities have also specified nomenclature for the prototype and updated vaccines within their territories (e.g., &#x201c;Novavax COVID-19 Vaccine, Adjuvanted&#x201d; and &#x201c;Novavax COVID-19, Adjuvanted (2023-2024 Formula)&#x201d;, respectively, for the U.S.). The Company&#x2019;s partner, Serum Institute of India Pvt. Ltd. (&#x201c;SIIPL&#x201d;), markets NVX-CoV2373 as &#x201c;Covovax&#x2122;.&#x201d; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in 2022, the Company received approval, interim authorization, provisional approval, conditional marketing authorization, and emergency use authorization (&#x201c;EUA&#x201d;) from multiple regulatory authorities globally for its prototype vaccine for both adult and adolescent populations as a primary series and for both homologous and heterologous booster indications in select territories. In October 2023, the U.S. Food and Drug Administration (&#x201c;U.S. FDA&#x201d;) amended the EUA for its prototype vaccine to include its updated vaccine. The amended EUA authorizes use of the Company&#x2019;s updated vaccine in individuals 12 years and older. In October 2023, the European Commission (&#x201c;EC&#x201d;) granted approval for the Company&#x2019;s updated vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 and older. Currently, the Company significantly depends on its supply agreement with SIIPL and its subsidiary, Serum Life Sciences Limited (&#x201c;SLS&#x201d;), for co-formulation, filling and finishing (other than in Europe) and on its service agreement with PCI Pharma Services for finishing in Europe. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Novavax is advancing development of other vaccine candidates, including its COVID19-Influenza Combination (&#x201c;CIC&#x201d;) vaccine candidate and additional vaccine candidates. The Company&#x2019;s COVID-19 Vaccine and its other vaccine candidates incorporate the Company&#x2019;s proprietary Matrix-M&#x2122; adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-376">Summary of Significant Accounting Policies&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Novavax,&#160;Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern within one year after the date that the financial statements are issued and contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainty described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the Company had $568.5 million in cash and cash equivalents and had a working capital deficiency. In January 2024, pursuant to the June 2023 Amendment to the advance purchase agreement between the Company and the Canadian government (the &#x201c;Canada APA&#x201d;), the Company received the second installment of $174.8&#160;million from the Canadian government that was contingent and payable upon the Company&#x2019;s delivery of vaccine doses (see Note 3). During the year ended December&#160;31, 2023, the Company incurred a net loss of $545.1 million and had net cash flows used in operating activities of $714.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 205-40&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, Presentation of Financial Statements - Going Concern&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that these consolidated financial &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;statements are issued. While the Company&#x2019;s current cash flow forecast for the one-year going concern look forward period estimates that there will be sufficient capital available to fund operations, this forecast is subject to significant uncertainty, including as it relates to revenue for the next 12 months and the Company&#x2019;s ability to execute on certain cost-reduction initiatives. The Company&#x2019;s revenue projections depend on its ability to successfully develop, manufacture, distribute and market its updated vaccine for the 2024-2025 vaccination season, which is inherently uncertain and subject to a number of risks, including the Company&#x2019;s ability to obtain regulatory authorizations, introduce a single-dose vial or pre-filled syringe  product presentation for the U.S. commercial and certain other markets, the incidence of COVID-19 during the 2024-2025 vaccination season, the Company&#x2019;s ability to timely deliver doses and achieve commercial adoption and market acceptance of its updated vaccine. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Failure to meet regulatory milestones or achieve product volume or delivery timing obligations under the Company&#x2019;s advance purchase agreements (&#x201c;APAs&#x201d;) may require the Company to refund portions of upfront and other payments or result in reduced future payments which would adversely affect the Company&#x2019;s ability to continue as a going concern. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management believes that, given the history of recurring losses, negative working capital and accumulated deficit, conditions or events exist that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern through one year from the date that these financial statements are issued. Management&#x2019;s plans to alleviate the conditions that exist include restructuring and cost reduction measures and successful execution of its commercial plans. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2023, the Company announced a global restructuring and cost reduction plan (the &#x201c;Restructuring Plan&#x201d;), which includes a more focused investment in its COVID-19 Vaccine, reduction to its pipeline spending, the continued rationalization of its manufacturing network, a reduction to the Company&#x2019;s global workforce, as well as the consolidation of facilities, and infrastructure. In January 2024, as part of reducing combined research and development and selling, general and administrative expenses, the Company announced further reductions in its global workforce (the &#x201c;2024 Cost Reduction Plan&#x201d;) (see Note 18). The Company intends to prioritize improvements to its long-term supply chain efficiency. The Company expects the full annual impact of the Restructuring Plan to be realized in 2024 and the full annual impact of the 2024 Cost Reduction Plan to be realized in 2025 and approximately 85% of the annual impact, excluding one-time charges, to be realized in 2024. During the year ended December&#160;31, 2023, the Company recorded a charge of $4.5&#160;million related to one-time employee severance and benefit costs and recorded an impairment charge of $10.1&#160;million related to the consolidation of facilities and infrastructure (see Note 17) and expects to record an additional charge of approximately $4&#160;million to $7&#160;million related to one-time employee severance and benefit costs, the majority of which is expected to be incurred in the first quarter of 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Management&#x2019;s plans may also include raising additional capital through a combination of equity and debt financing, collaborations, strategic alliances, asset sales, and marketing, distribution, or licensing arrangements. New financings may not be available to the Company on commercially acceptable terms, or at all. Also, any collaborations, strategic alliances, asset sales and marketing, distribution, or licensing arrangements may require the Company to give up some or all of its rights to a product or technology, which in some cases may be at less than the full potential value of such rights. If the Company is unable to obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate some or all of its operations, or further downsize its organization, any of which may have a material adverse effect on its business, financial condition, results of operations, and ability to operate as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Due to the uncertainties associated with management&#x2019;s plans, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern for at least one year from the date that these financial statements are issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in conformity with generally accepted accounting principles in the United States (&#x201c;U.S. GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company analyzes its revenue arrangements to determine the appropriate accounting under U.S. GAAP. Currently, the Company&#x2019;s revenue arrangements represent customer contracts within the scope of ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 606&#x201d;), or are contributions subject to the guidance in ASC Topic 958-605, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Not-for-Profit Entities &#x2013; Revenue Recognition &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 958-605&#x201d;). The Company recognizes revenue from arrangements within the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;scope of ASC 606 following the five-step model: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) it satisfies a performance obligation. The Company only recognizes revenue under the five-step model when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to its customer. The Company recognizes contribution revenue within the scope of ASC 958-605 when the funder-imposed conditions have been substantially met. Contributions are recorded as deferred revenue until the period in which research and development activities are performed that satisfy the funder-imposed conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product Sales - Advance Purchase Agreements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales include sales associated with COVID-19 Vaccine supply agreements, sometimes referred to as APAs, with various international governments. The Company recognizes revenue from product sales related to these APA&#x2019;s based on the transaction price per dose calculated in accordance with ASC 606 at the point in time when control of the product transfers to the customer and customer acceptance has occurred, unless such acceptance provisions are deemed perfunctory. The APAs typically contain terms that include upfront payments which are reflected in Deferred revenue. The Company constrains the transaction price for APA&#x2019;s until it is probable that a significant reversal in revenue recognized will not occur. Specifically, if an APA includes a provision whereby the customer may request a discount, return, or refund, or includes a term that may have the effect of decreasing the price per dose of previously delivered shipments, revenue is constrained based on an estimate of the impact of the transaction price until it is probable that a significant reversal in revenue recognized will not occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product Sales - U.S. Commercial &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2023, the Company commenced sales of COVID-19 Vaccine to the U.S. commercial market. Product sales in the U.S. are primarily made through large pharmaceutical wholesale distributors at the wholesale acquisition cost (&#x201c;WAC&#x201d;). The Company recognizes revenue upon title transfer (which is typically at time of delivery), provided all other revenue recognition criteria have been met. The transaction price includes estimates of variable consideration for which reserves are established that primarily result from invoice discounts for prompt payment, wholesale distributor fees, chargebacks, and product returns (collectively, &#x201c;gross-to-net deductions&#x201d;). These estimates are based on the amounts earned or to be claimed for related sales and are classified as either reductions of gross accounts receivable or a current liability based on the nature of the estimate, the expected settlement method, and net position by individual customer. Where appropriate, these estimates are based on factors such as industry data and forecasted customer buying and payment patterns, the Company&#x2019;s experience, current contractual and statutory requirements, specific known market events, and trends. Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. If actual results vary from estimates, the Company will adjust the estimates, which would affect product sales in the period such variances become known. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross-to-net deductions include the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Wholesale distributor fees, discounts, and chargebacks: The Company has arrangements under which indirect customers such as retailers, healthcare providers, and others receive discounts to the WAC. The chargeback represents the difference between the WAC and this negotiated discounted price. For distribution and related services, the Company incurs service fees to its wholesale distributors. In addition, the Company typically offers wholesale distributor customers invoice discounts on product sales for prompt payments. The Company estimates chargebacks, discounts, and fees it will owe and deducts these amounts from gross product sales at the time the revenue is recognized based on the contractual terms and the Company&#x2019;s expectations regarding future customer behaviors. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Product returns: The Company offers U.S. customers the right to return COVID-19 Vaccine. These return rights include the right of wholesale distributors to return unsold and expired doses and the right of indirect customers to return any partial or unused vials upon expiry. Estimated returns for COVID-19 Vaccine are determined considering levels of inventory in the distribution channel, projected market demand, utilization data, returns claims received, and product shelf life. The estimated amount for product returns is deducted from gross product sales in the period the related product sales are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Other: Fees payable to retailers, healthcare providers, and buying groups, including certain patient assistance programs, are deducted from gross product sales in the period the related product sales are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Grant revenue includes both revenue from government contracts and grants from organizations such as the Coalition for Epidemic Preparedness Innovations (&#x201c;CEPI&#x201d;). The Company performs research and development under government funding, grant, license, and clinical development agreements. The revenue primarily consists of funding under U.S. government contracts and other arrangements to advance the clinical development and manufacturing of COVID-19 Vaccine.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under U.S. government contracts, the Company is entitled to receive funding on a cost-reimbursable or cost-reimbursable-plus-fixed-fee basis, to support certain activities related to the development, manufacture, and delivery of COVID-19 Vaccine to the U.S. government. The Company analyzed these contracts and determined that they are within the scope of ASC 606. The obligations under each of the contracts are not distinct in the context of the contract as they are highly interdependent or interrelated and, as such, they are accounted for as a single performance obligation. The transaction price under these arrangements is the consideration the Company is expecting to receive and consists of the funded contract amount and the unfunded variable amount to the extent that it is probable that a significant reversal of revenue will not occur. The Company recognizes revenue for these contracts over time as the Company transfers control over the goods and services and satisfies the performance obligation. The Company measures progress toward satisfaction of the performance obligation using an Estimate-at-Completion (&#x201c;EAC&#x201d;) process, which is a cost-based input method that reviews and monitors the progress towards the completion of the Company&#x2019;s performance obligation. Under this process, management considers the costs that have been incurred to-date, as well as projections to completion using various inputs and assumptions, including, but not limited to, progress towards completion, labor costs and level of effort, material and subcontractor costs, indirect administrative costs, and other identified risks. Estimating the total allowable cost at completion of the performance obligation under a contract is subjective and requires the Company to make assumptions about future activity and cost drivers. Changes in these estimates can occur for a variety of reasons and, if significant, may impact the timing of revenue and fee recognition on the Company&#x2019;s contracts. Allowable contract costs include direct costs incurred on the contract and indirect costs that are applied in the form of rates to the direct costs. Progress billings under the contracts are initially based on provisional indirect billing rates, agreed upon between the Company and the U.S. government. These indirect rates are subject to review on an annual basis. The Company records the impact of changes in the indirect billing rates in the period when such changes are identified. These changes reflect the difference between actual indirect costs incurred compared to the estimated amounts used to determine the provisional indirect billing rates agreed upon with the U.S. government. The Company recognizes revenue on the U.S. government contracts based on reimbursable allowable contract costs incurred in the period up to the transaction price. For cost-reimbursable-plus-fixed-fee contracts, the Company recognizes the fixed-fee based on the proportion of reimbursable contract costs incurred to total estimated allowable contract costs expected to be incurred on completion of the underlying performance obligation as determined under the EAC process. The Company recognizes changes in estimates related to the EAC process in the period when such changes are made on a cumulative catch-up basis. The Company includes the transaction price comprising both funded and unfunded portions of customer contracts in this estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:28.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s other funding agreements currently include funding from CEPI in the form of a grant (&#x201c;CEPI Grant Funding&#x201d;) and one or more forgivable no interest term loans (&#x201c;CEPI Forgivable Loan Funding&#x201d;). Under the Company&#x2019;s grant funding arrangements, including the CEPI arrangement, the Company is primarily entitled to reimbursement for costs that support development related activities of COVID-19 Vaccine. The Company analyzed these other funding arrangements and determined that they are not within the scope of ASC 606 as they do not provide a direct economic benefit to the grantor. Payments received under the grant funding arrangements are considered conditional contributions under the scope of ASC 958-605 and are recorded as deferred revenue until the period in which such research and development activities are actually performed in a manner that satisfies the funder-imposed conditions. Payments received under the CEPI Forgivable Loan Funding are only repayable if project vaccine, as defined under the CEPI funding agreement, manufactured by the contract manufacturing organization (&#x201c;CMO&#x201d;) network funded by CEPI is sold to one or more third parties (which could include sales credited under the Gavi Settlement Agreement), and such sales cover the Company&#x2019;s costs of manufacturing such vaccine, not including manufacturing costs funded by CEPI. As the financial risk remains with CEPI, the Company determined that the use of the funds from the CEPI agreement is outside the scope of ASC Topic 470, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The research and development risk was considered substantive, such that it was not probable that the development would be successful at the inception of the contract. Therefore, the Company concluded that ASC Topic 730, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 730&#x201d;) was considered applicable and most appropriate. Given the financial risk associated with the research and development activities lies with CEPI because repayment of any funds provided by CEPI depends solely on the results of the research and development activities having future economic benefit, the Company has accounted for the obligation under the CEPI Forgivable Loan Funding as a contract to perform research and development for others. The Company has determined that payments received under these agreements should be recorded as revenue under ASC 958-605 rather than a reduction to research and development expenses. This is consistent with the Company&#x2019;s policy of presenting such amounts as revenue. In reaching this determination, the Company &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;considered a number of factors, including whether it is principal under the arrangement, and whether the arrangement is significant to, and part of, the Company&#x2019;s core operations. The Company will record revenue as it performs the contractual research and development services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments received in advance related to arrangements where revenue is recognized under ASC 958-605 that are related to future performance are deferred and recognized as revenue when the research and development activities are performed. Such cash payments are restricted as to their use and are reflected in Restricted cash until expenditures contemplated in the funding agreements are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Royalties and Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also has various arrangements that include a right for a customer to use the Company's intellectual property as a functional license, where the Company&#x2019;s performance obligation is satisfied at the point in time at which the license is granted. These licensing arrangements include sales-based royalties, certain development and commercial milestone payments, and the sale of proprietary Matrix-M&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; adjuvant. Because development milestone payments are contingent on the achievement of milestones, such as regulatory approvals, that are not within the Company or licensee's control, the payments are not considered probable of being achieved and are excluded from the transaction price until the milestone is achieved, at which point the Company recognizes revenue. For arrangements that include sales-based royalties related to a previously granted license, including milestone payments based upon the achievement of a certain level of product sales, the license is deemed to be the sole or predominant item to which the royalties relate and the Company recognizes revenue when the related sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocates the transaction price to each performance obligation based on a relative standalone selling price basis. It develops assumptions that require judgment to determine the standalone selling price for each performance obligation in consideration of applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales includes cost of raw materials, production, and manufacturing overhead costs associated with the Company&#x2019;s product sales during the period. Cost of sales also includes adjustments for excess, obsolete, or expired inventory; idle capacity; and losses on firm purchase commitments to the extent the cost cannot be recovered based on estimates about future demand. Cost of sales does not include certain expenses related to raw materials, production, and manufacturing overhead costs that were expensed prior to regulatory authorization as described under the caption &#x201c;Inventory.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include salaries; stock-based compensation; laboratory supplies; consultants and subcontractors, including external contract research organizations (&#x201c;CROs&#x201d;), CMOs, and contract development and manufacturing organizations (&#x201c;CDMOs&#x201d;); and other expenses associated with the Company&#x2019;s process development, manufacturing, clinical, regulatory, and quality assurance activities for its clinical development programs. In addition, related indirect costs such as fringe benefits and overhead expenses are also included in research and development expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates its research and development expense related to services performed under its contracts with external service providers based on an estimate of the level of service performed in the period. Research and development activities are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accrues research and development expenses, including clinical trial-related expenses, as the services are performed, which may include estimates of those expenses incurred, but not invoiced. The Company uses information provided by third-party service providers and CRO, CMO, and CDMO invoices and internal estimates to determine the progress of work performed on the Company&#x2019;s behalf. Assumptions based on clinical trial protocols, contracts, and participant enrollment data are also used to estimate these accruals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising costs are expensed as incurred. The Company had advertising costs of $91.5&#160;million, $84.0&#160;million and $8.9&#160;million during the years ended December&#160;31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation related to grants of stock options, stock appreciation rights (&#x201c;SARs&#x201d;), and restricted stock awards (&#x201c;RSUs&#x201d;), and purchases under the Company&#x2019;s Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;), at fair value. The Company recognizes compensation expense related to such awards on a straight-line basis over the requisite service period (generally the vesting period) of the equity awards, based on the award's fair value at the grant date. The requisite service period is typically &lt;span style="-sec-ix-hidden:f-398"&gt;one&lt;/span&gt; to four years. Forfeitures for all awards are recognized as incurred. The Company generally settles stock-based awards with newly issued shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options and SARs is measured on the date of grant using the Black-Scholes option pricing model. The expected term of stock options and SARs is based on the Company&#x2019;s historical option exercise experience and post-vesting forfeiture experience using the historical expected term from the vesting date, and the expected term for purchases under the ESPP is based on the purchase periods included in the offering. The expected volatility is determined using historical volatilities based on stock prices over a look-back period corresponding to the expected term. The risk-free interest rate is determined using the yield available for zero-coupon U.S. government issues with a remaining term equal to the expected term. The Company has never paid a dividend and the Company does not intend to pay dividends in the foreseeable future, and as such, the expected dividend yield is zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of highly liquid investments with maturities of three months or less from the date of purchase. Cash equivalents are recorded at cost, which approximates fair value due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 820&#x201d;), for financial and non-financial assets and liabilities. ASC 820 discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The statement utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3: Unobservable inputs that reflect the reporting entity&#x2019;s own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s current and non-current restricted cash includes payments received under grant agreements and cash collateral accounts under letters of credit that serve as security deposits for certain facility leases. Payments received under grant agreements become unrestricted as the Company incurs expenses for services performed under these agreements. As of December&#160;31, 2023 and 2022, restricted cash balances (both current and non-current) consisted primarily of payments under the CEPI funding agreements and letter of credits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes amounts due from customers as accounts receivable when its right to payment is unconditional. Gross-to-net deductions are classified as reductions of gross accounts receivable if settlement is expected to occur through a reduction in the amount paid to Novavax by its customer. Account receivables are recorded net of any &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;allowance for credit losses. The Company&#x2019;s estimate for the allowance for credit losses, which has not been significant to date, is determined based on the credit risk of its customers based on historical loss experience, economic conditions, the aging of receivables, and customer-specific risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments expose the Company to concentration of credit risk and consist primarily of cash and cash equivalents. The Company&#x2019;s investment policy limits investments to certain types of instruments, including asset-backed securities, high-grade corporate debt securities, and money market funds; places restrictions on maturities and concentrations in certain industries; and requires the Company to maintain a certain level of liquidity. At times, the Company maintains cash balances in financial institutions that may exceed federally insured limits. The Company has not experienced any losses relating to such accounts and believes it is not exposed to a significant credit risk on its cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's accounts receivable arise from revenue arrangements with customers in different countries. The Company's revenue is primarily due to product sales, grants made by government-sponsored and private organizations, and royalties from its collaboration and license partners. The following customers accounted for more than 10% of total revenue or accounts receivable for the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.209%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Percentage of Revenue&lt;br/&gt;&#160;for Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Percentage of Accounts Receivable as of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;European Commission&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government of Australia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government of Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government of Israel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CEPI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;SK bioscience, Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*Amounts represent less than 10%&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Including the USG Agreement (as defined in Note 3) and the U.S. Department of Defense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently depends significantly on one supplier for co-formulation, filling, and finishing of COVID-19 Vaccine. The loss of this supplier could prevent or delay the Company&#x2019;s delivery of customer orders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is recorded at the lower of cost or net realizable value under the First In, First Out methodology, taking into consideration the expiration of the inventory item. The Company determines the cost of raw materials using moving average costs and the cost of semi-finished and finished goods using a standard cost method adjusted on a periodic basis to reflect the deviation in the actual cost from the standard cost estimate. Standard costs consist primarily of the cost of manufacturing goods, including direct materials, direct labor, and the services and products of third-party suppliers. Manufacturing overhead costs are applied to semi-finished and finished goods based on expected production levels. The Company utilizes third-party CMOs, CDMOs, and other suppliers and service organizations to support the procurement and processing of raw materials, management of inventory, packaging, and the delivery process. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess, obsolete, or expired inventory through cost of sales. At each reporting period, the Company assesses whether there are excess firm, non-cancelable, purchase commitment liabilities, resulting from supply agreements with third-party CMOs and CDMOs. The determination of net realizable value of inventory and firm purchase commitment liabilities requires judgment, including consideration of many factors, such as estimates of future product demand, current and future market conditions, potential product obsolescence, expiration and utilization of raw materials under firm purchase commitments, and contractual minimums.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to initial regulatory authorization for its product candidates, the Company expenses costs relating to raw materials, production, and manufacturing overhead costs as research and development expenses in the consolidated statements of operations, in the period incurred. Subsequent to initial regulatory authorization for a product candidate, the Company &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;capitalizes the costs of production for a particular supply chain as inventory when the Company determines that it has a present right to the economic benefit associated with the product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, net of accumulated depreciation. and are depreciated using the straight-line method over the estimated useful lives of the assets. Repairs and maintenance costs are expensed as incurred. The estimated useful lives of property and equipment are described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.316%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of useful life or remaining term of the lease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lease Accounting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into manufacturing supply agreements with CMOs and CDMOs to manufacture its vaccine candidates. Certain of these manufacturing supply agreements include the use of identified manufacturing facilities and equipment that are controlled by the Company and for which the Company obtains substantially all the output and may qualify as an embedded lease. The Company treats manufacturing supply agreements that contain an embedded lease as lease arrangements in their entirety. The evaluation of leases that are embedded in the Company&#x2019;s CMO and CDMO agreements is complex and requires judgment in determining whether the contract, either explicitly or implicitly, is for the use of an identified asset and the Company has the right to direct the use of, and obtain substantially all of the benefit from, the identified asset which generally is the use of a portion of the manufacturing facility of the CMO or CDMO, the term of the lease, and the fixed lease payments under the contract. Depending on the contract, the lease commencement date, defined as the date on which the lessor makes the underlying asset available for use by the lessee and on which the Company is required to accrue lease expenses, may be different than the inception date of the contract. The Company determines the non-cancellable lease term of its embedded leases based on the impact of certain expected milestones on its option to terminate the lease where it is reasonably certain to not exercise that option. The Company evaluates changes to the terms and conditions of a lease contract to determine if they result in a new lease or a modification of an existing lease. For lease modifications, the Company remeasures and reallocates the remaining consideration in the contract and reassesses the lease classification at the effective date of the modification. Leases are classified as either operating or finance leases based on the economic substance of the agreement. The Company also enters into non-cancelable lease agreements for facilities and certain equipment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For leases that have a lease term of more than 12 months at the lease commencement date, the Company recognizes lease liabilities, which represent the Company&#x2019;s obligation to make lease payments arising from the lease, and corresponding right-of-use (&#x201c;ROU&#x201d;) assets, which represent the right to use an underlying asset for the lease term, based on the present value of the fixed future payments over the lease term. The Company calculates the present value of future payments using the discount rate implicit in the lease, if available, or the Company&#x2019;s incremental borrowing rate. For all leases that have a lease term of 12 months or less at the commencement date (referred to as &#x201c;short-term&#x201d; leases), the Company has elected to apply the practical expedient in ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 842&#x201d;), to not recognize a lease liability or ROU asset but, instead, recognize lease payments as an expense on a straight-line basis over the lease term and variable lease payments that do not depend on an index or rate as an expense in the period in which the variable lease costs are incurred based on performance or usage in accordance with contractual agreements. In determining the lease period, the Company evaluates facts and circumstances that could affect the period over which it is reasonably certain to use the underlying asset while taking into consideration the non-cancelable period over which it has the right to use the underlying asset and any option period to extend or terminate the lease if it is reasonably certain to exercise the option. The Company re-evaluates short-term leases that are modified and if they no longer meet the requirements to be treated as a short-term lease, recognizes and measures the lease liability and ROU asset as if the date of the modification is the lease commencement date. For short-term leases that are modified and continue to meet the requirements to be treated as a short-term lease, the Company remeasures the fixed lease payments under the modified lease and recognize lease payments as an expense on a straight-line basis over the modified lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For operating leases, the Company recognizes lease expense related to fixed payments on a straight-line basis from the lease commencement date through the end of the lease term and lease expense related to variable payments as incurred based on performance or usage in accordance with the contractual agreements. For finance leases, the Company recognizes the amortization of the ROU asset over the shorter of the lease term or useful life of the underlying asset. The Company expenses ROU assets acquired for research and development activities under ASC 730 if they do not have an alternative future use, in research and development projects or otherwise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses significant assumptions and judgment in evaluating its lease contracts and other agreements under ASC 842, including the determination of whether an agreement is or contains a lease; whether a change in the terms and conditions of a lease contract represent a new or modified lease; whether a lease represents an operating or finance lease; the discount rate used to determine the present value of lease obligations; the term of a lease embedded in its manufacturing supply agreements; and the Company&#x2019;s incremental borrowing rate, which is determined using estimates such as the estimated value of the underlying leased asset and financial profile of comparable companies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets, including property and equipment, internal-use software, and ROU assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable based on the criteria for accounting for the impairment or disposal of long-lived assets under ASC Topic 360, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, Plant and Equipment.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; If such events or changes in circumstances occur, the Company assesses the recoverability of the long-lived assets (or asset group) by comparing their projected future undiscounted net cash flows over their remaining lives against their respective carrying amounts. If the cash flows are not expected to be sufficient to recover the carrying amount of the assets (or asset group), they are written down to their estimated fair values.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes restructuring charges when such costs are incurred. The Company&#x2019;s restructuring charges consist of employee severance and other termination benefits related to the reduction of its workforce, the consolidation of facilities and infrastructure and other costs. Termination benefits are expensed on the date the Company notifies the employee, unless the employee must provide future service, in which case the benefits are expensed ratably over the future service period. Ongoing benefits are expensed when restructuring activities are probable and the benefit estimable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 17 for additional information on the severance and employee benefit costs for terminated employees and impairment of long-lived assets in connection with the Company&#x2019;s Restructuring Plan and Note 18 for information on the expected severance and employee benefit costs as a result of the Company&#x2019;s workforce reduction announced on January 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Goodwill is subject to impairment tests annually or more frequently should indicators of impairment arise. The Company has determined that, because its only business is the development and commercialization of innovative vaccines, it operates as a single operating segment and has one reporting unit. The one-step impairment test, which requires a comparison of the fair value of a reporting unit to its carrying value, including goodwill, is required to be applied to all reporting units including reporting units with zero or negative carrying value. A reporting unit with a zero or negative carrying value likely will not have an impairment. If the carrying value of the reporting unit exceeds its fair value, step two of the impairment analysis is performed. In step two of the analysis, an impairment loss is recorded equal to the excess of the carrying value of the reporting unit&#x2019;s goodwill over its implied fair value, should such a circumstance arise. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2023 and 2022, the Company had a negative carrying value and did not have any impairment of goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes in accordance with ASC Topic 740,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Under the liability method, deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect of changes in tax rates on deferred tax assets and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;liabilities is recognized in income in the period such changes are enacted. A valuation allowance is established when necessary to reduce net deferred tax assets to the amount expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Global Intangible Low-Taxed Income (&#x201c;GILTI&#x201d;) provisions under the Tax Cuts and Jobs Act of 2017 impose U.S. tax on certain foreign income in excess of a deemed return on tangible assets of foreign corporations. The Company has elected to treat any potential GILTI inclusions as period costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax benefits associated with uncertain tax positions are recognized in the period in which one of the following conditions is satisfied: (1) the more-likely-than-not recognition threshold is satisfied; (2) the position is ultimately settled through negotiation or litigation; or (3) the statute of limitations for the taxing authority to examine and challenge the position has expired. Tax benefits associated with an uncertain tax position are reversed in the period in which the more-likely-than-not recognition threshold is no longer satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has historically generated significant federal, state, and foreign tax net operating losses, which may be subject to limitation in future periods. Management has fully reserved the related deferred tax assets with a valuation allowance in the current reporting period as it is more likely than not that the related benefit will not be realized. The Company is currently subject to examination in all open tax years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted net loss per share is computed using the treasury stock method by dividing net loss by the weighted-average number of common shares outstanding after giving consideration to the dilutive effect of certain securities outstanding during the period. As of December&#160;31, 2023, the Company's 2027 Notes (see Note 10) would have been convertible into approximately 14&#160;million shares of the Company's common stock assuming the common stock price is equal to or greater than $12.50. These shares, after giving effect to the add back of interest expense and unamortized discounts and debt issuance costs on the Notes and any shares due to the Company upon settlement of its capped call transactions, are excluded from the computation, as their effect is antidilutive under the if-converted method. In addition, all stock options, SARs, and unvested RSUs are excluded from the computation as their effect is antidilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements are presented in U.S. dollars. The functional currency of the Company&#x2019;s international subsidiaries is generally the local currency. The financial statements of international subsidiaries are translated to U.S. dollars using the exchange rate in effect at the consolidated balance sheet date for assets and liabilities, historical rates for equity accounts, and average exchange rates for the consolidated statement of operations. Cash flows from operations are translated at the average exchange rate in effect for the period, while cash flows from investing and financing activities are translated at the exchange rate in effect at the date of the underlying transaction. Translation gains and losses are recognized as a component of accumulated other comprehensive income (loss) in the accompanying consolidated balance sheets. The foreign currency translation adjustment balance included in accumulated other comprehensive income (loss) was $2.7 million of income and $6.4 million losses at December&#160;31, 2023 and 2022, respectively. The aggregate foreign currency transaction gains and losses resulting from the conversion of the transaction currency to functional currency were $7.9&#160;million of gains, $2.5&#160;million of losses, and $5.3&#160;million of losses for the years ended December&#160;31, 2023, 2022, and 2021, respectively, which are reflected in Other income (expense).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages its business as one operating segment, the development and commercialization of innovative vaccines. The Company does not operate separate lines of business with respect to its vaccine or vaccine candidates. Accordingly, the Company does not have separately reportable segments as defined by ASC Topic 280, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-06, Disclosure Improvements (&#x201c;ASU 2023-06&#x201d;), to clarify or improve disclosure and presentation requirements of a variety of topics and align the requirements in the FASB ASC with the SEC's regulations. The Company is currently evaluating ASU 2023-06 to determine its impact on the Company's consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (&#x201c;ASU 2023-09&#x201d;). The standard enhances transparency in income tax disclosures by requiring, on an annual basis, certain disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation and income taxes paid. The ASU also requires disaggregated disclosure related to pre-tax income (or loss) and income tax expense (or benefit) and eliminates certain disclosures related to the balance of an entity&#x2019;s unrecognized tax benefit and the cumulative amount of certain temporary differences. The ASU is effective for the Company beginning on January 1, 2025. The Company is currently evaluating ASU 2023-09 to determine its impact on the Company's disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline"&gt;Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU 2016-13&#x201d;), with amendments in 2018, 2019, 2020, and 2022. The ASU sets forth a &#x201c;current expected credit loss&#x201d; model that requires companies to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. ASU 2016-13 applies to financial instruments that are not measured at fair value, including receivables that result from revenue transactions. The Company adopted ASU 2020-06 on January 1, 2023, using a modified retrospective approach, and it did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-377">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Novavax,&#160;Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <nvax:LiquidityAndGoingConcernPolicyTextBlock contextRef="c-1" id="f-378">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern within one year after the date that the financial statements are issued and contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainty described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the Company had $568.5 million in cash and cash equivalents and had a working capital deficiency. In January 2024, pursuant to the June 2023 Amendment to the advance purchase agreement between the Company and the Canadian government (the &#x201c;Canada APA&#x201d;), the Company received the second installment of $174.8&#160;million from the Canadian government that was contingent and payable upon the Company&#x2019;s delivery of vaccine doses (see Note 3). During the year ended December&#160;31, 2023, the Company incurred a net loss of $545.1 million and had net cash flows used in operating activities of $714.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 205-40&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, Presentation of Financial Statements - Going Concern&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that these consolidated financial &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;statements are issued. While the Company&#x2019;s current cash flow forecast for the one-year going concern look forward period estimates that there will be sufficient capital available to fund operations, this forecast is subject to significant uncertainty, including as it relates to revenue for the next 12 months and the Company&#x2019;s ability to execute on certain cost-reduction initiatives. The Company&#x2019;s revenue projections depend on its ability to successfully develop, manufacture, distribute and market its updated vaccine for the 2024-2025 vaccination season, which is inherently uncertain and subject to a number of risks, including the Company&#x2019;s ability to obtain regulatory authorizations, introduce a single-dose vial or pre-filled syringe  product presentation for the U.S. commercial and certain other markets, the incidence of COVID-19 during the 2024-2025 vaccination season, the Company&#x2019;s ability to timely deliver doses and achieve commercial adoption and market acceptance of its updated vaccine. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Failure to meet regulatory milestones or achieve product volume or delivery timing obligations under the Company&#x2019;s advance purchase agreements (&#x201c;APAs&#x201d;) may require the Company to refund portions of upfront and other payments or result in reduced future payments which would adversely affect the Company&#x2019;s ability to continue as a going concern. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management believes that, given the history of recurring losses, negative working capital and accumulated deficit, conditions or events exist that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern through one year from the date that these financial statements are issued. Management&#x2019;s plans to alleviate the conditions that exist include restructuring and cost reduction measures and successful execution of its commercial plans. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2023, the Company announced a global restructuring and cost reduction plan (the &#x201c;Restructuring Plan&#x201d;), which includes a more focused investment in its COVID-19 Vaccine, reduction to its pipeline spending, the continued rationalization of its manufacturing network, a reduction to the Company&#x2019;s global workforce, as well as the consolidation of facilities, and infrastructure. In January 2024, as part of reducing combined research and development and selling, general and administrative expenses, the Company announced further reductions in its global workforce (the &#x201c;2024 Cost Reduction Plan&#x201d;) (see Note 18). The Company intends to prioritize improvements to its long-term supply chain efficiency. The Company expects the full annual impact of the Restructuring Plan to be realized in 2024 and the full annual impact of the 2024 Cost Reduction Plan to be realized in 2025 and approximately 85% of the annual impact, excluding one-time charges, to be realized in 2024. During the year ended December&#160;31, 2023, the Company recorded a charge of $4.5&#160;million related to one-time employee severance and benefit costs and recorded an impairment charge of $10.1&#160;million related to the consolidation of facilities and infrastructure (see Note 17) and expects to record an additional charge of approximately $4&#160;million to $7&#160;million related to one-time employee severance and benefit costs, the majority of which is expected to be incurred in the first quarter of 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Management&#x2019;s plans may also include raising additional capital through a combination of equity and debt financing, collaborations, strategic alliances, asset sales, and marketing, distribution, or licensing arrangements. New financings may not be available to the Company on commercially acceptable terms, or at all. Also, any collaborations, strategic alliances, asset sales and marketing, distribution, or licensing arrangements may require the Company to give up some or all of its rights to a product or technology, which in some cases may be at less than the full potential value of such rights. If the Company is unable to obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate some or all of its operations, or further downsize its organization, any of which may have a material adverse effect on its business, financial condition, results of operations, and ability to operate as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Due to the uncertainties associated with management&#x2019;s plans, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern for at least one year from the date that these financial statements are issued.&lt;/span&gt;&lt;/div&gt;</nvax:LiquidityAndGoingConcernPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-19" decimals="-5" id="f-379" unitRef="usd">568500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <nvax:InstallmentChargesOfTheCompany contextRef="c-58" decimals="-5" id="f-380" unitRef="usd">174800000</nvax:InstallmentChargesOfTheCompany>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-381" unitRef="usd">-545100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-5" id="f-382" unitRef="usd">-714000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent contextRef="c-19" decimals="2" id="f-383" unitRef="number">0.85</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent>
    <us-gaap:SeveranceCosts1 contextRef="c-1" decimals="-5" id="f-384" unitRef="usd">4500000</us-gaap:SeveranceCosts1>
    <us-gaap:AssetImpairmentCharges contextRef="c-1" decimals="-5" id="f-385" unitRef="usd">10100000</us-gaap:AssetImpairmentCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-59" decimals="-5" id="f-386" unitRef="usd">4000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1 contextRef="c-60" decimals="-5" id="f-387" unitRef="usd">7000000</us-gaap:SeveranceCosts1>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-388">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;The preparation of the consolidated financial statements in conformity with generally accepted accounting principles in the United States (&#x201c;U.S. GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</us-gaap:UseOfEstimates>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c-1" id="f-389">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company analyzes its revenue arrangements to determine the appropriate accounting under U.S. GAAP. Currently, the Company&#x2019;s revenue arrangements represent customer contracts within the scope of ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 606&#x201d;), or are contributions subject to the guidance in ASC Topic 958-605, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Not-for-Profit Entities &#x2013; Revenue Recognition &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 958-605&#x201d;). The Company recognizes revenue from arrangements within the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;scope of ASC 606 following the five-step model: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) it satisfies a performance obligation. The Company only recognizes revenue under the five-step model when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to its customer. The Company recognizes contribution revenue within the scope of ASC 958-605 when the funder-imposed conditions have been substantially met. Contributions are recorded as deferred revenue until the period in which research and development activities are performed that satisfy the funder-imposed conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product Sales - Advance Purchase Agreements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales include sales associated with COVID-19 Vaccine supply agreements, sometimes referred to as APAs, with various international governments. The Company recognizes revenue from product sales related to these APA&#x2019;s based on the transaction price per dose calculated in accordance with ASC 606 at the point in time when control of the product transfers to the customer and customer acceptance has occurred, unless such acceptance provisions are deemed perfunctory. The APAs typically contain terms that include upfront payments which are reflected in Deferred revenue. The Company constrains the transaction price for APA&#x2019;s until it is probable that a significant reversal in revenue recognized will not occur. Specifically, if an APA includes a provision whereby the customer may request a discount, return, or refund, or includes a term that may have the effect of decreasing the price per dose of previously delivered shipments, revenue is constrained based on an estimate of the impact of the transaction price until it is probable that a significant reversal in revenue recognized will not occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product Sales - U.S. Commercial &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2023, the Company commenced sales of COVID-19 Vaccine to the U.S. commercial market. Product sales in the U.S. are primarily made through large pharmaceutical wholesale distributors at the wholesale acquisition cost (&#x201c;WAC&#x201d;). The Company recognizes revenue upon title transfer (which is typically at time of delivery), provided all other revenue recognition criteria have been met. The transaction price includes estimates of variable consideration for which reserves are established that primarily result from invoice discounts for prompt payment, wholesale distributor fees, chargebacks, and product returns (collectively, &#x201c;gross-to-net deductions&#x201d;). These estimates are based on the amounts earned or to be claimed for related sales and are classified as either reductions of gross accounts receivable or a current liability based on the nature of the estimate, the expected settlement method, and net position by individual customer. Where appropriate, these estimates are based on factors such as industry data and forecasted customer buying and payment patterns, the Company&#x2019;s experience, current contractual and statutory requirements, specific known market events, and trends. Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. If actual results vary from estimates, the Company will adjust the estimates, which would affect product sales in the period such variances become known. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross-to-net deductions include the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Wholesale distributor fees, discounts, and chargebacks: The Company has arrangements under which indirect customers such as retailers, healthcare providers, and others receive discounts to the WAC. The chargeback represents the difference between the WAC and this negotiated discounted price. For distribution and related services, the Company incurs service fees to its wholesale distributors. In addition, the Company typically offers wholesale distributor customers invoice discounts on product sales for prompt payments. The Company estimates chargebacks, discounts, and fees it will owe and deducts these amounts from gross product sales at the time the revenue is recognized based on the contractual terms and the Company&#x2019;s expectations regarding future customer behaviors. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Product returns: The Company offers U.S. customers the right to return COVID-19 Vaccine. These return rights include the right of wholesale distributors to return unsold and expired doses and the right of indirect customers to return any partial or unused vials upon expiry. Estimated returns for COVID-19 Vaccine are determined considering levels of inventory in the distribution channel, projected market demand, utilization data, returns claims received, and product shelf life. The estimated amount for product returns is deducted from gross product sales in the period the related product sales are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Other: Fees payable to retailers, healthcare providers, and buying groups, including certain patient assistance programs, are deducted from gross product sales in the period the related product sales are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Grant revenue includes both revenue from government contracts and grants from organizations such as the Coalition for Epidemic Preparedness Innovations (&#x201c;CEPI&#x201d;). The Company performs research and development under government funding, grant, license, and clinical development agreements. The revenue primarily consists of funding under U.S. government contracts and other arrangements to advance the clinical development and manufacturing of COVID-19 Vaccine.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under U.S. government contracts, the Company is entitled to receive funding on a cost-reimbursable or cost-reimbursable-plus-fixed-fee basis, to support certain activities related to the development, manufacture, and delivery of COVID-19 Vaccine to the U.S. government. The Company analyzed these contracts and determined that they are within the scope of ASC 606. The obligations under each of the contracts are not distinct in the context of the contract as they are highly interdependent or interrelated and, as such, they are accounted for as a single performance obligation. The transaction price under these arrangements is the consideration the Company is expecting to receive and consists of the funded contract amount and the unfunded variable amount to the extent that it is probable that a significant reversal of revenue will not occur. The Company recognizes revenue for these contracts over time as the Company transfers control over the goods and services and satisfies the performance obligation. The Company measures progress toward satisfaction of the performance obligation using an Estimate-at-Completion (&#x201c;EAC&#x201d;) process, which is a cost-based input method that reviews and monitors the progress towards the completion of the Company&#x2019;s performance obligation. Under this process, management considers the costs that have been incurred to-date, as well as projections to completion using various inputs and assumptions, including, but not limited to, progress towards completion, labor costs and level of effort, material and subcontractor costs, indirect administrative costs, and other identified risks. Estimating the total allowable cost at completion of the performance obligation under a contract is subjective and requires the Company to make assumptions about future activity and cost drivers. Changes in these estimates can occur for a variety of reasons and, if significant, may impact the timing of revenue and fee recognition on the Company&#x2019;s contracts. Allowable contract costs include direct costs incurred on the contract and indirect costs that are applied in the form of rates to the direct costs. Progress billings under the contracts are initially based on provisional indirect billing rates, agreed upon between the Company and the U.S. government. These indirect rates are subject to review on an annual basis. The Company records the impact of changes in the indirect billing rates in the period when such changes are identified. These changes reflect the difference between actual indirect costs incurred compared to the estimated amounts used to determine the provisional indirect billing rates agreed upon with the U.S. government. The Company recognizes revenue on the U.S. government contracts based on reimbursable allowable contract costs incurred in the period up to the transaction price. For cost-reimbursable-plus-fixed-fee contracts, the Company recognizes the fixed-fee based on the proportion of reimbursable contract costs incurred to total estimated allowable contract costs expected to be incurred on completion of the underlying performance obligation as determined under the EAC process. The Company recognizes changes in estimates related to the EAC process in the period when such changes are made on a cumulative catch-up basis. The Company includes the transaction price comprising both funded and unfunded portions of customer contracts in this estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:28.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s other funding agreements currently include funding from CEPI in the form of a grant (&#x201c;CEPI Grant Funding&#x201d;) and one or more forgivable no interest term loans (&#x201c;CEPI Forgivable Loan Funding&#x201d;). Under the Company&#x2019;s grant funding arrangements, including the CEPI arrangement, the Company is primarily entitled to reimbursement for costs that support development related activities of COVID-19 Vaccine. The Company analyzed these other funding arrangements and determined that they are not within the scope of ASC 606 as they do not provide a direct economic benefit to the grantor. Payments received under the grant funding arrangements are considered conditional contributions under the scope of ASC 958-605 and are recorded as deferred revenue until the period in which such research and development activities are actually performed in a manner that satisfies the funder-imposed conditions. Payments received under the CEPI Forgivable Loan Funding are only repayable if project vaccine, as defined under the CEPI funding agreement, manufactured by the contract manufacturing organization (&#x201c;CMO&#x201d;) network funded by CEPI is sold to one or more third parties (which could include sales credited under the Gavi Settlement Agreement), and such sales cover the Company&#x2019;s costs of manufacturing such vaccine, not including manufacturing costs funded by CEPI. As the financial risk remains with CEPI, the Company determined that the use of the funds from the CEPI agreement is outside the scope of ASC Topic 470, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The research and development risk was considered substantive, such that it was not probable that the development would be successful at the inception of the contract. Therefore, the Company concluded that ASC Topic 730, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 730&#x201d;) was considered applicable and most appropriate. Given the financial risk associated with the research and development activities lies with CEPI because repayment of any funds provided by CEPI depends solely on the results of the research and development activities having future economic benefit, the Company has accounted for the obligation under the CEPI Forgivable Loan Funding as a contract to perform research and development for others. The Company has determined that payments received under these agreements should be recorded as revenue under ASC 958-605 rather than a reduction to research and development expenses. This is consistent with the Company&#x2019;s policy of presenting such amounts as revenue. In reaching this determination, the Company &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;considered a number of factors, including whether it is principal under the arrangement, and whether the arrangement is significant to, and part of, the Company&#x2019;s core operations. The Company will record revenue as it performs the contractual research and development services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments received in advance related to arrangements where revenue is recognized under ASC 958-605 that are related to future performance are deferred and recognized as revenue when the research and development activities are performed. Such cash payments are restricted as to their use and are reflected in Restricted cash until expenditures contemplated in the funding agreements are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Royalties and Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also has various arrangements that include a right for a customer to use the Company's intellectual property as a functional license, where the Company&#x2019;s performance obligation is satisfied at the point in time at which the license is granted. These licensing arrangements include sales-based royalties, certain development and commercial milestone payments, and the sale of proprietary Matrix-M&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; adjuvant. Because development milestone payments are contingent on the achievement of milestones, such as regulatory approvals, that are not within the Company or licensee's control, the payments are not considered probable of being achieved and are excluded from the transaction price until the milestone is achieved, at which point the Company recognizes revenue. For arrangements that include sales-based royalties related to a previously granted license, including milestone payments based upon the achievement of a certain level of product sales, the license is deemed to be the sole or predominant item to which the royalties relate and the Company recognizes revenue when the related sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocates the transaction price to each performance obligation based on a relative standalone selling price basis. It develops assumptions that require judgment to determine the standalone selling price for each performance obligation in consideration of applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="c-1" id="f-390">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales includes cost of raw materials, production, and manufacturing overhead costs associated with the Company&#x2019;s product sales during the period. Cost of sales also includes adjustments for excess, obsolete, or expired inventory; idle capacity; and losses on firm purchase commitments to the extent the cost cannot be recovered based on estimates about future demand. Cost of sales does not include certain expenses related to raw materials, production, and manufacturing overhead costs that were expensed prior to regulatory authorization as described under the caption &#x201c;Inventory.&#x201d;&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-391">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include salaries; stock-based compensation; laboratory supplies; consultants and subcontractors, including external contract research organizations (&#x201c;CROs&#x201d;), CMOs, and contract development and manufacturing organizations (&#x201c;CDMOs&#x201d;); and other expenses associated with the Company&#x2019;s process development, manufacturing, clinical, regulatory, and quality assurance activities for its clinical development programs. In addition, related indirect costs such as fringe benefits and overhead expenses are also included in research and development expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates its research and development expense related to services performed under its contracts with external service providers based on an estimate of the level of service performed in the period. Research and development activities are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <nvax:AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock contextRef="c-1" id="f-392">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accrues research and development expenses, including clinical trial-related expenses, as the services are performed, which may include estimates of those expenses incurred, but not invoiced. The Company uses information provided by third-party service providers and CRO, CMO, and CDMO invoices and internal estimates to determine the progress of work performed on the Company&#x2019;s behalf. Assumptions based on clinical trial protocols, contracts, and participant enrollment data are also used to estimate these accruals.&lt;/span&gt;&lt;/div&gt;</nvax:AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="c-1" id="f-393">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising costs are expensed as incurred. The Company had advertising costs of $91.5&#160;million, $84.0&#160;million and $8.9&#160;million during the years ended December&#160;31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense contextRef="c-1" decimals="-5" id="f-394" unitRef="usd">91500000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c-17" decimals="-5" id="f-395" unitRef="usd">84000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c-18" decimals="-5" id="f-396" unitRef="usd">8900000</us-gaap:AdvertisingExpense>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="c-1" id="f-397">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation related to grants of stock options, stock appreciation rights (&#x201c;SARs&#x201d;), and restricted stock awards (&#x201c;RSUs&#x201d;), and purchases under the Company&#x2019;s Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;), at fair value. The Company recognizes compensation expense related to such awards on a straight-line basis over the requisite service period (generally the vesting period) of the equity awards, based on the award's fair value at the grant date. The requisite service period is typically &lt;span style="-sec-ix-hidden:f-398"&gt;one&lt;/span&gt; to four years. Forfeitures for all awards are recognized as incurred. The Company generally settles stock-based awards with newly issued shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options and SARs is measured on the date of grant using the Black-Scholes option pricing model. The expected term of stock options and SARs is based on the Company&#x2019;s historical option exercise experience and post-vesting forfeiture experience using the historical expected term from the vesting date, and the expected term for purchases under the ESPP is based on the purchase periods included in the offering. The expected volatility is determined using historical volatilities based on stock prices over a look-back period corresponding to the expected term. The risk-free interest rate is determined using the yield available for zero-coupon U.S. government issues with a remaining term equal to the expected term. The Company has never paid a dividend and the Company does not intend to pay dividends in the foreseeable future, and as such, the expected dividend yield is zero.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c-62" id="f-399">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-400">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of highly liquid investments with maturities of three months or less from the date of purchase. Cash equivalents are recorded at cost, which approximates fair value due to their short-term nature.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-401">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 820&#x201d;), for financial and non-financial assets and liabilities. ASC 820 discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The statement utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3: Unobservable inputs that reflect the reporting entity&#x2019;s own assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c-1" id="f-402">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s current and non-current restricted cash includes payments received under grant agreements and cash collateral accounts under letters of credit that serve as security deposits for certain facility leases. Payments received under grant agreements become unrestricted as the Company incurs expenses for services performed under these agreements. As of December&#160;31, 2023 and 2022, restricted cash balances (both current and non-current) consisted primarily of payments under the CEPI funding agreements and letter of credits.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c-1" id="f-403">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes amounts due from customers as accounts receivable when its right to payment is unconditional. Gross-to-net deductions are classified as reductions of gross accounts receivable if settlement is expected to occur through a reduction in the amount paid to Novavax by its customer. Account receivables are recorded net of any &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;allowance for credit losses. The Company&#x2019;s estimate for the allowance for credit losses, which has not been significant to date, is determined based on the credit risk of its customers based on historical loss experience, economic conditions, the aging of receivables, and customer-specific risks.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-404">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments expose the Company to concentration of credit risk and consist primarily of cash and cash equivalents. The Company&#x2019;s investment policy limits investments to certain types of instruments, including asset-backed securities, high-grade corporate debt securities, and money market funds; places restrictions on maturities and concentrations in certain industries; and requires the Company to maintain a certain level of liquidity. At times, the Company maintains cash balances in financial institutions that may exceed federally insured limits. The Company has not experienced any losses relating to such accounts and believes it is not exposed to a significant credit risk on its cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently depends significantly on one supplier for co-formulation, filling, and finishing of COVID-19 Vaccine. The loss of this supplier could prevent or delay the Company&#x2019;s delivery of customer orders.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="c-1" id="f-405">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's accounts receivable arise from revenue arrangements with customers in different countries. The Company's revenue is primarily due to product sales, grants made by government-sponsored and private organizations, and royalties from its collaboration and license partners. The following customers accounted for more than 10% of total revenue or accounts receivable for the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.209%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Percentage of Revenue&lt;br/&gt;&#160;for Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Percentage of Accounts Receivable as of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;European Commission&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government of Australia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government of Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government of Israel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CEPI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;SK bioscience, Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*Amounts represent less than 10%&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Including the USG Agreement (as defined in Note 3) and the U.S. Department of Defense.&lt;/span&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-63" decimals="2" id="f-406" unitRef="number">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-64" decimals="2" id="f-407" unitRef="number">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-65" decimals="2" id="f-408" unitRef="number">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-66" decimals="2" id="f-409" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-67" decimals="2" id="f-410" unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-68" decimals="2" id="f-411" unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-69" decimals="2" id="f-412" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-70" decimals="2" id="f-413" unitRef="number">0.59</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-71" decimals="2" id="f-414" unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-72" decimals="2" id="f-415" unitRef="number">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-73" decimals="2" id="f-416" unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-74" decimals="2" id="f-417" unitRef="number">0.71</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-75" decimals="2" id="f-418" unitRef="number">0.46</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-76" decimals="2" id="f-419" unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-77" decimals="2" id="f-420" unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-421">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is recorded at the lower of cost or net realizable value under the First In, First Out methodology, taking into consideration the expiration of the inventory item. The Company determines the cost of raw materials using moving average costs and the cost of semi-finished and finished goods using a standard cost method adjusted on a periodic basis to reflect the deviation in the actual cost from the standard cost estimate. Standard costs consist primarily of the cost of manufacturing goods, including direct materials, direct labor, and the services and products of third-party suppliers. Manufacturing overhead costs are applied to semi-finished and finished goods based on expected production levels. The Company utilizes third-party CMOs, CDMOs, and other suppliers and service organizations to support the procurement and processing of raw materials, management of inventory, packaging, and the delivery process. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess, obsolete, or expired inventory through cost of sales. At each reporting period, the Company assesses whether there are excess firm, non-cancelable, purchase commitment liabilities, resulting from supply agreements with third-party CMOs and CDMOs. The determination of net realizable value of inventory and firm purchase commitment liabilities requires judgment, including consideration of many factors, such as estimates of future product demand, current and future market conditions, potential product obsolescence, expiration and utilization of raw materials under firm purchase commitments, and contractual minimums.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to initial regulatory authorization for its product candidates, the Company expenses costs relating to raw materials, production, and manufacturing overhead costs as research and development expenses in the consolidated statements of operations, in the period incurred. Subsequent to initial regulatory authorization for a product candidate, the Company &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;capitalizes the costs of production for a particular supply chain as inventory when the Company determines that it has a present right to the economic benefit associated with the product.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-422">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;Property and equipment are stated at cost, net of accumulated depreciation. and are depreciated using the straight-line method over the estimated useful lives of the assets. Repairs and maintenance costs are expensed as incurred.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-423">The estimated useful lives of property and equipment are described below:&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.316%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of useful life or remaining term of the lease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is comprised of the following as of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.706%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and buildings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;380,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;341,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74,968)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;305,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;294,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-78" id="f-424">P25Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-79" id="f-425">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-80" id="f-426">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-81" id="f-427">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-428">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lease Accounting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into manufacturing supply agreements with CMOs and CDMOs to manufacture its vaccine candidates. Certain of these manufacturing supply agreements include the use of identified manufacturing facilities and equipment that are controlled by the Company and for which the Company obtains substantially all the output and may qualify as an embedded lease. The Company treats manufacturing supply agreements that contain an embedded lease as lease arrangements in their entirety. The evaluation of leases that are embedded in the Company&#x2019;s CMO and CDMO agreements is complex and requires judgment in determining whether the contract, either explicitly or implicitly, is for the use of an identified asset and the Company has the right to direct the use of, and obtain substantially all of the benefit from, the identified asset which generally is the use of a portion of the manufacturing facility of the CMO or CDMO, the term of the lease, and the fixed lease payments under the contract. Depending on the contract, the lease commencement date, defined as the date on which the lessor makes the underlying asset available for use by the lessee and on which the Company is required to accrue lease expenses, may be different than the inception date of the contract. The Company determines the non-cancellable lease term of its embedded leases based on the impact of certain expected milestones on its option to terminate the lease where it is reasonably certain to not exercise that option. The Company evaluates changes to the terms and conditions of a lease contract to determine if they result in a new lease or a modification of an existing lease. For lease modifications, the Company remeasures and reallocates the remaining consideration in the contract and reassesses the lease classification at the effective date of the modification. Leases are classified as either operating or finance leases based on the economic substance of the agreement. The Company also enters into non-cancelable lease agreements for facilities and certain equipment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For leases that have a lease term of more than 12 months at the lease commencement date, the Company recognizes lease liabilities, which represent the Company&#x2019;s obligation to make lease payments arising from the lease, and corresponding right-of-use (&#x201c;ROU&#x201d;) assets, which represent the right to use an underlying asset for the lease term, based on the present value of the fixed future payments over the lease term. The Company calculates the present value of future payments using the discount rate implicit in the lease, if available, or the Company&#x2019;s incremental borrowing rate. For all leases that have a lease term of 12 months or less at the commencement date (referred to as &#x201c;short-term&#x201d; leases), the Company has elected to apply the practical expedient in ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 842&#x201d;), to not recognize a lease liability or ROU asset but, instead, recognize lease payments as an expense on a straight-line basis over the lease term and variable lease payments that do not depend on an index or rate as an expense in the period in which the variable lease costs are incurred based on performance or usage in accordance with contractual agreements. In determining the lease period, the Company evaluates facts and circumstances that could affect the period over which it is reasonably certain to use the underlying asset while taking into consideration the non-cancelable period over which it has the right to use the underlying asset and any option period to extend or terminate the lease if it is reasonably certain to exercise the option. The Company re-evaluates short-term leases that are modified and if they no longer meet the requirements to be treated as a short-term lease, recognizes and measures the lease liability and ROU asset as if the date of the modification is the lease commencement date. For short-term leases that are modified and continue to meet the requirements to be treated as a short-term lease, the Company remeasures the fixed lease payments under the modified lease and recognize lease payments as an expense on a straight-line basis over the modified lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For operating leases, the Company recognizes lease expense related to fixed payments on a straight-line basis from the lease commencement date through the end of the lease term and lease expense related to variable payments as incurred based on performance or usage in accordance with the contractual agreements. For finance leases, the Company recognizes the amortization of the ROU asset over the shorter of the lease term or useful life of the underlying asset. The Company expenses ROU assets acquired for research and development activities under ASC 730 if they do not have an alternative future use, in research and development projects or otherwise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses significant assumptions and judgment in evaluating its lease contracts and other agreements under ASC 842, including the determination of whether an agreement is or contains a lease; whether a change in the terms and conditions of a lease contract represent a new or modified lease; whether a lease represents an operating or finance lease; the discount rate used to determine the present value of lease obligations; the term of a lease embedded in its manufacturing supply agreements; and the Company&#x2019;s incremental borrowing rate, which is determined using estimates such as the estimated value of the underlying leased asset and financial profile of comparable companies.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-429">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets, including property and equipment, internal-use software, and ROU assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable based on the criteria for accounting for the impairment or disposal of long-lived assets under ASC Topic 360, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, Plant and Equipment.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; If such events or changes in circumstances occur, the Company assesses the recoverability of the long-lived assets (or asset group) by comparing their projected future undiscounted net cash flows over their remaining lives against their respective carrying amounts. If the cash flows are not expected to be sufficient to recover the carrying amount of the assets (or asset group), they are written down to their estimated fair values.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy contextRef="c-1" id="f-430">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes restructuring charges when such costs are incurred. The Company&#x2019;s restructuring charges consist of employee severance and other termination benefits related to the reduction of its workforce, the consolidation of facilities and infrastructure and other costs. Termination benefits are expensed on the date the Company notifies the employee, unless the employee must provide future service, in which case the benefits are expensed ratably over the future service period. Ongoing benefits are expensed when restructuring activities are probable and the benefit estimable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 17 for additional information on the severance and employee benefit costs for terminated employees and impairment of long-lived assets in connection with the Company&#x2019;s Restructuring Plan and Note 18 for information on the expected severance and employee benefit costs as a result of the Company&#x2019;s workforce reduction announced on January 31, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="c-1" id="f-431">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Goodwill is subject to impairment tests annually or more frequently should indicators of impairment arise. The Company has determined that, because its only business is the development and commercialization of innovative vaccines, it operates as a single operating segment and has one reporting unit. The one-step impairment test, which requires a comparison of the fair value of a reporting unit to its carrying value, including goodwill, is required to be applied to all reporting units including reporting units with zero or negative carrying value. A reporting unit with a zero or negative carrying value likely will not have an impairment. If the carrying value of the reporting unit exceeds its fair value, step two of the impairment analysis is performed. In step two of the analysis, an impairment loss is recorded equal to the excess of the carrying value of the reporting unit&#x2019;s goodwill over its implied fair value, should such a circumstance arise. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2023 and 2022, the Company had a negative carrying value and did not have any impairment of goodwill.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:NumberOfReportingUnits
      contextRef="c-1"
      decimals="INF"
      id="f-432"
      unitRef="reporting_unit">1</us-gaap:NumberOfReportingUnits>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-17" decimals="INF" id="f-433" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="INF" id="f-434" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-435">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes in accordance with ASC Topic 740,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Under the liability method, deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect of changes in tax rates on deferred tax assets and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;liabilities is recognized in income in the period such changes are enacted. A valuation allowance is established when necessary to reduce net deferred tax assets to the amount expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Global Intangible Low-Taxed Income (&#x201c;GILTI&#x201d;) provisions under the Tax Cuts and Jobs Act of 2017 impose U.S. tax on certain foreign income in excess of a deemed return on tangible assets of foreign corporations. The Company has elected to treat any potential GILTI inclusions as period costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax benefits associated with uncertain tax positions are recognized in the period in which one of the following conditions is satisfied: (1) the more-likely-than-not recognition threshold is satisfied; (2) the position is ultimately settled through negotiation or litigation; or (3) the statute of limitations for the taxing authority to examine and challenge the position has expired. Tax benefits associated with an uncertain tax position are reversed in the period in which the more-likely-than-not recognition threshold is no longer satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has historically generated significant federal, state, and foreign tax net operating losses, which may be subject to limitation in future periods. Management has fully reserved the related deferred tax assets with a valuation allowance in the current reporting period as it is more likely than not that the related benefit will not be realized. The Company is currently subject to examination in all open tax years.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-436">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted net loss per share is computed using the treasury stock method by dividing net loss by the weighted-average number of common shares outstanding after giving consideration to the dilutive effect of certain securities outstanding during the period.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="c-82" decimals="-6" id="f-437" unitRef="shares">14000000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-83"
      decimals="2"
      id="f-438"
      unitRef="usdPerShare">12.50</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-439">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;The accompanying consolidated financial statements are presented in U.S. dollars. The functional currency of the Company&#x2019;s international subsidiaries is generally the local currency. The financial statements of international subsidiaries are translated to U.S. dollars using the exchange rate in effect at the consolidated balance sheet date for assets and liabilities, historical rates for equity accounts, and average exchange rates for the consolidated statement of operations. Cash flows from operations are translated at the average exchange rate in effect for the period, while cash flows from investing and financing activities are translated at the exchange rate in effect at the date of the underlying transaction. Translation gains and losses are recognized as a component of accumulated other comprehensive income (loss) in the accompanying consolidated balance sheets.</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax contextRef="c-19" decimals="-5" id="f-440" unitRef="usd">2700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax contextRef="c-20" decimals="-5" id="f-441" unitRef="usd">-6400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax contextRef="c-1" decimals="-5" id="f-442" unitRef="usd">7900000</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax contextRef="c-17" decimals="-5" id="f-443" unitRef="usd">-2500000</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax contextRef="c-18" decimals="-5" id="f-444" unitRef="usd">-5300000</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-445">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages its business as one operating segment, the development and commercialization of innovative vaccines. The Company does not operate separate lines of business with respect to its vaccine or vaccine candidates. Accordingly, the Company does not have separately reportable segments as defined by ASC Topic 280, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-446"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-447">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-06, Disclosure Improvements (&#x201c;ASU 2023-06&#x201d;), to clarify or improve disclosure and presentation requirements of a variety of topics and align the requirements in the FASB ASC with the SEC's regulations. The Company is currently evaluating ASU 2023-06 to determine its impact on the Company's consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (&#x201c;ASU 2023-09&#x201d;). The standard enhances transparency in income tax disclosures by requiring, on an annual basis, certain disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation and income taxes paid. The ASU also requires disaggregated disclosure related to pre-tax income (or loss) and income tax expense (or benefit) and eliminates certain disclosures related to the balance of an entity&#x2019;s unrecognized tax benefit and the cumulative amount of certain temporary differences. The ASU is effective for the Company beginning on January 1, 2025. The Company is currently evaluating ASU 2023-09 to determine its impact on the Company's disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline"&gt;Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU 2016-13&#x201d;), with amendments in 2018, 2019, 2020, and 2022. The ASU sets forth a &#x201c;current expected credit loss&#x201d; model that requires companies to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. ASU 2016-13 applies to financial instruments that are not measured at fair value, including receivables that result from revenue transactions. The Company adopted ASU 2020-06 on January 1, 2023, using a modified retrospective approach, and it did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-448">Revenue&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's accounts receivable, net, included $286.4 million and $53.8 million related to amounts that were billed to customers and $10.8 million and $28.6 million related to amounts which had not yet been billed to customers as of December&#160;31, 2023 and 2022, respectively. During the years ended December&#160;31, 2023 and 2022, changes in the Company's accounts receivables, deferred revenue, and allowance for doubtful accounts balances were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.747%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.010%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance, Beginning of Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deductions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance, End of Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts receivable:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,472,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,264,062)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,768,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,127,240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Allowance for doubtful accounts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,676)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(267,599)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,092,829)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Bad debt expense was $13.8&#160;million in the year ended 2022. There was no bad debt expense in the year ended December 31, 2023 or 2021. There was a $6.2&#160;million reversal of a bad debt expense during the year ended December&#160;31, 2023 due to the collection of a previously recognized allowance for doubtful accounts. To estimate the allowance for doubtful accounts, the Company evaluates the credit risk related to its customers based on historical loss experience, economic conditions, the aging of receivables, and customer-specific risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&#160;&#160;&#160;&#160;Deductions from Deferred revenue generally related to the recognition of revenue once performance obligations on a contract with a customer are met. Amount is comprised of $241.3&#160;million, $0.4&#160;billion, and $1.4&#160;billion current Deferred &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;revenue and $622.2&#160;million, $179.4&#160;million, and $172.5&#160;million non-current Deferred revenue as of December&#160;31, 2023, 2022, and 2021 respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&#160;&#160;&#160;&#160;In 2023, deductions from Deferred revenue included $151.1&#160;million that was realized in Revenue and $112.5&#160;million related to the Amended and Restated UK Supply Agreement (as described below), that was reclassified to Other current liabilities, as described below. In 2022, deduction from Deferred revenue included $273.8&#160;million that was realized in Revenue and $819.0&#160;million, including $697.4&#160;million related to the Advance Payment Amount (as described below) related to the Gavi arbitration and $112.5&#160;million related to the Amended and Restated UK Supply Agreement, that was reclassified to Other current liabilities, as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the aggregate amount of the transaction price allocated to performance obligations that were unsatisfied (or partially unsatisfied), excluding amounts related to sales-based royalties, the Gavi APA, and the reduction in doses related to the Amended and Restated SARS-CoV-2 Vaccine Supply Agreement, dated as of July 1, 2022 (as amended on September 26, 2022, the &#x201c;Amended and Restated UK Supply Agreement&#x201d;) between the Company and The Secretary of State for Business, Energy and Industrial Strategy (as assigned to the UK Health Security Agency), acting on behalf of the government of the United Kingdom of Great Britain and Northern Ireland (the &#x201c;Authority&#x201d;), which amended and restated the Original UK Supply Agreement, was approximately $2&#160;billion of which $863.5&#160;million was included in Deferred revenue. Failure to meet regulatory milestones, obtain timely supportive recommendations from governmental advisory committees, or achieve product volume or delivery timing obligations under the Company&#x2019;s APAs may require the Company to refund portions of upfront payments or result in reduced future payments, which could adversely impact the Company&#x2019;s ability to realize revenue from its unsatisfied performance obligations. The timing to fulfill performance obligations related to APAs will depend on timing of product manufacturing, receipt of marketing authorizations for additional indications, delivery of doses based on customer demand, and the ability of the customer to request variant vaccine in place of the prototype vaccine under certain of the Company&#x2019;s APAs. The remaining unfilled performance obligations not related to APAs are expected to be fulfilled in less than one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Gavi APA and a separate purchase agreement between Gavi and SIIPL, 1.1&#160;billion doses of the prototype vaccine were to be made available to countries participating in the COVAX Facility. The Company expected to manufacture and distribute 350&#160;million doses of the prototype vaccine to countries participating under the COVAX Facility. Under a separate purchase agreement with Gavi, SIIPL was expected to manufacture and deliver the balance of the 1.1&#160;billion doses of prototype vaccine for low- and middle-income countries participating in the COVAX Facility. The Company expected to deliver doses with antigen and adjuvant manufactured at facilities directly funded under the Company's funding agreement with CEPI, with initial doses supplied by SIIPL and SLS under a supply agreement. The Company expected to supply significant doses that Gavi would allocate to low-, middle- and high-income countries, subject to certain limitations, utilizing a tiered pricing schedule and Gavi could prioritize such doses to low- and middle- income countries, at lower prices. Additionally, the Company could provide additional doses of prototype vaccine, to the extent available from CEPI-funded manufacturing facilities, in the event that SIIPL could not materially deliver expected vaccine doses to the COVAX Facility. Under the agreement, the Company received an upfront payment of $350.0&#160;million from Gavi in 2021 and an additional payment of $350.0&#160;million in 2022 related to the Company&#x2019;s achieving an emergency use license for the Company&#x2019;s prototype vaccine by the World Health Organization (&#x201c;WHO&#x201d;) (the &#x201c;Advance Payment Amount&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 18, 2022, the Company delivered written notice to Gavi to terminate the Gavi APA on the basis of Gavi&#x2019;s failure to procure the purchase of 350&#160;million doses of the Company&#x2019;s prototype vaccine from the Company as required by the Gavi APA. As of November 18, 2022, the Company had only received orders under the Gavi APA for approximately 2&#160;million doses. On December 2, 2022, Gavi issued a written notice purporting to terminate the Gavi APA based on Gavi&#x2019;s contention that the Company repudiated the agreement and, therefore, materially breached the Gavi APA. Gavi also contended that, based on its purported termination of the Gavi APA, it was entitled to a refund of the Advance Payment Amount less any amounts that have been credited against the purchase price for binding orders placed by a buyer participating in the COVAX Facility. As of December&#160;31, 2023 and 2022, the remaining Gavi Advance Payment was $696.4&#160;million and $697.4&#160;million, respectively, pending resolution of the dispute with Gavi related to the return of the remaining Advance Payment Amount, and was classified within Other current liabilities in the Company&#x2019;s consolidated balance sheet. On January 24, 2023, Gavi filed a demand for arbitration with the International Court of Arbitration based on the claims described above. The Company filed its Answer and Counterclaims on March 2, 2023. On April 5, 2023, Gavi filed its Reply to the Company&#x2019;s Counterclaims. On February 16, 2024, the Company and Gavi entered into a Termination and Settlement Agreement (the &#x201c;Gavi Settlement Agreement&#x201d;) terminating the Gavi APA, settling the arbitration proceedings and releasing both parties of all claims arising from, under or otherwise in connection with the Gavi APA. Pursuant to the Gavi Settlement Agreement, the Company is responsible for payment to Gavi of (i) an initial settlement payment of $75&#160;million, which the Company paid on February 20, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024, and (ii) deferred payments, in equal annual amounts of $80&#160;million payable each calendar year through a deferred payment term ending December 31, 2028. The deferred payments are due in variable quarterly installments beginning in the first quarter of 2024 and total $400&#160;million during the deferred payment term. Such deferred payments may be reduced through Gavi&#x2019;s use of an annual vaccine credit equivalent to the unpaid balance of such deferred payments each year, which may be applied to qualifying sales of any of the Company&#x2019;s vaccines for supply to certain low-income and lower-middle income countries. The Company has the right to price the vaccines offered to such low-income and lower-middle income countries in its discretion, and, when utilized by Gavi, the Company will credit the actual price per vaccine paid against the applicable credit. The Company intends to price vaccines offered via the tender process, consistent with its shared goal with Gavi to provide equitable access to those countries. Also, pursuant to the Gavi Settlement Agreement, the Company granted Gavi an additional credit of up to $225&#160;million that may be applied against qualifying sales of any of the Company&#x2019;s vaccines for supply to such low-income and lower-middle income countries that exceed the $80&#160;million deferred payment amount in any calendar year during the deferred payment term. In addition, the Company and Gavi entered into a security agreement pursuant to which Novavax granted Gavi a security interest in accounts receivable from SIIPL under the SIIPL R21 Agreement (see Note 4), which will continue for the deferred payment term of the Gavi Settlement Agreement. On February 22, 2024, the claims and counterclaims were dismissed with prejudice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenue by the Company&#x2019;s customer&#x2019;s geographic location was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.615%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;North America&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Rest of the world&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,554,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2023, the Company commenced sales of COVID-19 Vaccine to the U.S. commercial market, in addition to continuing sales to various international governments. Product sales in the U.S. are primarily made through large pharmaceutical wholesale distributors at the WAC. Product sales in the U.S. are recorded net of gross-to-net deductions, as described in Note 2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2023, changes in the Company&#x2019;s gross-to-net deductions balances were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.497%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.727%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.247%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.827%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Wholesale Distributor Fees, Discounts, and Chargebacks&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Returns&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts charged against product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,956)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(26,028)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2023, $103.1&#160;million of gross-to-net deductions were included in Accrued expenses and $2.6&#160;million were included in Accounts receivable on the consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has an APA with the Commonwealth of Australia for the purchase of doses of COVID-19 Vaccine (the &#x201c;Australia APA&#x201d;). In May 2023, the Company extended a credit for certain doses delivered and recognized within product revenue in 2022 that qualified for replacement under the Australia APA. This credit is the result of a single lot sold to the Australian government that upon pre-planned 6-month stability testing was found to have fallen below the defined specifications and the lot therefore was removed from the market. The credit will be applied against the future sale of doses to Australia and, during the year ended December&#160;31, 2023, the Company recorded a reduction of $64.7&#160;million in product sales, with a corresponding increase to Deferred revenue, non-current. In July 2023, the Company amended the Australia APA to provide for replacement doses and to extend the delivery schedule through 2025. As of February 2024, the Company had not yet received Therapeutic Goods Administration (&#x201c;TGA&#x201d;) authorization or delivered doses as contemplated in the July 2023 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;amendment and is in active discussions with the Australian government on both the TGA authorization and delivery of the doses previously scheduled for the fourth quarter of 2023. In February 2024, the Company received notice from the Australian government purporting to cancel its order for such prototype vaccine doses. The Company believes the cancellation was not proper under the amended Australia APA. However, if such a cancellation were determined to be allowable, $6.0 million of the deferred revenue would become a credit towards future deliveries of doses and approximately $48 million of the contract value related to future deliverables would no longer be available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an APA with the European Commission (&#x201c;EC&#x201d;) acting on behalf of various European Union member states to supply a minimum of 20&#160;million and up to 100&#160;million initial doses of prototype vaccine, with the option for the EC to purchase an additional 100&#160;million doses up to a maximum aggregate of 200&#160;million doses in one or more tranches, through 2023. Under the terms of the APA, the Company agreed to manufacture the vaccine in facilities located in the European Union and ensure continued efficacy of the vaccine against variants of the SARS-CoV-2 virus. Pursuant to the terms of the APA, the Company is prohibited from supplying prototype vaccine to any third party if such delivery would impede or limit the fulfillment of the Company&#x2019;s obligations to the EC under the APA, except with respect to the Company&#x2019;s obligations under the Gavi APA. In 2022, the Company was notified by the EC that it was cancelling approximately 7&#160;million doses of its prior commitment originally scheduled for delivery in the first and second quarters of 2022, in accordance with the APA, and reducing the order to approximately 63&#160;million doses. In January 2023, the Company finalized a revised delivery schedule for the remaining 20&#160;million committed doses under the APA that were originally scheduled for delivery during the first and second quarters of 2022. The APA expired in August 2023 and required that any open and outstanding orders from European Union member states be satisfied by February 2024. Since August 2023, any additional doses have been managed by amending outstanding orders with deliveries made by February 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an APA with His Majesty the King in Right of Canada as represented by the Minister of Public Works and Government Services, as successor in interest to Her Majesty the Queen in Right of Canada, as represented by the Minister of Public Works and Government Services (the &#x201c;Canadian government&#x201d;), for the purchase of doses of COVID-19 Vaccine (the &#x201c;Canada APA&#x201d;). In April 2023, the Company amended the &#x201c;Canada APA&#x201d;, pursuant to which the Canadian government forfeited certain doses originally scheduled for delivery in 2022 for a payment of $100.4&#160;million, which the Company received in the second quarter of 2023. In June 2023, the Company entered into an additional amendment (the &#x201c;June 2023 Amendment&#x201d;) to the Canada APA. Pursuant to the June 2023 Amendment, (i) the Canadian government forfeited certain doses of COVID-19 Vaccine previously scheduled for delivery and agreed to pay a total amount of $349.6&#160;million to the Company in two equal installments, which total amount equaled the remaining balance owed by the Canadian government with respect to such forfeited vaccine doses, (ii) the amount of doses of COVID-19 Vaccine due for delivery was reduced, (iii) the delivery schedule for the remaining doses of COVID-19 Vaccine to be delivered was revised, and (iv) the parties agreed Novavax would use the Biologics Manufacturing Centre (&#x201c;BMC&#x201d;) Inc. to produce bulk antigen for doses in 2024 and 2025. The June 2023 Amendment maintained the total contract value of the original Canada APA. The first Installment of $174.8&#160;million was payable upon execution of the June 2023 Amendment and received by Novavax in July 2023, and the second installment of $174.8&#160;million was contingent and payable upon the delivery of vaccine doses in the second half of 2023 and received by Novavax in January 2024. The Canadian government may terminate the Canada APA, as amended, if the Company fails to receive regulatory approval for its COVID-19 Vaccine using bulk antigen produced at BMC on or before December 31, 2024. The Company&#x2019;s 2024 plans do not currently anticipate the submission for regulatory approval of its COVID-19 Vaccine using bulk antigen produced at BMC, and it plans to work with the Canadian government on an amendment that addresses possible alternatives, which may not be achievable. As of December 31, 2023, $102.8&#160;million &lt;span id="i6df5a9d3262e4de6b703aaf6230c4c93_96276"&gt;&lt;/span&gt;was classified as short-term Deferred revenue and $485.3&#160;million was classified as long-term Deferred revenue with respect to the Canadian APA in the Company&#x2019;s consolidated balance sheet. If the Canadian government terminates the Canada APA, $28.0&#160;million of the deferred revenue would become refundable and approximately $224&#160;million of the contract value related to future deliverables would no longer be available. Pursuant to the June 2023 Amendment, Novavax and the Canadian government will endeavor to expand the previously agreed in-country commitment to Canada and to further partner to provide health, economic, and future pandemic preparedness benefits to Canada, which value may be provided through a number of activities, including without limitation, capital investments, the performance of activities or services, or the provision of technology or intellectual property licenses. Further, the parties will endeavor to enter into a memorandum of understanding (the &#x201c;MOU&#x201d;) to illustrate the Company&#x2019;s ability to deliver such benefits over a 15-year period with an aggregate value of not less than 100% of the amount remaining to be paid under the June 2023 Amendment and ultimately received by the Company. As of December&#160;31, 2023, discussions regarding the MOU were ongoing. The Company agreed to hold, when received, $20.0&#160;million of the second installment payment in escrow for the benefit of the Canadian government, which amount is the sole recourse available to the Canadian government in the event of non-performance under the MOU. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2022, the Company entered into an Amended and Restated SARS-CoV-2 Vaccine Supply Agreement (as amended on September 26, 2022, the &#x201c;Amended and Restated UK Supply Agreement&#x201d;) with The Secretary of State for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Business, Energy and Industrial Strategy (as assigned to the UK Health Security Agency), acting on behalf of the government of the United Kingdom of Great Britain and Northern Ireland (the &#x201c;Authority&#x201d;), which amended and restated in its entirety the SARS-CoV-2 Vaccine Supply Agreement, dated October 22, 2020, between the parties (the &#x201c;Original UK Supply Agreement&#x201d;). Under the Original UK Supply Agreement, the Authority agreed to purchase 60&#160;million doses of prototype vaccine and made an upfront payment to the Company. Under the terms of the Amended and Restated UK Supply Agreement, the Authority agreed to purchase a minimum of 1&#160;million doses and up to an additional 15&#160;million doses (the &#x201c;Conditional Doses&#x201d;) of prototype vaccine, with the number of Conditional Doses contingent on, and subject to reduction based on, the Company&#x2019;s timely achievement of supportive recommendations from the Joint Committee on Vaccination and Immunisation (the &#x201c;JCVI&#x201d;) that is approved by the UK Secretary of State for Health, with respect to use of the vaccine for (a) the general adult population as part of a SARS-CoV-2 vaccine booster campaign in the United Kingdom or (b) the general adolescent population as part of a SARS-CoV-2 vaccine booster campaign in the United Kingdom or as a primary series SARS-CoV-2 vaccination, excluding where that recommendation relates only to one or more population groups comprising less than one million members in the United Kingdom. If the Authority did not purchase the Conditional Doses or the number of such Conditional Doses was reduced below 15&#160;million doses of prototype vaccine, the Company would have to repay up to $225.0&#160;million related to the upfront payment previously received from the Authority under the Original UK Supply Agreement. Under the Amended and Restated UK Supply Agreement, the Authority also has the option to purchase up to an additional 44&#160;million doses, in one or more tranches, through 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of November 30, 2022, the JCVI had not made a supportive recommendation with respect to prototype vaccine, thereby triggering, under the terms of the Amended and Restated UK Supply Agreement, (i) a reduction of the number of Conditional Doses from 15&#160;million doses to 7.5&#160;million doses, which reduced number of Conditional Doses are contingent on, and subject to further reduction based on, the Company&#x2019;s timely achievement by November 30, 2023 of a supportive recommendation from JCVI that is approved by the UK Secretary of State for Health as described in the paragraph above, and (ii) an obligation for the Company to repay $112.5&#160;million related to the upfront payment previously received from the Authority under the Original UK Supply Agreement. In April 2023, the Company repaid the $112.5&#160;million related to the November 30, 2022 triggering event. As of November 30, 2023, the JCVI had not made a supportive recommendation with respect to the prototype vaccine, thereby triggering a reduction in the number of Conditional Doses from 7.5&#160;million doses to zero. As of February 2024, the Company is in discussions with the Authority regarding the treatment of the remaining upfront payment previously received of $112.5&#160;million, which is reflected in Other current liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized grant revenue as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;USG Agreement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;U.S. DoD&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;CEPI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other grant revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;948,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. Government&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s U.S. government agreement consists of a Project Agreement (the &#x201c;Project Agreement&#x201d;) and a Base Agreement with Advanced Technology International, the Consortium Management Firm acting on behalf of the Medical CBRN Defense Consortium in connection with the partnership formerly known as Operation Warp Speed (the Base Agreement together with the Project Agreement the &#x201c;USG Agreement&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The original USG Agreement required the Company to conduct certain clinical, regulatory, and other activities, including a pivotal Phase 3 clinical trial to determine the safety and efficacy of prototype vaccine, and to manufacture and deliver to the U.S. government 100&#160;million doses of the vaccine candidate. Funding under the USG Agreement is payable to the Company for various development, clinical trial, manufacturing, regulatory, and other activities. The USG Agreement contains terms and conditions that are customary for U.S. government agreements of this nature, including provisions giving the U.S. government the right to terminate the Base Agreement or the Project Agreement based on a reasonable determination that the funded project will not produce beneficial results commensurate with the expenditure of resources and that termination would &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;be in the U.S. government&#x2019;s interest. If the Project Agreement is terminated prior to completion, the Company is entitled to be paid for work performed and costs or obligations incurred prior to termination and consistent with the terms of the USG Agreement. As of December 31, 2023, the Company has recognized the full $1.8&#160;billion funding under the USG Agreement in revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Coalition for Epidemic Preparedness Innovations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:28.8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, the Company entered into a restated funding agreement which was amended in November 2020 with CEPI, under which CEPI agreed to provide funding of up to $399.5&#160;million to the Company to support the development of prototype vaccine. The agreement provided up to $257.0&#160;million in CEPI Grant Funding and up to $142.5&#160;million in CEPI Forgivable Loan Funding, which are loans in the form of one or more forgivable no-interest term loans to fund certain manufacturing activities and are not subject to restrictive or financial covenants. As of December&#160;31, 2023 and 2022, the Company had recognized total revenue related to CEPI of $358.6&#160;million, with the unused amounts primarily related to CEPI Forgivable Loan Funding. Payments received under the CEPI Forgivable Loan Funding are only repayable if project vaccine, as defined under the CEPI funding agreement, manufactured by the CMO network funded by CEPI is sold to one or more third parties (which could include sales credited under the Gavi Settlement Agreement), and such sales cover the Company&#x2019;s costs of manufacturing such vaccine, not including manufacturing costs funded by CEPI.&#160;The timing and amount of any loan repayments is currently uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalties and Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties and other includes royalty milestone payments, sales-based royalties, and Matrix-M&#x2122; adjuvant sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2023, the Company recognized $8.5&#160;million in revenue related to license fees, and $16.5&#160;million in revenue related to a Matrix-M&#x2122; adjuvant sales. During the year ended December&#160;31, 2023, the Company did not recognize revenue related to milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2022, the Company recognized $9.0&#160;million in revenue related to sales-based royalties, $20.0&#160;million related to milestone payments, and $15.0&#160;million in revenue related to a Matrix-M&#x2122; adjuvant sales.&lt;/span&gt;&lt;/div&gt;During the year ended December&#160;31, 2021, the Company recognized $178.6&#160;million in revenue related to sales-based royalties and $20.0&#160;million related to milestone payments.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:BilledContractReceivables contextRef="c-19" decimals="-5" id="f-449" unitRef="usd">286400000</us-gaap:BilledContractReceivables>
    <us-gaap:BilledContractReceivables contextRef="c-20" decimals="-5" id="f-450" unitRef="usd">53800000</us-gaap:BilledContractReceivables>
    <us-gaap:UnbilledContractsReceivable contextRef="c-19" decimals="-5" id="f-451" unitRef="usd">10800000</us-gaap:UnbilledContractsReceivable>
    <us-gaap:UnbilledContractsReceivable contextRef="c-20" decimals="-5" id="f-452" unitRef="usd">28600000</us-gaap:UnbilledContractsReceivable>
    <nvax:ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock contextRef="c-1" id="f-453">During the years ended December&#160;31, 2023 and 2022, changes in the Company's accounts receivables, deferred revenue, and allowance for doubtful accounts balances were as follows (in thousands):&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.747%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.010%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance, Beginning of Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deductions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance, End of Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts receivable:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,472,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,264,062)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,768,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,127,240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Allowance for doubtful accounts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,676)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(267,599)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ended December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,092,829)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Bad debt expense was $13.8&#160;million in the year ended 2022. There was no bad debt expense in the year ended December 31, 2023 or 2021. There was a $6.2&#160;million reversal of a bad debt expense during the year ended December&#160;31, 2023 due to the collection of a previously recognized allowance for doubtful accounts. To estimate the allowance for doubtful accounts, the Company evaluates the credit risk related to its customers based on historical loss experience, economic conditions, the aging of receivables, and customer-specific risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&#160;&#160;&#160;&#160;Deductions from Deferred revenue generally related to the recognition of revenue once performance obligations on a contract with a customer are met. Amount is comprised of $241.3&#160;million, $0.4&#160;billion, and $1.4&#160;billion current Deferred &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;revenue and $622.2&#160;million, $179.4&#160;million, and $172.5&#160;million non-current Deferred revenue as of December&#160;31, 2023, 2022, and 2021 respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&#160;&#160;&#160;&#160;In 2023, deductions from Deferred revenue included $151.1&#160;million that was realized in Revenue and $112.5&#160;million related to the Amended and Restated UK Supply Agreement (as described below), that was reclassified to Other current liabilities, as described below. In 2022, deduction from Deferred revenue included $273.8&#160;million that was realized in Revenue and $819.0&#160;million, including $697.4&#160;million related to the Advance Payment Amount (as described below) related to the Gavi arbitration and $112.5&#160;million related to the Amended and Restated UK Supply Agreement, that was reclassified to Other current liabilities, as described below.&lt;/span&gt;&lt;/div&gt;</nvax:ScheduleOfIncreaseDecreaseInAccountsReceivableUnbilledServicesAndDeferredRevenueTableTextBlock>
    <us-gaap:AccountsReceivableGross contextRef="c-20" decimals="-3" id="f-454" unitRef="usd">96210000</us-gaap:AccountsReceivableGross>
    <nvax:AccountsReceivableBeforeAllowanceForCreditLossAdditions contextRef="c-1" decimals="-3" id="f-455" unitRef="usd">1472768000</nvax:AccountsReceivableBeforeAllowanceForCreditLossAdditions>
    <nvax:AccountsReceivableBeforeAllowanceForCreditLossDeductions contextRef="c-1" decimals="-3" id="f-456" unitRef="usd">1264062000</nvax:AccountsReceivableBeforeAllowanceForCreditLossDeductions>
    <us-gaap:AccountsReceivableGross contextRef="c-19" decimals="-3" id="f-457" unitRef="usd">304916000</us-gaap:AccountsReceivableGross>
    <us-gaap:AccountsReceivableGross contextRef="c-37" decimals="-3" id="f-458" unitRef="usd">454993000</us-gaap:AccountsReceivableGross>
    <nvax:AccountsReceivableBeforeAllowanceForCreditLossAdditions contextRef="c-17" decimals="-3" id="f-459" unitRef="usd">1768457000</nvax:AccountsReceivableBeforeAllowanceForCreditLossAdditions>
    <nvax:AccountsReceivableBeforeAllowanceForCreditLossDeductions contextRef="c-17" decimals="-3" id="f-460" unitRef="usd">2127240000</nvax:AccountsReceivableBeforeAllowanceForCreditLossDeductions>
    <us-gaap:AccountsReceivableGross contextRef="c-20" decimals="-3" id="f-461" unitRef="usd">96210000</us-gaap:AccountsReceivableGross>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-20" decimals="-3" id="f-462" unitRef="usd">13835000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <nvax:AccountsReceivableAllowanceForCreditLossDeductions contextRef="c-1" decimals="-3" id="f-463" unitRef="usd">-6159000</nvax:AccountsReceivableAllowanceForCreditLossDeductions>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-19" decimals="-3" id="f-464" unitRef="usd">7676000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-37" decimals="-3" id="f-465" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <nvax:AccountsReceivableAllowanceForCreditLossAdditions contextRef="c-17" decimals="-3" id="f-466" unitRef="usd">13835000</nvax:AccountsReceivableAllowanceForCreditLossAdditions>
    <nvax:AccountsReceivableAllowanceForCreditLossDeductions contextRef="c-17" decimals="-3" id="f-467" unitRef="usd">0</nvax:AccountsReceivableAllowanceForCreditLossDeductions>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-20" decimals="-3" id="f-468" unitRef="usd">13835000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ContractWithCustomerLiability contextRef="c-20" decimals="-3" id="f-469" unitRef="usd">549551000</us-gaap:ContractWithCustomerLiability>
    <nvax:ContractWithCustomerLiabilityAdditions contextRef="c-1" decimals="-3" id="f-470" unitRef="usd">581569000</nvax:ContractWithCustomerLiabilityAdditions>
    <nvax:ContractWithCustomerLiabilityDeductions contextRef="c-1" decimals="-3" id="f-471" unitRef="usd">267599000</nvax:ContractWithCustomerLiabilityDeductions>
    <us-gaap:ContractWithCustomerLiability contextRef="c-19" decimals="-3" id="f-472" unitRef="usd">863521000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-37" decimals="-3" id="f-473" unitRef="usd">1595472000</us-gaap:ContractWithCustomerLiability>
    <nvax:ContractWithCustomerLiabilityAdditions contextRef="c-17" decimals="-3" id="f-474" unitRef="usd">46908000</nvax:ContractWithCustomerLiabilityAdditions>
    <nvax:ContractWithCustomerLiabilityDeductions contextRef="c-17" decimals="-3" id="f-475" unitRef="usd">1092829000</nvax:ContractWithCustomerLiabilityDeductions>
    <us-gaap:ContractWithCustomerLiability contextRef="c-20" decimals="-3" id="f-476" unitRef="usd">549551000</us-gaap:ContractWithCustomerLiability>
    <nvax:AccountsReceivableAllowanceForCreditLossAdditions contextRef="c-17" decimals="-5" id="f-477" unitRef="usd">13800000</nvax:AccountsReceivableAllowanceForCreditLossAdditions>
    <nvax:AccountsReceivableAllowanceForCreditLossDeductions contextRef="c-1" decimals="-5" id="f-478" unitRef="usd">-6200000</nvax:AccountsReceivableAllowanceForCreditLossDeductions>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-19" decimals="-5" id="f-479" unitRef="usd">241300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-20" decimals="-8" id="f-480" unitRef="usd">400000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-37" decimals="-8" id="f-481" unitRef="usd">1400000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-19" decimals="-5" id="f-482" unitRef="usd">622200000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-20" decimals="-5" id="f-483" unitRef="usd">179400000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-37" decimals="-5" id="f-484" unitRef="usd">172500000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability contextRef="c-84" decimals="-5" id="f-485" unitRef="usd">151100000</us-gaap:ContractWithCustomerLiability>
    <nvax:CollaborationAgreementUpfrontPaymentAmount contextRef="c-85" decimals="-5" id="f-486" unitRef="usd">112500000</nvax:CollaborationAgreementUpfrontPaymentAmount>
    <us-gaap:ContractWithCustomerLiability contextRef="c-86" decimals="-5" id="f-487" unitRef="usd">273800000</us-gaap:ContractWithCustomerLiability>
    <nvax:CollaborationAgreementUpfrontPaymentAmount contextRef="c-87" decimals="-5" id="f-488" unitRef="usd">819000000</nvax:CollaborationAgreementUpfrontPaymentAmount>
    <nvax:CollaborationAgreementUpfrontPaymentAmount contextRef="c-88" decimals="-5" id="f-489" unitRef="usd">697400000</nvax:CollaborationAgreementUpfrontPaymentAmount>
    <nvax:CollaborationAgreementUpfrontPaymentAmount contextRef="c-85" decimals="-5" id="f-490" unitRef="usd">112500000</nvax:CollaborationAgreementUpfrontPaymentAmount>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-89" decimals="-9" id="f-491" unitRef="usd">2000000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiability contextRef="c-19" decimals="-5" id="f-492" unitRef="usd">863500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="c-89" id="f-493">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <nvax:NumberOfDosesToBeDistributed contextRef="c-90" decimals="-8" id="f-494" unitRef="dose">1100000000</nvax:NumberOfDosesToBeDistributed>
    <nvax:NumberOfDosesToBeDistributed contextRef="c-91" decimals="-6" id="f-495" unitRef="dose">350000000</nvax:NumberOfDosesToBeDistributed>
    <nvax:NumberOfDosesToBeDistributed contextRef="c-90" decimals="-8" id="f-496" unitRef="dose">1100000000</nvax:NumberOfDosesToBeDistributed>
    <us-gaap:ContractWithCustomerLiability contextRef="c-92" decimals="-5" id="f-497" unitRef="usd">350000000</us-gaap:ContractWithCustomerLiability>
    <nvax:RevenueRemainingPerformanceObligationVariableConsiderationAmount contextRef="c-93" decimals="-5" id="f-498" unitRef="usd">350000000</nvax:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <nvax:NumberOfDosesToBeDistributed contextRef="c-91" decimals="-6" id="f-499" unitRef="dose">350000000</nvax:NumberOfDosesToBeDistributed>
    <nvax:CollaborationAgreementUpfrontPaymentAmount contextRef="c-94" decimals="-5" id="f-500" unitRef="usd">696400000</nvax:CollaborationAgreementUpfrontPaymentAmount>
    <nvax:CollaborationAgreementUpfrontPaymentAmount contextRef="c-88" decimals="-5" id="f-501" unitRef="usd">697400000</nvax:CollaborationAgreementUpfrontPaymentAmount>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="c-95" decimals="-6" id="f-502" unitRef="usd">75000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementExpense contextRef="c-95" decimals="-6" id="f-503" unitRef="usd">80000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense contextRef="c-96" decimals="-6" id="f-504" unitRef="usd">400000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:GrantsReceivable contextRef="c-97" decimals="-6" id="f-505" unitRef="usd">225000000</us-gaap:GrantsReceivable>
    <us-gaap:LitigationSettlementExpense contextRef="c-95" decimals="-6" id="f-506" unitRef="usd">80000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c-1" id="f-507">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenue by the Company&#x2019;s customer&#x2019;s geographic location was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.615%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;North America&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Rest of the world&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,554,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:Revenues contextRef="c-98" decimals="-3" id="f-508" unitRef="usd">29959000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-99" decimals="-3" id="f-509" unitRef="usd">194480000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-100" decimals="-3" id="f-510" unitRef="usd">268361000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-101" decimals="-3" id="f-511" unitRef="usd">823542000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-102" decimals="-3" id="f-512" unitRef="usd">233069000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-103" decimals="-3" id="f-513" unitRef="usd">536939000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-8" decimals="-3" id="f-514" unitRef="usd">531389000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-9" decimals="-3" id="f-515" unitRef="usd">1554961000</us-gaap:Revenues>
    <nvax:ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock contextRef="c-1" id="f-516">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2023, changes in the Company&#x2019;s gross-to-net deductions balances were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.497%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.727%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.247%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.827%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Wholesale Distributor Fees, Discounts, and Chargebacks&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Returns&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts charged against product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,956)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(26,028)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nvax:ScheduleOfRevenueGrossToNetDeductionsBalancesTableTextBlock>
    <us-gaap:ContractWithCustomerLiability contextRef="c-104" decimals="-3" id="f-517" unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-105" decimals="-3" id="f-518" unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-106" decimals="-3" id="f-519" unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <nvax:AmountsChargedAgainstProductSales contextRef="c-107" decimals="-3" id="f-520" unitRef="usd">47028000</nvax:AmountsChargedAgainstProductSales>
    <nvax:AmountsChargedAgainstProductSales contextRef="c-108" decimals="-3" id="f-521" unitRef="usd">84688000</nvax:AmountsChargedAgainstProductSales>
    <nvax:AmountsChargedAgainstProductSales contextRef="c-8" decimals="-3" id="f-522" unitRef="usd">131716000</nvax:AmountsChargedAgainstProductSales>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-107" decimals="-3" id="f-523" unitRef="usd">-25956000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-108" decimals="-3" id="f-524" unitRef="usd">-72000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-8" decimals="-3" id="f-525" unitRef="usd">-26028000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-109" decimals="-3" id="f-526" unitRef="usd">21072000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-110" decimals="-3" id="f-527" unitRef="usd">84616000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-111" decimals="-3" id="f-528" unitRef="usd">105688000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-112" decimals="-5" id="f-529" unitRef="usd">103100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-113" decimals="-5" id="f-530" unitRef="usd">2600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-114" decimals="-5" id="f-531" unitRef="usd">-64700000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-115" decimals="-5" id="f-532" unitRef="usd">6000000</us-gaap:ContractWithCustomerLiability>
    <nvax:AmountsChargedAgainstProductSales contextRef="c-114" decimals="-6" id="f-533" unitRef="usd">48000000</nvax:AmountsChargedAgainstProductSales>
    <nvax:NumberOfDosesToBeDistributed contextRef="c-116" decimals="-6" id="f-534" unitRef="dose">20000000</nvax:NumberOfDosesToBeDistributed>
    <nvax:NumberOfDosesToBeDistributed contextRef="c-117" decimals="-6" id="f-535" unitRef="dose">100000000</nvax:NumberOfDosesToBeDistributed>
    <nvax:NumberOfDosesToBeDistributed contextRef="c-118" decimals="-6" id="f-536" unitRef="dose">100000000</nvax:NumberOfDosesToBeDistributed>
    <nvax:NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption contextRef="c-118" decimals="-6" id="f-537" unitRef="dose">200000000</nvax:NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption>
    <nvax:PurchaseAgreementNumberOfDosesCancelled contextRef="c-118" decimals="-6" id="f-538" unitRef="dose">7000000</nvax:PurchaseAgreementNumberOfDosesCancelled>
    <nvax:PurchaseAgreementNumberOfVaccineDoses contextRef="c-118" decimals="-6" id="f-539" unitRef="dose">63000000</nvax:PurchaseAgreementNumberOfVaccineDoses>
    <nvax:NumberOfDosesOfVaccineCandidate contextRef="c-119" decimals="-6" id="f-540" unitRef="dose">20000000</nvax:NumberOfDosesOfVaccineCandidate>
    <nvax:CollaborationAgreementUpfrontPaymentAmount contextRef="c-120" decimals="-5" id="f-541" unitRef="usd">100400000</nvax:CollaborationAgreementUpfrontPaymentAmount>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-58" decimals="-5" id="f-542" unitRef="usd">349600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <nvax:InstallmentChargesOfTheCompany contextRef="c-121" decimals="-5" id="f-543" unitRef="usd">174800000</nvax:InstallmentChargesOfTheCompany>
    <nvax:InstallmentChargesOfTheCompany contextRef="c-121" decimals="-5" id="f-544" unitRef="usd">174800000</nvax:InstallmentChargesOfTheCompany>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-120" decimals="-5" id="f-545" unitRef="usd">102800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-120" decimals="-5" id="f-546" unitRef="usd">485300000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-122" decimals="-5" id="f-547" unitRef="usd">28000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent contextRef="c-122" decimals="-6" id="f-548" unitRef="usd">224000000</us-gaap:CustomerRefundLiabilityCurrent>
    <nvax:ContractWithCustomerObligationToDeliverTerms contextRef="c-58" id="f-549">P15Y</nvax:ContractWithCustomerObligationToDeliverTerms>
    <nvax:PercentOfRemainingAmountToBePaid contextRef="c-120" decimals="2" id="f-550" unitRef="number">1</nvax:PercentOfRemainingAmountToBePaid>
    <nvax:EscrowDepositsRelatedToSalesHold contextRef="c-58" decimals="-5" id="f-551" unitRef="usd">20000000</nvax:EscrowDepositsRelatedToSalesHold>
    <nvax:PurchaseAgreementNumberOfVaccineDoses contextRef="c-123" decimals="-6" id="f-552" unitRef="dose">60000000</nvax:PurchaseAgreementNumberOfVaccineDoses>
    <nvax:NumberOfDosesToBeDistributed contextRef="c-124" decimals="-6" id="f-553" unitRef="dose">1000000</nvax:NumberOfDosesToBeDistributed>
    <nvax:NumberOfDosesToBeDistributed contextRef="c-125" decimals="-6" id="f-554" unitRef="dose">15000000</nvax:NumberOfDosesToBeDistributed>
    <nvax:NumberOfDosesToBeDistributed contextRef="c-125" decimals="-6" id="f-555" unitRef="dose">15000000</nvax:NumberOfDosesToBeDistributed>
    <nvax:CollaborationAgreementUpfrontPaymentAmount contextRef="c-126" decimals="-5" id="f-556" unitRef="usd">225000000</nvax:CollaborationAgreementUpfrontPaymentAmount>
    <nvax:NumberOfDosesToBeDistributed contextRef="c-126" decimals="-6" id="f-557" unitRef="dose">44000000</nvax:NumberOfDosesToBeDistributed>
    <nvax:NumberOfDosesToBeDistributed contextRef="c-125" decimals="-6" id="f-558" unitRef="dose">15000000</nvax:NumberOfDosesToBeDistributed>
    <nvax:NumberOfDosesToBeDistributed contextRef="c-127" decimals="-5" id="f-559" unitRef="dose">7500000</nvax:NumberOfDosesToBeDistributed>
    <nvax:CollaborationAgreementUpfrontPaymentAmount contextRef="c-85" decimals="-5" id="f-560" unitRef="usd">112500000</nvax:CollaborationAgreementUpfrontPaymentAmount>
    <nvax:CollaborationAgreementUpfrontPaymentAmount contextRef="c-85" decimals="-5" id="f-561" unitRef="usd">112500000</nvax:CollaborationAgreementUpfrontPaymentAmount>
    <nvax:NumberOfDosesToBeDistributed contextRef="c-127" decimals="-5" id="f-562" unitRef="dose">7500000</nvax:NumberOfDosesToBeDistributed>
    <nvax:NumberOfDosesToBeDistributed contextRef="c-128" decimals="INF" id="f-563" unitRef="dose">0</nvax:NumberOfDosesToBeDistributed>
    <nvax:CollaborationAgreementUpfrontPaymentAmount contextRef="c-85" decimals="-5" id="f-564" unitRef="usd">112500000</nvax:CollaborationAgreementUpfrontPaymentAmount>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock contextRef="c-1" id="f-565">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized grant revenue as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt 0 7pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;USG Agreement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;U.S. DoD&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;CEPI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other grant revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;948,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:Revenues contextRef="c-129" decimals="-3" id="f-566" unitRef="usd">427323000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-130" decimals="-3" id="f-567" unitRef="usd">380996000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-131" decimals="-3" id="f-568" unitRef="usd">788953000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-132" decimals="-3" id="f-569" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-133" decimals="-3" id="f-570" unitRef="usd">1925000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-134" decimals="-3" id="f-571" unitRef="usd">21683000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-135" decimals="-3" id="f-572" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-136" decimals="-3" id="f-573" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-137" decimals="-3" id="f-574" unitRef="usd">135445000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-138" decimals="-3" id="f-575" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-139" decimals="-3" id="f-576" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-140" decimals="-3" id="f-577" unitRef="usd">2628000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-11" decimals="-3" id="f-578" unitRef="usd">427323000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-12" decimals="-3" id="f-579" unitRef="usd">382921000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-13" decimals="-3" id="f-580" unitRef="usd">948709000</us-gaap:Revenues>
    <nvax:NumberOfDosesOfVaccineCandidate contextRef="c-141" decimals="-6" id="f-581" unitRef="dose">100000000</nvax:NumberOfDosesOfVaccineCandidate>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-142" decimals="-8" id="f-582" unitRef="usd">1800000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <nvax:ResearchAndDevelopmentArrangementContractToPerformForOthersFunding contextRef="c-143" decimals="-5" id="f-583" unitRef="usd">399500000</nvax:ResearchAndDevelopmentArrangementContractToPerformForOthersFunding>
    <nvax:ResearchAndDevelopmentArrangementContractToPerformForOthersGrant contextRef="c-143" decimals="-5" id="f-584" unitRef="usd">257000000</nvax:ResearchAndDevelopmentArrangementContractToPerformForOthersGrant>
    <nvax:ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans contextRef="c-143" decimals="-5" id="f-585" unitRef="usd">142500000</nvax:ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans>
    <nvax:RevenueFromContractWithCustomerCommitment contextRef="c-144" decimals="-5" id="f-586" unitRef="usd">358600000</nvax:RevenueFromContractWithCustomerCommitment>
    <nvax:RevenueFromContractWithCustomerCommitment contextRef="c-145" decimals="-5" id="f-587" unitRef="usd">358600000</nvax:RevenueFromContractWithCustomerCommitment>
    <us-gaap:Revenues contextRef="c-146" decimals="-5" id="f-588" unitRef="usd">8500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-147" decimals="-5" id="f-589" unitRef="usd">16500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-148" decimals="INF" id="f-590" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-149" decimals="-5" id="f-591" unitRef="usd">9000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-150" decimals="-5" id="f-592" unitRef="usd">20000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-151" decimals="-5" id="f-593" unitRef="usd">15000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-152" decimals="-5" id="f-594" unitRef="usd">178600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-153" decimals="-5" id="f-595" unitRef="usd">20000000</us-gaap:Revenues>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-596">Collaboration, License, and Supply Agreements &lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;SIIPL&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company previously granted SIIPL exclusive and non-exclusive licenses for the development, co-formulation, filling and finishing, registration, and commercialization of its prototype vaccine, its proprietary COVID-19 variant antigen candidate(s), and its CIC vaccine candidate. SIIPL agreed to purchase the Company's Matrix-M&#x2122; adjuvant and the Company granted SIIPL a non-exclusive license to manufacture the antigen drug substance component of the Company&#x2019;s COVID-19 Vaccine in SIIPL&#x2019;s licensed territory solely for use in the manufacture of COVID-19 Vaccine. The Company and SIIPL equally split the revenue from SIIPL&#x2019;s sale of COVID-19 Vaccine in its licensed territory, net of agreed costs. The Company also has a supply agreement with SIIPL and SLS under which SIIPL and SLS supply the Company with prototype vaccine, its proprietary COVID-19 variant antigen candidate(s), and its CIC vaccine candidate for commercialization and sale in certain territories, as well as a contract development manufacture agreement with SLS, under which SLS manufactures and supplies finished vaccine product to the Company using antigen drug substance and Matrix-M&#x2122; adjuvant supplied by the Company. In March 2020, the Company entered into an agreement with SIIPL that granted SIIPL a non-exclusive license for the use of Matrix-M&#x2122; adjuvant supplied by the Company to develop, manufacture, and commercialize R21/Matrix-M&#x2122; adjuvant (&#x201c;SIIPL R21 Agreement&#x201d;), a malaria vaccine created by the Jenner Institute, University of Oxford (&#x201c;R21/Matrix-M&#x2122;&#x201d;). In December 2023 received prequalification by the WHO. Under the SIIPL R21 Agreement, SIIPL purchases the Company's Matrix-M&#x2122; adjuvant for use in development activities at cost and for commercial purposes at a tiered commercial supply price, and pays a royalty in the single-to low- double-digit range based on vaccine sales for a period of 15 years after the first commercial sale of the vaccine in each country. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda Pharmaceutical Company Limited&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a collaboration and license agreement with Takeda Pharmaceutical Company Limited (&#x201c;Takeda&#x201d;) under which the Company granted Takeda an exclusive license to develop, manufacture, and commercialize the Company&#x2019;s COVID-19 Vaccine in Japan. Under the agreement, Takeda purchases Matrix-M&#x2122; adjuvant from the Company to manufacture doses of COVID-19 Vaccine, and the Company is entitled to receive milestone and sales-based royalty payments from Takeda based on the achievement of certain development and commercial milestones, as well as a portion of net profits from the sale of COVID-19 Vaccine. In September 2021, Takeda finalized an agreement with the Government of Japan&#x2019;s Ministry of Health, Labour and Welfare ("MHLW") for the purchase of 150&#160;million doses of its prototype vaccine. In February 2023, MHLW canceled the remainder of doses under its agreement with Takeda. As a result, it is uncertain whether the Company will receive future sales-based royalty payments from Takeda under the terms and conditions of their current collaboration and licensing agreement. For the year ended December&#160;31, 2023, the Company recognized $6.0&#160;million of revenue as consideration for changes to certain terms of the license agreement which is included in Royalties and other revenue on the consolidated statements of operations. For the year ended December 31, 2022, the Company recognized $20.0&#160;million, upon the sale of prototype vaccine in Japan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which is included in Royalties and other revenue on the consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Bill &amp;amp; Melinda Gates Medical Research Institute&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2023, the Company entered into a 3-year agreement with the Bill &amp;amp; Melinda Gates Medical Research Institute to provide the Company&#x2019;s Matrix-M&#x2122; adjuvant for use in preclinical vaccine research. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;SK bioscience, Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, the Company entered into a Collaboration and License Agreement (&#x201c;CLA&#x201d;) with SK bioscience, Co., Ltd. (&#x201c;SK&#x201d;) to manufacture and commercialize its prototype vaccine for sale to the government of South Korea. The CLA was amended in December 2021 and July 2022 to include the sale of its prototype vaccine to Thailand and Vietnam and to supply the Company with the antigen component of prototype vaccine for use in the final drug product globally, including product to be distributed by the COVAX Facility. Under the CLA, as amended, SK agreed to pay the Company a royalty on the sale of its prototype vaccine in the low to middle double-digit range. The CLA was in addition to the Company's existing manufacturing arrangement with SK under a Development and Supply Agreement (&#x201c;DSA&#x201d;) entered into in August 2020. In July 2022, the Company signed an additional agreement with SK for the technology transfer of the Company&#x2019;s proprietary COVID-19 variant antigen materials so that SK can manufacture the drug substance targeting COVID-19 variants, including the Omicron subvariants. The companies also signed an agreement to manufacture and supply its prototype vaccine in a prefilled syringe.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2023, the Company entered into a material transfer agreement with SK for the use by SK of the Company&#x2019;s Matrix-M&#x2122; adjuvant in preclinical vaccine experiments for shingles, influenza, and pan-sarbecovirus vaccine.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2023, the Company and SK entered into a Settlement Agreement and General Release (the &#x201c;Settlement Agreement&#x201d;) regarding mutual release by the parties of all claims arising from or in relation to statements of work (&#x201c;SOWs&#x201d;) canceled by the Company under the DSA and the CLA (collectively the &#x201c;Business Agreements&#x201d;), and other SOWs under the Business Agreements (collectively, the &#x201c;Subject SOWs&#x201d;), in each case, in connection with the cessation of all drug substance and drug product manufacturing activity at SK for supply to the Company. Subject SOWs canceled by the Company under the Settlement Agreement included (i) Statement of Work No. 1 dated as of December 23, 2021 as amended to date under the CLA; (ii) Statement of Work No. 5 dated as of July 18, 2022 under the DSA; and (iii) Statement of Work No. 6 dated as of July 18, 2022, and as amended as of December 28, 2022 under the DSA. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Settlement Agreement, the Company is responsible for payment of $149.8&#160;million to SK in connection with the cancellation of manufacturing activity for the SOWs under the Business Agreements, of which (i) $130.4&#160;million was paid in August 2023 and (ii) the remaining balance was paid in November 2023. Under the Settlement Agreement, the Company and SK agreed to a wind down plan with respect to the remaining products, materials and equipment under the SOWs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Settlement Agreement, the Company and SK agreed to remove certain restrictions under the CLA that have been triggered by the launch of SK&#x2019;s competing vaccine SKYCovione&#x2122; in the Republic of Korea. In addition, the Company agreed to extend the term of an exclusive license to SK under the CLA for the exploitation of antigen and vaccine products &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;utilizing Company&#x2019;s proprietary coronavirus vaccine antigens and Matrix-M adjuvant in certain territories. The Company recorded $4.0&#160;million to Deferred revenue related to the extended licenses granted to SK under the Settlement Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2023, the Company also entered into a Securities Subscription Agreement (the &#x201c;Subscription Agreement&#x201d;) with SK, pursuant to which the Company agreed to sell and issue to SK, in a private placement (the &#x201c;Private Placement&#x201d;), 6.5&#160;million shares of the Company&#x2019;s common stock, par value $0.01 per share (the &#x201c;Shares&#x201d;) at a price of $13.00 per share for aggregate gross proceeds to the Company of approximately $84.5&#160;million. The closing of the Private Placement occurred on August 10, 2023. The fair value of the Company&#x2019;s common stock on the date of closing, based on the quoted market price, was $46.5&#160;million, which results in a premium paid by SK of approximately $38&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Settlement Agreement and the Subscription Agreement were negotiated concurrently between the parties, and therefore were combined for accounting purposes and analyzed as a single arrangement. As a result, the Company recorded the $46.5&#160;million fair value of common stock issued to SK, based on the quoted market price on the date of close, as an equity transaction. The remaining elements of the arrangement were deemed to relate to the settlement of the Company&#x2019;s outstanding liabilities due to SK. These elements consist primarily of the cash payable to SK of $149.8&#160;million, offset by the premium paid on the common stock purchase by SK of $38.0&#160;million, which resulted in a net gain upon derecognition of the liabilities due to SK of $79.2&#160;million in connection with the settlement. As a result, during the year ended December&#160;31, 2023, the Company recorded this net gain of $79.2&#160;million between research and development expense, for $57.7&#160;million, and cost of sales, for $21.5&#160;million, proportionally based on the where the underlying costs were originally recorded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Supply Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 30, 2022, the Company, FUJIFILM Diosynth Biotechnologies UK Limited (&#x201c;FDBK&#x201d;), FUJIFILM Diosynth Biotechnologies Texas, LLC (&#x201c;FDBT&#x201d;), and FUJIFILM Diosynth Biotechnologies USA, Inc. (&#x201c;FDBU&#x201d; and together with FDBK and FDBT, &#x201c;Fujifilm&#x201d;) entered into a Confidential Settlement Agreement and Release (the &#x201c;Fujifilm Settlement Agreement&#x201d;) regarding amounts due to Fujifilm in connection with the termination of manufacturing activity at FDBT under the Commercial Supply Agreement (the &#x201c;Fujifilm CSA&#x201d;) dated August 20, 2021 and Master Services Agreement dated June 30, 2020 and associated statements of work (the &#x201c;Fujifilm MSA&#x201d;) by and between the Company and Fujifilm. The Fujifilm MSA and Fujifilm CSA established the general terms and conditions applicable to Fujifilm&#x2019;s manufacturing and supply activities related to prototype vaccine under the associated statements of work.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Fujifilm Settlement Agreement, the Company agreed to pay up to $185.0&#160;million (the &#x201c;Settlement Payment&#x201d;) to Fujifilm in connection with cancellation of manufacturing activity at FDBT under the CSA, of which (i) $47.8&#160;million, constituting the initial reservation fee under the CSA, was credited against the Settlement Payment on September&#160;30, 2022 and (ii) the remaining balance was to be paid in four equal quarterly installments of $34.3&#160;million each, which began on March 31, 2023. Under the Fujifilm Settlement Agreement, the final two quarterly installments due to Fujifilm were subject to Fujifilm&#x2019;s obligation to use commercially reasonable efforts to mitigate losses associated with the vacant manufacturing capacity caused by the termination of manufacturing activities at FDBT under the CSA. Any replacement revenue achieved by Fujifilm&#x2019;s mitigation efforts between July 1, 2023 and December 31, 2023 would offset the final two settlement payments owed by the Company. On October 2, 2023, the Company sent a notice of breach under the Fujifilm Settlement Agreement to Fujifilm setting forth the Company&#x2019;s position that Fujifilm had not used commercially reasonable efforts to mitigate losses. The Company withheld two installments of $34.3&#160;million due to Fujifilm on September&#160;30, 2023 and December&#160;31, 2023, pending resolution of the issues identified in the notice of breach. On October 30, 2023, FDBT filed a demand for arbitration with Judicial Arbitration and Mediation Services (&#x201c;JAMS&#x201d;) seeking payment of the third quarter installment of the Settlement Payment. As of December&#160;31, 2023, the remaining payment of $68.6&#160;million was reflected in Accrued expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to assess its manufacturing needs and intends to modify its global manufacturing footprint consistent with its contractual obligations to supply, and anticipated demand for, its COVID-19 Vaccine, and in doing so, recognizes that significant costs may be incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <nvax:RoyaltyPeriod contextRef="c-1" id="f-597">P15Y</nvax:RoyaltyPeriod>
    <nvax:NumberOfDosesToBeDistributed contextRef="c-154" decimals="-6" id="f-598" unitRef="dose">150000000</nvax:NumberOfDosesToBeDistributed>
    <us-gaap:Revenues contextRef="c-155" decimals="-5" id="f-599" unitRef="usd">6000000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-156" decimals="-5" id="f-600" unitRef="usd">20000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <nvax:SettlementPayment contextRef="c-157" decimals="-5" id="f-601" unitRef="usd">149800000</nvax:SettlementPayment>
    <nvax:SettlementAgreementInitialReservationFee contextRef="c-157" decimals="-5" id="f-602" unitRef="usd">130400000</nvax:SettlementAgreementInitialReservationFee>
    <us-gaap:ContractWithCustomerLiability contextRef="c-157" decimals="-5" id="f-603" unitRef="usd">4000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c-158"
      decimals="-5"
      id="f-604"
      unitRef="shares">6500000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-159"
      decimals="INF"
      id="f-605"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-159"
      decimals="INF"
      id="f-606"
      unitRef="usdPerShare">13.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-158" decimals="-5" id="f-607" unitRef="usd">84500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <nvax:CommonStockQuotedMarketPrice contextRef="c-159" decimals="-5" id="f-608" unitRef="usd">46500000</nvax:CommonStockQuotedMarketPrice>
    <nvax:CommonStockPremiumPaid contextRef="c-159" decimals="-5" id="f-609" unitRef="usd">38000000</nvax:CommonStockPremiumPaid>
    <nvax:CommonStockQuotedMarketPrice contextRef="c-159" decimals="-5" id="f-610" unitRef="usd">46500000</nvax:CommonStockQuotedMarketPrice>
    <nvax:SettlementPayment contextRef="c-157" decimals="-5" id="f-611" unitRef="usd">149800000</nvax:SettlementPayment>
    <nvax:CommonStockPremiumPaid contextRef="c-159" decimals="-5" id="f-612" unitRef="usd">38000000</nvax:CommonStockPremiumPaid>
    <nvax:SettlementAgreementBenefit contextRef="c-160" decimals="-5" id="f-613" unitRef="usd">79200000</nvax:SettlementAgreementBenefit>
    <nvax:SettlementAgreementBenefit contextRef="c-160" decimals="-5" id="f-614" unitRef="usd">79200000</nvax:SettlementAgreementBenefit>
    <nvax:SettlementAgreementBenefit contextRef="c-161" decimals="-5" id="f-615" unitRef="usd">57700000</nvax:SettlementAgreementBenefit>
    <nvax:SettlementAgreementBenefit contextRef="c-162" decimals="-5" id="f-616" unitRef="usd">21500000</nvax:SettlementAgreementBenefit>
    <nvax:SettlementPayment contextRef="c-163" decimals="-5" id="f-617" unitRef="usd">185000000</nvax:SettlementPayment>
    <nvax:SettlementAgreementInitialReservationFee contextRef="c-163" decimals="-5" id="f-618" unitRef="usd">47800000</nvax:SettlementAgreementInitialReservationFee>
    <nvax:NumberOfQuarterlyInstallmentPayments
      contextRef="c-163"
      decimals="INF"
      id="f-619"
      unitRef="installment">4</nvax:NumberOfQuarterlyInstallmentPayments>
    <nvax:SettlementAgreementQuarterlyInstallmentAmount contextRef="c-164" decimals="-5" id="f-620" unitRef="usd">34300000</nvax:SettlementAgreementQuarterlyInstallmentAmount>
    <nvax:NumberOfQuarterlyInstallmentPayments
      contextRef="c-164"
      decimals="INF"
      id="f-621"
      unitRef="installment">2</nvax:NumberOfQuarterlyInstallmentPayments>
    <nvax:NumberOfQuarterlyInstallmentPayments
      contextRef="c-164"
      decimals="INF"
      id="f-622"
      unitRef="installment">2</nvax:NumberOfQuarterlyInstallmentPayments>
    <nvax:NumberOfQuarterlyInstallmentPayments
      contextRef="c-164"
      decimals="INF"
      id="f-623"
      unitRef="installment">2</nvax:NumberOfQuarterlyInstallmentPayments>
    <nvax:SettlementAgreementQuarterlyInstallmentAmount contextRef="c-164" decimals="-5" id="f-624" unitRef="usd">34300000</nvax:SettlementAgreementQuarterlyInstallmentAmount>
    <nvax:SettlementPayment contextRef="c-165" decimals="-5" id="f-625" unitRef="usd">68600000</nvax:SettlementPayment>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="c-1" id="f-626">Cash, Cash Equivalents, and Restricted Cash&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the consolidated balance sheets that sum to the total of the same such amounts shown in the statement of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.207%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,336,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,515,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash non-current&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,348,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,528,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)&#160;&#160;&#160;&#160;Classified as Other non-current assets as of December&#160;31, 2023 and 2022</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="c-1" id="f-627">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the consolidated balance sheets that sum to the total of the same such amounts shown in the statement of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.207%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,336,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,515,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash non-current&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,348,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,528,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)&#160;&#160;&#160;&#160;Classified as Other non-current assets as of December&#160;31, 2023 and 2022</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-19" decimals="-3" id="f-628" unitRef="usd">568505000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-20" decimals="-3" id="f-629" unitRef="usd">1336883000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-37" decimals="-3" id="f-630" unitRef="usd">1515116000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-19" decimals="-3" id="f-631" unitRef="usd">10424000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-20" decimals="-3" id="f-632" unitRef="usd">10303000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-37" decimals="-3" id="f-633" unitRef="usd">11490000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-19" decimals="-3" id="f-634" unitRef="usd">4881000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-20" decimals="-3" id="f-635" unitRef="usd">1659000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-37" decimals="-3" id="f-636" unitRef="usd">1653000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-19" decimals="-3" id="f-637" unitRef="usd">583810000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-20" decimals="-3" id="f-638" unitRef="usd">1348845000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-37" decimals="-3" id="f-639" unitRef="usd">1528259000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-640">Fair Value Measurements&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the estimated fair value of the Company&#x2019;s financial assets and liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.209%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-backed securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75% Convertible notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00% Convertible notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total convertible notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;All investments are classified as Cash and cash equivalents as of December&#160;31, 2023 and 2022, on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed-income investments categorized as Level 2 are valued at the custodian bank by a third-party pricing vendor&#x2019;s valuation models that use verifiable observable market data, such as interest rates and yield curves observable at commonly quoted intervals and credit spreads, bids provided by brokers or dealers, or quoted prices of securities with similar characteristics.&#160;Pricing of the Company&#x2019;s convertible notes has been estimated using observable inputs, including the price of the Company&#x2019;s common stock, implied volatility, interest rates, and credit spreads.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2023 and 2022, the Company did not have any transfers between Levels.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount in the Company&#x2019;s consolidated balance sheets for accounts payable and accrued expenses approximates its fair value due to its short-term nature.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock contextRef="c-1" id="f-641">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the estimated fair value of the Company&#x2019;s financial assets and liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.209%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-backed securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75% Convertible notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00% Convertible notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total convertible notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;All investments are classified as Cash and cash equivalents as of December&#160;31, 2023 and 2022, on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-166" decimals="-3" id="f-642" unitRef="usd">171824000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-167" decimals="-3" id="f-643" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-168" decimals="-3" id="f-644" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-169" decimals="-3" id="f-645" unitRef="usd">398834000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-170" decimals="-3" id="f-646" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-171" decimals="-3" id="f-647" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-172" decimals="-3" id="f-648" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-173" decimals="-3" id="f-649" unitRef="usd">200000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-174" decimals="-3" id="f-650" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-175" decimals="-3" id="f-651" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-176" decimals="-3" id="f-652" unitRef="usd">296000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-177" decimals="-3" id="f-653" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-178" decimals="-3" id="f-654" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-179" decimals="-3" id="f-655" unitRef="usd">45622000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-180" decimals="-3" id="f-656" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-181" decimals="-3" id="f-657" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-182" decimals="-3" id="f-658" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-183" decimals="-3" id="f-659" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-184" decimals="-3" id="f-660" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-185" decimals="-3" id="f-661" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-186" decimals="-3" id="f-662" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-187" decimals="-3" id="f-663" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-188" decimals="-3" id="f-664" unitRef="usd">104536000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-189" decimals="-3" id="f-665" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-190" decimals="-3" id="f-666" unitRef="usd">171824000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-191" decimals="-3" id="f-667" unitRef="usd">245622000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-192" decimals="-3" id="f-668" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-193" decimals="-3" id="f-669" unitRef="usd">398834000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-194" decimals="-3" id="f-670" unitRef="usd">400536000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-195" decimals="-3" id="f-671" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="c-196"
      decimals="INF"
      id="f-672"
      unitRef="number">0.0375</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="c-197"
      decimals="INF"
      id="f-673"
      unitRef="number">0.0375</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-198" decimals="-3" id="f-674" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-199" decimals="-3" id="f-675" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-200" decimals="-3" id="f-676" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-201" decimals="-3" id="f-677" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-202" decimals="-3" id="f-678" unitRef="usd">322111000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-203" decimals="-3" id="f-679" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate contextRef="c-204" decimals="2" id="f-680" unitRef="number">0.0500</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate contextRef="c-83" decimals="2" id="f-681" unitRef="number">0.0500</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-205" decimals="-3" id="f-682" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-206" decimals="-3" id="f-683" unitRef="usd">100909000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-207" decimals="-3" id="f-684" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-208" decimals="-3" id="f-685" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-209" decimals="-3" id="f-686" unitRef="usd">172789000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-210" decimals="-3" id="f-687" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-190" decimals="-3" id="f-688" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-191" decimals="-3" id="f-689" unitRef="usd">100909000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-192" decimals="-3" id="f-690" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-193" decimals="-3" id="f-691" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-194" decimals="-3" id="f-692" unitRef="usd">494900000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-195" decimals="-3" id="f-693" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c-1" id="f-694">Inventory&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Semi-finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory write-downs as a result of excess, obsolescence, expiry, or other reasons, and losses on firm purchase commitments are recorded as a component of Cost of sales in the consolidated statements of operations. For the year ended December&#160;31, 2023, inventory write-downs were $72.4&#160;million and losses on firm purchase commitments were $73.5&#160;million. In addition, for the year ended December&#160;31, 2023, the Company recorded recoveries on firm purchase commitments of $40.2&#160;million related primarily to negotiated reductions to previously recognized firm purchase commitments. Also, during the year ended December&#160;31, 2023, the Company recorded an impairment charge of $6.1&#160;million in Cost of sales related to an embedded lease agreement with a CMO for production capacity in excess of production needs. For the year ended December 31, 2022, inventory write-downs and losses on firm purchase commitments were $447.6&#160;million and $155.9&#160;million respectively. There were no inventory write-downs or losses on firm purchase commitments during 2021. Inventory reserves for write-downs are relieved when the inventory is disposed of through scrap or sale. Activity in the reserve for excess and obsolete inventory was as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.306%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.905%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charged to Cost of sales, including impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other additions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(239,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79,214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Other additions include receipts of inventory previously recorded as losses on firm purchase commitments.</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-695">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Semi-finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials contextRef="c-19" decimals="-3" id="f-696" unitRef="usd">6614000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="c-20" decimals="-3" id="f-697" unitRef="usd">13912000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess contextRef="c-19" decimals="-3" id="f-698" unitRef="usd">7392000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="c-20" decimals="-3" id="f-699" unitRef="usd">21410000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods contextRef="c-19" decimals="-3" id="f-700" unitRef="usd">27690000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="c-20" decimals="-3" id="f-701" unitRef="usd">1361000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet contextRef="c-19" decimals="-3" id="f-702" unitRef="usd">41696000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-20" decimals="-3" id="f-703" unitRef="usd">36683000</us-gaap:InventoryNet>
    <us-gaap:InventoryWriteDown contextRef="c-1" decimals="-5" id="f-704" unitRef="usd">72400000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryFirmPurchaseCommitmentLoss contextRef="c-1" decimals="-5" id="f-705" unitRef="usd">-73500000</us-gaap:InventoryFirmPurchaseCommitmentLoss>
    <nvax:InventoryFirmPurchaseCommitmentRecoveries contextRef="c-1" decimals="-5" id="f-706" unitRef="usd">40200000</nvax:InventoryFirmPurchaseCommitmentRecoveries>
    <us-gaap:OperatingLeaseImpairmentLoss contextRef="c-211" decimals="-5" id="f-707" unitRef="usd">6100000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:InventoryWriteDown contextRef="c-17" decimals="-5" id="f-708" unitRef="usd">447600000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryFirmPurchaseCommitmentLoss contextRef="c-17" decimals="-5" id="f-709" unitRef="usd">155900000</us-gaap:InventoryFirmPurchaseCommitmentLoss>
    <us-gaap:InventoryFirmPurchaseCommitmentLoss contextRef="c-18" decimals="INF" id="f-710" unitRef="usd">0</us-gaap:InventoryFirmPurchaseCommitmentLoss>
    <us-gaap:InventoryWriteDown contextRef="c-18" decimals="INF" id="f-711" unitRef="usd">0</us-gaap:InventoryWriteDown>
    <nvax:ScheduleOfInventoryReserveTableTextBlock contextRef="c-1" id="f-712">Activity in the reserve for excess and obsolete inventory was as follows (in thousands): &lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.306%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.905%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charged to Cost of sales, including impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other additions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(239,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79,214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nvax:ScheduleOfInventoryReserveTableTextBlock>
    <us-gaap:InventoryValuationReserves contextRef="c-20" decimals="-3" id="f-713" unitRef="usd">368383000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="c-37" decimals="-3" id="f-714" unitRef="usd">0</us-gaap:InventoryValuationReserves>
    <nvax:InventoryReserveChargedToCostsOfSales contextRef="c-1" decimals="-3" id="f-715" unitRef="usd">72441000</nvax:InventoryReserveChargedToCostsOfSales>
    <nvax:InventoryReserveChargedToCostsOfSales contextRef="c-17" decimals="-3" id="f-716" unitRef="usd">447597000</nvax:InventoryReserveChargedToCostsOfSales>
    <nvax:InventoryReserveOtherAdditions contextRef="c-1" decimals="-3" id="f-717" unitRef="usd">65049000</nvax:InventoryReserveOtherAdditions>
    <nvax:InventoryReserveOtherAdditions contextRef="c-17" decimals="-3" id="f-718" unitRef="usd">0</nvax:InventoryReserveOtherAdditions>
    <nvax:InventoryReserveDeductions contextRef="c-1" decimals="-3" id="f-719" unitRef="usd">239814000</nvax:InventoryReserveDeductions>
    <nvax:InventoryReserveDeductions contextRef="c-17" decimals="-3" id="f-720" unitRef="usd">79214000</nvax:InventoryReserveDeductions>
    <us-gaap:InventoryValuationReserves contextRef="c-19" decimals="-3" id="f-721" unitRef="usd">266059000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="c-20" decimals="-3" id="f-722" unitRef="usd">368383000</us-gaap:InventoryValuationReserves>
    <us-gaap:GoodwillDisclosureTextBlock contextRef="c-1" id="f-723">Goodwill&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has one reporting unit, which has a negative carrying amount as of December&#160;31, 2023 and 2022, The change in the carrying amounts of goodwill was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;127,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;126,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillDisclosureTextBlock>
    <us-gaap:NumberOfReportingUnits
      contextRef="c-1"
      decimals="INF"
      id="f-724"
      unitRef="reporting_unit">1</us-gaap:NumberOfReportingUnits>
    <us-gaap:NumberOfReportingUnits
      contextRef="c-17"
      decimals="INF"
      id="f-725"
      unitRef="reporting_unit">1</us-gaap:NumberOfReportingUnits>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c-1" id="f-726">The change in the carrying amounts of goodwill was as follows (in thousands):&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;127,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;126,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill contextRef="c-20" decimals="-3" id="f-727" unitRef="usd">126331000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-37" decimals="-3" id="f-728" unitRef="usd">131479000</us-gaap:Goodwill>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-1" decimals="-3" id="f-729" unitRef="usd">1123000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-17" decimals="-3" id="f-730" unitRef="usd">-5148000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill contextRef="c-19" decimals="-3" id="f-731" unitRef="usd">127454000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-20" decimals="-3" id="f-732" unitRef="usd">126331000</us-gaap:Goodwill>
    <us-gaap:LesseeFinanceLeasesTextBlock contextRef="c-1" id="f-734">Leases &lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has embedded leases related to multiple manufacturing supply agreements with CMOs and CMOS to manufacture COVID-19 Vaccine, as well as operating and finance leases for its research and development and manufacturing facilities, corporate headquarters and offices. During the year ended December&#160;31, 2023, the Company continued to align its global manufacturing footprint as a result of its ongoing assessment of manufacturing needs consistent with its contractual obligations related to the supply, and anticipated demand for, its COVID-19 Vaccine.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2023 and 2022, the Company modified certain of its CMO and CDMO agreements that had previously been determined to represent embedded leases and, in accordance with its policy, the Company remeasured and reallocated the remaining consideration under the contracts and reassessed the lease classification as of the effective dates of the respective modifications. During the year ended December&#160;31, 2023 and 2022, as a result of new or modified leases, the Company recognized ROU assets, net of credits on modifications, and a corresponding lease liability of $6.8&#160;million and $18.6&#160;million, respectively, for its long-term finance and operating leases embedded in CMO and CDMO manufacturing supply agreements. Also, during the year ended December&#160;31, 2023, the Company recorded an impairment charge of $6.1&#160;million in Cost of sales related to an embedded lease agreement with a CMO for production capacity in excess of production needs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, the Company entered into a lease agreement for the premises located at 700 Quince Orchard Road, Gaithersburg, Maryland ("700QO"). The lease is for approximately 170,000 square feet of space that the Company is using for manufacturing, research and development, and offices. The term of the lease expires in 2035 with options to extend the lease. The lease provides for an annual base rent of $5.8&#160;million that is subject to future rent increases and obligates the Company to pay building operating costs. During the year ended December 31, 2022, the Company obtained the right to direct the use of, and obtain substantially all of the benefit from, certain floors located at the premises and recognized an ROU asset and related lease obligation of $73.2&#160;million as lease commencement for accounting purposes occurred in 2022. During the year ended December&#160;31, 2023, the Company obtained the right to direct the use of, and obtain substantially all of the benefit from, the remaining floors located at the premises and recognized a ROU asset and related lease obligation of $96.5&#160;million as the lease commencement dates for accounting purposes had occurred for such remaining floors. The lease obligation was reduced by $73.4&#160;million for prepaid rent and prior costs incurred on behalf of the landlord during 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, facility leases, including the 700QO lease, have expirations that range from approximately &lt;span style="-sec-ix-hidden:f-745"&gt;two&lt;/span&gt; to thirteen years, some of which include options to extend the lease term. The facility leases contain provisions for future rent increases and obligate the Company to pay building operating costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2023, the Company recorded an impairment charge of $5.9&#160;million related to ROU facility leases used for research and development, manufacturing and offices space that are impacted by the Restructuring Plan (see Note 17). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases as of December&#160;31, 2023 and 2022 was as follows (in thousands, except weighted-average remaining lease term and discount rate):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.577%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Lease Assets and Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets, operating, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-749"&gt;&lt;span style="-sec-ix-hidden:f-750"&gt;Right of use asset, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,985&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,384&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets, finance, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-753"&gt;&lt;span style="-sec-ix-hidden:f-754"&gt;Right of use asset, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,233&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,857&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-current ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,218&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,241&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-759"&gt;&lt;span style="-sec-ix-hidden:f-760"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,977&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,867&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,142&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,196&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,119&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,063&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-767"&gt;&lt;span style="-sec-ix-hidden:f-768"&gt;Other non-current liabilities&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,577&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,085&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current portion of finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,923&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,238&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,323&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average remaining lease term (years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease expense for the operating and short-term leases for the years ended December&#160;31, 2023, 2022, and 2021 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term lease expense (benefit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,009)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets expensed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total finance lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;119,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;During the year ended December&#160;31, 2023, the Company recognized a short-term lease benefit of $48.0&#160;million due to gains on the settlement of manufacturing supply agreements with CMOs and CDMOs that included embedded leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases for the year ended December&#160;31, 2023, 2022, and 2021 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows used in operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows used in finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing cash flows used in finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets obtained in exchange for operating lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets obtained in exchange for finance lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, maturities of lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-733">Leases &lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has embedded leases related to multiple manufacturing supply agreements with CMOs and CMOS to manufacture COVID-19 Vaccine, as well as operating and finance leases for its research and development and manufacturing facilities, corporate headquarters and offices. During the year ended December&#160;31, 2023, the Company continued to align its global manufacturing footprint as a result of its ongoing assessment of manufacturing needs consistent with its contractual obligations related to the supply, and anticipated demand for, its COVID-19 Vaccine.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2023 and 2022, the Company modified certain of its CMO and CDMO agreements that had previously been determined to represent embedded leases and, in accordance with its policy, the Company remeasured and reallocated the remaining consideration under the contracts and reassessed the lease classification as of the effective dates of the respective modifications. During the year ended December&#160;31, 2023 and 2022, as a result of new or modified leases, the Company recognized ROU assets, net of credits on modifications, and a corresponding lease liability of $6.8&#160;million and $18.6&#160;million, respectively, for its long-term finance and operating leases embedded in CMO and CDMO manufacturing supply agreements. Also, during the year ended December&#160;31, 2023, the Company recorded an impairment charge of $6.1&#160;million in Cost of sales related to an embedded lease agreement with a CMO for production capacity in excess of production needs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, the Company entered into a lease agreement for the premises located at 700 Quince Orchard Road, Gaithersburg, Maryland ("700QO"). The lease is for approximately 170,000 square feet of space that the Company is using for manufacturing, research and development, and offices. The term of the lease expires in 2035 with options to extend the lease. The lease provides for an annual base rent of $5.8&#160;million that is subject to future rent increases and obligates the Company to pay building operating costs. During the year ended December 31, 2022, the Company obtained the right to direct the use of, and obtain substantially all of the benefit from, certain floors located at the premises and recognized an ROU asset and related lease obligation of $73.2&#160;million as lease commencement for accounting purposes occurred in 2022. During the year ended December&#160;31, 2023, the Company obtained the right to direct the use of, and obtain substantially all of the benefit from, the remaining floors located at the premises and recognized a ROU asset and related lease obligation of $96.5&#160;million as the lease commencement dates for accounting purposes had occurred for such remaining floors. The lease obligation was reduced by $73.4&#160;million for prepaid rent and prior costs incurred on behalf of the landlord during 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, facility leases, including the 700QO lease, have expirations that range from approximately &lt;span style="-sec-ix-hidden:f-745"&gt;two&lt;/span&gt; to thirteen years, some of which include options to extend the lease term. The facility leases contain provisions for future rent increases and obligate the Company to pay building operating costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2023, the Company recorded an impairment charge of $5.9&#160;million related to ROU facility leases used for research and development, manufacturing and offices space that are impacted by the Restructuring Plan (see Note 17). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases as of December&#160;31, 2023 and 2022 was as follows (in thousands, except weighted-average remaining lease term and discount rate):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.577%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Lease Assets and Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets, operating, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-749"&gt;&lt;span style="-sec-ix-hidden:f-750"&gt;Right of use asset, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,985&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,384&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets, finance, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-753"&gt;&lt;span style="-sec-ix-hidden:f-754"&gt;Right of use asset, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,233&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,857&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-current ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,218&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,241&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-759"&gt;&lt;span style="-sec-ix-hidden:f-760"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,977&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,867&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,142&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,196&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,119&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,063&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-767"&gt;&lt;span style="-sec-ix-hidden:f-768"&gt;Other non-current liabilities&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,577&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,085&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current portion of finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,923&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,238&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,323&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average remaining lease term (years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease expense for the operating and short-term leases for the years ended December&#160;31, 2023, 2022, and 2021 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term lease expense (benefit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,009)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets expensed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total finance lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;119,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;During the year ended December&#160;31, 2023, the Company recognized a short-term lease benefit of $48.0&#160;million due to gains on the settlement of manufacturing supply agreements with CMOs and CDMOs that included embedded leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases for the year ended December&#160;31, 2023, 2022, and 2021 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows used in operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows used in finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing cash flows used in finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets obtained in exchange for operating lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets obtained in exchange for finance lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, maturities of lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <nvax:RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability contextRef="c-212" decimals="-5" id="f-735" unitRef="usd">6800000</nvax:RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability>
    <nvax:RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability contextRef="c-213" decimals="-5" id="f-736" unitRef="usd">18600000</nvax:RightOfUseAssetObtainedInExchangeForFinanceAndOperatingLeaseLiability>
    <us-gaap:OperatingLeaseImpairmentLoss contextRef="c-211" decimals="-5" id="f-737" unitRef="usd">6100000</us-gaap:OperatingLeaseImpairmentLoss>
    <nvax:FacilityNumberOfSquareFeet contextRef="c-214" decimals="INF" id="f-738" unitRef="sqft">170000</nvax:FacilityNumberOfSquareFeet>
    <us-gaap:OperatingLeaseExpense contextRef="c-215" decimals="-5" id="f-739" unitRef="usd">5800000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-216" decimals="-5" id="f-740" unitRef="usd">73200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability contextRef="c-216" decimals="-5" id="f-741" unitRef="usd">73200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-217" decimals="-5" id="f-742" unitRef="usd">96500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability contextRef="c-217" decimals="-5" id="f-743" unitRef="usd">96500000</us-gaap:OperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-218" decimals="-5" id="f-744" unitRef="usd">-73400000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-220" id="f-746">P13Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseImpairmentLoss contextRef="c-221" decimals="-5" id="f-747" unitRef="usd">5900000</us-gaap:OperatingLeaseImpairmentLoss>
    <nvax:ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock contextRef="c-1" id="f-748">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases as of December&#160;31, 2023 and 2022 was as follows (in thousands, except weighted-average remaining lease term and discount rate):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.577%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Lease Assets and Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets, operating, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-749"&gt;&lt;span style="-sec-ix-hidden:f-750"&gt;Right of use asset, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,985&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,384&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets, finance, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-753"&gt;&lt;span style="-sec-ix-hidden:f-754"&gt;Right of use asset, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,233&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,857&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-current ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,218&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,241&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-759"&gt;&lt;span style="-sec-ix-hidden:f-760"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,977&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,867&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,142&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,196&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,119&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,063&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-767"&gt;&lt;span style="-sec-ix-hidden:f-768"&gt;Other non-current liabilities&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,577&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,085&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current portion of finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,923&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,238&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,323&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average remaining lease term (years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nvax:ScheduleOfBalanceSheetInformationRelatedToLeaseTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-19" decimals="-3" id="f-751" unitRef="usd">24985000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-20" decimals="-3" id="f-752" unitRef="usd">36384000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-19" decimals="-3" id="f-755" unitRef="usd">160233000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-20" decimals="-3" id="f-756" unitRef="usd">69857000</us-gaap:FinanceLeaseRightOfUseAsset>
    <nvax:LeaseRightOfUseAsset contextRef="c-19" decimals="-3" id="f-757" unitRef="usd">185218000</nvax:LeaseRightOfUseAsset>
    <nvax:LeaseRightOfUseAsset contextRef="c-20" decimals="-3" id="f-758" unitRef="usd">106241000</nvax:LeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-19" decimals="-3" id="f-761" unitRef="usd">22977000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-20" decimals="-3" id="f-762" unitRef="usd">16867000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-19" decimals="-3" id="f-763" unitRef="usd">5142000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-20" decimals="-3" id="f-764" unitRef="usd">27196000</us-gaap:FinanceLeaseLiabilityCurrent>
    <nvax:LeaseLiabilityCurrent contextRef="c-19" decimals="-3" id="f-765" unitRef="usd">28119000</nvax:LeaseLiabilityCurrent>
    <nvax:LeaseLiabilityCurrent contextRef="c-20" decimals="-3" id="f-766" unitRef="usd">44063000</nvax:LeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-19" decimals="-3" id="f-769" unitRef="usd">28577000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-20" decimals="-3" id="f-770" unitRef="usd">50085000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-19" decimals="-3" id="f-771" unitRef="usd">55923000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-20" decimals="-3" id="f-772" unitRef="usd">31238000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <nvax:LeaseLiabilityNoncurrent contextRef="c-19" decimals="-3" id="f-773" unitRef="usd">84500000</nvax:LeaseLiabilityNoncurrent>
    <nvax:LeaseLiabilityNoncurrent contextRef="c-20" decimals="-3" id="f-774" unitRef="usd">81323000</nvax:LeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-19" id="f-775">P3Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-20" id="f-776">P4Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-19" id="f-777">P11Y7M6D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-20" id="f-778">P8Y3M18D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-19" decimals="3" id="f-779" unitRef="number">0.060</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-20" decimals="3" id="f-780" unitRef="number">0.064</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c-19" decimals="3" id="f-781" unitRef="number">0.089</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c-20" decimals="3" id="f-782" unitRef="number">0.054</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-783">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease expense for the operating and short-term leases for the years ended December&#160;31, 2023, 2022, and 2021 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term lease expense (benefit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,009)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets expensed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total finance lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;119,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;During the year ended December&#160;31, 2023, the Company recognized a short-term lease benefit of $48.0&#160;million due to gains on the settlement of manufacturing supply agreements with CMOs and CDMOs that included embedded leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-784" unitRef="usd">6929000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-17" decimals="-3" id="f-785" unitRef="usd">6903000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-18" decimals="-3" id="f-786" unitRef="usd">37027000</us-gaap:OperatingLeaseCost>
    <nvax:ShortTermLeaseCostBenefit contextRef="c-1" decimals="-3" id="f-787" unitRef="usd">-48009000</nvax:ShortTermLeaseCostBenefit>
    <nvax:ShortTermLeaseCostBenefit contextRef="c-17" decimals="-3" id="f-788" unitRef="usd">94726000</nvax:ShortTermLeaseCostBenefit>
    <nvax:ShortTermLeaseCostBenefit contextRef="c-18" decimals="-3" id="f-789" unitRef="usd">468210000</nvax:ShortTermLeaseCostBenefit>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-3" id="f-790" unitRef="usd">10292000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-17" decimals="-3" id="f-791" unitRef="usd">6836000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-18" decimals="-3" id="f-792" unitRef="usd">116435000</us-gaap:VariableLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-1" decimals="-3" id="f-793" unitRef="usd">12876000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-17" decimals="-3" id="f-794" unitRef="usd">7759000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-18" decimals="-3" id="f-795" unitRef="usd">112528000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-1" decimals="-3" id="f-796" unitRef="usd">2605000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-17" decimals="-3" id="f-797" unitRef="usd">1472000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-18" decimals="-3" id="f-798" unitRef="usd">7241000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-799" unitRef="usd">15481000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-17" decimals="-3" id="f-800" unitRef="usd">9231000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-18" decimals="-3" id="f-801" unitRef="usd">119769000</us-gaap:LeaseCost>
    <nvax:ShortTermLeaseCostBenefit contextRef="c-1" decimals="-5" id="f-802" unitRef="usd">-48000000</nvax:ShortTermLeaseCostBenefit>
    <nvax:ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock contextRef="c-1" id="f-803">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases for the year ended December&#160;31, 2023, 2022, and 2021 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows used in operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows used in finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing cash flows used in finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets obtained in exchange for operating lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets obtained in exchange for finance lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nvax:ScheduleOfSupplementalCashFlowInformationOfLeaseTableTextBlock>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-804" unitRef="usd">101297000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-17" decimals="-3" id="f-805" unitRef="usd">190158000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-18" decimals="-3" id="f-806" unitRef="usd">203991000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-1" decimals="-3" id="f-807" unitRef="usd">2605000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-17" decimals="-3" id="f-808" unitRef="usd">1472000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-18" decimals="-3" id="f-809" unitRef="usd">7241000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-1" decimals="-3" id="f-810" unitRef="usd">27345000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-17" decimals="-3" id="f-811" unitRef="usd">93595000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-18" decimals="-3" id="f-812" unitRef="usd">127907000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-813" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-17" decimals="-3" id="f-814" unitRef="usd">30675000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-18" decimals="-3" id="f-815" unitRef="usd">66682000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-1" decimals="-3" id="f-816" unitRef="usd">103299000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-17" decimals="-3" id="f-817" unitRef="usd">73240000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-18" decimals="-3" id="f-818" unitRef="usd">112528000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-819">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, maturities of lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-19" decimals="-3" id="f-820" unitRef="usd">34353000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-19" decimals="-3" id="f-821" unitRef="usd">17192000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-19" decimals="-3" id="f-822" unitRef="usd">13616000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-19" decimals="-3" id="f-823" unitRef="usd">14000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-19" decimals="-3" id="f-824" unitRef="usd">14375000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-19" decimals="-3" id="f-825" unitRef="usd">67296000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-19" decimals="-3" id="f-826" unitRef="usd">160832000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-19" decimals="-3" id="f-827" unitRef="usd">48213000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-19" decimals="-3" id="f-828" unitRef="usd">112619000</us-gaap:OperatingLeaseLiability>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-829">Long-Term Debt&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s long-term debt consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:12pt;padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75% Convertible notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current convertible notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:12pt;padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00% Convertible notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,784)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current convertible notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense incurred in connection with the convertible notes payable consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Coupon interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest expense on convertible notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, the Company issued $175.3 million aggregate principal amount of convertible senior unsecured notes that will mature on December 15, 2027 (the &#x201c;2027 Notes&#x201d;), unless earlier converted, redeemed, or repurchased. The 2027 Notes were issued in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended, and pursuant to an indenture dated December 20, 2022 (the &#x201c;2027 Indenture&#x201d;) between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee. Concurrently with the issuance of the 2027 Notes, the Company completed a public offering of shares of its common stock (see Note 11). The Company received $166.4 million in net proceeds from the issuance of the 2027 Notes after deducting the initial purchasers&#x2019; fees and the Company&#x2019;s offering expenses. The 2027 Notes bear cash interest at a rate of 5.00% per year, payable semiannually in arrears on June 15 and December 15 of each year, beginning on June 15, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2027 Notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding September 15, 2027, only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2023 (and only during such calendar quarter), if the last reported sale price of the Company&#x2019;s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for the 2027 Notes on each applicable trading day; (2) during the five business day period after any ten consecutive trading day period (the &#x201c;measurement period&#x201d;) in which the trading price (as defined in the 2027 Indenture) per $1,000 principal amount of the 2027 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company&#x2019;s common stock and the conversion rate for the 2027 Notes on each such trading day; (3) if the Company calls such 2027 Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the 2027 Notes called (or deemed called) for redemption; and (4) upon the occurrence of specified corporate events as set forth in the 2027 Indenture. On or after September 15, 2027, until the close of business on the business day immediately preceding the maturity date (December 15, 2027), holders of the 2027 Notes may convert all or any portion of their 2027 Notes at any time, regardless of the foregoing conditions. Upon conversion, the Company may satisfy its conversion obligation by paying or delivering, as the case may be, cash, shares of the Company&#x2019;s common stock, or a combination of cash and shares of the Company&#x2019;s common stock, at the Company&#x2019;s election, in the manner and subject to the terms and conditions provided in the 2027 Indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The conversion rate for the 2027 Notes will initially be 80.0000 shares of the Company&#x2019;s common stock per $1,000 principal amount of 2027 Notes, which is equivalent to an initial conversion price of $12.50 per share of common stock. The initial conversion price of the 2027 Notes represents a conversion premium of 25% of the public offering price in the Company&#x2019;s concurrent common stock offering that closed on December 20, 2022 (see Note 11). The conversion rate for the 2027 Notes is subject to adjustment under certain circumstances in accordance with the terms of the 2027 Indenture. In addition, following certain corporate events that occur prior to the maturity date of the 2027 Notes or if the Company delivers a notice of redemption in respect of the 2027 Notes, the Company will, under certain circumstances, increase the conversion rate of the 2027 Notes for a holder who elects to convert its 2027 Notes (or any portion thereof) in connection with such a corporate event or convert its 2027 Notes called (or deemed called) for redemption during the related redemption period (as defined in the 2027 Indenture), as the case may be.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may not redeem the 2027 Notes prior to December 22, 2025. The Company may redeem for cash all or any portion of the 2027 Notes, at its option, on or after December 22, 2025, if the last reported sale price of the common stock has been at least 130% of the conversion price for the 2027 Notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the 2027 Notes to be redeemed, plus accrued and unpaid interest, to, but excluding, the redemption date. If the Company redeems less than all the outstanding 2027 Notes, at least $50&#160;million aggregate principal amount of 2027 Notes must be outstanding and not subject to redemption as of the date of the relevant notice of redemption. No sinking fund is provided for the 2027 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company undergoes a Fundamental Change (as defined in the 2027 Indenture), holders may require, subject to certain conditions and exceptions as set forth in the 2027 Indenture, the Company to repurchase for cash all or any portion of their 2027 Notes at a Fundamental Change repurchase price equal to 100% of the principal amount of the 2027 Notes to be repurchased, plus accrued and unpaid interest, to, but excluding, the Fundamental Change repurchase date. If a holder of the 2027 Notes converted upon a Make-Whole Fundamental Change (as described in the 2027 Indenture), they may be eligible to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;receive a make-whole premium through an increase to the conversion rate up to a maximum of 20.0000 shares per $1,000 principal amount of 2027 Notes (subject to other adjustments as described in the 2027 Indenture).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accounting for the issuance of the 2027 Notes, the Company determined that the scope exceptions provided under ASC Topic 815-40,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(&#x201c;ASC 815-40&#x201d;) apply to all but one of the conversion features embedded in the 2027 Notes. This remaining conversion feature, which is associated with a Fundamental Change of the Company, was determined to have a de minimis value as of December&#160;31, 2023, and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial purchasers&#x2019; fees and the Company&#x2019;s issuance costs related to the 2027 Notes totaled $8.8 million, which were recorded as a reduction to the 2027 Notes on the consolidated balance sheet. The $8.8 million of debt issuance costs is being amortized and recognized as additional interest expense over the five-year contractual term of the 2027 Notes using an effective interest rate of 6.2%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2023 Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, the Company issued $325 million&#160;aggregate principal amount of convertible senior unsecured notes that matured on&#160;February&#160;1, 2023&#160;(the &#x201c;2023 Notes&#x201d;).&#160;The 2023 Notes were senior unsecured debt obligations and were issued at par. On January 31, 2023, the Company funded the outstanding principal amount of $325 million on the 2023 Notes, due February 1, 2023 and the indenture governing the 2023 Notes was subsequently satisfied and discharged in accordance with its terms. The Company&#x2019;s related &#x201c;capped call transactions&#x201d; expired by their terms on January 27, 2023. The Company repaid the outstanding principal amount of $325 million together with accrued but unpaid interest on the maturity date. The repayment was funded by the issuance of the 2027 Notes and the concurrent common stock offering, as well as cash on hand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2023 Notes were issued pursuant to an indenture dated January&#160;29, 2016 (the &#x201c;2023 Indenture&#x201d;) between the Company and the trustee.&#160;The Company received $315.0 million in net proceeds from the offering after deducting underwriting fees and offering expenses. The 2023 Notes bore cash interest at a rate of 3.75%, payable on&#160;February&#160;1&#160;and&#160;August&#160;1&#160;of each year. The 2023 Notes were not redeemable prior to maturity and were convertible into shares of&#160;the Company&#x2019;s&#160;common stock. As a result of the Company&#x2019;s one-for-twenty reverse stock split in 2019 and pursuant to Section&#160;14.04(a)&#160;of the 2023 Indenture, the 2023 Notes were initially convertible into approximately 2,385,800 shares of the Company&#x2019;s common stock based on the initial conversion rate of 7.3411 shares of the Company&#x2019;s common stock per&#160;$1,000&#160;principal amount of the 2023 Notes. This represents an initial conversion price of approximately $136.20&#160;per share of the Company&#x2019;s common stock,&#160;representing an approximate 22.5% conversion premium based on the last reported sale price of the Company&#x2019;s common stock of $111.20 per share on January&#160;25, 2016. In addition, the holders of the 2023 Notes may have required the Company to repurchase the 2023 Notes at par value plus accrued and unpaid interest following the occurrence of a Fundamental Change (as described in the 2023 Indenture). If a holder of the 2023 Notes converted upon a Make-Whole Adjustment Event (as described in the 2023 Indenture), they may have been eligible to receive a make-whole premium through an increase to the conversion rate up to a maximum of 8.9928 shares per $1,000 principal amount of 2023 Notes (subject to other adjustments as described in the 2023 Indenture).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2023 Notes are accounted for in accordance with ASC 470-20,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt with Conversion and Other Options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(&#x201c;ASC 470-20&#x201d;) and ASC 815-40.&#160;Under ASC 815-40, to qualify for equity classification (or non-bifurcation, if embedded) the instrument (or embedded feature) must be both (1)&#160;indexed to the issuer&#x2019;s stock and (2) meet the requirements of the equity classification guidance. Based upon the Company&#x2019;s analysis, it was determined the 2023 Notes did contain embedded features indexed to its own stock, but did not meet the requirements for bifurcation, and therefore do not need to be separately accounted for as an equity component. Since the embedded conversion feature met the equity scope exception from derivative accounting, and also since the embedded conversion option did not need to be separately accounted for as an equity component under ASC 470-20,&#160;the proceeds received from the issuance of the convertible debt were recorded as a liability on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the issuance of the 2023 Notes,&#160;the Company&#160;also paid $38.5 million, including expenses, to enter into privately negotiated capped call transactions with certain financial institutions (the &#x201c;capped call transactions&#x201d;). The capped call transactions expired by their terms on January 27, 2023. The capped call transactions were generally expected to reduce the potential dilution upon conversion of the 2023 Notes in the event that the market price per share of the Company&#x2019;s common stock, as measured under the terms of the capped call transactions, was greater than the strike price of the capped call transactions, which initially corresponded to the conversion price of the 2023 Notes, and was subject to anti-dilution adjustments generally similar to those applicable to the conversion rate of the 2023 Notes. The cap price of the capped call transactions was initially $194.60 per share, which represented a premium of approximately 75% based on the last reported sale &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;price of the Company&#x2019;s common stock of $111.20 per share on January&#160;25, 2016, and was subject to certain adjustments under the terms of the capped call transactions. If, however, the market price per share of the Company&#x2019;s common stock, as measured under the terms of the capped call transactions, exceeded the cap price, there would nevertheless have been dilution upon conversion of the 2023 Notes to the extent that such market price exceeded the cap price. The Company evaluated the capped call transactions under ASC Topic 815-10,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging &#x2013; Overall&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;and determined that they should be accounted for as a separate transaction and that the capped call transactions would be classified as an equity instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred approximately $10 million of debt issuance costs in 2016 relating to the issuance of the 2023 Notes, which were recorded as a reduction to the 2023 Notes on the consolidated balance sheet. The $10.0 million of debt issuance costs was amortized and recognized as additional interest expense over the seven-year contractual term of the 2023 Notes on a straight-line basis, which approximated the effective interest rate method. The Company also incurred $0.9 million of expenses related to the capped call transactions, which were recorded as a reduction to additional paid-in-capital.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="c-1" id="f-830">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s long-term debt consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:12pt;padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75% Convertible notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current convertible notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:12pt;padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00% Convertible notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,784)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current convertible notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="c-196"
      decimals="INF"
      id="f-831"
      unitRef="number">0.0375</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="c-197"
      decimals="INF"
      id="f-832"
      unitRef="number">0.0375</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <nvax:DebtInstrumentFaceAmountCurrent contextRef="c-222" decimals="-3" id="f-833" unitRef="usd">0</nvax:DebtInstrumentFaceAmountCurrent>
    <nvax:DebtInstrumentFaceAmountCurrent contextRef="c-223" decimals="-3" id="f-834" unitRef="usd">325000000</nvax:DebtInstrumentFaceAmountCurrent>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="c-19" decimals="-3" id="f-835" unitRef="usd">0</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="c-20" decimals="-3" id="f-836" unitRef="usd">119000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c-19" decimals="-3" id="f-837" unitRef="usd">0</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c-20" decimals="-3" id="f-838" unitRef="usd">324881000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate contextRef="c-204" decimals="2" id="f-839" unitRef="number">0.0500</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate contextRef="c-83" decimals="2" id="f-840" unitRef="number">0.0500</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-204" decimals="-3" id="f-841" unitRef="usd">175250000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-83" decimals="-3" id="f-842" unitRef="usd">175250000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c-19" decimals="-3" id="f-843" unitRef="usd">7234000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c-20" decimals="-3" id="f-844" unitRef="usd">8784000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c-19" decimals="-3" id="f-845" unitRef="usd">168016000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c-20" decimals="-3" id="f-846" unitRef="usd">166466000</us-gaap:ConvertibleLongTermNotesPayable>
    <nvax:InterestExpenseRelatedToConvertibleNotesTableTextBlock contextRef="c-1" id="f-847">&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense incurred in connection with the convertible notes payable consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Coupon interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest expense on convertible notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nvax:InterestExpenseRelatedToConvertibleNotesTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-1" decimals="-3" id="f-848" unitRef="usd">9779000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-17" decimals="-3" id="f-849" unitRef="usd">12542000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-18" decimals="-3" id="f-850" unitRef="usd">12188000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-1" decimals="-3" id="f-851" unitRef="usd">1689000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-17" decimals="-3" id="f-852" unitRef="usd">1497000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-18" decimals="-3" id="f-853" unitRef="usd">1424000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:InterestExpenseDebt contextRef="c-1" decimals="-3" id="f-854" unitRef="usd">11468000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-17" decimals="-3" id="f-855" unitRef="usd">14039000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-18" decimals="-3" id="f-856" unitRef="usd">13612000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-83" decimals="-5" id="f-857" unitRef="usd">175300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfUnsecuredDebt contextRef="c-224" decimals="-5" id="f-858" unitRef="usd">166400000</us-gaap:ProceedsFromIssuanceOfUnsecuredDebt>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate contextRef="c-204" decimals="2" id="f-859" unitRef="number">0.0500</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate contextRef="c-83" decimals="2" id="f-860" unitRef="number">0.0500</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays contextRef="c-225" decimals="INF" id="f-861" unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 contextRef="c-225" decimals="INF" id="f-862" unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c-225"
      decimals="INF"
      id="f-863"
      unitRef="number">1.30</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays contextRef="c-226" decimals="INF" id="f-864" unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 contextRef="c-226" decimals="INF" id="f-865" unitRef="day">10</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="c-226"
      decimals="INF"
      id="f-866"
      unitRef="number">0.98</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-83"
      decimals="2"
      id="f-867"
      unitRef="usdPerShare">12.50</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <nvax:ConversionPremiumPercentage contextRef="c-83" decimals="2" id="f-868" unitRef="number">0.25</nvax:ConversionPremiumPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c-225"
      decimals="INF"
      id="f-869"
      unitRef="number">1.30</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays contextRef="c-225" decimals="INF" id="f-870" unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 contextRef="c-225" decimals="INF" id="f-871" unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="c-225"
      decimals="INF"
      id="f-872"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-227" decimals="-6" id="f-873" unitRef="usd">50000000</us-gaap:DebtInstrumentFaceAmount>
    <nvax:DebtInstrumentRepurchaseOfPrincipalAmountPercentage
      contextRef="c-224"
      decimals="INF"
      id="f-874"
      unitRef="number">1</nvax:DebtInstrumentRepurchaseOfPrincipalAmountPercentage>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts contextRef="c-224" decimals="-5" id="f-875" unitRef="usd">8800000</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts contextRef="c-224" decimals="-5" id="f-876" unitRef="usd">8800000</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:DebtInstrumentTerm contextRef="c-224" id="f-877">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-83" decimals="3" id="f-878" unitRef="number">0.062</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-228" decimals="-6" id="f-879" unitRef="usd">325000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfDebt contextRef="c-229" decimals="-6" id="f-880" unitRef="usd">325000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-228" decimals="-6" id="f-881" unitRef="usd">325000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfDebt contextRef="c-229" decimals="-6" id="f-882" unitRef="usd">325000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-228" decimals="-6" id="f-883" unitRef="usd">325000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfDebt contextRef="c-229" decimals="-6" id="f-884" unitRef="usd">325000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:ProceedsFromIssuanceOfUnsecuredDebt contextRef="c-230" decimals="-5" id="f-885" unitRef="usd">315000000</us-gaap:ProceedsFromIssuanceOfUnsecuredDebt>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="c-196"
      decimals="INF"
      id="f-886"
      unitRef="number">0.0375</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="c-197"
      decimals="INF"
      id="f-887"
      unitRef="number">0.0375</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="c-230"
      decimals="INF"
      id="f-888"
      unitRef="shares">2385800</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-231"
      decimals="2"
      id="f-889"
      unitRef="usdPerShare">136.20</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <nvax:ConversionPremiumPercentage contextRef="c-231" decimals="3" id="f-890" unitRef="number">0.225</nvax:ConversionPremiumPercentage>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-232"
      decimals="2"
      id="f-891"
      unitRef="usdPerShare">111.20</us-gaap:SaleOfStockPricePerShare>
    <nvax:PaymentForCappedCallTransactions contextRef="c-233" decimals="-5" id="f-892" unitRef="usd">38500000</nvax:PaymentForCappedCallTransactions>
    <nvax:DebtCapPrice
      contextRef="c-234"
      decimals="2"
      id="f-893"
      unitRef="usdPerShare">194.60</nvax:DebtCapPrice>
    <nvax:ConversionPremiumPercentage contextRef="c-234" decimals="2" id="f-894" unitRef="number">0.75</nvax:ConversionPremiumPercentage>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-232"
      decimals="2"
      id="f-895"
      unitRef="usdPerShare">111.20</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts contextRef="c-235" decimals="-5" id="f-896" unitRef="usd">10000000</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts contextRef="c-235" decimals="-5" id="f-897" unitRef="usd">10000000</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:DebtInstrumentTerm contextRef="c-235" id="f-898">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts contextRef="c-233" decimals="-5" id="f-899" unitRef="usd">900000</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-905">Stockholders&#x2019; Deficit&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2023, the Company entered into an At Market Issuance Sales Agreement (the "August 2023 Sales Agreement"), which allows it to issue and sell up to $500 million in gross proceeds of shares of its common stock, and terminated its then-existing At Market Issuance Sales agreement entered in June 2021 (the &#x201c;June 2021 Sales Agreement&#x201d;). During the year ended December&#160;31, 2023, the Company sold 38.3 million shares of its common stock under its August 2023 Sales Agreement and 7.9 million shares of its common stock under its June 2021 Sales Agreement, resulting in net proceeds of approximately $321 million, of which $6.9&#160;million was included in Prepaid expenses and other current assets as of December 31, 2023 and received in cash in January 2024. As of December&#160;31, 2023, the remaining balance available under the August 2023 Sales Agreement was approximately $242 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2022, the Company sold &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.2 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; shares of its common stock resulting in net proceeds of approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$179 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, under its June 2021 Sales Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2023, pursuant to the Securities Subscription Agreement with SK, the Company agreed to sell and issue to SK 6.5 million shares of the Company&#x2019;s common stock at a price of $13.00 per share (the &#x201c;Shares&#x201d;) in a Private Placement for aggregate gross proceeds to the Company of approximately $84.5 million. The Company recognized the Shares at the settlement date fair value of $46.5 million (see Note 4 for additional discussion of the Securities Subscription Agreement with SK). The closing of the Private Placement occurred on August 10, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, the Company completed a public offering of 7,475,000 shares of its common stock, including 975,000 shares of common stock that were issued upon the exercise in full of the option to purchase additional shares granted to the underwriters, at a price of $10.00 per share resulting in net proceeds, net of offering costs of $4.9 million, of approximately $70 million. The Company completed this public offering concurrent with the issuance of the 2027 Notes (see Note 10).&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-238" decimals="INF" id="f-906" unitRef="usd">500000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-239"
      decimals="-5"
      id="f-907"
      unitRef="shares">38300000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-240"
      decimals="-5"
      id="f-908"
      unitRef="shares">7900000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-241" decimals="-5" id="f-909" unitRef="usd">321000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-242" decimals="-5" id="f-910" unitRef="usd">6900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <nvax:SaleOfStockAmountOfRemainingUnissuedShares contextRef="c-243" decimals="-6" id="f-911" unitRef="usd">242000000</nvax:SaleOfStockAmountOfRemainingUnissuedShares>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-244"
      decimals="-5"
      id="f-912"
      unitRef="shares">2200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-244" decimals="-6" id="f-913" unitRef="usd">179000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c-158"
      decimals="-5"
      id="f-914"
      unitRef="shares">6500000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-159"
      decimals="INF"
      id="f-915"
      unitRef="usdPerShare">13.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-158" decimals="-5" id="f-916" unitRef="usd">84500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssued1 contextRef="c-158" decimals="-5" id="f-917" unitRef="usd">46500000</us-gaap:StockIssued1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-245"
      decimals="INF"
      id="f-918"
      unitRef="shares">7475000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-246"
      decimals="INF"
      id="f-919"
      unitRef="shares">975000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c-247"
      decimals="2"
      id="f-920"
      unitRef="usdPerShare">10.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-246" decimals="-5" id="f-921" unitRef="usd">4900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-245" decimals="-5" id="f-922" unitRef="usd">70000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-923">Stock-Based Compensation&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, the Company established the 2023 Inducement Plan (the &#x201c;2023 Inducement Plan&#x201d;), which provides for the granting of share-based awards to individuals who were not previously employees, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with the Company. The Company reserved 1.0&#160;million shares of common stock for grants under the 2023 Inducement Plan. As of December&#160;31, 2023, there were 0.2&#160;million shares available for issuance under the 2023 Inducement Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2015 Stock Incentive Plan, as amended (&#x201c;2015 Plan&#x201d;), was approved at the Company&#x2019;s annual meeting of stockholders in June&#160;2015. Under the 2015 Plan, equity awards may be granted to officers, directors, employees, and consultants of and advisors to the Company and any present or future subsidiary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2015 Plan authorizes the issuance of up to 21.0 million shares of common stock under equity awards granted under the 2015 Plan, which includes an increase of 6.2 million shares approved for issuance under the 2015 Plan at the Company&#x2019;s 2023 annual meeting of stockholders. All such shares authorized for issuance under the 2015 Plan have been reserved.&#160;The 2015 Plan will expire on March&#160;30, 2033. As of December&#160;31, 2023, there were 6.9 million shares available for issuance under the 2015 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended and Restated 2005 Stock Incentive Plan (&#x201c;2005 Plan&#x201d;) expired in February&#160;2015 and no new awards may be made under such plan, although awards will continue to be outstanding in accordance with their terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2015 Plan permits and the 2005 Plan permitted the grant of stock options (including incentive stock options), restricted stock, SARs, and RSUs. In addition, under the 2015 Plan, unrestricted stock, stock units, and performance awards may be granted. Stock options and SARs generally have a maximum term of ten years and may be or were granted with an exercise price that is no less than 100% of the fair market value of the Company&#x2019;s common stock at the time of grant. Grants of stock options are generally subject to vesting over periods ranging from &lt;span style="-sec-ix-hidden:f-931"&gt;one&lt;/span&gt; to four years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense in the consolidated statements of operations as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.746%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2023 and 2022, total stock-based compensation capitalized in inventory was $0.5 million and $1.7 million, respectively. No stock-based compensation was capitalized in inventory during the year ended December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, there was approximately $81.4 million of total unrecognized compensation expense related to unvested stock options, SARs, RSUs, and the ESPP. This unrecognized non-cash compensation expense is expected to be recognized over a weighted-average period of approximately 1.0 year and will be allocated between cost of sales, research and development, and general and administrative expenses accordingly. This estimate does not include the impact of other possible stock-based awards that may be made during future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value represents the total intrinsic value (the difference between the Company&#x2019;s closing stock price on the last trading day of the period and the exercise price, multiplied by the number of in-the-money stock options and SARs) that would have been received by the holders had all stock option and SARs holders exercised their stock options and SARs on December&#160;31, 2023. This amount is subject to change based on changes to the closing price of the Company&#x2019;s common stock. The aggregate intrinsic value of stock options and SARs exercises and vesting of RSUs for the years ending December&#160;31, 2023, 2022, and 2021 was approximately $5 million, $21 million, and $454 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options and Stock Appreciation Rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of stock options and SARs activity under the 2023 Inducement Plan, 2015 Plan and the 2005 Plan for the year ended December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.212%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.460%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.378%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.460%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.378%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.460%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.460%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.460%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023 Inducement Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2015 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2005 Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Options &amp;amp; SARs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,053,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,021,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,483)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(278,361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,450)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,787,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares exercisable at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,436,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options granted under the 2023 Inducement Plan and the 2015 Plan was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average Black-Scholes fair value of stock&lt;br/&gt;options and SARs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$7.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$55.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$158.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5%-4.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4%-4.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5%-1.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.4%-140.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.5%-140.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124.7%-142.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9-6.4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0-6.3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1-6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total aggregate intrinsic value and weighted-average remaining contractual term of stock options and SARs outstanding under the 2023 Inducement Plan, 2015 Plan and 2005 Plan as of December&#160;31, 2023 was less than $0.1 million and 6.9 years, respectively. The total aggregate intrinsic value and weighted-average remaining contractual term of stock options and SARs exercisable under the 2023 Inducement Plan, 2015 Plan and 2005 Plan as of December&#160;31, 2023 was less than $0.1 million and 5.9 years, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of RSU activity for the year ended December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.481%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.527%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.527%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.398%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.527%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023 Inducement Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2015 Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Per Share&lt;br/&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Per Share&lt;br/&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding and unvested at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,034,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,314,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(696,553)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(937,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding and unvested at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,714,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ESPP was approved at the Company&#x2019;s annual meeting of stockholders in June&#160;2013. The ESPP currently authorizes an aggregate of 1.2 million shares of common stock to be purchased, and the aggregate amount of shares will continue to increase 5% on each anniversary of its adoption up to a maximum of 1.65 million shares. The ESPP allows employees to purchase shares of common stock of the Company at each purchase date through payroll deductions of up to a maximum of 15% of their compensation, at 85% of the lesser of the market price of the shares at the time of purchase or the market price on the beginning date of an option period (or, if later, the date during the option period when the employee was first eligible to participate). At December&#160;31, 2023, there were 0.5 million shares available for issuance under the ESPP.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-248"
      decimals="-5"
      id="f-924"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance
      contextRef="c-249"
      decimals="-5"
      id="f-925"
      unitRef="shares">200000</nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-250"
      decimals="INF"
      id="f-926"
      unitRef="shares">21000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-251"
      decimals="INF"
      id="f-927"
      unitRef="shares">6200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-250"
      decimals="INF"
      id="f-928"
      unitRef="shares">6900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-252" id="f-929">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent contextRef="c-253" decimals="2" id="f-930" unitRef="number">1</nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-255" id="f-932">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-933">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense in the consolidated statements of operations as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.746%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-256" decimals="-3" id="f-934" unitRef="usd">3417000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-257" decimals="-3" id="f-935" unitRef="usd">1032000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-258" decimals="-3" id="f-936" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-259" decimals="-3" id="f-937" unitRef="usd">41211000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-260" decimals="-3" id="f-938" unitRef="usd">66565000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-261" decimals="-3" id="f-939" unitRef="usd">86928000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-262" decimals="-3" id="f-940" unitRef="usd">40729000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-263" decimals="-3" id="f-941" unitRef="usd">62703000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-264" decimals="-3" id="f-942" unitRef="usd">96698000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-943" unitRef="usd">85357000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-17" decimals="-3" id="f-944" unitRef="usd">130300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-18" decimals="-3" id="f-945" unitRef="usd">183626000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-1" decimals="-5" id="f-946" unitRef="usd">500000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-17" decimals="-5" id="f-947" unitRef="usd">1700000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-19" decimals="-5" id="f-948" unitRef="usd">81400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-1" id="f-949">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-6" id="f-950" unitRef="usd">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-17" decimals="-6" id="f-951" unitRef="usd">21000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-18" decimals="-6" id="f-952" unitRef="usd">454000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-953">&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of stock options and SARs activity under the 2023 Inducement Plan, 2015 Plan and the 2005 Plan for the year ended December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.212%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.460%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.378%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.460%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.378%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.460%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.460%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.460%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023 Inducement Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2015 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2005 Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Options &amp;amp; SARs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,053,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,021,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,483)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(278,361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,450)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,787,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares exercisable at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,436,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-265"
      decimals="INF"
      id="f-954"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-265"
      decimals="2"
      id="f-955"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-266"
      decimals="INF"
      id="f-956"
      unitRef="shares">4053290</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-266"
      decimals="2"
      id="f-957"
      unitRef="usdPerShare">46.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-267"
      decimals="INF"
      id="f-958"
      unitRef="shares">63725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-267"
      decimals="2"
      id="f-959"
      unitRef="usdPerShare">112.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-268"
      decimals="INF"
      id="f-960"
      unitRef="shares">422800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-268"
      decimals="2"
      id="f-961"
      unitRef="usdPerShare">10.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-251"
      decimals="INF"
      id="f-962"
      unitRef="shares">1021596</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-251"
      decimals="2"
      id="f-963"
      unitRef="usdPerShare">7.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-269"
      decimals="INF"
      id="f-964"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-269"
      decimals="2"
      id="f-965"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-268"
      decimals="INF"
      id="f-966"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-268"
      decimals="2"
      id="f-967"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-251"
      decimals="INF"
      id="f-968"
      unitRef="shares">9483</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-251"
      decimals="2"
      id="f-969"
      unitRef="usdPerShare">6.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-269"
      decimals="INF"
      id="f-970"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-269"
      decimals="2"
      id="f-971"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-268"
      decimals="INF"
      id="f-972"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-268"
      decimals="2"
      id="f-973"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-251"
      decimals="INF"
      id="f-974"
      unitRef="shares">278361</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-251"
      decimals="2"
      id="f-975"
      unitRef="usdPerShare">41.38</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-269"
      decimals="INF"
      id="f-976"
      unitRef="shares">5450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-269"
      decimals="2"
      id="f-977"
      unitRef="usdPerShare">39.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-249"
      decimals="INF"
      id="f-978"
      unitRef="shares">422800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-249"
      decimals="2"
      id="f-979"
      unitRef="usdPerShare">10.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-250"
      decimals="INF"
      id="f-980"
      unitRef="shares">4787042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-250"
      decimals="2"
      id="f-981"
      unitRef="usdPerShare">38.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-270"
      decimals="INF"
      id="f-982"
      unitRef="shares">58275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-270"
      decimals="2"
      id="f-983"
      unitRef="usdPerShare">119.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-249"
      decimals="INF"
      id="f-984"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-249"
      decimals="2"
      id="f-985"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-250"
      decimals="INF"
      id="f-986"
      unitRef="shares">3436339</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-250"
      decimals="2"
      id="f-987"
      unitRef="usdPerShare">41.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-270"
      decimals="INF"
      id="f-988"
      unitRef="shares">58275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-270"
      decimals="2"
      id="f-989"
      unitRef="usdPerShare">119.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-990">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options granted under the 2023 Inducement Plan and the 2015 Plan was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average Black-Scholes fair value of stock&lt;br/&gt;options and SARs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$7.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$55.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$158.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5%-4.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4%-4.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5%-1.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.4%-140.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.5%-140.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124.7%-142.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9-6.4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0-6.3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1-6.1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-271"
      decimals="2"
      id="f-991"
      unitRef="usdPerShare">7.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-272"
      decimals="2"
      id="f-992"
      unitRef="usdPerShare">55.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-273"
      decimals="2"
      id="f-993"
      unitRef="usdPerShare">158.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-271" decimals="3" id="f-994" unitRef="number">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-271" decimals="3" id="f-995" unitRef="number">0.048</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-272" decimals="3" id="f-996" unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-272" decimals="3" id="f-997" unitRef="number">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-273" decimals="3" id="f-998" unitRef="number">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-273" decimals="3" id="f-999" unitRef="number">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-271"
      decimals="INF"
      id="f-1000"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-272"
      decimals="INF"
      id="f-1001"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-273"
      decimals="INF"
      id="f-1002"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="c-271"
      decimals="3"
      id="f-1003"
      unitRef="number">1.204</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="c-271"
      decimals="3"
      id="f-1004"
      unitRef="number">1.403</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="c-272"
      decimals="3"
      id="f-1005"
      unitRef="number">1.205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="c-272"
      decimals="3"
      id="f-1006"
      unitRef="number">1.401</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="c-273"
      decimals="3"
      id="f-1007"
      unitRef="number">1.247</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="c-273"
      decimals="3"
      id="f-1008"
      unitRef="number">1.420</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-274" id="f-1009">P3Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-275" id="f-1010">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-276" id="f-1011">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-277" id="f-1012">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-278" id="f-1013">P4Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-279" id="f-1014">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-19" decimals="-5" id="f-1015" unitRef="usd">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-1016">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-19" decimals="-5" id="f-1017" unitRef="usd">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-1018">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <nvax:ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock contextRef="c-1" id="f-1019">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of RSU activity for the year ended December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.481%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.527%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.527%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.398%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.527%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023 Inducement Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2015 Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Per Share&lt;br/&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Per Share&lt;br/&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding and unvested at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,034,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,314,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(696,553)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(937,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding and unvested at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,714,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nvax:ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-280"
      decimals="INF"
      id="f-1020"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-280"
      decimals="2"
      id="f-1021"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-281"
      decimals="INF"
      id="f-1022"
      unitRef="shares">2034574</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-281"
      decimals="2"
      id="f-1023"
      unitRef="usdPerShare">61.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-282"
      decimals="INF"
      id="f-1024"
      unitRef="shares">363990</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-282"
      decimals="2"
      id="f-1025"
      unitRef="usdPerShare">10.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-283"
      decimals="INF"
      id="f-1026"
      unitRef="shares">3314452</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-283"
      decimals="2"
      id="f-1027"
      unitRef="usdPerShare">7.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-282"
      decimals="INF"
      id="f-1028"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-282"
      decimals="2"
      id="f-1029"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-283"
      decimals="INF"
      id="f-1030"
      unitRef="shares">696553</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-283"
      decimals="2"
      id="f-1031"
      unitRef="usdPerShare">73.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-282"
      decimals="INF"
      id="f-1032"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-282"
      decimals="2"
      id="f-1033"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-283"
      decimals="INF"
      id="f-1034"
      unitRef="shares">937603</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-283"
      decimals="2"
      id="f-1035"
      unitRef="usdPerShare">27.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-284"
      decimals="INF"
      id="f-1036"
      unitRef="shares">363990</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-284"
      decimals="2"
      id="f-1037"
      unitRef="usdPerShare">10.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-285"
      decimals="INF"
      id="f-1038"
      unitRef="shares">3714870</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-285"
      decimals="2"
      id="f-1039"
      unitRef="usdPerShare">19.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-286"
      decimals="-5"
      id="f-1040"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease
      contextRef="c-287"
      decimals="INF"
      id="f-1041"
      unitRef="number">0.05</nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-287"
      decimals="-4"
      id="f-1042"
      unitRef="shares">1650000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <nvax:MaximumContributionOfEmployeesAsPayrollDeductions
      contextRef="c-286"
      decimals="2"
      id="f-1043"
      unitRef="number">0.15</nvax:MaximumContributionOfEmployeesAsPayrollDeductions>
    <nvax:PercentageOfMarketPriceForStockPurchase
      contextRef="c-286"
      decimals="2"
      id="f-1044"
      unitRef="number">0.85</nvax:PercentageOfMarketPriceForStockPurchase>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-287"
      decimals="INF"
      id="f-1045"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c-1" id="f-1046">Employee Benefits&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a defined contribution 401(k)&#160;retirement plan, pursuant to which employees may elect to contribute up to 100% of their compensation on a tax deferred basis up to the maximum amount permitted by the Internal Revenue Code of 1986, as amended. The Company matches 100% of the first 3% of the participants&#x2019; deferral, and 50% on the next 2% of the participants&#x2019; deferral, up to a potential 4% Company match. The Company&#x2019;s matching contributions to the 401(k)&#160;plan vest immediately. Under its 401(k)&#160;plan, the Company has recorded expense of $7.0 million, $6.0 million, and $3.4 million in 2023, 2022, and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s foreign subsidiaries have pension plans under local tax and labor laws and are obligated to make contributions to the plan. Contributions and other expenses related to this plan were $3.0 million, $2.4 million, and $1.7 million in 2023, 2022, and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="c-1"
      decimals="INF"
      id="f-1047"
      unitRef="number">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="c-288"
      decimals="INF"
      id="f-1048"
      unitRef="number">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="c-288"
      decimals="INF"
      id="f-1049"
      unitRef="number">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="c-289"
      decimals="INF"
      id="f-1050"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="c-289"
      decimals="INF"
      id="f-1051"
      unitRef="number">0.02</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="c-1"
      decimals="INF"
      id="f-1052"
      unitRef="number">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-1" decimals="-5" id="f-1053" unitRef="usd">7000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-17" decimals="-5" id="f-1054" unitRef="usd">6000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-18" decimals="-5" id="f-1055" unitRef="usd">3400000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-290" decimals="-5" id="f-1056" unitRef="usd">3000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-291" decimals="-5" id="f-1057" unitRef="usd">2400000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-292" decimals="-5" id="f-1058" unitRef="usd">1700000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock contextRef="c-1" id="f-1059">Other Financial Information &lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following as of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.706%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;160,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;155,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;226,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;237,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is comprised of the following as of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.706%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and buildings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;380,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;341,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74,968)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;305,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;294,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023 and 2022, approximately $155 million and $170 million, respectively, of net assets used in operations were located in the Czech Republic. Depreciation expense was approximately $41 million, $29 million, and $13 million for the years ended December&#160;31, 2023, 2022, and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following as of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.706%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee benefits and compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross-to-net deductions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. product sales returns accrual &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;468,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;104,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;394,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;591,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities consist of the following as of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.706%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refunds due to APA customers &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liability related to Gavi (see Note 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;861,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;930,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="c-1" id="f-1060">&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following as of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.706%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;160,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;155,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;226,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;237,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:Supplies contextRef="c-19" decimals="-3" id="f-1061" unitRef="usd">70297000</us-gaap:Supplies>
    <us-gaap:Supplies contextRef="c-20" decimals="-3" id="f-1062" unitRef="usd">160773000</us-gaap:Supplies>
    <us-gaap:OtherAssetsCurrent contextRef="c-19" decimals="-3" id="f-1063" unitRef="usd">155726000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-20" decimals="-3" id="f-1064" unitRef="usd">76374000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-19" decimals="-3" id="f-1065" unitRef="usd">226023000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-20" decimals="-3" id="f-1066" unitRef="usd">237147000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-293" decimals="-3" id="f-1067" unitRef="usd">102916000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-294" decimals="-3" id="f-1068" unitRef="usd">101342000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-295" decimals="-3" id="f-1069" unitRef="usd">148243000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-296" decimals="-3" id="f-1070" unitRef="usd">134809000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-297" decimals="-3" id="f-1071" unitRef="usd">48310000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-298" decimals="-3" id="f-1072" unitRef="usd">18895000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-299" decimals="-3" id="f-1073" unitRef="usd">5114000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-300" decimals="-3" id="f-1074" unitRef="usd">4927000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-301" decimals="-3" id="f-1075" unitRef="usd">76156000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-302" decimals="-3" id="f-1076" unitRef="usd">81566000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-19" decimals="-3" id="f-1077" unitRef="usd">380739000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-20" decimals="-3" id="f-1078" unitRef="usd">341539000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-19" decimals="-3" id="f-1079" unitRef="usd">74968000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-20" decimals="-3" id="f-1080" unitRef="usd">47292000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-19" decimals="-3" id="f-1081" unitRef="usd">305771000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-20" decimals="-3" id="f-1082" unitRef="usd">294247000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-303" decimals="-5" id="f-1083" unitRef="usd">155000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-304" decimals="-5" id="f-1084" unitRef="usd">170000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-5" id="f-1085" unitRef="usd">41000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-17" decimals="-5" id="f-1086" unitRef="usd">29000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-18" decimals="-5" id="f-1087" unitRef="usd">13000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-1088">&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following as of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.706%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee benefits and compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross-to-net deductions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. product sales returns accrual &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;468,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;104,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;394,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;591,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-19" decimals="-3" id="f-1089" unitRef="usd">55952000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-20" decimals="-3" id="f-1090" unitRef="usd">52569000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <nvax:AccruedGrossToNetDeductionsCurrent contextRef="c-19" decimals="-3" id="f-1091" unitRef="usd">20616000</nvax:AccruedGrossToNetDeductionsCurrent>
    <nvax:AccruedGrossToNetDeductionsCurrent contextRef="c-20" decimals="-3" id="f-1092" unitRef="usd">0</nvax:AccruedGrossToNetDeductionsCurrent>
    <nvax:U.S.ProductSalesReturnsAccrual contextRef="c-19" decimals="-3" id="f-1093" unitRef="usd">82506000</nvax:U.S.ProductSalesReturnsAccrual>
    <nvax:U.S.ProductSalesReturnsAccrual contextRef="c-20" decimals="-3" id="f-1094" unitRef="usd">0</nvax:U.S.ProductSalesReturnsAccrual>
    <nvax:ResearchAndDevelopmentAccrualsCurrent contextRef="c-19" decimals="-3" id="f-1095" unitRef="usd">131027000</nvax:ResearchAndDevelopmentAccrualsCurrent>
    <nvax:ResearchAndDevelopmentAccrualsCurrent contextRef="c-20" decimals="-3" id="f-1096" unitRef="usd">468214000</nvax:ResearchAndDevelopmentAccrualsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-19" decimals="-3" id="f-1097" unitRef="usd">104567000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-20" decimals="-3" id="f-1098" unitRef="usd">70375000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-19" decimals="-3" id="f-1099" unitRef="usd">394668000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-20" decimals="-3" id="f-1100" unitRef="usd">591158000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="c-1" id="f-1101">&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities consist of the following as of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.706%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refunds due to APA customers &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liability related to Gavi (see Note 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;861,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;930,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:CustomerRefundLiabilityCurrent contextRef="c-19" decimals="-3" id="f-1102" unitRef="usd">142165000</us-gaap:CustomerRefundLiabilityCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent contextRef="c-20" decimals="-3" id="f-1103" unitRef="usd">210362000</us-gaap:CustomerRefundLiabilityCurrent>
    <nvax:OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements contextRef="c-19" decimals="-3" id="f-1104" unitRef="usd">696390000</nvax:OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements>
    <nvax:OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements contextRef="c-20" decimals="-3" id="f-1105" unitRef="usd">697384000</nvax:OtherCurrentLiabilityRelatedToAdvancePurchaseAgreements>
    <us-gaap:OtherSundryLiabilitiesCurrent contextRef="c-19" decimals="-3" id="f-1106" unitRef="usd">22853000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent contextRef="c-20" decimals="-3" id="f-1107" unitRef="usd">22309000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-19" decimals="-3" id="f-1108" unitRef="usd">861408000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-20" decimals="-3" id="f-1109" unitRef="usd">930055000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-1110">Income Taxes&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s loss before income tax expense by jurisdiction is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(628,984)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(712,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,633,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;85,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;58,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(81,520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(543,031)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(653,647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,714,536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the current and deferred income tax expense (benefit) are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current income tax expense (benefit)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred: &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income tax expense to the amount computed by applying the U.S. federal statutory tax rate to the Company&#x2019;s effective tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Statutory federal tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development and other tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-cash stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. taxation of foreign operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancellation of Indebtedness&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-US tax credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the Company has available federal and state net operating losses of $2.4&#160;billion, $877.6&#160;million, respectively, that may be applied against future taxable income in the respective jurisdiction. The federal net operating losses of $2.4&#160;billion can be carried forward indefinitely, with all but $11.3&#160;million, which expires in 2037, limited to 80% of annual taxable income. State net operating losses of $457.4&#160;million have various expiration dates between 2028 and 2042. The remaining state net operating losses of $420.2&#160;million can be carried forward indefinitely. The Company also has research tax credits of $51.9&#160;million that will begin to expire in 2024 through 2043 and a foreign tax credit carryforward of $18.7&#160;million that will expire in 2030.&#160;Utilization of the federal and state net operating loss carryforwards and research tax credits may be subject to an annual limitation due to potential ownership changes of the Company. As of December&#160;31, 2023, the Company does not expect such limitation, if any, to impact the use of its net operating losses and research tax credits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company files income tax returns in the U.S. federal jurisdiction and in various states, as well as in multiple foreign jurisdictions including Sweden and the Czech Republic. The Company has U.S. federal and state net operating losses and credit carryforwards that are subject to examination from 2003 through 2023. The returns in Sweden are subject to examination from 2016 through 2023 and the returns for the Czech Republic are subject to examination from 2019 through 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant components of the Company&#x2019;s deferred tax assets and liabilities as of December 31 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.706%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal and state net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;550,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;479,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liability &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;266,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allowance for sales returns&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-cash stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;132,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign tax credit carryforward&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,186,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,056,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,128,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,020,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;57,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(41,456)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(23,330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,587)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(59,895)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(36,676)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated the positive and negative evidence bearing upon the realization of its deferred tax assets, including its history of significant losses in every year since inception and, in accordance with U.S GAAP, has fully reserved the net deferred tax asset. The Company concluded that realization of its net deferred tax assets is not more-likely-than-not to be realized as of December&#160;31, 2023 and 2022. The valuation allowance increased by $108.8 million and $4.8 million for the years ended December&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net deferred tax liability of $2.0&#160;million at December&#160;31, 2023 is included within other non-current liabilities on the accompanying consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the effect of an income tax position when it is more likely than not, based on the technical merits, that the income tax position will be sustained upon examination. A reconciliation of the beginning and ending amounts of unrecognized tax benefits in the year ended December&#160;31, 2023, 2022, and 2021 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrecognized tax benefits balance at January 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions for tax positions of current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reductions for tax positions of prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,027)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,770)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Settlements of tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrecognized tax benefits balance at December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s policy is to recognize interest and penalties related to income tax matters in income tax expense. As of December&#160;31, 2023 and 2022, the Company had no accruals for interest or penalties. The total amount of unrecognized tax benefits that, if recognized, could affect the effective tax rate was $4.2 million and $5.2 million as of December&#160;31, 2023 and 2022, respectively. However, the Company maintains a full valuation allowance as of December&#160;31, 2023 and 2022 and the recognition of any unrecognized tax benefits would be offset with a change in the valuation allowance and therefore there would be no income statement impact. As of December&#160;31, 2023, the Company does not expect a significant change in the recorded unrecognized tax benefits liability balance during the next twelve months. The unrecognized tax benefits are presented in the financial statements as a reduction to the deferred tax assets for all periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021 the Organization for Economic Cooperation and Development (&#x201c;OECD&#x201d;) developed guidance on Base Erosion and Profit Shifting (&#x201c;BEPS&#x201d;) Pillar Two Model Rules (&#x201c;Pillar Two&#x201d;), which addresses corporate tax planning strategies used by some large multinational corporations to shift profits from higher-tax jurisdictions to lower-tax jurisdictions or zero-tax locations. This guidance imposes a 15% minimum tax on the earnings of large multinational corporations. Pillar Two is expected to be effective in 2024 for the jurisdictions in which the Company operates. The Company is currently evaluating the application of Pillar Two and does not expect these rules to have a significant impact on its effective tax rate or its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock contextRef="c-1" id="f-1111">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s loss before income tax expense by jurisdiction is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(628,984)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(712,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,633,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;85,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;58,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(81,520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(543,031)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(653,647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,714,536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-3" id="f-1112" unitRef="usd">-628984000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-17" decimals="-3" id="f-1113" unitRef="usd">-712183000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-18" decimals="-3" id="f-1114" unitRef="usd">-1633016000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-3" id="f-1115" unitRef="usd">85953000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-17" decimals="-3" id="f-1116" unitRef="usd">58536000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-18" decimals="-3" id="f-1117" unitRef="usd">-81520000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-1118" unitRef="usd">-543031000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-17" decimals="-3" id="f-1119" unitRef="usd">-653647000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-18" decimals="-3" id="f-1120" unitRef="usd">-1714536000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-1121">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the current and deferred income tax expense (benefit) are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current income tax expense (benefit)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred: &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1122" unitRef="usd">-1300000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-1123" unitRef="usd">1300000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-18" decimals="-3" id="f-1124" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1125" unitRef="usd">-157000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-1126" unitRef="usd">503000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-18" decimals="-3" id="f-1127" unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1128" unitRef="usd">1445000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-1129" unitRef="usd">2489000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-18" decimals="-3" id="f-1130" unitRef="usd">29215000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1131" unitRef="usd">-12000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-1132" unitRef="usd">4292000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-18" decimals="-3" id="f-1133" unitRef="usd">29215000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1134" unitRef="usd">2043000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-1135" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-18" decimals="-3" id="f-1136" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1137" unitRef="usd">2031000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-1138" unitRef="usd">4292000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-18" decimals="-3" id="f-1139" unitRef="usd">29215000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-1140">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income tax expense to the amount computed by applying the U.S. federal statutory tax rate to the Company&#x2019;s effective tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Statutory federal tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development and other tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-cash stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. taxation of foreign operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancellation of Indebtedness&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-US tax credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-1"
      decimals="INF"
      id="f-1141"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-17"
      decimals="INF"
      id="f-1142"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-18"
      decimals="INF"
      id="f-1143"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="2" id="f-1144" unitRef="number">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-17" decimals="2" id="f-1145" unitRef="number">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-18" decimals="2" id="f-1146" unitRef="number">0.06</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-1" decimals="2" id="f-1147" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-17" decimals="2" id="f-1148" unitRef="number">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-18" decimals="2" id="f-1149" unitRef="number">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-1" decimals="2" id="f-1150" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-17" decimals="2" id="f-1151" unitRef="number">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-18" decimals="2" id="f-1152" unitRef="number">-0.02</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <nvax:EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent contextRef="c-1" decimals="2" id="f-1153" unitRef="number">-0.01</nvax:EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent>
    <nvax:EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent contextRef="c-17" decimals="2" id="f-1154" unitRef="number">-0.01</nvax:EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent>
    <nvax:EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent contextRef="c-18" decimals="2" id="f-1155" unitRef="number">0.04</nvax:EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNonCashShareBasedPaymentArrangementPercent>
    <nvax:EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations contextRef="c-1" decimals="2" id="f-1156" unitRef="number">-0.04</nvax:EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations>
    <nvax:EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations contextRef="c-17" decimals="2" id="f-1157" unitRef="number">-0.03</nvax:EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations>
    <nvax:EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations contextRef="c-18" decimals="2" id="f-1158" unitRef="number">0</nvax:EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperations>
    <nvax:EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent contextRef="c-1" decimals="2" id="f-1159" unitRef="number">-0.01</nvax:EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent>
    <nvax:EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent contextRef="c-17" decimals="2" id="f-1160" unitRef="number">0</nvax:EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent>
    <nvax:EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent contextRef="c-18" decimals="2" id="f-1161" unitRef="number">-0.01</nvax:EffectiveIncomeTaxRateReconciliationCancellationOfIndebtednessPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="2" id="f-1162" unitRef="number">0.04</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-17" decimals="2" id="f-1163" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-18" decimals="2" id="f-1164" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="2" id="f-1165" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-17" decimals="2" id="f-1166" unitRef="number">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-18" decimals="2" id="f-1167" unitRef="number">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c-1" decimals="2" id="f-1168" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c-17" decimals="2" id="f-1169" unitRef="number">-0.20</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c-18" decimals="2" id="f-1170" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="2" id="f-1171" unitRef="number">-0.20</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-17" decimals="2" id="f-1172" unitRef="number">-0.02</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-18" decimals="2" id="f-1173" unitRef="number">-0.30</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="2" id="f-1174" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-17" decimals="2" id="f-1175" unitRef="number">-0.01</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-18" decimals="2" id="f-1176" unitRef="number">-0.02</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:OperatingLossCarryforwards contextRef="c-305" decimals="-8" id="f-1177" unitRef="usd">2400000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-306" decimals="-5" id="f-1178" unitRef="usd">877600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-305" decimals="-8" id="f-1179" unitRef="usd">2400000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-307" decimals="-5" id="f-1180" unitRef="usd">11300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-308" decimals="-5" id="f-1181" unitRef="usd">457400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-309" decimals="-5" id="f-1182" unitRef="usd">420200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-310" decimals="-5" id="f-1183" unitRef="usd">51900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-311" decimals="-5" id="f-1184" unitRef="usd">18700000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-1185">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant components of the Company&#x2019;s deferred tax assets and liabilities as of December 31 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.706%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal and state net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;550,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;479,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liability &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;266,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allowance for sales returns&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-cash stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;132,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign tax credit carryforward&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,186,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,056,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,128,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,020,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;57,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(41,456)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(23,330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,587)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(59,895)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(36,676)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="c-19" decimals="-3" id="f-1186" unitRef="usd">550272000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="c-20" decimals="-3" id="f-1187" unitRef="usd">479134000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="c-19" decimals="-3" id="f-1188" unitRef="usd">0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="c-20" decimals="-3" id="f-1189" unitRef="usd">5752000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-19" decimals="-3" id="f-1190" unitRef="usd">51878000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-20" decimals="-3" id="f-1191" unitRef="usd">45560000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <nvax:DeferredTaxAssetLeasingLiability contextRef="c-19" decimals="-3" id="f-1192" unitRef="usd">25207000</nvax:DeferredTaxAssetLeasingLiability>
    <nvax:DeferredTaxAssetLeasingLiability contextRef="c-20" decimals="-3" id="f-1193" unitRef="usd">27625000</nvax:DeferredTaxAssetLeasingLiability>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-19" decimals="-3" id="f-1194" unitRef="usd">266392000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-20" decimals="-3" id="f-1195" unitRef="usd">195049000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsInventory contextRef="c-19" decimals="-3" id="f-1196" unitRef="usd">79386000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory contextRef="c-20" decimals="-3" id="f-1197" unitRef="usd">213076000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts contextRef="c-19" decimals="-3" id="f-1198" unitRef="usd">20756000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts contextRef="c-20" decimals="-3" id="f-1199" unitRef="usd">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-19" decimals="-3" id="f-1200" unitRef="usd">30727000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-20" decimals="-3" id="f-1201" unitRef="usd">27599000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-19" decimals="-3" id="f-1202" unitRef="usd">132500000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-20" decimals="-3" id="f-1203" unitRef="usd">49309000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign contextRef="c-19" decimals="-3" id="f-1204" unitRef="usd">18679000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign contextRef="c-20" decimals="-3" id="f-1205" unitRef="usd">0</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-19" decimals="-3" id="f-1206" unitRef="usd">10996000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-20" decimals="-3" id="f-1207" unitRef="usd">13695000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-19" decimals="-3" id="f-1208" unitRef="usd">1186793000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-20" decimals="-3" id="f-1209" unitRef="usd">1056799000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-19" decimals="-3" id="f-1210" unitRef="usd">1128941000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-20" decimals="-3" id="f-1211" unitRef="usd">1020123000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-19" decimals="-3" id="f-1212" unitRef="usd">57852000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-20" decimals="-3" id="f-1213" unitRef="usd">36676000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-19" decimals="-3" id="f-1214" unitRef="usd">41456000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-20" decimals="-3" id="f-1215" unitRef="usd">23330000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-19" decimals="-3" id="f-1216" unitRef="usd">17160000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-20" decimals="-3" id="f-1217" unitRef="usd">11587000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-19" decimals="-3" id="f-1218" unitRef="usd">1279000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-20" decimals="-3" id="f-1219" unitRef="usd">1055000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-20" decimals="-3" id="f-1220" unitRef="usd">704000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-19" decimals="-3" id="f-1221" unitRef="usd">59895000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-20" decimals="-3" id="f-1222" unitRef="usd">36676000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-19" decimals="-3" id="f-1223" unitRef="usd">2043000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-20" decimals="-3" id="f-1224" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-1" decimals="-5" id="f-1225" unitRef="usd">108800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-17" decimals="-5" id="f-1226" unitRef="usd">4800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxLiabilities contextRef="c-19" decimals="-5" id="f-1227" unitRef="usd">2000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-1228">A reconciliation of the beginning and ending amounts of unrecognized tax benefits in the year ended December&#160;31, 2023, 2022, and 2021 is as follows (in thousands):&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrecognized tax benefits balance at January 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions for tax positions of current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reductions for tax positions of prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,027)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,770)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Settlements of tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrecognized tax benefits balance at December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-20" decimals="-3" id="f-1229" unitRef="usd">5194000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-37" decimals="-3" id="f-1230" unitRef="usd">11154000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-26" decimals="-3" id="f-1231" unitRef="usd">8766000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-1232" unitRef="usd">271000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-17" decimals="-3" id="f-1233" unitRef="usd">1260000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-18" decimals="-3" id="f-1234" unitRef="usd">4158000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-1235" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-17" decimals="-3" id="f-1236" unitRef="usd">807000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-18" decimals="-3" id="f-1237" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-1238" unitRef="usd">1228000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-17" decimals="-3" id="f-1239" unitRef="usd">8027000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-18" decimals="-3" id="f-1240" unitRef="usd">1770000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-1" decimals="-3" id="f-1241" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-17" decimals="-3" id="f-1242" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-18" decimals="-3" id="f-1243" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-19" decimals="-3" id="f-1244" unitRef="usd">4237000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-20" decimals="-3" id="f-1245" unitRef="usd">5194000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-37" decimals="-3" id="f-1246" unitRef="usd">11154000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-19" decimals="-5" id="f-1247" unitRef="usd">4200000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-20" decimals="-5" id="f-1248" unitRef="usd">5200000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-1249">Commitment and Contingencies&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stockholder Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On November 12, 2021, Sothinathan Sinnathurai filed a purported securities class action in the U.S. District Court for the District of Maryland (the &#x201c;Maryland Court&#x201d;) against the Company and certain members of senior management, captioned Sothinathan Sinnathurai v. Novavax, Inc., et al., No. 8:21-cv-02910-TDC (the &#x201c;Sinnathurai Action&#x201d;). On January 26, 2022, the Maryland Court entered an order designating David Truong, Nuggehalli Balmukund Nandkumar, and Jeffrey Gabbert as co-lead plaintiffs in the Sinnathurai Action. The co-lead plaintiffs filed a consolidated amended complaint on March 11, 2022, alleging that the defendants made certain purportedly false and misleading statements concerning the Company&#x2019;s ability to manufacture prototype vaccine on a commercial scale and to secure the prototype vaccine&#x2019;s regulatory approval. The amended complaint defines the purported class as those stockholders who purchased the Company&#x2019;s securities between February 24, 2021 and October 19, 2021. On April 25, 2022, the defendants filed a motion to dismiss the consolidated amended complaint. On December 12, 2022, the Maryland Court issued a ruling granting in part and denying in part defendants&#x2019; motion to dismiss. The Maryland Court dismissed all claims against two individual defendants and claims based on certain public statements challenged in the consolidated amended complaint. The Maryland Court denied the motion to dismiss as to the remaining claims and defendants, and directed the Company and other remaining defendants to answer within fourteen days. On December 27, 2022, the Company filed its answer and affirmative defenses. On March 16, 2023, the plaintiffs filed a motion for class certification and to appoint class representatives and counsel. Due to the Maryland Court&#x2019;s ruling on the dismissal motion, the motion sought to certify a class of stockholders who purchased the Company&#x2019;s securities between May 11, 2021, and October 19, 2021. The Company filed its opposition to the plaintiffs&#x2019; motion on September 22, 2023. On December 4, 2023, the parties agreed to a binding settlement in principle (the &#x201c;Proposed Settlement&#x201d;) to fully resolve the surviving claims in the Sinnathurai Action. Under the Proposed Settlement&#x2019;s terms, the Company agreed to pay $47 million into a settlement fund, which will be funded by the Company&#x2019;s directors and officers&#x2019; liability insurance and paid to members of a putative settlement class. On January 12, 2024, after the parties negotiated and executed a written agreement governing the Proposed Settlement, plaintiffs filed an unopposed motion for the Proposed Settlement&#x2019;s preliminary approval. On January 23, 2024, the Maryland Court granted the motion for preliminary approval and, as requested by the parties, preliminarily certified, for the purposes of settlement only, the settlement class. The court also scheduled a settlement hearing to consider final approval of the settlement for May 23, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;After the Sinnathurai Action was filed, eight derivative lawsuits were filed: (i) Robert E. Meyer v. Stanley C. Erck, et al., No. 8:21-cv-02996-TDC (the &#x201c;Meyer Action&#x201d;), (ii) Shui Shing Yung v. Stanley C. Erck, et al., No. 8:21-cv-03248-TDC (the &#x201c;Yung Action&#x201d;), (iii) William Kirst, et al. v. Stanley C. Erck, et al., No. C-15-CV-21-000618 (the &#x201c;Kirst Action&#x201d;), (iv) Amy Snyder v. Stanley C. Erck, et al., No. 8:22-cv-01415-TDC (the &#x201c;Snyder Action&#x201d;), (v) Charles R. Blackburn, et al. v. Stanley C. Erck, et al., No. 1:22-cv-01417-TDC (the &#x201c;Blackburn Action&#x201d;), (vi) Diego J. Mesa v. Stanley C. Erck, et al., No. 2022-0770-NAC (the &#x201c;Mesa Action&#x201d;), (vii) Sean Acosta v. Stanley C. Erck, et al., No. 2022-1133-NAC (the &#x201c;Acosta Action&#x201d;), and (viii) Jared Needelman v. Stanley C. Erck, et al., No. C-15-CV-23-001550 (the &#x201c;Needelman Action&#x201d;). The Meyer, Yung, Snyder, and Blackburn Actions were filed in the Maryland Court. The Kirst and Needelman Actions were filed in the Circuit Court for Montgomery County, Maryland. The Mesa and Acosta Actions were filed in the Delaware Court of Chancery (the &#x201c;Delaware Court&#x201d;). The derivative lawsuits name members of the Company&#x2019;s board of directors and certain members of senior management as defendants. The Company is deemed a nominal defendant. The plaintiffs assert derivative claims arising out of &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;substantially the same alleged facts and circumstances as the Sinnathurai Action. Collectively, the derivative complaints assert claims for breach of fiduciary duty, insider selling, unjust enrichment, violation of federal securities law, abuse of control, waste, and mismanagement. Plaintiffs seek declaratory and injunctive relief, as well as an award of monetary damages and attorneys&#x2019; fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 7, 2022, the Maryland Court entered an order consolidating the Meyer and Yung Actions (the &#x201c;First Consolidated Derivative Action&#x201d;). The plaintiffs in the First Consolidated Derivative Action filed their consolidated derivative complaint on April 25, 2022. On May 10, 2022, the Maryland Court entered an order granting the parties&#x2019; request to stay all proceedings and deadlines pending the earlier of dismissal or the filing of an answer in the Sinnathurai Action. On June 10, 2022, the Snyder and Blackburn Actions were filed. On October 5, 2022, the Maryland Court entered an order granting a request by the plaintiffs in the First Consolidated Derivative Action and the Snyder and Blackburn Actions to consolidate all three actions and appoint co-lead plaintiffs and co-lead and liaison counsel (the &#x201c;Second Consolidated Derivative Action&#x201d;). The co-lead plaintiffs in the Second Consolidated Derivative Action filed a consolidated amended complaint on November 21, 2022. On February 10, 2023, defendants filed a motion to dismiss the Second Consolidated Derivative Action. The plaintiffs filed their opposition to the motion to dismiss on April 11, 2023. Defendants filed their reply brief in further support of their motion to dismiss on May 11, 2023. On August 21, 2023, the court entered an order granting in part and denying in part the motion to dismiss; the court allowed claims for alleged insider selling under Brophy v. Cities Service Co., et al., 70 A.2d 5 (Del. Ch. 1949) and unjust enrichment claims to proceed, but dismissed the remaining claims in the second consolidated amended complaint. On September 5, 2023, the Company filed an Answer to the consolidated amended complaint. On September 6, 2023, the court entered an order granting the individual defendants an extension of time to file their answer until November 6, 2023. On October 6, 2023, the Board of Directors of the Company formed a Special Litigation Committee (&#x201c;SLC&#x201d;) with full and exclusive power and authority of the Board to, among other things, investigate, review, and analyze the facts and circumstances surrounding the claims asserted in the pending derivative actions, including the claims that remain following the court&#x2019;s order on the motion to dismiss in the Second Consolidated Derivative Action. On November 7, 2023, the court entered an order granting the parties&#x2019; request to stay the Second Consolidated Derivative Action for up to six months from the date of entry of the order. This includes staying the deadline for the individual defendants to respond to the consolidated amended complaint.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Kirst Action was filed on December 28, 2021, and the defendants immediately removed the case to the Maryland Court. On July 21, 2022, the Maryland Court issued a memorandum opinion and order remanding the Kirst Action to state court. The plaintiffs filed an amended complaint on December 30, 2022. On January 23, 2023, defendants filed a motion to stay the Kirst action. On February 22, 2023, the parties in the Kirst Action filed for the Court&#x2019;s approval of a stipulation staying the Kirst Action pending the resolution of defendants&#x2019; motion to dismiss in the Second Consolidated Derivative Action. On March 22, 2023, the Court entered the parties&#x2019; stipulated stay of the Kirst Action pending resolution of the motion to dismiss in the Second Consolidated Derivative Action.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 30, 2022, the Mesa Action was filed. On October 3, 2022, the Delaware Court entered an order granting the parties&#x2019; request to stay all proceedings and deadlines in the Mesa Action pending the earlier of dismissal of the Sinnathurai Action or the filing of an answer to the operative complaint in the Sinnathurai Action. On January 18, 2023, defendants filed a motion to stay the Mesa Action pending a final judgment in the Second Consolidated Derivative Action. The plaintiff filed his opposition on February 8, 2023. Defendants filed their reply on February 22, 2023. On February 28, 2023, the court granted the defendants&#x2019; motion to stay. On August 31, 2023, the plaintiff filed a motion to lift the stay. On October 6, 2023, the Company filed an opposition to plaintiff&#x2019;s motion to lift the stay. Plaintiff filed his reply on October 17, 2023.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 27, 2023, the parties filed a letter informing the Court that the Second Consolidated Derivative Action had been stayed for a period of six months and asked the Court to stay further proceedings in the Mesa Action until expiration of that stay.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 7, 2022, the Acosta Action was filed. On February 6, 2023, defendants accepted service of the complaint and summons in the Acosta Action. On March 9, 2023, the court entered an order granting the parties&#x2019; request to stay the Acosta Action pending the entry of a final, non-appealable judgment in the Second Consolidated Derivative Action. On October 13, 2023, the parties filed, and the Delaware Court entered, a stipulated order providing that (i) if the Delaware Court declines to lift the stay in the Mesa Action, the Acosta Action will also remain stayed, and (ii) if the Delaware Court lifts the stay in the Mesa Action, the stay in the Acosta Action will also be lifted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 17, 2023, the Needelman Action was filed. On July 12, 2023, the parties filed a stipulation and proposed order to stay the Needelman Action pending the Maryland Court&#x2019;s decision on the motion to dismiss in the Second Consolidated Derivative Action. The court entered that order on July 17, 2023. The parties continue to discuss next steps in the litigation following the Maryland Court&#x2019;s ruling on the motion to dismiss the Second Consolidated Derivative Action. The court entered that order on July 17, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 30, 2023, the court entered an order consolidating the Kirst and Needelman Actions.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 14, 2023, the parties filed a stipulation (i) extending the plaintiffs&#x2019; deadline to file a consolidated complaint until January 29, 2024, and (ii) otherwise staying all other proceedings in the case (including the defendants&#x2019; deadline to respond to the consolidated complaint) until February 12, 2024. The stipulation entered by the court instructs the parties to discuss whether the stay should be further extended in light of the then-current status of the SLC&#x2019;s investigation. The financial impact of the derivative claims is not estimable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 18, 2022, the Company delivered written notice to Gavi to terminate the Gavi APA based on Gavi&#x2019;s failure to procure the purchase of 350&#160;million doses of prototype vaccine from the Company as required by the Gavi APA. As of November 18, 2022, the Company had only received orders under the Gavi APA for approximately 2&#160;million doses. On December 2, 2022, Gavi issued a written notice purporting to terminate the Gavi APA based on Gavi&#x2019;s contention that the Company repudiated the agreement and, therefore, materially breached the Gavi APA. Gavi also contended that, based on its purported termination of the Gavi APA, it was entitled to a refund of the Advance Payment Amount less any amounts that have been credited against the purchase price for binding orders placed by a buyer participating in the COVAX Facility. Since December 31, 2022, the remaining Gavi Advance Payment Amount, which is $696.4&#160;million as of December 31, 2023, pending resolution of the dispute with Gavi related to a return of the remaining Advance Payment Amount, has been classified within Other current liabilities in the Company&#x2019;s consolidated balance sheet. On January 24, 2023, Gavi filed a demand for arbitration with the International Court of Arbitration based on the claims described above. The Company filed its Answer and Counterclaims on March 2, 2023. On April 5, 2023, Gavi filed its Reply to the Company&#x2019;s Counterclaims. On February 16, 2024, the Company and Gavi entered into a Termination and Settlement Agreement (the &#x201c;Gavi Settlement Agreement&#x201d;) terminating the Gavi APA, settling the arbitration proceedings and releasing both parties of all claims arising from, under or otherwise in connection with the Gavi APA. Pursuant to the Gavi Settlement Agreement, the Company is responsible for payment to Gavi of (i) an initial settlement payment of $75&#160;million, which the Company paid on February 20, 2024, and (ii) deferred payments, in equal annual amounts of $80&#160;million payable each calendar year through a deferred payment term ending December 31, 2028. The deferred payments are due in variable quarterly installments beginning in the first quarter of 2024 and total $400&#160;million during the deferred payment term. Such deferred payments may be reduced through Gavi&#x2019;s use of an annual vaccine credit equivalent to the unpaid balance of such deferred payments each year, which may be applied to qualifying sales of any of the Company&#x2019;s vaccines funded by Gavi for supply to certain low-income and lower-middle income countries. The Company has the right to price the vaccines offered to such low-income and lower-middle income countries at its discretion, and, when utilized by Gavi, the Company will credit the actual price per vaccine paid against the applicable credit. The Company intends to price vaccines offered via the tender process, consistent with its shared goal with Gavi to provide equitable access to those countries. On February 22, 2024, the claims and counterclaims were dismissed with prejudice.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On September 30, 2022, the Company and Fujifilm entered into the Fujifilm Settlement Agreement regarding amounts due to Fujifilm in connection with the termination of manufacturing activity at FDBT under the CSA dated August 20, 2021 and the MSA by and between the Company and Fujifilm. The MSA and CSA established the general terms and conditions applicable to Fujifilm&#x2019;s manufacturing and supply activities related to the Company&#x2019;s prototype vaccine under the associated statements of work. Pursuant to the Fujifilm Settlement Agreement, the Company agreed to pay up to $185.0&#160;million (the &#x201c;Settlement Payment&#x201d;) to Fujifilm in connection with cancellation of manufacturing activity at FDBT. Under the Fujifilm Settlement Agreement, the final two quarterly installments due to Fujifilm were subject to Fujifilm&#x2019;s obligation to use commercially reasonable efforts to mitigate losses associated with the vacant manufacturing capacity caused by the termination of manufacturing activities at FDBT under the CSA. Any replacement revenue achieved by Fujifilm&#x2019;s mitigation efforts between July 1, 2023 and December 31, 2023 would offset the final two settlement payments owed by the Company. On October 2, 2023, the Company sent a notice of breach under the Fujifilm Settlement Agreement to Fujifilm setting forth the Company&#x2019;s position that Fujifilm had not used commercially reasonable efforts to mitigate losses. The Company withheld two installments of $34.3&#160;million due to Fujifilm on September&#160;30, 2023 and December&#160;31, 2023, pending resolution of the issues identified in the notice of breach. On October 30, 2023, FDBT filed a demand for arbitration with Judicial Arbitration and Mediation Services (&#x201c;JAMS&#x201d;) seeking payment of the third quarter installment of the Settlement Payment. An arbitration hearing has been scheduled for May 2024. As of December&#160;31, 2023, the remaining payment of $68.6&#160;million was reflected in Accrued expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also involved in various other legal proceedings arising in the normal course of business. Although the outcomes of these other legal proceedings are inherently difficult to predict, the Company does not expect the resolution of these other legal proceedings to have a material adverse effect on its financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into agreements in the normal course of business with CMOs and CDMOs supplying the Company with production capabilities, and with vendors for preclinical studies, clinical trials, and other goods or services. A number of these arrangements are within the scope of lease accounting (see Note 9). Certain agreements provide for termination rights subject to termination fees. Under such agreements, the Company is contractually obligated to make payments to vendors, mainly to reimburse them for their estimated unrecoverable expenses. The exact amount of such obligations are dependent on the timing of termination and the terms of the relevant agreement, and cannot be reasonably estimated. As of December&#160;31, 2023, most of these agreements were active ongoing arrangements and the Company expects to receive value from these arrangements in the future. The Company recognizes fees related to obligations for terminated contracts where such fees are reasonably estimable. The Company did not accrue obligations that were not reasonably estimable. As of December&#160;31, 2023, the Company had no non-cancelable purchase commitments with a remaining term of more than one year.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyNumberOfDefendants
      contextRef="c-312"
      decimals="INF"
      id="f-1250"
      unitRef="defendant">2</us-gaap:LossContingencyNumberOfDefendants>
    <nvax:LossContingencyPeriodToAnswer contextRef="c-312" id="f-1251">P14D</nvax:LossContingencyPeriodToAnswer>
    <nvax:NumberOfDosesToBeDistributed contextRef="c-91" decimals="-6" id="f-1252" unitRef="dose">350000000</nvax:NumberOfDosesToBeDistributed>
    <nvax:PurchaseAgreementNumberOfVaccineDoses contextRef="c-91" decimals="-6" id="f-1253" unitRef="dose">2000000</nvax:PurchaseAgreementNumberOfVaccineDoses>
    <nvax:CollaborationAgreementRemainingPaymentAmount contextRef="c-88" decimals="-5" id="f-1254" unitRef="usd">696400000</nvax:CollaborationAgreementRemainingPaymentAmount>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="c-95" decimals="-6" id="f-1255" unitRef="usd">75000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementExpense contextRef="c-95" decimals="-6" id="f-1256" unitRef="usd">80000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense contextRef="c-96" decimals="-6" id="f-1257" unitRef="usd">400000000</us-gaap:LitigationSettlementExpense>
    <nvax:SettlementPayment contextRef="c-163" decimals="-5" id="f-1258" unitRef="usd">185000000</nvax:SettlementPayment>
    <nvax:NumberOfQuarterlyInstallmentPayments
      contextRef="c-164"
      decimals="INF"
      id="f-1259"
      unitRef="installment">2</nvax:NumberOfQuarterlyInstallmentPayments>
    <nvax:NumberOfSettlementPayments
      contextRef="c-163"
      decimals="INF"
      id="f-1260"
      unitRef="payment">2</nvax:NumberOfSettlementPayments>
    <nvax:NumberOfSettlementPayments
      contextRef="c-163"
      decimals="INF"
      id="f-1261"
      unitRef="payment">2</nvax:NumberOfSettlementPayments>
    <nvax:SettlementAgreementQuarterlyInstallmentAmount contextRef="c-164" decimals="-5" id="f-1262" unitRef="usd">34300000</nvax:SettlementAgreementQuarterlyInstallmentAmount>
    <nvax:SettlementPayment contextRef="c-165" decimals="-5" id="f-1263" unitRef="usd">68600000</nvax:SettlementPayment>
    <us-gaap:PurchaseObligation contextRef="c-19" decimals="INF" id="f-1264" unitRef="usd">0</us-gaap:PurchaseObligation>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c-1" id="f-1265">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restructuring &lt;/span&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the restructuring charge recorded by the Company comprised (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.818%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.982%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Severance and employee benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Impairment of assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Restructuring charge &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Restructuring charges of $0.5&#160;million, $2.3&#160;million and $11.5&#160;million are included in Cost of sales, Research and development and Selling, general, and administrative expenses, respectively, in the Consolidated Statements of Operations for the period ended December&#160;31, 2023. These charges reflect substantially all expected restructuring charges under the Restructuring Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Severance and employee benefit costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employees affected by the reduction in force under the Restructuring Plan are entitled to receive severance payments and certain termination benefits. The Company recorded a severance and termination benefit cost in full for employees who were notified of their termination during the year ended December&#160;31, 2023 and had no requirements for future service. The Company fully paid $4.5&#160;million for severance and employee benefit costs during the year ended December&#160;31, 2023 and no remaining liability for the severance and employee benefit costs is included in the Company&#x2019;s consolidated balance sheet as of December&#160;31, 2023. There were no severance and employee benefit costs during the year ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Restructuring Plan, the Company evaluated its long-lived assets for impairment including certain leased laboratory and office spaces located in Gaithersburg, Maryland. The evaluation is subject to judgment and actual results may vary from the estimates, resulting in potential future adjustments to amounts recorded. During the year ended December&#160;31, 2023, the Company recorded an impairment charge of $10.1&#160;million related to the impairment of long-lived assets, including $5.9&#160;million related to ROU assets for facility leases. There were no impairment charges recorded during the year ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="c-1" id="f-1266">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the restructuring charge recorded by the Company comprised (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.818%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.982%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Severance and employee benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Impairment of assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Restructuring charge &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Restructuring charges of $0.5&#160;million, $2.3&#160;million and $11.5&#160;million are included in Cost of sales, Research and development and Selling, general, and administrative expenses, respectively, in the Consolidated Statements of Operations for the period ended December&#160;31, 2023. These charges reflect substantially all expected restructuring charges under the Restructuring Plan.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1 contextRef="c-1" decimals="-3" id="f-1267" unitRef="usd">4503000</us-gaap:SeveranceCosts1>
    <us-gaap:AssetImpairmentCharges contextRef="c-1" decimals="-3" id="f-1268" unitRef="usd">10081000</us-gaap:AssetImpairmentCharges>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-3" id="f-1269" unitRef="usd">14584000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-256" decimals="-5" id="f-1270" unitRef="usd">500000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-259" decimals="-5" id="f-1271" unitRef="usd">2300000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-313" decimals="-5" id="f-1272" unitRef="usd">11500000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-314" decimals="-5" id="f-1273" unitRef="usd">4500000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1 contextRef="c-315" decimals="INF" id="f-1274" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1 contextRef="c-316" decimals="INF" id="f-1275" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:AssetImpairmentCharges contextRef="c-1" decimals="-5" id="f-1276" unitRef="usd">10100000</us-gaap:AssetImpairmentCharges>
    <us-gaap:OperatingLeaseImpairmentLoss contextRef="c-221" decimals="-5" id="f-1277" unitRef="usd">5900000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-1278">Subsequent Events&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 31, 2024, the Company announced that the Board of Directors of the Company approved an approximately 12% reduction of its global workforce, comprised of an approximately 9% reduction in the Company&#x2019;s full-time employees and the remainder comprised of contractors and consultants. &lt;/span&gt;&lt;/div&gt;On February 16, 2024, the Company and Gavi entered into the Gavi Settlement Agreement terminating the Gavi APA, settling the arbitration proceedings and releasing both parties of all claims arising from, under or otherwise in connection with the Gavi APA. The terms of the Gavi Settlement Agreement are outlined in Note 3 and Note 16.</us-gaap:SubsequentEventsTextBlock>
    <nvax:RestructuringAndRelatedCostNumberOfPositionsEliminatedGlobalPercent
      contextRef="c-317"
      decimals="2"
      id="f-1279"
      unitRef="number">0.12</nvax:RestructuringAndRelatedCostNumberOfPositionsEliminatedGlobalPercent>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="c-317"
      decimals="2"
      id="f-1280"
      unitRef="number">0.09</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
